

## MIT Open Access Articles

### *Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

**Citation:** Klionsky, Daniel J., et al. "Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd Edition)." *Autophagy*, vol. 12, no. 1, Jan. 2016, pp. 1–222.

**As Published:** <http://dx.doi.org/10.1080/15548627.2015.1100356>

**Publisher:** Informa UK Limited

**Persistent URL:** <http://hdl.handle.net/1721.1/116122>

**Version:** Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

**Terms of use:** Creative Commons Attribution-Noncommercial-Share Alike



EDITORIAL

## Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J Klionsky<sup>1745,1749\*</sup>, Kotb Abdelmohsen<sup>840</sup>, Akihisa Abe<sup>1237</sup>, Md Joynal Abedin<sup>1762</sup>, Hagai Abeliovich<sup>425</sup>, Abraham Acevedo Arozena<sup>789</sup>, Hiroaki Adachi<sup>1800</sup>, Christopher M Adams<sup>1669</sup>, Peter D Adams<sup>57</sup>, Khosrow Adeli<sup>1981</sup>, Peter J Adhihetty<sup>1625</sup>, Sharon G Adler<sup>700</sup>, Galila Agam<sup>67</sup>, Rajesh Agarwal<sup>1587</sup>, Manish K Aghi<sup>1537</sup>, Maria Agnello<sup>1826</sup>, Patrizia Agostinis<sup>664</sup>, Patricia V Aguilar<sup>1960</sup>, Julio Aguirre-Ghiso<sup>784,786</sup>, Edoardo M Airolidi<sup>89,422</sup>, Slimane Ait-Si-Ali<sup>1376</sup>, Takahiko Akematsu<sup>2010</sup>, Emmanuel T Akporiaye<sup>1097</sup>, Mohamed Al-Rubeai<sup>1394</sup>, Guillermo M Albaiceta<sup>1294</sup>, Chris Albanese<sup>363</sup>, Diego Albani<sup>561</sup>, Matthew L Albert<sup>517</sup>, Jesus Aldudo<sup>128</sup>, Hana Algül<sup>1164</sup>, Mehrdad Alirezaei<sup>1198</sup>, Iraide Alloza<sup>642,888</sup>, Alexandru Almasan<sup>206</sup>, Maylin Almonte-Beceril<sup>524</sup>, Emad S Alnemri<sup>1212</sup>, Covadonga Alonso<sup>544</sup>, Nihal Altan-Bonnet<sup>848</sup>, Dario C Altieri<sup>1205</sup>, Silvia Alvarez<sup>1497</sup>, Lydia Alvarez-Erviti<sup>1395</sup>, Sandro Alves<sup>107</sup>, Giuseppina Amadoro<sup>860</sup>, Atsuo Amano<sup>930</sup>, Consuelo Amantini<sup>1554</sup>, Santiago Ambrosio<sup>1458</sup>, Ivano Amelio<sup>756</sup>, Amal O Amer<sup>918</sup>, Mohamed Amessou<sup>2089</sup>, Angelika Amon<sup>726</sup>, Zhenyi An<sup>1538</sup>, Frank A Anania<sup>291</sup>, Stig U Andersen<sup>6</sup>, Usha P Andley<sup>2079</sup>, Catherine K Andreadi<sup>1690</sup>, Nathalie Andrieu-Abadie<sup>502</sup>, Alberto Anel<sup>2027</sup>, David K Ann<sup>58</sup>, Shailendra Anoopkumar-Dukie<sup>388</sup>, Manuela Antonioli<sup>832,858</sup>, Hiroshi Aoki<sup>1791</sup>, Nadezda Apostolova<sup>2007</sup>, Saveria Aquila<sup>1500</sup>, Katia Aquilano<sup>1876</sup>, Koichi Araki<sup>292</sup>, Eli Arama<sup>2098</sup>, Agustin Aranda<sup>456</sup>, Jun Araya<sup>591</sup>, Alexandre Arcaro<sup>1472</sup>, Esperanza Arias<sup>26</sup>, Hirokazu Arimoto<sup>1225</sup>, Aileen R Ariosa<sup>1749</sup>, Jane L Armstrong<sup>1930</sup>, Thierry Arnould<sup>1773</sup>, Ivica Arsov<sup>2120</sup>, Katsuhiko Asanuma<sup>675</sup>, Valerie Askanas<sup>1924</sup>, Eric Asselin<sup>1867</sup>, Ryuichiro Atarashi<sup>794</sup>, Sally S Atherton<sup>369</sup>, Julie D Atkin<sup>713</sup>, Laura D Attardi<sup>1131</sup>, Patrick Auburger<sup>1787</sup>, Georg Auburger<sup>379</sup>, Laure Aurelian<sup>1727</sup>, Riccardo Autelli<sup>1992</sup>, Laura Avagliano<sup>1029,1755</sup>, Maria Laura Avantaggiati<sup>364</sup>, Limor Avrahami<sup>1166</sup>, Suresh Awale<sup>1986</sup>, Neelam Azad<sup>404</sup>, Tiziana Bachetti<sup>568</sup>, Jonathan M Backer<sup>28</sup>, Dong-Hun Bae<sup>1933</sup>, Jae-sung Bae<sup>677</sup>, Ok-Nam Bae<sup>409</sup>, Soo Han Bae<sup>2117</sup>, Eric H Baehrecke<sup>1729</sup>, Seung-Hoon Baek<sup>17</sup>, Stephen Baghdiguian<sup>1368</sup>, Agnieszka Bagniewska-Zadworna<sup>2</sup>, Hua Bai<sup>90</sup>, Jie Bai<sup>667</sup>, Xue-Yuan Bai<sup>1133</sup>, Yannick Bailly<sup>884</sup>, Kithiganahalli Narayanaswamy Balaji<sup>473</sup>, Walter Balduini<sup>2002</sup>, Andrea Ballabio<sup>316</sup>, Rena Balzan<sup>1711</sup>, Rajkumar Banerjee<sup>239</sup>, Gábor Bánhegyi<sup>1052</sup>, Haijun Bao<sup>2109</sup>, Benoit Barbeau<sup>1363</sup>, Maria D Barrachina<sup>2007</sup>, Esther Barreiro<sup>467</sup>, Bonnie Bartel<sup>997</sup>, Alberto Bartolomé<sup>222</sup>, Diane C Bassham<sup>550</sup>, Maria Teresa Bassi<sup>1046</sup>, Robert C Bast Jr<sup>1273</sup>, Alakananda Basu<sup>1798</sup>, Maria Teresa Batista<sup>1578</sup>, Henri Batoko<sup>1336</sup>, Maurizio Battino<sup>970</sup>, Kyle Bauckman<sup>2085</sup>, Bradley L Baumgarner<sup>1909</sup>, K Ulrich Bayer<sup>1594</sup>, Rupert Beale<sup>1553</sup>, Jean-François Beaulieu<sup>1360</sup>, George R. Beck Jr<sup>48,294</sup>, Christoph Becker<sup>336</sup>, J David Beckham<sup>1595</sup>, Pierre-André Bédard<sup>749</sup>, Patrick J Bednarski<sup>301</sup>, Thomas J Begley<sup>1135</sup>, Christian Behl<sup>1419</sup>, Christian Behrends<sup>757</sup>, Georg MN Behrens<sup>406</sup>, Kevin E Behrns<sup>1627</sup>, Eloy Bejarano<sup>26</sup>, Amine Belaid<sup>490</sup>, Francesca Belleudi<sup>1041</sup>, Giovanni Bénard<sup>497</sup>, Guy Berchem<sup>706</sup>, Daniele Bergamaschi<sup>983</sup>, Matteo Bergami<sup>1401</sup>, Ben Berkhout<sup>1441</sup>, Laura Berliocchi<sup>714</sup>, Amélie Bernard<sup>1749</sup>, Monique Bernard<sup>1354</sup>, Francesca Bernassola<sup>1880</sup>, Anne Bertolotti<sup>791</sup>, Amanda S Bess<sup>272</sup>, Sébastien Besteiro<sup>1351</sup>, Saverio Bettuzzi<sup>1828</sup>, Savita Bhalla<sup>913</sup>, Shalmoli Bhattacharyya<sup>973</sup>, Sujit K Bhutia<sup>838</sup>, Caroline Biagosch<sup>1159</sup>, Michele Wolfe Bianchi<sup>520,1378,1381</sup>, Martine Biard-Piechaczyk<sup>210</sup>, Viktor Billes<sup>298</sup>, Claudia Bincoletto<sup>1314</sup>, Baris Bingol<sup>350</sup>, Sara W Bird<sup>1128</sup>, Marc Bitoun<sup>1112</sup>, Ivana Bjedov<sup>1258</sup>, Craig Blackstone<sup>843</sup>, Lionel Blanc<sup>1183</sup>, Guillermo A Blanco<sup>1496</sup>, Heidi Kiil Blomhoff<sup>1812</sup>, Emilio Boada-Romero<sup>1297</sup>, Stefan Böckler<sup>1464</sup>, Marianne Boes<sup>1423</sup>, Kathleen Boesze-Battaglia<sup>1835</sup>, Lawrence H Boise<sup>286,287</sup>, Alessandra Bolino<sup>2063</sup>, Andrea Boman<sup>693</sup>, Paolo Bonaldo<sup>1823</sup>, Matteo Bordi<sup>897</sup>, Jürgen Bosch<sup>608</sup>, Luis M Botana<sup>1308</sup>, Joelle Botti<sup>1375</sup>, German Bou<sup>1405</sup>, Marina Bouche<sup>1038</sup>, Marion Bouche-careilh<sup>1331</sup>, Marie-Josée Boucher<sup>1901</sup>, Michael E Boulton<sup>481</sup>, Sebastien G Bouret<sup>1926</sup>, Patricia Boya<sup>133</sup>, Michaël Boyer-Guittaut<sup>1345</sup>, Peter V Bozhkov<sup>1141</sup>, Nathan Brady<sup>374</sup>, Vania MM Braga<sup>469</sup>, Claudio Brancolini<sup>1997</sup>, Gerhard H Braus<sup>353</sup>, José M Bravo-San Pedro<sup>299,393,508,1374</sup>, Lisa A Brennan<sup>322</sup>, Emery H Bresnick<sup>2022</sup>, Patrick Brest<sup>490</sup>, Dave Bridges<sup>1939</sup>, Marie-Agnès Bringer<sup>124</sup>, Marisa Brini<sup>1822</sup>, Glauber C Brito<sup>1311</sup>, Bertha Brodin<sup>631</sup>, Paul S Brookes<sup>1872</sup>, Eric J Brown<sup>352</sup>, Karen Brown<sup>1690</sup>, Hal E Broxmeyer<sup>480</sup>, Alain Bruhat<sup>486,1339</sup>, Patricia Chakur Brum<sup>1893</sup>, John H Brumell<sup>446</sup>, Nicola Brunetti-Pierri<sup>315,1171</sup>, Robert J Bryson-Richardson<sup>781</sup>, Shilpa Buch<sup>1777</sup>, Alastair M Buchan<sup>1819</sup>, Hikmet Budak<sup>1022</sup>, Dmitry V Bulavin<sup>118,505,1789</sup>, Scott J Bultman<sup>1792</sup>, Geert Bultynck<sup>665</sup>, Vladimir Bumbasirevic<sup>1470</sup>, Yan Burrelle<sup>1356</sup>, Robert E Burke<sup>216,217</sup>, Margit Burmeister<sup>1750</sup>, Peter Bütikofer<sup>1473</sup>, Laura Caberlotto<sup>1987</sup>, Ken Cadwell<sup>896</sup>, Monika Cahova<sup>112</sup>, Dongsheng Cai<sup>24</sup>, Jingjing Cai<sup>2099</sup>, Qian Cai<sup>1018</sup>, Sara Calatayud<sup>2007</sup>, Nadine Camougrand<sup>1343</sup>, Michelangelo Campanella<sup>1700</sup>, Grant R Campbell<sup>1525</sup>, Matthew Campbell<sup>1249</sup>, Silvia Campello<sup>556,1876</sup>, Robin Candau<sup>1769</sup>, Isabella Caniggia<sup>1983</sup>, Lavinia Cantoni<sup>560</sup>, Lizhi Cao<sup>116</sup>, Allan B Caplan<sup>1656</sup>, Michele Caraglia<sup>1051</sup>, Claudio Cardinali<sup>1043</sup>

Sandra Morais Cardoso<sup>1579</sup>, Jennifer S Carew<sup>208</sup>, Laura A Carleton<sup>874</sup>, Cathleen R Carlin<sup>101</sup>, Silvia Carloni<sup>2002</sup>,  
 Sven R Carlsson<sup>1267</sup>, Didac Carmona-Gutierrez<sup>1643</sup>, Leticia AM Carneiro<sup>312</sup>, Oliana Carnevali<sup>971</sup>, Serena Carra<sup>1318</sup>,  
 Alice Carrier<sup>120</sup>, Bernadette Carroll<sup>900</sup>, Caty Casas<sup>1324</sup>, Josefina Casas<sup>1116</sup>, Giuliana Cassinelli<sup>324</sup>, Perrine Castets<sup>1462</sup>,  
 Susana Castro-Obregon<sup>214</sup>, Gabriella Cavallini<sup>1841</sup>, Isabella Ceccherini<sup>568</sup>, Francesco Cecconi<sup>253,555,1884</sup>,  
 Arthur I Cederbaum<sup>459</sup>, Valentín Ceña<sup>199,1281</sup>, Simone Cenci<sup>1323,2064</sup>, Claudia Cerella<sup>444</sup>, Davide Cervia<sup>1996</sup>,  
 Silvia Cetrullo<sup>1478</sup>, Hassan Chaachouay<sup>2028</sup>, Han-Jung Chae<sup>187</sup>, Andrei S Chagin<sup>634</sup>, Chee-Yin Chai<sup>626,628</sup>,  
 Gopal Chakrabarti<sup>1502</sup>, Georgios Chamilos<sup>1601</sup>, Edmond YW Chan<sup>1142</sup>, Matthew TV Chan<sup>181</sup>, Dhyana Chandra<sup>1003</sup>,  
 Pallavi Chandra<sup>548</sup>, Chih-Peng Chang<sup>818</sup>, Raymond Chuen-Chung Chang<sup>1653</sup>, Ta Yuan Chang<sup>345</sup>, John C Chatham<sup>1434</sup>,  
 Saurabh Chatterjee<sup>1910</sup>, Santosh Chauhan<sup>527</sup>, Yongsheng Che<sup>62</sup>, Michael E Cheetham<sup>1263</sup>, Rajkumar Cheluvappa<sup>1783</sup>,  
 Chun-Jung Chen<sup>1153</sup>, Gang Chen<sup>598,1676</sup>, Guang-Chao Chen<sup>9</sup>, Guoqiang Chen<sup>1078</sup>, Hongzhuan Chen<sup>1077</sup>, Jeff W Chen<sup>1514</sup>,  
 Jian-Kang Chen<sup>370,371</sup>, Min Chen<sup>249</sup>, Mingzhou Chen<sup>2104</sup>, Peiwen Chen<sup>1823</sup>, Qi Chen<sup>1674</sup>, Quan Chen<sup>172</sup>,  
 Shang-Der Chen<sup>138</sup>, Si Chen<sup>325</sup>, Steve S-L Chen<sup>10</sup>, Wei Chen<sup>2125</sup>, Wei-Jung Chen<sup>829</sup>, Wen Qiang Chen<sup>979</sup>, Wenli Chen<sup>1113</sup>,  
 Xiangmei Chen<sup>1133</sup>, Yau-Hung Chen<sup>1157</sup>, Ye-Guang Chen<sup>1250</sup>, Yin Chen<sup>1447</sup>, Yingyu Chen<sup>953,955</sup>, Yongshun Chen<sup>2135</sup>,  
 Yu-Jen Chen<sup>712</sup>, Yue-Qin Chen<sup>1145</sup>, Yujie Chen<sup>1208</sup>, Zhen Chen<sup>339</sup>, Zhong Chen<sup>2123</sup>, Alan Cheng<sup>1702</sup>,  
 Christopher HK Cheng<sup>184</sup>, Hua Cheng<sup>1728</sup>, Heesun Cheong<sup>814</sup>, Sara Cherry<sup>1836</sup>, Jason Chesney<sup>1703</sup>,  
 Chun Hei Antonio Cheung<sup>817</sup>, Eric Chevet<sup>1359</sup>, Hsiang Cheng Chi<sup>140</sup>, Sung-Gil Chi<sup>656</sup>, Fulvio Chiacchiera<sup>308</sup>,  
 Hui-Ling Chiang<sup>958</sup>, Roberto Chiarelli<sup>1826</sup>, Mario Chiariello<sup>235,567,577</sup>, Marcello Chieppa<sup>835</sup>, Lih-Shen Chin<sup>290</sup>,  
 Mario Chiong<sup>1285</sup>, Gigi NC Chiu<sup>878</sup>, Dong-Hyung Cho<sup>676</sup>, Ssang-Goo Cho<sup>650</sup>, William C Cho<sup>982</sup>, Yong-Yeon Cho<sup>105</sup>,  
 Young-Seok Cho<sup>1064</sup>, Augustine MK Choi<sup>2095</sup>, Eui-Ju Choi<sup>656</sup>, Eun-Kyoung Choi<sup>387,400,685</sup>, Jayoung Choi<sup>1563</sup>,  
 Mary E Choi<sup>2093</sup>, Seung-Il Choi<sup>2116</sup>, Tsui-Fen Chou<sup>412</sup>, Salem Chouaib<sup>395</sup>, Divaker Choubey<sup>1574</sup>, Vinay Choubey<sup>1936</sup>,  
 Kuan-Chih Chow<sup>822</sup>, Kamal Chowdhury<sup>730</sup>, Charleen T Chu<sup>1856</sup>, Tsung-Hsien Chuang<sup>827</sup>, Taehoon Chun<sup>657</sup>,  
 Hyewon Chung<sup>652</sup>, Taijoon Chung<sup>978</sup>, Yuen-Li Chung<sup>1194</sup>, Yong-Joon Chwae<sup>18</sup>, Valentina Cianfanelli<sup>254</sup>,  
 Roberto Ciarcia<sup>1775</sup>, Iwona A Ciechomska<sup>886</sup>, Maria Rosa Ciriolo<sup>1876</sup>, Mara Cirone<sup>1042</sup>, Sofie Claerhout<sup>1694</sup>,  
 Michael J Clague<sup>1698</sup>, Joan Clària<sup>1457</sup>, Peter GH Clarke<sup>1687</sup>, Robert Clarke<sup>361</sup>, Emilio Clementi<sup>1045,1398</sup>, Cédric Cleyrat<sup>1781</sup>,  
 Miriam Cnop<sup>1366</sup>, Eliana M Coccia<sup>574</sup>, Tiziana Cocco<sup>1459</sup>, Patrice Codogno<sup>1375</sup>, Jörn Coers<sup>271</sup>, Ezra EW Cohen<sup>1533</sup>,  
 David Colecchia<sup>235,567,577</sup>, Luisa Coletto<sup>25</sup>, Núria S Coll<sup>123</sup>, Emma Colucci-Guyon<sup>516</sup>, Sergio Comincini<sup>1829</sup>,  
 Maria Condello<sup>578</sup>, Katherine L Cook<sup>2073</sup>, Graham H Coombs<sup>1929</sup>, Cynthia D Cooper<sup>2076</sup>, J Mark Cooper<sup>1395</sup>,  
 Isabelle Coppens<sup>601</sup>, Maria Tiziana Corasaniti<sup>1387</sup>, Marco Corazzari<sup>485,1884</sup>, Ramon Corbalan<sup>1566</sup>,  
 Elisabeth Corcelle-Termeau<sup>251</sup>, Mario D Cordero<sup>1899</sup>, Cristina Corral-Ramos<sup>1289</sup>, Olga Corti<sup>507,1109</sup>, Andrea Cossarizza<sup>1767</sup>,  
 Paola Costelli<sup>1993</sup>, Safia Costes<sup>1518</sup>, Susan L Cotman<sup>721</sup>, Ana Coto-Montes<sup>946</sup>, Sandra Cottet<sup>566,1688</sup>, Eduardo Couve<sup>1301</sup>,  
 Lori R Covey<sup>1015</sup>, L Ashley Cowart<sup>762</sup>, Jeffery S Cox<sup>1536</sup>, Fraser P Coxon<sup>1427</sup>, Carolyn B Coyne<sup>1846</sup>, Mark S Cragg<sup>1919</sup>,  
 Rolf J Craven<sup>1679</sup>, Tiziana Crepaldi<sup>1995</sup>, Jose L Crespo<sup>1300</sup>, Alfredo Criollo<sup>1285</sup>, Valeria Crippa<sup>558</sup>, Maria Teresa Cruz<sup>1576</sup>,  
 Ana Maria Cuervo<sup>26</sup>, Jose M Cuezva<sup>1277</sup>, Taixing Cui<sup>1907</sup>, Pedro R Cutillas<sup>987</sup>, Mark J Czaja<sup>27</sup>, Maria F Czyzyk-Krzeska<sup>1572</sup>,  
 Ruben K Dagda<sup>2068</sup>, Uta Dahmen<sup>1404</sup>, Chunsun Dai<sup>800</sup>, Wenjie Dai<sup>1187</sup>, Yun Dai<sup>2059</sup>, Kevin N Dalby<sup>1940</sup>,  
 Luisa Dalla Valle<sup>1822</sup>, Guillaume Dalmasso<sup>1340</sup>, Marcello D'Amelio<sup>557</sup>, Markus Damme<sup>188</sup>, Arlette Darfeuille-Michaud<sup>1340</sup>,  
 Catherine Dargemont<sup>950</sup>, Victor M Darley-Usmar<sup>1433</sup>, Srinivasan Dasarathy<sup>205</sup>, Biplab Dasgupta<sup>202</sup>, Srikanta Dash<sup>1254</sup>,  
 Crispin R Dass<sup>242</sup>, Hazel Marie Davey<sup>8</sup>, Lester M Davids<sup>1560</sup>, David Dávila<sup>227</sup>, Roger J Davis<sup>1731</sup>, Ted M Dawson<sup>604</sup>,  
 Valina L Dawson<sup>606</sup>, Paula Daza<sup>1898</sup>, Jackie de Belleruche<sup>470</sup>, Paul de Figueiredo<sup>1180,1182</sup>,  
 Regina Celia Bressan Queiroz de Figueiredo<sup>135</sup>, José de la Fuente<sup>1023</sup>, Luisa De Martino<sup>1775</sup>,  
 Antonella De Matteis<sup>1171</sup>, Guido RY De Meyer<sup>1443</sup>, Angelo De Milito<sup>631</sup>, Mauro De Santi<sup>2002</sup>, Wanderley de Souza<sup>1000</sup>,  
 Vincenzo De Tata<sup>1840</sup>, Daniela De Zio<sup>252</sup>, Jayanta Debnath<sup>1543</sup>, Reinhard Dechant<sup>303</sup>, Jean-Paul Decuyper<sup>661,1412</sup>,  
 Shane Deegan<sup>874</sup>, Benjamin Dehay<sup>1342</sup>, Barbara Del Bello<sup>1902</sup>, Dominic P Del Re<sup>1017</sup>, Régis Delage-Mourroux<sup>1344</sup>,  
 Lea MD Delbridge<sup>1735</sup>, Louise Deldicque<sup>1337</sup>, Elizabeth Delorme-Axford<sup>1749</sup>, Yizhen Deng<sup>1172</sup>, Joern Dengjel<sup>1630</sup>,  
 Melanie Denizot<sup>1684</sup>, Paul Dent<sup>2051</sup>, Channing J Der<sup>1794</sup>, Vojo Deretic<sup>1782</sup>, Benoît Derrien<sup>306</sup>, Eric Deutsch<sup>1382</sup>,  
 Timothy P Devarenne<sup>1179</sup>, Rodney J Devenish<sup>778</sup>, Sabrina Di Bartolomeo<sup>1876</sup>, Nicola Di Daniele<sup>1882</sup>,  
 Fabio Di Domenico<sup>1040</sup>, Alessia Di Nardo<sup>153</sup>, Simone Di Paola<sup>1171</sup>, Antonio Di Pietro<sup>1289</sup>, Livia Di Renzo<sup>1042</sup>,  
 Aaron DiAntonio<sup>2082</sup>, Guillermo Díaz-Araya<sup>1286</sup>, Ines Díaz-Laviada<sup>1437</sup>, Maria T Diaz-Meco<sup>1034</sup>, Javier Diaz-Nido<sup>1275</sup>,  
 Chad A Dickey<sup>1914</sup>, Robert C Dickson<sup>1678</sup>, Marc Diederich<sup>1061</sup>, Paul Digard<sup>1612</sup>, Ivan Dikic<sup>381</sup>,  
 Savithrama P Dinesh-Kumar<sup>1511</sup>, Chan Ding<sup>1088</sup>, Wen-Xing Ding<sup>1674</sup>, Zufeng Ding<sup>1448</sup>, Luciana Dini<sup>1886</sup>,  
 Jörg HW Distler<sup>1615</sup>, Abhinav Diwan<sup>2087</sup>, Mojgan Djavaheri-Mergny<sup>1341</sup>, Kostyantyn Dmytruk<sup>808</sup>, Renwick CJ Dobson<sup>1558</sup>,  
 Volker Doetsch<sup>380</sup>, Karol Dokladny<sup>1780</sup>, Svetlana Dokudovskaya<sup>1383</sup>, Massimo Donadelli<sup>2009</sup>, X Charlie Dong<sup>478</sup>,  
 Xiaonan Dong<sup>1942</sup>, Zheng Dong<sup>370</sup>, Terrence M Donohue Jr<sup>1776,2038</sup>, Kelly S Doran<sup>1027</sup>, Gabriella D'Orazi<sup>1386</sup>,  
 Gerald W Dorn II<sup>2078</sup>, Victor Dosenko<sup>77</sup>, Sami Dridi<sup>1451</sup>, Liat Drucker<sup>1168</sup>, Jie Du<sup>61</sup>, Li-Lin Du<sup>834</sup>, Lihuan Du<sup>343</sup>,  
 André du Toit<sup>1136</sup>, Priyamvada Dua<sup>985</sup>, Lei Duan<sup>1012</sup>, Pu Duann<sup>923</sup>, Vikash Kumar Dubey<sup>475</sup>, Michael R Duchon<sup>1397</sup>,  
 Michel A Duchosal<sup>1408</sup>, Helene Duez<sup>1415</sup>, Isabelle Dugail<sup>503</sup>, Verónica I Dumit<sup>333</sup>, Mara C Duncan<sup>1742</sup>, Elaine A Dunlop<sup>98</sup>,  
 William A Dunn Jr<sup>1621</sup>, Nicolas Dupont<sup>1375</sup>, Luc Dupuis<sup>493,1361</sup>, Raúl V Durán<sup>499</sup>, Thomas M Durcan<sup>748</sup>,  
 Stéphane Duvezin-Caubet<sup>1333</sup>, Umamaheswar Duvvuri<sup>2039</sup>, Vinay Eapen<sup>82</sup>, Darius Ebrahimi-Fakhari<sup>1011</sup>,  
 Arnaud Echard<sup>514</sup>, Leopold Eckhart<sup>768</sup>, Charles L Edelstein<sup>1585</sup>, Aimee L Edinger<sup>1513</sup>, Ludwig Eichinger<sup>1584</sup>,

Tobias Eisenberg<sup>1643</sup>, Avital Eisenberg-Lerner<sup>2097</sup>, N Tony Eissa<sup>54</sup>, Wafik S El-Deiry<sup>962</sup>, Victoria El-Khoury<sup>708</sup>,  
 Zvulun Elazar<sup>2096</sup>, Hagit Eldar-Finkelman<sup>1166</sup>, Chris JH Elliott<sup>2026</sup>, Enzo Emanuele<sup>1830</sup>, Urban Emmenegger<sup>1982</sup>,  
 Nikolai Engedal<sup>1813</sup>, Anna-Mart Engelbrecht<sup>1136</sup>, Simone Engelender<sup>1160</sup>, Jorrit M Enserink<sup>942</sup>, Ralf Erdmann<sup>1009</sup>,  
 Jekaterina Erenpreisa<sup>687</sup>, Rajaraman Eri<sup>1938</sup>, Jason L Eriksen<sup>1654</sup>, Andreja Erman<sup>1699</sup>, Ricardo Escalante<sup>93</sup>,  
 Eeva-Liisa Eskelinen<sup>1648</sup>, Lucile Espert<sup>210</sup>, Lorena Esteban-Martínez<sup>133</sup>, Thomas J Evans<sup>1639</sup>, Mario Fabri<sup>1581</sup>,  
 Gemma Fabrias<sup>1116</sup>, Cinzia Fabrizi<sup>1039</sup>, Antonio Facchiano<sup>559</sup>, Nils J Færgeman<sup>1927</sup>, Alberto Faggioni<sup>1042</sup>,  
 W Douglas Fairlie<sup>679,681,682</sup>, Chunhai Fan<sup>167</sup>, Daping Fan<sup>1907</sup>, Jie Fan<sup>1849</sup>, Shengyun Fang<sup>1721</sup>, Manolis Fanto<sup>645</sup>,  
 Alessandro Fanzani<sup>1482</sup>, Thomas Farkas<sup>251</sup>, Mathias Faure<sup>1349</sup>, Francois B Favier<sup>487,1353</sup>, Howard Fearnhead<sup>875</sup>,  
 Massimo Federici<sup>1883</sup>, Erkang Fei<sup>799</sup>, Tania C Felizardo<sup>844</sup>, Hua Feng<sup>1208</sup>, Yibin Feng<sup>1652</sup>, Yuchen Feng<sup>1745,1749</sup>,  
 Thomas A Ferguson<sup>2079</sup>, Álvaro F Fernández<sup>1295</sup>, Maite G Fernandez-Barrena<sup>1293</sup>, Jose C Fernandez-Checa<sup>538,1925</sup>,  
 Arsenio Fernández-López<sup>1292</sup>, Martin E Fernandez-Zapico<sup>736</sup>, Olivier Feron<sup>1335</sup>, Elisabetta Ferraro<sup>554</sup>,  
 Carmen Veríssima Ferreira-Halder<sup>1557</sup>, Laszlo Fesus<sup>1603</sup>, Ralph Feuer<sup>1028</sup>, Fabienne C Fiesel<sup>733</sup>,  
 Eduardo C Filippi-Chiela<sup>1303</sup>, Giuseppe Filomeni<sup>252,1876</sup>, Gian Maria Fimia<sup>832,1887</sup>, John H Fingert<sup>1137,1671</sup>,  
 Steven Finkbeiner<sup>1542</sup>, Toren Finkel<sup>848</sup>, Filomena Fiorito<sup>513,1775</sup>, Paul B Fisher<sup>2056</sup>, Marc Flajolet<sup>1002</sup>, Flavio Flamigni<sup>1478</sup>,  
 Oliver Florey<sup>52</sup>, Salvatore Florio<sup>1775</sup>, R Andres Floto<sup>1548</sup>, Marco Folini<sup>324</sup>, Carlo Follo<sup>1319</sup>, Edward A Fon<sup>747</sup>,  
 Francesco Fornai<sup>553,1840</sup>, Franco Fortunato<sup>1390</sup>, Alessandro Fraldi<sup>1171</sup>, Rodrigo Franco<sup>1778</sup>, Arnaud Francois<sup>119,1365</sup>,  
 Aurélie François<sup>511</sup>, Lisa B Frankel<sup>1596</sup>, Iain DC Fraser<sup>852</sup>, Norbert Frey<sup>1681</sup>, Damien G Freyssenet<sup>1348</sup>, Christian Frezza<sup>788</sup>,  
 Scott L Friedman<sup>787</sup>, Daniel E Frigo<sup>448,1655</sup>, Dongxu Fu<sup>989</sup>, José M Fuentes<sup>1291</sup>, Juan Fueyo<sup>1954</sup>, Yoshio Fujitani<sup>612</sup>,  
 Yuuki Fujiwara<sup>837</sup>, Mikihiro Fujiya<sup>45</sup>, Mitsunori Fukuda<sup>1221</sup>, Simone Fulda<sup>383</sup>, Carmela Fusco<sup>552</sup>, Bozena Gabryel<sup>761</sup>,  
 Matthias Gaestel<sup>407</sup>, Philippe Gailly<sup>1338</sup>, Malgorzata Gajewska<sup>2075</sup>, Sehamuddin Galadari<sup>21,1257</sup>, Gad Galili<sup>1204</sup>,  
 Inmaculada Galindo<sup>544</sup>, Maria F Galindo<sup>226</sup>, Giovanna Gallicciotti<sup>1418</sup>, Lorenzo Galluzzi<sup>299,393,508,1374</sup>, Luca Galluzzi<sup>2002</sup>,  
 Vincent Galy<sup>1108</sup>, Noor Gammoh<sup>1613</sup>, Sam Gandy<sup>460,582</sup>, Anand K Ganesan<sup>1516</sup>, Swamynathan Ganesan<sup>1428</sup>,  
 Ian G Ganley<sup>1608</sup>, Monique Gannagé<sup>1634</sup>, Fen-Biao Gao<sup>1730</sup>, Feng Gao<sup>1189</sup>, Jian-Xin Gao<sup>1083</sup>, Lorena García Nannig<sup>1566</sup>,  
 Eleonora García Vescovi<sup>534</sup>, Marina Garcia-Macia<sup>31</sup>, Carmen Garcia-Ruiz<sup>542</sup>, Abhishek D Garg<sup>1692</sup>, Pramod Kumar Garg<sup>37</sup>,  
 Ricardo Gargini<sup>1276</sup>, Nils Christian Gassen<sup>731</sup>, Damián Gatica<sup>1745,1749</sup>, Evelina Gatti<sup>16,212,506</sup>, Julie Gavard<sup>121</sup>,  
 Evripidis Gavathiotis<sup>30</sup>, Liang Ge<sup>1506</sup>, Pengfei Ge<sup>318</sup>, Shengfang Ge<sup>1076</sup>, Po-Wu Gean<sup>819</sup>, Vania Gelmetti<sup>240</sup>,  
 Armando A Genazzani<sup>1320</sup>, Jiefei Geng<sup>414</sup>, Pascal Genschik<sup>125</sup>, Lisa Gerner<sup>1813</sup>, Jason E Gestwicki<sup>1540</sup>, David A Gewirtz<sup>2060</sup>,  
 Saeid Ghavami<sup>1716</sup>, Eric Ghigo<sup>15</sup>, Debabrata Ghosh<sup>38</sup>, Anna Maria Giammarioli<sup>576,1030</sup>, Francesca Giampieri<sup>970</sup>,  
 Claudia Giampietri<sup>1038</sup>, Alexandra Giatromanolaki<sup>256</sup>, Derrick J Gibbins<sup>1817</sup>, Lara Gibellini<sup>1766</sup>, Spencer B Gibson<sup>1715</sup>,  
 Vanessa Ginet<sup>1687</sup>, Antonio Giordano<sup>1173,1874</sup>, Flaviano Giorgini<sup>1691</sup>, Elisa Giovannetti<sup>570,2065</sup>, Stephen E Girardin<sup>1977</sup>,  
 Suzana Gispert<sup>379</sup>, Sandy Giuliano<sup>491,492</sup>, Candace L Gladson<sup>206</sup>, Alvaro Glavic<sup>1287</sup>, Martin Gleave<sup>1492</sup>, Nelly Godefroy<sup>1770</sup>,  
 Robert M Gogal Jr<sup>1635</sup>, Kuppan Gokulan<sup>2036</sup>, Gustavo H Goldman<sup>1309</sup>, Delia Goletti<sup>833</sup>, Michael S Goligorsky<sup>893</sup>,  
 Aldrin V Gomes<sup>1510</sup>, Ligia C Gomes<sup>254</sup>, Hernando Gomez<sup>1845</sup>, Candelaria Gomez-Manzano<sup>1954</sup>,  
 Rubén Gómez-Sánchez<sup>1291</sup>, Dawit AP Gonçalves<sup>1891</sup>, Ebru Goncu<sup>284</sup>, Qingqiu Gong<sup>805</sup>, Céline Gongora<sup>564</sup>,  
 Carlos B Gonzalez<sup>1274</sup>, Pedro Gonzalez-Alegre<sup>1833</sup>, Pilar Gonzalez-Cabo<sup>197,975</sup>, Rosa Ana González-Polo<sup>1291</sup>,  
 Ing Swie Goping<sup>1436</sup>, Carlos Gorbea<sup>2003</sup>, Nikolai V Gorbunov<sup>1271</sup>, Daphne R Goring<sup>1976</sup>, Adrienne M Gorman<sup>874</sup>,  
 Sharon M Gorski<sup>87,1098</sup>, Sandro Goruppi<sup>722</sup>, Shino Goto-Yamada<sup>673</sup>, Cecilia Gotor<sup>232</sup>, Roberta A Gottlieb<sup>108</sup>,  
 Illana Gozes<sup>1170</sup>, Devrim Gozuacik<sup>1022</sup>, Yacine Graba<sup>14</sup>, Martin Graef<sup>727</sup>, Giovanna E Granato<sup>1173</sup>, Gary Dean Grant<sup>388</sup>,  
 Steven Grant<sup>2054</sup>, Giovanni Luca Gravina<sup>1685</sup>, Douglas R Green<sup>1123</sup>, Alexander Greenhough<sup>1484</sup>,  
 Michael T Greenwood<sup>1005</sup>, Benedetto Grimaldi<sup>569</sup>, Frédéric Gros<sup>1362</sup>, Charles Grose<sup>1667</sup>, Jean-Francois Groulx<sup>1033</sup>,  
 Florian Gruber<sup>767</sup>, Paolo Grumati<sup>381,1823</sup>, Tilman Grune<sup>376</sup>, Jun-Lin Guan<sup>1572</sup>, Kun-Liang Guan<sup>1526</sup>, Barbara Guerra<sup>1927</sup>,  
 Carlos Guillen<sup>1279</sup>, Kailash Gulshan<sup>207</sup>, Jan Gunst<sup>660</sup>, Chuanyong Guo<sup>1241</sup>, Lei Guo<sup>325</sup>, Ming Guo<sup>1264</sup>, Wenjie Guo<sup>590</sup>,  
 Xu-Guang Guo<sup>1202</sup>, Andrea A Gust<sup>1990</sup>, Åsa B Gustafsson<sup>1535</sup>, Elaine Gutierrez<sup>1933</sup>, Maximiliano G Gutierrez<sup>332</sup>,  
 Ho-Shin Gwak<sup>386</sup>, Albert Haas<sup>1480</sup>, James E Haber<sup>82</sup>, Shinji Hadano<sup>1228</sup>, Monica Hagedorn<sup>68</sup>, David R Hahn<sup>200</sup>,  
 Andrew J Halayko<sup>1717</sup>, Anne Hamacher-Brady<sup>373</sup>, Kozo Hamada<sup>998</sup>, Ahmed Hamal<sup>1375</sup>, Andrea Hamann<sup>384</sup>,  
 Maho Hamasaki<sup>934</sup>, Isabelle Hamer<sup>1774</sup>, Qutayba Hamid<sup>1084</sup>, Ester M Hammond<sup>1820</sup>, Feng Han<sup>2130</sup>, Weidong Han<sup>2133</sup>,  
 James T Handa<sup>609</sup>, John A Hanover<sup>855</sup>, Malene Hansen<sup>1034</sup>, Masaru Harada<sup>1801</sup>, Ljubica Harhaji-Trajkovic<sup>1466</sup>,  
 J Wade Harper<sup>418</sup>, Abdel Halim Harrath<sup>643</sup>, Adrian L Harris<sup>947</sup>, James Harris<sup>777</sup>, Udo Hasler<sup>1633</sup>, Peter Hasselblatt<sup>1403</sup>,  
 Kazuhisa Hasui<sup>618</sup>, Robert G Hawley<sup>358</sup>, Teresa S Hawley<sup>359</sup>, Congcong He<sup>911</sup>, Cynthia Y He<sup>877</sup>, Fengtian He<sup>1207</sup>,  
 Gu He<sup>1096</sup>, Rong-Rong He<sup>594</sup>, Xian-Hui He<sup>595</sup>, You-Wen He<sup>269</sup>, Yu-Ying He<sup>1562</sup>, Joan K Heath<sup>1203</sup>, Marie-Josée Hébert<sup>1354</sup>,  
 Robert A Heinzen<sup>856</sup>, Gudmundur Vignir Helgason<sup>1640</sup>, Michael Hensel<sup>1814</sup>, Elizabeth P Henske<sup>85</sup>, Chengtao Her<sup>2077</sup>,  
 Paul K Herman<sup>920</sup>, Agustín Hernández<sup>1310</sup>, Carlos Hernandez<sup>319</sup>, Sonia Hernández-Tiedra<sup>227</sup>, Claudio Hetz<sup>1539,1570</sup>,  
 P Robin Hiesinger<sup>1964</sup>, Katsumi Higaki<sup>1244</sup>, Sabine Hilfiker<sup>231</sup>, Bradford G Hill<sup>1704</sup>, Joseph A Hill<sup>1968</sup>,  
 William D Hill<sup>366,367,368,370</sup>, Keisuke Hino<sup>637</sup>, Daniel Hofius<sup>1152</sup>, Paul Hofman<sup>1788</sup>, Günter U Höglinger<sup>375,1163</sup>,  
 Jörg Höhfeld<sup>1480</sup>, Marina K Holz<sup>23,2113</sup>, Yonggeun Hong<sup>484</sup>, David A Hood<sup>2121</sup>, Jeroen JM Hoozemans<sup>2067</sup>,  
 Thorsten Hoppe<sup>1582</sup>, Chin Hsu<sup>1675</sup>, Chin-Yuan Hsu<sup>141</sup>, Li-Chung Hsu<sup>869</sup>, Dong Hu<sup>41</sup>, Guochang Hu<sup>1659</sup>, Hong-Ming Hu<sup>976</sup>,  
 Hongbo Hu<sup>157</sup>, Ming Chang Hu<sup>1965</sup>, Yu-Chen Hu<sup>871</sup>, Zhuo-Wei Hu<sup>163</sup>, Fang Hua<sup>163</sup>, Ya Hua<sup>1751</sup>, Canhua Huang<sup>1095</sup>,  
 Huey-Lan Huang<sup>143</sup>, Kuo-How Huang<sup>867</sup>, Kuo-Yang Huang<sup>142</sup>, Shile Huang<sup>701</sup>, Shiqian Huang<sup>1081</sup>, Wei-Pang Huang<sup>865</sup>,  
 Yi-Ran Huang<sup>1079</sup>, Yong Huang<sup>458</sup>, Yunfei Huang<sup>22</sup>, Tobias B Huber<sup>35,76,1416</sup>, Patricia Huebbe<sup>1683</sup>, Won-Ki Huh<sup>1060</sup>,

Juha J Hulmi<sup>1649,1672</sup>, Gang Min Hur<sup>193</sup>, James H Hurley<sup>1505</sup>, Zvenyslava Husak<sup>1118</sup>, Sabah NA Hussain<sup>739,744</sup>,  
 Salik Hussain<sup>850</sup>, Jung Jin Hwang<sup>46</sup>, Seungmin Hwang<sup>1563</sup>, Thomas IS Hwang<sup>1091</sup>, Atsuhiko Ichihara<sup>1240</sup>, Yuzuru Imai<sup>610</sup>,  
 Carol Imbriano<sup>1765</sup>, Megumi Inomata<sup>44</sup>, Takeshi Into<sup>44</sup>, Valentina Iovane<sup>1888</sup>, Juan L Iovanna<sup>120</sup>, Renato V Iozzo<sup>1213</sup>,  
 Nancy Y Ip<sup>441</sup>, Javier E Irazoqui<sup>419</sup>, Pablo Iribarren<sup>134</sup>, Yoshitaka Isaka<sup>931</sup>, Aleksandra J Isakovic<sup>1388</sup>,  
 Harry Ischiropoulos<sup>152,966</sup>, Jeffrey S Isenberg<sup>1860</sup>, Mohammad Ishaq<sup>528</sup>, Hiroyuki Ishida<sup>1224</sup>, Isao Ishii<sup>640</sup>, Jane E Ishmael<sup>928</sup>,  
 Ciro Isidoro<sup>1319</sup>, Ken-ichi Isobe<sup>797</sup>, Erika Isono<sup>1165</sup>, Shohreh Issazadeh-Navikas<sup>1596</sup>, Koji Itahana<sup>273</sup>, Eisuke Itakura<sup>150</sup>,  
 Andrei I Ivanov<sup>2052</sup>, Anand Krishnan V Iyer<sup>404</sup>, José M Izquierdo<sup>129</sup>, Yotaro Izumi<sup>1025</sup>, Valentina Izzo<sup>299,393,508,1374</sup>,  
 Marja Jäätelä<sup>251</sup>, Nadia Jaber<sup>1139</sup>, Daniel John Jackson<sup>1641</sup>, William T Jackson<sup>1725</sup>, Tony George Jacob<sup>36</sup>,  
 Thomas S Jacques<sup>1260</sup>, Chinnaswamy Jagannath<sup>1944</sup>, Ashish Jain<sup>941,1805</sup>, Nihar Ranjan Jana<sup>812</sup>, Byoung Kuk Jang<sup>639</sup>,  
 Alkesh Jani<sup>1588</sup>, Bassam Janji<sup>707</sup>, Paulo Roberto Jannig<sup>1893</sup>, Patric J Jansson<sup>1933</sup>, Steve Jean<sup>1360</sup>, Marina Jendrach<sup>146</sup>,  
 Ju-Hong Jeon<sup>1056</sup>, Niels Jessen<sup>5</sup>, Eui-Bae Jeung<sup>191</sup>, Kailiang Jia<sup>321</sup>, Lijun Jia<sup>340</sup>, Hong Jiang<sup>1954</sup>, Hongchi Jiang<sup>1186</sup>,  
 Liwen Jiang<sup>186</sup>, Teng Jiang<sup>801</sup>, Xiaoyan Jiang<sup>1493</sup>, Xuejun Jiang<sup>177</sup>, Xuejun Jiang<sup>782</sup>, Ying Jiang<sup>111,898</sup>, Yongjun Jiang<sup>335,452</sup>,  
 Alberto Jiménez<sup>1296</sup>, Cheng Jin<sup>177</sup>, Hongchuan Jin<sup>2126</sup>, Lei Jin<sup>1786</sup>, Meiyang Jin<sup>1745,1749</sup>, Shengkan Jin<sup>1020</sup>,  
 Umesh Kumar Jinwal<sup>1918</sup>, Eun-Kyeong Jo<sup>194</sup>, Terje Johansen<sup>1989</sup>, Daniel E Johnson<sup>1843</sup>, Gail VW Johnson<sup>1872</sup>,  
 James D Johnson<sup>1487</sup>, Eric Jonasch<sup>1956</sup>, Chris Jones<sup>525</sup>, Leo AB Joosten<sup>991</sup>, Joaquin Jordan<sup>1282</sup>, Anna-Maria Joseph<sup>1623</sup>,  
 Bertrand Joseph<sup>631</sup>, Annie M Joubert<sup>1866</sup>, Dianwen Ju<sup>341</sup>, Jingfang Ju<sup>1140</sup>, Hsueh-Fen Juan<sup>864</sup>, Katrin Juenemann<sup>1439</sup>,  
 Gábor Juhász<sup>296</sup>, Hye Seung Jung<sup>1058</sup>, Jae U Jung<sup>1922</sup>, Yong-Keun Jung<sup>1060</sup>, Heinz Jungbluth<sup>310,645,646</sup>,  
 Matthew J Justice<sup>477,857</sup>, Barry Jutten<sup>709</sup>, Nadeem O Kaakoush<sup>1784</sup>, Kai Kaarniranta<sup>1611</sup>, Allen Kaasik<sup>1937</sup>,  
 Tomohiro Kabuta<sup>837</sup>, Bertrand Kaeffer<sup>1268</sup>, Katarina Kagedal<sup>691</sup>, Alon Kahana<sup>1752</sup>, Shingo Kajimura<sup>1544</sup>, Or Kakhlon<sup>398</sup>,  
 Manjula Kalia<sup>1245</sup>, Dhan V Kalvakolanu<sup>1725</sup>, Yoshiaki Kamada<sup>831</sup>, Konstantinos Kambas<sup>257</sup>, Vitaliy O Kaminsky<sup>635</sup>,  
 Harm H Kampinga<sup>1454</sup>, Mustapha Kandouz<sup>2089</sup>, Chanhee Kang<sup>415,449</sup>, Rui Kang<sup>1848</sup>, Tae-Cheon Kang<sup>399</sup>,  
 Tomotake Kanki<sup>903</sup>, Thirumala-Devi Kanneganti<sup>1120</sup>, Haruo Kanno<sup>1227</sup>, Anumantha G Kanthasamy<sup>549</sup>, Marc Kantorow<sup>322</sup>,  
 Maria Kaparakis-Liaskos<sup>454</sup>, Orsolya Kapuy<sup>262</sup>, Vassiliki Karantza<sup>774</sup>, Md Razaul Karim<sup>1763</sup>, Parimal Karmakar<sup>581</sup>,  
 Arthur Kaser<sup>1546</sup>, Susmita Kaushik<sup>25</sup>, Thomas Kawula<sup>1796</sup>, A Murat Kaynar<sup>1854,1853</sup>, Po-Yuan Ke<sup>139</sup>, Zun-Ji Ke<sup>1087</sup>,  
 John H Kehrl<sup>846</sup>, Kate E Keller<sup>926</sup>, Jongsook Kim Kemper<sup>1663</sup>, Anne K Kenworthy<sup>2047</sup>, Oliver Kepp<sup>494</sup>, Andreas Kern<sup>753</sup>,  
 Santosh Kesari<sup>600</sup>, David Kessel<sup>2091</sup>, Robin Ketteler<sup>1396</sup>, Isis do Carmo Kettelhut<sup>1891</sup>, Bilal Khambu<sup>482</sup>,  
 Muzamil Majid Khan<sup>630</sup>, Vinoth KM Khandelwal<sup>2050</sup>, Sangeeta Khare<sup>2036</sup>, Juliann G Kiang<sup>1272</sup>, Amy A Kiger<sup>1529</sup>,  
 Akio Kihara<sup>437</sup>, Arianna L Kim<sup>218</sup>, Cheol Hyeon Kim<sup>654</sup>, Deok Ryong Kim<sup>396</sup>, Do-Hyung Kim<sup>1760</sup>, Eung Kweon Kim<sup>2116</sup>,  
 Hye Young Kim<sup>263</sup>, Hyung-Ryong Kim<sup>2103</sup>, Jae-Sung Kim<sup>1628</sup>, Jeong Hun Kim<sup>1054,1055</sup>, Jin Cheon Kim<sup>2000</sup>,  
 Jin Hyoung Kim<sup>1054,1055</sup>, Kwang Woon Kim<sup>2045</sup>, Michael D Kim<sup>1737</sup>, Moon-Moo Kim<sup>264</sup>, Peter K Kim<sup>1980</sup>,  
 Seong Who Kim<sup>1999</sup>, Soo-Youl Kim<sup>813</sup>, Yong-Sun Kim<sup>401</sup>, Yonghyun Kim<sup>1435</sup>, Adi Kimchi<sup>2098</sup>, Alec C Kimmelman<sup>416</sup>,  
 Tomonori Kimura<sup>1782</sup>, Jason S King<sup>1900</sup>, Karla Kirkegaard<sup>1128</sup>, Vladimir Kirkin<sup>773</sup>, Lorrie A Kirshenbaum<sup>1718</sup>, Shuji Kishi<sup>1199</sup>,  
 Yasuo Kitajima<sup>1223</sup>, Katsuhiko Kitamoto<sup>1973</sup>, Yasushi Kitaoka<sup>1125</sup>, Kaio Kitazato<sup>795</sup>, Rudolf A Kley<sup>1010</sup>,  
 Walter T Klimecki<sup>1447</sup>, Michael Klinkenberg<sup>379</sup>, Jochen Klucken<sup>1402</sup>, Helene Knævelsrud<sup>1357</sup>, Erwin Knecht<sup>131</sup>,  
 Laura Knuppertz<sup>384</sup>, Jiunn-Liang Ko<sup>195</sup>, Satoru Kobayashi<sup>892</sup>, Jan C Koch<sup>1424</sup>, Christelle Koechlin-Ramonatxo<sup>1768</sup>,  
 Ulrich Koenig<sup>2101</sup>, Young Ho Koh<sup>402</sup>, Katja Köhler<sup>305</sup>, Sepp D Kohlwein<sup>1643</sup>, Masato Koike<sup>611</sup>, Masaaki Komatsu<sup>904</sup>,  
 Eiki Kominami<sup>617</sup>, Dexin Kong<sup>1219</sup>, Hee Jeong Kong<sup>825</sup>, Eumorphia G Konstantakou<sup>1452</sup>, Benjamin T Kopp<sup>883</sup>,  
 Tamas Korcsmaros<sup>1191</sup>, Laura Korhonen<sup>432</sup>, Viktor I Korolchuk<sup>900</sup>, Nadya V Koshkina<sup>1956</sup>, Yanjun Kou<sup>1172</sup>,  
 Michael I Koukourakis<sup>259</sup>, Constantinos Koumenis<sup>1831</sup>, Attila L Kovács<sup>296</sup>, Tibor Kovács<sup>298</sup>, Werner J Kovacs<sup>302</sup>,  
 Daisuke Koya<sup>622</sup>, Claudine Kraft<sup>2011</sup>, Dimitri Krainc<sup>914</sup>, Helmut Kramer<sup>1967</sup>, Tamara Kravic-Stevovic<sup>1467</sup>, Wilhelm Krek<sup>304</sup>,  
 Carole Kretz-Remy<sup>213,1347</sup>, Roswitha Krick<sup>356</sup>, Malathi Krishnamurthy<sup>1975</sup>, Janos Kriston-Vizi<sup>1396</sup>,  
 Guido Kroemer<sup>394,443,504,1370</sup>, Michael C Kruer<sup>1445</sup>, Rejko Kruger<sup>1709</sup>, Nicholas T Ktistakis<sup>51</sup>, Kazuyuki Kuchitsu<sup>1239</sup>,  
 Christian Kuhn<sup>1681</sup>, Addanki Pratap Kumar<sup>1949</sup>, Anuj Kumar<sup>1745</sup>, Ashok Kumar<sup>1707</sup>, Deepak Kumar<sup>1970</sup>, Dhiraj Kumar<sup>548</sup>,  
 Rakesh Kumar<sup>327</sup>, Sharad Kumar<sup>1905</sup>, Mondira Kundu<sup>1121</sup>, Hsing-Jien Kung<sup>826,1507</sup>, Atsushi Kuno<sup>1044</sup>, Sheng-Han Kuo<sup>216</sup>,  
 Jeff Kuret<sup>919</sup>, Tino Kurz<sup>692</sup>, Terry Kwok<sup>779,780</sup>, Taeg Kyu Kwon<sup>638</sup>, Yong Tae Kwon<sup>1063</sup>, Irene Kyrnizi<sup>1601</sup>,  
 Albert R La Spada<sup>1032,1528</sup>, Frank Lafont<sup>515</sup>, Tim Lahm<sup>483</sup>, Aparna Lakkaraju<sup>2021</sup>, Truong Lam<sup>1962</sup>, Trond Lamark<sup>1988</sup>,  
 Steve Lancel<sup>1415</sup>, Terry H Landowski<sup>1444</sup>, Darius JR Lane<sup>1933</sup>, Jon D Lane<sup>1483</sup>, Cinzia Lanzi<sup>324</sup>, Pierre Lapaquette<sup>1334</sup>,  
 Louis R Lapierre<sup>91</sup>, Jocelyn Laporte<sup>501</sup>, Johanna Laukkarinen<sup>1158</sup>, Gordon W Laurie<sup>2013</sup>, Sergio Lavandero<sup>1285,1966</sup>,  
 Lena Lavie<sup>1161</sup>, Matthew J LaVoie<sup>84</sup>, Betty Yuen Kwan Law<sup>711</sup>, Helen Ka-wai Law<sup>440</sup>, Kelsey B Law<sup>1980</sup>, Robert Layfield<sup>1799</sup>,  
 Pedro A Lazo<sup>234,535</sup>, Laurent Le Cam<sup>463,498,512</sup>, Karine G Le Roch<sup>1519</sup>, Hervé Le Stunff<sup>1377,1380</sup>, Vijitra Leardkamolkarn<sup>715</sup>,  
 Marc Lecuit<sup>518</sup>, Byung-Hoon Lee<sup>1059</sup>, Che-Hsin Lee<sup>158</sup>, Erinna F Lee<sup>679,681,682</sup>, Gyun Min Lee<sup>620</sup>, He-Jin Lee<sup>653</sup>,  
 Hsinyu Lee<sup>863</sup>, Jae Keun Lee<sup>656</sup>, Jongdae Lee<sup>1521</sup>, Ju-hyun Lee<sup>897</sup>, Jun Hee Lee<sup>1744</sup>, Michael Lee<sup>472</sup>, Myung-Shik Lee<sup>1150</sup>,  
 Patty J Lee<sup>2111</sup>, Sam W Lee<sup>722</sup>, Seung-Jae Lee<sup>1057</sup>, Shiow-Ju Lee<sup>828</sup>, Stella Y Lee<sup>625</sup>, Sug Hyung Lee<sup>106</sup>, Sung Sik Lee<sup>303,307</sup>,  
 Sung-Joon Lee<sup>655</sup>, Sunhee Lee<sup>266</sup>, Ying-Ray Lee<sup>149</sup>, Yong J Lee<sup>1849</sup>, Young H Lee<sup>847</sup>, Christiaan Leeuwenburgh<sup>1629</sup>,  
 Sylvain Lefort<sup>88</sup>, Renaud Legouis<sup>1380</sup>, Jinzhi Lei<sup>1252</sup>, Qun-Ying Lei<sup>337</sup>, David A Leib<sup>346</sup>, Gil Leibowitz<sup>397</sup>, Istvan Lekli<sup>1604</sup>,  
 Stéphane D Lemaire<sup>126</sup>, John J Lemasters<sup>766</sup>, Marius K Lemberg<sup>1645</sup>, Antoinette Lemoine<sup>445</sup>, Shuilong Leng<sup>389</sup>,  
 Guido Lenz<sup>1303</sup>, Paola Lenzi<sup>1840</sup>, Lilach O Lerman<sup>734</sup>, Daniele Lettieri Barbato<sup>1876</sup>, Julia I-Ju Leu<sup>965</sup>, Hing Y Leung<sup>1637,1638</sup>,  
 Beth Levine<sup>450,1942</sup>, Patrick A Lewis<sup>1261,1871</sup>, Frank Lezoualc'h<sup>2032</sup>, Chi Li<sup>1706</sup>, Faqiang Li<sup>2019</sup>, Feng-Jun Li<sup>877</sup>, Jun Li<sup>2046</sup>,  
 Ke Li<sup>161</sup>, Lian Li<sup>290</sup>, Min Li<sup>439</sup>, Min Li<sup>1144</sup>, Qiang Li<sup>166</sup>, Rui Li<sup>740</sup>, Sheng Li<sup>173</sup>, Wei Li<sup>95</sup>, Wei Li<sup>178</sup>, Xiaotao Li<sup>278</sup>, Yumin Li<sup>1047</sup>,

Jiqin Lian<sup>1207</sup>, Chengyu Liang<sup>1922</sup>, Qiangrong Liang<sup>892</sup>, Yulin Liao<sup>1114</sup>, Joana Liberal<sup>1576</sup>, Pawel P Liberski<sup>760</sup>, Pearl Lie<sup>111</sup>, Andrew P Lieberman<sup>1740</sup>, Hyunjung Jade Lim<sup>651</sup>, Kah-Leong Lim<sup>859,880</sup>, Kyu Lim<sup>192</sup>, Raquel T Lima<sup>1862,1864,1865</sup>, Chang-Shen Lin<sup>627,862</sup>, Chiou-Feng Lin<sup>1155</sup>, Fang Lin<sup>1106</sup>, Fangming Lin<sup>219</sup>, Fu-Cheng Lin<sup>2127</sup>, Kui Lin<sup>351</sup>, Kwang-Huei Lin<sup>140</sup>, Pei-Hui Lin<sup>921</sup>, Tianwei Lin<sup>2105</sup>, Wan-Wan Lin<sup>866</sup>, Yee-Shin Lin<sup>818</sup>, Yong Lin<sup>703</sup>, Rafael Linden<sup>1265</sup>, Dan Lindholm<sup>1647</sup>, Lisa M Lindqvist<sup>1733</sup>, Paul Lingor<sup>1642</sup>, Andreas Linkermann<sup>189</sup>, Lance A Liotta<sup>357</sup>, Marta M Lipinski<sup>1723</sup>, Vitor A Lira<sup>1668</sup>, Michael P Lisanti<sup>1712</sup>, Paloma B Liton<sup>268</sup>, Bo Liu<sup>1094</sup>, Chong Liu<sup>1049</sup>, Chun-Feng Liu<sup>1103</sup>, Fei Liu<sup>1753</sup>, Hung-Jen Liu<sup>823</sup>, Jianxun Liu<sup>154</sup>, Jing-Jing Liu<sup>1531</sup>, Jing-Lan Liu<sup>136</sup>, Ke Liu<sup>1093</sup>, Leyuan Liu<sup>1176</sup>, Liang Liu<sup>711</sup>, Quentin Liu<sup>250</sup>, Rong-Yu Liu<sup>1185</sup>, Shiming Liu<sup>1201</sup>, Shuwen Liu<sup>1115</sup>, Wei Liu<sup>2132</sup>, Xian-De Liu<sup>1952</sup>, Xiangguo Liu<sup>1068</sup>, Xiao-Hong Liu<sup>2127</sup>, Xinfeng Liu<sup>802</sup>, Xu Liu<sup>1745,1749</sup>, Xueqin Liu<sup>335,452</sup>, Yang Liu<sup>1942</sup>, Yule Liu<sup>1250</sup>, Zexian Liu<sup>453</sup>, Zhe Liu<sup>1218</sup>, Juan P Liuzzi<sup>323</sup>, Gérard Lizard<sup>1389</sup>, Mila Ljubic<sup>874</sup>, Irfan J Lodhi<sup>2086</sup>, Susan E Logue<sup>874</sup>, Bal L Lokeshwar<sup>365</sup>, Yun Chau Long<sup>881</sup>, Sagar Lonial<sup>295</sup>, Benjamin Loos<sup>1136</sup>, Carlos López-Otín<sup>1295</sup>, Cristina López-Vicario<sup>1457</sup>, Mar Lorente<sup>227</sup>, Philip L Lorenzi<sup>1951,1957</sup>, Péter Lőrincz<sup>296</sup>, Marek Los<sup>690</sup>, Michael T Lotze<sup>1850</sup>, Penny E Lovat<sup>901</sup>, Binfeng Lu<sup>1855</sup>, Bo Lu<sup>1211</sup>, Jiahong Lu<sup>1710</sup>, Qing Lu<sup>39</sup>, She-Min Lu<sup>2107</sup>, Shuyan Lu<sup>967</sup>, Yingying Lu<sup>203</sup>, Frédéric Luciano<sup>489</sup>, Shirley Luckhart<sup>1508</sup>, John Milton Lucocq<sup>1928</sup>, Paula Ludovico<sup>1757,1759</sup>, Aurelia Lugea<sup>110</sup>, Nicholas W Lukacs<sup>1740</sup>, Julian J Lum<sup>1246</sup>, Anders H Lund<sup>1596</sup>, Honglin Luo<sup>1489</sup>, Jia Luo<sup>1676</sup>, Shouqing Luo<sup>968</sup>, Claudio Luparello<sup>1826</sup>, Timothy Lyons<sup>989</sup>, Jianjie Ma<sup>921</sup>, Yi Ma<sup>1075</sup>, Yong Ma<sup>1186</sup>, Zhenyi Ma<sup>1217</sup>, Juliano Machado<sup>1891</sup>, Glaucia M Machado-Santelli<sup>1890</sup>, Fernando Macian<sup>29</sup>, Gustavo C MacIntosh<sup>551</sup>, Jeffrey P MacKeigan<sup>2043</sup>, Kay F Macleod<sup>1565</sup>, John D MacMicking<sup>2110</sup>, Lee Ann MacMillan-Crow<sup>1450</sup>, Frank Madeo<sup>1643</sup>, Muniswamy Madesh<sup>1174</sup>, Julio Madrigal-Matute<sup>25</sup>, Akiko Maeda<sup>100</sup>, Tatsuya Maeda<sup>1974</sup>, Gustavo Maegawa<sup>1626</sup>, Emilia Maellaro<sup>1902</sup>, Hannelore Maes<sup>664</sup>, Marta Magariños<sup>1278</sup>, Kenneth Maiese<sup>1732</sup>, Tapas K Maiti<sup>476</sup>, Luigi Maiuri<sup>2062</sup>, Maria Chiara Maiuri<sup>1270</sup>, Carl G Maki<sup>1012</sup>, Roland Malli<sup>759</sup>, Walter Malorni<sup>576,1030</sup>, Alina Maloyan<sup>927</sup>, Fathia Mami-Chouaib<sup>395</sup>, Na Man<sup>1738,1894</sup>, Joseph D Mancias<sup>417</sup>, Eva-Maria Mandelkow<sup>276</sup>, Michael A Mandell<sup>1782</sup>, Angelo A Manfredi<sup>2064</sup>, Serge N Manié<sup>1269</sup>, Claudia Manzoni<sup>1262,1870</sup>, Kai Mao<sup>723</sup>, Zixu Mao<sup>289</sup>, Zong-Wan Mao<sup>1146</sup>, Philippe Marambaud<sup>1184</sup>, Anna Maria Marconi<sup>1755</sup>, Zvonimir Marelja<sup>949</sup>, Gabriella Marfe<sup>1050</sup>, Marta Margeta<sup>1543</sup>, Eva Margittai<sup>1053</sup>, Muriel Mari<sup>1420</sup>, Francesca V Mariani<sup>1923</sup>, Concepcio Marin<sup>563</sup>, Sara Marinelli<sup>209</sup>, Guillermo Mariño<sup>1818</sup>, Ivanka Markovic<sup>1468</sup>, Rebecca Marquez<sup>1673</sup>, Alberto M Martelli<sup>1477</sup>, Sascha Martens<sup>2011</sup>, Katie R Martin<sup>2043</sup>, Seamus J Martin<sup>1247</sup>, Shaun Martin<sup>662</sup>, Miguel A Martin-Acebes<sup>130</sup>, Paloma Martín-Sanz<sup>536</sup>, Camille Martinand-Mari<sup>1770</sup>, Wim Martinet<sup>1443</sup>, Jennifer Martinez<sup>1414</sup>, Nuria Martinez-Lopez<sup>32</sup>, Ubaldo Martinez-Outschoorn<sup>1215</sup>, Moisés Martínez-Velázquez<sup>132</sup>, Marta Martinez-Vicente<sup>2041</sup>, Waleska Kerllen Martins<sup>1037</sup>, Hirosato Mashima<sup>20</sup>, James A Mastrianni<sup>1564</sup>, Giuseppe Matarese<sup>562,1321</sup>, Paola Matarrese<sup>575</sup>, Roberto Mateo<sup>1128</sup>, Satoaki Matoba<sup>669</sup>, Naomichi Matsumoto<sup>2114</sup>, Takehiko Matsushita<sup>648</sup>, Akira Matsuura<sup>150</sup>, Takeshi Matsuzawa<sup>929</sup>, Mark P Mattson<sup>839</sup>, Soledad Matus<sup>890,1539,1568</sup>, Norma Maugeri<sup>2061</sup>, Caroline Mauvezin<sup>1761</sup>, Andreas Mayer<sup>1686</sup>, Dusica Maysinger<sup>741</sup>, Guillermo D Mazzolini<sup>49</sup>, Mary Kate McBrayer<sup>111</sup>, Kimberly McCall<sup>80</sup>, Craig McCormick<sup>244</sup>, Gerald M McInerney<sup>633</sup>, Skye C McIver<sup>2022</sup>, Sharon McKenna<sup>1392</sup>, John J McMahon<sup>267</sup>, Iain A McNeish<sup>1638</sup>, Fatima Mechta-Grigoriou<sup>496</sup>, Jan Paul Medema<sup>1438</sup>, Diego L Medina<sup>1171</sup>, Klara Megyeri<sup>1934</sup>, Maryam Mehrpour<sup>1375</sup>, Jawahar L Mehta<sup>1448</sup>, Yide Mei<sup>1895</sup>, Ute-Christiane Meier<sup>985</sup>, Alfred J Meijer<sup>1440</sup>, Alicia Meléndez<sup>204</sup>, Gerry Melino<sup>793,1881</sup>, Sonia Melino<sup>1878</sup>, Edesio Jose Tenorio de Melo<sup>1312</sup>, Maria A Mena<sup>447</sup>, Marc D Meneghini<sup>1978</sup>, Javier A Menendez<sup>378</sup>, Regina Menezes<sup>457,540</sup>, Liesu Meng<sup>2107</sup>, Ling-hua Meng<sup>1070</sup>, Songshu Meng<sup>247</sup>, Rossella Menghini<sup>1883</sup>, A Sue Menko<sup>1214</sup>, Rubem FS Menna-Barreto<sup>547</sup>, Manoj B Menon<sup>407</sup>, Marco A Meraz-Ríos<sup>113</sup>, Giuseppe Merla<sup>552</sup>, Luciano Merlini<sup>571</sup>, Angelica M Merlot<sup>1933</sup>, Andreas Meryk<sup>1665</sup>, Stefania Meschini<sup>578</sup>, Joel N Meyer<sup>272</sup>, Man-tian Mi<sup>1210</sup>, Chao-Yu Miao<sup>1049</sup>, Lucia Micale<sup>552</sup>, Simon Michaeli<sup>72</sup>, Carine Michiels<sup>1773</sup>, Anna Rita Migliaccio<sup>783</sup>, Anastasia Susie Mihailidou<sup>1006,1931</sup>, Dalibor Mijaljica<sup>778</sup>, Katsuhiko Mikoshiba<sup>998</sup>, Enrico Milan<sup>1323,2064</sup>, Leonor Miller-Fleming<sup>1550</sup>, Gordon B Mills<sup>1955</sup>, Ian G Mills<sup>943,1808,1811</sup>, Georgia Minakaki<sup>1402</sup>, Berge A Minassian<sup>1193</sup>, Xiu-Fen Ming<sup>1632</sup>, Farida Minibayeva<sup>1013</sup>, Elena A Minina<sup>1141</sup>, Justine D Mintern<sup>71</sup>, Saverio Minucci<sup>1754</sup>, Antonio Miranda-Vizuete<sup>1298</sup>, Claire H Mitchell<sup>1834</sup>, Shigeki Miyamoto<sup>1527</sup>, Keisuke Miyazawa<sup>1237</sup>, Noboru Mizushima<sup>1972</sup>, Katarzyna Mnich<sup>874</sup>, Baharia Mograbi<sup>490</sup>, Simin Mohseni<sup>691</sup>, Luis Ferreira Moita<sup>541</sup>, Marco Molinari<sup>557</sup>, Maurizio Molinari<sup>280,281</sup>, Andreas Buch Møller<sup>7</sup>, Bertrand Mollereau<sup>1350</sup>, Faustino Mollinedo<sup>233</sup>, Marco Mongillo<sup>1825</sup>, Martha M Monick<sup>1670</sup>, Serena Montagnaro<sup>1775</sup>, Craig Montell<sup>889,1545</sup>, Darren J Moore<sup>2042</sup>, Michael N Moore<sup>1616</sup>, Rodrigo Mora-Rodriguez<sup>1290</sup>, Paula I Moreira<sup>1575</sup>, Etienne Morel<sup>1375</sup>, Maria Beatrice Morelli<sup>1043</sup>, Sandra Moreno<sup>2034</sup>, Michael J Morgan<sup>1594</sup>, Arnaud Moris<sup>1111</sup>, Yuji Moriyasu<sup>1026</sup>, Janna L Morrison<sup>1906</sup>, Lynda A Morrison<sup>1024</sup>, Eugenia Morselli<sup>972</sup>, Jorge Moscat<sup>1031</sup>, Pope L Moseley<sup>1780</sup>, Serge Mostowy<sup>471</sup>, Elisa Motori<sup>727</sup>, Denis Mottet<sup>1695</sup>, Jeremy C Mottram<sup>2025</sup>, Charbel E-H Moussa<sup>360</sup>, Vassiliki E Mpakou<sup>1453</sup>, Hasan Mukhtar<sup>2018</sup>, Jean M Mulcahy Levy<sup>1589</sup>, Sylviane Muller<sup>211</sup>, Raquel Muñoz-Moreno<sup>544</sup>, Cristina Muñoz-Pinedo<sup>64</sup>, Christian Münz<sup>2030</sup>, Maureen E Murphy<sup>1206</sup>, James T Murray<sup>1248</sup>, Aditya Murthy<sup>348</sup>, Indira U Mysorekar<sup>2085</sup>, Ivan R Nabi<sup>1487</sup>, Massimo Nabissi<sup>1555</sup>, Gustavo A Nader<sup>634</sup>, Yukitoshi Nagahara<sup>1231</sup>, Yoshitaka Nagai<sup>815</sup>, Kazuhiro Nagata<sup>671</sup>, Anika Nagelkerke<sup>993</sup>, Péter Nagy<sup>296</sup>, Samisubbu R Naidu<sup>479</sup>, Sreejayan Nair<sup>2024</sup>, Hiroyasu Nakano<sup>1220</sup>, Hitoshi Nakatogawa<sup>1233</sup>, Meera Nanjundan<sup>1915</sup>, Gennaro Napolitano<sup>1171</sup>, Naweed I Naqvi<sup>1172</sup>, Roberta Nardacci<sup>832</sup>, Derek P Narendra<sup>420</sup>, Masashi Narita<sup>1549</sup>, Anna Chiara Nascimbeni<sup>1375</sup>, Ramesh Natarajan<sup>2053</sup>,

Luiz C Navegantes<sup>1892</sup>, Steffan T Nawrocki<sup>1946</sup>, Taras Y Nazarko<sup>1530</sup>, Volodymyr Y Nazarko<sup>1661</sup>, Thomas Neill<sup>1213</sup>,  
 Luca M Neri<sup>1619</sup>, Mihai G Netea<sup>991</sup>, Romana T Netea-Maier<sup>990</sup>, Bruno M Neves<sup>1456</sup>, Paul A Ney<sup>891</sup>, Ioannis P Nezis<sup>2014</sup>,  
 Hang TT Nguyen<sup>1340</sup>, Huu Phuc Nguyen<sup>1991</sup>, Anne-Sophie Nicot<sup>501</sup>, Hilde Nilsen<sup>19,1809</sup>, Per Nilsson<sup>632,684</sup>,  
 Mikio Nishimura<sup>830</sup>, Ichizo Nishino<sup>816</sup>, Mireia Niso-Santano<sup>1291</sup>, Hua Niu<sup>1104</sup>, Ralph A Nixon<sup>899</sup>, Vincent CO Njar<sup>1724</sup>,  
 Takeshi Noda<sup>935</sup>, Angelika A Noegel<sup>1583</sup>, Elsie Magdalena Nolte<sup>1866</sup>, Erik Norberg<sup>634</sup>, Koenraad K Norga<sup>1442</sup>,  
 Sakineh Kazemi Noureini<sup>1689</sup>, Shoji Notomi<sup>421</sup>, Lucia Notterpek<sup>1622</sup>, Karin Nowikovsky<sup>769</sup>, Nobuyuki Nukina<sup>613</sup>,  
 Thorsten Nürnberger<sup>1990</sup>, Valerie B O'Donnell<sup>99</sup>, Tracey O'Donovan<sup>1392</sup>, Peter J O'Dwyer<sup>1832</sup>, Ina Oehme<sup>372</sup>,  
 Clara L Oeste<sup>230</sup>, Michinaga Ogawa<sup>836</sup>, Besim Ogretmen<sup>763</sup>, Yuji Ogura<sup>1126</sup>, Young J Oh<sup>2115</sup>, Masaki Ohmuraya<sup>666</sup>,  
 Takayuki Ohshima<sup>1229</sup>, Rani Ojha<sup>974</sup>, Koji Okamoto<sup>936</sup>, Toshiro Okazaki<sup>621</sup>, F Javier Oliver<sup>539</sup>, Karin Ollinger<sup>691</sup>,  
 Stefan Olsson<sup>1598</sup>, Daniel P Orban<sup>1745,1749</sup>, Paulina Ordonez<sup>1525</sup>, Idil Orhon<sup>1375</sup>, Laszlo Orosz<sup>1934</sup>, Eyleen J O'Rourke<sup>1969</sup>,  
 Helena Orozco<sup>2005,2006</sup>, Angel L Ortega<sup>2008</sup>, Elena Ortona<sup>572</sup>, Laura D Osellame<sup>778</sup>, Junko Oshima<sup>2015</sup>,  
 Shigeru Oshima<sup>1235</sup>, Heinz D Osiewacz<sup>384</sup>, Takanobu Otomo<sup>932</sup>, Kinya Otsu<sup>644</sup>, Jing-hsiung James Ou<sup>1922</sup>,  
 Tiago F Outeiro<sup>1422</sup>, Dong-yun Ouyang<sup>595</sup>, Hongjiao Ouyang<sup>1852</sup>, Michael Overholtzer<sup>772</sup>, Michelle A Ozbun<sup>1779</sup>,  
 P Hande Ozdinler<sup>912</sup>, Bulent Ozpolat<sup>1273</sup>, Consiglia Pacelli<sup>1355</sup>, Paolo Paganetti<sup>683</sup>, Guylène Page<sup>1861</sup>, Gilles Pages<sup>492</sup>,  
 Ugo Pagnini<sup>1775</sup>, Beata Pajak<sup>782,2074</sup>, Stephen C Pak<sup>1857</sup>, Karolina Pakos-Zebrucka<sup>874</sup>, Nazy Pakpour<sup>1508</sup>,  
 Zdena Palková<sup>148</sup>, Francesca Palladino<sup>1367</sup>, Kathrin Pallaur<sup>1683</sup>, Nicolas Pallet<sup>495</sup>, Marta Palmieri<sup>2009</sup>, Søren R Paludan<sup>4</sup>,  
 Camilla Palumbo<sup>1879</sup>, Silvia Palumbo<sup>1829</sup>, Olatz Pampliega<sup>26</sup>, Hongming Pan<sup>2134</sup>, Wei Pan<sup>870</sup>, Theocharis Panaretakis<sup>631</sup>,  
 Aseem Pandey<sup>1180,1182</sup>, Areti Pantazopoulou<sup>133</sup>, Zuzana Papackova<sup>519</sup>, Daniela L Papademetrio<sup>1280</sup>,  
 Issidora Papassideri<sup>811</sup>, Alessio Papini<sup>1620</sup>, Nirmala Parajuli<sup>1450</sup>, Julian Pardo<sup>1302</sup>, Vrajesh V Parekh<sup>2049</sup>,  
 Giancarlo Parenti<sup>316</sup>, Jong-In Park<sup>754</sup>, Junsoo Park<sup>2119</sup>, Ohkmae K Park<sup>658</sup>, Roy Parker<sup>1590</sup>, Rosanna Parlato<sup>1646,1998</sup>,  
 Jan B Parys<sup>665</sup>, Katherine R Parzych<sup>1745,1749</sup>, Jean-Max Pasquet<sup>1332</sup>, Benoit Pasquier<sup>1036</sup>, Kishore BS Pasumarthi<sup>246</sup>,  
 Daniel Patschan<sup>1407</sup>, Cam Patterson<sup>902</sup>, Sophie Pattingre<sup>565,1352</sup>, Scott Pattison<sup>1911</sup>, Arnim Pause<sup>742</sup>,  
 Hermann Pavenstädt<sup>1406</sup>, Flaminia Pavone<sup>209</sup>, Zully Pedrozo<sup>1567</sup>, Fernando J Peña<sup>1618</sup>, Miguel A Peñalva<sup>133</sup>,  
 Mario Pende<sup>1372</sup>, Jianxin Peng<sup>114</sup>, Fabio Penna<sup>1993</sup>, Josef M Penninger<sup>530</sup>, Anna Pensalfini<sup>111</sup>, Salvatore Pepe<sup>1736</sup>,  
 Gustavo JS Pereira<sup>314</sup>, Paulo C Pereira<sup>1580</sup>, Verónica Pérez-de la Cruz<sup>545</sup>, María Esther Pérez-Pérez<sup>1300</sup>,  
 Diego Pérez-Rodríguez<sup>1292</sup>, Dolores Pérez-Sala<sup>230</sup>, Celine Perier<sup>2040</sup>, Andras Perl<sup>1134</sup>, David H Perlmutter<sup>1851</sup>,  
 Ida Perrotta<sup>1499</sup>, Shazib Pervaiz<sup>241,873,880</sup>, Maija Pesonen<sup>1610</sup>, Jeffrey E Pessin<sup>32</sup>, Godefridus J Peters<sup>2065</sup>,  
 Morten Petersen<sup>1597</sup>, Irina Petrache<sup>857</sup>, Basil J Petrof<sup>743</sup>, Goran Petrovski<sup>937,1810,1935</sup>, James M Phang<sup>885</sup>,  
 Mauro Piacentini<sup>1876</sup>, Marina Pierdominici<sup>572</sup>, Philippe Pierre<sup>16,212,506,1455</sup>, Valérie Pierrefite-Carle<sup>1369</sup>,  
 Federico Pietrocola<sup>299,393,508,1374</sup>, Felipe X Pimentel-Muñoz<sup>1297</sup>, Mario Pinar<sup>133</sup>, Benjamin Pineda<sup>546</sup>,  
 Ronit Pinkas-Kramarski<sup>1167</sup>, Marcello Pinti<sup>1765</sup>, Paolo Pinton<sup>1619</sup>, Bilal Piperdi<sup>34</sup>, James M Piret<sup>1494</sup>,  
 Leonidas C Platanias<sup>584,915</sup>, Harald W Platta<sup>1007</sup>, Edward D Plowey<sup>1130</sup>, Stefanie Pöggeler<sup>354</sup>, Marc Poirot<sup>1984</sup>,  
 Peter Polčič<sup>225</sup>, Angelo Poletti<sup>1317</sup>, Audrey H Poon<sup>745</sup>, Hana Popelka<sup>1749</sup>, Blagovesta Popova<sup>353</sup>, Izabela Poprawa<sup>1903</sup>,  
 Shibu M Poulouse<sup>2037</sup>, Joanna Poulton<sup>1821</sup>, Scott K Powers<sup>1625</sup>, Ted Powers<sup>1509</sup>, Mercedes Pozuelo-Rubio<sup>127</sup>,  
 Krisna Prak<sup>1396</sup>, Reinhild Prange<sup>599</sup>, Mark Prescott<sup>778</sup>, Muriel Priault<sup>1330</sup>, Sharon Prince<sup>1559</sup>, Richard L Proia<sup>854</sup>,  
 Tassula Proikas-Cezanne<sup>279</sup>, Holger Prokisch<sup>1159</sup>, Vasilis J Promponas<sup>1602</sup>, Karin Przyklenk<sup>2088</sup>, Rosa Puertollano<sup>842</sup>,  
 Subbiah Pugazhenthil<sup>1591</sup>, Luigi Puglielli<sup>2020</sup>, Aurora Pujol<sup>65,198,464</sup>, Julien Puyal<sup>1400,1687</sup>, Dohun Pyeon<sup>1593</sup>, Xin Qi<sup>102</sup>,  
 Wen-bin Qian<sup>2128</sup>, Zheng-Hong Qin<sup>1107</sup>, Yu Qiu<sup>1122</sup>, Ziwei Qu<sup>1172</sup>, Joe Quadrilatero<sup>2017</sup>, Frederick Quinn<sup>1636</sup>,  
 Nina Raben<sup>853</sup>, Hannah Rabinowich<sup>1847</sup>, Flavia Radogna<sup>444</sup>, Michael J Ragusa<sup>255</sup>, Mohamed Rahmani<sup>2058</sup>,  
 Komal Raina<sup>1587</sup>, Sasanka Ramanadham<sup>1430</sup>, Rajagopal Ramesh<sup>1803</sup>, Abdelhaq Rami<sup>1391</sup>, Sarron Randall-Demllo<sup>1938</sup>,  
 Felix Randow<sup>791,1552</sup>, Hai Rao<sup>1947</sup>, V Ashutosh Rao<sup>1256</sup>, Blake B Rasmussen<sup>1959</sup>, Tobias M Rasse<sup>426</sup>, Edward A Ratovitski<sup>602</sup>,  
 Pierre-Emmanuel Rautou<sup>442,509,948,1373</sup>, Swapan K Ray<sup>1908</sup>, Babak Razani<sup>2081,2084</sup>, Bruce H Reed<sup>2016</sup>, Fulvio Reggiori<sup>1420</sup>,  
 Markus Rehm<sup>1004</sup>, Andreas S Reichert<sup>1329</sup>, Theo Rein<sup>731</sup>, David J Reiner<sup>1181</sup>, Eric Reits<sup>13</sup>, Jun Ren<sup>2024</sup>, Xingcong Ren<sup>960</sup>,  
 Maurizio Renna<sup>1551</sup>, Jane EB Reusch<sup>260,1592</sup>, Jose L Revuelta<sup>1316</sup>, Leticia Reyes<sup>2023</sup>, Alireza R Rezaie<sup>1124</sup>,  
 Robert I Richards<sup>1429</sup>, Des R Richardson<sup>1933</sup>, Clémence Richetta<sup>1111</sup>, Michael A Riehle<sup>1446</sup>, Bertrand H Rihn<sup>699</sup>,  
 Yasuko Rikihisa<sup>922</sup>, Brigit E Riley<sup>1035</sup>, Gerald Rimbach<sup>1683</sup>, Maria Rita Rippo<sup>1322</sup>, Konstantinos Ritis<sup>257</sup>, Federica Rizzi<sup>1827</sup>,  
 Elizete Rizzo<sup>1313</sup>, Peter J Roach<sup>478</sup>, Jeffrey Robbins<sup>1573</sup>, Michel Roberge<sup>1485</sup>, Gabriela Roca<sup>1162</sup>,  
 Maria Carmela Roccheri<sup>1826</sup>, Sonia Rocha<sup>1607</sup>, Cecilia MP Rodrigues<sup>1307</sup>, Clara I Rodríguez<sup>236</sup>,  
 Santiago Rodriguez de Cordoba<sup>261</sup>, Natalia Rodriguez-Muela<sup>133</sup>, Jeroen Roelofs<sup>625</sup>, Vladimir V Rogov<sup>380</sup>, Troy T Rohn<sup>78</sup>,  
 Bärbel Rohrer<sup>765</sup>, Davide Romanelli<sup>1666</sup>, Luigina Romani<sup>1839</sup>, Patricia Silvia Romano<sup>1304</sup>, M Isabel G Roncero<sup>1289</sup>,  
 Jose Luis Rosa<sup>1327</sup>, Alicia Rosello<sup>977</sup>, Kirill V Rosen<sup>243,245</sup>, Philip Rosenstiel<sup>1682</sup>, Magdalena Rost-Roszkowska<sup>1903</sup>,  
 Kevin A Roth<sup>1432</sup>, Gael Roué<sup>510</sup>, Mustapha Rouis<sup>2033</sup>, Kasper M Rouschop<sup>709</sup>, Daniel T Ruan<sup>69</sup>, Diego Ruano<sup>1299</sup>,  
 David C Rubinsztein<sup>1547</sup>, Edmund B Rucker III<sup>1677</sup>, Assaf Rudich<sup>66</sup>, Emil Rudolf<sup>147</sup>, Ruediger Rudolf<sup>719</sup>,  
 Markus A Ruegg<sup>1462</sup>, Carmen Ruiz-Roldan<sup>1289</sup>, Avnika Ashok Ruparelia<sup>781</sup>, Paola Rusmini<sup>1317</sup>, David W Russ<sup>925</sup>,  
 Gian Luigi Russo<sup>861</sup>, Giuseppe Russo<sup>1173</sup>, Rossella Russo<sup>1501</sup>, Tor Erik Rusten<sup>941,1805</sup>, Victoria Ryabovol<sup>523</sup>,  
 Kevin M Ryan<sup>1637</sup>, Stefan W Ryter<sup>2094</sup>, David M Sabatini<sup>2102</sup>, Michael Sacher<sup>229,737</sup>, Carsten Sachse<sup>309</sup>, Michael N Sack<sup>841</sup>,  
 Junichi Sadoshima<sup>1014</sup>, Paul Saftig<sup>188</sup>, Ronit Sagi-Eisenberg<sup>1169</sup>, Sumit Sahni<sup>1933</sup>, Pothana Saikumar<sup>1948</sup>,  
 Tsunenori Saito<sup>906</sup>, Tatsuya Saitoh<sup>1230</sup>, Koichi Sakakura<sup>390</sup>, Machiko Sakoh-Nakatogawa<sup>1232</sup>, Yasuhito Sakuraba<sup>1062</sup>,  
 María Salazar-Roa<sup>1117</sup>, Paolo Salomoni<sup>1259</sup>, Ashok K Saluja<sup>1764</sup>, Paul M Salvaterra<sup>59</sup>, Rosa Salvioli<sup>573</sup>, Afshin Samali<sup>874</sup>,

Anthony MJ Sanchez<sup>1838</sup>, José A Sánchez-Alcázar<sup>1305</sup>, Ricardo Sanchez-Prieto<sup>1283</sup>, Marco Sandri<sup>1825</sup>, Miguel A Sanjuan<sup>770</sup>,  
 Stefano Santaguida<sup>726</sup>, Laura Santambrogio<sup>33</sup>, Giorgio Santoni<sup>1556</sup>, Claudia Nunes dos Santos<sup>457,540</sup>, Shweta Saran<sup>583</sup>,  
 Marco Sardiello<sup>55</sup>, Graeme Sargent<sup>1980</sup>, Pallabi Sarkar<sup>111</sup>, Sovan Sarkar<sup>1475</sup>, Maria Rosa Sarrias<sup>424</sup>, Minnie M Sarwal<sup>1541</sup>,  
 Chihiro Sasakawa<sup>151</sup>, Motoko Sasaki<sup>623</sup>, Miklos Sass<sup>296</sup>, Ken Sato<sup>392</sup>, Miyuki Sato<sup>391</sup>, Joseph Satriano<sup>1522</sup>,  
 Niramol Savaraj<sup>775</sup>, Svetlana Saveljeva<sup>94</sup>, Liliana Schaefer<sup>382</sup>, Ulrich E Schaible<sup>995</sup>, Michael Scharl<sup>1411</sup>,  
 Hermann M Schatzl<sup>1504</sup>, Randy Schekman<sup>1506</sup>, Wiep Scheper<sup>2069,2070,2071</sup>, Alfonso Schiavi<sup>579,1877</sup>,  
 Hyman M Schipper<sup>586,746</sup>, Hana Schmeisser<sup>849</sup>, Jens Schmidt<sup>1421</sup>, Ingo Schmitz<sup>431,945</sup>, Bianca E Schneider<sup>995</sup>,  
 E Marion Schneider<sup>1410</sup>, Jaime L Schneider<sup>26</sup>, Eric A Schon<sup>218</sup>, Miriam J Schönenberger<sup>2031</sup>, Axel H Schönthal<sup>1921</sup>,  
 Daniel F Schorderet<sup>566,1688</sup>, Bernd Schröder<sup>188</sup>, Sebastian Schuck<sup>427</sup>, Ryan J Schulze<sup>732</sup>, Melanie Schwarten<sup>326</sup>,  
 Thomas L Schwarz<sup>79</sup>, Sebastiano Sciarretta<sup>553,1014,1875</sup>, Kathleen Scotto<sup>1021</sup>, A Ivana Scovassi<sup>531</sup>, Robert A Screaton<sup>1151</sup>,  
 Mark Screen<sup>433</sup>, Hugo Seca<sup>1862,1863,1865</sup>, Simon Sedej<sup>758</sup>, Laura Segatori<sup>996,997</sup>, Nava Segev<sup>1661</sup>, Per O Seglen<sup>1806</sup>,  
 Jose M Seguí-Simarro<sup>1328</sup>, Juan Segura-Aguilar<sup>1569</sup>, Iban Seiliez<sup>488</sup>, Ekihiro Seki<sup>109</sup>, Christian Sell<sup>265</sup>,  
 Clay F Semenkovich<sup>2080</sup>, Gregg L Semenza<sup>605</sup>, Utpal Sen<sup>1705</sup>, Andreas L Serra<sup>2029</sup>, Ana Serrano-Puebla<sup>133</sup>,  
 Hiromi Sesaki<sup>602</sup>, Takao Setoguchi<sup>619</sup>, Carmine Settembre<sup>274</sup>, John J Shacka<sup>1432</sup>, Ayesha N Shajahan-Haq<sup>695</sup>,  
 Irving M Shapiro<sup>1216</sup>, Shweta Sharma<sup>1719</sup>, Hua She<sup>290</sup>, C-K James Shen<sup>11</sup>, Chiung-Chyi Shen<sup>455</sup>, Han-Ming Shen<sup>880</sup>,  
 Sanbing Shen<sup>876</sup>, Weili Shen<sup>1080</sup>, Rui Sheng<sup>1105</sup>, Xianyong Sheng<sup>96</sup>, Zu-Hang Sheng<sup>905</sup>, Trevor G Shepherd<sup>2100</sup>,  
 Junyan Shi<sup>1127,1490</sup>, Qiang Shi<sup>2035</sup>, Qinghua Shi<sup>1896</sup>, Yuguang Shi<sup>958</sup>, Shusaku Shibutani<sup>2112</sup>, Kenichi Shibuya<sup>807</sup>,  
 Yoshihiro Shidoji<sup>1772</sup>, Jeng-Jer Shieh<sup>824</sup>, Chwen-Ming Shih<sup>1154</sup>, Yohta Shimada<sup>592</sup>, Shigeomi Shimizu<sup>1236</sup>,  
 Dong Wook Shin<sup>40</sup>, Mari L Shinohara<sup>269</sup>, Michiko Shintani<sup>647</sup>, Takahiro Shintani<sup>1226</sup>, Tetsuo Shioi<sup>674</sup>, Ken Shirabe<sup>678</sup>,  
 Ronit Shiri-Sverdlov<sup>710</sup>, Orian Shirihai<sup>81</sup>, Gordon C Shore<sup>738</sup>, Chih-Wen Shu<sup>629</sup>, Deepak Shukla<sup>1660</sup>,  
 Andriy A Sibirny<sup>810,1885</sup>, Valentina Sica<sup>299,393,508,1374</sup>, Christina J Sigurdson<sup>1523</sup>, Einar M Sigurdsson<sup>895</sup>,  
 Puran Singh Sijwali<sup>238</sup>, Beata Sikorska<sup>760</sup>, Wilian A Silveira<sup>1892</sup>, Sandrine Silvente-Poirot<sup>1984</sup>, Gary A Silverman<sup>1857</sup>,  
 Jan Simak<sup>1255</sup>, Thomas Simmet<sup>1266</sup>, Anna Katharina Simon<sup>790</sup>, Hans-Uwe Simon<sup>1474</sup>, Cristiano Simone<sup>1461</sup>,  
 Matias Simons<sup>949</sup>, Anne Simonsen<sup>1812</sup>, Rajat Singh<sup>24</sup>, Shivendra V Singh<sup>1842</sup>, Shrawan K Singh<sup>974</sup>, Debasish Sinha<sup>607</sup>,  
 Sangita Sinha<sup>907</sup>, Frank A Sinicropo<sup>735</sup>, Agnieszka Sirko<sup>969</sup>, Kapil Sirohi<sup>122</sup>, Balindiwe JN Sishi<sup>1136</sup>, Annie Sittler<sup>1110</sup>,  
 Parco M Siu<sup>440</sup>, Efthimios Sivridis<sup>258</sup>, Anna Skwarska<sup>344</sup>, Ruth Slack<sup>1816</sup>, Iva Slaninová<sup>720</sup>, Nikolai Slavov<sup>909</sup>,  
 Soraya S Smalli<sup>314</sup>, Keiran SM Smalley<sup>776</sup>, Duncan R Smith<sup>717</sup>, Stefaan J Soenen<sup>663</sup>, Scott A Soleimanpour<sup>1739</sup>,  
 Anita Solhaug<sup>916</sup>, Kumaravel Somasundaram<sup>474</sup>, Jin H Son<sup>311</sup>, Avinash Sonawane<sup>466</sup>, Chunjuan Song<sup>42</sup>, Fuyong Song<sup>1066</sup>,  
 Hyun Kyu Song<sup>658</sup>, Ju-Xian Song<sup>439</sup>, Wei Song<sup>585</sup>, Kai Y Soo<sup>680</sup>, Anil K Sood<sup>750,752</sup>, Tuck Wah Soong<sup>879</sup>,  
 Virawudh Soontornniyomkij<sup>1534</sup>, Maurizio Sorice<sup>1042</sup>, Federica Sotgia<sup>1714</sup>, David R Soto-Pantoja<sup>2072</sup>,  
 Areechun Sotthibundhu<sup>716</sup>, Maria João Sousa<sup>1758</sup>, Herman P Spaink<sup>688</sup>, Paul N Span<sup>992</sup>, Anne Spang<sup>1463</sup>,  
 Janet D Sparks<sup>1873</sup>, Peter G Speck<sup>320</sup>, Stephen A Spector<sup>1524</sup>, Claudia D Spies<sup>145</sup>, Wolfdieter Springer<sup>733</sup>, Daret St Clair<sup>1680</sup>,  
 Alessandra Stacchiotti<sup>83</sup>, Bart Staels<sup>1696</sup>, Michael T Stang<sup>1859</sup>, Daniel T Starczynowski<sup>201</sup>, Petro Starokadomskyy<sup>1966</sup>,  
 Clemens Steegborn<sup>1465</sup>, John W Steele<sup>1520</sup>, Leonidas Stefanis<sup>74</sup>, Joan Steffan<sup>1515</sup>, Christine M Stellrecht<sup>1273</sup>,  
 Harald Stenmark<sup>940</sup>, Tomasz M Stepkowski<sup>533</sup>, Stephan T Stern<sup>689</sup>, Craig Stevens<sup>282</sup>, Brent R Stockwell<sup>220,221</sup>,  
 Veronika Stoka<sup>580</sup>, Zuzana Storchova<sup>728</sup>, Björn Stork<sup>430</sup>, Vassilis Stratoulis<sup>1648</sup>, Dimitrios J Stravopodis<sup>811,1452</sup>,  
 Pavel Strnad<sup>1399</sup>, Anne Marie Strohecker<sup>924</sup>, Anna-Lena Ström<sup>1138</sup>, Per Stromhaug<sup>70</sup>, Jiri Stulik<sup>532</sup>, Yu-Xiong Su<sup>1651</sup>,  
 Zhaoliang Su<sup>589</sup>, Carlos S Subauste<sup>103</sup>, Srinivasa Subramaniam<sup>1200</sup>, Carolyn M Sue<sup>1932</sup>, Sang Won Suh<sup>403</sup>, Xinbing Sui<sup>2134</sup>,  
 Supawadee Sukserree<sup>768</sup>, David Sulzer<sup>216</sup>, Fang-Lin Sun<sup>1242</sup>, Jiaren Sun<sup>1958</sup>, Jun Sun<sup>1662</sup>, Shi-Yong Sun<sup>293</sup>, Yang Sun<sup>804</sup>,  
 Yi Sun<sup>1748</sup>, Yingjie Sun<sup>1088</sup>, Vinod Sundaramoorthy<sup>713</sup>, Joseph Sung<sup>183</sup>, Hidekazu Suzuki<sup>641</sup>, Kuninori Suzuki<sup>1971</sup>,  
 Naoki Suzuki<sup>1222</sup>, Tadashi Suzuki<sup>999</sup>, Yuichiro J Suzuki<sup>362</sup>, Michele S Swanson<sup>1743</sup>, Charles Swanton<sup>698</sup>, Karl Swärd<sup>705</sup>,  
 Ghanshyam Swarup<sup>122</sup>, Sean T Sweeney<sup>2026</sup>, Paul W Sylvester<sup>1701</sup>, Zsuzsanna Szatmari<sup>296</sup>, Eva Szegezdi<sup>874</sup>,  
 Peter W Szlosarek<sup>984</sup>, Heinrich Taegtmeier<sup>1962</sup>, Marco Tafani<sup>1042</sup>, Emmanuel Taillebourg<sup>1364</sup>, Stephen WG Tait<sup>1637</sup>,  
 Krisztina Takacs-Vellai<sup>297</sup>, Yoshinori Takahashi<sup>963</sup>, Szabolcs Takáts<sup>296</sup>, Genzou Takemura<sup>43</sup>, Nagio Takigawa<sup>636</sup>,  
 Nicholas J Talbot<sup>1617</sup>, Elena Tamagno<sup>1994</sup>, Jerome Tamburini<sup>1371</sup>, Cai-Ping Tan<sup>1146</sup>, Lan Tan<sup>981</sup>, Mei Lan Tan<sup>718,1385</sup>,  
 Ming Tan<sup>1904</sup>, Yee-Joo Tan<sup>1882</sup>, Keiji Tanaka<sup>1238</sup>, Masaki Tanaka<sup>668</sup>, Daolin Tang<sup>1848</sup>, Dingzhong Tang<sup>179</sup>, Guomei Tang<sup>216</sup>,  
 Isei Tanida<sup>615</sup>, Kunikazu Tanji<sup>435</sup>, Bakhos A Tannous<sup>724</sup>, Jose A Tapia<sup>1618</sup>, Inmaculada Tasset-Cuevas<sup>26</sup>, Marc Tatar<sup>90</sup>,  
 Iman Tavassoly<sup>785</sup>, Nektarios Tavernarakis<sup>328,1599,1600</sup>, Allen Taylor<sup>1253</sup>, Graham S Taylor<sup>1476</sup>, Gregory A Taylor<sup>269,270,271,275</sup>,  
 J Paul Taylor<sup>1119</sup>, Mark J Taylor<sup>694</sup>, Elena V Tchetina<sup>809</sup>, Andrew R Tee<sup>97</sup>, Fatima Teixeira-Clerc<sup>500,1379</sup>, Sucheta Telang<sup>1703</sup>,  
 Tewin Tencomnao<sup>190</sup>, Ba-Bie Teng<sup>1943</sup>, Ru-Jeng Teng<sup>755</sup>, Faraj Terro<sup>1697</sup>, Gianluca Tettamanti<sup>1666</sup>, Arianne L Theiss<sup>56</sup>,  
 Anne E Theron<sup>1866</sup>, Kelly Jean Thomas<sup>215</sup>, Marcos P Thomé<sup>1303</sup>, Paul G Thomes<sup>1776</sup>, Andrew Thorburn<sup>1594</sup>,  
 Jeremy Thorner<sup>1505</sup>, Thomas Thum<sup>408</sup>, Michael Thumm<sup>356</sup>, Teresa LM Thurston<sup>468</sup>, Ling Tian<sup>173</sup>, Andreas Till<sup>1481,1532</sup>,  
 Jenny Pan-yun Ting<sup>1793,1795</sup>, Vladimir I Titorenko<sup>228</sup>, Lilach Toker<sup>1491</sup>, Stefano Toldo<sup>2057</sup>, Sharon A Tooze<sup>697</sup>,  
 Ivan Topisirovic<sup>587,746</sup>, Maria Lyngaas Torgersen<sup>938,1195,1807</sup>, Liliana Torosantucci<sup>240</sup>, Alicia Torriglia<sup>494</sup>,  
 Maria Rosaria Torrisi<sup>1041</sup>, Cathy Tournier<sup>1713</sup>, Roberto Towns<sup>1741</sup>, Vladimir Trajkovic<sup>1469</sup>, Leonardo H Travasso<sup>313</sup>,  
 Gemma Triola<sup>522</sup>, Durga Nand Tripathi<sup>1177</sup>, Daniela Trisciuglio<sup>994</sup>, Rodrigo Troncoso<sup>1284,1288</sup>, Ioannis P Trougakos<sup>1452</sup>,  
 Anita C Truttman<sup>1400</sup>, Kuen-Jer Tsai<sup>820</sup>, Mario P Tschan<sup>1471</sup>, Yi-Hsin Tseng<sup>140</sup>, Takayuki Tsukuba<sup>796</sup>, Allan Tsung<sup>1844</sup>,  
 Andrey S Tsvetkov<sup>1961</sup>, Shuiping Tu<sup>1085</sup>, Hsing-Yu Tuan<sup>871</sup>, Marco Tucci<sup>1460</sup>, David A Tumbarello<sup>1920</sup>, Boris Turk<sup>580</sup>,  
 Vito Turk<sup>580</sup>, Robin FB Turner<sup>1495</sup>, Anders A Tveita<sup>939</sup>, Suresh C Tyagi<sup>1708</sup>, Makoto Ubukata<sup>438</sup>, Yasuo Uchiyama<sup>615</sup>,



Andrej Udelnow<sup>944</sup>, Takashi Ueno<sup>614</sup>, Midori Umekawa<sup>1001</sup>, Rika Umemiya-Shirafuji<sup>917</sup>, Benjamin R Underwood<sup>60</sup>,  
 Christian Ungermann<sup>1815</sup>, Rodrigo P. Ureshino<sup>314</sup>, Ryo Ushioda<sup>672</sup>, Vladimir N Uversky<sup>1916</sup>, Néstor L Uzcátegui<sup>117</sup>,  
 Thomas Vaccari<sup>465</sup>, Maria I Vaccaro<sup>1498</sup>, Libuše Váchová<sup>529</sup>, Helin Vakifahmetoglu-Norberg<sup>634</sup>, Rut Valdor<sup>1771</sup>,  
 Enza Maria Valente<sup>1889</sup>, Francois Vallette<sup>1358</sup>, Angela M Valverde<sup>537</sup>, Greet Van den Berghe<sup>660</sup>, Ludo Van Den Bosch<sup>659</sup>,  
 Gijs R van den Brink<sup>12</sup>, F Gisou van der Goot<sup>281</sup>, Ida J van der Klei<sup>1644</sup>, Luc JW van der Laan<sup>300</sup>, Wouter G van Doorn<sup>1512</sup>,  
 Marjolein van Egmond<sup>2066</sup>, Kenneth L van Golen<sup>1192,1605,1606</sup>, Luc Van Kaer<sup>2048</sup>, Menno van Lookeren Campagne<sup>349</sup>,  
 Peter Vandenabeele<sup>377</sup>, Wim Vandenberghé<sup>1413,1693</sup>, Ilse Vanhorebeek<sup>660</sup>, Isabel Varela-Nieto<sup>237</sup>,  
 M Helena Vasconcelos<sup>1862,1863,1865</sup>, Radovan Vasko<sup>355</sup>, Demetrios G Vavvas<sup>421</sup>, Ignacio Vega-Naredo<sup>1577</sup>,  
 Guillermo Velasco<sup>227</sup>, Athanassios D Velentzas<sup>1452</sup>, Panagiotis D Velentzas<sup>1729</sup>, Tibor Vellai<sup>298</sup>, Edo Vellenga<sup>1417</sup>,  
 Mikkel Holm Vendelbo<sup>3</sup>, Kartik Venkatachalam<sup>1950</sup>, Natascia Ventura<sup>428,579</sup>, Salvador Ventura<sup>1325</sup>, Patrícia ST Veras<sup>385</sup>,  
 Mireille Verdier<sup>1346</sup>, Beata G Vertessy<sup>92</sup>, Andrea Viale<sup>751</sup>, Michel Vidal<sup>1426</sup>, Helena LA Vieira<sup>1315</sup>, Richard D Vierstra<sup>2019</sup>,  
 Nadarajah Vigneswaran<sup>1945</sup>, Neeraj Vij<sup>115</sup>, Miquel Vila<sup>50,104,887</sup>, Margarita Villar<sup>1023</sup>, Victor H Villar<sup>499</sup>, Joan Villarroya<sup>26</sup>,  
 Cécile Vindis<sup>1985</sup>, Giampietro Viola<sup>1824</sup>, Maria Teresa Viscomi<sup>557</sup>, Giovanni Vitale<sup>1756</sup>, Dan T Vogl<sup>1832</sup>,  
 Olga V Voitsekhovskaja<sup>649</sup>, Clarissa von Haefen<sup>145</sup>, Karin von Schwarzenberg<sup>704</sup>, Daniel E Voth<sup>1449</sup>,  
 Valérie Vouret-Craviari<sup>1790</sup>, Kristina Vuori<sup>1034</sup>, Jatin M Vyas<sup>725</sup>, Christian Waeber<sup>1393</sup>, Cheryl Lyn Walker<sup>1176</sup>,  
 Mark J Walker<sup>1868</sup>, Jochen Walter<sup>1479</sup>, Lei Wan<sup>47,159</sup>, Xiangbo Wan<sup>1101</sup>, Bo Wang<sup>980</sup>, Caihong Wang<sup>2085</sup>,  
 Chao-Yung Wang<sup>137</sup>, Chengshu Wang<sup>171</sup>, Chenran Wang<sup>1572</sup>, Chuangui Wang<sup>277</sup>, Dong Wang<sup>410</sup>, Fen Wang<sup>1175</sup>,  
 Fuxin Wang<sup>170</sup>, Guanghui Wang<sup>1102</sup>, Hai-jie Wang<sup>1086</sup>, Haichao Wang<sup>908</sup>, Hong-Gang Wang<sup>959</sup>, Hongmin Wang<sup>1912</sup>,  
 Horng-Dar Wang<sup>872</sup>, Jing Wang<sup>1425</sup>, Junjun Wang<sup>155</sup>, Mei Wang<sup>273</sup>, Mei-Qing Wang<sup>330</sup>, Pei-Yu Wang<sup>868</sup>, Peng Wang<sup>339</sup>,  
 Richard C Wang<sup>1963</sup>, Shuo Wang<sup>165</sup>, Ting-Fang Wang<sup>11</sup>, Xian Wang<sup>1100</sup>, Xiao-jia Wang<sup>2122</sup>, Xiao-Wei Wang<sup>2129</sup>,  
 Xin Wang<sup>86</sup>, Xuejun Wang<sup>1913</sup>, Yan Wang<sup>1250</sup>, Yanming Wang<sup>964</sup>, Ying Wang<sup>63</sup>, Ying-Jan Wang<sup>821</sup>, Yipeng Wang<sup>276</sup>,  
 Yu Wang<sup>1650</sup>, Yu Tian Wang<sup>1488</sup>, Yuqing Wang<sup>1980</sup>, Zhi-Nong Wang<sup>144</sup>, Pablo Wappner<sup>543</sup>, Carl Ward<sup>1475</sup>,  
 Diane McVey Ward<sup>2004</sup>, Gary Warnes<sup>986</sup>, Hirotaka Watada<sup>612</sup>, Yoshihisa Watanabe<sup>670</sup>, Kei Watase<sup>1234</sup>,  
 Timothy E Weaver<sup>1571</sup>, Colin D Weekes<sup>1586</sup>, Jiwu Wei<sup>803</sup>, Thomas Weide<sup>1409</sup>, Conrad C Wehl<sup>2083</sup>, Günther Weindl<sup>334</sup>,  
 Simone Nardin Weis<sup>1306</sup>, Longping Wen<sup>1894</sup>, Xin Wen<sup>1745,1749</sup>, Yunfei Wen<sup>750,752</sup>, Benedikt Westermann<sup>1464</sup>,  
 Cornelia M Weyand<sup>1132</sup>, Anthony R White<sup>1734</sup>, Eileen White<sup>1019</sup>, J Lindsay Whitton<sup>1198</sup>, Alexander J Whitworth<sup>792</sup>,  
 Joëlle Wiels<sup>1384</sup>, Franziska Wild<sup>719</sup>, Manon E Wildenberg<sup>12</sup>, Tom Wileman<sup>1609</sup>, Deepti Srinivas Wilkinson<sup>1034</sup>,  
 Simon Wilkinson<sup>1614</sup>, Dieter Willbold<sup>326,429</sup>, Chris Williams<sup>75,1644</sup>, Katherine Williams<sup>2036</sup>, Peter R Williamson<sup>845</sup>,  
 Konstanze F Winkhofer<sup>1008</sup>, Steven S Witkin<sup>2092</sup>, Stephanie E Wohlgemuth<sup>1624</sup>, Thomas Wollert<sup>729</sup>,  
 Ernst J Wolvetang<sup>1869</sup>, Esther Wong<sup>806</sup>, G William Wong<sup>603</sup>, Richard W Wong<sup>624</sup>, Vincent Kam Wai Wong<sup>711</sup>,  
 Elizabeth A Woodcock<sup>53</sup>, Karen L Wright<sup>686</sup>, Chunlai Wu<sup>702</sup>, Defeng Wu<sup>462</sup>, Gen Sheng Wu<sup>2090</sup>, Jian Wu<sup>338</sup>,  
 Junfang Wu<sup>1722</sup>, Mian Wu<sup>1897</sup>, Min Wu<sup>1797</sup>, Shengzhou Wu<sup>2099</sup>, William KK Wu<sup>180</sup>, Yaohua Wu<sup>1187</sup>, Zhenlong Wu<sup>156</sup>,  
 Cristina PR Xavier<sup>1862,1865</sup>, Ramnik J Xavier<sup>413</sup>, Gui-Xian Xia<sup>170</sup>, Tian Xia<sup>1517</sup>, Weiliang Xia<sup>1073,1083</sup>, Yong Xia<sup>1202</sup>,  
 Hengyi Xiao<sup>1092</sup>, Jian Xiao<sup>1048</sup>, Shi Xiao<sup>1148</sup>, Wuhan Xiao<sup>169</sup>, Chuan-Ming Xie<sup>1747</sup>, Zhiping Xie<sup>1074</sup>, Zhonglin Xie<sup>1804</sup>,  
 Maria Xilouri<sup>73</sup>, Yuyan Xiong<sup>1632</sup>, Chuanshan Xu<sup>185</sup>, Congfeng Xu<sup>1081</sup>, Feng Xu<sup>342</sup>, Haoxing Xu<sup>1745</sup>, Hongwei Xu<sup>411</sup>,  
 Jian Xu<sup>1802</sup>, Jianzhen Xu<sup>1090</sup>, Jinxian Xu<sup>370,371</sup>, Liang Xu<sup>1673</sup>, Xiaolei Xu<sup>735</sup>, Yangqing Xu<sup>418</sup>, Ye Xu<sup>593</sup>, Zhi-Xiang Xu<sup>1431</sup>,  
 Ziheng Xu<sup>1745,1749</sup>, Yu Xue<sup>453</sup>, Takahiro Yamada<sup>436</sup>, Ai Yamamoto<sup>223</sup>, Koji Yamanaka<sup>798</sup>, Shunhei Yamashina<sup>616</sup>,  
 Shigeiko Yamashiro<sup>1016</sup>, Bing Yan<sup>1067</sup>, Bo Yan<sup>597</sup>, Xianghua Yan<sup>451</sup>, Zhen Yan<sup>2012</sup>, Yasuo Yanagi<sup>1099</sup>, Dun-Sheng Yang<sup>894</sup>,  
 Jin-Ming Yang<sup>961</sup>, Liu Yang<sup>1188</sup>, Minghua Yang<sup>116</sup>, Pei-Ming Yang<sup>1156</sup>, Peixin Yang<sup>1726</sup>, Qian Yang<sup>1190</sup>, Wannian Yang<sup>347</sup>,  
 Wei Yuan Yang<sup>9</sup>, Xuesong Yang<sup>596</sup>, Yi Yang<sup>405</sup>, Ying Yang<sup>1072</sup>, Zhifen Yang<sup>1129</sup>, Zhihong Yang<sup>1631</sup>, Meng-Chao Yao<sup>11</sup>,  
 Pamela J Yao<sup>851</sup>, Xiaofeng Yao<sup>248</sup>, Zhenyu Yao<sup>174</sup>, Zhiyuan Yao<sup>1745,1749</sup>, Linda S Yasui<sup>910</sup>, Mingxiang Ye<sup>329</sup>,  
 Barry Yedvobnick<sup>285</sup>, Behzad Yeganeh<sup>1979</sup>, Elizabeth S Yeh<sup>764</sup>, Patricia L Yeyati<sup>283</sup>, Fan Yi<sup>1069</sup>, Long Yi<sup>1210</sup>,  
 Xiao-Ming Yin<sup>482</sup>, Calvin K Yip<sup>1486</sup>, Yeong-Min Yoo<sup>2118</sup>, Young Hyun Yoo<sup>263</sup>, Seung-Yong Yoon<sup>2001</sup>, Ken-Ichi Yoshida<sup>771</sup>,  
 Tamotsu Yoshimori<sup>933</sup>, Ken H Young<sup>1953</sup>, Huixin Yu<sup>588</sup>, Jane J Yu<sup>85</sup>, Jin-Tai Yu<sup>981</sup>, Jun Yu<sup>182</sup>, Li Yu<sup>1251</sup>, W Haung Yu<sup>224</sup>,  
 Xiao-Fang Yu<sup>317</sup>, Zhengping Yu<sup>1209</sup>, Junying Yuan<sup>418</sup>, Zhi-Min Yuan<sup>423</sup>, Beatrice YJT Yue<sup>1657</sup>, Jianbo Yue<sup>203</sup>,  
 Zhenyu Yue<sup>461</sup>, David N Zacks<sup>1746</sup>, Eldad Zacksenhaus<sup>1243</sup>, Nadia Zaffaroni<sup>324</sup>, Tania Zaglia<sup>1825</sup>, Zahra Zakeri<sup>988</sup>,  
 Vincent Zecchini<sup>788</sup>, Jinsheng Zeng<sup>1143</sup>, Min Zeng<sup>1197</sup>, Qi Zeng<sup>1</sup>, Antonis S Zervos<sup>1561</sup>, Donna D Zhang<sup>1447</sup>,  
 Fan Zhang<sup>2044</sup>, Guo Zhang<sup>1196</sup>, Guo-Chang Zhang<sup>1664</sup>, Hao Zhang<sup>1089</sup>, Hong Zhang<sup>168</sup>, Hong Zhang<sup>952</sup>,  
 Hongbing Zhang<sup>160,951</sup>, Jian Zhang<sup>329</sup>, Jian Zhang<sup>331</sup>, Jiangwei Zhang<sup>1178</sup>, Jianhua Zhang<sup>1432</sup>, Jing-pu Zhang<sup>161</sup>,  
 Li Zhang<sup>588</sup>, Lin Zhang<sup>1837</sup>, Lin Zhang<sup>1858</sup>, Long Zhang<sup>2131</sup>, Ming-Yong Zhang<sup>175</sup>, Xiangnan Zhang<sup>339</sup>,  
 Xu Dong Zhang<sup>1785</sup>, Yan Zhang<sup>1065</sup>, Yang Zhang<sup>1654</sup>, Yanjin Zhang<sup>1720</sup>, Yingmei Zhang<sup>2024,2108</sup>, Yunjiao Zhang<sup>1894</sup>,  
 Mei Zhao<sup>2106</sup>, Wei-Li Zhao<sup>1082</sup>, Xiaonan Zhao<sup>1081</sup>, Yan G Zhao<sup>176</sup>, Ying Zhao<sup>956</sup>, Yongchao Zhao<sup>1748</sup>, Yu-xia Zhao<sup>980</sup>,  
 Zhendong Zhao<sup>162</sup>, Zhizhuang J Zhao<sup>1803</sup>, Dexian Zheng<sup>164</sup>, Xi-Long Zheng<sup>1503</sup>, Xiaoxiang Zheng<sup>2124</sup>,  
 Boris Zhivotovsky<sup>526,696</sup>, Qing Zhong<sup>1941,1942</sup>, Guang-Zhou Zhou<sup>434</sup>, Guofei Zhou<sup>1658</sup>, Huiping Zhou<sup>2055</sup>,  
 Shu-Feng Zhou<sup>1917</sup>, Xu-jie Zhou<sup>952,954,957</sup>, Hongxin Zhu<sup>1071</sup>, Hua Zhu<sup>921</sup>, Wei-Guo Zhu<sup>956</sup>, Wenhua Zhu<sup>2107</sup>,  
 Xiao-Feng Zhu<sup>1149</sup>, Yuhua Zhu<sup>155</sup>, Shi-Mei Zhuang<sup>1147</sup>, Xiaohong Zhuang<sup>186</sup>, Elio Ziparo<sup>1038</sup>, Christos E Zois<sup>947</sup>,  
 Teresa Zoladek<sup>969</sup>, Wei-Xing Zong<sup>1139</sup>, Antonio Zorzano<sup>196,521,1326</sup>, and Susu M Zughaier<sup>288</sup>

<sup>1</sup>A\*STAR (Agency for Science, Technology and Research), Institute of Molecular and Cell Biology, Singapore; <sup>2</sup>A. Mickiewicz University, Department of General Botany, Institute of Experimental Biology, Faculty of Biology, Poznań, Poland; <sup>3</sup>Aarhus University Hospital, Department of Nuclear Medicine and PET Center, Aarhus, Denmark; <sup>4</sup>Aarhus University, Department of Biomedicine, Aarhus, Denmark; <sup>5</sup>Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; <sup>6</sup>Aarhus University, Department of Molecular Biology and Genetics, Aarhus, Denmark; <sup>7</sup>Aarhus University, Medical Research Laboratory, Institute for Clinical Medicine, Aarhus, Denmark; <sup>8</sup>Alberystwyth University, Institute of Biological, Environmental and Rural Sciences, Penglais, Aberystwyth, Wales, UK; <sup>9</sup>Academia Sinica, Institute of Biological Chemistry, Taipei, Taiwan; <sup>10</sup>Academia Sinica, Institute of Biomedical Sciences, Taipei, Taiwan; <sup>11</sup>Academia Sinica, Institute of Molecular Biology, Taipei, Taiwan; <sup>12</sup>Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands; <sup>13</sup>Academic Medical Center, University of Amsterdam, Department of Cell Biology and Histology, Amsterdam, The Netherlands; <sup>14</sup>Aix Marseille Université, CNRS, IBDM, UMR 7288, Campus de Luminy, Marseille, France; <sup>15</sup>Aix-Marseille Université, CNRS UMR 7278, IRD198, INSERM U1095, Medicine Faculty, Marseille, France; <sup>16</sup>Aix-Marseille Université, U2M, Centre d'Immunologie de Marseille-Luminy, Marseille, France; <sup>17</sup>Ajou University, College of Pharmacy, Gyeonggi-do, Korea; <sup>18</sup>Ajou University, School of Medicine, Department of Microbiology, Gyeonggi-do, Korea; <sup>19</sup>Akershus University Hospital, Oslo, Norway; <sup>20</sup>Akita University, Graduate School of Medicine, Akita, Japan; <sup>21</sup>Al Jalila Foundation Research Centre, Dubai, UAE; <sup>22</sup>Albany Medical College, Center for Neuropharmacology and Neuroscience, Albany, NY, USA; <sup>23</sup>Albert Einstein Cancer Center, New York, NY, USA; <sup>24</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>25</sup>Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY, USA; <sup>26</sup>Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Institute for Aging Studies, Bronx, NY, USA; <sup>27</sup>Albert Einstein College of Medicine, Department of Medicine, Bronx, NY, USA; <sup>28</sup>Albert Einstein College of Medicine, Department of Molecular Pharmacology, Bronx, NY, USA; <sup>29</sup>Albert Einstein College of Medicine, Department of Pathology, Bronx, NY, USA; <sup>30</sup>Albert Einstein College of Medicine, Departments of Biochemistry and of Medicine, Bronx, NY, USA; <sup>31</sup>Albert Einstein College of Medicine, Departments of Medicine (Endocrinology) and Molecular Pharmacology, Bronx, NY, USA; <sup>32</sup>Albert Einstein College of Medicine, Departments of Medicine and Molecular Pharmacology, Bronx, NY, USA; <sup>33</sup>Albert Einstein College of Medicine, Departments of Pathology, Microbiology and Immunology, New York, NY, USA; <sup>34</sup>Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA; <sup>35</sup>Albert Ludwigs University, Renal Division, Freiburg, Germany; <sup>36</sup>All India Institute of Medical Sciences, Department of Anatomy, New Delhi, India; <sup>37</sup>All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India; <sup>38</sup>All India Institute of Medical Sciences, Department of Physiology, New Delhi, India; <sup>39</sup>Alpert Medical School of Brown University, Vascular Research Laboratory, Providence Veterans Affairs Medical Center, Department of Medicine, Providence, RI, USA; <sup>40</sup>Amorepacific Corporation RandD Center, Bioscience Research Institute, Gyeonggi, Korea; <sup>41</sup>Anhui University of Science and Technology, Department of Immunology and Medical Inspection, Huainan, Anhui, China; <sup>42</sup>Applied Genetic Technologies Corporation, Alachua, FL, USA; <sup>43</sup>Asahi University, Department of Internal Medicine, Gifu, Japan; <sup>44</sup>Asahi University, School of Dentistry, Department of Oral Microbiology, Division of Oral Infections and Health Sciences, Mizuho, Gifu, Japan; <sup>45</sup>Asahikawa Medical University, Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Hokkaido, Japan; <sup>46</sup>Asan Medical Center, Asan Institute for Life Sciences, Seoul, Korea; <sup>47</sup>Asia University, Department of Biotechnology, Taichung, Taiwan; <sup>48</sup>Atlanta Department of Veterans Affairs Medical Center, Decatur, GA; <sup>49</sup>Austral University-CONICET, Gene and Cell Therapy Laboratory, Pilar, Buenos Aires, Argentina; <sup>50</sup>Autonomous University of Barcelona (UAB), Department of Biochemistry and Molecular Biology, Barcelona, Spain; <sup>51</sup>Babraham Institute, Cambridge, UK; <sup>52</sup>Babraham Institute, Signalling Program, Cambridge, UK; <sup>53</sup>Baker IDI Heart and Diabetes Institute, Molecular Cardiology Laboratory, Melbourne, Australia; <sup>54</sup>Baylor College of Medicine, Department of Medicine, Houston, TX, USA; <sup>55</sup>Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, TX, USA; <sup>56</sup>Baylor University Medical Center, Department of Internal Medicine, Division of Gastroenterology, Baylor Research Institute, Dallas, TX; <sup>57</sup>Beatson Institute for Cancer Research, University of Glasgow, Glasgow, UK; <sup>58</sup>Beckman Research Institute, City of Hope, Department of Molecular Pharmacology, Duarte, CA, USA; <sup>59</sup>Beckman Research Institute, City of Hope, Department of Neuroscience, Irell and Manella Graduate School of Biological Science, Duarte, CA, USA; <sup>60</sup>Beechcroft, Fulbourn Hospital, Cambridge, UK; <sup>61</sup>Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China; <sup>62</sup>Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China; <sup>63</sup>Beijing Jishuitan Hospital, Department of Molecular Orthopedics, Beijing Institute of Traumatology and Orthopedics, Beijing, China; <sup>64</sup>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Cell Death Regulation Group, Barcelona, Spain; <sup>65</sup>Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, Barcelona, Spain; <sup>66</sup>Ben-Gurion University, Department of Clinical Biochemistry and the National Institute of Biotechnology in the Negev, Beer-Sheva, Israel; <sup>67</sup>Ben-Gurion University of the Negev and Mental Health Center, Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Beer-Sheva, Israel; <sup>68</sup>Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; <sup>69</sup>Beth Israel Deaconess Medical Center, Medical Genetics, Boston, MA, USA; <sup>70</sup>Binghamton University, State University of New York, Binghamton, NY, USA; <sup>71</sup>Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Molecular Biology, Parkville, Victoria, Australia; <sup>72</sup>Biochimie et Physiologie Moléculaire des Plantes, UMR5004 CNRS/INRA/UM2/SupAgro, Institut de Biologie Intégrative des Plantes, Montpellier, France; <sup>73</sup>Biomedical Research Foundation of the Academy of Athens, Center of Clinical, Experimental Surgery and Translational Research, Athens, Greece; <sup>74</sup>Biomedical Research Foundation of the Academy of Athens, Laboratory of Neurodegenerative Diseases, Athens, Attiki, Greece; <sup>75</sup>Biomolecular Sciences and Biotechnology Institute (GBB), Groningen, The Netherlands; <sup>76</sup>BIOSS Centre for Biological Signalling Studies, Freiburg, Germany; <sup>77</sup>Bogomoletz Institute of Physiology, National Academy of Sciences Ukraine, General and Molecular Pathophysiology Department, Kiev, Ukraine; <sup>78</sup>Boise State University, Department of Biological Sciences, Boise, ID, USA; <sup>79</sup>Boston Children's Hospital, F.M. Kirby Neuroscience Center, Boston, MA, USA; <sup>80</sup>Boston University, Department of Biology, Boston, MA, USA; <sup>81</sup>Boston University, Department of Medicine, Boston, MA, USA; <sup>82</sup>Brandeis University, Department of Biology, Waltham, MA, USA; <sup>83</sup>Brescia University, Department of Clinical and Experimental Sciences, Brescia, Italy; <sup>84</sup>Brigham and Women's Hospital, Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School, Boston, MA, USA; <sup>85</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>86</sup>Brigham and Women's Hospital, Harvard Medical School, Department of Neurosurgery, Boston, MA; <sup>87</sup>British Columbia Cancer Agency, Genome Sciences Centre, Vancouver, BC, Canada; <sup>88</sup>British Columbia Cancer Agency, Terry Fox Laboratory, Vancouver, BC, Canada; <sup>89</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>90</sup>Brown University, Department of Ecology and Evolutionary Biology, Providence, RI, USA; <sup>91</sup>Brown University, Department of Molecular Biology, Cell Biology and Biochemistry, Providence, RI, USA; <sup>92</sup>Budapest University of Technology and Economics, Institute of Enzymology, RCNC, HAS and Department of Applied Biotechnology, Budapest, Hungary; <sup>93</sup>C.S.I.C./U. A.M., Instituto de Investigaciones Biomédicas Alberto Sols, Madrid, Spain; <sup>94</sup>Cambridge University, Department of Medicine, Cambridge, UK; <sup>95</sup>Capital Medical University, Center for Medical Genetics, Beijing Children's Hospital, Beijing, China; <sup>96</sup>Capital Normal University, Beijing, China; <sup>97</sup>Cardiff University, Heath Park, Institute of Cancer and Genetics, Cardiff, Wales, UK; <sup>98</sup>Cardiff University, Institute of Cancer and Genetics, Cardiff, Wales, UK; <sup>99</sup>Cardiff University, Systems Immunity Research Institute, Cardiff, Wales, UK; <sup>100</sup>Case Western Reserve University, Department of Ophthalmology and Visual Sciences, Cleveland, OH, USA; <sup>101</sup>Case Western Reserve University, Molecular Biology and Microbiology, Cleveland, OH, USA; <sup>102</sup>Case Western Reserve University, School of Medicine, Department of Physiology and Biophysics, Cleveland, OH, USA; <sup>103</sup>Case Western Reserve University, School of Medicine, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Cleveland, OH, USA; <sup>104</sup>Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; <sup>105</sup>Catholic University of Korea, College of Pharmacy, Bucheon, Korea; <sup>106</sup>Catholic University of Korea, Seoul, Korea; <sup>107</sup>CEA/DSV/12/BM, INSERM U1169, Gene Therapy for Neurodegenerative Diseases, Fontenay-aux-Roses Cedex, France; <sup>108</sup>Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center, Los Angeles, CA, USA; <sup>109</sup>Cedars-Sinai Medical Center, Department of Medicine, Los Angeles, CA, USA;

<sup>110</sup>Cedars-Sinai Medical Center, VAGLAHS-UCLA, Pancreatic Research Group, Los Angeles, CA, USA; <sup>111</sup>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA; <sup>112</sup>Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; <sup>113</sup>Center of Investigation and Advanced Studies, Cinvestav-IPN, Mexico City, Mexico; <sup>114</sup>College of Science, Central China Normal University, Wuhan, China; <sup>115</sup>Central Michigan University, College of Medicine, Mt. Pleasant, MI, USA; <sup>116</sup>Central South University, Department of Pediatrics, Xiangya Hospital, Changsha, Hunan, China; <sup>117</sup>Central University of Venezuela, Institute for Anatomy, Caracas, Venezuela; <sup>118</sup>Centre Antoine Lacassagne, Nice, France; <sup>119</sup>Centre de Recherche du CHU de Québec, Faculty of Pharmacy, Québec, Canada; <sup>120</sup>Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université, Institut Paoli-Calmette, Parc Scientifique et Technologique de Luminy, Marseille, France; <sup>121</sup>Centre de Recherche en Cancérologie de Nantes-Angers, CNRS UMR6299, INSERM U892, Nantes, France; <sup>122</sup>Centre for Cellular and Molecular Biology, Council of Scientific and Industrial Research, Hyderabad, India; <sup>123</sup>Centre for Research in Agricultural Genomics (CSIC-IRTA-UAB-UB), Bellaterra, Catalonia, Spain; <sup>124</sup>UMR 1324 INRA, 6265 CNRS, Université de Bourgogne Franche-Comté, Centre des Sciences du Goût et de l'Alimentation, Dijon, France; <sup>125</sup>Centre National de la Recherche Scientifique, Institut de Biologie Moléculaire des Plantes, Unité Propre de Recherche, Strasbourg, France; <sup>126</sup>Centre National de la Recherche Scientifique, Sorbonne Universités UPMC Univ Paris 06, UMR 8226, Laboratoire de Biologie Moléculaire et Cellulaire des Eucaryotes, Institut de Biologie Physico-Chimique, Paris, France; <sup>127</sup>Centro Andaluz de Biología Molecular y Medicina Regenerativa, Consejo Superior de Investigaciones Científicas, Sevilla, Spain; <sup>128</sup>Centro de Biología Molecular "Severo Ochoa" (UAM/CSIC), Centro de Investigación Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; <sup>129</sup>Centro de Biología Molecular "Severo Ochoa" (UAM/CSIC), Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Department of Cell Biology and Immunology, Madrid, Spain; <sup>130</sup>Centro de Biología Molecular "Severo Ochoa" (UAM/CSIC), Department of Virology and Microbiology, Madrid, Spain; <sup>131</sup>Centro de Investigación Príncipe Felipe, Valencia, Spain; <sup>132</sup>Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, AC, Unidad de Biotecnología Médica y Farmacéutica, Guadalajara, Jalisco, México; <sup>133</sup>Centro de Investigaciones Biológicas (CSIC), Department of Cellular and Molecular Biology, Madrid, Spain; <sup>134</sup>Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Universidad Nacional de Córdoba, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Córdoba, Argentina; <sup>135</sup>Centro de Pesquisas Aggeu Magalhães/FIOCRUZ-PE, Departamento de Microbiologia, Recife, PE, Brazil; <sup>136</sup>Chang Gung Memorial Hospital, Department of Pathology, Chiayi, Taiwan; <sup>137</sup>Chang Gung University, Chang Gung Memorial Hospital, Department of Cardiology, Internal Medicine, Taoyuan, Taiwan; <sup>138</sup>Chang Gung University, College of Medicine, Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; <sup>139</sup>Chang Gung University, Department of Biochemistry and Molecular Biology and Graduate Institute of Biomedical Sciences, College of Medicine, Taoyuan County, Taiwan; <sup>140</sup>Chang Gung University, Department of Biochemistry, College of Medicine, Taoyuan, Taiwan; <sup>141</sup>Chang Gung University, Department of Biomedical Sciences, College of Medicine, Taoyuan, Taiwan; <sup>142</sup>Chang Gung University, Molecular Regulation and Bioinformatics Laboratory, Department of Parasitology, Taoyuan, Taiwan; <sup>143</sup>Chang Jung Christian University, Department of Bioscience Technology, Tainan, Taiwan; <sup>144</sup>Changzheng Hospital, The Second Military Medical University, Department of Cardiothoracic Surgery, Shanghai, China; <sup>145</sup>Charité - Universitätsmedizin Berlin, Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte, Berlin, Germany; <sup>146</sup>Charité - Universitätsmedizin Berlin, Department of Neuropathology, Campus Charité Mitte, Berlin, Germany; <sup>147</sup>Charles University in Prague, Faculty of Medicine in Hradec Kralove, Department of Medical Biology and Genetics, Hradec Kralove, Czech Republic; <sup>148</sup>Charles University in Prague, Faculty of Science, Department of Genetics and Microbiology, Prague, Czech Republic; <sup>149</sup>Ditmans Medical Foundation Chia-Yi Christian Hospital, Center for Translational Medicine, Chiayi City, Taiwan; <sup>150</sup>Chiba University, Department of Nanobiology, Chiba, Japan; <sup>151</sup>Chiba University, Medical Mycology Research Center, Chiba, Japan; <sup>152</sup>Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA, USA; <sup>153</sup>Children's Hospital, Department of Neurology, Boston, MA, USA; <sup>154</sup>China Academy of Chinese Medical Sciences, Institute of Basic Medical Sciences of Xiyuan Hospital, Beijing, China; <sup>155</sup>China Agricultural University, College of Animal Science and Technology, State Key Laboratory of Animal Nutrition, Beijing, China; <sup>156</sup>China Agricultural University, Department of Animal Nutrition and Feed Science, Beijing, China; <sup>157</sup>China Agricultural University, Department of Nutrition and Food Safety, Beijing, China; <sup>158</sup>China Medical University, Department of Microbiology, Taichung, Taiwan; <sup>159</sup>China Medical University, School of Chinese Medicine, Taichung, Taiwan; <sup>160</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Physiology, Institute of Basic Medical Sciences, Beijing, China; <sup>161</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Medicinal Biotechnology, Beijing, China; <sup>162</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Beijing, China; <sup>163</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Molecular Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Beijing, China; <sup>164</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Beijing, China; <sup>165</sup>Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Beijing, China; <sup>166</sup>Chinese Academy of Sciences, Division of Medical Physics, Institute of Modern Physics, Lanzhou, Gansu Province, China; <sup>167</sup>Chinese Academy of Sciences, Division of Physical Biology and Bioimaging Center, Shanghai Synchrotron Radiation Facility, Shanghai Institute of Applied Physics, Shanghai, China; <sup>168</sup>Chinese Academy of Sciences, Institute of Biophysics, State Key Laboratory of Biomacromolecules, Beijing, China; <sup>169</sup>Chinese Academy of Sciences, Institute of Hydrobiology, Wuhan, Hubei, China; <sup>170</sup>Chinese Academy of Sciences, Institute of Microbiology, Beijing, China; <sup>171</sup>Chinese Academy of Sciences, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Shanghai, China; <sup>172</sup>Chinese Academy of Sciences, Institute of Zoology, Beijing, China; <sup>173</sup>Chinese Academy of Sciences, Key Laboratory of Developmental and Evolutionary Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Shanghai, China; <sup>174</sup>Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Guangdong, China; <sup>175</sup>Chinese Academy of Sciences, South China Botanical Garden, Guangzhou, China; <sup>176</sup>Chinese Academy of Sciences, State Key Laboratory of Biomacromolecules, Institute of Biophysics, Beijing, China; <sup>177</sup>Chinese Academy of Sciences, State Key Laboratory of Mycology, Institute of Microbiology, Beijing, China; <sup>178</sup>Chinese Academy of Sciences, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Beijing, China; <sup>179</sup>Chinese Academy of Sciences, State Key Laboratory of Plant Cell and Chromosome Engineering, Institute of Genetics and Developmental Biology, Beijing, China; <sup>180</sup>Chinese University of Hong Kong, Department of Anaesthesia and Intensive Care, Hong Kong; <sup>181</sup>Chinese University of Hong Kong, Department of Anaesthesia and Intensive Care, Shatin, NT, Hong Kong; <sup>182</sup>Chinese University of Hong Kong, Institute of Digestive Diseases, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Hong Kong; <sup>183</sup>Chinese University of Hong Kong, Institute of Digestive Diseases, Shatin, Hong Kong; <sup>184</sup>Chinese University of Hong Kong, School of Biomedical Sciences, Faculty of Medicine, Shatin, NT, Hong Kong; <sup>185</sup>Chinese University of Hong Kong, School of Chinese Medicine, Faculty of Medicine, Shatin, NT, Hong Kong; <sup>186</sup>Chinese University of Hong Kong, School of Life Science, Centre for Cell and Developmental Biology and State Key Laboratory of Agrobiotechnology, Sha Tin, Hong Kong; <sup>187</sup>Chonbuk National University, Department of Pharmacology, Medical School, Chonbuk, Korea; <sup>188</sup>Christian Albrechts University, Institut für Biochemie, Kiel, Germany; <sup>189</sup>Christian-Albrechts-University of Kiel, Department of Nephrology and Hypertension, Kiel, Germany; <sup>190</sup>Chulalongkorn University, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Bangkok, Thailand; <sup>191</sup>Chungbuk National University, College of Veterinary Medicine, Cheongju, Chungbuk, Korea; <sup>192</sup>Chungnam National University, School of Medicine, Department of Biochemistry, Infection Signaling Network Research Center, Cancer Research Institute, Daejeon, Korea; <sup>193</sup>Chungnam National University, School of Medicine, Department of Pharmacology, Daejeon, Korea; <sup>194</sup>Chungnam National University, School of Medicine, Infection Signaling Network Research Center, Daejeon, Korea; <sup>195</sup>Chung-Shan Medical University, Institute of Medicine, Taichung, Taiwan; <sup>196</sup>CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain; <sup>197</sup>CIBER de Enfermedades Raras (CIBERER), Valencia, Spain; <sup>198</sup>CIBERER Spanish Network for Rare Diseases, Madrid,

Spain; <sup>199</sup>CIBERNED, ISCIII, Unidad Asociada Neurodeath, Madrid, Spain; <sup>200</sup>Cincinnati Children's Hospital Medical Center, Division of Clinical Pharmacology, Cincinnati, OH, USA; <sup>201</sup>Cincinnati Children's Hospital Medical Center, Division of Experimental Hematology and Cancer Biology, Cincinnati, OH, USA; <sup>202</sup>Cincinnati Children's Hospital Medical Center, Division of Oncology, Cincinnati, OH, USA; <sup>203</sup>City University of Hong Kong, Department of Biomedical Sciences, Kowloon Tong, Hong Kong, China; <sup>204</sup>City University of New York, Department of Biology, Queens College and The Graduate Center, Flushing, NY, USA; <sup>205</sup>Cleveland Clinic, Cleveland, OH, USA; <sup>206</sup>Cleveland Clinic, Department of Cancer Biology, Cleveland, OH, USA; <sup>207</sup>Cleveland Clinic, Department of Cellular and Molecular Medicine, Cleveland, OH, USA; <sup>208</sup>Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA; <sup>209</sup>CNR, Institute of Cell Biology and Neurobiology and IRCCS Santa Lucia Foundation, Rome, Italy; <sup>210</sup>CNRS UM, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé, Montpellier, France; <sup>211</sup>CNRS, Immunopathology and Therapeutic Chemistry, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France; <sup>212</sup>CNRS, UMR 7280, Marseille, France; <sup>213</sup>CNRS, UMR 5534, Villeurbanne, France; <sup>214</sup>Colonia Ciudad Universitaria, Neurodevelopment and Physiology Department, Neuroscience Division, Instituto de Fisiología Celular, UNAM, Mexico, DF, Mexico; <sup>215</sup>Colorado Mesa University, Department of Biological Sciences, Grand Junction, CO, USA; <sup>216</sup>Columbia University Medical Center, Department of Neurology, New York, NY, USA; <sup>217</sup>Columbia University Medical Center, Department of Pathology and Cell Biology, New York, NY, USA; <sup>218</sup>Columbia University Medical Center, New York, NY, USA; <sup>219</sup>Columbia University, College of Physicians and Surgeons, Department of Pediatrics, New York, NY, USA; <sup>220</sup>Columbia University, Department of Biological Sciences, New York, NY, USA; <sup>221</sup>Columbia University, Department of Chemistry, New York, NY, USA; <sup>222</sup>Columbia University, Department of Medicine, New York, NY, USA; <sup>223</sup>Columbia University, Department of Neurology, New York, NY, USA; <sup>224</sup>Columbia University, Taub Institute for Alzheimer's Disease Research, Department of Pathology and Cell Biology, New York, NY, USA; <sup>225</sup>Comenius University in Bratislava, Department of Biochemistry, Faculty of Natural Sciences, Bratislava, Slovak Republic; <sup>226</sup>Complejo Hospitalario Universitario de Albacete, Unidad de Neuropsicofarmacología, Albacete, Spain; <sup>227</sup>Complutense University, Instituto de Investigaciones Sanitarias San Carlos (IdISSC), Department of Biochemistry and Molecular Biology I, School of Biology, Madrid, Spain; <sup>228</sup>Concordia University, Biology Department, Montreal, Quebec, Canada; <sup>229</sup>Concordia University, Department of Biology, Montreal, Canada; <sup>230</sup>Consejo Superior de Investigaciones Científicas (CSIC), Centro de Investigaciones Biológicas, Madrid, Spain; <sup>231</sup>Consejo Superior de Investigaciones Científicas (CSIC), Institute of Parasitology and Biomedicine López-Neyra, Granada, Spain; <sup>232</sup>Consejo Superior de Investigaciones Científicas (CSIC), Instituto de Bioquímica Vegetal y Fotosíntesis, Sevilla, Spain; <sup>233</sup>Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Campus Miguel de Unamuno, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Salamanca, Spain; <sup>234</sup>Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain; <sup>235</sup>Consiglio Nazionale delle Ricerche, Core Research Laboratory, Siena, Italy; <sup>236</sup>BioCruces Health Research Institute, Cruces University Hospital, Stem Cells and Cell Therapy Laboratory, Barakaldo, Spain; <sup>237</sup>CSIC-UAM and CIBERER, Institute for Biomedical Research "Alberto Sols", Madrid, Spain; <sup>238</sup>CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India; <sup>239</sup>CSIR, Indian Institute of Chemical Technology, Biomaterials Group, Hyderabad, India; <sup>240</sup>CSS-Mendel Institute, Neurogenetics Unit, Rome, Italy; <sup>241</sup>Curtin University, School of Biomedical Sciences, Perth, Australia; <sup>242</sup>Curtin University, School of Pharmacy, Bentley, Australia; <sup>243</sup>Dalhousie University, Biochemistry and Molecular Biology, Halifax, NS, Canada; <sup>244</sup>Dalhousie University, Department of Microbiology and Immunology, Halifax, Nova Scotia, Canada; <sup>245</sup>Dalhousie University, Department of Pediatrics, Halifax, Nova Scotia, Canada; <sup>246</sup>Dalhousie University, Department of Pharmacology, Halifax, Nova Scotia, Canada; <sup>247</sup>Dalian Medical University, Cancer Center, Institute of Cancer Stem Cell, Dalian, Liaoning Province, China; <sup>248</sup>Dalian Medical University, Department of Environmental and Occupational Hygiene, Dalian, China; <sup>249</sup>Dalian Medical University, Department of Food Nutrition and Safety, Dalian, China; <sup>250</sup>Dalian Medical University, Institute of Cancer Stem Cell, Dalian, China; <sup>251</sup>Danish Cancer Society Research Center, Cell Death and Metabolism Unit, Center for Autophagy, Recycling and Disease, Copenhagen, Denmark; <sup>252</sup>Danish Cancer Society Research Center, Cell Stress and Survival Unit, Copenhagen, Denmark; <sup>253</sup>Danish Cancer Society Research Center, Unit of Cell Stress and Survival (CSS), Copenhagen, Denmark; <sup>254</sup>Danish Cancer Society Research Center, Unit of Cell Stress and Survival, Copenhagen, Denmark; <sup>255</sup>Dartmouth College, Department of Chemistry, Hanover, NH, USA; <sup>256</sup>Democritus University of Thrace, Department of Pathology, Alexandroupolis, Greece; <sup>257</sup>Democritus University of Thrace, Laboratory of Molecular Hematology, Alexandroupolis, Greece; <sup>258</sup>Democritus University of Thrace, Medical School, Department of Pathology, Alexandroupolis, Greece; <sup>259</sup>Democritus University of Thrace, School of Medicine, Alexandroupolis, Greece; <sup>260</sup>Denver VAMC, Denver, CO, USA; <sup>261</sup>Department of Cellular and Molecular Medicine, Center for Biological Research and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain; <sup>262</sup>Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Budapest, Hungary; <sup>263</sup>Dong-A University, College of Medicine and Mitochondria Hub Regulation Center, Department of Anatomy and Cell Biology, Busan, Korea; <sup>264</sup>Dong-Eui University, Department of Chemistry, Busan, Korea; <sup>265</sup>Drexel University, College of Medicine, Department of Pathology, Philadelphia, PA, USA; <sup>266</sup>Duke University, Department of Medicine, Human Vaccine Institute, Durham, NC, USA; <sup>267</sup>Duke University, Department of Molecular Genetics and Microbiology, Durham, NC, USA; <sup>268</sup>Duke University, Department of Ophthalmology, Durham, NC, USA; <sup>269</sup>Duke University, Medical Center, Department of Immunology, Durham, NC, USA; <sup>270</sup>Duke University, Medical Center, Department of Medicine, Durham, NC, USA; <sup>271</sup>Duke University, Medical Center, Department of Molecular Genetics and Microbiology, Durham, NC, USA; <sup>272</sup>Duke University, Nicholas School of the Environment, Durham, NC, USA; <sup>273</sup>Duke-NUS Graduate Medical School, Cancer and Stem Cell Biology Program, Singapore; <sup>274</sup>Dulbecco Telethon Institute and Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; <sup>275</sup>Durham VA Medical Center, GRECC, Durham, NC, USA; <sup>276</sup>DZNE, German Center for Neurodegenerative Diseases, and CAESAR Research Center, Bonn, Germany; <sup>277</sup>East China Normal University, School of Life Science, Shanghai, China; <sup>278</sup>East China Normal University, Shanghai, China; <sup>279</sup>Eberhard Karls University Tübingen, Interfaculty Institute of Cell Biology, Tübingen, Germany; <sup>280</sup>Institute for Research in Biomedicine, Bellinzona, Switzerland, Università Svizzera italiana, Lugano, Switzerland; <sup>281</sup>Ecole Polytechnique Federale de Lausanne, Global Health Institute, School of Life Sciences, Lausanne, Switzerland; <sup>282</sup>Edinburgh Napier University, School of Life, Sport and Social Sciences, Edinburgh, UK; <sup>283</sup>Edinburgh University, MRC Human Genetics Unit, Edinburgh, UK; <sup>284</sup>Ege University, Faculty of Science, Department of Biology, Bornova, Izmir, Turkey; <sup>285</sup>Emory University, Department of Biology, Atlanta, GA, USA; <sup>286</sup>Emory University, Department of Cell Biology, Atlanta, GA, USA; <sup>287</sup>Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA; <sup>288</sup>Emory University, School of Medicine, Department of Microbiology and Immunology, Atlanta, GA, USA; <sup>289</sup>Emory University, School of Medicine, Department of Pharmacology and Neurology, Atlanta, GA, USA; <sup>290</sup>Emory University, School of Medicine, Department of Pharmacology, Atlanta, GA, USA; <sup>291</sup>Emory University, School of Medicine, Division of Digestive Diseases, Atlanta, GA, USA; <sup>292</sup>Emory University, School of Medicine, Emory Vaccine Center and Department of Microbiology and Immunology, Atlanta, GA, USA; <sup>293</sup>Emory University, School of Medicine, Winship Cancer Institute, Atlanta, GA, USA; <sup>294</sup>Emory University, Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Atlanta, GA, USA; <sup>295</sup>Emory University, Winship Cancer Institute, Department of Hematology and Medical Oncology, Atlanta, GA, USA; <sup>296</sup>Eötvös Loránd University, Department of Anatomy, Cell and Developmental Biology, Budapest, Hungary; <sup>297</sup>Eötvös Loránd University, Department of Biological Anthropology, Budapest, Hungary; <sup>298</sup>Eötvös Loránd University, Department of Genetics, Budapest, Hungary; <sup>299</sup>Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Paris, France; <sup>300</sup>Erasmus MC-University Medical Center Rotterdam, Department of Surgery, Rotterdam, The Netherlands; <sup>301</sup>Ernst-Moritz-Arndt University, Institute of Pharmacy, Greifswald, Germany; <sup>302</sup>ETH Zurich, Department of Biology, Institute of Molecular Health Sciences, Zurich, Switzerland; <sup>303</sup>ETH Zurich, Institute of Biochemistry, Zurich, Switzerland; <sup>304</sup>ETH Zurich, Institute of Molecular Health Sciences, Zurich, Switzerland; <sup>305</sup>ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland; <sup>306</sup>ETH Zürich, LFW D 18.1, Zürich, Switzerland; <sup>307</sup>ETH Zurich, ScopeM (Scientific Center for Optical and Electron Microscopy), Zurich, Switzerland; <sup>308</sup>European Institute of Oncology (IEO), Department of Experimental Oncology, Milan, Italy; <sup>309</sup>European Molecular Biology Laboratory (EMBL), Structural and Computational Biology Unit,

Heidelberg, Germany; <sup>310</sup>Evelina's Children Hospital, Guy's and St. Thomas' Hospital NHS Foundation Trust, Department of Paediatric Neurology, Neuromuscular Service, London, UK; <sup>311</sup>Ewha W. University, Brain and Cognitive Sciences/Pharmacy, Seoul, Korea; <sup>312</sup>Federal University of Rio de Janeiro, Institute of Microbiology, Department of Immunology, Rio de Janeiro, Brazil; <sup>313</sup>Federal University of Rio de Janeiro, Institute of Biophysics Carlos Chagas Filho, Laboratory of Immunoreceptors and Signaling, Rio de Janeiro, Brazil; <sup>314</sup>Federal University of São Paulo, Department of Pharmacology, Paulista School of Medicine, São Paulo, Brazil; <sup>315</sup>Federico II University, Department of Translational Medicine, Naples, Italy; <sup>316</sup>Federico II University, Telethon Institute of Genetics and Medicine (TIGEM), Department of Medical and Translational Sciences, Naples, Italy; <sup>317</sup>First Hospital of Jilin University, Changchun, Jilin, China; <sup>318</sup>First Hospital of Jilin University, Department of Neurosurgery, Changchun, China; <sup>319</sup>FISABIO, Hospital Dr. Peset, Valencia, Spain; <sup>320</sup>Flinders University, School of Biological Sciences, Bedford Park, South Australia, Australia; <sup>321</sup>Florida Atlantic University, Department of Biological Sciences, Jupiter, FL, USA; <sup>322</sup>Florida Atlantic University, Schmidt College of Medicine, Department of Biomedical Sciences, Boca Raton, FL, USA; <sup>323</sup>Florida International University, Department of Dietetics and Nutrition, Miami, FL, USA; <sup>324</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Experimental Oncology and Molecular Medicine, Milan, Italy; <sup>325</sup>Food and Drug Administration (FDA), Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), Jefferson, AR, USA; <sup>326</sup>Forschungszentrum Juelich, ICS-6/Structural Biochemistry, Juelich, Germany; <sup>327</sup>George Washington University, Department of Biochemistry and Molecular Medicine, Washington, DC, USA; <sup>328</sup>Foundation for Research and Technology - Hellas, Heraklion, Crete, Greece; <sup>329</sup>Fourth Military Medical University, Department of Biochemistry and Molecular Biology, Xi'an, China; <sup>330</sup>Fourth Military Medical University, Department of Oral Anatomy and Physiology and TMD, College of Stomatology, Xi'an, China; <sup>331</sup>Fourth Military Medical University, Department of Pulmonary Medicine, Xijing Hospital, Xi'an, Shaanxi Province, China; <sup>332</sup>The Francis Crick Institute, Mill Hill Laboratory, London, UK; <sup>333</sup>Freiburg University, Center for Biological Systems Analysis (ZBSA), Core Facility Proteomics, Freiburg, Germany; <sup>334</sup>Freie Universität Berlin, Institute of Pharmacy (Pharmacology and Toxicology), Berlin, Germany; <sup>335</sup>Freshwater Aquaculture Collaborative Innovation Center of Hubei Province, Wuhan, China; <sup>336</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany; <sup>337</sup>Fudan University Shanghai Medical College, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Institute of Biomedical Sciences, Shanghai, China; <sup>338</sup>Fudan University Shanghai Medical College, Key Laboratory of Molecular Virology, Shanghai, China; <sup>339</sup>Fudan University, Cancer Center, Department of Integrative Oncology, Shanghai, China; <sup>340</sup>Cancer Institute, Fudan University Shanghai Cancer Center, Collaborative Innovation Center of Cancer Medicine, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; <sup>341</sup>Fudan University, Department of Biosynthesis, Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Shanghai, China; <sup>342</sup>Fudan University, Department of Neurosurgery, Shanghai, China; <sup>343</sup>Fujian Provincial Hospital, Department of Urology, Fuzhou, China; <sup>344</sup>Gdansk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Gdansk, Poland; <sup>345</sup>Geisel School of Medicine at Dartmouth, Department of Biochemistry, Hanover, NH, USA; <sup>346</sup>Geisel School of Medicine at Dartmouth, Department of Microbiology and Immunology, Lebanon, NH, USA; <sup>347</sup>Geisinger Clinic, Weis Center for Research, Danville, PA, USA; <sup>348</sup>Genentech Inc., Department of Cancer Immunology, South San Francisco, CA, USA; <sup>349</sup>Genentech Inc., Department of Immunology, South San Francisco, CA, USA; <sup>350</sup>Genentech Inc., Department of Neuroscience, South San Francisco, CA, USA; <sup>351</sup>Genentech Inc., Department of Translational Oncology, South San Francisco, CA, USA; <sup>352</sup>Genentech Inc., Immunology and Infectious Diseases, South San Francisco, CA, USA; <sup>353</sup>Georg-August-Universität Göttingen, Department of Molecular Microbiology and Genetics, Institute of Microbiology and Genetics, Göttingen, Germany; <sup>354</sup>Georg-August-Universität Göttingen, Institute of Microbiology and Genetics, Department of Genetics of Eukaryotic Microorganisms, Göttingen, Germany; <sup>355</sup>Georg-August-Universität Göttingen, Department of Nephrology and Rheumatology, Göttingen, Germany; <sup>356</sup>Georg-August-Universität Göttingen, Institute of Cellular Biochemistry, Göttingen, Germany; <sup>357</sup>George Mason University, Manassas, VA, USA; <sup>358</sup>George Washington University, Department of Anatomy and Regenerative Biology, Washington, DC, USA; <sup>359</sup>George Washington University, Flow Cytometry Core Facility, Washington, DC, USA; <sup>360</sup>Georgetown University Medical Center, Department of Neuroscience, Washington, DC, USA; <sup>361</sup>Georgetown University Medical Center, Department of Oncology, Washington, DC, USA; <sup>362</sup>Georgetown University, Department of Pharmacology and Physiology, Washington, DC, USA; <sup>363</sup>Georgetown University, Lombardi Comprehensive Cancer Center, Departments of Oncology and Pathology, Washington, DC, USA; <sup>364</sup>Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA; <sup>365</sup>Georgia Regents University, Cancer Center, Department of Medicine, Augusta, GA, USA; <sup>366</sup>Georgia Regents University, Department of Neurology, Augusta, GA, USA; <sup>367</sup>Georgia Regents University, Department of Orthopaedic Surgery, Augusta, GA, USA; <sup>368</sup>Georgia Regents University, Institute for Regenerative and Reparative Medicine, Augusta, GA, USA; <sup>369</sup>Georgia Regents University, Medical College of Georgia, Augusta, GA, USA; <sup>370</sup>Georgia Regents University, Medical College of Georgia, Department of Cellular Biology and Anatomy, Augusta, GA, USA; <sup>371</sup>Georgia Regents University, Medical College of Georgia, Department of Medicine, Augusta, GA, USA; <sup>372</sup>German Cancer Research Center (DKFZ), Clinical Cooperation Unit (CCU) Pediatric Oncology, Heidelberg, Germany; <sup>373</sup>German Cancer Research Center (DKFZ), Lysosomal Systems Biology, Heidelberg, Germany; <sup>374</sup>German Cancer Research Center (DKFZ), Systems Biology of Cell Death Mechanisms, Heidelberg, Germany; <sup>375</sup>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; <sup>376</sup>German Institute of Human Nutrition, Department of Molecular Toxicology, Nuthetal, Germany; <sup>377</sup>Ghent University, Department of Biomedical Molecular Biology, Inflammation Research Center, VIB, Methusalem Program, Gent, Belgium; <sup>378</sup>Girona Biomedical Research Institute (IDIBGI), Catalan Institute of Oncology (ICO), Catalonia, Spain; <sup>379</sup>Goethe University Medical School, Experimental Neurology, Frankfurt am Main, Germany; <sup>380</sup>Goethe University of Frankfurt, Institute of Biophysical Chemistry, Frankfurt am Main, Germany; <sup>381</sup>Goethe University School of Medicine, Institute of Biochemistry II and Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; <sup>382</sup>Goethe University, Institute of Pharmacology and Toxicology, Frankfurt am Main, Germany; <sup>383</sup>Goethe University, Institute for Experimental Cancer Research in Pediatrics, Frankfurt, Germany; <sup>384</sup>Goethe University, Institute for Molecular Biosciences, Molecular Developmental Biology, Frankfurt, Hesse, Germany; <sup>385</sup>Gonçalo Moniz Research Center, Oswaldo Cruz Foundation, FIOCRUZ-BA, Laboratory of Pathology and Biointervention, Salvador, BA, Brazil; <sup>386</sup>Graduate School of Cancer Science and Policy, Department of System Cancer Science, Goyang, Korea; <sup>387</sup>Graduate School of Hallam University, Chuncheon, Kangwon-do, Korea; <sup>388</sup>Griffith University, Menzies Health Institute Queensland, Australia; <sup>389</sup>Guangzhou Medical University, Department of Human Anatomy, School of Basic Science, Guangzhou, Guangdong, China; <sup>390</sup>Gunma University Graduate School of Medicine, Department of Otolaryngology-Head and Neck Surgery, Gunma, Japan; <sup>391</sup>Gunma University, Laboratory of Molecular Membrane Biology, Institute for Molecular and Cellular Regulation, Gunma, Japan; <sup>392</sup>Gunma University, Laboratory of Molecular Traffic, Institute for Molecular and Cellular Regulation, Gunma, Japan; <sup>393</sup>Gustave Roussy Cancer Campus, Villejuif, France; <sup>394</sup>Gustave Roussy Comprehensive Cancer Center, Villejuif, France; <sup>395</sup>Gustave Roussy Institute, Villejuif, France; <sup>396</sup>Gyeongsang National University School of Medicine, Department of Biochemistry and Convergence Medical Science and Institute of Health Sciences, Jinju, Korea; <sup>397</sup>Hadassah Hebrew University Medical Center, Endocrinology and Metabolism Service, Department of Medicine, Jerusalem, Israel; <sup>398</sup>Hadassah Hebrew University Medical Center, Department of Neurology, Jerusalem, Israel; <sup>399</sup>Hallym University, Department of Anatomy and Neurobiology, College of Medicine, Kangwon-Do, Korea; <sup>400</sup>Hallym University, Department of Biomedical Gerontology, Chuncheon, Kangwon-do, Korea; <sup>401</sup>Hallym University, Department of Anyang, Gyeonggi-do, Korea; <sup>402</sup>Hallym University, Department of Microbiology, College of Medicine, Chuncheon, Gangwon, Korea; <sup>403</sup>Hallym University, Ilsong Institute of Life Science, Chuncheon, Korea; <sup>404</sup>Hallym University, School of Medicine, Department of Physiology, Chuncheon, Korea; <sup>405</sup>Hampton University, Department of Pharmaceutical Sciences, School of Pharmacy, Hampton, VA, USA; <sup>406</sup>Hangzhou Normal University, Department of Pharmacology, School of Medicine, Hangzhou, China; <sup>407</sup>Hannover Medical School, Department for Clinical Immunology and Rheumatology, Hannover, Germany; <sup>408</sup>Hannover Medical School, Department of Biochemistry, Hannover, Germany; <sup>409</sup>Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany; <sup>410</sup>Hanyang University, College of Pharmacy, Ansan, Korea; <sup>410</sup>Harbin Medical University, College of Bioinformatics Science and Technology, Harbin, Heilongjiang,

China; <sup>411</sup>Harbin Medical University, Department of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin, China; <sup>412</sup>Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Division of Medical Genetics, Department of Pediatrics, Torrance, CA, USA; <sup>413</sup>Harvard Medical School and Broad Institute, Boston, MA, USA; <sup>414</sup>Harvard Medical School, Boston, MA, USA; <sup>415</sup>Harvard Medical School, Brigham and Women's Hospital, Department of Genetics, Division of Genetics, Boston, MA, USA; <sup>416</sup>Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA; <sup>417</sup>Harvard Medical School, Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, Department of Radiation Oncology, Boston, MA, USA; <sup>418</sup>Harvard Medical School, Department of Cell Biology, Boston, MA, USA; <sup>419</sup>Harvard Medical School, Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital Research Institute, Boston, MA, USA; <sup>420</sup>Harvard Medical School, Neurology Residency Program, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA, USA; <sup>421</sup>Harvard Medical School, Ophthalmology, Boston, MA, USA; <sup>422</sup>Harvard University, Department of Statistics, Cambridge, MA, USA; <sup>423</sup>Harvard University, School of Public Health, Department of Genetics and Complex Diseases, Boston, MA, USA; <sup>424</sup>Health Research Institute Germans Trias i Pujol, Badalona, Spain; <sup>425</sup>Hebrew University of Jerusalem, Faculty of Agriculture, Food, and Environment, Biochemistry and Food Science, Rehovot, Israel; <sup>426</sup>Heidelberg University, Deutsches Krebsforschungszentrum, Proteostasis in Neurodegenerative Disease (B180), CHS Research Group at CellNetworks, Heidelberg, Germany; <sup>427</sup>Heidelberg University, Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), Heidelberg, Germany; <sup>428</sup>Heinrich Heine University, Institute of Clinical Chemistry and Laboratory Diagnostic, Medical Faculty, Duesseldorf, Germany; <sup>429</sup>Heinrich-Heine-University, Institut für Physikalische Biologie, Duesseldorf, Germany; <sup>430</sup>Heinrich-Heine-University, Institute of Molecular Medicine, Düsseldorf, Germany; <sup>431</sup>Systems-oriented Immunology and Inflammation Research, Helmholtz Centre for Infection Research, Braunschweig, Germany; <sup>432</sup>Helsinki University, Central Hospital, Medical Faculty, Division of Child Psychiatry, Helsinki, Finland; <sup>433</sup>Helsinki University, Department of Medical Genetics, Helsinki, Finland; <sup>434</sup>Henan University of Technology, College of Bioengineering, Zhengzhou, Henan Province, China; <sup>435</sup>Hirosaki University Graduate School of Medicine, Hirosaki, Japan; <sup>436</sup>Hokkaido University Graduate School of Medicine, Department of Obstetrics and Gynecology, Sapporo, Hokkaido, Japan; <sup>437</sup>Hokkaido University, Faculty of Pharmaceutical Sciences, Sapporo, Japan; <sup>438</sup>Hokkaido University, Research Faculty of Agriculture, Sapporo, Japan; <sup>439</sup>Hong Kong Baptist University, School of Chinese Medicine, Kowloon Tong, Hong Kong; <sup>440</sup>Hong Kong Polytechnic University, Department of Health Technology and Informatics, Faculty of Health and Social Sciences, Kowloon, Hong Kong; <sup>441</sup>The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong; <sup>442</sup>Hôpital Beaujon, Paris, France; <sup>443</sup>Hôpital Européen Georges Pompidou, AP-HP, Paris, France; <sup>444</sup>Hôpital Kirchberg, Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg; <sup>445</sup>Hôpital Paul Brousse - Hôpitaux Universitaires Paris-Sud, Biochimie et Oncogénétique, Villejuif, France; <sup>446</sup>Hospital for Sick Children, Toronto, ON, Canada; <sup>447</sup>Hospital Universitario Ramón y Cajal, CIBERNED, Neurobiology Department, Madrid, Spain; <sup>448</sup>Houston Methodist Research Institute, Genomic Medicine Program, Houston, TX, USA; <sup>449</sup>Howard Hughes Medical Institute, Boston, MA, USA; <sup>450</sup>Howard Hughes Medical Institute, Dallas, TX; <sup>451</sup>Huazhong Agricultural University, College of Animal Sciences and Technology, Wuhan, Hubei, China; <sup>452</sup>Huazhong Agricultural University, Department of Aquatic Animal Medicine, College of Fisheries, Wuhan, China; <sup>453</sup>Huazhong University of Science and Technology, Department of Biomedical Engineering, College of Life Science and Technology, Wuhan, Hubei, China; <sup>454</sup>Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Melbourne, Victoria, Australia; <sup>455</sup>Hungkuang University, Department of Physical Therapy, Taichung, Taiwan; <sup>456</sup>IATA-CSIC, Institute of Agrochemistry and Food Technology, Paterna (Valencia), Spain; <sup>457</sup>I BET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal; <sup>458</sup>Icahn School of Medicine at Mount Sinai, Department of Neuroscience, New York, NY, USA; <sup>459</sup>Icahn School of Medicine at Mount Sinai, Department of Pharmacology and Systems Therapeutics, New York, NY, USA; <sup>460</sup>Icahn School of Medicine at Mount Sinai, Departments of Neurology and Psychiatry, Center for Cognitive Health, Mount Sinai Alzheimer's Disease Research Center, New York, NY, USA; <sup>461</sup>Icahn School of Medicine at Mount Sinai, Friedman Brain Institute, New York, NY, USA; <sup>462</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>463</sup>ICM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; <sup>464</sup>ICREA Catalan Institution for Research and Advanced Studies, Catalonia, Spain; <sup>465</sup>IFOM - The FIRI Institute of Molecular Oncology, Milan, Italy; <sup>466</sup>IIT University, School of Biotechnology, Orissa, India; <sup>467</sup>IMIM-Hospital del Mar CIBERES, Pompeu Fabra University, Barcelona Biomedical Research Park, Respiratory Medicine Department, Lung Cancer and Muscle Research Group, Barcelona, Spain; <sup>468</sup>Imperial College London, MRC Centre for Molecular Bacteriology and Infection, London, UK; <sup>469</sup>Imperial College London, National Heart and Lung Institute, London, UK; <sup>470</sup>Imperial College London, Neurogenetics Group, Division of Brain Sciences, London, UK; <sup>471</sup>Imperial College London, Section of Microbiology, MRC Centre for Molecular Bacteriology and Infection, London, UK; <sup>472</sup>Incheon National University, Division of Life Sciences, Incheon, Korea; <sup>473</sup>Indian Institute of Science, Department of Microbiology and Cell Biology, Bangalore, India; <sup>474</sup>Indian Institute of Science, Microbiology and Cell Biology, Bangalore, India; <sup>475</sup>Indian Institute of Technology Guwahati, Department of Biosciences and Bioengineering, Guwahati, Assam, India; <sup>476</sup>Indian Institute of Technology Kharagpur, Department of Biotechnology, Kharagpur, India; <sup>477</sup>Indiana University School of Medicine, Biochemistry and Molecular Biology, Denver, CO, USA; <sup>478</sup>Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA; <sup>479</sup>Indiana University School of Medicine, Department of Dermatology, Indianapolis, IN, USA; <sup>480</sup>Indiana University School of Medicine, Department of Microbiology and Immunology, Indianapolis, IN, USA; <sup>481</sup>Indiana University School of Medicine, Department of Ophthalmology, Indianapolis, IN, USA; <sup>482</sup>Indiana University School of Medicine, Department of Pathology and Laboratory Medicine, Indianapolis, IN, USA; <sup>483</sup>Indiana University School of Medicine, Richard L. Roudebush VA Medical Center, Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis, IN, USA; <sup>484</sup>Inje University, Department of Rehabilitation Science, College of Biomedical Science & Engineering, u-Healthcare & Anti-aging Research Center (u-HARC), Gimhae, Korea; <sup>485</sup>INMI-IRCCS "L. Spallanzani", Rome, Italy; <sup>486</sup>INRA, UMR 1019 Nutrition Humaine, Centre de Clermont Theix, Saint Genès Champanelle, France; <sup>487</sup>INRA, UMR866 Dynamique Musculaire et Métabolisme, Montpellier, France; <sup>488</sup>INRA, UR1067, Nutrition Métabolisme Aquaculture, St-Pée-sur-Nivelle, France; <sup>489</sup>INSERM U1065, C3M, Team 2, Nice, France; <sup>490</sup>INSERM U1081, CNRS UMR7284, Institute of Research on Cancer and Ageing of Nice (IRCAN), Nice, France; <sup>491</sup>Centre Scientifique de Monaco, Biomedical Department, Monaco, Principality of Monaco; <sup>492</sup>University of Nice Sophia Antipolis, Institute of Research on Cancer and Ageing of Nice, CNRS UMR 7284/INSERM U1081, Nice, France; <sup>493</sup>INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France; <sup>494</sup>INSERM U1138, Paris, France; <sup>495</sup>INSERM U1147, Paris, France; <sup>496</sup>INSERM U830, Stress and Cancer Laboratory, Institut Curie, Paris, France; <sup>497</sup>INSERM U862, Neurocentre Magendie, Bordeaux, France; <sup>498</sup>INSERM U896, Montpellier, France; <sup>499</sup>INSERM U916, Université de Bordeaux, Institut Européen de Chimie et Biologie, Pessac, France; <sup>500</sup>INSERM U955, Faculté de Médecine de Créteil, UMR-S955, Créteil, France; <sup>501</sup>INSERM U964, CNRS UMR7104, Université de Strasbourg, Department of Translational Medicine, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France; <sup>502</sup>INSERM UMR1037, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; <sup>503</sup>INSERM UMRS 1166, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition, Paris, France; <sup>504</sup>INSERM, Cordeliers Research Cancer, Paris, France; <sup>505</sup>INSERM, U1081-UMR CNRS 7284, Nice, France; <sup>506</sup>INSERM, U1104, Marseille, France; <sup>507</sup>INSERM, U1127, CNRS, UMR 7225, Paris, France; <sup>508</sup>INSERM, U1138, Paris, France; <sup>509</sup>INSERM, U970, Paris, France; <sup>510</sup>Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hemato-oncology Department, Barcelona, Spain; <sup>511</sup>Institut de Cancèrologie de Lorraine, Vandoeuvre-Lès-Nancy Cedex, France; <sup>512</sup>Institut du Cancer de Montpellier, Montpellier, France; <sup>513</sup>Istituto Zooprofilattico Sperimentale del Mezzogiorno, Department of Chemistry, Portici (Naples), Italy; <sup>514</sup>Institut Pasteur, CNRS URA2582, Cell Biology and Infection Department, Membrane Traffic and Cell Division Lab, Paris, France; <sup>515</sup>Center for Infection and Immunity of Lille, Institut Pasteur de Lille, CNRS, INSERM, Lille Regional University Hospital Centre, Lille University, Lille, France; <sup>516</sup>Institut Pasteur, CNRS, URA2578, Unité Macrophages et Développement de l'Immunité, Département de Biologie du Développement et des Cellules Souches, Paris, France; <sup>517</sup>Institut Pasteur, Department of Immunology, Paris, France; <sup>518</sup>Institut Pasteur, INSERM, Biology of Infection Unit, Paris, France; <sup>519</sup>Institute for Clinical and Experimental Medicine, Centre for Experimental Medicine, Department of

Metabolism and Diabetes, Prague, Czech Republic; <sup>520</sup>Institute for Integrative Biology of the Cell, Université Paris-Saclay, Gif-sur-Yvette, France; <sup>521</sup>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain; <sup>522</sup>Institute of Advanced Chemistry of Catalonia, Spanish Research Council (IQAC-CSIC), Department of Biomedical Chemistry, Barcelona, Spain; <sup>523</sup>Institute of Biochemistry and Biophysics, Kazan, Russia; <sup>524</sup>Institute of Biomedical Investigation (INIBIC), Aging, Inflammation and Regenerative Medicine, Coruña, Spain; <sup>525</sup>Institute of Cancer Research, Divisions of Molecular Pathology and Cancer Therapeutics, London, UK; <sup>526</sup>Institute of Environmental Medicine, Division of Toxicology, Karolinska Institute, Stockholm, Sweden; <sup>527</sup>Institute of Life Sciences, Bhubaneswar, Odisha, India; <sup>528</sup>Institute of Microbial Technology (IMTECH), Cell Biology and Immunology Division, Chandigarh, India; <sup>529</sup>Institute of Microbiology ASCR, v.v.i., Prague, Czech Republic; <sup>530</sup>Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria; <sup>531</sup>Institute of Molecular Genetics, National Research Council, Pavia, Italy; <sup>532</sup>Institute of Molecular Pathology and Biology, FMHS UO, Hradec Kralove, Czech Republic; <sup>533</sup>Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Dorodna, Poland; <sup>534</sup>Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET), Rosario, Argentina; <sup>535</sup>Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain; <sup>536</sup>Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; <sup>537</sup>Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM, Madrid, Spain; <sup>538</sup>Instituto de Investigaciones Biomédicas de Barcelona, CSIC-IDIBAPS and Centro de Investigación en Red en enfermedades hepáticas y digestivas, CIBEREHD, ISCIII, Barcelona, Spain; <sup>539</sup>Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain; <sup>540</sup>Instituto de Tecnología Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal; <sup>541</sup>Instituto Gulbenkian de Ciência, Oeiras, Portugal; <sup>542</sup>Instituto de Investigaciones Biomédicas de Barcelona IIBB-CSIC, Liver Unit, Hospital Clinic de Barcelona-IDIBAPS and CIBEREHD, Barcelona, Spain; <sup>543</sup>Instituto Leloir, Buenos Aires, Argentina; <sup>544</sup>Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Departamento de Biología Celular, Madrid, Spain; <sup>545</sup>Instituto Nacional de Neurología y Neurocirugía, Neuroquímica Unit, Mexico City, Mexico; <sup>546</sup>Instituto Nacional de Neurología y Neurocirugía, Neuroimmunology and Neuro-Oncology Unit, Mexico City, Mexico; <sup>547</sup>Instituto Oswaldo Cruz, FIOCRUZ, Laboratório de Biologia Celular, Rio de Janeiro, Brazil; <sup>548</sup>International Center for Genetic Engineering and Biotechnology, Immunology Group, New Delhi, India; <sup>549</sup>Iowa State University, Department of Biomedical Science, Iowa Center for Advanced Neurotoxicology, Ames, IA, USA; <sup>550</sup>Iowa State University, Department of Genetics, Development and Cell Biology, Ames, IA, USA; <sup>551</sup>Iowa State University, Roy J. Carver Department of Biochemistry, Biophysics, and Molecular Biology, Ames, IA, USA; <sup>552</sup>IRCCS Casa Sollievo della Sofferenza, Medical Genetics Unit, San Giovanni Rotondo (FG), Italy; <sup>553</sup>IRCCS Neuromed, Pozzilli, IS, Italy; <sup>554</sup>IRCCS San Raffaele Pisana, Laboratory of Skeletal Muscle Development and Metabolism, Rome, Italy; <sup>555</sup>IRCCS Santa Lucia Foundation, Rome, Italy; <sup>556</sup>IRCCS Santa Lucia Foundation, Department of Experimental Neurosciences, Rome, Italy; <sup>557</sup>IRCCS Santa Lucia Foundation, Rome, Italy; <sup>558</sup>IRCCS, “C. Mondino” National Neurological Institute, Experimental Neurobiology Lab, Pavia, Italy; <sup>559</sup>IRCCS, Istituto Dermatologico dell’Immacolata, Rome, Italy; <sup>560</sup>IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Department of Molecular Biochemistry and Pharmacology, Milan, Italy; <sup>561</sup>IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Department of Neuroscience, Milan, Italy; <sup>562</sup>IRCCS-MultiMedica, Milan, Italy; <sup>563</sup>IRCE, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; <sup>564</sup>IRCM, INSERM, U896, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; <sup>565</sup>IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; <sup>566</sup>IRO, Institute for Research in Ophthalmology, Sion, Switzerland; <sup>567</sup>Istituto di Fisiologia Clinica, Siena, Italy; <sup>568</sup>Istituto Giannina Gaslini, UOC Medical Genetics, Genova, Italy; <sup>569</sup>Istituto Italiano di Tecnologia, Department of Drug Discovery and Development, Laboratory of Molecular Medicine, Genoa, Italy; <sup>570</sup>Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy; <sup>571</sup>Istituto Ortopedico Rizzoli IOR-IRCCS, Laboratory of Musculoskeletal Cell Biology, Bologna, Italy; <sup>572</sup>Istituto Superiore di Sanità, Department of Cell Biology and Neurosciences, Rome, Italy; <sup>573</sup>Istituto Superiore di Sanità, Department of Haematology, Oncology and Molecular Medicine, Rome, Italy; <sup>574</sup>Istituto Superiore di Sanità, Department of Infectious, Parasitic and Immunomediated Diseases, Rome, Italy; <sup>575</sup>Istituto Superiore di Sanità, Department of Therapeutic Research and Medicine, Evaluation Section of Cell Aging, Degeneration and Gender Medicine, Rome, Italy; <sup>576</sup>Istituto Superiore di Sanità, Rome, Italy; <sup>577</sup>Istituto Toscano Tumori, Siena, Italy; <sup>578</sup>Italian National Institute of Health, Department of Technology and Health, Rome, Italy; <sup>579</sup>IUF-Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany; <sup>580</sup>J. Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Ljubljana, Slovenia; <sup>581</sup>Jadavpur University, Life Science and Biotechnology, Kolkata, West Bengal, India; <sup>582</sup>James J. Peters VA Medical Center, Bronx, NY, USA; <sup>583</sup>Jawaharlal Nehru University, School of Life Sciences, New Delhi, India; <sup>584</sup>Jesse Brown VA Medical Center, Department of Medicine, Chicago, IL, USA; <sup>585</sup>Jewish General Hospital, Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada; <sup>586</sup>Jewish General Hospital, Department of Neurology and Neurosurgery, Department of Medicine, Montreal, Quebec, Canada; <sup>587</sup>Jewish General Hospital, Department of Oncology, Montreal, Quebec, Canada; <sup>588</sup>Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China; <sup>589</sup>Jiangsu University, Department of Immunology, Zhenjiang, Jiangsu, China; <sup>590</sup>Jiangsu University, School of Pharmacy, Zhenjiang, Jiangsu, China; <sup>591</sup>Jikei University School of Medicine, Division of Respiratory Disease, Department of Internal Medicine, Tokyo, Japan; <sup>592</sup>Jikei University School of Medicine, Research Center for Medical Sciences, Division of Gene Therapy, Tokyo, Japan; <sup>593</sup>Jilin Medical University, Medical Research Laboratory, Jilin City, Jilin Province, China; <sup>594</sup>Jinan University, Anti-stress and Health Center, College of Pharmacy, Guangzhou, China; <sup>595</sup>Jinan University, Department of Immunobiology, College of Life Science and Technology, Guangzhou, China; <sup>596</sup>Jinan University, Medical College, Division of Histology and Embryology, Guangzhou, Guangdong, China; <sup>597</sup>Jining Medical University, Shandong Provincial Sino-US Cooperation Research Center for Translational Medicine, Shandong, China; <sup>598</sup>Jinshan Hospital of Fudan University, Department of Urology, Shanghai, China; <sup>599</sup>Johannes Gutenberg University Mainz, University Medical Center, Department of Medical Microbiology and Hygiene, Mainz, Germany; <sup>600</sup>John Wayne Cancer Institute, Department of Neurosciences, Santa Monica, CA, USA; <sup>601</sup>Johns Hopkins University, Bloomberg School of Public Health, Malaria Research Institute, Department of Molecular Microbiology and Immunology, Baltimore, MD, USA; <sup>602</sup>Johns Hopkins University, School of Medicine, Baltimore, MD, USA; <sup>603</sup>Johns Hopkins University, School of Medicine, Department of Physiology and Center for Metabolism and Obesity Research, Baltimore, MD, USA; <sup>604</sup>Johns Hopkins University, School of Medicine, Departments of Neurology, Neuroscience and Pharmacology and Molecular Sciences; Neuroregeneration Program, Institute for Cell Engineering, Baltimore, MD, USA; <sup>605</sup>Johns Hopkins University, School of Medicine, Institute for Cell Engineering and McKusick-Nathans Institute of Genetic Medicine, Baltimore, MD, USA; <sup>606</sup>Johns Hopkins University, School of Medicine, Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Department of Physiology, Baltimore, MD, USA; <sup>607</sup>Johns Hopkins University, School of Medicine, Wilmer Eye Institute, Baltimore, MD, USA; <sup>608</sup>Johns Hopkins, Bloomberg School of Public Health, Department of Biochemistry and Molecular Biology and Johns Hopkins Malaria Research Institute, Baltimore, MD, USA; <sup>609</sup>Johns Hopkins, School of Medicine, Wilmer Eye Institute, Baltimore, MD, USA; <sup>610</sup>Juntendo University, Department of Research for Parkinson’s Disease, Tokyo, Japan; <sup>611</sup>Juntendo University, Graduate School of Medicine, Department of Cell Biology and Neuroscience, Tokyo, Japan; <sup>612</sup>Juntendo University, Graduate School of Medicine, Department of Metabolism and Endocrinology, Tokyo, Japan; <sup>613</sup>Juntendo University, Graduate School of Medicine, Department of Neuroscience for Neurodegenerative Disorders, Tokyo, Japan; <sup>614</sup>Juntendo University, Graduate School of Medicine, Laboratory of Proteomics and Biomolecular Science, Tokyo, Japan; <sup>615</sup>Juntendo University, School of Medicine, Department of Cell Biology and Neuroscience, Tokyo, Japan; <sup>616</sup>Juntendo University, School of Medicine, Department of Gastroenterology, Tokyo, Japan; <sup>617</sup>Juntendo University, Tokyo, Japan; <sup>618</sup>Kagoshima University, Graduate School of Medical and Dental Sciences, Division of Human Pathology, Department of Oncology, Course of Advanced Therapeutics, Kagoshima, Japan; <sup>619</sup>Kagoshima University, The Near-Future Locomotor Organ Medicine Creation Course, Graduate School of Medical and Dental Sciences, Kagoshima, Japan; <sup>620</sup>KAIST, Department of Biological Sciences, Daejeon, Korea; <sup>621</sup>Kanazawa Medical University, Department of Medicine, Ishikawa, Japan; <sup>622</sup>Kanazawa Medical University, Diabetology and Endocrinology, Ishikawa, Japan; <sup>623</sup>Kanazawa University Graduate

School of Medical Sciences, Department of Human Pathology, Kanazawa, Japan; <sup>624</sup>Kanazawa University, Cell-bionomics Unit and Laboratory of Molecular and Cellular Biology, Department of Biology, Faculty of Natural Systems, Institute of Science and Engineering, Ishikawa, Japan; <sup>625</sup>Kansas State University, Division of Biology, Manhattan, KS, USA; <sup>626</sup>Kaohsiung Medical University Hospital, Department of Pathology, Kaohsiung City, Taiwan; <sup>627</sup>Kaohsiung Medical University, Graduate Institute of Medicine, Kaohsiung, Taiwan; <sup>628</sup>Kaohsiung Medical University, Faculty of Medicine, Department of Pathology, Kaohsiung City, Taiwan; <sup>629</sup>Kaohsiung Veterans General Hospital, Department of Medical Education and Research, Kaohsiung, Taiwan; <sup>630</sup>Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, Karlsruhe, Germany; <sup>631</sup>Karolinska Institute, Cancer Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden; <sup>632</sup>Karolinska Institute, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Division for Neurogeriatrics, Huddinge, Sweden; <sup>633</sup>Karolinska Institute, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden; <sup>634</sup>Karolinska Institute, Department of Physiology and Pharmacology, Stockholm, Sweden; <sup>635</sup>Karolinska Institute, Institute of Environmental Medicine, Stockholm, Sweden; <sup>636</sup>Kawasaki Medical School, Department of General Internal Medicine 4, Okayama, Japan; <sup>637</sup>Kawasaki Medical School, Department of Hepatology and Pancreatology, Kurashiki, Okayama, Japan; <sup>638</sup>Keimyung University, Daegu, Korea; <sup>639</sup>Keimyung University, School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, Korea; <sup>640</sup>Keio University, Graduate School of Pharmaceutical Sciences, Department of Biochemistry, Tokyo, Japan; <sup>641</sup>Keio University, School of Medicine, Medical Education Center, Tokyo, Japan; <sup>642</sup>KERBASQUE, Basque Foundation for Sciences, Bilbao, Spain; <sup>643</sup>King Saud University, College of Science, Department of Zoology, Riyadh, Saudi Arabia; <sup>644</sup>King's College London, Cardiovascular Division, London, UK; <sup>645</sup>King's College London, Department of Basic and Clinical Neuroscience, IoPPN, London, UK; <sup>646</sup>King's College, Randall Division of Cell and Molecular Biophysics, Muscle Signalling Section, London, UK; <sup>647</sup>Kobe University, Graduate School of Health Sciences, Laboratory of Pathology, Division of Medical Biophysics, Hyogo, Japan; <sup>648</sup>Kobe University, Graduate School of Medicine, Department of Orthopaedic Surgery, Hyogo, Japan; <sup>649</sup>Komarov Botanical Institute RAS, Plant Ecological Physiology Laboratory, Saint Petersburg, Russian Federation; <sup>650</sup>Konkuk University, Department of Animal Biotechnology, Seoul, Korea; <sup>651</sup>Konkuk University, Department of Veterinary Medicine, Seoul, Korea; <sup>652</sup>Konkuk University School of Medicine, Department of Ophthalmology, Seoul, Korea; <sup>653</sup>Konkuk University, School of Medicine, Department of Anatomy, Seoul, Korea; <sup>654</sup>Korea Cancer Center Hospital, Department of Internal Medicine, Seoul, Korea; <sup>655</sup>Korea University, Department of Biotechnology, BK21-PLUS Graduate School of Life Sciences and Biotechnology, Seoul, Korea; <sup>656</sup>Korea University, Department of Life Science and Biotechnology, Seoul, Korea; <sup>657</sup>Korea University, Department of Biotechnology, College of Life Sciences and Biotechnology, Seoul, Korea; <sup>658</sup>Korea University, Division of Life Sciences, Seoul, Korea; <sup>659</sup>KU Leuven and VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium; <sup>660</sup>KU Leuven, Clinical Division and Laboratory of Intensive Care Medicine, Department Cellular and Molecular Medicine, Leuven, Belgium; <sup>661</sup>KU Leuven, Department of Abdominal Transplant Surgery, Leuven, Belgium; <sup>662</sup>KU Leuven, Department of Cellular and Molecular Medicine, Leuven, Belgium; <sup>663</sup>KU Leuven, Department of Imaging and Pathology, Leuven, Belgium; <sup>664</sup>KU Leuven, Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, Campus Gasthuisberg, Leuven, Belgium; <sup>665</sup>KU Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, Leuven, Belgium; <sup>666</sup>Kumamoto University, Institute of Resource Development and Analysis, Kumamoto, Japan; <sup>667</sup>Kunming University of Science and Technology, Medical School, Kunming, Yunnan, China; <sup>668</sup>Kyoto Prefectural University of Medicine, Department of Basic Geriatrics, Kyoto, Japan; <sup>669</sup>Kyoto Prefectural University of Medicine, Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto, Japan; <sup>670</sup>Kyoto Prefectural University of Medicine, Department of Basic Geriatrics, Kyoto, Japan; <sup>671</sup>Kyoto Sangyo University, Department of Life Sciences, Kyoto, Japan; <sup>672</sup>Kyoto Sangyo University, Department of Molecular Biosciences, Faculty of Life Sciences, Kyoto, Japan; <sup>673</sup>Kyoto University, Department of Botany, Kyoto, Japan; <sup>674</sup>Kyoto University, Department of Cardiovascular Medicine, Kyoto, Japan; <sup>675</sup>Kyoto University, Graduate School of Medicine, Medical Innovation Center (TMK project), Kyoto, Japan; <sup>676</sup>Kyung Hee University, Graduate School of East-West Medical Science, Seoul, Korea; <sup>677</sup>Kyungpook National University, Department of Physiology, School of Medicine, Jung-gu, Daegu, Korea; <sup>678</sup>Kyushu University, Department of Surgery and Science, Fukuoka, Japan; <sup>679</sup>Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; <sup>680</sup>La Trobe University, Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Melbourne, Victoria, Australia; <sup>681</sup>La Trobe University, Department of Chemistry and Physics, Melbourne, Victoria, Australia; <sup>682</sup>La Trobe University, School of Cancer Medicine, Melbourne, Victoria, Australia; <sup>683</sup>Laboratory for Biomedical Neurosciences NSI/EOC, Neurodegeneration Group, Torricella-Taverne, Switzerland; <sup>684</sup>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako, Saitama, Japan; <sup>685</sup>Laboratory of Cellular Aging and Neurodegeneration, Ilsong Institute of Life Science, Anyang, Gyeonggi-do, Korea; <sup>686</sup>Lancaster University, Faculty of Health and Medicine, Division of Biomedical and Life Sciences, Lancaster, UK; <sup>687</sup>Latvian Biomedical Research and Study Centre, Riga, Latvia; <sup>688</sup>Leiden University, Institute of Biology, Leiden, The Netherlands; <sup>689</sup>Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick, MD, USA; <sup>690</sup>Medical University of Silesia, ENT Department, School of Medicine, Katowice, Poland; <sup>691</sup>Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden; <sup>692</sup>Linköping University, Department of Medical and Health Sciences, Linköping, Sweden; <sup>693</sup>Linköping University, Experimental Pathology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping, Sweden; <sup>694</sup>Liverpool School of Tropical Medicine, Department of Parasitology, Liverpool, Merseyside, UK; <sup>695</sup>Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Department of Oncology, Washington, DC, USA; <sup>696</sup>Lomonosov Moscow State University, Faculty of Basic Medicine, Moscow, Russia; <sup>697</sup>London Research Institute, Cancer Research UK, London, UK; <sup>698</sup>University College London Cancer Institute, London, UK; <sup>699</sup>Lorraine University, CITHÉFOR EA3452, Faculté de Pharmacie, Nancy, France; <sup>700</sup>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; <sup>701</sup>Louisiana State University Health Sciences Center, Department of Biochemistry and Molecular Biology, Shreveport, LA, USA; <sup>702</sup>Louisiana State University Health Sciences Center, Neuroscience Center of Excellence, New Orleans, LA, USA; <sup>703</sup>Lovelace Respiratory Research Institute, Molecular Biology and Lung Cancer Program, Albuquerque, NM, USA; <sup>704</sup>Ludwig-Maximilians-University Munich, Department of Pharmacy, Munich, Germany; <sup>705</sup>Lund University, Biomedical Centre, Department of Experimental Medical Science, Lund, Sweden; <sup>706</sup>Luxembourg Institute of Health and Centre Hospitalier de Luxembourg, Luxembourg; <sup>707</sup>Luxembourg Institute of Health, Laboratory of Experimental Hemato-Oncology, Department of Oncology, Luxembourg City, Luxembourg; <sup>708</sup>Luxembourg Institute of Health, Department of Oncology, Luxembourg City, Luxembourg; <sup>709</sup>Maastricht University, Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht, The Netherlands; <sup>710</sup>Maastricht University, Medical Centre, NUTRIM, Department of Molecular Genetics, Maastricht, The Netherlands; <sup>711</sup>Macau University of Science and Technology, State Key Laboratory of Quality Research in Chinese Medicine, Macau, China; <sup>712</sup>Mackay Memorial Hospital, Department of Radiation Oncology, Taipei, Taiwan; <sup>713</sup>Macquarie University, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Sydney, NSW, Australia; <sup>714</sup>Magna Graecia University, Department of Health Sciences, Catanzaro, Italy; <sup>715</sup>Mahidol University, Department of Anatomy, Faculty of Science, Bangkok, Thailand; <sup>716</sup>Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand; <sup>717</sup>Mahidol University, Salaya Campus, Institute of Molecular Biosciences, Nakorn Pathom, Thailand; <sup>718</sup>Malaysian Institute of Pharmaceuticals and Nutraceuticals, Pulau Pinang, Malaysia; <sup>719</sup>Mannheim University of Applied Sciences, Institute of Molecular and Cell Biology, Mannheim, Germany; <sup>720</sup>Masaryk University, Department of Biology, Faculty of Medicine, Brno, Czech Republic; <sup>721</sup>Massachusetts General Hospital and Harvard Medical School, Center for Human Genetic Research and Department of Neurology, Boston, MA, USA; <sup>722</sup>Massachusetts General Hospital and Harvard Medical School, Cutaneous Biology Research Center, Charlestown, MA; <sup>723</sup>Massachusetts General Hospital and Harvard Medical School, Department of Molecular Biology; Department of Genetics, Boston, MA, USA; <sup>724</sup>Massachusetts General Hospital and Harvard Medical School, Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Charlestown, MA, USA; <sup>725</sup>Massachusetts General Hospital, Division of Infectious Disease, Boston, MA, USA; <sup>726</sup>Massachusetts Institute of Technology, Koch Institute for



Integrative Cancer Research, Cambridge, MA, USA; <sup>727</sup>Max Planck Institute for Biology of Ageing, Cologne, Germany; <sup>728</sup>Max Planck Institute of Biochemistry, Group Maintenance of Genome Stability, Martinsried, Germany; <sup>729</sup>Max Planck Institute of Biochemistry, Molecular Membrane and Organelle Biology, Martinsried, Germany; <sup>730</sup>Max Planck Institute of Biophysical Chemistry, Department of Molecular Cell Biology, Göttingen, Germany; <sup>731</sup>Max Planck Institute of Psychiatry, Translational Research in Psychiatry, Munich, Germany; <sup>732</sup>Mayo Clinic, Department of Biochemistry, Rochester, MN, USA; <sup>733</sup>Mayo Clinic, Department of Neuroscience, Jacksonville, FL, USA; <sup>734</sup>Mayo Clinic, Division of Nephrology and Hypertension, Rochester, MN, USA; <sup>735</sup>Mayo Clinic, Rochester, MN, USA; <sup>736</sup>Mayo Clinic, Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Rochester, MN, USA; <sup>737</sup>McGill University, Department of Anatomy and Cell Biology, Montreal, Canada; <sup>738</sup>McGill University, Department of Biochemistry, Montreal, Quebec, Canada; <sup>739</sup>McGill University, Department of Critical Care, Montreal, Quebec, Canada; <sup>740</sup>McGill University, Department of Neuroscience, Montreal Neurological Institute, Montreal, QC, Canada; <sup>741</sup>McGill University, Department of Pharmacology and Therapeutics, Montreal, Quebec, Canada; <sup>742</sup>McGill University, Goodman Cancer Research Centre and Department of Biochemistry, Montreal, Quebec, Canada; <sup>743</sup>McGill University, Health Centre Research Institute, Meakins Christie Laboratories, Montreal, Quebec, Canada; <sup>744</sup>McGill University, Health Centre, Department of Medicine, Montreal, Quebec, Canada; <sup>745</sup>McGill University, Health Centre Research Institute, Meakins-Christie Laboratories, Montreal, Quebec, Canada; <sup>746</sup>McGill University, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada; <sup>747</sup>McGill University, McGill Parkinson Program, Department of Neurology and Neurosurgery, Montreal, QC, Canada; <sup>748</sup>McGill University, Montreal Neurological Institute, Montreal, QC, Canada; <sup>749</sup>McMaster University, Department of Biology, Hamilton, Ontario, Canada; <sup>750</sup>MD Anderson Cancer Center, Department of Cancer Biology, Houston, TX, USA; <sup>751</sup>MD Anderson Cancer Center, Department of Genomic Medicine, Houston, TX, USA; <sup>752</sup>MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, USA; <sup>753</sup>Medical Center of the Johannes Gutenberg University, Mainz, Germany; <sup>754</sup>Medical College of Wisconsin, Department of Biochemistry, Milwaukee, WI, USA; <sup>755</sup>Medical College of Wisconsin, Department of Pediatrics, Milwaukee, WI, USA; <sup>756</sup>Medical Research Council (MRC), Toxicology Unit, Leicester, UK; <sup>757</sup>Medical School Goethe University, Institute of Biochemistry II, Frankfurt, Germany; <sup>758</sup>Medical University of Graz, Division of Cardiology, Graz, Austria; <sup>759</sup>Medical University of Graz, Institute of Molecular Biology and Biochemistry, Centre of Molecular Medicine, Graz, Austria; <sup>760</sup>Medical University of Lodz, Department of Molecular Pathology and Neuropathology, Lodz, Poland; <sup>761</sup>Medical University of Silesia, Department of Pharmacology, Katowice, Poland; <sup>762</sup>Medical University of South Carolina, Biochemistry and Molecular Biology, Charleston, SC, USA; <sup>763</sup>Medical University of South Carolina, Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Charleston, SC, USA; <sup>764</sup>Medical University of South Carolina, Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Charleston, SC, USA; <sup>765</sup>Medical University of South Carolina, Department of Ophthalmology, Charleston, SC, USA; <sup>766</sup>Medical University of South Carolina, Departments of Drug Discovery and Biomedical Sciences, and Biochemistry and Molecular Biology, Charleston, SC, USA; <sup>767</sup>Medical University of Vienna, Department of Dermatology, CD Lab - Skin Aging, Vienna, Austria; <sup>768</sup>Medical University of Vienna, Department of Dermatology, Vienna, Austria; <sup>769</sup>Medical University of Vienna, Internal Medicine I, Vienna, Austria; <sup>770</sup>MedImmune, Respiratory, Inflammation and Autoimmunity Research Department, Gaithersburg, MD, USA; <sup>771</sup>Meiji University, Department of Life Sciences, Kanagawa, Japan; <sup>772</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>773</sup>Merck KGaA, RandD Merck Serono, Darmstadt, Germany; <sup>774</sup>Merck Research Laboratories, Rahway, NJ, USA; <sup>775</sup>Miami VA Healthcare System and University of Miami Miller School of Medicine, Oncology/Hematology, Miami, FL, USA; <sup>776</sup>Moffitt Cancer Center, Department of Tumor Biology, Tampa, FL, USA; <sup>777</sup>Monash University, Centre for Inflammatory Diseases, Lupus Research Laboratory, Clayton, Victoria, Australia; <sup>778</sup>Monash University, Clayton Campus, Department of Biochemistry and Molecular Biology, Melbourne, Victoria, Australia; <sup>779</sup>Monash University, Department of Biochemistry and Molecular Biology, Victoria, Australia; <sup>780</sup>Monash University, Department of Microbiology, Victoria, Australia; <sup>781</sup>Monash University, School of Biological Sciences, Melbourne, Victoria, Australia; <sup>782</sup>Mossakowski Medical Research Centre, Polish Academy of Sciences, Electron Microscopy Platform, Warsaw, Poland; <sup>783</sup>Icahn School of Medicine at Mount Sinai, Department of Medicine, New York, NY, USA; <sup>784</sup>Icahn School of Medicine at Mount Sinai, Department of Otolaryngology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA; <sup>785</sup>Icahn School of Medicine at Mount Sinai, Department of Pharmacology and Systems Therapeutics, New York, NY, USA; <sup>786</sup>Icahn School of Medicine at Mount Sinai, Division of Hematology and Oncology, Department of Medicine, New York, NY, USA; <sup>787</sup>Icahn School of Medicine at Mount Sinai, Division of Liver Diseases, New York, NY, USA; <sup>788</sup>MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK; <sup>789</sup>MRC Harwell, Mammalian Genetics Unit, Oxfordshire, UK; <sup>790</sup>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine and BRC Translational Immunology Lab, NDM, Oxford, UK; <sup>791</sup>MRC Laboratory of Molecular Biology, Cambridge, UK; <sup>792</sup>MRC Mitochondrial Biology Unit, Cambridge, UK; <sup>793</sup>MRC Toxicology Unit, Leicester, UK; <sup>794</sup>Nagasaki University Graduate School of Biomedical Sciences, Department of Molecular Microbiology and Immunology, Nagasaki, Japan; <sup>795</sup>Nagasaki University, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki, Japan; <sup>796</sup>Nagasaki University, Division of Dental Pharmacology, Graduate School of Biomedical Sciences, Nagasaki, Japan; <sup>797</sup>Nagoya University School of Medicine, Nagoya, Japan; <sup>798</sup>Nagoya University, Research Institute of Environmental Medicine, Nagoya, Aichi, Japan; <sup>799</sup>Nanchang University, Institute of Life Science, Nanchang, China; <sup>800</sup>Nanjing Medical University, Center for Kidney Disease, 2nd Affiliated Hospital, Jiangsu, China; <sup>801</sup>Nanjing Medical University, Department of Neurology, Nanjing First Hospital, Nanjing, China; <sup>802</sup>Nanjing University School of Medicine, Jinling Hospital, Department of Neurology, Nanjing, China; <sup>803</sup>Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing, Jiangsu Province, China; <sup>804</sup>Nanjing University, School of Life Sciences, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing, Jiangsu, China; <sup>805</sup>Nankai University, College of Life Sciences, Tianjin, China; <sup>806</sup>Nanyang Technological University, School of Biological Sciences, Singapore; <sup>807</sup>NARO Institute of Floricultural Science, Tsukuba, Japan; <sup>808</sup>NAS of Ukraine, Department of Molecular Genetics and Biotechnology, Institute of Cell Biology, Lviv, Ukraine; <sup>809</sup>Nasonova Research Institute of Rheumatology, Immunology and Molecular Biology Laboratory, Moscow, Russia; <sup>810</sup>National Academy of Sciences of Ukraine, Department of Biotechnology and Microbiology, Lviv, Ukraine; <sup>811</sup>National and Kapodistrian University of Athens, Department of Cell Biology and Biophysics, Faculty of Biology, Athens, Greece; <sup>812</sup>National Brain Research Centre, Manesar, Gurgaon, India; <sup>813</sup>National Cancer Center, Cancer Cell and Molecular Biology Branch, Division of Cancer Biology, Research Institute, Goyang, Korea; <sup>814</sup>National Cancer Center, Division of Cancer Biology, Research Institute, Gyeonggi, Korea; <sup>815</sup>National Center of Neurology and Psychiatry, Department of Degenerative Neurological Diseases, Kodaira, Tokyo, Japan; <sup>816</sup>National Center of Neurology and Psychiatry, Department of Neuromuscular Research, National Institute of Neuroscience, Tokyo, Japan; <sup>817</sup>National Cheng Kung University, College of Medicine, Department of Pharmacology and Institute of Basic Medical Sciences, Tainan, Taiwan; <sup>818</sup>National Cheng Kung University, Department of Microbiology and Immunology, College of Medicine, Tainan, Taiwan; <sup>819</sup>National Cheng Kung University, Department of Pharmacology, Tainan, Taiwan; <sup>820</sup>National Cheng Kung University, Institute of Clinical Medicine, Tainan, Taiwan; <sup>821</sup>National Cheng Kung University, Medical College, Department of Environmental and Occupational Health, Tainan, Taiwan; <sup>822</sup>National Chung Hsing University, Graduate Institute of Biomedical Sciences, Taichung, Taiwan; <sup>823</sup>National Chung Hsing University, Institute of Molecular Biology, Taichung, Taiwan; <sup>824</sup>National Chung-Hsing University, Institute of Biomedical Sciences, College of Life Sciences, Taichung, Taiwan; <sup>825</sup>National Fisheries Research and Development Institute (NFRDI), Busan, Korea; <sup>826</sup>National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli, Taiwan; <sup>827</sup>National Health Research Institutes, Immunology Research Center, Miaoli, Taiwan; <sup>828</sup>National Health Research Institutes, Institute of Biotechnology and Pharmaceutical Research, Miaoli County, Taiwan; <sup>829</sup>National Ilan University, Department of Biotechnology and Animal Science, Yilan City, Taiwan; <sup>830</sup>National Institute for Basic Biology, Department of Cell Biology, Okazaki, Japan; <sup>831</sup>National Institute for Basic Biology, Sokendai, Okazaki, Japan; <sup>832</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy; <sup>833</sup>National Institute for Infectious Diseases, Department of Epidemiology and Preclinical Research, Translational Research Unit, Rome, Italy; <sup>834</sup>National Institute of Biological Sciences, Beijing, China; <sup>835</sup>National Institute of

Gastroenterology, Laboratory of Experimental Immunopathology, Castellana Grotte (BA), Italy; <sup>836</sup>National Institute of Infectious Diseases, Department of Bacteriology I, Tokyo, Japan; <sup>837</sup>National Institute of Neuroscience, National Center of Neurology and Psychiatry, Department of Degenerative Neurological Diseases, Tokyo, Japan; <sup>838</sup>National Institute of Technology Rourkela, Department of Life Science, Rourkela, Odisha, India; <sup>839</sup>National Institute on Aging, Intramural Research Program, Laboratory of Neurosciences, Baltimore, MD, USA; <sup>840</sup>National Institute on Aging, National Institutes of Health, Biomedical Research Center, RNA Regulation Section, Laboratory of Genetics, Baltimore, MD, USA; <sup>841</sup>National Institutes of Health, Cardiovascular Branch, NHLB, Bethesda, MD, USA; <sup>842</sup>National Institutes of Health, Cell Biology and Physiology Center, National Heart, Lung, and Blood Institute, Bethesda, MD, USA; <sup>843</sup>National Institutes of Health, Cell Biology Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA; <sup>844</sup>National Institutes of Health, Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD, USA; <sup>845</sup>National Institutes of Health, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; <sup>846</sup>National Institutes of Health, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; <sup>847</sup>National Institutes of Health, National Cancer Institute, Urologic Oncology Branch, Bethesda, MD, USA; <sup>848</sup>National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, USA; <sup>849</sup>National Institutes of Health, National Institute of Allergy and Infectious Disease, Cytokine Biology Section, Bethesda, MD, USA; <sup>850</sup>National Institutes of Health, National Institute of Environmental Health Sciences, Clinical Research Program, Research Triangle Park, NC, USA; <sup>851</sup>National Institutes of Health, National Institute on Aging, Biomedical Research Center, Laboratory of Neurosciences, Baltimore, MD, USA; <sup>852</sup>National Institutes of Health, NIAID, Laboratory of Systems Biology, Bethesda, MD, USA; <sup>853</sup>National Institutes of Health, NIAMS, Laboratory of Muscle Stem Cells and Gene Regulation, Bethesda, MD, USA; <sup>854</sup>National Institutes of Health, NIDDK, Genetics of Development and Disease Branch, Bethesda, MD, USA; <sup>855</sup>National Institutes of Health, NIDDK, LCMB, Bethesda, MD, USA; <sup>856</sup>National Institutes of Health, Rocky Mountain Laboratories, NIAID, Coxiella Pathogenesis Section, Hamilton, MT, USA; <sup>857</sup>National Jewish Health, Denver, CO, USA; <sup>858</sup>Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, Germany; <sup>859</sup>National Neuroscience Institute, Singapore; <sup>860</sup>National Research Council (CNR), Institute of Translational Pharmacology (IFT), Rome, Italy; <sup>861</sup>National Research Council, Institute of Food Sciences, Avellino, Italy; <sup>862</sup>National Sun Yat-Sen University, Department of Biological Sciences, Kaohsiung, Taiwan; <sup>863</sup>National Taiwan University, Department of Life Science and Center for Biotechnology, Taipei, Taiwan; <sup>864</sup>National Taiwan University, Department of Life Science, Institute of Molecular and Cellular Biology, Taipei, Taiwan; <sup>865</sup>National Taiwan University, Department of Life Science, Taipei, Taiwan; <sup>866</sup>National Taiwan University, Department of Pharmacology, College of Medicine, Taipei, Taiwan; <sup>867</sup>National Taiwan University, Department of Urology, College of Medicine, Taipei, Taiwan; <sup>868</sup>National Taiwan University, Graduate Institute of Brain and Mind Sciences, College of Medicine, Taipei, Taiwan; <sup>869</sup>National Taiwan University, Institute of Molecular Medicine, College of Medicine, Taipei, Taiwan; <sup>870</sup>Department of Cardiology, Nanhai Hospital Affiliated to Southern Medical University, Foshan, Guangdong Province, China; <sup>871</sup>National Tsing Hua University, Department of Chemical Engineering, Hsinchu, Taiwan; <sup>872</sup>National Tsing Hua University, Institute of Biotechnology, Institute of Systems Neuroscience, and Department of Life Science, HsinChu City, Taiwan; <sup>873</sup>National University Cancer Institute, National University Health System, Singapore; <sup>874</sup>National University of Ireland, Apoptosis Research Centre, Galway, Ireland; <sup>875</sup>National University of Ireland, Pharmacology and Therapeutics, Galway, Ireland; <sup>876</sup>National University of Ireland, Regenerative Medicine Institute, Galway, Ireland; <sup>877</sup>National University of Singapore, Department of Biological Sciences, Singapore; <sup>878</sup>National University of Singapore, Department of Pharmacy, Singapore; <sup>879</sup>National University of Singapore, Department of Physiology, Singapore; <sup>880</sup>National University of Singapore, Department of Physiology, Yong Loo Lin School of Medicine, Singapore; <sup>881</sup>National University of Singapore, Yong Loo Lin School of Medicine, Department of Biochemistry, Singapore; <sup>882</sup>National University of Singapore, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), Singapore; <sup>883</sup>Nationwide Children's Hospital, Center for Microbial Pathogenesis, Columbus, OH, USA; <sup>884</sup>INCI, CNRS UPR3212, Institut des Neurosciences Cellulaires and Intégratives, Strasbourg, France; <sup>885</sup>NCI/CCR, Basic Research Laboratory, Frederick, MD, USA; <sup>886</sup>Nencki Institute of Experimental Biology, Neurobiology Center, Laboratory of Molecular Neurobiology, Warsaw, Poland; <sup>887</sup>Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute-CIBERNED, Barcelona, Spain; <sup>888</sup>Neurogenomik, Neurosciences Department, Faculty of Medicine and Odontology, University of Basque, Leioa, Spain; <sup>889</sup>Neuroscience Research Institute, Santa Barbara, CA, USA; <sup>890</sup>Neurounion Biomedical Foundation, Santiago, Chile; <sup>891</sup>New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA; <sup>892</sup>New York Institute of Technology, Department of Biomedical Sciences, College of Osteopathic Medicine, Old Westbury, NY, USA; <sup>893</sup>New York Medical College, Department of Medicine, Pharmacology, and Physiology, Valhalla, NY, USA; <sup>894</sup>New York University Langone Medical Center, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; <sup>895</sup>New York University School of Medicine, Departments of Neuroscience and Physiology, and Psychiatry, New York, NY, USA; <sup>896</sup>New York University School of Medicine, Skirball Institute, Department of Microbiology, New York, NY, USA; <sup>897</sup>New York University, Department of Psychiatry, New York, NY; and Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA; <sup>898</sup>New York University, Department of Psychiatry, New York, NY, USA; <sup>899</sup>New York University, Nathan Kline Institute, Orangeburg, NY, USA; <sup>900</sup>Newcastle University, Campus for Ageing and Vitality, Institute for Cell and Molecular Biosciences and Institute for Ageing, Newcastle upon Tyne, UK; <sup>901</sup>Newcastle University, The Medical School, Institute of Cellular Medicine, Newcastle upon Tyne, UK; <sup>902</sup>New York-Presbyterian Hospital/Weill-Cornell Medical Center, New York, NY, USA; <sup>903</sup>Niigata University Graduate School of Medical and Dental Sciences, Laboratory of Biosignaling, Niigata, Japan; <sup>904</sup>Niigata University, School of Medicine, Department of Biochemistry, Niigata, Japan; <sup>905</sup>NINDS, National Institutes of Health, Synaptic Function Section, Bethesda, MD, USA; <sup>906</sup>Nippon Medical School, Department of Cardiovascular Medicine, Tokyo, Japan; <sup>907</sup>North Dakota State University, Department of Chemistry and Biochemistry, Fargo, ND, USA; <sup>908</sup>North Shore University Hospital, Department of Emergency Medicine, Manhasset, NY, USA; <sup>909</sup>Northeastern University, Department of Bioengineering, Boston, MA, USA; <sup>910</sup>Northern Illinois University, Department of Biological Sciences, DeKalb, IL, USA; <sup>911</sup>Northwestern University, Department of Cell and Molecular Biology, Feinberg School of Medicine, Chicago, IL, USA; <sup>912</sup>Northwestern University, Department of Neurology, Feinberg School of Medicine, Chicago, IL, USA; <sup>913</sup>Northwestern University, Division of Hematology/Oncology, Chicago, IL, USA; <sup>914</sup>Northwestern University, Feinberg School of Medicine, Department of Neurology, Chicago, IL, USA; <sup>915</sup>Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; <sup>916</sup>Norwegian Veterinary Institute, Oslo, Norway; <sup>917</sup>Obihiro University of Agriculture and Veterinary Medicine, National Research Center for Protozoan Diseases, Obihiro, Hokkaido, Japan; <sup>918</sup>Ohio State University, Department of Microbial Infection and Immunity, Columbus, OH, USA; <sup>919</sup>Ohio State University, Department of Molecular and Cellular Biochemistry, Columbus, OH, USA; <sup>920</sup>Ohio State University, Department of Molecular Genetics, Columbus, OH, USA; <sup>921</sup>Ohio State University, Department of Surgery, Davis Heart and Lung Research Institute, Columbus, OH, USA; <sup>922</sup>Ohio State University, Department of Veterinary Biosciences, College of Veterinary Medicine, Columbus, OH, USA; <sup>923</sup>Ohio State University, DHLRI, Department of Medicine, Columbus, OH, USA; <sup>924</sup>Ohio State University, The James Comprehensive Cancer Center, Department of Molecular Virology, Immunology and Medical Genetics and Department of Surgery, Division of Surgical Oncology, Columbus, OH, USA; <sup>925</sup>Ohio University, Division of Physical Therapy, Athens, OH, USA; <sup>926</sup>Oregon Health and Science University, Casey Eye Institute, Portland, OR, USA; <sup>927</sup>Oregon Health and Science University, Knight Cardiovascular Institute, Portland, OR, USA; <sup>928</sup>Oregon State University, Department of Pharmaceutical Sciences, College of Pharmacy, Corvallis, OR, USA; <sup>929</sup>Osaka Prefecture University, Graduate School of Life and Environmental Science, Osaka, Japan; <sup>930</sup>Osaka University Graduate School of Dentistry, Department of Preventive Dentistry, Osaka, Japan; <sup>931</sup>Osaka University Graduate School of Medicine, Department of Nephrology, Osaka, Japan; <sup>932</sup>Osaka University Graduate School of Medicine, Department of Pediatrics, Osaka, Japan; <sup>933</sup>Osaka University, Department of Genetics, Graduate School of Medicine, Laboratory of Intracellular Membrane Dynamics, Graduate School of Frontier Biosciences, Osaka, Japan; <sup>934</sup>Osaka University, Department of Genetics, Graduate School of Medicine, Osaka, Japan; <sup>935</sup>Osaka University, Graduate School of Dentistry, Osaka, Japan; <sup>936</sup>Osaka University, Graduate School of Frontier Biosciences, Osaka, Japan;

<sup>937</sup>Oslo University Hospital, Center for Eye Research, Oslo, Norway; <sup>938</sup>Oslo University Hospital, Centre for Cancer Biomedicine, Oslo, Norway; <sup>939</sup>Oslo University Hospital, Centre for Immune Regulation, Oslo, Norway; <sup>940</sup>Oslo University Hospital, Department of Biochemistry, Institute for Cancer Research, Oslo, Norway; <sup>941</sup>Oslo University Hospital, Department of Molecular Cell Biology, Institute for Cancer Research, Oslo, Norway; <sup>942</sup>Oslo University Hospital, Institute for Microbiology, Oslo, Norway; <sup>943</sup>University of Oslo and Oslo University Hospital, Prostate Cancer Research Group, Centre for Molecular Medicine (Norway), Oslo, Norway; <sup>944</sup>Otto-von-Guericke-University Magdeburg, Department of General, Visceral and Vascular Surgery, Magdeburg, Germany; <sup>945</sup>Otto-von-Guericke-University Magdeburg, Institute of Molecular and Clinical Immunology, Magdeburg, Germany; <sup>946</sup>Oviedo University, Morphology and Cellular Biology Department, Oviedo, Spain; <sup>947</sup>Oxford University, Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Molecular Oncology Laboratories, Oxford, UK; <sup>948</sup>Paris Cardiovascular Research Center - PARCC, Clichy, France; <sup>949</sup>Paris Descartes University-Sorbonne Paris Cité, Imagine Institute, Paris, France; <sup>950</sup>Paris Diderot University, Sorbonne Paris Cité, INSERM, CNRS, Paris, France; <sup>951</sup>Peking University First Hospital, Department of Internal Medicine, Beijing, China; <sup>952</sup>Peking University First Hospital, Renal Division, Beijing, China; <sup>953</sup>Peking University, Department of Immunology, Beijing, China; <sup>954</sup>Peking University, Department of Medicine, Beijing, China; <sup>955</sup>Peking University, Health Science Center, Center for Human Disease Genomics, Beijing, China; <sup>956</sup>Peking University, Health Science Center, Department of Biochemistry and Molecular Biology, Beijing, China; <sup>957</sup>Peking University, Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing, China; <sup>958</sup>Pennsylvania State University, College of Medicine, Department of Cellular and Molecular Physiology, Hershey, PA, USA; <sup>959</sup>Pennsylvania State University, College of Medicine, Department of Pediatrics, Hershey, PA, USA; <sup>960</sup>Pennsylvania State University, College of Medicine, Department of Pharmacology, Hershey, PA, USA; <sup>961</sup>Pennsylvania State University, College of Medicine, Department of Pharmacology, Pennsylvania State University Hershey Cancer Institute, Hershey, PA, USA; <sup>962</sup>Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA; <sup>963</sup>Pennsylvania State University, College of Medicine, Hershey Cancer Institute and Department of Pediatrics, Hershey, PA, USA; <sup>964</sup>Pennsylvania State University, Department of Biochemistry and Molecular Biology, Center for Eukaryotic Gene Regulation, University Park, PA, USA; <sup>965</sup>Perelman School of Medicine at the University of Pennsylvania, Department of Genetics, Philadelphia, PA, USA; <sup>966</sup>Perelman School of Medicine at the University of Pennsylvania, Departments of Pediatrics and Systems Pharmacology and Translational Therapeutics, Philadelphia, PA, USA; <sup>967</sup>Pfizer Inc., Drug Safety Research and Development, San Diego, CA, USA; <sup>968</sup>Plymouth University, Peninsula School of Medicine and Dentistry, Plymouth, UK; <sup>969</sup>Polish Academy of Sciences, Institute of Biochemistry and Biophysics, Warsaw, Poland; <sup>970</sup>Polytechnic University of Marche, Department of Clinical Science, Faculty of Medicine, Ancona, Italy; <sup>971</sup>Polytechnic University of Marche, Department of Life and Environmental Sciences, Ancona, Italy; <sup>972</sup>Pontificia Universidad Católica de Chile, Physiology Department, Santiago, Chile; <sup>973</sup>Post Graduate Institute of Medical Education and Research (PGIMER), Department of Biophysics, Chandigarh, India; <sup>974</sup>Post Graduate Institute of Medical Education and Research (PGIMER), Department of Urology, Chandigarh, India; <sup>975</sup>Program in Rare and Genetic Diseases, Centro de Investigación Príncipe Felipe (CIPF), IBV/CSIC Associated Unit at CIPF, Valencia, Spain; <sup>976</sup>Providence Portland Medical Center, Earle A. Chiles Research Institute, Portland, OR, USA; <sup>977</sup>Public Health England, Health Protection Services, Modelling and Economics Unit, Colindale, London, UK; <sup>978</sup>Pusan National University, Department of Biological Sciences, Busan, Korea; <sup>979</sup>Qilu Hospital of Shandong University, Cardiology, Jinan, Shandong, China; <sup>980</sup>Qilu Hospital of Shandong University, Department of Traditional Chinese Medicine, Jinan, China; <sup>981</sup>Qingdao University, Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao, Shandong Province, China; <sup>982</sup>Queen Elizabeth Hospital, Department of Clinical Oncology, Kowloon, Hong Kong; <sup>983</sup>Queen Mary University of London, Blizard Institute, Centre for Cell Biology and Cutaneous Research, London, UK; <sup>984</sup>Queen Mary University of London, Barts Cancer Institute, Center for Molecular Oncology, London, UK; <sup>985</sup>Queen Mary University of London, Blizard Institute, Department of Neuroscience and Trauma, London, UK; <sup>986</sup>Queen Mary University of London, Blizard Institute, Flow Cytometry Core Facility, London, UK; <sup>987</sup>Queen Mary University of London, Centre for Haemato-Oncology, Barts Cancer Institute, London, UK; <sup>988</sup>Queens College of the City University of New York, Department of Biology, Flushing, NY, USA; <sup>989</sup>Queen's University of Belfast, Centre for Experimental Medicine, Belfast, UK; <sup>990</sup>Radboud University Nijmegen Medical Center, Department of Internal Medicine, Division of Endocrinology, Nijmegen, The Netherlands; <sup>991</sup>Radboud University Nijmegen Medical Center, Department of Internal Medicine, Nijmegen, The Netherlands; <sup>992</sup>Radboud University Nijmegen Medical Center, Department of Radiation Oncology, Nijmegen, The Netherlands; <sup>993</sup>Radboud University, Institute for Molecules and Materials, Department of Molecular Materials, Nijmegen, The Netherlands; <sup>994</sup>Regina Elena National Cancer Institute, Experimental Chemotherapy Laboratory, Rome, Italy; <sup>995</sup>Research Center Borstel, Borstel, Germany; <sup>996</sup>Rice University, Chemical and Biomolecular Engineering, Houston, TX, USA; <sup>997</sup>Rice University, Department of BioSciences, Houston, TX, USA; <sup>998</sup>RIKEN Brain Science Institute, Laboratory for Developmental Neurobiology, Saitama, Japan; <sup>999</sup>RIKEN Global Research Cluster, Glycometabolome Team, Systems Glycobiology Research Group, Saitama, Japan; <sup>1000</sup>Rio de Janeiro Federal University, Instituto de Biofísica Carlos Chagas Filho, Rio de Janeiro, Brazil; <sup>1001</sup>Ritsumeikan University, Department of Biotechnology, Shiga, Japan; <sup>1002</sup>Rockefeller University, New York, NY, USA; <sup>1003</sup>Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics, Buffalo, NY, USA; <sup>1004</sup>Royal College of Surgeons in Ireland, Department of Physiology and Medical Physics, Dublin, Ireland; <sup>1005</sup>Royal Military College, Chemistry and Chemical Engineering, Kingston, ON, Canada; <sup>1006</sup>Royal North Shore Hospital, Cardiovascular and Hormonal Research Laboratory, Royal North Shore Hospital and Kolling Institute, Sydney, NSW, Australia; <sup>1007</sup>Ruhr University Bochum, Biochemie Intrazellulärer Transportprozesse, Bochum, Germany; <sup>1008</sup>Ruhr University Bochum, Department of Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany; <sup>1009</sup>Ruhr University Bochum, Medical Faculty, System Biochemistry, Bochum, Germany; <sup>1010</sup>Ruhr University Bochum, University Hospital Bergmannsheil, Department of Neurology, Heimer Institute for Muscle Research, Bochum, Germany; <sup>1011</sup>Ruprecht-Karls-University Heidelberg, Division of Pediatric Neurology, Department of Pediatrics, Heidelberg University Hospital, Heidelberg, Germany; <sup>1012</sup>Rush University Medical Center, Department of Anatomy and Cell Biology, Chicago, IL, USA; <sup>1013</sup>Russian Academy of Sciences, Kazan Institute of Biochemistry and Biophysics, Kazan, Tatarstan, Russia; <sup>1014</sup>Rutgers New Jersey Medical School, Department of Cell Biology and Molecular Medicine, Newark, NJ, USA; <sup>1015</sup>Rutgers University, Department of Cell Biology and Neuroscience, Piscataway, NJ, USA; <sup>1016</sup>Rutgers University, Molecular Biology and Biochemistry, Piscataway, NJ, USA; <sup>1017</sup>Rutgers University, New Jersey Medical School, Department of Cell Biology and Molecular Medicine, Newark, NJ, USA; <sup>1018</sup>Rutgers University, The State University of New Jersey, Department of Cell Biology and Neuroscience, Piscataway, NJ, USA; <sup>1019</sup>Rutgers University, The State University of New Jersey, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>1020</sup>Rutgers University-Robert Wood Johnson Medical School, Pharmacology Department, Piscataway, NJ, USA; <sup>1021</sup>Rutgers University-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, Piscataway, NJ, USA; <sup>1022</sup>Sabancı University, Molecular Biology, Genetics and Bioengineering Program, Istanbul, Turkey; <sup>1023</sup>SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain; <sup>1024</sup>Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, USA; <sup>1025</sup>Saitama Medical University, Saitama Medical Center, Department of General Thoracic Surgery, Saitama, Japan; <sup>1026</sup>Saitama University, Graduate School of Science and Engineering, Saitama, Japan; <sup>1027</sup>San Diego State University, Department of Biology and Center for Microbial Sciences, San Diego, CA, USA; <sup>1028</sup>San Diego State University, Department of Biology, San Diego, CA, USA; <sup>1029</sup>San Paolo Hospital Medical School, Unit of Obstetrics and Gynecology, Milano, Italy; <sup>1030</sup>San Raffaele Institute, Dept. of Therapeutic Research and Medicine Evaluation, Sirmione, L'Aquila, Italy; <sup>1031</sup>Sanford Burnham Prebys NCI-Cancer Center, Cell Death and Survival Networks Program, La Jolla, CA, USA; <sup>1032</sup>Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA; <sup>1033</sup>Sanford Burnham Medical Research Institute, Cell Death and Survival Networks Program, La Jolla, CA, USA; <sup>1034</sup>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA; <sup>1035</sup>Sangamo Biosciences, Richmond, CA, USA; <sup>1036</sup>Sanofi, Vitry Sur Seine, France; <sup>1037</sup>São Paulo University, Biochemistry Department; and Santo Amaro University, Life Sciences, São Paulo, Brazil; <sup>1038</sup>Sapienza University

of Rome, DAHFMO-Section of Histology, Rome, Italy; <sup>1039</sup>Sapienza University of Rome, DAHFMO-Section of Anatomy, Rome, Italy; <sup>1040</sup>Sapienza University of Rome, Department of Biochemical Sciences "A. Rossi Fanelli", Rome, Italy; <sup>1041</sup>Sapienza University of Rome, Department of Clinical and Molecular Medicine, Rome, Italy; <sup>1042</sup>Sapienza University of Rome, Department of Experimental Medicine, Rome, Italy; <sup>1043</sup>Sapienza University of Rome, Department of Molecular Medicine, Rome, Italy; <sup>1044</sup>Sapporo Medical University School of Medicine, Department of Pharmacology, Sapporo, Japan; <sup>1045</sup>Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, Italy; <sup>1046</sup>Scientific Institute IRCCS Eugenio Medea, Laboratory of Molecular Biology, Bosisio Parini, Lecco, Italy; <sup>1047</sup>Second Hospital of Lanzhou University, Key Laboratory of Digestive System Tumors, Gansu, China; <sup>1048</sup>Second Military Medical University, Department of Cardiothoracic Surgery, Changzheng Hospital, Shanghai, China; <sup>1049</sup>Second Military Medical University, Department of Pharmacology, Shanghai, China; <sup>1050</sup>Second University of Naples, Department of Biochemistry and Biophysics, Naples, Italy; <sup>1051</sup>Second University of Naples, Department of Biochemistry, Biophysics and General Pathology, Naples, Italy; <sup>1052</sup>Semmelweis University, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Budapest, Hungary; <sup>1053</sup>Semmelweis University, Institute of Human Physiology and Clinical Experimental Research, Budapest, Hungary; <sup>1054</sup>Seoul National University College of Medicine, Department of Advanced Education for Clinician-Scientists (AECS), Seoul, Korea; <sup>1055</sup>Seoul National University College of Medicine, Department of Ophthalmology, Seoul, Korea; <sup>1056</sup>Seoul National University College of Medicine, Department of Physiology and Biomedical Sciences, Seoul, Korea; <sup>1057</sup>Seoul National University College of Medicine, Neuroscience Research Institute, Department of Medicine, Seoul, Korea; <sup>1058</sup>Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea; <sup>1059</sup>Seoul National University, College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul, Korea; <sup>1060</sup>Seoul National University, Department of Biological Sciences, Seoul, Korea; <sup>1061</sup>Seoul National University, College of Pharmacy, Seoul, Korea; <sup>1062</sup>Seoul National University, Department of Plant Science, Seoul, Korea; <sup>1063</sup>Seoul National University, Protein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul, Korea; <sup>1064</sup>Seoul St. Mary's Hospital, Department of Internal Medicine, Seoul, Korea; <sup>1065</sup>Shandong Agricultural University, State Key Laboratory of Crop Science, Tai'an, China; <sup>1066</sup>Shandong University, Department of Toxicology, Jinan, Shandong, China; <sup>1067</sup>Shandong University, School of Chemistry and Chemical Engineering, Jinan, Shandong, China; <sup>1068</sup>Shandong University, School of Life Sciences, Jinan, China; <sup>1069</sup>Shandong University, School of Medicine, Department of Pharmacology, Jinan, Shandong Province, China; <sup>1070</sup>Shanghai Institute of Materia Medica, Division of Antitumor Pharmacology, Shanghai, China; <sup>1071</sup>Shanghai Jiao Tong University, Bio-X Institutes, Shanghai, China; <sup>1072</sup>Shanghai Jiao Tong University, Department of Endocrinology and Metabolism, Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai, China; <sup>1073</sup>Shanghai Jiao Tong University, School of Biomedical Engineering and Med-X Research Institute, Shanghai, China; <sup>1074</sup>Shanghai Jiao Tong University, School of Life Sciences and Biotechnology, Shanghai, China; <sup>1075</sup>Shanghai Jiao Tong University, School of Medicine, Center for Reproductive Medicine, Renji Hospital, Shanghai, China; <sup>1076</sup>Shanghai Jiao Tong University, School of Medicine, Department of Biochemistry and Molecular Biology, Shanghai, China; <sup>1077</sup>Shanghai Jiao Tong University, School of Medicine, Department of Pharmacology and Chemical Biology, Shanghai, China; <sup>1078</sup>Shanghai Jiao Tong University, School of Medicine, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai, China; <sup>1079</sup>Shanghai Jiao Tong University, School of Medicine, Renji Hospital, Shanghai, China; <sup>1080</sup>Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of Hypertension, Shanghai, China; <sup>1081</sup>Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of Immunology, Shanghai, China; <sup>1082</sup>Shanghai Jiao Tong University, School of Medicine, State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Shanghai Rui Jin Hospital, Shanghai, China; <sup>1083</sup>Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai, China; <sup>1084</sup>University of Sharjah, College of Medicine, United Arab Emirates; <sup>1085</sup>Shanghai Jiao Tong University, School of Medicine, Renji Hospital, Shanghai, China; <sup>1086</sup>Shanghai Medical School of Fudan University, Department of Anatomy, Histology and Embryology, Shanghai, China; <sup>1087</sup>Shanghai University of Traditional Chinese Medicine, Department of Biochemistry, Shanghai, China; <sup>1088</sup>Shanghai Veterinary Research Institute, Shanghai, China; <sup>1089</sup>Shantou University Medical College, Cancer Research Center, Shantou, Guangdong, China; <sup>1090</sup>Shantou University Medical College, Department of Biochemistry and Molecular Biology, Shantou, China; <sup>1091</sup>Shin Kong Wu Ho-Su Memorial Hospital, Department of Urology, Taipei, Taiwan; <sup>1092</sup>Sichuan University, Aging Research Group, State Key Lab for Biotherapy, West China Hospital, Chengdu, China; <sup>1093</sup>Sichuan University, Key Laboratory of Bio-Resources and Eco-Environment of Ministry of Education, College of Life Science, Chengdu, Sichuan, China; <sup>1094</sup>Sichuan University, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, China; <sup>1095</sup>Sichuan University, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy; West China Hospital, Chengdu, China; <sup>1096</sup>Sichuan University, West China Hospital, State Key Laboratory of Biotherapy, Sichuan, China; <sup>1097</sup>Sidra Medical and Research Centre, Doha, Qatar; <sup>1098</sup>Simon Fraser University, Department of Molecular Biology and Biochemistry, Burnaby, BC, Canada; <sup>1099</sup>Singapore Eye Research Institute, Singapore National Eye Center, Singapore; <sup>1100</sup>Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Department of Medical Oncology, Hangzhou, China; <sup>1101</sup>Sixth Affiliated Hospital of Sun Yat-Sen University, Gastrointestinal Institute, Department of Radiation Oncology, Guangzhou, Guangdong, China; <sup>1102</sup>Soochow University, College of Pharmaceutical Sciences, Jiangsu, China; <sup>1103</sup>Soochow University, Department of Neurology, Second Affiliated Hospital of Soochow University and Institute of Neuroscience, Suzhou, China; <sup>1104</sup>Soochow University, Department of Pathogenic Biology, Suzhou, Jiangsu, China; <sup>1105</sup>Soochow University, School of Pharmaceutical Science, Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Suzhou, China; <sup>1106</sup>Soochow University, School of Pharmaceutical Science, Department of Pharmacology, Laboratory of Aging and Nervous Diseases, Su Zhou, Jiangsu Province, China; <sup>1107</sup>Soochow University, School of Pharmaceutical Science, Department of Pharmacology, Suzhou, China; <sup>1108</sup>Sorbonne Universités, CNRS, UPMC, Univ Paris 06, UMR 7622, IBPS, Paris, France; <sup>1109</sup>Sorbonne Universités, UMR S1127, Paris, France; <sup>1110</sup>Sorbonne Universités, University Pierre and Marie Curie, Paris 6, Brain and Spine Institute, INSERM U1127, CNRS UMR722, Paris, France; <sup>1111</sup>Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center for Immunology and Microbial Infections – CIMI-Paris, Paris, France; <sup>1112</sup>Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS974, CNRS FRE 3617, Center for Research in Myology, Paris, France; <sup>1113</sup>South China Normal University, College of Biophotonics, Guangdong, China; <sup>1114</sup>Southern Medical University, Department of Cardiology, Nanfang Hospital, Guangzhou, China; <sup>1115</sup>Southern Medical University, School of Pharmaceutical Sciences, Guangzhou, Guangdong, China; <sup>1116</sup>Spanish Council for Scientific Research, Institute for Advanced Chemistry of Catalonia, Department of Biomedical Chemistry, Barcelona, Spain; <sup>1117</sup>Spanish National Cancer Research Centre (CNIO), Cell Division and Cancer Group, Madrid, Spain; <sup>1118</sup>St. Anna Kinderkrebsforschung, Children's Cancer Research Institute, Immunological Diagnostics, Vienna, Austria; <sup>1119</sup>Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Cell and Molecular Biology, Memphis, TN, USA; <sup>1120</sup>St. Jude Children's Research Hospital, Department of Immunology, Memphis, TN, USA; <sup>1121</sup>St. Jude Children's Research Hospital, Department of Pathology, Memphis, TN, USA; <sup>1122</sup>St. Jude Children's Research Hospital, Department of Structural Biology, Memphis, TN, USA; <sup>1123</sup>St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>1124</sup>St. Louis University School of Medicine, Department of Biochemistry and Molecular Biology, St. Louis, MO, USA; <sup>1125</sup>St. Marianna University School of Medicine, Department of Ophthalmology, Kawasaki, Kanagawa, Japan; <sup>1126</sup>St. Marianna University School of Medicine, Department of Physiology, Kanagawa, Japan; <sup>1127</sup>St. Paul's Hospital, Centre for Heart Lung Innovation, Vancouver, BC, Canada; <sup>1128</sup>Stanford University, Department of Microbiology and Immunology, Stanford, CA, USA; <sup>1129</sup>Stanford University, Department of Radiation Oncology, Stanford, CA, USA; <sup>1130</sup>Stanford University, School of Medicine, Department of Pathology, Stanford, CA, USA; <sup>1131</sup>Stanford University, School of Medicine, Departments of Radiation Oncology and Genetics, Stanford, CA, USA; <sup>1132</sup>Stanford University, School of Medicine, Stanford, CA, USA; <sup>1133</sup>State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, Beijing, China; <sup>1134</sup>State University of New York, College of Medicine, Departments of Medicine, Microbiology and Immunology, Biochemistry and Molecular Biology, Syracuse, NY, USA; <sup>1135</sup>State University of New York,

College of Nanoscale Science and Engineering, Albany, NY, USA; <sup>1136</sup>Stellenbosch University, Department of Physiological Sciences, Stellenbosch, South Africa; <sup>1137</sup>Stephen A. Wynn Institute for Vision Research, Iowa City, IA, USA; <sup>1138</sup>Stockholm University, Department of Neurochemistry, Stockholm, Sweden; <sup>1139</sup>Stony Brook University, Department of Molecular Genetics and Microbiology, Stony Brook, NY, USA; <sup>1140</sup>Stony Brook University, Department of Pathology, Stony Brook, NY, USA; <sup>1141</sup>Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, Department of Chemistry and Biotechnology, Uppsala BioCenter, Uppsala, Sweden; <sup>1142</sup>Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; <sup>1143</sup>Sun Yat-Sen University, Department of Neurology and Stroke Center, The First Affiliated Hospital, Guangzhou, China; <sup>1144</sup>Sun Yat-Sen University, Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Guangzhou, China; <sup>1145</sup>Sun Yat-Sen University, Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Science, Guangzhou, China; <sup>1146</sup>Sun Yat-Sen University, School of Chemistry and Chemical Engineering, Guangzhou, China; <sup>1147</sup>Sun Yat-Sen University, School of Life Sciences, Guangzhou, China; <sup>1148</sup>Sun Yat-Sen University, State Key Laboratory of Biotechnology, School of Life Sciences, Guangzhou, China; <sup>1149</sup>Sun Yat-Sen University, State Key Laboratory of Oncology in South China, Cancer Center, Guangzhou, China; <sup>1150</sup>Yonsei University College of Medicine, Severans Biomedical Science Institute and Department of Internal Medicine, Seoul, Korea; <sup>1151</sup>Sunnybrook Research Institute; and University of Toronto, Department of Biochemistry, Toronto, Ontario, Canada; <sup>1152</sup>Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, Department of Plant Biology, Uppsala BioCenter, Uppsala, Sweden; <sup>1153</sup>Taichung Veterans General Hospital, Department of Medical Research, Taichung City, Taiwan; <sup>1154</sup>Taipei Medical University, Department of Biochemistry, College of Medicine, Taipei City, Taiwan; <sup>1155</sup>Taipei Medical University, Department of Microbiology and Immunology, Institute of Medical Sciences, Taipei, Taiwan; <sup>1156</sup>Taipei Medical University, Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei, Taiwan; <sup>1157</sup>Tamkang University, Department of Chemistry, Tamsui, New Taipei City, Taiwan; <sup>1158</sup>Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland; <sup>1159</sup>Technical University Munich, Institute of Human Genetics, Munich, Bavaria, Germany; <sup>1160</sup>Technion-Israel Institute of Technology, The Rappaport Faculty of Medicine and Research Institute, Department of Biochemistry, Haifa, Israel; <sup>1161</sup>Technion-Israel Institute of Technology, Unit of Anatomy and Cell Biology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; <sup>1162</sup>Technische Universität Braunschweig, Biozentrum, Braunschweig, Germany; <sup>1163</sup>Technische Universität München, Department of Neurology, Munich, Germany; <sup>1164</sup>Technische Universität München, II. Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany; <sup>1165</sup>Technische Universität München, Plant Systems Biology, Freising, Germany; <sup>1166</sup>Tel Aviv University, Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv, Israel; <sup>1167</sup>Tel Aviv University, Department of Neurobiology, Tel-Aviv, Israel; <sup>1168</sup>Tel Aviv University, Oncogenetic Laboratory, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv, Israel; <sup>1169</sup>Tel Aviv University, Sackler Faculty of Medicine, Department of Cell and Developmental Biology, Tel Aviv, Israel; <sup>1170</sup>Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel; <sup>1171</sup>Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy; <sup>1172</sup>Temasek Life Sciences Laboratory, Singapore; <sup>1173</sup>Temple University, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Philadelphia, PA, USA; <sup>1174</sup>Temple University, School of Medicine, Department of Biochemistry; and Center for Translational Medicine, Philadelphia, PA, USA; <sup>1175</sup>Texas A&M Health Science Center, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Houston, TX, USA; <sup>1176</sup>Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, TX, USA; <sup>1177</sup>Texas A&M University Health Science Center, Center for Translational Cancer Research, Institute of Bioscience and Technology, Houston, TX, USA; <sup>1178</sup>Texas A&M University Health Science Center, Center for Translational Cancer Research, Institute of Biosciences and Technology, Houston, TX, USA; <sup>1179</sup>Texas A&M University, Department of Biochemistry and Biophysics, College Station, TX, USA; <sup>1180</sup>Texas A&M University, Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX, USA; <sup>1181</sup>Texas A&M University, Texas A&M Health Science Center, College of Medicine, Institute of Biosciences and Technology, Houston, TX, USA; <sup>1182</sup>Texas A&M University, The Norman Borlaug Center, College Station, TX, USA; <sup>1183</sup>The Feinstein Institute for Medical Research, Laboratory of Developmental Erythropoiesis, Manhasset, NY; <sup>1184</sup>The Feinstein Institute for Medical Research, North Shore LIJ Health System, Litwin-Zucker Research Center for the Study of Alzheimer's Disease, New York, NY, USA; <sup>1185</sup>The First Affiliated Hospital of Anhui Medical University, Department of Pulmonary, Anhui Geriatric Institute, Anhui, China; <sup>1186</sup>The First Affiliated Hospital of Harbin Medical University, Department of General Surgery, Harbin, Heilongjiang Province, China; <sup>1187</sup>The First Affiliated Hospital of Harbin Medical University, Key Laboratory of Hepatosplenic Surgery, Department of General Surgery, Harbin, China; <sup>1188</sup>The Fourth Military Medical University, Institute of Orthopaedics, Xijing Hospital, Xi'an, Shanxi, China; <sup>1189</sup>The Fourth Military Medical University, School of Basic Medical Sciences, Department of Physiology, Xi'an, China; <sup>1190</sup>The Fourth Military Medical University, Xi'an, China; <sup>1191</sup>The Genome Analysis Centre (TGAC), Institute of Food Research, Gut Health and Food Safety Programme, Norwich, UK; <sup>1192</sup>The Helen F. Graham Cancer Center, Newark, DE, USA; <sup>1193</sup>The Hospital for Sick Children, Department of Paediatrics, Toronto, Ontario, Canada; <sup>1194</sup>The Institute of Cancer Research, Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, Sutton, Surrey, UK; <sup>1195</sup>The Norwegian Radium Hospital, Faculty of Medicine, Oslo, Norway; <sup>1196</sup>The People's Hospital of Guangxi Zhuang Autonomous Region, Department of Gastroenterology, Nanning, Guangxi, China; <sup>1197</sup>The People's Hospital of Hainan Province, Medical Care Center, Haikou, Hainan, China; <sup>1198</sup>The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, CA, USA; <sup>1199</sup>The Scripps Research Institute, Department of Metabolism and Aging, Jupiter, FL, USA; <sup>1200</sup>The Scripps Research Institute, Department of Neuroscience, Jupiter, FL, USA; <sup>1201</sup>The Second Hospital Affiliated to Guangzhou Medical University, Guangzhou Institute of Cardiovascular Disease, Guangzhou, Guangdong Province, China; <sup>1202</sup>The Third Affiliated Hospital of Guangzhou Medical University, Department of Clinical Laboratory Medicine, Guangzhou, Guangdong, China; <sup>1203</sup>The Walter and Eliza Hall Institute of Medical Research, Development and Cancer Division, Parkville, VIC, Australia; <sup>1204</sup>The Weizmann Institute of Science, Department of Plant Sciences, Rehovot, Israel; <sup>1205</sup>The Wistar Institute, Philadelphia, PA, USA; <sup>1206</sup>The Wistar Institute, Program in Molecular and Cellular Oncogenesis, Philadelphia, PA, USA; <sup>1207</sup>Third Military Medical University, Department of Biochemistry and Molecular Biology, Chongqing, China; <sup>1208</sup>Third Military Medical University, Department of Neurosurgery, Southwest Hospital, Shapingba District, Chongqing, China; <sup>1209</sup>Third Military Medical University, Department of Occupational Health, Chongqing, China; <sup>1210</sup>Third Military Medical University, Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Chongqing, China; <sup>1211</sup>Thomas Jefferson University Hospitals, Department of Radiation Oncology, Philadelphia, PA, USA; <sup>1212</sup>Thomas Jefferson University, Department of Biochemistry and Molecular Biology, Philadelphia, PA, USA; <sup>1213</sup>Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology, Philadelphia, PA, USA; <sup>1214</sup>Thomas Jefferson University, Department of Pathology, Anatomy, and Cell Biology, Sydney Kimmel Medical College, Philadelphia, PA, USA; <sup>1215</sup>Thomas Jefferson University, Philadelphia, PA, USA; <sup>1216</sup>Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, PA, USA; <sup>1217</sup>Tianjin Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin, China; <sup>1218</sup>Tianjin Medical University, Department of Immunology, Tianjin Key Laboratory of Medical Epigenetics, Tianjin, China; <sup>1219</sup>Tianjin Medical University, School of Pharmaceutical Sciences, Tianjin, China; <sup>1220</sup>Toho University, School of Medicine, Department of Biochemistry, Tokyo, Japan; <sup>1221</sup>Tohoku University, Department of Developmental Biology and Neurosciences, Graduate School of Life Sciences, Sendai, Miyagi, Japan; <sup>1222</sup>Tohoku University, Department of Neurology, Sendai, Japan; <sup>1223</sup>Tohoku University, Division of Biomedical Engineering for Health and Welfare, Sendai, Japan; <sup>1224</sup>Tohoku University, Graduate School of Agricultural Sciences, Sendai, Japan; <sup>1225</sup>Tohoku University, Graduate School of Life Sciences, Sendai, Miyagi, Japan; <sup>1226</sup>Tohoku University, Laboratory of Bioindustrial Genomics, Graduate School of Agricultural Science, Miyagi, Japan; <sup>1227</sup>Tohoku University School of Medicine, Department of Orthopaedic Surgery, Miyagi, Japan; <sup>1228</sup>Tokai University School of Medicine, Department of Molecular Life Sciences, Kanagawa, Japan; <sup>1229</sup>Tokushima Bunri University, Faculty of Pharmaceutical Sciences at Kagawa Campus, Sanuki City, Kagawa, Japan; <sup>1230</sup>Tokushima University, Division of Molecular Genetics, Institute for Enzyme Research, Tokushima, Japan; <sup>1231</sup>Tokyo Denki University, Division of Life Science and Engineering,

Hatoyama, Hiki-gun, Saitama, Japan; <sup>1232</sup>Tokyo Institute of Technology, Frontier Research Center, Yokohama, Japan; <sup>1233</sup>Tokyo Institute of Technology, Graduate School of Bioscience and Biotechnology, Tokyo, Japan; <sup>1234</sup>Tokyo Medical and Dental University, Center for Brain Integration Research, Bunkyo, Tokyo, Japan; <sup>1235</sup>Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan; <sup>1236</sup>Tokyo Medical and Dental University, Medical Research Institute, Pathological Cell Biology, Tokyo, Japan; <sup>1237</sup>Tokyo Medical University, Department of Biochemistry, Tokyo, Japan; <sup>1238</sup>Tokyo Metropolitan Institute of Medical Science, Laboratory of Protein Metabolism, Tokyo, Japan; <sup>1239</sup>Tokyo University of Science, Department of Applied Biological Science and Imaging Frontier Center, Noda, Chiba, Japan; <sup>1240</sup>Tokyo Women's Medical University, Department of Endocrinology and Hypertension, Tokyo, Japan; <sup>1241</sup>Tongji University School of Medicine, Department of Gastroenterology, Shanghai Tenth People's Hospital, Shanghai, China; <sup>1242</sup>Tongji University, School of Life Science and Technology, Shanghai, China; <sup>1243</sup>Toronto General Research Institute - University Health Network, Division of Advanced Diagnostics, Toronto, Ontario, Canada; <sup>1244</sup>Tottori University, Research Center for Bioscience and Technology, Yonago, Japan; <sup>1245</sup>Translational Health Science and Technology Institute, Vaccine and Infectious Disease Research Centre, Faridabad, India; <sup>1246</sup>Trev and Joyce Deeley Research Centre; and University of Victoria, BC Cancer Agency; and Department of Biochemistry and Microbiology, Victoria, BC, Canada; <sup>1247</sup>Trinity College Dublin, Department of Genetics, The Smurfit Institute, Dublin, Ireland; <sup>1248</sup>Trinity College Dublin, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland; <sup>1249</sup>Trinity College Dublin, Smurfit Institute of Genetics, Dublin, Ireland; <sup>1250</sup>Tsinghua University, School of Life Sciences, Beijing, China; <sup>1251</sup>Tsinghua University, State Key Laboratory of Biomembrane and Membrane Biotechnology, Tsinghua University-Peking University Joint Center for Life Sciences, School of Life Science, Beijing, China; <sup>1252</sup>Tsinghua University, Zhou Pei-Yuan Center for Applied Mathematics, Beijing, China; <sup>1253</sup>Tufts University, USDA Human Nutrition Research Center on Aging, Boston, MA, USA; <sup>1254</sup>Tulane University Health Sciences Center, Department of Pathology and Laboratory Medicine, New Orleans, LA, USA; <sup>1255</sup>U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA; <sup>1256</sup>U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA; <sup>1257</sup>UAE University, Cell Signaling Laboratory, Department of Biochemistry, College of Medicine and Health Sciences, Al Ain, Abu Dhabi, UAE; <sup>1258</sup>UCL Cancer Institute, London, UK; <sup>1259</sup>UCL Cancer Institute, Samantha Dickson Brain Cancer Unit, London, UK; <sup>1260</sup>UCL Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; <sup>1261</sup>UCL Institute of Neurology, Department of Molecular Neuroscience, London, UK; <sup>1262</sup>UCL Institute of Neurology, London, UK; <sup>1263</sup>UCL Institute of Ophthalmology, London, UK; <sup>1264</sup>UCLA David Geffen School of Medicine, Brain Research Institute, Los Angeles, CA, USA; <sup>1265</sup>UFRRJ, Instituto de Biofísica Carlos Chagas Filho, Rio de Janeiro, Brazil; <sup>1266</sup>Ulm University, Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, Ulm, Germany; <sup>1267</sup>Umeå University, Department of Medical Biochemistry and Biophysics, Umeå, Sweden; <sup>1268</sup>UMR 1280, Nantes, France; <sup>1269</sup>UMR CNRS 5286, INSERM 1052, Cancer Research Center of Lyon, Lyon, France; <sup>1270</sup>UMRS 1138, Centre de Recherche des Cordeliers, Paris, France; <sup>1271</sup>Uniformed Services University of the Health Sciences, Department of Anesthesiology, Bethesda, MD, USA; <sup>1272</sup>Uniformed Services University of the Health Sciences, Radiation Combined Injury Program, Armed Forces Radiobiology Research Institute, Bethesda, MD, USA; <sup>1273</sup>University of Texas, MD Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX, USA; <sup>1274</sup>Universidad Austral de Chile, Department of Physiology, Valdivia, Chile; <sup>1275</sup>Universidad Autónoma de Madrid, Centro de Biología Molecular Severo Ochoa, CIBERER, Madrid, Spain; <sup>1276</sup>Universidad Autónoma de Madrid, Centro Nacional de Biotecnología (CNB-CSIC), Centro de Biología Molecular Severo Ochoa, Departamento de Biología Molecular, Madrid, Spain; <sup>1277</sup>Universidad Autónoma de Madrid, Departamento de Biología Molecular, Madrid, Spain; <sup>1278</sup>Universidad Autónoma de Madrid, Departamento de Biología, Madrid, Spain; <sup>1279</sup>Universidad Complutense, School of Pharmacy, Madrid, Spain; and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; <sup>1280</sup>Universidad de Buenos Aires, Inmunología, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; <sup>1281</sup>Universidad de Castilla-La Mancha, Albacete, Spain; <sup>1282</sup>Universidad de Castilla-La Mancha, Facultad de Medicina, Departamento Ciencias Médicas, Albacete, Spain; <sup>1283</sup>Universidad de Castilla-La Mancha, Laboratorio de Oncología Molecular, Centro Regional de Investigaciones Biomédicas, Albacete, Spain; <sup>1284</sup>Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Santiago, Chile; <sup>1285</sup>Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; <sup>1286</sup>Universidad de Chile, Facultad de Ciencias Químicas y Farmacéuticas, Santos Dumont, Santiago de Chile; <sup>1287</sup>Universidad de Chile, Facultad de Ciencias, Departamento de Biología, Centro de Regulación del Genoma, Santiago, Chile; <sup>1288</sup>Universidad de Chile, Instituto de Nutrición y Tecnología de los Alimentos (INTA), Santiago, Chile; <sup>1289</sup>Universidad de Córdoba, Campus de Excelencia Agroalimentario (ceiA3), Departamento de Genética, Córdoba, Spain; <sup>1290</sup>Universidad de Costa Rica, CIET, San José, Costa Rica; <sup>1291</sup>Universidad de Extremadura, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Cáceres, Spain; <sup>1292</sup>Universidad de León, Área de Biología Celular, Instituto de Biomedicina, León, Spain; <sup>1293</sup>Universidad de Navarra, Centro de Investigación Médica Aplicada, Pamplona, Spain; <sup>1294</sup>Universidad de Oviedo, Departamento de Biología Funcional, Oviedo, Spain; <sup>1295</sup>Universidad de Oviedo, Instituto Universitario de Oncología, Departamento de Bioquímica y Biología Molecular, Oviedo, Spain; <sup>1296</sup>Universidad de Salamanca, Campus Miguel de Unamuno, Departamento de Microbiología y Genética, Salamanca, Spain; <sup>1297</sup>Universidad de Salamanca, Campus Unamuno, Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Centro de Investigación del Cáncer, Salamanca, Spain; <sup>1298</sup>Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, Spain; <sup>1299</sup>Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Sevilla, Spain; <sup>1300</sup>Universidad de Sevilla, Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC, Sevilla, Spain; <sup>1301</sup>Universidad de Valparaíso, Instituto de Biología, Facultad de Ciencias, Valparaíso, Chile; <sup>1302</sup>IIS Aragón, Universidad de Zaragoza/Araid, Centro de Investigación Biomédica de Aragón, Zaragoza, Spain; <sup>1303</sup>Universidad Federal do Rio Grande do Sul (UFRGS), Department of Biophysics and Center of Biotechnology, Porto Alegre, Brazil; <sup>1304</sup>Universidad Nacional de Cuyo (FCM-UNCUYO), Instituto de Histología y Embriología (IHEM-CONICET), Facultad de Ciencias Médicas, Mendoza, Argentina; <sup>1305</sup>Universidad Pablo de Olavide, Centro Andaluz de Biología del Desarrollo (CABD), Consejo Superior de Investigaciones Científicas-Junta de Andalucía, Sevilla, Spain; <sup>1306</sup>Universidade de Brasília, Departamento de Biologia Celular, Brasília, DF, Brazil; <sup>1307</sup>Universidade de Lisboa, Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Lisboa, Portugal; <sup>1308</sup>Universidade de Santiago de Compostela, Departamento Farmacología, Facultad de Veterinaria, Lugo, Spain; <sup>1309</sup>Faculdade de Ciências Farmacéuticas de Ribeirão Preto, Universidade de São Paulo (FCFRP, USP), São Paulo, Brazil; <sup>1310</sup>Universidade de São Paulo, Departamento de Parasitologia, Instituto de Ciências Biomédicas, São Paulo, Brazil; <sup>1311</sup>Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, São Paulo, SP, Brazil; <sup>1312</sup>Universidade Estadual do Norte Fluminense Darcy Ribeiro, Centro de Biotecnologia, Lab Biologia Celular e Tecidual, Setor de Toxicologia Celular, Campos dos Goytacazes, Rio de Janeiro, Brazil; <sup>1313</sup>Universidade Federal de Minas Gerais, UFMG, Departamento de Morfologia, Instituto de Ciências Biológicas, Belo Horizonte, Minas Gerais, Brazil; <sup>1314</sup>Universidade Federal de São Paulo (UNIFESP), Departamento de Farmacologia, Escola Paulista de Medicina, São Paulo, SP, Brazil; <sup>1315</sup>Universidade Nova de Lisboa, CEDOC, NOVA Medical School, Lisboa, Portugal; <sup>1316</sup>Universidat de Salamanca, Campus Miguel de Unamuno, Departamento de Microbiología y Genética, Salamanca, Spain; <sup>1317</sup>Universita' degli Studi di Milano, Dipartimento di Scienze Farmacologiche e Biomolecolari, Milan, Italy; <sup>1318</sup>Universita' degli Studi di Modena e Reggio Emilia, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Modena, Italy; <sup>1319</sup>Università del Piemonte Orientale "A. Avogadro", Dipartimento di Scienze della Salute, Novara, Italy; <sup>1320</sup>Università del Piemonte Orientale, Novara, Italy; <sup>1321</sup>Università di Salerno, Dipartimento di Medicina e Chirurgia, Baronissi, Salerno, Italy; <sup>1322</sup>Università Politecnica delle Marche, Department of Clinical and Molecular Sciences, Ancona, Italy; <sup>1323</sup>Università Vita-Salute San Raffaele, Milan, Italy; <sup>1324</sup>Universitat Autònoma de Barcelona, Department of Cell Biology, Physiology and Immunology, Institut de Neurociències, Barcelona, Spain; <sup>1325</sup>Universitat Autònoma de Barcelona, Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Bellaterra (Barcelona), Spain; <sup>1326</sup>Universitat de Barcelona, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Barcelona, Spain; <sup>1327</sup>Universitat de

Barcelona, L'Hospitalet de Llobregat, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; <sup>1328</sup>Universitat Politècnica de València, COMAV Institute, Valencia, Spain; <sup>1329</sup>Universitätsklinikum Düsseldorf, Institute for Biochemistry and Molecular Biology I, Düsseldorf, Germany; <sup>1330</sup>Université Bordeaux Segalen, Institut de Biochimie et de Génétique Cellulaires, CNRS, UMR 5095, Bordeaux, France; <sup>1331</sup>Université Bordeaux Segalen, Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, Bordeaux, France; <sup>1332</sup>Université Bordeaux Segalen, U1035 INSERM, Hématopoïèse Leucémique et Cibles Thérapeutiques, Bordeaux, France; <sup>1333</sup>Université Bordeaux, CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, Bordeaux, France; <sup>1334</sup>Université Bourgogne Franche-Comté, Agropur Dijon, UMR PAM, Équipe Vin, Aliment, Microbiologie, Stress, Dijon, France; <sup>1335</sup>Université Catholique de Louvain (UCL), Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium; <sup>1336</sup>Université Catholique de Louvain (UCL), Institut des Sciences de la Vie, Louvain-la-Neuve, Belgium; <sup>1337</sup>Université Catholique de Louvain (UCL), Institute of Neuroscience, Louvain-la-Neuve, Belgium; <sup>1338</sup>Université Catholique de Louvain (UCL), Laboratory of Cell Physiology, Brussels, Belgium; <sup>1339</sup>Université Clermont 1, UFR Médecine, UMR1019 Nutrition Humaine, Clermont-Ferrand, France; <sup>1340</sup>Université d'Auvergne, M2iSH "Microbes, Intestine, Inflammation, Susceptibility of the Host", UMR 1071 INSERM, Centre Biomédical de Recherche et Valorisation, Faculté de Médecine, Clermont-Ferrand, France; <sup>1341</sup>Université de Bordeaux, INSERM U916, Institut Bergonié, Bordeaux cedex, France; <sup>1342</sup>Université de Bordeaux, Institut des Maladies Neurodégénératives, CNRS UMR 5293, Bordeaux, France; <sup>1343</sup>Université de Bordeaux, UMR 5095, CNRS, Institut de Biochimie et génétique Cellulaires, Bordeaux, France; <sup>1344</sup>Université de Franche-Comté, UFR Sciences et Techniques EA3922/SFR IBCT FED 4234, Estrogènes, Expression Génique et Pathologies du Système Nerveux Central, Besançon, France; <sup>1345</sup>Université de Franche-Comté, UFR Sciences et Techniques, Laboratoire de Biochimie, Besançon, France; <sup>1346</sup>Université de Limoges, EA 3842, LHCP, Faculté de Médecine, Limoges, France; <sup>1347</sup>Université de Lyon, Lyon France; and Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Université Lyon 1, Villeurbanne, France; <sup>1348</sup>Université de Lyon, Faculty of Medicine, Saint Etienne, France; <sup>1349</sup>Université de Lyon, INSERM, U 1111, Centre International de Recherche en Infectiologie (CIRI), Ecole Normale Supérieure de Lyon, CNRS, UMR 5308, Lyon, France; <sup>1350</sup>Université de Lyon, UMR 5239 CNRS, Laboratory of Molecular Biology of the Cell, Ecole Normale Supérieure de Lyon, Lyon, France; <sup>1351</sup>Université de Montpellier, DIMNP, UMR 5235, CNRS, Montpellier, France; <sup>1352</sup>Université de Montpellier, Institut régional du Cancer de Montpellier, INSERM, U 1194, Montpellier, France; <sup>1353</sup>Université de Montpellier, Montpellier, France; <sup>1354</sup>Université de Montréal, Department of Medicine, Montréal, Quebec, Canada; <sup>1355</sup>Université de Montréal, Department of Pharmacology, Faculty of Medicine, Montreal, QC, Canada; <sup>1356</sup>Université de Montréal, Faculty of Pharmacy, Montréal, Québec, Canada; <sup>1357</sup>Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Québec, Canada; <sup>1358</sup>Université de Nantes, CRCNA, UMRINSERM 892/CNRS 6299, Nantes, France; <sup>1359</sup>Université de Rennes-1, Oncogenesis, stress, Signaling" (OSS), ERL 440 INSERM, Centre de Lutte Contre le Cancer Eugene Marquis, Rennes, France; <sup>1360</sup>Université de Sherbrooke, Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada; <sup>1361</sup>Université de Strasbourg, Faculté de Médecine, UMRS 1118, Strasbourg, France; <sup>1362</sup>Université de Strasbourg/CNRS UPR3572, Immunopathologie et Chimie Thérapeutique, IBMC, Strasbourg, France; <sup>1363</sup>Université du Québec à Montréal, Département des Sciences Biologiques and Centre de Recherche BioMed, Montréal, Québec, Canada; <sup>1364</sup>Université Grenoble-Alpes, CEA-DSV-iRTSV-BGE-GenadChem, INSERM, U1038, Grenoble, France; <sup>1365</sup>Université Laval, Neurosciences Axis, Québec, Canada; <sup>1366</sup>Université Libre de Bruxelles, ULB Center for Diabetes Research, Brussels, Belgium; <sup>1367</sup>Université Lyon, Ecole Normale Supérieure de Lyon, Lyon, France; <sup>1368</sup>Université Montpellier 2, Institut des Sciences de l'Évolution - UMR CNRS 5554, Montpellier, Languedoc-Roussillon, France; <sup>1369</sup>Université Nice Sophia Antipolis, UMR E-4320TIRO-MATOs CEA/iBEB, Faculté de Médecine, Nice, France; <sup>1370</sup>Université Paris Descartes, Apoptosis, Cancer and Immunity Laboratory, Team 11, Equipe Labellisée Ligue contre le Cancer and Cell Biology and Metabolomics Platforms, Paris, France; <sup>1371</sup>Université Paris Descartes, Institut Cochin, Faculté de Médecine Sorbonne Paris Cité, Paris, France; <sup>1372</sup>Université Paris Descartes, Institut Necker-Enfants Malades, INSERM, U1151, Paris, France; <sup>1373</sup>Université Paris Descartes, Paris, France; <sup>1374</sup>Université Paris Descartes/Paris V, Paris, France; <sup>1375</sup>Université Paris Descartes-Sorbonne Paris Cité, Institut Necker Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253, Paris, France; <sup>1376</sup>Université Paris Diderot, Sorbonne Paris Cité, Centre Epigénétique et Destin Cellulaire, UMR 7216, Centre National de la Recherche Scientifique CNRS, Paris, France; <sup>1377</sup>Université Paris Diderot, Unité Biologie Fonctionnelle et Adaptative - CNRS UMR 8251, Paris, France; <sup>1378</sup>Université Paris-Est Créteil, Créteil, France; <sup>1379</sup>Université Paris-Est, Institut Mondor de Recherche Biomédicale, Paris, France; <sup>1380</sup>Université Paris-Sud, CEA, CNRS, Institute for Integrative Biology of the Cell, Gif-sur-Yvette Cedex, France; <sup>1381</sup>Université Paris-Sud, CEA, CNRS, Paris, France; <sup>1382</sup>Université Paris-Sud, INSERM 1030, Gustave Roussy Cancer Campus, Paris, France; <sup>1383</sup>Université Paris-Sud, Institut Gustave Roussy, CNRS UMR 8126, Villejuif, France; <sup>1384</sup>Université Paris-Sud, Université Paris-Saclay, UMR 8126CNRS, Institut Gustave Roussy, Villejuif, France; <sup>1385</sup>Universiti Sains Malaysia, Advanced Medical and Dental Institute, Ministry of Science, Technology and Innovation, Pulau Pinang, Malaysia; <sup>1386</sup>University "G. d'Annunzio", Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy; <sup>1387</sup>University "Magna Graecia" of Catanzaro, Department of Health Sciences, Catanzaro, Italy; <sup>1388</sup>University Belgrade, School of Medicine, Belgrade, Serbia; <sup>1389</sup>University Bourgogne Franche Comté, EA 7270/INSERM, Dijon, France; <sup>1390</sup>University Clinic Heidelberg, Department of Experimental Surgery, Heidelberg, Germany; <sup>1391</sup>University Clinics, Institute of Cellular and Molecular Anatomy (Anatomie 3), Frankfurt, Germany; <sup>1392</sup>University College Cork, Cork Cancer Research Centre, BioSciences Institute, Co. Cork, Ireland; <sup>1393</sup>University College Cork, School of Pharmacy, Department of Pharmacology and Therapeutics, Cork, Ireland; <sup>1394</sup>University College Dublin, School of Chemical and Bioprocess Engineering, Dublin, Ireland; <sup>1395</sup>University College London, Department of Clinical Neurosciences, London, UK; <sup>1396</sup>University College London, MRC Laboratory for Molecular Cell Biology, London, UK; <sup>1397</sup>University College London, UCL Consortium for Mitochondrial Research and Department of Cell and Developmental Biology, London, UK; <sup>1398</sup>University Hospital "Luigi Sacco", Università di Milano, Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences "Luigi Sacco", Milano, Italy; <sup>1399</sup>University Hospital Aachen, IZKF and Department of Internal Medicine III, Aachen, Germany; <sup>1400</sup>University Hospital Center, University of Lausanne, Clinic of Neonatology, Department of Pediatrics and Pediatric Surgery, Lausanne, Switzerland; <sup>1401</sup>University Hospital Cologne, CECAD Research Center, Cologne, Germany; <sup>1402</sup>University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; <sup>1403</sup>University Hospital Freiburg, Department of Medicine II, Freiburg, Germany; <sup>1404</sup>University Hospital Jena, Department of General, Visceral and Vascular Surgery, Experimental Transplantation Surgery, Jena, Germany; <sup>1405</sup>University Hospital La Coruña, Microbiology Department, La Coruña, Spain; <sup>1406</sup>University Hospital Muenster Albert-Schweitzer-Campus, Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Münster, Germany; <sup>1407</sup>University Hospital of Göttingen, Department of Nephrology and Rheumatology, Göttingen, Germany; <sup>1408</sup>University Hospital of Lausanne, Service and Central Laboratory of Hematology, Lausanne, Switzerland; <sup>1409</sup>University Hospital of Muenster, Department of Internal Medicine D, Molecular Nephrology, Muenster, Germany; <sup>1410</sup>University Hospital Ulm, Sektion Experimentelle Anaesthesiologie, Ulm, Germany; <sup>1411</sup>University Hospital Zürich, Division of Gastroenterology and Hepatologist, Zürich, Switzerland; <sup>1412</sup>University Hospitals Leuven, Department of Microbiology and Immunology, Laboratory of Abdominal Transplantation, Leuven, Belgium; <sup>1413</sup>University Hospitals Leuven, Department of Neurology, Leuven, Belgium; <sup>1414</sup>National Institute of Environmental Health Sciences, Immunity, Inflammation, and Disease Laboratory, Research Triangle Park, NC, USA; <sup>1415</sup>University Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Lille, France; <sup>1416</sup>University Medical Center Freiburg, Freiburg, Germany; <sup>1417</sup>University Medical Center Groningen, University of Groningen, Department of Hematology, Groningen, The Netherlands; <sup>1418</sup>University Medical Center Hamburg-Eppendorf, Institute of Neuropathology, Hamburg, Germany; <sup>1419</sup>University Medical Center of the Johannes Gutenberg-University, Institute for Pathobiochemistry, Mainz, Germany; <sup>1420</sup>University Medical Center Utrecht, Department of Cell Biology, Groningen, The Netherlands; <sup>1421</sup>University Medical Centre Göttingen, Clinic for Neurology and Department of Neuroimmunology, Göttingen, Germany; <sup>1422</sup>University Medical Centre Göttingen, Department of Neurodegeneration and Restorative Research, Göttingen, Germany; <sup>1423</sup>University Medical Centre Utrecht, Laboratory of Translational Immunology and Department of Pediatric Immunology, Utrecht, The Netherlands;

<sup>1424</sup>University Medicine Göttingen, Department of Neurology, Göttingen, Germany; <sup>1425</sup>University Montpellier 1, INSERM U1051, Montpellier, France; <sup>1426</sup>University Montpellier, UMR5235, Montpellier, France; <sup>1427</sup>University of Aberdeen, Division of Applied Medicine, Aberdeen, UK; <sup>1428</sup>University of Adelaide, Alzheimer's Disease Genetics Laboratory, Adelaide, Australia; <sup>1429</sup>University of Adelaide, Department of Genetics and Evolution, School of Biological Sciences, Adelaide, SA, Australia; <sup>1430</sup>University of Alabama at Birmingham, Department of Cell, Developmental, and Integrative Biology (CDIB), Comprehensive Diabetes Center (UCDC), Birmingham, AL, USA; <sup>1431</sup>University of Alabama at Birmingham, Department of Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center, Birmingham, AL, USA; <sup>1432</sup>University of Alabama at Birmingham, Department of Pathology, Birmingham, AL, USA; <sup>1433</sup>University of Alabama at Birmingham, Department of Pathology, Center for Free Radical Biology, Birmingham, AL, USA; <sup>1434</sup>University of Alabama at Birmingham, Division of Molecular and Cellular Pathology, Department of Pathology, Birmingham, AL, USA; <sup>1435</sup>University of Alabama, Department of Chemical and Biological Engineering, Tuscaloosa, AL, USA; <sup>1436</sup>University of Alberta, Department of Biochemistry, Edmonton, Alberta, Canada; <sup>1437</sup>University of Alcalá, Department of System Biology, Biochemistry and Molecular Biology Unit, School of Medicine, Madrid, Spain; <sup>1438</sup>University of Amsterdam, Academic Medical Center, Laboratory of Experimental Oncology and Radiobiology, Amsterdam, North Holland, The Netherlands; <sup>1439</sup>University of Amsterdam, Department of Cellbiology and Histology, Academic Medical Center, Amsterdam, The Netherlands; <sup>1440</sup>University of Amsterdam, Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands; <sup>1441</sup>University of Amsterdam, Laboratory of Experimental Virology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center (AMC), Amsterdam, The Netherlands; <sup>1442</sup>University of Antwerp, Department of Paediatric Oncology, Antwerp, Belgium; <sup>1443</sup>University of Antwerp, Laboratory of Physiopharmacology, Wilrijk, Antwerp, Belgium; <sup>1444</sup>University of Arizona Cancer Center, Department of Medicine, Tucson, AZ, USA; <sup>1445</sup>University of Arizona College of Medicine, Barrow Neurological Institute, Phoenix Children's Hospital, Department of Child Health, Phoenix, AZ, USA; <sup>1446</sup>University of Arizona, Department of Entomology, Tucson, AZ, USA; <sup>1447</sup>University of Arizona, Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ, USA; <sup>1448</sup>University of Arkansas for Medical Sciences, Department of Cardiology, Little Rock, AR, USA; <sup>1449</sup>University of Arkansas for Medical Sciences, Department of Microbiology and Immunology, Little Rock, AR, USA; <sup>1450</sup>University of Arkansas for Medical Sciences, Department of Pharmacology/Toxicology, Little Rock, AR, USA; <sup>1451</sup>University of Arkansas, Center of Excellence for Poultry Science, Fayetteville, AR, USA; <sup>1452</sup>University of Athens, Department of Cell Biology and Biophysics, Faculty of Biology, Athens, Greece; <sup>1453</sup>University of Athens, Medical School, Second Department of Internal Medicine and Research Institute, Attikon University General Hospital, Athens, Greece; <sup>1454</sup>University of Groningen, Department of Cell Biology, Groningen, The Netherlands; <sup>1455</sup>University of Aveiro, Institute for Research in Biomedicine - iBIMED, Aveiro Health Sciences Program, Aveiro, Portugal; <sup>1456</sup>University of Aveiro/QOPNA, Department of Chemistry, Aveiro, Portugal; <sup>1457</sup>University of Barcelona, Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS-CIBERehd, Barcelona, Spain; <sup>1458</sup>University of Barcelona, School of Medicine, Campus Bellvitge, Hospitalet del Llobregat, Spain; <sup>1459</sup>University of Bari 'Aldo Moro', Department of Basic Medical Sciences, Neurosciences and Organs of Senses, Bari, Italy; <sup>1460</sup>University of Bari 'Aldo Moro', Department of Biomedical Sciences and Clinical Oncology, Bari, Italy; <sup>1461</sup>University of Bari 'Aldo Moro', Division of Medical Genetics, DIMO, School of Medicine, Bari, Italy; <sup>1462</sup>University of Basel, Biozentrum, Basel, BS, Switzerland; <sup>1463</sup>University of Basel, Biozentrum, Basel, Switzerland; <sup>1464</sup>University of Bayreuth, Cell Biology, Bayreuth, Germany; <sup>1465</sup>University of Bayreuth, Department of Biochemistry, Bayreuth, Germany; <sup>1466</sup>University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Belgrade, Serbia; <sup>1467</sup>University of Belgrade, Institute of Histology and Embryology, School of Medicine, Belgrade, Serbia; <sup>1468</sup>University of Belgrade, Institute of Medical and Clinical Biochemistry, Faculty of Medicine, Belgrade, Serbia; <sup>1469</sup>University of Belgrade, School of Medicine, Belgrade, Serbia; <sup>1470</sup>University of Belgrade, School of Medicine, Institute of Histology and Embryology, Belgrade, Serbia; <sup>1471</sup>University of Bern, Division of Experimental Pathology, Institute of Pathology, Bern, Switzerland; <sup>1472</sup>University of Bern, Division of Pediatric Hematology/Oncology, Department of Clinical Research, Bern, Switzerland; <sup>1473</sup>University of Bern, Institute of Biochemistry and Molecular Medicine, Bern, Switzerland; <sup>1474</sup>University of Bern, Institute of Pharmacology, Bern, Switzerland; <sup>1475</sup>University of Birmingham, Institute of Biomedical Research, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Edgbaston, Birmingham, UK; <sup>1476</sup>University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, West Midlands, UK; <sup>1477</sup>University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy; <sup>1478</sup>University of Bologna, Dipartimento di Scienze Biomediche e Neuromotorie, Bologna, Italy; <sup>1479</sup>University of Bonn, Department of Neurology, Bonn, Germany; <sup>1480</sup>University of Bonn, Institute for Cell Biology, Bonn, Germany; <sup>1481</sup>University of Bonn, Institute of Reconstructive Neurobiology, Bonn, Germany; <sup>1482</sup>University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy; <sup>1483</sup>University of Bristol, School of Biochemistry, Bristol, UK; <sup>1484</sup>University of Bristol, School of Cellular and Molecular Medicine, Bristol, UK; <sup>1485</sup>University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, BC Canada; <sup>1486</sup>University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, British Columbia, Canada; <sup>1487</sup>University of British Columbia, Department of Cellular and Physiological Sciences, Vancouver, BC, Canada; <sup>1488</sup>University of British Columbia, Department of Medicine and Brain Research Center, Vancouver, BC, Canada; <sup>1489</sup>University of British Columbia, Department of Pathology and Laboratory Medicine, James Hogg Research Centre, Vancouver, BC, Canada; <sup>1490</sup>University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada; <sup>1491</sup>University of British Columbia, Department of Psychiatry, Vancouver, BC, Canada; <sup>1492</sup>University of British Columbia, Department of Urological Sciences, Vancouver, BC, Canada; <sup>1493</sup>University of British Columbia, Medical Genetics, and BC Cancer Agency, Terry Fox Laboratory, Vancouver, BC, Canada; <sup>1494</sup>University of British Columbia, Michael Smith Laboratories, Department of Chemical and Biological Engineering, Vancouver, BC, Canada; <sup>1495</sup>University of British Columbia, Michael Smith Laboratories, Vancouver, British Columbia, Canada; <sup>1496</sup>University of Buenos Aires, IDEHU-CONICET, Faculty of Pharmacy and Biochemistry, Buenos Aires, Argentina; <sup>1497</sup>University of Buenos Aires, Institute of Biochemistry and Biophysics, School of Pharmacy and Biochemistry, Buenos Aires, Argentina; <sup>1498</sup>University of Buenos Aires, National Council for Scientific and Technical Research (CONICET), Institute for Biochemistry and Molecular Medicine, Department of Pathophysiology, School of Pharmacy and Biochemistry, Buenos Aires, Argentina; <sup>1499</sup>University of Calabria, Department of Biology, Ecology and Earth Science, Laboratory of Electron Microscopy, Cosenza, Italy; <sup>1500</sup>University of Calabria, Department of Pharmacy, Health and Nutritional Sciences, Arcavacata di Rende (Cosenza), Italy; <sup>1501</sup>University of Calabria, Department of Pharmacy, Health and Nutritional Sciences, Section of Preclinical and Translational Pharmacology, Rende (Cosenza), Italy; <sup>1502</sup>University of Calcutta, Department of Biotechnology, Dr.B.C. Guha Centre for Genetic Engineering and Biotechnology, Kolkata, WB, India; <sup>1503</sup>University of Calgary, Department of Biochemistry and Molecular Biology, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada; <sup>1504</sup>University of Calgary, Faculty of Veterinary Medicine, Calgary, AB, Canada; <sup>1505</sup>University of California Berkeley, Department of Molecular and Cell Biology, Berkeley, CA, USA; <sup>1506</sup>University of California Berkeley, Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Berkeley, CA, USA; <sup>1507</sup>University of California Davis, Cancer Center, Davis, CA, USA; <sup>1508</sup>University of California Davis, Department of Medical Microbiology and Immunology, School of Medicine, Davis, CA, USA; <sup>1509</sup>University of California Davis, Department of Molecular and Cellular Biology, Davis, CA, USA; <sup>1510</sup>University of California Davis, Department of Neurobiology, Physiology, and Behavior, Davis, CA, USA; <sup>1511</sup>University of California Davis, Department of Plant Biology and the Genome Center, College of Biological Sciences, Davis, CA, USA; <sup>1512</sup>University of California Davis, Mann Laboratory, Department of Plant Sciences, Davis, CA, USA; <sup>1513</sup>University of California Irvine, Department of Developmental and Cell Biology, Irvine, CA, USA; <sup>1514</sup>University of California Irvine, Department of Neurosurgery, Irvine, CA, USA; <sup>1515</sup>University of California Irvine, Department of Psychiatry and Human Behavior, Irvine, CA, USA; <sup>1516</sup>University of California Irvine, Irvine, CA, USA; <sup>1517</sup>University of California Los Angeles, Department of Medicine, Los Angeles, CA, USA; <sup>1518</sup>University of California Los Angeles, Larry Hillblom Islet Research Center, David Geffen School of Medicine, Los Angeles, CA, USA; <sup>1519</sup>University of California Riverside, Department of Cell Biology and Neuroscience, Riverside, CA, USA; <sup>1520</sup>University of California San Diego, Department of Cellular and Molecular Medicine, La Jolla, CA, USA; <sup>1521</sup>University of California San Diego, Department of Medicine, La Jolla, CA, USA; <sup>1522</sup>University of



California San Diego, Department of Medicine, San Diego, CA, USA; <sup>1523</sup>University of California San Diego, Department of Pathology, La Jolla, CA, USA; <sup>1524</sup>University of California San Diego, Department of Pediatrics, Division of Infectious Diseases, La Jolla, CA, USA; <sup>1525</sup>University of California San Diego, Department of Pediatrics, La Jolla, CA, USA; <sup>1526</sup>University of California San Diego, Department of Pharmacology and Moores Cancer Center, La Jolla, CA, USA; <sup>1527</sup>University of California San Diego, Department of Pharmacology, La Jolla, CA, USA; <sup>1528</sup>University of California San Diego, Departments of Cellular and Molecular Medicine, Neurosciences, and Pediatrics, Division of Biological Sciences Institute for Genomic Medicine, La Jolla, CA, USA; <sup>1529</sup>University of California San Diego, Division of Biological Sciences, La Jolla, CA, USA; <sup>1530</sup>University of California San Diego, Division of Biological Sciences, Section of Molecular Biology, La Jolla, CA, USA; <sup>1531</sup>University of California San Diego, Division of Biological Sciences, Section of Molecular Biology, La Jolla, CA, USA; <sup>1532</sup>University of California San Diego, San Diego Center for Systems Biology, La Jolla, CA, USA; <sup>1533</sup>University of California San Diego, Moores Cancer Center, La Jolla, CA, USA; <sup>1534</sup>University of California San Diego, School of Medicine, Department of Psychiatry, La Jolla, CA, USA; <sup>1535</sup>University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA; <sup>1536</sup>University of California San Francisco, Department of Microbiology and Immunology, San Francisco, CA, USA; <sup>1537</sup>University of California San Francisco, Department of Neurological Surgery, San Francisco, CA, USA; <sup>1538</sup>University of California San Francisco, Department of Neurology, San Francisco, CA, USA; <sup>1539</sup>FONDAP Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; <sup>1540</sup>University of California San Francisco, Department of Pharmaceutical Chemistry, San Francisco, CA, USA; <sup>1541</sup>University of California San Francisco, Department of Surgery, San Francisco, CA, USA; <sup>1542</sup>University of California San Francisco, Departments of Neurology and Physiology; Gladstone Institute of Neurological Disease, San Francisco, CA, USA; <sup>1543</sup>University of California San Francisco, School of Medicine, Department of Pathology, San Francisco, CA, USA; <sup>1544</sup>University of California San Francisco, UCSF Diabetes Center, Department of Cell and Tissue Biology, San Francisco, CA, USA; <sup>1545</sup>University of California Santa Barbara, Department of Molecular, Cellular, and Developmental Biology, Santa Barbara, CA, USA; <sup>1546</sup>University of Cambridge, Addenbrooke's Hospital, Department of Medicine, Cambridge, UK; <sup>1547</sup>University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Department of Medical Genetics, Cambridge, UK; <sup>1548</sup>University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK; <sup>1549</sup>University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK; <sup>1550</sup>University of Cambridge, Department of Biochemistry, Cambridge, UK; <sup>1551</sup>University of Cambridge, Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, UK; <sup>1552</sup>University of Cambridge, Department of Medicine, Addenbrooke's Hospital, Cambridge, UK; <sup>1553</sup>University of Cambridge, Division of Virology, Department of Pathology, Cambridge, UK; <sup>1554</sup>University of Camerino, School of Biosciences and Veterinary Medicine, Camerino, Italy; <sup>1555</sup>University of Camerino, School of Pharmacy, Camerino, Italy; <sup>1556</sup>University of Camerino, School of Pharmacy, Section of Experimental Medicine, Camerino, MC, Italy; <sup>1557</sup>University of Campinas, Department of Biochemistry and Tissue Biology, Campinas, São Paulo, Brazil; <sup>1558</sup>University of Canterbury, Biomolecular Interaction Centre, School of Biological Sciences, Christchurch, New Zealand; <sup>1559</sup>University of Cape Town, Department of Human Biology, Cape Town, Western Province, South Africa; <sup>1560</sup>University of Cape Town, Redox Laboratory, Department of Human Biology, Cape Town, South Africa; <sup>1561</sup>University of Central Florida College of Medicine, Burnett School of Biomedical Sciences, Orlando, FL, USA; <sup>1562</sup>University of Chicago, Department of Medicine, Section of Dermatology, Chicago, IL, USA; <sup>1563</sup>University of Chicago, Department of Pathology, Chicago, IL, USA; <sup>1564</sup>University of Chicago, Pritzker School of Medicine, Department of Neurology, Chicago, IL, USA; <sup>1565</sup>University of Chicago, The Ben May Department for Cancer Research, Chicago, IL, USA; <sup>1566</sup>University of Chile, Advanced Center for Chronic Diseases (ACCDiS), Division of Cardiovascular Diseases, Faculty of Medicine, Santiago, Chile; <sup>1567</sup>P Catholic University of Chile, Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, Santiago, Chile; <sup>1568</sup>University of Chile, Biomedical Neuroscience Institute, Santiago, Chile; <sup>1569</sup>University of Chile, Faculty of Medicine, ICBM, Molecular and Clinical Pharmacology, Santiago, Chile; <sup>1570</sup>University of Chile, Institute of Biomedical Sciences, Center for Molecular Studies of the Cell, Program of Cellular, Molecular Biology and Biomedical Neuroscience Institute, Faculty of Medicine, Santiago, Chile; <sup>1571</sup>University of Cincinnati College of Medicine, Cincinnati Children's Research Foundation and Department of Pediatrics, Cincinnati, OH, USA; <sup>1572</sup>University of Cincinnati College of Medicine, Department of Cancer Biology, Cincinnati, OH, USA; <sup>1573</sup>University of Cincinnati, Cincinnati Children's Hospital, Cincinnati, OH, USA; <sup>1574</sup>University of Cincinnati, Cincinnati, OH, USA; <sup>1575</sup>University of Coimbra, CNC – Center for Neuroscience and Cell Biology and Faculty of Medicine, Coimbra, Portugal; <sup>1576</sup>University of Coimbra, Center for Neuroscience and Cell Biology and Faculty of Pharmacy, Coimbra, Portugal; <sup>1577</sup>University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Cantanhede, Portugal; <sup>1578</sup>University of Coimbra, Coimbra, Portugal; <sup>1579</sup>University of Coimbra, Faculty of Medicine, Center for Neuroscience and Cell Biology, Coimbra, Portugal; <sup>1580</sup>University of Coimbra, IBILI, Faculty of Medicine, Coimbra, Portugal; <sup>1581</sup>University of Cologne, Department of Dermatology, Cologne, Germany; <sup>1582</sup>University of Cologne, Institute for Genetics, CECAD Research Center, Cologne, Germany; <sup>1583</sup>University of Cologne, Institute of Biochemistry I, Medical Faculty, Koeln, Germany; <sup>1584</sup>University of Cologne, Medical Faculty, Center for Biochemistry, Cologne, Germany; <sup>1585</sup>University of Colorado Denver, Boulder, CO, USA; <sup>1586</sup>University of Colorado Denver, Division of Medical Oncology, Department of Medicine, Aurora, CO, USA; <sup>1587</sup>University of Colorado Denver, Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Aurora, CO, USA; <sup>1588</sup>University of Colorado, Denver; and Denver VAMC, Denver, CO, USA; <sup>1589</sup>University of Colorado, Department of Pediatrics, Center for Cancer and Blood Disorders, Aurora, CO, USA; <sup>1590</sup>University of Colorado, HHMI, Department of Chemistry and Biochemistry, Aurora, CO, USA; <sup>1591</sup>University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA; <sup>1592</sup>University of Colorado, School of Medicine, Aurora, CO, USA; <sup>1593</sup>University of Colorado, School of Medicine, Department of Immunology and Microbiology, Aurora, CO, USA; <sup>1594</sup>University of Colorado, School of Medicine, Department of Pharmacology, Aurora, CO, USA; <sup>1595</sup>University of Colorado, School of Medicine, Division of Infectious Diseases, Aurora, CO, USA; <sup>1596</sup>University of Copenhagen, Biotech Research and Innovative Center (BRIC), Copenhagen, Denmark; <sup>1597</sup>University of Copenhagen, Department of Biology, Copenhagen, Denmark; <sup>1598</sup>University of Copenhagen, Department of Plant and Environmental Sciences, Section for Genetics and Microbiology, Copenhagen, Denmark; <sup>1599</sup>University of Crete, Department of Basic Sciences, Faculty of Medicine, Heraklion, Crete, Greece; <sup>1600</sup>University of Crete, Institute of Molecular Biology and Biotechnology, Heraklion, Crete, Greece; <sup>1601</sup>University of Crete, School of Medicine, Department of Infectious Diseases, Heraklion, Crete, Greece; <sup>1602</sup>University of Cyprus, Department of Biological Sciences, Bioinformatics Research Laboratory, Nicosia, Cyprus; <sup>1603</sup>University of Debrecen, Debrecen, Hungary; <sup>1604</sup>University of Debrecen, Faculty of Pharmacy, Department of Pharmacology, Debrecen, Hungary; <sup>1605</sup>University of Delaware, Department of Biological Sciences, Newark, DE, USA; <sup>1606</sup>University of Delaware, The Center for Translational Cancer Research, Newark, DE, USA; <sup>1607</sup>University of Dundee, Centre for Gene Regulation and Expression, College of Life Sciences, UK; <sup>1608</sup>University of Dundee, MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, Dundee, UK; <sup>1609</sup>University of East Anglia, Norwich Medical School, Norfolk, UK; <sup>1610</sup>University of Eastern Finland, Faculty of Health Science, School of Pharmacy/Toxicology, Kuopio, Finland; <sup>1611</sup>University of Eastern Finland, Kuopio University Hospital, Department of Ophthalmology, Kuopio, Finland; <sup>1612</sup>University of Edinburgh, Easter Bush, The Roslin Institute, Midlothian, UK; <sup>1613</sup>University of Edinburgh, Edinburgh Cancer Research Centre, Edinburgh, UK; <sup>1614</sup>University of Edinburgh, Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK; <sup>1615</sup>University of Erlangen-Nuremberg, Department of Internal Medicine 3, Erlangen, Germany; <sup>1616</sup>University of Exeter Medical School, European Centre for Environment and Human Health (ECEHH), Truro, Cornwall, UK; <sup>1617</sup>University of Exeter, School of Biosciences, Exeter, UK; <sup>1618</sup>University of Extremadura, Department of Medicine, Faculty of Veterinary Medicine, Cáceres, Spain; <sup>1619</sup>University of Ferrara, Department of Morphology, Surgery and Experimental Medicine, Ferrara, Italy; <sup>1620</sup>University of Florence, Department of Biology, Florence, Italy; <sup>1621</sup>University of Florida, College of Medicine, Department of Anatomy and Cell Biology, Gainesville, FL, USA; <sup>1622</sup>University of Florida, College of Medicine, Department of Neuroscience, Gainesville, FL, USA; <sup>1623</sup>University of Florida, Department of Aging and Geriatric Research, Gainesville, FL, USA; <sup>1624</sup>University of Florida, Department of Animal Sciences, IFAS/College of Agriculture and Life Science, Gainesville, FL, USA; <sup>1625</sup>University of Florida, Department of Applied Physiology and

Kinesiology, Gainesville, FL, USA; <sup>1626</sup>University of Florida, Department of Pediatrics/Genetics and Metabolism, Gainesville, FL, USA; <sup>1627</sup>University of Florida, Department of Surgery, Gainesville, FL, USA; <sup>1628</sup>University of Florida, Gainesville, FL, USA; <sup>1629</sup>University of Florida, Institute on Aging, Gainesville, FL, USA; <sup>1630</sup>University of Freiburg, Department of Dermatology, Medical Center, Center for Biological Systems Analysis (ZBSA), Freiburg, Germany; <sup>1631</sup>University of Fribourg, Department of Medicine, Division of Physiology, Faculty of Science, Fribourg, Switzerland; <sup>1632</sup>University of Fribourg, Department of Medicine, Division of Physiology, Fribourg, Switzerland; <sup>1633</sup>University of Geneva, Department of Cellular Physiology and Metabolism, Geneva, Switzerland; <sup>1634</sup>University of Geneva, School of Medicine, Department of Pathology and Immunology, Geneva, Switzerland; <sup>1635</sup>University of Georgia, College of Veterinary Medicine, Department of Biosciences and Diagnostic Imaging, Athens, GA, USA; <sup>1636</sup>University of Georgia, Department of Infectious Diseases, Athens, GA, USA; <sup>1637</sup>University of Glasgow, Cancer Research UK Beatson Institute, Glasgow, UK; <sup>1638</sup>University of Glasgow, Institute of Cancer Sciences, Glasgow, UK; <sup>1639</sup>University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; <sup>1640</sup>University of Glasgow, Wolfson Wohl Cancer Research Centre, MVLS, Institute of Cancer Sciences, Glasgow, UK; <sup>1641</sup>University of Göttingen, Department of Geobiology, Göttingen, Germany; <sup>1642</sup>University of Göttingen, Department of Neurology, Göttingen, Germany; <sup>1643</sup>University of Graz, Institute of Molecular Biosciences, BioTechMed Graz, Graz, Austria; <sup>1644</sup>University of Groningen, Molecular Cell Biology, Groningen, The Netherlands; <sup>1645</sup>University of Heidelberg, Center for Molecular Biology, Heidelberg, Germany; <sup>1646</sup>University of Heidelberg, Institute of Anatomy and Cell Biology, Heidelberg, Germany; <sup>1647</sup>University of Helsinki, Biomedicum, Helsinki, Finland; <sup>1648</sup>University of Helsinki, Department of Biosciences, Helsinki, Finland; <sup>1649</sup>University of Helsinki, Department of Physiology, Faculty of Medicine, Helsinki, Finland; <sup>1650</sup>University of Hong Kong, Department of Pharmacology and Pharmacy, Hong Kong, China; <sup>1651</sup>University of Hong Kong, Division of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hong Kong; <sup>1652</sup>University of Hong Kong, Hong Kong, China; <sup>1653</sup>University of Hong Kong, Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, Hong Kong, China; <sup>1654</sup>University of Houston, College of Pharmacy, Pharmacological and Pharmaceutical Sciences, Houston, TX, USA; <sup>1655</sup>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Houston, TX, USA; <sup>1656</sup>University of Idaho, Plant, Soil, and Entomological Sciences, Moscow, ID, USA; <sup>1657</sup>University of Illinois at Chicago, College of Medicine, Department of Ophthalmology and Visual Sciences, Chicago, IL, USA; <sup>1658</sup>University of Illinois at Chicago, College of Medicine, Department of Pediatrics, Chicago, IL, USA; <sup>1659</sup>University of Illinois at Chicago, Departments of Anesthesiology and Pharmacology, Chicago, IL, USA; <sup>1660</sup>University of Illinois at Chicago, Departments of Ophthalmology and Microbiology and Immunology, Chicago, IL, USA; <sup>1661</sup>University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, Chicago, IL, USA; <sup>1662</sup>University of Illinois at Chicago, Division of Gastroenterology and Hepatology, Department of Medicine, Chicago, IL, USA; <sup>1663</sup>University of Illinois at Urbana-Champaign, Department of Molecular and Integrative Physiology, Urbana, IL, USA; <sup>1664</sup>University of Illinois at Urbana-Champaign, Institute for Genomic Biology, Urbana, IL, USA; <sup>1665</sup>University of Innsbruck, Institute for Biomedical Aging Research, Innsbruck, Austria; <sup>1666</sup>University of Insubria, Department of Biotechnology and Life Sciences, Varese, Italy; <sup>1667</sup>University of Iowa, Children's Hospital, Iowa City, IA, USA; <sup>1668</sup>University of Iowa, Department of Health and Human Physiology, Iowa City, IA, USA; <sup>1669</sup>University of Iowa, Department of Internal Medicine, Iowa City, IA, USA; <sup>1670</sup>University of Iowa, Department of Medicine, Iowa City, IA, USA; <sup>1671</sup>University of Iowa, Department of Ophthalmology and Visual Sciences, Iowa City, IA, USA; <sup>1672</sup>University of Jyväskylä, Department of Biology of Physical Activity, Jyväskylä, Finland; <sup>1673</sup>University of Kansas and University of Kansas Cancer Center, Departments of Molecular Biosciences and Radiation Oncology, Lawrence, KS, USA; <sup>1674</sup>University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics, Kansas City, KS, USA; <sup>1675</sup>University of Kaohsiung Medical University, Department of Physiology, Faculty of Medicine, College of Medicine, Kaohsiung, Taiwan; <sup>1676</sup>University of Kentucky, College of Medicine, Department of Pharmacology and Nutritional Sciences, Lexington, KY, USA; <sup>1677</sup>University of Kentucky, Department of Biology, Lexington, KY, USA; <sup>1678</sup>University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, KY, USA; <sup>1679</sup>University of Kentucky, Department of Pharmacology and Nutritional Sciences, Lexington, KY, USA; <sup>1680</sup>University of Kentucky, Department of Toxicology and Cancer Biology, Lexington, KY, USA; <sup>1681</sup>University of Kiel, Department of Cardiology, Kiel, Germany; <sup>1682</sup>University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany; <sup>1683</sup>University of Kiel, Institute of Human Nutrition and Food Science, Kiel, Germany; <sup>1684</sup>University of La Réunion, CYROI, IRG Immunopathology and Infection Research Grouping, Reunion, France; <sup>1685</sup>University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences, Division of Radiotherapy and Radiobiology, L'Aquila, Italy; <sup>1686</sup>University of Lausanne, Department of Biochemistry, Epalinges, Switzerland; <sup>1687</sup>University of Lausanne, Department of Fundamental Neurosciences, Faculty of Biology and Medicine, Lausanne, Switzerland; <sup>1688</sup>University of Lausanne, Department of Ophthalmology, Lausanne, Switzerland; <sup>1689</sup>Hakim Sabzevari University, Department of Biology, Faculty of Basic Sciences, Sabzevar, Iran; <sup>1690</sup>University of Leicester, Department of Cancer Studies, Leicester, UK; <sup>1691</sup>University of Leicester, Department of Genetics, Leicester, UK; <sup>1692</sup>University of Leuven, Campus Gasthuisberg, Department of Cellular and Molecular Medicine, Laboratory for Cell Death Research and Therapy, Leuven, Belgium; <sup>1693</sup>University of Leuven, Department of Neurosciences, Leuven, Belgium; <sup>1694</sup>KU Leuven—University of Leuven, Center for Human Genetics; VIB Center for the Biology of Disease, Leuven, Belgium; <sup>1695</sup>University of Liege, GIGA-Signal Transduction Department, Protein Signalisation and Interaction Laboratory, Liège, Belgium; <sup>1696</sup>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, EGID, Lille, France; <sup>1697</sup>University of Limoges, Department of Histology and Cell Biology, Limoges, France; <sup>1698</sup>University of Liverpool, Cellular and Molecular Physiology, Institute of Translational Medicine, Liverpool, UK; <sup>1699</sup>University of Ljubljana, Institute of Cell Biology, Faculty of Medicine, Ljubljana, Slovenia; <sup>1700</sup>University of London, RVC Department of Comparative Biomedical Sciences, UCL Consortium for Mitochondrial Research, London, UK; <sup>1701</sup>University of Louisiana at Monroe, School of Pharmacy, Monroe, LA, USA; <sup>1702</sup>University of Louisville, Department of Biochemistry and Molecular Genetics, Louisville, KY, USA; <sup>1703</sup>University of Louisville, Department of Medicine (Hem-Onc), Louisville, KY, USA; <sup>1704</sup>University of Louisville, Department of Medicine, Institute of Molecular Cardiology, Diabetes and Obesity Center, Louisville, KY, USA; <sup>1705</sup>University of Louisville, Department of Physiology, Louisville, KY, USA; <sup>1706</sup>University of Louisville, James Graham Brown Cancer Center, Department of Medicine, Department of Pharmacology and Toxicology, Louisville, KY, USA; <sup>1707</sup>University of Louisville, School of Medicine, Department of Anatomical Sciences and Neurobiology, Louisville, KY, USA; <sup>1708</sup>University of Louisville, School of Medicine, Department of Physiology and Biophysics, Louisville, KY, USA; <sup>1709</sup>University of Luxembourg, Luxembourg Center for Systems Biomedicine, Luxembourg; <sup>1710</sup>University of Macau, State Key Lab of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, Macao, China; <sup>1711</sup>University of Malta, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, Msida, Malta; <sup>1712</sup>University of Manchester, Breakthrough Breast Cancer Research Unit, Manchester Centre for Cellular Metabolism, UK; <sup>1713</sup>University of Manchester, Faculty of Life Sciences, Manchester, UK; <sup>1714</sup>University of Manchester, Institute of Cancer Sciences, Faculty of Medical and Human Sciences, Manchester, UK; <sup>1715</sup>University of Manitoba, CancerCare Manitoba, Manitoba Institute of Cell Biology, Departments of Biochemistry and Medical Genetics and Immunology, Winnipeg, Manitoba, Canada; <sup>1716</sup>University of Manitoba, Department of Human Anatomy and Cell Science, Winnipeg, Manitoba, Canada; <sup>1717</sup>University of Manitoba, Department of Physiology and Pathophysiology, Winnipeg, Manitoba, Canada; <sup>1718</sup>University of Manitoba, Institute of Cardiovascular Sciences, College of Medicine, Faculty of Health Sciences, Winnipeg, Manitoba, Canada; <sup>1719</sup>University of Maryland, Department of Nutrition and Food Science, College Park, MD, USA; <sup>1720</sup>University of Maryland, Department of Veterinary Medicine, College Park, MD, USA; <sup>1721</sup>University of Maryland, School of Medicine, Center for Biomedical Engineering and Technology, Department of Physiology, Baltimore, MD, USA; <sup>1722</sup>University of Maryland, School of Medicine, Department of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research (STAR), National Study Center for Trauma and EMS, Baltimore, MD, USA; <sup>1723</sup>University of Maryland, School of Medicine, Department of Anesthesiology, Baltimore, MD, USA; <sup>1724</sup>University of Maryland, School of Medicine, Department of Chemistry, Baltimore, MD, USA; <sup>1725</sup>University of Maryland, School of Medicine, Department of Microbiology and Immunology, Baltimore, MD, USA; <sup>1726</sup>University of Maryland, School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Baltimore, MD, USA; <sup>1727</sup>University of Maryland, School of Medicine, Department of

Pharmacology, Baltimore, MD, USA; <sup>1728</sup>University of Maryland, School of Medicine, Institute of Human Virology, Baltimore, MD, USA; <sup>1729</sup>University of Massachusetts, Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, MA, USA; <sup>1730</sup>University of Massachusetts, Medical School, Department of Neurology, Worcester, MA, USA; <sup>1731</sup>University of Massachusetts, Medical School, Howard Hughes Medical Institute, Worcester, MA, USA; <sup>1732</sup>University of Medicine and Dentistry of New Jersey, Cellular and Molecular Signaling, Newark, NJ, USA; <sup>1733</sup>Cell Signalling and Cell Death Division, and University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, Parkville, Victoria, Australia; <sup>1734</sup>University of Melbourne, Department of Pathology, Parkville, Victoria, Australia; <sup>1735</sup>University of Melbourne, Department of Physiology, Parkville, Australia; <sup>1736</sup>Murdoch Childrens Research Institute, University of Melbourne, Department of Paediatrics, Royal Children's Hospital, Melbourne, Victoria, Australia; <sup>1737</sup>University of Miami, Miller School of Medicine, Department of Molecular and Cellular Pharmacology, Miami, FL, USA; <sup>1738</sup>University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA; <sup>1739</sup>University of Michigan Medical School, Department of Internal Medicine, Ann Arbor, MI, USA; <sup>1740</sup>University of Michigan Medical School, Department of Pathology, Ann Arbor, MI, USA; <sup>1741</sup>University of Michigan, Ann Arbor, MI, USA; <sup>1742</sup>University of Michigan, Department of Cell and Developmental Biology, Ann Arbor, MI, USA; <sup>1743</sup>University of Michigan, Department of Microbiology and Immunology, Ann Arbor, MI, USA; <sup>1744</sup>University of Michigan, Department of Molecular and Integrative Physiology, Ann Arbor, MI, USA; <sup>1745</sup>University of Michigan, Department of Molecular, Cellular, and Developmental Biology, Ann Arbor, MI, USA; <sup>1746</sup>University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, MI, USA; <sup>1747</sup>University of Michigan, Department of Radiation Oncology, Ann Arbor, MI, USA; <sup>1748</sup>University of Michigan, Department of Radiation Oncology, Division of Radiation and Cancer Biology, Ann Arbor, MI, USA; <sup>1749</sup>University of Michigan, Life Sciences Institute, Ann Arbor, MI, USA; <sup>1750</sup>University of Michigan, Molecular and Behavioral Neuroscience Institute, Departments of Computational Medicine and Bioinformatics, Psychiatry, and Human Genetics, Ann Arbor, MI, USA; <sup>1751</sup>University of Michigan, Neurosurgery, Ann Arbor, MI, USA; <sup>1752</sup>University of Michigan, Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, MI, USA; <sup>1753</sup>University of Michigan, School of Dentistry, Department of Biologic and Materials Sciences, Ann Arbor, MI, USA; <sup>1754</sup>University of Milan, Department of Experimental Oncology, European Institute of Oncology and Department of Biosciences, Milan, Italy; <sup>1755</sup>University of Milan, Department of Health Sciences, Milan, Italy; <sup>1756</sup>University of Milan, Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, Milan, Italy; <sup>1757</sup>Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; <sup>1758</sup>University of Minho, Molecular and Environmental Biology Centre (CBMA)/Department of Biology, Braga, Portugal; <sup>1759</sup>ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal; <sup>1760</sup>University of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics, Minneapolis, MN, USA; <sup>1761</sup>University of Minnesota, Department of Genetics, Cell Biology and Development, Minneapolis, MN, USA; <sup>1762</sup>University of Minnesota, Department of Lab Medicine and Pathology, Minneapolis, MN, USA; <sup>1763</sup>University of Minnesota, Department of Neuroscience, Minneapolis, MN, USA; <sup>1764</sup>University of Minnesota, Department of Surgery, Minneapolis, MN, USA; <sup>1765</sup>University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy; <sup>1766</sup>University of Modena and Reggio Emilia, Department of Surgery, Medicine, Dentistry and Morphological Sciences, Modena, Italy; <sup>1767</sup>University of Modena and Reggio Emilia, School of Medicine, Department of Surgery, Medicine, Dentistry and Morphological Sciences, Modena, Italy; <sup>1768</sup>University of Montpellier, INRA, UMR 866, Dynamique Musculaire et Métabolisme, Montpellier, France; <sup>1769</sup>University of Montpellier, UMR 866, Dynamique Musculaire et Métabolisme, Montpellier, France; <sup>1770</sup>University of Montpellier, UMR 5554, Montpellier, France; <sup>1771</sup>University of Murcia-IMIB Virgen de la Arrixaca Hospital, Human Anatomy and Psychobiology Department, Cell Therapy and Hematopoietic Transplantation Unit, Murcia, Spain; <sup>1772</sup>University of Nagasaki, Molecular and Cellular Biology, Graduate School of Human Health Science, Nagasaki, Japan; <sup>1773</sup>University of Namur, Laboratory of Biochemistry and Cell Biology (URBC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium; <sup>1774</sup>University of Namur, Research Unit in Molecular Physiology (URPhyM), Namur, Belgium; <sup>1775</sup>University of Naples Federico II, Department of Veterinary Medicine and Animal Production, Naples, Italy; <sup>1776</sup>University of Nebraska Medical Center, Department of Internal Medicine, Omaha, NE, USA; <sup>1777</sup>University of Nebraska Medical Center, Omaha, NE, USA; <sup>1778</sup>University of Nebraska-Lincoln, Redox Biology Center and School of Veterinary Medicine and Biomedical Sciences, Lincoln, NE, USA; <sup>1779</sup>University of New Mexico, Comprehensive Cancer Center, Department of Molecular Genetics and Microbiology, Albuquerque, NM, USA; <sup>1780</sup>University of New Mexico, Department of Internal Medicine, Albuquerque, NM, USA; <sup>1781</sup>University of New Mexico, Department of Pathology and Cancer Research and Treatment Center, Albuquerque, NM, USA; <sup>1782</sup>University of New Mexico, Health Sciences Center, Department of Molecular Genetics and Microbiology, Albuquerque, NM, USA; <sup>1783</sup>University of New South Wales, Inflammation and Infection Research Centre, School of Medical Sciences, Sydney, NSW, Australia; <sup>1784</sup>University of New South Wales, School of Biotechnology and Biomolecular Sciences, Sydney, NSW, Australia; <sup>1785</sup>University of Newcastle, School of Biomedical Sciences and Pharmacy, Newcastle, NSW, Australia; <sup>1786</sup>University of Newcastle, School of Medicine and Public Health, Callaghan, NSW, Australia; <sup>1787</sup>University of Nice, INSERM U1065, C3M, Nice, France; <sup>1788</sup>University of Nice-Sophia Antipolis, INSERM U1081, CNRS 7284, Faculty of Medicine, Nice, France; <sup>1789</sup>University of Nice-Sophia Antipolis, Institute for Research on Cancer and Aging of Nice (IRCAN), Nice, France; <sup>1790</sup>University of Nice-Sophia Antipolis, IRCAN, Nice, France; <sup>1791</sup>University of Niigata, Department of Neurosurgery, Brain Research Institute, Niigata, Japan; <sup>1792</sup>University of North Carolina, Department of Genetics, Chapel Hill, NC, USA; <sup>1793</sup>University of North Carolina, Department of Microbiology-Immunology, Chapel Hill, NC, USA; <sup>1794</sup>University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA; <sup>1795</sup>University of North Carolina, Lineberger Comprehensive Cancer Center, Institute of Inflammatory Diseases, Center for Translational Immunology, Chapel Hill, NC, USA; <sup>1796</sup>University of North Carolina, Microbiology and Immunology, Chapel Hill, NC, USA; <sup>1797</sup>University of North Dakota, Department of Biomedical Sciences, School of Medicine and Health Sciences, Grand Forks, ND, USA; <sup>1798</sup>University of North Texas Health Science Center, Department of Molecular and Medical Genetics, Fort Worth, TX, USA; <sup>1799</sup>University of Nottingham, School of Life Sciences, Nottingham, UK; <sup>1800</sup>University of Occupational and Environmental Health School of Medicine, Department of Neurology, Fukuoka, Japan; <sup>1801</sup>University of Occupational and Environmental Health, Third Department of Internal Medicine, Kitakyushu, Japan; <sup>1802</sup>University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK, USA; <sup>1803</sup>University of Oklahoma Health Sciences Center, Department of Pathology, Oklahoma City, OK, USA; <sup>1804</sup>University of Oklahoma, Health Sciences Center, Section of Molecular Medicine, Department of Medicine, Oklahoma City, OK, USA; <sup>1805</sup>University of Oslo, Centre for Cancer Biomedicine, Oslo, Norway; <sup>1806</sup>University of Oslo, Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; <sup>1807</sup>University of Oslo, Department of Biochemistry, Institute for Cancer Research, Oslo, Norway; <sup>1808</sup>University of Oslo, Department of Molecular Oncology, Department of Urology, Oslo, Norway; <sup>1809</sup>University of Oslo, Department of Clinical Molecular Biology, Oslo, Norway; <sup>1810</sup>University of Oslo, Department of Ophthalmology, Oslo, Norway; <sup>1811</sup>Centre for Cancer Research and Cell Biology, Queen's University Belfast, Lisburn Road, Belfast, UK; <sup>1812</sup>University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway; <sup>1813</sup>University of Oslo, Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway; <sup>1814</sup>University of Osnabrueck, Division of Microbiology, Osnabrueck, Germany; <sup>1815</sup>University of Osnabrueck, Fachbereich Biologie/Chemie, Osnabrueck, Germany; <sup>1816</sup>University of Ottawa, Department of Cellular and Molecular Medicine, Faculty of Medicine, Ottawa, Ontario, Canada; <sup>1817</sup>University of Ottawa, Department of Cellular and Molecular Medicine, Ottawa, Ontario, Canada; <sup>1818</sup>University of Oviedo, Department of Animal Physiology, Faculty of Medicine, Campus del Cristo, Oviedo, Spain; <sup>1819</sup>University of Oxford, Acute Stroke Programme, Radcliffe Department of Medicine, Oxford, UK; <sup>1820</sup>University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK; <sup>1821</sup>University of Oxford, Nuffield Department of Obstetrics and Gynaecology, Oxford, UK; <sup>1822</sup>University of Padova, Department of Biology, Padova, Italy; <sup>1823</sup>University of Padova, Department of Molecular Medicine, Padova, Italy; <sup>1824</sup>University of Padova, Department of Woman's and Child's Health, Laboratory of Oncohematology, Padova, Italy; <sup>1825</sup>University of Padova, Venetian Institute of Molecular Medicine, Department of Biomedical Science, Padova, Italy; <sup>1826</sup>University of Palermo, Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Palermo, Italy; <sup>1827</sup>University of Parma, Department of Biomedical, Biotechnological and Translational Sciences,

Parma, Italy; <sup>1828</sup>University of Parma, Department of Biomedicine, Biotechnology and Translational Research, Parma, Italy; <sup>1829</sup>University of Pavia, Department of Biology and Biotechnology, Pavia, Italy; <sup>1830</sup>University of Pavia, Department of Health Sciences, Pavia, Italy; <sup>1831</sup>University of Pennsylvania Perelman School of Medicine, Department of Radiation Oncology, Philadelphia, PA, USA; <sup>1832</sup>University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, USA; <sup>1833</sup>University of Pennsylvania, Center for Cell and Molecular Therapy, The Children Hospital of Philadelphia, Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA; <sup>1834</sup>University of Pennsylvania, Department of Anatomy and Cell Biology, Philadelphia, PA, USA; <sup>1835</sup>University of Pennsylvania, Department of Biochemistry, SDM, Philadelphia, PA, USA; <sup>1836</sup>University of Pennsylvania, Department of Microbiology, Philadelphia, PA, USA; <sup>1837</sup>University of Pennsylvania, Department of Obstetrics and Gynecology; Perelman School of Medicine, Philadelphia, PA, USA; <sup>1838</sup>Laboratoire Européen Performance Santé Altitude, EA 4604, University of Perpignan Via Domitia, Font-Romeu, France; <sup>1839</sup>University of Perugia, Department of Experimental Medicine, Perugia, Italy; <sup>1840</sup>University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy; <sup>1841</sup>University of Pisa, Interdepartmental Research Centre on Biology and Pathology of Aging, Pisa, Italy; <sup>1842</sup>University of Pittsburgh Cancer Institute, Hillman Cancer Center Research Pavilion, Pittsburgh, PA, USA; <sup>1843</sup>University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; <sup>1844</sup>University of Pittsburgh Medical Center, Department of Surgery, Pittsburgh, PA, USA; <sup>1845</sup>University of Pittsburgh, Department of Critical Care Medicine, Center for Critical Care Nephrology, Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Pittsburgh, PA, USA; <sup>1846</sup>University of Pittsburgh, Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA; <sup>1847</sup>University of Pittsburgh, Department of Pathology, Pittsburgh, PA, USA; <sup>1848</sup>University of Pittsburgh, Department of Surgery, Hillman Cancer Center, Pittsburgh, PA, USA; <sup>1849</sup>University of Pittsburgh, Department of Surgery, Pittsburgh, PA, USA; <sup>1850</sup>University of Pittsburgh, Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; <sup>1851</sup>University of Pittsburgh, Pittsburgh, PA, USA; <sup>1852</sup>University of Pittsburgh, School of Dental Medicine, Department of Endodontics, Pittsburgh, PA, USA; <sup>1853</sup>University of Pittsburgh, School of Medicine, Department of Anesthesiology, Pittsburgh, PA, USA; <sup>1854</sup>University of Pittsburgh, School of Medicine, Department of Critical Care Medicine, Pittsburgh, PA, USA; <sup>1855</sup>University of Pittsburgh, School of Medicine, Department of Immunology, Pittsburgh, PA, USA; <sup>1856</sup>University of Pittsburgh, School of Medicine, Department of Pathology and Center for Neuroscience, Pittsburgh, PA, USA; <sup>1857</sup>University of Pittsburgh, School of Medicine, Department of Pediatrics, Pittsburgh, PA, USA; <sup>1858</sup>University of Pittsburgh, School of Medicine, Department of Pharmacology and Chemical Biology, Pittsburgh, PA, USA; <sup>1859</sup>University of Pittsburgh, School of Medicine, Department of Surgery, Division of Endocrine Surgery, Pittsburgh, PA, USA; <sup>1860</sup>University of Pittsburgh, Vascular Medicine Institute, Pittsburgh, PA, USA; <sup>1861</sup>University of Poitiers, EA3808 Molecular Targets and Therapeutics in Alzheimer's Disease, Poitiers, France; <sup>1862</sup>University of Porto, Cancer Drug Resistance Group, IPA-TIMUP - Institute of Molecular Pathology and Immunology, Porto, Portugal; <sup>1863</sup>University of Porto, Department of Biological Sciences, Faculty of Pharmacy, Porto, Portugal; <sup>1864</sup>University of Porto, Department of Pathology and Oncology, Faculty of Medicine, Porto, Portugal; <sup>1865</sup>University of Porto, i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal; <sup>1866</sup>University of Pretoria, Department of Physiology, Pretoria, Gauteng, South Africa; <sup>1867</sup>University of Quebec at Trois-Rivieres, Department of Biology and Medicine, Trois-Rivieres, Quebec, Canada; <sup>1868</sup>University of Queensland, Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, Brisbane, Queensland, Australia; <sup>1869</sup>University of Queensland, Australian Institute for Bioengineering and Nanotechnology (AIBN), Brisbane, Australia; <sup>1870</sup>University of Reading, School of Pharmacy, Reading, UK; <sup>1871</sup>University of Reading, School of Pharmacy, Whiteknights, Reading, UK; <sup>1872</sup>University of Rochester Medical Center, Department of Anesthesiology, Rochester, NY, USA; <sup>1873</sup>University of Rochester Medical Center, Department of Pathology and Laboratory Medicine, Rochester, NY, USA; <sup>1874</sup>University of Siena, Department of Medicine, Surgery & Neuroscience, Siena, Italy; <sup>1875</sup>University of Rome "Sapienza", Department of Medical-Surgical Sciences and Biotechnologies, Latina, Italy; <sup>1876</sup>University of Rome "Tor Vergata", Department of Biology, Rome, Italy; <sup>1877</sup>University of Rome "Tor Vergata", Department of Biomedicine and Prevention, Rome, Italy; <sup>1878</sup>University of Rome "Tor Vergata", Department of Chemistry, Rome, Italy; <sup>1879</sup>University of Rome "Tor Vergata", Department of Clinical Sciences and Translational Medicine, Rome, Italy; <sup>1880</sup>University of Rome "Tor Vergata", Department of Experimental Medicine and Surgery, Rome, Italy; <sup>1881</sup>University of Rome "Tor Vergata", Department of Surgery and Experimental Medicine, Rome, Italy; <sup>1882</sup>University of Rome "Tor Vergata", Department of System Medicine, Rome, Italy; <sup>1883</sup>University of Rome "Tor Vergata", Department of Systems Medicine, Rome, Italy; <sup>1884</sup>University of Rome "Tor Vergata", Department of Biology, Rome, Italy; <sup>1885</sup>University of Rzeszow, Institute of Cell Biology, Rzeszow, Poland; <sup>1886</sup>University of Salento, Department of Biological and Environmental Science and Technology, Lecce, Italy; <sup>1887</sup>University of Salento, Department of Biological and Environmental Sciences and Technologies (DiSteBA), Lecce, Italy; <sup>1888</sup>University of Salerno, Department of Pharmacy, Fisciano, Salerno, Italy; <sup>1889</sup>University of Salerno, Section of Neurosciences, Department of Medicine and Surgery, Salerno, Italy; <sup>1890</sup>University of São Paulo, Institute of Biomedical Science, Department of Cell and Developmental Biology, São Paulo, SP, Brazil; <sup>1891</sup>University of São Paulo, Ribeirão Preto Medical School, Department of Biochemistry and Immunology, Ribeirão Preto, São Paulo, Brazil; <sup>1892</sup>University of São Paulo, Ribeirão Preto Medical School, Department of Physiology, Ribeirão Preto, São Paulo, Brazil; <sup>1893</sup>University of São Paulo, School of Physical Education and Sport, Cellular and Molecular Exercise Physiology Laboratory, São Paulo, Brazil; <sup>1894</sup>University of Science and Technology of China, Anhui, China; <sup>1895</sup>University of Science and Technology of China, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Lifesciences, Hefei, Anhui, China; <sup>1896</sup>University of Science and Technology of China, School of Life Sciences, and Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui, China; <sup>1897</sup>University of Science and Technology of China, School of Life Sciences, Hefei, Anhui, China; <sup>1898</sup>University of Sevilla, Department of Cell Biology, Sevilla, Spain; <sup>1899</sup>University of Sevilla, Instituto de Biomedicina de Sevilla (IBIS), Oral Medicine Department, Sevilla, Spain; <sup>1900</sup>University of Sheffield, Department of Biomedical Sciences, Sheffield, UK; <sup>1901</sup>University of Sherbrooke, Faculté de Médecine et des Sciences de la Santé, Department of Medicine/Gastroenterology Division, Sherbrooke, Québec, Canada; <sup>1902</sup>University of Siena, Department of Molecular and Developmental Medicine, Siena, Italy; <sup>1903</sup>University of Silesia, Department of Animal Histology and Embryology, Katowice, Poland; <sup>1904</sup>University of South Alabama, Mitchell Cancer Institute, Mobile, AL, USA; <sup>1905</sup>University of South Australia and SA Pathology, Centre for Cancer Biology, Adelaide, SA, Australia; <sup>1906</sup>University of South Australia, Early Origins of Adult Health Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, Adelaide, SA, Australia; <sup>1907</sup>University of South Carolina School of Medicine, Department of Cell Biology and Anatomy, Columbia, SC, USA; <sup>1908</sup>University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC, USA; <sup>1909</sup>University of South Carolina Upstate, Department of Biology, Division of Natural Sciences and Engineering, Spartanburg, SC; <sup>1910</sup>University of South Carolina, Environmental Health and Disease Laboratory, Department of Environmental Health Sciences, Columbia, SC, USA; <sup>1911</sup>University of South Dakota, Division of Basic Biomedical Sciences, Vermillion, SD, USA; <sup>1912</sup>University of South Dakota, Sanford School of Medicine, Division of Basic Biomedical Sciences, Vermillion, SD, USA; <sup>1913</sup>University of South Dakota, Vermillion, SD, USA; <sup>1914</sup>University of South Florida, Byrd Alzheimer's Institute, Tampa, FL, USA; <sup>1915</sup>University of South Florida, Department of Cell Biology, Microbiology, and Molecular Biology, Tampa, FL, USA; <sup>1916</sup>University of South Florida, Department of Molecular Medicine, Tampa, FL, USA; <sup>1917</sup>University of South Florida, Department of Pharmaceutical Science, Tampa, FL, USA; <sup>1918</sup>University of South Florida, Department of Pharmaceutical Sciences, College of Pharmacy, Byrd Alzheimer's Institute, Tampa, FL, USA; <sup>1919</sup>University of Southampton, Cancer Sciences, Southampton, UK; <sup>1920</sup>University of Southampton, Centre for Biological Sciences, Highfield Campus, Southampton, UK; <sup>1921</sup>University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, CA, USA; <sup>1922</sup>University of Southern California, Keck School of Medicine, Department of Molecular Microbiology and Immunology, Los Angeles, CA, USA; <sup>1923</sup>University of Southern California, Keck School of Medicine, Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, Department of Cell and Neurobiology, Los Angeles, CA, USA; <sup>1924</sup>University of Southern California, Keck School of Medicine, Neurology and Pathology, Los Angeles, CA, USA; <sup>1925</sup>University of Southern California, Research ALPD and Cirrhosis Center, Keck School of Medicine, Los Angeles, CA, USA; <sup>1926</sup>University of Southern California, The Saban

Research Institute, Developmental Neuroscience Program, Children's Hospital Los Angeles, Los Angeles, CA, USA; <sup>1927</sup>University of Southern Denmark, Villum Center for Bioanalytical Sciences, Department of Biochemistry and Molecular Biology, Odense, Denmark; <sup>1928</sup>University of St Andrews, School of Medicine, St Andrews, Fife, UK; <sup>1929</sup>University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; <sup>1930</sup>University of Sunderland, Department of Pharmacy, Health and Wellbeing, Faculty of Applied Sciences, Sunderland, UK; <sup>1931</sup>University of Sydney, Department of Cardiology, Sydney, NSW, Australia; <sup>1932</sup>University of Sydney, Department of Neurogenetics, Kolling Institute, St Leonards, NSW, Australia; <sup>1933</sup>University of Sydney, Department of Pathology and Bosch Institute, Sydney, New South Wales, Australia; <sup>1934</sup>University of Szeged, Department of Medical Microbiology and Immunobiology, Szeged, Csongrád, Hungary; <sup>1935</sup>University of Szeged, Department of Ophthalmology, Faculty of Medicine, Szeged, Hungary; <sup>1936</sup>University of Tartu, Department of Pharmacology, Tartu, Estonia; <sup>1937</sup>University of Tartu, Institute of Biomedicine and Translational Medicine, Tartu, Estonia; <sup>1938</sup>University of Tasmania, School of Health Sciences, Launceston, Tasmania; <sup>1939</sup>University of Tennessee Health Science Center, Department of Physiology, Memphis, TN, USA; <sup>1940</sup>University of Texas at Austin, College of Pharmacy, Division of Medicinal Chemistry, Austin, TX, USA; <sup>1941</sup>University of Texas, Department of Biochemistry, Dallas, TX, USA; <sup>1942</sup>University of Texas, Southwestern Medical Center, Department of Internal Medicine, Center for Autophagy Research, Dallas, TX, USA; <sup>1943</sup>University of Texas, Health Science Center at Houston, Center for Human Genetics, Institute of Molecular Medicine, Houston, TX, USA; <sup>1944</sup>University of Texas, Health Science Center at Houston, Department of Pathology and Laboratory Medicine, Houston, TX, USA; <sup>1945</sup>University of Texas, Health Science Center at Houston, School of Dentistry, Houston, TX, USA; <sup>1946</sup>University of Texas, Health Science Center at San Antonio, CTCRC Institute for Drug Development, San Antonio, TX, USA; <sup>1947</sup>University of Texas, Health Science Center at San Antonio, Department of Molecular Medicine, San Antonio, TX, USA; <sup>1948</sup>University of Texas, Health Science Center at San Antonio, Department of Pathology, San Antonio, TX, USA; <sup>1949</sup>University of Texas, Health Science Center at San Antonio, Department of Urology, San Antonio, TX, USA; <sup>1950</sup>University of Texas, Health Sciences Center-Houston (UTHSC), Department of Integrative Biology and Pharmacology, Houston, TX, USA; <sup>1951</sup>University of Texas, MD Anderson Cancer Center, Department of Bioinformatics and Computational Biology, Houston, TX, USA; <sup>1952</sup>University of Texas, MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA; <sup>1953</sup>University of Texas, MD Anderson Cancer Center, Department of Hematopathology, Houston, TX, USA; <sup>1954</sup>University of Texas, MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX, USA; <sup>1955</sup>University of Texas, MD Anderson Cancer Center, Department of Systems Biology, Houston, TX, USA; <sup>1956</sup>University of Texas, MD Anderson Cancer Center, Houston, TX, USA; <sup>1957</sup>University of Texas, MD Anderson Cancer Center, The Proteomics and Metabolomics Core Facility, Houston, TX, USA; <sup>1958</sup>University of Texas, Medical Branch, Department of Microbiology and Immunology, Galveston, TX, USA; <sup>1959</sup>University of Texas, Medical Branch, Department of Nutrition and Metabolism, Galveston, TX, USA; <sup>1960</sup>University of Texas, Medical Branch, Department of Pathology, Galveston, TX, USA; <sup>1961</sup>University of Texas, Medical School at Houston, Department of Neurobiology and Anatomy, Houston, TX, USA; <sup>1962</sup>University of Texas, Medical School at Houston, Division of Cardiovascular Medicine, Department of Medicine, Houston, TX, USA; <sup>1963</sup>University of Texas, Southwestern Medical Center at Dallas, Department of Dermatology, Dallas, TX; <sup>1964</sup>University of Texas, Southwestern Medical Center, Dallas, TX, USA; <sup>1965</sup>University of Texas, Southwestern Medical Center, Department of Internal Medicine, Center for Mineral Metabolism and Clinical Research, Dallas, TX, USA; <sup>1966</sup>University of Texas, Southwestern Medical Center, Department of Internal Medicine, Dallas, TX; <sup>1967</sup>University of Texas, Southwestern Medical Center, Department of Neuroscience, Dallas, TX; <sup>1968</sup>University of Texas, Southwestern Medical Center, Medicine and Molecular Biology, Dallas, TX; <sup>1969</sup>University of Virginia, Departments of Biology and Cell Biology, Charlottesville, VA, USA; <sup>1970</sup>University of the District of Columbia, Cancer Research Laboratory, Washington, DC, USA; <sup>1971</sup>University of Tokyo, Bioimaging Center, Graduate School of Frontier Sciences, Chiba, Japan; <sup>1972</sup>University of Tokyo, Department of Biochemistry and Molecular Biology, Graduate School and Faculty of Medicine, Tokyo, Japan; <sup>1973</sup>University of Tokyo, Department of Biotechnology, Tokyo, Japan; <sup>1974</sup>University of Tokyo, Institute of Molecular and Cellular Biosciences, Tokyo, Japan; <sup>1975</sup>University of Toledo, Department of Biological Sciences, Toledo, OH, USA; <sup>1976</sup>University of Toronto, Department of Cell and Systems Biology, Toronto, Ontario, Canada; <sup>1977</sup>University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada; <sup>1978</sup>University of Toronto, Department of Molecular Genetics, Toronto, Ontario, Canada; <sup>1979</sup>University of Toronto, Hospital for Sick Children Research Institute, Department of Physiology and Experimental Medicine, Toronto, Canada; <sup>1980</sup>University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada; <sup>1981</sup>University of Toronto, Molecular Structure and Function, Research Institute, Hospital for Sick Children, Toronto, ON, Canada; <sup>1982</sup>University of Toronto, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>1983</sup>University of Toronto/Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Department of Obstetrics and Gynecology, Toronto, Ontario, Canada; <sup>1984</sup>University of Toulouse, INSERM UMR 1037, Cancer Research Center of Toulouse, Toulouse, France; <sup>1985</sup>University of Toulouse, INSERM UMR 1048, Toulouse, France; <sup>1986</sup>University of Toyama, Division of Natural Drug Discovery, Institute of Natural Medicine, Toyama, Japan; <sup>1987</sup>University of Trento, The Microsoft Research, Centre for Computational and Systems Biology (COSBI), Rovereto, TN, Italy; <sup>1988</sup>University of Tromsø - The Arctic University of Norway, Department of Medical Biology, Tromsø, Norway; <sup>1989</sup>University of Tromsø - The Arctic University of Norway, Molecular Cancer Research Group, Institute of Medical Biology, Tromsø, Norway; <sup>1990</sup>University of Tübingen, Center for Plant Molecular Biology (ZMBP), Department of Plant Biochemistry, Tübingen, Germany; <sup>1991</sup>University of Tübingen, Institute of Medical Genetics and Applied Genomics, Tübingen, Germany; <sup>1992</sup>University of Turin, Department of Clinical and Biological Sciences, Turin, TO, Italy; <sup>1993</sup>University of Turin, Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Clinical Pathology, Turin, Italy; <sup>1994</sup>University of Turin, Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy; <sup>1995</sup>University of Turin, Turin, Italy; <sup>1996</sup>University of Tuscia, Department for Innovation in Biological, Agro-food and Forest Systems (DIBAF), Viterbo, Italy; <sup>1997</sup>University of Udine, Dipartimento di Scienze Mediche e Biologiche, Udine, Italy; <sup>1998</sup>University of Ulm, Institute of Applied Physiology, Ulm, Germany; <sup>1999</sup>University of Ulsan College of Medicine, Asan Medical Center, Department of Biochemistry and Molecular Biology, Seoul, Korea; <sup>2000</sup>University of Ulsan College of Medicine, Asan Medical Center, Department of Surgery, Seoul, Korea; <sup>2001</sup>University of Ulsan College of Medicine, Department of Brain Science, Seoul, Korea; <sup>2002</sup>University of Urbino "Carlo Bo", Department of Biomolecular Sciences, Urbino, Italy; <sup>2003</sup>University of Utah School of Medicine, Department of Biochemistry, Salt Lake City, UT, USA; <sup>2004</sup>University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA; <sup>2005</sup>University of Valencia, Departamento de Bioquímica y Biología Molecular, IATA-CSIC, Valencia, Spain; <sup>2006</sup>University of Valencia, Departamento de Biotecnología, IATA-CSIC, Valencia, Spain; <sup>2007</sup>University of Valencia, Department of Pharmacology, Valencia, Spain; <sup>2008</sup>University of Valencia, Department of Physiology, Burjassot, Valencia, Spain; <sup>2009</sup>University of Verona, Department of Neurological, Biomedical and Movement Sciences, Verona, Italy; <sup>2010</sup>University of Vienna, Department of Chromosome Biology, Max F. Perutz Laboratories, Vienna, Austria; <sup>2011</sup>University of Vienna, Max F. Perutz Laboratories, Vienna, Austria; <sup>2012</sup>University of Virginia, Charlottesville, VA, USA; <sup>2013</sup>University of Virginia, Department of Cell Biology, Charlottesville, VA, USA; <sup>2014</sup>University of Warwick, Life Sciences, Coventry, UK; <sup>2015</sup>University of Washington, Department of Pathology, Seattle, WA; <sup>2016</sup>University of Waterloo, Department of Biology, Waterloo, Ontario, Canada; <sup>2017</sup>University of Waterloo, Department of Kinesiology, Waterloo, Ontario, Canada; <sup>2018</sup>University of Wisconsin, Department of Dermatology, Madison, WI, USA; <sup>2019</sup>Washington University in St Louis, Department of Biology, St. Louis, MO, USA; <sup>2020</sup>University of Wisconsin, Department of Medicine, Madison, WI, USA; <sup>2021</sup>University of Wisconsin, Department of Ophthalmology and Visual Sciences, McPherson Eye Research Institute, Madison, WI, USA; <sup>2022</sup>University of Wisconsin, School of Medicine and Public Health, Department of Cell and Regenerative Biology, Carbone Cancer Center, Madison, WI, USA; <sup>2023</sup>University of Wisconsin, School of Veterinary Medicine, Department of Pathobiological Sciences, Madison, WI, USA; <sup>2024</sup>University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY, USA; <sup>2025</sup>University of York, Centre for Immunology and Infection, Department of Biology, Hull York Medical School, York, UK; <sup>2026</sup>University of York, Department of Biology, Heslington, York, UK; <sup>2027</sup>University of Zaragoza, Department of Biochemistry and Molecular and Cell

Biology, Faculty of Sciences, Zaragoza, Spain; <sup>2028</sup>University of Zürich, Department of Radiation Oncology, Zurich, Switzerland; <sup>2029</sup>University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland; <sup>2030</sup>University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland; <sup>2031</sup>University of Zürich, Institute of Physiology, Zürich, Switzerland; <sup>2032</sup>University Paul Sabatier, INSERM U1048, Toulouse, France; <sup>2033</sup>University Pierre et Marie Curie, UMR8256/INSERM U-1164, Biological Adaptation and Ageing (B2A), Paris, France; <sup>2034</sup>University Roma Tre, Department of Science, LIME, Rome, Italy; <sup>2035</sup>US Food and Drug Administration, National Center for Toxicological Research, Division of Systems Biology, Jefferson, AR, USA; <sup>2036</sup>US Food and Drug Administration, National Center for Toxicology Research, Division of Microbiology, Jefferson, AR, USA; <sup>2037</sup>USDA-Human Nutrition Research Center on Aging at Tufts University, Department of Neuroscience and Aging, Boston, MA, USA; <sup>2038</sup>VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA; <sup>2039</sup>VA Pittsburgh Health System, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; <sup>2040</sup>Vall d'Hebron Research Institute, Neurodegenerative Diseases Lab, Barcelona, Spain; <sup>2041</sup>Vall d'Hebron Research Institute-CIBERNED, Neurodegenerative Diseases Research Group, Barcelona, Spain; <sup>2042</sup>Van Andel Institute, Center for Neurodegenerative Science, Grand Rapids, MI, USA; <sup>2043</sup>Van Andel Research Institute, Laboratory of Systems Biology, Grand Rapids, MI, USA; <sup>2044</sup>Vancouver Prostate Centre, Vancouver, BC, Canada; <sup>2045</sup>Vanderbilt University Medical Center, Department of Pediatric Surgery, Nashville, TN, USA; <sup>2046</sup>Vanderbilt University, Department of Neurology, Nashville, TN, USA; <sup>2047</sup>Vanderbilt University, School of Medicine, Department of Molecular Physiology and Biophysics, Nashville, TN, USA; <sup>2048</sup>Vanderbilt University, School of Medicine, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA; <sup>2049</sup>Vanderbilt University, School of Medicine, Pathology Microbiology and Immunology, Nashville, TN, USA; <sup>2050</sup>Venus Medicine Research Center (VMRC), Baddi, Himachal Pradesh, India; <sup>2051</sup>Virginia Commonwealth University, Department of Biochemistry and Molecular Biology, Richmond, VA, USA; <sup>2052</sup>Virginia Commonwealth University, Department of Human and Molecular Genetics, Richmond, VA, USA; <sup>2053</sup>Virginia Commonwealth University, Department of Internal Medicine, Division of Pulmonary Disease and Critical Care Medicine, Richmond, VA, USA; <sup>2054</sup>Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, USA; <sup>2055</sup>Virginia Commonwealth University, Department of Microbiology and Immunology, Richmond, VA, USA; <sup>2056</sup>Virginia Commonwealth University, Institute of Molecular Medicine, Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Department of Human and Molecular Genetics, Richmond, VA, USA; <sup>2057</sup>Virginia Commonwealth University, Internal Medicine, VCU Pauley Heart Center, Richmond, VA, USA; <sup>2058</sup>Virginia Commonwealth University, Massey Cancer Center, Department of Internal Medicine, Richmond, VA, USA; <sup>2059</sup>Virginia Commonwealth University, Massey Cancer Center, Department of Medicine, Richmond, VA, USA; <sup>2060</sup>Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA; <sup>2061</sup>Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Autoimmunity and Vascular Inflammation Unit, Milan, Italy; <sup>2062</sup>San Raffaele Scientific Institute, European Institute for Research in Cystic Fibrosis, Milan, Italy; <sup>2063</sup>INSPE, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy; <sup>2064</sup>San Raffaele Scientific Institute, Milan, Italy; <sup>2065</sup>VU University Medical Center, Department of Medical Oncology, Amsterdam, The Netherlands; <sup>2066</sup>VU University Medical Center, Department of Molecular Cell Biology and Immunology, Amsterdam, The Netherlands; <sup>2067</sup>VU University Medical Center, Department of Pathology, Amsterdam, The Netherlands; <sup>2068</sup>University of Nevada School of Medicine, Department of Pharmacology, Reno, NV, USA; <sup>2069</sup>VU University, Medical Center, Academic Medical Center, Department of Clinical Genetics and Alzheimer Center, Amsterdam, Netherlands; <sup>2070</sup>Department of Genome Analysis, Amsterdam, Netherlands; <sup>2071</sup>VU University, Departments of Functional Genomics and Molecular and Cellular Neuroscience, Center for Neurogenomics and Cognitive Research, Amsterdam, Netherlands; <sup>2072</sup>Wake Forest University, Department of Surgery and Cancer Biology, Winston-Salem, NC, USA; <sup>2073</sup>Wake Forest University, Department of Surgery, Hypertension and Vascular Research Center, Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA; <sup>2074</sup>Warsaw University of Life Sciences - SGGW, Faculty of Veterinary Medicine, Department of Physiological Sciences, Warsaw, Poland; <sup>2075</sup>Warsaw University of Life Sciences (SGGW), Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw, Poland; <sup>2076</sup>Washington State University Vancouver, School of Molecular Biosciences, Vancouver, WA, USA; <sup>2077</sup>Washington State University, School of Molecular Biosciences, Pullman, WA, USA; <sup>2078</sup>Washington University in St. Louis, School of Medicine, Department of Internal Medicine, St. Louis, MO, USA; <sup>2079</sup>Washington University in St. Louis, School of Medicine, Department of Ophthalmology and Visual Sciences, St. Louis, MO, USA; <sup>2080</sup>Washington University, Department of Medicine, St. Louis, MO, USA; <sup>2081</sup>Washington University, School of Medicine, Cardiovascular Division, Department of Medicine, St. Louis, MO, USA; <sup>2082</sup>Washington University, School of Medicine, Department of Developmental Biology, St. Louis, MO, USA; <sup>2083</sup>Washington University, School of Medicine, Department of Neurology, St. Louis, MO, USA; <sup>2084</sup>Washington University, School of Medicine, Department of Pathology and Immunology, St. Louis, MO, USA; <sup>2085</sup>Washington University, School of Medicine, Departments of Obstetrics and Gynecology, and Pathology and Immunology, St. Louis, MO, USA; <sup>2086</sup>Washington University, School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, St. Louis, MO, USA; <sup>2087</sup>Washington University, School of Medicine, John Cochran VA Medical Center, Center for Cardiovascular Research, St. Louis, MO, USA; <sup>2088</sup>Wayne State University, School of Medicine, Cardiovascular Research Institute, Detroit, MI, USA; <sup>2089</sup>Wayne State University, School of Medicine, Department of Pathology, Karmanos Cancer Institute, Detroit, MI, USA; <sup>2090</sup>Wayne State University, School of Medicine, Departments of Oncology and Pathology, Detroit, MI, USA; <sup>2091</sup>Wayne State University, School of Medicine, Detroit, MI, USA; <sup>2092</sup>Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA; <sup>2093</sup>Weill Cornell Medical College, Division of Nephrology and Hypertension, Joan and Sanford I. Weill Department of Medicine, New York, NY, USA; <sup>2094</sup>Weill Cornell Medical College, Joan and Sanford I. Weill Department of Medicine, New York, NY, USA; <sup>2095</sup>Weill Cornell Medical College, New York, NY, USA; <sup>2096</sup>Weizmann Institute of Science, Department of Biological Chemistry, Rehovot, Israel; <sup>2097</sup>Weizmann Institute of Science, Department of Chemical Biology, Rehovot, Israel; <sup>2098</sup>Weizmann Institute of Science, Department of Molecular Genetics, Rehovot, Israel; <sup>2099</sup>Wenzhou Medical University, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou, Zhejiang, China; <sup>2100</sup>Western University, Department of Obstetrics and Gynaecology, London, ON, Canada; <sup>2101</sup>Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Campus 1, Institute of Experimental Musculoskeletal Medicine, Münster, Germany; <sup>2102</sup>Whitehead Institute, HHMI and Massachusetts Institute of Technology, Cambridge, MA, USA; <sup>2103</sup>Wonkwang University, Department of Dental Pharmacology, School of Dentistry, Chonbuk, Korea; <sup>2104</sup>Wuhan University, College of Life Science, State Key Laboratory of Virology, Wuhan, Hubei, China; <sup>2105</sup>Xiamen University, School of Life Sciences, Fujian, China; <sup>2106</sup>Xi'an Jiaotong University Health Center, Department of Pharmacology, Xi'an, Shaanxi, China; <sup>2107</sup>Xi'an Jiaotong University Health Science Center, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shaanxi, China; <sup>2108</sup>Xijing Hospital, The Fourth Military Medical University, Xi'an, China; <sup>2109</sup>Xuzhou Medical College, Department of Pathology, Xuzhou, Jiangsu, China; <sup>2110</sup>Yale University School of Medicine, Department of Microbial Pathogenesis and Howard Hughes Medical Institute, New Haven, CT, USA; <sup>2111</sup>Yale University School of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, New Haven, CT, USA; <sup>2112</sup>Yamaguchi University, Joint Faculty of Veterinary Medicine, Laboratory of Veterinary Hygiene, Yamaguchi, Japan; <sup>2113</sup>Yeshiva University, New York, NY, USA; <sup>2114</sup>Yokohama City University Graduate School of Medicine, Department of Human Genetics, Yokohama, Japan; <sup>2115</sup>Yonsei University, College of Life Science and Biotechnology, Department of Systems Biology, Seoul, Korea; <sup>2116</sup>Yonsei University, College of Medicine, Corneal Dystrophy Research Institute; and Department of Ophthalmology, Seoul, Korea; <sup>2117</sup>Yonsei University, College of Medicine, Severance Biomedical Science Institute, Seoul, Korea; <sup>2118</sup>Yonsei University, Department of Biomedical Engineering, College of Health Science, Seoul, Korea; <sup>2119</sup>Yonsei University, Division of Biological Science and Technology, Wonju, Korea; <sup>2120</sup>York College/The City University of New York, Department of Biology, Jamaica, NY, USA; <sup>2121</sup>York University, School of Kinesiology and Health Science, Toronto, Ontario, Canada; <sup>2122</sup>Zhejiang Cancer Hospital, Department of Medical Oncology, Hangzhou, China; <sup>2123</sup>Zhejiang University, Department of Pharmacology, College of Pharmaceutical Sciences, Hangzhou, Zhejiang, China; <sup>2124</sup>Zhejiang University, Department of

Biomedical Engineering, Qiushi Academy for Advanced Studies, Hangzhou, China; <sup>2125</sup>Zhejiang University, Department of Food Science and Nutrition, Hangzhou, China; <sup>2126</sup>Zhejiang University, Hangzhou, China; <sup>2127</sup>Zhejiang University, Institute of Agriculture and Biotechnology, Hangzhou, China; <sup>2128</sup>Zhejiang University, Institute of Hematology, First Affiliated Hospital, College of Medicine, Hangzhou, China; <sup>2129</sup>Zhejiang University, Institute of Insect Science, Hangzhou, China; <sup>2130</sup>Zhejiang University, Institute of Pharmacology, Toxicology and Biochemical Pharmaceutics, Hangzhou, China; <sup>2131</sup>Zhejiang University, Life Sciences Institute, Zhejiang, China; <sup>2132</sup>Zhejiang University, School of Medicine, Department of Biochemistry, Hangzhou, Zhejiang, China; <sup>2133</sup>Zhejiang University, Sir Run Run Shaw Hospital, College of Medicine, Hangzhou, Zhejiang, China; <sup>2134</sup>Zhejiang University, Sir Run Run Shaw Hospital, Department of Medical Oncology, Hangzhou, Zhejiang, China; <sup>2135</sup>Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, China

**Abbreviations:** 3-MA, 3-methyladenine; ABC, avidin-biotin peroxidase complex; AIM, Atg8-family interacting motif; ALIS, aggresome-like induced structures; Ape1, aminopeptidase I; ARN, autophagy regulatory network; ASFV, African swine fever virus; Atg, autophagy-related; AV, autophagic vacuole; BDI, bright detail intensity; CASA, chaperone-assisted selective autophagy; CLEAR, coordinated lysosomal enhancement and regulation; CLEM, correlative light and electron microscopy; CMA, chaperone-mediated autophagy; cryo-SXT, cryo-soft X-ray tomography; Cvt, cytoplasm-to-vacuole targeting; DAMP, danger/damage-associated molecular pattern; DQ-BSA, dequenched bovine serum albumin; e-MI, endosomal microautophagy; EBSS, Earle's balanced salt solution; EM, electron microscopy; ER, endoplasmic reticulum; FACS, fluorescence-activated cell sorter; FRET, fluorescence resonance energy transfer; GAP, GTPase activating protein; GBP, guanylate binding protein; GFP, green fluorescent protein; HIV-1, human immunodeficiency virus type 1; HKP, housekeeping protein; HSV-1, herpes simplex virus type 1; Hyp-PDT, hypericin-based photodynamic therapy; ICD, immunogenic cell death; IHC, immunohistochemistry; IMP, intramembrane particle; LAMP2, lysosomal-associated membrane protein 2; LAP, LC3-associated phagocytosis; LIR, LC3-interacting region; LN, late nucleophagy; MAP1LC3/LC3, microtubule associated protein 1 light chain 3; MDC, monodansylcadaverine; MEC, mammary epithelial cell; mRFP, monomeric red fluorescent protein; mtDNA, mitochondrial DNA; MTOR, mechanistic target of rapamycin (serine/threonine kinase); MVB, multivesicular body; NASH, nonalcoholic steatohepatitis; ncRNA, noncoding RNA; NET, neutrophil extracellular trap; NVJ, nucleus-vacuole junction; PAMP, pathogen-associated molecular pattern; PAS, phagophore assembly site; PDT, photodynamic therapy; PE, phosphatidylethanolamine; PI3K, phosphoinositide 3-kinase; PMN, piecemeal microautophagy of the nucleus; PMSF, phenylmethylsulfonylfluoride; POF, postovulatory follicle; PSSM, position-specific scoring matrix; PtdIns3K, phosphatidylinositol 3-kinase; PtdIns3P, phosphatidylinositol 3-phosphate; PTM, posttranslational modification; PVM, parasitophorus vacuole membrane; qRT-PCR, quantitative real-time reverse transcription polymerase chain reaction; RBC, red blood cell; RCBs, Rubisco-containing bodies; Rluc, *Renilla reniformis* luciferase; ROS, reactive oxygen species; SD, standard deviation; SKL, serine-lysine-leucine (a peroxisome targeting signal); SOD, superoxide dismutase; TEM, transmission electron microscopy; tflc3, tandem fluorescent LC3; TORC1, TOR complex I; TR-FRET, time-resolved fluorescence resonance energy transfer; TVA, tubulovesicular autophagosome; UPR, unfolded protein response; UPS, ubiquitin-proteasome system; V-ATPase, vacuolar-type H<sup>+</sup>-ATPase; xLIR, extended LIR-motif

#### ARTICLE HISTORY

Received 22 September 2015

Accepted 22 September 2015

#### KEYWORDS

autolysosome; autophagosome; chaperone-mediated autophagy; flux; LC3; lysosome; macroautophagy; phagophore; stress; vacuole

## Table of Contents

<b>Introduction</b> .....	33
<b>A. Methods for monitoring autophagy</b> .....	35
1. Transmission electron microscopy .....	35
2. Atg8/LC3 detection and quantification .....	41
a. Western blotting and ubiquitin-like protein conjugation systems .....	41
b. Turnover of LC3-II/Atg8-PE .....	46
c. GFP-Atg8/LC3 lysosomal delivery and partial proteolysis .....	48
d. GFP-Atg8/LC3 fluorescence microscopy .....	51
e. Tandem mRFP/mCherry-GFP fluorescence microscopy .....	54
f. Autophagic flux determination using flow and multispectral imaging cytometry .....	59
g. Immunohistochemistry .....	60
3. SQSTM1 and related LC3 binding protein turnover assays .....	61
4. MTOR, AMPK and Atg1/ULK1 .....	63
5. Additional autophagy-related protein markers .....	67
a. Atg9 .....	67
b. Atg12-Atg5 .....	67
c. ATG14 .....	68
d. ATG16L1 .....	68
e. Atg18/WIP1 family .....	68
f. BECN1/Vps30/Atg6 .....	69
g. DRAM1 .....	69

h.	ZFYVE1/DFCP1 .....	69
i.	STX17 .....	70
j.	TECPR1 .....	70
6.	Sphingolipids .....	70
7.	Transcriptional, translational and posttranslational regulation .....	70
8.	Posttranslational modification of ATG proteins .....	73
9.	Autophagic protein degradation .....	73
10.	Selective types of autophagy .....	74
a.	The Cvt pathway, mitophagy, pexophagy, piecemeal microautophagy of the nucleus and late nucleophagy in yeast and filamentous fungi .....	74
b.	Aggrephagy .....	77
c.	Allophagy .....	77
d.	Animal mitophagy and pexophagy .....	77
e.	Chlorophagy .....	81
f.	Chromatophagy .....	82
g.	Ferritinophagy .....	82
h.	Intraplasmidic autophagy .....	82
i.	Lipophagy .....	83
j.	Lysophagy .....	83
k.	Oxiapoptophagy .....	83
l.	Reticulophagy .....	83
m.	Ribophagy .....	83
n.	RNA-silencing components .....	84
o.	Vacuole import and degradation pathway .....	84
p.	Xenophagy .....	84
q.	Zymophagy .....	86
11.	Autophagic sequestration assays .....	86
12.	Turnover of autophagic compartments .....	86
13.	Autophagosome-lysosome colocalization and dequenching assay .....	87
14.	Tissue fractionation .....	88
15.	Analyses in vivo .....	89
16.	Clinical setting .....	92
17.	Cell death .....	93
18.	Chaperone-mediated autophagy .....	94
19.	Chaperone-assisted selective autophagy .....	97
<b>B.</b>	<b>Comments on additional methods</b> .....	97
1.	Acidotropic dyes .....	97
2.	Autophagy inhibitors and inducers .....	98
3.	Basal autophagy .....	103
4.	Experimental systems .....	103
5.	Nomenclature .....	103
<b>C.</b>	<b>Methods and challenges of specialized topics/model systems</b> .....	103
1.	<i>C. elegans</i> .....	104
2.	Chicken B-lymphoid DT40 cells, retina and inner ear .....	105
3.	<i>Chlamydomonas</i> .....	106
4.	<i>Drosophila</i> .....	106
5.	Erythroid cells .....	106
6.	Filamentous fungi .....	107
7.	Food biotechnology .....	108
8.	Honeybee .....	108
9.	Human .....	109
10.	Hydra .....	110
11.	Large animals .....	111
12.	Lepidoptera .....	112
13.	Marine invertebrates .....	112
14.	Neotropical teleosts .....	112
15.	Odontoblasts .....	113
16.	Planarians .....	113
17.	Plants .....	113



18. Protists .....	114
19. Rainbow trout .....	115
20. Sea urchin .....	116
21. Ticks .....	116
22. Zebrafish .....	117
<b>D. Noncanonical use of autophagy-related proteins</b> .....	117
1. LC3-associated phagocytosis .....	117
2. LC3-associated picoplast .....	117
3. LC3 conjugation system for IFNG-mediated pathogen control .....	118
4. Intracellular trafficking of bacterial pathogens .....	118
5. Other processes .....	118
<b>E. Interpretation of in silico assays for monitoring autophagy</b> .....	118
1. Sequence comparison and comparative genomics approaches .....	118
2. Web-based resources related to autophagy .....	119
a. The THANATOS database .....	119
b. The human autophagy database (HADb) .....	119
c. The Autophagy Database .....	119
d. The Autophagy Regulatory Network (ARN) .....	119
e. Prediction of Atg8-family interacting proteins .....	119
f. The iLIR server .....	119
g. The Eukaryotic Linear Motif resource (ELM) .....	120
h. The ncRNA-associated cell death database (ncRDeathDB) .....	120
3. Dynamic and mathematical models of autophagy .....	120
<b>Conclusions and future perspectives</b> .....	121
<b>Acknowledgments</b> .....	122
<b>Disclaimer</b> .....	122
<b>References</b> .....	122
<b>Glossary</b> .....	186
<b>Quick guide</b> .....	220
<b>Index</b> .....	220

In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes.

For example, a key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure flux through the autophagy pathway (i.e., the complete process including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as *Dictyostelium*) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome

biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy.

Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation, it is imperative to target by gene knockout or RNA interference more than one autophagy-related protein. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways implying that not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular assays, we hope to encourage technical innovation in the field.


## Introduction

Many researchers, especially those new to the field, need to determine which criteria are essential for demonstrating autophagy, either for the purposes of their own research, or in the capacity of a manuscript or grant review.<sup>1</sup> Acceptable standards are an important issue, particularly considering that each of us may have his/her own opinion regarding the answer. Unfortunately, the answer is in part a “moving target” as the field evolves.<sup>2</sup> This can be extremely frustrating for researchers who may think they have met those criteria, only to find out that the reviewers of their papers have different ideas. Conversely, as a reviewer, it is tiresome to raise the same objections


repeatedly, wondering why researchers have not fulfilled some of the basic requirements for establishing the occurrence of an autophagic process. In addition, drugs that potentially modulate autophagy are increasingly being used in clinical trials, and screens are being carried out for new drugs that can modulate autophagy for therapeutic purposes. Clearly it is important to determine whether these drugs are truly affecting autophagy, and which step(s) of the process is affected, based on a set of accepted criteria. Accordingly, we describe here a basic set of contemporary guidelines that can be used by researchers to plan and interpret their experiments, by clinicians to evaluate the literature with regard to autophagy-modulating therapies, and by both authors and reviewers to justify or criticize an experimental approach.

Several fundamental points must be kept in mind as we establish guidelines for the selection of appropriate methods to monitor autophagy.<sup>2</sup> Importantly, there are no absolute criteria for determining autophagic status that are applicable in every biological or experimental context. This is because some assays are inappropriate, problematic or may not work at all in particular cells, tissues or organisms.<sup>3–6</sup> For example, autophagic responses to drugs may be different in transformed versus non-transformed cells, and in confluent versus nonconfluent cells, or in cells grown with or without glucose.<sup>4</sup> In addition, these guidelines are likely to evolve as new methodologies are developed and current assays are superseded. Nonetheless, it is useful to establish guidelines for acceptable assays that can reliably monitor autophagy in many experimental systems. It is important to note that in this set of guidelines the term “autophagy” generally refers to macroautophagy; other autophagy-related processes are specifically designated when appropriate.

For the purposes of this review, the autophagic compartments (Fig. 1) are referred to as the sequestering (pre-autophagosomal) phagophore (PG; previously called the isolation or sequestration membrane<sup>5,6</sup>),<sup>7</sup> the autophagosome (AP),<sup>8</sup> the amphisome (AM; generated by the fusion of autophagosomes with endosomes),<sup>9</sup> the lysosome, the autolysosome (AL; generated by fusion of autophagosomes or amphisomes with a lysosome), and the autophagic body (AB; generated by fusion and release of the internal autophagosomal compartment into the vacuole in fungi and plants). Except for cases of highly stimulated autophagic sequestration (Fig. 2), autophagic bodies are



**Figure 1.** Schematic model demonstrating the induction of autophagosome formation when turnover is blocked versus normal autophagic flux, and illustrating the morphological intermediates of macroautophagy. (A) The initiation of autophagy includes the formation of the phagophore, the initial sequestering compartment, which expands into an autophagosome. Completion of the autophagosome is followed by fusion with lysosomes and degradation of the contents, allowing complete flux, or flow, through the entire pathway. This is a different outcome than the situation shown in (B) where induction results in the initiation of autophagy, but a defect in autophagosome turnover due, for example, to a block in fusion with lysosomes or disruption of lysosomal functions will result in an increased number of autophagosomes. In this scenario, autophagy has been induced, but there is no or limited autophagic flux. (C) An autophagosome can fuse with an endosome to generate an amphisome, prior to fusion with the lysosome. (D) Schematic drawing showing the formation of an autophagic body in fungi. The large size of the fungal vacuole relative to autophagosomes allows the release of the single-membrane autophagic body within the vacuole lumen. In cells that lack vacuolar hydrolase activity, or in the presence of inhibitors that block hydrolase activity, intact autophagic bodies accumulate within the vacuole lumen and can be detected by light microscopy. The lysosome of most higher eukaryotes is too small to allow the release of an autophagic body.



**Figure 2.** An autophagic body in a large lysosome of a mouse epithelial cell from a seminal vesicle *in vitro*. The arrow shows the single limiting membrane covering the sequestered rough ER. Image provided by A.L. Kovács.

not seen in animal cells, because lysosomes/autolysosomes are typically smaller than autophagosomes.<sup>6,8,10</sup> One critical point is that autophagy is a highly dynamic, multi-step process. Like other cellular pathways, it can be modulated at several steps, both positively and negatively. An accumulation of autophagosomes (measured by transmission electron microscopy [TEM] image analysis,<sup>11</sup> as green fluorescent protein [GFP]-MAP1LC3 [GFP-LC3] puncta, or as changes in the amount of lipidated LC3 [LC3-II] on a western blot), could, for example, reflect a reduction in autophagosome turnover,<sup>12-14</sup> or the inability of turnover to keep pace with increased autophagosome formation (Fig. 1B).<sup>15</sup> For example, inefficient fusion with endosomes and/or lysosomes, or perturbation of the transport machinery,<sup>16</sup> would inhibit autophagosome maturation to amphisomes or autolysosomes (Fig. 1C), whereas decreased flux could also be due to inefficient degradation of the cargo once fusion has occurred.<sup>17</sup> Moreover, GFP-LC3 puncta and LC3 lipidation can reflect the induction of a different/modified pathway such as LC3-associated phagocytosis (LAP),<sup>18</sup> and the noncanonical destruction pathway of the paternal mitochondria after fertilization.<sup>19,20</sup>

Accordingly, the use of autophagy markers such as LC3-II must be complemented by assays to estimate overall autophagic flux, or flow, to permit a correct interpretation of the results. That is, autophagic activity includes not just the increased synthesis or lipidation of Atg8/LC3 (LC3 is the mammalian homolog of yeast Atg8), or an increase in the formation of autophagosomes, but, most importantly, flux through the entire system, including lysosomes or the vacuole, and the subsequent release of the breakdown products. Therefore, autophagic substrates need to be monitored dynamically over time to verify that they have reached the lysosome/vacuole, and whether or not they are degraded. By responding to perturbations in the extracellular environment, cells tune the autophagic flux to

meet intracellular metabolic demands. The impact of autophagic flux on cell death and human pathologies therefore demands accurate tools to measure not only the current flux of the system, but also its capacity,<sup>21</sup> and its response time, when exposed to a defined stress.<sup>22</sup>

One approach to evaluate autophagic flux is to measure the rate of general protein breakdown by autophagy.<sup>6,23</sup> It is possible to arrest the autophagic flux at a given point, and then record the time-dependent accumulation of an organelle, an organelle marker, a cargo marker, or the entire cargo at the point of blockage; however, this approach, sometimes incorrectly referred to as autophagic flux, does not assess complete autophagy because the experimental block is usually induced (at least in part) by inhibiting lysosomal proteolysis, which precludes the evaluation of lysosomal functions. In addition, the latter assumes there is no feedback of the accumulating structure on its own rate of formation.<sup>24</sup> In an alternative approach, one can follow the time-dependent decrease of an autophagy-degradable marker (with the caveat that the potential contribution of other proteolytic systems and of new protein synthesis need to be experimentally addressed). In theory, these nonautophagic processes can be assessed by blocking autophagic sequestration at specific steps of the pathway (e.g., blocking further induction or nucleation of new phagophores) and by measuring the decrease of markers distal to the block point.<sup>12,14,25</sup>

The key issue is to differentiate between the often transient accumulation of autophagosomes due to increased induction, and their accumulation due to inefficient clearance of sequestered cargos by both measuring the levels of autophagosomes at static time points and by measuring changes in the rates of autophagic degradation of cellular components.<sup>17</sup> Both processes have been used to estimate “autophagy,” but unless the experiments can relate changes in autophagosome quantity to a direct or indirect measurement for autophagic flux, the results may be difficult to interpret.<sup>26</sup> A general caution regarding the use of the term “steady state” is warranted at this point. It should not be assumed that an autophagic system is at steady state in the strict biochemical meaning of this term, as this implies that the level of autophagosomes does not change with time, and the flux through the system is constant. In these guidelines, we use steady state to refer to the baseline range of autophagic flux in a system that is not subjected to specific perturbations that increase or decrease that flux.

Autophagic flux refers to the entire process of autophagy, which encompasses the inclusion (or exclusion) of cargo within the autophagosome, the delivery of cargo to lysosomes (via fusion of the latter with autophagosomes or amphisomes) and its subsequent breakdown and release of the resulting macromolecules back into the cytosol (this may be referred to as productive or complete autophagy). Thus, increases in the level of phosphatidylethanolamine (PE)-modified Atg8/LC3 (Atg8-PE/LC3-II), or even the appearance of autophagosomes, are not measures of autophagic flux per se, but can reflect the induction of autophagic sequestration and/or inhibition of autophagosome or amphisome clearance. Also, it is important to realize that while formation of Atg8-PE/LC3-II appears to correlate with the induction of autophagy, we do not know, at present, the actual mechanistic relationship between Atg8-PE/LC3-II formation and the rest of the autophagic process;

indeed, it may be possible to execute “self-eating” in the absence of LC3-II.<sup>27</sup>

As a final note, we also recommend that researchers refrain from the use of the expression “percent autophagy” when describing experimental results, as in “The cells displayed a 25% increase in autophagy.” Instead, it is appropriate to indicate that the average number of GFP-Atg8/LC3 puncta per cell is increased or a certain percentage of cells displayed punctate GFP-Atg8/LC3 that exceeds a particular threshold (and this threshold should be clearly defined in the Methods section), or that there is a particular increase or decrease in the rate of cargo sequestration or the degradation of long-lived proteins, when these are the actual measurements being quantified.

In a previous version of these guidelines,<sup>2</sup> the methods were separated into 2 main sections—steady state and flux. In some instances, a lack of clear distinction between the actual methodologies and their potential uses made such a separation somewhat artificial. For example, fluorescence microscopy was initially listed as a steady-state method, although this approach can clearly be used to monitor flux as described in this article, especially when considering the increasing availability of new technologies such as microfluidic chambers. Furthermore, the use of multiple time points and/or lysosomal fusion/degradation inhibitors can turn even a typically static method such as TEM into one that monitors flux. Therefore, although we maintain the importance of monitoring autophagic flux and not just induction, this revised set of guidelines does not separate the methods based on this criterion. Readers should be aware that this article is not meant to present protocols, but rather guidelines, including information that is typically not presented in protocol papers. For detailed information on experimental procedures we refer readers to various protocols that have been published elsewhere.<sup>28–43,44</sup> Finally, throughout the guidelines we provide specific cautionary notes, and these are important to consider when planning experiments and interpreting data; however, these cautions are not meant to be a deterrent to undertaking any of these experiments or a hindrance to data interpretation.

Collectively, we propose the following guidelines for measuring various aspects of selective and nonselective autophagy in eukaryotes.

## A. Methods for monitoring autophagy

### 1. Transmission electron microscopy

Autophagy was first detected by TEM in the 1950s (reviewed in ref. 6). It was originally observed as focal degradation of cytoplasmic areas performed by lysosomes, which remains the hallmark of this process. Later analyses revealed that it starts with the sequestration of portions of the cytoplasm by a special double-membrane structure (now termed the phagophore), which matures into the autophagosome, still bordered by a double membrane. Subsequent fusion events expose the cargo to the lysosome (or the vacuole in fungi or plants) for enzymatic breakdown.


The importance of TEM in autophagy research lies in several qualities. It is the only tool that reveals the morphology of autophagic structures at a resolution in the nm range; shows

these structures in their natural environment and position among all other cellular components; allows their exact identification; and, in addition, it can support quantitative studies if the rules of proper sampling are followed.<sup>11</sup>

Autophagy can be both selective and nonselective, and TEM can be used to monitor both. In the case of selective autophagy, the cargo is the specific substrate being targeted for sequestration—bulk cytoplasm is essentially excluded. In contrast, during nonselective autophagy, the various cytoplasmic constituents are sequestered randomly, resulting in autophagosomes in the size range of normal mitochondria. Sequestration of larger structures (such as big lipid droplets, extremely elongated or branching mitochondria or the entire Golgi complex) is rare, indicating an apparent upper size limit for individual autophagosomes. However, it has been observed that under special circumstances the potential exists for the formation of huge autophagosomes, which can even engulf a complete nucleus.<sup>25</sup> Cellular components that form large confluent areas excluding bulk cytoplasm, such as organized, functional myofibrillar structures, do not seem to be sequestered by macroautophagy. The situation is less clear with regard to glycogen.<sup>45–47</sup>

After sequestration, the content of the autophagosome and its bordering double membrane remain morphologically unchanged, and clearly recognizable for a considerable time, which can be measured for at least many minutes. During this period, the membranes of the sequestered organelles (for example, the ER or mitochondria) remain intact, and the density of ribosomes is conserved at normal levels. Degradation of the sequestered material and the corresponding deterioration of ultrastructure commences and runs to completion within the amphisome and the autolysosome after fusion with a late endosome and lysosome (the vacuole in fungi and plants), respectively (Fig. 1).<sup>48</sup> The sequential morphological changes during the autophagic process can be followed by TEM. The maturation from the phagophore through the autolysosome is a dynamic and continuous process,<sup>49</sup> and, thus, the classification of compartments into discrete morphological subsets can be problematic; therefore, some basic guidelines are offered below.

In the preceding sections the “autophagosome,” the “amphisome” and the “autolysosome” were terms used to describe or indicate 3 basic stages and compartments of autophagy. It is important to make it clear that for instances (which may be many) when we cannot or do not want to differentiate among the autophagosomal, amphisomal and autolysosomal stage we use the general term “autophagic vacuole”. In the yeast autophagy field the term “autophagic vesicle” is used to avoid confusion with the primary vacuole, and by now the 2 terms are used in parallel and can be considered synonyms. It is strongly recommended, however, to use only the term “autophagic vacuole” when referring to macroautophagy in higher eukaryotic cells. Autophagosomes, also referred to as initial autophagic vacuoles (AVi), typically have a double membrane. This structure is usually distinctly visible by EM as 2 parallel membrane layers (bilayers) separated by a relatively narrower or wider electron-translucent cleft, even when applying the simplest routine EM fixation procedure (Fig. 3A).<sup>50,51</sup> This electron-translucent cleft, however, is less visible or not visible in freeze-fixed samples, suggesting it is an artifact of sample preparation (see ref. 25, 68 and Fig. S3 in ref. 52). In the case of



**Figure 3.** TEM images of autophagic vacuoles in isolated mouse hepatocytes. (A) One autophagosome or early initial autophagic vacuole (AVi) and one degradative autophagic vacuole (AVd) are shown. The AVi can be identified by its contents (morphologically intact cytoplasm, including ribosomes, and rough ER), and the limiting membrane that is partially visible as 2 bilayers separated by a narrow electron-lucent cleft, i.e., as a double membrane (arrow). The AVd can be identified by its contents, partially degraded, electron-dense rough ER. The vesicle next to the AVd is an endosomal/lysosomal structure containing 5-nm gold particles that were added to the culture medium to trace the endocytic pathway. (B) One AVi, containing rough ER and a mitochondrion, and one AVd, containing partially degraded rough ER, are shown. Note that the limiting membrane of the AVi is not clearly visible, possibly because it is tangentially sectioned. However, the electron-lucent cleft between the 2 limiting membranes is visible and helps in the identification of the AVi. The AVd contains a region filled by small internal vesicles (asterisk), indicating that the AVd has fused with a multivesicular endosome. mi, mitochondrion. Image provided by E.-L. Eskelinen.

nonselective autophagy, autophagosomes contain cytosol and/or organelles appearing morphologically intact as also described above.<sup>48,53</sup> Amphisomes<sup>54</sup> can sometimes be identified by the presence of small intraluminal vesicles.<sup>55</sup> These intraluminal vesicles are delivered into the lumen by fusion of the autophagosome/autophagic vacuole (AV) limiting

membrane with multivesicular endosomes, and care should therefore be taken in the identification of the organelles, especially in cells that produce large numbers of multivesicular body (MVB)-derived exosomes (such as tumor or stem cells).<sup>56</sup> Late/degradative autophagic vacuoles/autolysosomes (AVd or AL) typically have only one limiting membrane; frequently they contain electron dense cytoplasmic material and/or organelles at various stages of degradation (Fig. 3A and B);<sup>48,53</sup> although late in the digestion process, they may contain only a few membrane fragments and be difficult to distinguish from lysosomes, endosomes, or tubular smooth ER cut in cross-section. Unequivocal identification of these structures and of lysosomes devoid of visible content requires immuno-EM detection of a cathepsin or other lysosomal hydrolase (e.g., ACP2 [acid phosphatase 2, lysosomal]<sup>57,58</sup>) that is detected on the limiting membrane of the lysosome.<sup>59</sup> Smaller, often electron dense, lysosomes may predominate in some cells and exhibit hydrolase immunoreactivity within the lumen and on the limiting membrane.<sup>60</sup>

In addition, structural proteins of the lysosome/late endosome, such as LAMP1 and LAMP2 or SCARB2/LIMP-2, can be used for confirmation. No single protein marker, however, has been effective in discriminating autolysosomes from the compartments mentioned above, in part due to the dynamic fusion and “kiss-and-run” events that promote interchange of components that can occur between these organelle subtypes. Rigorous further discrimination of these compartments from each other and other vesicles ultimately requires demonstrating the colocalization of a second marker indicating the presence of an autophagic substrate (e.g., LC3-CTSD [cathepsin D] colocalization) or the acidification of the compartment (e.g., mRFP/mCherry-GFP-LC3 probes [see *Tandem mRFP/mCherry-GFP fluorescence microscopy*], or Bodipy-pepstatin A detection of CTSD in an activated form within an acidic compartment), and, when appropriate, by excluding markers of other vesicular components.<sup>57,61,62</sup>

The sequential deterioration of cytoplasmic structures being digested can be used for identifying autolysosomes by TEM. Even when the partially digested and destroyed structure cannot be recognized in itself, it can be traced back to earlier forms by identifying preceding stages of sequential morphological deterioration. Degradation usually leads first to increased density of still recognizable organelles, then to vacuoles with heterogeneous density, which become more homogenous and amorphous, mostly electron dense, but sometimes light (i.e., electron translucent). It should be noted that, in pathological states, it is not uncommon that active autophagy of autolysosomes and damaged lysosomes (“lysosophagy”) may yield populations of double-membrane limited autophagosomes containing partially digested amorphous substrates in the lumen. These structures, which are enriched in hydrolases, are seen in swollen dystrophic neurites in some neurodegenerative diseases,<sup>60</sup> and in cerebellar slices cultured in vitro and infected with prions.<sup>63</sup>

It must be emphasized that in addition to the autophagic input, other processes (e.g., endosomal, phagosomal, chaperone-mediated) also carry cargo to the lysosomes,<sup>64,65</sup> in some cases through the intermediate step of direct endosome fusion with an autophagosome to form an amphisome. This process is

exceptionally common in the axons of neurons.<sup>66</sup> Therefore, strictly speaking, we can only have a lytic compartment containing cargos arriving from several possible sources; however, we still may use the term “autolysosome” if the content appears to be overwhelmingly autophagic. Note that the engulfment of apoptotic cells via phagocytosis also produces lysosomes that contain cytoplasmic structures, but in this case it originates from the dying cell; hence the possibility of an extracellular origin for such content must be considered when monitoring autophagy in settings where apoptotic cell death may be reasonably expected or anticipated.

For many physiological and pathological situations, examination of both early and late autophagic vacuoles yields valuable data regarding the overall autophagy status in the cells.<sup>15</sup> Along these lines, it is possible to use immunocytochemistry to follow particular cytosolic proteins such as SOD1/CuZn superoxide dismutase and CA/carbonic anhydrase to determine the stage of autophagy; the former is much more resistant to lysosomal degradation.<sup>67</sup>

In some autophagy-inducing conditions it is possible to observe multi-lamellar membrane structures in addition to the conventional double-membrane autophagosomes, although the nature of these structures is not fully understood. These multi-lamellar structures may indeed be multiple double layers of phagophores<sup>68</sup> and positive for LC3,<sup>69</sup> they could be autolysosomes,<sup>70</sup> or they may form artifactually during fixation.<sup>68</sup>

Special features of the autophagic process may be clarified by immuno-TEM with gold-labeling,<sup>71,72</sup> using antibodies, for example, to cargo proteins of cytoplasmic origin and to LC3 to verify the autophagic nature of the compartment. LC3 immunogold labeling also makes it possible to detect novel degradative organelles within autophagy compartments. This is the case with the autophagoproteasome<sup>73</sup> where costaining for LC3 and ubiquitin-proteasome system (UPS) antigens occurs. The autophagoproteasome consists of single-, double-, or multiple-membrane LC3-positive autophagosomes costaining for specific components of the UPS. It may be that a rich multi-enzymatic (both autophagic and UPS) activity takes place within these organelles instead of being segregated within different cell domains.


Although labeling of LC3 can be difficult, an increasing number of commercial antibodies are becoming available, among them good ones to visualize the GFP moiety of GFP-LC3 reporter constructs.<sup>74</sup> It is important to keep in mind that LC3 can be associated with nonautophagic structures (see *Xenophagy*, and *Noncanonical use of autophagy-related proteins*). LC3 is involved in specialized forms of endocytosis like LC3-associated phagocytosis. In addition, LC3 can decorate vesicles dedicated to exocytosis in nonconventional secretion systems (reviewed in ref. 75,76). Antibodies against an abundant cytosolic protein will result in high labeling all over the cytoplasm; however, organelle markers work well. Because there are very few characterized proteins that remain associated with the completed autophagosome, the choices for confirmation of its autophagic nature are limited. Furthermore, autophagosome-associated proteins may be cell type-specific. At any rate, the success of this methodology depends on the quality of the antibodies and also on the TEM preparation and fixation procedures utilized. With immuno-TEM, authors should provide

controls showing that labeling is specific. This may require quantitative comparison of labeling over different cellular compartments not expected to contain antigen and those containing the antigen of interest.

In clinical situations it is difficult to demonstrate autophagy clearly in tissues of formalin-fixed and paraffin-embedded biopsy samples retrospectively, because (1) tissues fixed in formalin have low or no LC3 detectable by routine immunostaining, because phospholipids melt together with paraffin during the sample preparation, and (2) immunogold electron microscopy of many tissues not optimally fixed for this purpose (e.g., using rapid fixation) produces low-quality images. Combining antigen retrieval with the avidin-biotin peroxidase complex (ABC) method may be quite useful for these situations. For example, immunohistochemistry can be performed using an antigen retrieval method, then tissues are stained by the ABC technique using a labeled anti-human LC3 antibody. After imaging by light microscopy, the same prepared slides can be remade into sections for TEM examination, which can reveal peroxidase reaction deposits in vacuoles within the region that is LC3-immunopositive by light microscopy.<sup>77</sup> In addition, statistical information should be provided due to the necessity of showing only a selective number of sections in publications.

We note here again that for quantitative data it is necessary to use proper volumetric analysis rather than just counting numbers of sectioned objects. On the one hand, it must be kept in mind that even volumetric morphometry/stereology only shows either steady state levels, or a snapshot in a changing dynamic process. Such data by themselves are not informative regarding autophagic flux, unless carried out over multiple time points. Alternatively, investigation in the presence and absence of flux inhibitors can reveal the dynamic changes in various stages of the autophagic process.<sup>12,21,78,79,42</sup> On the other hand, if the turnover of autolysosomes is very rapid, a low number/volume will not necessarily be an accurate reflection of low autophagic activity. However, quantitative analyses indicate that autophagosome volume in many cases does correlate with the rates of protein degradation.<sup>80-82</sup> One potential compromise is to perform whole cell quantification of autophagosomes using fluorescence methods, with qualitative verification by TEM,<sup>83</sup> to show that the changes in fluorescent puncta reflect corresponding changes in autophagic structures.

One additional caveat with TEM, and to some extent with confocal fluorescence microscopy, is that the analysis of a single plane within a cell can be misleading and may make the identification of autophagic structures difficult. Confocal microscopy and fluorescence microscopy with deconvolution software (or with much more work, 3-dimensional TEM) can be used to generate multiple/serial sections of the same cell to reduce this concern; however, in many cases where there is sufficient structural resolution, analysis of a single plane in a relatively large cell population can suffice given practical limitations. Newer EM technologies, including focused ion beam dual-beam EM, should make it much easier to apply three-dimensional analyses. An additional methodology to assess autophagosome accumulation is correlative light and electron microscopy (CLEM), which is helpful in confirming that fluorescent structures are autophagosomes.<sup>84-86</sup> Along these lines, it is important to note that even though GFP fluorescence will be quenched in the



**Figure 4.** Cryoelectron microscopy can be used as a three-dimensional approach to monitor the autophagic process. Two computed sections of an electron tomogram of the autophagic vacuole-rich cytoplasm in a hemophagocyte of a semi-thin section after high-pressure freezing preparation. The dashed area is membrane-free (A) but tomography reveals newly formed or degrading membranes with a parallel stretch (B). Image published previously<sup>2185</sup> and provided by M. Schneider and P. Walter.

acidic environment of the autolysosome, some of the GFP puncta detected by light microscopy may correspond to early autolysosomes prior to GFP quenching. The mini Singlet Oxygen Generator (miniSOG) fluorescent flavoprotein, which is less than half the size of GFP, provides an additional means to genetically tag proteins for CLEM analysis under conditions that are particularly suited to subsequent TEM analysis.<sup>87</sup> Combinatorial assays using tandem monomeric red fluorescent protein (mRFP)-GFP-LC3 (see *Tandem mRFP/mCherry-GFP fluorescence microscopy*) along with static TEM images should help in the analysis of flux and the visualization of cargo structures.<sup>88</sup>


Another technique that has proven quite useful for analyzing the complex membrane structures that participate in autophagy is 3-dimensional electron tomography,<sup>89,90</sup> and cryoelectron microscopy (Fig. 4). More sophisticated, cryo-soft X-ray tomography (cryo-SXT) is an emerging imaging technique used to visualize autophagosomes.<sup>91</sup> Cryo-SXT extracts ultrastructural information from whole, unstained mammalian cells as close to the “near-native” fully-hydrated (living) state as possible. Correlative studies combining cryo-fluorescence and cryo-SXT workflow (cryo-CLXM) have been applied to capture early autophagosomes.

Finally, although only as an indirect measurement, the comparison of the ratio of autophagosomes to autolysosomes by TEM can support alterations in autophagy identified by other procedures.<sup>92</sup> In this case it is important to always compare samples to the control of the same cell type and in the same growth phase, and to acquire data at different time points, as the autophagosome/autolysosome ratio varies in time in a cell context-dependent fashion, depending on their clearance activity. It may also be necessary to distinguish autolysosomes from telolysosomes/late secondary lysosomes (the former are actively engaged in degradation, whereas the latter have reached an end point in the breakdown of luminal contents) because the lysosome number generally increases when autophagy is induced.

An additional category of lysosomal compartments, especially common in disease states and aged postmitotic cells such as neurons, is the residual body. This category includes ceroid and lipofuscin, lobulated vesicular compartments of varying size composed of highly indigestible complexes of protein and lipid and abundant, mostly inactive, acid hydrolases. Reflecting end-stage unsuccessful incomplete autolysosomal digestion, lipofuscin is fairly easily distinguished from AVs and lysosomes by TEM but can be easily confused with autolysosomes in immunocytochemistry studies at the light microscopy level.<sup>57</sup>

TEM observations of platinum-carbon replicas obtained by the freeze fracture technique can also supply useful ultrastructural information on the autophagic process. In quickly frozen and fractured cells the fracture runs preferentially along the hydrophobic plane of the membranes, allowing characterization of the limiting membranes of the different types of autophagic vacuoles and visualization of their limited protein intramembrane particles (IMPs, or integral membrane proteins). Several studies have been carried out using this technique on yeast,<sup>93</sup> as well as on mammalian cells or tissues; first on mouse exocrine pancreas,<sup>94</sup> then on mouse and rat liver,<sup>95,96</sup> mouse seminal vesicle epithelium,<sup>25,68</sup> rat tumor and heart,<sup>97</sup> or cancer cell lines (e.g., breast cancer MDA-MB-231)<sup>98</sup> to investigate the various phases of autophagosome maturation, and to reveal useful details about the origin and evolution of their limiting membranes.<sup>6,99-102</sup>

The phagophore and the limiting membranes of autophagosomes contain few, or no detectable, IMPs (Fig. 5A, B), when compared to other cellular membranes and to the membranes of lysosomes. In subsequent stages of the autophagic process the fusion of the autophagosome with an endosome and a lysosome results in increased density of IMPs in the membrane of the formed autophagic compartments (amphisomes, autolysosomes; Fig. 5C).<sup>6,25,93-96,103,104</sup> Autolysosomes are delimited by a single membrane because, in addition to the engulfed material, the inner membrane is also degraded by the lytic enzymes. Similarly, the limiting membrane of autophagic bodies in yeast (and



**Figure 5.** Different autophagic vacuoles observed after freeze fracturing in cultured osteosarcoma cells after treatment with the autophagy inducer voacamine.<sup>101</sup> (A) Early autophagosome delimited by a double membrane. (B) Inner monolayer of an autophagosomal membrane deprived of protein particles. (C) Autolysosome delimited by a single membrane rich in protein particles. In the cross-fractured portion (on the right) the profile of the single membrane and the inner digested material are easily visible. Images provided by S. Meschini, M. Condello and A. Giuseppe.

presumably plants) is also quickly broken down under normal conditions. Autophagic bodies can be stabilized, however, by the addition of phenylmethylsulfonylfluoride (PMSF) or genetically by the deletion of the yeast *PEP4* gene (see *The Cvt pathway, mitophagy, pexophagy, piecemeal microautophagy of the nucleus and late nucleophagy in yeast and filamentous fungi.*). Thus, another method to consider for monitoring autophagy in yeast (and potentially in plants) is to count autophagic bodies by TEM using at least 2 time points.<sup>105</sup> The advantage of this approach is that it can provide accurate information on flux even when the autophagosomes are abnormally small.<sup>106,107</sup> Thus, although a high frequency of “abnormal” structures presents a challenge, TEM is still very helpful in analyzing autophagy.

**Cautionary notes:** Despite the introduction of many new methods TEM maintains its special role in autophagy research. There are, however, difficulties in utilizing TEM. It is relatively time consuming, and needs technical expertise to ensure proper handling of samples in all stages of preparation from fixation to sectioning and staining (contrasting). After all these criteria are met, we face the most important problem of proper identification of autophagic structures. This is crucial for both qualitative and quantitative characterization, and needs considerable experience, even in the case of one cell type. The difficulty lies in the fact that many subcellular components may be mistaken for autophagic structures. For example, some authors (or reviewers of manuscripts) assume that almost all cytoplasmic structures that, in the section plane, are surrounded by 2 (more or less) parallel membranes are autophagosomes. Structures appearing to be limited by a double membrane, however, may include swollen mitochondria, plastids in plant cells, cellular interdigitations, endocytosed apoptotic bodies, circular structures of lamellar smooth endoplasmic reticulum (ER), and even areas surrounded by rough ER. Endosomes, phagosomes and secretory vacuoles may have heterogenous content that makes it possible to confuse them with autolysosomes. Additional identification problems may arise from damage caused by improper sample taking or fixation artifacts.<sup>50,51,108,109</sup>

Whereas fixation of *in vitro* samples is relatively straightforward, fixation of excised tissues requires care to avoid sampling a nonrepresentative, uninformative, or damaged part of

the tissue. For instance, if 95% of a tumor is necrotic, TEM analysis of the necrotic core may not be informative, and if the sampling is from the viable rim, this needs to be specified when reported. Clearly this introduces the potential for subjectivity because reviewers of a paper cannot request multiple images with a careful statistical analysis with these types of samples. In addition, *ex vivo* samples are not typically randomized during processing, further complicating the possibility of valid statistical analyses. *Ex vivo* tissue should be fixed immediately and systematically across samples to avoid changes in autophagy that may occur simply due to the elapsed time *ex vivo*. It is recommended that for tissue samples, perfusion fixation should be used when possible. For yeast, rapid freezing techniques such as high pressure freezing followed by freeze substitution (i.e., dehydration at low temperature) may be particularly useful.

Quantification of autophagy by TEM morphometry has been rather controversial, and unreliable procedures still continue to be used. For the principles of reliable quantification and to avoid misleading results, excellent reviews are available.<sup>11,110-112</sup> In line with the basic principles of morphometry we find it necessary to emphasize here some common problems with regard to quantification. Counting autophagic vacuole profiles in sections of cells (i.e., number of autophagic profiles per cell profile) may give unreliable results, partly because both cell areas and profile areas are variable and also because the frequency of section profiles depends on the size of the vacuoles. However, estimation of the number of autophagic profiles per cell area is more reliable and correlates well with the volume fraction mentioned below.<sup>53</sup> There are morphometric procedures to measure or estimate the size range and the number of spherical objects by profiles in sections;<sup>111</sup> however, such methods have been used in autophagy research only a few times.<sup>32,107,113,114</sup>

Proper morphometry described in the cited reviews will give us data expressed in  $\mu\text{m}^3$  autophagic vacuole/ $\mu\text{m}^3$  cytoplasm for relative volume (also called volume fraction or volume density), or  $\mu\text{m}^2$  autophagic vacuole surface/ $\mu\text{m}^3$  cytoplasm for relative surface (surface density). Examples of actual morphometric measurements for the characterization of autophagic processes can be found in several



articles.<sup>21,108,111,115,116</sup> It is appropriate to note here that a change in the volume fraction of the autophagic compartment may come from 2 sources; from the real growth of its size in a given cytoplasmic volume, or from the decrease of the cytoplasmic volume itself. To avoid this so-called “reference trap,” the reference space volume can be determined by different methods.<sup>112,117</sup> If different magnifications are used for measuring the autophagic vacuoles and the cytoplasm (which may be practical when autophagy is less intense) correction factors should always be used.

In some cases, it may be prudent to employ tomographic reconstructions of the TEM images to confirm that the autophagic compartments are spherical and are not being confused with interdigitations observed between neighboring cells, endomembrane cisternae or damaged mitochondria with similar appearance in thin-sections (e.g., see ref. 118), but this is obviously a time-consuming approach requiring sophisticated equipment. In addition, interpretation of tomographic images can be problematic. For example, starvation-induced autophagosomes should contain cytoplasm (i.e., cytosol and possibly organelles), but autophagosome-related structures involved in specific types of autophagy should show the selective cytoplasmic target, but may be relatively devoid of bulk cytoplasm. Such processes include selective peroxisome or mitochondria degradation (pexophagy or mitophagy, respectively),<sup>119,120</sup> targeted degradation of pathogenic microbes (xenophagy),<sup>121-126</sup> a combination of xenophagy and stress-induced mitophagy,<sup>127</sup> as well as the yeast biosynthetic cytoplasm-to-vacuole targeting (Cvt) pathway.<sup>128</sup> Furthermore, some pathogenic microbes express membrane-disrupting factors during infection (e.g., phospholipases) that disrupt the normal double-membrane architecture of autophagosomes.<sup>129</sup> It is not even clear if the sequestering compartments used for specific organelle degradation or xenophagy should be termed autophagosomes or if alternate terms such as pexophagosome,<sup>130</sup> mitophagosome and xenophagosome should be used, even though the membrane and mechanisms involved in their formation may be identical to those for starvation-induced autophagosomes; for example, the double-membrane vesicle of the Cvt pathway is referred to as a Cvt vesicle.<sup>131</sup>

The confusion of heterophagic structures with autophagic ones is a major source of misinterpretation. A prominent example of this is related to apoptosis. Apoptotic bodies from neighboring cells are readily phagocytosed by surviving cells of the same tissue.<sup>132,133</sup> Immediately after phagocytic uptake of apoptotic bodies, phagosomes may have double limiting membranes. The inner one is the plasma membrane of the apoptotic body and the outer one is that of the phagocytizing cell. The early heterophagic vacuole formed in this way may appear similar to an autophagosome or, in a later stage, an early autolysosome in that it contains recognizable or identifiable cytoplasmic material. A major difference, however, is that the surrounding membranes are the thicker plasma membrane type, rather than the thinner sequestration membrane type (9–10 nm, versus 7–8 nm, respectively).<sup>109</sup> A good feature to distinguish between autophagosomes and double plasma membrane-

bound structures is the lack of the distended empty space (characteristic for the sequestration membranes of autophagosomes) between the 2 membranes of the phagocytic vacuoles. In addition, engulfed apoptotic bodies usually have a larger average size than autophagosomes.<sup>134,135</sup> The problem of heterophagic elements interfering with the identification of autophagic ones is most prominent in cell types with particularly intense heterophagic activity (such as macrophages, and amoeboid or ciliate protists). Special attention has to be paid to this problem in cell cultures or in vivo treatments (e.g., with toxic or chemotherapeutic agents) causing extensive apoptosis.

The most common organelles confused with autophagic vacuoles are mitochondria, ER, endosomes, and also (depending on their structure) plastids in plants. Due to the cisternal structure of the ER, double-membrane-like structures surrounding mitochondria or other organelles are often observed after sectioning,<sup>136</sup> but these can also correspond to cisternae of the ER coming into and out of the section plane.<sup>50</sup> If there are ribosomes associated with these membranes they can help in distinguishing them from the ribosome-free double-membrane of the phagophore and autophagosome. Observation of a mixture of early and late autophagic vacuoles that is modulated by the time point of collection and/or brief pulses of bafilomycin A<sub>1</sub> (a vacuolar-type H<sup>+</sup>-ATPase [V-ATPase] inhibitor) to trap the cargo in a recognizable early state<sup>42</sup> increases the confidence that an autophagic process is being observed. In these cases, however, the possibility that feedback activation of sequestration gets involved in the autophagic process has to be carefully considered. To minimize the impact of errors, exact categorization of autophagic elements should be applied. Efforts should be made to clarify the nature of questionable structures by extensive preliminary comparison in many test areas. Elements that still remain questionable should be categorized into special groups and measured separately. Should their later identification become possible, they can be added to the proper category or, if not, kept separate.

For nonspecialists it can be particularly difficult to distinguish among amphisomes, autolysosomes and lysosomes, which are all single-membrane compartments containing more or less degraded material. Therefore, we suggest in general to measure autophagosomes as a separate category for a start, and to compile another category of degradative compartments (including amphisomes, autolysosomes and lysosomes). All of these compartments increase in quantity upon true autophagy induction; however, in pathological states, it may be informative to discriminate among these different forms of degradative compartments, which may be differentially affected by disease factors.

In yeast, it is convenient to identify autophagic bodies that reside within the vacuole lumen, and to quantify them as an alternative to the direct examination of autophagosomes. However, it is important to keep in mind that it may not be possible to distinguish between autophagic bodies that are derived from the fusion of autophagosomes with the vacuole, and the single-membrane vesicles that are generated during microautophagy-like processes such as micropexophagy and micromitophagy.

**Conclusion:** EM is an extremely informative and powerful method for monitoring autophagy and remains the only technique that shows autophagy in its complex cellular environment with subcellular resolution. The cornerstone of successfully using TEM is the proper identification of autophagic structures, which is also the prerequisite to get reliable quantitative results by EM morphometry. EM is best used in combination with other methods to ensure the complex and holistic approach that is becoming increasingly necessary for further progress in autophagy research.

## 2. Atg8/LC3 detection and quantification

Atg8/LC3 is the most widely monitored autophagy-related protein. In this section we describe multiple assays that utilize this protein, separating the descriptions into several subsections for ease of discussion.

### a. Western blotting and ubiquitin-like protein conjugation systems

The Atg8/LC3 protein is a ubiquitin-like protein that can be conjugated to PE (and possibly to phosphatidylserine<sup>137</sup>). In yeast and several other organisms, the conjugated form is referred to as Atg8-PE. The mammalian homologs of Atg8 constitute a family of proteins subdivided in 2 major subfamilies: MAP1LC3/LC3 and GABARAP. The former consists of LC3A, B, B2 and C, whereas the latter family includes GABARAP, GABARAPL1 and GABARAPL2/GATE-16.<sup>138</sup> After cleavage of the precursor protein mostly by the cysteine protease ATG4B,<sup>139,140</sup> the nonlipidated and lipidated forms are usually referred to respectively as LC3-I and LC3-II, or GABARAP and GABARAP-PE, etc. The PE-conjugated form of Atg8/LC3, although larger in mass, shows faster electrophoretic mobility in SDS-PAGE gels, probably as a consequence of increased hydrophobicity. The positions of both Atg8/LC3-I (approximately 16–18 kDa) and Atg8-PE/LC3-II (approximately 14–16 kDa) should be indicated on western blots whenever both are detectable. The differences among the LC3 proteins with regard to function and tissue-specific expression are not known. Therefore, it is important to indicate the isoform being analyzed just as it is for the GABARAP subfamily.

The mammalian Atg8 homologs share from 29% to 94% sequence identity with the yeast protein and have all, apart from GABARAPL3, been demonstrated to be involved in autophagosome biogenesis.<sup>141</sup> The LC3 proteins are involved in phagophore formation, with participation of GABARAP subfamily members in later stages of autophagosome formation, in particular phagophore elongation and closure.<sup>142</sup> Some evidence, however, suggests that at least in certain cell types the LC3 subfamily may be dispensable for bulk autophagic sequestration of cytosolic proteins, whereas the GABARAP subfamily is absolutely required.<sup>143</sup> Due to unique features in their molecular surface charge distribution,<sup>144</sup> emerging evidence indicates that LC3 and GABARAP proteins may be involved in recognizing distinct sets of cargoes for selective autophagy.<sup>145–147</sup> Nevertheless, in most published studies, LC3 has been the primary Atg8 homolog examined in mammalian cells and the one that is typically characterized as an autophagosome marker per se. Note that although this protein is referred to as “Atg8” in many other systems, we primarily refer to it here as LC3 to

distinguish it from the yeast protein and from the GABARAP subfamily. LC3, like the other Atg8 homologs, is initially synthesized in an unprocessed form, proLC3, which is converted into a proteolytically processed form lacking amino acids from the C terminus, LC3-I, and is finally modified into the PE-conjugated form, LC3-II (Fig. 6). Atg8-PE/LC3-II is the only protein marker that is reliably associated with completed autophagosomes, but is also localized to phagophores. In yeast, Atg8 amounts increase at least 10-fold when autophagy is induced.<sup>148</sup> In mammalian cells, however, the total levels of LC3 do not necessarily change in a predictable manner, as there may be increases in the conversion of LC3-I to LC3-II, or a decrease in LC3-II relative to LC3-I if degradation of LC3-II via lysosomal turnover is particularly rapid (this can also be a concern in yeast with regard to vacuolar turnover of Atg8-PE). Both of these events can be seen sequentially in several cell types as a response to total nutrient and serum starvation. In cells of neuronal origin a high ratio of LC3-I to LC3-II is a common finding.<sup>149</sup> For instance, SH-SY5Y neuroblastoma cell lines display only a slight increase of LC3-II after nutrient deprivation, whereas LC3-I is clearly reduced. This is likely related to a high basal autophagic flux, as suggested by the higher increase in LC3-II when cells are treated with NH<sub>4</sub>Cl,<sup>150,151</sup> although cell-specific differences in transcriptional regulation of LC3 may also play a role. In fact stimuli or stress that inhibit transcription or translation of LC3 might actually be misinterpreted as inhibition of autophagy. Importantly, in brain tissue, LC3-I is much more abundant than LC3-II and the latter form is most easily discernible in enriched fractions of autophagosomes, autolysosomes and ER, and may be more difficult to detect in crude homogenate or cytosol.<sup>152</sup> Indeed, when brain crude homogenate is run in parallel to a crude liver fraction, both LC3-I and LC3-II are observed in the liver, but only LC3-I may be discernible in brain homogenate (L. Toker and G. Agam, personal communication), depending on the LC3 antibody used.<sup>153</sup> In studies of the brain, immunoblot analysis of the membrane and cytosol fraction from a cell lysate, upon appropriate loading of samples to achieve quantifiable and comparative signals, can be useful to measure LC3 isoforms.

The pattern of LC3-I to LC3-II conversion seems not only to be cell specific, but also related to the kind of stress to which cells are subjected. For example, SH-SY5Y cells display a strong increase of LC3-II when treated with the mitochondrial uncoupler CCCP, a well-known inducer of mitophagy (although it has also been reported that CCCP may actually inhibit mitophagy<sup>154</sup>). Thus, neither assessment of LC3-I consumption nor the evaluation of LC3-II levels would necessarily reveal a slight induction of autophagy (e.g., by rapamycin). Also, there is not always a clear precursor/product relationship between LC3-I and LC3-II, because the conversion of the former to the latter is cell type-specific and dependent on the treatment used to induce autophagy. Accumulation of LC3-II can be obtained by interrupting the autophagosome-lysosome fusion step (e.g., by depolymerizing acetylated microtubules with vinblastine), by inhibiting the ATP2A/SERCA Ca<sup>2+</sup> pump, by specifically inhibiting the V-ATPase with bafilomycin A<sub>1</sub><sup>155–157</sup> or by raising the lysosomal pH by the addition of chloroquine,<sup>158,159</sup> although some of these treatments may increase autophagosome numbers by disrupting the lysosome-

dependent activation of MTOR (mechanistic target of rapamycin [serine/threonine kinase] complex 1 [MTORC1; note that the original term “mTOR” was named to distinguish the “mammalian” target of rapamycin from the yeast proteins<sup>160</sup>], a major suppressor of autophagy induction),<sup>161,162</sup> or by

inhibiting lysosome-mediated proteolysis (e.g., with a cysteine protease inhibitor such as E-64d, the aspartic protease inhibitor pepstatin A, the cysteine, serine and threonine protease inhibitor leupeptin or treatment with bafilomycin A<sub>1</sub>, NH<sub>4</sub>Cl or chloroquine<sup>158,163,164</sup>). Western blotting can be used to




Figure 6. (For figure caption see page 43)

monitor changes in LC3 amounts (Fig. 6);<sup>26,165</sup> however, even if the total amount of LC3 does increase, the magnitude of the response is generally less than that documented in yeast. It is worth noting that since the conjugated forms of the GABARAP subfamily members are usually undetectable without induction of autophagy in mammalian and other vertebrate cells,<sup>166,167</sup> these proteins might be more suitable than LC3 to study and quantify subtle changes in autophagy induction.

In most organisms, Atg8/LC3 is initially synthesized with a C-terminal extension that is removed by the Atg4 protease. Accordingly, it is possible to use this processing event to monitor Atg4 activity. For example, when GFP is fused at the C terminus of Atg8 (Atg8-GFP), the GFP moiety is removed in the cytosol to generate free Atg8 and GFP. This processing can be easily monitored by western blot.<sup>168</sup> It is also possible to use assays with an artificial fluorogenic substrate, or a fusion of LC3B to phospholipase A2 that allows the release of the active phospholipase for a subsequent fluorogenic assay,<sup>169</sup> and there is a fluorescence resonance energy transfer (FRET)-based assay utilizing CFP and YFP tagged versions of LC3B and GABARAPL2/GATE-16 that can be used for high-throughput screening.<sup>170</sup> Another method to monitor ATG4 activity in vivo uses the release of Gaussia luciferase from the C terminus of LC3 that is tethered to actin.<sup>171</sup> Note that there are 4 Atg4 homologs in mammals, and they have different activities with regard to the Atg8 subfamilies of proteins.<sup>172</sup> ATG4A is able to cleave the GABARAP subfamily, but has very limited activity toward the LC3 subfamily, whereas ATG4B is apparently active against most or all of these proteins.<sup>139,140</sup> The ATG4C and ATG4D isoforms have minimal activity for any of the Atg8 homologs. In particular because a C-terminal fusion will be cleaved immediately by Atg4, researchers should be careful to specify whether they are using GFP-Atg8/LC3 (an N-terminal fusion, which can be used to monitor various steps of autophagy) or Atg8/LC3-GFP (a C-terminal fusion, which can only be used to monitor Atg4 activity).<sup>173</sup>

**Cautionary notes:** There are several important caveats to using Atg8/LC3-II or GABARAP-II to visualize fluctuations in autophagy. First, changes in LC3-II amounts are tissue- and cell context-dependent.<sup>153,174</sup> Indeed, in some cases, autophagosome accumulation detected by TEM does not correlate well with the amount of LC3-II (Z. Tallóczy, R.L.A. de Vries, and

D. Sulzer, unpublished results; E.-L. Eskelinen, unpublished results). This is particularly evident in those cells that show low levels of LC3-II (based on western blotting) because of an intense autophagic flux that consumes this protein,<sup>175</sup> or in cell lines having high levels of LC3-II that are tumor-derived, such as MDA-MB-231.<sup>174</sup> Conversely, without careful quantification the detectable formation of LC3-II is not sufficient evidence for autophagy. For example, homozygous deletion of *Becn1* does not prevent the formation of LC3-II in embryonic stem cells even though autophagy is substantially reduced, whereas deletion of *Atg5* results in the complete absence of LC3-II (see Fig. 5A and supplemental data in ref. 176). The same is true for the generation of Atg8-PE in yeast in the absence of *VPS30/ATG6* (see Fig. 7 in ref. 177). Thus, it is important to remember that not all of the autophagy-related proteins are required for Atg8/LC3 processing, including lipidation.<sup>177</sup> Variations in the detection and amounts of LC3-I versus LC3-II present technical problems. For example, LC3-I is very abundant in brain tissue, and the intensity of the LC3-I band may obscure detection of LC3-II, unless the polyacrylamide crosslinking density is optimized, or the membrane fraction of LC3 is first separated from the cytosolic fraction.<sup>44</sup> Conversely, certain cell lines have much less visible LC3-I compared to LC3-II. In addition, tissues may have asynchronous and heterogeneous cell populations, and this variability may present challenges when analyzing LC3 by western blotting.

Second, LC3-II also associates with the membranes of non-autophagic structures. For example, some members of the PCDHGC/ $\gamma$ -protocadherin family undergo clustering to form intracellular tubules that emanate from lysosomes.<sup>178</sup> LC3-II is recruited to these tubules, where it appears to promote or stabilize membrane expansion. Furthermore, LC3 can be recruited directly to apoptotic cell-containing phagosome membranes,<sup>179,180</sup> macropinosomes,<sup>179</sup> the parasitophorous vacuole of *Toxoplasma gondii*,<sup>181</sup> and single-membrane entotic vacuoles,<sup>179</sup> as well as to bacteria-containing phagosome membranes under certain immune activating conditions, for example, toll-like receptor (TLR)-mediated stimulation in LC3-associated phagocytosis.<sup>182,183</sup> Importantly, LC3 is involved in secretory trafficking as it has been associated with secretory granules in mast cells<sup>184</sup> and PC12 hormone-secreting cells.<sup>185</sup> LC3 is also detected on secretory lysosomes in osteoblasts<sup>186</sup> and in amphisome-like structures involved in

**Figure 6.** (See previous page for Figure 6.) LC3-I conversion and LC3-II turnover. (A) Expression levels of LC3-I and LC3-II during starvation. *Atg5*<sup>+/+</sup> (wild-type) and *atg5*<sup>-/-</sup> MEFs were cultured in DMEM without amino acids and serum for the indicated times, and then subjected to immunoblot analysis using anti-LC3 antibody and anti-tubulin antibody. E-64d (10  $\mu$ g/ml) and pepstatin A (10  $\mu$ g/ml) were added to the medium where indicated. Positions of LC3-I and LC3-II are marked. The inclusion of lysosomal protease inhibitors reveals that the apparent decrease in LC3-II is due to lysosomal degradation as easily seen by comparing samples with and without inhibitors at the same time points (the overall decrease seen in the presence of inhibitors may reflect decreasing effectiveness of the inhibitors over time). Monitoring autophagy by following steady state amounts of LC3-II without including inhibitors in the analysis can result in an incorrect interpretation that autophagy is not taking place (due to the apparent absence of LC3-II). Conversely, if there are high levels of LC3-II but there is no change in the presence of inhibitors, this may indicate that induction has occurred but that the final steps of autophagy are blocked, resulting in stabilization of this protein. This figure was modified from data previously published in ref. 26, and is reproduced by permission of Landes Bioscience, copyright 2007. (B) Lysates of 4 human adipose tissue biopsies were resolved on 2-12% polyacrylamide gels, as described previously.<sup>217</sup> Proteins were transferred in parallel to either a PVDF or a nitrocellulose membrane, and blotted with anti-LC3 antibody, and then identified by reacting the membranes with an HRP-conjugated anti-rabbit IgG antibody, followed by ECL. The LC3-II/LC3-I ratio was calculated based on densitometry analysis of both bands. \*,  $P < 0.05$ . (C) HEK 293 and HeLa cells were cultured in nutrient-rich medium (DMEM containing 10% fetal calf serum) or incubated for 4 h in starvation conditions (Krebs-Ringer medium) in the absence (-) or presence (+) of E-64d and pepstatin at 10  $\mu$ g/ml each (inhibitors). Cells were then lysed and the proteins resolved by SDS-PAGE. Endogenous LC3 was detected by immunoblotting. Positions of LC3-I and LC3-II are indicated. In the absence of lysosomal protease inhibitors, starvation results in a modest increase (HEK 293 cells) or even a decrease (HeLa cells) in the amount of LC3-II. The use of inhibitors reveals that this apparent decrease is due to lysosome-dependent degradation. This figure was modified from data previously published in ref. 174, and is reproduced by permission of Landes Bioscience, copyright 2005. (D) Sequence and schematic representation of the different forms of LC3B. The sequence for the nascent (proLC3) from mouse is shown. The glycine at position 120 indicates the cleavage site for ATG4. After this cleavage, the truncated LC3 is referred to as LC3-I, which is still a soluble form of the protein. Conjugation to PE generates the membrane-associated LC3-II form (equivalent to Atg8-PE).

mucin secretion by goblet cells.<sup>187</sup> Therefore, in studies of infection of mammalian cells by bacterial pathogens, the identity of the LC3-II labeled compartment as an autophagosome should be confirmed by a second method, such as TEM. It is also worth noting that autophagy induced in response to bacterial infection is not directed solely against the bacteria but can also be a response to remnants of the phagocytic membrane.<sup>188</sup> Similar cautions apply with regard to viral infection. For example, coronaviruses induce autophagosomes during infection through the expression of *nsp6*; however, coronaviruses also induce the formation of double-membrane vesicles that are coated with LC3-I, the nonlipidated form of LC3 that plays an autophagy-independent role in viral replication.<sup>189,190</sup> Similarly, nonlipidated LC3 marks replication complexes in flavivirus (Japanese encephalitis virus)-infected cells and is essential for viral replication.<sup>191</sup> Along these lines, during herpes simplex virus type 1 (HSV-1) infection, an LC3<sup>+</sup> autophagosome-like organelle that is derived from nuclear membranes and that contains viral proteins is observed,<sup>192</sup> whereas influenza A virus directs LC3 to the plasma membrane via a LC3-interacting region (LIR) motif in its M2 protein.<sup>193</sup> Moreover, *in vivo* studies have shown that coxsackievirus (an enterovirus) induces formation of autophagy-like vesicles in pancreatic acinar cells, together with extremely large autophagy-related compartments that have been termed megaphagosomes;<sup>194</sup> the absence of ATG5 disrupts viral replication and prevents the formation of these structures.<sup>195</sup>

Third, caution must be exercised in general when evaluating LC3 by western blotting, and appropriate standardization controls are necessary. For example, LC3-I may be less sensitive to detection by certain anti-LC3 antibodies. Moreover, LC3-I is more labile than LC3-II, being more sensitive to freezing-thawing and to degradation in SDS sample buffer. Therefore, fresh samples should be boiled and assessed as soon as possible and should not be subjected to repeated freeze-thaw cycles. Alternatively, trichloroacetic acid precipitation of protein from fresh cell homogenates can be used to protect against degradation of LC3 by proteases that may be present in the sample. A general point to consider when examining transfected cells concerns the efficiency of transfection. A western blot will detect LC3 in the entire cell population, including those that are not transfected. Thus, if transfection efficiency is too low, it may be necessary to use methods, such as fluorescence microscopy, that allow autophagy to be monitored in single cells. The critical point is that the analysis of the gel shift of transfected LC3 or GFP-LC3 can be employed to follow LC3 lipidation only in highly transfectable cells.<sup>196</sup>

When dealing with animal tissues, western blotting of LC3 should be performed on frozen biopsy samples homogenized in the presence of general protease inhibitors (C. Isidoro, personal communication; see also *Human*).<sup>197</sup> Caveats regarding detection of LC3 by western blotting have been covered in a review.<sup>26</sup> For example, PVDF membranes may result in a stronger LC3-II retention than nitrocellulose membranes, possibly due to a higher affinity for hydrophobic proteins (Fig. 6B; J. Kovsan and A. Rudich, personal communication), and Triton X-100 may not efficiently solubilize LC3-II in some systems.<sup>198</sup> Heating in the presence of 1% SDS, or analysis of membrane fractions,<sup>44</sup> may assist in the detection of the lipidated form of this protein.

This observation is particularly relevant for cells with a high nucleocytoplasmic ratio, such as lymphocytes. Under these constraints, direct lysis in Laemmli loading buffer, containing SDS, just before heating, greatly improves LC3 detection on PVDF membranes, especially when working with a small number of cells (F. Gros, unpublished observations).<sup>199</sup> Analysis of a membrane fraction is particularly useful for brain where levels of soluble LC3-I greatly exceed the level of LC3-II.

One of the most important issues is the quantification of changes in LC3-II, because this assay is one of the most widely used in the field and is often prone to misinterpretation. Levels of LC3-II should be compared to actin (e.g., ACTB), but not to LC3-I (see the caveat in the next paragraph), and, ideally, to more than one “housekeeping” protein (HKP). Actin and other HKPs are usually abundant and can easily be overloaded on the gel<sup>200</sup> such that they are not detected within a linear range. Moreover, actin levels may decrease when autophagy is induced in many organisms from yeast to mammals. For any proteins used as “loading controls” (including actin, tubulin and GAPDH) multiple exposures of the western blot are generally necessary to ensure that the signals are detected in the linear range. An alternative approach is to stain for total cellular proteins with Coomassie Brilliant Blue and Ponceau Red,<sup>201</sup> but these methods are generally less sensitive and may not reveal small differences in protein loading. Stain-Free gels, which also stain for total cellular proteins, have been shown to be an excellent alternative to HKPs.<sup>202</sup>

It is important to realize that ignoring the level of LC3-I in favor of LC3-II normalized to HKPs may not provide the full picture of the cellular autophagic response.<sup>153,203</sup> For example, in aging skeletal muscle the increase in LC3-I is at least as important as that for LC3-II.<sup>204,205</sup> Quantification of both isoforms is therefore informative, but requires adequate conditions of electrophoretic separation. This is particularly important for samples where the amount of LC3-I is high relative to LC3-II (as in brain tissues, where the LC3-I signal can be overwhelming). Under such a scenario, it may be helpful to use gradient gels to increase the separation of LC3-I from LC3-II and/or cut away the part of the blot with LC3-I prior to the detection of LC3-II. Furthermore, since the dynamic range of LC3 immunoblots is generally quite limited, it is imperative that other assays be used in parallel in order to draw valid conclusions about changes in autophagy activity.

Fourth, in mammalian cells LC3 is expressed as multiple isoforms (LC3A, LC3B, LC3B2 and LC3C<sup>206,207</sup>), which exhibit different tissue distributions and whose functions are still poorly understood. A point of caution along these lines is that the increase in LC3A-II versus LC3B-II levels may not display equivalent changes in all organisms under autophagy-inducing conditions, and it should not be assumed that LC3B is the optimal protein to monitor.<sup>208</sup> A key technical consideration is that the isoforms may exhibit different specificities for antisera or antibodies. Thus, it is highly recommended that investigators report exactly the source and catalog number of the antibodies used to detect LC3 as this might help avoid discrepancies between studies. The commercialized anti-LC3B antibodies also recognize LC3A, but do not recognize LC3C, which shares less sequence homology. It is important to note that LC3C

possesses in its primary amino acid sequence the DYKD motif that is recognized with a high affinity by anti-FLAG antibodies. Thus, the standard anti-FLAG M2 antibody can detect and immunoprecipitate overexpressed LC3C, and caution has to be taken in experiments using FLAG-tagged proteins (M. Biard-Piechaczyk and L. Espert, personal communication). Note that according to Ensembl there is no *LC3C* in mouse or rat.

In addition, it is important to keep in mind the other subfamily of Atg8 proteins, the GABARAP subfamily (see above).<sup>141,209</sup> Certain types of mitophagy induced by BNIP3L/NIX are highly dependent on GABARAP and less dependent on LC3 proteins.<sup>210,211</sup> Furthermore, commercial antibodies for GABARAPL1 also recognize GABARAP,<sup>138,143</sup> which might lead to misinterpretation of experiments, in particular those using immunohistochemical techniques. Sometimes the problem with cross-reactivity of the anti-GABARAPL1 antibody can be overcome when analyzing these proteins by western blot because the isoforms can be resolved during SDS-PAGE using high concentration (15%) gels, as GABARAP migrates faster than GABARAPL1 (M. Boyer-Guittaut, personal communication; also see Fig. S4 in ref. 143). Because GABARAP and GABARAPL1 can both be proteolytically processed and lipidated, generating GABARAP-I or GABARAPL1-I and GABARAP-II or GABARAPL1-II, respectively, this may lead to a misassignment of the different bands. As soon as highly specific antibodies that are able to discriminate between GABARAP and GABARAPL1 become available, we strongly advise their use; until then, we advise caution in interpreting results based on the detection of these proteins by western blot. Antibody specificity can be assessed after complete inhibition of GABARAP (or any other Atg8 family protein) expression by RNA interference.<sup>143,167</sup> In general, we advise caution in choosing antibodies for western blotting and immunofluorescence experiments and in interpreting results based on stated affinities of antibodies unless these have been clearly determined. As with any western blot, proper methods of quantification must be used, which are, unfortunately, often not well disseminated; readers are referred to an excellent paper on this subject (see ref. 212). Unlike the other members of the GABARAP family, almost no information is available on GABARAPL3, perhaps because it is not yet possible to differentiate between GABARAPL1 and GABARAPL3 proteins, which have 94% identity. As stated by the laboratory that described the cloning of the human *GABARAPL1* and *GABARAPL3* genes,<sup>209</sup> their expression patterns are apparently identical. It is worth noting that *GABARAPL3* is the only gene of the *GABARAP* subfamily that seems to lack an ortholog in mice.<sup>209</sup> *GABARAPL3* might therefore be considered as a pseudogene without an intron that is derived from *GABARAPL1*. Hence, until new data are published, *GABARAPL3* should not be considered as the fourth member of the *GABARAP* family.

Fifth, in non-mammalian species, the discrimination of Atg8-PE from the nonlipidated form can be complicated by their nearly identical SDS-PAGE mobilities and the presence of multiple isoforms (e.g., there are 9 in *Arabidopsis*). In yeast, it is possible to resolve Atg8 (the nonlipidated form) from Atg8-PE by including 6 M urea in the SDS-PAGE separating gel,<sup>213</sup> or by using a 15% resolving gel without urea (F. Reggiari,

personal communication). Similarly, urea combined with prior treatment of the samples with (or without) phospholipase D (that will remove the PE moiety) can often resolve the ATG8 species in plants.<sup>214,215</sup> It is also possible to label cells with radioactive ethanolamine, followed by autoradiography to identify Atg8-PE, and a C-terminal peptide can be analyzed by mass spectrometry to identify the lipid modification at the terminal glycine residue. Special treatments are not needed for the separation of mammalian LC3-I from LC3-II.

Sixth, it is important to keep in mind that *ATG8*, and to a lesser extent *LC3*, undergoes substantial transcriptional and posttranscriptional regulation. Accordingly, to obtain an accurate interpretation of Atg8/LC3 protein levels it is also necessary to monitor the mRNA levels. Without analyzing the corresponding mRNA it is not possible to discriminate between changes that are strictly reflected in altered amounts of protein versus those that are due to changes in transcription (e.g., the rate of transcription, or the stability of the message). For example, in cells treated with the calcium ionophore A23187 or the ER calcium pump blocker thapsigargin, an obvious correlation is found between the time-dependent increases in LC3B-I and LC3B-II protein levels, as well as with the observed increase in *LC3B* mRNA levels.<sup>216</sup> Clinically, in human adipose tissue, protein and mRNA levels of LC3 in omental fat are similarly elevated in obese compared to lean individuals.<sup>217</sup>

Seventh, LC3-I can be fully degraded by the 20S proteasome or, more problematically, processed to a form appearing equal in size to LC3-II on a western blot (LC3-T); LC3-T was identified in HeLa cells and is devoid of the ubiquitin conjugation domain, thus lacking its adaptor function for autophagy.<sup>218</sup>

Eighth, a general issue when working with cell lines is that we recommend that validation be performed to verify the cell line(s) being used, and to verify the presence of genetic alterations as appropriate. Depending on the goal (e.g., to indicate general applicability of a particular treatment) it may be important to use more than one cell line to confirm the results. It is also critical to test for mycoplasma because the presence of this contaminant can significantly alter the results with regard to any autophagic response. For these reasons, we also recommend the use of low passage numbers for nonprimary cells or cell lines (no more than 40 passages or 6 months after thawing).

Finally, we would like to point out that one general issue with regard to any assay is that experimental manipulation could introduce some type of stress—for example, mechanical stress due to lysis, temperature stress due to heating or cooling a sample, or oxidative stress on a microscope slide, which could lead to potential artifacts including the induction of autophagy—even maintaining cells in higher than physiologically normal oxygen levels can be a stress condition.<sup>219</sup> Special care should be taken with cells in suspension, as the stress resulting from centrifugation can induce autophagy. This point is not intended to limit the use of any specific methodology, but rather to note that there are no perfect assays. Therefore, it is important to verify that the positive (e.g., treatment with rapamycin, torin1 or other inducers) and negative (e.g., inhibitor treatment) controls behave as expected in any assays being utilized. Similarly, plasmid transfection or nucleofection can result in the potent induction of autophagy (based on increases in LC3-II or SQSTM1/p62 degradation). In some cell types, the

amount of autophagy induced by transfection of a control empty vector may be so high that it is virtually impossible to examine the effect of enforced gene expression on autophagy (B. Levine, personal communication). It is thus advisable to perform time course experiments to determine when the transfection effect returns to acceptably low levels and to use appropriate time-matched transfection controls (see also the discussion in *GFP-Atg8/LC3 fluorescence microscopy*). This effect is generally not observed with siRNA transfection; however, it is an issue for plasmid expression constructs including those for shRNA and for viral delivery systems. The use of endotoxin-free DNA reduces, but does not eliminate, this problem. In many cells the cationic polymers used for DNA transfection, such as liposomes and polyplex, induce large tubulovesicular autophagosomes (TVAs) in the absence of DNA.<sup>220</sup> These structures accumulate SQSTM1 and fuse slowly with lysosomes. Interestingly, these TVAs appear to reduce gene delivery, which increases 8–10 fold in cells that are unable to make TVAs due to the absence of ATG5. Finally, the precise composition of media components and the density of cells in culture can have profound effects on basal autophagy levels and may need to be modified empirically depending on the cell lines being used. Along these lines various types of media, in particular those with different serum levels (ranging from 0–15%), may have profound effects with regard to how cells (or organs) perceive a fed versus starved state. For example, normal serum contains significant levels of cytokines and hormones that likely regulate the basal levels of autophagy; thus, the use of dialyzed serum might be an alternative for these studies. In addition, the amino acid composition of the medium/assay buffer may have profound effects on initiation or progression of autophagy. For example, in the protozoan parasite *Trypanosoma brucei* starvation-induced autophagy can be prevented by addition of histidine to the incubation buffer.<sup>221</sup> For these reasons, the cell culture conditions should be fully described. It is also important to specify duration of autophagy stimulation, as long-term autophagy can modify signal transduction pathways of importance in cell survival.<sup>222</sup>

**Conclusion:** Atg8/LC3 is often an excellent marker for autophagic structures; however, it must be kept in mind that there are multiple LC3 isoforms, there is a second family of mammalian Atg8-like proteins (GABARAPs), and antibody affinity (for LC3-I versus LC3-II) and specificity (for example, for LC3A versus LC3B) must be considered and/or determined. Moreover, LC3 levels on their own do not address issues of autophagic flux. Finally, even when flux assays are carried out, there is a problem with the limited dynamic range of LC3 immunoblots; accordingly, this method should not be used by itself to analyze changes in autophagy.

#### **b. Turnover of LC3-II/Atg8-PE**

Autophagic flux is often inferred on the basis of LC3-II turnover, measured by western blot (Fig. 6C)<sup>174</sup> in the presence and absence of lysosomal, or vacuolar degradation. However, it should be cautioned that such LC3 assays are merely indicative of autophagic “carrier flux”, not of actual autophagic cargo/substrate flux. It has, in fact, been observed that in rat hepatocytes, an autophagic-lysosomal flux of LC3-II can take place in the

absence of an accompanying flux of cytosolic bulk cargo.<sup>223</sup> The relevant parameter in LC3 assays is the difference in the amount of LC3-II in the presence and absence of saturating levels of inhibitors, which can be used to examine the transit of LC3-II through the autophagic pathway; if flux is occurring, the amount of LC3-II will be higher in the presence of the inhibitor.<sup>174</sup> Lysosomal degradation can be prevented through the use of protease inhibitors (e.g., pepstatin A, leupeptin and E-64d), compounds that neutralize the lysosomal pH such as bafilomycin A<sub>1</sub>, chloroquine or NH<sub>4</sub>Cl,<sup>16,149,158,164,224,225</sup> or by treatment with agents that block the fusion of autophagosomes with lysosomes (note that bafilomycin A<sub>1</sub> will ultimately cause a fusion block as well as neutralize the pH,<sup>156</sup> but the inhibition of fusion may be due to a block in ATP2A/SERCA activity<sup>226</sup>).<sup>155–157,227</sup> Alternatively, knocking down or knocking out LAMP2 (lysosomal-associated membrane protein 2) represents a genetic approach to block the fusion of autophagosomes and lysosomes (for example, inhibiting LAMP2 in myeloid leukemic cells results in a marked increase of GFP-LC3 dots and endogenous LC3-II protein compared to control cells upon autophagy induction during myeloid differentiation [M.P. Tschan, unpublished data]).<sup>228</sup> This approach, however, is only valid when the knockdown of LAMP2 is directed against the mRNA region specific for the *LAMP2B* spliced variant, as targeting the region common to the 3 variants would also inhibit chaperone-mediated autophagy, which may result in the compensatory upregulation of macroautophagy.<sup>92,229,230</sup>

Increased levels of LC3-II in the presence of lysosomal inhibition or interfering with autophagosome-lysosome fusion alone (e.g., with bafilomycin A<sub>1</sub>) may be indicative of autophagic carrier flux (to the stage of cargo reaching the lysosome), but to assess whether a particular treatment alters complete autophagic flux through substrate digestion, the treatment plus bafilomycin A<sub>1</sub> must be compared with results obtained with treatment alone as well as with bafilomycin A<sub>1</sub> alone. An additive or supra-additive effect in LC3-II levels may indicate that the treatment enhances autophagic flux (Fig. 6C). Moreover, higher LC3-II levels with treatment plus bafilomycin A<sub>1</sub> compared to bafilomycin A<sub>1</sub> alone may indicate that the treatment increases the synthesis of autophagy-related membranes. If the treatment by itself increases LC3-II levels, but the treatment plus bafilomycin A<sub>1</sub> does not increase LC3-II levels compared to bafilomycin A<sub>1</sub> alone, this may indicate that the treatment induced a partial block in autophagic flux. Thus, a treatment condition increasing LC3-II on its own that has no difference in LC3-II in the presence of bafilomycin A<sub>1</sub> compared to treatment alone may suggest a complete block in autophagy at the terminal stages.<sup>231</sup> This procedure has been validated with several autophagy modulators.<sup>232</sup> With each of these techniques, it is essential to avoid assay saturation. The duration of the bafilomycin A<sub>1</sub> treatment (or any other inhibitor of autophagic flux such as chloroquine) needs to be relatively short (1–4 h)<sup>233</sup> to allow comparisons of the amount of LC3 that is lysosomally degraded over a given time frame under one treatment condition to another treatment condition. A dose-curve and time-course standardization for the use of autophagic flux inhibitors is required for the initial optimization of the conditions to detect LC3-II accumulation and avoid non-specific or secondary effects. By using a rapid screening

approach, such as a colorimetric-based platform method,<sup>234</sup> it is possible to monitor a long time frame for autolysosome accumulation, which closely associates with autophagy efficiency.<sup>235</sup> Positive control experiments using treatment with known autophagy inducers, along with bafilomycin A<sub>1</sub> versus vehicle, are important to demonstrate the utility of this approach in each experimental context. The same type of assay monitoring the turnover of Atg8-PE can be used to monitor flux in yeast, by comparing the amount of Atg8 present in a wild-type versus a *pep4Δ* strain following autophagy induction;<sup>236</sup> however, it is important to be aware that the *PEP4* knockout can influence yeast cell physiology. PMSF, which inhibits the activity of Prb1, can also be used to block Atg8-PE turnover.

An additional methodology for monitoring autophagy relies on the observation that in some cell types a subpopulation of LC3-II exists in a cytosolic form (LC3-IIs).<sup>237-239</sup> The amount of cytosolic LC3-IIs and the ratio between LC3-I and LC3-IIs appears to correlate with changes in autophagy and may provide a more accurate measure of autophagic flux than ratios based on the total level of LC3-II.<sup>239</sup> The validity of this method has been demonstrated by comparing autophagic proteolytic flux in rat hepatocytes, hepatoma cells and myoblasts. One advantage of this approach is that it does not require the presence of autophagic or lysosomal inhibitors to block the degradation of LC3-II.

Due to the advances in time-lapse fluorescence microscopy and the development of photoswitchable fluorescent proteins, autophagic flux can also be monitored by assessing the half-life of the LC3 protein<sup>240</sup> post-photoactivation or by quantitatively measuring the autophagosomal pool size and its transition time.<sup>241</sup> These approaches deliver invaluable information on the kinetics of the system and the time required to clear a complete autophagosomal pool. Nonetheless, care must be taken for this type of analysis as changes in translational/transcriptional regulation of LC3 might also affect the readout.

Finally, autophagic flux can be monitored based on the turnover of LC3-II, by utilizing a luminescence-based assay. For example, a reporter assay based on the degradation of *Renilla reniformis* luciferase (Rluc)-LC3 fusion proteins is well suited for screening compounds affecting autophagic flux.<sup>242</sup> In this assay, Rluc is fused N-terminally to either wild-type LC3 (LC3<sup>WT</sup>) or a lipidation-deficient mutant of LC3 (G120A). Since Rluc-LC3<sup>WT</sup>, in contrast to Rluc-LC3<sup>G120A</sup>, specifically associates with the autophagosomal membranes, Rluc-LC3<sup>WT</sup> is more sensitive to autophagic degradation. A change in autophagy-dependent LC3 turnover can thus be estimated by monitoring the change in the ratio of luciferase activities between the 2 cell populations expressing either Rluc-LC3<sup>WT</sup> or Rluc-LC3<sup>G120A</sup>. In its simplest form, the Rluc-LC3-assay can be used to estimate autophagic flux at a single time point by defining the luciferase activities in cell extracts. Moreover, the use of a live cell luciferase substrate makes it possible to monitor changes in autophagic activity in live cells in real time. This method has been successfully used to identify positive and negative regulators of autophagy from cells treated with micro-RNA, siRNA and small molecule libraries.<sup>242-248</sup>

**Cautionary notes:** The main caveat regarding the measurement of LC3-IIs/LC3-I is that this method has only been tested in isolated rat hepatocytes and H4-II-E cells. Thus, it is not yet

known whether it is generally applicable to other cell types. Indeed, a soluble form of LC3-II (i.e., LC3-IIs) is not observed in many standard cell types including HeLa, HEK 293 and PC12. In addition, the same concerns apply regarding detection of LC3-I by western blotting. It should be noted that the LC3-IIs/LC3-I ratio must be analyzed using the cytosolic fractions rather than the total homogenates. Furthermore, the same caveats mentioned above regarding the use of LC3 for qualitatively monitoring autophagy also apply to the use of this marker for evaluating flux.

The use of a radioactive pulse-chase analysis, which assesses complete autophagic flux, provides an alternative to lysosomal protease inhibitors,<sup>148</sup> although such inhibitors should still be used to verify that degradation is lysosome-dependent. In addition, drugs must be used at concentrations and for time spans that are effective in inhibiting fusion or degradation, but that do not provoke cell death. Thus, these techniques may not be practical in all cell types or in tissues from whole organisms where the use of protease inhibitors is problematic, and where pulse labeling requires artificial short-term culture conditions that may induce autophagy. Another concern when monitoring flux via LC3-II turnover may be seen in the case of a partial autophagy block; in this situation, agents that disrupt autophagy (e.g., bafilomycin A<sub>1</sub>) will still result in an increase in LC3-II. Thus, care is needed in interpretation. For characterizing new autophagy modulators, it is ideal to test autophagic flux at early (e.g., 4 h) and late (e.g., 24 h) time-points, since in certain instances, such as with calcium phosphate precipitates, a compound may increase or decrease flux at these 2 time points, respectively.<sup>233</sup> Moreover, it is important to consider assaying autophagy modulators in a long-term response in order to further understand their effects. Finally, many of the chemicals used to inhibit autophagy, such as bafilomycin A<sub>1</sub>, NH<sub>4</sub>Cl (see *Autophagy inhibitors and inducers*) or chloroquine, also directly inhibit the endocytosis/uncoating of viruses (D.R. Smith, personal communication), and other endocytic events requiring low pH, as well as exit from the Golgi (S. Tooze, personal communication). As such, agents that neutralize endosomal compartments should be used only with extreme caution in studies investigating autophagy-virus interactions.

One additional consideration is that it may not be absolutely necessary to follow LC3-II turnover if other substrates are being monitored simultaneously. For example, an increase in LC3-II levels in combination with the lysosomal (or ideally autophagy-specific) removal of an autophagic substrate (such as an organelle<sup>249,250</sup>) that is not a good proteasomal substrate provides an independent assessment of autophagic flux. However, it is probably prudent to monitor both turnover of LC3-II and an autophagosome substrate in parallel, due to the fact that LC3 might be coupled to endosomal membranes and not just autophagosomes, and the levels of well-characterized autophagosome substrates such as SQSTM1 can also be affected by proteasome inhibitors.<sup>251</sup>

Another issue relates to the use of protease inhibitors (see *Autophagy inhibitors and inducers*). When using lysosomal protease inhibitors, it is of fundamental importance to assess proper conditions of inhibitor concentration and time of pre-incubation to ensure full inhibition of lysosomal cathepsins.




In this respect, 1 h of pre-incubation with 10  $\mu\text{g/ml}$  E-64d is sufficient in most cases, since this inhibitor is membrane permeable and rapidly accumulates within lysosomes, but another frequently used inhibitor, leupeptin, requires at least 6 h pre-incubation.<sup>59</sup> Moreover, pepstatin A is membrane impermeable (ethanol or preferably DMSO must be employed as a vehicle) and requires a prolonged incubation (>8 h) and a relatively high concentration (>50  $\mu\text{g/ml}$ ) to fully inhibit lysosomal CTSD (Fig. 7). An incubation of this duration, however, can be problematic due to indirect effects (see *GFP-Atg8/LC3 lysosomal delivery and proteolysis*). At least in neurons, pepstatin alone is a less effective lysosomal proteolytic block, and combining a cysteine protease inhibitor with it is most effective.<sup>59</sup> Also, note that the relative amount of lysosomal CTSD (cathepsin B) and CTSD is cell-specific and changes with culture conditions. A possible alternative to pepstatin A is the pepstatin A, BODIPY<sup>®</sup> FL conjugate,<sup>252,253</sup> which is transported to lysosomes via endocytosis. In contrast to the protease inhibitors, chloroquine (10–40  $\mu\text{M}$ ) or bafilomycin A<sub>1</sub> (1–100 nM) can be added to cells immediately prior to autophagy induction. Because cysteine protease inhibitors upregulate CTSD and have potential inhibitory activity toward calpains and other cysteine proteases, whereas bafilomycin A<sub>1</sub> can have potential significant cytotoxicity, especially in cultured neurons and pathological states, the use of both methods may be important in some experiments to exclude off-target effects of a single method.

**Conclusion:** It is important to be aware of the difference between monitoring the steady-state level of Atg8/LC3 and autophagic flux. The latter may be assessed by following Atg8/LC3 in the absence and presence of autophagy inhibitors, and by examining the autophagy-dependent degradation of appropriate substrates. In particular, if there is any evidence of an increase in LC3-II (or autophagosomes), it is essential to determine whether this represents increased flux, or a block in fusion or degradation through the use of inhibitors such as chloroquine or bafilomycin A<sub>1</sub>. In the case of a suspected impaired degradation, assessment of lysosomal function is then required to validate the conclusion and to establish the basis.


### c. *GFP-Atg8/LC3 lysosomal delivery and partial proteolysis*

GFP-LC3B (hereafter referred to as GFP-LC3) has also been used to follow flux. It should be cautioned that, as with endogenous LC3, an assessment of autophagic GFP-LC3 flux is a carrier flux that cannot be equated with, and is not necessarily representative of, an autophagic cargo flux. When GFP-Atg8 or GFP-LC3 is delivered to a lysosome/vacuole, the Atg8/LC3 part of the chimera is sensitive to degradation, whereas the GFP protein is relatively resistant to hydrolysis (note, however, that GFP fluorescence is quenched by low pH; see *GFP-Atg8/LC3 fluorescence microscopy* and *Tandem mRFP/mCherry-GFP fluorescence microscopy*). Therefore, the appearance of free GFP on western blots can be used to monitor lysis of the inner autophagosome membrane and breakdown of the cargo in metazoans (Fig. 8A),<sup>236,254,255</sup> or the delivery of autophagosomes to, and the breakdown of autophagic bodies within, the fungal and plant vacuole.<sup>214,215,236,256</sup> Reports on *Dictyostelium* and mammalian cells highlight the importance of lysosomal pH as a critical factor in the detection of free GFP that results from the



**Figure 7.** Effect of different inhibitors on LC3-II accumulation. SH-SY5Y human neuroblastoma cells were plated and allowed to adhere for a minimum of 24 h, then treated in fresh medium. Treatments were as follows: rapamycin (Rap), (A) 1  $\mu\text{M}$ , 4 h or (B) 10  $\mu\text{M}$ , 4 h; E-64d, final concentration 10  $\mu\text{g/ml}$  from a 1 mg/ml stock in ethanol (EtOH); NH<sub>4</sub>Cl (NH<sub>4</sub><sup>+</sup>), final concentration 10 mM from a 1 M stock in water; pepstatin A (Pst), final concentration 10  $\mu\text{g/ml}$  from a 1 mg/ml stock in ethanol, or 68.6  $\mu\text{g/ml}$  from a 6.86 mg/ml stock in DMSO; ethanol or DMSO, final concentration 1%. Pre-incubations in (B) were for 1 or 4 h as indicated. 10 mM NH<sub>4</sub>Cl (or 30  $\mu\text{M}$  chloroquine, not shown) were the most effective compounds for demonstrating the accumulation of LC3-II. E-64d was also effective in preventing the degradation of LC3-II, with or without a preincubation, but ammonium chloride (or chloroquine) may be more effective. Pepstatin A at 10  $\mu\text{g/ml}$  with a 1 h pre-incubation was not effective at blocking degradation, whereas a 100  $\mu\text{M}$  concentration with 4 h pre-incubation had a partial effect. Thus, alkalizing compounds are more effective in blocking LC3-II degradation, and pepstatin A must be used at saturating conditions to have any noticeable effect. Images provided by C. Isidoro. Note that the band running just below LC3-I at approximately 17.5 kDa may be a processing intermediate of LC3-I; it is detectable in freshly prepared homogenates, but is less visible after the sample is subjected to a freeze-thaw cycle.

degradation of fused proteins. In these cell types, free GFP fragments are only detectable in the presence of nonsaturating levels of lysosomotropic compounds (NH<sub>4</sub>Cl or chloroquine) or under conditions that attenuate lysosomal acidity; otherwise,



**Figure 8.** GFP-LC3 processing can be used to monitor delivery of autophagosomal membranes. (A) *atg5*<sup>-/-</sup> MEFs engineered to express Atg5 under the control of the Tet-off promoter were grown in the presence of doxycycline (Dox; 10 ng/ml) for one week to suppress autophagy. Cells were then cultured in the absence of drug for the indicated times, with or without a final 2 h starvation. Protein lysates were analyzed by western blot using anti-LC3 and anti-GFP antibodies. The positions of untagged and GFP-tagged LC3-I and LC3-II, and free GFP are indicated. This figure was modified from data previously published in ref. 255, FEBS Letters, 580, Hosokawa N, Hara Y, Mizushima N, Generation of cell lines with tetracycline-regulated autophagy and a role for autophagy in controlling cell size, pp. 2623–2629, copyright 2006, with permission from Elsevier. (B) Differential role of unsaturating and saturating concentrations of lysosomal inhibitors on GFP-LC3 cleavage. HeLa cells stably transfected with GFP-LC3 were treated with various concentrations of chloroquine (CQ) for 6 h. Total lysates were prepared and subjected to immunoblot analysis. (C) CQ-induced free GFP fragments require classical autophagy machinery. Wild-type and *atg5*<sup>-/-</sup> MEFs were first infected with adenovirus GFP-LC3 (100 viral particles per cell) for 24 h. The cells were then either cultured in regular culture medium with or without CQ (10  $\mu$ M), or subjected to starvation in EBSS in the absence or presence of CQ for 6 h. Total lysates were prepared and subjected to immunoblot analysis. Panel (B) and (C) are modified from the data previously published in ref. 257.

the autophagic/degradative machinery appears to be too efficient to allow the accumulation of the proteolytic fragment (Fig. 8B,C).<sup>37,257</sup> Hence, a reduction in the intensity of the free GFP band may indicate reduced flux, but it may also be due to efficient turnover. Using a range of concentrations and treatment times of compounds that inhibit autophagy can be useful in distinguishing between these possibilities.<sup>258</sup> Since the pH in the yeast vacuole is higher than that in mammalian or *Dictyostelium* lysosomes, the levels of free GFP fragments are detectable in yeast even in the absence of lysosomotropic compounds.<sup>30</sup> Additionally, in yeast the diffuse fluorescent haze from the released GFP moiety within the vacuole lumen can be observed by fluorescence microscopy.


The dynamic movement to lysosomes of GFP-LC3, or of its associated cargo, also can be monitored by time-lapse fluorescence microscopy, although, as mentioned above, the GFP

fluorescent signal is more sensitive to acidic pH than other fluorophores (see *GFP-Atg8/LC3 fluorescence microscopy*). A time-course evaluation of the cell population showing GFP-LC3 puncta can serve to monitor the autophagic flux, since a constant increase in the number of cells accumulating GFP-LC3 puncta is suggestive of defective fusion of autophagosomes with lysosomes. Conversely, a decline implies that GFP-LC3 is delivered to properly acidified lysosomes and may, in addition, reflect proteolytic elimination within them, although the latter needs to be independently established. In either case, it can be problematic to use GFP fluorescence to follow flux, as new GFP-LC3 is continuously being synthesized. A potential solution to this problem is to follow the fluorescence of a photoactivatable version of the fluorescent protein,<sup>259</sup> which allows this assay to be performed essentially as a pulse-chase analysis. Another alternative to follow flux is to monitor GFP-LC3 fluorescence by adding lysosomal

protease or fusion inhibitors to cells expressing GFP-LC3 and monitoring changes in the number of puncta. In this case, the presence of lysosomal inhibitors should increase the number of GFP-LC3-positive structures, and the absence of an effect on the total number of GFP-LC3 puncta or on the percentage of cells displaying numerous puncta is indicative of a defect(s) in autophagic flux.<sup>260</sup> The combination of protease inhibitors (to prevent the degradation of GFP) or compounds that modify lysosomal pH such as  $\text{NH}_4\text{Cl}$  or chloroquine, or compounds that block fusion of autophagosomes with lysosomes such as bafilomycin  $\text{A}_1$  or others (e.g., vinblastine) may be most effective in preventing lysosome-dependent decreases in GFP-LC3 puncta. However, because the stability of GFP is affected by lysosomal pH, researchers may also consider the use of protease inhibitors whether or not lysosomotropic compounds or fusion inhibitors are included.

**Cautionary notes:** The GFP-Atg8 processing assay is used routinely to monitor autophagy in yeast. One caveat, however, is that this assay is not always carried out in a quantitative manner. For example, western blot exposures need to be in the linear range. Accordingly, an enzymatic assay such as the Pho8 $\Delta$ 60 assay may be preferred (see *Autophagic protein degradation*),<sup>261,262</sup> especially when the differences in autophagic activity need to be determined precisely (note that an equivalent assay has not been developed for higher eukaryotic cells); however, as with any enzyme assay, appropriate caution must be used regarding, for example, substrate concentrations and linearity. The Pho8 $\Delta$ 60 assay also requires a control to verify equal Pho8 $\Delta$ 60 expression in the different genetic backgrounds or conditions to be tested;<sup>261</sup> differences in Pho8 $\Delta$ 60 expression potentially affect its activity and may thus cause misinterpretation of results. Another issue to keep in mind is that GFP-Atg8 processing correlates with the surface area of the inner sphere of the autophagosome, and thus provides a smaller signal than assays that measure the volume of the autophagosome. Therefore, Pgk1-GFP processing<sup>30</sup> or the Pho8 $\Delta$ 60 assay are generally more sensitive assays.

The main limitation of the GFP-LC3 processing assay in mammalian cells is that it seems to depend on cell type and culture conditions (N. Hosokawa and N. Mizushima, unpublished data). Apparently, GFP is more sensitive to mammalian lysosomal hydrolases than to the degradative milieu of the yeast vacuole or the lysosomes in *Drosophila*. Alternatively, the lower pH of mammalian lysosomes relative to that of the yeast vacuole may contribute to differences in detecting free GFP. Under certain conditions (such as Earle's balanced salt solution [EBSS]-induced starvation) in some cell lines, when the lysosomal pH becomes particularly low, free GFP is undetectable because both the LC3-II and free GFP fragments are quickly degraded.<sup>257</sup> Therefore, if this method is used it should be accompanied by immunoblotting and include controls to address the stability of nonlysosomal GFP such as GFP-LC3-I. It should also be noted that free GFP can be detected when cells are treated with nonsaturating doses of inhibitors such as chloroquine, E-64d and bafilomycin  $\text{A}_1$ . The saturating concentrations of these lysosomal inhibitors vary in different cell lines, and it would be better to use a saturating concentration of lysosomal inhibitors when performing an autophagic flux



**Figure 9.** Movement of activated pDendra2-hp62 (SQSTM1; orange) from the nucleus (middle) to an aggregate in ARPE-19 cells, revealed by confocal microscopy. Cells were exposed to 5  $\mu\text{M}$  MG132 for 24 h to induce the formation of perinuclear aggregates.<sup>2186</sup> The cells were then exposed to a UV pulse (the UV-induced area is shown by red lines that are inside of the nucleus) that converts Dendra2 from green to red, and the time shown after the pulse is indicated. SQSTM1 is present in a small nuclear aggregate, and is shuttled from the nucleus to a perinuclear large protein aggregate (detected as red). Scale bar: 5  $\mu\text{m}$ . Image provided by K. Kaarniranta.

assay.<sup>257</sup> Therefore, caution must be exercised in interpreting the data using this assay; it would be helpful to combine an analysis of GFP-LC3 processing with other assays, such as the monitoring of endogenous LC3-II by western blot.

Along these lines, a caution concerning the use of the EGFP fluorescent protein for microscopy is that this fluorophore has a relatively neutral pH optimum for fluorescence,<sup>263</sup> and its signal diminishes quickly during live cell imaging due to the acidic environment of the lysosome. It is possible to circumvent this latter problem by imaging paraformaldehyde-fixed cultures that are maintained in a neutral pH buffer, which retains EGFP fluorescence (M. Kleinman and J.J. Reiners, personal communication). Alternatively, it may be preferable to use a different fluorophore such as mRFP or mCherry, which retain fluorescence even at acidic pH.<sup>264</sup> On the one hand, a putative advantage of mCherry over mRFP is its enhanced photostability and intensity, which are an order of magnitude higher (and comparable to GFP), enabling acquisition of images at similar exposure settings as are used for GFP, thus minimizing potential bias in interpretation.<sup>265</sup> On the other hand, caution is required when evaluating the localization of mCherry fusion proteins during autophagy due to the persistence of the mCherry signal in acidic environments; all tagged proteins are prone to show enrichment in lysosomes during nonselective autophagy of the cytoplasm, especially at higher expression levels. In addition, red fluorescent proteins (even the monomeric forms) can be toxic due to oligomer formation.<sup>266</sup> Dendra2 is an improved version of the green-to-red photoswitchable fluorescent protein Dendra, which is derived from the octocoral *Dendronephthya* sp.<sup>267</sup> Dendra2 is capable of irreversible photoconversion from a green to a red fluorescent form, but can be used also as a normal GFP or RFP vector. This modified version of the fluorophore has certain properties including a monomeric state, low phototoxic activation and efficient chromophore maturation, which make it suitable for real-time tracking of LC3 and SQSTM1 (Fig. 9; K. Kaarniranta, personal communication). Another alternative to mRFP or mCherry is to use the Venus variant of YFP, which is brighter than mRFP and less sensitive to pH than GFP.<sup>268</sup>

The pH optimum of EGFP is important to consider when using GFP-LC3 constructs, as the original GFP-LC3 marker<sup>269</sup> uses the EGFP variant, which may result in a reduced signal upon the formation of amphisomes or autolysosomes. An additional caveat when using the photoactivatable construct PA-GFP<sup>263</sup> is that the process of activation by photons may induce DNA damage, which could, in turn, induce autophagy. Also, GFP is relatively resistant to denaturation, and boiling for 5 min may be needed to prevent the folded protein from being trapped in the stacking gel during SDS-PAGE.

As noted above (see *Western blotting and ubiquitin-like protein conjugation systems*), Atg4/ATG4 cleaves the residue(s) that follow the C-terminal glycine of Atg8/LC3 that will be conjugated to PE. Accordingly, it is critical that any chimeras be constructed with the fluorescent tag at the amino terminus of Atg8/LC3 (unless the goal is to monitor Atg4/ATG4 activity).

Finally, lysosomal inhibition needs to be carefully controlled. Prolonged inhibition of lysosomal hydrolases (>6 h) is likely to induce a secondary autophagic response triggered by the accumulated undigested autophagic cargo. This secondary autophagic response can complicate the analysis of the autophagic flux, making it appear more vigorous than it would in the absence of the lysosomal inhibitors.


**Conclusion:** The GFP-Atg8/LC3 processing assay, which monitors free GFP generated within the vacuole/lysosome, is a convenient way to follow autophagy, but it does not work in all cell types, and is not as easy to quantify as enzyme-based assays. Furthermore, the assay measures the flux of an autophagic carrier, which may not necessarily be equivalent to autophagic cargo flux.

#### d. GFP-Atg8/LC3 fluorescence microscopy

LC3B, or the protein tagged at its N terminus with a fluorescent protein such as GFP (GFP-LC3), has been used to monitor autophagy through indirect immunofluorescence or direct fluorescence microscopy (Fig. 10), measured as an increase in punctate LC3 or GFP-LC3.<sup>269,270</sup> The detection of GFP-LC3/Atg8 is also useful for in vivo studies using transgenic organisms such as *Caenorhabditis elegans*,<sup>271</sup> *Dictyostelium discoideum*,<sup>272</sup> filamentous ascomycetes,<sup>273-277</sup> *Ciona intestinalis*,<sup>278</sup> *Drosophila melanogaster*,<sup>279-281</sup> *Arabidopsis thaliana*,<sup>282</sup> *Zea mays*,<sup>283</sup> *Trypanosoma brucei*,<sup>221,284,285</sup> *Leishmania major*<sup>286-288</sup> and mice.<sup>153</sup> It is also possible to use anti-LC3/Atg8 antibodies

for immunocytochemistry or immunohistochemistry (IHC),<sup>197,289-294</sup> procedures that have the advantages of detecting the endogenous protein, obviating the need for transfection and/or the generation of a transgenic organism, as well as avoiding potential artifacts resulting from overexpression. For example, high levels of overexpressed GFP-LC3 can result in its nuclear localization, although the protein can still relocate to the cytosol upon starvation. The use of imaging cytometry allows rapid and quantitative measures of the number of LC3 puncta and their relative number in individual or mixed cell types, using computerized assessment, enumeration, and data display (e.g., see refs. 44, 295). In this respect, the alternative use of an automated counting system may be helpful for obtaining an objective number of puncta per cell. For this purpose, the WatershedCounting3D plug-in for ImageJ may be useful.<sup>296,297</sup> Changes in the number of GFP-Atg8 puncta can also be monitored using flow cytometry (see *Autophagic flux determination using flow and multispectral imaging cytometry*).<sup>221</sup>

Monitoring the endogenous Atg8/LC3 protein obviously depends on the ability to detect it in the system of interest, which is not always possible. If the endogenous amount is below the level of detection, the use of an exogenous construct is warranted. In this case, it is important to consider the use of stable transformants versus transient transfections. On the one hand, stable transformants may have reduced background resulting from the lower gene expression, and artifacts resulting from recent exposure to transfection reagents (see below) are eliminated. Furthermore, with stable transformants more cells can be easily analyzed because nearly 100% of the population will express tagged LC3. On the other hand, a disadvantage of stable transfectants is that the integration sites cannot always be predicted, and expression levels may not be optimal. Therefore, it is worth considering the use of stable episomal plasmids that avoid the problem of unsuitable integration.<sup>264</sup> An important advantage of transient transfection is that this approach is better for examining the immediate effects of the transfected protein on autophagy; however, the transient transfection approach restricts the length of time that the analysis can be performed, and consideration must be given to the induction of autophagy resulting from exposure to the transfection reagents (see below). One word of caution is that optimizing the time of transient expression of GFP-LC3 is necessary, as



**Figure 10.** Changes in the detection and localization of GFP-LC3 upon the induction of autophagy. U87 cells stably expressing GFP-LC3 were treated with PBS, rapamycin (200 nM), or rapamycin in combination with 3-MA (2 mM) for 24 h. Representative fluorescence images of cells counterstained with DAPI (nuclei) are shown. Scale bar: 10  $\mu$ m. This figure was modified from Figure 6 published in ref. 270, Badr et al. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. *Neuro-Oncology*, 13:1213–24, 2011, by permission of Oxford University Press.

some cell types (e.g., HeLa cells) may require 1 day for achieving optimal expression to visualize GFP-LC3 puncta, whereas neuronal cell lines such as SH-SY5Y cells typically need at least 48 h of expression prior to performing GFP-LC3 puncta analyses. In addition, a double transfection can be used (e.g., with GFP-LC3 and the protein of interest) to visually tag the cells that express the protein being examined.

A disadvantage of transfecting GFP-LC3 with liposomes is that frequently it leads to an unstable efficiency of transfection, causing a reduction in the number of cells effectively expressing GFP-LC3, and degradation of the plasmid, thus decreasing the numbers of GFP-LC3 puncta. Stable cell lines expressing GFP-LC3 can be generated using lentiviral systems and efficiently selected through antibiotic resistance leading to uniform and prolonged expression levels. These stable cell lines are sensitive to autophagy inducers as measured by the LC3-II/LC3-I ratio by western blot, and also show increased numbers of cytoplasmic GFP-LC3 puncta upon autophagic stimuli (R. Muñoz-Moreno, R. I. Galindo, L. Barrado-Gil and C. Alonso, unpublished results).

In conclusion, there is no simple rule for the use of stable versus transient transfections. When stable transfections are utilized through a nonlentiviral system, it is worthwhile screening for stable clones that give the best signal-to-noise ratio; when transient transfections are used, it is worthwhile optimizing the GFP-LC3 DNA concentration to give the best signal-to-noise ratio. In clones, the uniformity of expression of GFP-LC3 facilitates “thresholding” when scoring puncta-positive cells (see below). However, there is also a need to be aware that a single cell clone may not be representative of the overall pool. Using a pool of multiple selected clones may reduce artifacts that can arise from the selection and propagation of individual clones from a single transfected cell (although the use of a pool is also problematic as its composition will change over time). Another possibility is using fluorescence-activated cell sorter (FACS) sorting to select a mixed stable population with uniform GFP-LC3 expression levels.<sup>298</sup> Optimization, together with including the appropriate controls (e.g., transfecting GFP-LC3<sup>G120A</sup> as a negative control), will help overcome the effects of the inherent variability in these analyses. For accurate interpretations, it is also important to assess the level of overexpression of the GFP-LC3 constructs relative to endogenous LC3 by western blot.

An additional use of GFP-LC3 is to monitor colocalization with a target during autophagy-related processes such as organelle degradation or the sequestration of pathogenic microbes.<sup>299-302</sup> Preincubation of cells stably expressing GFP-LC3 with leupeptin can help stabilize the GFP-LC3 signal during fluorescence microscopy, especially under conditions of induced autophagic flux. Leupeptin is an inhibitor of lysosomal cysteine and serine proteases and will therefore inhibit degradation of membrane-conjugated GFP-LC3 that is present within autolysosomes.

**Cautionary notes:** Quantification of autophagy by measuring GFP-LC3 puncta (or LC3 by immunofluorescence) can, depending on the method used, be more tedious than monitoring LC3-II by western blot; however, the former may be more sensitive and quantitative. Ideally, it is preferable to include both assays and to compare the 2 sets of results. In addition, if

GFP-LC3 is being quantified, it is better to determine the number of puncta corresponding to GFP-LC3 on a per cell basis (or per cell area basis) rather than simply the total number (or percentage) of cells displaying puncta. This latter point is critical because, even in nutrient-rich conditions, cells display some basal level of GFP-LC3 puncta. There are, however, practical issues with counting puncta manually and reliably, especially if there are large numbers per cell. Nevertheless, manual scoring may be more accurate than relying on a software program, in which case it is important to ensure that only appropriate puncta are being counted (applicable programs include ImageJ, Imaris, and the open-source software CellProfiler<sup>303</sup>). Moreover, when autophagosome-lysosome fusion is blocked, larger autophagosomes are detected, possibly due to autophagosome-autophagosome fusion, or to an inability to resolve individual autophagosomes when they are present in large numbers. Although it is possible to detect changes in the size of GFP-Atg8/LC3 puncta by fluorescence microscopy, it is not possible to correlate size with autophagy activity without additional assay methods. Size determinations can be problematic by fluorescence microscopy unless careful standardization is carried out,<sup>304</sup> and size estimation on its own without considering puncta number per cell is not recommended as a method for monitoring autophagy; however, it is possible to quantify the fluorescence intensity of GFP-Atg8/LC3 at specific puncta, which does provide a valid measure of protein recruitment.<sup>305</sup>

In addition to autophagosome size, the number of puncta visible to the eye will also be influenced by both the level of expression of GFP-LC3 in a given cell (an issue that can be avoided by analyzing endogenous LC3 by immunofluorescence) and by the exposure time of the microscope, if using widefield microscopy. Another way to account for differential GFP-LC3 expression levels and/or exposure is to normalize the intensity of GFP-LC3 present in the puncta to the total GFP-LC3 intensity in the cell. This can be done either on the population level<sup>306</sup> or individual cell level.<sup>298</sup> In many cell types it may be possible to establish a threshold value for the number of puncta per cell in conditions of “low” and “high” autophagy.<sup>307</sup> This can be tested empirically by exposing cells to autophagy-inducing and -blocking agents. Thus, cell populations showing significantly greater proportions of cells with autophagosome numbers higher than the threshold in perturbation conditions compared to the control cells could provide quantitative evidence of altered autophagy. It is then possible to score the population as the percentage of cells displaying numerous autophagosomes. This approach will only be feasible if the background number of puncta is relatively low. For this method, it is particularly important to count a large number of cells and multiple representative sections of the sample. Typically, it is appropriate to score on the order of 50 or more cells, preferably in at least 3 different trials, depending on the particular system and experiment, but the critical point is that this determination should be based on statistical power analysis. Accordingly, high-content imaging analysis methods enable quantification of GFP-LC3 puncta (or overall fluorescence intensity) in thousands of cells per sample (e.g., see refs. 243, 258, 308). When using automated analysis methods, care must be taken to manually evaluate parameters used to establish background threshold values for different treatment conditions

and cell types, particularly as many systems image at lower magnifications that may be insufficient to resolve individual puncta. Another note of caution is that treatments affecting cell morphology, leading to the “rounding up” of cells, for example, can result in apparent changes in the number of GFP-LC3 puncta per cell. To avoid misinterpretation of results due to such potential artifacts, manual review of cell images is highly recommended. If cells are rounding up due to apoptosis or mitosis, it is easy to automatically remove them from analysis based on nuclear morphology (using DAPI or Hoechst staining) or cell roundness. If levels of autophagy in the rounded up cells are of particular interest, images can be acquired as z-stacks and either analyzed as a z-series or processed to generate maximum projection or extended depth-of-field images and then analyzed.<sup>309</sup>

To allow comparisons by other researchers attempting to repeat these experiments, it is critical that the authors also specify the baseline number of puncta that are used to define “normal” or “low” autophagy. Furthermore, the cells should be counted using unbiased procedures (e.g., using a random start point followed by inclusion of all cells at regular intervals), and statistical information should be provided for both baseline and altered conditions, as these assays can be highly variable. One possible method to obtain unbiased counting of GFP-LC3 puncta in a large number of cells is to perform multispectral imaging flow cytometry (see *Autophagic flux determination using flow and multispectral imaging cytometry*).<sup>310</sup> Multispectral imaging flow cytometry allows characterization of single cells within a population by assessing a combination of morphology and immunofluorescence patterns, thereby providing statistically meaningful data.<sup>311</sup> This method can also be used for endogenous LC3, and, therefore, is useful for nontransfected primary cells.<sup>312</sup> For adherent cell cultures, one caution for flow cytometry is that the techniques necessary to produce single cell suspensions can cause significant injury to the cells, leading to secondary changes in autophagy. Therefore, staining for plasma membrane permeabilization (e.g., cell death) before versus after isolation is an important control, and allowing a period of recovery between harvesting the culture and staining is also advisable.<sup>313</sup>

An important caveat in the use of GFP-LC3 is that this chimera can associate with aggregates, especially when expressed at high levels in the presence of aggregate-prone proteins, which can lead to a misinterpretation of the results.<sup>314</sup> Of note, GFP-LC3 can associate with ubiquitinated protein aggregates;<sup>315</sup> however, this does not occur if the GFP-LC3 is expressed at low levels (D.C. Rubinsztein, unpublished observations). These aggregates have been described in many systems and are also referred to as aggresome-like induced structures (ALIS),<sup>315-317</sup> dendritic cell ALIS,<sup>318</sup> SQSTM1/p62 bodies/sequestosomes<sup>319</sup> and inclusions. Indeed, many pathogen-associated molecular patterns (PAMPs) described to induce the formation of autophagosomes in fact trigger massive formation of SQSTM1 bodies (L.H. Travassos, unpublished observations). Inhibition of autophagy in vitro and in vivo leads to the accumulation of these aggregates, suggesting a role for autophagy in mediating their clearance.<sup>315,316,320-322</sup> One way to control for background levels of puncta is to determine fluorescence from untagged GFP.

The receptor protein SQSTM1 is required for the formation of ubiquitinated protein aggregates in vitro (see *SQSTM1 and related LC3 binding protein turnover assays*).<sup>319</sup> In this case, the interaction of SQSTM1 with both ubiquitinated proteins and LC3 is thought to mediate delivery of these aggregates to the autophagy system.<sup>323,324</sup> Many cellular stresses can induce the formation of aggregates, including transfection reagents,<sup>315</sup> or foreign DNA (especially if the DNA is not extracted endotoxin free). SQSTM1-positive aggregates are also formed by proteasome inhibition or puromycin treatment and can be found in cells exposed to rapamycin for extended periods where the rates of autophagy are elevated.<sup>325</sup> Calcium phosphate transfection of COS7 cells or lipofectamine transfection of MEFs (R. Pinkas-Kramarski, personal communication), primary neurons (A.R. La Spada, personal communication) or neuronal cells (C.T. Chu, personal communication) transiently increases basal levels of GFP-LC3 puncta and/or the amount of LC3-II. One solution to this artifact is to examine GFP-LC3 puncta in cells stably expressing GFP-LC3; however, as transfection-induced increases in GFP-LC3 puncta and LC3-II are often transient, another approach is to use cells transfected with GFP, with cells subjected to a mock time-matched transfection as the background (negative) control. A lipidation-defective LC3 mutant where glycine 120 is mutated to alanine is targeted to these aggregates independently of autophagy (likely via its interaction with SQSTM1, see above); as a result, this mutant can serve as another specificity control.<sup>315</sup> When carrying out transfections it may be necessary to alter the protocol depending on the level of background fluorescence. For example, changing the medium and waiting 24 to 48 h after the transfection can help to reduce the background level of GFP-LC3 puncta that is due to the transfection reagent (M. I. Colombo, personal communication). Similarly, when using an mCherry-GFP-SQSTM1 double tag (see *Tandem mRFP/mCherry-GFP fluorescence microscopy*) in transient transfections it is best to wait 48 h after transfection to reduce the level of aggregate formation and potential inhibition of autophagy (T. Johansen, personal communication). An additional consideration is that, in addition to transfection, viral infection can activate stress pathways in some cells and possibly induce autophagy, again emphasizing the importance of appropriate controls, such as control viruses expressing GFP.<sup>326</sup>

Ubiquitinated protein aggregate formation and clearance appear to represent a cellular recycling process. Aggregate formation can occur when autophagy is either inhibited or when its capacity for degradation is exceeded by the formation of proteins delivered to the aggregates. In principle, formation of GFP-LC3-positive aggregates represents a component of the autophagy process. However, the formation of GFP-LC3-positive ubiquitinated protein aggregates does not directly reflect either the induction of autophagy (or autophagosome formation) or flux through the system. Indeed, formation of ubiquitinated protein aggregates that are GFP-LC3 positive can occur in autophagy-deficient cells.<sup>315</sup> Therefore, it should be remembered that GFP-LC3 puncta likely represent a mix of ubiquitinated protein aggregates in the cytosol, ubiquitinated protein aggregates within autophagosomes and/or more “conventional” phagophores and autophagosomes bearing other cytoplasmic cargo (this is one example where CLEM could help in resolving

this question<sup>84</sup>). In *Dictyostelium*, inhibition of autophagy leads to huge ubiquitinated protein aggregates containing SQSTM1 and GFP-Atg8, when the latter is co-expressed; the large size of the aggregates makes them easily distinguishable from autophagosomes. Saponin treatment has been used to reduce background fluorescence under conditions where no aggregation of GFP-LC3 is detected in hepatocytes, GFP-LC3 stably-transfected HEK 293<sup>326</sup> and human osteosarcoma cells, and in non-transfected cells;<sup>327</sup> however, because treatment with saponin and other detergents can provoke artifactual GFP-LC3 puncta formation,<sup>328</sup> specificity controls need to be included in such experiments. In general, it is preferable to include additional assays that measure autophagy rather than relying solely on monitoring GFP-LC3. In addition, we recommend that researchers validate their assays by demonstrating the absence or reversal of GFP-LC3 puncta formation in cells treated with pharmacological or RNA interference-based autophagy inhibitors (Table 1). For example, 3-MA is commonly used to inhibit starvation- or rapamycin-induced autophagy,<sup>329</sup> but it has no effect on BECN1-independent forms of autophagy,<sup>83,151</sup> and some data indicate that this compound can also have stimulatory effects on autophagy (see *Autophagy inhibitors and inducers*).<sup>330</sup>

Another general limitation of the GFP-LC3 assay is that it requires a system amenable to the introduction of an exogenous gene. Accordingly, the use of GFP-LC3 in primary nontransgenic cells is more challenging. Here again, controls need to be included to verify that the transfection protocol itself does not artifactually induce GFP-LC3 puncta or cause LC3 aggregation. Furthermore, transfection should be performed with low levels of constructs, and the transfected cells should be followed to determine 1) when sufficient expression for detection is achieved, and 2) that, during the time frame of the assay, basal GFP-LC3 puncta remain appropriately low. In addition, the demonstration of a reduction in the number of induced GFP-LC3 puncta under conditions of autophagy inhibition is helpful. For some primary cells, delivering GFP-LC3 to precursor cells by infection with recombinant lentivirus, retrovirus or adenovirus,<sup>331</sup> and subsequent differentiation into the cell type of interest, is a powerful alternative to transfection of the already differentiated cell type.<sup>74</sup>

To implement the scoring of autophagy via fluorescence microscopy, one option is to measure pixel intensity. Since the expression of GFP-LC3 may not be the same in all cells—as discussed above—it is possible to use specific imaging software to calculate the standard deviation (SD) of pixel intensity within the fluorescence image and divide this by the mean intensity of the pixels within the area of analysis. This will provide a ratio useful for establishing differences in the degree of autophagy between cells. Cells with increased levels of autophagic activity, and hence a greater number of autophagosomes in their cytosol, are associated with a greater variability in pixel intensity (i.e., a high SD). Conversely, in cells where autophagy is not occurring, GFP-LC3 is uniformly distributed throughout the cytosol and a variation in pixel intensity is not observed (i.e., a low SD; M. Campanella, personal communication).

Although LC3-II is primarily membrane-associated, it is not necessarily associated with autophagosomes as is often assumed; the protein is also found on phagophores, the precursors to autophagosomes, as well as on amphisomes and phagosomes (see *Western blotting and ubiquitin-like protein conjugation systems*).<sup>183,332,333</sup> Along these lines, yeast Atg8 can associate with the vacuole membrane independent of lipidation, so that a punctate pattern does not necessarily correspond to autophagic compartments.<sup>334</sup> Thus, the use of additional markers is necessary to specify the identity of an LC3-positive structure; for example, ATG12-ATG5-ATG16L1 would be present on a phagophore, but not an autophagosome, and thus colocalization of LC3 with any of these proteins would indicate the former structure. In addition, the site(s) of LC3 conjugation to PE is not definitively known, and levels of Atg8-PE/LC3-II can increase even in autophagy mutants that cannot form autophagosomes.<sup>335</sup> One method that can be used to examine LC3-II membrane association is differential extraction in Triton X-114, which can be used with mammalian cells,<sup>331</sup> or western blot analysis of total membrane fractions following solubilization with Triton X-100, which is helpful in plants.<sup>214,215</sup> Importantly, we stress again that numbers of GFP-LC3 puncta, similar to steady state LC3-II levels, reflect only a snapshot of the numbers of autophagy-related structures (e.g., autophagosomes) in a cell at one time, not autophagic flux.

Finally, we offer a general note of caution with regard to using GFP. First, the GFP tag is large, in particular relative to the size of LC3; therefore, it is possible that a chimera may behave differently from the native protein in some respects. Second, GFP is not native to most systems, and as such it may be recognized as an aberrant protein and targeted for degradation, which has obvious implications when studying autophagy. Third, some forms of GFP tend to oligomerize, which may interfere with protein function and/or localization. Fourth, EGFP inhibits polyubiquitination<sup>336</sup> and may cause defects in other cellular processes. Fifth, not all LC3 puncta represent LC3-II and correspond to autophagosomes.<sup>190,191,337,338</sup> Accordingly it would be prudent to complement any assays that rely on GFP fusions (to Atg8/LC3 or any protein) with additional methods that avoid the use of this fluorophore. Similarly, with the emergence of “super-resolution” microscopy methods such as photoactivated localization microscopy (PALM), new tags are being used (e.g., the EosFP green to red photoconvertible fluorescent protein, or the Dronpa GFP-like protein) that will need to be tested and validated.<sup>339</sup>

**Conclusion:** GFP-LC3 provides a marker that is relatively easy to use for monitoring autophagy induction (based on the appearance of puncta), or colocalization with cargo; however, monitoring this chimera does not determine flux unless utilized in conjunction with inhibitors of lysosomal fusion and/or degradation. In addition, it is recommended that results obtained by GFP-LC3 fluorescence microscopy be verified by additional assays.

#### e. Tandem mRFP/mCherry-GFP fluorescence microscopy


A fluorescence assay that is designed to monitor flux relies on the use of a tandem monomeric RFP-GFP-tagged LC3 (tfLC3; Fig. 11).<sup>264</sup> The GFP signal is sensitive to the acidic and/or proteolytic conditions of the lysosome lumen,

**Table 1.** Genetic and pharmacological regulation of autophagy.<sup>1</sup>

Method	Comments
1. 3-methyladenine	A PtdIns3K inhibitor that effectively blocks an early stage of autophagy by inhibiting the class III PtdIns3K, but not a specific autophagy inhibitor. 3-MA also inhibits the class I PI3K and can thus, at suboptimal concentrations in long-term experiments, promote autophagy in some systems, as well as affect cell survival through AKT and other kinases. 3-MA does not inhibit BECN1-independent autophagy.
2. 10-NCP	10-(4'-N-diethylamino)butyl)-2-chlorophenoxazine; an AKT inhibitor that induces autophagy in neurons. <sup>1200</sup>
3. 17-AAG	An inhibitor of the HSP90-CDC37 chaperone complex; induces autophagy in certain systems (e.g., neurons), but impairs starvation-induced autophagy and mitophagy in others by promoting the turnover of ULK1. <sup>458</sup>
4. Akti-1/2	An allosteric inhibitor of AKT1 and AKT2 that promotes autophagy in B-cell lymphoma. <sup>1495</sup>
5. AR7	AR7 was developed as a highly potent and selective enhancer of CMA through antagonizing RARA/RAR $\alpha$ ; AR7 is the first small molecule developed to selectively stimulate CMA without affecting macroautophagy. <sup>1496</sup>
6. ARN5187	Lysosomotropic compound with a dual inhibitory activity against the circadian regulator NR1D2/REV-ERB $\beta$ and autophagy. <sup>1497</sup>
7. ATG4 <sup>C74A</sup>	An active site mutant of ATG4 that is defective for autophagy. <sup>1498</sup>
8. Bafilomycin A <sub>1</sub>	A V-ATPase inhibitor that causes an increase in lysosomal/vacuolar pH, and, ultimately, blocks fusion of autophagosomes with the vacuole; the latter may result from inhibition of ATP2A/SERCA. <sup>226</sup>
9. Betulinic acid	A pentacyclic triterpenoid that promotes parallel damage in mitochondrial and lysosomal compartments, and, ultimately, jeopardizes lysosomal degradative capacity. <sup>235</sup>
10. Calcium	An autophagy activator that can be released from ER or lysosomal stores under stress conditions; however, calcium can also inhibit autophagy. <sup>216,1245</sup>
11. Chloroquine, NH <sub>4</sub> Cl	Lysosomotropic compounds that elevate/neutralize the lysosomal/vacuolar pH. <sup>163</sup>
12. DFMO	$\alpha$ -difluoromethylornithine, an irreversible inhibitor of ODC1 (ornithine decarboxylase 1) that blocks spermidine synthesis and ATG gene expression. <sup>1499</sup>
13. E-64d	A membrane-permeable cysteine protease inhibitor that can block the activity of a subset of lysosomal hydrolases; should be used in combination with pepstatin A to inhibit lysosomal protein degradation.
14. ESC8	A cationic estradiol derivative that induces autophagy and apoptosis simultaneously by downregulating the MTOR kinase pathway in breast cancer cells.
15. Everolimus	An inhibitor of MTORC1 that induces both autophagy and apoptosis in B-cell lymphoma primary cultures. <sup>1495</sup>
16. Fumonisin B1	An inhibitor of ceramide synthesis that interferes with macroautophagy.
17. Gene deletion	This method provides the most direct evidence for the role of an autophagic component; however, more than one gene involved in autophagy should be targeted to avoid indirect effects.
18. HMOX1 induction	Mitophagy and the formation of iron-containing cytoplasmic inclusions and corpora amylacea are accelerated in HMOX1-transfected rat astroglia and astrocytes of GFAP-HMOX1 transgenic mice. Heme derived ferrous iron and carbon monoxide, products of the HMOX1 reaction, promote macroautophagy in these cells. <sup>1500-1502</sup>
19. Knockdown	This method (including miRNA, RNAi, shRNA and siRNA) can be used to inhibit gene expression and provides relatively direct evidence for the role of an autophagic component. However, the efficiency of knockdown varies, as does the stability of the targeted protein. In addition, more than one gene involved in autophagy should be targeted to avoid misinterpreting indirect effects.
20. KU-0063794	An MTOR inhibitor that binds the catalytic site and activates autophagy. <sup>341,1503</sup>
21. Leupeptin	An inhibitor of cysteine, serine and threonine proteases that can be used in combination with pepstatin A and/or E-64d to block lysosomal protein degradation. Leupeptin is not membrane permeable, so its effect on cathepsins may depend on endocytic activity.
22. microRNA	Can be used to reduce the levels of target mRNA(s) or block translation.
23. MLN4924	A small molecule inhibitor of NAE (NEDD8 activating enzyme); <sup>1504</sup> induces autophagy by blockage of MTOR signals via DEPTOR and the HIF1A-DDIT4/REDD1-TSC1/2 axis as a result of inactivation of CUL/cullin-RING ligases. <sup>1505-1507</sup>
24. NAADP-AM	Activates the lysosomal TPCN/two-pore channel and induces autophagy. <sup>1225</sup>
25. NED-19	Inhibits the lysosomal TPCN and NAADP-induced autophagy. <sup>1225</sup>
26. NVP-BEZ235	A dual inhibitor of PIK3CA/p110 and the MTOR catalytic site that activates autophagy. <sup>1508,1509</sup>
27. Pathogen-derived	Virally-encoded autophagy inhibitors including HSV-1 ICP34.5, Kaposi sarcoma-associated herpesvirus vBCL2, $\gamma$ -herpesvirus 68 M11, ASFV vBCL2, HIV-1 Nef and influenza A virus M2. <sup>566,892,896,897,902</sup>
28. Pepstatin A	An aspartyl protease inhibitor that can be used to partially block lysosomal degradation; should be used in combination with other inhibitors such as E-64d. Pepstatin A is not membrane permeable.
29. Protease inhibitors	These chemicals inhibit the degradation of autophagic substrates within the lysosome/vacuole lumen. A combination of inhibitors (e.g., leupeptin, pepstatin A and E-64d) is needed for complete blockage of degradation.
30. PMI	p62 (SQSTM1)-mediated mitophagy inducer is a pharmacological activator of autophagic selection of mitochondria that operates without collapsing the mitochondrial membrane potential ( $\Delta\Psi_m$ ) and hence by exploiting the autophagic component of the process. <sup>713</sup>
31. Rapamycin	Binds to FKBP1A/FKBP12 and inhibits MTORC1; the complex binds to the FRB domain of MTOR and limits its interaction with RPTOR, thus inducing autophagy, but only providing partial MTORC1 inhibition. Rapamycin also inhibits yeast TOR.
32. Resveratrol	A natural polyphenol that affects many proteins <sup>1510</sup> and induces autophagy via activation of AMPK. <sup>1511,1512</sup>
33. RNAi	Can be used to inhibit gene expression.
34. RSVAs	Synthetic small-molecule analogs of resveratrol that potently activate AMPK and induce autophagy. <sup>1513</sup>
35. Saikosaponin-d	A natural small-molecule inhibitor of ATP2A/SERCA that induces autophagy and autophagy-dependent cell death in apoptosis-resistant cells. <sup>1514</sup>
36. Tat-Beclin 1	A cell penetrating peptide that potently induces macroautophagy. <sup>1080,1226</sup>
37. Thapsigargin	An inhibitor of ATP2A/SERCA that inhibits autophagic sequestration through the depletion of intracellular Ca <sup>2+</sup> stores; <sup>216,1515</sup> however, thapsigargin may also block fusion of autophagosomes with endosomes by interfering with recruitment of RAB7, resulting in autophagosome accumulation. <sup>1516</sup>
38. TMS	Trans-3,5,4-trimethoxystilbene upregulates the expression of TRPC4, resulting in MTOR inhibition. <sup>1517</sup>
39. Torin1	A catalytic MTOR inhibitor that induces autophagy and provides more complete inhibition than rapamycin (it inhibits all forms of MTOR). <sup>1193</sup>
40. Trehalose	An inducer of autophagy that may be relevant for the treatment of different neurodegenerative diseases. <sup>1241,1518,1519</sup>
41. Tunicamycin	A glycosylation inhibitor that induces autophagy due to ER stress. <sup>1520</sup>
42. Vacuolin-1	A RAB5A activator that reversibly blocks autophagosome-lysosome fusion. <sup>1521</sup>
43. Vinblastine	A depolymerizer of both normal and acetylated microtubules that interferes with autophagosome-lysosome fusion. <sup>227</sup>
44. Wortmannin	An inhibitor of PI3K and PtdIns3K that blocks autophagy, but not a specific inhibitor (see 3-MA above).

<sup>1</sup>This table is not meant to be complete, as there are many compounds and genetic methods that regulate autophagy, and new ones are being discovered routinely.





**Figure 11.** The GFP and mRFP signals of tandem fluorescent LC3 (tfLC3, mRFP-GFP-LC3) show different localization patterns. HeLa cells were cotransfected with plasmids expressing either tfLC3 or LAMP1-CFP. Twenty-four h after transfection, the cells were starved in Hanks balanced salt solution for 2 h, fixed and analyzed by microscopy. The lower panels are a higher magnification of the upper panels. Bar: 10  $\mu\text{m}$  in the upper panels and 2  $\mu\text{m}$  in the lower panels. Arrows in the lower panels point to (or mark the location of) typical examples of colocalized signals of mRFP and LAMP1. Arrowheads point to (or mark the location of) typical examples of colocalized particles of GFP and mRFP signals. This figure was previously published in ref. 264, and is reproduced by permission of Landes Bioscience, copyright 2007.

whereas mRFP is more stable. Therefore, colocalization of both GFP and mRFP fluorescence indicates a compartment that has not fused with a lysosome, such as the phagophore or an autophagosome. In contrast, a mRFP signal without

GFP corresponds to an amphisome or autolysosome. Other fluorophores such as mCherry are also suitable instead of mRFP,<sup>319</sup> and an image-recognition algorithm has been developed to quantify flux of the reporter to acidified

compartments.<sup>340-342</sup> One of the major advantages of the tandem mRFP/mCherry-GFP reporter method is that it enables simultaneous estimation of both the induction of autophagy and flux through autophagic compartments without requiring the use of any lysosomal inhibitors. The competence of lysosomal digestion of the substrate requires additional analysis using methods described above. The use of more than one time point allows visualization of increased early autophagosomes followed by increases in late autophagosomes as an additional assurance that flux has been maintained.<sup>343</sup> In addition, this method can be used to monitor autophagy in high-throughput drug screening studies.<sup>341</sup> The quantification of “yellow only” (where the yellow signal results from merging the red and green channels) and “red only” dots in a stable tandem-fluorescent LC3-reporter cell line can be automated by a Cellomics microscope that can be used to assess a huge population of cells (1,000 or more) over a large number of random fields of view.<sup>233,344</sup> Notably, organelle-specific variations of the tandem mRFP/mCherry-GFP reporter system have successfully been used to analyze selective types of autophagy, such as pexophagy<sup>345</sup> and mitophagy<sup>346,347</sup> in mammalian cells.

An alternative dual fluorescence assay involves the Rosella pH biosensor. This assay monitors the uptake of material to the lysosome/vacuole and complements the use of the tandem mRFP/mCherry-GFP reporter. The assay is based upon the genetically encoded dual color-emission biosensor Rosella, a fusion between a relatively pH-stable fast-maturing RFP variant, and a pH-sensitive GFP variant. When targeted to specific cellular compartments or fused to an individual protein, the Rosella biosensor provides information about the identity of the cellular component being delivered to the lysosome/vacuole for degradation. Importantly, the pH-sensitive dual color fluorescence emission provides information about the environment of the biosensor during autophagy of various cellular components. In yeast, Rosella has been successfully used to monitor autophagy of cytosol, mitochondria (mitophagy) and the nucleus (nucleophagy).<sup>348-350</sup> Furthermore, the Rosella biosensor can be used as a reporter under various conditions including nitrogen depletion-dependent induction of autophagy.<sup>348,349</sup> The Rosella biosensor can also be expressed in mammalian cells to follow either nonselective autophagy (cytoplasmic turnover), or mitophagy.<sup>349</sup>

**Cautionary notes:** The use of tandem mRFP/mCherry-GFP-LC3/Atg8 reporters in live imaging experiments can be complicated by the motion of LC3/Atg8 puncta. As a consequence, conventional confocal microscopy may not allow visualization of colocalized mRFP/mCherry-GFP puncta. In this case, GFP colocalized puncta represent newly formed autophagic structures whereas mRFP/mCherry-only puncta are ambiguous. Spinning disk confocal microscopy or rapid acquisition times may be required for imaging tandem mRFP/mCherry-GFP proteins, although these techniques require a brighter fluorescent signal associated with what may be undesirably higher levels of transgene expression. One solution is to use the mTagRFP-mWasabi-LC3 chimera,<sup>351</sup> as mTagRFP is brighter than mRFP1 and mCherry, and mWasabi is brighter than EGFP.<sup>352</sup> Another possibility is to use fixed cells; however, this presents an additional

concern: The use of tandem mRFP/mCherry-GFP relies on the quenching of the GFP signal in the acidic autolysosome; however, fixation solutions are often neutral or weak bases, which will increase the pH of the entire cell. Accordingly, the GFP signal may be restored after fixation (Fig. 12), which would cause an underestimation of the amount of signal that corresponds only to RFP (i.e., in the autolysosome). Thus, the tissue or cell samples must be properly processed to avoid losing the acidic environment of the autolysosomes. In addition, there may be weak fluorescence of EGFP even in an acidic environment (pH between 4 and 5).<sup>263,331</sup> Therefore, it may be desirable to choose a monomeric green fluorescent protein that is more acid sensitive than EGFP for assaying autophagic flux.

Another caution in the interpretation of the tandem fluorescent marker is that colocalization of GFP and mRFP/mCherry might also be seen in the case of impaired proteolytic degradation within autolysosomes or altered lysosomal pH. Finally, expression of tandem mRFP-GFP-LC3 is toxic to some cancer cell lines relative to GFP-LC3 or RFP-LC3 (K.S. Choi, personal communication). The cytotoxicity of DsRed and its variants such as mRFP1 is associated with downregulation of BCL2L1/Bcl-x<sub>L</sub>.<sup>353</sup> In contrast to mRFP-GFP-LC3, overexpression of mTagRFP-mWasabi-LC3 does not appear to be toxic to HeLa cells (J. Lin, personal communication).


The Rosella assay has not been tested in a wide range of mammalian cell types. Accordingly, the sensitivity and the specificity of the assay must be verified independently until this method has been tested more extensively and used more widely.

Finally, it may be desirable to capture the dynamic behavior of autophagy in real time, to generate data revealing the rate of formation and clearance of autophagosomes over time, rather than single data points. For example, by acquiring signals from 2 fluorescent constructs in real time, the rate of change in colocalization signal as a measure of the fusion rate and recycling rate between autophagosomes and lysosomes can be assessed.<sup>354</sup> Importantly, due to the integral dynamic relationship of autophagic flux with the onset of apoptosis and necrosis, it is advantageous to monitor cell death and autophagic flux parameters concomitantly over time, which FRET-based reporter constructs make possible.<sup>355</sup>

In addition, as the metabolic control of autophagy is becoming increasingly clear, highlighting a tight network between the autophagy machinery, energy sensing pathways and the cell's metabolic circuits,<sup>356,357</sup> mitochondrial parameters such as fission and fusion rate as well as the cell's ATP demand should be monitored and correlated with autophagic flux data. This will provide a better understanding of the variability of autophagy and cell death susceptibility.

Tandem fluorescent markers show real-time changes in autophagosome fusion with lysosomes, due to entry into an acidic environment; however, fusion is not definitive evidence of substrate or carrier degradation. Lysosomes may be able to fuse, but be unable to degrade newly delivered cargo, as occurs in some lysosomal storage diseases. Best practice would be to perform an autophagic flux assay in parallel with quantification of tandem fluorescent markers to confirm completion of carrier flux.

**Conclusion:** The use of tandem fluorescent constructs, which display different emission signals depending on the



**Figure 12.** GFP fluorescence in the autolysosome can be recovered upon neutralization of the pH. (A) GFP-LC3 emits green fluorescence in the autolysosomes of post-mortem processed heart sections. Cryosections of 3.8% paraformaldehyde-fixed ventricular myocardium from 3-wk-old GFP-LC3 transgenic mice at the baseline (control) or starved for 24 h (starved) were processed for immunostaining using a standard protocol (buffered at pH 7.4). Most of the GFP-LC3 puncta are positive for LAMP1, suggesting that the autolysosomes had recovered GFP fluorescence. (B) Colocalization between GFP-LC3 direct fluorescence (green) and indirect immunostaining for GFP (red). Sections processed as in (A) were immunostained for GFP using a red fluorescence-tagged secondary antibody, and the colocalization with GFP fluorescence was examined by confocal microscopy. Almost all of the red puncta emit green fluorescence. Image provided by Xuejun Wang.

environment (in particular, GFP fluorescence is sensitive to an acidic pH), provides a convenient way to monitor autophagic flux in many cell types.

#### f. Autophagic flux determination using flow and multispectral imaging cytometry

Whereas fluorescence microscopy, in combination with novel autophagy probes, has permitted single-cell analysis of autophagic flux, automation for allowing medium- to high-throughput analysis has been challenging. A number of methods have been developed that allow the determination of autophagic flux using flow cytometry,<sup>225,311,327,358-361</sup> and commercial kits are now available for monitoring autophagy by flow cytometry. These approaches make it possible to capture data or, in specialized instruments, high-content, multiparametric images of cells in flow (at rates of up to 1,000 cells/sec for imaging, and higher in nonimaging flow cytometers), and are particularly useful for cells that grow in suspension. Optimization of image analysis permits the study of cells with heterogeneous LC3 puncta, thus making it possible to quantify autophagic flux accurately in situations that might perturb normal processes (e.g., microbial infection).<sup>360,362</sup> Since EGFP-LC3 is a substrate for autophagic degradation, total fluorescence intensity of EGFP-LC3 can be used to indicate levels of autophagy in living mammalian cells.<sup>358</sup> When autophagy is induced, the decrease in total cellular fluorescence can be precisely quantified in large numbers of cells to obtain robust data. In another approach, soluble EGFP-LC3-I can be depleted from the cell by a brief saponin extraction so that the total fluorescence of EGFP-LC3 then represents that of EGFP-LC3-II alone (Fig. 13A).<sup>326,327</sup> Since EGFP-LC3 transfection typically results in high relative levels of EGFP-LC3-I, this treatment significantly reduces the background fluorescence due to nonautophagosome-associated reporter protein. By comparing treatments in the presence or absence of lysosomal degradation inhibitors, subtle changes in the flux rate of the GFP-LC3 reporter construct can be detected. If it is not desirable to


treat cells with lysosomal inhibitors to determine rates of autophagic flux, a tandem mRFP/mCherry-EGFP-LC3 (or similar) construct can also be used for autophagic flux measurements in flow cytometry experiments (see *Tandem mRFP/mCherry-GFP fluorescence microscopy*).<sup>359</sup>

These methods, however, require the cells of interest to be transfected with reporter constructs. Since the saponin extraction method can also be combined with intracellular staining for endogenous LC3 protein, subtle changes in autophagic flux can be measured without the need for reporter transfections (Fig. 13B).


**Cautionary notes:** Care must be taken when applying flow cytometry measurements to adherent cells, particularly neurons and other cells with interdigitated processes, as the preparation of single cell suspensions entails significant levels of plasma membrane disruption and injury that can secondarily induce autophagy.

Users of the saponin extraction method should carefully titrate saponin concentrations and times of treatment to ensure specific extraction of LC3-I in their systems. Also, it has been observed in some cell types that saponin treatment can lead to nonautophagic aggregation of LC3,<sup>328</sup> which should be controlled for in these assays (see *GFP-Atg8/LC3 fluorescence microscopy*).

Cell membrane permeabilization with digitonin and extraction of the nonmembrane-bound form of LC3 allows combined staining of membrane-associated LC3-II protein and any markers for detection of autophagy in relation to other cellular events/processes. Based on this approach, a method for monitoring autophagy in different stages of the cell cycle was developed.<sup>363</sup> Thus, the presence of basal or starvation-induced autophagy is detected in G<sub>1</sub>, S, and G<sub>2</sub>/M phases of the cell cycle in MEFs with doxycycline-regulated ATG5 expression. In these experiments cells were gated based on their DNA content and the relative intensity of GFP-LC3-II and LC3-II expression. This approach might also be used for the detection of autophagic flux in different stages of the cell cycle or subG<sub>1</sub> apoptotic



**Figure 13.** Saponin extraction allows quantification of LC3-II fluorescence by FACS. (A) Schematic diagram of the effects of the saponin wash. Due to the reorganization of the EGFP-LC3 reporter protein, induction of autophagosome formation does not change the total levels of fluorescence in EGFP-LC3-transfected cells. However, extraction of EGFP-LC3-I with saponin results in a higher level of fluorescence in cells with proportionally higher levels of EGFP-LC3-II-containing autophagosomes. This figure was previously published in ref. 327. (B) Saponin extraction can also be used to measure flux of endogenous LC3 protein. Human osteosarcoma cells were starved of amino acids and serum by incubation in EBSS, for the indicated times in the presence or absence of a 1 h chloroquine (50  $\mu$ M) treatment. Cells were then washed with PBS containing 0.05% saponin and processed for FACS analysis for endogenous LC3. Image provided by K.E. Eng and G.M. McInerney.



**Figure 14.** Assessing autophagy with multispectral imaging cytometry. (A) Bright Detail Intensity (BDI) measures the foreground intensity of bright puncta (that are 3 pixels or less) within the cell image. For each cell, the local background around the spots is removed before intensity calculation. Thus, autophagic cells with puncta have higher BDI values. (B) Media control (untreated wild type), rapamycin-treated wild-type and *atg5*<sup>-/-</sup> MEFs were gated based on BDI. Representative images of cells with high or low BDI values. Scale bar: 10  $\mu$ m. Images provided by M.L. Albert.

cell population by measuring accumulation of LC3-II in the presence or absence of lysosomal inhibitors.

Although GFP-LC3 can be used as a reporter for flow cytometry, it is more stable (which is not necessarily ideal for flux measurements) than GFP-SQSTM1 or GFP-NBR1 (NBR1 is a selective autophagic substrate with structural similarity to SQSTM1<sup>364</sup>). GFP-SQSTM1 displays the largest magnitude change following the induction of autophagy by amino acid deprivation or rapamycin treatment, and may thus be a better marker for following autophagic flux by this method (confirmed in SH-SY5Y neuronal cell lines stably expressing GFP-SQSTM1; E.M. Valente, personal communication).<sup>365</sup>

**Conclusion:** Medium- to high-throughput analysis of autophagy is possible using flow and multispectral imaging cytometry (Fig. 14). The advantage of this approach is that larger numbers of cells can be analyzed with regard to GFP-LC3 puncta, cell morphology and/or autophagic flux, and concomitant detection of surface markers can be included, potentially providing more robust data than is achieved with other methods. A major disadvantage, however, is that flow cytometry only measures changes in total GFP-LC3 levels, which can be subject to modification by changes in transcription or translation, or by pH, and this approach cannot accurately evaluate localization

(e.g., to autophagosomes) or lipidation (generation of LC3-II) without further permeabilization of the cell.

### g. Immunohistochemistry

Immunodetection of ATG proteins (particularly LC3 and BECN1) has been reported as a prognostic factor in various human carcinomas, including lymphoma,<sup>197,366</sup> breast carcinoma,<sup>367</sup> endometrial adenocarcinoma,<sup>368,369</sup> head and neck squamous cell carcinoma,<sup>370-372</sup> hepatocellular carcinoma,<sup>373,374</sup> gliomas,<sup>375</sup> non-small cell lung carcinomas,<sup>376</sup> pancreatic<sup>377</sup> and colon adenocarcinomas,<sup>378-380</sup> as well as in cutaneous and uveal melanomas.<sup>381,382</sup> Unfortunately, the reported changes often reflect overall diffuse staining intensity rather than appropriately compartmentalized puncta. Therefore, the observation of increased levels of diffuse LC3 staining (which may reflect a decrease in autophagy) should not be used to draw conclusions that autophagy is increased in cancer or other tissue samples. Importantly, this kind of assay should be performed as recommended by the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK).<sup>383</sup> As we identify new drugs for modulating autophagy in clinical applications, this type of information may prove useful in the identification of subgroups of patients for targeted therapy.<sup>384-386</sup>


In mouse and rat tissues, endogenous LC3, ATG4B, and ATG9A have been detected by immunohistochemical analyses using both paraffin sections and cryosections.<sup>293,387-389</sup> When autophagosomes are absent, the localization pattern of LC3 in the cells of various tissues is diffuse and cytosolic. Moreover, intense fibrillary staining of LC3 is detectable along dendrites of intact neurons, whereas granular staining for LC3 appears mainly in the perikarya of neurons in CTSD- or CTSB- and CTSL (cathepsin L)-deficient mouse brains.<sup>293</sup> LC3 puncta are also observed in mice in the peripheral nerves, specifically in Schwann cells after neurodegeneration,<sup>390</sup> and Paneth cells of the small intestine from human Crohn disease patients and mouse models of intestinal inflammation driven by ER-stress exhibit strong LC3 puncta staining.<sup>391,392</sup> In various neurodegenerative states, LC3 puncta may be numerous in neurites, especially within dystrophic swellings and, in many cases, these vacuoles are amphisomes or autolysosomes, reflecting the delayed or inhibited degradation of LC3 despite the presence of abundant hydrolase activity.<sup>57,66</sup> In developing inner ear and retinal tissue in chicken, BECN1 is detected by immunofluorescence; in chick retina AMBRA1 is also detected.<sup>393-395</sup> Finally, in non-mammalian vertebrates, BECN1 was detected during follicular atresia in the ovary of 3 fish species using paraffin sections; a punctate immunostaining for BECN1 is scattered throughout the cytoplasm of the follicular cells when they are in intense phagocytic activity for yolk removal.<sup>396</sup>

**Cautionary notes:** One problem with LC3 IHC is that in some tissues this protein can be localized in structures other than autophagosomes. For example, in murine hepatocytes and cardiomyocytes under starved conditions, endogenous LC3 is detected not only in autophagosomes but also on lipid droplets.<sup>397</sup> In neurons in ATG7-deficient mice, LC3 accumulates in ubiquitin- and SQSTM1-positive aggregates.<sup>398</sup> In neurons in aging or neurodegenerative disease states, LC3 is commonly present in autolysosomes and may be abundant in lipofuscin and other lysosomal residual bodies.<sup>57</sup> Thus, immunodetection of LC3 in cytoplasmic granules is not sufficient to monitor autophagy *in vivo*. To evaluate autophagy by the methods of immunohistochemistry, it is necessary to identify the autophagosomes directly using the ABC technique for TEM observation (see *Transmission electron microscopy*).<sup>77</sup>

**Conclusion:** It has not been clearly demonstrated that IHC of ATG proteins in tissues corresponds to autophagy activity, and this area of research needs to be further explored before we can make specific recommendations.

### 3. SQSTM1 and related LC3 binding protein turnover assays

In addition to LC3, SQSTM1/p62 or other receptors such as NBR1, can also be used as protein markers, at least in certain settings.<sup>26,399</sup> For example, SQSTM1 can be detected as puncta by IHC in cancer cells, similar to LC3.<sup>372</sup> The SQSTM1 protein serves as a link between LC3 and ubiquitinated substrates.<sup>84</sup> SQSTM1 and SQSTM1-bound polyubiquitinated proteins become incorporated into the completed autophagosome and are degraded in autolysosomes, thus serving as an index of autophagic degradation (Fig. 15). Inhibition of autophagy



**Figure 15.** Regulation of the SQSTM1 protein during autophagy. The level of SQSTM1 during starvation. *Atg5<sup>+/+</sup>* and *atg5<sup>-/-</sup>* MEFs were cultured in DMEM without amino acids and serum for the indicated times, and then subjected to immunoblot analysis using anti-SQSTM1 antibody (Progen Biotechnik, GP62). This figure was previously published in ref. 26, and is reproduced by permission of Landes Bioscience, copyright 2007.

correlates with increased levels of SQSTM1 in mammals and *Drosophila*, suggesting that steady state levels of this protein reflect the autophagic status.<sup>61,389,400-404</sup> Similarly, decreased SQSTM1 levels are associated with autophagy activation. The phosphorylation of SQSTM1 at Ser403 appears to regulate its role in the autophagic clearance of ubiquitinated proteins, and anti-phospho-SQSTM1 antibodies can be used to detect the modified form of the protein.<sup>324</sup>

**Cautionary notes:** SQSTM1 changes can be cell type and context specific. In some cell types, there is no change in the overall amount of SQSTM1 despite strong levels of autophagy induction, verified by the tandem mRFP/mCherry-GFP-LC3 reporter as well as ATG7- and lysosome-dependent turnover of cargo proteins (C.T. Chu, personal observation). In other contexts, a robust loss of SQSTM1 does not correlate with increased autophagic flux as assessed by a luciferase-based measure of flux;<sup>245</sup> a decrease of SQSTM1 can even relate to a blockage of autophagy due to cleavage of the protein, together with other autophagy proteins, by caspases or calpains.<sup>405</sup> SQSTM1 may be transcriptionally upregulated under certain conditions,<sup>317,406-409</sup> further complicating the interpretation of results. For example, SQSTM1 upregulation, and at least transient increases in the amount of SQSTM1, is seen in some situations where there is an increase in autophagic flux.<sup>410-412</sup> One such case is seen during retinoic acid-induced differentiation of AML cells where SQSTM1 is upregulated<sup>407</sup> with concomitant increased autophagic flux.<sup>413</sup> Activation of a signaling pathway, e.g., RAF1/Raf-MAP2K/MEK-MAPK/ERK, can also upregulate SQSTM1 transcription.<sup>414</sup> SQSTM1 mRNA is also upregulated following prolonged starvation, which can restore the SQSTM1 protein level to that before starvation.<sup>415,416</sup> In the same way, physical exercise, especially when performed during starvation, increases the SQSTM1 mRNA level in skeletal muscle, and can lead to an incorrect interpretation of autophagic flux if only the protein level is measured.<sup>417,418</sup> Another instance when both mRNA and protein levels of SQSTM1 are elevated even though autophagic flux is not impaired is observed in aneuploid human and murine cells that are generated by introduction of 1 or 2 extra chromosomes.<sup>419,420</sup> Thus, appropriate positive and negative controls are needed prior to the use of SQSTM1 as a flux indicator in a particular cellular

context, and we recommend monitoring the *SQSTM1* mRNA level as part of a complete analysis, or determining the SQSTM1 protein level in the presence of actinomycin D.

Of interest, SQSTM1 hyperexpression at both gene and protein levels can be observed in muscle atrophy induced by cancer, though not by glucocorticoids, suggesting that the stimulus inducing autophagy may also be relevant to the differential regulation of autophagy-related proteins.<sup>421</sup> One solution to problems relating to variations in SQSTM1 expression levels is to use a HaloTag<sup>®</sup>-p62 (SQSTM1) chimera.<sup>422</sup> The chimeric protein can be covalently labeled with HaloTag<sup>®</sup> ligands, and the loss of signal can then be monitored without interference by subsequent changes in protein synthesis. Similarly, a stable cell line expressing EGFP-tagged SQSTM1 under the control of an inducible promoter can be used to assess the rates of SQSTM1 degradation, taking into account the limitations outlined above (see *Autophagic flux determination using flow and multispectral imaging cytometry*).<sup>365</sup> A similar system exists in *Drosophila* in which a GFP-tagged SQSTM1 can be expressed using the *UAS-GAL4* system.<sup>423</sup> It is worth noting that tetracycline can reduce autophagy levels; therefore, the appropriate control of only tetracycline addition has to be included if using an inducible promoter that responds to this drug.<sup>424</sup> Yet another solution is to employ a radioactive pulse-chase assay to measure the rates of SQSTM1 degradation.<sup>425</sup>

SQSTM1 contains a LIR motif as well as a ubiquitin binding domain, and appears to act by linking ubiquitinated substrates with the autophagic machinery. Nonetheless, it would be prudent to keep in mind that SQSTM1 contains domains that interact with several signaling molecules,<sup>426</sup> and SQSTM1 may be part of MTORC1.<sup>427</sup> Thus, it may have additional functions that need to be considered with regard to its role in autophagy. In the context of autophagy as a stress response, the complexity of using SQSTM1 as an autophagy marker protein is underscored by its capacity to modulate the NFE2L2/NRF2 anti-oxidant response pathway through a KEAP1 binding domain.<sup>428,429</sup> In fact, SQSTM1 may, itself, be transcriptionally induced by NFE2L2.<sup>430</sup> Furthermore, it is preferable to examine endogenous SQSTM1 because overexpression of this protein leads to the formation of protein inclusions. In fact, even endogenous SQSTM1 becomes Triton X-100-insoluble in the presence of protein aggregates and when autophagic degradation is inhibited; thus, results with this protein are often context-dependent. Indeed, there is a reciprocal crosstalk between the UPS and autophagy, with SQSTM1 being a key link between them.<sup>431</sup> First, SQSTM1 participates in proteasomal degradation, and its level may also increase when the proteasome is inhibited.<sup>432</sup> Accordingly, the SQSTM1 degradation rate should be analyzed in the presence of an inhibitor such as epoxomicin or lactacystin to determine the contribution from the proteasome (see *Autophagy inhibitors and inducers* for potential problems with MG132).<sup>433</sup> Second, the accumulation of SQSTM1 due to autophagy inhibition can impair UPS function by competitively binding ubiquitinated proteins, preventing their delivery to, and degradation by, the proteasome.<sup>434</sup> Accordingly, it may be advisable to measure the UPS flux by using Ub<sup>G76V</sup>-GFP, a ubiquitin-proteasome activity reporter, when SQSTM1 accumulation is observed. Thus, it is very

important to determine whether autophagy alone or in conjunction with the UPS accounts for substrate degradation induced by a particular biological change. A number of stressors that impair the UPS induce the aggregation/dimerization of SQSTM1, and this can be seen by the detection of a high molecular mass (150 kDa) protein complex by western blot, which is recognized by SQSTM1 antibodies (R. Franco, personal communication).<sup>435,436</sup> Although the accumulation of this protein complex can be related to the accumulation of ubiquitinated SQSTM1-bound proteins, or the dimerization/inactivation of SQSTM1 (R. Franco, personal communication),<sup>437</sup> evaluation of the ratio between SQSTM1 (aggregates/dimers) and SQSTM1 monomers is likely a better measurement of changes in SQSTM1 dynamics linked to autophagy or the UPS.

SQSTM1 is also a substrate for CASP6/caspase 6 and CASP8 (as well as CAPN1/calpain 1), which may confound its use in examining cell death and autophagy.<sup>438</sup> This is one reason why SQSTM1 degradation should also be analyzed in the presence of a pan-caspase inhibitor such as Q-VD-OPh before concluding that autophagy is activated based on a decrease of this protein.<sup>405</sup> Another issue is that some phosphatidylinositol 3-kinase (PtdIns3K) inhibitors such as LY294002, and to a lesser extent wortmannin (but apparently not 3-MA),<sup>329</sup> can inhibit protein synthesis;<sup>439</sup> this might in turn affect the turnover of SQSTM1 and LC3, which could influence conclusions that are drawn from the status of these proteins regarding autophagic flux or ALIS formation. Accordingly, it may be advisable to measure protein synthesis and proteasome activity along with autophagy under inhibitory or activating conditions. With regard to protein synthesis, it is worth noting that this can be monitored through a nonradioactive method.<sup>440</sup>

Western blot analysis of cell lysates prepared using NP40- or Triton X-100-containing lysis buffers in autophagic conditions typically shows a reduction in SQSTM1 levels. However, this does not necessarily indicate that SQSTM1 is degraded, because SQSTM1 aggregates are insoluble in these detergent lysis conditions.<sup>317,441</sup> Moreover, in some instances SQSTM1 levels do not change in the soluble fractions despite autophagic degradation, a finding that might be explained by simultaneous transcriptional induction of the gene encoding SQSTM1, since the soluble fraction accounts only for the diffuse or free form of SQSTM1. Accumulation of SQSTM1 in the Triton X-100-insoluble fraction can be observed when autophagy-mediated degradation is inhibited. Under conditions of higher autophagic flux, accumulation of SQSTM1 in Triton X-100-insoluble fractions may not be observed and SQSTM1 levels may be reduced or maintained. The simplest approach to circumvent many of these problems is using lysis buffer that allows identification of the entire cellular pool of SQSTM1 (e.g., containing 1% SDS); however, additional assessment of both Triton X-100-soluble and -insoluble fractions will provide further information regarding the extent of SQSTM1 oligomerization.<sup>398</sup> Note, when performing a western blot using an SQSTM1 antibody, it is always a good idea to include a positive control in which SQSTM1 accumulates, such as an *atg8a* mutant (e.g., see Fig. S3 in ref. 442).

To conclusively establish SQSTM1 degradation by autophagy, SQSTM1 levels in both Triton X-100-soluble and -insoluble fractions need to be determined upon treatment with autophagy inducers in combination with autophagy inhibitors, such as those that inhibit the autolysosomal degradation steps (e.g., protease inhibitors, chloroquine or bafilomycin A<sub>1</sub>). Additionally, an alteration in the level of SQSTM1 may not be immediately evident with changes observed in autophagic flux upon certain chemical perturbations (S. Sarkar, personal communication). Whereas LC3 changes may be rapid, clearance of autophagy substrates may require a longer time. Therefore, if LC3 changes are assessed at 6 h or 24 h after a drug treatment, SQSTM1 levels can be tested not only at the same time points, but also at later time points (24 h or 48 h) to determine the maximal impact on substrate clearance. An alternative method is immunostaining, with and without autophagy inhibitors, for SQSTM1, which will appear as either a diffuse or punctate pattern. Experiments with autophagy inducers and inhibitors, in combination with western blot and immunostaining analyses, best establish autophagic degradation based on SQSTM1 turnover. A final point, however, is that empirical evidence suggests that the species specificity of antibodies for detecting SQSTM1 must be taken into account. For example, some commercial antibodies recognize both human and mouse SQSTM1, whereas others detect the human, but not the mouse protein.<sup>443</sup> Another issue with detecting SQSTM1 in the context of human diseases is that it can be mutated (e.g., in Paget disease of bone).<sup>444</sup> Thus, care should be taken to ensure that potential mutations are not affecting the epitopes that are recognized by anti-SQSTM1 antibodies when using western blotting to detect this protein.

As an alternative, the SQSTM1:BECN1 protein level ratio can be used as a readout of autophagy.<sup>445</sup> Since both decreased SQSTM1 levels and increased BECN1 levels correlate with enhanced autophagy (as noted in the present article), a decreased SQSTM1:BECN1 protein level ratio (when derived from the same protein extract) may, cautiously, be interpreted as augmented autophagy, keeping in mind that *SQSTM1* gene expression varies significantly under different conditions and may obscure the meaning of a change in the amount of SQSTM1 protein. As a general note, using ratios of the levels of proteins changing in opposite directions, rather than the protein levels themselves, could be beneficial since it overcomes the loading normalization issue. The often-used alternative approach of housekeeping proteins to normalize for loading biases among samples is sometimes problematic as levels of the HKPs change under various physiological, pathological and pharmacological conditions.<sup>446-450</sup>

Finally, a novel protein family of autophagy receptors, named CUET (from Cue5/Tollip), was identified, which in contrast to SQSTM1 and NBR1 has members that are present in all eukaryotes.<sup>451</sup> The CUET proteins also possess a ubiquitin-binding CUE-domain and an Atg8-family interacting motif (AIM)/LIR sequence that interacts with Atg8/LC3. In their absence, cells are more vulnerable to the toxicity resulting from aggregation-prone proteins showing that CUET proteins, and

more generally autophagy, play a critical evolutionarily conserved role in the clearance of cytotoxic protein aggregates.<sup>451</sup> Experiments in yeast have shown that Cue5 and the cytoplasmic proteins that require this autophagy receptor for rapid degradation under starvation conditions could be potentially good marker proteins for measuring autophagic flux.

Special caution must be taken when evaluating SQSTM1 levels in models of protein aggregation. Small protoaggregates often stain positively for SQSTM1 and may be similar in size to autophagic puncta. Similarly, GFP-u/GFP-degron reporters (designed as an unstable variant that undergoes proteasome-dependent degradation) will mark SQSTM1-positive protein inclusions. Last, some types of aggregates and inclusions will release soluble SQSTM1 or GFP-u/GFP-degron under cell lysis or denaturing conditions, which can skew the interpretation of soluble SQSTM1 and/or proteasomal function, accordingly.

**Conclusion:** There is not always a clear correlation between increases in LC3-II and decreases in SQSTM1. Thus, although analysis of SQSTM1 can assist in assessing the impairment of autophagy or autophagic flux, we recommend using SQSTM1 only in combination with other methods detailed in these guidelines to monitor flux. See also the discussion in *Autophagic flux determination using flow and multispectral imaging cytometry*.

#### 4. TOR/MTOR, AMPK and Atg1/ULK1

Atg1/ULK1 are central components in autophagy that likely act at more than one stage of the process. There are multiple ULK isoforms in mammalian cells including ULK1, ULK2, ULK3, ULK4 and STK36.<sup>452</sup> ULK3 is a positive regulator of the Hedgehog signaling pathway,<sup>453</sup> and its overexpression induces both autophagy and senescence.<sup>454</sup> Along these lines, ectopic ULK3 displays a punctate pattern upon starvation-induced autophagy induction.<sup>454</sup> ULK3, ULK4 and STK36, however, lack the domains present on ULK1 and ULK2 that bind ATG13 and RB1CC1/FIP200.<sup>455</sup> Thus, ULK3 may play a role that is restricted to senescence and that is independent of the core autophagy machinery. ULK2 has a higher degree of identity with ULK1 than any of the other homologs, and they may have similar functions that are tissue specific. However, ULK1 may be the predominant isoform involved in autophagy, as knockdown of ULK2 does not affect movement of ATG9.<sup>456</sup> Similarly, pharmacological inhibition of ULK1 and ULK2, with the compound MRT68921, blocks macroautophagy and expression of a drug-resistant ULK1 mutant is sufficient to rescue this block.<sup>457</sup> The stability and activation of ULK1, but not ULK2, is dependent on its interaction with the HSP90-CDC37 chaperone complex. Pharmacological or genetic inhibition of the chaperone complex increases proteasome-mediated turnover of ULK1, impairing its kinase activity and ability to promote both starvation-induced autophagy and mitophagy.<sup>458</sup>

AMP-activated protein kinase (AMPK) is a multimeric serine/threonine protein kinase comprised of PRKAA1/AMPK $\alpha$ 1 or PRKAA2/AMPK $\alpha$ 2 ( $\alpha$ , catalytic), the PRKAB1/AMPK $\beta$ 1 or PRKAB2/AMPK $\beta$ 2 ( $\beta$ , scaffold), and the PRKAG1/AMPK $\gamma$ 1, PRKAG2/AMPK $\gamma$ 2 or PRKAG3/AMPK $\gamma$ 3 ( $\gamma$ , regulatory)



subunits. The enzyme activity of AMPK is dependent on phosphorylation of the PRKAA $\alpha$ -subunit on Thr172,<sup>459,460</sup> and, therefore, can be conveniently monitored by western blotting with a phosphospecific antibody against this site. In some cells, Thr172 is phosphorylated by CAMKK2/CaMKK $\beta$ , whereas in others it is a substrate of the STK11/LKB1 kinase. Regulation of AMPK activity is mediated primarily by Thr172-dephosphorylating protein phosphatases such as PPP1/PP1 (protein phosphatase 1) and PPP2/PP2A (protein phosphatase 2).<sup>461</sup> Thr172 dephosphorylation is modulated by adenine nucleotides that bind competitively to regulatory sites in the PRKAG $\gamma$ -subunit. AMP and ADP inhibit dephosphorylation and promote AMPK activity, whereas Mg<sup>2+</sup>-ATP has the opposite effect.<sup>460</sup> Thus, AMPK acts as a fine-tuned sensor of the overall cellular energy charge that regulates cellular metabolism to maintain energy homeostasis. Overexpression of a dominant negative mutant (R531G) of PRKAG2, the  $\gamma$ -subunit isoform 2 of AMPK that is unable to bind AMP, makes it possible to analyze the relationship between AMP modulation (or alteration of energetic metabolism) and AMPK activity.<sup>462,463</sup> Activation of AMPK is also associated with the phosphorylation of downstream enzymes involved in ATP-consuming processes, such as fatty acid (ACAC [acetyl-CoA carboxylase]) and cholesterol (HMGCR [3-hydroxy-3-methylglutaryl-CoA reductase]) biosynthesis.

The role of AMPK in autophagy is complex and highly dependent on both cell type and metabolic conditions. Furthermore, as noted above, there are 2 isoforms of the catalytic subunit, PRKAA1/AMPK $\alpha$ 1 and PRKAA2/AMPK $\alpha$ 2, and these may have distinct effects with regard to autophagy (C. Koumenis, personal communication). In liver cells, AMPK suppresses autophagy at the level of cargo sequestration, as indicated by the rapid sequestration-inhibitory effects of a variety of AMPK activators, whereas it appears to stimulate autophagy in many other cell types, including fibroblasts, colon carcinoma cells and skeletal muscle.<sup>464-473</sup> Autophagy-promoting effects of AMPK are most evident in cells cultured in a complete medium with serum and amino acids, where cargo sequestration is otherwise largely suppressed.<sup>470</sup> Presumably, AMPK antagonizes the autophagy-inhibitory effect of amino acids (at the level of phagophore assembly) by phosphorylating proteins involved in MTORC1 signaling, such as TSC2<sup>474</sup> and RPTOR<sup>475</sup> as well the MTORC1 target ULK1 (see below).<sup>476-478</sup>

Compound C is an effective and widely used inhibitor of activated (phosphorylated) AMPK.<sup>479,480</sup> However, being a nonspecific inhibitor of oxidative phosphorylation,<sup>481,482</sup> this drug has been observed to *inhibit* autophagy under conditions where AMPK is already inactive or knocked out,<sup>483</sup> and it has even been shown to *stimulate* autophagy by an AMP-independent mechanism.<sup>482,484</sup> Compound C thus cannot be used as a stand-alone indicator of AMPK involvement, but can be used along with shRNA-mediated inhibition of AMPK.

TORC1 is an autophagy-suppressive regulator that integrates growth factor, nutrient and energy signals. In most systems, inhibition of MTOR leads to induction of autophagy, and AMPK activity is generally antagonistic toward MTOR function. MTORC1 mediates the autophagy-inhibitory effect of amino acids, which stimulate the MTOR protein kinase through a RAG GTPase dimer. INS/insulin and growth

factors activate MTORC1 through upstream kinases including AKT/protein kinase B and MAPK1/ERK2-MAPK3/ERK1 when the energy supply is sufficient, whereas energy depletion may induce AMPK-mediated MTORC1 inhibition and autophagy stimulation, for example, during glucose starvation. In contrast, amino acid starvation can strongly induce autophagy even in cells completely lacking AMPK catalytic activity.<sup>485</sup>

AMPK and MTORC1 regulate autophagy through coordinated phosphorylation of ULK1. Under glucose starvation, AMPK promotes autophagy by directly activating ULK1 through phosphorylation, although the exact AMPK-mediated ULK1 phosphorylation site(s) remains unclear (Table 2).<sup>473,476-478</sup> Under conditions of nutrient sufficiency, high MTORC1 activity prevents ULK1 activation by phosphorylating alternate ULK1 residues and disrupting the interaction between ULK1 and AMPK. There are commercially available phospho-specific antibodies that recognize different forms of ULK1. For example, phosphorylation at Ser555, an AMPK site, is indicative of increased autophagy in response to nutrient stress, whereas Ser757 is targeted by MTOR to inhibit autophagy. Even the autophagy-suppressive effects of AMPK could, conceivably, be mediated through ULK1 phosphorylation, for example, at the inhibitory site Ser638.<sup>486</sup> AMPK inhibits MTOR by phosphorylating and activating TSC2.<sup>487</sup> Therefore, AMPK is involved in processes that synergize to activate autophagy, by directly activating ULK1, and indirectly impairing MTOR-dependent inhibition of ULK1. The identification of ULK1 as a direct target of MTORC1 and AMPK represents a significant step toward the definition of new tools to monitor the induction of autophagy. However, further studies directed at identifying physiological substrates of ULK1 will be essential to understand how ULK1 activation results in initiation of the autophagy program. Along these lines, ULK1 phosphorylates AMBRA1,<sup>488</sup> and the MLCK-like protein Sqa,<sup>489</sup> as well as ATG13, ATG9 and RB1CC1/FIP200.<sup>423,490-493</sup> Furthermore, following amino acid starvation or MTOR inhibition, the activated ULK1 phosphorylates BECN1 on Ser14, enhancing the activity of the complexes containing ATG14 and PIK3C3/VPS34. This BECN1 phosphorylation by ULK1 is required for full autophagic induction.<sup>494</sup> In addition, ULK1 binds to, and phosphorylates, RPTOR, leading to inhibition of MTORC1.<sup>495</sup> Furthermore, ULK1 itself appears to be able to mediate inhibitory AMPK phosphorylation to generate a negative feedback loop.<sup>496</sup> Note that caution should be taken to use appropriate inhibitors of phosphatases (e.g., sodium fluoride, and beta-glycerophosphate) in cell lysis buffer before analyzing the phosphorylation of AMPK and ULK1 at serine and threonine sites.

TORC1 activity can be monitored by following the phosphorylation of its substrates, such as EIF4EBP1/4E-BP1/PHAS-I and RPS6KB/p70S6 kinase or the latter's downstream target, RPS6/S6, for which good commercial antibodies are available.<sup>497-499</sup> In mammalian cells, the analysis should focus on the phosphorylation of RPS6KB1/S6K1 at Thr389, and EIF4EBP1 at Thr37 and Thr46, which are directly phosphorylated by MTORC1.<sup>500</sup> The MTORC1-dependent phosphorylation of EIF4EBP1 can be detected as a molecular mass shift by western blot.<sup>499</sup> Examining the phosphorylation status of RPS6KB and EIF4EBP1 may be a


**Table 2.** Phosphorylation targets of AKT, AMPK, GSK3B, MTORC1, PKA and Atg1/ULK1.

Protein and phosphorylation site	Main kinase	Function	Ref
AMBRA1 S52	TORC1	Inhibits AMBRA1-dependent activation of ULK1	501
Atg1	TORC1	Inhibits Atg1 kinase activity	504
Atg1	PKA	Regulation of kinase activity	1522
Atg9	Atg1	Recruitment of Atg protein to the PAS	493
Atg13	TORC1	Interaction with Atg1, assembly of Atg1 kinase complex	504,1523
Atg13	PKA	Regulates localization to the PAS	1524
BECN1 S14	ULK1	Increases the activity of the PtdIns3K	494
BECN1 S90	MAPKAPK2- MAPKAPK3	Stimulates macroautophagy	1525
BECN1 S91, S94 (S93, S96 in human)	AMPK	Required for glucose starvation-induced macroautophagy	1526
BECN1 Y229, Y233	EGFR	Inhibits macroautophagy	523
BECN1 S234, S295	AKT	Suppresses macroautophagy	522
LC3 S12	PKA	Inhibits macroautophagy by reducing recruitment to phagophores	343
MTOR S2448	AKT	Correlates with the activity of MTORC1	1527
MTOR S2481	Autophosphorylation	Necessary for MTORC1 formation and kinase activity	1528
NBR1 T586	GSK3A/B	Modulates protein aggregation	1529
RPS6KB T389	MTORC1 (apparently indirect, through reduction of dephosphorylation)	Necessary for protein activity	1530
RPS6KB S371	GSK3B	Necessary for T389 phosphorylation and the activity of RPS6KB	1531
RPTOR S792	AMPK	Suppresses MTORC1	475
SQSTM1 S403	ULK1 (also TBK1, CSNK, CDK1)	Promotes autophagic degradation of SQSTM1 and its substrates	1532
ULK1 S555	AMPK (direct)	Necessary for ATG13-ULK1 interaction and for autophagy mediated by ULK complex	477
ULK1 S317, S467, S555, S574, S777	AMPK (direct)	Necessary for the kinase activity of ULK1	477,478
ULK1 S757	MTORC1	Prevents ULK1 interaction with AMPK	478
ULK1 S758	MTORC1	Facilitates ULK1 interaction with AMPK	478,512
ULK1 S637	MTORC1, AMPK	Facilitates ULK1 interaction with AMPK	477,512
ULK1 (uncertain site between 278 and 351)	Autophosphorylation	Modulates the conformation of the C-terminal tail and prevents its interaction with ATG13	492,1533

better method for monitoring MTORC1 activity than following the phosphorylation of proteins such as RPS6, because the latter is not a direct substrate of MTORC1 (although RPS6 phosphorylation is a good readout for RPS6KB1/2 activities, which are directly dependent on MTOR), and it can also be phosphorylated by other kinases such as RPS6KA/RSK. Furthermore, the mechanisms that determine the selectivity as well as the sensitivity of MTORC1 for its substrates seem to be dependent on the integrity and configuration of MTORC1. For example, rapamycin strongly reduces RPS6KB1 phosphorylation, whereas its effect on EIF4EBP1 is more variable. In the case of rapamycin treatment, EIF4EBP1 can be phosphorylated by MTORC1 until rapamycin disrupts MTORC1 dimerization and its integrity, whereas RPS6KB1 phosphorylation is quickly reduced when rapamycin simply interacts with MTOR in MTORC1 (see *Autophagy inhibitors and inducers* for information on catalytic MTOR inhibitors such as torin1).<sup>500</sup> Since it is likely that other inhibitors, stress, and stimuli may also affect the integrity of MTORC1, a decrease or increase in the phosphorylation status of one MTORC1 substrate does not necessarily correlate with changes in others, including ULK1. Therefore, reliable anti-phospho-ULK1 antibodies should be used to directly examine the phosphorylation state of ULK1, along with additional experimental approaches to analyze the role of the MTOR complex in regulating autophagy. The MTORC1-mediated phosphorylation of AMBRA1 on Ser52 has also been described as relevant to ULK1 regulation and autophagy induction.<sup>488,501</sup> In line with what is described for ULK1, the anti-phospho-AMBRA1 antibody, which is

commercially available, could be used to indirectly measure MTORC1 activity.<sup>501</sup>

Activation/assembly of the Atg1 complex in yeast (composed of at least Atg1-Atg13-Atg17-Atg31-Atg29) or the ULK1 complex in mammals (ULK1-RB1CC1/FIP200-ATG13-ATG101) is one of the first steps of autophagy induction. Therefore, activation of this complex can be assessed to monitor autophagy induction. In yeast, dephosphorylation of Atg13 is associated with activation/assembly of the core complex that reflects the reduction of TORC1 and PKA activities. Therefore, assessing the phosphorylation levels of this protein by immunoprecipitation or western blotting<sup>502-505</sup> can be used not only to follow the early steps of autophagy but also to monitor the activity of some of the upstream nutrient-sensing kinases. Because this protein is not easily detected when cells are lysed using conventional procedures, a detailed protocol has been described.<sup>506</sup> In addition, the autophosphorylation of Atg1 at Thr226 is required for its kinase activity and for autophagy induction; this can be detected using phospho-specific antibodies, by immunoprecipitation or western blotting (Fig. 16).<sup>507,508</sup> In *Drosophila*, TORC1-dependent phosphorylation of Atg1 and Atg1-dependent phosphorylation of Atg13 can be indirectly determined by monitoring phosphorylation-induced electromobility retardation (gel shift) of protein bands in immunoblot images.<sup>423,509,510</sup> Nutritional starvation suppresses TORC1-mediated Atg1 phosphorylation,<sup>423,509</sup> while stimulating Atg1-mediated Atg13 phosphorylation.<sup>423,509,510</sup> In mammalian cells, the phosphorylation status of ULK1 at the activating sites (Ser317, 777, 467, 555, 637, or Thr574) or dephosphorylation at inactivating sites (Ser637, 757) can be



**Figure 16.** *S. cerevisiae* cells transformed with a plasmid encoding HA-Atg1 were cultured to mid-log phase and shifted to SD-N (minimal medium lacking nitrogen that induces a starvation response). Immunoblotting was done with anti-HA antibody. The upper band corresponds to autophosphorylation of Atg1. This figure was modified from data previously published in ref. 508, and is reproduced by permission of the American Society for Cell Biology, copyright 2011.

determined by western blot using phospho-specific antibodies.<sup>477,478,480,486,511,512</sup> In general, the core complex is stable in mammalian cells, although, as noted above, upstream inhibitors (MTOR) or activators (AMPK) may interact dynamically with it, thereby determining the status of autophagy.

One additional topic that bears on ULK1 concerns the process of LC3-associated phagocytosis (see *Noncanonical use of autophagy-related proteins*). LAP is a type of phagocytosis in macrophages that involves the conjugation of LC3 to single-membrane pathogen-containing phagosomes, a process that promotes phagosome acidification and fusion with lysosomes.<sup>182</sup> Although ULK1 is not required for LAP, in this context it is important to note that UNC-51 (the Atg1 homolog in *C. elegans*) is required for apoptotic cell corpse clearance (a process corresponding to LAP) during embryonic development in worms,<sup>513</sup> whereas this process is mediated by LAP in mammals,<sup>180</sup> and does not require UNC-51 in *C. elegans* Q cell neuroblasts.<sup>514</sup> In human macrophages infected with *Mycobacterium tuberculosis*, MORN2 is recruited at the phagosome membrane containing *M. tuberculosis* to induce the recruitment of LC3, and subsequent maturation into phagolysosomes. In addition, MORN2 drives trafficking of *M. tuberculosis* to a single-membrane compartment. Thus, in certain conditions MORN2 can be used to help to make the distinction between autophagy and LAP.<sup>515</sup>

**Cautionary notes:** A decrease in TORC1 activity is a good measure for autophagy induction; however, TORC1 activity does not necessarily preclude autophagy induction because there are TOR-independent mechanisms that induce autophagy both in mammals and yeast.<sup>516–520</sup> Along these lines, whereas in most systems inhibition of MTOR leads to the induction of autophagy, there are instances in commonly used cancer cell lines in which MTOR appears to be a positive effector.<sup>521</sup> Also, MTOR suppression does not always induce autophagy, such as when BECN1 undergoes inhibitory phosphorylation by the growth factor signaling molecules EGFR and AKT.<sup>522,523</sup> Note that the effect of everolimus in EGFR-transgenic mice is not mainly attributable to autophagy although it suppresses MTOR and induces autophagy in EGFR-driven lung cancer cell lines.<sup>524</sup> In adult skeletal muscle, active MTORC1 phosphorylates ULK1 at Ser757 to inhibit the induction of autophagosome formation. Thus, induction of autophagy requires inhibition of MTORC1 and not of MTORC2.<sup>525,526</sup> There is also evidence that inhibition of MTORC1 is not sufficient to maintain autophagic flux, but requires additional activation of FOXO transcription factors for the upregulation of autophagy gene expression.<sup>468</sup> In addition, MTORC1 is downstream of AKT; however, oxidative stress inhibits MTOR, thus allowing autophagy induction, despite the

concomitant activation of AKT.<sup>150</sup> Also, persistent MTORC1 inhibition can cause downregulation of negative feedback loops on IRS-MTORC2-AKT that results in the reactivation of MTORC2 under conditions of ongoing starvation.<sup>222,415,527</sup>

Along these lines, both TORC1 and autophagy can be active in specific cell subpopulations of yeast colonies.<sup>520</sup> Thus, it is necessary to be cautious in deciding how to monitor the TOR/MTOR pathway, and to verify that the pathway being analyzed displays TOR/MTOR-dependent inhibition.

In addition, the regulation of autophagy by MTOR can be ULK1-independent. During mycobacterial infection of macrophages, MTOR induces the expression of *MIR155* and *MIR31* to sustain the activation of the WNT5A and SHH/sonic hedgehog pathways. Together, these pathways contribute to the expression of lipoxygenases and downregulation of IFNG-induced autophagy.<sup>528</sup> Signaling pathways can be monitored by western blotting, and TaqMan miRNA assays are available to detect these miRNAs.

One problem in monitoring assembly of the ULK1 complex is the low abundance of endogenous ULK1 in many systems, which makes it difficult to detect phospho-ULK1 by western blot analysis. In addition, Atg1/ULK1 is phosphorylated by multiple kinases, and the amount of phosphorylation at different sites can increase or decrease during autophagy induction. Thus, although there is an increase in phosphorylation at the activating sites upon induction, the overall phosphorylation states of ULK1 and ATG13 are decreased under conditions that lead to induction of autophagy; therefore, monitoring changes in phosphorylation by following molecular mass shifts upon SDS-PAGE may not be informative. In addition, such phosphorylation/dephosphorylation events are expected to occur relatively early (1–2 h) in the signaling cascade of autophagy. Therefore, it is necessary to optimize treatment time conditions. Finally, in *Arabidopsis* and possibly other eukaryotes, the ATG1 and ATG13 proteins are targets of autophagy, which means that their levels may drop substantially under conditions that induce autophagic turnover.<sup>256</sup>

At present, the use of Atg1/ULK1 kinase activity as a tool to monitor autophagy is limited because only a few physiological substrates have been identified, and the importance of the Atg1/ULK1-dependent phosphorylation has not always been determined. Nonetheless, Atg1/ULK1 kinase activity appears to increase when autophagy is induced, irrespective of the pathway leading to induction. As additional physiological substrates of Atg1/ULK1 are identified, it will be possible to follow their phosphorylation in vivo as is done with analyses for MTOR. Nonetheless, it must be kept in mind that monitoring changes in the activity of Atg1/ULK1 is not a direct assay for autophagy, although such changes may correlate with autophagy activity. Furthermore, in some cells ULK1 has functions in addition to autophagy, such as in axonal transport and outgrowth, and its activity state may thus reflect its role in these processes.<sup>529–534</sup> Accordingly, other methods as described throughout these guidelines should also be used to follow autophagy directly.

Finally, there is not a complete consensus on the specific residues of ULK1 that are targeted by AMPK or MTOR. Similarly, apparently contradictory data have been published regarding the association of AMPK and MTOR with the ULK1 kinase

complex under different conditions. Therefore, caution should be used in monitoring ULK1 phosphorylation or the status of ULK1 association with AMPK until these issues are resolved.

**Conclusion:** Assays for Atg1/ULK1 can provide detailed insight into the induction of autophagy, but they are not a direct measurement of the process. Similarly, since MTOR substrates such as RPS6KB1 and EIF4EBP1 are not recommended readouts for autophagy, their analysis needs to be combined with other assays that directly monitor autophagy activity.

### 5. Additional autophagy-related protein markers

Although Atg8/LC3 has been the most extensively used protein for monitoring autophagy, other proteins can also be used for this purpose. Here, we discuss some of the more commonly used or better-characterized possibilities.

#### a. Atg9


Atg9 is the only integral membrane Atg protein that is essential for autophagosome formation in all eukaryotes. Mammalian ATG9 displays partial colocalization with GFP-LC3.<sup>535</sup> Perhaps the most unique feature of Atg9, however, is that it localizes to multiple discrete puncta, whereas most Atg proteins are detected primarily in a single punctum or diffusely within the cytosol. Yeast Atg9 may cycle between the phagophore assembly site (PAS) and peripheral reservoirs;<sup>536</sup> the latter correspond to tubulovesicular clusters that are precursors to the phagophore.<sup>537</sup> Anterograde movement to the PAS is dependent on Atg11, Atg23, Atg27 and actin. Retrograde movement requires Atg1-Atg13, Atg2-Atg18 and the PtdIns3K complex I.<sup>538</sup> Mutants such as *atg1Δ* accumulate Atg9 primarily at the PAS, and this phenotype forms the basis of the “transport of Atg9 after knocking out *ATG1*” (TAKA) assay.<sup>106</sup> In brief, this is an epistasis analysis in which a double-mutant strain is constructed (one of the mutations being *atg1Δ*) that expresses Atg9-GFP. If the second mutated gene encodes a protein that is needed for Atg9 anterograde transport, the double mutant will display multiple Atg9-GFP puncta. In contrast, if the protein acts along with or after Atg1, all of the Atg9-GFP will be confined to the PAS. Monitoring the localization of ATG9 has not been used

extensively in higher eukaryotes, but this protein displays the same type of dependence on Atg1/ULK1 and PtdIns3P for cycling as seen in yeast,<sup>535,538</sup> suggesting that it is possible to follow this ATG9 as an indication of ULK1 and ATG13 function.<sup>492</sup>

#### b. Atg12-Atg5

ATG5, ATG12 and ATG16L1 associate with the phagophore and have been detected by fluorescence or immunofluorescence (Fig. 17).<sup>539,540</sup> The endogenous proteins form puncta that can be followed to monitor autophagy upregulation. Under physiological conditions, these proteins are predominantly diffusely distributed throughout the cytoplasm. Upon induction of autophagy, for example during starvation, there is a marked increase in the proportion of cells with punctate ATG5, ATG12 and ATG16L1. Furthermore, upstream inhibitors of autophagosome formation result in a block in this starvation-induced puncta formation, and this assay is very robust in some mammalian cells. Conversely, downstream inhibition of autophagy at the level of autophagosome elongation, such as with inhibition of LC3/GABARAP expression, results in an accumulation of the phagophore-associated ATG5, ATG12 and ATG16L1 immunofluorescent puncta.<sup>541</sup>

ATG12-ATG5 conjugation has been used in some studies to measure autophagy. In *Arabidopsis* and some mammalian cells it appears that essentially all of the ATG5 and ATG12 proteins exist in the conjugated form and the expression levels do not change, at least during short-term starvation.<sup>214,539,540,542</sup> Therefore, monitoring ATG12-ATG5 conjugation per se may not be a useful method for following the induction of autophagy. It is worth noting, however, that in some cell lines free ATG5 can be detected,<sup>543</sup> suggesting that the amount of free ATG5 may be cell line-dependent; free ATG5 levels also vary in response to stress such as DNA damage.<sup>544</sup> One final parameter that may be considered is that the total amount of the ATG12-ATG5 conjugate may increase following prolonged starvation as has been observed in hepatocytes and both mouse and human fibroblasts (A.M. Cuervo, personal communication; S. Sarkar, personal communication).



**Figure 17.** Confocal microscopy image of HCT116 cells immunostained with antibody specific to human ATG12. Cells were starved for 8 h or treated with chloroquine (50  $\mu$ M) for 3 h. Scale bar: 10  $\mu$ m. Image provided by M. Llanos Valero, M.A. de la Cruz and R. Sanchez-Prieto.

### c. ATG14

Yeast Atg14 is the autophagy-specific subunit of the Vps34 complex I,<sup>545</sup> and a human homolog, named ATG14/ATG14L/BARKOR, has been identified.<sup>546-549</sup> ATG14 localizes primarily to phagophores. The C-terminal fragment of the protein, named the BATS domain, is able to direct GFP and BECN1 to autophagosomes in the context of a chimeric protein.<sup>550</sup> ATG14-GFP or BATS-GFP detected by fluorescence microscopy or TEM can be used as a phagophore marker protein; however, ATG14 is not localized exclusively to phagophores, as it can also be detected on mature autophagosomes as well as the ER.<sup>550,551</sup> Accordingly, detection of ATG14 should be carried out in combination with other phagophore and autophagosome markers. A good antibody that can be used to detect endogenous ATG14 is now available commercially (D.-H. Kim, personal communication).


### d. ATG16L1

ATG16L1 has been used to monitor the movement of plasma membrane as a donor for autophagy, and thus an early step in the process. Indeed, ATG16L1 is located on phagophores, but not on completed autophagosomes.<sup>344,552</sup> ATG16L1 can be detected by immuno-TEM, by immunostaining of Flag epitope-tagged ATG16L1, and/or by the use of GFP-tagged ATG16L1.

### e. Atg18/WIPI family

Yeast Atg18<sup>553,554</sup> and Atg21<sup>335</sup> (or the mammalian WIPI homologs<sup>555</sup>) are required for both macroautophagy (i.e., nonselective sequestration of cytoplasm) and autophagy-related processes (e.g., the Cvt pathway,<sup>556,557</sup> specific organelle degradation,<sup>119</sup> and

autophagic elimination of invasive microbes<sup>122,123,125,126,553,558</sup>). These proteins bind phosphatidylinositol 3-phosphate (PtdIns3P) that is present at the phagophore and autophagosome<sup>559,560</sup> and also PtdIns(3,5)P<sub>2</sub>. Human WIPI1 and WIPI2 function downstream of the class III phosphatidylinositol 3-kinase complex I (PIK3C3/VPS34, BECN1, PIK3R4/VPS15, ATG14) and upstream of both the ATG12 and LC3 ubiquitin-like conjugation systems.<sup>559,561,562</sup> Upon the initiation of the autophagic pathway, WIPI1 and WIPI2 bind PtdIns3P and accumulate at limiting membranes, such as those of the ER, where they participate in the formation of omegasomes and/or autophagosomes. On the basis of quantitative fluorescence microscopy, this specific WIPI protein localization has been used as an assay to monitor autophagy in human cells.<sup>560</sup> Using either endogenous WIPI1 or WIPI2, detected by indirect fluorescence microscopy or EM, or transiently or stably expressed tagged fusions of GFP to WIPI1 or WIPI2, basal autophagy can be detected in cells that display WIPI puncta at autophagosomal membranes. In circumstances of increased autophagic activity, such as nutrient starvation or rapamycin administration, the induction of autophagy is reflected by the elevated number of cells that display WIPI puncta when compared to the control setting. Also, in circumstances of reduced autophagic activity such as wortmannin treatment, the reduced number of WIPI puncta-positive cells reflects the inhibition of autophagy. Basal, induced and inhibited formation of WIPI puncta closely correlates with both the protein level of LC3-II and the formation of GFP-LC3 puncta.<sup>560,562</sup> Accordingly, WIPI puncta can be assessed as an alternative to LC3. Automated imaging and analysis of fluorescent WIPI1 (Fig. 18) or WIPI2 puncta represent an



**Figure 18.** Automated WIPI1 puncta image acquisition and analysis monitors the induction and inhibition of autophagy. Stable U2OS clones expressing GFP-WIPI1 were selected using 0.6  $\mu\text{g/ml}$  G418 and then cultured in 96-well plates. Cells were treated for 3 h with nutrient-rich medium (control), nutrient-free medium (EBSS), or with 233 nM wortmannin. Cells were fixed in 3.7% paraformaldehyde and stained with DAPI (5  $\mu\text{g/ml}$  in PBS). An automated imaging and analysis platform was used to determine the number of both GFP-WIPI1 puncta-positive cells and the number of GFP-WIPI1 puncta per individual cell.<sup>470</sup> Cells without GFP-WIPI1 puncta are highlighted in red (cell detection) and purple (nuclei detection), whereas GFP-WIPI1 puncta-positive cells are highlighted in yellow (GFP-WIPI1 puncta detection), green (cell detection) and blue (nuclei detection). Scale bars: 20  $\mu\text{m}$ . Images provided by S. Pfisterer and T. Proikas-Cezanne.

efficient and reliable opportunity to combine the detection of WIPI proteins with other parameters. It should be noted that there are 2 isoforms of WIPI2 (2B and 2D),<sup>562</sup> and in *C. elegans* WIPI4 (EPG-6) has been identified as the WIPI homolog required for autophagy.<sup>563</sup> Thus, these proteins, along with the currently uncharacterized WDR45B/WIPI3, provide additional possibilities for monitoring phagophore and autophagosome formation.

**Cautionary notes:** With regard to detection of the WIPI proteins, endogenous WIPI1 puncta cannot be detected in many cell types,<sup>559</sup> and the level of transiently expressed GFP-WIPI1 puncta is cell context-dependent;<sup>559,560</sup> however, this approach has been used in human and mouse cell systems<sup>470,560</sup> and mCherry-Atg18 also works well for monitoring autophagy in transgenic *Drosophila*,<sup>135</sup> although one caution with regard to the latter is that GFP-Atg18 expression enhances Atg8 lipidation in the fat body of fed larvae. GFP-WIPI1 and GFP-WIPI2 have been detected on the completed (mature) autophagosome by freeze-fracture analysis,<sup>102</sup> but endogenous WIPI2 has not been detected on mRFP-LC3- or LAMP2-positive autophagosomes or autolysosomes using immunolabeling.<sup>559</sup> Accordingly, it may be possible to follow the formation and subsequent disappearance of WIPI puncta to monitor autophagy induction and flux using specific techniques. As with GFP-LC3, overexpression of WIPI1 or WIPI2 can lead to the formation of aggregates, which are stable in the presence of PtdIns3K inhibitors.

#### f. *BECN1/Vps30/Atg6*

BECN1 (yeast Vps30/Atg6) and PIK3C3/VPS34 are essential partners in the autophagy interactome that signals the onset of autophagy,<sup>545,564,565</sup> and many researchers use this protein as a way to monitor autophagy. BECN1 is inhibited by its binding to the anti-apoptotic protein BCL2.<sup>566</sup> Autophagy is induced by the release of BECN1 from BCL2 by pro-apoptotic BH3 proteins, phosphorylation of BECN1 by DAPK1 (at Thr119, located in the BH3 domain),<sup>567</sup> or phosphorylation of BCL2 by MAPK8/JNK1 (at Thr69, Ser70 and Ser87).<sup>568,569</sup> The relationship between BECN1 and BCL2 is more complex in developing cerebellar neurons, as it appears that the cellular levels of BCL2 are, in turn, post-translationally regulated by an autophagic mechanism linked to a switch from immaturity to maturity.<sup>570,571</sup> It is important to be aware, however, that certain forms of macroautophagy are induced in a BECN1-independent manner and are not blocked by PtdIns3K inhibitors.<sup>83,572</sup> Interestingly, caspase-mediated cleavage of BECN1 inactivates BECN1-induced autophagy and enhances apoptosis in several cell types,<sup>573</sup> emphasizing that the crosstalk between apoptosis and autophagy is complex.

Although a population of BECN1 may localize in proximity to the trans-Golgi network,<sup>574</sup> it is also present at the ER and mitochondria.<sup>566</sup> In keeping with these observations, in cerebellar organotypic cultures BECN1 co-immunoprecipitates with BCL2 that is primarily localized at the mitochondria and ER; and in a mouse model of neurodegeneration, autophagic vacuoles in Purkinje neurons contain partially digested organelles that are immunoreactive for BCL2.<sup>571,575</sup> In addition, BECN1 and PIK3C3/VPS34 can be present in multiple complexes, so caution must be exercised when monitoring localization. On induction of autophagy by various stimuli the

presence of BECN1- and PIK3C3/VPS34-positive macroaggregates can be detected in the region of the Golgi complex by immunofluorescence.<sup>150,576</sup> Thus, BECN1-GFP puncta detected by fluorescence microscopy or TEM may serve as an additional marker for autophagy induction;<sup>577</sup> however, it should be noted that caspase cleavage of BECN1 can be detected in normal culture conditions (S. Luo, personal communication), and cleaved BECN1 is translocated into the nucleus,<sup>578</sup> thus care needs to be taken with these assays under stress conditions in which more pronounced BECN1 cleavage occurs. In addition, as with any GFP chimeras there is a concern that the GFP moiety interferes with correct localization of BECN1. To demonstrate that BECN1 or PtdIns3K macroaggregates are an indirect indication of ongoing autophagy, it is mandatory to show their specific association with the process by including appropriate controls with inhibitors (e.g., 3-MA) or autophagy gene silencing. When a BECN1-independent autophagy pathway is induced, such aggregates are not formed regardless of the fact that the cell expresses BECN1 (e.g., as assessed by western blotting; C. Isidoro, personal communication). As BECN1-associated PtdIns3K activity is crucial in autophagosome formation in BECN1-dependent autophagy, the measurement of PtdIns3K in vitro lipid kinase activity in BECN1 immunoprecipitates can be a useful technique to monitor the functional activity of this complex during autophagy modulation.<sup>522,523,579</sup>

#### g. *DRAM1*

*DRAM1* is a gene induced by activated TP53 in response to different types of cellular stress, including DNA damage.<sup>580,581</sup> *DRAM1* is a small hydrophobic protein with 6 transmembrane domains. It is detected as a subpopulation in the Golgi and cis-Golgi, colocalizing with GOLGB1/giantin and GOLGA2/GM130, and also in early and late endosomes and lysosomes, colocalizing with EEA1 and LAMP2.<sup>581</sup> The elimination of *DRAM1* by siRNA blocks autophagy,<sup>581,582</sup> as effectively as elimination of BECN1, indicating it is an essential component for this process, although its mechanism of action is not known. The time course of autophagy as a consequence of *DRAM1* activation can be monitored by immunoblot by following the disappearance of the VRK1 protein, a direct target of this process.<sup>581</sup> Detection of *DRAM1* RNA is very easy by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) during autophagy;<sup>580,581</sup> however, detection of the *DRAM1* protein is very difficult because of its small size and hydrophobicity, features that complicate the generation of specific antibodies, which in general have very low sensitivity. A commercial *DRAM1* antibody may allow the detection of this protein in rat skeletal muscle (D.W. Russ, personal communication).

#### h. *ZFYVE1/DFCP1*

*ZFYVE1* binds PtdIns3P that localizes to the ER and Golgi. Starvation induces the translocation of *ZFYVE1* to punctate structures on the ER; the ER population of *ZFYVE1* marks the site of omegasome formation.<sup>583</sup> *ZFYVE1* partially colocalizes with WIPI1 upon nutrient starvation<sup>562</sup> and also with WIPI2.<sup>559</sup>

### i. STX17

STX17 is a SNARE protein that is recruited to completely sealed autophagosomes, but not to phagophores.<sup>584,585</sup> As little STX17 is present on autolysosomes, STX17 is enriched on completed autophagosomes among autophagy-related structures. However, STX17 as a competence factor may be recruited just prior to fusion of autophagosomes with lysosomes, and not all autophagosomes are positive for this protein. Moreover, it is also present at the ER and mitochondria.

### j. TECPR1

TECPR1 binds ATG5 through an AFIM (ATG5 [five] interacting motif). TECPR1 competes with ATG16L1 for binding to ATG5, suggesting that there is a transition from the ATG5-ATG16L1 complex that is involved in phagophore expansion to an ATG5-TECPR1 complex that plays a role in autophagosome-lysosome fusion. TECPR1 thus marks lysosomes and autolysosomes.<sup>586</sup>

**Conclusion:** Proteins other than Atg8/LC3 can be monitored to follow autophagy, and these can be important tools to define specific steps of the process. For example, WIPI puncta formation can be used to monitor autophagy, but, similar to Atg8/LC3, should be examined in the presence and absence of lysosomal inhibitors. Analysis of WIPI puncta should be combined with other assays because individual members of the WIPI family might also participate in additional, uncharacterized functions apart from their role in autophagy. At present, we caution against the use of changes in BECN1 localization as a marker of autophagy induction. It is also worth considering the use of different markers depending on the specific autophagic stimuli.

## 6. Sphingolipids

Sphingolipids are ubiquitous membrane lipids that can be produced in a de novo manner from the ER or by cleavage of sphingomyelin by phosphodiesterases (sphingomyelinases). The multiple different metabolites of the sphingolipid pathway, which are distinct by even a single double bond, carbon chain length of the fatty acid, or presence of a phosphate group, can have quite varied cellular functions. Sphingolipids were first recognized for their role in the architecture of membrane bilayers affecting parameters such as bilayer stiffness, neighboring lipid order parameter and microdomain/raft formation. They also act as second messengers in vital cellular signaling pathways and as key determinants of cellular homeostasis in what is called a sphingolipid rheostat.<sup>587</sup> Sphingolipids participate in the formation of different membrane structures and subcellular organelles, such as mitochondria and ER, and are also involved in the fusion and biophysical properties of cell membranes.<sup>588</sup>

Ceramides, positioned at the core of sphingolipid metabolism, play several roles that affect multiple steps of macroautophagy, by inhibition of nutrient transporters,<sup>589</sup> by modulation of BCL2-BECN1 association at the level of AKT signaling,<sup>590</sup> and by regulation of mitophagy.<sup>591</sup> The latter function is regulated by a particular ceramide species, steroyl (C18:0)-ceramide, a sphingolipid generated by CERS1 (ceramide synthase 1). C18-ceramide, in association with LC3-II, targets damaged

mitochondria for autophagic sequestration in response to ceramide stress, leading to tumor suppression.<sup>591-593</sup> The binding of ceramide to LC3-II can be detected using anti-ceramide and anti-LC3 antibodies by immunofluorescence and confocal microscopy, co-immunoprecipitation using anti-LC3 antibody followed by liquid chromatography-tandem mass spectrometry, using appropriate standards (targeted lipidomics), or labeling cells with biotin-sphingosine to generate biotin-ceramide, and immunoprecipitation using avidin-columns followed by western blotting to detect LC3-II. It should be noted that inhibitors of ceramide generation, and mutants of LC3 with altered ceramide binding (F52A or I35A), and/or that are conjugation defective (e.g., G120A), should be used as negative controls.

Other sphingolipids are also involved in autophagy. For example, accumulation of endogenous sphingosine-1-phosphate, a pro-survival downstream metabolite from ceramide triggers ER-stress associated macroautophagy, by activation of AKT.<sup>594</sup> In addition, gangliosides, have been implicated in autolysosome morphogenesis.<sup>595</sup> To analyze the role of gangliosides in autophagy, 2 main technical approaches can be used: co-immunoprecipitation and fluorescence resonance energy transfer. For the first method, lysates from untreated or autophagy-induced cells have to be immunoprecipitated with an anti-LC3 polyclonal antibody (a rabbit IgG isotypic control should be used as a negative control). The obtained immunoprecipitates are subjected to ganglioside extraction, and the extracts run on an HPTLC aluminum-backed silica gel and analyzed for the presence of specific gangliosides by using monoclonal antibodies. Alternatively, the use of FRET by flow cytometry appears to be highly sensitive to small changes in distance between 2 molecules and is thus suitable to study molecular interactions, for example, between ganglioside and LC3. Furthermore, FRET requires ~10 times less biological material than immunoprecipitation.

**Conclusion:** Sphingolipids are bioactive molecules that play key roles in the regulation of autophagy at various stages, including upstream signal transduction pathways to regulate autophagy via transcriptional and/or translational mechanisms, autolysosome morphogenesis, and/or targeting phagophores to mitochondria for degradation via sphingolipid-LC3 association.<sup>204,593,596</sup>


## 7. Transcriptional, translational and posttranslational regulation

The induction of autophagy in certain scenarios is accompanied by an increase in the mRNA levels of certain autophagy genes, such as *ATG7*,<sup>597,598</sup> *ATG8/Lc3*,<sup>599,600</sup> *ATG9*,<sup>601</sup> *Atg12*,<sup>602</sup> and *Atg14*,<sup>603</sup> and an autophagy-dedicated microarray was developed as a high-throughput tool to simultaneously monitor the transcriptional regulation of all genes involved in, and related to, autophagy.<sup>604</sup> The mammalian gene that shows the greatest transcriptional regulation in the liver (in response to starvation and circadian signals) is *Ulk1*, but others also show more limited changes in mRNA levels including *Gabarapl1*, *Bnip3* and, to a minor extent, *Lc3b* (J.D. Lin, personal communication). In several mouse and human cancer cell lines, ER stress and hypoxia increase the transcription of *Lc3/LC3*, *Atg5/ATG5* and *Atg12/ATG12* by a mechanism involving the unfolded protein response (UPR). Similarly, a stimulus-dependent

increase in *LC3B* expression is detected in neural stem cells undergoing autophagy induction.<sup>605</sup> Increased expression of *Atg5* in vivo after optic nerve axotomy in mice<sup>606</sup> and increased expression of *Atg7*, *Becn1* and *Lc3a* during neurogenesis at different embryonic stages in the mouse olfactory bulb are also seen.<sup>607</sup> LC3 and ATG5 are not required for the initiation of autophagy, but mediate phagophore expansion and autophagosome formation. In this regard, the transcriptional induction of *LC3* may be necessary to replenish the LC3 protein that is turned over during extensive ER stress- and hypoxia-induced autophagy.<sup>602,608</sup> In the clinical setting, tissue expression of *ATG5*, *LC3A* and *LC3B* and their respective proteins accompanies elevated autophagy flux in human adipose tissue in obesity.<sup>217,609</sup> Thus, assessing the mRNA levels of *LC3* and other autophagy-related genes by northern blot or qRT-PCR may provide correlative data relating to the induction of autophagy. Downregulation of autophagy-related mRNAs has been observed in human islets under conditions of lipotoxicity<sup>409</sup> that impair autophagic flux.<sup>610</sup> It is not clear if these changes are sufficient to regulate autophagy, however, and therefore these are not direct measurements.

Several transcription factors of the nuclear receptor superfamily modulate gene expression of autophagy genes. For instance, NR1D1/Rev-erba represses *Ulk1*, *Bnip3*, *Atg5*, *Park2/parkin* and *Becn1* gene expression in mouse skeletal muscle by directly binding to regulatory regions in their DNA sequences. Consistently, *nr1d1*<sup>-/-</sup> mice display an increased LC3-II/LC3-I ratio, as well as PARK2 and BNIP3 protein levels, elevated autophagic flux as measured upon different inhibitor (3-MA, NH<sub>4</sub>Cl, bafilomycin A<sub>1</sub> and chloroquine) treatment and autophagosomes detected by EM of skeletal muscle sections.<sup>611</sup> The nuclear receptors PPARA (peroxisome proliferator-activated receptor alpha) and NR1H4/FXR (nuclear receptor subfamily 1, group H, member 4) also regulate hepatic autophagy in mice. Indeed, PPARA and NR1H4 compete for the control of lipophagy in response to fasting and feeding nutritional cues, respectively.<sup>612</sup> NR1H4 may also inhibit autophagy via inhibition of CREB-CRTC2 complex assembly.<sup>613</sup> Consistent with in vitro studies utilizing human cancer cell lines,<sup>614,615</sup> in human adipose tissue explants, E2F1 binds the *LC3B* promoter, in association with increased expression of several autophagy genes and elevated adipose tissue autophagic flux.<sup>217,609</sup> In this instance, classical promoter analysis studies, including chromatin immunoprecipitation and *ATG* promoter-luciferase constructs provide insights on the putative transcriptional regulation of autophagy genes by demonstrating promoter binding in situ, and promoter activity in vitro.<sup>609</sup>

Of note, large changes in *Atg* gene transcription just prior to *Drosophila* salivary gland cell death (that is accompanied by an increase in autophagy) are detected for *Atg2*, *Atg4*, *Atg5* and *Atg7*, whereas there is no significant change in *Atg8a* or *Atg8b* mRNA.<sup>616,617</sup> Autophagy is critical for *Drosophila* midgut cell death, which is accompanied by transcriptional upregulation of all of the *Atg* genes tested, including *Atg8a* (Fig. 19).<sup>281,618</sup> Similarly, in the silkworm (*Bombyx mori*) larval midgut<sup>619</sup> and fat body,<sup>620</sup> the occurrence of autophagy is accompanied by an upregulation of the mRNA levels of several *Atg* genes. Transcriptional upregulation of *Drosophila Atg8a* and *Atg8b* is also observed in the fat body following induction of autophagy at



**Figure 19.** pGFP-Atg8a can be used to monitor autophagy in *Drosophila melanogaster*. The autophagosome marker pGFP-Atg8a, results in expression of Atg8a fused to GFP from the endogenous *Atg8a* promoter.<sup>281</sup> Live imaging of gastric caeca from *Drosophila melanogaster* midgut pGFP-Atg8a puncta (green) and Hoechst 33342 (blue). Midgut from early third instar larvae prior to the onset of cell death (top) and from dying midgut at 2 h after puparium formation (bottom). Bar: 25  $\mu$ m. Image provided by D. Denton and S. Kumar.

the end of larval development,<sup>621</sup> and these genes as well as *Atg2*, *Atg9* and *Atg18* show a more than 10-fold induction during starvation.<sup>622</sup> *Atg5*, *Atg6*, *Atg8a* and *Atg18* are upregulated in the ovary of starved flies,<sup>623</sup> and an increase in *Drosophila Atg8b* is observed in cultured *Drosophila l(2)mbn* cells following starvation (S. Gorski, personal communication). An upregulation of plant ATG8 may be needed during the adaptation to reproductive growth; a T-DNA inserted mutation of rice *ATG8b* blocked the change from vegetative growth to reproductive growth in both homozygous and heterozygous plant lines (M.-Y. Zhang, unpublished results).

Similarly, the upregulation of autophagy-related genes (*Lc3*, *Gabarap1*, *Bnip3*, *Atg4b*, *Atg12l*) has been documented at the transcriptional and translational level in several other species (e.g., *C. elegans*,<sup>624</sup> mouse, rat, human,<sup>625</sup> trout, *Arabidopsis* and maize) under conditions of ER stress,<sup>602</sup> and diverse types of prolonged (several days) catabolic situations including cancer cachexia, diabetes mellitus, uremia and fasting.<sup>215,468,626-628</sup> Along these lines, *ATG9* and *ATG16L1* are transcriptionally upregulated upon influenza virus infection (H. Khalil, personal communication), and in *C. elegans*, the FOXA transcription factor PHA-4 and the TFEB ortholog HLH-30 regulate the expression of several autophagy-related genes (see *Methods*



and challenges of specialized topics/model systems. *C. elegans*).<sup>624,629,1704</sup> Such prolonged induction of the expression of *ATG* genes has been thought to allow the replenishment of critical proteins (e.g., LC3 and GABARAP) that are destroyed during autophagosome fusion with the lysosome.<sup>630</sup> The polyamine spermidine increases life span and induces autophagy in cultured yeast and mammalian cells, as well as in nematodes and flies. In aging yeast, spermidine treatment triggers epigenetic deacetylation of histone H3 through inhibition of histone acetyltransferases, leading to significant upregulation of various autophagy-related transcripts.<sup>631</sup>

In addition to the *ATG* genes, transcriptional upregulation of *VMP1* (a protein that is involved in autophagy regulation and that remains associated with the completed autophagosome) can be detected in mammalian cells subjected to rapamycin treatment or starvation, and in tissues undergoing disease-induced autophagy such as cancer.<sup>632</sup> *VMP1* is an essential autophagy gene that is conserved from *Dictyostelium* to mammals,<sup>322,633</sup> and the *VMP1* protein regulates early steps of the autophagic pathway.<sup>561</sup> *VMP1* is poorly expressed in mammalian cells under nutrient-normal conditions, but is highly upregulated in cells undergoing autophagy, and the expression of *VMP1* induces autophagosome formation. The *GLI3* transcription factor is an effector of *KRAS* that regulates the expression and promoter activity of *VMP1*, using the histone acetyltransferase *EP300/p300* as a co-activator.<sup>634</sup>

A gene regulatory network, named CLEAR (coordinated lysosomal expression and regulation) that controls both lysosome and autophagosome biogenesis was identified using a systems-biology approach.<sup>625,635,636</sup> The basic helix-loop-helix transcription factor *TFEB* acts as a master gene of the CLEAR network and positively regulates the expression of both lysosomal and autophagy genes, thus linking the biogenesis of 2 distinct types of cellular compartments that cooperate in the autophagic pathway. *TFEB* activity is regulated by starvation and is controlled by both *MAPK1/ERK2*- and *MTOR*-mediated phosphorylation at specific serine residues;<sup>625,637,638</sup> thus, it can serve as a new tool for monitoring transcriptional regulation connected with autophagy. *TFEB* is phosphorylated by *MTORC1* on the lysosomal surface, preventing its nuclear translocation. A lysosome-to-nucleus signaling mechanism transcriptionally regulates autophagy and lysosomal biogenesis via *MTOR* and *TFEB*.<sup>638</sup> A very useful readout of endogenous *TFEB* activity is the evaluation of *TFEB* subcellular localization, as activation of *TFEB* correlates with its translocation from the cytoplasm to the nucleus. This shift can be monitored by immunofluorescence using antibodies against *TFEB*. *TFEB* localization may also be studied to monitor *MTOR* activity, as in most cases *TFEB* nuclear localization correlates with inhibition of *MTOR*. However, due to the low expression levels of *TFEB* in most cells and tissues, it may be difficult to visualize the endogenous protein. Thus a *TFEB* nuclear translocation assay was developed in a HeLa cell line stably transfected with *TFEB*-GFP. This fluorescence assay can be used to identify the conditions and factors that promote *TFEB* activation.<sup>638</sup> *TFE3* and *MITF*, 2 other members of the *MiT/TFE* family of transcription factors, in some cases can compensate for *TFEB* and are regulated in a similar manner.<sup>639,640</sup>

Similar to *TFEB*, the erythroid transcription factor *GATA1* and its coregulator *ZFPM1/FOG1* induce the transcription of multiple genes encoding autophagy components. This developmentally regulated transcriptional response is coupled to increases in autophagosome number as well as the percent of cells that contain autophagosomes.<sup>641</sup> *FOXO* transcription factors, especially *FOXO1* and *FOXO3*, also play critical roles in the regulation of autophagy gene expression.<sup>468,603,642</sup> A zinc finger family DNA-binding protein, *ZKSCAN3* is a master transcriptional repressor of autophagy and lysosome biogenesis; starvation and *MTOR* inhibition with *torin1* induce nucleus-to-cytoplasm translocation of *ZKSCAN3*.<sup>643</sup> Finally, *CEBPB/C/EBPβ* is a transcription factor that regulates autophagy in response to the circadian cycle.<sup>644</sup>

Although less work has been done on post-transcriptional regulation, several studies implicate microRNAs in controlling the expression of proteins associated with autophagy.<sup>243,247,248,645-647</sup>

**Cautionary notes:** Most of the *ATG* genes do not show significant changes in mRNA levels when autophagy is induced. Even increases in *LC3* mRNA can be quite modest and are cell type- and organism-dependent.<sup>648</sup> In addition, it is generally better to follow protein levels, which, ultimately, are the significant parameter with regard to the initiation and completion of autophagy. However, *ATG* protein amounts do not always change significantly and the extent of increase is again cell type- and tissue-dependent. Finally, changes in autophagy protein levels are not sufficient evidence of autophagy induction and must be accompanied by additional assays as described herein. Thus, monitoring changes in mRNA levels for either *ATG* genes or autophagy regulators may provide some evidence supporting upregulation of the potential to undergo autophagy, but should be used along with other methods.

Another general caution pertains to the fact that in any cell culture system mixed populations of cells (for example, those undergoing autophagy or not) exist simultaneously. Therefore, only an average level of protein or mRNA expression can be evaluated with most methods. This means that the results regarding specific changes in autophagic cells could be hidden due to the background of the average data. Along these lines, experiments using single-cell real-time PCR to examine gene expression in individual cardiomyocytes with and without signs of autophagy revealed that the transcription of *MTOR* markedly and significantly increases in autophagic cells in intact cultures (spontaneously undergoing autophagy) as well as in cultures treated with proteasome inhibitors to induce autophagy (V. Doshenko, personal communication). Finally, researchers need to realize that mammalian cell lines may have mutations that alter autophagy signaling or execution; this problem can be avoided by using primary cells.

**Conclusion:** Although there are changes in *ATG* gene expression that coincide with, and may be needed for, autophagy, this has not been carefully studied experimentally. Therefore, at the present time we do not recommend the monitoring of *ATG* gene transcription as a general readout for autophagy unless there is clear documentation that the change(s) correlates with autophagy activity.

## 8. Posttranslational modification of ATG proteins

Autophagy is controlled by posttranslational modification (PTM) of ATG proteins such as phosphorylation, ubiquitination, acetylation, oxidation and cleavage, which can be monitored to analyze the status of the process.<sup>343,438,519,523,649-652</sup> The global deacetylation of proteins, which often accompanies autophagy, can be conveniently measured by quantitative immunofluorescence with antibodies specifically recognizing acetylated lysine residues.<sup>653</sup> Indeed, depletion of the nutrient supply causes autophagy in yeast or mammalian cells by reducing the nucleo-cytosolic pool of acetyl-coenzyme A, which provides acetyl groups to acetyltransferases, thus reducing the acetylation level of hundreds of cytoplasmic and nuclear proteins.<sup>654</sup> A global deacetylation of cellular proteins is also observed in response to so-called “caloric restriction mimetics”, that is, a class of pharmacological agents that deplete the nucleo-cytosolic pool of acetyl-coenzyme A, inhibit acetyltransferases (such as EP300) or activate deacetylases (such as SIRT1). All these agents reduce protein acetylation levels in cells as they induce autophagy.<sup>655</sup> One prominent ATG protein that is subjected to pro-autophagic deacetylation is LC3.<sup>656,657</sup>

## 9. Autophagic protein degradation

Protein degradation assays represent a well-established methodology for measuring autophagic flux, and they allow good quantification. The general strategy is first to label cellular proteins by incorporation of a radioactive amino acid (e.g., [<sup>14</sup>C]- or [<sup>3</sup>H]-leucine, [<sup>14</sup>C]-valine or [<sup>35</sup>S]-methionine; although valine may be preferred over leucine due to the strong inhibitory effects of the latter on autophagy), preferably for a period sufficient to achieve labeling of the long-lived proteins that best represent autophagic substrates, and then to follow this with a long cold-chase so that the assay starts well after labeled short-lived proteins are degraded (which occurs predominantly via the proteasome). Next, the time-dependent release of acid-soluble radioactivity from the labeled protein in intact cells or perfused organs is measured.<sup>3,658,659</sup> Note that the inclusion of the appropriate unlabeled amino acid (i.e., valine, leucine or methionine) in the starvation medium at a concentration equivalent to that of other amino acids in the chase medium is necessary; otherwise, the released [<sup>14</sup>C]-amino acid is effectively re-incorporated into cellular proteins, which results in a significant underestimation of protein degradation. A newer method of quantifying autophagic protein degradation is based on L-azidohomoalanine (AHA) labeling.<sup>660</sup> When added to cultured cells, L-azidohomoalanine is incorporated into proteins during active protein synthesis. After a click reaction between an azide and an alkyne, the azide-containing proteins can be detected with an alkyne-tagged fluorescent dye, coupled with flow cytometry. The turnover of specific proteins can also be measured in a pulse-chase regimen using the Tet-ON/OFF or GeneSwitch systems and subsequent western blot analysis.<sup>661-663</sup>

In this type of assay a considerable fraction of the measured degradation will be nonautophagic, and thus it is important to also measure, in parallel, cell samples treated with autophagy-suppressive concentrations of 3-MA or amino acids, or

obtained from mutants missing central ATG components (however, it is important to note that these controls are only appropriate assuming that nonautophagic proteolytic activity remains unchanged, which is unlikely); these values are then subtracted from the total readouts. The complementary approach of using compounds that block other degradative pathways, such as proteasome inhibitors, may cause unexpected results and should be interpreted with caution due to crosstalk among the degradative systems. For example, blocking proteasome function may activate autophagy.<sup>664-667</sup> Thus, when using inhibitors it is critical to know whether the inhibitors being used alter autophagy in the particular cell type and context being examined. In addition, because 3-MA could have some autophagy-independent effects in particular settings it is advisable to verify that the 3-MA-sensitive degradation is also sensitive to general lysosomal inhibitors (such as NH<sub>4</sub>Cl or leupeptin).

The use of stable isotopes, such as <sup>13</sup>C and <sup>15</sup>N, in quantitative mass spectrometry-based proteomics allows the recording of degradation rates of thousands of proteins simultaneously. These assays may be applied to autophagy-related questions enabling researchers to investigate differential effects in global protein or even organelle degradation studies.<sup>668,669</sup> Stable isotope labeling with amino acids in cell culture (SILAC) can also provide comparative information between different treatment conditions, or between a wild type and mutant.

Another assay that could be considered relies on the limited proteolysis of a BHMT (betaine-homocysteine S-methyltransferase) fusion protein. The 44-kDa full-length BHMT protein is cleaved in hepatocyte amphisomes in the presence of leupeptin to generate 32-kDa and 10-kDa fragments.<sup>670-673</sup> Accumulation of these fragments is time dependent and is blocked by treatment with autophagy inhibitors. A modified version of this marker, GST-BHMT, can be expressed in other cell lines where it behaves similar to the wild-type protein.<sup>674</sup> Additional substrates may be considered for similar types of assays. For example, the neomycin phosphotransferase II-GFP (NeoR-GFP) fusion protein is a target of autophagy.<sup>675</sup> Transfection of lymphoblastoid cells with a plasmid encoding NeoR-GFP followed by incubation in the presence of 3-MA leads to an accumulation of the NeoR-GFP protein as measured by flow cytometry.<sup>676</sup>

A similar western blot assay is based on the degradation of a cytosolic protein fused to GFP. This method has been used in yeast and *Dictyostelium* cells using GFP-Pgk1 and GFP-Tkt-1 (phosphoglycerate kinase and transketolase, respectively). In this case the relative amount of free GFP versus the complete fusion protein is the relevant parameter for quantification; although it may not be possible to detect clear changes in the amount of the full-length chimera, especially under conditions of limited flux.<sup>30,37</sup> As described above for the marker GFP-Atg8/LC3, nonsaturating levels of lysosomal inhibitors are also needed in *Dictyostelium* cells to slow down the autophagic degradation, allowing the accumulation and detection of free GFP. It should be noted that this method monitors bulk autophagy since it relies on the passive transit of a cytoplasmic marker to the lysosome. Consequently, it is important to determine that the marker is distributed homogeneously in the cytoplasm.

One of the most useful methods for monitoring autophagy in *Saccharomyces cerevisiae* is the Pho8 $\Delta$ 60 assay. *PHO8* encodes a vacuolar phosphatase, which is synthesized as a zymogen before finally being transported to and activated in the vacuole.<sup>677</sup> A molecular genetic modification that eliminates the first 60 amino acids prevents the mutant (Pho8 $\Delta$ 60) from entering the ER, leaving the zymogen in the cytosol. When autophagy is induced, the mutant zymogen is delivered to the vacuole nonselectively inside autophagosomes along with other cytoplasmic material. The resulting activation of the zymogen can be easily measured by enzymatic assays for phosphatase activity.<sup>261</sup> To minimize background activity, it is preferable to have the gene encoding the cytosolic phosphatase (*PHO13*) additionally deleted (although this is not necessary when assaying certain substrates).

**Cautionary notes:** Measuring the degradation of long-lived proteins requires prior radiolabeling of the cells, and subsequent separation of acid-soluble from acid-insoluble radioactivity. The labeling can be done with relative ease both in cultured cells and in live animals.<sup>3</sup> In cells, it is also possible to measure the release of an unlabeled amino acid by chromatographic methods, thereby obviating the need for prelabeling;<sup>678</sup> however, it is important to keep in mind that amino acid release is also regulated by protein synthesis, which in turn is modulated by many different factors. In either case, one potential problem is that the released amino acid may be further metabolized. For example, branched chain amino acids are good indicators of proteolysis in hepatocytes, but not in muscle cells where they are further oxidized (A.J. Meijer, personal communication). In addition, the amino acid can be reincorporated into protein; for this reason, such experiments can be carried out in the presence of cycloheximide, but this raises additional concerns (see *Turnover of autophagic compartments*). In the case of labeled amino acids, a nonlabeled chase is added where the tracer amino acid is present in excess (being cautious to avoid using an amino acid that inhibits autophagy), or by use of single pass perfused organs or superfused cells.<sup>679,680</sup> The perfused organ system also allows for testing the reversibility of effects on proteolysis and the use of autophagy-specific inhibitors in the same experimental preparation, which are crucial controls for proper assessment.

If the autophagic protein degradation is low (as it will be in cells in replete medium), it may be difficult to measure it reliably above the relatively high background of nonautophagic degradation. It should also be noted that the usual practice of incubating the cells under “degradation conditions,” that is, in a saline buffer, indicates the potential autophagic *capacity* (maximal attainable activity) of the cells rather than the autophagic *activity* that prevails in vivo or under rich culture conditions. Finally, inhibition of a particular degradative pathway is typically accompanied by an increase in a separate pathway as the cell attempts to compensate for the loss of degradative capacity.<sup>229,666</sup> This compensation might interfere with control measurements under conditions that attempt to inhibit macroautophagy; however, as the latter is the major degradative pathway, the contributions of other types of degradation over the course of this type of experiment are most often negligible. Another issue of concern, however, is that most

pharmacological protease inhibitors have “off target” effects that complicate the interpretation of the data.

The Pho8 $\Delta$ 60 assay requires standard positive and negative controls (such as an *atg1* $\Delta$  strain), and care must be taken to ensure the efficiency of cell lysis. Glass beads lysis works well in general, provided that the agitation speed of the instrument is adequate. Instruments designed for liquid mixing with lower speeds should be avoided. We also recommend against holding individual sample tubes on a vortex, as it is difficult to maintain reproducibility; devices or attachments are available to allow multiple tubes to be agitated simultaneously. Finally, it is also important to realize that the deletion of *PHO8* can affect yeast cell physiology, especially depending on the growth conditions, and this may in turn have consequences for the cell wall; cells under starvation stress generate thicker cell walls that can be difficult to degrade enzymatically.


**Conclusion:** Measuring the turnover of long-lived proteins is a standard method for determining autophagic flux. Newer proteomic techniques that compare protein levels in autophagy-deficient animals relative to wild-type animals are promising,<sup>681</sup> but the current ratiometric methods are affected by both protein synthesis and degradation, and thus analyze protein turnover, not just degradation.

## 10. Selective types of autophagy

Although autophagy can be nonselective, in particular during starvation, there are many examples of selective types of autophagy.

### a. The Cvt pathway, mitophagy, pexophagy, piecemeal microautophagy of the nucleus and late nucleophagy in yeast and filamentous fungi

The precursor form of aminopeptidase I (prApe1) is the major cargo of the Cvt pathway in yeast, a biosynthetic autophagy-related pathway.<sup>128</sup> The propeptide of prApe1 is proteolytically cleaved upon vacuolar delivery, and the resulting shift in molecular mass can be monitored by western blot. Under starvation conditions, prApe1 can enter the vacuole through nonselective autophagy, and thus has been used as a marker for both the Cvt pathway and autophagy. The yeast Cvt pathway is unique in that it is a biosynthetic route that utilizes the autophagy-related protein machinery, whereas other types of selective autophagy are degradative. The latter include pexophagy, mitophagy, reticulophagy, ribophagy and xenophagy, and each process has its own marker proteins, although these are typically variations of other assays used to monitor the Cvt pathway or autophagy. One common type of assay involves the processing of a GFP chimera similar to the GFP-Atg8/LC3 processing assay (see *GFP-Atg8/LC3 lysosomal delivery and proteolysis*). For example, yeast pexophagy utilizes the processing of Pex14-GFP and Pot1/Fox3/thiolase-GFP,<sup>682,683</sup> whereas mitophagy can be monitored by the generation of free GFP from Om45-GFP, Idh1-GFP, Idp1-GFP or mito-DHFR-GFP.<sup>684,685-688</sup> Localization of these mitochondrially targeted proteins (or specific MitoTracker dyes) or similar organelle markers such as those for the peroxisome (e.g., GFP-SKL with Ser-Lys-Leu at the C terminus that acts as a peroxisomal targeting signal, acyl-CoA oxidase 3 [Aox3-EYFP] that allows simultaneous



**Figure 20.** *S. cerevisiae* cells were cultured to mid-log phase and shifted to SD-N for the indicated times. Samples were taken before (+) and at the indicated times after (-) nitrogen starvation. Immunoblotting was done with anti-phospho-Slt2 and anti-phospho-Hog1 antibody. This figure was modified from data previously published in ref. 508, and is reproduced by permission of the American Society for Cell Biology, copyright 2011.

observation of peroxisome-vacuole dynamics with the single FITC filter set, or GFP-catalase) can also be followed by fluorescence microscopy.<sup>553,683,689-691</sup> In addition, yeast mitophagy requires both the Slt2 and Hog1 signaling pathways; the activation and phosphorylation of Slt2 and Hog1 can be monitored with commercially available phospho-specific antibodies (Fig. 20).<sup>508</sup> It is also possible to monitor pexophagy in yeasts by the disappearance of activities of specific peroxisome markers such as catalase, alcohol oxidase or amine oxidase in cell-free extracts,<sup>692</sup> or permeabilized cell suspensions. Catalase activity, however, is a useful marker only when peroxisomal catalases are the only such enzymes present or when activities of different catalases can be distinguished. In *S. cerevisiae* there are 2 genes, *CTT1* and *CTA1*, encoding catalase activity, and only one of these gene products, Cta1, is localized in peroxisomes. Activities of both catalases can be distinguished using an in-gel activity assay after PAGE under nondenaturing conditions by staining with diaminobenzidine.<sup>693,694</sup> Plate assays for monitoring the activity of peroxisomal oxidases in yeast colonies are also available.<sup>689,695</sup> The decrease in the level of endogenous proteins such as alcohol oxidase, Pex14 or Pot1 can be followed by western blotting,<sup>553,696-699</sup> TEM,<sup>700</sup> fluorescence microscopy<sup>553,701,702</sup> or laser confocal scanning microscopy of GFP-labeled peroxisomes.<sup>703,704</sup>

Bimolecular fluorescence complementation (BiFC) may be useful to study protein-protein interactions in the autophagic pathway.<sup>705-707</sup> In this assay, a protein of interest is cloned into a vector containing one half of a fluorescent reporter (e.g., YFP), while a second protein is cloned into a different vector containing the other half of the reporter. Constructs are cotransfected into cells. If the 2 proteins of interest interact, the 2 halves of the reporter are brought into close proximity and a fluorescent signal is reconstituted, which can be monitored by confocal microscopy. This assay can be used to determine protein interactions without prior knowledge of the location or structural nature of the interaction interface. Moreover, it is applicable to living cells, and relatively low concentrations of recombinant protein are required to generate a detectable signal.

In yeast, nonselective autophagy can be induced by nitrogen starvation conditions, whereas degradative types of selective autophagy generally require a carbon source change or ER stress for efficient induction. For example, in *S. cerevisiae*, to induce a substantial level of mitophagy, cells need to be precultured in a nonfermentable carbon source such as lactate or glycerol to stimulate the proliferation of mitochondria (although this is not the case in *Pichia pastoris*). After sufficient mitochondria proliferation, shifting the cells back to a fermentable carbon source such as glucose will cause the autophagic degradation of superfluous mitochondria.<sup>685</sup> It should be noted that in addition to carbon source change, simultaneous nitrogen starvation is also required for efficient mitophagy induction. This is possibly because excessive mitochondria can be segregated into daughter cells by cell division if growth continues.<sup>685</sup> A similar carbon source change from oleic acid or methanol to ethanol or glucose (with or without nitrogen starvation) can be used to assay for pexophagy.<sup>708</sup> Mitophagy can also be induced by treatment with ROS, to induce mitochondria damage.<sup>709</sup> In addition, mitophagy can be induced by culturing the cells in a nonfermentable carbon source to post-log phase. In this case, mitophagy may be induced because the energy demand is lower at post-log phase and the mitochondrial mass exceeds the cell's needs.<sup>120,710,711</sup> It has been suggested that this type of mitophagy, also known as “stationary phase mitophagy,” reflects a quality-control function that culls defective mitochondria that accumulate in nondividing, respiring cells.<sup>712</sup> The recently developed tool PMI that pharmacologically induces mitophagy without disrupting mitochondrial respiration<sup>713</sup> should provide further insight as it circumvents the acute, chemically induced, blockade of mitochondrial respiration hitherto adopted to dissect the process. Similarly, pexophagy can be induced by culturing the cells in a peroxisome proliferation medium to post-log phase (J.-C. Farré, unpublished results). Along these lines, it should also be realized that selective types of autophagy continuously occur at a low level under noninducing conditions. Thus, organelles such as peroxisomes have a finite life span and are turned over at a slow rate by autophagy-related pathways.<sup>714</sup>

Piecemeal microautophagy of the nucleus (PMN, also micronucleophagy) is another selective autophagic subtype, which targets portions of the nucleus for degradation.<sup>715-717</sup> In *S. cerevisiae*, the nuclear outer membrane, which is continuous with the nuclear ER, forms contact sites with the vacuolar membrane. These nucleus-vacuole junctions (NVJs) are generated by interaction of the outer nuclear membrane protein Nvj1 with the vacuolar protein Vac8.<sup>718</sup> Nvj1 further recruits the ER-membrane protein Tsc13, which is involved in the synthesis of very-long-chain fatty acids (VLCFAs) and Swl1/Osh1, a member of a family of oxysterol-binding proteins. Upon starvation the NVJs bulge into the vacuole and subsequently a PMN-vesicle pinches off into the vacuole. PMN vesicles thus contain nuclear material and are limited by 3 membranes with the outermost derived from the vacuole, and the 2 inner ones from the nuclear ER. It is not clear which nuclear components are removed by PMN, but since PMN is not a cell death mechanism per se, most likely superfluous material is recycled. During PMN the NVJs are selectively incorporated into the PMN vesicles and degraded. Accordingly,

PMN can be monitored using the proteins that are associated with the NVJs as markers. To quantitatively follow PMN, an assay analogous to the above-described GFP-Atg8/LC3 processing assay has been established using either GFP-Swh1/Osh1 or Nvj1-GFP. These GFP chimeras are, together with the PMN-vesicles, degraded in the vacuole. Thus, the formation of the relatively proteolysis-resistant GFP detected in western blots correlates with the PMN rate. In fluorescence microscopy, PMN can be visualized with the same constructs, and a chimera of mCherry fused to a nuclear localization signal (NLS-mCherry) can also be used. To assure that the measured PMN rate is indeed due to selective micronucleophagy, appropriate controls such as cells lacking Nvj1 or Vac8 should be included. Detailed protocols for the described assays are provided in ref. 719.

Late nucleophagy (LN) is another type of selective degradation of the nucleus, which specifically targets bulk nucleoplasm for degradation after prolonged periods (20–24 h) of nitrogen starvation.<sup>720</sup> LN induction occurs in the absence of the essential PMN proteins Nvj1 and Vac8 and, therefore, the formation of NVJs. Although some components of the core Atg machinery are required for LN, Atg11 and the Vps34-containing PtdIns3K complex I are not needed. LN can be monitored by employing a nuclear-targeted version of the Rosella biosensor (n-Rosella) and following either its accumulation (by confocal microscopy), or degradation (by immunoblotting), within the vacuole.<sup>720</sup> Dual labeling of cells with Nvj1-EYFP, a nuclear membrane reporter of PMN, and the nucleoplasm-targeted NAB35-DsRed.T3 (NAB35 is a target sequence for the Nab2 RNA-binding protein, and DsRed.T3 is the pH-stable, red fluorescent component of n-Rosella) allows detection of PMN soon after the commencement of nitrogen starvation, whereas delivery to the vacuole of the nucleoplasm reporter, indicative of LN, is observed only after prolonged periods of nitrogen starvation. Few cells show simultaneous accumulation of both reporters in the vacuole indicating PMN and LN are temporally and spatially separated.<sup>720</sup>

In contrast to unicellular yeasts, filamentous fungi form an interconnected mycelium of multinucleate hyphae containing up to 100 nuclei in a single hyphal compartment. A mycelial colony grows by tip extension with actively growing hyphae at the colony margin surrounded by an older, inner hyphal network that recycles nutrients to fuel the hyphal tips. By labeling organelle markers with GFP it is possible to show in *Aspergillus oryzae* that macroautophagy mediates degradation of basal hyphal organelles such as peroxisomes, mitochondria and entire nuclei.<sup>721</sup> In contrast to yeast, PMN has not been observed in filamentous ascomycetes.<sup>723</sup> In *Magnaporthe oryzae*, germination of the conidiospore and formation of the appressorium are accompanied by nuclear degeneration in the spore.<sup>275</sup> The degradation of nuclei in spores requires the non-selective autophagy machinery, whereas conserved components of the PMN pathway such as Vac8 and Tsc13 are dispensable for nuclear breakdown during plant infection.<sup>723</sup> Nuclei are proposed to function in storage of growth-limiting nutrients such as phosphate and nitrogen.<sup>724,725</sup> Similar to nuclei, mitochondria and peroxisomes are also preferentially degraded in the basal hyphae of filamentous ascomycetes.<sup>275,721,723-726</sup>

**Cautionary notes:** The Cvt pathway has been demonstrated to occur only in yeast. In addition, the sequestration of prApe1 is specific, even under starvation conditions, as it involves the recognition of the propeptide by a receptor, Atg19, which in turn interacts with the scaffold protein Atg11.<sup>727,728</sup> Thus, unless the propeptide is removed or *ATG19* is deleted, prApe1 is recognized as a selective substrate. Overexpression of prApe1 saturates import by the Cvt pathway, and the precursor form accumulates, but is rapidly matured upon autophagy induction.<sup>305</sup> In addition, mutants such as *vac8Δ* and *tlg2Δ* accumulate prApe1 under rich conditions, but not during autophagy.<sup>505,729</sup> Accordingly, it is possible to monitor the processing of prApe1 when overexpressed, or in certain mutant strains to follow autophagy induction. However, under the latter conditions it must be kept in mind that the sequestering vesicles are substantially smaller than typical autophagosomes generated during nonselective autophagy; the Cvt complex (prApe1 bound to Atg19) is smaller than typical peroxisomes or mitochondrial fragments that are subject to autophagic degradation. Accordingly, particular mutants may display complete maturation of prApe1 under autophagy-inducing conditions, but may still have a defect in other types of selective autophagy, as well as being unable to induce a normal level of nonselective autophagy.<sup>106</sup> For this reason, it is good practice to evaluate autophagosome size and number by TEM. Actually, it is much simpler to monitor autophagic bodies (rather than autophagosomes) in yeast. First, the vacuole is easily identified, making the identification of autophagic bodies much simpler. Second, autophagic bodies can be accumulated within the vacuole, allowing for an increased sample size. It is best to use a strain background that is *pep4Δ vps4Δ* to prevent the breakdown of the autophagic bodies, and to eliminate confounding vesicles from the multivesicular body pathway. One caveat to the detection of autophagic bodies, however, is that they may coalesce in the vacuole lumen, making it difficult to obtain an accurate quantification. Finally, it is important to account for biases in sample sectioning to obtain an accurate estimate of autophagic body number or size.<sup>105</sup>

In general, when working with yeast it is preferable to use strains that have the marker proteins integrated into the chromosome rather than relying on plasmid-based expression, because plasmid numbers can vary from cell to cell. The GFP-Atg8, or similar, processing assay is easy to perform and is suitable for analysis by microscopy as well as western blotting; however, particular care is needed to obtain quantitative data for GFP-Atg8, Pex14-GFP or Om45-GFP, etc. processing assays (see cautionary notes for *GFP-Atg8/LC3 lysosomal delivery and proteolysis*). An alternative is an organelle-targeted Pho8Δ60 assay. For example, mitoPho8Δ60 can be used to quantitatively measure mitophagy.<sup>686</sup> In addition, for the GFP-Atg8 processing assay, 2 h of starvation is generally sufficient to detect a significant level of free (i.e., vacuolar) GFP by western blotting as a measure of nonselective autophagy. For selective types of autophagy, the length of induction needed for a clearly detectable free GFP band will vary depending on the rate of cargo delivery/degradation. Usually 6 h of mitophagy induction is needed to be able to detect free GFP (e.g., from Om45-GFP) by western blot under starvation conditions, whereas stationary phase mitophagy typically requires 3 days before a free GFP

band is observed. However, as with animal systems (see *Animal mitophagy and pexophagy*), it would be prudent to follow more than one GFP-tagged protein, as the kinetics, and even the occurrence of mitophagic trafficking, seems to be protein species-dependent, even within the mitochondrial matrix.<sup>730</sup>

Care should be taken when choosing antibodies to assess the degree of mitochondrial protein removal by autophagy; the quality and clarity of the result may vary depending on the specifics of the antibody. In testing the efficiency of mitophagy clearer results may be obtained by using antibodies against mtDNA-encoded proteins. This experimental precaution may prove critical to uncover subtle differences that could be missed when evaluating the process with antibodies against nuclear encoded, mitochondrially imported proteins (M. Campanella, personal communication).

### b. Aggrephagy

Aggrephagy is the selective removal of aggregates by macroautophagy.<sup>731</sup> This process can be followed in vitro (in cell culture) and in vivo (in mice) by monitoring the levels of an aggregate-prone protein such as an expanded polyglutamine (polyQ)-containing protein or mutant SNCA/ $\alpha$ -synuclein (synuclein, alpha [non A4 component of amyloid precursor]). Levels are quantified by immunofluorescence, immunogold labeling or traditional immunoblot. In yeast, degradation of SNCA aggregates can be followed by promoter shut-off assays. Expression of the inducible *GALI* promoter of GFP-tagged SNCA is stopped by glucose repression. The removal of aggregates is thus monitored with fluorescence microscopy. The contribution of autophagy to SNCA aggregate clearance can be studied by the use of different autophagy mutants or by pharmacological treatment with the proteinase B inhibitor PMSF.<sup>732,733</sup> Similarly, fluorescently tagged aggregated proteins such as polyQ80-CFP can be monitored via immunoblot and immunofluorescence. In addition to fluorescence methods, aggregates formed by a splice variant of *CCND2* (cyclin D2) can also be monitored in electron-dense lysosomes and autophagosomes by immunogold labeling and TEM techniques.<sup>734</sup> A polyQ80-luciferase reporter, which forms aggregates, can also be used to follow aggrephagy.<sup>735</sup> A nonaggregating polyQ19-luciferase or untagged full-length luciferase serves as a control. The ratio of luciferase activity from these 2 constructs can be calculated to determine autophagic flux.

Autophagic degradation of endogenous aggregates such as lipofuscin can be monitored in some cell types by fluorescence microscopy, utilizing the autofluorescence of lipofuscin particles. Although under normal conditions almost 99% of the lipofuscin particles are located in the autophagosomes/lysosomes, an impairment of macroautophagy leads to free lipofuscin in the cytosol.<sup>736,737</sup> The amount of lipofuscin in primary human adipocytes can be reduced by activation of macroautophagy, and the amount of lipofuscin is dramatically reduced in adipocytes from patients with type 2 diabetes and chronically enhanced macroautophagy.<sup>294</sup>

**Cautionary notes:** Caution must be used when performing immunoblots of aggregated proteins, as many protein aggregates fail to enter the resolving gel and are retained in the stacking gel. In addition, the polyQ80-luciferase in the aggregated state lacks luciferase activity whereas soluble polyQ80-luciferase retains

activity. Therefore, caution must be used when interpreting results with these vectors, as treatments that increase aggrephagy or enhance protein aggregation can lead to a decrease in luciferase activity.<sup>738</sup> Finally, soluble polyQ reporters can be degraded by the proteasome; thus, changes in the ratio of polyQ19-luciferase: polyQ80-luciferase may also reflect proteasomal effects and not just changes in autophagic flux.

### c. Allophagy


In *C. elegans*, mitochondria, and hence mitochondrial DNA, from sperm are eliminated by an autophagic process. This process of allogeneic (nonself) organelle autophagy is termed “allophagy.”<sup>739,740</sup> During allophagy in *C. elegans*, both paternal mitochondria and membranous organelles (a sperm-specific membrane compartment) are eliminated by the 16-cell stage (100–120 min post-fertilization).<sup>741,742</sup> The degradation process can be monitored in living embryos with GFP::ubiquitin, which appears in the vicinity of the sperm chromatin (labeled for example with mCherry-histone H2B) on the membranous organelles within 3 min after fertilization. GFP fusions and antibodies specific for LGG-1 and LGG-2 (Atg8/LC3 homologs), which appear next to the sperm DNA, membranous organelles and mitochondria (labeled with CMXRos or mitochondria-targeted GFP) within 15 to 30 min post-fertilization, can be used to verify the autophagic nature of the degradation. TEM can also be utilized to demonstrate the presence of mitochondria within autophagosomes in the early embryo.

**Conclusion:** There are many assays that can be used to monitor selective types of autophagy, but caution must be used in choosing an appropriate marker(s). The potential role of other degradative pathways for any individual organelle or cargo marker should be considered, and it is advisable to use more than one marker or technique.

### d. Animal mitophagy and pexophagy

There is no consensus at the present time with regard to the best method for monitoring mitophagy in animals. As with any organelle-specific form of autophagy, it is necessary to demonstrate: i) increased levels of autophagosomes containing mitochondria, ii) maturation of these autophagosomes that culminates with mitochondrial degradation, which can be blocked by specific inhibitors of autophagy or of lysosomal degradation, and iii) whether the changes are due to selective mitophagy or increased mitochondrial degradation during nonselective autophagy. Techniques to address each of these points have been reviewed.<sup>42,743</sup>

Antibodies against phosphorylated ubiquitin (p-S65-Ub) have very recently been described as novel tools to detect the activation of PINK1-PARK2-mediated mitophagy.<sup>744</sup> p-S65-Ub is formed by the kinase PINK1 specifically upon mitochondrial stress, and is amplified in the presence of the E3 Ub ligase PARK2 (reviewed in ref. 745).<sup>746</sup> p-S65-Ub antibodies have been used to demonstrate stress-induced activation of PINK1 in various cells including primary human fibroblasts (Fig. 21). Phosphorylated poly-ubiquitin chains specifically accumulate on damaged mitochondria, and staining with p-S65-Ub antibodies can be used, in addition to translocation of PARK2, to monitor the initiation of mitophagy. Given the complete conservation of the epitopes across species, mitochondrial p-S65-




**Figure 21.** PINK1-dependent phosphorylation of ubiquitin (p-S65-Ub) upon mitophagic stress. (A) Human dermal fibroblasts from healthy controls or Parkinson disease patients carrying a PINK1 loss-of-function mutation (Q456X) were treated with valinomycin for the indicated times and lysates were analyzed by western blot. The p-S65-Ub signal is almost undetectable under nonstress conditions in controls, but is strongly induced in a PINK1 kinase-dependent manner during its stabilization on the outer mitochondrial membrane. MFN2 serves as a control substrate and VCL (vinculin) as a loading control. (B) HeLa cells stably expressing GFP-PARK2 (wild type) were treated with CCCP for the indicated times, fixed and stained with p-S65-Ub (red) and GFP-PARK2 (green) as well as mitochondrial (TOMM20, cyan) and nuclear (Hoechst, blue) markers. The p-S65-Ub staining is almost undetectable in nonstressed cells, but rapidly accumulates on damaged mitochondria where it functions to activate PARK2. On mitochondria, PINK1 and PARK2 together amplify the p-S65-Ub signal. Scale bar: 10  $\mu$ m. Image provided by F.C. Fiesel and W. Springer.

Ub could also be detected in mouse primary neurons upon mitochondrial depolarization. Furthermore, the p-S65-Ub signal partially colocalizes with mitochondrial, lysosomal, and total ubiquitin markers in cytoplasmic granules that appear to increase with age and disease in human postmortem brain samples.<sup>744</sup> Along with the excellent performance of p-S65-Ub antibodies in a range of applications, these findings highlight the potential for future biomarker development.

Ultrastructural analysis at early time points can be used to establish selective mitophagy, although a maturation inhibitor may be needed to trap early autophagosomes with recognizable cargo (Fig. 22). Depending on the use of specific imaging techniques, dyes for living cells or antibodies for fixed cells have to be chosen. In any case, transfection of the phagophore and autophagosome marker GFP-LC3 to monitor the initiation of mitophagy, or RFP-LC3 to assess mitophagy progression, and

visualization of mitochondria (independent of their mitochondrial membrane potential) makes it possible to determine the association of these 2 cellular components. Qualitatively, this may appear as fluorescence colocalization or as rings of GFP-LC3 surrounding mitochondria in higher resolution images.<sup>747,748</sup> For live cell imaging microscopy, mitochondria should be labeled by a matrix-targeted fluorescent protein transfection or by mitochondria-specific dyes. When using matrix-targeted fluorophores for certain cell lines (e.g., SH-SY5Y), it is important to allow at least 48 h of transient expression for sufficient targeting/import of mitochondrial GFP/RFP prior to analyzing mitophagy. MitoTracker probes are lipophilic cations that include a chloromethyl group and a fluorescent moiety. They concentrate in mitochondria due to their negative charge and react with the reduced thiols present in mitochondrial matrix proteins.<sup>749-751</sup> After this reaction the




**Figure 22.** Autophagosomes with recognizable cargo are rare in cells. (A) To assess relative rates of autophagosome formation, the fusion inhibitor bafilomycin A<sub>1</sub> (10 nM) was applied for 2 h prior to fixation with 2% glutaraldehyde in order to trap newly formed autophagosomes. Two different PINK1 shRNA lines (A14 and D14) exhibit increased AV formation over 2 h compared to the control shRNA line. \*,  $p < 0.05$  vs. Control. (B) Autophagosomes in bafilomycin A<sub>1</sub>-treated control cells contain a variety of cytoplasmic structures (left, arrow), while mitochondria comprise a prominent component of autophagosomes in bafilomycin A<sub>1</sub>-treated (PINK1 shRNA) cells (right, arrow). Scale bar: 500 nm. These data indicate induction of selective mitophagy in PINK1-deficient cells. This figure was modified from Figure 2 published in ref. 1951, Chu CT. A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. *Human Molecular Genetics* 2010; 19:R28-R37.

probe can be fixed and remains in the mitochondria independent of altered mitochondrial function or mitochondrial membrane potential.<sup>750,752,753</sup> This method can thus be used when cells remain healthy as the dye will remain in the mitochondria and is retained after fixation, although, as stated above, accumulation is dependent on the membrane potential. In addition, some of the MitoTracker probes, including MitoTracker Green FM and MitoTracker Red FM, are not well retained after fixation. Antibodies that specifically recognize mitochondrial proteins such as VDAC, TOMM20 or COX4I1 (cytochrome c oxidase subunit IV isoform I) may be used to visualize mitochondria in immunohistochemical experimental procedures.<sup>754,755</sup> In neuronal cells, stabilized PINK1 on the mitochondrial outer membrane that accumulates in response to certain forms of acute mitochondrial damage is also a useful marker because it differentiates between healthy mitochondria and those that have lost their membrane potential. Redistribution of cardiolipin to the outer mitochondrial membrane acts as an elimination signal for mitophagy in mammalian cells, including primary neurons, and an ANXA5 (annexin A5) binding assay for externalized cardiolipin can also be considered a good marker for damaged mitochondria and early mitophagy.<sup>145</sup> Colocalization analyses of mitochondria and autophagosomes provide an indication of the degree of autophagic sequestration. TEM can be used to demonstrate the presence of mitochondria within autophagosomes (referred to as mitophagosomes during mitophagy), and this can be coupled with bafilomycin A<sub>1</sub> treatment to prevent fusion with the lysosome.<sup>42</sup> To quantify early mitophagy, the percentage of LC3 puncta (endogenous, RFP- or GFP-LC3 puncta) that colocalize with mitochondria and the number of colocalizing LC3 puncta per cell—as assessed by either confocal microscopy or high-throughput imaging—in response to mitophagic stimuli can be employed as well.<sup>756</sup> In addition, the percentage of lysosomes that colocalize with mitochondria can be used to quantify macroautophagy-mediated delivery of mitochondria. Overall, it is important to quantify mitophagy at various stages (initiation, progression, and late mitophagy) to identify stimuli that elicit this process.<sup>757,758</sup>

The fusion process of mitophagosomes with hydrolase-containing lysosomes represents the next step in the degradation process. To monitor the amount of fused organelles via live cell imaging microscopy, MitoTracker<sup>®</sup> Green FM and LysoTracker<sup>®</sup> Red DND-99 may be used to visualize the fusion process (Fig. 23). Independent of the cell-type specific concentration used for both dyes, we recommend exchanging


MitoTracker<sup>®</sup> Green FM with normal medium (preferably phenol-free and CO<sub>2</sub> independent to reduce unwanted autofluorescence) after incubation with the dye, whereas it is best to maintain the LysoTracker<sup>®</sup> Red stain in the incubation medium during the acquisition of images. Given that these fluorescent dyes are extremely sensitive to photobleaching, it is critical to perform live cell mitophagy experiments via confocal microscopy, preferably by using a spinning disc confocal microscope for long-term imaging experiments. For immunocytochemical experiments, antibodies specific for mitochondrial proteins and an antibody against LAMP1 (lysosomal-associated membrane protein 1) can be used. Overlapping signals appear as a merged color and can be used as indicators for successful fusion of autophagosomes that contain mitochondria with lysosomal structures.<sup>759</sup> To measure the correlation between 2 variables by imaging techniques, such as the colocalization of 2 different stainings, we recommend some form of correlation analysis to assess the value correlating with the strength of the association. This may use, for example, ImageJ software or other colocalization scores that can be derived from consideration not only of pixel colocalization, but also from a determination that the structures have the appropriate shape. During live-cell imaging, the 2 structures (autophagosomes and mitochondria) should move together in more than one frame. Mitophagy can also be quantitatively monitored using a mitochondria-targeted version of the pH-dependent Keima protein.<sup>760</sup> The peak of the excitation spectrum of the protein shifts from 440 nm to 586 nm when mitochondria are delivered to acidic lysosomes, which allows easy quantification of mitophagy (Fig. 24). However, it should be noted that long exposure time of the specimen to intense laser light lead to a similar spectral change. Finally, a mitochondrially-targeted version of the tandem mCherry-GFP fluorescent reporter (see *Tandem mRFP/mCherry-GFP fluorescence microscopy*) using a targeting sequence from the mitochondrial membrane protein FIS1<sup>346,347</sup> can be used to monitor mitophagy flux.<sup>347</sup>

The third and last step of the degradation process is the monitoring of the amount of remaining mitochondria by analyzing the mitochondrial mass. This final step provides the opportunity to determine the efficiency of degradation of dysfunctional, aged or impaired mitochondria. Mitochondrial mass can be measured by a flow cytometry technique using MitoTracker<sup>®</sup> Green FM or MitoTracker Deep Red FM,<sup>750</sup> on a single cell basis, by either live cell imaging or immunocytochemistry (using antibodies specifically raised against different mitochondrial proteins). Alternatively,



**Figure 23.** Human fibroblasts showing colocalization of mitochondria with lysosomes. The degree of colocalization of mitochondria with lysosomes in human fibroblasts was measured via live cell imaging microscopy at 37°C and 5% CO<sub>2</sub> atmosphere using the ApoTome<sup>®</sup> technique. LysoTracker<sup>®</sup> Red DND-99 staining was applied to mark lysosomal structures (red), and MitoTracker<sup>®</sup> Green FM to visualize mitochondria (green). Hoechst 33342 dye was used to stain nuclei (blue). A positive colocalization is indicated by yellow signals (merge) due to the overlap of LysoTracker<sup>®</sup> Red and MitoTracker<sup>®</sup> Green staining (white arrows). Scale bars: 10 μm. Statistical evaluation is performed by calculating the Pearson's coefficient for colocalizing pixels. Image provided by L. Burbulla and R. Krüger.





**Figure 24.** Detection of mitophagy in primary cortical neurons using mitochondria-targeted Keima. Neurons transfected with mito-Keima were visualized using 458-nm (green, mitochondria at neutral pH) and 561-nm (red, mitochondria in acidic pH) laser lines and 575-nm band pass filter. Compared with the control (A) wild-type PINK1 overexpression (B) increases the number of the mitochondria exposed to acidic conditions. Scale bar: 2  $\mu$ m. (C) Quantification of red dots suggests increased mitophagy in wild-type PINK1 but not in the kinase dead (kd) PINK1<sup>K219M</sup>-overexpressing neurons. Image provided by V. Choubey and A. Kaasik.

mitochondrial content in response to mitophagic stimuli (in the presence and absence of autophagy inhibitors to assess the contribution of mitophagy) in live or fixed cells can be quantified at the single-cell level as the percentage of cytosol occupied by mitochondrial-specific fluorescent pixels using NIH ImageJ.<sup>758</sup> Immunoblot analysis of the levels of mitochondrial proteins from different mitochondrial subcompartments is valuable for validating the data from flow cytometry or microscopy studies, and it should be noted that outer mitochondrial membrane proteins in particular can be degraded by the proteasome, especially in the context of mitochondrial depolarization.<sup>761,762</sup> EM can also be used to verify loss of entire mitochondria, and PCR (or fluorescence microscopy) to quantify mitochondrial DNA (mtDNA). A reliable estimation of mtDNA can be performed by real-time PCR of the *MT-ND2* (mitochondrially encoded NADH dehydrogenase 2) gene expressed as a ratio of mtDNA:nuclear DNA by normalizing to that of *TERT* (telomerase reverse transcriptase) genomic DNA.<sup>763</sup> The spectrophotometric measurement of the activity of CS (citrate synthase), a mitochondrial matrix enzyme of the TCA cycle, which remains highly constant in these organelles and is considered a reliable marker of their intracellular content, can also be used to estimate the mitochondrial mass.<sup>763</sup>

In addition to monitoring the steady state levels of different steps of mitophagy—whether by single-cell analyses of LC3 mitochondrial colocalization or by immunoblotting for mitochondrial markers—investigation of the mitophagic flux is needed to determine whether mitophagy is impaired or activated in response to stimuli, and at which steps. Therefore, appropriate treatment (pharmacological inhibition and/or siRNA-mediated knockdown of *ATG* genes) may be applied to prevent mitochondrial degradation at distinct steps of the process. A recent method using flow cytometry in combination with autophagy and mitophagy inhibitors has been developed to determine mitophagic flux using MitoTracker probes.<sup>750</sup>

Certain cellular models require stress conditions to measure the mitochondrial degradation capacity, as basal levels are too low to reliably assess organelle clearance. However, one exception has been identified in *Drosophila* where large numbers of mitochondria are cleared by mitophagy during

developmentally triggered autophagy.<sup>764</sup> Hence, in many cases, it may be useful to pretreat the cells with uncoupling agents, such as CCCP, that stimulate mitochondrial degradation and allow measurements of mitophagic activity; however, it should be kept in mind that, although helpful to stimulate mitochondrial degradation, this treatment is not physiological and promotes the rapid degradation of outer membrane-localized mitochondrial proteins. In part for this reason a milder mitophagy stimulus has been developed that relies on a combination of antimycin A and oligomycin, inhibitors of the electron transport chain and ATP synthase, respectively;<sup>765</sup> this treatment is less toxic, and the resulting damage is time dependent. Another method to induce mitophagy is by expressing and activating a mitochondrially localized fluorescent protein photosensitizer such as Killer Red.<sup>766</sup> The excitation of Killer Red results in an acute increase of superoxide, due to phototoxicity, that causes mitochondrial damage resulting in mitophagy.<sup>767</sup> The advantage of using a genetically encoded photosensitizer is that it allows for both spatial and temporal control in inducing mitophagy. Finally, the forced targeting of AMBRA1 to the external mitochondrial membrane is sufficient to induce massive mitophagy.<sup>768</sup>

A new classification suggests that mitophagy can be divided into 3 types.<sup>769</sup> Type 1 mitophagy, involves the formation of a phagophore, and typically also requires mitochondrial fission; the PtdIns3K containing BECN1 mediates this process. In contrast, type 2 mitophagy is independent of BECN1 and takes place when mitochondria have been damaged, resulting in depolarization; sequestration involves the coalescence of GFP-LC3 membranes around the mitochondria rather than through fission and engulfment within a phagophore. In type 3 mitophagy, mitochondrial fragments or vesicles from damaged organelles are sequestered through a microautophagy-like process that is independent of ATG5 and LC3, but requires PINK1 and PARK2.

Although the process of pexophagy is prominent and well described in yeast cells,<sup>696,770</sup> relatively little work has been done in the area of selective mammalian peroxisome degradation by autophagy (for a review see ref. 771). Typically, peroxisomes are induced by treatment with hypolipidemic drugs such as clofibrate or dioctyl phthalate, which bind to a subfamily of nuclear receptors, referred to as peroxisome

proliferator-activated receptors.<sup>772</sup> Degradation of excess organelles is induced by drug withdrawal, although starvation without prior proliferation can also be used. EPAS1 activation in liver-specific *vhl*<sup>-/-</sup> and *vhl*<sup>-/-</sup> *hif1a*<sup>-/-</sup> mice reduces peroxisome abundance by pexophagy, whereas ER and mitochondrial protein levels are not affected.<sup>773</sup> Pexophagy can also be induced by the expression of a nondegradable active EPAS1 variant.<sup>773</sup> Induction of pexophagy in response to endogenous and exogenous reactive oxygen species (ROS) and reactive nitrogen species has been observed in mammalian cells. In this setting, pexophagy is induced via ROS/reactive nitrogen species-mediated activation of ATM,<sup>774,775</sup> repression of MTORC1 and phosphorylation of PEX5 by ATM;<sup>776,777</sup> ATM phosphorylation of PEX5 at S141 triggers PEX5 ubiquitination and binding of SQSTM1 to peroxisomes targeted for pexophagy.<sup>777</sup> Loss of peroxisomes can be followed enzymatically or by immunoblot, monitoring enzymes such as ACOX/fatty acyl-CoA oxidase (note that this enzyme is sometimes abbreviated “AOX,” but should not be confused with the enzyme alcohol oxidase that is frequently used in assays for yeast pexophagy) or CAT/catalase, and also by EM, cytochemistry or immunocytochemistry.<sup>778-781</sup> Finally, a HaloTag®-PTS1 marker that is targeted to peroxisomes has been used to fluorescently label the organelle.<sup>782</sup> An alternative approach uses a peroxisome-specific tandem fluorochrome assay (RFP-EGFP localizing to peroxisomes by the C-terminal addition of the tripeptide SKL, or a peroxisomal membrane protein tagged with mCherry-mGFP), which has been used to demonstrate the involvement of ACBD5/ATG37, NBR1 and SQSTM1 in mammalian pexophagy.<sup>345,783</sup>

**Cautionary notes:** There are many assays that can be used to monitor specific types of autophagy, but caution must be used in choosing an appropriate marker(s). To follow mitophagy it is best to monitor more than one protein and to include an inner membrane or matrix component in the analysis. In particular, it is not sufficient to follow a single mitochondrial outer membrane protein because these can be degraded independently of mitophagy. Although the localization of PARK2 to mitochondria as monitored by fluorescence microscopy is associated with the early stages of protonophore uncoupler (CCCP)-driven mitochondria degradation,<sup>250</sup> this by itself cannot be used as a marker for mitophagy, as these events can be dissociated.<sup>784</sup> Moreover, mitophagy elicited in a number of disease models does not involve mitochondrial PARK2 translocation.<sup>145,347,785</sup> Along these lines, recent studies implicate an essential role for TRAF2, an E3 ubiquitin ligase, as a mitophagy effector in concert with PARK2 in cardiac myocytes; whereby mitochondrial proteins accumulate differentially with deficiency of either, indicating nonredundant roles for these E3 ubiquitin ligases in mitophagy.<sup>786</sup> This finding necessitates an integrated approach to assess mitophagy based on a broad evaluation of multiple mitochondrial effectors and proteins.

PARK2 translocates to damaged mitochondria and ubiquitinates a wide range of outer membrane proteins including VDAC1, MFN1/2 and TOMM20/TOM20.<sup>755,761,762,787</sup> This results in the preferential degradation of mitochondrial outer membrane proteins by the proteasome, while inner membrane proteins and mitochondrial DNA<sup>788</sup> remain intact. Monitoring loss of a single protein such as TOMM20 by western blot or


fluorescence microscopy to follow mitophagy may thus be misleading, as noted above.<sup>787</sup> MitoTracker dyes are widely used to stain mitochondria and, when colocalized with GFP-LC3, they can function as a marker for mitophagy. However, staining with MitoTracker dyes depends on mitochondrial membrane potential (although MitoTracker Green FM is less sensitive to loss of membrane potential), so that damaged, or sequestered nonfunctional mitochondria may not be stained. In vitro this can be avoided by labeling the cells with MitoTracker before the induction by the mitophagic stimuli.<sup>750,789</sup> One additional point is that MitoTracker dyes might influence mitochondrial motility in axons (D. Ebrahimi-Fakhari, personal communication).

Although it is widely assumed that macroautophagy is the major mechanism for degradation of entire organelles, there are multiple mechanisms that may account for the disappearance of mitochondrial markers. These include proteasomal degradation of outer membrane proteins and/or proteins that fail to correctly translocate into the mitochondria, degradation due to proteases within the mitochondria, and reduced biosynthesis or import of mitochondrial proteins. PINK1 and PARK2 also participate in an ATG gene-independent pathway for lysosomal degradation of small mitochondria-derived vesicles.<sup>790</sup> Furthermore, the PINK1-PARK2 mitophagy pathway is also transcriptionally upregulated in response to starvation-triggered generalized autophagy, and is intertwined with the lipogenesis pathway.<sup>791-794</sup> In addition to mitophagy, mitochondria can be eliminated by extrusion from the cell (mitoptosis).<sup>795,759,755,742</sup> Transcellular degradation of mitochondria, or transmitophagy, also occurs in the nervous system when astrocytes degrade axon-derived mitochondria.<sup>796</sup> Thus, it is advisable to use a variety of complementary methods to monitor mitochondria loss including TEM, single cell analysis of LC3 fluorescent puncta that colocalize with mitochondria, and western blot, in conjunction with flux inhibitors and specific inhibitors of autophagy induction compared with inhibitors of the other major degradation systems (see cautions in *Autophagy inhibitors and inducers*). To monitor and/or rule out changes in cellular capacity to undergo mitochondrial biogenesis, a process that is tightly coordinated with mitophagy and can dictate the outcome following mitophagy-inducing insults especially in primary neurons and other mitochondria-dependent cells, colocalization analysis after double staining for the mitochondrial marker TOMM20 and BrdU (for visualization of newly synthesized mtDNA) can be performed (Fig. 25).

Likewise, although the mechanism(s) of peroxisomal protein degradation in mammals awaits further elucidation, it can occur by both autophagic and proteasome-dependent mechanisms.<sup>797</sup> Thus, controls are needed to determine the extent of degradation that is due to the proteasome. Moreover, 2 additional degradation mechanisms have been suggested: the action of the peroxisome-specific LONP2/Lon (lon peptidase 2, peroxisomal) protease and the membrane disruption effect of 15-lipoxygenase.<sup>798</sup>

#### e. Chlorophagy

Besides functioning as the primary energy suppliers for plants, chloroplasts represent a major source of fixed carbon and nitrogen to be remobilized from senescing leaves to storage organs



**Figure 25.** Confocal microscopy deconvolved (AutoQuant X3) images and colocalization image analysis (ImageJ 1.47; Imaris 7.6) through a local approach showing perinuclear mitochondrial biogenesis in hippocampal neuronal cultures. The upper channels show TOMM20 (green channel), BrdU (for visualization of newly synthesized mitochondrial DNA, red channel), and merged fluorescence channels. Overlay, corresponds to the spatial pattern of software thresholded colocalized structures (white spots) layered on the merged fluorescence channels. Surface Plot, or luminance intensity height, is proportional to the colocalization strength of the colocalized structures (white spots). Plot Profile, corresponds to the spatial intensity profiles of the fluorescence channels of the white line positioned in the Merge image. Yellow arrows indicate a qualitative evaluation of the spatial association trends for the fluorescence intensities. Arrows pointing up indicate an increase in the colocalization, while arrows pointing down show a decrease. Scale bar: 2  $\mu\text{m}$ . This figure was modified from previously published data<sup>2187</sup> and provided by F. Florenzano.

and newly developing tissues. As such, the turnover of these organelles has long been considered to occur via an autophagy-type mechanism. However, while the detection of chloroplasts within autophagic body-like vesicles or within vacuole-like compartments has been observed for decades, only recently has a direct connection between chloroplast turnover and autophagy been made through the analysis of *atg* mutants combined with the use of fluorescent ATG8 reporters.<sup>799,800</sup> In fact, it is now clear that chlorophagy, the selective degradation of chloroplasts by macroautophagy, can occur via several routes, including the encapsulation of whole chloroplasts, or the budding of chloroplast material into small distinct autophagic vesicles called Rubisco-containing bodies (RCBs) and ATII plastid-associated bodies (ATI-PS), which then transport chloroplast cargo to the vacuole.<sup>799,801</sup> Chloroplasts produce long tubes called stromules that project out from the organelle outer membrane. Recent studies suggest that stromules are part of the chlorophagy process, by which the stromule tips presumably containing unwanted or damaged chloroplast material are engulfed by autophagic membranes using ESCRTIII endocytic machinery that depends on ATG8.<sup>802</sup> The appearance of RCBs is tightly linked with leaf carbon status, indicating that chlorophagy through RCBs represents an important route for recycling plant nutrients provided in plastid stores.

#### f. Chromatophagy

Autophagy has been known for its pro-survival role in cells under metabolic stress and other conditions. However, excessively induced autophagy may be cytotoxic and may lead to cell death. Chromatophagy (chromatin-specific autophagy) comes into view as one of the autophagic responses that can contribute to cell death.<sup>803</sup> Chromatophagy can be seen in cells during nutrient depletion, such as arginine starvation, and its phenotype consists of giant-autophagosome formation, nucleus membrane rupture and histone-associated-chromatin/DNA leakage that is captured by autophagosomes.<sup>803</sup> Arginine starvation can be achieved by adding purified arginine deiminase to remove

arginine from the culture medium, or by using arginine-drop-out medium. The degradation of leaked nuclear DNA/chromatin can be observed by fluorescence microscopy; with GFP-LC3 or anti-LC3 antibody, and LysoTracker Red or anti-LAMP1, multiple giant autophagosomes or autolysosomes containing leaked nuclear DNA can be detected. In addition, the chromatophagy-related autophagosomes also contain parts of the nuclear outer-membrane, including NUP98 (nucleoporin 98kDa), indicating that the process involves a fusion event.<sup>803</sup>

#### g. Ferritinophagy

Ferritinophagy is a selective form of autophagy that functions in intracellular iron processing.<sup>804</sup> Iron is recruited to ferritin for storage and to prevent the generation of free radical iron.<sup>805,806</sup> To release iron from ferritin, the iron-bound form is sequestered within an autophagosome.<sup>807</sup> Fusion with a lysosome leads to breakdown of ferritin and release of iron. Furthermore, iron can be acidified in the lysosome, converting it from an inactive state of  $\text{Fe}^{3+}$  to  $\text{Fe}^{2+}$ .<sup>808,809</sup> Iron can be detected in the autolysosome via TEM.<sup>808</sup> Colocalization of iron with autolysosomes may also be determined utilizing calcein AM to tag iron.<sup>808,810</sup> NCOA4 is a cargo receptor that recruits ferritin to the autophagosome.<sup>804</sup>

#### h. Intraplastidial autophagy

Intraplastidial autophagy is a process whereby plastids of some cell types adopt autophagic functions, engulfing and digesting portions of the cytoplasm. These plastids are characterized by formation of invaginations in their double-membrane envelopes that eventually generate a cytoplasmic compartment within the plastidial stroma, isolated from the outer cytoplasm. W. Nagl coined the term “plastolysome” to define this special plastid type.<sup>811</sup> Initially, the engulfed cytoplasm is identical to the outer cytoplasm, containing ribosomes, vesicles and even larger organelles. Lytic activity was demonstrated in these plastids, in both the cytoplasmic compartment and the stroma. Therefore, it was suggested that plastolysomes digest themselves together with

their cytoplasmic cargo, and transform into lytic vacuoles. Intra-plastidial autophagy has been reported in plastids of suspensor cells of *Phaseolus coccineus*<sup>811</sup> and *Phaseolus vulgaris*,<sup>812</sup> where plastids transformed into autophagic vacuoles during the senescence of the suspensor. This process was also demonstrated in petal cells of *Dendrobium*<sup>813</sup> and in *Brassica napus* microspores experimentally induced towards embryogenesis.<sup>814</sup> All these reports established a clear link between these plastid transformations and their engagement in autophagy. At present, descriptions of this process are limited to a few, specialized plant cell types. However, pictures of cytoplasm-containing plastids in other plant cell types have been occasionally published, although the authors did not make any mention of this special plastid type. For example, this has been seen in pictures of fertile and Ogu-INRA male sterile tetrads of *Brassica napus*,<sup>815</sup> and *Phaseolus vulgaris* root cells.<sup>816</sup> Possibly, this process is not as rare as initially thought, but authors have only paid attention to it in those cell types where it is particularly frequent.

### i. Lipophagy

The specific macroautophagic degradation of lipid droplets represents another type of selective autophagy.<sup>817</sup> Lipophagy requires the core autophagic machinery and can be monitored by following triglyceride content, or total lipid levels using BODIPY 493/503 or HCS LipidTOX neutral lipid stains with fluorescence microscopy, cell staining with Oil Red O, the cholesterol dye filipin III,<sup>818</sup> or ideally label-free techniques such as CARS or SRS microscopy. BODIPY 493/503 should be used with caution, however, when performing costains (especially in the green and red spectra) because this commonly used fluorescent marker of neutral lipids is highly susceptible to bleed-through into the other fluorescence channels (hence often yielding false positives), unlike the LipidTOX stain that has a narrow emission spectrum.<sup>819</sup> In addition, BODIPY 493/503 cannot be used to monitor lipophagy in *C. elegans* because it stains both lipid droplets and the lysosome.<sup>820</sup> TEM can also be used to monitor lipid droplet size and number, as well as lipid droplet-associated double-membrane structures, which correspond to autophagosomes.<sup>817,821,822</sup> The transcription factor TFEB positively regulates lipophagy,<sup>624</sup> and promotes fatty acid  $\beta$ -oxidation,<sup>823</sup> thus providing a regulatory link between different lipid degradation pathways.<sup>824</sup> Accordingly, TFEB overexpression rescues fat accumulation and metabolic syndrome in a diet-induced model of obesity.<sup>823,825</sup> The regulation of expression of lipid droplet regulators (such as the PLIN/perilipin family) and of autophagy adaptors (such as the TBC1D1 family) during starvation and disease is one of several areas in this topic that deserves further exploration.<sup>826-828</sup>

**Cautionary notes:** With regard to changes in the cellular neutral lipid content, the presence and potential activation of cytoplasmic lipases that are unrelated to lysosomal degradation must be considered.

### j. Lysophagy

Lysophagy is a selective macroautophagy process that participates in cellular quality control through lysosome turnover. By eliminating ruptured lysosomes, lysophagy prevents the subsequent activation of the inflammasome complex and innate immune response.<sup>829,830</sup>

### k. Oxiapoptophagy

There are now several lines of evidence indicating that autophagy is an essential process in vascular functions. Autophagy can be considered as atheroprotective in the early stages of atherosclerosis and detrimental in advanced atherosclerotic plaques.<sup>831</sup> Currently, little is known about the molecules that promote autophagy on the cells of the vascular wall. As increased levels of cholesterol oxidation products (also named oxysterols) are found in atherosclerotic lesions,<sup>832</sup> the part taken by these molecules has been investigated, and several studies support the idea that some of them could contribute to the induction of autophagy.<sup>833,834</sup> It is now suggested that oxysterols, especially 7-ketocholesterol, which can be increased under various stress conditions in numerous age-related diseases not only including vascular diseases but also neurodegenerative diseases,<sup>835</sup> could trigger a particular type of autophagy termed oxiapoptophagy (OXIdation + APOPTOSis + auto-PHAGY)<sup>836</sup> characterized by the simultaneous induction of oxidative stress associated with apoptosis and autophagic criteria in different cell types from different species.<sup>837,838</sup> As oxiapoptophagy has also been observed with 7 $\beta$ -hydroxycholesterol and 24S-hydroxycholesterol, which are potent inducers of cell death, it is suggested that oxiapoptophagy could characterize the effect of cytotoxic oxysterols.<sup>837</sup>

### l. Reticulophagy

Starvation in yeast induces a type of selective macroautophagy of the ER, which depends on the autophagy receptors Atg39 and Atg40.<sup>839</sup> ER stress also triggers an autophagic response,<sup>840</sup> which includes the formation of multi-lamellar ER whorls and their degradation by a microautophagic mechanism.<sup>841</sup> ER-selective autophagy has been termed ER-phagy or reticulophagy.<sup>842,843</sup> Selective autophagy of the ER has also been observed in mammalian cells,<sup>844</sup> and FAM134B has been identified as an ER-specific macroautophagy receptor that appears to be functionally homologous to Atg40.<sup>845</sup> Since reticulophagy is selective, it should be able to act in ER quality control,<sup>846</sup> sequester parts of the ER that are damaged, and eliminate protein aggregates that cannot be removed in other ways. It may also serve to limit stress-induced ER expansion,<sup>841</sup> for example by reducing the ER to a normal level after a particular stress condition has ended.

### m. Ribophagy

Autophagy is also used for the selective removal of ribosomes, particularly upon nitrogen starvation.<sup>847</sup> This process can be monitored by western blot, following the generation of free GFP from Rpl25-GFP or Rpl5-GFP,<sup>848</sup> or the disappearance of ribosomal subunits such as Rps3. Vacuolar localization of Rpl25-GFP or Rpl5-GFP can also be seen by fluorescence microscopy. The Rkr1/Ltn1 ubiquitin ligase acts as an inhibitor of 60S ribosomal subunit ribophagy via, at least, Rpl25 as a target, and is antagonized by the deubiquitinase Ubp3-Bre5 complex.<sup>847,848</sup> Rkr1/Ltn1 and Ubp3-Bre5 likely contribute to adapt ribophagy activity to both nutrient supply and protein translation.

#### n. RNA-silencing components

Several components of the RNA-silencing machinery are selectively degraded by autophagy in different organisms. This was first shown for the plant AGO1/ARGONAUTE1 protein, a key component of the *Arabidopsis* RNA-induced silencing complex (RISC) that, after ubiquitination by a virus encoded F-box protein, is targeted to the vacuole.<sup>849</sup> AGO1 colocalizes with *Arabidopsis* ATG8a-positive bodies and its degradation is impaired by various drugs such as 3-MA and E64d, or in *Arabidopsis* mutants in which autophagy is compromised such as the TOR-overexpressing mutant line G548 or the *atg7-2* mutant allele (P. Genschik, unpublished data). Moreover, this pathway also degrades AGO1 in a nonviral context, especially when the production of miRNAs is impaired. In mammalian cells, not only the main miRNA effector AGO2, but also the miRNA-processing enzyme DICER1, is degraded as a miRNA-free entity by selective autophagy.<sup>850</sup> Chemical inhibitors of autophagy (bafilomycin A<sub>1</sub> and chloroquine) and, in HeLa cells, depletion of key autophagy components ATG5, ATG6 or ATG7 using short interfering RNAs, blocks the degradation of both proteins. Electron microscopy shows that DICER1 is associated with membrane-bound structures having the hallmarks of autophagosomes. Moreover, the selectivity of DICER1 and AGO2 degradation might depend on the autophagy receptor CALCOCO2/NDP52, at least in these cell types. Finally, in *C. elegans*, AIN-1, a homolog of mammalian TNRC6A/GW182 that interacts with AGO and mediates silencing, is also degraded by autophagy.<sup>851</sup> AIN-1 colocalizes with SQST-1 that acts as a receptor for autophagic degradation of ubiquitinated protein aggregates and also directly interacts with LGG-1 (Atg8/LC3) contributing to cargo specificity.

#### o. Vacuole import and degradation pathway

In yeast, gluconeogenic enzymes such as fructose-1,6-bisphosphatase (Fbp1/FBPase), malate dehydrogenase (Mdh2), isocitrate lyase (Icl1) and phosphoenolpyruvate carboxykinase (Pck1) constitute the cargo of the vacuole import and degradation (Vid) pathway.<sup>852</sup> These enzymes are induced when yeast cells are glucose starved (grown in a medium containing 0.5% glucose and potassium acetate). Upon replenishing these cells with fresh glucose (a medium containing 2% glucose), these enzymes are degraded in either the proteasome<sup>853-855</sup> or the vacuole<sup>852,856</sup> depending on the duration of starvation. Following glucose replenishment after 3 d glucose starvation, the gluconeogenic enzymes are delivered to the vacuole for degradation.<sup>857</sup> These enzymes are sequestered in specialized 30- to 50-nm Vid vesicles.<sup>858</sup> Vid vesicles can be purified by fractionation and gradient centrifugation; western blotting analysis using antibodies against organelle markers and Fbp1, and the subsequent verification of fractions by EM facilitate their identification.<sup>858</sup> Furthermore, the amount of marker proteins in the cytosol compared to the Vid vesicles can be examined by differential centrifugation. In this case, yeast cells are lysed and subjected to differential centrifugation. The Vid vesicle-enriched pellet fraction and the cytosolic supernatant fraction are examined with antibodies against Vid24, Vid30, Sec28 and Fbp1.<sup>859-861</sup>

The distribution of Vid vesicles containing cargo destined for endosomes, and finally for the vacuole, can be examined

using FM 4-64, a lipophilic dye that primarily stains endocytic compartments and the vacuole limiting membrane.<sup>862</sup> In these experiments, starved yeast cells are replenished with fresh glucose and FM 4-64, and cells are collected at appropriate time points for examination by fluorescence microscopy.<sup>860</sup> The site of degradation of the cargo in the vacuole can be determined by studying the distribution of Fbp1-GFP, or other Vid cargo markers in wild-type and *pep4Δ* cells.<sup>863</sup> Cells can also be examined for the distribution of Fbp1 at the ultrastructural level by immuno-TEM.<sup>864</sup>

As actin patch polymerization is required for the delivery of cargo to the vacuole in the Vid pathway, distribution of Vid vesicles containing cargo and actin patches can be examined by actin staining (with phalloidin conjugated to rhodamine) using fluorescence microscopy.<sup>864</sup> The distribution of GFP tagged protein and actin is examined by fluorescence microscopy. GFP-Vid24, Vid30-GFP and Sec28-GFP colocalize with actin during prolonged glucose starvation and for up to 30 min following glucose replenishment in wild-type cells; however, colocalization is less obvious by the 60-min time point.<sup>859,864</sup>

#### p. Xenophagy

The macroautophagy pathway has emerged as an important cellular factor in both innate and adaptive immunity. Many *in vitro* and *in vivo* studies have demonstrated that genes encoding macroautophagy components are required for host defense against infection by bacteria, parasites and viruses. Xenophagy is often used as a term to describe autophagy of microbial pathogens, mediating their capture and delivery to lysosomes for degradation. Since xenophagy presents an immune defense, it is not surprising that microbial pathogens have evolved strategies to overcome it. The interactions of such pathogens with the autophagy system of host cells are complex and have been the subject of several excellent reviews.<sup>121-126,865-871</sup> Here we will make note of a few key considerations when studying interactions of microbial pathogens with the autophagy system. Importantly, autophagy should no longer be considered as strictly antibacterial, and several studies have described the fact that autophagy may serve to either restrict or promote bacterial replication both *in vivo*<sup>872</sup> and *in vitro* (reviewed in refs. 874, 875).

LC3 is commonly used as a marker of macroautophagy. However, studies have established that LC3 can promote phagosome maturation independently of macroautophagy through LC3-associated phagocytosis (see cautionary notes in *Atg8/LC3 detection and quantification*, and *Noncanonical use of autophagy-related proteins*). Other studies show that macroautophagy of *Salmonella enterica* serovar Typhimurium (*S. typhimurium*) is dependent on ATG9, an essential macroautophagy protein, whereas LC3 recruitment to bacteria does not require ATG9.<sup>875</sup> In contrast, macroautophagy of these bacteria requires either glycan-dependent binding of LGALS8/galectin-8 (lectin, galactoside-binding, soluble, 8) to damaged membranes and subsequent recruitment of the cargo receptor CALCOCO2/NDP52<sup>876</sup> or ubiquitination of target proteins (not yet identified) and recruitment of 4 different ubiquitin-binding receptor proteins, SQSTM1,<sup>877</sup> CALCOCO2/NDP52,<sup>878</sup> TAX1BP1/CALCOCO3<sup>879</sup> and OPTN.<sup>880</sup> Therefore, the currently available criteria to differentiate LAP from

macroautophagy include: i) LAP involves LC3 recruitment to bacteria in a manner that requires ROS production by an NADPH oxidase. It should be noted that most cells express at least one member of the NADPH oxidase family. Targeting expression of the common CYBA/p22<sup>phox</sup> subunit is an effective way to disrupt the NADPH oxidases. Scavenging of ROS by antioxidants such as resveratrol and alpha-tocopherol is also an effective way to inhibit LAP. In contrast, N-acetylcysteine, which raises cellular glutathione levels, does not inhibit LAP.<sup>881</sup> ii) Macroautophagy of bacteria requires ATG9, whereas LAP apparently does not.<sup>875</sup> iii) LAP involves single-membrane structures. For LAP, CLEM (with LC3 as a marker) is expected to show single-membrane structures that are LC3<sup>+</sup> with LAP.<sup>182</sup> In contrast, macroautophagy is expected to generate double-membrane structures surrounding cargo (which may include single membrane phagosomes, giving rise to triple-membrane structures<sup>875</sup>). It is anticipated that more specific markers of LAP will be identified as these phagosomes are further characterized.

Nonmotile *Listeria monocytogenes* can be targeted to double-membrane autophagosomes upon antibiotic treatment,<sup>882</sup> which indicates that macroautophagy serves as a cellular defense to microbes in the cytosol. However, subsequent studies have revealed that macroautophagy can also target pathogens within phagosomes, damaged phagosomes or the cytosol. Therefore, when studying microbial interactions by EM, many structures can be visualized, with any number of membranes encompassing microbes, all of which may be LC3<sup>+</sup>.<sup>883,884</sup> As discussed above, single-membrane structures that are LC3<sup>+</sup> may arise through LAP, and we cannot rule out the possibility that both LAP and macroautophagy may operate at the same time to target the same phagosome. Indeed macroautophagy may facilitate phagocytosis and subsequent bacterial clearance (X. Li and M. Wu, submitted). Macroautophagy is not only induced by intracellular bacteria, but also can be activated by extracellular bacteria such as *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*, which may involve complex mechanisms.<sup>885-887</sup> Furthermore, macroautophagy can be induced by all intracellular and extracellular Gram-negative bacteria via a common mechanism involving naturally produced bacterial outer membrane vesicles;<sup>888,889</sup> these vesicles enter human epithelial cells, resulting in autophagosome formation and inflammatory responses mediated via the host pathogen recognition receptor NOD1.<sup>888</sup>

Viruses can also be targeted by autophagy, and in turn can act to inhibit autophagy. For example, infection of a cell by influenza and dengue viruses<sup>890</sup> or enforced expression of the hepatitis B virus C protein<sup>891</sup> have profound consequences for autophagy, as viral proteins such as NS4A stimulate autophagy and protect the infected cell against apoptosis, thus extending the time in which the virus can replicate. Conversely, the HSV-1 ICP34.5 protein inhibits autophagy by targeting BECN1.<sup>892</sup> While the impact of ICP34.5's targeting of BECN1 on viral replication in cultured permissive cells is minimal, it has a significant impact upon pathogenesis in vivo, most likely through interfering with activation of CD4<sup>+</sup> T cells,<sup>893,894</sup> and through cell-intrinsic antiviral effects in neurons.<sup>895</sup> Also, viral BCL2 proteins, encoded by large DNA viruses, are able to inhibit autophagy by interacting with BECN1<sup>565</sup> through their BH3

homology domain. An example of these include  $\gamma$ -herpesvirus<sup>68,896</sup> Kaposi sarcoma-associated herpesvirus<sup>566</sup> and African swine fever virus (ASFV) vBCL2 homologs.<sup>897</sup> ASFV encodes a protein homologous to HSV-1 ICP34.5, which, similar to its herpesvirus counterpart, inhibits the ER stress response activating PPP1/protein phosphatase 1; however, in contrast to HSV-1 ICP34.5 it does not interact with BECN1. ASFV vBCL2 strongly inhibits both autophagy (reviewed in ref. 898) and apoptosis.<sup>899</sup>

HIV-1 utilizes the initial, nondegradative stages of autophagy to promote its replication in macrophages. In addition, the HIV-1 protein Nef acts as an anti-autophagic maturation factor protecting the virus from degradation by physically blocking BECN1.<sup>900-902</sup> Autophagy contributes to limiting viral pathogenesis in HIV-1 nonprogressor-infected patients by targeting viral components for degradation.<sup>903</sup>

Care must be taken in determining the role of autophagy in viral replication, as some viruses such as vaccinia virus use double-membrane structures that form independently of the autophagy machinery.<sup>904</sup> Similarly, dengue virus replication, which appears to involve a double-membrane compartment, requires the ER rather than autophagosomes,<sup>905</sup> whereas coronaviruses and Japanese encephalitis virus use a nonlipidated version of LC3 (see *Atg8/LC3 detection and quantification*).<sup>190,191</sup> Yet another type of variation is seen with hepatitis C virus, which requires BECN1, ATG4B, ATG5 and ATG12 for initiating replication, but does not require these proteins once an infection is established.<sup>906</sup>

Finally, it is important to realize that there may be other macroautophagy-like pathways that have yet to be characterized. For example, in response to cytotoxic stress (treatment with etoposide), autophagosomes are formed in an ATG5- and ATG7-independent manner (see *Noncanonical use of autophagy-related proteins*).<sup>27</sup> While this does not rule out involvement of other macroautophagy regulators/components in the formation of these autophagosomes, it does establish that the canonical macroautophagy pathway involving LC3 conjugation is not involved. In contrast, RAB9 is required for this alternative pathway, potentially providing a useful marker for analysis of these structures. Returning to xenophagy, *M. tuberculosis* can be targeted to autophagosomes in an ATG5-independent manner.<sup>907</sup> Furthermore, up to 25% of intracellular *S. typhimurium* are observed in multi-lamellar membrane structures resembling autophagosomes in *atg5*<sup>-/-</sup> MEFs.<sup>877</sup> These findings indicate that an alternate macroautophagy pathway is relevant to host-pathogen interactions. Moreover, differences are observed that depend on the cell type being studied. *Yersinia pseudotuberculosis* is targeted to autophagosomes where they can replicate in bone marrow-derived macrophages,<sup>908</sup> whereas in RAW264.7 and J774 cells, bacteria are targeted both to autophagosomes, and LC3-negative, single-membrane vacuoles (F. Lafont, personal communication).

One key consideration has recently emerged in studying xenophagy. Whereas the basal autophagic flux in most cells is essential for their survival, infecting pathogens can selectively modulate antibacterial autophagy (i.e., xenophagy) without influencing basal autophagy. This may help pathogens ensure prolonged cellular (i.e., host) survival. Thus, in the case of xenophagy it would be prudent to monitor substrate

(pathogen)-specific autophagic flux to understand the true nature of the perturbation of infecting pathogens on autophagy (D. Kumar, personal communication). Furthermore, this consideration particularly limits the sensitivity of LC3 western blots for use in monitoring autophagy regulation.

#### q. Zymophagy

Zymophagy was originally defined as a specific mechanism that eliminates pancreatitis-activated zymogen granules in the pancreatic acinar cells and, thus, prevents deleterious effects of prematurely activated and intracellularly released proteolytic enzymes, when impairment of secretory function occurs.<sup>909</sup> Therefore, zymophagy is primarily considered to be a protective mechanism implemented to sustain secretory homeostasis and to mitigate pancreatitis. The presence of zymogen granules, however, is not only attributed to pancreatic acinar cells. Thus, zymophagy was also reported in activated secretory Paneth cells of the crypts of Lieberkuhn in the small intestine.<sup>910</sup> Note that one of the major functions of Paneth cells is to prevent translocation of intestinal bacteria by secreting hydrolytic enzymes and antibacterial peptides to the crypt lumens. The similarity in mechanisms of degradation of secretory granules in these 2 different types of secretory cells sustains the concept of the protective role of autophagy when “self-inflicted” damage may occur due to overreaction and/or secretory malfunction in specialized cells.

Zymophagy can be monitored by TEM, identifying autophagosomes containing secretory granules, by following SQSTM1 degradation by western blot, and by examining the subcellular localization of VMP1-EGFP, which relocates to granular areas of the cell upon zymophagy induction. Colocalization of PRSS1/trypsinogen (which is packaged within zymogen granules) and LC3, or of GFP-ubiquitin (which is recruited to the activated granules) with RFP-LC3 can also be observed by indirect or direct immunofluorescence microscopy, respectively. Active trypsin is also detectable in zymophagosomes and participates in the early onset of acute pancreatitis (F. Fortunato et al., unpublished data).

### 11. Autophagic sequestration assays

Although it is useful to employ autophagic markers such as LC3 in studies of autophagy, LC3-II levels or LC3 dots cannot quantify actual autophagic activity, since LC3-II is not involved in all cargo sequestration events, and LC3-II can be found on phagophores and nonautophagosomal membranes in addition to autophagosomes. Thus, quantification of autophagic markers such as LC3 does not tell how much cargo material has actually been sequestered inside autophagosomes. Moreover, LC3 and several other autophagic markers cannot be used to monitor noncanonical autophagy. Autophagic sequestration assays constitute marker-independent methods to measure the sequestration of autophagic cargo into autophagosomal compartments, and are among the few functional autophagy assays described to date. Macroautophagic cargo sequestration activity can be monitored using either an (electro)injected, inert cytosolic marker such as [<sup>3</sup>H]-raffinose<sup>911</sup> or an endogenous cytosolic protein such as LDH/lactate dehydrogenase,<sup>912</sup> in the latter case along with treatment with a protease inhibitor (e.g.,

leupeptin) or other inhibitors of lysosomal activity (e.g., bafilomycin A<sub>1</sub>)<sup>216</sup> to prevent intralysosomal degradation of the protein marker. The assay simply measures the transfer of cargo from the soluble (cytosol) to the insoluble (sedimentable) cell fraction (which includes autophagic compartments), with no need for a sophisticated subcellular fractionation. Electrodissolution of the plasma membrane followed by centrifugation through a density cushion was originally used to separate cytosol from sedimentable cell fractions in primary hepatocytes.<sup>913</sup> This method has also been used in various human cancer cell lines and mouse embryonic fibroblasts, where the LDH sequestration assay has been validated with pharmacological agents as well as genetic silencing or knockout of key factors of the autophagic machinery (N. Engedal, unpublished results).<sup>143,216,914</sup> Moreover, a downscaling and simplification of the method that avoids the density cushion has been introduced.<sup>914</sup> Homogenization and sonication techniques have also been successfully used for the LDH sequestration assay.<sup>658,915</sup> The endogenous LDH cargo marker can be quantified by an enzymatic assay, or by western blotting. In principle, any intracellular component can be used as a cargo marker, but cytosolic enzymes having low sedimentable backgrounds are preferable. Membrane-associated markers are less suitable, and proteins such as LC3, which are part of the sequestering system itself, will have a much more complex relationship to the autophagic flux than a pure cargo marker such as LDH.

In yeast, sequestration assays are typically done by monitoring protease protection of an autophagosome marker or a cargo protein. For example, prApe1, and GFP-Atg8 have been used to follow completion of the autophagosome.<sup>916</sup> The relative resistance or sensitivity to an exogenous protease in the absence of detergent is an indication of whether the autophagosome (or other sequestering vesicle) is complete or incomplete, respectively. Thus, this method also distinguishes between a block in autophagosome formation versus fusion with the vacuole. The critical issues to keep in mind involve the use of appropriate control strains and/or proteins, and deciding on the correct reporter protein. In addition to protease protection assays, sequestration can be monitored by fluorescence microscopy during pexophagy of methanol-induced peroxisomes, using GFP-Atg8 as a pexophagosome marker and BFP-SKL to label the peroxisomes. The vacuolar sequestration process during micropexophagy can also be monitored by formation of the vacuolar sequestering membrane stained with FM 4-64.<sup>689,697</sup>

Sequestration assays can be designed to measure flux through individual steps of the autophagy pathway. For example, intralysosomally degraded sequestration probes such as [<sup>14</sup>C]-lactate or LDH will mark prelysosomal compartments in the absence of degradation inhibitors. Hence, their accumulation in such compartments can be observed when fusion with lysosomes is suppressed, for example, by a microtubule inhibitor such as vinblastine.<sup>917</sup> Furthermore, lactate hydrolysis can be used to monitor the overall autophagic pathway (autophagic lactolysis).<sup>918</sup> One caveat, however, is that inhibitors may affect sequestration indirectly, for example, by modifying the uptake and metabolism (including protein synthesis) of autophagy-suppressive amino acids (see *Autophagy inhibitors and inducers*). Under

some conditions, such as amino acid starvation, sequestered LDH *en route* through the autophagosome-lysosome pathway can also be detected in the absence of inhibitors.<sup>216</sup>

A variation of this approach applicable to mammalian cells includes live cell imaging. Autophagy induction is monitored as the movement of cargo, such as mitochondria, to GFP-LC3-colocalizing compartments, and then fusion/flux is measured by delivery of cargo to lysosomal compartments.<sup>331,919</sup> In addition, sequestration of fluorescently tagged cytosolic proteins into membranous compartments can be measured, as fluorescent puncta become resistant to the detergent digitonin.<sup>920</sup> Use of multiple time points and monitoring colocalization of a particular cargo with GFP-LC3 and lysosomes can also be used to assess sequestration of cargo with autophagosomes as well as delivery to lysosomes.<sup>758</sup>

In the *Drosophila* fat body, the localization of free cytosolic mCherry changes from a diffuse to a punctate pattern in an *Atg* gene-dependent manner, and these mCherry dots colocalize with the lysosomal marker Lamp1-GFP during starvation (G. Juhasz, unpublished data). Thus, the redistribution of free cytosolic mCherry may be used to follow bulk, nonselective autophagy due to its stability and accumulation in autolysosomes.

**Cautionary notes:** The electro-injection of radiolabeled probes is technically demanding, but the use of an endogenous cytosolic protein probe is very simple and requires no pretreatment of the cells other than with a protease inhibitor. Another concern with electro-injection is that it can affect cellular physiology, so it is necessary to verify that the cells behave properly under control situations such as amino acid deprivation. An alternate approach for incorporating exogenous proteins into mammalian cell cytosol is to use “scrape-loading,” a method that works for cells that are adherent to tissue culture plates.<sup>921</sup> Finally, these assays work well with hepatocytes but may be problematic with other cell types, and it can be difficult to load the cell while retaining the integrity of the compartments in the post-nuclear supernatant (S. Tooze, unpublished results). General points of caution to be addressed with regard to live cell imaging relate to photobleaching of the fluorophore, cell injury due to repetitive imaging, autofluorescence in tissues containing lipofuscin, and the pH sensitivity of the fluorophore.

There are several issues to keep in mind when monitoring sequestration by the protease protection assay in yeast.<sup>916</sup> First, as discussed in *Selective types of autophagy*, prApe1 is not an accurate marker for nonselective autophagy; import of prApe1 utilizes a receptor (Atg19) and a scaffold (Atg11) that make the process specific. In addition, vesicles that are substantially smaller than autophagosomes can effectively sequester the Cvt complex. Another problem is that prApe1 cannot be used as an autophagy reporter for mutants that are not defective in the Cvt pathway, although this can be bypassed by using a *vac8Δ* background.<sup>922</sup> At present, the prApe1 assay cannot be used in any system other than yeast. The GFP-Atg8 protease protection assay avoids these problems, but the signal-to-noise ratio is typically substantially lower. In theory, it should be possible to use this assay in other cell types, and protease protection of GFP-LC3 and GFP-SQSTM1 has been analyzed in HeLa cells.<sup>923</sup> Finally, tendencies of GFP-LC3 and particularly GFP-SQSTM1 to aggregate may make LC3 and SQSTM1 inaccessible to proteases.

**Conclusion:** Sequestration assays represent the most direct method for monitoring autophagy, and in particular for discriminating between conditions where the autophagosome is complete (but not fused with the lysosome/vacuole) or open (that is, a phagophore). These assays can also be modified to measure autophagic flux.

## 12. Turnover of autophagic compartments

Inhibitors of autophagic sequestration (e.g., amino acids, 3-MA or wortmannin) can be used to monitor the disappearance of autophagic elements (phagophores, autophagosomes, autolysosomes) to estimate their half-life by TEM morphometry/stereology. The turnover of the autophagosome or the autolysosome will be differentially affected if fusion or intralysosomal degradation is inhibited.<sup>12,14,25,924</sup> The duration of such experiments is usually only a few hours; therefore, long-term side effects or declining effectiveness of the inhibitors can be avoided. It should be noted that fluorescence microscopy has also been used to monitor the half-life of autophagosomes, monitoring GFP-LC3 in the presence and absence of bafilomycin A<sub>1</sub> or following GFP-LC3 after starvation and recovery in amino acid-rich medium (see *Atg8/LC3 detection and quantification*).<sup>16,925</sup>

**Cautionary notes:** The inhibitory effect must be strong and the efficiency of the inhibitor needs to be tested under the experimental conditions to be employed. Cycloheximide is sometimes used as an autophagy inhibitor, but its use in long-term experiments is problematic because of the many potential indirect effects. Cycloheximide inhibits translational elongation, and therefore protein synthesis. In addition, it decreases the efficiency of protein degradation in several cell types (A.M. Cuervo, personal communication) including hematopoietic cells (A. Edinger, personal communication). Treatment with cycloheximide causes a potent increase in MTORC1 activity, which can decrease autophagy in part as a result of the increase in the amino acid pool resulting from suppressed protein synthesis (H.-M. Shen, personal communication; I. Topisirovic, personal communication).<sup>926,927</sup> In addition, at high concentrations (in the millimolar range) cycloheximide inhibits complex I of the mitochondrial respiratory chain,<sup>928,929</sup> but this is not a problem, at least in hepatocytes, at low concentrations (10–20 μM) that are sufficient to prevent protein synthesis (A.J. Meijer, personal communication).

**Conclusion:** The turnover of autophagic compartments is a valid method for monitoring autophagic-lysosomal flux, but cycloheximide must be used with caution in long-term experiments.

## 13. Autophagosome-lysosome colocalization and dequenching assay

Another method to demonstrate the convergence of the autophagic pathway with a functional degradative compartment is to incubate cells with the bovine serum albumin derivative dequenched (DQ)-BSA that has been labeled with the red-fluorescent BODIPY TR-X dye; this conjugate will accumulate in lysosomes. The labeling of DQ-BSA is so extensive that the fluorophore is self-quenched. Proteolysis of this compound results in dequenching and the release of brightly fluorescent



fragments. Thus, DQ-BSA is useful for detecting intracellular proteolytic activity as a measure of a functional lysosome.<sup>930</sup>

Furthermore, DQ-BSA labeling can be combined with GFP-LC3 to monitor colocalization, and thus visualize the convergence, of amphisomes with a functional degradative compartment (DQ-BSA is internalized by endocytosis). This method can also be used to visualize fusion events in real-time experiments by confocal microscopy (live cell imaging). Along similar lines, other approaches for monitoring convergence are to follow the colocalization of RFP-LC3 and LysoSensor Green (M. Bains and K.A. Heidenreich, personal communication), mCherry-LC3 and LysoSensor Blue,<sup>332</sup> or tagged versions of LC3 and LAMP1 (K. Macleod, personal communication) or CD63<sup>331</sup> as a measure of the fusion of autophagosomes with lysosomes. It is also possible to trace autophagic events by visualizing the pH-dependent excitation changes of the coral protein Keima.<sup>760</sup> This quantitative technique is capable of monitoring the fusion of autophagosomes with lysosomes, that is, the formation of an autolysosome, and the assay does not depend on the analysis of LC3.

**Cautionary notes:** Some experiments require the use of inhibitors (e.g., 3-MA or wortmannin) or overexpression of proteins (e.g., RAB7 dominant negative mutants) that may also affect the endocytic pathway or the delivery of DQ-BSA to lysosomes (e.g., wortmannin causes the swelling of late endosomes<sup>931</sup>). In this case, the lysosomal compartment can be labeled with DQ-BSA overnight before treating the cells with the drugs, or prior to the transfection.

**Conclusion:** DQ-BSA provides a relatively convenient means for monitoring lysosomal protease function and can also be used to follow the fusion of amphisomes with the lysosome. Colocalization of autophagosomes (fluorescently tagged LC3) with lysosomal proteins or dyes can also be monitored.

#### 14. Tissue fractionation

The study of autophagy in the organs of larger animals, in large numbers of organisms with very similar characteristics, or in tissue culture cells provides an opportunity to use tissue fractionation techniques as has been possible with autophagy in rat liver.<sup>35,54,932-937</sup> Because of their sizes (smaller than nuclei but larger than membrane fragments [microsomes]), differential centrifugation can be used to obtain a subcellular fraction enriched in mitochondria and organelles of the autophagy-lysosomal system, which can then be subjected to density gradient centrifugation to enrich autophagosomes, amphisomes, autolysosomes and lysosomes.<sup>35,54,937-941</sup> Any part of such a fraction can be considered to be a representative sample of tissue constituents and used in quantitative biochemical, centrifugational and morphological studies of autophagic particle populations.

The simplest studies of the autophagic process take advantage of sequestered marker enzymes, changes in location of these enzymes, differences in particle/compartment size and differential sensitivity of particles of different sizes to mechanical and osmotic stress (e.g., acid hydrolases are found primarily in membrane-bound compartments and their latent activities cannot be measured unless these membranes are lysed). Such a change in enzyme accessibility can be used to follow the time

course of an exogenously induced, or naturally occurring, autophagic process.<sup>932,934,936</sup>

Quantitative localization of enzymatic activity (or any other marker) to specific cytoplasmic particle populations and changes in the location of such markers during autophagy can be assessed by using rate sedimentation ultracentrifugation.<sup>938</sup> Similar results can be obtained with isopycnic centrifugation where particles enter a density gradient (sometimes made with sucrose but iso-osmotic media such as iodixanol, metrizamide and Nycodenz may be preferred as discussed below under *Cautionary notes*) and are centrifuged until they reach locations in the gradient where their densities are equal to those of the gradient.<sup>938</sup>

The fractionation of organelles can also be evaluated by protein-correlation-profiling, a quantitative mass spectrometry-based proteomics approach. Similar to the biochemical assays described above, gradient profiles of marker proteins can be recorded and compared to proteins of interest.<sup>362</sup> Compared to classical biochemical approaches, protein-correlation-profiling allows the proteome-wide recording of protein gradient profiles.

Particle populations in subcellular fractions evaluated with quantitative biochemical and centrifugational approaches can also be studied with quantitative morphological methods. Detailed morphological study of the particle populations involved in the autophagic process usually requires the use of EM. The thin sections required for such studies pose major sampling problems in both intact cells<sup>942</sup> and subcellular fractions.<sup>938</sup> With the latter, 2,000,000 sections can be obtained from each 0.1 ml of pellet volume, so any practical sample size is an infinitesimally small subsample of the total sample.<sup>938</sup> However, through homogenization and resuspension, complex and heterogeneous components of subcellular fractions become randomly distributed throughout the fraction volume. Therefore, any aliquot of that volume can be considered a random sample of the whole volume. What is necessary is to conserve this property of subcellular fractions in the generation of a specimen that can be examined with the electron microscope. This can be done with the use of a pressure filtration procedure.<sup>942,938</sup> Because of the thinness of the sections, multiple sections of individual particles are possible so morphometric/stereological methods<sup>942</sup> must be used to determine the volume occupied by a given class of particles, as well as the size distribution and average size of the particle class. From this information the number of particles in a specific particle class can be calculated.<sup>944</sup> Examination of individual profiles gives information on the contents of different types of particles and their degree of degradation, as well as their enclosing membranes.<sup>932,934</sup>

**Cautionary notes:** When isolating organelles from tissues and cells in culture it is essential to use disruption methods that do not alter the membrane of lysosomes and autophagosomes, compartments that are particularly sensitive to some of those procedures. For example teflon/glass motor homogenization is suitable for tissues with abundant connective tissue, such as liver, but for circulating cells or cells in culture, disruption by nitrogen cavitation is a good method to preserve lysosomal membrane stability;<sup>945</sup> however, this method is not suitable for small samples and may not be readily available. Other methods,

including “Balch” or “Dounce” homogenizers also work well.<sup>946,947</sup> During the isolation procedure it is essential to always use iso-osmotic solutions to avoid hypotonic or hypertonic disruption of the organelles. In that respect, because lysosomes are able to take up sucrose if it is present at high concentrations, the use of sucrose gradients for the isolation of intact lysosome-related organelles is strongly discouraged. It should also be noted that several commercially available kits for subcellular fractionation contain reducing compounds such as dithiothreitol, which may affect the redox status of any prepared fractions. Since numerous proteins involved in autophagy are redox sensitive (an area requiring much additional experimentation), there exists the potential for redox-active compounds in kits to interfere with results. As such, it is suggested to make solutions for fractionation within the laboratory, whenever possible.

As with the isolation of any other intracellular organelle, it is essential to assess the purity of each preparation, as there is often considerable variability from experiment to experiment due to the many steps involved in the process. Correction for purity can be done through calculation of recovery (percentage of the total activity present in the homogenate) and enrichment (dividing by the specific activity in the homogenate) of enzymes or protein markers for those compartments (e.g., HEX/β-hexosaminidase is routinely used to assess lysosomal purity, but enzymes such as CTSB may also be used and may provide more accurate readouts).<sup>945</sup> Because of the time-consuming nature of quantitative morphological studies, such studies should not be carried out until simpler biochemical procedures have established the circumstances most likely to give meaningful morphometric/stereological results.

Finally, it is worthwhile noting that not all lysosomes are alike. For example, there are differences among primary lysosomes, autolysosomes and telolysosomes. Furthermore, what we refer to as “lysosomes” are actually a very heterogeneous pool of organelles that simply fulfill 5 classical criteria, having a pH <5.6, mature cathepsins, the presence of LAMP proteins, a single membrane, and the absence of endosomal and recycling compartment markers (e.g., M6PR/mannose-6-phosphate receptor or RAB5). But even applying those criteria we can separate lysosomes with clear differences in their proteome and other properties, and these distinct populations of lysosomes are likely to participate in different functions in the cell (see *Chaperone-mediated autophagy*).<sup>948</sup>

**Conclusion:** Considering the limited methods available for in vivo analysis of autophagy, tissue fractionation is a valid, although relatively laborious, method for monitoring autophagy. Care must be taken to ensure that sample analysis is representative.

## 15. Analyses in vivo

Monitoring autophagic flux in vivo or in organs is one of the least developed areas at present, and ideal methods relative to the techniques possible with cell culture may not exist. Importantly, the level of basal autophagy, time course of autophagic induction, and the bioavailability of autophagy-stimulating and -inhibiting drugs is likely tissue specific. Moreover, basal autophagy or sensitivity to autophagic induction may vary with

animal age, sex or strain background. Therefore methods may need to be optimized for the tissue of interest. One method for in vivo studies is the analysis of GFP-LC3/Atg8 (see *GFP-Atg8/LC3 fluorescence microscopy*). Autophagy can be monitored in tissue (e.g., skeletal muscle, liver, brain and retina) in vivo in transgenic mice systemically expressing GFP-LC3,<sup>153,606,949,950</sup> or in other models by transfection with GFP-LC3 plasmids or in transgenic strains that possess either mCherry- or GFP-LC3/Atg8 under control of either inducible or *LC3/Atg8* promoter sequences.<sup>281,468,764</sup> It should be noted that tissues such as white adipose tissue, ovary, and testes and some brain regions such as the hypothalamus do not appear to express the *Actb* promoter-driven *GFP-Lc3* transgene strongly enough to allow detection of the fluorescent protein.<sup>153</sup> In addition, tissue-specific GFP-LC3 mice have been generated for monitoring cardiac myocytes.<sup>951,952</sup> In these settings, GFP fluorescent puncta are indicative of autophagic structures; however, the use of a lysosomal fusion or protease inhibitor would be needed to assess flux. Cleavage of GFP-LC3 to generate free GFP can be evaluated as one method to monitor the completion of autophagy. This has been successfully performed in mouse liver,<sup>257,747</sup> suggesting the GFP-LC3 cleavage assay may also be applied to in vivo studies. Note that the accumulation of free GFP in the mouse brain is minimal after autophagy is induced with rapamycin (autophagy induction based on GFP-LC3 imaging and SQSTM1 IHC; M. Lipinski, personal communication), but significant when autophagic flux is partially blocked after traumatic brain injury.<sup>950</sup> Thus, caution needs to be taken when interpreting results of these assays in different tissues. We also recommend including a control under conditions known to induce autophagic flux such as starvation. A simple methodology to measure autophagic flux in the brain was described.<sup>953</sup> This strategy combines the generation of adeno-associated virus and the use of the dynamic fluorescent reporter mCherry-GFP-LC3, that allows an extended transduction and stable expression of mCherry-GFP-LC3 after intracerebroventricular injection in newborn animals. With this approach, a widespread transduction level is achieved along neurons at the central nervous system when newborn pups are injected, including pyramidal cortical and hippocampal neurons, Purkinje cells, and motor neurons in the spinal cord and also, to a lesser extent, in oligodendrocytes.<sup>953</sup> The use of different serotypes of adeno-associated virus could be used to transduce other cell types at the CNS.<sup>953,954</sup> This methodology allows a reproducible and sensitive mCherry-GFP-LC3 detection, and a strong LC3 flux when animals are treated with autophagy inducers including rapamycin and trehalose.<sup>955</sup> Therefore, these combined strategies can be applied to monitor autophagy activity in mice and also determine autophagy alterations in animal models of diseases affecting the nervous system.<sup>953,954</sup> Alternatively, confocal laser scanning microscopy, which makes it possible to obtain numerous sections and substantial data about spatial localization features, can be a suitable system for studying autophagic structures (especially for whole mount embryo in vivo analysis).<sup>956</sup> In addition, this method can be used to obtain quantitative data through densitometric analysis of fluorescent signals.<sup>957</sup>

Another possibility is immunohistochemical staining, an important procedure that may be applicable to human studies

as well considering the role of autophagy in neurodegeneration, myopathies and cardiac disease where samples may be limited to biopsy/autopsy tissue. Immunodetection of LC3 as definite puncta is possible in paraffin-embedded tissue sections and fresh frozen tissue, by either IHC or immunofluorescence;<sup>197,958-964</sup> however, this methodology has not received extensive evaluation, and does not lend itself well to dynamic assays. Other autophagic substrates can be evaluated via IHC and include SQSTM1, NBR1, ubiquitinated inclusions and protein aggregates. Similarly, autophagy can be evaluated by measuring levels of these autophagic substrates via traditional immunoblot; however, their presence or absence needs to be cautiously interpreted as some of these substrates can accumulate with either an increase or a decrease in autophagic flux (see *SQSTM1 and related LC3 binding protein turnover assays*). Bone marrow transfer has been used to document in vivo the role of autophagy in the reverse cholesterol transport pathway from peripheral tissues or cells (e.g., macrophages) to the liver for secretion in bile and for excretion,<sup>965</sup> and a study shows that TGM2 (transglutaminase 2) protein levels decrease in mouse liver in vivo upon starvation in an autophagy-dependent manner (and in human cell lines in vitro in response to various stimuli; M. Piacentini, personal communication), presenting additional possible methods for following autophagy activity. In that respect, it is noteworthy to mention that TGM2 can negatively affect autophagy by modifying ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) and suppressing its Ca<sup>2+</sup>-release activity.<sup>966</sup>

It is also possible to analyze tissues ex vivo, and these studies can be particularly helpful in assessing autophagic flux as they avoid the risks of toxicity and bioavailability of compounds such as bafilomycin A<sub>1</sub> or other autophagy inhibitors. Along these lines, autophagic flux can be determined by western blot in retinas placed in culture for 4 h with protease inhibitors.<sup>967,968</sup> This method could be used in tissues that can remain “alive” for several hours in culture such as the retina,<sup>967,968</sup> brain slices,<sup>950,969</sup> and spinal cord slices.<sup>970</sup>

Several studies have demonstrated the feasibility of monitoring autophagic flux in vivo in skeletal muscle. Starvation is one of the easiest and most rapid methods for stimulating the autophagic machinery in skeletal muscles. 12 h of fasting in mice may be sufficient to trigger autophagy in muscle,<sup>971,972</sup> but the appropriate time should be determined empirically. It is also important to consider that the expression of autophagy-related factors, as well as the autophagic response to various stimuli and disease states, can differ between muscles of different fiber type, metabolic, and contractile properties.<sup>153,974-976</sup> Thus, which muscle(s) or portion of muscle(s) used for analysis should be carefully considered and clearly outlined. Although food deprivation does not induce detectable macroautophagy in the brain it induces macroautophagy in the retina, and by the use of in vivo injection of leupeptin autophagic flux can be evaluated with LC3 lipidation by western blot.<sup>968</sup> Although difficult to standardize and multifactorial, exercise may be a particularly appropriate stimulus to use for assessing macroautophagy in skeletal muscle.<sup>950,977</sup> Data about the autophagic flux can be obtained by treating mice with, for example, chloroquine,<sup>972</sup> leupeptin<sup>969,978</sup> or colchicine<sup>224</sup> and then monitoring the change in accumulation of LC3 (see cautionary

notes). This type of analysis can also be done with liver, by comparing the LC3-II level in untreated liver (obtained by a partial hepatectomy) to that following subsequent exposure to chloroquine (V. Skop, Z. Papackova and M. Cahová, personal communication). Additional reporter assays to monitor autophagic flux in vivo need to be developed, including tandem fluorescent-LC3 transgenic mice, or viral vectors to express this construct in vivo in localized areas. One of the challenges of studying autophagic flux in intact animals is the demonstration of cargo clearance, but studies of fly intestines that combine sophisticated mosaic mutant cell genetics with imaging of mitochondrial clearance reveal that such analyses are possible.<sup>764</sup>

Another organ particularly amenable to ex vivo analysis is the heart, with rodent hearts easily subjected to perfusion by the methods of Langendorff established in 1895 (for review see ref. 978). Autophagy has been monitored in perfused hearts,<sup>979</sup> where it is thought to be an important process in several modes of cardioprotection against ischemic injury.<sup>980</sup> It should be noted that baseline autophagy levels (as indicated by LC3-II) appear relatively high in the perfused heart, although this may be due to perceived starvation by the ex vivo organ, highlighting the need to ensure adequate delivery of metabolic substrates in perfusion media, which may include the addition of INS/insulin. Another concern is that the high partial pressure of oxygen of the perfusate (e.g., buffer perfused with 95%/5% [O<sub>2</sub>/CO<sub>2</sub>]) used in the Langendorff method makes this preparation problematic for the study of autophagy because of the high levels of oxidation (redox disturbances) resulting from the preparation. Therefore, great caution should be exercised in interpretation of these results.

Human placenta also represents an organ suitable for ex vivo studies, such as to investigate pregnancy outcome abnormalities. Autophagy has been evaluated in placentas from normal pregnancies<sup>981-983</sup> identifying a baseline autophagy level (as indicated by LC3-II) in uneventful gestation. In cases with abnormal pregnancy outcome, LC3-II is increased in placentas complicated by intrauterine growth restriction in cases both from singleton pregnancies<sup>984</sup> and from monochorionic twins pregnancies.<sup>985</sup> Moreover, placentas from pregnancies complicated by preeclampsia show a higher level of LC3-II than normal pregnancies.<sup>986</sup> Finally, placentas from acidotic newborns developing neonatal encephalopathy exhibit a higher IHC LC3 expression than placentas from newborn without neonatal encephalopathy.<sup>987</sup> For this reported association, further investigations are needed to assess if autophagy protein expression in placentas with severe neonatal acidosis could be a potential marker for poor neurological outcome.

The retina is a very suitable organ for ex vivo as well as in vivo autophagy determination. The retina is a part of the central nervous system, is readily accessible and can be maintained in organotypic cultures for some time allowing treatment with protease and autophagy inhibitors. This allows determination of autophagic flux ex vivo in adult and embryonic retinas by western blot<sup>394,967</sup> as well as by flow cytometry and microscopy analysis.<sup>968</sup> Moreover, only 4 h of leupeptin injection in fasted mice allows for autophagic flux assessment in the retina<sup>968</sup> indicating 2 things: first, food deprivation induces autophagy in selected areas of the central nervous system; and second, leupeptin can cross the blood-retinal barrier.

In vivo analysis of the autophagic flux in the brain tissue of neonatal rats can also be performed. These studies use the intraperitoneal administration of the acidotropic dye monodansylcadaverine (MDC) to pup rats 1 h before sacrifice, followed by the analysis of tissue labeling through fluorescence or confocal laser scanning microscopy (365/525-nm excitation/emission filter). This method was adapted to study autophagy in the central nervous system after its validation in cardiac tissue.<sup>988</sup> MDC labels acidic endosomes, lysosomes, and late-stage autophagosomes, and its labeling is upregulated under conditions that increase autophagy.<sup>989</sup> In a neonatal model of hypoxic-ischemic brain injury, where autophagy activation is a direct consequence of the insult,<sup>990</sup> MDC labeling is detectable only in the ischemic tissue, and colocalizes with LC3-II.<sup>991</sup> The number of MDC- and LC3-II-positive structures changes when autophagy is pharmacologically up- or downregulated.<sup>991,992</sup> Whether this method can also be used in adult animals needs to be determined. Furthermore, it should be kept in mind that staining with MDC is not, by itself, a sufficient method for monitoring autophagy (see *Acidotropic dyes*).

Another approach that can be used in vivo in brain tissue is to stain for lysosomal enzymes. In situations where an increase in autophagosomes has been shown (e.g., by immunostaining for LC3 and immunoblotting for LC3-II), it is important to show whether this is due to a shutdown of the lysosomal system, causing an accumulation of autophagosomes, or whether this is due to a true increase in autophagic flux. The standard methods described above for in vitro research, such as the study of clearance of a substrate, are difficult to use in vivo, but if it can be demonstrated that the increase in autophagosomes is accompanied by an increase in lysosomes, this makes it very likely that there has been a true increase in autophagic flux. Lysosomal enzymes can be detected by IHC (e.g., for LAMP1 or CTSD) or by classical histochemistry to reveal their activity (e.g., ACP/acid phosphatase or HEX/ $\beta$ -hexosaminidase).<sup>993-995</sup>

Some biochemical assays may be used to at least provide indirect correlative data relating to autophagy, in particular when examining the role of autophagy in cell death. For example, cellular viability is related to high CTSD activity and low CTSD activities.<sup>996</sup> Therefore, the appearance of the opposite levels of activities may be one indication of the initiation of autophagy (lysosome)-dependent cell death. The question of “high” versus “low” activities can be determined by comparison to the same tissue under control conditions, or to a different tissue in the same organism, depending on the specific question.

**Cautionary notes:** The major hurdle with in vivo analyses is the identification of autophagy-specific substrates and the ability to “block” autophagosome degradation with a compound such as bafilomycin A<sub>1</sub>. Regardless, it is still essential to adapt the same rigors for measuring autophagic flux in vitro to measurements made with in vivo systems. Moreover, as with cell culture, to substantiate a change in autophagic flux it is not adequate to rely solely on the analysis of static levels or changes in LC3-II protein levels on western blot using tissue samples. To truly measure in vivo autophagic flux using LC3-II as a biomarker, it is necessary to block lysosomal degradation of the protein. Several studies have successfully done this in select tissues in vivo. Certain general principles need to be kept in

mind: (a) Any autophagic blocker, whether leupeptin, bafilomycin A<sub>1</sub>, chloroquine or microtubule depolarizing agents such as colchicine or vinblastine, must significantly increase basal LC3-II levels. The turnover of LC3-II or rate of basal autophagic flux is not known for tissues in vivo, and therefore short treatments (e.g., 4 h) may not be as effective as blocking for longer times (e.g., 12 to 24 h). (b) The toxicity of the blocking agent needs to be considered (e.g., treating animals with bafilomycin A<sub>1</sub> for 2 h can be quite toxic), and food intake must be monitored. If long-term treatment is needed to see a change in LC3-II levels, then confirmation that the animals have not lost weight may be needed. Mice may lose a substantial portion of their body weight when deprived of food for 24 h, and starvation is a potent stimulus for the activation of autophagy. (c) The bioavailability of the agent needs to be considered. For example, many inhibitors such as bafilomycin A<sub>1</sub> or chloroquine have relatively poor bioavailability to the central nervous system. To overcome this problem, intracerebroventricular injection can be performed.

A dramatic increase of intracellular free poly-unsaturated fatty acid levels can be observed by proton nuclear magnetic resonance spectroscopy in living pancreatic cancer cells within 4 h of autophagy inhibition by omeprazole, which interacts with the V-ATPase and probably inhibits autophagosome-lysosome fusion. Omeprazole is one of the most frequently prescribed drugs worldwide and shows only minor side effects even in higher doses. Proton nuclear magnetic resonance spectroscopy is a noninvasive method that can be also applied as localized spectroscopy in magnetic resonance tomography and therefore opens the possibility of a noninvasive, clinically applicable autophagy monitoring method, although technical issues still have to be solved.<sup>997</sup>

When analyzing autophagic flux in vivo, one major limitation is the variability between animals. Different animals do not always activate autophagy at the same time. To improve the statistical relevance and avoid unclear results, these experiments should be repeated more than once, with each experiment including several animals. Induction of autophagy in a time-dependent manner by fasting mice for different times requires appropriate caution. Mice are nocturnal animals, so they preferentially move and eat during the night, while they mostly rest during daylight. Therefore, in such experiments it is better to start food deprivation early in the morning, to avoid the possibility that the animals have already been fasting for several hours. The use of chloroquine for flux analysis is technically easier, since it only needs one intraperitoneal injection per day, but the main concern is that chloroquine has some toxicity. Chloroquine suppresses the immunological response in a manner that is not due to its pH-dependent lysosomotropic accumulation (chloroquine interferes with lipopolysaccharide-induced *Tnf/Tnf- $\alpha$*  gene expression by a nonlysosomotropic mechanism),<sup>998</sup> as well as through its pH-dependent inhibition of antigen presentation.<sup>999</sup> Therefore, chloroquine treatment should be used for short times and at doses that do not induce severe collateral effects, which may invalidate the measurement of the autophagic flux, and care must be exercised in using chloroquine for studies on autophagy that involve immunological aspects. It is also important to have time-matched controls for in vivo analyses. That is, having only a zero hour time point

control is not sufficient because there may be substantial diurnal changes in basal autophagy.<sup>644</sup> For example, variations in basal flux in the liver associated with circadian rhythm may be several fold,<sup>1000</sup> which can equal or exceed the changes due to starvation. Along these lines, to allow comparisons of a single time-point it is important to specify what time of day the measurement is taken and the lighting conditions under which the animals are housed. It is also important that the replicate experiments are conducted at the same time of day. Controlling for circadian effects can greatly reduce the mouse-to-mouse variability in autophagy markers and flux (J.A. Haspel and A. M.K. Choi, personal communication).

When analyzing the basal autophagic level in vivo using GFP-LC3 transgenic mice,<sup>153</sup> one pitfall is that GFP-LC3 expression is driven by the *Cmv/cytomegalovirus* enhancer and *Actb/β-actin* (CAG) promoter, so that the intensity of the GFP signal may not always represent the actual autophagic activity, but rather the CAG promoter activity in individual cells. For example, GFP-LC3 transgenic mice exhibit prominent fluorescence in podocytes, but rarely in tubular epithelial cells in the kidney,<sup>153</sup> but a similar GFP pattern is observed in transgenic mice carrying CAG promoter-driven non-tagged GFP.<sup>1001</sup> Furthermore, proximal tubule-specific ATG5-deficient mice<sup>1002</sup> display a degeneration phenotype earlier than podocyte-specific ATG5-deficient mice,<sup>1003</sup> suggesting that autophagy, and hence LC3 levels, might actually be more prominent in the former.

One caution in using approaches that monitor ubiquitinated aggregates is that the accumulation of ubiquitin may indicate a block in autophagy or inhibition of proteasomal degradation, or it may correspond to structural changes in the substrate proteins that hinder their degradation. In addition, only cytosolic and not nuclear ubiquitin is subject to autophagic degradation. It is helpful to analyze aggregate degradation in an autophagy-deficient control strain, such as an autophagy mutant mouse, whenever possible to determine whether an aggregate is being degraded by an autophagic mechanism. This type of control will be impractical for some tissues such as those of the central nervous system because the absence of autophagy leads to rapid degeneration. Accordingly, the use of *Atg16l1* hypomorphs or *Becn1* heterozygotes may help circumvent this problem.

**Conclusion:** Although the techniques for analyzing autophagy in vivo are not as advanced as those for cell culture, it is still possible to follow this process (including flux) by monitoring, for example, GFP-LC3 by fluorescence microscopy, and SQSTM1 and NBR1 by IHC and/or western blotting.

## 16. Clinical setting

Altered autophagy is clearly relevant in neurodegenerative disease, as demonstrated by the accumulation of protein aggregates, for example in Alzheimer disease,<sup>1004,1005</sup> Parkinson disease,<sup>1006</sup> polyglutamine diseases,<sup>1007</sup> muscle diseases,<sup>1008</sup> and amyotrophic lateral sclerosis.<sup>1009</sup> Further evidence comes from the observations that the crucial mitophagy regulators PINK1 and PARK2 show loss-of-function mutations in autosomal recessive juvenile parkinsonism,<sup>1010</sup> and that the putative ribophagy regulator VCP/p97 (an ortholog of yeast Cdc48) as well as the autophagy receptor OPTN are mutated in motor neuron disease.<sup>1011,1012</sup> In addition to neurodegenerative

diseases, alterations in autophagy have also been implicated in other neurological diseases including some epilepsies, neuro-metabolic and neurodevelopmental disorders.<sup>969,1013-1015</sup> A very useful nonspecific indicator of deficient autophagy in autopsy brain or biopsy tissue is SQSTM1 IHC.<sup>1016,1017</sup> For clinical attempts to monitor autophagy alterations in peripheral tissues such as blood, it is important to know that eating behavior may be altered as a consequence of the disease,<sup>1018</sup> resulting in a need to control feeding-fasting conditions during the analyses. Recently, altered autophagy was also implicated in schizophrenia, with *BECN1* transcript levels decreasing in the postmortem hippocampus in comparison to appropriate controls.<sup>1019</sup> In the same hippocampal postmortem samples, the correlation between the RNA transcript content for ADNP (activity-dependent neuroprotective homeobox) and its sister protein ADNP2 is deregulated,<sup>1020</sup> and *ADNP* as well as *ADNP2* RNA levels increase in peripheral lymphocytes from schizophrenia patients compared to matched healthy controls, suggesting a potential biomarker.<sup>1019</sup>

Similarly, autophagy inhibition plays a key role in the pathogenesis of inherited autophagic vacuolar myopathies (including Danon disease, X-linked myopathy with excessive autophagy, and infantile autophagic vacuolar myopathy), all of which are characterized by lysosomal defects and an accumulation of autophagic vacuoles.<sup>1021</sup> Autophagic vacuolar myopathies and cardiomyopathies can also be secondary to treatment with autophagy-inhibiting drugs (chloroquine, hydroxychloroquine and colchicine), which are used experimentally to interrogate autophagic flux and clinically to treat malaria, rheumatological diseases, and gout.<sup>964</sup> Autophagy impairment has also been implicated in the pathogenesis of inclusion body myositis, an age-associated inflammatory myopathy that is currently refractory to any form of treatment,<sup>1022-1024</sup> along with other muscular dystrophies such as tibial muscular dystrophy.<sup>1025</sup> In all these striated muscle disorders, definitive tissue diagnosis used to require ultrastructural demonstration of accumulated autophagic vacuoles; more recently, it has been shown that IHC for LC3 and/or SQSTM1 can be used instead.<sup>962-964,1026</sup>

In addition, altered basal autophagy levels are seen in rheumatoid arthritis,<sup>1027,1028</sup> and osteoarthritis.<sup>1029</sup> Other aspects of the immune response associated with dysfunctional autophagy are seen in neutrophils from patients with familial Mediterranean fever<sup>1030</sup> and in monocytes from patients with TNF receptor-associated periodic syndrome,<sup>1031</sup> 2 autoinflammatory disorders. Moreover, autophagy regulates an important neutrophil function, the generation of neutrophil extracellular traps (NETs).<sup>1024,1032</sup> The important role of autophagy in the induction of NET formation has been studied in several neutrophil-associated disorders such as gout,<sup>1033</sup> sepsis,<sup>1034</sup> and lung fibrosis.<sup>1035</sup> Furthermore, there is an intersection between autophagy and the secretory pathway in mammalian macrophages for the release of IL1β,<sup>1036</sup> demonstrating a possible alternative role of autophagy for protein trafficking. This role has also been implied in neutrophils through exposure of protein epitopes on NETs by acidified LC3-positive vacuoles in sepsis<sup>1034</sup> and anti-neutrophil cytoplasmic antibody associated vasculitis.<sup>1037</sup> Patients with chronic kidney disease also have impaired autophagy activation in leukocytes, which is

closely related to their cardiac abnormalities. There is also evidence for altered autophagy in pancreatic beta cells,<sup>1038,1039</sup> and in adipocytes<sup>217,1040,1041</sup> of patients with type 2 diabetes.<sup>1042</sup> However, autophagy also plays an important role in the development in vitro of giant phagocytes, a long-lived neutrophil subpopulation, derived from neutrophils of healthy individuals.<sup>1043,1044</sup>

Photodynamic therapy (PDT), an FDA-approved anticancer therapy, has high selectivity for tumor cell elimination by eliciting efficient apoptosis and autophagy induction and fulfills the need to merge a direct cytotoxic action on tumor cells with potent immunostimulatory effects (i.e., immunogenic cell death, ICD).<sup>1045</sup> A few photosensitizers, such as Photofrin, Hypericin, Foscan, 5-ALA and Rose Bengal acetate, are associated with danger/damage-associated molecular pattern (DAMP) exposure and/or release that is a requisite to elicit ICD. Rose Bengal acetate PDT is the first treatment to induce autophagic HeLa cells to express and release DAMPS, thus suggesting a possible role of the autophagic cells in ICD induction.<sup>1046</sup> Similarly, the photosensitizer Hypocrellin B-acetate is able to induce macroautophagy at very low concentrations.<sup>1047</sup>

A crucial role for therapy-induced autophagy in cancer cells has recently emerged, in modulating the interface of cancer cells and the immune system;<sup>1048</sup> primarily, by affecting the nature of danger signaling (i.e., the signaling cascade that facilitates the exposure and/or release of danger signals) associated with ICD.<sup>1045,1048-1051</sup> This is an important point considering the recent clinical surge in the success of cancer immunotherapy in patients, and the emerging clinical relevance of ICD for positive patient prognosis. Several notorious autophagy-inducing anticancer therapies induce ICD including mitoxantrone, doxorubicin, oxaliplatin, radiotherapy, certain oncolytic viruses and hypericin-based photodynamic therapy (Hyp-PDT).<sup>1051-1054</sup> In fact, in the setting of Hyp-PDT, ER stress-induced autophagy in human cancer cells suppresses CALR (calreticulin) surface exposure (a danger signal crucial for ICD) thereby leading to suppression of human dendritic cell maturation and human CD4<sup>+</sup> and CD8<sup>+</sup> T cell stimulation.<sup>1053</sup> Conversely, chemotherapy (mitoxantrone or oxaliplatin)-induced autophagy facilitates ATP secretion (another crucial ICD-associated danger signal) thereby facilitating ICD and anti-tumor immunity in the murine system, the first documented instance of autophagy-based ICD modulation.<sup>1055</sup> The role of ATP as a DAMP becomes clear when the extracellular concentration of ATP becomes high and elicits activation of the purinergic receptor P2RX7. P2RX7 is involved in several pathways, including the sterile immune response, and its activation induces cancer cell death through PI3K, AKT and MTOR.<sup>1056,1057</sup> In addition, cells lacking the essential chaperone-mediated autophagy (CMA) gene *LAMP2A* fail to expose surface CALR after treatment with both Hyp-PDT and mitoxantrone.<sup>1058</sup> These observations have highlighted the important, context-dependent role of therapy-induced autophagy, in modulating the cancer cell-immune cell interface by regulating the emission of ICD-associated danger signals.<sup>1059</sup> Recent studies also have implicated insufficient autophagy in the pathogenesis of nonresolving vital organ failure and muscle weakness during critical illness, 2 leading causes of death in prolonged critically ill

patients.<sup>1060,1061</sup> Finally, a block of autophagy with consequent accumulation of autophagy substrates is detected in liver fibrosis,<sup>1062,1063</sup> and lysosomal storage diseases.<sup>1064</sup>

It is important to note that disease-associated autophagy defects are not restricted to macroautophagy but also concern other forms of autophagy. CMA impairment, for instance, is associated with several disease conditions, including neurodegenerative disorders,<sup>229,1065</sup> lysosomal storage diseases,<sup>1066,1067</sup> nephropathies<sup>1068</sup> and diabetes.<sup>1069</sup> In addition, it is very important to keep in mind that although human disease is mostly associated with inhibited autophagy, enhanced autophagy has also been proposed to participate in, and even contribute to, the pathogenesis of human diseases, such as chronic obstructive pulmonary disease,<sup>1070</sup> and adipocyte/adipose tissue dysfunction in obesity.<sup>217,1040</sup> Along these lines, chloroquine decreases diabetes risk in patients treated with the drug for rheumatoid arthritis.<sup>1071</sup>

A set of recommendations regarding the design of clinical trials modulating autophagy can be found in ref. 1072.

**Cautionary notes:** To establish a role for autophagy in modulating the interface with the immune system, specific tests need to be performed where genes encoding autophagy-relevant components (e.g., *ATG5*, *ATG7* or *BECN1*) have been knocked down through RNA silencing or other protein- or gene-specific targeting technologies.<sup>1053,1055,1058</sup> Usage of chemical inhibitors such as bafilomycin A<sub>1</sub>, 3-MA or chloroquine can create problems owing to their off-target effects, especially on immune cells, and thus their use should be subjected to due caution, and relevant controls are critical to account for any off-target effects. In the context of ICD, consideration should be given to the observations that autophagy can play a context-dependent role in modulating danger signaling;<sup>1053,1055,1058</sup> and thus, all the relevant danger signals (e.g., surface exposed CALR or secreted ATP) should be (re-)tested for new agents/therapies in the presence of targeted ablation of autophagy-relevant proteins/genes, accompanied by relevant immunological assays (e.g., in vivo rodent vaccination/anti-tumor immunity studies or *ex vivo* immune cell stimulation assays), in order to implicate autophagy in regulating ICD or general immune responses.

## 17. Cell death

In several cases, autophagy has been established as the cause of cell death;<sup>83,281,354,764,1073-1081</sup> although opposite results have been reported using analogous experimental settings.<sup>1082</sup> Furthermore, many of the papers claiming a causative role of autophagy in cell death fail to provide adequate evidence.<sup>1083</sup> Other papers suffer from ambiguous use of the term “autophagic cell death,” which was coined in the 1970s<sup>1084</sup> in a purely morphological context to refer to cell death with autophagic features (especially the presence of numerous secondary lysosomes); this was sometimes taken to suggest a role of autophagy in the cell death mechanism, but death-mediation was not part of the definition.<sup>1085</sup> Unfortunately, the term “autophagic cell death” is now used in at least 3 different ways: (a) Autophagy-associated cell death (the original meaning). (b) Autophagy-mediated cell death (which could involve a standard mechanism of cell death such as apoptosis, but triggered by

autophagy). (c) A distinct mechanism of cell death, independent of apoptosis or necrosis. Clearly claim (b) is stronger than claim (a), and needs to be justified by proof that inhibiting autophagy, through either genetic or chemical means, prevents cell death.<sup>1086</sup> Claim (c) is still stronger, because, even if the cell death is blocked by autophagy inhibition, proof needs to be provided that the cell death mechanism is not apoptosis or necrosis.<sup>1087</sup> In view of the current confusion it may be preferable to replace the term “autophagic cell death” by other terms such as “autophagy-associated cell death” or “autophagy-mediated cell death,” unless the criteria in claim (c) above have been satisfied. Along these lines, it is preferable to use the term “autophagy-dependent cell death” instead of “autophagy-mediated cell death” when it is proven that autophagy is a pre-requisite for the occurrence of cell death, but it is not proven that autophagy mechanistically mediates the switch to cell death. It is important to note that a stress/stimulus can in many circumstances induce different cell death pathways at the same time, which might lead to a “type” of cell death with mixed phenotypes.<sup>1088,1089</sup> Furthermore, inhibition of one cell death pathway (e.g., apoptosis) can either induce the compensatory activation of a secondary mechanism (e.g., necrosis),<sup>1090,1091</sup> or attenuate a primary mechanism (e.g., liponecrosis).<sup>1088</sup>

The role of autophagy in the death of plant cells is less ambiguous, because plants are devoid of the apoptotic machinery and use lytic vacuoles to disassemble dying cells from inside.<sup>1092</sup> This mode of cell death governs many plant developmental processes and was named “vacuolar cell death”.<sup>1093</sup> Recent studies have revealed a key role of autophagy in the execution of vacuolar cell death, where autophagy sustains the growth of lytic vacuoles.<sup>1094,1095</sup> Besides being an executioner of vacuolar cell death, autophagy can also play an upstream, initiator role in immunity-associated cell death related to the pathogen-triggered hypersensitive response.<sup>1092,1096</sup>

Upon induction by starvation during multicellular development in the protist *Dictyostelium*, autophagy (or at least Atg1) is required to protect against starvation-induced cell death, allowing vacuolar developmental cell death to take place instead.<sup>1097,1098</sup> Autophagy may be involved not only in allowing this death to occur, but also, as during vacuolar cell death in plants, in the vacuolization process itself.<sup>1099</sup>

Recently, a novel form of autophagy-dependent cell death has been described, autosis, which not only meets the criteria in claim (c) (i.e., blocked by autophagy inhibition, independent of apoptosis or necrosis), but also demonstrates unique morphological features and a unique ability to be suppressed by pharmacological or genetic inhibition of the Na<sup>+</sup>,K<sup>+</sup>-ATPase.<sup>1080</sup> In addition, the demonstration that autophagy is required for cell death during *Drosophila* development where caspases and necrosis do not appear to be involved may be the best known physiologically relevant model of cell death that involves autophagy.<sup>281,764</sup>

**Cautionary notes:** In brief, rigorous criteria must be met in order to establish a death-mediating role of autophagy, as this process typically promotes cell survival. These include a clear demonstration of autophagic flux as described in this article, as well as verification that inhibition of autophagy prevents cell death (claim [b] above; if using a knockdown approach, at least 2 *ATG* genes should be targeted), and that other mechanisms

of cell death are not responsible (claim [c] above). As part of this analysis, it is necessary to examine the effect of the specific treatment, conditions or mutation on cell viability using several methods.<sup>1090</sup> In the case of postmitotic cells such as neurons or retinal cells, cell death—and cell rescue by autophagy inhibition—can usually be established in vivo by morphological analysis,<sup>1100</sup> and in culture by cell counts and/or measurement of the release of an enzyme such as LDH into the medium at early and late time points; however, a substantial amount of neuronal cell death occurs during neurogenesis, making it problematic to carry out a correct analysis in vivo or ex vivo.<sup>1101,1102</sup> In populations of rapidly dividing cells, the problems may be greater. A commonly used method is the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or a related assay using a similar, or a water-soluble, tetrazolium salt. The main concern with the MTT assay is that it measures mitochondrial activity, but does not allow a precise determination of cellular viability or cell death, whereas methods that show cell death directly (e.g., trypan blue exclusion, or LDH release assay) fail to establish the viability of the remaining cell population.<sup>1103</sup> Accordingly, a preferred alternative is to accurately quantify cell death by appropriate cytofluorometric or microscopy assays.<sup>1090</sup> Moreover, long-term clonogenic assays should be employed when possible to measure the effective functional survival of cells.

**Conclusion:** In most systems, ascribing death to autophagy based solely on morphological criteria is insufficient; autophagic cell death can only be demonstrated as death that is suppressed by the inhibition of autophagy, through either genetic or chemical means.<sup>1086</sup> In addition, more than one assay should be used to measure cell death. In this regard, it is important to mention that neither changes in mitochondrial activity/potential, nor caspase activation or externalization of phosphatidylserine can be accurately used to determine cell death as all these phenomena have been reported to be reversible. Only the determination of cellular viability (ratio between dead/live cells) can be used to accurately determine cell death progression.

## 18. Chaperone-mediated autophagy

The primary characteristic that makes CMA different from the other autophagic variants described in these guidelines is that it does not require formation of intermediate vesicular compartments (autophagosomes or microvesicles) for the import of cargo into lysosomes.<sup>1104,1105</sup> Instead, the CMA substrates are translocated across the lysosomal membrane through the action of HSPA8/HSC70 (heat shock 70kDa protein 8) located in the cytosol and lysosome lumen, and the lysosome membrane protein LAMP2A. To date, CMA has only been identified in mammalian cells, and accordingly this section refers only to studies in mammals.

The following section discusses methods commonly utilized to determine if a protein is a CMA substrate (see ref. 1106 for experimental details):

- a. Analysis of the amino acid sequence of the protein to identify the presence of a KFERQ-related motif that is an absolute requirement for all CMA substrates.<sup>1107</sup>
- b. Colocalization studies with lysosomal markers (typically LAMP2A and/or LysoTracker) to identify a fraction of

the protein associated with lysosomes. The increase in association of the putative substrate under conditions that upregulate CMA (such as prolonged starvation) or upon blockage of lysosomal proteases (to prevent the degradation of the protein) helps support the hypothesis that the protein of interest is a CMA substrate. However, association with lysosomes is necessary but not sufficient to consider a protein an authentic CMA substrate, because proteins delivered by other pathways to lysosomes will also behave in a similar manner. A higher degree of confidence can be attained if the association is preferentially with the subset of lysosomes active for CMA (i.e., those containing HSPA8 in their lumen), which can be separated from other lysosomes following published procedures.<sup>948</sup>

- c. Co-immunoprecipitation of the protein of interest with cytosolic HSPA8. Due to the large number of proteins that interact with this chaperone, it is usually better to perform affinity isolation with the protein of interest and then analyze the isolated proteins for the presence of HSPA8 rather than vice versa.
- d. Co-immunoprecipitation of the protein of interest with LAMP2A.<sup>1108</sup> Due to the fact that the only antibodies specific for the LAMP2A variant (the only 1 of the 3 LAMP2 variants involved in CMA<sup>92,1109</sup>) are generated against the cytosolic tail of LAMP2A, where the substrate also binds, it is necessary to affinity isolate the protein of interest and then analyze for the presence of LAMP2A. Immunoblot for LAMP2A in the precipitate can only be done with the antibodies specific for LAMP2A and not just those that recognize the luminal portion of the protein that is identical in the other LAMP2 variants. If the protein of interest is abundant inside cells, co-immunoprecipitations with LAMP2A can be done in total cellular lysates, but for low abundance cellular proteins, preparation of a membrane fraction (enriched in lysosomes) by differential centrifugation may facilitate the detection of the population of the protein bound to LAMP2A.
- e. Selective upregulation and blockage of CMA to demonstrate that degradation of the protein of interest changes with these manipulations. Selective chemical inhibitors for CMA are not currently available. Note that general inhibitors of lysosomal proteases (e.g., bafilomycin A<sub>1</sub>, NH<sub>4</sub>Cl, leupeptin) also block the degradation of proteins delivered to lysosomes by other autophagic and endosomal pathways. The most selective way to block CMA is by knockdown of LAMP2A, which causes this protein to become a limiting factor.<sup>92</sup> The other components involved in CMA, including HSPA8, HSP90AA1, GFAP, and EEF1A/eF1 $\alpha$ , are all multifunctional cellular proteins, making it difficult to interpret the effects of knockdowns. Overexpression of LAMP2A<sup>1108</sup> is also a better approach to upregulate CMA than the use of chemical modulators. The 2 compounds demonstrated to affect degradation of long-lived proteins in lysosomes,<sup>1110</sup> 6-aminonicotinamide and geldanamycin, lack selectivity, as they affect many other cellular processes. In addition, in the case of geldanamycin, the effect on CMA can be the opposite (inhibition rather than stimulation)

depending on the cell type (this is due to the fact that the observed stimulation of CMA is actually a compensatory response to the blockage of HSP90AA1 in lysosomes, and different cells activate different compensatory responses).<sup>1111</sup>

- f. The most conclusive way to prove that a protein is a CMA substrate is by reconstituting its direct translocation into lysosomes using a cell-free system.<sup>1106</sup> This method is only possible when the protein of interest can be purified, and it requires the isolation of the population of lysosomes active for CMA. Internalization of the protein of interest inside lysosomes upon incubation with the isolated organelle can be monitored using protease protection assays (in which addition of an exogenous protease removes the protein bound to the cytosolic side of lysosomes, whereas it is inaccessible to the protein that has reached the lysosomal lumen; note that pre-incubation of lysosomes with lysosomal protease inhibitors before adding the substrate is required to prevent the degradation of the translocated substrate inside lysosomes).<sup>1112</sup> The use of exogenous protease requires numerous controls (see ref. 1106) to guarantee that the amount of protease is sufficient to remove all the substrate outside lysosomes, but will not penetrate inside the lysosomal lumen upon breaking the lysosomal membrane.

The difficulties in the adjustment of the amount of protease have led to the development of a second method that is more suitable for laboratories that have no previous experience with these procedures. In this case, the substrate is incubated with lysosomes untreated or previously incubated with inhibitors of lysosomal proteases, and then uptake is determined as the difference of protein associated with lysosomes not incubated with inhibitors (in which the only remaining protein will be the one associated with the cytosolic side of the lysosomal membrane) and those incubated with the protease inhibitors (which contain both the protein bound to the membrane and that translocated into the lumen).<sup>1113</sup>

Confidence that the lysosomal internalization is by CMA increases if the uptake of the substrate can be competed with proteins previously identified as substrates for CMA (e.g., GAPDH/glyceraldehyde-3-phosphate dehydrogenase or RNASE1/ribonuclease A, both commercially available as purified proteins), but is not affected by the presence of similar amounts of nonsubstrate proteins (such as SERPINB/ovalbumin or PPIA/cyclophilin A). Blockage of uptake by pre-incubation of the lysosomes with antibodies against the cytosolic tail of LAMP2A also reinforces the hypothesis that the protein is a CMA substrate. It should be noted that several commercially available kits for lysosome isolation separate a mixture of lysosomal populations and do not enrich in the subgroup of lysosomes active for CMA, which limits their use for CMA uptake assays.

In other instances, rather than determining if a particular protein is a CMA substrate, the interest may be to analyze possible changes in CMA activity under different conditions or in response to different modifications. We enumerate here the methods, from lower to higher complexity, that can be utilized to measure CMA in cultured cells and in tissues (see ref. 1106 for detailed experimental procedures).



- a. Measurement of changes in the intracellular rates of degradation of long-lived proteins, when combined with inhibitors of other autophagic pathways, can provide a first demonstration in support of changes that are due to CMA. For example, CMA is defined as lysosomal degradation upregulated in response to serum removal but insensitive to PtdIns3K inhibitors.
  - b. Measurement of levels of CMA components is insufficient to conclude changes in CMA because this does not provide functional information, and changes in CMA components can also occur under other conditions. However, analysis of the levels of LAMP2A can be used to support changes in CMA detected by other procedures. Cytosolic levels of HSPA8 remain constant and are not limiting for CMA, thus providing no information about this pathway. Likewise, changes in total cellular levels of LAMP2A do not have an impact on this pathway unless they also affect their lysosomal levels (i.e., conditions in which LAMP2A is massively overexpressed lead to its targeting to the plasma membrane where it cannot function in CMA). It is advisable that changes in the levels of these 2 CMA components are confirmed to occur in lysosomes, either by colocalization with lysosomal markers when using image-based procedures or by performing immunoblot of a lysosomal enriched fraction (purification of this fraction does not require the large amounts of cells/tissue necessary for the isolation of the subset of lysosomes active for CMA).
  - c. Tracking changes in the subset of lysosomes active for CMA. This group of lysosomes is defined as those containing HSPA8 in their lumen (note that LAMP2A is present in both lysosomes that are active and inactive for CMA, and it is the presence of HSPA8 that confers CMA capability). Immunogold or immunofluorescence against these 2 proteins (LAMP2A and HSPA8) makes it possible to quantify changes in the levels of these lysosomes present at a given time, which correlates well with CMA activity.<sup>948</sup>
  - d. Analysis of lysosomal association of fluorescent artificial CMA substrates. Two different fluorescent probes have been generated to track changes in CMA activity in cultured cells using immunofluorescence or flow cytometry analysis.<sup>948</sup> These probes contain the KFERQ and context sequences in frame with photoswitchable or photoactivated fluorescent proteins. Activation of CMA results in the mobilization of a fraction of the cytosolic probe to lysosomes and the subsequent change from a diffuse to a punctate pattern. CMA activity can be quantified as the number of fluorescent puncta per cell or as the decay in fluorescence activity over time because of degradation of the artificial substrate. Because the assay does not allow measuring accumulation of the substrate (which must unfold for translocation), it is advisable to perform a time-course analysis to determine gradual changes in CMA activity. Antibodies against the fluorescent protein in combination with inhibitors of lysosomal proteases can be used to monitor accumulation of the probe in lysosomes over a period of time, but both the photo-switchable and the unmodified probe will be detected by this procedure.<sup>1114</sup> As for any other fluorescence probe based on analysis of intracellular “puncta” it is essential to include controls to confirm that the puncta are indeed lysosomes (colocalization with LysoTracker or LAMPs and lack of colocalization with markers of cytosolic aggregation such as ubiquitin) and do not reach the lysosomes through other autophagic pathways (insensitivity to PtdIns3K inhibitors and sensitivity to LAMP2A knockdown are good controls in this respect).
  - e. Direct measurement of CMA using in vitro cell free assays. Although the introduction of the fluorescent probes should facilitate measurement of CMA in many instances, they are not applicable for tissue samples. In addition, because the probes measure binding of substrate to lysosomal membranes it is important to confirm that enhanced binding does not result from defective translocation. Last, the in vitro uptake assays are also the most efficient way to determine primary changes in CMA independently of changes in other proteolytic systems in the cells. These in vitro assays are the same ones described in the previous section on the identification of proteins as substrates of CMA, but are performed in this case with purified proteins previously characterized to be substrates for CMA. In this case the substrate protein is always the same, and what changes is the source of lysosomes (from the different tissues or cells that are to be compared). As described in the previous section, binding and uptake can be analyzed separately using lysosomes previously treated or not with protease inhibitors. The analysis of the purity of the lysosomal fractions prior to performing functional analysis is essential to conclude that changes in the efficiency to take up the substrates results from changes in CMA rather than from different levels of lysosomes in the isolated fractions. Control of the integrity of the lysosomal membrane and sufficiency of the proteases are also essential to discard the possibility that degradation is occurring outside lysosomes because of leakage, or that accumulation of substrates inside lysosomes is due to enhanced uptake rather than to decreased degradation.
- Cautionary notes:** The discovery of another selective form of protein degradation in mammals named endosomal microautophagy (e-MI)<sup>1115</sup> has made it necessary to reconsider some of the criteria that applied in the past for the definition of a protein as a CMA substrate. The KFERQ-like motif, previously considered to be exclusive for CMA, is also used to mediate selective targeting of cytosolic proteins to the surface of late endosomes. Once there, substrates can be internalized in microvesicles that form from the surface of these organelles in an ESCRT-dependent manner. HSPA8 has been identified as the chaperone that binds this subset of substrates and directly interacts with lipids in the late endosomal membrane, acting thus as a receptor for cytosolic substrates in this compartment. At a practical level, to determine if a KFERQ-containing protein is being degraded by CMA or e-MI the following criteria can be applied: (a) Inhibition of lysosomal proteolysis (for example with  $\text{NH}_4\text{Cl}$  and leupeptin) blocks degradation by both pathways. (b) Knockdown of LAMP2A inhibits CMA but not e-MI. (c) Knockdown of components

of ESCRTI and II (e.g., VPS4 and TSG101) inhibits e-MI but not CMA. (d) Interfering with the capability to unfold the substrate protein blocks its degradation by CMA, but does not affect e-MI of the protein. In this respect, soluble proteins, oligomers and protein aggregates can undergo e-MI, but only soluble proteins can be CMA substrates. (e) In vitro uptake of e-MI substrates can be reconstituted using isolated late endosomes whereas in vitro uptake of CMA substrates can only be reconstituted using lysosomes.

Another pathway that needs to be considered relative to CMA is chaperone-assisted selective autophagy (CASA).<sup>1116</sup> CASA is dependent on HSPA8 and LAMP2 (although it is not yet known if it is dependent solely on the LAMP2A isoform). Thus, a requirement for these 2 proteins is not sufficient to conclude that a protein is degraded by CMA. It should also be noted that LAMP1 and LAMP2 share common function as revealed by the embryonic lethal phenotype of *lamp1<sup>-/-</sup> lamp2<sup>-/-</sup>* double-deficient mice.<sup>1117</sup> In addition to CMA, LAMP2 is involved in the fusion of late endosomes and autophagosomes or phagosomes.<sup>1118,1119</sup> LAMP2C, one of the LAMP2 isoforms, can also function as an RNA/DNA receptor in RNautophagy and DNautophagy pathways, where RNA or DNA is taken up directly by lysosomes in an ATP-dependent manner.<sup>1120-1123</sup> LAMP1 and LAMP2 deficiency does not necessarily affect protein degradation under conditions when CMA is active,<sup>1117</sup> and the expression levels of neuronal CMA substrates does not change upon loss of LAMP2.<sup>1120,1124,1125</sup>

**Conclusion:** One of the key issues with the analysis of CMA is verifying that the protein of interest is an authentic substrate. Methods for monitoring CMA that utilize fluorescent probes are available that eliminate the need for the isolation of CMA-competent lysosomes, one of the most difficult aspects of assaying this process.

### 19. Chaperone-assisted selective autophagy

CASA is a recently identified, specialized form of autophagy whereby substrate proteins are ubiquitinated and targeted for lysosomal degradation by chaperone and co-chaperone proteins.<sup>1116</sup> The substrate protein does not require a KFERQ motif, which differentiates CASA from CMA. In CASA the substrate protein is recognized by the chaperone HSPA8, the small heat shock proteins HSPB6 and HSPB8, the ubiquitin ligase STUB1/CHIP, which forms a multidomain complex with the co-chaperone BAG3, and the receptor proteins SYNPO2/myopodin (synaptopodin 2) and SQSTM1. Following ubiquitination the substrate protein is loaded onto the CASA machinery. SYNPO2 and SQSTM1 then bind to core components of the autophagosome (VPS18 and LC3, respectively) resulting in engulfment of the substrate protein and associated multidomain complex into the autophagosome, and subsequent lysosomal degradation.<sup>1116,1126</sup>

To date, CASA has only been reported in muscle with the FLN (filamin) family of proteins being the most studied target. However, CASA may also be capable of targeting nonmuscle proteins for degradation as demonstrated by an in vitro study on BAG3-mediated degradation of mutant HTT.<sup>1127,1128</sup>

**Conclusion:** Given that the autophagy machinery involved in CASA is very similar to that in other forms of autophagy

there are currently no specific markers or inhibitors available to study this process specifically, but the involvement of BAG3 and ubiquitination of client proteins is highly suggestive of CASA activity.


## B. Comments on additional methods

### 1. Acidotropic dyes

Among the older methods for following autophagy is staining with acidotropic dyes such as monodansylcadaverine,<sup>1129</sup> acridine orange,<sup>1130</sup> Neutral Red,<sup>956</sup> LysoSensor Blue<sup>1131</sup> and LysoTracker Red.<sup>280,1132</sup> It should be emphasized that, whereas these dyes are useful to identify acidified vesicular compartments, they should not be relied upon to compare differences in endosomal or lysosomal pH between cells due to variables that can alter the intensity of the signal. For example, excessive incubation time and/or concentrations of LysoTracker Red can oversaturate labeling of the cell and mask differences in signal intensity that reflect different degrees of acidification within populations of compartments.<sup>1133</sup> Use of these dyes to detect, size, and quantify numbers of acidic compartments must involve careful standardization of the conditions of labeling and ideally should be confirmed by ancillary TEM and/or immunoblot analysis. Reliable measurements of vesicle pH require ratiometric measurements of 2 dyes with different peaks of optimal fluorescence (e.g., LysoSensor Blue and LysoSensor Yellow) to exclude variables related to uptake.<sup>62,1133</sup>

**Cautionary notes:** Although MDC was first described as a specific marker of autophagic vacuoles<sup>1134</sup> subsequent studies have suggested that this, and other acidotropic dyes, are not specific markers for early autophagosomes,<sup>331</sup> but rather label later stages in the degradation process. For example, autophagosomes are not acidic, and MDC staining can be seen in autophagy-defective mutants<sup>540</sup> and in the absence of autophagy activation.<sup>1135</sup> MDC may also show confounding levels of background labeling unless narrow bandpass filters are used. However, in the presence of vinblastine, which blocks fusion with lysosomes, MDC labeling increases, suggesting that under these conditions MDC can label late-stage autophagosomes.<sup>989</sup> Along these lines, cells that overexpress a dominant negative version of RAB7 (the T22N mutant) show colocalization of this protein with MDC; in this case fusion with lysosomes is also blocked<sup>1136</sup> indicating that MDC does not just label lysosomes. Nevertheless, MDC labeling could be considered to be an indicator of autophagy when the increased labeling of cellular compartments by this dye is prevented by treatment with specific autophagy inhibitors.

Overall, staining with MDC or its derivative monodansylmethylamine (MDH)<sup>1129</sup> is not, by itself, a sufficient method for monitoring autophagy. Similarly, LysoTracker Red, Neutral Red and acridine orange are not ideal markers for autophagy because they primarily detect lysosomes and an increase in lysosome size or number could reflect an increase in nonprofessional phagocytosis (often seen in embryonic tissues<sup>1137</sup>) rather than autophagy. These markers are, however, useful for monitoring selective autophagy when used in conjunction with protein markers or other dyes. For example, increased colocalization of mitochondria with both GFP-LC3 and



**Figure 26.** LysoTracker Red stains lysosomes and can be used to monitor autophagy in *Drosophila*. Live fat body tissues from *Drosophila* were stained with LysoTracker Red (red) and Hoechst 33342 (blue) to stain the nucleus. Tissues were isolated from fed (left) or 3-h starved (right) animals. Scale bar: 25  $\mu$ m. This figure was modified from data presented in ref. 280, *Developmental Cell*, 7, Scott RC, Schuldiner O, Neufeld TP, Role and regulation of starvation-induced autophagy in the *Drosophila* fat body, pp. 167–78, copyright 2004, with permission from Elsevier.

LysoTracker Red can be used as evidence of autophagic cargo delivery to lysosomes. Moreover, LysoTracker Red has been used to provide correlative data on autophagy in *D. melanogaster* fat body cells (Fig. 26).<sup>279,280</sup> However, additional assays, such as GFP-Atg8/LC3 fluorescence and EM, should be used to substantiate results obtained with acidotropic dyes whenever possible to rule out the possibility that LAP is involved (see *Noncanonical use of autophagy-related proteins*). Finally, one important caution when co-imaging with LysoTracker Red and a green-fluorescing marker (e.g., GFP-LC3 or MitoTracker Green) is that it is necessary to control for rapid red-to-green photoconversion of the LysoTracker, which can otherwise result in an incorrect interpretation of colocalization.<sup>1138</sup>

Some of the confusion regarding the interpretation of results with these dyes stems in part from the nomenclature in this field. Indeed, the discussion of acidotropic dyes points out why it is advisable to differentiate between the terms “autophagosome” and “autophagic vacuole,” although they are occasionally, and incorrectly, used interchangeably. The autophagosome is the sequestering compartment generated by the phagophore. The fusion of an autophagosome with an endosome or a lysosome generates an amphisome or an autolysosome, respectively.<sup>884</sup> The early autophagosome is not an acidic compartment, whereas amphisomes and autolysosomes are acidic. As noted in the section *Transmission electron microscopy*, earlier names for these compartments are “initial autophagic vacuole (AVi),” “intermediate or intermediate/degradative autophagic vacuole (AVi/d)” and “degradative autophagic vacuole (AVd),” respectively. Thus, acidotropic dyes can stain late autophagic vacuoles (in particular autolysosomes), but not the initial autophagic vacuole, the early autophagosome.

A recently developed dye for monitoring autophagy, Cyto-ID, stains vesicular structures shortly after amino acid deprivation, which extensively colocalize with RFP-LC3-positive structures, while colocalizing partially with lysosomal probes.<sup>1139</sup> Moreover, unlike MDC, Cyto-ID does not show background fluorescence under control conditions and the 2 dyes colocalize only marginally. Furthermore, the Cyto-ID signal responds to well-known autophagy modulators. Therefore, this amphiphilic dye, which partitions in hydrophobic environments, may prove more selective for autophagic vacuoles than the previously discussed lysosomotropic dyes.

With the above caveats in mind, the combined use of early and late markers of autophagy is highly encouraged, and when quantifying mammalian lysosomes, it is important to keep in mind that increases in both lysosome size and number are frequently observed. Finally, to avoid confusion with the plant and fungal vacuole, the equivalent organelle to the lysosome, we recommend the use of the term “autophagosome” instead of “autophagic vacuole” when possible, that is, when the specific nature of the structure is known.

**Conclusion:** Given the development of better techniques that are indicators of autophagy, the use of acidotropic dyes to study this process is discouraged, and relying entirely on such dyes is not acceptable.

## 2. Autophagy inhibitors and inducers

In many situations it is important to demonstrate an effect resulting from inhibition or stimulation of autophagy (see ref. 1140 for a partial listing of regulatory compounds), and a few words of caution are worthwhile in this regard. Most chemical inhibitors of autophagy are not entirely specific, and it is

important to consider possible dose- and time-dependent effects. Accordingly, it is generally preferable to analyze specific loss-of-function *Atg* mutants. However, it must be kept in mind that some apparently specific *Atg* gene products may have autophagy-independent roles (e.g., ATG5 in cell death, and the PIK3C3/VPS34-containing complexes—including BECN1—in apoptosis, endosomal function and protein trafficking), or may be dispensable for autophagy (see *Noncanonical use of autophagy-related proteins*).<sup>27,543,573,1141-1144</sup> Therefore, the experimental conditions of inhibitor application and their side effects must be carefully considered. In addition, it must be emphasized once again that autophagy, as a multi-step process, can be inhibited at different stages. Sequestration inhibitors, including 3-MA, LY294002 and wortmannin, inhibit class I phosphoinositide 3-kinases (PI3Ks) as well as class III PtdIns3Ks.<sup>132,330,1145</sup> The class I enzymes generate products such as PtdIns(3,4,5)P<sub>3</sub> that inhibit autophagic sequestration, whereas the class III product (PtdIns3P) generally stimulates autophagic sequestration. The overall effect of these inhibitors is typically to block autophagy because the class III enzymes that are required to activate autophagy act downstream of the negative regulatory class I enzymes, although cell death may ensue in cell types that are dependent upon high levels of AKT for survival. The effect of 3-MA (but not that of wortmannin) is further complicated by the fact that it has different temporal patterns of inhibition, causing a long-term suppression of the class I PI3K, but only a transient inhibition of the class III enzyme. In cells incubated in a complete medium for extended periods of time, 3-MA may, therefore (particularly at suboptimal concentrations), promote autophagy by inhibition of the class I enzyme.<sup>330</sup> Thus, wortmannin may be considered as an alternative to 3-MA for autophagy inhibition.<sup>330</sup> However, wortmannin can induce the formation of vacuoles that may have the appearance of autophagosomes, although they are swollen late endocytic compartments.<sup>931</sup> Furthermore, studies have demonstrated that inhibition of autophagy with 3-MA or wortmannin can have effects on cytokine transcription, processing and secretion, particularly of IL1 family members,<sup>1146-1148</sup> but 3-MA and wortmannin also inhibit the secretion of some cytokines and chemokines (e.g., TNF, IL6, CCL2/MCP-1) in an autophagy-independent manner (J. Harris, unpublished observations).<sup>1146,1149</sup> Thus, in studies where the effect of autophagy inhibition on specific cellular processes is being investigated, it is important to confirm results using other methods, such as RNA silencing. Due to these issues, it is of great interest that inhibitors with specificity for the class III PtdIns3Ks, and their consequent effects on autophagy, have been described.<sup>244,1150,1151</sup>

A mutant mouse line carrying a floxed allele of *Pik3c3* has been created.<sup>1152</sup> This provides a useful genetic tool that will help in defining the physiological role of the class III PtdIns3K with bona fide specificity by deleting the class III kinase in a cell type-specific manner in a whole animal using the Cre-LoxP strategy. For example, the phenotype resulting from a knockout of *Pik3c3* specifically in the kidney glomerular podocytes (*Pik3c3*<sup>pdKO</sup>) indicates that there is no compensation by other classes of PtdIns3Ks or related *Atg* genes, thus highlighting the functional specificity and physiological importance of class III PtdIns3K in these cells.

Cycloheximide, a commonly used protein synthesis inhibitor in mammals, is also an inhibitor of sequestration in vivo,<sup>12-14,78,924,1153-1157</sup> and in various cell types in vitro,<sup>466,1158</sup> and it has been utilized to investigate the dynamic nature of the regression of various autophagic elements.<sup>12-14,25,78,1154,1155</sup> The mechanism of action of cycloheximide in short-term experiments is not clear, but it has no direct relation to the inhibition of protein synthesis.<sup>466</sup> This latter activity, however, may complicate certain types of analysis when using this drug.

A significant challenge for a more detailed analysis of the dynamic role of autophagy in physiological and pathophysiological processes, for instance with regard to cancer and cancer therapy, is to find more specific inhibitors of autophagy signaling which do not affect other signaling cascades. For example, in the context of cellular radiation responses it is well known that PI3Ks, in addition to signaling through the PI3K-AKT pathway, have a major role in the regulation of DNA-damage repair.<sup>1159</sup> However, 3-MA, which is a nonspecific inhibitor of these lipid kinases, can alter the function of other classes of this enzyme, which are involved in the DNA-damage repair response. This is of particular importance for investigations into the role of radiation-induced autophagy in cellular radiation sensitivity or resistance.<sup>1160,1161</sup>

Most other inhibitory drugs act at post-sequestration steps. These types of agents have been used in many experiments to both inhibit endogenous protein degradation and to increase the number of autophagic compartments. They cause the accumulation of sequestered material in either autophagosomes or autolysosomes, or both, because they allow autophagic sequestration to proceed. The main categories of these types of inhibitors include the vinca alkaloids (e.g., vinblastine) and other microtubule poisons that inhibit fusion, inhibitors of lysosomal enzymes (e.g., leupeptin, pepstatin A and E-64d), and compounds that elevate lysosomal pH (e.g., inhibitors of V-ATPases such as bafilomycin A<sub>1</sub> and concanamycin A [another V-ATPase inhibitor], and weak base amines including methyl- or propylamine, chloroquine, and Neutral Red, some of which slow down fusion). Ammonia is a very useful agent for the elevation of lysosomal pH in short-term experiments, but it has been reported to cause a stimulation of autophagy during long-term incubation of cells in a full medium,<sup>1162</sup> under which conditions a good alternative might be methylamine or propylamine.<sup>1163</sup> Along these lines, it should be noted that the half-life of glutamine in cell culture media is approximately 2 weeks due to chemical decomposition, which results in media with lowered glutamine and elevated ammonia concentrations that can affect the autophagic flux (either inhibiting or stimulating autophagy, depending on the concentration<sup>1164</sup>). Thus, to help reduce experimental variation, the use of freshly prepared cell culture media with glutamine is advised. A special note of caution is also warranted in regard to chloroquine. Although this chemical is commonly used as an autophagy inhibitor, chloroquine may initially stimulate autophagy (F.C. Dorsey, personal communication; R. Franco, personal communication). In addition, culture conditions requiring acidic media preclude the use of chloroquine because intracellular accumulation of the chemical is dramatically reduced by low pH.<sup>1165</sup> To overcome this issue, it is possible to use acid compounds that modulate autophagy, such as betulinic acid and its derivatives.<sup>235,1166-1168</sup>

Betulinic acid damages lysosomal function differing from traditional inhibitors (e.g., chloroquine,  $\text{NH}_4\text{Cl}$  or bafilomycin  $\text{A}_1$ ) that raise the lysosomal pH; betulinic acid interacts with pure phospholipid membranes,<sup>235,1169</sup> and is capable of changing membrane permeability.<sup>235,1170,1171</sup> The lysosomal damage mediated by betulinic acid is capable of compromising autophagy without any incremental damage when lysosomal function is altered by lysosomal inhibitors (e.g., chloroquine or bafilomycin  $\text{A}_1$ );<sup>235</sup> however, betulinic acid is not lysosome specific, and will affect other organelles such as mitochondria.

Some data suggest that particular nanomaterials may also be novel inhibitors of autophagy, by as yet unidentified mechanisms.<sup>1172</sup>

It is worth noting that lysosomal proteases fall into 3 general groups, cysteine, aspartic acid and serine proteases. Therefore, the fact that leupeptin, a serine and cysteine protease inhibitor, has little or no effect does not necessarily indicate that lysosomal degradation is not taking place; a combination of leupeptin, pepstatin A and E-64d may be a more effective treatment. However, it should also be pointed out that these protease inhibitors can exert inhibitory effects not only on lysosomal proteases, but also on cytosolic proteases; that is, degradation of proteins might be blocked through inhibition of cytosolic instead of lysosomal proteases. Conversely, it should be noted that MG132 (Z-leu-leu-leu-al) and its related peptide aldehydes are commonly used as proteasomal inhibitors, but they can also inhibit certain lysosomal hydrolases such as cathepsins and calpains.<sup>1173</sup> Thus, any positive results using MG132 do not rule out the possibility of involvement of the autophagy-lysosomal system. Therefore, even if MG132 is effective in inhibiting autophagy, it is important to confirm the result using more specific proteasomal inhibitors such as lactacystin or epoxomicin. Finally, there are significant differences in cell permeability among protease inhibitors. For example, E-64d is membrane permeable, whereas leupeptin and pepstatin A are not (although there are derivatives that display greater permeability such as pepstatin A methyl ester).<sup>1174</sup> Thus, when analyzing whether a protein is an autophagy substrate, caution should be taken in utilizing these protease inhibitors to block autophagy.

As with the PtdIns3K inhibitors, many autophagy-suppressive compounds are not specific. For example, okadaic acid<sup>1175</sup> is a powerful general inhibitor of both type 1 (PPP1) and type 2A (PPP2) protein phosphatases.<sup>1176</sup> Bafilomycin  $\text{A}_1$  and other compounds that raise the lysosomal pH may have indirect effects on any acidified compartments. Moreover, treatment with bafilomycin  $\text{A}_1$  for extended periods (18 h) can cause significant disruption of the mitochondrial network in cultured cells (M.E. Gegg, personal communication), and either bafilomycin  $\text{A}_1$  or concanamycin A cause swelling of the Golgi in plants,<sup>1177</sup> and increase cell death by apoptosis in cancer cells (V.A. Rao, personal communication). Furthermore, bafilomycin  $\text{A}_1$  may have off-target effects on the cell, particularly on MTORC1.<sup>487,527,1178</sup> Bafilomycin  $\text{A}_1$  is often used at a final concentration of 100 nM, but much lower concentrations such as 1 nM may be sufficient to inhibit autophagic-lysosomal degradation and are less likely to cause indirect effects.<sup>157,225,1179</sup> For example, in pulmonary A549 epithelial cells bafilomycin  $\text{A}_1$  exhibits concentration-dependent effects on cellular

morphology and on protein expression; at concentrations of 10 and 100 nM the cells become more rounded accompanied by increased expression of VIM (vimentin) and a decrease in CDH1/E-cadherin (B. Yeganeh, M. Post and S. Ghavami, unpublished observations). Thus, appropriate inhibitory concentrations should be empirically determined for each cell type.<sup>231</sup>

Although these various agents can inhibit different steps of the autophagic pathway, their potential side effects must be considered in interpretation of the secondary consequences of autophagy inhibition, especially in long-term studies. For example, lysosomotropic compounds can increase the rate of autophagosome formation by inhibiting MTORC1, as activation of lysosomally localized MTORC1 depends on an active V-ATPase (as well as RRAG GTPases<sup>162</sup>).<sup>487,1180</sup> Along these lines, chloroquine treatment may cause an apparent increase in the formation of autophagosomes possibly by blocking fusion with the lysosome (F.C. Dorsey and J.L. Cleveland, personal communication). This conclusion is supported by the finding that chloroquine reduces the colocalization of LC3 and LysoTracker despite the presence of autophagosomes and lysosomes (A.K. Simon, personal communication). This mechanism might be cell-type specific, as other studies report that chloroquine prevents autolysosome clearance and degradation of cargo content, but not autophagosome-lysosome fusion.<sup>1181-1184</sup> Concanamycin A blocks sorting of vacuolar proteins in plant cells in addition to inhibiting vacuolar acidification.<sup>1185</sup> Furthermore, in addition to causing the accumulation of autophagic compartments, many of these drugs seem to stimulate sequestration in many cell types, especially *in vivo*.<sup>79,326,924,1154,1158,1186-1190</sup> Although it is clear why these drugs cause the accumulation of autophagic compartments, it is not known why they stimulate sequestration. One possibility, at least for hepatocytes, is that the inhibition of protein degradation reduces the intracellular amino acid pool, which in turn upregulates sequestration. A time-course study of the changes in both the intra- and extracellular fractions may provide accurate information regarding amino acid metabolism. For these various reasons, it is important to include appropriate controls; along these lines, MTOR inhibitors such as rapamycin or amino acid deprivation can be utilized as positive controls for inducing autophagy. In many cell types, however, the induction of autophagy by rapamycin is relatively slow, or transient, allowing more time for indirect effects.

Several small molecule inhibitors, including torin1, PP242, KU-0063794, PI-103 and NVP-BEZ235, have been developed that target the catalytic domain of MTOR in an ATP-competitive manner.<sup>225,1191-1195</sup> In comparison to rapamycin, these catalytic MTOR inhibitors are more potent, and hence are stronger autophagy agonists in most cell lines.<sup>341,1193,1196</sup> The use of these second-generation MTOR inhibitors may reveal that some reports of MTOR-independent autophagy may actually reflect the use of the relatively weak inhibitor rapamycin. Furthermore, the use of these compounds has revealed a role for MTORC1 and MTORC2 as independent regulators of autophagy.<sup>1197</sup>

Neurons, however, seem to be a particular case in regard to their response to MTOR inhibitors. Rapamycin may fail to activate autophagy in cultured primary neurons, despite its potent

stimulation of autophagy in some cancer cell lines,<sup>75,544,1198</sup> Interestingly, both rapamycin and catalytic MTOR inhibitors do not induce a robust autophagy in either cultured primary mouse neurons or human neuroblastoma SH-SY5Y cells, which can differentiate into neuron-like cells, whereas the drugs do elicit a potent autophagic response in cultured astrocytes (J. Diaz-Nido and R. Gargini, personal communication). This suggests a differential regulation of autophagy in neurons. It has been suggested that control of neuronal autophagy may reflect the particular physiological adaptations and metabolic requirements of neurons, which are very different from most peripheral cell types.<sup>1199</sup> For example, acute starvation in transgenic mice expressing GFP-LC3 leads to a potent induction of autophagy in the liver, muscle and heart but not in the brain.<sup>153</sup> Along these lines, glucose depletion may be much more efficient at inducing autophagy than rapamycin or amino acid starvation in neurons in culture (M. Germain and R. Slack, personal communication). Indeed treatment of cultured primary mouse neurons and human neuroblastoma SH-SY5Y cells with 2-deoxy-glucose, which hampers glucose metabolism and leads to activation of AMPK, results in robust autophagy induction (J. Diaz-Nido and R. Gargini, personal communication). Interestingly, a number of compounds can also be quite efficient autophagy inducers in neurons including the CAPN/calpain inhibitor calpeptin.<sup>1200-1202</sup> Thus, it has been suggested that autophagy induction in neurons may be achieved by molecular mechanisms relying on AMPK or increases in intracellular calcium concentration.<sup>1199</sup> An example where changes in cytosolic calcium levels, due to the incapacity of the mitochondria to buffer Ca<sup>2+</sup> release, result in an increase in autophagy is seen in a cellular model of the neurodegenerative disease Friedreich ataxia, based on FXN/frataxin silencing in SH-SY5Y human neuroblastoma cells.<sup>1203</sup>

Finally, a specialized class of compounds with  $\alpha,\beta$ -unsaturated ketone structure tends to induce autophagic cell death, accompanied by changes in mitochondrial morphology. Since the cytotoxic action of these compounds is efficiently blocked by *N*-acetyl-L-cysteine, the  $\beta$ -position in the structure may interact with an SH group of the targeted molecules.<sup>1204</sup> Due to the potential pleiotropic effects of various drug treatments, it is incumbent upon the researcher to demonstrate that autophagy is indeed inhibited, by using the methodologies described herein. Accordingly, it is critical to verify the effect of a particular biochemical treatment with regard to its effects on autophagy induction or inhibition when using a cell line that was previously uncharacterized for the chemical being used. Similarly, cytotoxicity of the relevant chemical should be assessed.

The use of gene deletions/inactivations (e.g., in primary or immortalized *atg*<sup>-/-</sup> MEFs,<sup>540</sup> plant T-DNA or transposon insertion mutants,<sup>282,1205</sup> or in vivo using transgenic knockout models<sup>1206,1207</sup> including Cre-lox based “conditional” knockouts<sup>320,321</sup>) or functional knockdowns (e.g., with RNAi against *ATG* genes) is the preferred approach when possible because these methods allow a more direct assessment of the resulting phenotype; however, different floxed genes are deleted with varying efficiency, and the proportion deleted must be carefully quantified.<sup>1208</sup> Studies also suggest that microRNAs may be used for blocking gene expression.<sup>243,645,646,1209,246-248</sup>

In most contexts, it is advisable when using a knockout or knockdown approach to examine multiple autophagy-related genes to exclude the possibility that the phenotype observed is due to effects on a nonautophagic function(s) of the corresponding protein, especially when examining the possibility of autophagic cell death. This is particularly the case in evaluating BECN1, which interacts with anti-apoptotic BCL2 family proteins,<sup>566</sup> or when low levels of a target protein are sufficient for maintaining autophagy as is the case with ATG5.<sup>255</sup> With regard to ATG5, a better approach may be to use a dominant negative (K130R) version.<sup>1144,1198,1210</sup> Also noteworthy is the role of ATG5 in mitotic catastrophe<sup>544</sup> and several other non-autophagic roles of ATG proteins (see *Noncanonical use of autophagy-related proteins*).<sup>75</sup> Along these lines, and as stated above for the use of inhibitors, when employing a knockout or especially a knockdown approach, it is again incumbent upon the researcher to demonstrate that autophagy is actually inhibited, by using the methodologies described herein.

Finally, we note that the long-term secondary consequences of gene knockouts or knockdowns are likely much more complex than the immediate effects of the actual autophagy inhibition. To overcome this concern, inducible knockout systems might be useful.<sup>255,404</sup> One additional caveat to knockdown experiments is that PAMP recognition pathways can be triggered by double-stranded RNAs (dsRNA), like siRNA probes, or the viral vector systems that deliver shRNA.<sup>1211</sup> Some of these, like TLR-mediated RNA recognition,<sup>1212</sup> can influence autophagy by either masking any inhibitory effect or compromising autophagy independent of the knockdown probe. Therefore, nontargeting (scrambled) siRNA or shRNA controls should be used with the respective transfection or transduction methods in the experiments that employ *ATG* knockdown. Another strategy to specifically interfere with autophagy is to use dominant negative inhibitors. Delivery of these agents by transient transfection, adenovirus, or TAT-mediated protein transduction offers the possibility of their use in cell culture or in vivo.<sup>1210</sup> However, since autophagy is an essential metabolic process for many cell types and tissues, loss of viability due to autophagy inhibition always has to be a concern when analyzing cell death-unrelated questions. In this respect it is noteworthy that some cell-types of the immune system such as dendritic cells<sup>333</sup> seem to tolerate loss of autophagy fairly well, whereas others such as T and B cells are compromised in their development and function after autophagy inhibition.<sup>1213,1214</sup>

In addition to pharmacological inhibition, RNA silencing, gene knockout and dominant negative RAB and ATG protein expression, pathogen-derived autophagy inhibitors can also be considered to manipulate autophagy. Along these lines ICP34.5, viral BCL2 homologs and viral FLIP of herpesviruses block autophagosome formation,<sup>566,892,1215</sup> whereas M2 of influenza virus and HIV-1 Nef block autophagosome degradation.<sup>362,902</sup> However, as with other tools discussed in this section, transfection or transduction of viral autophagy inhibitors should be used in parallel with other means of autophagy manipulation, because these proteins are used for the regulation of usually more than one cellular pathway by the respective pathogens.

There are fewer compounds that act as inducers of autophagy, but the initial characterization of this process was due in large part to the inducing effects of glucagon, which appears to act through indirect inhibition of MTOR via the activation of STK11/LKB1-AMPK.<sup>935,936,1216</sup> Currently, the most commonly used inducer of autophagy is rapamycin, an allosteric inhibitor of MTORC1 (although as mentioned above, catalytic inhibitors such as torin1 are increasingly being used). Nevertheless, one caution is that MTOR is a major regulatory protein that is part of several signaling pathways, including for example those that respond to INS/insulin, EGF/epidermal growth factor and amino acids, and it thus controls processes other than autophagy, so rapamycin will ultimately affect many metabolic pathways.<sup>504,1217-1219</sup> In particular, the strong effects of MTOR on protein synthesis may be a confounding factor when analyzing the effects of rapamycin. MTOR-independent regulation can be achieved through lithium, sodium valproate and carbamazepine, compounds that lower the myo-inositol 1,4,5-triphosphate levels,<sup>1220</sup> as well as FDA-approved compounds such as verapamil, trifluoperazine and clonidine.<sup>1221,1222</sup> In vivo treatment of embryos with cadmium results in an increase in autophagy, probably to counter the stress, allowing cell survival through the elimination/recycling of damaged structures.<sup>956</sup> Autophagy may also be regulated by the release of calcium from the ER under stress conditions;<sup>297,1175,1223,1224</sup> however, additional calcium signals from other stores such as the mitochondria and lysosomes could also play an important role in autophagy induction. The activation of the lysosomal TPCN/two-pore channel (two pore segment channel), by nicotinic acid adenine dinucleotide phosphate (NAADP) induces autophagy, which can selectively be inhibited by the TPCN blocker NED-19, or by pre-incubation with BAPTA, showing that lysosomal calcium also modulates autophagy.<sup>1225</sup> Cell penetrating autophagy-inducing peptides, such as Tat-vFLIP or Tat-Becn1 (Tat-BECN1), are also potent inducers of autophagy in cultured cells as well as in mice.<sup>1216,1227</sup> Other cell penetrating peptides, such as Tat-wtBH3D or Tat-dsBH3D, designed to disrupt very specific regulatory interactions such as the BCL2-BECN1 interaction, are potent, yet very specific, inducers of autophagy in cultured cells.<sup>1227</sup>

In contrast to other PtdIns3K inhibitors, caffeine induces macroautophagy in the food spoilage yeast *Zygosaccharomyces bailii*,<sup>1228</sup> mouse embryonic fibroblasts,<sup>1229</sup> and *S. cerevisiae*<sup>1230</sup> at millimolar concentrations. In higher eukaryotes this is accompanied by inhibition of the MTOR pathway. Similarly, in budding yeast caffeine is a potent TORC1 inhibitor suggesting that this drug induces autophagy via inhibition of the TORC1 signalling pathway; however, as with other PtdIns3K inhibitors caffeine targets other proteins, notably Mec1/ATR and Tel1/ATM, and affects the cellular response to DNA damage.

Another autophagy inducer is the histone deacetylase inhibitor valproic acid.<sup>1231,1232</sup> The mechanism by which valproic acid stimulates autophagy is not entirely clear but may occur due to inhibition of the histone deacetylase Rpd3, which negatively regulates the transcription of ATG genes (most notably ATG8<sup>1233</sup>) and, via deacetylation of Atg3, controls Atg8 lipidation.<sup>1234</sup>

It is also possible, depending on the organism or cell system, to modulate autophagy through transcriptional control. For

example, this can be achieved either through overexpression or post-translational activation of the gene encoding TFEB (see *Transcriptional and translational regulation*), a transcriptional regulator of the biogenesis of both lysosomes and autophagosomes.<sup>625,635</sup> Similarly, adenoviral-mediated expression of the transcription factor CEBPB induces autophagy in hepatocytes.<sup>644</sup> Recently, it has been shown that either the genetic ablation or the knockdown of the nucleolar transcription factor RRN3/TIF-IA, a crucial regulator of the recruitment of POLR1/RNA polymerase I to ribosomal DNA promoters, induces autophagy in neurons and in MCF-7 cancer cells, respectively, linking ribosomal DNA transcription to autophagy.<sup>1235,1236</sup>

Relatively little is known about direct regulation via the ATG proteins, but there is some indication that tamoxifen acts to induce autophagy by increasing the expression of BECN1 in MCF7 cells.<sup>1237</sup> However, BECN1 does not appear to be upregulated in U87MG cells treated with tamoxifen, whereas the levels of LC3-II and SQSTM1 are increased, while LAMP2B is downregulated and CTSD and CTSL activities are almost completely blocked (K.S. Choi, personal communication). Thus, the effect of tamoxifen may differ depending on the cell type. Other data suggest that tamoxifen acts by blocking cholesterol biosynthesis, and that the sterol balance may determine whether autophagy acts in a protective versus cytotoxic manner.<sup>1238,1239</sup> Finally, screens have identified small molecules that induce autophagy independently of rapamycin and allow the removal of misfolded or aggregate-prone proteins,<sup>1222,1240</sup> suggesting that they may prove useful in therapeutic applications. However, caution should be taken because of the crosstalk between autophagy and the proteasomal system. For example, trehalose, an MTOR-independent autophagy inducer,<sup>1241</sup> can compromise proteasomal activity in cultured primary neurons.<sup>1242</sup>

Because gangliosides are implicated in autophagosome morphogenesis, pharmacological or genetic impairment of gangliosidic compartment integrity and function can provide useful information in the analysis of autophagy. To deplete cells of gangliosides, an inhibitor of CERS/ceramide synthase, such as a fungal metabolite produced by *Fusarium moniliforme* (fumonisins B1), or, alternatively, siRNA to *CERS* or *ST8SIA1*, can be used.<sup>595</sup>

Finally, in addition to genetic and chemical compounds, it was recently reported that electromagnetic fields can induce autophagy in mammalian cells. Studies of biological effects of novel therapeutic approaches for cancer therapy based on the use of noninvasive radiofrequency fields reveals that autophagy, but not apoptosis, is induced in cancer cells in response to this treatment, which leads to cell death.<sup>1244</sup> This effect is tumor specific and different from traditional ionizing radiation therapy that induces apoptosis in cells.

**Conclusion:** Considering that pharmacological inhibitors or activators of autophagy have an impact on many other cellular pathways, the use of more than one methodology, including molecular methods, is desirable. Rapamycin is less effective at inhibiting MTOR and inducing autophagy than catalytic inhibitors; however, it must be kept in mind that catalytic inhibitors also affect MTORC2. The main concern with pharmacological manipulations is pleiotropic

effects of the compound being used. Accordingly, genetic confirmation is preferred whenever possible.

### 3. Basal autophagy

Basal levels of LC3-II or GFP-LC3 puncta may change according to the time after addition of fresh medium to cells, and this can lead to misinterpretations of what basal autophagy means. This is particularly important when comparing the levels of basal autophagy between different cell populations (such as knockout versus wild-type clones). If cells are very sensitive to nutrient supply and display a high variability of basal autophagy, the best experimental condition is to monitor the levels of basal autophagy at different times after the addition of fresh medium. One example is the chicken lymphoma DT40 cells (see *Chicken B-lymphoid DT40 cells*) and their knockout variant for all 3 ITPR isoforms.<sup>1244-1246</sup> In these cells, no differences in basal levels of LC3-II can be observed up to 4 h after addition of fresh medium, but differences can be observed after longer times (J.M. Vicencio and G. Szabadkai, personal communication). This concept should also be applied to experiments in which the effect of a drug upon autophagy is the subject of study. If the drugs are added after a time in which basal autophagy is already high, then the effects of the drug can be masked by the cell's basal autophagy, and wrong conclusions may be drawn. To avoid this, fresh medium should be added first (followed by incubation for 2–4 h) in order to reduce and equilibrate basal autophagy in cells under all conditions, and then the drugs can be added. The basal autophagy levels of the cell under study must be identified beforehand to know the time needed to reduce basal autophagy.

A similar caution must be exercised with regard to cell culture density and hypoxia. When cells are grown in normoxic conditions at high cell density, HIF1A/HIF-1 $\alpha$  is stabilized at levels similar to that obtained with low-density cultures under hypoxic conditions.<sup>1247</sup> This results in the induction of BNIP3 and BNIP3L and “hypoxia”-induced autophagy, even though the conditions are theoretically normoxic.<sup>1248</sup> Therefore, researchers need to be careful about cell density to avoid accidental induction of autophagy.

It should be realized that in yeast species, medium changes can trigger a higher “basal” level of autophagy in the cells. In the methylotrophic yeast species *P. pastoris* and *Hansenula polymorpha* a shift of cells grown in batch from glucose to methanol results in stimulation of autophagy.<sup>1249,1250</sup> A shift to a new medium can be considered a stress situation. Thus, it appears to be essential to cultivate the yeast cells for a number of hours to stabilize the level of basal autophagy before performing experiments intended to study levels of (selective) autophagy (e.g., pexophagy). Finally, plant root tips cultured in nutrient-sufficient medium display constitutive autophagic flux (i.e., a basal level), which is enhanced in nutrient-deprived medium.<sup>1132,1251,1252</sup>

**Conclusion:** The levels of basal autophagy can vary substantially and can mask the effects of the experimental parameters being tested. Changes in media and growth conditions need to be examined empirically to determine the effects on basal autophagy and the appropriate times for subsequent manipulations.

### 4. Experimental systems

Throughout these guidelines we have noted that it is not possible to state explicit rules that can be applied to all experimental systems. For example, some techniques may not work in particular cell types or organisms. In each case, efficacy of autophagy promoters, inhibitors and measurement techniques must be empirically determined, which is why it is important to include appropriate controls. Differences may also be seen between in vivo or perfused organ studies and cell culture analyses. For example, INS/insulin has no effect on proteolysis in suspended rat hepatocytes, in contrast to the result with perfused rat liver. The INS/insulin effect reappears, however, when isolated hepatocytes are incubated in stationary dishes<sup>1253,1254</sup> or are allowed to settle down on the matrix (D. Häussinger, personal communication). The reason for this might be that autophagy regulation by insulin and some amino acids requires volume sensing via integrin-matrix interactions and also intact microtubules.<sup>1255-1257</sup> Along these lines, the use of whole embryos makes it possible to investigate autophagy in multipotent cells, which interact among themselves in their natural environment, bypassing the disadvantages of isolated cells that are deprived of their normal network of interactions.<sup>956</sup> In general, it is important to keep in mind that results from one particular system may not be generally applicable to others.

**Conclusion:** Although autophagy is conserved from yeast to human, there may be tremendous differences in the specific details among systems. Thus, results based on one system should not be assumed to be applicable to another.

### 5. Nomenclature

To minimize confusion regarding nomenclature, we make the following notes: In general, we follow the conventions established by the nomenclature committees for each model organism whenever appropriate guidelines are available, and briefly summarize the information here using “ATG1” as an example for yeast and mammals. The standard nomenclature of autophagy-related wild-type genes, mutants and proteins for yeast is *ATG1*, *atg1* (or *atg1 $\Delta$*  in the case of deletions) and Atg1, respectively, according to the guidelines adopted by the *Saccharomyces* Genome Database ([http://www.yeastgenome.org/gene\\_guidelines.shtml](http://www.yeastgenome.org/gene_guidelines.shtml)). For mammals we follow the recommendations of the International Committee on Standardized Genetic Nomenclature for Mice (<http://www.informatics.jax.org/mgihome/nomen/>), which dictates the designations *Atg1*, *atg1* and ATG1 (for all rodents), respectively, and the guidelines for human genes established by the HUGO Nomenclature Committee (<http://www.genenames.org/guidelines.html>), which states that human gene symbols are in the form *ATG1* and recommends that proteins use the same designation without italics, as with ATG1; mutants are written for example as *ATG1<sup>-/-</sup>*.<sup>1258</sup>

### C. Methods and challenges of specialized topics/model systems

There are now a large number of model systems being used to study autophagy. These guidelines cannot cover every detail,




and as stated in the Introduction this article is not meant to provide detailed protocols. Nonetheless, we think it is useful to briefly discuss what techniques can be used in these systems and to highlight some of the specific concerns and/or challenges. We also refer readers to the 3 volumes of *Methods in Enzymology* that provide additional information for “nonstandard” model systems.<sup>39–41</sup>

## 1. *C. elegans*

*C. elegans* has a single ortholog of most yeast Atg proteins; however, 2 nematode homologs exist for Atg4, Atg8 and Atg16.<sup>1260–1262</sup> Multiple studies have established *C. elegans* as a useful multicellular genetic model to delineate the autophagy pathway and associated functions (see for example refs. 271, 633, 742, 743, 1263). The LGG-1/Atg8/LC3 reporter is the most commonly used tool to detect autophagy in *C. elegans*. Similar to Atg8, which is incorporated into the double membrane of autophagic vacuoles during autophagy,<sup>148,269,600</sup> the *C. elegans* LGG-1 localizes into cytoplasmic puncta under conditions known to induce autophagy. Fluorescent reporter fusions of LGG-1/Atg8 with GFP, DsRED or mCherry have been used to monitor autophagosome formation *in vivo*, in the nematode. These reporters can be expressed either in specific cells and tissues or throughout the animal.<sup>271,742,1263,1264</sup> Caution should be taken, however, when using protein markers fused to mCherry in worms. mCherry aggregates in autophagy-inducing conditions, such as fasting, even if not fused to LGG-1 or other autophagy markers (E. O’Rourke, personal communication); therefore mCherry puncta may not be a good readout to monitor autophagy in *C. elegans*. LGG-2 is the second LC3 homolog and is also a convenient marker for autophagy either using specific antibodies<sup>741</sup> or fused to GFP,<sup>1265</sup> especially when expressed from an integrated transgene to prevent its germline silencing.<sup>741</sup> The exact function of LGG-1 versus LGG-2 remains to be addressed.<sup>1266</sup>

For observing autophagy by GFP-LGG-1/2 (LC3) fluorescence in *C. elegans*, it is best to use integrated versions of the marker<sup>741,742,1267</sup> (GFP::LGG-1 and GFP::LGG-2; Fig. 27) rather than extrachromosomal transgenic strains<sup>271,1265</sup> because the latter show variable expression among different animals or mosaic expression (C. Kang, personal communication; V. Galy, personal communication). Nevertheless, evaluation of GFP::LGG-1 puncta is mostly restricted to seam cells, which is tedious because of a small number of puncta/cell even in autophagy-inducing conditions (<5/cell), error prone due to high background levels in the GFP channel, and extremely difficult to visualize in the adult. To increase signal to noise, it is also possible to carry out indirect immunofluorescence microscopy using antibodies against endogenous LGG-1,<sup>633,742</sup> or LGG-2;<sup>741</sup> however, anti-LGG-1 and anti-LGG-2 antibodies are not commercially available. In addition, with the integrated version, or with antibodies directed against endogenous LGG-1, it is possible to perform a western blot analysis for lipidation, at least in embryos (LGG-1-I is the nonlipidated soluble form and LGG-1-II/LGG-1-PE is the lipidated form).<sup>1267,742,633</sup>

The LGG-1 precursor accumulates in the *atg-4.1* mutant, but is undetectable in wild-type embryos.<sup>1260</sup> Moreover, the banding pattern of LGG-1 or LGG-1 fused to fluorescent



**Figure 27.** GFP::LGG-1 and GFP::LGG-2 are autophagy markers in *C. elegans*. (A–F) Animals were generated that carry an integrated transgene expressing a GFP-tagged version of *lgg-1*, the *C. elegans* ortholog of mammalian MAP1LC3. Representative green fluorescence images in the pharyngeal muscles of (A) control RNAi animals without starvation, (B) control RNAi animals after 9 d of starvation, (C) *atg-7* RNAi animals after 9 d of starvation, (D) starvation-hypersensitive *gpb-2* mutants without leucine after 3 d of starvation, and (E) *gpb-2* mutants with leucine after 3 d of starvation. The arrows show representative GFP::LGG-1-positive punctate areas that label pre-autophagosomal and autophagosomal structures. (F) The relative levels of PE-conjugated and unconjugated GFP::LGG-1 were determined by western blotting. These figures were modified from data previously published in ref. 1267, Kang, C., Y.J. You, and L. Avery. 2007. Dual roles of autophagy in the survival of *Caenorhabditis elegans* during starvation. *Genes & Development*. 21:2161–2171, Copyright © 2007, *Genes & Development* by Cold Spring Harbor Laboratory Press and Kang, C., and L. Avery. 2009. Systemic regulation of starvation response in *Caenorhabditis elegans*. *Genes & Development*. 23:12–17, Copyright © 2011, *Genes & Development* by Cold Spring Harbor Laboratory Press, www.genesdev.org. (G–H) GFP::LGG-2 serves as a marker for autophagosomes in early *C. elegans* embryos. (G) GFP::LGG-2 expressed in the germline of an integrated transgene reveals the formation of autophagosomes (green) around sperm-inherited membranous organelles (red). DNA of the 2 pronuclei is stained (blue). (H) Later during development, GFP::LGG-2-positive structures are present in all cells of the embryo. Scale bar: 10 μm. Images provided by V. Galy.

proteins in western blots may not be easy to interpret in larvae or the adult *C. elegans* because enrichment for a fast running band (the lipidated form) is not observed in some autophagy-

inducing conditions, such as fasting. In the embryos of some autophagy mutants, including *epg-3*, *epg-4*, *epg-5*, and *epg-6* mutants, levels of LGG-1-I and LGG-1-II are elevated.<sup>563,633,1268,1269</sup> In an immunostaining assay, endogenous LGG-1 forms distinct punctate structures, mostly at the ~64- to 100-cell embryonic stage. LGG-1 puncta are absent in *atg-3*, *atg-7*, *atg-5* and *atg-10* mutant embryos,<sup>633,1261</sup> but dramatically accumulate in other autophagy mutants.<sup>563,633</sup> The widely used GFP::LGG-1 reporter forms aggregates in *atg-3* and *atg-7* mutant embryos, in which endogenous LGG-1 puncta are absent, indicating that GFP::LGG-1 could be incorporated into protein aggregates during embryogenesis. Immunostaining for endogenous VPS-34 is also a useful marker of autophagy induction in *C. elegans* embryos.<sup>1270</sup>

A variety of protein aggregates, including PGL granules (PGL-1-PGL-3-SEPA-1) and the *C. elegans* SQSTM1 homolog SQST-1, are selectively degraded by autophagy during embryogenesis; impaired autophagy activity results in their accumulation and the generation of numerous aggregates.<sup>633,1262</sup> Thus, degradation of these autophagy substrates can also be used to monitor autophagy activity, with similar cautionary notes to those described in section A3 (see *SQSTM1 and related LC3 binding protein turnover assays*) for the SQST-1 turnover assay. Similar to mammalian cells, the total amount of GFP::LGG-1 along with SQST-1::GFP transcriptional expression coupled with its post-transcriptional accumulation can be informative with regard to autophagic flux in the embryo and in adult animals (again with the same cautionary notes described in section A3).<sup>629,1271</sup>

As with its mammalian counterpart, loss of the *C. elegans* TP53 ortholog, *cep-1*, increases autophagosome accumulation<sup>1272</sup> and extends the animal's life span.<sup>1273</sup> *bec-1*- and *cep-1*-regulated autophagy is also required for optimal life-span extension and to reduce lipid accumulation in response to silencing FRH-1/frataxin, a protein involved in mitochondrial respiratory chain functionality.<sup>1274</sup> FRH-1 silencing also induces mitophagy in an evolutionarily conserved manner.<sup>1271</sup> Moreover, the products of *C. elegans* mitophagy regulatory gene homologs (PDR-1/PARK2, PINK-1/PINK1, DCT-1/BNIP3, and SQST-1/SQSTM1) are required for induction of mitophagy (monitored through the Rosella biosensor<sup>1275</sup>) and life-span extension following FRH-1 silencing and iron deprivation.<sup>1271</sup> The TFEB ortholog HLH-30 transcriptionally regulates macroautophagy and promotes lipid degradation,<sup>624,824</sup> and worm life-span analyses uncovered a direct role for HLH-30/TFEB in life-span regulation in *C. elegans*, and likely in mammals.<sup>624,629,823</sup>

For a more complete review of methods for monitoring autophagy in *C. elegans* see ref. 1276. Note that most of these approaches have been optimized to monitor autophagy in embryos or early larval stages, and that autophagy markers in the adult *C. elegans* are currently rather poorly characterized or lacking.

## 2. Chicken B-lymphoid DT40 cells, retina and inner ear

The chicken B-lymphoid DT40 cell line represents a suitable tool for the analysis of autophagic processes in a nonmammalian vertebrate system. In DT40 cells, foreign DNA integrates with a very high frequency by homologous recombination compared to random integration. This makes the cell line a valuable

tool for the generation of cellular gene knockouts. Generally, the complete knockout of genes encoding autophagy-regulatory proteins is preferable compared to RNAi-mediated knockdown, because in some cases these proteins function normally when expressed at reduced levels.<sup>255</sup> Different Atg-deficient DT40 cell lines already exist, including *atg13*<sup>-/-</sup>, *ULK1*<sup>-/-</sup>, *ULK2*<sup>-/-</sup>, *ULK1/2*<sup>-/-</sup>,<sup>1278</sup> *becn1*<sup>-/-</sup>, and *rb1cc1/fip200*<sup>-/-</sup> (B. Stork, personal communication). Many additional non-autophagy-related gene knockout DT40 cell lines have been generated and are commercially available.<sup>1278</sup>

DT40 cells are highly proliferative (the generation time is approximately 10 h), and knockout cells can be easily reconstituted with cDNAs by retroviral gene transfer for the mutational analysis of signaling pathways. DT40 cells mount an autophagic response upon starvation in EBSS,<sup>1277</sup> and autophagy can be analyzed by a variety of assays in this cell line. Steady state methods that can be used include TEM, LC3 western blotting and fluorescence microscopy; flux measurements include monitoring LC3-II turnover and tandem mRFP/mCherry-GFP-LC3 fluorescence microscopy. Using *atg13*<sup>-/-</sup> and *ULK1/2*<sup>-/-</sup> DT40 cells, it was shown that ATG13 and its binding capacity for RB1CC1/FIP200 are mandatory for both basal and starvation-induced autophagy, whereas ULK1/2 and in vitro-mapped ULK1-dependent phosphorylation sites of ATG13 appear to be dispensable for these processes.<sup>1277</sup>

Another useful system is chick retina, which can be used for monitoring autophagy at different stages of development. For example, lipidation of LC3 is observed during starvation, and can be blocked with a short-term incubation with 3-MA.<sup>393,394</sup> LEP-100 antibody is commercially available for the detection of this lysosomal protein. In the developing chicken inner ear, LC3 flux can be detected in otic vesicles cultured in a serum-free medium exposed to either 3-MA or chloroquine.<sup>395</sup>

One of the salient features of chicken cells, including primary cells such as chicken embryo fibroblasts, is the capacity of obtaining rapid, efficient and sustained transcript/protein downregulation with replication-competent retrovirus for shRNA expression.<sup>1279</sup> In chicken embryo fibroblasts, nearly complete and general (i.e., in nearly all cells) protein downregulation can be observed within a few days after transfection of the shRNA retroviral vector.<sup>167</sup>

**Cautionary notes:** Since the DT40 cell line derives from a chicken bursal lymphoma, not all ATG proteins and autophagy-regulatory proteins are detected by the commercially available antibodies produced against their mammalian orthologs; however, commercially available antibodies for mammalian LC3 and GABARAP have been reported to detect the chicken counterparts in western blots.<sup>167</sup> The chicken genome is almost completely assembled, which facilitates the design of targeting constructs. However, in the May 2006 chicken (*Gallus gallus*) v2.1 assembly, 5% of the sequence has not been anchored to specific chromosomes, and this might also include genes encoding autophagy-regulatory proteins. It is possible that there is some divergence within the signaling pathways between mammalian and nonmammalian model systems. One example might be the role of ULK1/2 in starvation-induced autophagy described above. Additionally, neither rapamycin nor torin1 seem to be potent inducers of autophagy in DT40 cells, although MTOR activity is completely repressed as

detected by the level of phosphorylated RPS6KB via western blotting.<sup>1277</sup> Finally, DT40 cells represent a transformed cell line, being derived from an avian leukosis virus-induced bursal lymphoma. Thus, DT40 cells release avian leukosis virus into the medium, and the 3'-long terminal repeat has integrated upstream of the *MYC* gene, leading to increased *MYC* expression.<sup>1280</sup> Both circumstances might influence basal and starvation-induced autophagy.

### 3. *Chlamydomonas*

The unicellular green alga *Chlamydomonas reinhardtii* is an excellent model system to investigate autophagy in photosynthetic eukaryotes. Most of the *ATG* genes that constitute the autophagy core machinery including the *ATG8* and *ATG12* ubiquitin-like systems are conserved as single-copy genes in the nuclear genome of this model alga. Autophagy can be monitored in *Chlamydomonas* by western blotting through the detection of Atg8 lipidation as well as an increase in the abundance of this protein in response to autophagy activation.<sup>292</sup> Localization of Atg8 by immunofluorescence microscopy can also be used to study autophagy in *Chlamydomonas* since the cellular distribution of this protein changes drastically upon autophagy induction. The Atg8 signal is weak and usually detected as a single spot in nonstressed cells, whereas autophagy activation results in the localization of Atg8 in multiple spots with a very intense signal.<sup>292,1281,1282</sup> Finally, enhanced expression of *ATG8* and other *ATG* genes has also been reported in stressed *Chlamydomonas* cells.<sup>1281</sup> These methodological approaches have been used to investigate the activation of autophagy in *Chlamydomonas* under different stress conditions including nutrient (nitrogen or carbon) limitation, rapamycin treatment, ER stress, oxidative stress, photo-oxidative damage or high light stress.<sup>292,1281,1282</sup>


### 4. *Drosophila*

*Drosophila* provides an excellent system for in vivo analysis of autophagy, partly because the problem of animal-to-animal variability can be circumvented by the use of clonal mutant cell analysis, a major advantage of this model system. In this scenario, somatic clones of cells are induced that either overexpress the gene of interest, or silence the gene through expression of a transgenic RNA interference construct, or homozygous mutant cells are generated. These gain- or loss-of-function clones are surrounded by wild-type cells, which serve as an internal control for autophagy induction. In such an analysis, autophagy in these genetically distinct cells is always compared to neighboring cells of the same tissue, thus eliminating most of the variability and also ruling out potential non-cell-autonomous effects that may arise in mutant animals. Along these lines, clonal analysis should be an integral part of in vivo *Drosophila* studies when possible. Multiple steps of the autophagic pathway can now be monitored in *Drosophila* due to the recent development of useful markers, corresponding to every step of the process. Interested readers may find further information in 2 reviews with a detailed discussion of the currently available assays and reagents for the study of autophagy in *Drosophila*.<sup>135,1283</sup>

A commercial rabbit monoclonal anti-GABARAP (anti-Atg8) antibody can be used to detect endogenous levels of *Drosophila* Atg8a in both immunostaining and immunoblotting experiments.<sup>1284</sup> Western blotting and fluorescence microscopy have been used successfully in *Drosophila* by monitoring flies expressing human GFP-LC3,<sup>88,279</sup> GFP-Atg8a<sup>1285</sup> or using any of several antibodies directed against the endogenous Atg8 protein.<sup>510,623,1286</sup> In addition, cultured *Drosophila* (S2) cells can be stably transfected with GFP fused to *Drosophila* Atg8a, which generates easily resolvable GFP-Atg8a and GFP-Atg8a-PE forms that respond to autophagic stimuli (S. Wilkinson, personal communication); stable S2 cells with GFP-Atg8a under the control of a 2-kb *Atg8a* 5' UTR are also available.<sup>1287</sup> Similarly, cultured *Drosophila* cells (I[2]mbn or S2) stably transfected with EGFP-HsLC3B respond to autophagy stimuli (nutrient deprivation) and inhibitors (3-MA, bafilomycin A<sub>1</sub>) as expected, and can be used to quantify GFP-LC3 puncta, which works best using fixed cells with the aid of an anti-GFP antibody.<sup>1288</sup> However, in the *Drosophila* eye, overexpression of GFP-Atg8 results in a significant increase in Atg8-PE by western blot, and this occurs even in control flies in which punctate GFP-Atg8 is not detected by immunofluorescence (M. Fanto, unpublished results), and in transfected *Drosophila* Kc167 cells, uninducible but persistent GFP-Atg8 puncta are detected (A. Kiger, unpublished results). In contrast, expression of GFP-LC3 under the control of the *ninaE/rh1* promoter in wild-type flies does not result in the formation of LC3-II detectable by western blot, nor the formation of punctate staining; however, increased GFP-LC3 puncta by immunofluorescence or LC3-II by western blot are observed upon activation of autophagy.<sup>442</sup> Autophagy can also be monitored with mCherry-Atg18, which is displayed in punctate patterns that are very similar to mCherry-Atg8a.<sup>135</sup> Tandem fluorescence reporters have been established in *Drosophila* in vivo, where GFP-mCherry-Atg8a can be expressed in the nurse cells of the developing egg chamber or in other cell types.<sup>135,1077</sup> A *Drosophila* transgenic line (UAS-Ref[2]P-GFP) and different specific antibodies against Ref(2)P, the *Drosophila* SQSTM1 homolog, are available to follow Ref(2)P expression and localization.<sup>402,423,1289</sup> The advantage of UAS-Ref(2)P-GFP over the antibody against endogenous Ref(2)P is that its accumulation is independent of Ref(2)P promoter regulation and unambiguously reflects autophagy impairment (M. Robin and B. Mollereau, unpublished results). Finally, it is worth noting that Atg5 antibody can be used in the *Drosophila* eye and the staining is similar to GFP-LC3.<sup>1290</sup> In addition, Atg5-GFP and Atg6-GFP constructs are available in *Drosophila*.<sup>1291</sup>

### 5. Erythroid cells

The unique morphology of red blood cells (RBCs) is instrumental to their function. These cells have a bi-concave shape provided by a highly flexible membrane and a cytoplasm deficient in organelles. This architecture allows unimpeded circulation of the RBC even through the thinnest blood vessels, thereby delivering O<sub>2</sub> to all the tissues of the body. Erythroid cells acquire this unique morphology upon terminal erythroid maturation, which commences in the bone marrow and is completed in the circulation. This process involves extrusion of the



**Figure 28.** Transmission electron micrograph of erythroblasts obtained from the blood of regular donors after 10 days of culture in the presence of KITLG/SCF, IL3, EPO and dexamethasone. Original magnification 3000X. This figure shows 2 erythroblasts containing autophagic vacuoles. One erythroblast (red arrow) has the morphology of a live cell with several autophagic vacuoles that have engulfed cytoplasmic organelles. The other erythroblast (black arrow) has the electron-dense cytoplasm characteristic of a dead cell and is in the process of shedding its autolysosomes from the cytoplasm to the extracellular space. Image provided by A.R. Migliaccio and M. Zingariello.

pycnotic nucleus through a specialized form of asymmetric division, and degradation of the ribosome and mitochondria machinery via a specialized form of autophagy (Fig. 28). In the context of RBC biogenesis, autophagy exerts a unique function to sculpt the cytoplasm, with the mature autophagic vacuoles engulfing and degrading organelles, such as mitochondria and ribosomes, whose presence would impair the flexibility of the cells.

Another unique feature of erythropoiesis is that expression of genes required for autophagosome assembly/function, such as *LC3B*, does not appear to be regulated by nutrient deprivation, but rather is upregulated by the erythroid-specific transcription factor GATA1.<sup>641</sup> FOXO3, a transcription factor that modulates RBC production based on the levels of O<sub>2</sub> present in the tissues,<sup>1292</sup> amplifies GATA1-mediated activation of autophagy genes<sup>641</sup> and additional genes required for erythroid maturation.<sup>1293</sup> Furthermore, lipidation of the cytosolic form of *LC3B* into the lipidated *LC3-II* form is controlled by EPO (erythropoietin), the erythroid-specific growth factor that ensures survival of the maturing erythroid cells. The fact that the genes encoding the autophagic machinery are controlled by the same factors that regulate expression of genes encoding important red cell constituents (such as red blood cell antigens and cytoskeletal components, globin, and proteins mediating heme biosynthesis),<sup>1294-1296</sup> ensures that the process of terminal maturation progresses in a highly ordered fashion.

The importance of autophagy for RBC production has been established through the use of mutant mouse strains lacking genes encoding proteins of the autophagy machinery (*BNIP3L*, *ULK1*, *ATG7*).<sup>1297-1300</sup> These mutant mice exhibit erythroid cells blocked at various stages of terminal erythroid maturation and are anemic. Abnormalities of the autophagic machinery are also linked to anemia observed in certain human diseases, especially those categorized as ribosomopathies. As in other cell types, in erythroid cells TP53 activation may influence the functional consequences of autophagy—to determine cell death

rather than maturation. TP53, through MDM2, is the gatekeeper to ensure normal ribosome biosynthesis by inducing death of cells lacking sufficient levels of ribosomal proteins. Diseases associated with congenic or acquired loss-of-function mutations of genes encoding ribosomal proteins, such as Diamond-Blackfan anemia or myelodysplastic syndrome, are characterized by activated TP53 and abnormally high levels of autophagic death of erythroid cells and anemia. Conversely, the anemia of at least certain Diamond-Blackfan anemia patients may be treated with glucocorticoids that inhibit TP53 activity.

## 6. Filamentous fungi

As in yeast, autophagy is involved in nutrient recycling during starvation.<sup>275,276,1301-1306</sup> In addition, macroautophagy seems to be involved in many normal developmental processes such as sexual and asexual reproduction, where there is a need for reallocation of nutrients from one part of the mycelium to another to supply the developing spores and spore-bearing structures.<sup>276,726,1301,1302,1304,1307-1309</sup> Similarly, autophagy also affects conidial germination under nitrogen-limiting conditions.<sup>276</sup> In *Podospira anserina*, autophagy has been studied in relation to incompatibility reactions between mating strains where it seems to play a prosurvival role.<sup>274,1307</sup> During aging of this long-standing aging model, autophagy is increased (numbers of GFP-Atg8 puncta and increased autophagy-dependent degradation of a GFP reporter protein) and acts as a prosurvival pathway.<sup>1310</sup> Of special interest to many researchers of autophagy in filamentous fungi has been the possible involvement of autophagy in plant and insect pathogen infection and growth inside the host.<sup>275,709,1301,1302,1311-1314</sup> Autophagy also appears to be necessary for the development of aerial hyphae,<sup>276,1302,1307,1312</sup> and for appressorium function in *M. oryzae*, *Colletotrichum orbiculare* and *Metarhizium robertsii*.<sup>275,1311,1312,1314</sup> Some of these effects could be caused by the absence of autophagic processing of storage lipids (lipophagy) to generate glycerol for increasing turgor and recycling the contents of spores into the incipient appressorium, as a prerequisite to infection.<sup>1301,1312,1313</sup>

Methods for functional analysis of autophagy have been covered in a review article (see ref. 1315). Most studies on autophagy in filamentous fungi have involved deleting some of the key genes necessary for autophagy, followed by an investigation of what effects this has on the biology of the fungus. Most commonly, *ATG1*, *ATG4* and/or *ATG8* have been deleted.<sup>275,1301,1302,1304,1305,1307,1312,1314,1316,1317</sup> To confirm that the deletion(s) affects autophagy, the formation of autophagic bodies in the wild type and the mutant can be compared. In filamentous fungi the presence of autophagic bodies can be detected using MDC staining,<sup>275,1301</sup> TEM<sup>275,1302</sup> or fluorescence microscopy to monitor Atg8 tagged with a fluorescent protein.<sup>276,1304,1307</sup> This type of analysis is most effective after increasing the number of autophagic bodies by starvation or alternatively by adding the autophagy-inducing drug rapamycin,<sup>276,1301</sup> in combination with decreasing the degradation of the autophagic bodies through the use of the protease inhibitor PMSF.<sup>275,1302,1304,1307</sup> In filamentous fungi it might also be possible to detect the accumulation of autophagic bodies in the vacuoles using differential interference contrast microscopy, especially following PMSF treatment.<sup>1304,1307</sup> Additional

information regarding the timing of autophagy induction can be gained by monitoring transcript accumulation of *ATG1* and/or *ATG8* using qRT-PCR.<sup>1302</sup>

Autophagy has been investigated intensively in *Aspergilli*, and in particular in the genetically amenable species *Aspergillus nidulans*, which is well suited to investigate intracellular traffic.<sup>1318</sup> In *A. oryzae*, autophagy has been monitored by the rapamycin-induced and Atg8-dependent delivery of DsRed2, which is normally cytosolic, to the vacuoles.<sup>276</sup> In *A. nidulans*, autophagy has been monitored by the more “canonical” GFP-Atg8 proteolysis assays, by monitoring the delivery of GFP-Atg8 to the vacuole (by time-lapse microscopy), and by directly following the biogenesis of GFP-Atg8-labeled phagophores and autophagosomes, which can be tracked in large numbers using kymographs traced across the hyphal axis. In these kymographs, the autophagosome cycle starting from a PAS “draws” a cone whose apex and base correspond to the “parental” PAS punctum and to the diameter of the “final” autophagosome, respectively.<sup>1319</sup> Genetic analyses revealed that autophagosomes normally fuse with the vacuole in a Rab7-dependent manner. However, should Rab7 fusogenic activity be mutationally inactivated, autophagosomes can traffic to the endosomes in a RabB/Rab5- and CORVET-dependent manner.<sup>1319</sup> An important finding was that RabO/Rab1 plays a key role in *A. nidulans* autophagy (and actually can be observed on the phagophore membranes). This finding agrees with previous work in *S. cerevisiae* demonstrating that Ypt1 (the homolog of RAB1) is activated by the Trs85-containing version of TRAPP, TRAPPIII, for autophagy.<sup>1320,1321</sup> This crucial involvement of RabO/Ypt1 points at the ER as one source of membrane for autophagosomes. The suitability of *A. nidulans* for in vivo microscopy has been exploited to demonstrate that nascent phagophores are cradled by ER-associated structures resembling mammalian omegasomes.<sup>1319</sup> The macroautophagic degradation of whole nuclei that has been observed in *A. oryzae*<sup>721</sup> might be considered as a specialized version of reticulophagy. Finally, autophagosome biogenesis has also been observed using a PtdIns3P-binding GFP-tagged FYVE domain probe in mutant cells lacking RabB/Rab5. Under these genetic conditions Vps34 cannot be recruited to endosomes and is entirely at the disposition of autophagy,<sup>1320</sup> such that PtdIns3P is only present in autophagic membranes.

Mitophagy has been studied in *M. oryzae*, by detecting the endogenous level of porin (a mitochondrial outer membrane protein) by western blot, and by microscopy observation of vacuolar accumulation of mito-GFP.<sup>709</sup> Mitophagy is involved in regulating the dynamics of mitochondrial morphology and/or mitochondrial quality control, during asexual development and invasive growth in *M. oryzae*. Pexophagy has also been studied in rice-blast fungus and it serves no obvious biological function, but is naturally induced during appressorial development, likely for clearance of excessive peroxisomes prior to cell death.<sup>1322</sup> Methods to monitor pexophagy in *M. oryzae* include microscopy observation of the vacuolar accumulation of GFP-SRL (peroxisome-localized GFP), and detection of the endogenous thiolase,<sup>1323</sup> or Pex14 levels.

## 7. Food biotechnology

Required for yeast cell survival under a variety of stress conditions, autophagy has the potential to contribute to the outcome

of many food fermentation processes. For example, autophagy induction is observed during the primary fermentation of synthetic grape must<sup>1323</sup> and during sparkling wine production (secondary fermentation).<sup>1324</sup> A number of genome-wide studies have identified vacuolar functions and autophagy as relevant processes during primary wine fermentation or for ethanol tolerance, based on gene expression data or cell viability of knockout yeast strains.<sup>1323,1325-1329</sup> However, determining the relevance of autophagy to yeast-driven food fermentation processes requires experimentation using some of the methods available for *S. cerevisiae* as described in these guidelines.

Autophagy is a target for some widespread food preservatives used to prevent yeast-dependent spoilage. For example, the effect of benzoic acid is exacerbated when concurrent with nitrogen starvation.<sup>1330</sup> This observation opened the way to devise strategies to improve the usefulness of sorbic and benzoic acid, taking advantage of their combination with stress conditions that would require functional autophagy for yeast cell survival.<sup>1228</sup> Practical application of these findings would also require extending this research to other relevant food spoilage yeast species, which would be of obvious practical interest.

In the food/health interface, the effect of some food bioactive compounds on autophagy in different human cell types has already attracted some attention.<sup>1331,1332</sup> Interpreting the results of this type of research, however, warrants 2 cautionary notes.<sup>1333</sup> First, the relationship between health status and autophagic activity is obviously far from being direct. Second, experimental design in this field must take into account the actual levels of these molecules in the target organs after ingestion, as well as exposure time and their transformations in the human body. In addition, attention must be paid to the fact that several mechanisms might contribute to the observed biological effects. Thus, relevant conclusions about the actual involvement of autophagy on the health-related effect of food bioactive compounds would only be possible by assaying the correct molecules in the appropriate concentrations.

## 8. Honeybee

The reproductive system of bees, or insects whose ovaries exhibit a meroistic polytrophic developmental cycle can be a useful tool to analyze and monitor physiological autophagy. Both queen and worker ovaries of Africanized *A. mellifera* display time-regulated features of cell death that are, however, linked to external stimuli.<sup>1334</sup> Features of apoptosis and autophagy are frequently associated with the degeneration process in bee organs, but only more recently has the role of autophagy been highlighted in degenerating bee tissues. The primary method currently being used to monitor autophagy is following the formation of autophagosomes and autolysosomes by TEM. This technique can be combined with cytochemical and immunohistochemical detection of acid phosphatase as a marker for autolysosomes.<sup>1335,1336</sup> Acidotropic dyes can also be used to follow autophagy in bee organs, as long as the cautions noted in this article are followed. The honeybee genome has been sequenced, and differential gene expression has been used to monitor *Atg18* in bees parasitized by *Varroa destructor*.<sup>1337</sup>


## 9. Human

Considering that much of the research conducted today is directed at understanding the functioning of the human body, in both normal and disease states, it is pertinent to include humans and primary human tissues and cells as important models for the investigation of autophagy. Although clinical studies are not readily amenable to these types of analyses, it should be kept in mind that the mTORC1 inhibitor rapamycin, the lysosomal inhibitors chloroquine and hydroxychloroquine, and the microtubule depolymerizing agent colchicine are all available as clinically approved drugs. However, these drugs have serious side effects, which often impede their clinical use to study autophagy (e.g., severe immunosuppressive effects of rapamycin; gastrointestinal complaints, bone marrow depression, neuropathy and acute renal failure induced by colchicine; gastrointestinal complaints, neuropathy and convulsions, and retinopathy induced by [hydroxy]chloroquine). These side effects may in part be exacerbated by potential inhibition of macroautophagy in itself by these drugs.<sup>1338</sup> In cancer treatment, for example, autophagy-inhibiting drugs are used in combination with other anticancer drugs to increase their potency. Conversely, normal tissues such as kidney induce macroautophagy in response to anticancer drugs to resist their toxicity;<sup>1339</sup> additional blockade of autophagy could worsen normal tissue toxicity and cause serious side effects. Therefore, the potential for serious adverse effects and toxicity of these drugs warrants caution, especially when studying a role of autophagy in high-risk patients, such as the critically ill. Fortunately, it is possible to obtain fresh biopsies of some human tissues. Blood, in particular, as well as samples of adipose and muscle tissues, can be obtained from needle biopsies or from elective surgery. For example, in a large study, adipocytes were isolated from pieces of adipose tissue (obtained during surgery) and examined for INS/insulin signaling and autophagy. It was demonstrated that autophagy was strongly upregulated (based on LC3 flux, EM, and lipofuscin degradation) in adipocytes obtained from obese patients with type 2 diabetes compared with nondiabetic subjects.<sup>294</sup> In another study utilizing human adipose tissue biopsies and explants, elevated autophagic flux in obesity was associated with increased expression of several autophagy genes.<sup>217,609</sup>


The study of autophagy in the blood has revealed that SNCA may represent a further marker to evaluate the autophagy level in T lymphocytes isolated from peripheral blood.<sup>1340</sup> In these cells it has been shown that (a) knocking down the SNCA gene results in increased macroautophagy, (b) autophagy induction by energy deprivation is associated with a significant decrease of SNCA levels, (c) macroautophagy inhibition (e.g., with 3-MA or knocking down ATG5) leads to a significant increase of SNCA levels, and (d) SNCA levels negatively correlate with LC3-II levels. Thus, SNCA, and in particular the 14-kDa monomeric form, can be detected by western blot as a useful tool for the evaluation of macroautophagy in primary T lymphocytes. In contrast, the analysis of SQSTM1 or NBR1 in freshly isolated T lymphocytes fails to reveal any correlation with either LC3-II or SNCA, suggesting that these markers cannot be used to evaluate basal macroautophagy in these primary cells. Conversely, LC3-II upregulation is correlated with SQSTM1 degradation in neutrophils, as demonstrated in a human sepsis model.<sup>1034</sup>

A major caveat of the work concerning autophagy on human tissue is the problem of postmortem times, agonal state, premortem clinical history (medication, diet, etc.) and tissue fixation. Time to fixation is typically longer in autopsy material than when biopsies are obtained. For tumors, careful sampling to avoid necrosis, hemorrhagic areas and non-neoplastic tissue is required. The problem of fixation is that it can diminish the antibody binding capability; in addition, especially in autopsies, material is not obtained immediately after death.<sup>1341,1342</sup> The possibilities of postmortem autolysis and fixation artifacts must always be taken into consideration when interpreting changes attributed to autophagy.<sup>1343</sup> Analyses of these types of samples require not only special antigen retrieval techniques, but also histopathological experience to interpret autophagy studies by IHC, immunofluorescence or TEM. Nonetheless, at least one recent study demonstrated that LC3 and SQSTM1 accumulation can be readily detected in autopsy-derived cardiac tissue from patients with chloroquine- and hydroxychloroquine-induced autophagic vacuolar cardiomyopathy.<sup>962</sup> Despite significant postmortem intervals, sections of a few millimeters thickness cut from fresh autopsy brain and fixed in appropriate glutaraldehyde-formalin fixative for EM, can yield TEM images of sufficient ultrastructural morphology to discriminate different autophagic vacuole subtypes and their relative regional abundance in some cases (R. Nixon, personal communication).

The situation is, however, typically problematic with TEM, where postmortem delays can cause vacuolization. Researchers experienced in the analysis of TEM images corresponding to autophagy should be able to identify these potential artifacts because autophagic vacuoles should contain cytoplasm. While brain biopsies may be usable for high quality TEM (Fig. 29, 30), this depends upon proper handling at the intraoperative consultation stage, and such biopsies are performed infrequently except for brain tumor diagnostic studies. Conversely, biopsies of organs such as the digestive tract, the liver, muscle and the skin are routinely performed and thus nearly always yield high-quality TEM images. When possible, nonsurgical biopsies are preferable since surgery is usually performed in



**Figure 29.** A large dystrophic neurite from a brain biopsy of a patient with Gerstmann-Sträussler-Scheinker disease not unlike those reported for Alzheimer disease.<sup>60</sup> This structure is filled with innumerable autophagic vacuoles, some of which are covered by a double membrane. Electron dense lysosomal-like structures are also visible. The red arrow points to a double-membrane autophagic vacuole. Scale bar: 200 nm. Image provided by P. Liberski.



**Figure 30.** A high-power electron micrograph from a brain biopsy showing autophagic vacuoles in a case of ganglioglioma. Scale bar: 200 nm. Image provided by P. Liberski.

anesthetized and fasting patients, 2 conditions possibly affecting autophagy. Moreover, certain surgical procedures require tissue ischemia-reperfusion strategies that can also affect autophagy level.<sup>1344</sup> An analysis that examined liver and skeletal muscle from critically ill patients utilized tissue biopsies that were taken within  $30 \pm 20$  min after death and were flash-frozen in liquid nitrogen followed by storage at  $-80^{\circ}\text{C}$ .<sup>1061</sup> Samples could subsequently be used for EM and western blot analysis.

A major limitation of studying patient biopsies is that only static measurements can be performed. This limitation does not apply, however, for dynamic experiments on tissue biopsies or cells derived from biopsies, as described above.<sup>294</sup> Multiple measurements over time, especially when deep (vital) organs are involved, are impossible and ethically not justifiable. Hence, quantitative flux measurements are virtually impossible in patients. To overcome these problems to the extent possible and to gain a more robust picture of the autophagic status, observational studies need to include 2 different aspects. First, a static marker for phagophore or autophagosome formation needs to be measured. This can be done by assessing ultrastructural changes with TEM and/or on the molecular level by measuring LC3-II protein levels. Second, accumulation of autophagy substrates, such as SQSTM1 and (poly)ubiquitinated proteins, can provide information on the overall efficacy of the pathway and can be a surrogate marker of the consequences of altered autophagic flux, especially when autophagy is insufficient, although these changes can also be affected by the ubiquitin-proteasome system as mentioned above. In addition, and even more so when problems with specific pathways are suspected (e.g., mitophagy), specific substrates of these pathways should be determined. Again, none of these measurements on its own provides enough information on (the efficacy of) autophagy, because other processes may confound every single parameter. However, the combination of multiple analyses should be informative. Of note, there has been recent interest in assessing markers of autophagy and autophagic flux in right atrial biopsy samples obtained from patients undergoing cardiac surgery.<sup>1345,1346</sup> Evidence to date suggests that cardiac surgery may be associated with an increase in autophagic flux, and that this response may protect the heart from perioperative

cardiac ischemia-reperfusion injury.<sup>1345</sup> Although still in its infancy with regard to autophagy, it is worth pointing out that mathematical modeling has the power to bridge whole body in vivo data with in vitro data from tissues and cells. The usefulness of so-called hierarchical or multilevel modeling has thus been demonstrated when examining the relevance of INS/insulin signaling to glucose uptake in primary human adipocytes compared with whole-body glucose homeostasis.<sup>1347</sup>

Lipophagy is an important pathway of lipid droplet clearance in hepatocytes, and the extent of lipophagy modulates the lipid content in these cells. Hepatocytes break down lipid droplets through lipophagy as a pathway of endogenous lipid clearance in response to hormones or daily rhythms of nutrient supply.<sup>1062</sup> LC3-II colocalizes with lipid droplets, indicating a role for autophagy in the mobilization of free fatty acids.<sup>817</sup> Little is known regarding the changes of lipophagy under pathological conditions, such as drug toxicity, alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH). The accumulation of lipid droplets in hepatocytes activates ATG5 in the droplets, and initiates a lipophagy process; in addition, increased influx of fatty acids in hepatocytes results in oxidant stress, ER stress and autophagy,<sup>1348,1349</sup> as indicated by the fact that there is enhanced staining of LC3-II in NASH tissue.<sup>1348,1350</sup> However, autophagic flux is impaired in liver specimens of NASH patients as indicated by increased levels of SQSTM1.<sup>1351</sup> Therefore, the value of using LC3-II staining in tissue as an indication of autophagy or lipophagy is in question.

A stepwise process can be proposed for linking changes in the autophagic pathway to changes in disease outcome. First, in an observational study, the changes in the autophagic pathway (see above) should be quantified and linked to changes in disease outcome. To prove causality, a subsequent autophagy-modifying intervention should be tested in a randomized study. Before an intervention study is performed in human patients, the phenotype of (in)active autophagy contributing to poor outcome should be established in a validated animal model of the disease. For the validation of the hypothesis in an animal model, a similar 2-step process is suggested, with the assessment of the phenotype in a first stage, followed by a proof-of-concept intervention study (see *Large animals*).

## 10. Hydra

Hydra is a freshwater cnidarian animal that provides a unique model system to test autophagy. The process can be analyzed either in the context of nutrient deprivation, as these animals easily survive several weeks of starvation,<sup>1352,1353</sup> or in the context of regeneration, because in the absence of protease inhibitors, bisection of the animals leads to an uncontrolled wave of autophagy. In the latter case, an excess of autophagy in the regenerating tip immediately after amputation is deleterious.<sup>1354-1356</sup> Most components of the autophagy and MTOR pathways are evolutionarily conserved in Hydra.<sup>1353</sup> For steady-state measurements, autophagy can be monitored by western blot for ATG8/LC3, by immunofluorescence (using antibodies to ATG8/LC3, lysobisphosphatidic acid or RPS6KA/RSK), or with dyes such as MitoFluor Red 589 and LysoTracker Red. Flux measurements can be made by following ATG8/LC3 turnover using lysosomal protease inhibitors (leupeptin and

pepstatin A) or in vivo labeling using LysoTracker Red. It is also possible to monitor MTOR activity with phosphospecific antibodies to RPS6KB and EIF4EBP1 or to examine gene expression by semiquantitative RT-PCR, using primers that are designed for Hydra. Autophagy can be induced by RNAi-mediated knockdown of *Kazal1*,<sup>1354,1355</sup> or with rapamycin treatment, and can be inhibited with wortmannin or bafilomycin A<sub>1</sub>.<sup>1352,1353</sup>

## 11. Large animals

This section refers in particular to mammals other than humans. Assessment of autophagy (and, in particular, autophagic flux) in clinically relevant large animal models is critical in establishing its (patho)physiological role in multiple disease states. For example, evidence obtained in swine suggests that upregulation of autophagy may protect the heart against damage caused by acute myocardial infarction/heart attack.<sup>1357</sup> Ovine models of placental insufficiency leading to intrauterine growth restriction have shown that there is no change in the expression of markers of autophagy in the fetus in late gestation<sup>1358</sup> or in the lamb at 21 d after birth.<sup>1359</sup> Furthermore, there is an increase in markers of autophagy in the placenta of human intrauterine growth restriction pregnancies.<sup>1360</sup> Studies in rabbits suggest a protective role of upregulated autophagy against critical illness-induced multiple organ failure and muscle weakness,<sup>1361,1362</sup> which is corroborated by human studies.<sup>1060,1061</sup> Conversely, autophagy may contribute to the pathogenesis of some types of tissue injury, at least in the lung.<sup>1363,1364</sup>

Autophagy also plays an important role in the development and remodeling of the bovine mammary gland. In vitro studies with the use of a 3-dimensional culture model of bovine mammary epithelial cells (MECs) have shown that this process is involved in the formation of fully developed alveoli-like structures.<sup>1365</sup> Earlier studies show that intensified autophagy is observed in bovine MECs at the end of lactation and during the dry period, when there is a decrease in the levels of lactogenic hormones, increased expression of auto/paracrine apoptogenic peptides, increased influence of sex steroids and enhanced competition between the intensively developing fetus and the mother organism for nutritional and bioactive compounds.<sup>1366,1367</sup> These studies were based on some of the methods described elsewhere in these guidelines, including GFP-Atg8/LC3 fluorescence microscopy, TEM, and western blotting of LC3 and BECN1. Creation of a specific GFP-LC3 construct by insertion of cDNA encoding bovine LC3 into the pEGFP-C1 vector makes it possible to observe induction of autophagy in bovine MECs in a more specific manner than can be achieved by immunofluorescence techniques, in which the antibodies do not show specific reactivity to bovine cells and tissues.<sup>1365,1367</sup> However, it is important to remember that definitive confirmation of cause-and-effect is challenging for studies on large animals, given the lack or poor availability of specific antibodies and other molecular tools, the frequent inability to utilize genetic approaches, and the often prohibitive costs of administering pharmacological inhibitors in these translational preparations.

In contrast with cell culture experiments, precise monitoring of autophagic flux is practically impossible in vivo in large animals. Theoretically, repetitive analyses of small tissue biopsies should be performed to study ultrastructural and molecular alterations over time in the presence or absence of an autophagy inhibitor (e.g., chloroquine). However, several practical problems impede applicability of this approach. First, repetitive sampling of small needle biopsies in the same animal (a major challenge by itself) could be assumed to induce artifacts following repetitive tissue destruction, especially when deep (vital) organs are involved. In addition, chemical inhibitors of autophagy have considerable side effects and toxicity, hampering their usage. Also, the general physical condition of an animal may confound results obtained with administration of a certain compound, for instance altered uptake of the compound when perfusion is worse.

Therefore, in contrast to cells, where it is more practical to accurately document autophagic flux, we suggest the use of a stepwise approach in animal models to provide a proof of concept with an initial evaluation of sequellae of (in)active autophagy and the relation to the outcome of interest.

First, prior to an intervention, the static ultrastructural and molecular changes in the autophagic pathway should be documented and linked to the outcome of interest (organ function, muscle mass or strength, survival, etc.). These changes can be evaluated by light microscopy, EM and/or by molecular markers such as LC3-II. In addition, the cellular content of specific substrates normally cleared by autophagy should be quantified, as, despite its static nature, such measurement could provide a clue about the results of altered autophagic flux in vivo. These autophagic substrates can include SQSTM1 and (poly)ubiquitinated substrates or aggregates, but also specific substrates such as damaged mitochondria. As noted above, measurement of these autophagic substrates is mainly informative when autophagic flux is prohibited/insufficient, and, individually, all have specific limitations for interpretation. As mentioned several times in these guidelines, no single measurement provides enough information on its own to reliably assess autophagy, and all measurements should be interpreted in view of the whole picture. In every case, both static measurements reflecting the number of autophagosomes (ultrastructural and/or molecular) and measurements of autophagic substrates as surrogate markers of autophagic flux need to be combined. Depending on the study hypothesis, essential molecular markers can further be studied to pinpoint at which stage of the process autophagy may be disrupted.

Second, after having identified a potential role of autophagy in mediating an outcome in a clinically relevant large animal model, an autophagy-modifying intervention should be tested. For this purpose, an adequately designed, randomized controlled study of sufficient size on the effect of a certain intervention on the phenotype and outcome can be performed in a large animal model. Alternatively, the effect of a genetic intervention can be studied in a small animal model with clinical relevance to the studied disease.

As mentioned above, exact assessment of autophagic flux requires multiple time points, which cannot be done in the same animal. Alternatively, different animals can be studied for different periods of time. Due to the high variability between



animals, however, it is important to include an appropriate control group and a sufficiently high number of animals per time point as corroborated by statistical power analyses. This requirement limits feasibility and the number of time points that can be investigated. The right approach to studying autophagy in large animals likely differs depending on the question that is being addressed. Several shortcomings regarding the methodology, inherent to working with large animals, can be overcome by an adequate study design. As for every study question, the use of an appropriate control group with a sufficient number of animals is crucial in this regard.

## 12. Lepidoptera

Some of the earliest work in the autophagy field was carried out in the area of insect metamorphosis.<sup>1084</sup> Microscopy and biochemical research revealed autophagy during the metamorphosis of American silkmoths and the tobacco hornworm, *Manduca sexta*, and included studies of the intersegmental muscles, but they did not include molecular analysis of autophagy. Overall, these tissues cannot be easily maintained in culture, and antibodies against mammalian proteins often do not work. Accordingly, these studies were confined to biochemical measurements and electron micrographs. During metamorphosis, the bulk of the larval tissue is removed by autophagy and other forms of proteolysis.<sup>1368</sup> *Bombyx mori* is now used as a representative model among Lepidoptera, for studying not only the regulation of autophagy in a developmental setting, but also the relations between autophagy and apoptosis. The advantages of this model are the large amount of information gathered on its developmental biology, physiology and endocrinology, the availability of numerous genetic and molecular biology tools, and a completely sequenced genome.<sup>1369</sup> The basic studies of *B. mori* autophagy have been carried out in 4 main larval systems: the silk gland, the fat body, the midgut and the ovary.

The techniques used for these studies are comparatively similar, starting from EM, which is the most widely used method to follow the changes of various autophagic structures and other features of the cytosol and organelles that are degraded during autophagy.<sup>619,1370-1373</sup> Immuno-TEM also can be used, when specific antibodies for autophagic markers are available. As in other model systems the use of Atg8 antibodies has been reported in Lepidoptera. In *B. mori* midgut<sup>619</sup> and fat body,<sup>620</sup> as well as in various larval tissues of *Galleria mellonella*<sup>1374</sup> and *Helicoverpa armigera*,<sup>1375</sup> the use of custom antibodies makes it possible to monitor Atg8 conversion to Atg8-PE by western blotting. Moreover transfection of GFP-Atg8 or mCherry-GFP-Atg8 has been used to study autophagy in several lepidopteran cell lines.<sup>1375</sup> Activation of TOR can be monitored with a phosphospecific antibody against EIF4EBP1.<sup>620</sup> Acidotropic dyes such as MDC and LysoTracker Red staining have been used as markers for autophagy in silkworm egg chambers combined always with additional assays.<sup>1370,1371</sup> Acid phosphatase also can be used as a marker for autolysosomal participation in these tissues.<sup>619,1372,1376</sup> Systematic cloning and analysis revealed that homologs of most of the *Atg* genes identified in other insect species such as *Drosophila* are present in *B. mori*, and 14 *Atg* genes have now been identified in the silkworm

genome, as well as other genes involved in the TOR signal transduction pathway.<sup>1377-1379</sup> Variations in the expression of several of these genes have been monitored not only in silkworm larval organs, where autophagy is associated with development,<sup>619,1377,1378,1380</sup> but also in the fat body of larvae undergoing starvation.<sup>1377,1381</sup>


In the IPLB-LdFB cell line, derived from the fat body of the caterpillar of the gypsy moth *Lymantria dispar*, indirect immunofluorescence experiments have demonstrated an increased number of Atg8-positive dots in cells with increased autophagic activity; however, western blotting did not reveal the conversion of Atg8 into Atg8-PE. Instead, a single band with an approximate molecular mass of 42 kDa was observed that was independent of the percentage of cells displaying punctate Atg8 (D. Malagoli, unpublished results). In contrast, with *B. mori* midgut, the use of an antibody specific for BmAtg8 makes it possible to monitor BmAtg8 processing to BmAtg8-PE by western blotting.<sup>619</sup> Thus, the utility of monitoring Atg8 in insects may depend on the particular organism and antibody.

## 13. Marine invertebrates

The invaluable diversity of biological properties in marine invertebrates offers a unique opportunity to explore the different facets of autophagy at various levels from cell to tissue, and throughout development and evolution. For example, work on the tunicate *Ciona intestinalis* has highlighted the key role of autophagy during the late phases of development in lecithotrophic organisms (larvae during metamorphosis feed exclusively from the egg yolk resources).<sup>278,1382</sup> This work has also helped in pinpointing the coexistence of autophagy and apoptosis in cells as well as the beneficial value of combining complementary experimental data such as LC3 immunolabeling and TUNEL detection. This type of approach could shed a new light on the close relationship between autophagy and apoptosis and provide valuable information about how molecular mechanisms control the existing continuum between these 2 forms of programmed cell death. Autophagy plays a key role in the resistance to nutritional stress as is known to be the case in many Mediterranean bivalve molluscs in the winter. For example, the European clam *Ruditapes decussatus* is able to withstand strict fasting for 2 mo, and this resistant characteristic is accompanied by massive macroautophagy in the digestive gland (Fig. 31). This phenomenon, observed by TEM, demonstrates once again the advantage of using this classical ultrastructural method to study autophagy in unconventional biological models for which molecular tools may not be operational. Finally, autophagy also appears to play a role in the cell renewal process observed during the regeneration of the carnivorous sponge *Asbestopluma hypogea*.<sup>1383</sup> The presence of the autophagic machinery in this sister group of Eumetazoans should incite interest into considering the study of the molecular networks that regulate autophagy within an evolutionary framework.

## 14. Neotropical teleosts

In tropical environments, fish have developed different reproductive strategies, and many species have the potential for use as a biological model in cell and molecular biology, especially



**Figure 31.** Macroautophagy in the digestive gland of *Ruditapes decussatus* (Mollusca, Bivalvia) subjected to a strict starvation of 2 months. Image provided by S. Baghdiguian.

for studying the mechanisms that regulate gametogenesis and embryo development. In these fish, the ovary is a suitable experimental model system for studying autophagy and its interplay with cell death programs due to the presence of post-ovulatory follicles (POFs) and atretic follicles, which follow different routes during ovarian remodeling after spawning.<sup>1384</sup> In the fish reproductive biology, POFs are excellent morphological indicators of spawning, whereas atretic follicles are relevant biomarkers of environmental stress. In addition, many freshwater teleosts of commercial value do not spawn spontaneously in captivity, providing a suitable model for studying the mechanisms of follicular atresia under controlled conditions.<sup>1385</sup> When these species are subjected to induced spawning, the final oocyte maturation (resumption of meiosis) occurs, and POFs are formed and quickly reabsorbed in ovaries after spawning.<sup>1386</sup> Assessment of autophagy in fish has been primarily made using TEM at different times of ovarian regression.<sup>1387</sup> Due to the difficulty of obtaining antibodies specific for each fish species, immunodetection of ATG-proteins (mainly LC3 and BECN1) by IHC associated with analyses by western blotting can be performed using antibodies that are commercially available for other vertebrates.<sup>396</sup> Such studies suggest dual roles for autophagy in follicular cells;<sup>1384</sup> however, evaluation of the autophagic flux in different conditions is critical for establishing its physiological role during follicular regression and ovarian remodeling after spawning. Given the ease of obtaining samples and monitoring them during development, embryos of these fish are also suitable models for studying autophagy that is activated in response to different environmental stressors, particularly in studies in vivo.

### 15. Odontoblasts

Odontoblasts are long-lived dentin-forming postmitotic cells, which evolved from neural crest cells early during vertebrate

evolution. These cells are aligned at the periphery of the dental pulp and are maintained during the entire healthy life of a tooth. As opposed to other permanent postmitotic cells such as cardiac myocytes or central nervous system neurons, odontoblasts are significantly less protected from environmental insult such as dental caries and trauma. Mature odontoblasts develop a well-characterized autophagy-lysosomal system, including a conspicuous autophagic vacuole that ensures turnover and degradation of cell components. Immunocytochemical and TEM studies make it possible to monitor age-related changes in autophagic activity in human odontoblasts.<sup>1388</sup>

### 16. Planarians

Because planarians are one of the favorite model systems in which to study regeneration and stem cell biology, these flatworms represent a unique model where it is possible to investigate autophagy in the context of regeneration, stem cells and growth. Currently the method used to detect autophagy is TEM. A detailed protocol adapted to planarians has been described.<sup>1389,1390</sup> However, complementary methods to detect autophagy are also needed, since TEM cannot easily distinguish between activation and blockage of autophagy, which would both be observed as an accumulation of autophagosomes. Other methods to detect autophagy are being developed (C. González-Estévez, personal communication), including IHC and western blotting approaches for the planarian homolog of LC3. Several commercial antibodies against human LC3 have been tried for cross-reactivity without success, and 3 planarian-specific antibodies have been generated. Some preliminary results show that LysoTracker Red can be a useful reagent to analyze whole-mount planarians. Most of the components of the autophagy and MTOR signaling machinery are evolutionarily conserved in planarians. Whether autophagy genes vary at the mRNA level during starvation and after depletion of MTOR signaling components is still to be determined.

### 17. Plants

As stated above with regard to other organisms, staining with MDC or derivatives (such as monodansylamylamine) is not sufficient for detection of autophagy, as these stains also detect vacuoles. The same is true for the use of LysoTracker Red, Neutral Red or acridine orange. The fluorophore of the red fluorescent protein shows a relatively high stability under acidic pH conditions. Thus, chimeric RFP fusion proteins that are sequestered within autophagosomes and delivered to the plant vacuole can be easily detected by fluorescence microscopy. Furthermore, fusion proteins with some versions of RFP tend to form intracellular aggregates, allowing the development of a visible autophagic assay for plant cells.<sup>1391</sup> For example, fusion of cytochrome b5 and the original (tetrameric) RFP generate an aggregated cargo protein that displays cytosolic puncta of red fluorescence and, following vacuolar delivery, diffuse staining throughout the vacuolar lumen. However, it is not certain whether these puncta represent autophagosomes or small vacuoles, and therefore these data should be combined with immuno-TEM or with conventional TEM using high-pressure frozen and freeze-substituted samples.<sup>1392</sup>

In plant studies, GFP-Atg8 fluorescence is typically assumed to correspond to autophagosomes; however, as with other systems, caution needs to be exercised because it cannot be ruled out that Atg8 is involved in processes other than autophagy. Immunolabeled GFP-Atg8 can be detected both on the inner and outer membrane of an autophagosome in an *Arabidopsis* root cell, using chemical fixation (see Fig. 6b in ref. 1393), suggesting that it will be a useful marker to monitor autophagy. *Arabidopsis* cells can be stably transfected with GFP fused to plant ATG8, and the lipidated and nonlipidated forms can be separated by SDS-PAGE.<sup>214</sup> Furthermore, the GFP-ATG8 processing assay is particularly robust in *Arabidopsis* and can be observed by western blotting.<sup>215,256</sup> Two kinds of GFP-ATG8 transgenic seeds are currently available from the Arabidopsis Biological Resource Center, each expressing similar GFP-ATG8a transgenes but having different promoter strength. One transgene is under the control of the stronger *Cauliflower mosaic virus 35S* promoter,<sup>542</sup> while the other uses a promoter of the *Arabidopsis ubiquitin10* gene.<sup>1394</sup> In the GFP-ATG8 processing assay, the former has a higher ratio of GFP-ATG8a band intensity to that of free GFP than does the latter.<sup>1394</sup> Since free GFP level reflects vacuolar delivery of GFP-ATG8, the ubiquitin promoter line may be useful when studying an inhibitory effect of a drug/mutation on autophagic delivery. Likewise, the 35S promoter line may be used for testing potential autophagy inducers.

Thus, as with other systems, autophagosome formation in plants can be monitored through the combined use of fluorescent protein fusions to ATG8, immunolabeling and TEM (Fig. 32). A tandem fluorescence reporter system is also available in *Arabidopsis*.<sup>1395</sup> The number of fluorescent Atg8-labeled vesicles can be increased by pretreatment with concanamycin A, which inhibits vacuolar acidification;<sup>1095,1393</sup> however, this may interfere with the detection of MDC and LysoTracker Red. It is also possible to use plant homologs of SQSTM1 and NBR1 in *Arabidopsis*<sup>1395</sup> (the NBR1 homolog is called JOKA2 in tobacco<sup>1396</sup>) as markers for selective autophagy when constructed as fluorescent chimeras. In addition, detection of the NBR1 protein level by western blot, preferably accompanied by qPCR analysis of its transcript level, provides reliable semi-quantitative data about autophagic flux in plant cells.<sup>1397</sup>

It has been assumed that, just as in yeast, autophagic bodies are found in the vacuoles of plant cells, since both


microautophagy and macroautophagy are detected in plant cells.<sup>1398</sup> The data supporting this conclusion are mainly based on EM studies showing vesicles filled with material in the vacuole of the epidermis cells of *Arabidopsis* roots; these vesicles are absent in *ATG4a* and *ATG4b* mutant plants.<sup>282</sup> However, it cannot be excluded that these vacuolar vesicles are in fact cytoplasmic/protoplasmic strands, or that they arrived at the vacuole independent of macroautophagy; although the amount of such strands would not be expected to increase following treatment with concanamycin. Immunolabeling with an antibody to detect ATG8 could clarify this issue.

Other methods described throughout these guidelines can also be used in plants.<sup>1399</sup> For example, in tobacco cells cultured in sucrose starvation medium, the net degradation of cellular proteins can be measured by a standard protein assay; this degradation is inhibited by 3-MA and E-64c (an analog of E-64d), and is thus presumed to be due to autophagy.<sup>1400-1402</sup>

**Cautionary notes:** Although the detection of vacuolar RFP can be applied to both plant cell lines and to intact plants, it is not practical to measure RFP fluorescence in intact plant leaves, due to the very high red autofluorescence of chlorophyll in the chloroplasts. Furthermore, different autophagic induction conditions cause differences in protein synthesis rates; thus, special care should be taken to monitor the efficiency of autophagy by quantifying the intact and processed cargo proteins.

## 18. Protists

An essential role of autophagy during the differentiation of parasitic protists (formerly called protozoa) is clearly emerging. Only a few of the known ATG genes are present in these organisms, which raises the question about the minimal system that is necessary for the normal functioning of autophagy. The reduced complexity of the autophagic machinery in many protists provides a simplified model to investigate the core mechanisms of autophagosome formation necessary for selective proteolysis; accordingly, protist models have the potential to open a completely new area in autophagy research. Some of the standard techniques used in other systems can be applied to protists including indirect immunofluorescence using antibodies generated against ATG8 and the generation of stable lines expressing mCherry- or GFP-fused ATG8 for live microscopy and immuno-TEM analyses. Extrachromosomal constructs of



**Figure 32.** Detection of macroautophagy in tobacco BY-2 cells. (A) Induction of autophagosomes in tobacco BY-2 cells expressing YFP-NtAtg8 (shown in green for ease of visualization) under conditions of nitrogen limitation (Induced). Arrowheads indicate autophagosomes that can be seen as a bright green dot. No such structure was found in cells grown in normal culture medium (Control). Scale bar: 10  $\mu\text{m}$ . N, nucleus; V, vacuole. (B) Ultrastructure of an autophagosome in a tobacco BY-2 cell cultured for 24 h without a nitrogen source. Scale bar: 200  $\mu\text{m}$ . AP, autophagosome; CW, cell wall; ER, endoplasmic reticulum; P, plastid. Image provided by K. Toyooka.

GFP-ATG8 also work well with lower eukaryotes,<sup>287,288,1403</sup> as do other fluorescently tagged ATG proteins including ATG5 and ATG12.

The unicellular amoeba *Dictyostelium discoideum* provides another useful system for monitoring autophagy.<sup>1404</sup> The primary advantage of *Dictyostelium* is that it has a unique life cycle that involves a transition from a unicellular to a multicellular form. Upon starvation, up to 100,000 single cells aggregate by chemotaxis and form a multicellular structure that undergoes morphogenesis and cell-type differentiation. Development proceeds via the mound stage, the tipped aggregate and a motile slug, and culminates with the formation of a fruiting body that is composed of a ball of spores supported by a thin, long stalk made of vacuolized dead cells. Development is dependent on autophagy and, at present, all of the generated mutants in *Dictyostelium* autophagy genes display developmental phenotypes of varying severity.<sup>1404,1405</sup> *D. discoideum* is also a versatile model to study infection with human pathogens and the role of autophagy in the infection process. The susceptibility of *D. discoideum* to microbial infection and its strategies to counteract pathogens are similar to those in higher eukaryotes.<sup>1406</sup> Along these lines, *Dictyostelium* utilizes some of the proteins involved in autophagy that are not present in *S. cerevisiae* including ATG101 and VMP1, in addition to the core Atg proteins. The classical markers GFP-ATG8 and GFP-ATG18 can be used to detect autophagosomes by fluorescence microscopy. Flux assays based on the proteolytic cleavage of cytoplasmic substrates are also available.<sup>37,322</sup>

One cautionary note with regard to the use of GFP-ATG8 in protists is that these organisms display some “nonclassical” variations in their ATG proteins (see *LC3-associated apicoplast*) and possibly a wide phylogenetic variation since they constitute a paraphyletic taxon.<sup>1407</sup> For example, *Leishmania* contains many apparent ATG8-like proteins (the number varying per species; e.g., up to 25 in *L. major*) grouped in 4 families, but only one labels true autophagosomes even though the others form puncta,<sup>287</sup> and ATG12 requires truncation to provide the C-terminal glycine before it functions in the canonical way. Unusual variants in protein structures also exist in other protists, including apicomplexan parasites, for example, the malaria parasite *Plasmodium spp.* or *Toxoplasma gondii*, which express ATG8 with a terminal glycine not requiring cleavage to be membrane associated.<sup>1408</sup> Thus, in each case care needs to be applied and the use of the protein to monitor autophagy validated. In addition, due to possible divergence in the upstream signaling kinases, classical inhibitors such as 3-MA, or inducers such as rapamycin, which are not as potent for trypanosomes<sup>1409</sup> or apicomplexan parasites as in mammalian cells or yeast, must be used with caution (I. Coppens, personal communication);<sup>1403</sup> however, RNAi knockdown of TORC1 (e.g., TOR1 or RPTOR) is effective in inducing autophagy in trypanosomes. In addition, small molecule inhibitors of the protein-protein interaction of ATG8 and ATG3 in *Plasmodium falciparum* have been discovered that are potent in cell-based assays and useable at 1–10  $\mu\text{M}$  final concentration.<sup>1410,1411</sup> Note that although the lysosomal protease inhibitors E64 and pepstatin block lysosomal degradative activity in *Plasmodium*, these

inhibitors do not affect ATG8 levels and associated structures, suggesting a need for alternate methodologies to investigate autophagy in this model system.<sup>1412</sup>

In conventional autophagy, the final destination of autophagosomes is their fusion with lysosomes for intracellular degradation. However, *T. gondii* and certain stages of *Plasmodium* (insect and hepatic) lack degradative lysosomes, which makes questionable the presence of canonical autophagosomes and a process of autophagy in these parasites. Nevertheless, if protists employ their autophagic machineries in unconventional manners, studies of their core machinery of autophagy will provide information as to how autophagy has changed and adapted through evolution.

The scuticiliate *Philasterides dicentrarchi* has proven to be a good experimental organism for identifying autophagy-inducing drugs or for autophagy initiation by starvation-like conditions, since this process can be easily induced and visualized in this ciliate.<sup>1413</sup> In scuticiliates, the presence of autophagic vacuoles can be detected by TEM, fluorescence microscopy or confocal laser scanning microscopy by using dyes such as MitoTracker Deep Red FM and MDC.

Finally, a novel autophagy event has been found in *Tetrahymena thermophila*, which is a free-living ciliated protist. A remarkable, virtually unique feature of the ciliates is that they maintain spatially differentiated germline and somatic nuclear genomes within a single cell. The germline genome is housed in the micronucleus, while the somatic genome is housed in the macronucleus. These nuclei are produced during sexual reproduction (conjugation), which involves not only meiosis and mitosis of the micronucleus and its products, but also degradation of some of these nuclei as well as the parental old macronucleus. Hence, there should be a mechanism governing the degradation of these nuclei. The inhibition of PtdIns3Ks with wortmannin or LY294002 results in the accumulation of additional nuclei during conjugation.<sup>1414</sup> During degradation of the parental old macronucleus, the envelope of the nucleus becomes MDC- and LysoTracker Red-stainable without sequestration of the nucleus by a double membrane and with the exposure of certain sugars and phosphatidylserine on the envelope.<sup>1415</sup> Subsequently, lysosomes fuse only to the old parental macronucleus, but other co-existing nuclei such as developing new macro- and micronuclei are unaffected.<sup>1415</sup> Using gene technology it has been shown that ATG8 and VPS34 play critical roles in nuclear degradation.<sup>1416,1417</sup> Knockout mutations of the corresponding genes result in a block in nuclear acidification, suggesting that these proteins function in lysosome-nucleus fusion. In addition, the envelope of the nucleus in the VPS34 knockout mutant does not become stainable with MDC. This evidence suggests that selective autophagy may be involved in the degradation of the parental macronucleus and implies a link between VPS34 and ATG8 in controlling this event.

## 19. Rainbow trout

Salmonids (e.g., salmon, rainbow trout) experience long periods of fasting often associated with seasonal reductions in water temperature and prey availability or spawning

migrations. As such, they represent an interesting model system for studying and monitoring the long-term induction of autophagy. Moreover, the rainbow trout (*Oncorhynchus mykiss*) displays unusual metabolic features that may allow us to gain a better understanding of the nutritional regulation of this degradative system (i.e., a high dietary protein requirement, an important use of amino acids as energy sources, and an apparent inability to metabolize dietary carbohydrates). It is also probably one of the most deeply studied fish species with a long history of research carried out in physiology, nutrition, ecology, genetics, pathology, carcinogenesis and toxicology.<sup>1418</sup> Its relatively large size compared to model fish, such as zebrafish or medaka, makes rainbow trout a particularly well-suited alternative model to carry out biochemical and molecular studies on specific tissues or cells that are impossible to decipher in small fish models. The genomic resources in rainbow trout are now being extensively developed; a high-throughput DNA sequencing program of EST has been initiated associated with numerous transcriptomics studies,<sup>1419-1422</sup> and the full genome sequence is now available.

Most components of the autophagy and associated signaling pathways (AKT, TOR, AMPK, FOXO) are evolutionarily conserved in rainbow trout;<sup>628,1423-1425</sup> however, not all ATG proteins and autophagy-regulatory proteins are detected by the commercially available antibodies produced against their mammalian orthologs. Nonetheless, the expressed sequence transcript databases facilitate the design of targeting constructs. For steady-state measurement, autophagy can be monitored by western blot or by immunofluorescence using antibodies to ATG8/LC3.<sup>1425</sup> Flux measurements can be made in a trout cell culture model (for example, in primary culture of trout myocytes) by following ATG8/LC3 turnover in the absence and presence of bafilomycin A<sub>1</sub>. It is also possible to monitor the mRNA levels of ATG genes by real-time PCR using primer sequences chosen from trout sequences available in the above-mentioned expressed sequence transcript database. A major challenge in the near future will be to develop for this model the use of RNAi-mediated gene silencing to analyze the role of some signaling proteins in the control of autophagy, and also the function of autophagy-related proteins in this species.

## 20. Sea urchin

Sea urchin embryo is an appropriate model system for studying and monitoring autophagy and other defense mechanisms activated during physiological development and in response to stress.<sup>956</sup> This experimental model offers the possibility of detecting LC3 through both western blot and immunofluorescence in situ analysis. Furthermore, in vivo staining of autolysosomes with acidotropic dyes can also be carried out. Studies on whole embryos make it possible to obtain qualitative and quantitative data for autophagy and also to get information about spatial localization aspects in cells that interact among themselves in their natural environment. Furthermore, since embryogenesis of this model system occurs simply in a culture of sea water, it is

very easy to study the effects of inducers or inhibitors of autophagy by adding these substances directly into the culture. Exploiting this potential, it has recently been possible to understand the functional relationship between autophagy and apoptosis induced by cadmium stress during sea urchin development. In fact, inhibition of autophagy by 3-MA results in a concurrent reduction of apoptosis; however, using a substrate for ATP production, methyl pyruvate, apoptosis (assessed by TUNEL assay and cleaved CASP3 immunocytochemistry) is substantially induced in cadmium-treated embryos where autophagy is inhibited. Therefore, autophagy could play a crucial role in the stress response of this organism since it could energetically contribute to apoptotic execution through its catabolic role.<sup>1426</sup> Cautionary notes include the standard recommendation that it is always preferable to combine molecular and morphological parameters to validate the data.

## 21. Ticks

In the hard tick *Haemaphysalis longicornis*, endogenous autophagy-related proteins (Atg6 and Atg12) can be detected by western blotting and/or by immunohistochemical analysis of midgut sections.<sup>1427,1428</sup> It is also possible to detect endogenous Atg3 and Atg8 by western blotting using antibodies produced against the *H. longicornis* proteins (R. Umemiya-Shirafuji, unpublished results). Commercial antibodies against mammalian ATG orthologs (ATG3, ATG5, and BECN1) can also be used for western blotting. However, when the tick samples include blood of a host animal, the animal species immunized with autophagy-related proteins should be checked before use to avoid nonspecific background cross-reactivity. In addition to these methods, TEM is recommended to detect autophagosomes and autolysosomes. Although acidotropic dyes can be useful as a marker for autolysosomes in some animals, careful attention should be taken when using the dyes in ticks. Since the midgut epithelial cells contain acidic organelles (e.g., lysosomes) that are related to blood digestion during blood feeding, this method may cause confusion. It is difficult to distinguish between autophagy (autolysosomes) and blood digestion (lysosomes) with acidotropic dyes. Another available monitoring method is to assess the mRNA levels of tick ATG genes by real-time PCR.<sup>1429,1430</sup> However, this method should be used along with other approaches such as western blotting, immunostaining, and TEM as described in this article. Unlike model insects, such as *Drosophila*, powerful genetic tools to assess autophagy are still not established in ticks. However, RNAi-mediated gene silencing is now well established in ticks,<sup>1431</sup> and is currently being developed to analyze the function of autophagy-related genes in ticks during nonfeeding periods (R. Umemiya-Shirafuji, unpublished results) and in response to pathogen infection. Recently, “omics” technologies such as transcriptomics and proteomics have been applied to the study of apoptosis pathways in *Ixodes scapularis* ticks in response to infection with *Anaplasma phagocytophilum*.<sup>1432</sup> *I. scapularis*, the vector of Lyme disease and human granulocytic anaplasmosis, is the only tick species for which genome sequence information is available (assembly JCVI\_ISG\_i3\_1.0; [http://www.ncbi.nlm.nih.gov/assembly/JCVI\\_ISG\\_i3\\_1.0/](http://www.ncbi.nlm.nih.gov/assembly/JCVI_ISG_i3_1.0/)).

nih.gov/nuccore/NZ\_ABJB000000000). For related tick species such as *I. ricinus*, mapping to the *I. scapularis* genome sequence is possible,<sup>1433</sup> but for other tick species more sequence information is needed for these analyses.

## 22. Zebrafish

Zebrafish (*Danio rerio*) have many characteristics that make them a valuable vertebrate model organism for the analysis of autophagy. For example, taking advantage of the transparency of embryos, autophagosome formation can be visualized in vivo during development using transgenic GFP-Lc3 and GFP-Gabarap fish.<sup>36,1434,1435</sup> Visualization of later-stage embryos is enhanced when medium is supplemented with 1-phenyl-2-thiourea, which inhibits melanogenesis, or through the use of strains with mutations affecting pigment production. Lysosomes can also be readily detected in vivo by the addition of LysoTracker Red to fish media prior to visualization. Additionally, protocols have been developed to monitor Lc3 protein levels and conjugation to PE by western blot analysis using commercially available Lc3 antibodies.<sup>36,1436</sup>

Because of their translucent character and external fertilization and development, zebrafish have proven to be an exceptional choice for developmental research. In situ hybridization of whole embryos can be performed to determine expression patterns. Knockdown of gene function is performed by treatment with morpholinos; the core autophagy machinery protein Gabarap,<sup>1437</sup> and regulatory proteins such as the phosphoinositide phosphatase Mtmr14,<sup>1438</sup> Raptor and Mtor,<sup>1439</sup> have all been successfully knocked down by morpholino treatment. The CRISPR/Cas system is now being used for efficient targeted gene deletions.

Zebrafish are ideal organisms for in vivo drug discovery and/or verification because of their relatively small size and aqueous habitat, and several chemicals have been identified that modulate zebrafish autophagy activity.<sup>1436</sup> Many chemicals can be added to the media and are absorbed directly through the skin. Because of simple drug delivery and rapid embryonic development, zebrafish are a promising organism for the study of autophagy's role in disease including Huntington disease,<sup>1201</sup> Alzheimer disease,<sup>1440</sup> and myofibrillar myopathy.<sup>1441,1442</sup> In the case of infection, studies in zebrafish have made important contributions to understanding the role of bacterial autophagy in vivo.<sup>1443,1444</sup> Zebrafish studies have also contributed to understanding the role of autophagy in different aspects of development, including cardiac morphogenesis, caudal fin regeneration,<sup>1445</sup> and muscle and brain development.<sup>1434,1446,1447</sup>

## D. Noncanonical use of autophagy-related proteins

### 1. LC3-associated phagocytosis

Although the lipidation of LC3 to form LC3-II is a commonly used marker of macroautophagy, studies have established that LC3-II can also be targeted to phagosomes to promote maturation independently of traditional autophagy, in a noncanonical autophagic process termed LC3-associated phagocytosis.<sup>1,26,1448</sup> LAP occurs upon engulfment of particles that engage a receptor-mediated signaling pathway, resulting in the recruitment of some but not all of the autophagic machinery to the

phagosome. These autophagic components facilitate rapid phagosome maturation and degradation of engulfed cargo, and play roles in the generation of signaling molecules and regulation of immune responses.<sup>179,180,1449</sup> LAP thus represents a unique process that marries the ancient pathways of phagocytosis and autophagy.

Despite overlap in molecular machinery, there currently exist several criteria by which to differentiate LAP from macroautophagy: (a) Whereas LC3-decorated autophagosomes can take hours to form, LC3 can be detected on LAP-engaged phagosomes as early as 10 min after phagocytosis, and PtdIns3P can also be seen at LAP-engaged phagosomes minutes after phagocytosis.<sup>180,182,1449</sup> (b) EM analysis reveals that LAP involves single-membrane structures.<sup>182</sup> In contrast, macroautophagy is expected to generate double-membrane structures surrounding cargo. (c) Whereas most of the core autophagy components are required for LAP, the 2 processes can be distinguished by the involvement of the pre-initiation complex. RB1CC1, ATG13, and ULK1 are dispensable for LAP, which provides a convenient means for distinguishing between the 2 processes.<sup>180,1449</sup> (d) LAP involves LC3 recruitment in a manner that requires ROS production by the NADPH oxidase family, notably CYBB/NOX2/gp91<sup>phox</sup>. It should be noted that most cells express at least one member of the NADPH oxidase family. Silencing of the common subunits, CYBB or CYBA/p22<sup>phox</sup>, is an effective way to disrupt NADPH oxidase activity and therefore LAP. It is anticipated that more specific markers of LAP will be identified as this process is further characterized.

Finally, an ATG5- and CTSL-dependent cell death process has been reported that can be activated by the small molecule NID-1; this process depends on PtdIns3K signaling, generates LC3B puncta and single-membrane vacuoles, and results in the clearance of SQSTM1. Thus, LAP and/or related processes can be co-opted to cause cell death in some cases.<sup>1450</sup>

### 2. LC3-associated apicoplast

In the Apicomplexa parasitic protists (e.g., *T. gondii* and *Plasmodium spp.*), the single ATG8 homolog localizes to an endosymbiotic nonphotosynthetic plastid, called the apicoplast.<sup>1408,1451-1454</sup> This organelle is the product of a secondary endosymbiotic event, in which a red alga was endocytosed by an auxotrophic eukaryote (ancestor of an apicomplexan parasite); the apicoplast is the main remnant of this red alga. This organelle is approximately 300 nm in diameter, and is composed of 4 membranes that trace their ancestry to 3 different organisms. The outermost membranes of the apicoplast are derived from the plasma membrane of the auxotrophic eukaryote and the plasma membrane of the internalized alga. ATG8 is located in the outermost membranes that are enriched in PtdIns3P, which marks autophagic structures in mammalian cells; at that location it plays a role in the centrosome-mediated inheritance of the organelle in daughter cells during parasite division (M. Lévêque and S. Besteiro, unpublished results). Consequently, caution must be taken when identifying stress-induced autophagosomes by electron microscopy or by fluorescence microscopy with ATG8 labeling in these parasites.

### 3. LC3 conjugation system for IFNG-mediated pathogen control

Similar to LAP, LC3 localizes on the parasitophorus vacuole membrane (PVM) of *T. gondii*.<sup>181</sup> The parasitophorus vacuole is a vesicle-like structure formed from host plasma membrane during the invasion of *T. gondii*, and it sequesters and protects the invasive *T. gondii* from the hostile host cytoplasm. The cell-autonomous immune system uses IFNG-induced effectors, such as immunity related GTPases and guanylate binding proteins (GBPs), to attack and disrupt this type of membrane structure; consequently, naked *T. gondii* in the cytoplasm are killed by a currently unknown mechanism. Intriguingly, proper targeting of these effectors onto the PVM of *T. gondii* requires the autophagic ubiquitin-like conjugation system, including ATG7, ATG3, and the ATG12-ATG5-ATG16L1 complex, although the necessity of LC3-conjugation itself for the targeting is not yet clear. In contrast, up- or downregulation of canonical autophagy using rapamycin, wortmannin, or starvation do not significantly affect the IFNG-mediated control of *T. gondii*. Furthermore, the degradative function or other components of the autophagy pathway, such as ULK1/2 and ATG14, are dispensable. Many groups have confirmed the essential nature of the LC3-conjugation system for the control of *T. gondii*,<sup>1455-1457</sup> and the same or a similar mechanism also functions against other pathogens such as murine norovirus and *Chlamydia trachomatis*.<sup>1208,1455</sup> Although topologically and mechanistically similar to LAP, the one notable difference is that the parasitophorous vacuole of *T. gondii* is actively made by the pathogen itself using host membrane, and the LC3-conjugation system-dependent targeting happens even in nonphagocytic cells. GBP-mediated lysis of pathogen-containing vacuoles is important for the activation of noncanonical inflammasomes,<sup>1458</sup> but the targeting mechanism of GBPs to the vacuoles is unknown. Considering the necessity of the LC3-conjugation system to target GBPs to the PVM of *T. gondii*, this system may play crucial roles in the general guidance of various effector molecules to target membranes as well as in selective autophagosome-dependent sequestration, phagophore membrane expansion and autophagosome maturation.

### 4. Intracellular trafficking of bacterial pathogens

Some ATG proteins are involved in the intracellular trafficking and cell-to-cell spread of bacterial pathogens by noncanonical autophagic pathways. For example, ATG9 and WIPI1, but not ULK1, BECN1, ATG5, ATG7 or LC3B are required for the establishment of an endoplasmic reticulum-derived replicative niche after cell invasion with *Brucella abortus*.<sup>1459</sup> In addition, the cell-to-cell transmission of *B. abortus* seems to be dependent on ULK1, ATG14 and PIK3C3/VPS34, but independent of ATG5, ATG7, ATG4B and ATG16L1.<sup>1460</sup>

### 5. Other processes

ATG proteins are involved in various other nonautophagic processes, particularly apoptosis and noncanonical protein secretion, as discussed in various papers.<sup>27,75,76,544,572,1449,1461-1465,1466</sup>

## E. Interpretation of in silico assays for monitoring autophagy

The increasing availability of complete (or near complete) genomes for key species spanning the eukaryotic domain provides a unique opportunity for delineating the spread of autophagic machinery components in the eukaryotic world.<sup>1467,1468</sup> Fast and sensitive sequence similarity search procedures are already available; an increasing number of experimental biologists are now comfortable “BLASTing” their favorite sequences against the ever-increasing sequence databases for identifying putative homologs in different species.<sup>1469</sup> Nevertheless, several limiting factors and potential pitfalls need to be taken into account.

In addition to sequence comparison approaches, a number of computational tools and resources related to autophagy have become available online. All the aforementioned methods and approaches may be collectively considered as “in silico assays” for monitoring autophagy, in the sense that they can be used to identify the presence of autophagy components in different species and provide information on their known or predicted associations.

In the following sections we briefly present relevant in silico approaches, highlighting their strengths while underscoring some inherent limitations, with the hope that this information will provide guidelines for the most appropriate usage of these resources.

### 1. Sequence comparison and comparative genomics approaches

Apart from the generic shortcomings when performing sequence comparisons (discussed in ref. 1470), there are some important issues that need to be taken into account, especially for autophagy-related proteins. Since autophagy components seem to be conserved throughout the eukaryotic domain of life, the deep divergent relations of key subunits may reside in the so called “midnight zone” of sequence similarity: i.e., genuine orthologs may share even less than 10% sequence identity at the amino acid sequence level.<sup>1471</sup> This is the case with autophagy subunits in protists<sup>1472,1473</sup> and with other universally conserved eukaryotic systems, as for example the nuclear pore complex.<sup>1474</sup> This low sequence identity is especially pronounced in proteins that contain large intrinsically disordered regions.<sup>1475</sup> In such cases, sophisticated (manual) iterative database search protocols, including proper handling of compositionally biased subsequences and considering domain architecture may assist in eliminating spurious similarities or in the identification of homologs that share low sequence identity with the search molecule.<sup>1473-1475</sup>

Genome-aware comparative genomics methods<sup>1476</sup> can also provide invaluable information on yet unidentified components of autophagy. However, care should be taken to avoid possible Next Generation Sequencing artifacts (usually incorrect genome assemblies): these may directly (via a similarity to a protein encoded in an incorrectly assembled genomic region) or indirectly (via propagating erroneous annotations in databases) give misleading homolog assignments (V.J. Promponas, I. Iliopoulos and C.A. Ouzounis, submitted). In addition, taking

into account other types of high-throughput data available in publicly accessible repositories (e.g., EST/RNaseq data, expression data) can provide orthogonal evidence for validation purposes when sequence similarities are marginal.<sup>1474</sup>

## 2. Web-based resources related to autophagy

A number of autophagy-related resources are now available online, providing access to diverse data types ranging from gene lists and sequences to comprehensive catalogs of physical and indirect interactions. In the following we do not attempt to review all functionalities offered by the different servers, but to highlight those that (a) offer possibilities for identifying novel autophagy-related proteins or (b) characterize features that may link specific proteins to autophagic processes. Two comments regarding biological databases in general also apply to autophagy-related resources as well: (a) the need for regular updates, and (b) data and annotation quality. Nevertheless, these issues are not discussed further herein.

### a. The THANATOS database

THANATOS (THE Apoptosis, Necrosis, AuTophagy OrchestratorS) is a resource being developed by the CUCKOO Workgroup at the Huazhong University of Science and Technology (Wuhan, Hubei, China). THANATOS is still under development (Y. Xue, personal communication) and it is focused on the integration of sequence data related to the main mechanisms leading to programmed cell death in eukaryotes. A simple web interface assists in data retrieval, using keyword searches, browsing by species and cell death type, performing BLAST searches with user-defined sequences, and by requesting the display of orthologs among predefined species. A Java application is also available to download for standalone usage of the THANATOS resource. The THANATOS database is publicly available online at the URL <http://thanatos.biocuckoo.org/>.

### b. The Human Autophagy Database (HADb)

The human autophagy database, developed in the Laboratory of Experimental Hemato-Oncology (Luxembourg), lists over 200 human genes/proteins related to autophagy.<sup>604</sup> These entries have been manually collected from the biomedical literature and other online resources<sup>604</sup> and there is currently no information that the initially published list has been further updated. For each gene there exists information on its sequence, transcripts and isoforms (including exon boundaries) as well as links to external resources. HADb provides basic search and browsing functionalities and is publicly available online at the URL <http://autophagy.lu/>.

### c. The Autophagy Database

The Autophagy Database is a multifaceted online resource providing information for proteins related to autophagy and their homologs across several eukaryotic species, with a focus on functional and structural data.<sup>1477</sup> It is developed by the National Institute of Genetics (Japan) under the Targeted Proteins Research Program of the Ministry of Education, Culture, Sports, Science and Technology (<http://www.tanpaku.org/>). This resource is regularly updated and as of August 2014

contained information regarding 312 reviewed protein entries; when additional data regarding orthologous/homologous proteins from more than 50 eukaryotes is considered, the total number of entries reaches approximately 9,000. In addition to the browse functionalities offered under the “Protein List” and the “Homologs” menus, an instance of the NCBI-BLAST software facilitates sequence-based queries against the database entries. Moreover, interested users may download the gene list or the autophagy dump files licensed under a Creative Commons Attribution-ShareAlike 2.1 Japan License. The Autophagy Database is publicly available online at the URL <http://www.tanpaku.org/autophagy/index.html>.

### d. The Autophagy Regulatory Network (ARN)

The most recent addition to the web-based resources relevant to autophagy research is the Autophagy Regulatory Network (ARN), developed at the Eötvös Loránd University and Semeleweis University (Budapest, Hungary) in collaboration with the Institute of Food Research and The Genome Analysis Centre (Norfolk, UK). Maintenance and hosting the ARN resource is secured at The Genome Analysis Centre until at least 2019. ARN is an integrated systems-level resource aiming to collect and provide an interactive user interface enabling access to validated or predicted protein-protein, transcription factor-gene and miRNA-mRNA interactions related to autophagy in human.<sup>1479</sup> ARN contains data from 26 resources, including an in-house extensive manual curation, the dataset of the CHIP-MS study of Behrends et al.,<sup>464</sup> ADB and ELM. As of June 2015, a total of more than 14,000 proteins and 386 miRNAs are present in ARN, including 38 core autophagy proteins and 113 predicted regulators. Importantly, all autophagy-related proteins are linked to major signaling pathways. A flexible—in terms of both content and format—download functionality enables users to locally use the ARN data under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The autophagy regulatory network resource is publicly available online at the URL <http://autophagy-regulation.org>.

### e. Prediction of Atg8-family interacting proteins

Being central components of the autophagic core machinery, Atg8-family members (e.g., LC3 and GABARAP in mammals) and their interactome have attracted substantial interest.<sup>464,1479,1480</sup> During the last decade, a number of proteins have been shown to interact with Atg8 homologs via a short linear peptide; depending on context, different research groups have described this peptide as the LIR,<sup>319</sup> the LC3 recognition sequence (LRS),<sup>661</sup> or the AIM.<sup>1481</sup> Recently, 2 independent efforts resulted in the first online available tools for identification of these motifs (LIR-motifs for brevity) in combination with other sequence features, which may signify interesting targets for further validation (see below).

### f. The iLIR server

The iLIR server is a specialized web server that scans an input sequence for the presence of a degenerate version of LIR, the extended LIR-motif (xLIR).<sup>1482</sup> Currently, the server also reports additional matches to the “canonical” LIR motif (WxxL), described by the simple regular expression x(2-



[WYF]-x(2)-[LIV]. Kalvari and colleagues have also compiled a position-specific scoring matrix (PSSM) based on validated instances of the LIR motif, demonstrating that many of the false positive hits (i.e., spurious matches to the xLIR motif) are eliminated when a PSSM score > 15 is sought. In addition, iLIR also overlays the aforementioned results to segments that reside in or are adjacent to disordered regions and are likely to form stabilizing interactions upon binding to another globular protein as predicted by the ANCHOR package.<sup>1483</sup> A combination of an xLIR match with a high PSSM score (> 13) and/or an overlap with an ANCHOR segment is shown to give reliable predictions.<sup>1482</sup> It is worth mentioning that, intentionally, iLIR does not provide explicit predictions of functional LIR-motifs but rather displays all the above information accompanied by a graphical depiction of query matches to known protein domains and motifs; it is up to the user to interpret the iLIR output. As mentioned in the original iLIR publication, a limitation of this tool is that it does not handle any noncanonical LIR motifs at present. The iLIR server was jointly developed by the University of Warwick and University of Cyprus and is freely available online at the URL <http://repeat.biol.uct.ac.za/iLIR>.

### g. The Eukaryotic Linear Motif resource (ELM)

The Eukaryotic Linear Motif resource<sup>1484</sup> is a generic resource for examining functional sites in proteins in the form of short linear motifs, which have been manually curated from the literature. Sophisticated filters based on known (or predicted) query features (such as taxonomy, subcellular localization, structural context) are used to narrow down the results lists, which can be very long lists of potential matches due to the short lengths of ELMs. This resource has incorporated 4 entries related to the LIR-motif (since May 2014; <http://elm.eu.org/infos/news.html>), while another 3 are being evaluated as candidate ELM additions (Table 3). Again, the ELM resource displays matches to any motifs and users are left with the decision as to which of them are worth studying further. ELM is developed/maintained by a consortium of European groups coordinated by the European Molecular Biology Laboratory and is freely available online at the URL <http://elm.eu.org>.

### h. The ncRNA-associated cell death database (ncRDeathDB)

The noncoding RNA (ncRNA)-associated cell death database (ncRDeathDB),<sup>1485</sup> most recently developed at the Harbin

Medical University (Harbin, China) and Shantou University Medical College (Shantou, China), documents a total of more than 4,600 ncRNA-mediated programmed cell death entries. Compared to previous versions of the miRDeathDB,<sup>1486-1488</sup> the ncRDeathDB further collected a large amount of published data describing the roles of diverse ncRNAs (including microRNA, long noncoding RNA/lncRNA and small nucleolar RNA/snoRNA) in programmed cell death for the purpose of archiving comprehensive ncRNA-associated cell death interactions. The current version of ncRDeathDB provides an all-inclusive bioinformatics resource on information detailing the ncRNA-mediated cell death system and documents 4,615 ncRNA-mediated programmed cell death entries (including 1,817 predicted entries) involving 12 species, as well as 2,403 apoptosis-associated entries, 2,205 autophagy-associated entries and 7 necrosis-associated entries. The ncRDeathDB also integrates a variety of useful tools for analyzing RNA-RNA and RNA-protein binding sites and for network visualization. This resource will help researchers to visualize and navigate current knowledge of the noncoding RNA component of cell death and autophagy, to uncover the generic organizing principles of ncRNA-associated cell death systems, and to generate valuable biological hypotheses. The ncRNA-associated cell death interactions resource is publicly available online at the URL <http://www.rna-society.org/ncrdeathdb>.

### 3. Dynamic and mathematical models of autophagy

Mathematical modeling methods and approaches can be used as *in silico* models to study autophagy. For example, a systems pharmacology approach has been used to build an integrative dynamic model of interaction between macroautophagy and apoptosis in mammalian cells.<sup>1489</sup> This model is a general predictive *in silico* model of macroautophagy, and the model has translated the signaling networks that control cell fate concerning the crosstalk of macroautophagy and apoptosis to a set of ordinary differential equations.<sup>1489,1490</sup> The model can be adapted for any type of cells including cancer cell lines and drug interventions by adjusting the numerical parameters based on experimental data.<sup>1490</sup> Another example is seen with an agent-based mathematical model of autophagy that focuses on the dynamic process of autophagosome formation and degradation in cells,<sup>1491</sup> and there is a mathematical model of

**Table 3.** Eukaryotic linear motif entries related to the LIR-motif (obtained from <http://elm.eu.org/>).

ELM identifier	ELM	Description	Status
LIG_LIR_Gen_1	[EDST]{0,2}[WYF]..[ILV]	Canonical LIR motif that binds to Atg8 protein family members to mediate processes involved in autophagy.	ELM
LIG_LIR_Apic_2	[EDST]{0,2}[WYF]..P	Apicomplexa-specific variant of the canonical LIR motif that binds to Atg8 protein family members to mediate processes involved in autophagy.	ELM
LIG_LIR_Nem_3	[EDST]{0,2}[WYF]..[ILVYF]	Nematode-specific variant of the canonical LIR motif that binds to Atg8 protein family members to mediate processes involved in autophagy.	ELM
LIG_LIR_LC3C_4	[EDST]{0,2}LVV	Noncanonical variant of the LIR motif that binds to Atg8 protein family members to mediate processes involved in autophagy.	ELM
LIG_AIM	[WY]..[ILV]	Atg8-family interacting motif found in Atg19, SQSTM1/p62, ATG4B and CALR/calreticulin, involved in autophagy-related processes.	Candidate
LIG_LIR	WxxL or [WYF]xx[LIV]	The LIR might link ubiquitinated substrates that should be degraded to the autophagy-related proteins in the phagophore membrane.	Candidate
LIG_GABARAP	W.FL	GABA <sub>A</sub> receptor binding to clathrin and CALR; possibly linked to trafficking.	Candidate

macroautophagy that can be used to interpret the formation of autophagosomes in single cells.<sup>1492</sup> As this aspect of the field progresses we will likely start to see these models used to help predict and understand autophagic responses to new therapeutic treatments.

## Conclusions and future perspectives

There is no question that research on the topic of autophagy has expanded dramatically since the publication of the first set of guidelines.<sup>2</sup> To help keep track of the field we have published a glossary of autophagy-related molecules and processes,<sup>1493,1494</sup> and now include the glossary as part of these guidelines.

With this continued influx of new researchers we think it is critical to try to define standards for the field. Accordingly, we have highlighted the uses and caveats of an expanding set of recommended methods for monitoring macroautophagy in a wide range of systems (Table 4). Importantly, investigators need to determine whether they are evaluating levels of early or late autophagic compartments, or autophagic flux. If the question being asked is whether a particular condition changes autophagic flux (i.e., the rate of delivery of autophagy substrates

to lysosomes or the vacuole, followed by degradation and efflux), then assessment of steady state levels of autophagosomes (e.g., by counting GFP-LC3 puncta, monitoring the amount of LC3-II without examining turnover, or by single time point electron micrographs) is not sufficient as an isolated approach. In this case it is also necessary to directly measure the flux of autophagosomes and/or autophagy cargo (e.g., in wild-type cells compared to autophagy-deficient cells, the latter generated by treatment with an autophagy inhibitor or resulting from *ATG* gene knockdowns). Collectively, we strongly recommend the use of multiple assays whenever possible, rather than relying on the results from a single method.

As a final reminder, we stated at the beginning of this article that this set of guidelines is not meant to be a formulaic compilation of rules, because the appropriate assays depend in part on the question being asked and the system being used. Rather, these guidelines are presented primarily to emphasize key issues that need to be addressed such as the difference between measuring autophagy components, and flux or substrate clearance; they are not meant to constrain imaginative approaches to monitoring autophagy. Indeed, it is hoped that new methods for monitoring autophagy will continue to be developed, and new findings may alter our view of the current assays. Similar

**Table 4.** Recommended methods for monitoring autophagy.

Method	Description
1. Electron microscopy	Quantitative electron microscopy, immuno-TEM; monitor autophagosome number, volume, and content/cargo.
2. Atg8/LC3 western blotting	Western blot. The analysis is carried out in the absence and presence of lysosomal protease or fusion inhibitors to monitor flux; an increase in the LC3-II amount in the presence of the inhibitor is usually indicative of flux.
3. GFP-Atg8/LC3 lysosomal delivery and proteolysis	Western blot +/- lysosomal fusion or degradation inhibitors; the generation of free GFP indicates lysosomal/vacuolar delivery.
4. GFP-Atg8/LC3 fluorescence microscopy	Fluorescence microscopy, flow cytometry to monitor vacuolar/lysosomal localization. Also, increase in punctate GFP-Atg8/LC3 or Atg18/WIPI, and live time-lapse fluorescence microscopy to track the dynamics of GFP-Atg8/LC3-positive structures.
5. Tandem mRFP/mCherry-GFP fluorescence microscopy, Rosella	Flux can be monitored as a decrease in green/red (yellow) fluorescence (phagophores, autophagosomes) and an increase in red fluorescence (autolysosomes).
6. Autophagosome quantification	FACS/flow cytometry.
7. SQSTM1 and related LC3 binding protein turnover	The amount of SQSTM1 increases when autophagy is inhibited and decreases when autophagy is induced, but the potential impact of transcriptional/translational regulation or the formation of insoluble aggregates should be addressed in individual experimental systems.
8. MTOR, AMPK and Atg1/ULK1 kinase activity	Western blot, immunoprecipitation or kinase assays.
9. WIPI fluorescence microscopy	Quantitative fluorescence analysis using endogenous WIPI proteins, or GFP- or MYC-tagged versions. Suitable for high-throughput imaging procedures.
10. Bimolecular fluorescence complementation	Can be used to monitor protein-protein interaction in vivo.
11. FRET	Interaction of LC3 with gangliosides to monitor autophagosome formation.
12. Transcriptional and translational regulation	Northern blot, or qRT-PCR, autophagy-dedicated microarray.
13. Autophagic protein degradation	Turnover of long-lived proteins to monitor flux.
14. Pex14-GFP, GFP-Atg8, Om45-GFP, mitoPho8Δ60	A range of assays can be used to monitor selective types of autophagy. These typically involve proteolytic maturation of a resident enzyme or degradation of a chimera, which can be followed enzymatically or by western blot.
15. Autophagic sequestration assays	Accumulation of cargo in autophagic compartments in the presence of lysosomal protease or fusion inhibitors by biochemical or multilabel fluorescence techniques.
16. Turnover of autophagic compartments	Electron microscopy with morphometry/stereology at different time points.
17. Autophagosome-lysosome colocalization and dequenching assay	Fluorescence microscopy.
18. Sequestration and processing assays in plants	Chimeric RFP fluorescence and processing, and light and electron microscopy.
19. Tissue fractionation	Centrifugation, western blot and electron microscopy.
20. Degradation of endogenous lipofuscin	Fluorescence microscopy.

to the process of autophagy, this is a dynamic field, and we need to remain flexible in the standards we apply.

## Acknowledgments

In a rapidly expanding and highly dynamic field such as autophagy, it is possible that some authors who should have been included on this article have been missed. D.J.K. extends his apologies to researchers in the field of autophagy who, due to oversight or any other reason, could not be included on this article. I also note that two of our colleagues on this manuscript have passed away: Arlette Darfeuille-Michaud and Wouter van Doorn.

## Funding

This work was supported in part by the National Institutes of Health, including Public Health Service grant GM053396 to D.J.K. Due to space and other limitations, it is not possible to include all other sources of financial support.

## Disclaimer

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of Veterans Affairs, the U.S. Food and Drug Administration or the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

## References

- Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; 8:445-544; <http://dx.doi.org/10.4161/auto.19496>.
- Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. *Autophagy* 2008; 4:151-75; <http://dx.doi.org/10.4161/auto.5338>.
- Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. *Autophagy* 2007; 3:181-206; <http://dx.doi.org/10.4161/auto.3678>.
- Xia HG, Najafav A, Geng J, Galan-Acosta L, Han X, Guo Y, Shan B, Zhang Y, Norberg E, Zhang T, et al. Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death. *J Cell Biol* 2015; 210:705-16; <http://dx.doi.org/10.1083/jcb.201503044>.
- Klionsky DJ. The autophagosome is overrated! *Autophagy* 2011; 7:353-4; <http://dx.doi.org/10.4161/auto.7.4.14730>.
- Eskelinen E-L, Reggiori F, Baba M, Kovacs AL, Seglen PO. Seeing is believing: The impact of electron microscopy on autophagy research. *Autophagy* 2011; 7:935-56; <http://dx.doi.org/10.4161/auto.7.9.15760>.
- Seglen PO. Regulation of autophagic protein degradation in isolated liver cells. In: Glaumann H and Ballard FJ, eds. *Lysosomes: Their Role in Protein Breakdown*. London: Academic Press, 1987: 369-414.
- de Duve C, Wattiaux R. Functions of lysosomes. *Annu Rev Physiol* 1966; 28:435-92; <http://dx.doi.org/10.1146/annurev.ph.28.030166.002251>.
- Gordon PB, Seglen PO. Prelysosomal convergence of autophagic and endocytic pathways. *Biochem Biophys Res Commun* 1988; 151:40-7; [http://dx.doi.org/10.1016/0006-291X\(88\)90556-6](http://dx.doi.org/10.1016/0006-291X(88)90556-6).
- Dice JF, Klionsky DJ. Autophagy, the art of autophagy-macroautophagy. *Autophagy* 2010; 6.
- Lucocq JM, Hacker C. Cutting a fine figure: On the use of thin sections in electron microscopy to quantify autophagy. *Autophagy* 2013; 9:1443-8; <http://dx.doi.org/10.4161/auto.25570>.
- Kovács J, Fellingner E, Karpati AP, Kovács AL, Laszlo L, Réz G. Morphometric evaluation of the turnover of autophagic vacuoles after treatment with Triton X-100 and vinblastine in murine pancreatic acinar and seminal vesicle epithelial cells. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1987; 53:183-90; <http://dx.doi.org/10.1007/BF02890242>.
- Kovács J, Fellingner E, Karpati PA, Kovács AL, Laszlo L. The turnover of autophagic vacuoles: evaluation by quantitative electron microscopy. *Biomed Biochim Acta* 1986; 45:1543-7.
- Kovács J, Laszlo L, Kovács AL. Regression of autophagic vacuoles in pancreatic acinar, seminal vesicle epithelial, and liver parenchymal cells: a comparative morphometric study of the effect of vinblastine and leupeptin followed by cycloheximide treatment. *Exp Cell Res* 1988; 174:244-51; [http://dx.doi.org/10.1016/0014-4827\(88\)90158-9](http://dx.doi.org/10.1016/0014-4827(88)90158-9).
- Chu CT. Autophagic stress in neuronal injury and disease. *J Neuro-pathol Exp Neurol* 2006; 65:423-32; <http://dx.doi.org/10.1097/01.jnen.0000229233.75253.be>.
- Fass E, Shvets E, Degani I, Hirschberg K, Elazar Z. Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. *J Biol Chem* 2006; 281:36303-16; <http://dx.doi.org/10.1074/jbc.M607031200>.
- Kovács AL, Reith A, Seglen PO. Accumulation of autophagosomes after inhibition of hepatocytic protein degradation by vinblastine, leupeptin or a lysosomotropic amine. *Exp Cell Res* 1982; 137:191-201; [http://dx.doi.org/10.1016/0014-4827\(82\)90020-9](http://dx.doi.org/10.1016/0014-4827(82)90020-9).
- Bestebroer J, V'Kovski P, Mauthe M, Reggiori F. Hidden behind autophagy: the unconventional roles of ATG proteins. *Traffic* 2013; 14:1029-41; <http://dx.doi.org/10.1111/tra.12091>.
- Luo SM, Ge ZJ, Wang ZW, Jiang ZZ, Wang ZB, Ouyang YC, Hou Y, Schatten H, Sun QY. Unique insights into maternal mitochondrial inheritance in mice. *Proc Natl Acad Sci USA* 2013; 110:13038-43; <http://dx.doi.org/10.1073/pnas.1303231110>.
- Politi Y, Gal L, Kalifa Y, Ravid L, Elazar Z, Arama E. Paternal mitochondrial destruction after fertilization is mediated by a common endocytic and autophagic pathway in *Drosophila*. *Dev Cell* 2014; 29:305-20; <http://dx.doi.org/10.1016/j.devcel.2014.04.005>.
- Toth S, Nagy K, Palfia Z, Rez G. Cellular autophagic capacity changes during azaserine-induced tumour progression in the rat pancreas. Up-regulation in all premetastatic stages and down-regulation with loss of cycloheximide sensitivity of segregation along with malignant transformation. *Cell Tissue Res* 2002; 309:409-16; <http://dx.doi.org/10.1007/s00441-001-0506-7>.
- Loos B, Engelbrecht AM. Cell death: a dynamic response concept. *Autophagy* 2009; 5:590-603; <http://dx.doi.org/10.4161/auto.5.5.8479>.
- Seglen PO, Gordon PB, Grinde B, Solheim A, Kovacs AL, Poli A. Inhibitors and pathways of hepatocytic protein degradation. *Acta Biol Med Ger* 1981; 40:1587-98.
- Ktistakis NT, Andrews S, Long J. What is the advantage of a transient precursor in autophagosome biogenesis? *Autophagy* 2011; 7:118-22; <http://dx.doi.org/10.4161/auto.7.1.13697>.
- Kovács AL, Réz G, Pálfi Z, Kovács J. Autophagy in the epithelial cells of murine seminal vesicle in vitro. Formation of large sheets of nascent isolation membranes, sequestration of the nucleus and inhibition by wortmannin and 3-ethyladenine. *Cell Tissue Res* 2000; 302:253-61; <http://dx.doi.org/10.1007/s004410000275>.
- Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. *Autophagy* 2007; 3:542-5; <http://dx.doi.org/10.4161/auto.4600>.
- Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, Shimizu S. Discovery of Atg5/Atg7-independent alternative macroautophagy. *Nature* 2009; 461:654-8; <http://dx.doi.org/10.1038/nature08455>.
- Kanki T, Kang D, Klionsky DJ. Monitoring mitophagy in yeast: the Om45-GFP processing assay. *Autophagy* 2009; 5:1186-9; <http://dx.doi.org/10.4161/auto.5.8.9854>.
- Grander D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in

- hematological malignancies. *Autophagy* 2009; 5:1198-200; <http://dx.doi.org/10.4161/auto.5.8.10122>.
30. Welter E, Thumm M, Krick R. Quantification of nonselective bulk autophagy in *S. cerevisiae* using Pgk1-GFP. *Autophagy* 2010; 6:794-7; <http://dx.doi.org/10.4161/auto.6.6.12348>.
  31. Raju D, Jones NL. Methods to monitor autophagy in *H. pylori* vacuolating cytotoxin A (VacA)-treated cells. *Autophagy* 2010; 6:138-43; <http://dx.doi.org/10.4161/auto.6.1.10222>.
  32. Geng J, Klionsky DJ. Determining Atg protein stoichiometry at the phagophore assembly site by fluorescence microscopy. *Autophagy* 2010; 6:144-7; <http://dx.doi.org/10.4161/auto.6.1.10249>.
  33. Swanlund JM, Kregel KC, Oberley TD. Investigating autophagy: quantitative morphometric analysis using electron microscopy. *Autophagy* 2010; 6:270-7; <http://dx.doi.org/10.4161/auto.6.2.10439>.
  34. Zhang J, Ney PA. Reticulocyte mitophagy: monitoring mitochondrial clearance in a mammalian model. *Autophagy* 2010; 6:405-8; <http://dx.doi.org/10.4161/auto.6.3.11245>.
  35. Seglen PO, Brinchmann MF. Purification of autophagosomes from rat hepatocytes. *Autophagy* 2010; 6:542-7; <http://dx.doi.org/10.4161/auto.6.4.11272>.
  36. He C, Klionsky DJ. Analyzing autophagy in zebrafish. *Autophagy* 2010; 6.
  37. Calvo-Garrido J, Carilla-Latorre S, Mesquita A, Escalante R. A proteolytic cleavage assay to monitor autophagy in *Dictyostelium discoideum*. *Autophagy* 2011; 7:1063-8; <http://dx.doi.org/10.4161/auto.7.9.16629>.
  38. Xu F, Liu XH, Zhuang FL, Zhu J, Lin FC. Analyzing autophagy in *Magnaporthe oryzae*. *Autophagy* 2011; 7:525-30; <http://dx.doi.org/10.4161/auto.7.5.15020>.
  39. Klionsky DJ. *Autophagy: Lower Eukaryotes and Non-Mammalian Systems, Part A*. Amsterdam: Academic Press/Elsevier, 2008.
  40. Klionsky DJ. *Autophagy in Disease and Clinical Applications, Part C*. Amsterdam: Academic Press/Elsevier, 2008.
  41. Klionsky DJ. *Autophagy in Mammalian Systems, Part B*. Amsterdam: Academic Press/Elsevier, 2008.
  42. Zhu J, Dagda RK, Chu CT. Monitoring mitophagy in neuronal cell cultures. *Methods Mol Biol* 2011; 793:325-39; <http://dx.doi.org/10.1007/978-1-61779-328-8>.
  43. Klionsky DJ. Protocol URL.
  44. Chu CT, Plowey ED, Dagda RK, Hickey RW, Cherra SJ, 3rd, Clark RS. Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models. *Methods Enzymol* 2009; 453:217-49; [http://dx.doi.org/10.1016/S0076-6879\(08\)04011-1](http://dx.doi.org/10.1016/S0076-6879(08)04011-1).
  45. Singh PK, Singh S. Changing shapes of glycogen-autophagy nexus in neurons: perspective from a rare epilepsy. *Front Neurol* 2015; 6:14; <http://dx.doi.org/10.3389/fneur.2015.00014>.
  46. Kotoulas OB, Kalamidas SA, Kondomerkos DJ. Glycogen autophagy. *Microscopy Res Tech* 2004; 64:10-20; <http://dx.doi.org/10.1002/jemt.20046>.
  47. Kotoulas OB, Kalamidas SA, Kondomerkos DJ. Glycogen autophagy in glucose homeostasis. *Pathol Res Pract* 2006; 202:631-8; <http://dx.doi.org/10.1016/j.prp.2006.04.001>.
  48. Yla-Anttila P, Vihinen H, Jokitalo E, Eskelinen E-L. Monitoring autophagy by electron microscopy in mammalian cells. *Methods Enzymol* 2009; 452:143-64; [http://dx.doi.org/10.1016/S0076-6879\(08\)03610-0](http://dx.doi.org/10.1016/S0076-6879(08)03610-0).
  49. Eskelinen E-L. Maturation of autophagic vacuoles in mammalian cells. *Autophagy* 2005; 1:1-10; <http://dx.doi.org/10.4161/auto.1.1.1270>.
  50. Eskelinen E-L. To be or not to be? Examples of incorrect identification of autophagic compartments in conventional transmission electron microscopy of mammalian cells. *Autophagy* 2008; 4:257-60; <http://dx.doi.org/10.4161/auto.5179>.
  51. Eskelinen E-L, Kovacs AL. Double membranes vs. lipid bilayers, and their significance for correct identification of macroautophagic structures. *Autophagy* 2011; 7:931-2; <http://dx.doi.org/10.4161/auto.7.9.16679>.
  52. Biazik J, Yla-Anttila P, Vihinen H, Jokitalo E, Eskelinen EL. Ultrastructural relationship of the phagophore with surrounding organelles. *Autophagy* 2015; 11:439-51; <http://dx.doi.org/10.1080/15548627.2015.1017178>.
  53. Eskelinen E-L. Fine structure of the autophagosome. In: Deretic V, ed. *Autophagosome and Phagosome*. Totowa, NJ: Humana Press, 2008:11-28; <http://dx.doi.org/10.1007/978-1-59745-157-4>.
  54. Berg TO, Fengsrud M, Stromhaug PE, Berg T, Seglen PO. Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. *J Biol Chem* 1998; 273:21883-92; <http://dx.doi.org/10.1074/jbc.273.34.21883>.
  55. Eskelinen E-L. Macroautophagy in mammalian cells. In: Saftig P, ed. *Lysosomes*. Georgetown, TX: LandesBioscience/Eurekah.com, 2005.
  56. Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. *Am J Physiol Cell Physiol* 2014; 306:C621-33; <http://dx.doi.org/10.1152/ajpcell.00228.2013>.
  57. Yang DS, Lee JH, Nixon RA. Monitoring autophagy in Alzheimer's disease and related neurodegenerative diseases. *Methods Enzymol* 2009; 453:111-44; [http://dx.doi.org/10.1016/S0076-6879\(08\)04006-8](http://dx.doi.org/10.1016/S0076-6879(08)04006-8).
  58. Yokota S, Himeno M, Kato K. Immunocytochemical localization of acid phosphatase in rat liver. *Cell Struct Funct* 1989; 14:163-71; <http://dx.doi.org/10.1247/csf.14.163>.
  59. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J Neurosci* 2008; 28:6926-37; <http://dx.doi.org/10.1523/JNEUROSCI.0800-08.2008>.
  60. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J Neuropathol Exp Neuro* 2005; 64:113-22.
  61. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* 2010; 141:1146-58; <http://dx.doi.org/10.1016/j.cell.2010.05.008>.
  62. Lee JH, McBrayer MK, Wolfe DM, Haslett LJ, Kumar A, Sato Y, Lie PP, Mohan P, Coffey EE, Kompella U, et al. Presenilin 1 maintains lysosomal Ca<sup>2+</sup> homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. *Cell Rep* 2015; 12:1430-44.
  63. Sonati T, Reimann RR, Falsig J, Baral PK, O'Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, et al. The toxicity of anti-prion antibodies is mediated by the flexible tail of the prion protein. *Nature* 2013; 501:102-6; <http://dx.doi.org/10.1038/nature12402>.
  64. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. *Nature Rev Mol Cell Biol* 2007; 8:622-32; <http://dx.doi.org/10.1038/nrm2217>.
  65. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. *Annu Rev Cell Dev Biol* 2011; 27:107-32; <http://dx.doi.org/10.1146/annurev-cellbio-092910-154005>.
  66. Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. *J Neurosci* 2011; 31:7817-30; <http://dx.doi.org/10.1523/JNEUROSCI.6412-10.2011>.
  67. Rabouille C, Strous GJ, Crapo JD, Geuze HJ, Slot JW. The differential degradation of two cytosolic proteins as a tool to monitor autophagy in hepatocytes by immunocytochemistry. *J Cell Biol* 1993; 120:897-908; <http://dx.doi.org/10.1083/jcb.120.4.897>.
  68. Kovács AL, Pálfi Z, Réz G, Vellai T, Kovács J. Sequestration revisited: integrating traditional electron microscopy, de novo assembly and new results. *Autophagy* 2007; 3:655-62; <http://dx.doi.org/10.4161/auto.4590>.
  69. Gao W, Kang JH, Liao Y, Ding WX, Gambotto AA, Watkins SC, Liu YJ, Stolz DB, Yin XM. Biochemical isolation and characterization of the tubulovesicular LC3-positive autophagosomal compartment. *J Biol Chem* 2010; 285:1371-83; <http://dx.doi.org/10.1074/jbc.M109.054197>.
  70. Lajoie P, Guay G, Dennis JW, Nabi IR. The lipid composition of autophagic vacuoles regulates expression of multilamellar bodies. *J Cell Sci* 2005; 118:1991-2003; <http://dx.doi.org/10.1242/jcs.02324>.

71. Mayhew TM. Quantitative immunoelectron microscopy: alternative ways of assessing subcellular patterns of gold labeling. *Methods Mol Biol* 2007; 369:309-29; <http://dx.doi.org/10.1007/978-1-59745-294-6>.
72. Mayhew TM, Lucocq JM, Griffiths G. Relative labelling index: a novel stereological approach to test for non-random immunogold labelling of organelles and membranes on transmission electron microscopy thin sections. *J Microsc* 2002; 205:153-64; <http://dx.doi.org/10.1046/j.0022-2720.2001.00977.x>.
73. Isidoro C, Biagioni F, Giorgi FS, Fulceri F, Paparelli A, Fornai F. The role of autophagy on the survival of dopamine neurons. *Curr Top Med Chem* 2009; 9:869-79.
74. Schmid D, Pypaert M, Münz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. *Immunity* 2007; 26:79-92; <http://dx.doi.org/10.1016/j.immuni.2006.10.018>.
75. Subramani S, Malhotra V. Non-autophagic roles of autophagy-related proteins. *EMBO Rep* 2013; 14:143-51; <http://dx.doi.org/10.1038/embor.2012.220>.
76. Ponpuak M, Mandell MA, Kimura T, Chauhan S, Cleyrat C, Deretic V. Secretory autophagy. *Curr Opin Cell Biol* 2015; 35:106-16; <http://dx.doi.org/10.1016/j.ccb.2015.04.016>.
77. Saito T, Asai K, Sato S, Takano H, Adach A, Sasaki Y, Namimatsu S, Mizuno K. Proof of myocardial autophagy by combining antigen retrieval and the avidin-biotin peroxidase complex method. *Int J Cardiol* 2013; 168:4843-4; <http://dx.doi.org/10.1016/j.ijcard.2013.07.032>.
78. Kovács J. Regression of autophagic vacuoles in seminal vesicle cells following cycloheximide treatment. *Exp Cell Res* 1983; 144:231-4; [http://dx.doi.org/10.1016/0014-4827\(83\)90460-3](http://dx.doi.org/10.1016/0014-4827(83)90460-3).
79. Réz G, Csak J, Fellinger E, Laszlo L, Kovács AL, Oliva O, Kovács J. Time course of vinblastine-induced autophagocytosis and changes in the endoplasmic reticulum in murine pancreatic acinar cells: a morphometric and biochemical study. *Eur J Cell Biol* 1996; 71:341-50.
80. Kovács AL, Grinde B, Seglen PO. Inhibition of autophagic vacuole formation and protein degradation by amino acids in isolated hepatocytes. *Exp Cell Res* 1981; 133:431-6; [http://dx.doi.org/10.1016/0014-4827\(81\)90336-0](http://dx.doi.org/10.1016/0014-4827(81)90336-0).
81. Mortimore GE, Hutson NJ, Surmacz CA. Quantitative correlation between proteolysis and macro- and microautophagy in mouse hepatocytes during starvation and refeeding. *Proc Natl Acad Sci USA* 1983; 80:2179-83; <http://dx.doi.org/10.1073/pnas.80.8.2179>.
82. Mortimore GE, Lardeux BR, Adams CE. Regulation of microautophagy and basal protein turnover in rat liver. Effects of short-term starvation. *J Biol Chem* 1988; 263:2506-12.
83. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. *Amer J Pathol* 2007; 170:75-86; <http://dx.doi.org/10.2353/ajpath.2007.060524>.
84. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Øvervatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol* 2005; 171:603-14; <http://dx.doi.org/10.1083/jcb.200507002>.
85. Orvedahl A, Sumpter R, Jr., Xiao G, Ng A, Zou Z, Tang Y, Narimatsu M, Gilpin C, Sun Q, Roth M, et al. Image-based genome-wide siRNA screen identifies selective autophagy factors. *Nature* 2011; 480:113-7; <http://dx.doi.org/10.1038/nature10546>.
86. Razi M, Tooze SA. Correlative light and electron microscopy. *Methods Enzymol* 2009; 452:261-75; [http://dx.doi.org/10.1016/S0076-6879\(08\)03617-3](http://dx.doi.org/10.1016/S0076-6879(08)03617-3).
87. Shu X, Lev-Ram V, Deerinck TJ, Qi Y, Ramko EB, Davidson MW, Jin Y, Ellisman MH, Tsien RY. A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. *PLoS Biol* 2011; 9:e1001041.
88. Castillo K, Rojas-Rivera D, Lisbona F, Caballero B, Nassif M, Court F, Schuck S, Ibar C, Walter P, Sierralta J, et al. BAX inhibitor-1 regulates autophagy by controlling the IRE1 $\alpha$  branch of the unfolded protein response. *EMBO J* 2011; 30:4465-78.
89. Yla-Anttila P, Vihinen H, Jokitalo E, Eskelinen E-L. 3D tomography reveals connections between the phagophore and endoplasmic reticulum. *Autophagy* 2009; 5:1180-5; <http://dx.doi.org/10.4161/auto.5.8.10274>.
90. Hayashi-Nishino M, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A. Electron tomography reveals the endoplasmic reticulum as a membrane source for autophagosome formation. *Autophagy* 2010; 6:301-3; <http://dx.doi.org/10.4161/auto.6.2.11134>.
91. Duke EM, Razi M, Weston A, Guttmann P, Werner S, Henzler K, Schneider G, Tooze SA, Collinson LM. Imaging endosomes and autophagosomes in whole mammalian cells using correlative cryo-fluorescence and cryo-soft X-ray microscopy (cryo-CLXM). *Ultra-microscopy* 2014; 143:77-87; <http://dx.doi.org/10.1016/j.ultramicro.2013.10.006>.
92. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. *Proc Natl Acad Sci USA* 2006; 103:5805-10; <http://dx.doi.org/10.1073/pnas.0507436103>.
93. Baba M, Osumi M, Ohsumi Y. Analysis of the membrane structures involved in autophagy in yeast by freeze-replica method. *Cell Struct Funct* 1995; 20:465-71; <http://dx.doi.org/10.1247/csf.20.465>.
94. Rez G, Meldolesi J. Freeze-fracture of drug-induced autophagocytosis in the mouse exocrine pancreas. *Lab Invest* 1980; 43:269-77.
95. Punnonen E-L, Pihakaski K, Mattila K, Lounatmaa K, Hirsimäki P. Intramembrane particles and filipin labelling on the membranes of autophagic vacuoles and lysosomes in mouse liver. *Cell Tissue Res* 1989; 258:269-76; <http://dx.doi.org/10.1007/BF00239447>.
96. Fengsrud M, Erichsen ES, Berg TO, Raiborg C, Seglen PO. Ultrastructural characterization of the delimiting membranes of isolated autophagosomes and amphisomes by freeze-fracture electron microscopy. *Eur J Cell Biol* 2000; 79:871-82; <http://dx.doi.org/10.1078/0171-9335-00125>.
97. Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, et al. Mito-tempol and dexamethasone exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. *PLoS One* 2013; 8:e70575.
98. Rao VA, Klein SR, Bonar SJ, Zielonka J, Mizuno N, Dickey JS, Keller PW, Joseph J, Kalyanaraman B, Shacter E. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitquinone. *J Biol Chem* 2010; 285:34447-59; <http://dx.doi.org/10.1074/jbc.M110.133579>.
99. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nature Rev Mol Cell Biol* 2007; 8:931-7; <http://dx.doi.org/10.1038/nrm2245>.
100. Krick R, M(u)he Y, Prick T, Bredschneider M, Bremer S, Wenzel D, Eskelinen E-L, Thumm M. Piecemeal microautophagy of the nucleus: genetic and morphological traits. *Autophagy* 2009; 5:270-2; <http://dx.doi.org/10.4161/auto.5.2.7639>.
101. Meschini S, Condello M, Calcabrini A, Marra M, Formisano G, Lista P, De Milito A, Federici E, Arancia G. The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. *Autophagy* 2008; 4:1020-33; <http://dx.doi.org/10.4161/auto.6952>.
102. Proikas-Cezanne T, Robenek H. Freeze-fracture replica immunolabelling reveals human WIPI-1 and WIPI-2 as membrane proteins of autophagosomes. *J Cell Mol Med* 2011; 15:2007-10; <http://dx.doi.org/10.1111/j.1582-4934.2011.01339.x>.
103. Kovacs J, Rez G, Kovacs AL, Csak J, Zboray G. Autophagocytosis: freeze-fracture morphology, effects of vinblastine and influence of transcriptional and translational inhibitors. *Acta Biol Med Germanica* 1982; 41:131-5.
104. Hirsimäki Y, Hirsimäki P, Lounatmaa K. Vinblastine-induced autophagic vacuoles in mouse liver and Ehrlich ascites tumor cells as assessed by freeze-fracture electron microscopy. *Eur J Cell Biol* 1982; 27:298-301.
105. Backues SK, Chen D, Ruan J, Xie Z, Klionsky DJ. Estimating the size and number of autophagic bodies by electron microscopy. *Autophagy* 2014; 10:155-64; <http://dx.doi.org/10.4161/auto.26856>.

106. Cheong H, Yorimitsu T, Reggiori F, Legakis JE, Wang C-W, Klionsky DJ. Atg17 regulates the magnitude of the autophagic response. *Mol Biol Cell* 2005; 16:3438-53; <http://dx.doi.org/10.1091/mbc.E04-10-0894>.
107. Xie Z, Nair U, Klionsky DJ. Atg8 controls phagophore expansion during autophagosome formation. *Mol Biol Cell* 2008; 19:3290-8; <http://dx.doi.org/10.1091/mbc.E07-12-1292>.
108. Sigmond T, Feher J, Baksa A, Pasti G, Palfia Z, Takacs-Vellai K, Kovacs J, Vellai T, Kovacs AL. Qualitative and quantitative characterization of autophagy in *Caenorhabditis elegans* by electron microscopy. *Methods Enzymol* 2008; 451:467-91; [http://dx.doi.org/10.1016/S0076-6879\(08\)03228-X](http://dx.doi.org/10.1016/S0076-6879(08)03228-X).
109. Kovács AL, Vellai T, Müller F. Autophagy in *Caenorhabditis elegans*. In: Klionsky DJ, ed. *Autophagy*. Georgetown, Texas: Landes Bioscience, 2004:217-23.
110. Weibel ER. *Practical Methods for Biological Morphometry*. Academic Press, New York, 1979.
111. Williams MA. *Quantitative methods in biology: Practical methods in electron microscopy*. Amsterdam, New York, Oxford: North-Holland Publishing Company, 1977.
112. Howard V, Reed MG. *Unbiased stereology; three dimensional measurement in microscopy*. U Bios Scientific Publishers, 1998.
113. Kovacs AL. A simple method to estimate the number of autophagic elements by electron microscopic morphometry in real cellular dimensions. *BioMed Res Intl* 2014; 2014:578698.
114. Xie Z, Nair U, Geng J, Szefer MB, Rothman ED, Klionsky DJ. Indirect estimation of the area density of Atg8 on the phagophore. *Autophagy* 2009; 5:217-20; <http://dx.doi.org/10.4161/autophagy.5.2.7201>.
115. Punnonen EL, Reunanen H. Effects of vinblastine, leucine, and histidine, and 3-methyladenine on autophagy in Ehrlich ascites cells. *Exp Mol Pathol* 1990; 52:87-97; [http://dx.doi.org/10.1016/0014-4800\(90\)90061-H](http://dx.doi.org/10.1016/0014-4800(90)90061-H).
116. Kovacs AL, Laszlo L, Fellingner E, Jakab A, Orosz A, Rez G, Kovacs J. Combined effects of fasting and vinblastine treatment on serum insulin level, the size of autophagic-lysosomal compartment, protein content and lysosomal enzyme activities of liver and exocrine pancreatic cells of the mouse. *Comp Biochem Phys B Comp Biochem* 1989; 94:505-10; [http://dx.doi.org/10.1016/0305-0491\(89\)90189-2](http://dx.doi.org/10.1016/0305-0491(89)90189-2).
117. Griffiths G. *Fine structure immunocytochemistry Heidelberg, Germany: Springer-Verlag*, 1993; <http://dx.doi.org/10.1007/978-3-642-77095-1>.
118. Reyes FC, Chung T, Holding D, Jung R, Vierstra R, Otegui MS. Delivery of prolamins to the protein storage vacuole in maize aleurone cells. *Plant Cell* 2011; 23:769-84; <http://dx.doi.org/10.1105/tpc.110.082156>.
119. Dunn WA, Jr., Cregg JM, Kiel JAKW, van der Kleij IJ, Oku M, Sakai Y, Sibirny AA, Stasyk OV, Veenhuis M. Pexophagy: the selective autophagy of peroxisomes. *Autophagy* 2005; 1:75-83; <http://dx.doi.org/10.4161/autophagy.1.2.1737>.
120. Wang K, Klionsky DJ. Mitochondria removal by autophagy. *Autophagy* 2011; 7:297-300; <http://dx.doi.org/10.4161/autophagy.7.3.14502>.
121. Belanger M, Rodrigues PH, Dunn WA, Jr., Progulske-Fox A. Autophagy: a highway for *Porphyromonas gingivalis* in endothelial cells. *Autophagy* 2006; 2:165-70; <http://dx.doi.org/10.4161/autophagy.2.2828>.
122. Birmingham CL, Brumell JH. Autophagy recognizes intracellular *Salmonella enterica* serovar Typhimurium in damaged vacuoles. *Autophagy* 2006; 2:156-8; <http://dx.doi.org/10.4161/autophagy.2.2825>.
123. Colombo MI, Gutierrez MG, Romano PS. The two faces of autophagy: *Coxiella* and *Mycobacterium*. *Autophagy* 2006; 2:162-4; <http://dx.doi.org/10.4161/autophagy.2.2827>.
124. Ogawa M, Sasakawa C. *Shigella* and autophagy. *Autophagy* 2006; 2:171-4; <http://dx.doi.org/10.4161/autophagy.2.2829>.
125. Vergne I, Singh S, Roberts E, Kyei G, Master S, Harris J, de Haro S, Naylor J, Davis A, Delgado M, et al. Autophagy in immune defense against *Mycobacterium tuberculosis*. *Autophagy* 2006; 2:175-8; <http://dx.doi.org/10.4161/autophagy.2.2830>.
126. Yoshimori T. Autophagy vs. Group A Streptococcus. *Autophagy* 2006; 2:154-5; <http://dx.doi.org/10.4161/autophagy.2.2822>.
127. Gorbunov NV, McDaniel DP, Zhai M, Liao PJ, Garrison BR, Kiang JG. Autophagy and mitochondrial remodelling in mouse mesenchymal stromal cells challenged with *Staphylococcus epidermidis*. *J Cell Mol Med* 2015; 19:1133-50; <http://dx.doi.org/10.1111/jcmm.12518>.
128. Lynch-Day MA, Klionsky DJ. The Cvt pathway as a model for selective autophagy. *FEBS Lett* 2010; 584:1359-66; <http://dx.doi.org/10.1016/j.febslet.2010.02.013>.
129. Birmingham CL, Canadien V, Gouin E, Troy EB, Yoshimori T, Cossart P, Higgins DE, Brumell JH. *Listeria monocytogenes* evades killing by autophagy during colonization of host cells. *Autophagy* 2007; 3:442-51; <http://dx.doi.org/10.4161/autophagy.3.442-51>.
130. Klionsky DJ. Protein transport from the cytoplasm into the vacuole. *J Membr Biol* 1997; 157:105-15; <http://dx.doi.org/10.1007/s002329900220>.
131. Baba M, Osumi M, Scott SV, Klionsky DJ, Ohsumi Y. Two distinct pathways for targeting proteins from the cytoplasm to the vacuole/lysosome. *J Cell Biol* 1997; 139:1687-95; <http://dx.doi.org/10.1083/jcb.139.7.1687>.
132. Dini L, Pagliara P, Carla EC. Phagocytosis of apoptotic cells by liver: a morphological study. *Microsc Res Tech* 2002; 57:530-40; <http://dx.doi.org/10.1002/jemt.10107>.
133. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenaabee P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. *Cell Death Differ* 2005; 12:1463-7; <http://dx.doi.org/10.1038/sj.cdd.4401724>.
134. Rez G, Palfia Z, Fellingner E. Occurrence and inhibition by cycloheximide of apoptosis in vinblastine-treated murine pancreas. A role for autophagy? *Acta Biol Hungarica* 1991; 42:133-40.
135. Nagy P, Varga A, Kovács AL, Takács S, Juhász G. How and why to study autophagy in *Drosophila*: It's more than just a garbage chute. *Methods* 2015; 75:151-61; <http://dx.doi.org/10.1016/j.jymeth.2014.11.016>.
136. Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, Gnessi L, Griffin RJ, Minetti M, Malorni W. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. *Intl J Cancer* 2012; 131:E337-47.
137. Sou YS, Tanida I, Komatsu M, Ueno T, Kominami E. Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. *J Biol Chem* 2006; 281:3017-24; <http://dx.doi.org/10.1074/jbc.M505888200>.
138. Le Grand JN, Chakrama FZ, Seguin-Py S, Fraichard A, Delage-Mourroux R, Jouvenot M, Boyer-Guittaut M. GABARAP1 (GEC1): Original or copycat? *Autophagy* 2011; 7:1098-107; <http://dx.doi.org/10.4161/autophagy.7.10.15904>.
139. Hemelaar J, Lelyveld VS, Kessler BM, Ploegh HL. A single protease, Apg4B, is specific for the autophagy-related ubiquitin-like proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L. *J Biol Chem* 2003; 278:51841-50; <http://dx.doi.org/10.1074/jbc.M308762200>.
140. Tanida I, Sou YS, Ezaki J, Minematsu-Ikeguchi N, Ueno T, Kominami E. HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3- and GABAA receptor-associated protein-phospholipid conjugates. *J Biol Chem* 2004; 279:36268-76; <http://dx.doi.org/10.1074/jbc.M401461200>.
141. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. *J Cell Sci* 2004; 117:2805-12; <http://dx.doi.org/10.1242/jcs.01131>.
142. Weidberg H, Shvets E, Shpilka T, Shimron F, Shinder V, Elazar Z. LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. *EMBO J* 2010; 29:1792-802; <http://dx.doi.org/10.1038/emboj.2010.74>.
143. Szalai P, Hagen LK, Saetre F, Luhr M, Sponheim M, Overbye A, Mills IG, Seglen PO, Engedal N. Autophagic bulk sequestration of cytosolic cargo is independent of LC3, but requires GABARAPs.

- Exp Cell Res 2015; 333:21-38; <http://dx.doi.org/10.1016/j.yexcr.2015.02.003>.
144. Sugawara K, Suzuki NN, Fujioka Y, Mizushima N, Ohsumi Y, Inagaki F. The crystal structure of microtubule-associated protein light chain 3, a mammalian homologue of *Saccharomyces cerevisiae* Atg8. *Genes Cells* 2004; 9:611-8; <http://dx.doi.org/10.1111/j.1356-9597.2004.00750.x>.
  145. Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, Tyurin VA, Yanamala N, Shrivastava IH, Mohammadyani D, et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. *Nat Cell Biol* 2013; 15:1197-205; <http://dx.doi.org/10.1038/ncb2837>.
  146. Lystad AH, Ichimura Y, Takagi K, Yang Y, Pankiv S, Kanegae Y, Kageyama S, Suzuki M, Saito I, Mizushima T, et al. Structural determinants in GABARAP required for the selective binding and recruitment of ALFY to LC3B-positive structures. *EMBO Rep* 2014; 15:557-65; <http://dx.doi.org/10.1002/embr.201338003>.
  147. von Muhlinen N, Akutsu M, Ravenhill BJ, Foeglein A, Bloor S, Rutherford TJ, Freund SM, Komander D, Randow F. LC3C, bound selectively by a noncanonical LIR motif in NDP52, is required for antibacterial autophagy. *Mol Cell* 2012; 48:329-42; <http://dx.doi.org/10.1016/j.molcel.2012.08.024>.
  148. Huang W-P, Scott SV, Kim J, Klionsky DJ. The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways. *J Biol Chem* 2000; 275:5845-51; <http://dx.doi.org/10.1074/jbc.275.8.5845>.
  149. Cai Q, Lu L, Tian J-H, Zhu Y-B, Qiao H, Sheng Z-H. Snapin-regulated late endosomal transport is critical for efficient autophagy-lysosomal function in neurons. *Neuron* 2010; 68:73-86; <http://dx.doi.org/10.1016/j.neuron.2010.09.022>.
  150. Castino R, Fiorentino I, Cagnin M, Giovia A, Isidoro C. Chelation of lysosomal iron protects dopaminergic SH-SY5Y neuroblastoma cells from hydrogen peroxide toxicity by precluding autophagy and Akt dephosphorylation. *Toxicol Sci* 2011;523-41; <http://dx.doi.org/10.1093/toxsci/kfr179>.
  151. Michiorri S, Gelmetti V, Giarda E, Lombardi F, Romano F, Marongiu R, Nerini-Molteni S, Sale P, Vago R, Arena G, et al. The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy. *Cell Death Differ* 2010; 17:962-74; <http://dx.doi.org/10.1038/cdd.2009.200>.
  152. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. *Brain* 2011; 134:258-77; <http://dx.doi.org/10.1093/brain/awq341>.
  153. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell* 2004; 15:1101-11; <http://dx.doi.org/10.1091/mbc.E03-09-0704>.
  154. Padman BS, Bach M, Lucarelli G, Prescott M, Ramm G. The protonophore CCCP interferes with lysosomal degradation of autophagic cargo in yeast and mammalian cells. *Autophagy* 2013; 9:1862-75; <http://dx.doi.org/10.4161/auto.26557>.
  155. Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. *Traffic* 2008; 9:574-87; <http://dx.doi.org/10.1111/j.1600-0854.2008.00701.x>.
  156. Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? *Autophagy* 2008; 4:849-950; <http://dx.doi.org/10.4161/auto.6845>.
  157. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. *Cell Struct Funct* 1998; 23:33-42; <http://dx.doi.org/10.1247/csf.23.33>.
  158. Ahlberg J, Berkenstam A, Henell F, Glaumann H. Degradation of short and long lived proteins in isolated rat liver lysosomes. Effects of pH, temperature, and proteolytic inhibitors. *J Biol Chem* 1985; 260:5847-54.
  159. Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. *Invest Ophthalmol Vis Sci* 2010; 51:6030-7; <http://dx.doi.org/10.1167/iovs.10-5278>.
  160. Thomas G, Hall MN. TOR signalling and control of cell growth. *Curr Opin Cell Biol* 1997; 9:782-7; [http://dx.doi.org/10.1016/S0955-0674\(97\)80078-6](http://dx.doi.org/10.1016/S0955-0674(97)80078-6).
  161. Juhasz G. Interpretation of bafilomycin, pH neutralizing or protease inhibitor treatments in autophagic flux experiments: novel considerations. *Autophagy* 2012; 8:1875-6; <http://dx.doi.org/10.4161/auto.21544>.
  162. Li M, Khambu B, Zhang H, Kang JH, Chen X, Chen D, Vollmer L, Liu PQ, Vogt A, Yin XM. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. *J Biol Chem* 2013; 288:35769-80; <http://dx.doi.org/10.1074/jbc.M113.511212>.
  163. Seglen PO, Grinde B, Solheim AE. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. *Eur J Biochem* 1979; 95:215-25; <http://dx.doi.org/10.1111/j.1432-1033.1979.tb12956.x>.
  164. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. *J Biol Chem* 1991; 266:17707-12.
  165. McLeland CB, Rodriguez J, Stern ST. Autophagy monitoring assay: qualitative analysis of MAP LC3-I to II conversion by immunoblot. *Methods Mol Biol* 2011; 697:199-206; <http://dx.doi.org/10.1007/978-1-60327-198-1>.
  166. Chakrama FZ, Seguin-Py S, Le Grand JN, Fraichard A, Delage-Mourroux R, Despouy G, Perez V, Jouvenot M, Boyer-Guittaut M. GABARAP1 (GEC1) associates with autophagic vesicles. *Autophagy* 2010; 6:495-505; <http://dx.doi.org/10.4161/auto.6.4.11819>.
  167. Maynard S, Ghosh R, Wu Y, Yan S, Miyake T, Gagliardi M, Rethoret K, Bedard PA. GABARAP is a determinant of apoptosis in growth-arrested chicken embryo fibroblasts. *J Cell Physiol* 2015; 230:1475-88; <http://dx.doi.org/10.1002/jcp.24889>.
  168. Kim J, Huang W-P, Klionsky DJ. Membrane recruitment of Aut7p in the autophagy and cytoplasm to vacuole targeting pathways requires Aut1p, Aut2p, and the autophagy conjugation complex. *J Cell Biol* 2001; 152:51-64; <http://dx.doi.org/10.1083/jcb.152.1.51>.
  169. Shu CW, Drag M, Bekes M, Zhai D, Salvesen GS, Reed JC. Synthetic substrates for measuring activity of autophagy proteases: autophagins (Atg4). *Autophagy* 2010; 6:936-47; <http://dx.doi.org/10.4161/auto.6.7.13075>.
  170. Li M, Chen X, Ye Q-Z, Vogt A, Yin X-M. A High-throughput FRET-based Assay for Determination of Atg4 Activity. *Autophagy* 2012; 8:401-12.
  171. Ketteler R, Seed B. Quantitation of autophagy by luciferase release assay. *Autophagy* 2008; 4:801-6; <http://dx.doi.org/10.4161/auto.6401>.
  172. Li M, Hou Y, Wang J, Chen X, Shao ZM, Yin X-M. Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates. *J Biol Chem* 2011; 286:7327-38; <http://dx.doi.org/10.1074/jbc.M110.199059>.
  173. Klionsky DJ. For the last time, it is GFP-Atg8, not Atg8-GFP (and the same goes for LC3). *Autophagy* 2011; 7:1093-4; <http://dx.doi.org/10.4161/auto.7.10.15492>.
  174. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. *Autophagy* 2005; 1:84-91; <http://dx.doi.org/10.4161/auto.1.2.1697>.
  175. Castino R, Lazzeri G, Lenzi P, Bellio N, Follo C, Ferrucci M, Fornai F, Isidoro C. Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine. *J Neurochem* 2008; 106:1426-39; <http://dx.doi.org/10.1111/j.1471-4159.2008.05488.x>.
  176. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J. Distinct roles of autophagy in the heart during

- ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. *Circ Res* 2007; 100:914-22; <http://dx.doi.org/10.1161/01.RES.0000261924.76669.36>.
177. Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Ohsumi Y. The pre-autophagosomal structure organized by concerted functions of *APG* genes is essential for autophagosome formation. *EMBO J* 2001; 20:5971-81; <http://dx.doi.org/10.1093/emboj/20.21.5971>.
  178. Hanson HH, Kang S, Fernandez-Monreal M, Oung T, Yildirim M, Lee R, Suyama K, Hazan RB, Phillips GR. LC3-dependent intracellular membrane tubules induced by gamma-protocadherins A3 and B2: a role for intraluminal interactions. *J Biol Chem* 2010; 285:20982-92; <http://dx.doi.org/10.1074/jbc.M109.092031>.
  179. Florey O, Kim SE, Sandoval CP, Haynes CM, Overholtzer M. Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes. *Nat Cell Biol* 2011; 13:1335-43; <http://dx.doi.org/10.1038/ncb2363>.
  180. Martinez J, Almendinger J, Oberst A, Ness R, Dillon CP, Fitzgerald P, Hengartner MO, Green DR. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. *Proc Natl Acad Sci USA* 2011; 108:17396-401; <http://dx.doi.org/10.1073/pnas.1113421108>.
  181. Choi J, Park S, Biering SB, Selleck E, Liu CY, Zhang X, Fujita N, Saitoh T, Akira S, Yoshimori T, et al. The parasitophorous vacuole membrane of *Toxoplasma gondii* is targeted for disruption by ubiquitin-like conjugation systems of autophagy. *Immunity* 2014; 40:924-35; <http://dx.doi.org/10.1016/j.immuni.2014.05.006>.
  182. Sanjuan MA, Dillon CP, Tait SW, Moshiah S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. *Nature* 2007; 450:1253-7; <http://dx.doi.org/10.1038/nature06421>.
  183. Sanjuan MA, Milasta S, Green DR. Toll-like receptor signaling in the lysosomal pathways. *Immunol Rev* 2009; 227:203-20; <http://dx.doi.org/10.1111/j.1600-065X.2008.00732.x>.
  184. Ushio H, Ueno T, Kojima Y, Komatsu M, Tanaka S, Yamamoto A, Ichimura Y, Ezaki J, Nishida K, Komazawa-Sakon S, et al. Crucial role for autophagy in degranulation of mast cells. *J Allergy Clin Immunol* 2011; 127:1267-76 e6; <http://dx.doi.org/10.1016/j.jaci.2010.12.1078>.
  185. Ishibashi K, Uemura T, Waguri S, Fukuda M. Atg16L1, an essential factor for canonical autophagy, participates in hormone secretion from PC12 cells independently of autophagic activity. *Mol Biol Cell* 2012; 23:3193-202; <http://dx.doi.org/10.1091/mbc.E12-01-0010>.
  186. DeSelm CJ, Miller BC, Zou W, Beatty WL, van Meel E, Takahata Y, Klumperman J, Tooze SA, Teitelbaum SL, Virgin HW. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. *Dev Cell* 2011; 21:966-74; <http://dx.doi.org/10.1016/j.devcel.2011.08.016>.
  187. Patel KK, Miyoshi H, Beatty WL, Head RD, Malvin NP, Cadwell K, Guan JL, Saitoh T, Akira S, Seglen PO, et al. Autophagy proteins control goblet cell function by potentiating reactive oxygen species production. *EMBO J* 2013; 32:3130-44; <http://dx.doi.org/10.1038/emboj.2013.233>.
  188. Dupont N, Lacas-Gervais S, Bertout J, Paz I, Freche B, Van Nhieu GT, van der Goot FG, Sansonetti PJ, Lafont F. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. *Cell Host Microbe* 2009; 6:137-49; <http://dx.doi.org/10.1016/j.chom.2009.07.005>.
  189. Cottam EM, Maier HJ, Manifava M, Vaux LC, Chandra-Schoenfelder P, Gerner W, Britton P, Ktistakis NT, Wileman T. Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate. *Autophagy* 2011; 7:1335-47; <http://dx.doi.org/10.4161/auto.7.11.16642>.
  190. Reggiori F, Monastyrska I, Verheije MH, Cali T, Ulasli M, Bianchi S, Bernasconi R, de Haan CA, Molinari M. Coronaviruses hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. *Cell Host Microbe* 2010; 7:500-8; <http://dx.doi.org/10.1016/j.chom.2010.05.013>.
  191. Sharma M, Bhattacharyya S, Nain M, Kaur M, Sood V, Gupta V, Khasa R, Abdin MZ, Vrati S, Kalia M. Japanese encephalitis virus replication is negatively regulated by autophagy and occurs on LC3-I- and EDEM1-containing membranes. *Autophagy* 2014; 10:1637-51; <http://dx.doi.org/10.4161/auto.29455>.
  192. English L, Chemali M, Duron J, Rondeau C, Laplante A, Gingras D, Alexander D, Leib D, Norbury C, Lippe R, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. *Nat Immunol* 2009; 10:480-7; <http://dx.doi.org/10.1038/ni.1720>.
  193. Beale R, Wise H, Stuart A, Ravenhill BJ, Digard P, Randow F. A LC3-interacting motif in the influenza A virus M2 protein is required to subvert autophagy and maintain virion stability. *Cell Host Microbe* 2014; 15:239-47; <http://dx.doi.org/10.1016/j.chom.2014.01.006>.
  194. Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB, Whitton JL. Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. *J Virol* 2010; 84:12110-24; <http://dx.doi.org/10.1128/JVI.01417-10>.
  195. Alirezaei M, Flynn CT, Wood MR, Whitton JL. Pancreatic acinar cell-specific autophagy disruption reduces coxsackievirus replication and pathogenesis in vivo. *Cell Host Microbe* 2012; 11:298-305; <http://dx.doi.org/10.1016/j.chom.2012.01.014>.
  196. Plowey ED, Cherra SJ, 3rd, Liu YJ, Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. *J Neurochem* 2008; 105:1048-56; <http://dx.doi.org/10.1111/j.1471-4159.2008.05217.x>.
  197. Nicotra G, Mercalli F, Peracchio C, Castino R, Follo C, Valente G, Isidoro C. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. *Modern pathology: Pathol* 2010; 23:937-50; <http://dx.doi.org/10.1038/modpathol.2010.80>.
  198. Tanida I, Ueno T, Kominami E. LC3 and autophagy. *Methods Mol Biol* 2008; 445:77-88; <http://dx.doi.org/10.1007/978-1-59745-157-4>.
  199. Gros F, Arnold J, Page N, Decossas M, Korganow AS, Martin T, Muller S. Macroautophagy is deregulated in murine and human lupus T lymphocytes. *Autophagy* 2012; 8:1113-23; <http://dx.doi.org/10.4161/auto.20275>.
  200. Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. *J Proteome Res* 2011; 10:1416-9; <http://dx.doi.org/10.1021/pr1011476>.
  201. Colella AD, Chegenii N, Tea MN, Gibbins IL, Williams KA, Chataway TK. Comparison of Stain-Free gels with traditional immunoblot loading control methodology. *Anal Biochem* 2012; 430:108-10; <http://dx.doi.org/10.1016/j.ab.2012.08.015>.
  202. Ghosh R, Gilda JE, Gomes AV. The necessity of and strategies for improving confidence in the accuracy of western blots. *Expert Rev Proteomics* 2014; 11:549-60; <http://dx.doi.org/10.1586/14789450.2014.939635>.
  203. Yan L, Vatner DE, Kim SJ, Ge H, Masarekar M, Massover WH, Yang G, Matsui Y, Sadoshima J, Vatner SF. Autophagy in chronically ischemic myocardium. *Proc Natl Acad Sci USA* 2005; 102:13807-12; <http://dx.doi.org/10.1073/pnas.0506843102>.
  204. Russ DW, Boyd IM, McCoy KM, McCorkle KW. Muscle-specificity of age-related changes in markers of autophagy and sphingolipid metabolism. *Biogerontology* 2015; 16:747-59.
  205. Russ DW, Krause J, Wills A, Arreguin R. "SR stress" in mixed hindlimb muscles of aging male rats. *Biogerontology* 2012; 13:547-55; <http://dx.doi.org/10.1007/s10522-012-9399-y>.
  206. He H, Dang Y, Dai F, Guo Z, Wu J, She X, Pei Y, Chen Y, Ling W, Wu C, et al. Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. *J Biol Chem* 2003; 278:29278-87; <http://dx.doi.org/10.1074/jbc.M303800200>.
  207. Shpilka T, Weidberg H, Pietrokovski S, Elazar Z. Atg8: an autophagy-related ubiquitin-like protein family. *Genome Biol* 2011; 12:226; <http://dx.doi.org/10.1186/gb-2011-12-7-226>.
  208. Zois CE, Koukourakis MI. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-



- sensitization policies? *Autophagy* 2009; 5:442-50; <http://dx.doi.org/10.4161/auto.5.4.7667>.
209. Xin Y, Yu L, Chen Z, Zheng L, Fu Q, Jiang J, Zhang P, Gong R, Zhao S. Cloning, expression patterns, and chromosome localization of three human and two mouse homologues of GABA(A) receptor-associated protein. *Genomics* 2001; 74:408-13; <http://dx.doi.org/10.1006/geno.2001.6555>.
  210. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A, Rogov V, Lohr F, Popovic D, Occhipinti A, et al. Nix is a selective autophagy receptor for mitochondrial clearance. *EMBO Rep* 2010; 11:45-51; <http://dx.doi.org/10.1038/embor.2009.256>.
  211. Schwarten M, Mohrluder J, Ma P, Stoldt M, Thielmann Y, Stangler T, Hersch N, Hoffmann B, Merkel R, Willbold D. Nix directly binds to GABARAP: a possible crosstalk between apoptosis and autophagy. *Autophagy* 2009; 5:690-8; <http://dx.doi.org/10.4161/auto.5.5.8494>.
  212. Gassmann M, Grenacher B, Rohde B, Vogel J. Quantifying Western blots: pitfalls of densitometry. *Electrophoresis* 2009; 30:1845-55; <http://dx.doi.org/10.1002/elps.200800720>.
  213. Kirisako T, Ichimura Y, Okada H, Kabeya Y, Mizushima N, Yoshimori T, Ohsumi M, Takao T, Noda T, Ohsumi Y. The reversible modification regulates the membrane-binding state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. *J Cell Biol* 2000; 151:263-76; <http://dx.doi.org/10.1083/jcb.151.2.263>.
  214. Chung T, Phillips AR, Vierstra RD. ATG8 lipidation and ATG8-mediated autophagy in Arabidopsis require ATG12 expressed from the differentially controlled ATG12A AND ATG12B loci. *Plant J* 2010; 62:483-93; <http://dx.doi.org/10.1111/j.1365-313X.2010.04166.x>.
  215. Chung T, Suttangkakul A, Vierstra RD. The ATG autophagic conjugation system in maize: ATG transcripts and abundance of the ATG8-lipid adduct are regulated by development and nutrient availability. *Plant Physiol* 2009; 149:220-34; <http://dx.doi.org/10.1104/pp.108.126714>.
  216. Engedal N, Torgersen ML, Guldvik IJ, Barfeld SJ, Bakula D, Saetre F, Hagen LK, Patterson JB, Proikas-Cezanne T, Seglen PO, et al. Modulation of intracellular calcium homeostasis blocks autophagosome formation. *Autophagy* 2013; 9:1475-90; <http://dx.doi.org/10.4161/auto.25900>.
  217. Kovsan J, Bluher M, Tarnowski T, Kloting N, Kirshtein B, Madar L, Shai I, Golan R, Harman-Boehm I, Schon MR, et al. Altered autophagy in human adipose tissues in obesity. *J Clin Endocrinol Metab* 2011; 96:E268-77; <http://dx.doi.org/10.1210/jc.2010-1681>.
  218. Gao Z, Gammoh N, Wong PM, Erdjument-Bromage H, Tempst P, Jiang X. Processing of autophagic protein LC3 by the 20S proteasome. *Autophagy* 2010; 6:126-37; <http://dx.doi.org/10.4161/auto.6.1.10928>.
  219. King JS, Veltman DM, Insall RH. The induction of autophagy by mechanical stress. *Autophagy* 2011; 7:1490-9; <http://dx.doi.org/10.4161/auto.7.12.17924>.
  220. Roberts R, Al-Jamal WT, Whelband M, Thomas P, Jefferson M, van den Bossche J, Powell PP, Kostarelos K, Wileman T. Autophagy and formation of tubulovesicular autophagosomes provide a barrier against nonviral gene delivery. *Autophagy* 2013; 9:667-82; <http://dx.doi.org/10.4161/auto.23877>.
  221. Schmidt RS, Butikofer P. Autophagy in *Trypanosoma brucei*: amino acid requirement and regulation during different growth phases. *PLoS One* 2014; 9:e93875; <http://dx.doi.org/10.1371/journal.pone.0093875>.
  222. Bernard M, Dieude M, Yang B, Hamelin K, Underwood K, Hebert MJ. Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. *Autophagy* 2014; 10:2193-207.
  223. Saetre F, Hagen LK, Engedal N, Seglen PO. Novel steps in the autophagic-lysosomal pathway. *FEBS J* 2015; 282:2202-14; <http://dx.doi.org/10.1111/febs.13268>.
  224. Ju JS, Varadhachary AS, Miller SE, Wehl CC. Quantitation of "autophagic flux" in mature skeletal muscle. *Autophagy* 2010; 6:929-35; <http://dx.doi.org/10.4161/auto.6.7.12785>.
  225. Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. *J Cell Biol* 2008; 183:101-16; <http://dx.doi.org/10.1083/jcb.200801099>.
  226. Mauvezin C, Nagy P, Juhasz G, Neufeld TP. Autophagosome-lysosome fusion is independent of V-ATPase-mediated acidification. *Nat Commun* 2015; 6:7007; <http://dx.doi.org/10.1038/ncomms8007>.
  227. Xie R, Nguyen S, McKeehan WL, Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. *BMC Cell Biol* 2010; 11:89; <http://dx.doi.org/10.1186/1471-2121-11-89>.
  228. Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquere S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. *J Cell Sci* 2005; 118:3091-102; <http://dx.doi.org/10.1242/jcs.02447>.
  229. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant {alpha}-synuclein by chaperone-mediated autophagy. *Science* 2004; 305:1292-5; <http://dx.doi.org/10.1126/science.1101738>.
  230. Trincheri NF, Follo C, Nicotra G, Peracchio C, Castino R, Isidoro C. Resveratrol-induced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of autophagolysosomes. *Carcinogenesis* 2008; 29:381-9; <http://dx.doi.org/10.1093/carcin/bgm271>.
  231. Rubinsztein DC, Cuervo AM, Ravikumar B, Sarkar S, Korolchuk V, Kaushik S, Klionsky DJ. In search of an "autophagometer". *Autophagy* 2009; 5:585-9; <http://dx.doi.org/10.4161/auto.5.5.8823>.
  232. Sarkar S, Ravikumar B, Rubinsztein DC. Autophagic clearance of aggregate-prone proteins associated with neurodegeneration. *Methods Enzymol* 2009; 453:83-110; [http://dx.doi.org/10.1016/S0076-6879\(08\)04005-6](http://dx.doi.org/10.1016/S0076-6879(08)04005-6).
  233. Sarkar S, Korolchuk V, Renna M, Winslow A, Rubinsztein DC. Methodological considerations for assessing autophagy modulators: a study with calcium phosphate precipitates. *Autophagy* 2009; 5:307-13; <http://dx.doi.org/10.4161/auto.5.3.7664>.
  234. Martins WK, Severino D, Souza C, Stolf BS, Baptista MS. Rapid screening of potential autophagic inductor agents using mammalian cell lines. *Biotechnol J* 2013; 8:730-7; <http://dx.doi.org/10.1002/biot.201200306>.
  235. Martins WK, Costa ET, Cruz MC, Stolf BS, Miotto R, Cordeiro RM, Baptista MS. Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: The case of the pentacyclic triterpenoids. *Sci Rep* 2015; 5:12425; <http://dx.doi.org/10.1038/srep12425>.
  236. Shintani T, Klionsky DJ. Cargo proteins facilitate the formation of transport vesicles in the cytoplasm to vacuole targeting pathway. *J Biol Chem* 2004; 279:29889-94; <http://dx.doi.org/10.1074/jbc.M404399200>.
  237. Karim MR, Kanazawa T, Daigaku Y, Fujimura S, Miotto G, Kadowaki M. Cytosolic LC3 ratio as a sensitive index of macroautophagy in isolated rat hepatocytes and H4-II-E cells. *Autophagy* 2007; 3:553-60; <http://dx.doi.org/10.4161/auto.4615>.
  238. Kim CH, Kim KH, Yoo YM. Melatonin protects against apoptotic and autophagic cell death in C2C12 murine myoblast cells. *J Pineal Res* 2011; 50:241-9; <http://dx.doi.org/10.1111/j.1600-079X.2010.00833.x>.
  239. Karim MR, Kanazawa T, Daigaku Y, Fujimura S, Miotto G, Kadowaki M. Cytosolic LC3 ratio as a sensitive index of macroautophagy in isolated rat hepatocytes and H4-II-E cells. *Autophagy* 2007; 3:553-60.
  240. Tsvetkov AS, Arrasate M, Barmada S, Ando DM, Sharma P, Shaby BA, Finkbeiner S. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. *Nat Chem Biol* 2013; 9:586-92; <http://dx.doi.org/10.1038/nchembio.1308>.
  241. Loos B, du Toit A, Hofmeyr JH. Defining and measuring autophagosome flux-concept and reality. *Autophagy* 2014:0.
  242. Farkas T, Hoyer-Hansen M, Jaattela M. Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux. *Autophagy* 2009; 5:1018-25; <http://dx.doi.org/10.4161/auto.5.7.9443>.

243. Frankel LB, Wen J, Lees M, H(o)yer-Hansen M, Farkas T, Krogh A, Jaattela M, Lund AH. microRNA-101 is a potent inhibitor of autophagy. *EMBO J* 2011;4628-41; <http://dx.doi.org/10.1038/emboj.2011.331>.
244. Farkas T, Daugaard M, Jaattela M. Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy. *J Biol Chem* 2011; 286:38904-12; <http://dx.doi.org/10.1074/jbc.M111.269134>.
245. Szyliarski P, Corcelle-Termeau E, Farkas T, Hoyer-Hansen M, Nylandsted J, Kallunki T, Jaattela M. A comprehensive siRNA screen for kinases that suppress macroautophagy in optimal growth conditions. *Autophagy* 2011; 7:892-903; <http://dx.doi.org/10.4161/autophagy.7.8.15770>.
246. Nguyen HT, Dalmaso G, Muller S, Carriere J, Seibold F, Darfeuille-Michaud A. Crohn's disease-associated adherent invasive *Escherichia coli* modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. *Gastroenterology* 2014; 146:508-19; <http://dx.doi.org/10.1053/j.gastro.2013.10.021>.
247. Frankel LB, Di Malta C, Wen J, Eskelinen EL, Ballabio A, Lund AH. A non-conserved miRNA regulates lysosomal function and impacts on a human lysosomal storage disorder. *Nat Commun* 2014; 5:5840; <http://dx.doi.org/10.1038/ncomms6840>.
248. Frankel LB, Lund AH. MicroRNA regulation of autophagy. *Carcinogenesis* 2012; 33:2018-25; <http://dx.doi.org/10.1093/carcin/bgs266>.
249. Iwata J, Ezaki J, Komatsu M, Yokota S, Ueno T, Tanida I, Chiba T, Tanaka K, Kominami E. Excess peroxisomes are degraded by autophagic machinery in mammals. *J Biol Chem* 2006; 281:4035-41; <http://dx.doi.org/10.1074/jbc.M512283200>.
250. Narendran D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* 2008; 183:795-803; <http://dx.doi.org/10.1083/jcb.200809125>.
251. Nogalska A, Terracciano C, D'Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. *Acta Neuropathol* 2009; 118:407-13; <http://dx.doi.org/10.1007/s00401-009-0564-6>.
252. Chahory S, Keller N, Martin E, Omri B, Crisanti P, Torriglia A. Light induced retinal degeneration activates a caspase-independent pathway involving cathepsin D. *Neurochem Int* 2010; 57:278-87; <http://dx.doi.org/10.1016/j.neuint.2010.06.006>.
253. Padron-Barthe L, Courta J, Lepretre C, Nagbou A, Torriglia A. Leukocyte Elastase Inhibitor, the precursor of L-DNase II, inhibits apoptosis by interfering with caspase-8 activation. *Biochim Biophys Acta* 2008; 1783:1755-66; <http://dx.doi.org/10.1016/j.bbamer.2008.06.018>.
254. Gutierrez MG, Saka HA, Chinen I, Zoppino FC, Yoshimori T, Bocco JL, Colombo MI. Protective role of autophagy against *Vibrio cholerae* cytotoxin, a pore-forming toxin from *V. cholerae*. *Proc Natl Acad Sci USA* 2007; 104:1829-34; <http://dx.doi.org/10.1073/pnas.0601437104>.
255. Hosokawa N, Hara Y, Mizushima N. Generation of cell lines with tetracycline-regulated autophagy and a role for autophagy in controlling cell size. *FEBS Lett* 2006; 580:2623-9; <http://dx.doi.org/10.1016/j.febslet.2006.04.008>.
256. Suttangkakul A, Li F, Chung T, Vierstra RD. The ATG1/13 protein kinase complex is both a regulator and a substrate of autophagic recycling in *Arabidopsis*. *Plant Cell* 2011; 23:3761-79; <http://dx.doi.org/10.1105/tpc.111.090993>.
257. Ni HM, Bockus A, Wozniak AL, Jones K, Weinman S, Yin XM, Ding WX. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. *Autophagy* 2011; 7:188-204; <http://dx.doi.org/10.4161/autophagy.7.2.14181>.
258. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG, Nabi IR, Roberge M. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. *PLoS One* 2009; 4:e17124; <http://dx.doi.org/10.1371/journal.pone.0007124>.
259. Patterson GH, Lippincott-Schwartz J. Selective photolabeling of proteins using photoactivatable GFP. *Methods* 2004; 32:445-50; <http://dx.doi.org/10.1016/j.ymeth.2003.10.006>.
260. Hamacher-Brady A, Brady NR, Gottlieb RA. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. *J Biol Chem* 2006; 281:29776-87; <http://dx.doi.org/10.1074/jbc.M603783200>.
261. Noda T, Klionsky DJ. The quantitative Pho8Delta60 assay of non-specific autophagy. *Methods Enzymol* 2008; 451:33-42; [http://dx.doi.org/10.1016/S0076-6879\(08\)03203-5](http://dx.doi.org/10.1016/S0076-6879(08)03203-5).
262. Klionsky DJ. Monitoring autophagy in yeast: the Pho8Delta60 assay. *Methods Mol Biol* 2007; 390:363-71; <http://dx.doi.org/10.1007/978-1-59745-466-7>.
263. Patterson GH, Knobel SM, Sharif WD, Kain SR, Piston DW. Use of the green fluorescent protein and its mutants in quantitative fluorescence microscopy. *Biophys J* 1997; 73:2782-90; [http://dx.doi.org/10.1016/S0006-3495\(97\)78307-3](http://dx.doi.org/10.1016/S0006-3495(97)78307-3).
264. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. *Autophagy* 2007; 3:452-60; <http://dx.doi.org/10.4161/autophagy.4451>.
265. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from *Drosophila* sp. red fluorescent protein. *Nat Biotechnol* 2004; 22:1567-72; <http://dx.doi.org/10.1038/nbt1037>.
266. Strack RL, Keenan RJ, Glick BS. Noncytotoxic DsRed derivatives for whole-cell labeling. *Methods Mol Biol* 2011; 699:355-70; <http://dx.doi.org/10.1007/978-1-61737-950-5>.
267. Gurskaya NG, Verkhusha VV, Shcheglov AS, Staroverov DB, Chernykh TV, Fradkov AF, Lukyanov S, Lukyanov KA. Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. *Nat Biotechnol* 2006; 24:461-5; <http://dx.doi.org/10.1038/nbt1191>.
268. Rekas A, Alattia JR, Nagai T, Miyawaki A, Ikura M. Crystal structure of venus, a yellow fluorescent protein with improved maturation and reduced environmental sensitivity. *J Biol Chem* 2002; 277:50573-8; <http://dx.doi.org/10.1074/jbc.M209524200>.
269. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosomal membranes after processing. *EMBO J* 2000; 19:5720-8; <http://dx.doi.org/10.1093/emboj/19.21.5720>.
270. Badr CE, Wurdinger T, Nilsson J, Niers JM, Whalen M, Degtrev A, Tannous BA. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. *Neuro-oncology* 2011; 13:1213-24; <http://dx.doi.org/10.1093/neuonc/nor067>.
271. Meléndez A, Tallóczy Z, Seaman M, Eskelinen E-L, Hall DH, Levine B. Autophagy genes are essential for dauer development and lifespan extension in *C. elegans*. *Science* 2003; 301:1387-91; <http://dx.doi.org/10.1126/science.1087782>.
272. Otto GP, Wu MY, Kazgan N, Anderson OR, Kessin RH. Macroautophagy is required for multicellular development of the social amoeba *Dictyostelium discoideum*. *J Biol Chem* 2003; 278:17636-45; <http://dx.doi.org/10.1074/jbc.M212467200>.
273. Liu XH, Liu TB, Lin FC. Monitoring autophagy in *Magnaporthe oryzae*. *Methods Enzymol* 2008; 451:271-94; [http://dx.doi.org/10.1016/S0076-6879\(08\)03219-9](http://dx.doi.org/10.1016/S0076-6879(08)03219-9).
274. Pinan-Lucarre B, Paoletti M, Dementhon K, Couлары-Salin B, Clave C. Autophagy is induced during cell death by incompatibility and is essential for differentiation in the filamentous fungus *Podospira anserina*. *Mol Microbiol* 2003; 47:321-33; <http://dx.doi.org/10.1046/j.1365-2958.2003.03208.x>.
275. Veneault-Fourrey C, Barooah M, Egan M, Wakley G, Talbot NJ. Autophagic fungal cell death is necessary for infection by the rice blast fungus. *Science* 2006; 312:580-3; <http://dx.doi.org/10.1126/science.1124550>.
276. Kikuma T, Ohneda M, Arioka M, Kitamoto K. Functional analysis of the ATG8 homologue Aoa8 and role of autophagy in

- differentiation and germination in *Aspergillus oryzae*. Eukaryot Cell 2006; 5:1328-36; <http://dx.doi.org/10.1128/EC.00024-06>.
277. Nolting N, Bernhards Y, Poggeler S. SmATG7 is required for viability in the homothallic ascomycete *Sordaria macrospora*. Fungal Genet Biol 2009; 46:531-42; <http://dx.doi.org/10.1016/j.fgb.2009.03.008>.
  278. Baghdiguian S, Martinand-Mari C, Mangeat P. Using Ciona to study developmental programmed cell death. Semin Cancer Biol 2007; 17:147-53; <http://dx.doi.org/10.1016/j.semcancer.2006.11.005>.
  279. Rusten TE, Lindmo K, Juhász G, Sass M, Seglen PO, Brech A, Stenmark H. Programmed autophagy in the *Drosophila* fat body is induced by ecdysone through regulation of the PI3K pathway. Dev Cell 2004; 7:179-92; <http://dx.doi.org/10.1016/j.devcel.2004.07.005>.
  280. Scott RC, Schuldiner O, Neufeld TP. Role and regulation of starvation-induced autophagy in the *Drosophila* fat body. Dev Cell 2004; 7:167-78; <http://dx.doi.org/10.1016/j.devcel.2004.07.009>.
  281. Denton D, Shrivage B, Simin R, Mills K, Berry DL, Baehrecke EH, Kumar S. Autophagy, not apoptosis, is essential for midgut cell death in *Drosophila*. Curr Biol 2009; 19:1741-6; <http://dx.doi.org/10.1016/j.cub.2009.08.042>.
  282. Yoshimoto K, Hanaoka H, Sato S, Kato T, Tabata S, Noda T, Ohsumi Y. Processing of ATG8s, ubiquitin-like proteins, and their deconjugation by ATG4s are essential for plant autophagy. Plant Cell 2004; 16:2967-83; <http://dx.doi.org/10.1105/tpc.104.025395>.
  283. Li F, Chung T, Pennington JG, Federico ML, Kaeppler HF, Kaeppler SM, Otegui MS, Vierstra RD. Autophagic recycling plays a central role in maize nitrogen remobilization. Plant Cell 2015; 27:1389-408; <http://dx.doi.org/10.1105/tpc.15.00158>.
  284. Brennand A, Rico E, Rigden DJ, Van Der Smissen P, Courtoy PJ, Michels PA. ATG24 Represses Autophagy and Differentiation and Is Essential for Homeostasis of the Flagellar Pocket in *Trypanosoma brucei*. PLoS One 2015; 10:e0130365.
  285. Li FJ, Shen Q, Wang C, Sun Y, Yuan AY, He CY. A role of autophagy in *Trypanosoma brucei* cell death. Cell Microbiol 2012; 14:1242-56; <http://dx.doi.org/10.1111/j.1462-5822.2012.01795.x>.
  286. Besteiro S, Williams RA, Morrison LS, Coombs GH, Mottram JC. Endosome sorting and autophagy are essential for differentiation and virulence of *Leishmania major*. J Biol Chem 2006; 281:11384-96; <http://dx.doi.org/10.1074/jbc.M512307200>.
  287. Williams RA, Tetley L, Mottram JC, Coombs GH. Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in *Leishmania mexicana*. Mol Microbiol 2006; 61:655-74; <http://dx.doi.org/10.1111/j.1365-2958.2006.05274.x>.
  288. Williams RA, Woods KL, Juliano L, Mottram JC, Coombs GH. Characterization of unusual families of ATG8-like proteins and ATG12 in the protozoan parasite *Leishmania major*. Autophagy 2009; 5:159-72.
  289. Elsasser A, Vogt AM, Nef H, Kostin S, Mollmann H, Skwara W, Bode C, Hamm C, Schaper J. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J Am Coll Cardiol 2004; 43:2191-9; <http://dx.doi.org/10.1016/j.jacc.2004.02.053>.
  290. Knaapen MW, Davies MJ, De Bie M, Haven AJ, Martinet W, Kockx MM. Apoptotic versus autophagic cell death in heart failure. Cardiovasc Res 2001; 51:304-12; [http://dx.doi.org/10.1016/S0008-6363\(01\)00290-5](http://dx.doi.org/10.1016/S0008-6363(01)00290-5).
  291. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovekorn WP, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003; 92:715-24; <http://dx.doi.org/10.1161/01.RES.0000067471.95890.5C>.
  292. Perez-Perez ME, Florencio FJ, Crespo JL. Inhibition of target of rapamycin signaling and stress activate autophagy in *Chlamydomonas reinhardtii*. Plant Physiol 2010; 152:1874-88; <http://dx.doi.org/10.1104/pp.109.152520>.
  293. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, et al. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Amer J Pathol 2005; 167:1713-28; [http://dx.doi.org/10.1016/S0002-9440\(10\)61253-9](http://dx.doi.org/10.1016/S0002-9440(10)61253-9).
  294. O]st A, Svensson K, Ruishalme I, Brannmark C, Franck N, Krook H, Sandstrom P, Kjolhede P, Stralfors P. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. Mol Med 2010; 16:235-46; <http://dx.doi.org/10.1007/s00894-009-0539-5>.
  295. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, 3rd, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190:881-92; <http://dx.doi.org/10.1083/jcb.200911078>.
  296. Gniadek TJ, Warren G. WatershedCounting3D: a new method for segmenting and counting punctate structures from confocal image data. Traffic 2007; 8:339-46; <http://dx.doi.org/10.1111/j.1600-0854.2007.00538.x>.
  297. Decuyper J-P, Welkenhuyzen K, Luyten Y, Ponsaerts R, Dewaele M, Molgó J, Agostinis P, Missiaen L, De Smedt H, Parys JB, et al. IP3 receptor-mediated Ca<sup>2+</sup> signaling and autophagy induction are interrelated. Autophagy 2011; 7:1472-89; <http://dx.doi.org/10.4161/auto.7.12.17909>.
  298. Xu Y, Yuan J, Lipinski MM. Live imaging and single-cell analysis reveal differential dynamics of autophagy and apoptosis. Autophagy 2013; 9:1418-30; <http://dx.doi.org/10.4161/auto.25080>.
  299. Amer AO, Swanson MS. Autophagy is an immediate macrophage response to *Legionella pneumophila*. Cell Microbiol 2005; 7:765-78; <http://dx.doi.org/10.1111/j.1462-5822.2005.00509.x>.
  300. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. Cell 2004; 119:753-66; <http://dx.doi.org/10.1016/j.cell.2004.11.038>.
  301. Ogawa M, Sasakawa C. Intracellular survival of *Shigella*. Cell Microbiol 2006; 8:177-84; <http://dx.doi.org/10.1111/j.1462-5822.2005.00652.x>.
  302. Reyes L, Eiler-McManis E, Rodrigues PH, Chadda AS, Wallet SM, Belanger M, Barrett AG, Alvarez S, Akin D, Dunn WA, Jr., et al. Deletion of lipoprotein PG0717 in *Porphyromonas gingivalis* W83 reduces gingipain activity and alters trafficking in and response by host cells. PLoS One 2013; 8:e74230; <http://dx.doi.org/10.1371/journal.pone.0074230>.
  303. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 2011; 27:1179-80; <http://dx.doi.org/10.1093/bioinformatics/btr095>.
  304. Wu JQ, Pollard TD. Counting cytokinesis proteins globally and locally in fission yeast. Science 2005; 310:310-4; <http://dx.doi.org/10.1126/science.1113230>.
  305. Geng J, Baba M, Nair U, Klionsky DJ. Quantitative analysis of autophagy-related protein stoichiometry by fluorescence microscopy. J Cell Biol 2008; 182:129-40; <http://dx.doi.org/10.1083/jcb.200711112>.
  306. Lipinski MM, Hoffman G, Ng A, Zhou W, Py BF, Hsu E, Liu X, Eisenberg J, Liu J, Blenis J, et al. A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 2010; 18:1041-52; <http://dx.doi.org/10.1016/j.devcel.2010.05.005>.
  307. Brady NR, Hamacher-Brady A, Yuan H, Gottlieb RA. The autophagic response to nutrient deprivation in the HL-1 cardiac myocyte is modulated by Bcl-2 and sarco/endoplasmic reticulum calcium stores. FEBS J 2007; 274:3184-97; <http://dx.doi.org/10.1111/j.1742-4658.2007.05849.x>.
  308. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Tr 2008; 112:389-403; <http://dx.doi.org/10.1007/s10549-007-9873-4>.
  309. Furuya T, Kim M, Lipinski M, Li J, Kim D, Lu T, Shen Y, Rameh L, Yankner B, Tsai LH, et al. Negative regulation of Yps34 by Cdk mediated phosphorylation. Mol Cell 2010; 38:500-11; <http://dx.doi.org/10.1016/j.molcel.2010.05.009>.
  310. Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and



343. Cherra SJ, III, Kulich SM, Uechi G, Balasubramani M, Mountzouris J, Day BW, Chu CT. Regulation of the autophagy protein LC3 by phosphorylation. *J Cell Biol* 2010; 190:533-9; <http://dx.doi.org/10.1083/jcb.201002108>.
344. Sarkar S, Korolchuk VI, Renna M, Imarisio S, Fleming A, Williams A, Garcia-Arencibia M, Rose C, Luo S, Underwood BR, et al. Complex inhibitory effects of nitric oxide on autophagy. *Mol Cell* 2011; 43:19-32; <http://dx.doi.org/10.1016/j.molcel.2011.04.029>.
345. Nazarko TY, Ozeki K, Till A, Ramakrishnan G, Lotfi P, Yan M, Subramani S. Peroxisomal Atg37 binds Atg30 or palmitoyl-CoA to regulate phagophore formation during pexophagy. *J Cell Biol* 2014; 204:541-57; <http://dx.doi.org/10.1083/jcb.201307050>.
346. Kim SJ, Syed GH, Khan M, Chiu WW, Sohail MA, Gish RG, Siddiqui A. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. *Proc Natl Acad Sci USA* 2014; 111:6413-8; <http://dx.doi.org/10.1073/pnas.1321114111>.
347. Allen GF, Toth R, James J, Ganley IG. Loss of iron triggers PINK1/Parkin-independent mitophagy. *EMBO Rep* 2013; 14:1127-35; <http://dx.doi.org/10.1038/embor.2013.168>.
348. Rosado CJ, Mijaljica D, Hatzinisiriou I, Prescott M, Devenish RJ. Rosella: a fluorescent pH-biosensor for reporting vacuolar turnover of cytosol and organelles in yeast. *Autophagy* 2008; 4:205-13; <http://dx.doi.org/10.4161/autof.5331>.
349. Mijaljica D, Rosado CJ, Devenish RJ, Prescott M. Biosensors for monitoring autophagy In: Serra PA, ed. *Biosensors-Emerging Materials and Applications Croatia*: InTech, 2011:383-400.
350. Nowikovsky K, Reipert S, Devenish RJ, Schweyen RJ. Mdm38 protein depletion causes loss of mitochondrial K<sup>+</sup>/H<sup>+</sup> exchange activity, osmotic swelling and mitophagy. *Cell Death Differ* 2007; 14:1647-56; <http://dx.doi.org/10.1038/sj.cdd.4402167>.
351. Chudakov DM, Matz MV, Lukyanov S, Lukyanov KA. Fluorescent proteins and their applications in imaging living cells and tissues. *Physiol Rev* 2010; 90:1103-63; <http://dx.doi.org/10.1152/physrev.00038.2009>.
352. Zhou C, Zhong W, Zhou J, Sheng F, Fang Z, Wei Y, Chen Y, Deng X, Xia B, Lin J. Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells. *Autophagy* 2012; 8:1215-26; <http://dx.doi.org/10.4161/autof.20284>.
353. Zhou J, Lin J, Zhou C, Deng X, Xia B. Cytotoxicity of red fluorescent protein DsRed is associated with the suppression of Bcl-xL translation. *FEBS Lett* 2011; 585:821-7; <http://dx.doi.org/10.1016/j.febslet.2011.02.013>.
354. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. *Cell Rep* 2014; 7:488-500; <http://dx.doi.org/10.1016/j.celrep.2014.03.009>.
355. Loos B, Genade S, Ellis B, Lochner A, Engelbrecht AM. At the core of survival: autophagy delays the onset of both apoptotic and necrotic cell death in a model of ischemic cell injury. *Exp Cell Res* 2011; 317:1437-53; <http://dx.doi.org/10.1016/j.yexcr.2011.03.011>.
356. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic Control of Autophagy. *Cell* 2014; 159:1263-76; <http://dx.doi.org/10.1016/j.cell.2014.11.006>.
357. Loos B, Engelbrecht AM, Lockshin RA, Klionsky DJ, Zakeri Z. The variability of autophagy and cell death susceptibility: Unanswered questions. *Autophagy* 2013; 9:1270-85; <http://dx.doi.org/10.4161/autof.25560>.
358. Shvets E, Fass E, Elazar Z. Utilizing flow cytometry to monitor autophagy in living mammalian cells. *Autophagy* 2008; 4:621-8; <http://dx.doi.org/10.4161/autof.5939>.
359. Hundeshagen P, Hamacher-Brady A, Eils R, Brady NR. Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. *BMC Biol* 2011; 9:38; <http://dx.doi.org/10.1186/1741-7007-9-38>.
360. de la Calle C, Joubert PE, Law HK, Hasan M, Albert ML. Simultaneous assessment of autophagy and apoptosis using multispectral imaging cytometry. *Autophagy* 2011; 7:1045-51; <http://dx.doi.org/10.4161/autof.7.9.16252>.
361. Degtyarev M, Reichelt M, Lin K. Novel quantitative autophagy analysis by organelle flow cytometry after cell sonication. *PloS One* 2014; 9:e87707; <http://dx.doi.org/10.1371/journal.pone.0087707>.
362. Gannage M, Dormann D, Albrecht R, Dengel J, Torossi T, Ramer PC, Lee M, Strowig T, Arrey F, Conenello G, et al. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. *Cell Host Microbe* 2009; 6:367-80; <http://dx.doi.org/10.1016/j.chom.2009.09.005>.
363. Kaminskyy V, Abdi A, Zhivotovsky B. A quantitative assay for the monitoring of autophagosome accumulation in different phases of the cell cycle. *Autophagy* 2011; 7:83-90; <http://dx.doi.org/10.4161/autof.7.1.13893>.
364. Kirkin V, Lamark T, Sou YS, Bjorkoy G, Nunn JL, Bruun JA, Shvets E, McEwan DG, Clausen TH, Wild P, et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. *Mol Cell* 2009; 33:505-16; <http://dx.doi.org/10.1016/j.molcel.2009.01.020>.
365. Larsen KB, Lamark T, Overvatn A, Harneshaug I, Johansen T, Bjorkoy G. A reporter cell system to monitor autophagy based on p62/SQSTM1. *Autophagy* 2010; 6:784-93; <http://dx.doi.org/10.4161/autof.6.6.12510>.
366. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, et al. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. *Autophagy* 2010; 6:777-83; <http://dx.doi.org/10.4161/autof.6.6.12784>.
367. Sivridis E, Koukourakis MI, Zois CE, Ledaki I, Ferguson DJ, Harris AL, Gatter KC, Giatromanolaki A. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. *Amer J Pathol* 2010; 176:2477-89; <http://dx.doi.org/10.2353/ajpath.2010.090049>.
368. Sivridis E, Giatromanolaki A, Liberis V, Koukourakis MI. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): what is destined for the atypical endometrial hyperplasia? *Autophagy* 2011; 7:74-82; <http://dx.doi.org/10.4161/autof.7.1.13947>.
369. Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Chloropoulou P, Liberis V, Sivridis E. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. *Gynecol Oncol* 2011; 123:147-51; <http://dx.doi.org/10.1016/j.ygyno.2011.06.023>.
370. Chen Y, Lu Y, Lu C, Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. *Pathol Oncol Res* 2009; 15:487-93; <http://dx.doi.org/10.1007/s12253-008-9143-8>.
371. Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, et al. Elevated Beclin 1 expression is correlated with HIF-1[a] in predicting poor prognosis of nasopharyngeal carcinoma. *Autophagy* 2010; 6:395-404; <http://dx.doi.org/10.4161/autof.6.3.11303>.
372. Sakakura K, Takahashi H, Kaira K, Toyoda M, Oyama T, Chikamatsu K. Immunological significance of the accumulation of autophagy components in oral squamous cell carcinoma. *Cancer Sci* 2015; 106:1-8; <http://dx.doi.org/10.1111/cas.12559>.
373. Shi YH, Ding ZB, Zhou J, Qiu SJ, Fan J. Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. *Autophagy* 2009; 5:380-2; <http://dx.doi.org/10.4161/autof.5.3.7658>.
374. Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai Z, Shi GM, Wang XY, Ke AW, Wu B, et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. *Cancer Res* 2008; 68:9167-75; <http://dx.doi.org/10.1158/0008-5472.CAN-08-1573>.
375. Pirtoli L, Cevenini G, Tini P, Vannini M, Oliveri G, Marsili S, Mourmouras V, Rubino G, Miracco C. The prognostic role of Beclin 1 protein expression in high-grade gliomas. *Autophagy* 2009; 5:930-6; <http://dx.doi.org/10.4161/autof.5.7.9227>.
376. Karpathiou G, Sivridis E, Koukourakis MI, Mikroulis D, Bouros D, Froudarakis ME, Giatromanolaki A. Light-chain 3A autophagic activity and prognostic significance in non-small cell lung

- carcinomas. *Chest* 2011; 140:127-34; <http://dx.doi.org/10.1378/chest.10-1831>.
377. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima M, Kinoshita T, Ueno T, Esumi H, Ochiai A. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. *Cancer Sci* 2008; 99:1813-9; <http://dx.doi.org/10.1111/j.1349-7006.2008.00743.x>.
  378. Li BX, Li CY, Peng RQ, Wu XJ, Wang HY, Wan DS, Zhu XF, Zhang XS. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. *Autophagy* 2009; 5:303-6; <http://dx.doi.org/10.4161/auto.5.3.7491>.
  379. Koukourakis MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gatter KC, Harris AL. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. *Brit J Cancer* 2010; 103:1209-14; <http://dx.doi.org/10.1038/sj.bjc.6605904>.
  380. Giatromanolaki A, Koukourakis MI, Harris AL, Polychronidis A, Gatter KC, Sivridis E. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. *J Clin Pathol* 2010; 63:867-72; <http://dx.doi.org/10.1136/jcp.2010.079525>.
  381. Sivridis E, Koukourakis MI, Mendrinou SE, Karpouzis A, Fiska A, Kouskoukis C, Giatromanolaki A. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. *Melanoma Res* 2011; 21:188-95; <http://dx.doi.org/10.1097/CMR.0b013e328346612c>.
  382. Giatromanolaki AN, St Charitoudis G, Bechrakis NE, Kozobolis VP, Koukourakis MI, Foerster MH, Sivridis EL. Autophagy patterns and prognosis in uveal melanomas. *Modern Pathol* 2011; 24:1036-45; <http://dx.doi.org/10.1038/modpathol.2011.63>.
  383. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). *J Natl Cancer Inst* 2005; 97:1180-4; <http://dx.doi.org/10.1093/jnci/dji237>.
  384. Kuwahara Y, Oikawa T, Ochiai Y, Roudkenar MH, Fukumoto M, Shimura T, Ohtake Y, Ohkubo Y, Mori S, Uchiyama Y. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. *Cell Death Dis* 2011; 2:e177.
  385. Hou YJ, Dong LW, Tan YX, Yang GZ, Pan YF, Li Z, Tang L, Wang M, Wang Q, Wang HY. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. *Lab Invest* 2011; 91:1146-57; <http://dx.doi.org/10.1038/labinvest.2011.97>.
  386. O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. *Autophagy* 2011; 7:509-24; <http://dx.doi.org/10.4161/auto.7.5.15066>.
  387. Yoshimura K, Shibata M, Koike M, Gotoh K, Fukaya M, Watanabe M, Uchiyama Y. Effects of RNA interference of Atg4B on the limited proteolysis of LC3 in PC12 cells and expression of Atg4B in various rat tissues. *Autophagy* 2006; 2:200-8; <http://dx.doi.org/10.4161/auto.2744>.
  388. Tamura H, Shibata M, Koike M, Sasaki M, Uchiyama Y. Atg9A protein, an autophagy-related membrane protein, is localized in the neurons of mouse brains. *J Histochem Cytochem* 2010; 58:443-53; <http://dx.doi.org/10.1369/jhc.2010.955690>.
  389. Cui J, Bai XY, Shi S, Cui S, Hong Q, Cai G, Chen X. Age-related changes in the function of autophagy in rat kidneys. *Age* 2011; 10.1007/s11357-011-9237-1.
  390. Marinelli S, Nazio F, Tinari A, Ciarlo L, D'Amelio M, Pieroni L, Vacca V, Urbani A, Ceconi F, Malorni W, et al. Schwann cell autophagy counteracts the onset and chronification of neuropathic pain. *Pain* 2014; 155:93-107; <http://dx.doi.org/10.1016/j.pain.2013.09.013>.
  391. Adolph TE, Tomczak MF, Niederreiter L, Ko HJ, Bock J, Martinez-Naves E, Glickman JN, Tschurtschenthaler M, Hartwig J, Hosomi S, et al. Paneth cells as a site of origin for intestinal inflammation. *Nature* 2013; 503:272-6.
  392. Thachil E, Hugot JP, Arbeille B, Paris R, Grodet A, Peuchmaur M, Codogno P, Barreau F, Ogier-Denis E, Berrebi D, et al. Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease. *Gastroenterology* 2012; 142:1097-9 e4; <http://dx.doi.org/10.1053/j.gastro.2012.01.031>.
  393. Mellén MA, de la Rosa EJ, Boya P. The autophagic machinery is necessary for removal of cell corpses from the developing retinal neuroepithelium. *Cell Death Differ* 2008; 15:1279-90; <http://dx.doi.org/10.1038/cdd.2008.40>.
  394. Mellén MA, de la Rosa EJ, Boya P. Autophagy is not universally required for phosphatidyl-serine exposure and apoptotic cell engulfment during neural development. *Autophagy* 2009; 5:964-72; <http://dx.doi.org/10.4161/auto.5.7.9292>.
  395. Aburto MR, Sanchez-Calderon H, Hurlle JM, Varela-Nieto I, Magarinos M. Early otic development depends on autophagy for apoptotic cell clearance and neural differentiation. *Cell Death Dis* 2012; 3:e394; <http://dx.doi.org/10.1038/cddis.2012.132>.
  396. Morais RD, Thome RG, Lemos FS, Bazzoli N, Rizzo E. Autophagy and apoptosis interplay during follicular atresia in fish ovary: a morphological and immunocytochemical study. *Cell Tissue Res* 2012; 347:467-78; <http://dx.doi.org/10.1007/s00441-012-1327-6>.
  397. Shibata M, Yoshimura K, Furuya N, Koike M, Ueno T, Komatsu M, Arai H, Tanaka K, Kominami E, Uchiyama Y. The MAP1-LC3 conjugation system is involved in lipid droplet formation. *Biochem Biophys Res Commun* 2009; 382:419-23; <http://dx.doi.org/10.1016/j.bbrc.2009.03.039>.
  398. Komatsu M, Waguri S, Koike M, Sou Y-S, Ueno T, Hara T, Mizushima N, Iwata J-I, Ezaki J, Murata S, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 2007; 131:1149-63; <http://dx.doi.org/10.1016/j.cell.2007.10.035>.
  399. Germain M, Nguyen AP, Le Grand JN, Arbour N, Vanderluit JL, Park DS, Opferman JT, Slack RS. MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. *EMBO J* 2011; 30:395-407; <http://dx.doi.org/10.1038/emboj.2010.327>.
  400. Komatsu M, Wang QJ, Holstein GR, Friedrich VL, Jr., Iwata J, Kominami E, Chait BT, Tanaka K, Yue Z. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. *Proc Natl Acad Sci USA* 2007; 104:14489-94; <http://dx.doi.org/10.1073/pnas.0701311104>.
  401. Wang QJ, Ding Y, Kohtz DS, Mizushima N, Cristea IM, Rout MP, Chait BT, Zhong Y, Heintz N, Yue Z. Induction of autophagy in axonal dystrophy and degeneration. *J Neurosci* 2006; 26:8057-68; <http://dx.doi.org/10.1523/JNEUROSCI.2261-06.2006>.
  402. Nezis IP, Simonsen A, Sagona AP, Finley K, Gaumer S, Contamine D, Rusten TE, Stenmark H, Brech A. Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. *J Cell Biol* 2008; 180:1065-71; <http://dx.doi.org/10.1083/jcb.200711108>.
  403. Bartlett BJ, Isakson P, Lewerenz J, Sanchez H, Kotzebue RW, Cumming RC, Harris GL, Nezis IP, Schubert DR, Simonsen A, et al. p62, Ref(2)P and ubiquitinated proteins are conserved markers of neuronal aging, aggregate formation and progressive autophagic defects. *Autophagy* 2011; 7:572-83; <http://dx.doi.org/10.4161/auto.7.6.14943>.
  404. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M, Metzger D, Reggiani C, Schiaffino S, Sandri M. Autophagy is required to maintain muscle mass. *Cell Metab* 2009; 10:507-15; <http://dx.doi.org/10.1016/j.cmet.2009.10.008>.
  405. El-Khoury V, Pierson S, Szwarcbart E, Brons NH, Roland O, Cherrier-De Wilde S, Plawny L, Van Dyck E, Berchem G. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. *Leukemia* 2014; 28:1636-46; <http://dx.doi.org/10.1038/leu.2014.19>.
  406. Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, Araga S, Yanagawa T, Ishii T, Nakashima K. Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease. *Brain Res* 2004; 1012:42-51; <http://dx.doi.org/10.1016/j.brainres.2004.03.029>.

407. Trocoli A, Bensadoun P, Richard E, Labrunie G, Merhi F, Schlaflfi AM, Brigger D, Souquere S, Pierron G, Pasquet JM, et al. p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. *Cell Death Differ* 2014; 21:1852-61.
408. B'Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P, Bruhat A. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. *Nucleic Acids Res* 2013; 41:7683-99; <http://dx.doi.org/10.1093/nar/gkt563>.
409. Cnop M, Abdulkarim B, Bottu G, Cunha DA, Igoillo-Esteve M, Masini M, Turatsinze JV, Griebel T, Villate O, Santin I, et al. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. *Diabetes* 2014; 63:1978-93; <http://dx.doi.org/10.2337/db13-1383>.
410. Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, Cassuto JP, Auberger P. Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. *Autophagy* 2009; 5:1092-8; <http://dx.doi.org/10.4161/auto.5.8.9889>.
411. Toepfer N, Childress C, Parikh A, Ruktalis D, Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. *Cancer Biol Ther* 2011; 12:691-9; <http://dx.doi.org/10.4161/cbt.12.8.15978>.
412. Zheng Q, Su H, Ranek MJ, Wang X. Autophagy and p62 in cardiac proteinopathy. *Circ Res* 2011; 109:296-308; <http://dx.doi.org/10.1161/CIRCRESAHA.111.244707>.
413. Trocoli A, Mathieu J, Priault M, Reiffers J, Souquere S, Pierron G, Besancon F, Djavaheri-Mergny M. ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells. *Autophagy* 2011; 7:1108-14; <http://dx.doi.org/10.4161/auto.7.10.16623>.
414. Kim JH, Hong SK, Wu PK, Richards AL, Jackson WT, Park JI. Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels. *Exp Cell Res* 2014; 327:340-52; <http://dx.doi.org/10.1016/j.yexcr.2014.08.001>.
415. Sahani MH, Itakura E, Mizushima N. Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids. *Autophagy* 2014; 10:431-41; <http://dx.doi.org/10.4161/auto.27344>.
416. B'Chir W, Chaveroux C, Carraro V, Averous J, Maurin AC, Jousse C, Muranishi Y, Parry L, Fafournoux P, Bruhat A. Dual role for CHOP in the crosstalk between autophagy and apoptosis to determine cell fate in response to amino acid deprivation. *Cell Signal* 2014; 26:1385-91; <http://dx.doi.org/10.1016/j.cellsig.2014.03.009>.
417. Jamart C, Naslain D, Gilson H, Francaux M. Higher activation of autophagy in skeletal muscle of mice during endurance exercise in the fasted state. *Am J Physiol Endocrinol Metab* 2013; 305:E964-74; <http://dx.doi.org/10.1152/ajpendo.00270.2013>.
418. Sanchez AM, Bernardi H, Py G, Candau RB. Autophagy is essential to support skeletal muscle plasticity in response to endurance exercise. *Am J Physiol Regul Integr Comp Physiol* 2014; 307:R956-69; <http://dx.doi.org/10.1152/ajpregu.00187.2014>.
419. Stingle S, Stoehr G, Peplowska K, Cox J, Mann M, Storchova Z. Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. *Mol Syst Biol* 2012; 8:608; <http://dx.doi.org/10.1038/msb.2012.40>.
420. Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidy-selective antiproliferation compounds. *Cell* 2011; 144:499-512; <http://dx.doi.org/10.1016/j.cell.2011.01.017>.
421. Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, Chiarpotto EM, Cavallini G, Bonelli G, Baccino FM, Costelli P. Autophagic degradation contributes to muscle wasting in cancer cachexia. *Amer J Pathol* 2013; 182:1367-78; <http://dx.doi.org/10.1016/j.ajpath.2012.12.023>.
422. BenYounes A, Tajeddine N, Tailler M, Malik SA, Shen S, Metivier D, Kepp O, Vitale I, Maiuri MC, Kroemer G. A fluorescence-microscopic and cytofluorometric system for monitoring the turnover of the autophagic substrate p62/SQSTM1. *Autophagy* 2011; 7:883-91; <http://dx.doi.org/10.4161/auto.7.8.15538>.
423. Chang Y-Y, Neufeld TP. An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation. *Mol Biol Cell* 2009; 20:2004-14; <http://dx.doi.org/10.1091/mbc.E08-12-1250>.
424. Jiang Y, Zhu J, Wu L, Xu G, Dai J, Liu X. Tetracycline inhibits local inflammation induced by cerebral ischemia via modulating autophagy. *PloS One* 2012; 7:e48672; <http://dx.doi.org/10.1371/journal.pone.0048672>.
425. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. *Methods Enzymol* 2009; 452:181-97; [http://dx.doi.org/10.1016/S0076-6879\(08\)03612-4](http://dx.doi.org/10.1016/S0076-6879(08)03612-4).
426. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell* 2009; 137:1001-4; <http://dx.doi.org/10.1016/j.cell.2009.05.023>.
427. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, Hansen M, Moscat J, Diaz-Meco MT. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. *Mol Cell* 2011; 44:134-46; <http://dx.doi.org/10.1016/j.molcel.2011.06.038>.
428. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* 2010; 12:213-23.
429. Gonzalez Y, Aryal B, Chehab L, Rao VA. Atg7- and Keap1-dependent autophagy protects breast cancer cell lines against mitochon-dria-induced oxidative stress. *Oncotarget* 2014; 5:1526-37; <http://dx.doi.org/10.18632/oncotarget.1715>.
430. Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Overvatn A, McMahon M, Hayes JD, Johansen T. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. *J Biol Chem* 2010; 285:22576-91; <http://dx.doi.org/10.1074/jbc.M110.118976>.
431. Korolchuk VI, Muzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. *FEBS Lett* 2010; 584:1393-8; <http://dx.doi.org/10.1016/j.febslet.2009.12.047>.
432. Bardag-Gorce F, Francis T, Nan L, Li J, He Lue Y, French BA, French SW. Modifications in p62 occur due to proteasome inhibition in alcoholic liver disease. *Life Sci* 2005; 77:2594-602; <http://dx.doi.org/10.1016/j.lfs.2005.04.020>.
433. Myeku N, Figueiredo-Pereira ME. Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62. *J Biol Chem* 2011; 286:22426-40; <http://dx.doi.org/10.1074/jbc.M110.149252>.
434. Korolchuk VI, Mansilla A, Muzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. *Mol Cell* 2009; 33:517-27; <http://dx.doi.org/10.1016/j.molcel.2009.01.021>.
435. Monick MM, Powers LS, Walters K, Lovan N, Zhang M, Gerke A, Hansdottir S, Hunninghake GW. Identification of an autophagy defect in smokers' alveolar macrophages. *J Immunol* 2010; 185:5425-35; <http://dx.doi.org/10.4049/jimmunol.1001603>.
436. Vellelian F, Deuel JW, Opitz L, Schaer CA, Puglia M, Lonn M, Engelsberger W, Schauer S, Karnaukhova E, Spahn DR, et al. Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress. *Cell Death Differ* 2015; 22:597-611; <http://dx.doi.org/10.1038/cdd.2014.154>.
437. Long J, Garner TP, Pandya MJ, Craven CJ, Chen P, Shaw B, Williamson MP, Layfield R, Searle MS. Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and regulates NF-kappaB signalling. *J Mol Biol* 2010; 396:178-94; <http://dx.doi.org/10.1016/j.jmb.2009.11.032>.
438. Norman JM, Cohen GM, Bampton ET. The in vitro cleavage of the hAtg proteins by cell death proteases. *Autophagy* 2010; 6:1042-56; <http://dx.doi.org/10.4161/auto.6.8.13337>.

439. Lelouard H, Schmidt EK, Camosseto V, Clavarino G, Ceppi M, Hsu HT, Pierre P. Regulation of translation is required for dendritic cell function and survival during activation. *J Cell Biol* 2007; 179:1427-39; <http://dx.doi.org/10.1083/jcb.200707166>.
440. Schmidt EK, Clavarino G, Ceppi M, Pierre P. SuNSET, a nonradioactive method to monitor protein synthesis. *Nat Methods* 2009; 6:275-7; <http://dx.doi.org/10.1038/nmeth.1314>.
441. Lim J, Kim HW, Youdim MB, Rhyu IJ, Choe KM, Oh YJ. Binding preference of p62 towards LC3-II during dopaminergic neurotoxin-induced impairment of autophagic flux. *Autophagy* 2011; 7:51-60; <http://dx.doi.org/10.4161/auto.7.1.13909>.
442. Fouillet A, Levet C, Virgone A, Robin M, Dourlen P, Rieusset J, Belaïdi E, Ovize M, Touret M, Nataf S, et al. ER stress inhibits neuronal death by promoting autophagy. *Autophagy* 2012; 8:915-26; <http://dx.doi.org/10.4161/auto.19716>.
443. Waguri S, Komatsu M. Biochemical and morphological detection of inclusion bodies in autophagy-deficient mice. *Methods Enzymol* 2009; 453:181-96; [http://dx.doi.org/10.1016/S0076-6879\(08\)04009-3](http://dx.doi.org/10.1016/S0076-6879(08)04009-3).
444. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. *Hum Mol Genet* 2002; 11:2735-9; <http://dx.doi.org/10.1093/hmg/11.22.2735>.
445. Kara NZ, Toker L, Agam G, Anderson GW, Belmaker RH, Einat H. Trehalose induced antidepressant-like effects and autophagy enhancement in mice. *Psychopharmacology* 2013; 229:367-75; <http://dx.doi.org/10.1007/s00213-013-3119-4>.
446. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. *Proteomics* 2006; 6:3414-25; <http://dx.doi.org/10.1002/pmic.200500069>.
447. Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBPI and BASP1 protein expression. *Mol Psychiatr* 2009; 14:601-13; <http://dx.doi.org/10.1038/mp.2008.7>.
448. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR. Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment. *Psychiat Genet* 2008; 18:64-72; <http://dx.doi.org/10.1097/YPG.0b013e3282fb0051>.
449. Focking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. *Arch Gen Psychiatr* 2011; 68:477-88; <http://dx.doi.org/10.1001/archgenpsychiatry.2011.43>.
450. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. *Proc Natl Acad Sci USA* 2008; 105:3634-9; <http://dx.doi.org/10.1073/pnas.0800001105>.
451. Lu K, Psakhye I, Jentsch S. Autophagic Clearance of PolyQ Proteins Mediated by Ubiquitin-Atg8 Adaptors of the Conserved CUET Protein Family. *Cell* 2014; 158:549-63; <http://dx.doi.org/10.1016/j.cell.2014.05.048>.
452. Mizushima N, Levine B. Autophagy in mammalian development and differentiation. *Nat Cell Biol* 2010; 12:823-30; <http://dx.doi.org/10.1038/ncb0910-823>.
453. Maloverjan A, Piirsoo M, Michelson P, Kogerman P, Osterlund T. Identification of a novel serine/threonine kinase ULK3 as a positive regulator of Hedgehog pathway. *Exp Cell Res* 2010; 316:627-37; <http://dx.doi.org/10.1016/j.yexcr.2009.10.018>.
454. Young ARJ, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavaré S, Arakawa S, Shimizu S, Watt FM. Autophagy mediates the mitotic senescence transition. *Genes Dev* 2009; 23:798-803; <http://dx.doi.org/10.1101/gad.519709>.
455. Chan EY, Tooze SA. Evolution of Atg1 function and regulation. *Autophagy* 2009; 5:758-65; <http://dx.doi.org/10.4161/auto.8709>.
456. Chan EY, Kir S, Tooze SA. siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. *J Biol Chem* 2007; 282:25464-74; <http://dx.doi.org/10.1074/jbc.M703663200>.
457. Petherick KJ, Conway OJ, Mpanhanga C, Osborne SA, Kamal A, Saxty B, Ganley IG. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. *J Biol Chem* 2015; 290:11376-83; <http://dx.doi.org/10.1074/jbc.C114.627778>.
458. Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, Zhang J, Iyengar R, Jung CH, Suen DF, et al. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. *Mol Cell* 2011; 43:572-85; <http://dx.doi.org/10.1016/j.molcel.2011.06.018>.
459. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. *Genes Dev* 2011; 25:1895-908; <http://dx.doi.org/10.1101/gad.17420111>.
460. Carling D, Mayer FV, Sanders MJ, Gamblin SJ. AMP-activated protein kinase: nature's energy sensor. *Nat Chem Biol* 2011; 7:512-8; <http://dx.doi.org/10.1038/nchembio.610>.
461. Samari HR, Moller MT, Holden L, Asmyhr T, Seglen PO. Stimulation of hepatocytic AMP-activated protein kinase by okadaic acid and other autophagy-suppressive toxins. *Biochem J* 2005; 386:237-44; <http://dx.doi.org/10.1042/BJ20040609>.
462. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D'Alessandro A, Zolla L, Palmieri M. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Cell Death Dis* 2013; 4:e664.
463. Hawley SA, Ross FA, Chevztzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab* 2010; 11:554-65; <http://dx.doi.org/10.1016/j.cmet.2010.04.001>.
464. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. *Nature* 2010; 466:68-76; <http://dx.doi.org/10.1038/nature09204>.
465. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A, Simone C. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. *Cell Death Differ* 2009; 16:1203-14; <http://dx.doi.org/10.1038/cdd.2009.36>.
466. Kovács AL, Seglen PO. Inhibition of hepatocytic protein degradation by methylaminopurines and inhibitors of protein synthesis. *Biochim Biophys Acta* 1981; 676:213-20; [http://dx.doi.org/10.1016/0304-4165\(81\)90189-6](http://dx.doi.org/10.1016/0304-4165(81)90189-6).
467. Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, Liu Z, Cao W. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. *J Biol Chem* 2009; 284:31484-92; <http://dx.doi.org/10.1074/jbc.M109.033936>.
468. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, et al. FoxO3 controls autophagy in skeletal muscle in vivo. *Cell Metab* 2007; 6:458-71; <http://dx.doi.org/10.1016/j.cmet.2007.11.001>.
469. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG, Downes M, Evans RM, Montminy M, Shaw RJ. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. *Cell* 2011; 145:607-21; <http://dx.doi.org/10.1016/j.cell.2011.03.043>.
470. Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T. Ca<sup>2+</sup>/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy. *Mol Pharmacol* 2011; 80:1066-75; <http://dx.doi.org/10.1124/mol.111.071761>.
471. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. *FEBS Lett* 2008; 582:46-53; <http://dx.doi.org/10.1016/j.febslet.2007.11.034>.
472. Samari HR, Seglen PO. Inhibition of hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide riboside, and



- N6-mercaptopurine riboside. Evidence for involvement of amp-activated protein kinase. *J Biol Chem* 1998; 273:23758-63; <http://dx.doi.org/10.1074/jbc.273.37.23758>.
473. Sanchez AM, Csibi A, Raibon A, Cornille K, Gay S, Bernardi H, Candau R. AMPK promotes skeletal muscle autophagy through activation of Forkhead FoxO3a and interaction with Ulk1. *J Cell Biochem* 2011.
474. Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. *Cell* 2003; 115:577-90; [http://dx.doi.org/10.1016/S0092-8674\(03\)00929-2](http://dx.doi.org/10.1016/S0092-8674(03)00929-2).
475. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* 2008; 30:214-26; <http://dx.doi.org/10.1016/j.molcel.2008.03.003>.
476. Egan D, Kim J, Shaw RJ, Guan K-L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. *Autophagy* 2011; 7:643-4; <http://dx.doi.org/10.4161/autophagy.7.6.15123>.
477. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* 2011; 331:456-61; <http://dx.doi.org/10.1126/science.1196371>.
478. Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 2011; 13:132-41; <http://dx.doi.org/10.1038/ncb2152>.
479. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 2001; 108:1167-74; <http://dx.doi.org/10.1172/JCI13505>.
480. Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. *Cell Death Dis* 2013; 4:e628; <http://dx.doi.org/10.1038/cddis.2013.155>.
481. Emerling BM, Viollet B, Tormos KV, Chandel NS. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. *FEBS Lett* 2007; 581:5727-31; <http://dx.doi.org/10.1016/j.febslet.2007.11.038>.
482. Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V, et al. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. *Autophagy* 2011; 7:40-50; <http://dx.doi.org/10.4161/autophagy.7.1.13883>.
483. Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, Meijer AJ. AMP-activated protein kinase and the regulation of autophagic proteolysis. *J Biol Chem* 2006; 281:34870-9; <http://dx.doi.org/10.1074/jbc.M605488200>.
484. Grotomeier A, Alers S, Pfisterer SG, Paasch F, Daubrawa M, Dieterle A, Viollet B, Wesselborg S, Proikas-Cezanne T, Stork B. AMPK-independent induction of autophagy by cytosolic Ca<sup>2+</sup> increase. *Cell Signal* 2010; 22:914-25; <http://dx.doi.org/10.1016/j.cellsig.2010.01.015>.
485. Williams T, Forsberg LJ, Viollet B, Brenman JE. Basal autophagy induction without AMP-activated protein kinase under low glucose conditions. *Autophagy* 2009; 5:1155-65; <http://dx.doi.org/10.4161/autophagy.5.8.10090>.
486. Shang L, Chen S, Du F, Li S, Zhao L, Wang X. Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. *Proc Natl Acad Sci USA* 2011; 108:4788-93; <http://dx.doi.org/10.1073/pnas.1100844108>.
487. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. *Science* 2011; 334:678-83; <http://dx.doi.org/10.1126/science.1207056>.
488. Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, Antonioli M, Pagliarini V, Matteoni S, Fuoco C, Giunta L, et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. *J Cell Biol* 2010; 191:155-68; <http://dx.doi.org/10.1083/jcb.201002100>.
489. Tang HW, Wang YB, Wang SL, Wu MH, Lin SY, Chen GC. Atg1-mediated myosin II activation regulates autophagosome formation during starvation-induced autophagy. *EMBO J* 2011; 30:636-51; <http://dx.doi.org/10.1038/emboj.2010.338>.
490. Jung CH, Jun CB, Ro S-H, Kim Y-M, Otto NM, Cao J, Kundu M, Kim D-H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. *Mol Biol Cell* 2009; 20:1992-2003; <http://dx.doi.org/10.1091/mbc.E08-12-1249>.
491. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. *Mol Biol Cell* 2009; 20:1981-91; <http://dx.doi.org/10.1091/mbc.E08-12-1248>.
492. Chan EYW, Longatti A, McKnight NC, Tooze SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. *Mol Cell Biol* 2009; 29:157-71; <http://dx.doi.org/10.1128/MCB.01082-08>.
493. Papinski D, Schuschnig M, Reiter W, Wilhelm L, Barnes CA, Maiolica A, Hansmann I, Pfaffenwimmer T, Kijanska M, Stoffel I, et al. Early steps in autophagy depend on direct phosphorylation of Atg9 by the Atg1 kinase. *Mol Cell* 2014; 53:471-83; <http://dx.doi.org/10.1016/j.molcel.2013.12.011>.
494. Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, Kim H, Neufeld TP, Dillin A, Guan KL. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. *Nat Cell Biol* 2013; 15:741-50; <http://dx.doi.org/10.1038/ncb2757>.
495. Jung CH, Seo M, Otto NM, Kim DH. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. *Autophagy* 2011; 7:1212-21; <http://dx.doi.org/10.4161/autophagy.7.10.16660>.
496. Loffler AS, Alers S, Dieterle AM, Keppeler H, Franz-Wachtel M, Kundu M, Campbell DG, Wesselborg S, Alessi DR, Stork B. Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. *Autophagy* 2011; 7:696-706; <http://dx.doi.org/10.4161/autophagy.7.7.15451>.
497. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. *Neurobiol Dis* 2007; 26:86-93; <http://dx.doi.org/10.1016/j.nbd.2006.12.003>.
498. Lavie G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. *J Biol Chem* 2006; 281:8518-27; <http://dx.doi.org/10.1074/jbc.M506182200>.
499. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Jr., Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. *Science* 1997; 277:99-101; <http://dx.doi.org/10.1126/science.277.5322.99>.
500. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. *Mol Cell* 2010; 38:768-74; <http://dx.doi.org/10.1016/j.molcel.2010.05.017>.
501. Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordini M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. *Nat Cell Biol* 2013; 15:406-16; <http://dx.doi.org/10.1038/ncb2708>.
502. Cheong H, Nair U, Geng J, Klionsky DJ. The Atg1 kinase complex is involved in the regulation of protein recruitment to initiate sequestering vesicle formation for nonspecific autophagy in *Saccharomyces cerevisiae*. *Mol Biol Cell* 2008; 19:668-81; <http://dx.doi.org/10.1091/mbc.E07-08-0826>.
503. Kabeya Y, Kamada Y, Baba M, Takikawa H, Sasaki M, Ohsumi Y. Atg17 functions in cooperation with Atg1 and Atg13 in yeast autophagy. *Mol Biol Cell* 2005; 16:2544-53; <http://dx.doi.org/10.1091/mbc.E04-08-0669>.
504. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1

- protein kinase complex. *J Cell Biol* 2000; 150:1507-13; <http://dx.doi.org/10.1083/jcb.150.6.1507>.
505. Scott SV, Nice DC, III, Nau JJ, Weisman LS, Kamada Y, Keizer-Gunnink I, Funakoshi T, Veenhuis M, Ohsumi Y, Klionsky DJ. Apg13p and Vac8p are part of a complex of phosphoproteins that are required for cytoplasm to vacuole targeting. *J Biol Chem* 2000; 275:25840-9; <http://dx.doi.org/10.1074/jbc.M002813200>.
  506. Miller-Fleming L, Cheong H, Antas P, Klionsky DJ. Detection of *Saccharomyces cerevisiae* Atg13 by western blot. *Autophagy* 2014; 10:514-7; <http://dx.doi.org/10.4161/auto.27707>.
  507. Yeh YY, Wrasman K, Herman PK. Autophosphorylation within the Atg1 activation loop is required for both kinase activity and the induction of autophagy in *Saccharomyces cerevisiae*. *Genetics* 2010; 185:871-82; <http://dx.doi.org/10.1534/genetics.110.116566>.
  508. Mao K, Wang K, Zhao M, Xu T, Klionsky DJ. Two MAPK-signaling pathways are required for mitophagy in *Saccharomyces cerevisiae*. *J Cell Biol* 2011; 193:755-67; <http://dx.doi.org/10.1083/jcb.201102092>.
  509. Kim M, Park HL, Park HW, Ro SH, Nam SG, Reed JM, Guan JL, Lee JH. *Drosophila* Fip200 is an essential regulator of autophagy that attenuates both growth and aging. *Autophagy* 2013; 9:1201-13; <http://dx.doi.org/10.4161/auto.24811>.
  510. Nagy P, Karpati M, Varga A, Piracs K, Venkei Z, Takats S, Varga K, Erdi B, Hegedus K, Juhasz G. Atg17/FIP200 localizes to perilyosomal Ref(2)P aggregates and promotes autophagy by activation of Atg1 in *Drosophila*. *Autophagy* 2014; 10:453-67; <http://dx.doi.org/10.4161/auto.27442>.
  511. Singh K, Matsuyama S, Drazba JA, Almasan A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. *Autophagy* 2012; 8:236-51.
  512. Shang L, Wang X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. *Autophagy* 2011; 7:924-6; <http://dx.doi.org/10.4161/auto.7.8.15860>.
  513. Ruck A, Attonito J, Garces KT, Nunez L, Palmisano NJ, Rubel Z, Bai Z, Nguyen KC, Sun L, Grant BD, et al. The Atg6/Vps30/Beclin 1 ortholog BEC-1 mediates endocytic retrograde transport in addition to autophagy in *C. elegans*. *Autophagy* 2011; 7:386-400; <http://dx.doi.org/10.4161/auto.7.4.14391>.
  514. Li W, Zou W, Yang Y, Chai Y, Chen B, Cheng S, Tian D, Wang X, Vale RD, Ou G. Autophagy genes function sequentially to promote apoptotic cell corpse degradation in the engulfing cell. *J Cell Biol* 2012; 197:27-35; <http://dx.doi.org/10.1083/jcb.201111053>.
  515. Abnave P, Mottola G, Gimenez G, Boucherit N, Trouplin V, Torre C, Conti F, Ben Amara A, Lepolard C, Djian B, et al. Screening in planarians identifies MORN2 as a key component in LC3-associated phagocytosis and resistance to bacterial infection. *Cell Host Microbe* 2014; 16:338-50; <http://dx.doi.org/10.1016/j.chom.2014.08.002>.
  516. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besancon F, Bauvy C, Souquere S, Pierron G, Codogno P. NF- $\kappa$ B activation represses tumor necrosis factor- $\alpha$ -induced autophagy. *J Biol Chem* 2006; 281:30373-82.
  517. Liu Z, Lenardo MJ. Reactive oxygen species regulate autophagy through redox-sensitive proteases. *Dev Cell* 2007; 12:484-5; <http://dx.doi.org/10.1016/j.devcel.2007.03.016>.
  518. Scarlatti F, Bauvy C, Ventruiti A, Sala G, Cluzeaud F, Vandewalle A, Ghidoni R, Codogno P. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. *J Biol Chem* 2004; 279:18384-91; <http://dx.doi.org/10.1074/jbc.M313561200>.
  519. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J* 2007; 26:1749-60; <http://dx.doi.org/10.1038/sj.emboj.7601623>.
  520. Cap M, Stepanek L, Harant K, Vachova L, Palkova Z. Cell differentiation within a yeast colony: metabolic and regulatory parallels with a tumor-affected organism. *Mol Cell* 2012; 46:436-48; <http://dx.doi.org/10.1016/j.molcel.2012.04.001>.
  521. Zeng X, Kinsella TJ. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. *Cancer Res* 2008; 68:2384-90; <http://dx.doi.org/10.1158/0008-5472.CAN-07-6163>.
  522. Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J, Levine B. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. *Science* 2012; 338:956-9; <http://dx.doi.org/10.1126/science.1225967>.
  523. Wei Y, Zou Z, Becker N, Anderson M, Sumpster R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell* 2013; 154:1269-84; <http://dx.doi.org/10.1016/j.cell.2013.08.015>.
  524. Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, Murakami T, Honda Y, Ichihara E, Tanimoto M, et al. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. *Exp Cell Res* 2014; 326:201-9; <http://dx.doi.org/10.1016/j.yexcr.2014.04.012>.
  525. Castets P, Lin S, Rion N, Di Fulvio S, Romanino K, Guridi M, Frank S, Tintignac LA, Sinnreich M, Ruedg MA. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. *Cell Metab* 2013; 17:731-44; <http://dx.doi.org/10.1016/j.cmet.2013.03.015>.
  526. Castets P, Ruedg MA. mTORC1 determines autophagy through ULK1 regulation in skeletal muscle. *Autophagy* 2013; 9:1435-7; <http://dx.doi.org/10.4161/auto.25722>.
  527. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. *Nature* 2010; 465:942-6; <http://dx.doi.org/10.1038/nature09076>.
  528. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN. Selective inhibition of IFN $\gamma$ -induced autophagy by Mir155- and Mir31-responsive WNT5A and SHH signaling. *Autophagy* 2014; 10:311-30; <http://dx.doi.org/10.4161/auto.27225>.
  529. Mochizuki H, Toda H, Ando M, Kurusu M, Tomoda T, Furukubo-Tokunaga K. Unc-51/ATG1 controls axonal and dendritic development via kinesin-mediated vesicle transport in the *Drosophila* brain. *PLoS One* 2011; 6:e19632; <http://dx.doi.org/10.1371/journal.pone.0019632>.
  530. Wairkar YP, Toda H, Mochizuki H, Furukubo-Tokunaga K, Tomoda T, Diantonio A. Unc-51 controls active zone density and protein composition by downregulating ERK signaling. *J Neurosci* 2009; 29:517-28; <http://dx.doi.org/10.1523/JNEUROSCI.3848-08.2009>.
  531. Loh SH, Francescut L, Lingor P, Bahr M, Nicotera P. Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. *Cell Death Differ* 2008; 15:283-98; <http://dx.doi.org/10.1038/sj.cdd.4402258>.
  532. Zhou X, Babu JR, da Silva S, Shu Q, Graef IA, Oliver T, Tomoda T, Tani T, Wooten MW, Wang F. Unc-51-like kinase 1/2-mediated endocytic processes regulate filopodia extension and branching of sensory axons. *Proc Natl Acad Sci USA* 2007; 104:5842-7; <http://dx.doi.org/10.1073/pnas.0701402104>.
  533. Tomoda T, Kim JH, Zhan C, Hatten ME. Role of Unc51.1 and its binding partners in CNS axon outgrowth. *Genes Dev* 2004; 18:541-58; <http://dx.doi.org/10.1101/gad.1151204>.
  534. Okazaki N, Yan J, Yuasa S, Ueno T, Kominami E, Masuho Y, Koga H, Muramatsu M. Interaction of the Unc-51-like kinase and microtubule-associated protein light chain 3 related proteins in the brain: possible role of vesicular transport in axonal elongation. *Mol Brain Res* 2000; 85:1-12; [http://dx.doi.org/10.1016/S0169-328X\(00\)00218-7](http://dx.doi.org/10.1016/S0169-328X(00)00218-7).
  535. Young ARJ, Chan EYW, Hu XW, Köchl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. *J Cell Sci* 2006; 119:3888-900; <http://dx.doi.org/10.1242/jcs.03172>.
  536. Reggiori F, Shintani T, Nair U, Klionsky DJ. Atg9 cycles between mitochondria and the pre-autophagosomal structure in yeasts. *Autophagy* 2005; 1:101-9; <http://dx.doi.org/10.4161/auto.1.2.1840>.

537. Mari M, Griffith J, Rieter E, Krishnappa L, Klionsky DJ, Reggiori F. An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis. *J Cell Biol* 2010; 190:1005-22; <http://dx.doi.org/10.1083/jcb.200912089>.
538. Reggiori F, Tucker KA, Stromhaug PE, Klionsky DJ. The Atg1-Atg13 complex regulates Atg9 and Atg23 retrieval transport from the pre-autophagosomal structure. *Dev Cell* 2004; 6:79-90; [http://dx.doi.org/10.1016/S1534-5807\(03\)00402-7](http://dx.doi.org/10.1016/S1534-5807(03)00402-7).
539. Mizushima N, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T, Natsume T, Ohsumi Y, Yoshimori T. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. *J Cell Sci* 2003; 116:1679-88; <http://dx.doi.org/10.1242/jcs.00381>.
540. Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. *J Cell Biol* 2001; 152:657-68; <http://dx.doi.org/10.1083/jcb.152.4.657>.
541. Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. *Cancer Cell* 2012; 21:532-46; <http://dx.doi.org/10.1016/j.ccr.2012.02.019>.
542. Thompson AR, Doelling JH, Suttangkakul A, Vierstra RD. Autophagic nutrient recycling in Arabidopsis directed by the ATG8 and ATG12 conjugation pathways. *Plant Phys* 2005; 138:2097-110; <http://dx.doi.org/10.1104/pp.105.060673>.
543. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. *Nat Cell Biol* 2006; 8:1124-32; <http://dx.doi.org/10.1038/ncb1482>.
544. Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon HU. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. *Nat Commun* 2013; 4:2130; <http://dx.doi.org/10.1038/ncomms3130>.
545. Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in *Saccharomyces cerevisiae*. *J Cell Biol* 2001; 152:519-30; <http://dx.doi.org/10.1083/jcb.152.3.519>.
546. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. *Nat Cell Biol* 2009; 11:385-96; <http://dx.doi.org/10.1038/ncb1846>.
547. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. *Nat Cell Biol* 2009; 11:468-76; <http://dx.doi.org/10.1038/ncb1854>.
548. Sun Q, Fan W, Chen K, Ding X, Chen S, Zhong Q. Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. *Proc Natl Acad Sci USA* 2008; 105:19211-6; <http://dx.doi.org/10.1073/pnas.0810452105>.
549. Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. *Mol Biol Cell* 2008; 19:5360-72; <http://dx.doi.org/10.1091/mbc.E08-01-0080>.
550. Fan W, Nassiri A, Zhong Q. Autophagosome targeting and membrane curvature sensing by Barkor/Atg14(L). *Proc Natl Acad Sci USA* 2011; 108:7769-74; <http://dx.doi.org/10.1073/pnas.1016472108>.
551. Matsunaga K, Morita E, Saitoh T, Akira S, Ktistakis NT, Izumi T, Noda T, Yoshimori T. Autophagy requires endoplasmic reticulum targeting of the PI3-kinase complex via Atg14L. *J Cell Biol* 2010; 190:511-21; <http://dx.doi.org/10.1083/jcb.200911141>.
552. Ravikumar B, Moreau K, Jahreiss L, Puri C, Rubinsztein DC. Plasma membrane contributes to the formation of pre-autophagosomal structures. *Nat Cell Biol* 2010; 12:747-57; <http://dx.doi.org/10.1038/ncb2078>.
553. Guan J, Stromhaug PE, George MD, Habibzadegah-Tari P, Bevan A, Dunn WA, Jr., Klionsky DJ. Cvt18/Gsa12 is required for cytoplasm-to-vacuole transport, pexophagy, and autophagy in *Saccharomyces cerevisiae* and *Pichia pastoris*. *Mol Biol Cell* 2001; 12:3821-38; <http://dx.doi.org/10.1091/mbc.12.12.3821>.
554. Barth H, Meiling-Wesse K, Epple UD, Thumm M. Autophagy and the cytoplasm to vacuole targeting pathway both require Aut10p. *FEBS Lett* 2001; 508:23-8; [http://dx.doi.org/10.1016/S0014-5793\(01\)03016-2](http://dx.doi.org/10.1016/S0014-5793(01)03016-2).
555. Proikas-Cezanne T, Waddell S, Gaugel A, Frickey T, Lupas A, Nordheim A. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. *Oncogene* 2004; 23:9314-25; <http://dx.doi.org/10.1038/sj.onc.1208331>.
556. Monastyrska I, Klionsky DJ. Autophagy in organelle homeostasis: peroxisome turnover. *Mol Aspects Med* 2006; 27:483-94; <http://dx.doi.org/10.1016/j.mam.2006.08.004>.
557. Nair U, Klionsky DJ. Molecular mechanisms and regulation of specific and nonspecific autophagy pathways in yeast. *J Biol Chem* 2005; 280:41785-8; <http://dx.doi.org/10.1074/jbc.R500016200>.
558. Tallóczy Z, Virgin HW, IV, Levine B. PKR-dependent autophagic degradation of herpes simplex virus type 1. *Autophagy* 2006; 2:24-9; <http://dx.doi.org/10.4161/auto.2176>.
559. Polson HE, de Lartigue J, Rigden DJ, Reedijk M, Urbe S, Clague MJ, Tooze SA. Mammalian Atg18 (WIPI2) localizes to omega-lysosome-anchored phagophores and positively regulates LC3 lipidation. *Autophagy* 2010; 6:506-22; <http://dx.doi.org/10.4161/auto.6.4.11863>.
560. Proikas-Cezanne T, Ruckerbauer S, Stierhof YD, Berg C, Nordheim A. Human WIPI-1 puncta-formation: A novel assay to assess mammalian autophagy. *FEBS Lett* 2007; 581:3396-404; <http://dx.doi.org/10.1016/j.febslet.2007.06.040>.
561. Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. *Autophagy* 2010; 6:764-76; <http://dx.doi.org/10.4161/auto.6.6.12709>.
562. Mauthe M, Jacob A, Freiberger S, Hentschel K, Stierhof YD, Codogno P, Proikas-Cezanne T. Resveratrol-mediated autophagy requires WIPI-1 regulated LC3 lipidation in the absence of induced phagophore formation. *Autophagy* 2011; 7:1448-61; <http://dx.doi.org/10.4161/auto.7.12.17802>.
563. Lu Q, Yang P, Huang X, Hu W, Guo B, Wu F, Lin L, Kovacs AL, Yu L, Zhang H. The WD40 repeat PtdIns(3)P-binding protein EPG-6 regulates progression of omegasomes to autophagosomes. *Dev Cell* 2011; 21:343-57; <http://dx.doi.org/10.1016/j.devcel.2011.06.024>.
564. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol* 2010; 22:124-31; <http://dx.doi.org/10.1016/j.ceb.2009.11.014>.
565. Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. *Cell Res* 2007; 17:839-49; <http://dx.doi.org/10.1038/cr.2007.78>.
566. Patingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 2005; 122:927-39; <http://dx.doi.org/10.1016/j.cell.2005.07.002>.
567. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M, Sabanay H, Pinkas-Kramarski R, Kimchi A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. *EMBO Rep* 2009; 10:285-92; <http://dx.doi.org/10.1038/embor.2008.246>.
568. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. *Autophagy* 2008; 4:949-51; <http://dx.doi.org/10.4161/auto.6788>.
569. Wei Y, Patingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol Cell* 2008; 30:678-88; <http://dx.doi.org/10.1016/j.molcel.2008.06.001>.
570. Lossi L, Gambino G, Ferrini F, Alasia S, Merighi A. Posttranslational regulation of BCL2 levels in cerebellar granule cells: A

- mechanism of neuronal survival. *Dev Neurobiol* 2009; 69:855-70; <http://dx.doi.org/10.1002/dneu.20744>.
571. Lossi L, Gambino G, Salio C, Merighi A. Autophagy regulates the post-translational cleavage of BCL-2 and promotes neuronal survival. *Sci World J* 2010; 10:924-9; <http://dx.doi.org/10.1100/tsw.2010.82>.
  572. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. *Cell Death Differ* 2008; 15:1318-29; <http://dx.doi.org/10.1038/cdd.2008.51>.
  573. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* 2011; 18:571-80; <http://dx.doi.org/10.1038/cdd.2010.191>.
  574. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. *EMBO Rep* 2001; 2:330-5; <http://dx.doi.org/10.1093/embo-reports/kve061>.
  575. Amritraj A, Peake K, Kodam A, Salio C, Merighi A, Vance JE, Kar S. Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. *Am J Pathol* 2009; 175:2540-56; <http://dx.doi.org/10.2353/ajpath.2009.081096>.
  576. Castino R, Bellio N, Follo C, Murphy D, Isidoro C. Inhibition of PI3k class III-dependent autophagy prevents apoptosis and necrosis by oxidative stress in dopaminergic neuroblastoma cells. *Toxicol Sci* 2010; 117:152-62; <http://dx.doi.org/10.1093/toxsci/kfq170>.
  577. Yue Z, Horton A, Bravin M, DeJager PL, Selimi F, Heintz N. A novel protein complex linking the delta 2 glutamate receptor and autophagy: implications for neurodegeneration in lurcher mice. *Neuron* 2002; 35:921-33; [http://dx.doi.org/10.1016/S0896-6273\(02\)00861-9](http://dx.doi.org/10.1016/S0896-6273(02)00861-9).
  578. Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. *Cell Death Differ* 2010; 17:268-77; <http://dx.doi.org/10.1038/cdd.2009.121>.
  579. Furuya N, Yu J, Byfield M, Pattingre S, Levine B. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. *Autophagy* 2005; 1:46-52; <http://dx.doi.org/10.4161/auto.1.1.1542>.
  580. Crichton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. *Cell* 2006; 126:121-34; <http://dx.doi.org/10.1016/j.cell.2006.05.034>.
  581. Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VPK1 by p53 in response to DNA damage is mediated by the autophagic pathway. *PLoS One* 2011; 6:e17320; <http://dx.doi.org/10.1371/journal.pone.0017320>.
  582. Lorin S, Pierron G, Ryan KM, Codogno P, Djavaheri-Mergny M. Evidence for the interplay between JNK and p53-DRAM signalling pathways in the regulation of autophagy. *Autophagy* 2010; 6:153-4; <http://dx.doi.org/10.4161/auto.6.1.10537>.
  583. Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, Griffiths G, Ktistakis NT. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. *J Cell Biol* 2008; 182:685-701; <http://dx.doi.org/10.1083/jcb.200803137>.
  584. Itakura E, Kishi-Itakura C, Mizushima N. The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. *Cell* 2012; 151:1256-69; <http://dx.doi.org/10.1016/j.cell.2012.11.001>.
  585. Takats S, Nagy P, Varga A, Piracs K, Karpati M, Varga K, Kovacs AL, Hegedus K, Juhasz G. Autophagosomal Syntaxin17-dependent lysosomal degradation maintains neuronal function in *Drosophila*. *J Cell Biol* 2013; 201:531-9; <http://dx.doi.org/10.1083/jcb.201211160>.
  586. Chen D, Zhong Q. A tethering coherent protein in autophagosome maturation. *Autophagy* 2012; 8:985-6; <http://dx.doi.org/10.4161/auto.20255>.
  587. Taniguchi M, Kitatani K, Kondo T, Hashimoto-Nishimura M, Asano S, Hayashi A, Mitsutake S, Igarashi Y, Umehara H, Takeya H, et al. Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. *J Biol Chem* 2012; 287:39898-910; <http://dx.doi.org/10.1074/jbc.M112.416552>.
  588. Justice MJ, Petrusca DN, Rogozea AL, Williams JA, Schweitzer KS, Petrache I, Wassall SR, Petrache HI. Effects of lipid interactions on model vesicle engulfment by alveolar macrophages. *Biophys J* 2014; 106:598-609; <http://dx.doi.org/10.1016/j.bpj.2013.12.036>.
  589. Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL. Ceramide starves cells to death by downregulating nutrient transporter proteins. *Proc Natl Acad Sci USA* 2008; 105:17402-7; <http://dx.doi.org/10.1073/pnas.0802781105>.
  590. Pattingre S, Bauvy C, Levade T, Levine B, Codogno P. Ceramide-induced autophagy: to junk or to protect cells? *Autophagy* 2009; 5:558-60; <http://dx.doi.org/10.4161/auto.5.4.8390>.
  591. Sentelle RD, Senkal CE, Jiang W, Ponnusamy S, Gencer S, Selvam SP, Ramsesh VK, Peterson YK, Lemasters JJ, Szulc ZM, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. *Nat Chem Biol* 2012; 8:831-8; <http://dx.doi.org/10.1038/nchembio.1059>.
  592. Jiang W, Ogretmen B. Ceramide stress in survival versus lethal autophagy paradox: ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. *Autophagy* 2013; 9:258-9; <http://dx.doi.org/10.4161/auto.22739>.
  593. Jiang W, Ogretmen B. Autophagy paradox and ceramide. *Biochim Biophys Acta* 2014; 1841:783-92; <http://dx.doi.org/10.1016/j.bbali.2013.09.005>.
  594. Lepine S, Allegood JC, Park M, Dent P, Milstien S, Spiegel S. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. *Cell Death Differ* 2011; 18:350-61; <http://dx.doi.org/10.1038/cdd.2010.104>.
  595. Matarrese P, Garofalo T, Manganelli V, Gambardella L, Marconi M, Grasso M, Tinari A, Misasi R, Malorni W, Sorice M. Evidence for the involvement of GD3 ganglioside in autophagosome formation and maturation. *Autophagy* 2014; 10:750-65; <http://dx.doi.org/10.4161/auto.27959>.
  596. Russ DW, Wills AM, Boyd IM, Krause J. Weakness, SR function and stress in gastrocnemius muscles of aged male rats. *Exp Gastroenterol* 2014; 50:40-4; <http://dx.doi.org/10.1016/j.exger.2013.11.018>.
  597. Bernard A, Jin M, Gonzalez-Rodriguez P, Fullgrabe J, Delorme-Axford E, Backues SK, Joseph B, Klionsky DJ. Rph1/KDM4 mediates nutrient-limitation signaling that leads to the transcriptional induction of autophagy. *Curr Biol* 2015; 25:546-55; <http://dx.doi.org/10.1016/j.cub.2014.12.049>.
  598. Bernard A, Klionsky DJ. Rph1 mediates the nutrient-limitation signaling pathway leading to transcriptional activation of autophagy. *Autophagy* 2015; 11:718-9; <http://dx.doi.org/10.1080/15548627.2015.1018503>.
  599. Nara A, Mizushima N, Yamamoto A, Kabeya Y, Ohsumi Y, Yoshimori T. SKD1 AAA ATPase-dependent endosomal transport is involved in autolysosome formation. *Cell Struct Funct* 2002; 27:29-37; <http://dx.doi.org/10.1247/csf.27.29>.
  600. Kirisako T, Baba M, Ishihara N, Miyazawa K, Ohsumi M, Yoshimori T, Noda T, Ohsumi Y. Formation process of autophagosome is traced with Apg8/Aut7p in yeast. *J Cell Biol* 1999; 147:435-46; <http://dx.doi.org/10.1083/jcb.147.2.435>.
  601. Jin M, He D, Backues SK, Freeberg MA, Liu X, Kim JK, Klionsky DJ. Transcriptional regulation by Pho23 modulates the frequency of autophagosome formation. *Curr Biol* 2014; 24:1314-22; <http://dx.doi.org/10.1016/j.cub.2014.04.048>.
  602. Kouroku Y, Fujita E, Tanida I, Ueno T, Isoai A, Kumagai H, Ogawa S, Kaufman RJ, Kominami E, Momoi T. ER stress (PERK/eIF2 [alpha] phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. *Cell Death Differ* 2007; 14:230-9; <http://dx.doi.org/10.1038/sj.cdd.4401984>.
  603. Xiong X, Tao R, DePinho RA, Dong XC. The autophagy-related gene 14 (Atg14) is regulated by forkhead box O transcription factors and circadian rhythms and plays a critical role in hepatic autophagy and lipid metabolism. *J Biol Chem* 2012; 287:39107-14; <http://dx.doi.org/10.1074/jbc.M112.412569>.

604. Moussay E, Kaoma T, Baginska J, Muller A, Van Moer K, Nicot N, Nazarov PV, Vallar L, Chouaib S, Berchem G, et al. The acquisition of resistance to TNF $\alpha$  in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. *Autophagy* 2011; 7:760-70; <http://dx.doi.org/10.4161/auto.7.7.15454>.
605. Mitroulis I, Kourtzelis I, Kambas K, Rafail S, Chrysanthopoulou A, Speletas M, Ritis K. Regulation of the autophagic machinery in human neutrophils. *Eur J Immunol* 2010; 40:1461-72; <http://dx.doi.org/10.1002/eji.200940025>.
606. Rodriguez-Muela N, Germain F, Marino G, Fitze PS, Boya P. Autophagy promotes survival of retinal ganglion cells after optic nerve axotomy in mice. *Cell Death Differ* 2012; 19:162-9; <http://dx.doi.org/10.1038/cdd.2011.88>.
607. Vázquez P, Arroba AI, Cecconi F, de la Rosa EJ, Boya P, De Pablo F. Atg5 and Ambra1 differentially modulate neurogenesis in neural stem cells. *Autophagy* 2012; 8:187-99.
608. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkoul K, Keulers T, Mujcic H, Landuyt W, Voncken JW, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. *J Clin Invest* 2010; 120:127-41; <http://dx.doi.org/10.1172/JCI40027>.
609. Haim Y, Blüher M, Slutsky N, Goldstein N, Klötting N, Harman-Boehm I, Kirshtein B, Ginsberg D, Gericke M, Jurado EG, et al. Elevated autophagy gene expression in adipose tissue of obese humans: A potential non-cell-cycle-dependent function of E2F1. *Autophagy* 2015; 11:2074-88.
610. Las G, Serada SB, Wikstrom JD, Twig G, Shirihai OS. Fatty acids suppress autophagic turnover in beta-cells. *J Biol Chem* 2011; 286:42534-44; <http://dx.doi.org/10.1074/jbc.M111.242412>.
611. Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoutte J, Hesselink MK, Paquet C, Delhay S, Shin Y, et al. Rev-erb- $\alpha$  modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. *Nat Med* 2013; 19:1039-46; <http://dx.doi.org/10.1038/nm.3213>.
612. Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, Moore DD. Nutrient-sensing nuclear receptors coordinate autophagy. *Nature* 2014; 516:112-5.
613. Seok S, Fu T, Choi SE, Li Y, Zhu R, Kumar S, Sun X, Yoon G, Kang Y, Zhong W, et al. Transcriptional regulation of autophagy by an FXR-CREB axis. *Nature* 2014; 516:108-11.
614. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. *Oncogene* 2008; 27:4860-4; <http://dx.doi.org/10.1038/onc.2008.117>.
615. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 pathway regulates autophagy. *Cancer Res* 2010; 70:7882-93; <http://dx.doi.org/10.1158/0008-5472.CAN-10-1604>.
616. Gorski SM, Chittaranjan S, Pleasance ED, Freeman JD, Anderson CL, Varhol RJ, Coughlin SM, Zuyderduyn SD, Jones SJ, Marra MA. A SAGE approach to discovery of genes involved in autophagic cell death. *Curr Biol* 2003; 13:358-63; [http://dx.doi.org/10.1016/S0960-9822\(03\)00082-4](http://dx.doi.org/10.1016/S0960-9822(03)00082-4).
617. Lee C-Y, Clough EA, Yellon P, Teslovich TM, Stephan DA, Baehrecke EH. Genome-wide analyses of steroid- and radiation-triggered programmed cell death in *Drosophila*. *Curr Biol* 2003; 13:350-7; [http://dx.doi.org/10.1016/S0960-9822\(03\)00085-X](http://dx.doi.org/10.1016/S0960-9822(03)00085-X).
618. Denton D, Shrivage B, Simin R, Baehrecke EH, Kumar S. Larval midgut destruction in *Drosophila*: not dependent on caspases but suppressed by the loss of autophagy. *Autophagy* 2010; 6:163-5; <http://dx.doi.org/10.4161/auto.6.1.10601>.
619. Franzetti E, Huang ZJ, Shi YX, Xie K, Deng XJ, Li JP, Li QR, Yang WY, Zeng WN, Casartelli M, et al. Autophagy precedes apoptosis during the remodeling of silkworm larval midgut. *Apoptosis* 2012; 17:305-24; <http://dx.doi.org/10.1007/s10495-011-0675-0>.
620. Tian L, Ma L, Guo E, Deng X, Ma S, Xia Q, Cao Y, Li S. 20-Hydroxyecdysone upregulates Atg genes to induce autophagy in the *Bombyx* fat body. *Autophagy* 2013; 9:1172-87; <http://dx.doi.org/10.4161/auto.24731>.
621. Juhasz G, Puskas LG, Komonyi O, Erdi B, Maroy P, Neufeld TP, Sass M. Gene expression profiling identifies FKBP39 as an inhibitor of autophagy in larval *Drosophila* fat body. *Cell Death Differ* 2007; 14:1181-90; <http://dx.doi.org/10.1038/sj.cdd.4402123>.
622. Erdi B, Nagy P, Zvara A, Varga A, Piracs K, Menesi D, Puskas LG, Juhasz G. Loss of the starvation-induced gene Rack1 leads to glycogen deficiency and impaired autophagic responses in *Drosophila*. *Autophagy* 2012; 8:1124-35; <http://dx.doi.org/10.4161/auto.20069>.
623. Barth JM, Szabad J, Hafen E, Kohler K. Autophagy in *Drosophila* ovaries is induced by starvation and is required for oogenesis. *Cell Death Differ* 2011; 18:915-24; <http://dx.doi.org/10.1038/cdd.2010.157>.
624. O'Rourke EJ, Ruvkun G. MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability. *Nat Cell Biol* 2013; 15:668-76; <http://dx.doi.org/10.1038/ncb2741>.
625. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vettrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, et al. TFEB links autophagy to lysosomal biogenesis. *Science* 2011; 332:1429-33; <http://dx.doi.org/10.1126/science.1204592>.
626. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *The FASEB J* 2004; 18:39-51; <http://dx.doi.org/10.1096/fj.03-0610com>.
627. Phillips AR, Suttangkakul A, Vierstra RD. The ATG12-conjugating enzyme ATG10 is essential for autophagic vesicle formation in *Arabidopsis thaliana*. *Genetics* 2008; 178:1339-53; <http://dx.doi.org/10.1534/genetics.107.086199>.
628. Seiliez I, Gutierrez J, Salmeron C, Skiba-Cassy S, Chauvin C, Dias K, Kaushik S, Tesseraud S, Panserat S. An in vivo and in vitro assessment of autophagy-related gene expression in muscle of rainbow trout (*Oncorhynchus mykiss*). *Comp Biochem Phys B* 2010; 157:258-66; <http://dx.doi.org/10.1016/j.cbpb.2010.06.011>.
629. Lapierre LR, De Magalhaes Filho CD, McQuary PR, Chu CC, Visvikis O, Chang JT, Gelino S, Ong B, Davis AE, Irazoqui JE, et al. The TFEB orthologue HLH-30 regulates autophagy and modulates longevity in *Caenorhabditis elegans*. *Nat Commun* 2013; 4:2267.
630. Sandri M. Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. *Am J Physiol Cell Physiol* 2010; 298:C1291-7; <http://dx.doi.org/10.1152/ajpcell.00531.2009>.
631. Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstein C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, et al. Induction of autophagy by spermidine promotes longevity. *Nat Cell Biol* 2009; 11:1305-14; <http://dx.doi.org/10.1038/ncb1975>.
632. Ropolo A, Grasso D, Pardo R, Sacchetti ML, Archange C, Lo Re A, Seux M, Nowak J, Gonzalez CD, Iovanna JL, et al. The pancreatitis-induced vacuole membrane protein 1 triggers autophagy in mammalian cells. *J Biol Chem* 2007; 282:37124-33; <http://dx.doi.org/10.1074/jbc.M706956200>.
633. Tian Y, Li Z, Hu W, Ren H, Tian E, Zhao Y, Lu Q, Huang X, Yang P, Li X, et al. *C. elegans* screen identifies autophagy genes specific to multicellular organisms. *Cell* 2010; 141:1042-55; <http://dx.doi.org/10.1016/j.cell.2010.04.034>.
634. Lo Re AE, Fernandez-Barrena MG, Almada LL, Mills LD, ElSawa SF, Lund G, Ropolo A, Molejon MI, Vaccaro MI, Fernandez-Zapico ME. Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells. *J Biol Chem* 2012; 287:25325-34; <http://dx.doi.org/10.1074/jbc.M112.370809>.
635. Sardiello M, Palmieri M, Di Ronza A, Medina DL, Valenza M, Genarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, et al. A gene network regulating lysosomal biogenesis and function. *Science* 2009; 325:473-7.
636. Palmieri M, Impey S, Kang H, Di Ronza A, Pelz C, Sardiello M, Ballabio A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. *Hum Mol Genet* 2011; 20:3852-66; <http://dx.doi.org/10.1093/hmg/ddr306>.
637. Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. *Autophagy* 2012; 8:903-14; <http://dx.doi.org/10.4161/auto.19653>.

638. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J* 2012; 31:1095-108; <http://dx.doi.org/10.1038/emboj.2012.32>.
639. Nezich CL, Wang C, Fogel AI, Youle RJ. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. *J Cell Biol* 2015; 210:435-50; <http://dx.doi.org/10.1083/jcb.201501002>.
640. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. *Nature* 2015; 524:361-5; <http://dx.doi.org/10.1038/nature14587>.
641. Kang YA, Sanalkumar R, O'Geen H, Linnemann AK, Chang CJ, Bouhassira EE, Farnham PJ, Keles S, Bresnick EH. Autophagy driven by a master regulator of hematopoiesis. *Mol Cell Biol* 2012; 32:226-39; <http://dx.doi.org/10.1128/MCB.06166-11>.
642. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. *Cell Metab* 2007; 6:472-83; <http://dx.doi.org/10.1016/j.cmet.2007.11.004>.
643. Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. *Mol Cell* 2013; 50:16-28; <http://dx.doi.org/10.1016/j.molcel.2013.01.024>.
644. Ma D, Panda S, Lin JD. Temporal orchestration of circadian autophagy rhythm by C/EBP $\beta$ . *EMBO J* 2011; 30:4642-51.
645. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hebuterne X, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. *Nat Genet* 2011; 43:242-5; <http://dx.doi.org/10.1038/ng.762>.
646. Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM, Taskesen E, Stern P, de Ru AH, van Adrichem AJ, et al. MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. *Blood* 2011; 118:916-25; <http://dx.doi.org/10.1182/blood-2011-02-336487>.
647. Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenström macroglobulinemia. *Blood* 2010; 116:1506-14; <http://dx.doi.org/10.1182/blood-2010-01-265686>.
648. Martinet W, De Meyer GR, Andries L, Herman AG, Kockx MM. In situ detection of starvation-induced autophagy. *J Histochem Cytochem* 2006; 54:85-96; <http://dx.doi.org/10.1369/jhc.5A6743.2005>.
649. Banreti A, Sass M, Graba Y. The emerging role of acetylation in the regulation of autophagy. *Autophagy* 2013; 9:819-29; <http://dx.doi.org/10.4161/auto.23908>.
650. Jin M, Klionsky DJ. Regulation of autophagy: Modulation of the size and number of autophagosomes. *FEBS Lett* 2014; 588:2457-63; <http://dx.doi.org/10.1016/j.febslet.2014.06.015>.
651. Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. *Trends Cell Biology* 2015; 25:354-63; <http://dx.doi.org/10.1016/j.tcb.2015.02.002>.
652. Xie Y, Kang R, Sun X, Zhong M, Huang J, Klionsky DJ, Tang D. Posttranslational modification of autophagy-related proteins in macroautophagy. *Autophagy* 2015; 11:28-45; <http://dx.doi.org/10.4161/15548627.2014.984267>.
653. Pietrocola F, Marino G, Lissa D, Vacchelli E, Malik SA, Niso-Santano M, Zamzami N, Galluzzi L, Maiuri MC, Kroemer G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. *Cell Cycle* 2012; 11:3851-60; <http://dx.doi.org/10.4161/cc.22027>.
654. Mariño G, Pietrocola F, Madeo F, Kroemer G. Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers. *Autophagy*. 2014;10:1879-82. doi: 10.4161/auto.36413.
655. Madeo F, Pietrocola F, Eisenberg T, Kroemer G. Caloric restriction mimetics: towards a molecular definition. *Nat Rev Drug Discov* 2014; 13:727-40; <http://dx.doi.org/10.1038/nrd4391>.
656. Lee IH, Finkel T. Regulation of autophagy by the p300 acetyltransferase. *J Biol Chem* 2009; 284:6322-8; <http://dx.doi.org/10.1074/jbc.M807135200>.
657. Huang R, Xu Y, Wan W, Shou X, Qian J, You Z, Liu B, Chang C, Zhou T, Lippincott-Schwartz J, et al. Deacetylation of Nuclear LC3 Drives Autophagy Initiation under Starvation. *Mol Cell* 2015.
658. Pattingre S, Petiot A, Codogno P. Analyses of G[a]-interacting protein and activator of G-protein-signaling-3 functions in macroautophagy. *Methods Enzymol* 2004; 390:17-31; [http://dx.doi.org/10.1016/S0076-6879\(04\)90002-X](http://dx.doi.org/10.1016/S0076-6879(04)90002-X).
659. Bauvy C, Meijer AJ, Codogno P. Assaying of autophagic protein degradation. *Methods Enzymol* 2009; 452:47-61; [http://dx.doi.org/10.1016/S0076-6879\(08\)03604-5](http://dx.doi.org/10.1016/S0076-6879(08)03604-5).
660. Zhang J, Wang J, Ng S, Lin Q, Shen HM. Development of a novel method for quantification of autophagic protein degradation by AHA labeling. *Autophagy* 2014; 10:901-12; <http://dx.doi.org/10.4161/auto.28267>.
661. Ichimura Y, Kumanomidou T, Sou YS, Mizushima T, Ezaki J, Ueno T, Kominami E, Yamane T, Tanaka K, Komatsu M. Structural basis for sorting mechanism of p62 in selective autophagy. *J Biol Chem* 2008; 283:22847-57; <http://dx.doi.org/10.1074/jbc.M802182200>.
662. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. *J Biol Chem* 2008; 283:23731-8; <http://dx.doi.org/10.1074/jbc.M801918200>.
663. Saitoh Y, Fujikake N, Okamoto Y, Popiel HA, Hatanaka Y, Ueyama M, Suzuki M, Gaumer S, Murata M, Wada K, et al. p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies. *J Biol Chem* 2015; 290:1442-53; <http://dx.doi.org/10.1074/jbc.M114.590281>.
664. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. *Am J Pathol* 2007; 171:513-24; <http://dx.doi.org/10.2353/ajpath.2007.070188>.
665. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. *J Biol Chem* 2005; 280:40282-92; <http://dx.doi.org/10.1074/jbc.M508786200>.
666. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. *Nature* 2007; 447:859-63; <http://dx.doi.org/10.1038/nature05853>.
667. Tomek K, Wagner R, Varga F, Singer CF, Karlic H, Grunt TW. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. *Mol Cancer Res* 2011;1767-79; <http://dx.doi.org/10.1158/1541-7786.MCR-10-0467>.
668. Zimmermann AC, Zarei M, Eiselein S, Dengjel J. Quantitative proteomics for the analysis of spatio-temporal protein dynamics during autophagy. *Autophagy* 2010; 6:1009-16; <http://dx.doi.org/10.4161/auto.6.8.12786>.
669. Kristensen AR, Schandorff S, Hoyer-Hansen M, Nielsen MO, Jaatela M, Dengjel J, Andersen JS. Ordered organelle degradation during starvation-induced autophagy. *Mol Cell Proteomics: MCP* 2008; 7:2419-28; <http://dx.doi.org/10.1074/mcp.M800184-MCP200>.
670. Furuya N, Kanazawa T, Fujimura S, Ueno T, Kominami E, Kadowaki M. Leupeptin-induced appearance of partial fragment of betaine homocysteine methyltransferase during autophagic maturation in rat hepatocytes. *J Biochem (Tokyo)* 2001; 129:313-20; <http://dx.doi.org/10.1093/oxfordjournals.jbchem.a002859>.
671. Ueno T, Ishidoh K, Mineki R, Tanida I, Murayama K, Kadowaki M, Kominami E. Autolysosomal membrane-associated betaine homocysteine methyltransferase. Limited degradation fragment of a

- sequestered cytosolic enzyme monitoring autophagy. *J Biol Chem* 1999; 274:15222-9; <http://dx.doi.org/10.1074/jbc.274.21.15222>.
672. Overbye A, Saetre F, Hagen LK, Johansen HT, Seglen PO. Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain. *Autophagy* 2011; 7:1011-27; <http://dx.doi.org/10.4161/auto.7.9.16436>.
673. Seglen PO, Overbye A, Saetre F. Sequestration assays for mammalian autophagy. *Methods Enzymol* 2009; 452:63-83; [http://dx.doi.org/10.1016/S0076-6879\(08\)03605-7](http://dx.doi.org/10.1016/S0076-6879(08)03605-7).
674. Mercer CA, Kaliappan A, Dennis PB. Macroautophagy-dependent, intralysosomal cleavage of a betaine homocysteine methyltransferase fusion protein requires stable multimerization. *Autophagy* 2008; 4:185-94; <http://dx.doi.org/10.4161/auto.5275>.
675. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. *Eur J Immunol* 2003; 33:1250-9; <http://dx.doi.org/10.1002/eji.200323730>.
676. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. *J Immunol* 2006; 177:3746-56; <http://dx.doi.org/10.4049/jimmunol.177.6.3746>.
677. Klionsky DJ, Emr SD. Membrane protein sorting: biosynthesis, transport and processing of yeast vacuolar alkaline phosphatase. *EMBO J* 1989; 8:2241-50.
678. Venerando R, Miotto G, Kadowaki M, Siliprandi N, Mortimore GE. Multiphasic control of proteolysis by leucine and alanine in the isolated rat hepatocyte. *Am J Physiol* 1994; 266:C455-61.
679. Häussinger D, Hallbrucker C, vom Dahl S, Lang F, Gerok W. Cell swelling inhibits proteolysis in perfused rat liver. *Biochem J* 1990; 272:239-42; <http://dx.doi.org/10.1042/bj2720239>.
680. vom Dahl S, Häussinger D. Cell hydration and proteolysis control in liver. *Biochem J* 1995; 312:988-9; <http://dx.doi.org/10.1042/bj3120988>.
681. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, Pallanck LJ. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. *Proc Natl Acad Sci USA* 2013; 110:6400-5; <http://dx.doi.org/10.1073/pnas.1221132110>.
682. Reggiori F, Monastyrska I, Shintani T, Klionsky DJ. The actin cytoskeleton is required for selective types of autophagy, but not non-specific autophagy, in the yeast *Saccharomyces cerevisiae*. *Mol Biol Cell* 2005; 16:5843-56; <http://dx.doi.org/10.1091/mbc.E05-07-0629>.
683. Manjithaya R, Jain S, Farre JC, Subramani S. A yeast MAPK cascade regulates pexophagy but not other autophagy pathways. *J Cell Biol* 2010; 189:303-10; <http://dx.doi.org/10.1083/jcb.200909154>.
684. Journo D, Mor A, Abeliovich H. Aup1-mediated regulation of Rtg3 during mitophagy. *J Biol Chem* 2009; 284:35885-95; <http://dx.doi.org/10.1074/jbc.M109.048140>.
685. Kanki T, Klionsky DJ. Mitophagy in yeast occurs through a selective mechanism. *J Biol Chem* 2008; 283:32386-93; <http://dx.doi.org/10.1074/jbc.M802403200>.
686. Kanki T, Wang K, Baba M, Bartholomew CR, Lynch-Day MA, Du Z, Geng J, Mao K, Yang Z, Yen WL, et al. A genomic screen for yeast mutants defective in selective mitochondria autophagy. *Mol Biol Cell* 2009; 20:4730-8; <http://dx.doi.org/10.1091/mbc.E09-03-0225>.
687. Kanki T, Wang K, Cao Y, Baba M, Klionsky DJ. Atg32 is a mitochondrial protein that confers selectivity during mitophagy. *Dev Cell* 2009; 17:98-109; <http://dx.doi.org/10.1016/j.devcel.2009.06.014>.
688. Okamoto K, Kondo-Okamoto N, Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. *Dev Cell* 2009; 17:87-97; <http://dx.doi.org/10.1016/j.devcel.2009.06.013>.
689. Sakai Y, Koller A, Rangell LK, Keller GA, Subramani S. Peroxisome degradation by microautophagy in *Pichia pastoris*: identification of specific steps and morphological intermediates. *J Cell Biol* 1998; 141:625-36; <http://dx.doi.org/10.1083/jcb.141.3.625>.
690. Nazarko TY, Nicaud JM, Sibirny AA. Observation of the *Yarrowia lipolytica* peroxisome-vacuole dynamics by fluorescence microscopy with a single filter set. *Cell Biol Int* 2005; 29:65-70; <http://dx.doi.org/10.1016/j.cellbi.2004.11.014>.
691. Roetzer A, Gratz N, Kovarik P, Schuller C. Autophagy supports *Candida glabrata* survival during phagocytosis. *Cell Microbiol* 2010; 12:199-216; <http://dx.doi.org/10.1111/j.1462-5822.2009.01391.x>.
692. Bormann C, Sahn H. Degradation of microbodies in relation to activities of alcohol oxidase and catalase in *Candida boidinii*. *Arch Microbiol* 1978; 117:67-72; <http://dx.doi.org/10.1007/BF00689353>.
693. Clare DA, Duong MN, Darr D, Archibald F, Fridovich I. Effects of molecular oxygen on detection of superoxide radical with nitroblue tetrazolium and on activity stains for catalase. *Anal Biochem* 1984; 140:532-7; [http://dx.doi.org/10.1016/0003-2697\(84\)90204-5](http://dx.doi.org/10.1016/0003-2697(84)90204-5).
694. Vachova L, Kucerova H, Devaux F, Ulehlova M, Palkova Z. Metabolic diversification of cells during the development of yeast colonies. *Environ Microbiol* 2009; 11:494-504; <http://dx.doi.org/10.1111/j.1462-2920.2008.01789.x>.
695. Stasyk OV, Nazarko TY, Sibirny AA. Methods of plate pexophagy monitoring and positive selection for ATG gene cloning in yeasts. *Methods Enzymol* 2008; 451:229-39; [http://dx.doi.org/10.1016/S0076-6879\(08\)03216-3](http://dx.doi.org/10.1016/S0076-6879(08)03216-3).
696. Hutchins MU, Veenhuis M, Klionsky DJ. Peroxisome degradation in *Saccharomyces cerevisiae* is dependent on machinery of macroautophagy and the Cvt pathway. *J Cell Sci* 1999; 112:4079-87.
697. Mukaiyama H, Oku M, Baba M, Samizo T, Hammond AT, Glick BS, Kato N, Sakai Y. Paz2 and 13 other PAZ gene products regulate vacuolar engulfment of peroxisomes during micro-pexophagy. *Genes Cells* 2002; 7:75-90; <http://dx.doi.org/10.1046/j.1356-9597.2001.00499.x>.
698. Tuttle DL, Dunn WA, Jr. Divergent modes of autophagy in the methylotrophic yeast *Pichia pastoris*. *J Cell Sci* 1995; 108 (Pt 1): 25-35.
699. Nazarko TY, Huang J, Nicaud JM, Klionsky DJ, Sibirny AA. Trs85 is required for macroautophagy, pexophagy and cytoplasm to vacuole targeting in *Yarrowia lipolytica* and *Saccharomyces cerevisiae*. *Autophagy* 2005; 1:37-45; <http://dx.doi.org/10.4161/auto.1.1.1512>.
700. Veenhuis M, Douma A, Harder W, Osumi M. Degradation and turnover of peroxisomes in the yeast *Hansenula polymorpha* induced by selective inactivation of peroxisomal enzymes. *Arch Microbiol* 1983; 134:193-203; <http://dx.doi.org/10.1007/BF00407757>.
701. Monosov EZ, Wenzel TJ, Luers GH, Heyman JA, Subramani S. Labeling of peroxisomes with green fluorescent protein in living *P. pastoris* cells. *J Histochem Cytochem* 1996; 44:581-9; <http://dx.doi.org/10.1177/44.6.8666743>.
702. Wiemer EA, Wenzel T, Deerinck TJ, Ellisman MH, Subramani S. Visualization of the peroxisomal compartment in living mammalian cells: dynamic behavior and association with microtubules. *J Cell Biol* 1997; 136:71-80; <http://dx.doi.org/10.1083/jcb.136.1.71>.
703. Monastyrska I, van der Heide M, Krikken AM, Kiel JAKW, van der Klei IJ, Veenhuis M. Atg8 is essential for macropexophagy in *Hansenula polymorpha*. *Traffic* 2005; 6:66-74; <http://dx.doi.org/10.1111/j.1600-0854.2004.00252.x>.
704. Devenish RJ, Prescott M, Turcic K, Mijaljica D. Monitoring organelle turnover in yeast using fluorescent protein tags. *Methods Enzymol* 2008; 451:109-31; [http://dx.doi.org/10.1016/S0076-6879\(08\)03209-6](http://dx.doi.org/10.1016/S0076-6879(08)03209-6).
705. Mao K, Wang K, Liu X, Klionsky DJ. The scaffold protein Atg11 recruits fission machinery to drive selective mitochondria degradation by autophagy. *Dev Cell* 2013; 26:9-18; <http://dx.doi.org/10.1016/j.devcel.2013.05.024>.
706. Kerppola TK. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. *Nature Protocols* 2006; 1:1278-86; <http://dx.doi.org/10.1038/nprot.2006.201>.
707. Shyu YJ, Liu H, Deng X, Hu CD. Identification of new fluorescent protein fragments for bimolecular fluorescence complementation analysis under physiological conditions. *BioTechniques* 2006; 40:61-6; <http://dx.doi.org/10.2144/000112036>.

708. Farre JC, Manjithaya R, Mathewson RD, Subramani S. PpAtg30 tags peroxisomes for turnover by selective autophagy. *Dev Cell* 2008; 14:365-76; <http://dx.doi.org/10.1016/j.devcel.2007.12.011>.
709. He Y, Deng YZ, Naqvi NI. Atg24-assisted mitophagy in the foot cells is necessary for proper asexual differentiation in *Magnaporthe oryzae*. *Autophagy* 2013; 9:1818-27; <http://dx.doi.org/10.4161/auto.26057>.
710. Kanki T, Klionsky DJ. The molecular mechanism of mitochondria autophagy in yeast. *Mol Microbiol* 2010; 75:795-800; <http://dx.doi.org/10.1111/j.1365-2958.2009.07035.x>.
711. Tal R, Winter G, Ecker N, Klionsky DJ, Abeliovich H. Aup1p, a yeast mitochondrial protein phosphatase homolog, is required for efficient stationary phase mitophagy and cell survival. *J Biol Chem* 2007; 282:5617-24; <http://dx.doi.org/10.1074/jbc.M605940200>.
712. Abeliovich H. Stationary-phase mitophagy in respiring *Saccharomyces cerevisiae*. *Antioxid Redox Sign* 2011; 14:2003-11; <http://dx.doi.org/10.1089/ars.2010.3807>.
713. East DA, Fagiani F, Crosby J, Georgakopoulos ND, Bertrand H, Schaap M, Fowkes A, Wells J, Campanella M. PMI: a DeltaPsm independent pharmacological regulator of mitophagy. *Chem Biol* 2014; 21:1585-96; <http://dx.doi.org/10.1016/j.chembiol.2014.09.019>.
714. Aksam EB, Koek A, Kiel JAKW, Jourdan S, Veenhuis M, van der Klei IJ. A peroxisomal lon protease and peroxisome degradation by autophagy play key roles in vitality of *Hansenula polymorpha* cells. *Autophagy* 2007; 3:96-105; <http://dx.doi.org/10.4161/auto.3534>.
715. Roberts P, Moshitch-Moshkovitz S, Kvam E, O'Toole E, Winey M, Goldfarb DS. Piecemeal microautophagy of nucleus in *Saccharomyces cerevisiae*. *Mol Biol Cell* 2003; 14:129-41; <http://dx.doi.org/10.1091/mbc.E02-08-0483>.
716. Krick R, Muehe Y, Prick T, Bremer S, Schlotterhose P, Eskelinen EL, Millen J, Goldfarb DS, Thumm M. Piecemeal microautophagy of the nucleus requires the core macroautophagy genes. *Mol Biol Cell* 2008; 19:4492-505; <http://dx.doi.org/10.1091/mbc.E08-04-0363>.
717. Farre JC, Krick R, Subramani S, Thumm M. Turnover of organelles by autophagy in yeast. *Curr Opin Cell Biol* 2009; 21:522-30; <http://dx.doi.org/10.1016/j.ceb.2009.04.015>.
718. Kvam E, Goldfarb DS. Structure and function of nucleus-vacuole junctions: outer-nuclear-membrane targeting of Nvj1p and a role in tryptophan uptake. *J Cell Sci* 2006; 119:3622-33; <http://dx.doi.org/10.1242/jcs.03093>.
719. Millen JI, Krick R, Prick T, Thumm M, Goldfarb DS. Measuring piecemeal microautophagy of the nucleus in *Saccharomyces cerevisiae*. *Autophagy* 2009; 5:75-81; <http://dx.doi.org/10.4161/auto.5.1.7181>.
720. Mijaljica D, Prescott M, Devenish RJ. A late form of nucleophagy in *Saccharomyces cerevisiae*. *PloS One* 2012; 7:e40013.
721. Shoji JY, Kikuma T, Arioka M, Kitamoto K. Macroautophagy-mediated degradation of whole nuclei in the filamentous fungus *Aspergillus oryzae*. *PloS One* 2010; 5:e15650; <http://dx.doi.org/10.1371/journal.pone.0015650>.
722. Shoji J-Y, Kikuma T, Arioka M, Kitamoto K. Macroautophagy-mediated degradation of whole nuclei in the filamentous fungus *Aspergillus oryzae*. *PloS One* 2010; 5:e15650; <http://dx.doi.org/10.1371/journal.pone.0015650>.
723. He M, Kershaw MJ, Soanes DM, Xia Y, Talbot NJ. Infection-associated nuclear degeneration in the rice blast fungus *Magnaporthe oryzae* requires non-selective macro-autophagy. *PloS One* 2012; 7:e33270; <http://dx.doi.org/10.1371/journal.pone.0033270>.
724. Maheshwari R. Nuclear behavior in fungal hyphae. *FEMS Microbiol Lett* 2005; 249:7-14; <http://dx.doi.org/10.1016/j.femsle.2005.06.031>.
725. Shoji J-Y, Craven KD. Autophagy in basal hyphal compartments: A green strategy of great recyclers. *Fungal Biol Rev* 2011; 25:79-83; <http://dx.doi.org/10.1016/j.fbr.2011.04.001>.
726. Voigt O, Poggeler S. Autophagy genes Smatg8 and Smatg4 are required for fruiting-body development, vegetative growth and ascospore germination in the filamentous ascomycete *Sordaria macrospora*. *Autophagy* 2013; 9:33-49; <http://dx.doi.org/10.4161/auto.22398>.
727. Yorimitsu T, Klionsky DJ. Atg11 links cargo to the vesicle-forming machinery in the cytoplasm to vacuole targeting pathway. *Mol Biol Cell* 2005; 16:1593-605; <http://dx.doi.org/10.1091/mbc.E04-11-1035>.
728. Shintani T, Huang W-P, Stromhaug PE, Klionsky DJ. Mechanism of cargo selection in the cytoplasm to vacuole targeting pathway. *Dev Cell* 2002; 3:825-37; [http://dx.doi.org/10.1016/S1534-5807\(02\)00373-8](http://dx.doi.org/10.1016/S1534-5807(02)00373-8).
729. Abeliovich H, Darsow T, Emr SD. Cytoplasm to vacuole trafficking of aminopeptidase I requires a t-SNARE-Sec1p complex composed of Tlg2p and Vps45p. *EMBO J* 1999; 18:6005-16; <http://dx.doi.org/10.1093/emboj/18.21.6005>.
730. Abeliovich H, Zarei M, Rigbolt KT, Youle RJ, Dengjel J. Involvement of mitochondrial dynamics in the segregation of mitochondrial matrix proteins during stationary phase mitophagy. *Nat Commun* 2013; 4:2789; <http://dx.doi.org/10.1038/ncomms3789>.
731. Overbye A, Fengsrud M, Seglen PO. Proteomic analysis of membrane-associated proteins from rat liver autophagosomes. *Autophagy* 2007; 3:300-22; <http://dx.doi.org/10.4161/auto.3910>.
732. Petroi D, Popova B, Taheri-Talesh N, Irmiger S, Shahpasandzadeh H, Zweckstetter M, Outeiro TF, Braus GH. Aggregate clearance of alpha-synuclein in *Saccharomyces cerevisiae* depends more on autophagosome and vacuole function than on the proteasome. *J Biol Chem* 2012; 287:27567-79; <http://dx.doi.org/10.1074/jbc.M112.361865>.
733. Shahpasandzadeh H, Popova B, Kleinknecht A, Fraser PE, Outeiro TF, Braus GH. Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. *J Biol Chem* 2014; 289:31224-40; <http://dx.doi.org/10.1074/jbc.M114.559237>.
734. Wafa K, MacLean J, Zhang F, Pasumarthi KB. Characterization of growth suppressive functions of a splice variant of cyclin D2. *PloS One* 2013; 8:e53503; <http://dx.doi.org/10.1371/journal.pone.0053503>.
735. Ju JS, Miller SE, Jackson E, Cadwell K, Piwnica-Worms D, Wehl CC. Quantitation of selective autophagic protein aggregate degradation in vitro and in vivo using luciferase reporters. *Autophagy* 2009; 5:511-9; <http://dx.doi.org/10.4161/auto.5.4.7761>.
736. Hohn A, Sittig A, Jung T, Grimm S, Grune T. Lipofuscin is formed independently of macroautophagy and lysosomal activity in stress-induced prematurely senescent human fibroblasts. *Free Radical Bio Med* 2012; 53:1760-9; <http://dx.doi.org/10.1016/j.freeradbiomed.2012.08.591>.
737. Jung T, Hohn A, Catalgol B, Grune T. Age-related differences in oxidative protein-damage in young and senescent fibroblasts. *Arch Biochem Biophys* 2009; 483:127-35; <http://dx.doi.org/10.1016/j.abb.2008.12.007>.
738. Fuentelba RA, Marasa J, Diamond MI, Piwnica-Worms D, Wehl CC. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. *Hum Mol Genet* 2012; 21:664-80.
739. Al Rawi S, Louvet-Vallée S, Djeddi A, Sachse M, Culetto E, Hajjar C, Boyd L, Legouis R, Galy V. Allophagy: A macroautophagic process degrading spermatozoid-inherited organelles. *Autophagy* 2012; 8:421-3.
740. Sato M, Sato K. Maternal inheritance of mitochondrial DNA: Degradation of paternal mitochondria by allogeneic organelle autophagy, allophagy. *Autophagy* 2012; 8:424-5.
741. Al Rawi S, Louvet-Vallee S, Djeddi A, Sachse M, Culetto E, Hajjar C, Boyd L, Legouis R, Galy V. Postfertilization autophagy of sperm organelles prevents paternal mitochondrial DNA transmission. *Science* 2011; 334:1144-7.
742. Sato M, Sato K. Degradation of paternal mitochondria by fertilization-triggered autophagy in *C. elegans* embryos. *Science* 2011; 334:1141-4; <http://dx.doi.org/10.1126/science.1210333>.
743. Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. *Biol Chem* 2012; 393:547-64.
744. Fiesel FC, Ando M, Hudec R, Hill AR, Castanedes-Casey M, Caulfield TR, Moussaoui-Lamodiere EL, Stankowski JN, Bauer PO, Lorenzo-Betancor O, et al. (Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *EMBO Rep* 2015.
745. Herhaus L, Dikic I. Expanding the ubiquitin code through post-translational modification. *EMBO Rep* 2015.



746. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature* 2014; 510:162-6.
747. Ding WX, Li M, Chen X, Ni HM, Lin CW, Gao W, Lu B, Stolz DB, Clemens DL, Yin XM. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. *Gastroenterology* 2010; 139:1740-52; <http://dx.doi.org/10.1053/j.gastro.2010.07.041>.
748. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. *Arch Biochem Biophys* 2007; 462:245-53; <http://dx.doi.org/10.1016/j.abb.2007.03.034>.
749. Dong H, Cheung SH, Liang Y, Wang B, Ramalingam R, Wang P, Sun H, Cheng SH, Lam YW. "Stainomics": identification of mitotracker labeled proteins in mammalian cells. *Electrophoresis* 2013; 34:1957-64; <http://dx.doi.org/10.1002/elps.201200557>.
750. Mauro-Lizcano M, Esteban-Martinez L, Seco E, Serrano-Puebla A, Garcia-Ledo L, Figueiredo-Pereira C, Vieira HL, Boya P. New method to assess mitophagy flux by flow cytometry. *Autophagy* 2015; 11:833-43; <http://dx.doi.org/10.1080/15548627.2015.1034403>.
751. Presley AD, Fuller KM, Arriaga EA. MitoTracker Green labeling of mitochondrial proteins and their subsequent analysis by capillary electrophoresis with laser-induced fluorescence detection. *J Chromatogr B, Analytical technologies in the biomedical and life sciences* 2003; 793:141-50; [http://dx.doi.org/10.1016/S1570-0232\(03\)00371-4](http://dx.doi.org/10.1016/S1570-0232(03)00371-4).
752. Keij JF, Bell-Prince C, Steinkamp JA. Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. *Cytometry* 2000; 39:203-10; [http://dx.doi.org/10.1002/\(SICI\)1097-0320\(20000301\)39:3<203::AID-CYTO5>3.0.CO;2-Z](http://dx.doi.org/10.1002/(SICI)1097-0320(20000301)39:3<203::AID-CYTO5>3.0.CO;2-Z).
753. Poot M, Zhang YZ, Kramer JA, Wells KS, Jones LJ, Hanzel DK, Lugade AG, Singer VL, Haugland RP. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. *J Histochem Cytochem* 1996; 44:1363-72; <http://dx.doi.org/10.1177/44.12.8985128>.
754. Geisler S, Holmstrom KM, Treis A, Skujat D, Weber SS, Fiesel FC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations. *Autophagy* 2010; 6:871-8; <http://dx.doi.org/10.4161/auto.6.7.13286>.
755. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* 2010; 12:119-31; <http://dx.doi.org/10.1038/ncb2012>.
756. Diot A, Hinks-Roberts A, Lodge T, Liao C, Dombi E, Morten K, Brady S, Fratter C, Carver J, Muir R, et al. A novel quantitative assay of mitophagy: Combining high content fluorescence microscopy and mitochondrial DNA load to quantify mitophagy and identify novel pharmacological tools against pathogenic heteroplasmic mtDNA. *Pharmacol Res* 2015; 100:24-35; <http://dx.doi.org/10.1016/j.phrs.2015.07.014>.
757. Dagda RK, Cherra SJ, III, Kulich SM, Tandon A, Park D, Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. *J Biol Chem* 2009; 284:13843-55; <http://dx.doi.org/10.1074/jbc.M808515200>.
758. Dagda RK, Zhu J, Kulich SM, Chu CT. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. *Autophagy* 2008; 4:770-82; <http://dx.doi.org/10.4161/auto.6458>.
759. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, et al. Inhibition of macroautophagy triggers apoptosis. *Mol Cell Biol* 2005; 25:1025-40; <http://dx.doi.org/10.1128/MCB.25.3.1025-1040.2005>.
760. Katayama H, Kogure T, Mizushima N, Yoshimori T, Miyawaki A. A sensitive and quantitative technique for detecting autophagic events based on lysosomal delivery. *Chem Biol* 2011; 18:1042-52; <http://dx.doi.org/10.1016/j.chembiol.2011.05.013>.
761. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M, Youle RJ. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *J Cell Biol* 2010; 191:1367-80; <http://dx.doi.org/10.1083/jcb.201007013>.
762. Yoshii SR, Kishi C, Ishihara N, Mizushima N. Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. *J Biol Chem* 2011; 286:19630-40; <http://dx.doi.org/10.1074/jbc.M110.209338>.
763. Amadoro G, Corsetti V, Florenzano F, Atlante A, Ciotti MT, Mongiardi MP, Bussani R, Nicolin V, Nori SL, Campanella M, et al. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. *Neurobiol Dis* 2014; 62:489-507; <http://dx.doi.org/10.1016/j.nbd.2013.10.018>.
764. Chang TK, Shrivage BV, Hayes SD, Powers CM, Simin RT, WaDe Harper J, Baehrecke EH. Uba1 functions in Atg7- and Atg3-independent autophagy. *Nat Cell Biol* 2013; 15:1067-78; <http://dx.doi.org/10.1038/ncb2804>.
765. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* 2015; 85:257-73; <http://dx.doi.org/10.1016/j.neuron.2014.12.007>.
766. Yang JY, Yang WY. Spatiotemporally controlled initiation of Parkin-mediated mitophagy within single cells. *Autophagy* 2011; 7:1230-8; <http://dx.doi.org/10.4161/auto.7.10.16626>.
767. Wang Y, Nartiss Y, Steipe B, McQuibban GA, Kim PK. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mitochondrial degradation by autophagy. *Autophagy* 2012; 8:1462-76; <http://dx.doi.org/10.4161/auto.21211>.
768. Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, Campanella M, et al. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. *Cell Death Differ* 2014.
769. Lemasters JJ. Variants of mitochondrial autophagy: Types 1 and 2 mitophagy and micromitophagy (Type 3). *Redox Biol* 2014; 2:749-54; <http://dx.doi.org/10.1016/j.redox.2014.06.004>.
770. Manjithaya R, Nazarko TY, Farre JC, Subramani S. Molecular mechanism and physiological role of pexophagy. *FEBS Lett* 2010; 584:1367-73; <http://dx.doi.org/10.1016/j.febslet.2010.01.019>.
771. Till A, Lakhani R, Burnett SF, Subramani S. Pexophagy: the selective degradation of peroxisomes. *Int J Cell Biol* 2012; 2012:512721; <http://dx.doi.org/10.1155/2012/512721>.
772. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. *Pharmacol Rev* 2006; 58:726-41; <http://dx.doi.org/10.1124/pr.58.4.5>.
773. Walter KM, Schonenberger MJ, Trotschmuller M, Horn M, Elsasser HP, Moser AB, Lucas MS, Schwarz T, Gerber PA, Faust PL, et al. Hif-2alpha promotes degradation of mammalian peroxisomes by selective autophagy. *Cell Metab* 2014; 20:882-97; <http://dx.doi.org/10.1016/j.cmet.2014.09.017>.
774. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, Maclean KH, Inoki K, Guan K-L, Shen J, Person MD, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. *Proc Natl Acad Sci USA* 2010; 107:4153-8; <http://dx.doi.org/10.1073/pnas.0913860107>.
775. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, Wogan GN. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. *Proc Natl Acad Sci USA* 2013; 110:E2950-7; <http://dx.doi.org/10.1073/pnas.1307736110>.
776. Zhang J, Kim J, Alexander A, Cai S, Tripathi DN, Dere R, Tee AR, Tait-Mulder J, Di Nardo A, Han JM, et al. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. *Nat Cell Biol* 2013; 15:1186-96; <http://dx.doi.org/10.1038/ncb2822>.
777. Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, Dere R, Tait-Mulder J, Lee JH, Paull TT, et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. *Nat Cell Biol* 2015.
778. Luiken JJ, van den Berg M, Heikoop JC, Meijer AJ. Autophagic degradation of peroxisomes in isolated rat hepatocytes. *FEBS Lett* 1992; 304:93-7; [http://dx.doi.org/10.1016/0014-5793\(92\)80596-9](http://dx.doi.org/10.1016/0014-5793(92)80596-9).

779. Yokota S. Formation of autophagosomes during degradation of excess peroxisomes induced by administration of dioctyl phthalate. *Eur J Cell Biol* 1993; 61:67-80.
780. D'Eletto M, Farrace MG, Rossin F, Strappazon F, Giacomo GD, Cecconi F, Melino G, Sepe S, Moreno S, Fimia GM, et al. Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins. *Cell Death Differ* 2012; 19:1228-38; <http://dx.doi.org/10.1038/cdd.2012.2>.
781. Nardacci R, Sartori C, Stefanini S. Selective autophagy of clofibrate-induced rat liver peroxisomes. Cytochemistry and immunocytochemistry on tissue specimens and on fractions obtained by Nyco-denz density gradient centrifugation. *Cell Mol Biol* 2000; 46:1277-90.
782. Huybrechts SJ, Van Veldhoven PP, Brees C, Mannaerts GP, Los GV, Franssen M. Peroxisome dynamics in cultured mammalian cells. *Traffic* 2009; 10:1722-33; <http://dx.doi.org/10.1111/j.1600-0854.2009.00970.x>.
783. Deosaran E, Larsen KB, Hua R, Sargent G, Wang Y, Kim S, Lamark T, Jauregui M, Law K, Lippincott-Schwartz J, et al. NBR1 acts as an autophagy receptor for peroxisomes. *J Cell Sci* 2013; 126:939-52; <http://dx.doi.org/10.1242/jcs.114819>.
784. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. *J Cell Biol* 2010; 189:671-9; <http://dx.doi.org/10.1083/jcb.201001039>.
785. Kondapalli C, Kazlauskaitė A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. *Open Biol* 2012; 2:120080; <http://dx.doi.org/10.1098/rsob.120080>.
786. Yang KC, Ma X, Liu H, Murphy J, Barger PM, Mann DL, Diwan A. TNF-Receptor Associated Factor-2 Mediates Mitochondrial Autophagy. *Circ Heart Fail* 2014; 8:175-87.
787. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, Hess S, Chan DC. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet* 2011; 20:1726-37; <http://dx.doi.org/10.1093/hmg/ddr048>.
788. Okatsu K, Saisho K, Shimanuki M, Nakada K, Shitara H, Sou YS, Kimura M, Sato S, Hattori N, Komatsu M, et al. p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. *Genes Cells* 2010; 15:887-900.
789. Mauro-Lizcano . New method to assess mitophagy flux by flow cytometry. *Autophagy* 2015; 11:in press.
790. McLelland GL, Soubannier V, Chen CX, McBride HM, Fon EA. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. *EMBO J* 2014; 33:282-95.
791. Ivatt RM, Sanchez-Martinez A, Godena VK, Brown S, Ziviani E, Whitworth AJ. Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus SREBF1 as a regulator of mitophagy. *Proc Natl Acad Sci USA* 2014; 111:8494-9; <http://dx.doi.org/10.1073/pnas.1321207111>.
792. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL, et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. *J Clin Invest* 2011; 121:3701-12; <http://dx.doi.org/10.1172/JCI44736>.
793. Klinkenberg M, Gispert S, Dominguez-Bautista JA, Braun I, Auburger G, Jendrach M. Restriction of trophic factors and nutrients induces PARKIN expression. *Neurogenetics* 2012; 13:9-21; <http://dx.doi.org/10.1007/s10048-011-0303-8>.
794. Parganlija D, Klinkenberg M, Dominguez-Bautista J, Hetzel M, Gispert S, Chimi MA, Drose S, Mai S, Brandt U, Auburger G, et al. Loss of PINK1 Impairs Stress-Induced Autophagy and Cell Survival. *PLoS One* 2014; 9:e95288; <http://dx.doi.org/10.1371/journal.pone.0095288>.
795. Lyamzaev KG, Nepryakhina OK, Saprunova VB, Bakeeva LE, Pletjushkina OY, Chernyak BV, Skulachev VP. Novel mechanism of elimination of malfunctioning mitochondria (mitoptosis): formation of mitoptotic bodies and extrusion of mitochondrial material from the cell. *Biochim Biophys Acta* 2008; 1777:817-25; <http://dx.doi.org/10.1016/j.bbabi.2008.03.027>.
796. Davis CH, Kim KY, Bushong EA, Mills EA, Boassa D, Shih T, Kinebuchi M, Phan S, Zhou Y, Bihlmeyer NA, et al. Transcellular degradation of axonal mitochondria. *Proc Natl Acad Sci USA* 2014; 111:9633-8; <http://dx.doi.org/10.1073/pnas.1404651111>.
797. Hara-Kuge S, Fujiki Y. The peroxin Pex14p is involved in LC3-dependent degradation of mammalian peroxisomes. *Exp Cell Res* 2008; 314:3531-41; <http://dx.doi.org/10.1016/j.yexcr.2008.09.015>.
798. Ezaki J, Kominami E, Ueno T. Peroxisome degradation in mammals. *IUBMB Life* 2011; 63:1001-8; <http://dx.doi.org/10.1002/iub.537>.
799. Ishida H, Yoshimoto K, Izumi M, Reisen D, Yano Y, Makino A, Ohsumi Y, Hanson MR, Mae T. Mobilization of rubisco and stroma-localized fluorescent proteins of chloroplasts to the vacuole by an ATG gene-dependent autophagic process. *Plant Phys* 2008; 148:142-55; <http://dx.doi.org/10.1104/pp.108.122770>.
800. Wada S, Ishida H, Izumi M, Yoshimoto K, Ohsumi Y, Mae T, Makino A. Autophagy plays a role in chloroplast degradation during senescence in individually darkened leaves. *Plant Phys* 2009; 149:885-93; <http://dx.doi.org/10.1104/pp.108.130013>.
801. Michaeli S, Honig A, Levanony H, Peled-Zehavi H, Galili G. Arabidopsis ATG8-INTERACTING PROTEIN1 is involved in autophagy-dependent vesicular trafficking of plastid proteins to the vacuole. *Plant Cell* 2014; 26:4084-101; <http://dx.doi.org/10.1105/tpc.114.129999>.
802. Spitzer C, Li F, Buono R, Roschztardt H, Chung T, Zhang M, Osteryoung KW, Vierstra RD, Otegui MS. The endosomal protein CHARGED MULTIVESICULAR BODY PROTEIN1 regulates the autophagic turnover of plastids in Arabidopsis. *Plant Cell* 2015; 27:391-402.
803. Changou CA, Chen YR, Xing L, Yen Y, Chuang FY, Cheng RH, Bold RJ, Ann DK, Kung HJ. Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. *Proc Natl Acad Sci USA* 2014; 111:14147-52; <http://dx.doi.org/10.1073/pnas.1404171111>.
804. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* 2014.
805. Kurz T, Eaton JW, Brunk UT. The role of lysosomes in iron metabolism and recycling. *Int J Biochem Cell Biol* 2011; 43:1686-97; <http://dx.doi.org/10.1016/j.biocel.2011.08.016>.
806. Terman A, Kurz T. Lysosomal iron, iron chelation, and cell death. *Antioxid Redox Sign* 2013; 18:888-98; <http://dx.doi.org/10.1089/ars.2012.4885>.
807. Asano T, Komatsu M, Yamaguchi-Iwai Y, Ishikawa F, Mizushima N, Iwai K. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. *Mol Cell Biol* 2011; 31:2040-52; <http://dx.doi.org/10.1128/MCB.01437-10>.
808. Bauckman KA, Haller E, Flores I, Nanjundan M. Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. *Cell Death Dis* 2013; 4:e592; <http://dx.doi.org/10.1038/cddis.2013.87>.
809. De Domenico I, Ward DM, Kaplan J. Autophagy, ferritin and iron chelation. *Autophagy* 2010; 6:157; <http://dx.doi.org/10.4161/auto.6.1.10587>.
810. Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. *Eur J Biochem* 2003; 270:3731-8; <http://dx.doi.org/10.1046/j.1432-1033.2003.03759.x>.
811. Nagl W. "Plastolysomes" - Plastids involved in the autolysis of the embryo-suspensor in Phaseolus. *Zeitschrift Pflanzenphysiol* 1977; 85:45-51; [http://dx.doi.org/10.1016/S0044-328X\(77\)80263-8](http://dx.doi.org/10.1016/S0044-328X(77)80263-8).
812. Gartner PJ, Nagl W. Acid phosphatase activity in plastids (plastolysomes) of senescing embryo-suspensor cells. *Planta* 1980; 149:341-9; <http://dx.doi.org/10.1007/BF00571168>.
813. van Doorn WG, Kirasak K, Sonong A, Srihiran Y, van Lent J, Ketsa S. Do plastids in Dendrobium cv. Lucky Duan petals function similar to autophagosomes and autolysosomes? *Autophagy* 2011; 7:584-97; <http://dx.doi.org/10.4161/auto.7.6.15099>.

814. Parra-Vega V, Corral-Martínez P, Rivas-Sendra A, Seguí-Simarro JM. Formation and excretion of autophagic plastids (plastolysomes) in *Brassica napus* embryogenic microspores. *Front Plant Sci* 2015; 6:94.
815. Gonzalez-Melendi P, Uyttewaal M, Morcillo CN, Hernandez Mora JR, Fajardo S, Budar F, Lucas MM. A light and electron microscopy analysis of the events leading to male sterility in Ogu-INRA CMS of rapeseed (*Brassica napus*). *J Exp Bot* 2008; 59:827-38; <http://dx.doi.org/10.1093/jxb/erm365>.
816. Newcomb EH. Fine structure of protein-storing plastids in bean root tips. *J Cell Biol* 1967; 33:143-63; <http://dx.doi.org/10.1083/jcb.33.1.143>.
817. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. *Nature* 2009; 458:1131-5; <http://dx.doi.org/10.1038/nature07976>.
818. Koenig U, Fobker M, Lengauer B, Brandstetter M, Resch GP, Groger M, Plenz G, Pammer J, Barresi C, Hartmann C, et al. Autophagy facilitates secretion and protects against degeneration of the Harderian gland. *Autophagy* 2015; 11:298-313; <http://dx.doi.org/10.4161/15548627.2014.978221>.
819. Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, Howe MK, McDonnell DP, Frigo DE. Androgens promote prostate cancer cell growth through induction of autophagy. *Mol Endocrinol* 2013; 27:280-95; <http://dx.doi.org/10.1210/me.2012-1260>.
820. O'Rourke EJ, Soukas AA, Carr CE, Ruvkun G. *C. elegans* major fats are stored in vesicles distinct from lysosome-related organelles. *Cell Metab* 2009; 10:430-5; <http://dx.doi.org/10.1016/j.cmet.2009.10.002>.
821. Inokuchi-Shimizu S, Park EJ, Roh YS, Yang L, Zhang B, Song J, Liang S, Pimienta M, Taniguchi K, Wu X, et al. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. *J Clin Invest* 2014; 124:3566-78; <http://dx.doi.org/10.1172/JCI74068>.
822. Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park HW, Bandyopadhyay G, Li N, Aghajan M, Jang I, et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. *Cell Metab* 2012; 16:311-21; <http://dx.doi.org/10.1016/j.cmet.2012.08.004>.
823. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh T, Carissimo A, Palmer D, Klisch TJ, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. *Nat Cell Biol* 2013; 15:647-58; <http://dx.doi.org/10.1038/ncb2718>.
824. Cuervo AM. Preventing lysosomal fat indigestion. *Nat Cell Biol* 2013; 15:565-7; <http://dx.doi.org/10.1038/ncb2778>.
825. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nature Rev Mol Cell Biol* 2013; 14:283-96; <http://dx.doi.org/10.1038/nrm3565>.
826. Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. *Proc Natl Acad Sci USA* 2010; 107:16320-4; <http://dx.doi.org/10.1073/pnas.1002176107>.
827. Heck MV, Azizov M, Stehning T, Walter M, Kedersha N, Auburger G. Dysregulated expression of lipid storage and membrane dynamics factors in Tial knockout mouse nervous tissue. *Neurogenetics* 2014; 15:135-44; <http://dx.doi.org/10.1007/s10048-014-0397-x>.
828. Popovic D, Akutsu M, Novak I, Harper JW, Behrends C, Dikic I. Rab GTPase-activating proteins in autophagy: regulation of endocytic and autophagy pathways by direct binding to human ATG8 modifiers. *Mol Cell Biol* 2012; 32:1733-44; <http://dx.doi.org/10.1128/MCB.06717-11>.
829. Hung YH, Chen LM, Yang JY, Yang WY. Spatiotemporally controlled induction of autophagy-mediated lysosome turnover. *Nat Commun* 2013; 4:2111; <http://dx.doi.org/10.1038/ncomms3111>.
830. Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, Yamamoto A, Hamasaki M, Noda T, Isaka Y, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. *EMBO J* 2013; 32:2336-47; <http://dx.doi.org/10.1038/emboj.2013.171>.
831. De Meyer GR, Grootaert MO, Michiels CF, Kurdi A, Schrijvers DM, Martinet W. Autophagy in vascular disease. *Circ Res* 2015; 116:468-79; <http://dx.doi.org/10.1161/CIRCRESAHA.116.303804>.
832. Brown AJ, Jessup W. Oxysterols and atherosclerosis. *Atherosclerosis* 1999; 142:1-28; [http://dx.doi.org/10.1016/S0021-9150\(98\)00196-8](http://dx.doi.org/10.1016/S0021-9150(98)00196-8).
833. He C, Zhu H, Zhang W, Okon I, Wang Q, Li H, Le YZ, Xie Z. 7-Ketocholesterol induces autophagy in vascular smooth muscle cells through Nox4 and Atg4B. *Am J Pathol* 2013; 183:626-37; <http://dx.doi.org/10.1016/j.ajpath.2013.04.028>.
834. Martinet W, Schrijvers DM, Timmermans JP, Bult H. Interactions between cell death induced by statins and 7-ketocholesterol in rabbit aorta smooth muscle cells. *Br J Pharmacol* 2008; 154:1236-46; <http://dx.doi.org/10.1038/bjp.2008.181>.
835. Zarrouk A, Vejux A, Mackrill J, O'Callaghan Y, Hammami M, O'Brien N, Lizard G. Involvement of oxysterols in age-related diseases and ageing processes. *Ageing Res Rev* 2014; 18:148-62; <http://dx.doi.org/10.1016/j.arr.2014.09.006>.
836. Monier S, Samadi M, Prunet C, Denance M, Laubriet A, Athias A, Berthier A, Steinmetz E, Jurgens G, Negre-Salvayre A, et al. Impairment of the cytotoxic and oxidative activities of 7 beta-hydroxycholesterol and 7-ketocholesterol by esterification with oleate. *Biochem Biophys Res Commun* 2003; 303:814-24; [http://dx.doi.org/10.1016/S0006-291X\(03\)00412-1](http://dx.doi.org/10.1016/S0006-291X(03)00412-1).
837. Nury T, Zarrouk A, Mackrill JJ, Samadi M, Durand P, Riedinger JM, Doria M, Vejux A, Limagne E, Delmas D, et al. Induction of oxiaoptophagy on 158N murine oligodendrocytes treated by 7-ketocholesterol-, 7beta-hydroxycholesterol-, or 24(S)-hydroxycholesterol: Protective effects of alpha-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3). *Steroids* 2015; 99:194-203; <http://dx.doi.org/10.1016/j.steroids.2015.02.003>.
838. Nury T, Zarrouk A, Vejux A, Doria M, Riedinger JM, Delage-Mouroux R, Lizard G. Induction of oxiaoptophagy, a mixed mode of cell death associated with oxidative stress, apoptosis and autophagy, on 7-ketocholesterol-treated 158N murine oligodendrocytes: impairment by alpha-tocopherol. *Biochem Biophys Res Commun* 2014; 446:714-9; <http://dx.doi.org/10.1016/j.bbrc.2013.11.081>.
839. Mochida K, Oikawa Y, Kimura Y, Kirisako H, Hirano H, Ohsumi Y, Nakatogawa H. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. *Nature* 2015; 522:359-62; <http://dx.doi.org/10.1038/nature14506>.
840. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic reticulum stress triggers autophagy. *J Biol Chem* 2006; 281:30299-304; <http://dx.doi.org/10.1074/jbc.M607007200>.
841. Schuck S, Gallagher CM, Walter P. ER-phagy mediates selective degradation of endoplasmic reticulum independently of the core autophagy machinery. *J Cell Sci* 2014; 127:4078-88; <http://dx.doi.org/10.1242/jcs.154716>.
842. Bernales S, Schuck S, Walter P. ER-phagy: selective autophagy of the endoplasmic reticulum. *Autophagy* 2007; 3:285-7; <http://dx.doi.org/10.4161/auto.3930>.
843. Klionsky DJ, Cuervo AM, Dunn WA, Jr., Levine B, van der Klei I, Seglen PO. How shall I eat thee? *Autophagy* 2007; 3:413-6; <http://dx.doi.org/10.4161/auto.4377>.
844. Bolender RP, Weibel ER. A morphometric study of the removal of phenobarbital-induced membranes from hepatocytes after cessation of threatment. *J Cell Biol* 1973; 56:746-61; <http://dx.doi.org/10.1083/jcb.56.3.746>.
845. Khaminets A, Heinrich T, Mari M, Grumati P, Huebner AK, Akutsu M, Liebmann L, Stolz A, Nietzsche S, Koch N, et al. Regulation of endoplasmic reticulum turnover by selective autophagy. *Nature* 2015; 522:354-8; <http://dx.doi.org/10.1038/nature14498>.
846. Lipatova Z, Segev N. A Role for Macro-ER-Phagy in ER Quality Control. *PLoS Genet* 2015; 11:e1005390.
847. Kraft C, Deplazes A, Sohrmann M, Peter M. Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. *Nat Cell Biol* 2008; 10:602-10; <http://dx.doi.org/10.1038/ncb1723>.
848. Ossareh-Nazari B, Nino CA, Bengtson MH, Lee JW, Joazeiro CA, Dargemont C. Ubiquitylation by the Ltn1 E3 ligase protects 60S

- ribosomes from starvation-induced selective autophagy. *J Cell Biol* 2014; 204:909-17; <http://dx.doi.org/10.1083/jcb.201308139>.
849. Derrien B, Baumberger N, Schepetilnikov M, Viotti C, De Cillia J, Ziegler-Graff V, Isono E, Schumacher K, Genschik P. Degradation of the antiviral component ARGONAUTE1 by the autophagy pathway. *Proc Natl Acad Sci USA* 2012; 109:15942-6; <http://dx.doi.org/10.1073/pnas.1209487109>.
850. Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P, Voinnet O. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. *Nat Cell Biol* 2012; 14:1314-21; <http://dx.doi.org/10.1038/ncb2611>.
851. Zhang P, Zhang H. Autophagy modulates miRNA-mediated gene silencing and selectively degrades AIN-1/GW182 in *C. elegans*. *EMBO Rep* 2013; 14:568-76; <http://dx.doi.org/10.1038/embor.2013.53>.
852. Brown CR, Chiang H-L. A selective autophagy pathway that degrades gluconeogenic enzymes during catabolite inactivation. *Commun Integr Biol* 2009; 2:177-83; <http://dx.doi.org/10.4161/cib.7711>.
853. Schule T, Rose M, Entian KD, Thumm M, Wolf DH. Ubc8p functions in catabolite degradation of fructose-1, 6-bisphosphatase in yeast. *EMBO J* 2000; 19:2161-7; <http://dx.doi.org/10.1093/emboj/19.10.2161>.
854. Schork SM, Thumm M, Wolf DH. Catabolite inactivation of fructose-1,6-bisphosphatase of *Saccharomyces cerevisiae*. Degradation occurs via the ubiquitin pathway. *J Biol Chem* 1995; 270:26446-50; <http://dx.doi.org/10.1074/jbc.270.44.26446>.
855. Regelman J, Schule T, Josupeit FS, Horak J, Rose M, Entian KD, Thumm M, Wolf DH. Catabolite degradation of fructose-1,6-bisphosphatase in the yeast *Saccharomyces cerevisiae*: a genome-wide screen identifies eight novel GID genes and indicates the existence of two degradation pathways. *Mol Biol Cell* 2003; 14:1652-63; <http://dx.doi.org/10.1091/mbc.E02-08-0456>.
856. Hung GC, Brown CR, Wolfe AB, Liu J, Chiang HL. Degradation of the gluconeogenic enzymes fructose-1,6-bisphosphatase and malate dehydrogenase is mediated by distinct proteolytic pathways and signaling events. *J Biol Chem* 2004; 279:49138-50; <http://dx.doi.org/10.1074/jbc.M404544200>.
857. Chiang H-L, Schekman R, Hamamoto S. Selective uptake of cytosolic, peroxisomal, and plasma membrane proteins into the yeast lysosome for degradation. *J Biol Chem* 1996; 271:9934-41; <http://dx.doi.org/10.1074/jbc.271.50.32359>.
858. Huang PH, Chiang H-L. Identification of novel vesicles in the cytosol to vacuole protein degradation pathway. *J Cell Biol* 1997; 136:803-10; <http://dx.doi.org/10.1083/jcb.136.4.803>.
859. Alibhoy AA, Giardina BJ, Dunton DD, Chiang H-L. Vid30 is required for the association of Vid vesicles and actin patches in the vacuole import and degradation pathway. *Autophagy* 2012; 8:29-46.
860. Brown CR, Wolfe AB, Cui D, Chiang H-L. The vacuolar import and degradation pathway merges with the endocytic pathway to deliver fructose-1,6-bisphosphatase to the vacuole for degradation. *J Biol Chem* 2008; 283:26116-27; <http://dx.doi.org/10.1074/jbc.M709922200>.
861. Chiang MC, Chiang H-L. Vid24p, a novel protein localized to the fructose-1, 6-bisphosphatase-containing vesicles, regulates targeting of fructose-1,6-bisphosphatase from the vesicles to the vacuole for degradation. *J Cell Biol* 1998; 140:1347-56; <http://dx.doi.org/10.1083/jcb.140.6.1347>.
862. Vida TA, Emr SD. A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast. *J Cell Biol* 1995; 128:779-92; <http://dx.doi.org/10.1083/jcb.128.5.779>.
863. Brown CR, Hung GC, Dunton D, Chiang H-L. The TOR complex 1 is distributed in endosomes and in retrograde vesicles that form from the vacuole membrane and plays an important role in the vacuole import and degradation pathway. *J Biol Chem* 2010; 285:23359-70; <http://dx.doi.org/10.1074/jbc.M109.075143>.
864. Brown CR, Dunton D, Chiang H-L. The vacuole import and degradation pathway utilizes early steps of endocytosis and actin polymerization to deliver cargo proteins to the vacuole for degradation. *J Biol Chem* 2010; 285:1516-28; <http://dx.doi.org/10.1074/jbc.M109.028241>.
865. Webster P. Cytoplasmic bacteria and the autophagic pathway. *Autophagy* 2006; 2:159-61; <http://dx.doi.org/10.4161/auto.2826>.
866. Dubuisson JF, Swanson MS. Mouse infection by *Legionella*, a model to analyze autophagy. *Autophagy* 2006; 2:179-82; <http://dx.doi.org/10.4161/auto.2831>.
867. Jordan TX, Randall G. Manipulation or capitulation: virus interactions with autophagy. *Microbes Infect* 2011.
868. Knodler LA, Celli J. Eating the strangers within: host control of intracellular bacteria via xenophagy. *Cell Microbiol* 2011; 13:1319-27; <http://dx.doi.org/10.1111/j.1462-5822.2011.01632.x>.
869. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature* 2011; 469:323-35; <http://dx.doi.org/10.1038/nature09782>.
870. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. *Immunol Rev* 2011; 240:92-104; <http://dx.doi.org/10.1111/j.1600-065X.2010.00995.x>.
871. Dong X, Levine B. Autophagy and viruses: adversaries or allies? *J Innate Immun* 2013; 5:480-93; <http://dx.doi.org/10.1159/000346388>.
872. Wang C, Symington JW, Mysorekar IU. ATG16L1 and pathogenesis of urinary tract infections. *Autophagy* 2012; 8:1693-4; <http://dx.doi.org/10.4161/auto.21600>.
873. Choy A, Roy CR. Autophagy and bacterial infection: an evolving arms race. *Trends Microbiol* 2013; 21:451-6; <http://dx.doi.org/10.1016/j.tim.2013.06.009>.
874. Mostowy S, Cossart P. Bacterial autophagy: restriction or promotion of bacterial replication? *Trends Cell Biol* 2012; 22:283-91; <http://dx.doi.org/10.1016/j.tcb.2012.03.006>.
875. Kageyama S, Omori H, Saitoh T, Sone T, Guan JL, Akira S, Imaoto F, Noda T, Yoshimori T. The LC3 recruitment mechanism is separate from Atg9L1-dependent membrane formation in the autophagic response against *Salmonella*. *Mol Biol Cell* 2011; 22:2290-300; <http://dx.doi.org/10.1091/mbc.E10-11-0893>.
876. Thurston TL, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. *Nature* 2012; 482:414-8; <http://dx.doi.org/10.1038/nature10744>.
877. Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, Brumell JH. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. *J Immunol* 2009; 183:5909-16; <http://dx.doi.org/10.4049/jimmunol.0900441>.
878. Thurston TL, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. *Nat Immunol* 2009; 10:1215-21; <http://dx.doi.org/10.1038/ni.1800>.
879. Tumbarello DA, Manna PT, Allen M, Bycroft M, Arden SD, Kendrick-Jones J, Buss F. The autophagy receptor TAX1BP1 and the molecular motor myosin VI are required for clearance of *Salmonella Typhimurium* by autophagy. *PLoS Pathog* 2015; 11:e1005174.
880. Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, Brady NR, Richter B, Korac J, Waidmann O, Choudhary C, et al. Phosphorylation of the autophagy receptor optineurin restricts *Salmonella* growth. *Science* 2011; 333:228-33; <http://dx.doi.org/10.1126/science.1205405>.
881. Huang J, Canadien V, Lam GY, Steinberg BE, Dinanuer MC, Magalhaes MA, Glogauer M, Grinstein S, Brumell JH. Activation of antibacterial autophagy by NADPH oxidases. *Proc Natl Acad Sci USA* 2009; 106:6226-31; <http://dx.doi.org/10.1073/pnas.0811045106>.
882. Rich KA, Burkett C, Webster P. Cytoplasmic bacteria can be targets for autophagy. *Cell Microbiol* 2003; 5:455-68; <http://dx.doi.org/10.1046/j.1462-5822.2003.00292.x>.
883. Shahnazari S, Brumell JH. Mechanisms and consequences of bacterial targeting by the autophagy pathway. *Current opinion in microbiology* 2011; 14:68-75; <http://dx.doi.org/10.1016/j.mib.2010.11.001>.
884. Klionsky DJ, Eskelinen EL, Deretic V. Autophagosomes, phagosomes, autolysosomes, phagolysosomes, autophagolysosomes... wait, I'm confused. *Autophagy* 2014; 10:549-51; <http://dx.doi.org/10.4161/auto.28448>.
885. Li X, Ye Y, Zhou X, Huang C, Wu M. Atg7 enhances host defense against infection via downregulation of superoxide but upregulation

- of nitric oxide. *J Immunol* 2015; 194:1112-21; <http://dx.doi.org/10.4049/jimmunol.1401958>.
886. Ye Y, Tan S, Zhou X, Li X, Jundt MC, Lichter N, Hidebrand A, Dhasarathy A, Wu M. Inhibition of p-IkappaBalpha Ubiquitylation by Autophagy-Related Gene 7 to Regulate Inflammatory Responses to Bacterial Infection. *J Infect Dis* 2015; 212:1816-26.
887. Yuan K, Huang C, Fox J, Laturus D, Carlson E, Zhang B, Yin Q, Gao H, Wu M. Autophagy plays an essential role in the clearance of *Pseudomonas aeruginosa* by alveolar macrophages. *J Cell Sci* 2012; 125:507-15; <http://dx.doi.org/10.1242/jcs.094573>.
888. Irving AT, Mimuro H, Kufer TA, Lo C, Wheeler R, Turner LJ, Thomas BJ, Malosse C, Gantier MP, Casillas LN, et al. The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling. *Cell Host Microbe* 2014; 15:623-35; <http://dx.doi.org/10.1016/j.chom.2014.04.001>.
889. Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. *Nature reviews Immunology* 2015; 15:375-87; <http://dx.doi.org/10.1038/nri3837>.
890. McLean JE, Wudzinska A, Datan E, Quaglino D, Zakeri Z. Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication. *J Biol Chem* 2011; 286:22147-59; <http://dx.doi.org/10.1074/jbc.M110.192500>.
891. Mao Y, Da L, Tang H, Yang J, Lei Y, Tiollais P, Li T, Zhao M. Hepatitis B virus X protein reduces starvation-induced cell death through activation of autophagy and inhibition of mitochondrial apoptotic pathway. *Biochem Biophys Res Commun* 2011; 415:68-74; <http://dx.doi.org/10.1016/j.bbrc.2011.10.013>.
892. Orvedahl A, Alexander D, Talloczy Z, Sun Q, Wei Y, Zhang W, Burns D, Leib DA, Levine B. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. *Cell Host Microbe* 2007; 1:23-35; <http://dx.doi.org/10.1016/j.chom.2006.12.001>.
893. Alexander DE, Ward SL, Mizushima N, Levine B, Leib DA. Analysis of the role of autophagy in replication of herpes simplex virus in cell culture. *J Virol* 2007; 81:12128-34; <http://dx.doi.org/10.1128/JVI.01356-07>.
894. Leib DA, Alexander DE, Cox D, Yin J, Ferguson TA. Interaction of ICP34.5 with Beclin 1 modulates herpes simplex virus type 1 pathogenesis through control of CD4+ T-cell responses. *J Virol* 2009; 83:12164-71; <http://dx.doi.org/10.1128/JVI.01676-09>.
895. Yordy B, Iijima N, Huttner A, Leib D, Iwasaki A. A neuron-specific role for autophagy in antiviral defense against herpes simplex virus. *Cell Host Microbe* 2012; 12:334-45; <http://dx.doi.org/10.1016/j.chom.2012.07.013>.
896. Liang CEX, Jung JU. Downregulation of autophagy by herpesvirus Bcl-2 homologs. *Autophagy* 2008; 4:268-72; <http://dx.doi.org/10.4161/autophagy.5210>.
897. Hernaez B, Cabezas M, Munoz-Moreno R, Galindo I, Cuesta-Geijo MA, Alonso C. A179L, a new viral Bcl2 homolog targeting Beclin 1 autophagy related protein. *Curr Mol Med* 2013; 13:305-16; <http://dx.doi.org/10.2174/156652413804810736>.
898. Alonso C, Galindo I, Cuesta-Geijo MA, Cabezas M, Hernaez B, Munoz-Moreno R. African swine fever virus-cell interactions: from virus entry to cell survival. *Virus Res* 2013; 173:42-57; <http://dx.doi.org/10.1016/j.virusres.2012.12.006>.
899. Galindo I, Hernaez B, Diaz-Gil G, Escribano JM, Alonso C. A179L, a viral Bcl-2 homologue, targets the core Bcl-2 apoptotic machinery and its upstream BH3 activators with selective binding restrictions for Bid and Noxa. *Virology* 2008; 375:561-72; <http://dx.doi.org/10.1016/j.virol.2008.01.050>.
900. Gannage M, Ramer PC, Munz C. Targeting Beclin 1 for viral subversion of macroautophagy. *Autophagy* 2010; 6:166-7; <http://dx.doi.org/10.4161/autophagy.6.1.10624>.
901. Killian MS. Dual role of autophagy in HIV-1 replication and pathogenesis. *AIDS Res Ther* 2012; 9:16; <http://dx.doi.org/10.1186/1742-6405-9-16>.
902. Kyei GB, Dinkins C, Davis AS, Roberts E, Singh SB, Dong C, Wu L, Kominami E, Ueno T, Yamamoto A, et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. *J Cell Biol* 2009; 186:255-68; <http://dx.doi.org/10.1083/jcb.200903070>.
903. Nardacci R, Amendola A, Ciccocanti F, Corazzari M, Esposito V, Vlassi C, Taibi C, Fimia GM, Del Nonno F, Ippolito G, et al. Autophagy plays an important role in the containment of HIV-1 in non-progressor-infected patients. *Autophagy* 2014; 10:1167-78; <http://dx.doi.org/10.4161/auto.28678>.
904. Zhang H, Monken CE, Zhang Y, Lenard J, Mizushima N, Lattime EC, Jin S. Cellular autophagy machinery is not required for vaccinia virus replication and maturation. *Autophagy* 2006; 2:91-5; <http://dx.doi.org/10.4161/auto.2.2.2297>.
905. Heaton NS, Randall G. Dengue virus and autophagy. *Viruses* 2011; 3:1332-41; <http://dx.doi.org/10.3390/v3081332>.
906. Dreux M, Gastaminza P, Wieland SF, Chisari FV. The autophagy machinery is required to initiate hepatitis C virus replication. *Proc Natl Acad Sci USA* 2009; 106:14046-51; <http://dx.doi.org/10.1073/pnas.0907344106>.
907. Collins CA, De Maziere A, van Dijk S, Carlsson F, Klumperman J, Brown EJ. Atg5-independent sequestration of ubiquitinated mycobacteria. *PLoS Pathog* 2009; 5:e1000430; <http://dx.doi.org/10.1371/journal.ppat.1000430>.
908. Moreau K, Lacas-Gervais S, Fujita N, Sebbane F, Yoshimori T, Simonet M, Lafont F. Autophagosomes can support *Yersinia pseudotuberculosis* replication in macrophages. *Cell Microbiol* 2010; 12:1108-23; <http://dx.doi.org/10.1111/j.1462-5822.2010.01456.x>.
909. Grasso D, Ropolo A, Lo Re A, Boggio V, Molejon MI, Iovanna JL, Gonzalez CD, Urrutia R, Vaccaro MI. Zymophagy, a novel selective autophagy pathway mediated by VMP1-USP9x-p62, prevents pancreatic cell death. *J Biol Chem* 2011; 286:8308-24; <http://dx.doi.org/10.1074/jbc.M110.197301>.
910. Gorbunov NV, Kiang JG. Autophagy-Mediated Innate Defense Mechanism in Crypt Paneth Cells Responding to Impairment of Small Intestine Barrier after Total-Body Gamma-Photon Irradiation. In: Gorbunov NV, ed. *Autophagy: Principles, Regulation and Roles in Disease*. Hauppauge, NY: NOVA SCIENCE PUBLISHERS, INC., 2011:61-84.
911. Seglen PO, Gordon PB, Tolleshaug H, Høyvik H. Use of [3H]raffinose as a specific probe of autophagic sequestration. *Exp Cell Res* 1986; 162:273-7.
912. Kopitz J, Kisen GO, Gordon PB, Bohley P, Seglen PO. Nonselective autophagy of cytosolic enzymes by isolated rat hepatocytes. *J Cell Biol* 1990; 111:941-53; <http://dx.doi.org/10.1083/jcb.111.3.941>.
913. Gordon PB, Seglen PO. Autophagic sequestration of [14C]sucrose, introduced into rat hepatocytes by reversible electro-permeabilization. *Exp Cell Res* 1982; 142:1-14; [http://dx.doi.org/10.1016/0014-4827\(82\)90402-5](http://dx.doi.org/10.1016/0014-4827(82)90402-5).
914. Seglen PO, Luhr M, Mills IG, Saetre F, Szalai P, Engedal N. Macroautophagic cargo sequestration assays. *Methods* 2015; 75:25-36; <http://dx.doi.org/10.1016/j.jymeth.2014.12.021>.
915. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. *J Biol Chem* 2010; 285:37415-26; <http://dx.doi.org/10.1074/jbc.M110.186411>.
916. Nair U, Thumm M, Klionsky DJ, Krick R. GFP-Atg8 protease protection as a tool to monitor autophagosome biogenesis. *Autophagy* 2011; 7:1546-50; <http://dx.doi.org/10.4161/auto.7.12.18424>.
917. Plomp PJ, Gordon PB, Meijer AJ, Høyvik H, Seglen PO. Energy dependence of different steps in the autophagic-lysosomal pathway. *J Biol Chem* 1989; 264:6699-704.
918. Høyvik H, Gordon PB, Berg TO, Strømhaug PE, Seglen PO. Inhibition of autophagic-lysosomal delivery and autophagic lactolysis by asparagine. *J Cell Biol* 1991; 113:1305-12; <http://dx.doi.org/10.1083/jcb.113.6.1305>.
919. Rodriguez-Enriquez S, Kim I, Currin RT, Lemasters JJ. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. *Autophagy* 2006; 2:39-46; <http://dx.doi.org/10.4161/auto.2229>.
920. Lorenz H, Hailey DW, Lippincott-Schwartz J. Fluorescence protease protection of GFP chimeras to reveal protein topology and subcellular localization. *Nat Methods* 2006; 3:205-10; <http://dx.doi.org/10.1038/nmeth857>.

921. McNeil PL, Murphy RF, Lanni F, Taylor DL. A method for incorporating macromolecules into adherent cells. *J Cell Biol* 1984; 98:1556-64; <http://dx.doi.org/10.1083/jcb.98.4.1556>.
922. Kim J, Huang WP, Stromhaug PE, Klionsky DJ. Convergence of multiple autophagy and cytoplasm to vacuole targeting components to a perivacuolar membrane compartment prior to de novo vesicle formation. *J Biol Chem* 2002; 277:763-73; <http://dx.doi.org/10.1074/jbc.M109134200>.
923. Velikkakath AK, Nishimura T, Oita E, Ishihara N, Mizushima N. Mammalian Atg2 proteins are essential for autophagosome formation and important for regulation of size and distribution of lipid droplets. *Mol Biol Cell* 2012; 23:896-909; <http://dx.doi.org/10.1091/mbc.E11-09-0785>.
924. Kovács AL, Laszlo L, Kovács J. Effect of amino acids and cycloheximide on changes caused by vinblastine, leupeptin and methylamine in the autophagic/lysosomal system of mouse hepatocytes in vivo. *Exp Cell Res* 1985; 157:83-94; [http://dx.doi.org/10.1016/0014-4827\(85\)90154-5](http://dx.doi.org/10.1016/0014-4827(85)90154-5).
925. Swanson MS, Byrne BG, Dubuisson JF. Kinetic analysis of autophagosome formation and turnover in primary mouse macrophages. *Methods Enzymol* 2009; 452:383-402; [http://dx.doi.org/10.1016/S0076-6879\(08\)03623-9](http://dx.doi.org/10.1016/S0076-6879(08)03623-9).
926. Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. *Biochem J* 2003; 372:555-66; <http://dx.doi.org/10.1042/bj20021266>.
927. Urban J, Soulard A, Huber A, Lippman S, Mukhopadhyay D, Deloche O, Wanke V, Anrather D, Ammerer G, Riezman H, et al. Sch9 is a major target of TORC1 in *Saccharomyces cerevisiae*. *Mol Cell* 2007; 26:663-74; <http://dx.doi.org/10.1016/j.molcel.2007.04.020>.
928. Jomain-Baum M, Garber AJ, Farber E, Hanson RW. The effect of cycloheximide on the interaction between mitochondrial respiration and gluconeogenesis in guinea pig and rat liver. *J Biol Chem* 1973; 248:1536-43.
929. Garber AJ, Jomain-Baum M, Salganicoff L, Farber E, Hanson RW. The effects of cycloheximide on energy transfer in rat and guinea pig liver mitochondria. *J Biol Chem* 1973; 248:1530-5.
930. Mora R, Dokic I, Kees T, Huber CM, Keitel D, Geibig R, Brugge B, Zentgraf H, Brady NR, Regnier-Vigouroux A. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. *Glia* 2010; 58:1364-83.
931. Bright NA, Lindsay MR, Stewart A, Luzio JP. The relationship between luminal and limiting membranes in swollen late endocytic compartments formed after wortmannin treatment or sucrose accumulation. *Traffic* 2001; 2:631-42; <http://dx.doi.org/10.1034/j.1600-0854.2001.20906.x>.
932. Deter RL. Quantitative characterization of dense body, autophagic vacuole, and acid phosphatase-bearing particle populations during the early phases of glucagon-induced autophagy in rat liver. *J Cell Biol* 1971; 48:473-89; <http://dx.doi.org/10.1083/jcb.48.3.473>.
933. Deter RL. Analog modeling of glucagon-induced autophagy in rat liver. I. Conceptual and mathematical model of telolysosome-autophagosome-autolysosome interaction. *Exp Cell Res* 1975; 94:122-6; [http://dx.doi.org/10.1016/0014-4827\(75\)90538-8](http://dx.doi.org/10.1016/0014-4827(75)90538-8).
934. Deter RL. Analog modeling of glucagon-induced autophagy in rat liver. II. Evaluation of iron labeling as a means for identifying telolysosome, autophagosome and autolysosome populations. *Exp Cell Res* 1975; 94:127-39; [http://dx.doi.org/10.1016/0014-4827\(75\)90539-X](http://dx.doi.org/10.1016/0014-4827(75)90539-X).
935. Deter RL, Baudhuin P, de Duve C. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon. *J Cell Biol* 1967; 35:C11-6; <http://dx.doi.org/10.1083/jcb.35.2.C11>.
936. Deter RL, de Duve C. Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. *J Cell Biol* 1967; 33:437-49; <http://dx.doi.org/10.1083/jcb.33.2.437>.
937. Stromhaug PE, Berg TO, Fengsrud M, Seglen PO. Purification and characterization of autophagosomes from rat hepatocytes. *Biochem J* 1998; 335 (Pt 2):217-24; <http://dx.doi.org/10.1042/bj3350217>.
938. Deter RL. Electron microscopic evaluation of subcellular fractions obtained by ultracentrifugation. In: Hayat MA, ed. *Principles and Techniques of Electron Microscopy*. New York: Van Nostrand Reinhold Co., 1973:199-235.
939. Marzella L, Ahlberg J, Glaumann H. Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization. *J Cell Biol* 1982; 93:144-54; <http://dx.doi.org/10.1083/jcb.93.1.144>.
940. Wattiaux R, Wattiaux-De Coninck S, Ronveaux-Dupal M-F, Dubois F. Isolation of rat liver lysosomes by isopycnic centrifugation in a metrizamide gradient. *J Cell Biol* 1978; 78:349-68; <http://dx.doi.org/10.1083/jcb.78.2.349>.
941. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, Cuervo AM, Garcia de Yébenes J, Mena MA. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. *Neurobiol Dis* 2010; 39:423-38; <http://dx.doi.org/10.1016/j.nbd.2010.05.014>.
942. Weibel ER, Bolender RP. Stereological techniques for electron microscopic morphometry. In: Hayat MA, ed. *Principles and Techniques of Electron Microscopy*. New York: Van Nostrand Reinhold Co., 1973:237-96.
943. Baudhuin P, Evrard P, Berthet J. Electron microscopic examination of subcellular fractions. I. The preparation of representative samples from suspensions of particles. *J Cell Biol* 1967; 32:181-91; <http://dx.doi.org/10.1083/jcb.32.1.181>.
944. Baudhuin P, Berthet J. Electron microscopic examination of subcellular fractions. II. Quantitative analysis of the mitochondrial population isolated from rat liver. *J Cell Biol* 1967; 35:631-48; <http://dx.doi.org/10.1083/jcb.35.3.631>.
945. Storrie B, Madden EA. Isolation of subcellular organelles. *Methods Enzymol* 1990; 182:203-25; [http://dx.doi.org/10.1016/0076-6879\(90\)82018-W](http://dx.doi.org/10.1016/0076-6879(90)82018-W).
946. Balch WE, Rothman JE. Characterization of protein transport between successive compartments of the Golgi apparatus: asymmetric properties of donor and acceptor activities in a cell-free system. *Arch Biochem Biophys* 1985; 240:413-25; [http://dx.doi.org/10.1016/0003-9861\(85\)90046-3](http://dx.doi.org/10.1016/0003-9861(85)90046-3).
947. Graham JM. Isolation of lysosomes from tissues and cells by differential and density gradient centrifugation. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J and Yamada KM, eds. *Current Protocols in Cell Biology*: John Wiley & Sons, Inc., 2000:Unit 3.6.
948. Cuervo AM, Dice JF, Knecht E. A population of rat liver lysosomes responsible for the selective uptake and degradation of cytosolic proteins. *J Biol Chem* 1997; 272:5606-15; <http://dx.doi.org/10.1074/jbc.272.9.5606>.
949. He C, Sumpter R, Jr., Levine B. Exercise induces autophagy in peripheral tissues and in the brain. *Autophagy* 2012; 8:1548-51; <http://dx.doi.org/10.4161/auto.21327>.
950. Sarkar C, Zhao Z, Aungst S, Sabirzhanov B, Faden AI, Lipinski MM. Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury. *Autophagy* 2014:0.
951. Iwai-Kanai E, Yuan H, Huang C, Sayen MR, Perry-Garza CN, Kim L, Gottlieb RA. A method to measure cardiac autophagic flux in vivo. *Autophagy* 2008; 4:322-9; <http://dx.doi.org/10.4161/auto.5603>.
952. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, Le V, Levine B, Rothermel BA, Hill JA. Cardiac autophagy is a maladaptive response to hemodynamic stress. *J Clin Invest* 2007; 117:1782-93; <http://dx.doi.org/10.1172/JCI27523>.
953. Castillo K, Valenzuela V, Matus S, Nassif M, Onate M, Fuentealba Y, Encina G, Irrazabal T, Parsons G, Court FA, et al. Measurement of autophagy flux in the nervous system in vivo. *Cell Death Dis* 2013; 4:e917.
954. Matus S, Valenzuela V, Hetz C. A new method to measure autophagy flux in the nervous system. *Autophagy* 2014; 10:710-4; <http://dx.doi.org/10.4161/auto.28434>.
955. Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van Zundert B, Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. *Autophagy* 2013; 9:1308-20; <http://dx.doi.org/10.4161/auto.25188>.

956. Chiarelli R, Agnello M, Roccheri MC. Sea urchin embryos as a model system for studying autophagy induced by cadmium stress. *Autophagy* 2011; 7:1028-34; <http://dx.doi.org/10.4161/auto.7.9.16450>.
957. Morici G, Agnello M, Spagnolo F, Roccheri MC, Di Liegro CM, Rinaldi AM. Confocal microscopy study of the distribution, content and activity of mitochondria during *Paracentrotus lividus* development. *J Microsc* 2007; 228:165-73; <http://dx.doi.org/10.1111/j.1365-2818.2007.01860.x>.
958. Martinet W, De Meyer GR, Andries L, Herman AG, Kockx MM. Detection of autophagy in tissue by standard immunohistochemistry: possibilities and limitations. *Autophagy* 2006; 2:55-7; <http://dx.doi.org/10.4161/auto.2217>.
959. Holt SV, Wyspianska B, Randall KJ, James D, Foster JR, Wilkinson RW. The development of an immunohistochemical method to detect the autophagy-associated protein LC3-II in human tumor xenografts. *Toxicol Pathol* 2011; 39:516-23; <http://dx.doi.org/10.1177/0192623310396903>.
960. Kimura S, Fujita N, Noda T, Yoshimori T. Monitoring autophagy in mammalian cultured cells through the dynamics of LC3. *Methods Enzymol* 2009; 452:1-12; [http://dx.doi.org/10.1016/S0076-6879\(08\)03601-X](http://dx.doi.org/10.1016/S0076-6879(08)03601-X).
961. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M. Pathogenic lysosomal depletion in Parkinson's disease. *J Neurosci* 2010; 30:12535-44; <http://dx.doi.org/10.1523/JNEUROSCI.1920-10.2010>.
962. Daniels BH, McComb RD, Mobley BC, Gultekin SH, Lee HS, Margeta M. LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases. *Am J Surg Pathol* 2013; 37:1014-21; <http://dx.doi.org/10.1097/PAS.0b013e3182863fa8>.
963. Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. *Acta Neuropathol Commun* 2013; 1:29; <http://dx.doi.org/10.1186/2051-5960-1-29>.
964. Lee HS, Daniels BH, Salas E, Bollen AW, Debnath J, Margeta M. Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. *PloS One* 2012; 7:e36221.
965. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. *Cell Metab* 2011; 13:655-67; <http://dx.doi.org/10.1016/j.cmet.2011.03.023>.
966. Hamada K, Terauchi A, Nakamura K, Higo T, Nukina N, Matsumoto N, Hisatsune C, Nakamura T, Mikoshiba K. Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors. *Proc Natl Acad Sci USA* 2014; 111:E3966-75; <http://dx.doi.org/10.1073/pnas.1409730111>.
967. Rodriguez-Muela N, Koga H, Garcia-Ledo L, de la Villa P, de la Rosa EJ, Cuervo AM, Boya P. Balance between autophagic pathways preserves retinal homeostasis. *Aging Cell* 2013; 12:478-88; <http://dx.doi.org/10.1111/acel.12072>.
968. Esteban-Martinez L, Boya P. Autophagic flux determination in vivo and ex vivo. *Methods* 2015; 75:79-86; <http://dx.doi.org/10.1016/j.ymeth.2015.01.008>.
969. McMahan J, Huang X, Yang J, Komatsu M, Yue Z, Qian J, Zhu X, Huang Y. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. *J Neurosci* 2012; 32:15704-14; <http://dx.doi.org/10.1523/JNEUROSCI.2392-12.2012>.
970. Herrando-Grabulosa M, Casas C, Aguilera J. The C-terminal domain of tetanus toxin protects motoneurons against acute excitotoxic damage on spinal cord organotypic cultures. *J Neurochem* 2013; 124:36-44; <http://dx.doi.org/10.1111/jnc.12062>.
971. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. *Nat Cell Biol* 2011; 13:589-98; <http://dx.doi.org/10.1038/ncb2220>.
972. Grumati P, Coletto L, Sabatelli P, Cescon M, Angelin A, Bertaggia E, Blaauw B, Urciuolo A, Tiepolo T, Merlini L, et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. *Nat Med* 2010; 16:1313-20; <http://dx.doi.org/10.1038/nm.2247>.
973. Bloemberg D, McDonald E, Dulay D, Quadrilatero J. Autophagy is altered in skeletal and cardiac muscle of spontaneously hypertensive rats. *Acta Physiol (Oxf)* 2014; 210:381-91; <http://dx.doi.org/10.1111/apha.12178>.
974. Ogata T, Oishi Y, Higuchi M, Muraoka I. Fasting-related autophagic response in slow- and fast-twitch skeletal muscle. *Biochem Biophys Res Commun* 2010; 394:136-40; <http://dx.doi.org/10.1016/j.bbrc.2010.02.130>.
975. Yamada E, Bastie CC, Koga H, Wang Y, Cuervo AM, Pessin JE. Mouse skeletal muscle fiber-type-specific macroautophagy and muscle wasting are regulated by a Fyn/STAT3/Vps34 signaling pathway. *Cell Rep* 2012; 1:557-69; <http://dx.doi.org/10.1016/j.celrep.2012.03.014>.
976. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature* 2012; 481:511-5; <http://dx.doi.org/10.1038/nature10758>.
977. Haspel J, Shaik RS, Ifedigbo E, Nakahira K, Dolinay T, Englert JA, Choi AM. Characterization of macroautophagic flux in vivo using a leupeptin-based assay. *Autophagy* 2011; 7:629-42; <http://dx.doi.org/10.4161/auto.7.6.15100>.
978. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. *J Mol Cell Cardiol* 2011; 50:940-50; <http://dx.doi.org/10.1016/j.yjmcc.2011.02.018>.
979. Huang C, Andres AM, Ratliff EP, Hernandez G, Lee P, Gottlieb RA. Preconditioning involves selective mitophagy mediated by Parkin and p62/SQSTM1. *PloS One* 2011; 6:e20975; <http://dx.doi.org/10.1371/journal.pone.0020975>.
980. Gottlieb RA, Finley KD, Mentzer RM, Jr. Cardioprotection requires taking out the trash. *Basic Res Cardiol* 2009; 104:169-80; <http://dx.doi.org/10.1007/s00395-009-0011-9>.
981. Avagliano L, Virgili E, Garo C, Quadrelli F, Doi P, Samaja M, Bulfamante GP, Marconi AM. Autophagy and human parturition: evaluation of LC3 expression in placenta from spontaneous or medically induced onset of labor. *BioMed Res Intl* 2013; 2013:689768; <http://dx.doi.org/10.1155/2013/689768>.
982. Hung TH, Hsieh TT, Chen SF, Li MJ, Yeh YL. Autophagy in the human placenta throughout gestation. *PloS One* 2013; 8:e83475; <http://dx.doi.org/10.1371/journal.pone.0083475>.
983. Signorelli P, Avagliano L, Virgili E, Gagliostro V, Doi P, Braidotti P, Bulfamante GP, Ghidoni R, Marconi AM. Autophagy in term normal human placentas. *Placenta* 2011; 32:482-5; <http://dx.doi.org/10.1016/j.placenta.2011.03.005>.
984. Hung TH, Chen SF, Lo LM, Li MJ, Yeh YL, Hsieh TT. Increased autophagy in placentas of intrauterine growth-restricted pregnancies. *PloS One* 2012; 7:e40957; <http://dx.doi.org/10.1371/journal.pone.0040957>.
985. Chang YL, Wang TH, Chang SD, Chao AS, Hsieh PC, Wang CN. Increased autophagy in the placental territory of selective intrauterine growth-restricted monochorionic twins. *Prenatal Diag* 2013; 33:187-90; <http://dx.doi.org/10.1002/pd.4040>.
986. Oh SY, Choi SJ, Kim KH, Cho EY, Kim JH, Roh CR. Autophagy-related proteins, LC3 and Beclin-1, in placentas from pregnancies complicated by preeclampsia. *Reprod Sci* 2008; 15:912-20; <http://dx.doi.org/10.1177/1933719108319159>.
987. Avagliano L, Danti L, Doi P, Felis S, Guala M, Locatelli A, Maffeo I, Mecacci F, Plevani C, Simeone S, et al. Autophagy in placentas from acidotic newborns: an immunohistochemical study of LC3 expression. *Placenta* 2013; 34:1091-4; <http://dx.doi.org/10.1016/j.placenta.2013.09.004>.
988. Perry CN, Kyoi S, Hariharan N, Takagi H, Sadoshima J, Gottlieb RA. Novel methods for measuring cardiac autophagy in vivo. *Methods Enzymol* 2009; 453:325-42; [http://dx.doi.org/10.1016/S0076-6879\(08\)04016-0](http://dx.doi.org/10.1016/S0076-6879(08)04016-0).

989. Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. *J Cell Sci* 2001; 114:3619-29.
990. Carloni S, Buonocore G, Balduini W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. *Neurobiol Dis* 2008; 32:329-39; <http://dx.doi.org/10.1016/j.nbd.2008.07.022>.
991. Carloni S, Girelli S, Scopa C, Buonocore G, Longini M, Balduini W. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. *Autophagy* 2010; 6:366-77; <http://dx.doi.org/10.4161/auto.6.3.11261>.
992. Carloni S, Albertini MC, Galluzzi L, Buonocore G, Proietti F, Balduini W. Increased autophagy reduces endoplasmic reticulum stress after neonatal hypoxia-ischemia: Role of protein synthesis and autophagic pathways. *Exp Neurol* 2014; 57:192-9.
993. Ginet V, Puyal J, Clarke PG, Truttmann AC. Enhancement of autophagic flux after neonatal cerebral hypoxia-ischemia and its region-specific relationship to apoptotic mechanisms. *Am J Pathol* 2009; 175:1962-74; <http://dx.doi.org/10.2353/ajpath.2009.090463>.
994. Puyal J, Vaslin A, Mottier V, Clarke PG. Posts ischemic treatment of neonatal cerebral ischemia should target autophagy. *Annals Neurol* 2009; 66:378-89; <http://dx.doi.org/10.1002/ana.21714>.
995. Penas C, Font-Nieves M, Fores J, Pategnief V, Planas A, Navarro X, Casas C. Autophagy, and BIP level decrease are early key events in retrograde degeneration of motoneurons. *Cell Death Differ* 2011; 18:1617-27; <http://dx.doi.org/10.1038/cdd.2011.24>.
996. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. *Arch Histol Cytol* 2001; 64:233-46; <http://dx.doi.org/10.1679/aohc.64.233>.
997. Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, Wohlrab J, Henne-Bruns D, Knippschild U, Wurl P. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. *PLoS One* 2011; 6:e20143.
998. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomal mechanism. *J Immunol* 2000; 165:1534-40; <http://dx.doi.org/10.4049/jimmunol.165.3.1534>.
999. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. *Science* 2005; 307:593-6; <http://dx.doi.org/10.1126/science.1104904>.
1000. Ma D, Panda S, Lin JD. Temporal orchestration of circadian autophagy rhythm by C/EBPbeta. *EMBO J* 2011; 30:4642-51; <http://dx.doi.org/10.1038/emboj.2011.322>.
1001. Akagi Y, Isaka Y, Akagi A, Ikawa M, Takenaka M, Moriyama T, Yamauchi A, Horio M, Ueda N, Okabe M, et al. Transcriptional activation of a hybrid promoter composed of cytomegalovirus enhancer and beta-actin/beta-globin gene in glomerular epithelial cells in vivo. *Kidney Int* 1997; 51:1265-9; <http://dx.doi.org/10.1038/ki.1997.172>.
1002. Kimura T, Takabatake Y, Takahashi A, Kaimori JY, Matsui I, Namba T, Kitamura H, Niimura F, Matsusaka T, Soga T, et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. *J Am Soc Nephrol* 2011; 22:902-13; <http://dx.doi.org/10.1681/ASN.2010070705>.
1003. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S, Wiech T, Grahmmer F, Arnold SJ, Lindenmeyer MT, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. *J Clin Invest* 2010; 120:1084-96; <http://dx.doi.org/10.1172/JCI39492>.
1004. Vandrovcova J, Anaya F, Kay V, Lees A, Hardy J, de Silva R. Disentangling the role of the tau gene locus in sporadic tauopathies. *Curr Alzheimer Res* 2010; 7:726-34; <http://dx.doi.org/10.2174/156720510793611619>.
1005. Chen YS, Chen SD, Wu CL, Huang SS, Yang DI. Induction of sestrin2 as an endogenous protective mechanism against amyloid beta-peptide neurotoxicity in primary cortical culture. *Exp Neurol* 2014; 253:63-71; <http://dx.doi.org/10.1016/j.expneurol.2013.12.009>.
1006. Tofaris GK, Spillantini MG. Physiological and pathological properties of alpha-synuclein. *Cell Mol Life Sci* 2007; 64:2194-201; <http://dx.doi.org/10.1007/s00018-007-7217-5>.
1007. Wanker EE. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. *Biol Chem* 2000; 381:937-42.
1008. Sandri M, Coletto L, Grumati P, Bonaldo P. Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies. *J Cell Sci* 2013; 126:5325-33; <http://dx.doi.org/10.1242/jcs.114041>.
1009. Bentmann E, Haass C, Dormann D. Stress granules in neurodegeneration—lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. *FEBS J* 2013; 280:4348-70; <http://dx.doi.org/10.1111/febs.12287>.
1010. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. *Trends in Neurosci* 2014; 37:315-24; <http://dx.doi.org/10.1016/j.tins.2014.03.004>.
1011. Ossareh-Nazari B, Bonizec M, Cohen M, Dokudovskaya S, Delalande F, Schaeffer C, Van Dorsselaer A, Dargemont C. Cdc48 and Ufd3, new partners of the ubiquitin protease Ubp3, are required for ribophagy. *EMBO Rep* 2010; 11:548-54; <http://dx.doi.org/10.1038/embor.2010.74>.
1012. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. *Nat Neurosci* 2014; 17:17-23; <http://dx.doi.org/10.1038/nn.3584>.
1013. Ebrahimi-Fakhari D, Wahlster L, Hoffmann GF, Kolker S. Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases. *Pediatr Res* 2014; 75:217-26; <http://dx.doi.org/10.1038/pr.2013.185>.
1014. Lee KM, Hwang SK, Lee JA. Neuronal autophagy and neurodevelopmental disorders. *Exp Neurol* 2013; 22:133-42; <http://dx.doi.org/10.5607/en.2013.22.3.133>.
1015. Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, et al. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. *Acta Neuropathol* 2013; 126:207-18; <http://dx.doi.org/10.1007/s00401-013-1135-4>.
1016. Salminen A, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H, Alafuzoff I. Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease. *Prog Neurobiol* 2012; 96:87-95; <http://dx.doi.org/10.1016/j.pneurobio.2011.11.005>.
1017. Seidel K, Brunt ER, de Vos RA, Dijk F, van der Want HJ, Rub U, den Dunnen WF. The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia type 6. *Clin Neuropathol* 2009; 28:344-9; <http://dx.doi.org/10.5414/NPP28344>.
1018. Harada H, Warabi E, Matsuki T, Yanagawa T, Okada K, Uwayama J, Ikeda A, Nakaso K, Kirii K, Noguchi N, et al. Deficiency of p62/Sequestosome 1 causes hyperphagia due to leptin resistance in the brain. *J Neurosci* 2013; 33:14767-77; <http://dx.doi.org/10.1523/JNEUROSCI.2954-12.2013>.
1019. Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I. Autophagy has a key role in the pathophysiology of schizophrenia. *Mol Psychiatr* 2015; 20:126-32; <http://dx.doi.org/10.1038/mp.2013.174>.
1020. Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. *Eur Neuropsychopharm* 2011; 21:355-61; <http://dx.doi.org/10.1016/j.euroneuro.2010.06.004>.
1021. Nishino I. Autophagic vacuolar myopathy. *Semin Pediatr Neurol* 2006; 13:90-5; <http://dx.doi.org/10.1016/j.spen.2006.06.004>.
1022. Girolamo F, Lia A, Amati A, Strippoli M, Coppola C, Virgintino D, Roncali L, Toscano A, Serlenga L, Trojano M. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. *Neuropath Appl Neuro* 2013; 39:736-49; <http://dx.doi.org/10.1111/nan.12040>.
1023. Temiz F, Wehl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. *J Neurol Sci* 2009; 278:25-9; <http://dx.doi.org/10.1016/j.jns.2008.11.010>.
1024. Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C, Maiuri L, Maseri A, D'Angelo A, Bianchi ME, et al. Activated platelets present high mobility group box 1 to neutrophils,



- inducing autophagy and promoting the extrusion of neutrophil extracellular traps. *J Thromb Haemost* 2014; 12:2074-88; <http://dx.doi.org/10.1111/jth.12710>.
1025. Screen M, Raheem O, Holmlund-Hampf J, Jonson PH, Huovinen S, Hackman P, Udd B. Gene expression profiling in tibial muscular dystrophy reveals unfolded protein response and altered autophagy. *PLoS One* 2014; 9:e90819; <http://dx.doi.org/10.1371/journal.pone.0090819>.
1026. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. *BMJ Open* 2014; 4:e004552; <http://dx.doi.org/10.1136/bmjopen-2013-004552>.
1027. Lin NY, Beyer C, Giessel A, Kireva T, Scholtyssek C, Uderhardt S, Munoz LE, Dees C, Distler A, Wirtz S, et al. Autophagy regulates TNF $\alpha$ -mediated joint destruction in experimental arthritis. *Ann Rheum Dis* 2013; 72:761-8; <http://dx.doi.org/10.1136/annrheumdis-2012-201671>.
1028. Lin NY, Stefanica A, Distler JH. Autophagy: a key pathway of TNF-induced inflammatory bone loss. *Autophagy* 2013; 9:1253-5; <http://dx.doi.org/10.4161/auto.25467>.
1029. Tchetina EV, Poole AR, Zaitseva EM, Sharapova EP, Kashevarova NG, Taskina EA, Alekseeva LI, Semyonova LA, Glukhova SI, Kuzin AN, et al. Differences in Mammalian target of rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. *Arthritis* 2013; 2013:461486; <http://dx.doi.org/10.1155/2013/461486>.
1030. Mitroulis I, Kourtzelis I, Kambas K, Chrysanthopoulou A, Ritis K. Evidence for the involvement of mTOR inhibition and basal autophagy in familial Mediterranean fever phenotype. *Hum Immunol* 2011; 72:135-8; <http://dx.doi.org/10.1016/j.humimm.2010.11.006>.
1031. Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A, D'Osualdo A, Fraldi A, Ballabio A, Ravazzolo R, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). *Ann Rheum Dis* 2013; 72:1044-52; <http://dx.doi.org/10.1136/annrheumdis-2012-201952>.
1032. Remijnsen Q, Vanden Berghe T, Wirawan E, Asselbergh B, Parthoens E, De Rycke R, Noppen S, Delforge M, Willems J, Vandenaebelle P. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. *Cell Res* 2011; 21:290-304; <http://dx.doi.org/10.1038/cr.2010.150>.
1033. Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, Drosos GI, Boumpas DT, Ritis K. 2011. Neutrophil extracellular trap formation is associated with IL-1 $\beta$  and autophagy-related signaling in gout. *PLoS One*. 6, e29318.
1034. Kambas K, Mitroulis I, Apostolidou E, Girod A, Chrysanthopoulou A, Pneumatikos I, Skendros P, Kourtzelis I, Koffa M, Kotsianidis I, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. *PLoS One* 2012; 7: e45427; <http://dx.doi.org/10.1371/journal.pone.0045427>.
1035. Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, Sivridis E, Koffa M, Giatromanolaki A, Boumpas DT, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. *J Pathol* 2014; 233:294-307; <http://dx.doi.org/10.1002/path.4359>.
1036. Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1 $\beta$ . *EMBO J* 2011; 30:4701-11; <http://dx.doi.org/10.1038/emboj.2011.398>.
1037. Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, Arelaki S, Froudarakis M, Nakopoulou L, Giatromanolaki A, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. *Ann Rheum Dis* 2013.
1038. Masini M, Bugliani M, Lupi R, del Guerra S, Boggi U, Filipponi F, Marselli L, Masiello P, Marchetti P. Autophagy in human type 2 diabetes pancreatic beta cells. *Diabetologia* 2009; 52:1083-6; <http://dx.doi.org/10.1007/s00125-009-1347-2>.
1039. Mizukami H, Takahashi K, Inaba W, Tsuboi K, Osonoi S, Yoshida T, Yagihashi S. Involvement of oxidative stress-induced DNA damage, endoplasmic reticulum stress, and autophagy deficits in the decline of beta-cell mass in Japanese type 2 diabetic patients. *Diabetes Care* 2014; 37:1966-74; <http://dx.doi.org/10.2337/dc13-2018>.
1040. Ost A, Svensson K, Ruishalme I, Brannmark C, Franck N, Krook H, Sandstrom P, Kjolhede P, Stralfors P. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. *Mol Med* 2010; 16:235-46; <http://dx.doi.org/10.2119/molmed.2010.00023>.
1041. Kosacka J, Kern M, Kloting N, Paeschke S, Rudich A, Haim Y, Gericke M, Serke H, Stumvoll M, Bechmann I, et al. Autophagy in adipose tissue of patients with obesity and type 2 diabetes. *Mol Cell Endocrinol* 2015; 409:21-32; <http://dx.doi.org/10.1016/j.mce.2015.03.015>.
1042. Stienstra R, Haim Y, Riahi Y, Netea M, Rudich A, Leibowitz G. Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes. *Diabetologia* 2014; 57:1505-16; <http://dx.doi.org/10.1007/s00125-014-3255-3>.
1043. Berton G. Editorial: Gigantism: a new way to prolong neutrophil life. *J Leukocyte Biol* 2014; 96:505-6; <http://dx.doi.org/10.1189/jlb.3CE0214-107R>.
1044. Dyugovskaya L, Berger S, Polyakov A, Lavie L. The development of giant phagocytes in long-term neutrophil cultures. *J Leukocyte Biol* 2014; 96:511-21; <http://dx.doi.org/10.1189/jlb.0813437>.
1045. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. *EMBO J* 2012; 31:1055-7; <http://dx.doi.org/10.1038/emboj.2012.2>.
1046. Panzarini E, Inguscio V, Fimia GM, Dini L. Rose Bengal Acetate PhotoDynamic Therapy (RBAC-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells. *PLoS One* 2014; 9:e105778.
1047. Santin G, Bottone MG, Malatesta M, Scovassi AI, Bottiroli G, Pellicciari C, Croce AC. Regulated forms of cell death are induced by the photodynamic action of the fluorogenic substrate, Hypocrellin B-acetate. *J Photochem Photobiol B* 2013; 125:90-7; <http://dx.doi.org/10.1016/j.jphotobiol.2013.05.006>.
1048. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. *Trends Mol Med* 2013; 19:428-46; <http://dx.doi.org/10.1016/j.molmed.2013.04.005>.
1049. Garg AD, Krysko DV, Vandenaebelle P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. *Oncoimmunology* 2012; 1:786-8; <http://dx.doi.org/10.4161/onci.19750>.
1050. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. *Cell Death Differ* 2014; 21:26-38; <http://dx.doi.org/10.1038/cdd.2013.48>.
1051. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol* 2013; 31:51-72; <http://dx.doi.org/10.1146/annurev-immunol-032712-100008>.
1052. Dudek AM, Garg AD, Krysko DV, De Ruyscher D, Agostinis P. Inducers of immunogenic cancer cell death. *Cytokine Growth Fact Rev* 2013; 24:319-33; <http://dx.doi.org/10.1016/j.cytogr.2013.01.005>.
1053. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenaebelle P, Krysko DV, Mathieu C, Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. *Autophagy* 2013; 9:1292-307; <http://dx.doi.org/10.4161/auto.25399>.
1054. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. *EMBO J* 2012; 31:1062-79; <http://dx.doi.org/10.1038/emboj.2011.497>.
1055. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegratti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. *Science* 2011; 334:1573-7; <http://dx.doi.org/10.1126/science.1208347>.
1056. Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K, Junger WG, Robson SC, Wu Y. P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR

- signaling pathways to mediate tumor cell death. *PLoS One* 2013; 8: e60184; <http://dx.doi.org/10.1371/journal.pone.0060184>.
1057. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. *Trends Pharmacol Sci* 2007; 28:465-72; <http://dx.doi.org/10.1016/j.tips.2007.07.002>.
1058. Garg AD, Dudek AM, Agostinis P. Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A. *Cell Death Dis* 2013; 4:e826; <http://dx.doi.org/10.1038/cddis.2013.372>.
1059. Garg AD, Dudek AM, Agostinis P. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. *Oncoimmunology* 2013; 2:e26260; <http://dx.doi.org/10.4161/onci.26260>.
1060. Hermans G, Casaer MP, Clerckx B, Guiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. *Lancet Respir Med* 2013; 1:621-9; [http://dx.doi.org/10.1016/S2213-2600\(13\)70183-8](http://dx.doi.org/10.1016/S2213-2600(13)70183-8).
1061. Vanhorebeek I, Gunst J, Derde S, Derese I, Boussemaere M, Guiza F, Martinet W, Timmermans JP, D'Hoore A, Wouters PJ, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. *J Clin Endocrinol Metab* 2011; 96: E633-45; <http://dx.doi.org/10.1210/jc.2010-2563>.
1062. Czaja MJ, Ding WX, Donohue TM, Jr., Friedman SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD, Ou JH, et al. Functions of autophagy in normal and diseased liver. *Autophagy* 2013; 9:1131-58; <http://dx.doi.org/10.4161/auto.25063>.
1063. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* 2012; 142:938-46; <http://dx.doi.org/10.1053/j.gastro.2011.12.044>.
1064. Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A. Autophagy in lysosomal storage disorders. *Autophagy* 2012; 8:719-30; <http://dx.doi.org/10.4161/auto.19469>.
1065. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, et al. Interplay of LRRK2 with chaperone-mediated autophagy. *Nat Neurosci* 2013; 16:394-406; <http://dx.doi.org/10.1038/nn.3350>.
1066. Napolitano G, Johnson JL, He J, Rocca CJ, Monfregola J, Pestonjasp K, Cherqui S, Katz SD. Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis. *EMBO Mol Med* 2015; 7:158-74; <http://dx.doi.org/10.15252/emmm.201404223>.
1067. Venugopal B, Mesires NT, Kennedy JC, Curcio-Morelli C, Laplante JM, Dice JF, Slaugenhaupt SA. Chaperone-mediated autophagy is defective in mucopolidosis type IV. *J Cell Physiol* 2009; 219:344-53; <http://dx.doi.org/10.1002/jcp.21676>.
1068. Franch HA. Pathways of proteolysis affecting renal cell growth. *Curr Opin Nephrol Hypertens* 2002; 11:445-50; <http://dx.doi.org/10.1097/00041552-200207000-00012>.
1069. Sooparb S, Price SR, Shaoguang J, Franch HA. Suppression of chaperone-mediated autophagy in the renal cortex during acute diabetes mellitus. *Kidney Int* 2004; 65:2135-44; <http://dx.doi.org/10.1111/j.1523-1755.2004.00639.x>.
1070. Chen ZH, Kim HP, Sciarba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, Dhir R, Landreneau RJ, Schuchert MJ, Yousem SA, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. *PLoS One* 2008; 3:e3316.
1071. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. *JAMA* 2007; 298:187-93; <http://dx.doi.org/10.1001/jama.298.2.187>.
1072. Merlini L, Nishino I, Consortium for Autophagy in Muscular D. 201st ENMC International Workshop: Autophagy in muscular dystrophies—translational approach, 1-3 November 2013, Bussum, The Netherlands. *Neuromuscular Disord* 2014; 24:546-61; <http://dx.doi.org/10.1016/j.nmd.2014.03.009>.
1073. Berry DL, Baehrecke EH. Growth arrest and autophagy are required for salivary gland cell degradation in *Drosophila*. *Cell* 2007; 131:1137-48; <http://dx.doi.org/10.1016/j.cell.2007.10.048>.
1074. Aits S, Gustafsson L, Hallgren O, Brest P, Gustafsson M, Trullsson M, Mossberg AK, Simon HU, Mograbi B, Svanborg C. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death. *Int J Cancer* 2009; 124:1008-19; <http://dx.doi.org/10.1002/ijc.24076>.
1075. Koike M, Shibata M, Tadakoshi M, Gotoh K, Komatsu M, Waguri S, Kawahara N, Kuida K, Nagata S, Kominami E, et al. Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. *Am J Pathol* 2008; 172:454-69; <http://dx.doi.org/10.2353/ajpath.2008.070876>.
1076. Hou YC, Hannigan AM, Gorski SM. An executioner caspase regulates autophagy. *Autophagy* 2009; 5:530-3; <http://dx.doi.org/10.4161/auto.5.4.8061>.
1077. Nezis IP, Shrivage BV, Sagona AP, Lamark T, Bjorkoy G, Johansen T, Rusten TE, Brech A, Baehrecke EH, Stenmark H. Autophagic degradation of dBruce controls DNA fragmentation in nurse cells during late *Drosophila melanogaster* oogenesis. *J Cell Biol* 2010; 190:523-31; <http://dx.doi.org/10.1083/jcb.201002035>.
1078. Piras A, Gianetto D, Conte D, Bosone A, Vercelli A. Activation of autophagy in a rat model of retinal ischemia following high intraocular pressure. *PLoS One* 2011; 6:e22514; <http://dx.doi.org/10.1371/journal.pone.0022514>.
1079. Schwarze PE, Seglen PO. Reduced autophagic activity, improved protein balance and enhanced in vitro survival of hepatocytes isolated from carcinogen-treated rats. *Exp Cell Res* 1985; 157:15-28; [http://dx.doi.org/10.1016/0014-4827\(85\)90148-X](http://dx.doi.org/10.1016/0014-4827(85)90148-X).
1080. Liu Y, Shoji-Kawata S, Sumpter RM, Jr., Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, et al. Autosis is a Na<sup>+</sup>, K<sup>+</sup>-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc Natl Acad Sci USA* 2013; 110:20364-71; <http://dx.doi.org/10.1073/pnas.1319661110>.
1081. Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonfilii L, Eleuteri AM, Mozzicafreddo M, Burattini L, et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. *Brit J Cancer* 2013; 109:1040-50; <http://dx.doi.org/10.1038/bjc.2013.420>.
1082. Russo R, Berliocchi L, Adornetto A, Varano GP, Cavaliere F, Nucci C, Rotiroli D, Morrone LA, Bagetta G, Corasaniti MT. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo. *Cell Death Dis* 2011; 2:e144.
1083. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. *Cell Death Differ* 2012; 19:87-95.
1084. Beaulaton J, Lockshin RA. Ultrastructural study of the normal degeneration of the intersegmental muscles of *Antheraea polyphemus* and *Manduca sexta* (Insecta, Lepidoptera) with particular reference of cellular autophagy. *J Morphol* 1977; 154:39-57; <http://dx.doi.org/10.1002/jmor.1051540104>.
1085. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. *Anat Embryol* 1990; 181:195-213.
1086. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death Differ* 2011.
1087. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. *Nature Rev Mol Cell Biol* 2008; 9:1004-10; <http://dx.doi.org/10.1038/nrm2529>.
1088. Richard VR, Beach A, Piano A, Leonov A, Feldman R, Burstein MT, Kyrakov P, Gomez-Perez A, Arlia-Ciommo A, Baptista S, et al. Mechanism of liponecrosis, a distinct mode of programmed cell death. *Cell Cycle* 2014; 13:3707-26; <http://dx.doi.org/10.4161/15384101.2014.965003>.
1089. Sheibani S, Richard VR, Beach A, Leonov A, Feldman R, Mattie S, Khelghatybana L, Piano A, Greenwood M, Vali H, et al. Macromitophagy, neutral lipids synthesis, and peroxisomal fatty acid

- oxidation protect yeast from “liponecrosis”, a previously unknown form of programmed cell death. *Cell Cycle* 2014; 13:138-47; <http://dx.doi.org/10.4161/cc.26885>.
1090. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death Differ* 2009; 16:1093-107; <http://dx.doi.org/10.1038/cdd.2009.44>.
  1091. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ* 2015; 22:58-73; <http://dx.doi.org/10.1038/cdd.2014.137>.
  1092. Minina EA, Bozhkov PV, Hofius D. Autophagy as initiator or executioner of cell death. *Trends Plant Sci* 2014; 19:692-7.
  1093. van Doorn WG, Beers EP, Dangel JL, Franklin-Tong VE, Gallois P, Hara-Nishimura I, Jones AM, Kawai-Yamada M, Lam E, Mundy J, et al. Morphological classification of plant cell deaths. *Cell Death Differ* 2011; 18:1241-6; <http://dx.doi.org/10.1038/cdd.2011.36>.
  1094. Kwon SI, Cho HJ, Jung JH, Yoshimoto K, Shirasu K, Park OK. The Rab GTPase RabG3b functions in autophagy and contributes to tracheary element differentiation in Arabidopsis. *Plant J* 2010; 64:151-64.
  1095. Minina EA, Filonova LH, Fukada K, Savenkov EI, Gogvadze V, Clapham D, Sanchez-Vera V, Suarez MF, Zhivotovskiy B, Daniel G, et al. Autophagy and metacaspase determine the mode of cell death in plants. *J Cell Biol* 2013; 203:917-27; <http://dx.doi.org/10.1083/jcb.201307082>.
  1096. Hofius D, Schultz-Larsen T, Joensen J, Tsitsigiannis DI, Petersen NH, Mattsson O, Jorgensen LB, Jones JD, Mundy J, Petersen M. Autophagic components contribute to hypersensitive cell death in Arabidopsis. *Cell* 2009; 137:773-83; <http://dx.doi.org/10.1016/j.cell.2009.02.036>.
  1097. Giusti C, Tresse E, Luciani MF, Golstein P. Autophagic cell death: analysis in Dictyostelium. *Biochim Biophys Acta* 2009; 1793:1422-31; <http://dx.doi.org/10.1016/j.bbamcr.2008.12.005>.
  1098. Luciani MF, Giusti C, Harms B, Oshima Y, Kikuchi H, Kubohara Y, Golstein P. Atg1 allows second-signaled autophagic cell death in Dictyostelium. *Autophagy* 2011; 7:501-8; <http://dx.doi.org/10.4161/autophagy.7.5.14957>.
  1099. Uchikawa T, Yamamoto A, Inouye K. Origin and function of the stalk-cell vacuole in Dictyostelium. *Dev Biol* 2011; 352:48-57; <http://dx.doi.org/10.1016/j.ydbio.2011.01.014>.
  1100. Guimar[ã]es CA, Benchimol M, Amarante-Mendes GP, Linden R. Alternative programs of cell death in developing retinal tissue. *J Biol Chem* 2003; 278:41938-46; <http://dx.doi.org/10.1074/jbc.M306547200>.
  1101. Lossi L, Gambino G, Mioletti S, Merighi A. In vivo analysis reveals different apoptotic pathways in pre- and postmigratory cerebellar granule cells of rabbit. *J Neurobiol* 2004; 60:437-52; <http://dx.doi.org/10.1002/neu.20032>.
  1102. Lossi L, Alasia S, Salio C, Merighi A. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. *Prog Neurobiol* 2009; 88:221-45; <http://dx.doi.org/10.1016/j.pneurobio.2009.01.002>.
  1103. Thorburn A. I think autophagy controls the death of my cells: what do I do to get my paper published? *Autophagy* 2011; 7:455-6; <http://dx.doi.org/10.4161/autophagy.7.5.14797>.
  1104. Kaushik S, Bandyopadhyay U, Sridhar S, Kiffin R, Martinez-Vicente M, Kon M, Orenstein SJ, Wong E, Cuervo AM. Chaperone-mediated autophagy at a glance. *J Cell Sci* 2011; 124:495-9; <http://dx.doi.org/10.1242/jcs.073874>.
  1105. Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. *Curr Opin Cell Biol* 2010; 23:184-9; <http://dx.doi.org/10.1016/j.ceb.2010.10.009>.
  1106. Kaushik S, Cuervo AM. Methods to monitor chaperone-mediated autophagy. *Methods Enzymol* 2009; 452:297-324; [http://dx.doi.org/10.1016/S0076-6879\(08\)03619-7](http://dx.doi.org/10.1016/S0076-6879(08)03619-7).
  1107. Dice JF. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. *Trends Biochem Sci* 1990; 15:305-9; [http://dx.doi.org/10.1016/0968-0004\(90\)90019-8](http://dx.doi.org/10.1016/0968-0004(90)90019-8).
  1108. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* 1996; 273:501-3; <http://dx.doi.org/10.1126/science.273.5274.501>.
  1109. Cuervo AM, Dice JF. Unique properties of lamp2a compared to other lamp2 isoforms. *J Cell Sci* 2000; 113:4441-50.
  1110. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. *Autophagy* 2005; 1:141-5; <http://dx.doi.org/10.4161/autophagy.1.3.2000>.
  1111. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. *Mol Cell Biol* 2008; 28:5747-63; <http://dx.doi.org/10.1128/MCB.02070-07>.
  1112. Aniento F, Emans N, Griffiths G, Gruenberg J. Cytoplasmic dynein-dependent vesicular transport from early to late endosomes. *J Cell Biol* 1993; 123:1373-87; <http://dx.doi.org/10.1083/jcb.123.6.1373>.
  1113. Salvador N, Aguado C, Horst M, Knecht E. Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. *J Biol Chem* 2000; 275:27447-56.
  1114. Koga H, Martinez-Vicente M, Macian F, Verkhusha VV, Cuervo AM. A photoconvertible fluorescent reporter to track chaperone-mediated autophagy. *Nat Commun* 2011; 2:386; <http://dx.doi.org/10.1038/ncomms1393>.
  1115. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, Potolicchio I, Nieves E, Cuervo AM, Santambrogio L. Microautophagy of cytosolic proteins by late endosomes. *Dev Cell* 2011; 20:131-9; <http://dx.doi.org/10.1016/j.devcel.2010.12.003>.
  1116. Arndt V, Dick N, Tawo R, Dreiseidler M, Wenzel D, Hesse M, Furst DO, Saftig P, Saint R, Fleischmann BK, et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. *Curr Biol* 2010; 20:143-8; <http://dx.doi.org/10.1016/j.cub.2009.11.022>.
  1117. Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, Tanaka Y, Lullmann-Rauch R, Hartmann D, Heeren J, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. *Mol Biol Cell* 2004; 15:3132-45; <http://dx.doi.org/10.1091/mbc.E04-02-0103>.
  1118. Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, Von Figura K, Saftig P. Role of LAMP-2 in lysosome biogenesis and autophagy. *Mol Biol Cell* 2002; 13:3355-68; <http://dx.doi.org/10.1091/mbc.E02-02-0114>.
  1119. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. *EMBO J* 2007; 26:313-24; <http://dx.doi.org/10.1038/sj.emboj.7601511>.
  1120. Fujiwara Y, Furuta A, Kikuchi H, Aizawa S, Hatanaka Y, Konya C, Uchida K, Yoshimura A, Tamai Y, Wada K, et al. Discovery of a novel type of autophagy targeting RNA. *Autophagy* 2013; 9:403-9; <http://dx.doi.org/10.4161/autophagy.23002>.
  1121. Fujiwara Y, Hase K, Wada K, Kabuta T. An RNautophagy/DNautophagy receptor, LAMP2C, possesses an arginine-rich motif that mediates RNA/DNA-binding. *Biochem Biophys Res Commun* 2015; 460:281-6; <http://dx.doi.org/10.1016/j.bbrc.2015.03.025>.
  1122. Fujiwara Y, Kikuchi H, Aizawa S, Furuta A, Hatanaka Y, Konya C, Uchida K, Wada K, Kabuta T. Direct uptake and degradation of DNA by lysosomes. *Autophagy* 2013; 9:1167-71; <http://dx.doi.org/10.4161/autophagy.24880>.
  1123. Hase K, Fujiwara Y, Kikuchi H, Aizawa S, Hakuno F, Takahashi S, Wada K, Kabuta T. RNautophagy/DNautophagy possesses selectivity for RNA/DNA substrates. *Nucleic Acids Res* 2015; 43:6439-49; <http://dx.doi.org/10.1093/nar/gkv579>.
  1124. Furuta A, Kikuchi H, Fujita H, Yamada D, Fujiwara Y, Kabuta T, Nishino I, Wada K, Uchiyama Y. Property of lysosomal storage disease associated with midbrain pathology in the central nervous system of lamp-2-deficient mice. *Am J Pathol* 2015; 185:1713-23; <http://dx.doi.org/10.1016/j.ajpath.2015.02.015>.
  1125. Rothaug M, Stroobants S, Schweizer M, Peters J, Zunke F, Allerding M, D'Hooge R, Saftig P, Blanz J. LAMP-2 deficiency leads to hippocampal dysfunction but normal clearance of neuronal substrates of chaperone-mediated autophagy in a mouse model for Danon disease. *Acta Neuropathol Commun* 2015; 3:6; <http://dx.doi.org/10.1186/s40478-014-0182-y>.

1126. Ulbricht A, Eppler FJ, Tapia VE, van der Ven PF, Hampe N, Hersch N, Vakeel P, Stadel D, Haas A, Saftig P, et al. Cellular mechano-transduction relies on tension-induced and chaperone-assisted autophagy. *Curr Biol* 2013; 23:430-5; <http://dx.doi.org/10.1016/j.cub.2013.01.064>.
1127. Carra S, Seguin SJ, Lambert H, Landry J. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. *J Biol Chem* 2008; 283:1437-44; <http://dx.doi.org/10.1074/jbc.M706304200>.
1128. Carra S, Seguin SJ, Landry J. HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. *Autophagy* 2008; 4:237-9; <http://dx.doi.org/10.4161/auto.5407>.
1129. Niemann A, Baltes J, Elsasser HP. Fluorescence properties and staining behavior of monodansylpentane, a structural homologue of the lysosomotropic agent monodansylcadaverine. *J Histochem Cytochem* 2001; 49:177-85; <http://dx.doi.org/10.1177/002215540104900205>.
1130. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, Yahalom J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res* 2001; 61:439-44.
1131. Florez-McClure ML, Linseman DA, Chu CT, Barker PA, Bouchard RJ, Le SS, Laessig TA, Heidenreich KA. The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons. *J Neurosci* 2004; 24:4498-509; <http://dx.doi.org/10.1523/JNEUROSCI.5744-03.2004>.
1132. Moriyasu Y, Hattori M, Jauh G-Y, Rogers JC. Alpha tonoplast intrinsic protein is specifically associated with vacuole membrane involved in an autophagic process. *Plant Cell Physiol* 2003; 44:795-802; <http://dx.doi.org/10.1093/pcp/pcg100>.
1133. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. *Eur J Neurosci* 2013; 37:1949-61; <http://dx.doi.org/10.1111/ejn.12169>.
1134. Biederbick A, Kern HF, Elsasser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. *Eur J Cell Biol* 1995; 66:3-14.
1135. Hoyer-Hansen M, Bastholm L, Mathiasen IS, Elling F, Jaattela M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. *Cell Death Differ* 2005; 12:1297-309; <http://dx.doi.org/10.1038/sj.cdd.4401651>.
1136. Gutierrez MG, Munafò DB, Beron W, Colombo MI. Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. *J Cell Sci* 2004; 117:2687-97; <http://dx.doi.org/10.1242/jcs.01114>.
1137. Fogel JL, Thein TZ, Mariani FV. Use of LysoTracker to detect programmed cell death in embryos and differentiating embryonic stem cells. *J Vis Exp* 2012; 68; doi: 10.3791/4254
1138. Freundt EC, Czapiga M, Lenardo MJ. Photoconversion of LysoTracker Red to a green fluorescent molecule. *Cell Res* 2007; 17:956-8; <http://dx.doi.org/10.1038/cr.2007.80>.
1139. Oeste CL, Seco E, Patton WF, Boya P, Perez-Sala D. Interactions between autophagic and endo-lysosomal markers in endothelial cells. *Histochem Cell Biol* 2013; 139:659-70; <http://dx.doi.org/10.1007/s00418-012-1057-6>.
1140. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. *Nat Rev Drug Discov* 2007; 6:304-12; <http://dx.doi.org/10.1038/nrd2272>.
1141. Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex—at the crossroads of autophagy and beyond. *Trends Cell Biol* 2010; 20:355-62; <http://dx.doi.org/10.1016/j.tcb.2010.03.002>.
1142. Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. *Autophagy* 2008; 4:600-6; <http://dx.doi.org/10.4161/auto.6260>.
1143. Simonsen A, Tooze SA. Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. *J Cell Biol* 2009; 186:773-82; <http://dx.doi.org/10.1083/jcb.200907014>.
1144. Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun JI, Woo HN, Cho DH, Choi B, Lee H, Kim JH, et al. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. *J Biol Chem* 2005; 280:20722-9; <http://dx.doi.org/10.1074/jbc.M413934200>.
1145. Petiot A, Ogier-Denis E, Blommaert EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. *J Biol Chem* 2000; 275:992-8; <http://dx.doi.org/10.1074/jbc.275.2.992>.
1146. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschoop J, et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. *J Biol Chem* 2011; 286:9587-97; <http://dx.doi.org/10.1074/jbc.M110.202911>.
1147. Crisan TO, Plantinga TS, van de Veerdonk FL, Farcas MF, Stoffels M, Kullberg BJ, van der Meer JW, Joosten LA, Netea MG. Inflammation-independent modulation of cytokine response by autophagy in human cells. *PLoS One* 2011; 6:e18666.
1148. Kleinnijenhuis J, Oosting M, Plantinga TS, van der Meer JW, Joosten LA, Crevel RV, Netea MG. Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. *Immunology* 2011; 134:341-8; <http://dx.doi.org/10.1111/j.1365-2567.2011.03494.x>.
1149. Peral de Castro C, Jones SA, Ni Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. *J Immunol* 2012; 189:4144-53; <http://dx.doi.org/10.4049/jimmunol.1201946>.
1150. Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. *Nat Cell Biol* 2014; 16:1069-79; <http://dx.doi.org/10.1038/ncb3053>.
1151. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, Bachelot MF, Lambert A, Mathieu M, Bertrand T, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. *Nat Chem Biol* 2014; 10:1013-9; <http://dx.doi.org/10.1038/nchembio.1681>.
1152. Chen J, Chen MX, Fogo AB, Harris RC, Chen JK. mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking. *J Am Soc Nephrol* 2013; 24:198-207; <http://dx.doi.org/10.1681/ASN.2012010101>.
1153. Cantino D, Mosso R, Baccino FM. Changes induced by fasting and cycloheximide in the vacuolar apparatus of rat hepatocytes. A morphometric investigation. *Boll Soc Ital Biol Sper* 1979; 55:1884-9.
1154. Kovács J. Morphometric study of the effect of leupeptin, vinblastine, estron acetate and cycloheximide on the autophagic vacuole-lysosomal compartments in mouse seminal vesicle cells. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1983; 42:83-93; <http://dx.doi.org/10.1007/BF02890372>.
1155. Papadopoulos T, Pfeifer U. Regression of rat liver autophagic vacuoles by locally applied cycloheximide. *Lab Invest* 1986; 54:100-7.
1156. Rumpelt HJ, Albring M, Thoenes W. Prevention of D-galactosamine-induced hepatocellular autophagocytosis by cycloheximide. *Virchows Arch B Cell Pathol* 1974; 16:195-203; <http://dx.doi.org/10.1007/BF02894074>.
1157. Rumpelt HJ, Weisbach T. Effect of cycloheximide on glucagon-induced autophagy. Quantitative examinations on hepatocytes in the rat. *Am J Pathol* 1978; 91:49-55.
1158. Kovács AL, Kovács J. Autophagocytosis in mouse seminal vesicle cells in vitro. Temperature dependence and effects of vinblastine and inhibitors of protein synthesis. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1980; 32:97-104; <http://dx.doi.org/10.1007/BF02889018>.
1159. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. *Int J Radiat Biol* 2007; 83:781-91; <http://dx.doi.org/10.1080/09553000701769970>.
1160. Chaachouay H, Ohneseit P, Toulany M, Kehlback R, Multhoff G, Rodemann HP. Autophagy contributes to resistance of tumor cells to ionizing radiation. *Radiother Oncol* 2011; 99:287-92; <http://dx.doi.org/10.1016/j.radonc.2011.06.002>.
1161. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy.

- Cancer Res 2008; 68:1485-94; <http://dx.doi.org/10.1158/0008-5472.CAN-07-0562>.
1162. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Sci Signal* 2010; 3:ra31.
1163. Seglen PO, Gordon PB. Effects of lysosomotropic monoamines, diamines, amino alcohols, and other amino compounds on protein degradation and protein synthesis in isolated rat hepatocytes. *Mol Pharmacol* 1980; 18:468-75.
1164. Cheong H, Lindsten T, Wu J, Lu C, Thompson CB. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. *Proc Natl Acad Sci USA* 2011; 108:11121-6; <http://dx.doi.org/10.1073/pnas.1107969108>.
1165. Pellegrini P, Strambi A, Zipoli C, Hagg-Olofsson M, Buoncervello M, Linder S, De Milito A. Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. *Autophagy* 2014; 10:562-71; <http://dx.doi.org/10.4161/auto.27901>.
1166. Fischer S, Ronellenfitch MW, Thiebold AL, Harter PN, Reichert S, Kogel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, et al. Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. *PLoS One* 2014; 9:e94921; <http://dx.doi.org/10.1371/journal.pone.0094921>.
1167. Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F, Debatin KM, Fulda S. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. *Cell Death Differ* 2012; 19:1337-46; <http://dx.doi.org/10.1038/cdd.2012.10>.
1168. Potze L, Mullauer FB, Colak S, Kessler JH, Medema JP. Betulinic acid-induced mitochondrial-dependent cell death is counterbalanced by an autophagic salvage response. *Cell Death Dis* 2014; 5:e1169; <http://dx.doi.org/10.1038/cddis.2014.139>.
1169. Broniatowski M, Flasiński M, Wydro P. Investigation of the interactions of lupane type pentacyclic triterpenes with outer leaflet membrane phospholipids—Langmuir monolayer and synchrotron X-ray scattering study. *J Colloid Interface Sci* 2012; 381:116-24; <http://dx.doi.org/10.1016/j.jcis.2012.05.020>.
1170. Chen Y, Sun R, Wang B. Monolayer behavior of binary systems of betulinic acid and cardiolipin: thermodynamic analyses of Langmuir monolayers and AFM study of Langmuir-Blodgett monolayers. *J Colloid Interface Sci* 2011; 353:294-300; <http://dx.doi.org/10.1016/j.jcis.2010.09.019>.
1171. Gao M, Lau PM, Kong SK. Mitochondrial toxin betulinic acid induces in vitro eryptosis in human red blood cells through membrane permeabilization. *Arch Toxicol* 2014; 88:755-68.
1172. Wei P, Zhang L, Lu Y, Man N, Wen L. C60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy. *Nanotechnology* 2010; 21:495101; <http://dx.doi.org/10.1088/0957-4484/21/49/495101>.
1173. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. *Trends Cell Biol* 1998; 8:397-403; [http://dx.doi.org/10.1016/S0962-8924\(98\)01346-4](http://dx.doi.org/10.1016/S0962-8924(98)01346-4).
1174. Mehdi S. Cell-penetrating inhibitors of calpain. *Trends Biochem Sci* 1991; 16:150-3; [http://dx.doi.org/10.1016/0968-0004\(91\)90058-4](http://dx.doi.org/10.1016/0968-0004(91)90058-4).
1175. Holen I, Gordon PB, Seglen PO. Inhibition of hepatocytic autophagy by okadaic acid and other protein phosphatase inhibitors. *Eur J Biochem* 1993; 215:113-22; <http://dx.doi.org/10.1111/j.1432-1033.1993.tb18013.x>.
1176. Sasaki K, Murata M, Yasumoto T, Mieskes G, Takai A. Affinity of okadaic acid to type-1 and type-2A protein phosphatases is markedly reduced by oxidation of its 27-hydroxyl group. *Biochem J* 1994; 298:259-62; <http://dx.doi.org/10.1042/bj2980259>.
1177. Robinson DG, Albrecht S, Moriyasu Y. The V-ATPase inhibitors concanamycin A and bafilomycin A lead to Golgi swelling in tobacco BY-2 cells. *Protoplasma* 2004; 224:255-60; <http://dx.doi.org/10.1007/s00709-004-0070-6>.
1178. Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, Wu YQ, Li TY, Liang Y, Lu Z, et al. The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. *Cell Metab* 2014; 20:526-40; <http://dx.doi.org/10.1016/j.cmet.2014.06.014>.
1179. Wu YC, Wu WK, Li Y, Yu L, Li ZJ, Wong CC, Li HT, Sung JJ, Cho CH. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. *Biochem Biophys Res Commun* 2009; 382:451-6; <http://dx.doi.org/10.1016/j.bbrc.2009.03.051>.
1180. Ostefeld MS, Hoyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sorensen T, Nylandsted J, Farkas T, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. *Autophagy* 2008; 4:487-99; <http://dx.doi.org/10.4161/auto.5774>.
1181. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest* 2007.
1182. Garcia-Garcia A, Anandhan A, Burns M, Chen H, Zhou Y, Franco R. Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP(+)-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. *Toxicol Sci* 2013; 136:166-82; <http://dx.doi.org/10.1093/toxsci/kft188>.
1183. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. *J Clin Invest* 2008; 118:79-88; <http://dx.doi.org/10.1172/JCI33700>.
1184. Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. *J Cell Biol* 1981; 90:665-9; <http://dx.doi.org/10.1083/jcb.90.3.665>.
1185. Matsuo K, Higuchi T, Maeshima M, Nakamura K. A vacuolar-type H<sup>+</sup>-ATPase in a nonvacuolar organelle is required for the sorting of soluble vacuolar protein precursors in tobacco cells. *Plant Cell* 1997; 9:533-46.
1186. Arstila AU, Nuuja IJ, Trump BF. Studies on cellular autophagocytosis. Vinblastine-induced autophagy in the rat liver. *Exp Cell Res* 1974; 87:249-52; [http://dx.doi.org/10.1016/0014-4827\(74\)90477-7](http://dx.doi.org/10.1016/0014-4827(74)90477-7).
1187. Hirsimaki Y, Arstila AU, Trump BF. Autophagocytosis: in vitro induction by microtubule poisons. *Exp Cell Res* 1975; 92:11-4; [http://dx.doi.org/10.1016/0014-4827\(75\)90630-8](http://dx.doi.org/10.1016/0014-4827(75)90630-8).
1188. Kominami E, Hashida S, Khairallah EA, Katunuma N. Sequestration of cytoplasmic enzymes in an autophagic vacuole-lysosomal system induced by injection of leupeptin. *J Biol Chem* 1983; 258:6093-100.
1189. Réz G, Fellingner E, Reti M, Biczo I, Kovács AL. Time course of quantitative morphological changes of the autophagic-lysosomal compartment of murine seminal vesicle epithelial cells under the influence of vinblastine. *J Submicrosc Cytol Pathol* 1990; 22:529-34.
1190. Oliva O, Réz G, Pálfi Z, Fellingner E. Dynamics of vinblastine-induced autophagocytosis in murine pancreatic acinar cells: influence of cycloheximide post-treatments. *Exp Mol Pathol* 1992; 56:76-86; [http://dx.doi.org/10.1016/0014-4800\(92\)90025-7](http://dx.doi.org/10.1016/0014-4800(92)90025-7).
1191. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggiero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. *PLoS Biol* 2009; 7:e38; <http://dx.doi.org/10.1371/journal.pbio.1000038>.
1192. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. *Nat Chem Biol* 2011; 7:9-17; <http://dx.doi.org/10.1038/nchembio.500>.
1193. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J Biol Chem* 2009; 284:8023-32; <http://dx.doi.org/10.1074/jbc.M900301200>.
1194. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. *Cancer Res* 2009; 69:6232-40; <http://dx.doi.org/10.1158/0008-5472.CAN-09-0299>.

1195. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. *Cancer Res* 2010; 70:288-98; <http://dx.doi.org/10.1158/0008-5472.CAN-09-1751>.
1196. Roscic A, Baldo B, Crochemore C, Marcellin D, Paganetti P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. *J Neurochem* 2011; 119:398-407; <http://dx.doi.org/10.1111/j.1471-4159.2011.07435.x>.
1197. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. *Sci Signal* 2010; 3:ra81.
1198. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. *Cell Metab* 2010; 11:467-78; <http://dx.doi.org/10.1016/j.cmet.2010.04.005>.
1199. Yamamoto A, Yue Z. Autophagy and its normal and pathogenic States in the brain. *Annu Rev Neurosci* 2014; 37:55-78; <http://dx.doi.org/10.1146/annurev-neuro-071013-014149>.
1200. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. *Proc Natl Acad Sci USA* 2010; 107:16982-7; <http://dx.doi.org/10.1073/pnas.1004498107>.
1201. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. *Nat Chem Biol* 2008; 4:295-305; <http://dx.doi.org/10.1038/nchembio.79>.
1202. Palomo GM, Cerrato T, Gargini R, Diaz-Nido J. Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells. *Hum Mol Genet* 2011; 20:2807-22; <http://dx.doi.org/10.1093/hmg/ddr187>.
1203. Bolinches-Amoros A, Molla B, Pla-Martin D, Palau F, Gonzalez-Cabo P. Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism. *Front Cell Neurosci* 2014; 8:124.
1204. Sakagami H, Kawase M, Wakabayashi H, Kurihara T. Factors that affect the type of cell death induced by chemicals. *Autophagy* 2007; 3:493-5; <http://dx.doi.org/10.4161/auto.4594>.
1205. Doelling JH, Walker JM, Friedman EM, Thompson AR, Vierstra RD. The APG8/12-activating enzyme APG7 is required for proper nutrient recycling and senescence in *Arabidopsis thaliana*. *J Biol Chem* 2002; 277:33105-14; <http://dx.doi.org/10.1074/jbc.M204630200>.
1206. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, et al. Ambra1 regulates autophagy and development of the nervous system. *Nature* 2007; 447:1121-5.
1207. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. *Nature* 2004; 432:1032-6; <http://dx.doi.org/10.1038/nature03029>.
1208. Hwang S, Maloney NS, Bruinsma MW, Goel G, Duan E, Zhang L, Shrestha B, Diamond MS, Dani A, Sosnovtsev SV, et al. Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. *Cell Host Microbe* 2012; 11:397-409; <http://dx.doi.org/10.1016/j.chom.2012.03.002>.
1209. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu CG, Yang JM. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. *Autophagy* 2009; 5:816-23; <http://dx.doi.org/10.4161/auto.9064>.
1210. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA, Gottlieb RA, Gustafsson AB. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. *Cell Death Differ* 2007; 14:146-57; <http://dx.doi.org/10.1038/sj.cdd.4401936>.
1211. Poock H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. *Nat Med* 2008; 14:1256-63; <http://dx.doi.org/10.1038/nm.1887>.
1212. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. *EMBO J* 2008; 27:1110-21; <http://dx.doi.org/10.1038/emboj.2008.31>.
1213. Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. *J Exp Med* 2007; 204:25-31; <http://dx.doi.org/10.1084/jem.20061303>.
1214. Miller BC, Zhao Z, Stephenson LM, Cadwell K, Pua HH, Lee HK, Mizushima NN, Iwasaki A, He YW, Swat W, et al. The autophagy gene ATG5 plays an essential role in B lymphocyte development. *Autophagy* 2008; 4:309-14; <http://dx.doi.org/10.4161/auto.5474>.
1215. Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, Lee HR, Chang H, Zhou FC, Gao SJ, Liang C, et al. FLIP-mediated autophagy regulation in cell death control. *Nat Cell Biol* 2009; 11:1355-62; <http://dx.doi.org/10.1038/ncb1980>.
1216. Kimball SR, Siegfried BA, Jefferson LS. Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase. *J Biol Chem* 2004; 279:54103-9; <http://dx.doi.org/10.1074/jbc.M410755200>.
1217. Blommaert EF, Luiken JJ, Blommaert PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. *J Biol Chem* 1995; 270:2320-6; <http://dx.doi.org/10.1074/jbc.270.5.2320>.
1218. Klionsky DJ, Meijer AJ, Codogno P, Neufeld TP, Scott RC. Autophagy and p70S6 kinase. *Autophagy* 2005; 1:59-61; <http://dx.doi.org/10.4161/auto.1.1.1536>.
1219. Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. *J Biol Chem* 1998; 273:3963-6; <http://dx.doi.org/10.1074/jbc.273.7.3963>.
1220. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol monophosphatase. *J Cell Biol* 2005; 170:1101-11; <http://dx.doi.org/10.1083/jcb.200504035>.
1221. Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. *J Biol Chem* 2010; 285:11061-7; <http://dx.doi.org/10.1074/jbc.R109.072181>.
1222. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. *Proc Natl Acad Sci USA* 2007; 104:19023-8; <http://dx.doi.org/10.1073/pnas.0709695104>.
1223. Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase- $\beta$ , and Bcl-2. *Mol Cell* 2007; 25:193-205; <http://dx.doi.org/10.1016/j.molcel.2006.12.009>.
1224. Decuyper JP, Kindt D, Luyten T, Welkenhuyzen K, Missiaen L, De Smedt H, Bultynck G, Parys JB. mTOR-Controlled Autophagy Requires Intracellular Ca<sup>2+</sup> Signaling. *PLoS One* 2013; 8:e61020; <http://dx.doi.org/10.1371/journal.pone.0061020>.
1225. Pereira GW, Hirata H, Fimia GM, do Carmo LG, Bincoletto C, Han SW, Stilhano RS, Ureshino RP, Bloor-Young D, Churchill G, et al. Nicotinic acid adenine dinucleotide phosphate (NAADP) regulates autophagy in cultured astrocytes. *J Biol Chem* 2011; 286:27875-81; <http://dx.doi.org/10.1074/jbc.C110.216580>.
1226. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, Wilkins AD, Sun Q, Pallauf K, MacDuff D, et al. Identification of a candidate therapeutic autophagy-inducing peptide. *Nature* 2013; 494:201-6; <http://dx.doi.org/10.1038/nature11866>.
1227. Su M, Mei Y, Sanishvili R, Levine B, Colbert CL, Sinha S. Targeting gamma-herpesvirus 68 Bcl-2-mediated down-regulation of autophagy. *J Biol Chem* 2014; 289:8029-40; <http://dx.doi.org/10.1074/jbc.M113.515361>.
1228. Winter G, Hazan R, Bakalinsky AT, Abeliovich H. Caffeine induces macroautophagy and confers a cytotoxic effect on food spoilage yeast in combination with benzoic acid. *Autophagy* 2008; 4:28-36; <http://dx.doi.org/10.4161/auto.5127>.

1229. Saiki S, Sasazawa Y, Imamichi Y, Kawajiri S, Fujimaki T, Tanida I, Kobayashi H, Sato F, Sato S, Ishikawa K, et al. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. *Autophagy* 2011; 7:176-87; <http://dx.doi.org/10.4161/autof.7.2.14074>.
1230. Tsabar M, Eapen VV, Mason JM, Memisoglu G, Waterman DP, Long MJ, Bishop DK, Haber JE. Caffeine impairs resection during DNA break repair by reducing the levels of nucleases Sae2 and Dna2. *Nucleic Acids Res* 2015; 43:6889-901; <http://dx.doi.org/10.1093/nar/gkv520>.
1231. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. *Neuro-oncology* 2010; 12:328-40; <http://dx.doi.org/10.1093/neuonc/nop005>.
1232. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, Parazzoli D, Oldani A, Minucci S, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. *Nature* 2011; 471:74-9; <http://dx.doi.org/10.1038/nature09803>.
1233. Bartholomew CR, Suzuki T, Du Z, Backues SK, Jin M, Lynch-Day MA, Umekawa M, Kamath A, Zhao M, Xie Z, et al. Ume6 transcription factor is part of a signaling cascade that regulates autophagy. *Proc Natl Acad Sci USA* 2012; 109:11206-10; <http://dx.doi.org/10.1073/pnas.1200313109>.
1234. Yi C, Ma M, Ran L, Zheng J, Tong J, Zhu J, Ma C, Sun Y, Zhang S, Feng W, et al. Function and molecular mechanism of acetylation in autophagy regulation. *Science* 2012; 336:474-7; <http://dx.doi.org/10.1126/science.1216990>.
1235. Katagiri N, Kuroda T, Kishimoto H, Hayashi Y, Kumazawa T, Kimura K. The nucleolar protein nucleophosmin is essential for autophagy induced by inhibiting Pol I transcription. *Sci Rep* 2015; 5:8903; <http://dx.doi.org/10.1038/srep08903>.
1236. Kreiner G, Bierhoff H, Armentano M, Rodriguez-Parkitna J, Sowodniok K, Naranjo JR, Bonfanti L, Liss B, Schutz G, Grummt I, et al. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. *Cell Death Differ* 2013; 20:1455-64.
1237. Furuya N, Liang XH, Levine B. Autophagy and cancer. In: Klionsky DJ, ed. *Autophagy*. Georgetown, TX: Landes Bioscience, 2004:241-55.
1238. de Medina P, Paillasse MR, Segala G, Khallouki F, Brillouet S, Dalenc F, Courbon F, Record M, Poirot M, Silvente-Poirot S. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. *Chem Phys Lipids* 2011; 164:432-7.
1239. de Medina P, Payre B, Boubekour N, Bertrand-Michel J, Terce F, Silvente-Poirot S, Poirot M. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. *Cell Death Differ* 2009; 16:1372-84.
1240. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. *Nat Chem Biol* 2007; 3:331-8.
1241. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and [a]-synuclein. *J Biol Chem* 2007; 282:5641-52.
1242. Kruger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. *Neurobiol Aging* 2012; 33:2291-305.
1243. Koshkina NV, Briggs K, Palalon F, Curley SA. Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment. *Cancer* 2014; 120:480-91.
1244. Cardenas C, Miller RA, Smith I, Bui T, Molgo J, Muller M, Vais H, Cheung KH, Yang J, Parker I, et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca<sup>2+</sup> transfer to mitochondria. *Cell* 2010; 142:270-83.
1245. Decuyper JP, Bultynck G, Parys JB. A dual role for Ca<sup>2+</sup> in autophagy regulation. *Cell Calcium* 2011; 50:242-50.
1246. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Tailler M, et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. *Cell Death Differ* 2009; 16:1006-17.
1247. Dayan F, Bilton RL, Laferriere J, Trottier E, Roux D, Pouyssegur J, Mazure NM. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway. *J Cell Physiol* 2009; 218:167-74.
1248. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. *Mol Cell Biol* 2009; 29:2570-81.
1249. Yamashita S, Yurimoto H, Murakami D, Yoshikawa M, Oku M, Sakai Y. Lag-phase autophagy in the methylotrophic yeast *Pichia pastoris*. *Genes Cells* 2009; 14:861-70.
1250. van Zutphen T, Baerends RJ, Susanna KA, de Jong A, Kuipers OP, Veenhuis M, van der Klei IJ. Adaptation of *Hansenula polymorpha* to methanol: a transcriptome analysis. *BMC Genomics* 2010; 11:1.
1251. Inoue Y, Suzuki T, Hattori M, Yoshimoto K, Ohsumi Y, Moriyasu Y. AtATG genes, homologs of yeast autophagy genes, are involved in constitutive autophagy in Arabidopsis root tip cells. *Plant Cell Physiol* 2006; 47:1641-52.
1252. Yano K, Suzuki T, Moriyasu Y. Constitutive autophagy in plant root cells. *Autophagy* 2007; 3:360-2.
1253. Gordon PB, Kisen GO, Kovacs AL, Seglen PO. Experimental characterization of the autophagic-lysosomal pathway in isolated rat hepatocytes. *Biochem Soc Symp* 1989; 55:129-43.
1254. Poli A, Gordon PB, Schwarze PE, Grinde B, Seglen PO. Effects of insulin and anchorage on hepatocytic protein metabolism and amino acid transport. *J Cell Sci* 1981; 48:1-18.
1255. Schliess F, Reissmann R, Reinehr R, vom Dahl S, Häussinger D. Involvement of integrins and Src in insulin signaling toward autophagic proteolysis in rat liver. *J Biol Chem* 2004; 279:21294-301.
1256. vom Dahl S, Dombrowski F, Schmitt M, Schliess F, Pfeifer U, Häussinger D. Cell hydration controls autophagosome formation in rat liver in a microtubule-dependent way downstream from p38MAPK activation. *Biochem J* 2001; 354:31-6.
1257. vom Dahl S, Stoll B, Gerok W, Häussinger D. Inhibition of proteolysis by cell swelling in the liver requires intact microtubular structures. *Biochem J* 1995; 308 (Pt 2):529-36.
1258. Klionsky DJ, Bruford EA, Cherry JM, Hodgkin J, Laudederkind SJ, Singer AG. In the beginning there was babble. *Autophagy* 2012; 8:1165-7.
1259. Kovacs AL, Zhang H. Role of autophagy in *Caenorhabditis elegans*. *FEBS Lett* 2010; 584:1335-41.
1260. Wu F, Li Y, Wang F, Noda NN, Zhang H. Differential function of the two Atg4 homologues in the aggregate pathway in *Caenorhabditis elegans*. *J Biol Chem* 2012; 287:29457-67.
1261. Zhang H, Wu F, Wang X, Du H, Wang X, Zhang H. The two C. elegans ATG-16 homologs have partially redundant functions in the basal autophagy pathway. *Autophagy* 2013; 9:1965-74.
1262. Zhang Y, Yan L, Zhou Z, Yang P, Tian E, Zhang K, Zhao Y, Li Z, Song B, Han J, et al. SEPA-1 mediates the specific recognition and degradation of P granule components by autophagy in *C. elegans*. *Cell* 2009; 136:308-21.
1263. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. *Cell Death Dis* 2010; 1:e10.
1264. Samara C, Syntichaki P, Tavernarakis N. Autophagy is required for necrotic cell death in *Caenorhabditis elegans*. *Cell Death Differ* 2008; 15:105-12.
1265. Alberti A, Michelet X, Djeddi A, Legouis R. The autophagosomal protein LGG-2 acts synergistically with LGG-1 in dauer formation and longevity in *C. elegans*. *Autophagy* 2010; 6:622-33.
1266. Manil-Segalen M, Lefebvre C, Jenzer C, Trichet M, Boulogne C, Satiat-Jeunemaitre B, Legouis R. The *C. elegans* LC3 acts downstream of GABARAP to degrade autophagosomes by interacting with the HOPS subunit VPS39. *Dev Cell* 2014; 28:43-55; <http://dx.doi.org/10.1016/j.devcel.2013.11.022>.

1267. Kang C, You YJ, Avery L. Dual roles of autophagy in the survival of *Caenorhabditis elegans* during starvation. *Genes Dev* 2007; 21:2161-71; <http://dx.doi.org/10.1101/gad.1573107>.
1268. Liang Q, Yang P, Tian E, Han J, Zhang H. Dual roles of autophagy in the survival of *Caenorhabditis elegans* during starvation. *Autophagy* 2012; 8:1426-33; <http://dx.doi.org/10.4161/auto.21163>.
1269. Yang P, Zhang H. The coiled-coil domain protein EPG-8 plays an essential role in the autophagy pathway in *C. elegans*. *Autophagy* 2011; 7:159-65; <http://dx.doi.org/10.4161/auto.7.2.14223>.
1270. SenGupta T, Torgersen ML, Kassahun H, Vellai T, Simonsen A, Nilsen H. Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy. *Nat Commun* 2013; 4:2674; <http://dx.doi.org/10.1038/ncomms3674>.
1271. Schiavi A, Maglioni S, Palikaras K, Shaik A, Strappazon F, Brinkmann V, Torgovnick A, Castelein N, De Henau S, Braeckman BP, et al. Iron-starvation-induced mitophagy mediates lifespan extension upon mitochondrial stress in *C. elegans*. *Curr Biol* 2015; 25:1810-22; <http://dx.doi.org/10.1016/j.cub.2015.05.059>.
1272. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, et al. Regulation of autophagy by cytoplasmic p53. *Nat Cell Biol* 2008; 10:676-87; <http://dx.doi.org/10.1038/ncb1730>.
1273. Tavernarakis N, Pasparaki A, Tasdemir E, Maiuri MC, Kroemer G. The effects of p53 on whole organism longevity are mediated by autophagy. *Autophagy* 2008; 4:870-3; <http://dx.doi.org/10.4161/auto.6730>.
1274. Schiavi A, Torgovnick A, Kell A, Megalou E, Castelein N, Guccini I, Marzocchella L, Gelino S, Hansen M, Malisan F, et al. Autophagy induction extends lifespan and reduces lipid content in response to frataxin silencing in *C. elegans*. *Exp Gerontol* 2013; 48:191-201; <http://dx.doi.org/10.1016/j.exger.2012.12.002>.
1275. Palikaras K, Lionaki E, Tavernarakis N. Coordination of mitophagy and mitochondrial biogenesis during ageing in *C. elegans*. *Nature* 2015; 521:525-8; <http://dx.doi.org/10.1038/nature14300>.
1276. Zhang H, Chang JT, Guo B, Hansen M, Jia K, Kovacs AL, Kumsta C, Lapiere LR, Legouis R, Lin L, et al. Guidelines for monitoring autophagy in *Caenorhabditis elegans*. *Autophagy* 2015; 11:9-27.
1277. Alers S, Löffler AS, Paasch F, Dieterle AM, Keppeler H, Lauber K, Campbell DG, Fehrenbacher B, Schaller M, Wesselborg S, et al. Atg13 and FIP200 act independently of Ulk1 and Ulk2 in autophagy induction. *Autophagy* 2011; 7:1424-33; <http://dx.doi.org/10.4161/auto.7.12.18027>.
1278. Brown WR, Hubbard SJ, Tickle C, Wilson SA. The chicken as a model for large-scale analysis of vertebrate gene function. *Nature reviews Genetics* 2003; 4:87-98; <http://dx.doi.org/10.1038/nrg998>.
1279. Wang L, Rodrigues NA, Wu Y, Maslikowski BM, Singh N, Lacroix S, Bedard PA. Pleiotropic action of AP-1 in v-Src-transformed cells. *J Virol* 2011; 85:6725-35; <http://dx.doi.org/10.1128/JVI.01013-10>.
1280. Baba TW, Giroir BP, Humphries EH. Cell lines derived from avian lymphomas exhibit two distinct phenotypes. *Virology* 1985; 144:139-51; [http://dx.doi.org/10.1016/0042-6822\(85\)90312-5](http://dx.doi.org/10.1016/0042-6822(85)90312-5).
1281. Perez-Martin M, Perez-Perez ME, Lemaire SD, Crespo JL. Oxidative Stress Contributes to Autophagy Induction in Response to Endoplasmic Reticulum Stress in *Chlamydomonas reinhardtii*. *Plant Physiol* 2014; 166:997-1008; <http://dx.doi.org/10.1104/pp.114.243659>.
1282. Perez-Perez ME, Couso I, Crespo JL. Carotenoid deficiency triggers autophagy in the model green alga *Chlamydomonas reinhardtii*. *Autophagy* 2012; 8:376-88; <http://dx.doi.org/10.4161/auto.18864>.
1283. Mauvezin C, Ayala C, Braden CR, Kim J, Neufeld TP. Assays to monitor autophagy in *Drosophila*. *Methods* 2014; 68:134-9; <http://dx.doi.org/10.1016/j.ymeth.2014.03.014>.
1284. Kim M, Semple I, Kim B, Kiers A, Nam S, Park HW, Park H, Ro SH, Kim JS, Juhasz G, et al. *Drosophila* Gyf/GRB10 interacting GYF protein is an autophagy regulator that controls neuron and muscle homeostasis. *Autophagy* 2015; 11:1358-72; <http://dx.doi.org/10.1080/15548627.2015.1063766>.
1285. Juhasz G, Hill JH, Yan Y, Sass M, Baehrecke EH, Backer JM, Neufeld TP. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in *Drosophila*. *J Cell Biol* 2008; 181:655-66; <http://dx.doi.org/10.1083/jcb.200712051>.
1286. Shelly S, Lukinova N, Bambina S, Berman A, Cherry S. Autophagy is an essential component of *Drosophila* immunity against vesicular stomatitis virus. *Immunity* 2009; 30:588-98; <http://dx.doi.org/10.1016/j.immuni.2009.02.009>.
1287. Anding AL, Baehrecke EH. Vps15 is required for stress induced and developmentally triggered autophagy and salivary gland protein secretion in *Drosophila*. *Cell Death Differ* 2014.
1288. Hou YC, Chittaranjan S, Barbosa SG, McCall K, Gorski SM. Effector caspase Dcp-1 and IAP protein Bruce regulate starvation-induced autophagy during *Drosophila melanogaster* oogenesis. *J Cell Biol* 2008; 182:1127-39; <http://dx.doi.org/10.1083/jcb.200712091>.
1289. Piracs K, Nagy P, Varga A, Venkei Z, Erdi B, Hegedus K, Juhasz G. Advantages and limitations of different p62-based assays for estimating autophagic activity in *Drosophila*. *PLoS One* 2012; 7:e44214; <http://dx.doi.org/10.1371/journal.pone.0044214>.
1290. Hindle SJ, Elliott CJ. Spread of neuronal degeneration in a dopaminergic, Lrrk-G2019S model of Parkinson disease. *Autophagy* 2013; 9:936-8; <http://dx.doi.org/10.4161/auto.24397>.
1291. Shrivastava BV, Hill JH, Powers CM, Wu L, Baehrecke EH. Atg6 is required for multiple vesicle trafficking pathways and hematopoiesis in *Drosophila*. *Development* 2013; 140:1321-9; <http://dx.doi.org/10.1242/dev.089490>.
1292. Marinkovic D, Zhang X, Yalcin S, Luciano JP, Brugnara C, Huber T, Ghaffari S. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. *J Clin Invest* 2007; 117:2133-44; <http://dx.doi.org/10.1172/JCI31807>.
1293. McIver SC, Kang YA, DeVilbiss AW, O'Driscoll CA, Ouellette JN, Pope NJ, Camprecios G, Chang CJ, Yang D, Bouhassira EE, et al. The exosome complex establishes a barricade to erythroid maturation. *Blood* 2014; 124:2285-97; <http://dx.doi.org/10.1182/blood-2014-04-571083>.
1294. Fujiwara T, O'Geen H, Keles S, Blahnik K, Linnemann AK, Kang YA, Choi K, Farnham PJ, Bresnick EH. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. *Mol Cell* 2009; 36:667-81; <http://dx.doi.org/10.1016/j.molcel.2009.11.001>.
1295. Welch JJ, Watts JA, Vakoc CR, Yao Y, Wang H, Hardison RC, Blobel GA, Chodosh LA, Weiss MJ. Global regulation of erythroid gene expression by transcription factor GATA-1. *Blood* 2004; 104:3136-47; <http://dx.doi.org/10.1182/blood-2004-04-1603>.
1296. Yu M, Riva L, Xie H, Schindler Y, Moran TB, Cheng Y, Yu D, Hardison R, Weiss MJ, Orkin SH, et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. *Mol Cell* 2009; 36:682-95; <http://dx.doi.org/10.1016/j.molcel.2009.11.002>.
1297. Kundu M, Lindsten T, Yang CY, Wu J, Zhao F, Zhang J, Selak MA, Ney PA, Thompson CB. Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. *Blood* 2008; 112:1493-502; <http://dx.doi.org/10.1182/blood-2008-02-137398>.
1298. Mortensen M, Ferguson DJ, Edelmann M, Kessler B, Morten KJ, Komatsu M, Simon AK. Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo. *Proc Natl Acad Sci USA* 2010; 107:832-7; <http://dx.doi.org/10.1073/pnas.0913170107>.
1299. Sandoval H, Thiagarajan P, Dasgupta SK, Schumacher A, Prchal JT, Chen M, Wang J. Essential role for Nix in autophagic maturation of erythroid cells. *Nature* 2008; 454:232-5; <http://dx.doi.org/10.1038/nature07006>.
1300. Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC, Kundu M, Opferman JT, Cleveland JL, Miller JL, et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. *Proc Natl Acad Sci USA* 2007; 104:19500-5; <http://dx.doi.org/10.1073/pnas.0708818104>.
1301. Josefsen L, Droce A, Sondergaard TE, Sørensen JL, Bormann J, Schäfer W, Giese H, Olsson S. Autophagy provides nutrients for nonassimilating fungal structures and is necessary for plant colonization but not for infection in the necrotrophic plant pathogen *Fusarium gaminearum*. *Autophagy* 2012; 8:326-37.



1302. Nadal M, Gold SE. The autophagy genes ATG8 and ATG1 affect morphogenesis and pathogenicity in *Ustilago maydis*. *Mol Plant Pathol* 2010; 11:463-78; <http://dx.doi.org/10.1111/j.1364-3703.2010.00620.x>.
1303. Pollack JK, Harris SD, Marten MR. Autophagy in filamentous fungi. *Fungal Genet Biol* 2009; 46:1-8; <http://dx.doi.org/10.1016/j.fgb.2008.10.010>.
1304. Richie DL, Fuller KK, Fortwendel J, Miley MD, McCarthy JW, Feldmesser M, Rhodes JC, Askew DS. Unexpected link between metal ion deficiency and autophagy in *Aspergillus fumigatus*. *Eukaryot Cell* 2007; 6:2437-47; <http://dx.doi.org/10.1128/EC.00224-07>.
1305. Voigt O, Poggeler S. Self-eating to grow and kill: autophagy in filamentous ascomycetes. *Appl Microbiol Biot* 2013; 97:9277-90; <http://dx.doi.org/10.1007/s00253-013-5221-2>.
1306. Kim Y, Islam N, Moss BJ, Nandakumar MP, Marten MR. Autophagy induced by rapamycin and carbon-starvation have distinct proteome profiles in *Aspergillus nidulans*. *Biotechnol Bioeng* 2011; 108:2705-15; <http://dx.doi.org/10.1002/bit.23223>.
1307. Pinan-Lucarre B, Balguerie A, Clave C. Accelerated cell death in *Podospora* autophagy mutants. *Eukaryot Cell* 2005; 4:1765-74; <http://dx.doi.org/10.1128/EC.4.11.1765-1774.2005>.
1308. Deng YZ, Naqvi NI. A vacuolar glucoamylase, Sga1, participates in glycogen autophagy for proper asexual differentiation in *Magnaporthe oryzae*. *Autophagy* 2010; 6:455-61; <http://dx.doi.org/10.4161/auto.6.4.11736>.
1309. Deng YZ, Ramos-Pamplona M, Naqvi NI. Autophagy-assisted glycogen catabolism regulates asexual differentiation in *Magnaporthe oryzae*. *Autophagy* 2009; 5:33-43; <http://dx.doi.org/10.4161/auto.5.1.7175>.
1310. Knuppertz L, Hamann A, Pampaloni F, Stelzer E, Osiewacz HD. Identification of autophagy as a longevity-assurance mechanism in the aging model *Podospora anserina*. *Autophagy* 2014; 10:822-34; <http://dx.doi.org/10.4161/auto.28148>.
1311. Asakura M, Ninomiya S, Sugimoto M, Oku M, Yamashita S, Okuno T, Sakai Y, Takano Y. Atg26-mediated pexophagy is required for host invasion by the plant pathogenic fungus *Colletotrichum orbiculare*. *Plant Cell* 2009; 21:1291-304; <http://dx.doi.org/10.1105/tpc.108.060996>.
1312. Liu XH, Lu JP, Zhang L, Dong B, Min H, Lin FC. Involvement of a *Magnaporthe grisea* serine/threonine kinase gene, MgATG1, in appressorium turgor and pathogenesis. *Eukaryot Cell* 2007; 6:997-1005; <http://dx.doi.org/10.1128/EC.00011-07>.
1313. Nguyen LN, Bormann J, Le GT, Starkel C, Olsson S, Nosanchuk JD, Giese H, Schafer W. Autophagy-related lipase FgATG15 of *Fusarium graminearum* is important for lipid turnover and plant infection. *Fungal Genet Biol* 2011; 48:217-24; <http://dx.doi.org/10.1016/j.fgb.2010.11.004>.
1314. Duan Z, Chen Y, Huang W, Shang Y, Chen P, Wang C. Linkage of autophagy to fungal development, lipid storage and virulence in *Metarhizium robertsii*. *Autophagy* 2013; 9:538-49; <http://dx.doi.org/10.4161/auto.23575>.
1315. Deng YZ, Ramos-Pamplona M, Naqvi NI. Methods for functional analysis of macroautophagy in filamentous fungi. *Methods Enzymol* 2008; 451:295-310; [http://dx.doi.org/10.1016/S0076-6879\(08\)03220-5](http://dx.doi.org/10.1016/S0076-6879(08)03220-5).
1316. Kershaw MJ, Talbot NJ. Genome-wide functional analysis reveals that infection-associated fungal autophagy is necessary for rice blast disease. *Proc Natl Acad Sci USA* 2009; 106:15967-72; <http://dx.doi.org/10.1073/pnas.0901477106>.
1317. Liu TB, Liu XH, Lu JP, Zhang L, Min H, Lin FC. The cysteine protease MoAtg4 interacts with MoAtg8 and is required for differentiation and pathogenesis in *Magnaporthe oryzae*. *Autophagy* 2010; 6:74-85; <http://dx.doi.org/10.4161/auto.6.1.10438>.
1318. Penalva MA, Galindo A, Abenza JF, Pinar M, Calcagno-Pizarelli AM, Arst HN, Pantazopoulou A. Searching for gold beyond mitosis: Mining intracellular membrane traffic in *Aspergillus nidulans*. *Cell Log* 2012; 2:2-14; <http://dx.doi.org/10.4161/cl.19304>.
1319. Pinar M, Pantazopoulou A, Penalva MA. Live-cell imaging of *Aspergillus nidulans* autophagy: RAB1 dependence, Golgi independence and ER involvement. *Autophagy* 2013; 9:1024-43; <http://dx.doi.org/10.4161/auto.24483>.
1320. Lipatova Z, Belogortseva N, Zhang XQ, Kim J, Taussig D, Segev N. Regulation of selective autophagy onset by a Ypt/Rab GTPase module. *Proc Natl Acad Sci USA* 2012; 109:6981-6; <http://dx.doi.org/10.1073/pnas.1121299109>.
1321. Lynch-Day MA, Bhandari D, Menon S, Huang J, Cai H, Bartholomew CR, Brumell JH, Ferro-Novick S, Klionsky DJ. Trs85 directs a Ypt1 GEF, TRAPPIII, to the phagophore to promote autophagy. *Proc Natl Acad Sci USA* 2010; 107:7811-6; <http://dx.doi.org/10.1073/pnas.1000063107>.
1322. Deng Y, Qu Z, Naqvi NI. The role of snx41-based pexophagy in magnaporthe development. *PLoS One* 2013; 8:e79128.
1323. Piggott N, Cook MA, Tyers M, Measday V. Genome-wide fitness profiles reveal a requirement for autophagy during yeast fermentation. *Genes Genomes Genetics* 2011; 1:353-67.
1324. Cebollero E, Gonzalez R. Induction of autophagy by second-fermentation yeasts during elaboration of sparkling wines. *Appl Environ Microbiol* 2006; 72:4121-7; <http://dx.doi.org/10.1128/AEM.02920-05>.
1325. Marks VD, Ho Sui SJ, Erasmus D, van der Merwe GK, Brumm J, Wasserman WW, Bryan J, van Vuuren HJ. Dynamics of the yeast transcriptome during wine fermentation reveals a novel fermentation stress response. *FEMS Yeast Res* 2008; 8:35-52; <http://dx.doi.org/10.1111/j.1567-1364.2007.00338.x>.
1326. Mendes-Ferreira A, Sampaio-Marques B, Barbosa C, Rodrigues F, Costa V, Mendes-Faia A, Ludovico P, Leao C. Accumulation of non-superoxide anion reactive oxygen species mediates nitrogen-limited alcoholic fermentation by *Saccharomyces cerevisiae*. *Appl Environ Microbiol* 2010; 76:7918-24; <http://dx.doi.org/10.1128/AEM.01535-10>.
1327. Rossignol T, Dulau L, Julien A, Blondin B. Genome-wide monitoring of wine yeast gene expression during alcoholic fermentation. *Yeast* 2003; 20:1369-85; <http://dx.doi.org/10.1002/yea.1046>.
1328. Teixeira MC, Raposo LR, Mira NP, Lourenco AB, Sa-Correia I. Genome-wide identification of *Saccharomyces cerevisiae* genes required for maximal tolerance to ethanol. *Appl Environ Microbiol* 2009; 75:5761-72; <http://dx.doi.org/10.1128/AEM.00845-09>.
1329. Yoshikawa K, Tanaka T, Furusawa C, Nagahisa K, Hirasawa T, Shimizu H. Comprehensive phenotypic analysis for identification of genes affecting growth under ethanol stress in *Saccharomyces cerevisiae*. *FEMS Yeast Res* 2009; 9:32-44; <http://dx.doi.org/10.1111/j.1567-1364.2008.00456.x>.
1330. Hazan R, Levine A, Abeliovich H. Benzoic acid, a weak organic acid food preservative, exerts specific effects on intracellular membrane trafficking pathways in *Saccharomyces cerevisiae*. *Appl Environ Microbiol* 2004; 70:4449-57; <http://dx.doi.org/10.1128/AEM.70.8.4449-4457.2004>.
1331. Singletary K, Milner J. Diet, autophagy, and cancer: a review. *Cancer Epidemiol Biomark Prev* 2008; 17:1596-610; <http://dx.doi.org/10.1158/1055-9965.EPI-07-2917>.
1332. Su CL, Chen FN, Won SJ. Involvement of apoptosis and autophagy in reducing mouse hepatoma ML-1 cell growth in inbred BALB/c mice by bacterial fermented soybean products. *Food Chem Toxicol* 2011; 49:17-24; <http://dx.doi.org/10.1016/j.fct.2010.08.017>.
1333. Abeliovich H, Gonzalez R. Autophagy in food biotechnology. *Autophagy* 2009; 5:925-9; <http://dx.doi.org/10.4161/auto.5.7.9213>.
1334. Berger B, Abdalla FC, Cruz-Landim C. Effect of narcosis with CO2 on the ovarian development in queens of *Apis mellifera* (Hymenoptera, Apini). *Sociobiology* 2005; 45:261-70.
1335. Silva-Zacarin ECM, Tomaino GA, Brocheto-Braga MR, Taboga SR, Silva de Moraes RLM. Programmed cell death in the larval salivary glands of *Apis mellifera* (Hymenoptera, Apidae). *J Biosci* 2007; 32:309-28; <http://dx.doi.org/10.1007/s12038-007-0031-2>.
1336. Gregorc A, Bowen ID. Programmed cell death in the honey-bee (*Apis mellifera* L.) larvae midgut. *Cell Biol Int* 1997; 21:151-8; <http://dx.doi.org/10.1006/cbir.1997.0127>.
1337. Navajas M, Migeon A, Alaux C, Martin-Magniette M, Robinson G, Evans J, Cros-Arteil S, Crauser D, Le Conte Y. Differential gene expression of the honey bee *Apis mellifera* associated with *Varroa destructor* infection. *BMC Genomics* 2008; 9:301; <http://dx.doi.org/10.1186/1471-2164-9-301>.

1338. Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. *Cancer Res* 2013; 73:3-7; <http://dx.doi.org/10.1158/0008-5472.CAN-12-2464>.
1339. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, Matsui I, Niimura F, Matsusaka T, Fujita N, et al. Autophagy guards against cisplatin-induced acute kidney injury. *Am J Pathol* 2012; 180:517-25; <http://dx.doi.org/10.1016/j.ajpath.2011.11.001>.
1340. Colasanti T, Vomero M, Alessandri C, Barbati C, Maselli A, Campario C, Conti F, Tinari A, Carlo-Stella C, Tuosto L, et al. Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. *Cell Death Dis* 2014; 5:e1265; <http://dx.doi.org/10.1038/cddis.2014.211>.
1341. Spruessel A, Steimann G, Jung M, Lee SA, Carr T, Fentz AK, Spangenberg J, Zornig C, Juhl HH, David KA. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. *BioTechniques* 2004; 36:1030-7.
1342. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. *Mol Cell Proteomics: MCP* 2008; 7:1998-2018; <http://dx.doi.org/10.1074/mcp.M700596-MCP200>.
1343. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. *J Pathol* 2010; 221:117-24; <http://dx.doi.org/10.1002/path.2694>.
1344. Domart MC, Esposti DD, Sebah M, Olaya N, Harper F, Pierron G, Franc B, Tanabe KK, Debuire B, Azoulay D, et al. Concurrent induction of necrosis, apoptosis, and autophagy in ischemic preconditioned human livers formerly treated by chemotherapy. *J Hepatol* 2009; 51:881-9; <http://dx.doi.org/10.1016/j.jhep.2009.06.028>.
1345. Jahania SM, Sengstock D, Vaitkevicius P, Andres A, Ito BR, Gottlieb RA, Mentzer RM, Jr. Activation of the homeostatic intracellular repair response during cardiac surgery. *J Am Coll Surgeons* 2013; 216:719-26; discussion 26-9; <http://dx.doi.org/10.1016/j.jamcollsurg.2012.12.034>.
1346. Singh KK, Yanagawa B, Quan A, Wang R, Garg A, Khan R, Pan Y, Wheatcroft MD, Lovren F, Teoh H, et al. Autophagy gene fingerprint in human ischemia and reperfusion. *J Thor Cardio Surg* 2014; 147:1065-72 e1; <http://dx.doi.org/10.1016/j.jtcvs.2013.04.042>.
1347. Nyman E, Brannmark C, Palmer R, Brugard J, Nystrom FH, Stralfors P, Cedersund G. A hierarchical whole-body modeling approach elucidates the link between in Vitro insulin signaling and in Vivo glucose homeostasis. *J Biol Chem* 2011; 286:26028-41; <http://dx.doi.org/10.1074/jbc.M110.188987>.
1348. Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Kelley DS, Wu J. A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance. *Lab Invest* 2013; 93:1313-22; <http://dx.doi.org/10.1038/labinvest.2013.123>.
1349. Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimacki WT, Cherrington NJ. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. *Toxicol Sci* 2014; 137:26-35; <http://dx.doi.org/10.1093/toxsci/kft230>.
1350. Sinha RA, Farah BL, Singh BK, Siddique MM, Li Y, Wu Y, Ilkayeva OR, Gooding J, Ching J, Zhou J, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. *Hepatology* 2014; 59:1366-80; <http://dx.doi.org/10.1002/hep.26667>.
1351. Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillon J, Lo Iacono O, Corazzari M, Fimia GM, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. *Cell Death Dis* 2014; 5:e1179; <http://dx.doi.org/10.1038/cddis.2014.162>.
1352. Buzgariu W, Chera S, Galliot B. Methods to investigate autophagy during starvation and regeneration in hydra. *Methods Enzymol* 2008; 451:409-37; [http://dx.doi.org/10.1016/S0076-6879\(08\)03226-6](http://dx.doi.org/10.1016/S0076-6879(08)03226-6).
1353. Chera S, Buzgariu W, Ghila L, Galliot B. Autophagy in Hydra: a response to starvation and stress in early animal evolution. *Biochim Biophys Acta* 2009; 1793:1432-43; <http://dx.doi.org/10.1016/j.bbamcr.2009.03.010>.
1354. Chera S, de Rosa R, Miljkovic-Licina M, Dobretz K, Ghila L, Kaloulis K, Galliot B. Silencing of the hydra serine protease inhibitor Kazal1 gene mimics the human SPINK1 pancreatic phenotype. *J Cell Sci* 2006; 119:846-57; <http://dx.doi.org/10.1242/jcs.02807>.
1355. Galliot B. Autophagy and self-preservation: a step ahead from cell plasticity? *Autophagy* 2006; 2:231-3; <http://dx.doi.org/10.4161/aut.2706>.
1356. Galliot B, Miljkovic-Licina M, de Rosa R, Chera S. Hydra, a niche for cell and developmental plasticity. *Seminars Cell Dev Biol* 2006; 17:492-502; <http://dx.doi.org/10.1016/j.semcd.2006.05.005>.
1357. Sala-Mercado JA, Wider J, Undyala VV, Jahania S, Yoo W, Mentzer RM, Jr., Gottlieb RA, Przyklenk K. Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. *Circulation* 2010; 122:S179-84; <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.928242>.
1358. Botting KJ, McMillen IC, Forbes H, Nyengaard JR, Morrison JL. Chronic hypoxemia in late gestation decreases cardiomyocyte number but does not change expression of hypoxia-responsive genes. *J Am Heart Assoc* 2014; 3.
1359. Wang KC, Brooks DA, Summers-Pearce B, Bobrovskaya L, Tosh DN, Duffield JA, Botting KJ, Zhang S, Caroline McMillen I, Morrison JL. Low birth weight activates the renin-angiotensin system, but limits cardiac angiogenesis in early postnatal life. *Physiol Rep* 2015; 3.
1360. Zhang S, Regnault TR, Barker PL, Botting KJ, McMillen IC, McMillan CM, Roberts CT, Morrison JL. Placental adaptations in growth restriction. *Nutrients* 2015; 7:360-89; <http://dx.doi.org/10.3390/nu7010360>.
1361. Derde S, Vanhorebeek I, Guiza F, Derese I, Gunst J, Fahrenkrog B, Martinet W, Vervenne H, Ververs EJ, Larsson L, et al. Early parental nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill rabbits. *Endocrinology* 2012; 153:2267-76; <http://dx.doi.org/10.1210/en.2011-2068>.
1362. Gunst J, Derese I, Aertgeerts A, Ververs EJ, Wauters A, Van den Berghe G, Vanhorebeek I. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. *Crit Care Med* 2013; 41:182-94; <http://dx.doi.org/10.1097/CCM.0b013e3182676657>.
1363. Lopez-Alonso I, Aguirre A, Gonzalez-Lopez A, Fernandez AF, Amado-Rodriguez L, Astudillo A, Batalla-Solis E, Albaiceta GM. Impairment of autophagy decreases ventilator-induced lung injury by blockade of the NF-kappaB pathway. *Am J Physiol Lung Cell Mol Physiol* 2013; 304:L844-52; <http://dx.doi.org/10.1152/ajplung.00422.2012>.
1364. Sun Y, Li C, Shu Y, Ju X, Zou Z, Wang H, Rao S, Guo F, Liu H, Nan W, et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. *Sci Signal* 2012; 5:ra16.
1365. Sobolewska A, Motyl T, Gajewska M. Role and regulation of autophagy in the development of acinar structures formed by bovine BME-UV1 mammary epithelial cells. *Eur J Cell Biol* 2011; 90:854-64; <http://dx.doi.org/10.1016/j.ejcb.2011.06.007>.
1366. Motyl T, Gajewska M, Zarzynska J, Sobolewska A, Gajkowska B. Regulation of autophagy in bovine mammary epithelial cells. *Autophagy* 2007; 3:484-6; <http://dx.doi.org/10.4161/aut.4491>.
1367. Sobolewska A, Gajewska M, Zarzynska J, Gajkowska B, Motyl T. IGF-I, EGF, and sex steroids regulate autophagy in bovine mammary epithelial cells via the mTOR pathway. *Eur J Cell Biol* 2009; 88:117-30; <http://dx.doi.org/10.1016/j.ejcb.2008.09.004>.
1368. Facey CO, Lockshin RA. The execution phase of autophagy associated PCD during insect metamorphosis. *Apoptosis* 2010; 15:639-52; <http://dx.doi.org/10.1007/s10495-010-0499-3>.
1369. Malagoli D, Abdalla FC, Cao Y, Feng Q, Fujisaki K, Gregorc A, Matsuo T, Nezis IP, Papassideri IS, Sass M, et al. Autophagy and its physiological relevance in arthropods: Current knowledge and perspectives. *Autophagy* 2010; 6:575-88; <http://dx.doi.org/10.4161/aut.6.5.11962>.
1370. Mpakou VE, Nezis IP, Stravopodis DJ, Margaritis LH, Papassideri IS. Programmed cell death of the ovarian nurse cells during oogenesis of the silkworm *Bombyx mori*. *Dev Growth Differ* 2006; 48:419-28; <http://dx.doi.org/10.1111/j.1440-169X.2006.00878.x>.

1371. Mpakou VE, Nezis IP, Stravopodis DJ, Margaritis LH, Papassideri IS. Different modes of programmed cell death during oogenesis of the silkworm *Bombyx mori*. *Autophagy* 2008; 4:97-100; <http://dx.doi.org/10.4161/auto.5205>.
1372. Sumithra P, Britto CP, Krishnan M. Modes of cell death in the pupal perivisceral fat body tissue of the silkworm *Bombyx mori* L. *Cell Tissue Res* 2010; 339:349-58; <http://dx.doi.org/10.1007/s00441-009-0898-3>.
1373. Tettamanti G, Grimaldi A, Casartelli M, Ambrosetti E, Ponti B, Congiu T, Ferrarese R, Rivas-Pena ML, Pennacchio F, Eguileor M. Programmed cell death and stem cell differentiation are responsible for midgut replacement in *Heliothis virescens* during prepupal instar. *Cell Tissue Res* 2007; 330:345-59; <http://dx.doi.org/10.1007/s00441-007-0449-8>.
1374. Khoa DB, Takeda M. Expression of autophagy 8 (Atg8) and its role in the midgut and other organs of the greater wax moth, *Galleria mellonella*, during metamorphic remodelling and under starvation. *Insect Mol Biol* 2012; 21:473-87; <http://dx.doi.org/10.1111/j.1365-2583.2010.01026.x>.
1375. Gai Z, Zhang X, Islam M, Wang X, Li A, Yang Y, Li Y, Peng J, Hong H, Liu K. Characterization of Atg8 in lepidopteran insect cells. *Arch Insect Biochem* 2013; 84:57-77.
1376. Goncu E, Parlak O. Some autophagic and apoptotic features of programmed cell death in the anterior silk glands of the silkworm, *Bombyx mori*. *Autophagy* 2008; 4:1069-72; <http://dx.doi.org/10.4161/auto.6953>.
1377. Zhou S, Zhou Q, Liu Y, Wang S, Wen D, He Q, Wang W, Bendena WG, Li S. Two Tor genes in the silkworm *Bombyx mori*. *Insect Mol Biol* 2010; 19:727-35; <http://dx.doi.org/10.1111/j.1365-2583.2010.01026.x>.
1378. Zhang X, Hu ZY, Li WF, Li QR, Deng XJ, Yang WY, Cao Y, Zhou CZ. Systematic cloning and analysis of autophagy-related genes from the silkworm *Bombyx mori*. *BMC Mol Biol* 2009; 10:50; <http://dx.doi.org/10.1186/1471-2199-10-50>.
1379. Romanelli D, Casati B, Franzetti E, Tettamanti G. A molecular view of autophagy in Lepidoptera. *Biomed Res Int* 2014; 2014:902315; <http://dx.doi.org/10.1155/2014/902315>.
1380. Li Q, Deng X, Huang Z, Zheng S, Tettamanti G, Cao Y, Feng Q. Expression of autophagy-related genes in the anterior silk gland of the silkworm (*Bombyx mori*) during metamorphosis. *Can J Zool* 2011; 89:1019-26; <http://dx.doi.org/10.1139/z11-075>.
1381. Casati B, Terova G, Cattaneo AG, Rimoldi S, Franzetti E, de Eguileor M, Tettamanti G. Molecular cloning, characterization and expression analysis of ATG1 in the silkworm, *Bombyx mori*. *Gene* 2012; 511:326-37; <http://dx.doi.org/10.1016/j.gene.2012.09.086>.
1382. Godefroy N, Hoa C, Tsokanos F, Le Goff E, Douzery EJ, Baghdiguian S, Martinand-Mari C. Identification of autophagy genes in *Ciona intestinalis*: a new experimental model to study autophagy mechanism. *Autophagy* 2009; 5:805-15; <http://dx.doi.org/10.4161/auto.8995>.
1383. Martinand-Mari C, Vacelet J, Nickel M, Worheide G, Mangeat P, Baghdiguian S. Cell death and renewal during prey capture and digestion in the carnivorous sponge *Asbestopluma hypogea* (Porifera: Poecilosclerida). *J Exp Biol* 2012; 215:3937-43; <http://dx.doi.org/10.1242/jeb.072371>.
1384. Thomé RG, Santos HB, Arantes FP, Domingos FF, Bazzoli N, Rizzo E. Dual roles for autophagy during follicular atresia in fish ovary. *Autophagy* 2009; 5:117-9; <http://dx.doi.org/10.4161/auto.5.1.7302>.
1385. Santos HB, Thome RG, Arantes FP, Sato Y, Bazzoli N, Rizzo E. Ovarian follicular atresia is mediated by heterophagy, autophagy, and apoptosis in *Prochilodus argenteus* and *Leporinus taeniatus* (Teleostei: Characiformes). *Theriogenology* 2008; 70:1449-60; <http://dx.doi.org/10.1016/j.theriogenology.2008.06.091>.
1386. Santos HB, Sato Y, Moro L, Bazzoli N, Rizzo E. Relationship among follicular apoptosis, integrin beta1 and collagen type IV during early ovarian regression in the teleost *Prochilodus argenteus* after induced spawning. *Cell Tissue Res* 2008; 332:159-70; <http://dx.doi.org/10.1007/s00441-007-0540-1>.
1387. Santos HB, Rizzo E, Bazzoli N, Sato Y, Moro L. Ovarian regression and apoptosis in the South American teleost *Leporinus taeniatus* Lutken (Characiformes, Anostomidae) from the São Francisco Basin. 2005; 67:1446-59.
1388. Couve E, Schmachtenberg O. Autophagic activity and aging in human odontoblasts. *J Dent Res* 2011; 90:523-8; <http://dx.doi.org/10.1177/0022034510393347>.
1389. Gonzalez-Estevez C. Autophagy in freshwater planarians. *Methods Enzymol* 2008; 451:439-65; [http://dx.doi.org/10.1016/S0076-6879\(08\)03227-8](http://dx.doi.org/10.1016/S0076-6879(08)03227-8).
1390. Gonzalez-Estevez C, Felix DA, Aboobaker AA, Salo E. Gtdap-1 promotes autophagy and is required for planarian remodeling during regeneration and starvation. *Proc Natl Acad Sci USA* 2007; 104:13373-8; <http://dx.doi.org/10.1073/pnas.0703588104>.
1391. Toyooka K, Moriyasu Y, Goto Y, Takeuchi M, Fukuda H, Matsuoka K. Protein aggregates are transported to vacuoles by a macroautophagic mechanism in nutrient-starved plant cells. *Autophagy* 2006; 2:96-106; <http://dx.doi.org/10.4161/auto.2.2.2366>.
1392. Corral-Martinez P, Parra-Vega V, Segui-Simarro JM. Novel features of Brassica napus embryogenic microspores revealed by high pressure freezing and freeze substitution: evidence for massive autophagy and excretion-based cytoplasmic cleaning. *J Exp Bot* 2013; 64:3061-75.
1393. Le Bars R, Marion J, Le Borgne R, Satiat-Jeunemaitre B, Bianchi MW. ATG5 defines a phagophore domain connected to the endoplasmic reticulum during autophagosome formation in plants. *Nat Commun* 2014; 5:4121; <http://dx.doi.org/10.1038/ncomms5121>.
1394. Shin KD, Lee HN, Chung T. A revised assay for monitoring autophagic flux in *Arabidopsis thaliana* reveals involvement of AUTOPHAGY-RELATED9 in autophagy. *Mol Cells* 2014; 37:399-405; <http://dx.doi.org/10.14348/molcells.2014.0042>.
1395. Svenning S, Lamark T, Krause K, Johansen T. Plant NBR1 is a selective autophagy substrate and a functional hybrid of the mammalian autophagic adapters NBR1 and p62/SQSTM1. *Autophagy* 2011; 7:993-1010; <http://dx.doi.org/10.4161/auto.7.9.16389>.
1396. Zientara-Rytter K, Lukomska J, Moniuszko G, Gwozdecki R, Surowiecki P, Lewandowska M, Liszewska F, Wawrzynska A, Sirko A. Identification and functional analysis of Joka2, a tobacco member of the family of selective autophagy cargo receptors. *Autophagy* 2011; 7:1145-58; <http://dx.doi.org/10.4161/auto.7.10.16617>.
1397. Minina EA, Sanchez-Vera V, Moschou PN, Suarez MF, Sundberg E, Weih M, Bozhkov PV. Autophagy mediates caloric restriction-induced lifespan extension in *Arabidopsis*. *Aging Cell* 2013; 12:327-9; <http://dx.doi.org/10.1111/acer.12048>.
1398. van Doorn WG, Papini A. Ultrastructure of autophagy in plant cells: a review. *Autophagy* 2013; 9:1922-36; <http://dx.doi.org/10.4161/auto.26275>.
1399. Moriyasu Y, Inoue Y. Use of protease inhibitors for detecting autophagy in plants. *Methods Enzymol* 2008; 451:557-80; [http://dx.doi.org/10.1016/S0076-6879\(08\)03232-1](http://dx.doi.org/10.1016/S0076-6879(08)03232-1).
1400. Moriyasu Y, Ohsumi Y. Autophagy in tobacco suspension-cultured cells in response to sucrose starvation. *Plant Phys* 1996; 111:1233-41.
1401. Inoue Y, Moriyasu Y. Autophagy is not a main contributor to the degradation of phospholipids in tobacco cells cultured under sucrose starvation conditions. *Plant Cell Physiol* 2006; 47:471-80; <http://dx.doi.org/10.1093/pcp/pcj013>.
1402. Takatsuka C, Inoue Y, Matsuoka K, Moriyasu Y. 3-methyladenine inhibits autophagy in tobacco culture cells under sucrose starvation conditions. *Plant Cell Physiol* 2004; 45:265-74; <http://dx.doi.org/10.1093/pcp/pcj031>.
1403. Besteiro S, Brooks CF, Striepen B, Dubremetz J-F. Autophagy protein Atg3 is essential for maintaining mitochondrial integrity and for normal intracellular development of *Toxoplasma gondii* tachyzoites. *PLoS Pathog* 2011; 7:e1002416.
1404. Calvo-Garrido J, Carilla-Latorre S, Kubohara Y, Santos-Rodrigo N, Mesquita A, Soldati T, Golstein P, Escalante R. Autophagy in *Dictyostelium*: genes and pathways, cell death and infection. *Autophagy* 2010; 6:686-701; <http://dx.doi.org/10.4161/auto.6.6.12513>.
1405. Tung SM, Unal C, Ley A, Pena C, Tunggal B, Noegel AA, Krut O, Steinert M, Eichinger L. Loss of *Dictyostelium* ATG9 results in a pleiotropic phenotype affecting growth, development, phagocytosis and clearance and replication of *Legionella pneumophila*. *Cell*

- Microbiol 2010; 12:765-80; <http://dx.doi.org/10.1111/j.1462-5822.2010.01432.x>.
1406. Bozzaro S, Eichinger L. The professional phagocyte *Dictyostelium discoideum* as a model host for bacterial pathogens. *Curr Drug Targets* 2011; 12:942-54; <http://dx.doi.org/10.2174/138945011795677782>.
1407. Schlegel M, Hülsmann N. Protists – A textbook example for a paraphyletic taxon. *Org Divers Evol* 2007; 7:166-72; <http://dx.doi.org/10.1016/j.ode.2006.11.001>.
1408. Kitamura K, Kishi-Itakura C, Tsuboi T, Sato S, Kita K, Ohta N, Mizushima N. Autophagy-related Atg8 localizes to the apicoplast of the human malaria parasite *Plasmodium falciparum*. *PLoS One* 2012; 7:e42977; <http://dx.doi.org/10.1371/journal.pone.0042977>.
1409. Barquilla A, Crespo JL, Navarro M. Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. *Proc Natl Acad Sci USA* 2008; 105:14579-84; <http://dx.doi.org/10.1073/pnas.0802668105>.
1410. Hain AU, Bartee D, Sanders NG, Miller AS, Sullivan DJ, Levitskaya J, Meyers CF, Bosch J. Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage *Plasmodium falciparum* parasites. *J Med Chem* 2014; 57:4521-31; <http://dx.doi.org/10.1021/jm401675a>.
1411. Hain AU, Weltzer RR, Hammond H, Jayabalasingham B, Dinglasan RR, Graham DR, Colquhoun DR, Coppens I, Bosch J. Structural characterization and inhibition of the Plasmodium Atg8-Atg3 interaction. *J Struct Biol* 2012; 180:551-62; <http://dx.doi.org/10.1016/j.jsb.2012.09.001>.
1412. Navale R, Atul, Allanki AD, Sijwali PS. Characterization of the autophagy marker protein Atg8 reveals atypical features of autophagy in *Plasmodium falciparum*. *PLoS One* 2014; 9:e113220; <http://dx.doi.org/10.1371/journal.pone.0113220>.
1413. Morais P, Lamas J, Sanmartin ML, Orallo F, Leiro J. Resveratrol induces mitochondrial alterations, autophagy and a cryptobiosis-like state in scuticociliates. *Protist* 2009; 160:552-64; <http://dx.doi.org/10.1016/j.protis.2009.04.004>.
1414. Yakisich JS, Kapler GM. The effect of phosphoinositide 3-kinase inhibitors on programmed nuclear degradation in *Tetrahymena* and fate of surviving nuclei. *Cell Death Differ* 2004; 11:1146-9; <http://dx.doi.org/10.1038/sj.cdd.4401473>.
1415. Akematsu T, Pearlman RE, Endoh H. Gigantic macroautophagy in programmed nuclear death of *Tetrahymena thermophila*. *Autophagy* 2010; 6:901-11; <http://dx.doi.org/10.4161/auto.6.7.13287>.
1416. Akematsu T, Fukuda Y, Attiq R, Pearlman RE. Role of class III phosphatidylinositol 3-kinase during programmed nuclear death of *Tetrahymena thermophila*. *Autophagy* 2014; 10:209-25; <http://dx.doi.org/10.4161/auto.26929>.
1417. Liu ML, Yao MC. Role of ATG8 and autophagy in programmed nuclear degradation in *Tetrahymena thermophila*. *Eukaryot Cell* 2012; 11:494-506; <http://dx.doi.org/10.1128/EC.05296-11>.
1418. Thorgaard GH, Bailey GS, Williams D, Buhler DR, Kaattari SL, Ristow SS, Hansen JD, Winton JR, Bartholomew JL, Nagler JJ, et al. Status and opportunities for genomics research with rainbow trout. *Comp Biochem Phys B* 2002; 133:609-46; [http://dx.doi.org/10.1016/S1096-4959\(02\)00167-7](http://dx.doi.org/10.1016/S1096-4959(02)00167-7).
1419. Govoroun M, Le Gac F, Guiguen Y. Generation of a large scale repertoire of Expressed Sequence Tags (ESTs) from normalised rainbow trout cDNA libraries. *BMC Genomics* 2006; 7:196; <http://dx.doi.org/10.1186/1471-2164-7-196>.
1420. Rexroad CE, III, Lee Y, Keele JW, Karamycheva S, Brown G, Koop B, Gahr SA, Palti Y, Quackenbush J. Sequence analysis of a rainbow trout cDNA library and creation of a gene index. *Cytogenetic Genome Res* 2003; 102:347-54; <http://dx.doi.org/10.1159/000075773>.
1421. Rise ML, von Schalburg KR, Brown GD, Mawer MA, Devlin RH, Kuipers N, Busby M, Beetz-Sargent M, Alberto R, Gibbs AR, et al. Development and application of a salmonid EST database and cDNA microarray: data mining and interspecific hybridization characteristics. *Genome Res* 2004; 14:478-90; <http://dx.doi.org/10.1101/gr.1687304>.
1422. Salem M, Rexroad CE, III, Wang J, Thorgaard GH, Yao J. Characterization of the rainbow trout transcriptome using Sanger and 454-pyrosequencing approaches. *BMC Genomics* 2010; 11:564; <http://dx.doi.org/10.1186/1471-2164-11-564>.
1423. Polakof S, Panserat S, Craig PM, Martyres DJ, Plagnes-Juan E, Savari S, Aris-Brosou S, Moon TW. The metabolic consequences of hepatic AMP-kinase phosphorylation in rainbow trout. *PLoS One* 2011; 6:e20228; <http://dx.doi.org/10.1371/journal.pone.0020228>.
1424. Seiliez I, Gabillard JC, Skiba-Cassy S, Garcia-Serrana D, Gutierrez J, Kaushik S, Panserat S, Tesseraud S. An in vivo and in vitro assessment of TOR signaling cascade in rainbow trout (*Oncorhynchus mykiss*). *Am J Physiol Reg Integ Comp Physiol* 2008; 295:R329-35; <http://dx.doi.org/10.1152/ajpregu.00146.2008>.
1425. Seiliez I, Gabillard J-C, Riffled M, Sadoul B, Dias K, Avérous J, Tesseraud S, Skiba S, Panserat S. Amino acids downregulate the expression of several autophagy-related genes in rainbow trout myoblasts. *Autophagy* 2012; 8:364-75.
1426. Chiarelli R, Agnello M, Bosco L, Roccheri MC. Sea urchin embryos exposed to cadmium as an experimental model for studying the relationship between autophagy and apoptosis. *Mar Environ Res* 2014; 93:47-55; <http://dx.doi.org/10.1016/j.marenvres.2013.06.001>.
1427. Umemiya R, Matsuo T, Hatta T, Sakakibara S, Boldbaatar D, Fujisaki K. Cloning and characterization of an autophagy-related gene, *ATG12*, from the three-host tick *Haemaphysalis longicornis*. *Insect Biochem Molec* 2007; 37:975-84; <http://dx.doi.org/10.1016/j.ibmb.2007.05.006>.
1428. Kawano S, Umemiya-Shirafuji R, Boldbaatar D, Matsuoka K, Tanaka T, Fujisaki K. Cloning and characterization of the autophagy-related gene 6 from the hard tick, *Haemaphysalis longicornis*. *Parasitol Res* 2011; 109:1341-9; <http://dx.doi.org/10.1007/s00436-011-2429-x>.
1429. Umemiya-Shirafuji R, Matsuo T, Liao M, Boldbaatar D, Battur B, Suzuki HI, Fujisaki K. Increased expression of *ATG* genes during nonfeeding periods in the tick *Haemaphysalis longicornis*. *Autophagy* 2010; 6:473-81; <http://dx.doi.org/10.4161/auto.6.4.11668>.
1430. Umemiya-Shirafuji R, Galay RL, Maeda H, Kawano S, Tanaka T, Fukumoto S, Suzuki H, Tsuji N, Fujisaki K. Expression analysis of autophagy-related genes in the hard tick *Haemaphysalis longicornis*. *Vet Parasitol* 2014; 201:169-75; <http://dx.doi.org/10.1016/j.vetpar.2014.01.024>.
1431. de la Fuente J, Kocan KM, Almazan C, Blouin EF. RNA interference for the study and genetic manipulation of ticks. *Trends Parasitol* 2007; 23:427-33; <http://dx.doi.org/10.1016/j.pt.2007.07.002>.
1432. Ayllón N, Villar V, Galindo RC, Kocan KM, Šíma R, López JA, Vázquez J, Alberdi P, Cabezas-Cruz A, Kopáček P, et al. Systems biology of tissue-specific response to *Anaplasma phagocytophilum* reveals differentiated apoptosis in the tick vector *Ixodes scapularis*. *PLoS Genet* 2015; 11:e1005120; <http://dx.doi.org/10.1371/journal.pgen.1005120>.
1433. Genomic Resources Development C, Contreras M, de la Fuente J, Estrada-Pena A, Grubhoffer L, Tobes R. Genomic resources notes accepted 1 April 2014 - 31 May 2014. *Mol Ecol Resour* 2014; 14:1095.
1434. Lee E, Koo Y, Ng A, Wei Y, Luby-Phelps K, Juraszek A, Xavier RJ, Cleaver O, Levine B, Amatruda JF. Autophagy is essential for cardiac morphogenesis during vertebrate development. *Autophagy* 2014; 10:572-87; <http://dx.doi.org/10.4161/auto.27649>.
1435. Sasaki T, Lian S, Qi J, Bayliss PE, Carr CE, Johnson JL, Guha S, Kobler P, Catz SD, Gill M, et al. Aberrant autolysosomal regulation is linked to the induction of embryonic senescence: differential roles of Beclin 1 and p53 in vertebrate Spn1 deficiency. *PLoS Genet* 2014; 10:e1004409; <http://dx.doi.org/10.1371/journal.pgen.1004409>.
1436. He C, Bartholomew CR, Zhou W, Klionsky DJ. Assaying autophagic activity in transgenic GFP-Lc3 and GFP-Gabarap zebrafish embryos. *Autophagy* 2009; 5:520-6; <http://dx.doi.org/10.4161/auto.5.4.7768>.

1437. Komoike Y, Shimojima K, Liang JS, Fujii H, Maegaki Y, Osawa M, Fujii S, Higashinakagawa T, Yamamoto T. A functional analysis of GABARAP on 17p13.1 by knockdown zebrafish. *J Hum Genet* 2010; 55:155-62; <http://dx.doi.org/10.1038/jhg.2010.1>.
1438. Dowling JJ, Low SE, Busta AS, Feldman EL. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. *Hum Mol Genet* 2010; 19:2668-81; <http://dx.doi.org/10.1093/hmg/ddq153>.
1439. Makky K, Tekiel J, Mayer AN. Target of rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine. *Dev Biol* 2007; 303:501-13; <http://dx.doi.org/10.1016/j.ydbio.2006.11.030>.
1440. Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M, Bento CF, Puri C, Zavodszky E, Siddiqi F, et al. PICALM modulates autophagy activity and tau accumulation. *Nat Commun* 2014; 5:4998; <http://dx.doi.org/10.1038/ncomms5998>.
1441. Hishiya A, Salman MN, Carra S, Kampinga HH, Takayama S. BAG3 directly interacts with mutated alphaB-crystallin to suppress its aggregation and toxicity. *PLoS One* 2011; 6:e16828; <http://dx.doi.org/10.1371/journal.pone.0016828>.
1442. Ruparelia AA, Oorschot V, Vaz R, Ramm G, Bryson-Richardson RJ. Zebrafish models of BAG3 myofibrillar myopathy suggest a toxic gain of function leading to BAG3 insufficiency. *Acta Neuropathol* 2014; 128:821-33; <http://dx.doi.org/10.1007/s00401-014-1344-5>.
1443. Mostowy S, Boucontet L, Mazon Moya MJ, Sirianni A, Boudinot P, Hollinshead M, Cossart P, Herbomel P, Levraud JP, Colucci-Guyon E. The zebrafish as a new model for the in vivo study of Shigella flexneri interaction with phagocytes and bacterial autophagy. *PLoS Pathog* 2013; 9:e1003588; <http://dx.doi.org/10.1371/journal.ppat.1003588>.
1444. van der Vaart M, Korbee CJ, Lamers GE, Tengeler AC, Hosseini R, Haks MC, Ottenhoff TH, Spaik HP, Meijer AH. The DNA Damage-Regulated Autophagy Modulator DRAM1 Links Mycobacterial Recognition via TLP-MYD88 to Autophagic Defense. *Cell Host Microbe* 2014; 15:753-67; <http://dx.doi.org/10.1016/j.chom.2014.05.005>.
1445. Varga M, Sass M, Papp D, Takacs-Vellai K, Kobolak J, Dinnyes A, Klionsky DJ, Vellai T. Autophagy is required for zebrafish caudal fin regeneration. *Cell Death Differ* 2014; 21:547-56; <http://dx.doi.org/10.1038/cdd.2013.175>.
1446. Benato F, Skobo T, Gioacchini G, Moro I, Ciccocanti F, Piacentini M, Fimia GM, Carnevali O, Dalla Valle L. Ambral knockdown in zebrafish leads to incomplete development due to severe defects in organogenesis. *Autophagy* 2013; 9:476-95; <http://dx.doi.org/10.4161/auto.23278>.
1447. Skobo T, Benato F, Grumati P, Meneghetti G, Cianfanelli V, Castagnaro S, Chrisam M, Di Bartolomeo S, Bonaldo P, Cecconi F, et al. Zebrafish ambrala and ambrala1b knockdown impairs skeletal muscle development. *PLoS One* 2014; 9:e99210; <http://dx.doi.org/10.1371/journal.pone.0099210>.
1448. Mizushima N. Methods for monitoring autophagy using GFP-LC3 transgenic mice. *Methods Enzymol* 2009; 452:13-23; [http://dx.doi.org/10.1016/S0076-6879\(08\)03602-1](http://dx.doi.org/10.1016/S0076-6879(08)03602-1).
1449. Henault J, Martinez J, Riggs JM, Tian J, Mehta P, Clarke L, Sasai M, Latz E, Brinkmann MM, Iwasaki A, et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. *Immunity* 2012; 37:986-97; <http://dx.doi.org/10.1016/j.immuni.2012.09.014>.
1450. Varma H, Gangadhar NM, Letso RR, Wolpaw AJ, Sriramaratnam R, Stockwell BR. Identification of a small molecule that induces ATG5-and-cathepsin-l-dependent cell death and modulates polyglutamine toxicity. *Exp Cell Res* 2013; 319:1759-73; <http://dx.doi.org/10.1016/j.yexcr.2013.03.019>.
1451. Kong-Hap MA, Mouammine A, Daher W, Berry L, Lebrun M, Dubremetz JF, Besteiro S. Regulation of ATG8 membrane association by ATG4 in the parasitic protist *Toxoplasma gondii*. *Autophagy* 2013; 9:1334-48; <http://dx.doi.org/10.4161/auto.25189>.
1452. Jayabalasingham B, Voss C, Ehrenman K, Romano JD, Smith ME, Fidock DA, Bosch J, Coppens I. Characterization of the ATG8-conjugation system in 2 Plasmodium species with special focus on the liver stage: possible linkage between the apicoplastic and autophagic systems? *Autophagy* 2014; 10:269-84; <http://dx.doi.org/10.4161/auto.27166>.
1453. Tomlins AM, Ben-Rached F, Williams RA, Proto WR, Coppens I, Ruch U, Gilberger TW, Coombs GH, Mottram JC, Muller S, et al. Plasmodium falciparum ATG8 implicated in both autophagy and apicoplast formation. *Autophagy* 2013; 9:1540-52; <http://dx.doi.org/10.4161/auto.25832>.
1454. Mizushima N, Sahani MH. ATG8 localization in apicomplexan parasites: apicoplast and more? *Autophagy* 2014; 10:1487-94; <http://dx.doi.org/10.4161/auto.32183>.
1455. Haldar AK, Piro AS, Pilla DM, Yamamoto M, Coers J. The E2-like conjugation enzyme Atg3 promotes binding of IRG and Gbp proteins to Chlamydia- and Toxoplasma-containing vacuoles and host resistance. *PLoS One* 2014; 9:e86684; <http://dx.doi.org/10.1371/journal.pone.0086684>.
1456. Ohshima J, Lee Y, Sasai M, Saitoh T, Su Ma J, Kamiyama N, Matsuura Y, Pann-Ghill S, Hayashi M, Ebisu S, et al. Role of mouse and human autophagy proteins in IFN-gamma-induced cell-autonomous responses against *Toxoplasma gondii*. *J Immunol* 2014; 192:3328-35; <http://dx.doi.org/10.4049/jimmunol.1302822>.
1457. Zhao YO, Khaminets A, Hunn JP, Howard JC. Disruption of the *Toxoplasma gondii* parasitophorous vacuole by IFN-gamma-inducible immunity-related GTPases (IRG proteins) triggers necrotic cell death. *PLoS Pathog* 2009; 5:e1000288; <http://dx.doi.org/10.1371/journal.ppat.1000288>.
1458. Meunier E, Dick MS, Dreier RF, Schurmann N, Kenzelmann Broz D, Warming S, Roose-Girma M, Bumann D, Kayagaki N, Takeda K, et al. Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases. *Nature* 2014; 509:366-70; <http://dx.doi.org/10.1038/nature13157>.
1459. Taguchi Y, Imaoka K, Kataoka M, Uda A, Nakatsu D, Horii-Okazaki S, Kunishige R, Kano F, Murata M. Yip1A, a novel host factor for the activation of the IRE1 pathway of the unfolded protein response during Brucella infection. *PLoS Pathog* 2015; 11:e1004747; <http://dx.doi.org/10.1371/journal.ppat.1004747>.
1460. Starr T, Child R, Wehrly TD, Hansen B, Hwang S, Lopez-Otin C, Virgin HW, Celli J. Selective subversion of autophagy complexes facilitates completion of the Brucella intracellular cycle. *Cell Host Microbe* 2012; 11:33-45; <http://dx.doi.org/10.1016/j.chom.2011.12.002>.
1461. Ferguson TA, Green DR. Autophagy and phagocytosis converge for better vision. *Autophagy* 2014; 10:165-7; <http://dx.doi.org/10.4161/auto.26735>.
1462. Mehta P, Henault J, Kolbeck R, Sanjuan MA. Noncanonical autophagy: one small step for LC3, one giant leap for immunity. *Curr Opin Immunol* 2014; 26:69-75; <http://dx.doi.org/10.1016/j.coi.2013.10.012>.
1463. Scarlatti F, Maffei R, Beau I, Ghidoni R, Codogno P. Non-canonical autophagy: an exception or an underestimated form of autophagy? *Autophagy* 2008; 4:1083-5; <http://dx.doi.org/10.4161/auto.7068>.
1464. Takeshita F, Kobiyama K, Miyawaki A, Jounai N, Okuda K. The non-canonical role of Atg family members as suppressors of innate antiviral immune signaling. *Autophagy* 2008; 4:67-9; <http://dx.doi.org/10.4161/auto.5055>.
1465. Deretic V, Jiang S, Dupont N. Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. *Trends Cell Biol* 2012; 22:397-406; <http://dx.doi.org/10.1016/j.tcb.2012.04.008>.
1466. Cleyrat C, Darehshouri A, Steinkamp MP, Vilaine M, Boassa D, Ellisman MH, Hermouet S, Wilson BS. Mpl traffics to the cell surface through conventional and unconventional routes. *Traffic* 2014; 15:961-82; <http://dx.doi.org/10.1111/tra.12185>.
1467. Hughes T, Rusten TE. Origin and evolution of self-consumption: autophagy. *Adv Exp Med Biol* 2007; 607:111-8; <http://dx.doi.org/10.1007/978-0-387-74021-8>.
1468. Kiel JA. Autophagy in unicellular eukaryotes. *Philos Trans R Soc B* 2010; 365:819-30; <http://dx.doi.org/10.1098/rstb.2009.0237>.
1469. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of

- protein database search programs. *Nucleic Acids Res* 1997; 25:3389-402; <http://dx.doi.org/10.1093/nar/25.17.3389>.
1470. Pertsemlidis A, Fondon JW, III. Having a BLAST with bioinformatics (and avoiding BLASTphemy). *Genome Biol* 2001; 2:REVIEWS2002; <http://dx.doi.org/10.1186/gb-2001-2-10-reviews2002>.
1471. Rost B. Twilight zone of protein sequence alignments. *Protein engineering* 1999; 12:85-94; <http://dx.doi.org/10.1093/protein/12.2.85>.
1472. Duszzenko M, Ginger ML, Brennand A, Gualdron-Lopez M, Colombo MI, Coombs GH, Coppens I, Jayabalasingham B, Langsley G, de Castro SL, et al. Autophagy in protists. *Autophagy* 2011; 7:127-58; <http://dx.doi.org/10.4161/auto.7.2.13310>.
1473. Rigden DJ, Michels PA, Ginger ML. Autophagy in protists: Examples of secondary loss, lineage-specific innovations, and the conundrum of remodeling a single mitochondrion. *Autophagy* 2009; 5:784-94; <http://dx.doi.org/10.4161/auto.8838>.
1474. Katsani KR, Irimia M, Karapiperis C, Scouras ZG, Blencowe BJ, Promponas VJ, Ouzounis CA. Functional genomics evidence unearths new moonlighting roles of outer ring coat nucleoporins. *Sci Rep* 2014; 4:4655; <http://dx.doi.org/10.1038/srep04655>.
1475. Mei Y, Su M, Soni G, Salem S, Colbert CL, Sinha SC. Intrinsically disordered regions in autophagy proteins. *Proteins* 2014; 82:565-78; <http://dx.doi.org/10.1002/prot.24424>.
1476. Promponas VJ, Ouzounis CA, Iliopoulos I. Experimental evidence validating the computational inference of functional associations from gene fusion events: a critical survey. *Brief Bioinform* 2014; 15:443-54; <http://dx.doi.org/10.1093/bib/bbs072>.
1477. Homma K, Suzuki K, Sugawara H. The Autophagy Database: an all-inclusive information resource on autophagy that provides nourishment for research. *Nucleic Acids Res* 2011; 39:D986-90; <http://dx.doi.org/10.1093/nar/gkq995>.
1478. Turei D, Foldvari-Nagy L, Fazekas D, Modos D, Kubisch J, Kadlecik T, Demeter A, Lenti K, Csermely P, Vellai T, et al. Autophagy Regulatory Network - a systems-level bioinformatics resource for studying the mechanism and regulation of autophagy. *Autophagy* 2015; 11:155-65; <http://dx.doi.org/10.4161/15548627.2014.994346>.
1479. Birgisdottir AB, Lamark T, Johansen T. The LIR motif - crucial for selective autophagy. *J Cell Sci* 2013; 126:3237-47.
1480. Wild P, McEwan DG, Dikic I. The LC3 interactome at a glance. *J Cell Sci* 2014; 127:3-9; <http://dx.doi.org/10.1242/jcs.140426>.
1481. Noda NN, Ohsumi Y, Inagaki F. Atg8-family interacting motif crucial for selective autophagy. *FEBS Lett* 2010; 584:1379-85; <http://dx.doi.org/10.1016/j.febslet.2010.01.018>.
1482. Kalvari I, Tsompanis S, Mulakkal NC, Osgood R, Johansen T, Nezis IP, Promponas VJ. iLIR: A web resource for prediction of Atg8-family interacting proteins. *Autophagy* 2014; 10:913-25; <http://dx.doi.org/10.4161/auto.28260>.
1483. Dosztanyi Z, Meszaros B, Simon I. ANCHOR: web server for predicting protein binding regions in disordered proteins. *Bioinformatics* 2009; 25:2745-6; <http://dx.doi.org/10.1093/bioinformatics/btp518>.
1484. Dinkel H, Van Roey K, Michael S, Davey NE, Weatheritt RJ, Born D, Speck T, Kruger D, Grebnev G, Kuban M, et al. The eukaryotic linear motif resource ELM: 10 years and counting. *Nucleic Acids Res* 2014; 42:D259-66; <http://dx.doi.org/10.1093/nar/gkt1047>.
1485. Wu D, Huang Y, Kang JJ, Li KN, Bi XM, Zhang T, Jin NN, Hu YF, Tan PW, Zhang L, et al. ncRDeathDB: a comprehensive bioinformatics resource for deciphering network organization of the ncRNA-mediated cell death system. *Autophagy* 2015; 11:1917-26.
1486. Li Y, Zhuang L, Wang Y, Hu Y, Wu Y, Wang D, Xu J. Connect the dots: a systems level approach for analyzing the miRNA-mediated cell death network. *Autophagy* 2013; 9:436-9; <http://dx.doi.org/10.4161/auto.23096>.
1487. Xu J, Li YH. miRDeathDB: a database bridging microRNAs and the programmed cell death. *Cell Death Differ* 2012; 19:1571; <http://dx.doi.org/10.1038/cdd.2012.87>.
1488. Xu J, Wang Y, Tan X, Jing H. MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. *Autophagy* 2012; 8:873-82; <http://dx.doi.org/10.4161/auto.19629>.
1489. Tavassoly I, Parmar J, Shajahan-Haq AN, Clarke R, Baumann WT, Tyson JJ. Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells. *CPT Pharmacometrics Syst Pharmacol* 2015; 4:263-72; <http://dx.doi.org/10.1002/psp4.29>.
1490. Tavassoly I. Dynamics of Cell Fate Decision Mediated by the Interplay of Autophagy and Apoptosis in Cancer Cells: Mathematical Modeling and Experimental Observations. Springer, 2015.
1491. Borlin CS, Lang V, Hamacher-Brady A, Brady NR. Agent-based modeling of autophagy reveals emergent regulatory behavior of spatio-temporal autophagy dynamics. *Cell Commun Signal* 2014; 12:56; <http://dx.doi.org/10.1186/s12964-014-0056-8>.
1492. Martin KR, Barua D, Kauffman AL, Westrate LM, Posner RG, Hlavacek WS, Mackeigan JP. Computational model for autophagic vesicle dynamics in single cells. *Autophagy* 2013; 9:74-92; <http://dx.doi.org/10.4161/auto.22532>.
1493. Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, Debnath J, Deretic V, Elazar Z, Eskelinen EL, et al. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). *Autophagy* 2011; 7:1273-94; <http://dx.doi.org/10.4161/auto.7.11.17661>.
1494. Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo-Margareto J, Gewirtz DA, Kroemer G, Levine B, Mizushima N, et al. A comprehensive glossary of autophagy-related molecules and processes. *Autophagy* 2010; 6:438-48; <http://dx.doi.org/10.4161/auto.6.4.12244>.
1495. Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. *Clin Cancer Res* 2012; 18:5278-89; <http://dx.doi.org/10.1158/1078-0432.CCR-12-0351>.
1496. Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. *Nat Chem Biol* 2013; 9:374-82; <http://dx.doi.org/10.1038/nchembio.1230>.
1497. De Mei C, Ercolani L, Parodi C, Veronesi M, Vecchio CL, Bottegoni G, Torrente E, Scarpelli R, Marotta R, Ruffili R, et al. Dual inhibition of REV-ERBbeta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. *Oncogene* 2015; 34:2597-608; <http://dx.doi.org/10.1038/onc.2014.203>.
1498. Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, Yoshimori T. An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure. *Mol Biol Cell* 2008; 19:4651-9; <http://dx.doi.org/10.1091/mbc.E08-03-0312>.
1499. Vanrell MC, Cueto JA, Barclay JJ, Carrillo C, Colombo MI, Gottlieb RA, Romano PS. Polyamine depletion inhibits the autophagic response modulating *Trypanosoma cruzi* infectivity. *Autophagy* 2013; 9:1080-93; <http://dx.doi.org/10.4161/auto.24709>.
1500. Song W, Zukor H, Liberman A, Kaduri S, Arvanitakis Z, Bennett DA, Schipper HM. Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. *Exp Neurol* 2014; 254:78-89; <http://dx.doi.org/10.1016/j.expneurol.2014.01.006>.
1501. Song W, Zukor H, Lin SH, Liberman A, Tavittian A, Mui J, Vali H, Fillebeen C, Pantopoulos K, Wu TD, et al. Unregulated brain iron deposition in transgenic mice over-expressing HMOX1 in the astrocytic compartment. *J Neurochem* 2012; 123:325-36; <http://dx.doi.org/10.1111/j.1471-4159.2012.07914.x>.
1502. Zukor H, Song W, Liberman A, Mui J, Vali H, Fillebeen C, Pantopoulos K, Wu TD, Guerquin-Kern JL, Schipper HM. HO-1-mediated macroautophagy: a mechanism for unregulated iron deposition in aging and degenerating neural tissues. *J Neurochem* 2009; 109:776-91; <http://dx.doi.org/10.1111/j.1471-4159.2009.06007.x>.
1503. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). *Biochem J* 2009; 421:29-42; <http://dx.doi.org/10.1042/BJ20090489>.
1504. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 2009; 458:732-6; <http://dx.doi.org/10.1038/nature07884>.
1505. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, et al. The Nedd8-activating enzyme inhibitor MLN4924

- induces autophagy and apoptosis to suppress liver cancer cell growth. *Cancer Res* 2012; 72:3360-71; <http://dx.doi.org/10.1158/0008-5472.CAN-12-0388>.
1506. Yang D, Zhao Y, Liu J, Sun Y, Jia L. Protective autophagy induced by RBX1/ROC1 knockdown or CRL inactivation via modulating the DEPTOR-mTOR axis. *Autophagy* 2012; 8:1856-8; <http://dx.doi.org/10.4161/auto.22024>.
  1507. Zhao Y, Xiong X, Jia L, Sun Y. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. *Cell Death Dis* 2012; 3:e386; <http://dx.doi.org/10.1038/cddis.2012.125>.
  1508. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. *Cancer Res* 2008; 68:8022-30; <http://dx.doi.org/10.1158/0008-5472.CAN-08-1385>.
  1509. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echeverria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. *Mol Cancer Ther* 2009; 8:2204-10; <http://dx.doi.org/10.1158/1535-7163.MCT-09-0160>.
  1510. Pirola L, Frojdo S. Resveratrol: one molecule, many targets. *IUBMB Life* 2008; 60:323-32; <http://dx.doi.org/10.1002/iub.47>.
  1511. Vingtdoux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. *J Biol Chem* 2010; 285:9100-13; <http://dx.doi.org/10.1074/jbc.M109.060061>.
  1512. Puissant A, Auberger P. AMPK- and p62/SQSTM1-dependent autophagy mediate Resveratrol-induced cell death in chronic myelogenous leukemia. *Autophagy* 2010; 6:655-7; <http://dx.doi.org/10.4161/auto.6.5.12126>.
  1513. Vingtdoux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-[b] peptide degradation. *The FASEB J* 2011; 25:219-31; <http://dx.doi.org/10.1096/fj.10-167361>.
  1514. Wong VK, Li T, Law BY, Ma ED, Yip NC, Michelangeli F, Law CK, Zhang MM, Lam KY, Chan PL, et al. Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. *Cell Death Dis* 2013; 4:e720; <http://dx.doi.org/10.1038/cddis.2013.217>.
  1515. Gordon PB, Holen I, Fosse M, Rotnes JS, Seglen PO. Dependence of hepatocytic autophagy on intracellularly sequestered calcium. *J Biol Chem* 1993; 268:26107-12.
  1516. Ganley IG, Wong PM, Gammoh N, Jiang X. Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. *Mol Cell* 2011; 42:731-43; <http://dx.doi.org/10.1016/j.molcel.2011.04.024>.
  1517. Zhang L, Dai F, Cui L, Jing H, Fan P, Tan X, Guo Y, Zhou G. Novel role for TRPC4 in regulation of macroautophagy by a small molecule in vascular endothelial cells. *Biochim Biophys Acta* 2015; 1853:377-87; <http://dx.doi.org/10.1016/j.bbamcr.2014.10.030>.
  1518. Casarejos MJ, Solano RM, Gomez A, Perucho J, de Yébenes JG, Mena MA. The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells. *Neurochem Int* 2011; 58:512-20; <http://dx.doi.org/10.1016/j.neuint.2011.01.008>.
  1519. Fernandez-Estevéz MA, Casarejos MJ, Lopez Sendon J, Garcia Caldentey J, Ruiz C, Gomez A, Perucho J, de Yébenes JG, Mena MA. Trehalose reverses cell malfunction in fibroblasts from normal and Huntington's disease patients caused by proteasome inhibition. *PLoS One* 2014; 9:e90202; <http://dx.doi.org/10.1371/journal.pone.0090202>.
  1520. Carpenter JE, Jackson W, Benetti L, Grose C. Autophagosome formation during varicella-zoster virus infection following endoplasmic reticulum stress and the unfolded protein response. *J Virol* 2011; 85:9414-24; <http://dx.doi.org/10.1128/JVI.00281-11>.
  1521. Lu Y, Dong S, Hao B, Li C, Zhu K, Guo W, Wang Q, Cheung KH, Wong CW, Wu WT, et al. Vacuolin-1 potently and reversibly inhibits autophagosome-lysosome fusion by activating RAB5A. *Autophagy* 2014; 10:1895-905; <http://dx.doi.org/10.4161/auto.32200>.
  1522. Kijanska M, Dohnal I, Reiter W, Kaspar S, Stoffel I, Ammerer G, Kraft C, Peter M. Activation of Atg1 kinase in autophagy by regulated phosphorylation. *Autophagy* 2010; 6:1168-78; <http://dx.doi.org/10.4161/auto.6.8.13849>.
  1523. Kamada Y, Yoshino K, Kondo C, Kawamata T, Oshiro N, Yonezawa K, Ohsumi Y. Tor directly controls the Atg1 kinase complex to regulate autophagy. *Mol Cell Biol* 2010; 30:1049-58; <http://dx.doi.org/10.1128/MCB.01344-09>.
  1524. Stephan JS, Yeh YY, Ramachandran V, Deminoff SJ, Herman PK. The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to control autophagy. *Proc Natl Acad Sci USA* 2009; 106:17049-54; <http://dx.doi.org/10.1073/pnas.0903316106>.
  1525. Wei Y, An Z, Zou Z, Sumpter R, Su M, Zang X, Sinha S, Gaestel M, Levine B. The stress-responsive kinases MAPKAPK2/MAPKAPK3 activate starvation-induced autophagy through Beclin 1 phosphorylation. *eLife* 2015; 4.
  1526. Kim J, Kim YC, Fang C, Russell RC, Kim JH, Fan W, Liu R, Zhong Q, Guan KL. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. *Cell* 2013; 152:290-303; <http://dx.doi.org/10.1016/j.cell.2012.12.016>.
  1527. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. *Biochem J* 1999; 344 Pt 2:427-31; <http://dx.doi.org/10.1042/bj3440427>.
  1528. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. *J Biol Chem* 2000; 275:7416-23; <http://dx.doi.org/10.1074/jbc.275.10.7416>.
  1529. Nicot AS, Lo Verso F, Ratti F, Pilot-Storck F, Streichenberger N, Sandri M, Schaeffer L, Goillot E. Phosphorylation of NBR1 by GSK3 modulates protein aggregation. *Autophagy* 2014; 10:1036-53; <http://dx.doi.org/10.4161/auto.28479>.
  1530. Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. *Hum Mol Genet* 2009; 18:3298-310; <http://dx.doi.org/10.1093/hmg/ddp271>.
  1531. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. *Proc Natl Acad Sci USA* 2011; 108:E1204-13; <http://dx.doi.org/10.1073/pnas.1110195108>.
  1532. Ro SH, Sempole IA, Park H, Park H, Park HW, Kim M, Kim JS, Lee JH. Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. *FEBS J* 2014; 281:3816-27.
  1533. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, Guan J-L, Mizushima N. FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. *J Cell Biol* 2008; 181:497-510; <http://dx.doi.org/10.1083/jcb.200712064>.
  1534. Xue L, Fletcher GC, Tolkovsky AM. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. *Mol Cell Neurosci* 1999; 14:180-98; <http://dx.doi.org/10.1006/mcne.1999.0780>.
  1535. Zhang N, Chen Y, Jiang R, Li E, Chen X, Xi Z, Guo Y, Liu X, Zhou Y, Che Y, et al. PARG and RIP 1 are required for autophagy induced by 11'-deoxyverticillin A, which precedes caspase-dependent apoptosis. *Autophagy* 2011; 7:598-612; <http://dx.doi.org/10.4161/auto.7.6.15103>.
  1536. Radoshevich L, Murrow L, Chen N, Fernandez E, Roy S, Fung C, Debnath J. ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. *Cell* 2010; 142:590-600; <http://dx.doi.org/10.1016/j.cell.2010.07.018>.
  1537. Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, Geneste O, Kroemer G. BH3-only proteins and BH3

- mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). *Autophagy* 2007; 3:374-6; <http://dx.doi.org/10.4161/auto.4237>.
1538. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005; 435:677-81; <http://dx.doi.org/10.1038/nature03579>.
1539. Nazarko TY. Atg37 regulates the assembly of the pexophagic receptor protein complex. *Autophagy* 2014; 10:1348-9; <http://dx.doi.org/10.4161/auto.29073>.
1540. Eisenberg T, Schroeder S, Andryushkova A, Pendl T, Kuttner V, Bhukel A, Marino G, Pietrocola F, Harger A, Zimmermann A, et al. Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates autophagy and prolongs lifespan. *Cell Metab* 2014; 19:431-44; <http://dx.doi.org/10.1016/j.cmet.2014.02.010>.
1541. Marino G, Pietrocola F, Eisenberg T, Kong Y, Malik SA, Andryushkova A, Schroeder S, Pendl T, Harger A, Niso-Santano M, et al. Regulation of autophagy by cytosolic acetyl-coenzyme a. *Mol Cell* 2014; 53:710-25; <http://dx.doi.org/10.1016/j.molcel.2014.01.016>.
1542. Nandi N, Tyra LK, Stenesen D, Kramer H. Acinus integrates AKT1 and subapoptotic caspase activities to regulate basal autophagy. *J Cell Biol* 2014; 207:253-68; <http://dx.doi.org/10.1083/jcb.201404028>.
1543. Haberman AS, Akbar MA, Ray S, Kramer H. *Drosophila acinus* encodes a novel regulator of endocytic and autophagic trafficking. *Development* 2010; 137:2157-66.
1544. Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, Kim M, Mimuro H, Nakagawa I, Yanagawa T, Ishii T, et al. Listeria monocytogenes ActA-mediated escape from autophagic recognition. *Nat Cell Biol* 2009; 11:1233-40; <http://dx.doi.org/10.1038/ncb1967>.
1545. Till A, Lipinski S, Ellinghaus D, Mayr G, Subramani S, Rosenstiel P, Franke A. Autophagy receptor CALCOCO2/NDP52 takes center stage in Crohn disease. *Autophagy* 2013; 9:1256-7; <http://dx.doi.org/10.4161/auto.25483>.
1546. Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA. ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy. *Mol Cancer* 2010; 9:95; <http://dx.doi.org/10.1186/1476-4598-9-95>.
1547. Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh HJ, 3rd. The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. *Antioxid Redox Sign* 2011; 15:2175-84; <http://dx.doi.org/10.1089/ars.2010.3378>.
1548. Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh HJ. The receptor for advanced glycation end-products (RAGE) protects pancreatic tumor cells against oxidative injury. *Antioxid Redox Sign* 2011; 15:2175-84.
1549. Gamberdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C. BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. *EMBO Rep* 2011; 12:149-56; <http://dx.doi.org/10.1038/embor.2010.203>.
1550. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. *J Cell Biol* 1998; 143:1883-98; <http://dx.doi.org/10.1083/jcb.143.7.1883>.
1551. Viana R, Aguado C, Esteban I, Moreno D, Viollet B, Knecht E, Sanz P. Role of AMP-activated protein kinase in autophagy and proteasome function. *Biochem Biophys Res Commun* 2008; 369:964-8; <http://dx.doi.org/10.1016/j.bbrc.2008.02.126>.
1552. Hadano S, Otomo A, Kunita R, Suzuki-Utsunomiya K, Akatsuka A, Koike M, Aoki M, Uchiyama Y, Itoyama Y, Ikeda JE. Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking. *PLoS One* 2010; 5:e9805; <http://dx.doi.org/10.1371/journal.pone.0009805>.
1553. Otomo A, Kunita R, Suzuki-Utsunomiya K, Ikeda JE, Hadano S. Defective relocalization of ALS2/alsin missense mutants to Rac1-induced macropinosomes accounts for loss of their cellular function and leads to disturbed amphisome formation. *FEBS Lett* 2011; 585:730-6; <http://dx.doi.org/10.1016/j.febslet.2011.01.045>.
1554. Antonioli M, Albiero F, Nazio F, Vescovo T, Perdomo AB, Corazzari M, Marsella C, Piselli P, Gretzmeier C, Dengjel J, et al. AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics. *Dev Cell* 2014; 31:734-46; <http://dx.doi.org/10.1016/j.devcel.2014.11.013>.
1555. Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini PF, De Zio D, Nazio F, Antonioli M, D'Orazio M, et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. *Nat Cell Biol* 2015; 17:20-30; <http://dx.doi.org/10.1038/ncb3072>.
1556. Fu M, St-Pierre P, Shankar J, Wang PT, Joshi B, Nabi IR. Regulation of mitophagy by the Gp78 E3 ubiquitin ligase. *Mol Biol Cell* 2013; 24:1153-62; <http://dx.doi.org/10.1091/mbc.E12-08-0607>.
1557. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. *Hepatology* 2014; 59:505-17; <http://dx.doi.org/10.1002/hep.26659>.
1558. Lee KY, Oh S, Choi YJ, Oh SH, Yang YS, Yang MJ, Lee K, Lee BH. Activation of autophagy rescues amiodarone-induced apoptosis of lung epithelial cells and pulmonary toxicity in rats. *Toxicol Sci* 2013; 136:193-204; <http://dx.doi.org/10.1093/toxsci/kft168>.
1559. Seglen PO, Berg TO, Blankson H, Fengsrud M, Hølen I, Stromhaug PE. Structural aspects of autophagy. *Adv Exp Med Biol* 1996; 389:103-11; <http://dx.doi.org/10.1007/978-1-4613-0335-0>.
1560. Meijer AJ, Codogno P. AMP-activated protein kinase and autophagy. *Autophagy* 2007; 3:238-40; <http://dx.doi.org/10.4161/auto.3710>.
1561. Katsiarimpa A, Anzenberger F, Schlager N, Neubert S, Hauser MT, Schwechheimer C, Isono E. The Arabidopsis deubiquitinating enzyme AMSH3 interacts with ESCRT-III subunits and regulates their localization. *Plant Cell* 2011; 23:3026-40; <http://dx.doi.org/10.1105/tpc.111.087254>.
1562. Katsiarimpa A, Kalinowska K, Anzenberger F, Weis C, Ostertag M, Tsutsumi C, Schwechheimer C, Brunner F, Huckelhoven R, Isono E. The deubiquitinating enzyme AMSH1 and the ESCRT-III subunit VPS2.1 are required for autophagic degradation in Arabidopsis. *Plant Cell* 2013; 25:2236-52; <http://dx.doi.org/10.1105/tpc.113.113399>.
1563. Costa R, Morrison A, Wang J, Manithody C, Li J, Rezaie AR. Activated protein C modulates cardiac metabolism and augments autophagy in the ischemic heart. *J Thromb Haemost* 2012; 10:1736-44; <http://dx.doi.org/10.1111/j.1538-7836.2012.04833.x>.
1564. Yuga M, Gomi K, Klionsky DJ, Shintani T. Aspartyl aminopeptidase is imported from the cytoplasm to the vacuole by selective autophagy in *Saccharomyces cerevisiae*. *J Biol Chem* 2011; 286:13704-13; <http://dx.doi.org/10.1074/jbc.M110.173906>.
1565. Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. *Cell Host Microbe* 2009; 5:527-49; <http://dx.doi.org/10.1016/j.chom.2009.05.016>.
1566. Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H, Su DF, Pei G, Miao CY. ARRB1/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. *Autophagy* 2014; 10:1535-48; <http://dx.doi.org/10.4161/auto.29203>.
1567. Keller KE, Yang YF, Sun YY, Sykes R, Acott TS, Wirtz MK. Ankyrin repeat and suppressor of cytokine signaling box containing protein-10 is associated with ubiquitin-mediated degradation pathways in trabecular meshwork cells. *Mol Vis* 2013; 19:1639-55.
1568. Rzymiski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I, Harris AL. Regulation of autophagy by ATF4 in response to severe hypoxia. *Oncogene* 2010; 29:4424-35; <http://dx.doi.org/10.1038/onc.2010.191>.
1569. Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. *Blood* 2011; 118:2840-8; <http://dx.doi.org/10.1182/blood-2010-12-322537>.
1570. Klionsky DJ, Cregg JM, Dunn WA, Jr., Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, et al. A



- unified nomenclature for yeast autophagy-related genes. *Dev Cell* 2003; 5:539-45; [http://dx.doi.org/10.1016/S1534-5807\(03\)00296-X](http://dx.doi.org/10.1016/S1534-5807(03)00296-X).
1571. Matsuura A, Tsukada M, Wada Y, Ohsumi Y. Apg1p, a novel protein kinase required for the autophagic process in *Saccharomyces cerevisiae*. *Gene* 1997; 192:245-50; [http://dx.doi.org/10.1016/S0378-1119\(97\)00084-X](http://dx.doi.org/10.1016/S0378-1119(97)00084-X).
  1572. Shintani T, Suzuki K, Kamada Y, Noda T, Ohsumi Y. Apg2p functions in autophagosome formation on the perivacuolar structure. *J Biol Chem* 2001; 276:30452-60; <http://dx.doi.org/10.1074/jbc.M102346200>.
  1573. Wang C-W, Kim J, Huang W-P, Abeliovich H, Stromhaug PE, Dunn WA, Jr., Klionsky DJ. Apg2 is a novel protein required for the cytoplasm to vacuole targeting, autophagy, and pexophagy pathways. *J Biol Chem* 2001; 276:30442-51; <http://dx.doi.org/10.1074/jbc.M102342200>.
  1574. Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimonishi Y, Ishihara N, Mizushima N, Tanida I, Kominami E, Ohsumi M, et al. A ubiquitin-like system mediates protein lipidation. *Nature* 2000; 408:488-92; <http://dx.doi.org/10.1038/35044114>.
  1575. Schlumpberger M, Schaeffeler E, Straub M, Bredschneider M, Wolf DH, Thumm M. *AUT1*, a gene essential for autophagocytosis in the yeast *Saccharomyces cerevisiae*. *J Bacteriol* 1997; 179:1068-76.
  1576. Tanida I, Sou YS, Minematsu-Ikeguchi N, Ueno T, Kominami E. Atg8L/Apg8L is the fourth mammalian modifier of mammalian Atg8 conjugation mediated by human Atg4B, Atg7 and Atg3. *FEBS J* 2006; 273:2553-62; <http://dx.doi.org/10.1111/j.1742-4658.2006.05260.x>.
  1577. Mizushima N, Noda T, Yoshimori T, Tanaka Y, Ishii T, George MD, Klionsky DJ, Ohsumi M, Ohsumi Y. A protein conjugation system essential for autophagy. *Nature* 1998; 395:395-8; <http://dx.doi.org/10.1038/26506>.
  1578. Kim J, Dalton VM, Eggerton KP, Scott SV, Klionsky DJ. Apg7p/Cvt2p is required for the cytoplasm-to-vacuole targeting, macroautophagy, and peroxisome degradation pathways. *Mol Biol Cell* 1999; 10:1337-51; <http://dx.doi.org/10.1091/mbc.10.5.1337>.
  1579. Tanida I, Mizushima N, Kiyooka M, Ohsumi M, Ueno T, Ohsumi Y, Kominami E. Apg7p/Cvt2p: A novel protein-activating enzyme essential for autophagy. *Mol Biol Cell* 1999; 10:1367-79; <http://dx.doi.org/10.1091/mbc.10.5.1367>.
  1580. Noda T, Kim J, Huang W-P, Baba M, Tokunaga C, Ohsumi Y, Klionsky DJ. Apg9p/Cvt7p is an integral membrane protein required for transport vesicle formation in the Cvt and autophagy pathways. *J Cell Biol* 2000; 148:465-80; <http://dx.doi.org/10.1083/jcb.148.3.465>.
  1581. Yamada T, Carson AR, Caniggia I, Umebayashi K, Yoshimori T, Nakabayashi K, Scherer SW. Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast. *J Biol Chem* 2005; 280:18283-90; <http://dx.doi.org/10.1074/jbc.M413957200>.
  1582. Shintani T, Mizushima N, Ogawa Y, Matsuura A, Noda T, Ohsumi Y. Apg10p, a novel protein-conjugating enzyme essential for autophagy in yeast. *EMBO J* 1999; 18:5234-41; <http://dx.doi.org/10.1093/emboj/18.19.5234>.
  1583. Kim J, Kamada Y, Stromhaug PE, Guan J, Hefner-Gravink A, Baba M, Scott SV, Ohsumi Y, Dunn WA, Jr., Klionsky DJ. Cvt9/Gsa9 functions in sequestering selective cytosolic cargo destined for the vacuole. *J Cell Biol* 2001; 153:381-96; <http://dx.doi.org/10.1083/jcb.153.2.381>.
  1584. Kamber RA, Shoemaker CJ, Denic V. receptor-bound targets of selective autophagy use a scaffold protein to activate the Atg1 kinase. *Mol Cell* 2015; 59:372-81; <http://dx.doi.org/10.1016/j.molcel.2015.06.009>.
  1585. Lin L, Yang P, Huang X, Zhang H, Lu Q, Zhang H. The scaffold protein EPG-7 links cargo-receptor complexes with the autophagic assembly machinery. *J Cell Biol* 2013; 201:113-29; <http://dx.doi.org/10.1083/jcb.201209098>.
  1586. Li F, Chung T, Vierstra RD. AUTOPHAGY-RELATED11 plays a critical role in general autophagy- and senescence-induced mitophagy in *Arabidopsis*. 2014.
  1587. Funakoshi T, Matsuura A, Noda T, Ohsumi Y. Analyses of *APG13* gene involved in autophagy in yeast, *Saccharomyces cerevisiae*. *Gene* 1997; 192:207-13; [http://dx.doi.org/10.1016/S0378-1119\(97\)00031-0](http://dx.doi.org/10.1016/S0378-1119(97)00031-0).
  1588. Kametaka S, Okano T, Ohsumi M, Ohsumi Y. Apg14p and Apg6/Vps30p form a protein complex essential for autophagy in the yeast, *Saccharomyces cerevisiae*. *J Biol Chem* 1998; 273:22284-91; <http://dx.doi.org/10.1074/jbc.273.35.22284>.
  1589. Epple UD, Suriapranata I, Eskelinen E-L, Thumm M. Aut5/Cvt17p, a putative lipase essential for disintegration of autophagic bodies inside the vacuole. *J Bacteriol* 2001; 183:5942-55; <http://dx.doi.org/10.1128/JB.183.20.5942-5955.2001>.
  1590. Teter SA, Eggerton KP, Scott SV, Kim J, Fischer AM, Klionsky DJ. Degradation of lipid vesicles in the yeast vacuole requires function of Cvt17, a putative lipase. *J Biol Chem* 2001; 276:2083-7; <http://dx.doi.org/10.1074/jbc.C000739200>.
  1591. van Zutphen T, Todde V, de Boer R, Kreim M, Hofbauer HF, Wolinski H, Veenhuis M, van der Klei IJ, Kohlwein SD. Lipid droplet autophagy in the yeast *Saccharomyces cerevisiae*. *Mol Biol Cell* 2014; 25:290-301; <http://dx.doi.org/10.1091/mbc.E13-08-0448>.
  1592. Mizushima N, Noda T, Ohsumi Y. Apg16p is required for the function of the Apg12p-Apg5p conjugate in the yeast autophagy pathway. *EMBO J* 1999; 18:3888-96; <http://dx.doi.org/10.1093/emboj/18.14.3888>.
  1593. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, *ATG16L1* and *IRGM*, as being significantly associated with Crohn's disease. *Autophagy* 2007; 3:649-51; <http://dx.doi.org/10.4161/auto.5075>.
  1594. Yang SK, Hong M, Zhao W, Jung Y, Baek J, Tayebi N, Kim KM, Ye BD, Kim KJ, Park SH, et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. *Gut* 2014; 63:80-7; <http://dx.doi.org/10.1136/gutjnl-2013-305193>.
  1595. Chew LH, Setiaputra D, Klionsky DJ, Yip CK. Structural characterization of the *Saccharomyces cerevisiae* autophagy regulatory complex Atg17-Atg31-Atg29. *Autophagy* 2013; 9:1467-74; <http://dx.doi.org/10.4161/auto.25687>.
  1596. Mao K, Chew LH, Inoue-Aono Y, Cheong H, Nair U, Popelka H, Yip CK, Klionsky DJ. Atg29 phosphorylation regulates coordination of the Atg17-Atg31-Atg29 complex with the Atg11 scaffold during autophagy initiation. *Proc Natl Acad Sci USA* 2013; 110:E2875-84; <http://dx.doi.org/10.1073/pnas.1300064110>.
  1597. Mao K, Chew LH, Yip CK, Klionsky DJ. The role of Atg29 phosphorylation in PAS assembly. *Autophagy* 2013; 9:2178-9; <http://dx.doi.org/10.4161/auto.26740>.
  1598. Leber R, Silles E, Sandoval IV, Mazon MJ. Yol082p, a novel CVT protein involved in the selective targeting of aminopeptidase I to the yeast vacuole. *J Biol Chem* 2001; 276:29210-7; <http://dx.doi.org/10.1074/jbc.M101438200>.
  1599. Scott SV, Guan J, Hutchins MU, Kim J, Klionsky DJ. Cvt19 is a receptor for the cytoplasm-to-vacuole targeting pathway. *Mol Cell* 2001; 7:1131-41; [http://dx.doi.org/10.1016/S1097-2765\(01\)00263-5](http://dx.doi.org/10.1016/S1097-2765(01)00263-5).
  1600. Nice DC, Sato TK, Stromhaug PE, Emr SD, Klionsky DJ. Cooperative binding of the cytoplasm to vacuole targeting pathway proteins, Cvt13 and Cvt20, to phosphatidylinositol 3-phosphate at the pre-autophagosomal structure is required for selective autophagy. *J Biol Chem* 2002; 277:30198-207; <http://dx.doi.org/10.1074/jbc.M204736200>.
  1601. Deng YZ, Qu Z, He Y, Naqvi NI. Sorting nexin Snx41 is essential for condensation and mediates glutathione-based antioxidant defense during invasive growth in *Magnaporthe oryzae*. *Autophagy* 2012; 8:1058-70; <http://dx.doi.org/10.4161/auto.20217>.
  1602. Suriapranata I, Epple UD, Bernreuther D, Bredschneider M, Sovarasteanu K, Thumm M. The breakdown of autophagic vesicles inside the vacuole depends on Aut4p. *J Cell Sci* 2000; 113:4025-33.
  1603. Yang Z, Huang J, Geng J, Nair U, Klionsky DJ. Atg22 recycles amino acids to link the degradative and recycling functions of autophagy. *Mol Biol Cell* 2006; 17:5094-104; <http://dx.doi.org/10.1091/mbc.E06-06-0479>.

1604. Legakis JE, Yen W-L, Klionsky DJ. A cycling protein complex required for selective autophagy. *Autophagy* 2007; 3:422-32; <http://dx.doi.org/10.4161/auto.4129>.
1605. Tucker KA, Reggiori F, Dunn WA, Jr., Klionsky DJ. Atg23 is essential for the cytoplasm to vacuole targeting pathway and efficient autophagy but not pexophagy. *J Biol Chem* 2003; 278:48445-52; <http://dx.doi.org/10.1074/jbc.M309238200>.
1606. Monastyrska I, Kiel JAKW, Krikken AM, Komduur JA, Veenhuis M, van der Klei IJ. The *Hansenula polymorpha* ATG25 gene encodes a novel coiled-coil protein that is required for macropexophagy. *Autophagy* 2005; 1:92-100; <http://dx.doi.org/10.4161/auto.1.2.1832>.
1607. Cao Y, Klionsky DJ. Atg26 is not involved in autophagy-related pathways in *Saccharomyces cerevisiae*. *Autophagy* 2007; 3:17-20; <http://dx.doi.org/10.4161/auto.3371>.
1608. Yamashita S, Oku M, Wasada Y, Ano Y, Sakai Y. PI4P-signaling pathway for the synthesis of a nascent membrane structure in selective autophagy. *J Cell Biol* 2006; 173:709-17; <http://dx.doi.org/10.1083/jcb.200512142>.
1609. Yen W-L, Legakis JE, Nair U, Klionsky DJ. Atg27 is required for autophagy-dependent cycling of Atg9. *Mol Biol Cell* 2007; 18:581-93; <http://dx.doi.org/10.1091/mbc.E06-07-0612>.
1610. Stasyk OV, Stasyk OG, Mathewson RD, Farre JC, Nazarko VY, Krasovska OS, Subramani S, Cregg JM, Sibirny AA. Atg28, a novel coiled-coil protein involved in autophagic degradation of peroxisomes in the methylotrophic yeast *Pichia pastoris*. *Autophagy* 2006; 2:30-8; <http://dx.doi.org/10.4161/auto.2226>.
1611. Kawamata T, Kamada Y, Suzuki K, Kuboshima N, Akimatsu H, Ota S, Ohsumi M, Ohsumi Y. Characterization of a novel autophagy-specific gene, ATG29. *Biochem Biophys Res Commun* 2005; 338:1884-9; <http://dx.doi.org/10.1016/j.bbrc.2005.10.163>.
1612. Kabeya Y, Kawamata T, Suzuki K, Ohsumi Y. Cis1/Atg31 is required for autophagosome formation in *Saccharomyces cerevisiae*. *Biochem Biophys Res Commun* 2007; 356:405-10; <http://dx.doi.org/10.1016/j.bbrc.2007.02.150>.
1613. Watanabe Y, Noda NN, Kumeta H, Suzuki K, Ohsumi Y, Inagaki F. Selective transport of alpha-mannosidase by autophagic pathways: structural basis for cargo recognition by Atg19 and Atg34. *J Biol Chem* 2010; 285:30026-33; <http://dx.doi.org/10.1074/jbc.M110.143545>.
1614. Meijer WH, van der Klei IJ, Veenhuis M, Kiel JAKW. ATG genes involved in non-selective autophagy are conserved from yeast to man, but the selective Cvt and pexophagy pathways also require organism-specific genes. *Autophagy* 2007; 3:106-16.
1615. Nazarko VY, Nazarko TY, Farre JC, Stasyk OV, Warnecke D, Ulaszewski S, Cregg JM, Sibirny AA, Subramani S. Atg35, a micropexophagy-specific protein that regulates micropexophagic apparatus formation in *Pichia pastoris*. *Autophagy* 2011; 7:375-85; <http://dx.doi.org/10.4161/auto.7.4.14369>.
1616. Motley AM, Nuttall JM, Hetteema EH. Pex3-anchored Atg36 tags peroxisomes for degradation in *Saccharomyces cerevisiae*. *EMBO J* 2012; 31:2852-68; <http://dx.doi.org/10.1038/emboj.2012.151>.
1617. Araki Y, Ku WC, Akioka M, May AI, Hayashi Y, Arisaka F, Ishihama Y, Ohsumi Y. Atg38 is required for autophagy-specific phosphatidylinositol 3-kinase complex integrity. *J Cell Biol* 2013; 203:299-313; <http://dx.doi.org/10.1083/jcb.201304123>.
1618. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. *Autophagy* 2009; 5:973-9; <http://dx.doi.org/10.4161/auto.5.7.9296>.
1619. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. *Autophagy* 2009; 5:649-62; <http://dx.doi.org/10.4161/auto.5.5.8249>.
1620. Honig A, Avin-Wittenberg T, Ufaz S, Galili G. A new type of compartment, defined by plant-specific Atg8-interacting proteins, is induced upon exposure of Arabidopsis plants to carbon starvation. *Plant Cell* 2012; 24:288-303; <http://dx.doi.org/10.1105/tpc.111.093112>.
1621. Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezaud E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. *Proc Natl Acad Sci USA* 2012; 109:9611-6; <http://dx.doi.org/10.1073/pnas.1112368109>.
1622. Gusdon AM, Zhu J, Van Houten B, Chu CT. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. *Neurobiol Dis* 2012; 45:962-72; <http://dx.doi.org/10.1016/j.nbd.2011.12.015>.
1623. Niu H, Rikihisa Y. Ats-1: a novel bacterial molecule that links autophagy to bacterial nutrition. *Autophagy* 2013; 9:787-8; <http://dx.doi.org/10.4161/auto.23693>.
1624. Niu H, Xiong Q, Yamamoto A, Hayashi-Nishino M, Rikihisa Y. Autophagosomes induced by a bacterial Beclin 1 binding protein facilitate obligatory intracellular infection. *Proc Natl Acad Sci USA* 2012; 109:20800-7; <http://dx.doi.org/10.1073/pnas.1218674109>.
1625. Isakson P, BJORAS M, BOE SO, SIMONSEN A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. *Blood* 2010; 116:2324-31; <http://dx.doi.org/10.1182/blood-2010-01-261040>.
1626. Orfali N, McKenna SL, Cahill MR, Gudas LJ, Mongan NP. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. *Exp Cell Res* 2014; 324:1-12; <http://dx.doi.org/10.1016/j.yexcr.2014.03.018>.
1627. Vanhee C, Zapotocny G, Masquelier D, Ghislain M, Batoko H. The Arabidopsis multistress regulator TSPO is a heme binding membrane protein and a potential scavenger of porphyrins via an autophagy-dependent degradation mechanism. *Plant Cell* 2011; 23:785-805; <http://dx.doi.org/10.1105/tpc.110.081570>.
1628. Papp D, Kovacs T, Billes V, Varga M, Tarnoci A, Hackler L Jr, et al. AUTEN-67, an autophagy-enhancing drug candidate with potent antiangiogenic and neuroprotective effects. *Autophagy* 2015; 11:in press.
1629. Dunn WA, Jr. Studies on the mechanisms of autophagy: formation of the autophagic vacuole. *J Cell Biol* 1990; 110:1923-33; <http://dx.doi.org/10.1083/jcb.110.6.1923>.
1630. Schulze RJ, Weller SG, Schroeder B, Krueger EW, Chi S, Casey CA, McNiven MA. Lipid droplet breakdown requires dynamin 2 for vesiculation of autolysosomal tubules in hepatocytes. *J Cell Biol* 2013; 203:315-26; <http://dx.doi.org/10.1083/jcb.201306140>.
1631. Gundara JS, Robinson BG, Sidhu SB. Evolution of the "autophagamiR". *Autophagy* 2011; 7:1553-4; <http://dx.doi.org/10.4161/auto.7.12.17762>.
1632. Mijaljica D, Nazarko TY, Brumell JH, Huang WP, Komatsu M, Prescott M, Simonsen A, Yamamoto A, Zhang H, Klionsky DJ, et al. Receptor protein complexes are in control of autophagy. *Autophagy* 2012; 8:1701-5; <http://dx.doi.org/10.4161/auto.21332>.
1633. Shpilka T, Welter E, Borovsky N, Amar N, Mari M, Reggiori F, Elazar Z. Lipid droplets and their component triglycerides and steryl esters regulate autophagosome biogenesis. *EMBO J* 2015; 34:2117-31; <http://dx.doi.org/10.15252/emboj.201490315>.
1634. Gamberdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU, Behl C. Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. *EMBO J* 2009; 28:889-901; <http://dx.doi.org/10.1038/emboj.2009.29>.
1635. Sebti S, Prebois C, Perez-Gracia E, Bauvy C, Desmots F, Pirot N, Gongora C, Bach AS, Hubberstey AV, Palissot V, et al. BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy. *Proc Natl Acad Sci USA* 2014; 111:4115-20; <http://dx.doi.org/10.1073/pnas.1313618111>.
1636. Noda NN, Kobayashi T, Adachi W, Fujioka Y, Ohsumi Y, Inagaki F. Structure of the novel C-terminal domain of vacuolar protein sorting 30/autophagy-related protein 6 and its specific role in autophagy. *J Biol Chem* 2012; 287:16256-66; <http://dx.doi.org/10.1074/jbc.M112.348250>.
1637. Lindqvist LM, Heinlein M, Huang DC, Vaux DL. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. *Proc Natl Acad Sci USA* 2014; 111:8512-7; <http://dx.doi.org/10.1073/pnas.1406425111>.
1638. Murakawa T, Yamaguchi O, Hashimoto A, Hikoso S, Takeda T, Oka T, Yasui H, Ueda H, Akazawa Y, Nakayama H, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates

- mitophagy and mitochondrial fragmentation. *Nat Commun* 2015; 6:7527; <http://dx.doi.org/10.1038/ncomms8527>.
1639. Paul S, Kashyap AK, Jia W, He YW, Schaefer BC. Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-kappaB. *Immunity* 2012; 36:947-58; <http://dx.doi.org/10.1016/j.immuni.2012.04.008>.
1640. Liang X, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by *beclin 1*. *Nature* 1999; 402:672-6; <http://dx.doi.org/10.1038/45257>.
1641. Hurlley JH, Schulman BA. Atomistic autophagy: the structures of cellular self-digestion. *Cell* 2014; 157:300-11; <http://dx.doi.org/10.1016/j.cell.2014.01.070>.
1642. Cheng B, Xu A, Qiao M, Wu Q, Wang W, Mei Y, Wu M. BECN1s, a short splice variant of BECN1, functions in mitophagy. *Autophagy* 2015; in press.
1643. He C, Wei Y, Sun K, Li B, Dong X, Zou Z, Liu Y, Kinch LN, Khan S, Sinha S, et al. Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism. *Cell* 2013; 154:1085-99; <http://dx.doi.org/10.1016/j.cell.2013.07.035>.
1644. Yang LJ, Chen Y, He J, Yi S, Wen L, Zhao J, Zhang BP, Cui GH. Betulinic acid inhibits autophagic flux and induces apoptosis in human multiple myeloma cells in vitro. *Acta Pharmacol Sin* 2012; 33:1542-8; <http://dx.doi.org/10.1038/aps.2012.102>.
1645. Minoia M, Boncoraglio A, Vinet J, Morelli FF, Brunsting JF, Poletti A, Krom S, Reits E, Kampinga HH, Carra S. BAG3 induces the sequestration of proteasomal clients into cytoplasmic puncta: Implications for a proteasome-to-autophagy switch. *Autophagy* 2014; 10.
1646. Boyd JM, Malstrom S, Subramanian T, Venkatesh LK, Schaeper U, Elangovan B, D'Sa-Eipper C, Chinnadurai G. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. *Cell* 1994; 79:341-51; [http://dx.doi.org/10.1016/0092-8674\(94\)90202-X](http://dx.doi.org/10.1016/0092-8674(94)90202-X).
1647. Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson AB. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. *J Biol Chem* 2012; 287:19094-104; <http://dx.doi.org/10.1074/jbc.M111.322933>.
1648. Chourasia AH, Boland ML, Macleod KF. Mitophagy and cancer. *Cancer Metab* 2015; 3:4; <http://dx.doi.org/10.1186/s40170-015-0130-8>.
1649. Landes T, Emorine LJ, Courilleau D, Rojo M, Belenguer P, Arnaune-Pelloquin L. The BH3-only Bnip3 binds to the dynamin Opal to promote mitochondrial fragmentation and apoptosis by distinct mechanisms. *EMBO Rep* 2010; 11:459-65; <http://dx.doi.org/10.1038/embo.2010.50>.
1650. Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J, Baudino TA, Cleveland JL, Brindle PK. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. *EMBO J* 2005; 24:3846-58; <http://dx.doi.org/10.1038/sj.emboj.7600846>.
1651. Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. *Mol Cell Biol* 2007; 27:6229-42; <http://dx.doi.org/10.1128/MCB.02246-06>.
1652. Feng X, Liu X, Zhang W, Xiao W. p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death. *EMBO J* 2011; 30:3397-415; <http://dx.doi.org/10.1038/emboj.2011.248>.
1653. Shaw J, Yurkova N, Zhang T, Gang H, Aguilar F, Weidman D, Scramstad C, Weisman H, Kirshenbaum LA. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival. *Proc Natl Acad Sci USA* 2008; 105:20734-9; <http://dx.doi.org/10.1073/pnas.0807735105>.
1654. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. *J Clin Invest* 2007; 117:2825-33; <http://dx.doi.org/10.1172/JCI32490>.
1655. Glick D, Zhang W, Beaton M, Marsboom G, Gruber M, Simon MC, Hart J, Dorn GW, 2nd, Brady MJ, Macleod KF. BNIP3 regulates mitochondrial function and lipid metabolism in the liver. *Mol Cell Biol* 2012; 32:2570-84; <http://dx.doi.org/10.1128/MCB.00167-12>.
1656. Melsner S, Chatelain EH, Lavie J, Mahfouf W, Jose C, Obre E, Goorden S, Priault M, Elgersma Y, Rezvani HR, et al. Rheb regulates mitophagy induced by mitochondrial energetic status. *Cell Metab* 2013; 17:719-30; <http://dx.doi.org/10.1016/j.cmet.2013.03.014>.
1657. Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V, Halloran MA, Gleeson PA, Blair IP, Soo KY, et al. C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. *Hum Mol Genet* 2014; 23:3579-95; <http://dx.doi.org/10.1093/hmg/ddu068>.
1658. O'Farrell F, Wang S, Katheder N, Rusten TE, Samakovlis C. Two-tiered control of epithelial growth and autophagy by the insulin receptor and the ret-like receptor, sticher. *PLoS Biol* 2013; 11:e1001612.
1659. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Mimura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. *Blood* 2010; 116:1460-8; <http://dx.doi.org/10.1182/blood-2009-06-222943>.
1660. Xia HG, Zhang L, Chen G, Zhang T, Liu J, Jin M, Ma X, Ma D, Yuan J. Control of basal autophagy by calpain1 mediated cleavage of ATG5. *Autophagy* 2010; 6:61-6; <http://dx.doi.org/10.4161/auto.6.1.10326>.
1661. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. *Clin Cancer Res* 2010; 16:3100-4; <http://dx.doi.org/10.1158/1078-0432.CCR-09-2891>.
1662. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nat Med* 2007; 13:54-61; <http://dx.doi.org/10.1038/nm1523>.
1663. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. *Photoch Photobio Sci* 2014; 13:474-87; <http://dx.doi.org/10.1039/c3pp50333j>.
1664. Hurlley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *J Biol Chem* 2005; 280:29060-6; <http://dx.doi.org/10.1074/jbc.M503824200>.
1665. Demarchi F, Bertoli C, Copetti T, Tanida I, Brancolini C, Eskelinen E-L, Schneider C. Calpain is required for macroautophagy in mammalian cells. *J Cell Biol* 2006; 175:595-605; <http://dx.doi.org/10.1083/jcb.200601024>.
1666. Zhu Y, Zhao L, Liu L, Gao P, Tian W, Wang X, Jin H, Xu H, Chen Q. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. *Protein Cell* 2010; 1:468-77; <http://dx.doi.org/10.1007/s13238-010-0048-4>.
1667. Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW, Stolz DB, Yu J, Zhang L. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. *Cancer Res* 2011; 71:3625-34; <http://dx.doi.org/10.1158/0008-5472.CAN-10-4475>.
1668. Garcia-Marcos M, Ear J, Farquhar MG, Ghosh P. A GDI (AGS3) and a GEF (GIV) regulate autophagy by balancing G protein activity and growth factor signals. *Mol Biol Cell* 2011; 22:673-86; <http://dx.doi.org/10.1091/mbc.E10-08-0738>.
1669. Latterich M, Frohlich KU, Schekman R. Membrane fusion and the cell cycle: Cdc48p participates in the fusion of ER membranes. *Cell* 1995; 82:885-93; [http://dx.doi.org/10.1016/0092-8674\(95\)90268-6](http://dx.doi.org/10.1016/0092-8674(95)90268-6).
1670. Krick R, Bremer S, Welter E, Schlotterhose P, Muehe Y, Eskelinen E-L, Thumm M. Cdc48/p97 and Shp1/p47 regulate autophagosome biogenesis in concert with ubiquitin-like Atg8. *J Cell Biol* 2010; 190:965-73; <http://dx.doi.org/10.1083/jcb.201002075>.
1671. Joubert PE, Meiffren G, Gregoire IP, Pontini G, Richetta C, Flacher M, Azocar O, Vidalain PO, Vidal M, Lotteau V, et al. Autophagy induction by the pathogen receptor CD46. *Cell Host Microbe* 2009; 6:354-66; <http://dx.doi.org/10.1016/j.chom.2009.09.006>.
1672. Orloff NI, Cimino-Reale G, Borghini E, Pennati M, Sissi C, Perrone F, Palumbo M, Daidone MG, Folini M, Zaffaroni N. Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. *Autophagy* 2012; 8:1185-96; <http://dx.doi.org/10.4161/auto.20519>.

1673. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. *Nat Cell Biol* 2007; 9:218-24; <http://dx.doi.org/10.1038/ncb1537>.
1674. Budina-Kolomets A, Hontz RD, Pimkina J, Murphy ME. A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. *Autophagy* 2013; 9:1553-65; <http://dx.doi.org/10.4161/auto.25831>.
1675. Cuervo AM. Chaperone-mediated autophagy: selectivity pays off. *Trends Endocrinol Metab* 2010; 21:142-50; <http://dx.doi.org/10.1016/j.tem.2009.10.003>.
1676. Dice J. Chaperone-mediated autophagy. *Autophagy* 2007; 3:295-9; <http://dx.doi.org/10.4161/auto.4144>.
1677. Agarraberes F, Terlecky S, Dice J. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. *J Cell Biol* 1997; 137:825-34; <http://dx.doi.org/10.1083/jcb.137.4.825>.
1678. Cuervo A, Dice J. A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* 1996; 273:501-3; <http://dx.doi.org/10.1126/science.273.5274.501>.
1679. Mitsuhashi S, Hatakeyama H, Karahashi M, Koumura T, Nonaka I, Hayashi YK, Noguchi S, Sher RB, Nakagawa Y, Manfredi G, et al. Muscle choline kinase beta defect causes mitochondrial dysfunction and increased mitophagy. *Hum Mol Genet* 2011; 20:3841-51; <http://dx.doi.org/10.1093/hmg/ddr305>.
1680. Fedorko M. Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes—an ultrastructural study. *J Clin Invest* 1967; 46:1932-42; <http://dx.doi.org/10.1172/JCI105683>.
1681. Chang NC, Nguyen M, Germain M, Shore GC. Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1. *EMBO J* 2010; 29:606-18; <http://dx.doi.org/10.1038/emboj.2009.369>.
1682. Chen YF, Kao CH, Chen YT, Wang CH, Wu CY, Tsai CY, Liu FC, Yang CW, Wei YH, Hsu MT, et al. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. *Genes Dev* 2009; 23:1183-94; <http://dx.doi.org/10.1101/gad.1779509>.
1683. Yang Z, Geng J, Yen W-L, Wang K, Klionsky DJ. Positive or negative regulatory roles of different cyclin-dependent kinase Pho85-cyclin complexes orchestrate induction of autophagy in *Saccharomyces cerevisiae*. *Mol Cell* 2010; 38:250-64; <http://dx.doi.org/10.1016/j.molcel.2010.02.033>.
1684. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME, Cotman SL. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. *J Biol Chem* 2006; 281:20483-93; <http://dx.doi.org/10.1074/jbc.M602180200>.
1685. Chandrachud U, Walker MW, Simas AM, Heetveld S, Petcherski A, Klein M, Oh H, Wolf P, Zhao WN, Norton S, et al. Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between Ca<sup>2+</sup> Homeostasis, Autophagy, and CLN3 Protein Function. *J Biol Chem* 2015; 290:14361-80; <http://dx.doi.org/10.1074/jbc.M114.621706>.
1686. Cortese A, Tucci A, Piccolo G, Galimberti CA, Fratta P, Marchioni E, Grampa G, Cereda C, Grieco G, Ricca I, et al. Novel CLN3 mutation causing autophagic vacuolar myopathy. *Neurology* 2014; 82:2072-6; <http://dx.doi.org/10.1212/WNL.0000000000000490>.
1687. Wang F, Wang H, Tuan HF, Nguyen DH, Sun V, Keser V, Bowne SJ, Sullivan LS, Luo H, Zhao L, et al. Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements. *Hum Genet* 2014; 133:331-45; <http://dx.doi.org/10.1007/s00439-013-1381-5>.
1688. Yen W-L, Shintani T, Nair U, Cao Y, Richardson BC, Li Z, Hughson FM, Baba M, Klionsky DJ. The conserved oligomeric Golgi complex is involved in double-membrane vesicle formation during autophagy. *J Cell Biol* 2010; 188:101-14; <http://dx.doi.org/10.1083/jcb.200904075>.
1689. Lancel S, Montaigne D, Marechal X, Marciniak C, Hassoun SM, Decoster B, Ballot C, Blazewski C, Corseaux D, Lescure B, et al. Carbon monoxide improves cardiac function and mitochondrial population quality in a mouse model of metabolic syndrome. *PLoS One* 2012; 7:e41836; <http://dx.doi.org/10.1371/journal.pone.0041836>.
1690. Chen LL, Song JX, Lu JH, Yuan ZW, Liu LF, Durairajan SS, Li M. Corynoxine, a Natural Autophagy Enhancer, Promotes the Clearance of Alpha-Synuclein via Akt/mTOR Pathway. *J Neuroimmune Pharm* 2014; 3:380-7; <http://dx.doi.org/10.1007/s11481-014-9528-2>.
1691. Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, Shen HM, Chan HY, Li M. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. *Autophagy* 2012; 8:98-108 (see also the erratum in *Autophagy* 2012; 8:864-6); <http://dx.doi.org/10.4161/auto.8.1.18313>.
1692. Smith RE, Farquhar MG. Lysosome function in the regulation of the secretory process in cells of the anterior pituitary gland. *J Cell Biol* 1966; 31:319-47; <http://dx.doi.org/10.1083/jcb.31.2.319>.
1693. Ponpuak M, Davis AS, Roberts EA, Delgado MA, Dinkins C, Zhao Z, Virgin HWI, Kyei GB, Johansen T, Vergne I, et al. Delivery of cytosolic components by autophagic adaptor protein p62 endows autophagosomes with unique antimicrobial properties. *Immunity* 2010; 32:329-41; <http://dx.doi.org/10.1016/j.immuni.2010.02.009>.
1694. Song H, Pu J, Wang L, Wu L, Xiao J, Liu Q, Chen J, Zhang M, Liu Y, Ni M, et al. ATG16L1 phosphorylation is oppositely regulated by CSNK2/casein kinase 2 and PPP1/protein phosphatase 1 which determines the fate of cardiomyocytes during hypoxia/reoxygenation. *Autophagy* 2015:0.
1695. Sun LL, Li M, Suo F, Liu XM, Shen EZ, Yang B, Dong MQ, He WZ, Du LL. Global analysis of fission yeast mating genes reveals new autophagy factors. *PLoS Genet* 2013; 9:e1003715; <http://dx.doi.org/10.1371/journal.pgen.1003715>.
1696. Campbell EM, Fares H. Roles of CUP-5, the *Caenorhabditis elegans* orthologue of human TRPML1, in lysosome and gut granule biogenesis. *BMC Cell Biol* 2010; 11:40; <http://dx.doi.org/10.1186/1471-2121-11-40>.
1697. Fares H, Greenwald I. Regulation of endocytosis by CUP-5, the *Caenorhabditis elegans* mucopolipin-1 homolog. *Nat Genet* 2001; 28:64-8.
1698. Hersh BM, Hartwig E, Horvitz HR. The *Caenorhabditis elegans* mucopolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types. *Proc Natl Acad Sci USA* 2002; 99:4355-60; <http://dx.doi.org/10.1073/pnas.062065399>.
1699. Sun T, Wang X, Lu Q, Ren H, Zhang H. CUP-5, the *C. elegans* ortholog of the mammalian lysosomal channel protein MLN1/TRPML1, is required for proteolytic degradation in autolysosomes. *Autophagy* 2011; 7:1308-15; <http://dx.doi.org/10.4161/auto.7.11.17759>.
1700. Bruns C, McCaffery JM, Curwin AJ, Duran JM, Malhotra V. Biogenesis of a novel compartment for autophagosome-mediated unconventional protein secretion. *J Cell Biol* 2011; 195:979-92; <http://dx.doi.org/10.1083/jcb.201106098>.
1701. Wang M, Tan W, Zhou J, Leow J, Go M, Lee HS, Casey PJ. A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. *J Biol Chem* 2008; 283:18678-84; <http://dx.doi.org/10.1074/jbc.M801855200>.
1702. Harding TM, Morano KA, Scott SV, Klionsky DJ. Isolation and characterization of yeast mutants in the cytoplasm to vacuole protein targeting pathway. *J Cell Biol* 1995; 131:591-602; <http://dx.doi.org/10.1083/jcb.131.3.591>.
1703. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in *C. elegans*. *PLoS Genet* 2008; 4:e24; <http://dx.doi.org/10.1371/journal.pgen.0040024>.
1704. Lapiere LR, Gelino S, Melendez A, Hansen M. Autophagy and lipid metabolism coordinately modulate life span in germline-less *C. elegans*. *Curr Biol* 2011; 21:1507-14; <http://dx.doi.org/10.1016/j.cub.2011.07.042>.
1705. Netea-Maier RT, Plantinga TS, Van De Veerdonk FL, Smit JW, Netea MG. Modulation of inflammation by autophagy: consequences for human disease. *Autophagy* 2015:0; <http://dx.doi.org/10.1080/15548627.2015.1071759>.
1706. Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. *Curr Biol* 2010; 20:1093-8; <http://dx.doi.org/10.1016/j.cub.2010.04.041>.

1707. Inbal B, Bialik S, Sabanay I, Shani G, Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. *J Cell Biol* 2002; 157:455-68; <http://dx.doi.org/10.1083/jcb.200109094>.
1708. Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schaefer L, Torres A, Iozzo RV. Decorin causes autophagy in endothelial cells via Peg3. *Proc Natl Acad Sci USA* 2013; 110:E2582-91; <http://dx.doi.org/10.1073/pnas.1305732110>.
1709. DeVorkin L, Go NE, Hou Y-CC, Moradian A, Morin GB, Gorski SM. The *Drosophila* effector caspase Dcp-1 regulates mitochondrial dynamics and autophagic flux via SesB. *J Cell Biol* 2014; 205:477-92; <http://dx.doi.org/10.1083/jcb.201303144>.
1710. Hu G, McQuiston T, Bernard A, Park YD, Qiu J, Vural A, Zhang N, Waterman SR, Blewett NH, Myers TG, et al. A conserved mechanism of TOR-dependent RCK-mediated mRNA degradation regulates autophagy. *Nat Cell Biol* 2015; 17:930-42; <http://dx.doi.org/10.1038/ncb3189>.
1711. Molitoris JK, McColl KS, Swerdlow S, Matsuyama M, Lam M, Finkel TH, Matsuyama S, Distelhorst CW. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. *J Biol Chem* 2011; 286:30181-9; <http://dx.doi.org/10.1074/jbc.M111.245423>.
1712. Slavov N, Botstein D. Decoupling nutrient signaling from growth rate causes aerobic glycolysis and deregulation of cell size and gene expression. *Mol Biol Cell* 2013; 24:157-68; <http://dx.doi.org/10.1091/mbc.E12-09-0670>.
1713. Kohler K, Brunner E, Guan XL, Boucke K, Greber UF, Mohanty S, Barth JM, Wenk MR, Hafen E. A combined proteomic and genetic analysis identifies a role for the lipid desaturase Desat1 in starvation-induced autophagy in *Drosophila*. *Autophagy* 2009; 5:980-90; <http://dx.doi.org/10.4161/auto.5.7.9325>.
1714. Shahnazari S, Yen W-L, Birmingham CL, Shiu J, Namolovan A, Zheng YT, Nakayama K, Klionsky DJ, Brumell JH. A diacylglycerol-dependent signaling pathway contributes to regulation of antibacterial autophagy. *Cell Host Microbe* 2010; 8:137-46; <http://dx.doi.org/10.1016/j.chom.2010.07.002>.
1715. Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC, Jr. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. *Autophagy* 2014; 10:1071-92; <http://dx.doi.org/10.4161/auto.28577>.
1716. Mao K, Liu X, Feng Y, Klionsky DJ. The progression of peroxisomal degradation through autophagy requires peroxisomal division. *Autophagy* 2014; 10:652-61; <http://dx.doi.org/10.4161/auto.27852>.
1717. Dagda RK, Gusdon AM, Pien I, Strack S, Green S, Li C, Van Houten B, Cherra SJ, 3rd, Chu CT. Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease. *Cell Death Differ* 2011; 18:1914-23; <http://dx.doi.org/10.1038/cdd.2011.74>.
1718. Kwon MH, Callaway H, Zhong J, Yedvobnick B. A targeted genetic modifier screen links the SWI2/SNF2 protein domino to growth and autophagy genes in *Drosophila melanogaster*. *G3 (Bethesda)* 2013; 3:815-25; <http://dx.doi.org/10.1534/g3.112.005496>.
1719. Gomez-Santos C, Ferrer I, Santidrian AF, Barrachina M, Gil J, Ambrosio S. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. *J Neurosci Res* 2003; 73:341-50; <http://dx.doi.org/10.1002/jnr.10663>.
1720. McPhee CK, Logan MA, Freeman MR, Baehrecke EH. Activation of autophagy during cell death requires the engulfment receptor Draper. *Nature* 2010; 465:1093-6; <http://dx.doi.org/10.1038/nature09127>.
1721. Ragusa MJ, Stanley RE, Hurlley JH. Architecture of the Atg17 complex as a scaffold for autophagosome biogenesis. *Cell* 2012; 151:1501-12; <http://dx.doi.org/10.1016/j.cell.2012.11.028>.
1722. Jia K, Levine B. Autophagy is required for dietary restriction-mediated life span extension in *C. elegans*. *Autophagy* 2007; 3:597-9; <http://dx.doi.org/10.4161/auto.4989>.
1723. Toth ML, Sigmond T, Borsos E, Barna J, Erdelyi P, Takacs-Vellai K, Orosz L, Kovacs AL, Csikos G, Sass M, et al. Longevity pathways converge on autophagy genes to regulate life span in *Caenorhabditis elegans*. *Autophagy* 2008; 4:330-8; <http://dx.doi.org/10.4161/auto.5618>.
1724. Bandyopadhyay U, Sridhar S, Kaushik S, Kiffin R, Cuervo AM. Identification of regulators of chaperone-mediated autophagy. *Mol Cell* 2010; 39:535-47; <http://dx.doi.org/10.1016/j.molcel.2010.08.004>.
1725. Dubouloz F, Deloche O, Wanke V, Cameroni E, De Virgilio C. The TOR and EGO protein complexes orchestrate microautophagy in yeast. *Mol Cell* 2005; 19:15-26; <http://dx.doi.org/10.1016/j.molcel.2005.05.020>.
1726. Talloczy Z, Jiang W, Virgin HWT, Leib DA, Scheuner D, Kaufman RJ, Eskelinen EL, Levine B. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. *Proc Natl Acad Sci USA* 2002; 99:190-5; <http://dx.doi.org/10.1073/pnas.012485299>.
1727. Zhao X, Fang Y, Yang Y, Qin Y, Wu P, Wang T, Lai H, Meng L, Wang D, Zheng Z, et al. Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. *Autophagy* 2015:0.
1728. Kim S, Naylor SA, DiAntonio A. *Drosophila* Golgi membrane protein Ema promotes autophagosomal growth and function. *Proc Natl Acad Sci USA* 2012; 109:E1072-81; <http://dx.doi.org/10.1073/pnas.1120320109>.
1729. Berge T, Leikfoss IS, Harbo HF. From Identification to Characterization of the Multiple Sclerosis Susceptibility Gene CLEC16A. *Int J Mol Sci* 2013; 14:4476-97; <http://dx.doi.org/10.3390/ijms14034476>.
1730. Soleimanpour SA, Gupta A, Bakay M, Ferrari AM, Groff DN, Fadista J, Spruce LA, Kushner JA, Groop L, Seeholzer SH, et al. The diabetes susceptibility gene Clec16a regulates mitophagy. *Cell* 2014; 157:1577-90; <http://dx.doi.org/10.1016/j.cell.2014.05.016>.
1731. Li Y, Zhao Y, Hu J, Xiao J, Qu L, Wang Z, Ma D, Chen Y. A novel ER-localized transmembrane protein, EMC6, interacts with RAB5A and regulates cell autophagy. *Autophagy* 2013; 9:150-63; <http://dx.doi.org/10.4161/auto.22742>.
1732. Poluzzi C, Casulli J, Goyal A, Mercer TJ, Neill T, Iozzo RV. Endorepellin evokes autophagy in endothelial cells. *J Biol Chem* 2014; 289:16114-28; <http://dx.doi.org/10.1074/jbc.M114.556530>.
1733. Tian E, Wang F, Han J, Zhang H. epg-1 functions in autophagy-regulated processes and may encode a highly divergent Atg13 homolog in *C. elegans*. *Autophagy* 2009; 5:608-15; <http://dx.doi.org/10.4161/auto.5.5.8624>.
1734. Cullup T, Kho AL, Dionisi-Vici C, Brandmeier B, Smith F, Urry Z, Simpson MA, Yau S, Bertini E, McClelland V, et al. Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. *Nat Genet* 2013; 45:83-7; <http://dx.doi.org/10.1038/ng.2497>.
1735. Li S, Yang P, Tian E, Zhang H. Arginine methylation modulates autophagic degradation of PGL granules in *C. elegans*. *Mol Cell* 2013; 52:421-33; <http://dx.doi.org/10.1016/j.molcel.2013.09.014>.
1736. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P, de Cordoba SR, Knecht E, Rubinsztein DC. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. *Hum Mol Genet* 2010; 19:2867-76; <http://dx.doi.org/10.1093/hmg/ddq190>.
1737. Bockler S, Westermann B. Mitochondrial ER contacts are crucial for mitophagy in yeast. *Dev Cell* 2014; 28:450-8; <http://dx.doi.org/10.1016/j.devcel.2014.01.012>.
1738. Sinha S, Roy S, Reddy BS, Pal K, Sudhakar G, Iyer S, Dutta S, Wang E, Vohra PK, Roy KR, et al. A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis. *Mol Cancer Res* 2011; 9:364-74; <http://dx.doi.org/10.1158/1541-7786.MCR-10-0526>.
1739. Wang L, Yu C, Lu Y, He P, Guo J, Zhang C, Song Q, Ma D, Shi T, Chen Y. TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. *Apoptosis* 2007; 12:1489-502; <http://dx.doi.org/10.1007/s10495-007-0073-9>.
1740. Yu C, Wang L, Lv B, Lu Y, Zeng L, Chen Y, Ma D, Shi T. TMEM74, a lysosome and autophagosome protein, regulates autophagy.

- Biochem Biophys Res Commun 2008; 369:622-9; <http://dx.doi.org/10.1016/j.bbrc.2008.02.055>.
1741. Bodemann BO, Orvedahl A, Cheng T, Ram RR, Ou YH, Formstecher E, Maiti M, Hazelett CC, Wauson EM, Balakireva M, et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosomal assembly. *Cell* 2011; 144:253-67; <http://dx.doi.org/10.1016/j.cell.2010.12.018>.
1742. Abrahamsen H, Stenmark H. Protein secretion: unconventional exit by exophagy. *Curr Biol* 2010; 20:R415-8; <http://dx.doi.org/10.1016/j.cub.2010.03.011>.
1743. Duran JM, Anjard C, Loomis WF, Malhotra V. Unconventional secretion of Acb1 is mediated by autophagosomes. *J Cell Biol* 2010; 188:527-36; <http://dx.doi.org/10.1083/jcb.200911154>.
1744. Manjithaya R, Anjard C, Loomis WF, Subramani S. Unconventional secretion of *Pichia pastoris* Acb1 is dependent on GRASP protein, peroxisomal functions, and autophagosomal formation. *J Cell Biol* 2010; 188:537-46; <http://dx.doi.org/10.1083/jcb.200911149>.
1745. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. *Proc Natl Acad Sci USA* 2010; 107:14621-6; <http://dx.doi.org/10.1073/pnas.1000138107>.
1746. Lisa-Santamaria P, Jimenez A, Revuelta JL. The protein factor-arrest 11 (Far11) is essential for the toxicity of human caspase-10 in yeast and participates in the regulation of autophagy and the DNA damage signaling. *J Biol Chem* 2012; 287:29636-47; <http://dx.doi.org/10.1074/jbc.M112.344192>.
1747. McKnight NC, Jefferies HB, Alemu EA, Saunders RE, Howell M, Johansen T, Tooze SA. Genome-wide siRNA screen reveals amino acid starvation-induced autophagy requires SCOC and WAC. *EMBO J* 2012; 31:1931-46; <http://dx.doi.org/10.1038/emboj.2012.36>.
1748. Vaccari I, Carbone A, Previtali SC, Mironova YA, Alberizzi V, Noseda R, Rivellini C, Bianchi F, Del Carro U, D'Antonio M, et al. Loss of Fig4 in both Schwann cells and motor neurons contributes to CMT4J neuropathy. *Hum Mol Genet* 2015; 24:383-96; <http://dx.doi.org/10.1093/hmg/ddu451>.
1749. Romano S, D'Angelillo A, Pacelli R, Staibano S, De Luna E, Bisogni R, Eskelinen EL, Mascolo M, Cali G, Arra C, et al. Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. *Cell Death Differ* 2010; 17:145-57; <http://dx.doi.org/10.1038/cdd.2009.115>.
1750. Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, Kirmeier T, Kollmannsberger L, Wagner KV, Dedic N, et al. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. *PLoS Med* 2014; 11:e1001755; <http://dx.doi.org/10.1371/journal.pmed.1001755>.
1751. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. *Cancer Cell* 2002; 2:157-64; [http://dx.doi.org/10.1016/S1535-6108\(02\)00104-6](http://dx.doi.org/10.1016/S1535-6108(02)00104-6).
1752. Dunlop EA, Seifan S, Claessens T, Behrends C, Kamps MA, Rozycka E, Kemp AJ, Nookala RK, Blenis J, Coull BJ, et al. FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation. *Autophagy* 2014; 10:1749-60; <http://dx.doi.org/10.4161/auto.29640>.
1753. Petit CS, Roczniak-Ferguson A, Ferguson SM. Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. *J Cell Biol* 2013; 202:1107-22; <http://dx.doi.org/10.1083/jcb.201307084>.
1754. Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E, Sabatini DM. The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. *Mol Cell* 2013; 52:495-505; <http://dx.doi.org/10.1016/j.molcel.2013.09.016>.
1755. Huett A, Ng A, Cao Z, Kuballa P, Komatsu M, Daly MJ, Podolsky DK, Xavier RJ. A novel hybrid yeast-human network analysis reveals an essential role for FBNP1L in antibacterial autophagy. *J Immunol* 2009; 182:4917-30; <http://dx.doi.org/10.4049/jimmunol.0803050>.
1756. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L, Zhu WG. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. *Nat Cell Biol* 2010; 12:665-75; <http://dx.doi.org/10.1038/ncb2069>.
1757. Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. *Circulation Research* 2010; 107:1470-82; <http://dx.doi.org/10.1161/CIRCRESAHA.110.227371>.
1758. Attaix D, Bechet D. FoxO3 controls dangerous proteolytic liaisons. *Cell Metab* 2007; 6:425-7; <http://dx.doi.org/10.1016/j.cmet.2007.11.005>.
1759. Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P, Ma Q, Zhu C, Wang R, Qi W, et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. *Nat Cell Biol* 2012; 14:177-85; <http://dx.doi.org/10.1038/ncb2422>.
1760. Ryu HH, Jun MH, Min KJ, Jang DJ, Lee YS, Kim HK, Lee JA. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. *Neurobiol Aging* 2014; 35:2822-31; <http://dx.doi.org/10.1016/j.neurobiolaging.2014.07.026>.
1761. Pankiv S, Alemu EA, Brech A, Bruun JA, Lamark T, {O}jervatn A, Bjorkoy G, Johansen T. FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. *J Cell Biol* 2010; 188:253-69; <http://dx.doi.org/10.1083/jcb.200907015>.
1762. Lakhani R, Vogel KR, Till A, Liu J, Burnett SF, Gibson KM, Subramani S. Defects in GABA metabolism affect selective autophagy pathways and are alleviated by mTOR inhibition. *EMBO Mol Med* 2014; 6:551-66; <http://dx.doi.org/10.1002/emmm.201303356>.
1763. Ogier-Denis E, Couvineau A, Maoret JJ, Hourii JJ, Bauvy C, De Stefanis D, Isidoro C, Laburthe M, Codogno P. A heterotrimeric Gi3-protein controls autophagic sequestration in the human colon cancer cell line HT-29. *J Biol Chem* 1995; 270:13-6; <http://dx.doi.org/10.1074/jbc.270.1.13>.
1764. Ogier-Denis E, Hourii JJ, Bauvy C, Codogno P. Guanine nucleotide exchange on heterotrimeric Gi3 protein controls autophagic sequestration in HT-29 cells. *J Biol Chem* 1996; 271:28593-600; <http://dx.doi.org/10.1074/jbc.271.45.28593>.
1765. Tanida I, Tanida-Miyake E, Ueno T, Kominami E. The human homolog of *Saccharomyces cerevisiae* Apg7p is a Protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. *J Biol Chem* 2001; 276:1701-6; <http://dx.doi.org/10.1074/jbc.C000752200>.
1766. Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, Schellenberg GD, Sidransky E, Bird TD, Leverenz JB, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. *Arch Neurol* 2008; 65:379-82; <http://dx.doi.org/10.1001/archneurol.2007.68>.
1767. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, Fukuda Y, Date H, Iwata A, Yamamoto M, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. *Arch Neurol* 2009; 66:571-6; <http://dx.doi.org/10.1001/archneurol.2009.72>.
1768. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New Engl J Med* 2009; 361:1651-61; <http://dx.doi.org/10.1056/NEJMoa0901281>.
1769. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, Duchon MR. Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease. *Cell Metab* 2013; 17:941-53; <http://dx.doi.org/10.1016/j.cmet.2013.04.014>.
1770. Webster BR, Scott I, Han K, Li JH, Lu Z, Stevens MV, Malide D, Chen Y, Samsel L, Connelly PS, et al. Restricted mitochondrial protein acetylation initiates mitochondrial autophagy. *J Cell Sci* 2013; 126:4843-9; <http://dx.doi.org/10.1242/jcs.131300>.

1771. Moreau K, Rubinsztein DC. The plasma membrane as a control center for autophagy. *Autophagy* 2012; 8:861-3; <http://dx.doi.org/10.4161/auto.20060>.
1772. Todd LR, Damin MN, Gomathinayagam R, Horn SR, Means AR, Sankar U. Growth factor erv1-like modulates Drp1 to preserve mitochondrial dynamics and function in mouse embryonic stem cells. *Mol Biol Cell* 2010; 21:1225-36; <http://dx.doi.org/10.1091/mbc.E09-11-0937>.
1773. Kalamidas SA, Kotoulas OB. Glycogen autophagy in newborn rat hepatocytes. *Histol Histopathol* 2000; 15:1011-8.
1774. Delbridge LM, Mellor KM, Taylor DJ, Gottlieb RA. Myocardial autophagic energy stress responses—macroautophagy, mitophagy, and glycolipid. *Am J Physiol Heart Circ Physiol* 2015; 308:H1194-204; <http://dx.doi.org/10.1152/ajpheart.00002.2015>.
1775. Mellor KM, Varma U, Stapleton DI, Delbridge LM. Cardiomyocyte glycolipid is regulated by insulin and exposure to high extracellular glucose. *Am J Physiol Heart Circ Physiol* 2014; 306:H1240-5; <http://dx.doi.org/10.1152/ajpheart.00059.2014>.
1776. Li B, Castano AP, Hudson TE, Nowlin BT, Lin S-L, Bonventre JV, Swanson KD, Duffield JS. The melanoma-associated transmembrane glycoprotein Gpmb controls trafficking of cellular debris for degradation and is essential for tissue repair. *FASEB J* 2010; 24:4767-81; <http://dx.doi.org/10.1096/fj.10-154757>.
1777. Buchan JR, Kolaitis RM, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. *Cell* 2013; 153:1461-74; <http://dx.doi.org/10.1016/j.cell.2013.05.037>.
1778. Lin SY, Li TY, Liu Q, Zhang C, Li X, Chen Y, Zhang SM, Lian G, Liu Q, Ruan K, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. *Science* 2012; 336:477-81; <http://dx.doi.org/10.1126/science.1217032>.
1779. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. *EMBO J* 2010; 29:969-80; <http://dx.doi.org/10.1038/emboj.2009.405>.
1780. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* 2003; 115:727-38; [http://dx.doi.org/10.1016/S0092-8674\(03\)00939-5](http://dx.doi.org/10.1016/S0092-8674(03)00939-5).
1781. Bohensky J, Shapiro IM, Leshinsky S, Terkhorn SP, Adams CS, Srinivas V. HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway. *Autophagy* 2007; 3:207-14; <http://dx.doi.org/10.4161/auto.3708>.
1782. Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. *Cancer Metastasis Rev* 2007; 26:553-66; <http://dx.doi.org/10.1007/s10555-007-9080-0>.
1783. Mimouna S, Bazin M, Mograbi B, Darfeuille-Michaud A, Brest P, Hofman P, Vouret-Craviari V. HIF1A regulates xenophagic degradation of adherent and invasive *Escherichia coli* (AIEC). *Autophagy* 2014; 10:2333-45; <http://dx.doi.org/10.4161/15548627.2014.984275>.
1784. Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: Acting on mitochondria and TORC1 to autophagy. *Cell Death Differ* 2015; 22:248-57; <http://dx.doi.org/10.1038/cdd.2014.173>.
1785. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. *Oncogene* 2010; 29:5299-310; <http://dx.doi.org/10.1038/onc.2010.261>.
1786. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. *Cell Death Differ* 2009; 16:175-83; <http://dx.doi.org/10.1038/cdd.2008.143>.
1787. Mao K, Zhao M, Xu T, Klionsky DJ. Two MAPK-signaling pathways are required for mitophagy in *Saccharomyces cerevisiae*. *J Cell Biol* 2011; 193:755-67; <http://dx.doi.org/10.1083/jcb.201102092>.
1788. Pfaffenwimmer T, Reiter W, Brach T, Nogellova V, Papinski D, Schuschnig M, Abert C, Ammerer G, Martens S, Kraft C. Hrr25 kinase promotes selective autophagy by phosphorylating the cargo receptor Atg19. *EMBO Rep* 2014; 15:862-70; <http://dx.doi.org/10.15252/embr.201438932>.
1789. Tanaka C, Tan LJ, Mochida K, Kirisako H, Koizumi M, Asai E, Sakoh-Nakatogawa M, Ohsumi Y, Nakatogawa H. Hrr25 triggers selective autophagy-related pathways by phosphorylating receptor proteins. *J Cell Biol* 2014; 207:91-105; <http://dx.doi.org/10.1083/jcb.201402128>.
1790. Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. *Mol Cell* 2009; 36:15-27; <http://dx.doi.org/10.1016/j.molcel.2009.09.023>.
1791. Li J, Ni M, Lee B, Barron E, Hinton DR, Lee AS. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. *Cell Death Differ* 2008; 15:1460-71; <http://dx.doi.org/10.1038/cdd.2008.81>.
1792. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. *Science* 1989; 246:382-5; <http://dx.doi.org/10.1126/science.2799391>.
1793. Kaushik S, Massey AC, Cuervo AM. Lysosome membrane lipid microdomains: novel regulators of chaperone-mediated autophagy. *EMBO J* 2006; 25:3921-33; <http://dx.doi.org/10.1038/sj.emboj.7601283>.
1794. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. *Traffic* 2002; 3:388-96; <http://dx.doi.org/10.1034/j.1600-0854.2002.30602.x>.
1795. Xu C, Liu J, Hsu LC, Luo Y, Xiang R, Chuang TH. Functional interaction of heat shock protein 90 and Beclin 1 modulates Toll-like receptor-mediated autophagy. *FASEB J* 2011; 25:2700-10; <http://dx.doi.org/10.1096/fj.10-167676>.
1796. Bandhyopadhyay U, Kaushik S, Vartikovskiy L, Cuervo AM. Dynamic organization of the receptor for chaperone-mediated autophagy at the lysosomal membrane. *Mol Cell Biol* 2008; 28:5747-63; <http://dx.doi.org/10.1128/MCB.02070-07>.
1797. Li B, Hu Q, Wang H, Man N, Ren H, Wen L, Nukina N, Fei E, Wang G. Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. *Cell Death Differ* 2010; 17:1773-84; <http://dx.doi.org/10.1038/cdd.2010.55>.
1798. Cilentì L, Ambivero CT, Ward N, Alnemri ES, Germain D, Zervos AS. Inactivation of Omi/HtrA2 protease leads to the deregulation of mitochondrial Mulan E3 ubiquitin ligase and increased mitophagy. *Biochim Biophys Acta* 2014; 1843:1295-307; <http://dx.doi.org/10.1016/j.bbamcr.2014.03.027>.
1799. Kang S, Fernandes-Alnemri T, Alnemri ES. A novel role for the mitochondrial HTRA2/OMI protease in aging. *Autophagy* 2013; 9:420-1; <http://dx.doi.org/10.4161/auto.22920>.
1800. Kang S, Louboutin JP, Datta P, Landel CP, Martinez D, Zervos AS, Strayer DS, Fernandes-Alnemri T, Alnemri ES. Loss of HtrA2/Omi activity in non-neuronal tissues of adult mice causes premature aging. *Cell Death Differ* 2013; 20:259-69; <http://dx.doi.org/10.1038/cdd.2012.117>.
1801. Coll NS, Smidler A, Puigvert M, Popa C, Valls M, Dangl JL. The plant metacaspase AtMCI in pathogen-triggered programmed cell death and aging: functional linkage with autophagy. *Cell Death Differ* 2014; 21:1399-408; <http://dx.doi.org/10.1038/cdd.2014.50>.
1802. Kim J, Cheon H, Jeong YT, Quan W, Kim KH, Cho JM, Lim YM, Oh SH, Jin SM, Kim JH, et al. Amyloidogenic peptide oligomer accumulation in autophagy-deficient beta cells induces diabetes. *J Clin Invest* 2014; 124:3311-24; <http://dx.doi.org/10.1172/JCI69625>.
1803. Rivera JF, Costes S, Gurlo T, Glabe CG, Butler PC. Autophagy defends pancreatic beta cells from human islet amyloid polypeptide-induced toxicity. *J Clin Invest* 2014; 124:3489-500; <http://dx.doi.org/10.1172/JCI71981>.
1804. Shigihara N, Fukunaka A, Hara A, Komiyama K, Honda A, Uchida T, Abe H, Toyofuku Y, Tamaki M, Ogihara T, et al. Human IAPP-induced pancreatic beta cell toxicity and its regulation by autophagy. *J Clin Invest* 2014; 124:3634-44; <http://dx.doi.org/10.1172/JCI69866>.

1805. Lotze MT, Buchser WJ, Liang X. Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. *Autophagy* 2012; 8:1264-6; <http://dx.doi.org/10.4161/auto.20752>.
1806. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW, et al. Intrinsically disordered protein. *J Mol Graph Model* 2001; 19:26-59; [http://dx.doi.org/10.1016/S1093-3263\(00\)00138-8](http://dx.doi.org/10.1016/S1093-3263(00)00138-8).
1807. Tompa P. Intrinsically unstructured proteins. *Trends Biochem Sci* 2002; 27:527-33; [http://dx.doi.org/10.1016/S0968-0004\(02\)02169-2](http://dx.doi.org/10.1016/S0968-0004(02)02169-2).
1808. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? *Proteins* 2000; 41:415-27; [http://dx.doi.org/10.1002/1097-0134\(20001115\)41:3<415::AID-PROT130>3.0.CO;2-7](http://dx.doi.org/10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7).
1809. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. *J Mol Biol* 1999; 293:321-31; <http://dx.doi.org/10.1006/jmbi.1999.3110>.
1810. Peng Z, Yan J, Fan X, Mizianty MJ, Xue B, Wang K, Hu G, Uversky VN, Kurgan L. Exceptionally abundant exceptions: comprehensive characterization of intrinsic disorder in all domains of life. *Cell Mol Life Sci* 2015; 72:137-51; <http://dx.doi.org/10.1007/s00018-014-1661-9>.
1811. De Guzman RN, Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE. CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. *Biochemistry* 2005; 44:490-7; <http://dx.doi.org/10.1021/bi048161t>.
1812. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z. Intrinsic disorder and protein function. *Biochemistry* 2002; 41:6573-82; <http://dx.doi.org/10.1021/bi012159+>.
1813. Dunker AK, Silman I, Uversky VN, Sussman JL. Function and structure of inherently disordered proteins. *Curr Opin Struct Biol* 2008; 18:756-64; <http://dx.doi.org/10.1016/j.sbi.2008.10.002>.
1814. Tompa P. The interplay between structure and function in intrinsically unstructured proteins. *FEBS Lett* 2005; 579:3346-54; <http://dx.doi.org/10.1016/j.febslet.2005.03.072>.
1815. Peng Z, Xue B, Kurgan L, Uversky VN. Resilience of death: intrinsic disorder in proteins involved in the programmed cell death. *Cell Death Differ* 2013; 20:1257-67; <http://dx.doi.org/10.1038/cdd.2013.65>.
1816. Popelka H, Uversky VN, Klionsky DJ. Identification of Atg3 as an intrinsically disordered polypeptide yields insights into the molecular dynamics of autophagy-related proteins in yeast. *Autophagy* 2014; 10:1093-104; <http://dx.doi.org/10.4161/auto.28616>.
1817. van der Lee R, Buljan M, Lang B, Weatheritt RJ, Daughdrill GW, Dunker AK, Fuxreiter M, Gough J, Gsponer J, Jones DT, et al. Classification of intrinsically disordered regions and proteins. *Chem Rev* 2014; 114:6589-631; <http://dx.doi.org/10.1021/cr400525m>.
1818. Uversky VN. Intrinsic disorder-based protein interactions and their modulators. *Curr Pharm Des* 2013; 19:4191-213; <http://dx.doi.org/10.2174/1381612811319230005>.
1819. Pejaver V, Hsu WL, Xin F, Dunker AK, Uversky VN, Radivojac P. The structural and functional signatures of proteins that undergo multiple events of post-translational modification. *Protein Sci* 2014; 23:1077-93; <http://dx.doi.org/10.1002/pro.2494>.
1820. Chiang HS, Maric M. Lysosomal thiol reductase negatively regulates autophagy by altering glutathione synthesis and oxidation. *Free Radical Bio Med* 2011; 51:688-99; <http://dx.doi.org/10.1016/j.freeradbiomed.2011.05.015>.
1821. Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, Vitale I, Kepp O, Tasdemir E, Galluzzi L, Shen S, et al. The IKK complex contributes to the induction of autophagy. *EMBO J* 2010; 29:619-31; <http://dx.doi.org/10.1038/emboj.2009.364>.
1822. Wu X, Tu BP. Selective regulation of autophagy by the Iml1-Npr2-Npr3 complex in the absence of nitrogen starvation. *Mol Biol Cell* 2011; 22:4124-33; <http://dx.doi.org/10.1091/mbc.E11-06-0525>.
1823. Blanchet FP, Moris A, Nikolic DS, Lehmann M, Cardinaud S, Stalder R, Garcia E, Dinkins C, Leuba F, Wu L, et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. *Immunity* 2010; 32:654-69; <http://dx.doi.org/10.1016/j.immuni.2010.04.011>.
1824. Deretic V. Autophagy in innate and adaptive immunity. *Trends Immunol* 2005; 26:523-8; <http://dx.doi.org/10.1016/j.it.2005.08.003>.
1825. Dortet L, Mostowy S, Samba-Louaka A, Gouin E, Nahori MA, Wiemer EA, Dussurget O, Cossart P. Recruitment of the major vault protein by InlK: a *Listeria monocytogenes* strategy to avoid autophagy. *PLoS Pathog* 2011; 7:e1002168.
1826. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science* 2006; 313:1438-41; <http://dx.doi.org/10.1126/science.1129577>.
1827. Bugnicourt A, Mari M, Reggiori F, Haguenaer-Tsapis R, Galan JM. Irs4p and Tax4p: two redundant EH domain proteins involved in autophagy. *Traffic* 2008; 9:755-69; <http://dx.doi.org/10.1111/j.1600-0854.2008.00715.x>.
1828. Namkoong S, Lee KI, Lee JI, Park R, Lee EJ, Jang IS, Park J. The integral membrane protein ITM2A, a transcriptional target of PKA-CREB, regulates autophagic flux via interaction with the vacuolar ATPase. *Autophagy* 2015; 11:756-68; <http://dx.doi.org/10.1080/15548627.2015.1034412>.
1829. Yogev O, Goldberg R, Anzi S, Yogev O, Shaulian E. Jun proteins are starvation-regulated inhibitors of autophagy. *Cancer Res* 2010; 70:2318-27; <http://dx.doi.org/10.1158/0008-5472.CAN-09-3408>.
1830. Taylor R, Jr., Chen PH, Chou CC, Patel J, Jin SV. KCS1 deletion in *Saccharomyces cerevisiae* leads to a defect in translocation of autophagic proteins and reduces autophagosome formation. *Autophagy* 2012; 8:1300-11; <http://dx.doi.org/10.4161/auto.20681>.
1831. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. *Mol Cell* 2009; 36:131-40; <http://dx.doi.org/10.1016/j.molcel.2009.07.025>.
1832. Stepkowski TM, Kruszewski MK. Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis. *Free Radical Bio Med* 2011; 50:1186-95; <http://dx.doi.org/10.1016/j.freeradbiomed.2011.01.033>.
1833. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, Jaatela M. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. *J Cell Biol* 2014; 204:713-27; <http://dx.doi.org/10.1083/jcb.201304012>.
1834. Feng MM, Baryla J, Liu H, Laurie GW, McKown RL, Ashki N, Bhayana D, Hutnik CM. Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro. *Curr Eye Res* 2014; 39:604-10; <http://dx.doi.org/10.3109/02713683.2013.859275>.
1835. Ma P, Beck SL, Raab RW, McKown RL, Coffman GL, Utani A, Chirico WJ, Rapraeger AC, Laurie GW. Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. *J Cell Biol* 2006; 174:1097-106; <http://dx.doi.org/10.1083/jcb.200511134>.
1836. Wang N, Zimmerman K, Raab RW, McKown RL, Hutnik CM, Talla V, Tyler MFT, Lee JK, Laurie GW. Lacritin rescues stressed epithelia via rapid forkhead box O3 (FOXO3)-associated autophagy that restores metabolism. *J Biol Chem* 2013; 288:18146-61; <http://dx.doi.org/10.1074/jbc.M112.436584>.
1837. Eskelinen E-L, Illert A, Tanaka Y, Schwarzmann G, Blanz J, Von Figura K, Saftig P. Role of LAMP-2 in lysosome biogenesis and autophagy. *Mol Biol Cell* 2002; 13:3355-68; <http://dx.doi.org/10.1091/mbc.E02-02-0114>.
1838. Eskelinen E-L, Schmidt C, Neu S, Willenborg M, Fuertes G, Salvador N, Tanaka Y, Lullmann-Rauch R, Hartmann D, Heeren J, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. *Mol Biol Cell* 2004; 15:3132-45; <http://dx.doi.org/10.1091/mbc.E04-02-0103>.
1839. Tanaka Y, Guhde G, Suter A, Eskelinen E-L, Hartmann D, Lullmann-Rauch R, Janssen P, Blanz J, von Figura K, Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in Lamp-2-deficient mice. *Nature* 2000; 406:902-6; <http://dx.doi.org/10.1038/35022595>.
1840. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). *Nature* 2000; 406:906-10; <http://dx.doi.org/10.1038/35022604>.



1841. Bertolo C, Roa S, Sagardoy A, Mena-Varas M, Robles EF, Martinez-Ferrandis JJ, Sagaert X, Tousseyn T, Orta A, Lossos IS, et al. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. *Br J Haematol* 2013; 162:621-30; <http://dx.doi.org/10.1111/bjh.12440>.
1842. Boya P. Lysosomal function and dysfunction: mechanism and disease. *Antioxid Redox Sign* 2012; 17:766-74; <http://dx.doi.org/10.1089/ars.2011.4405>.
1843. Gabande-Rodriguez E, Boya P, Labrador V, Dotti CG, Ledesma MD. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. *Cell Death Differ* 2014; 21:864-75; <http://dx.doi.org/10.1038/cdd.2014.4>.
1844. Rodriguez-Muela N, Hernandez-Pinto AM, Serrano-Puebla A, Garcia-Ledo L, Latorre SH, de la Rosa EJ, Boya P. Lysosomal membrane permeabilization and autophagy blockade contribute to photoreceptor cell death in a mouse model of retinitis pigmentosa. *Cell Death Differ* 2014.
1845. Farmer LM, Rinaldi MA, Young PG, Danan CH, Burkhart SE, Bartel B. Disrupting autophagy restores peroxisome function to an Arabidopsis lon2 mutant and reveals a role for the LON2 protease in peroxisomal matrix protein degradation. *Plant Cell* 2013; 25:4085-100; <http://dx.doi.org/10.1105/tpc.113.113407>.
1846. Carew JS, Espitia CM, Esquivel JA, II, Mahalingam D, Kelly KR, Reddy G, Giles FJ, Nawrocki ST. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. *J Biol Chem* 2011; 286:6602-13; <http://dx.doi.org/10.1074/jbc.M110.151324>.
1847. Zou J, Yue F, Jiang X, Li W, Yi J, Liu L. Mitochondrion-associated protein LRPPRC suppresses the initiation of basal levels of autophagy via enhancing Bcl-2 stability. *Biochem J* 2013; 454:447-57; <http://dx.doi.org/10.1042/BJ20130306>.
1848. Zou J, Yue F, Li W, Song K, Jiang X, Yi J, Liu L. Autophagy inhibitor LRPPRC suppresses mitophagy through interaction with mitophagy initiator Parkin. *PLoS One* 2014; 9:e94903; <http://dx.doi.org/10.1371/journal.pone.0094903>.
1849. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. *Hum Mol Genet* 2009; 18:4022-34; <http://dx.doi.org/10.1093/hmg/ddp346>.
1850. Ng ACY, Eisenberg JM, Heath RJW, Huett A, Robinson CM, Nau GJ, Xavier RJ. Human leucine-rich repeat proteins: a genome-wide bioinformatic categorization and functional analysis in innate immunity. *Proc Natl Acad Sci USA* 2011; 108:4631-8; <http://dx.doi.org/10.1073/pnas.1000093107>.
1851. Blommaert EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. *Eur J Biochem* 1997; 243:240-6; <http://dx.doi.org/10.1111/j.1432-1033.1997.0240a.x>.
1852. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, Lynch JP, Uehara T, Sepulveda AR, Davis LE, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. *Proc Natl Acad Sci USA* 2012; 109:8253-8; <http://dx.doi.org/10.1073/pnas.1118193109>.
1853. Amaravadi RK, Winkler JD. Lys05: a new lysosomal autophagy inhibitor. *Autophagy* 2012; 8:1383-4; <http://dx.doi.org/10.4161/auto.20958>.
1854. Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou YH, White MA, Potts PR. Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase. *Cell* 2015; 160:715-28; <http://dx.doi.org/10.1016/j.cell.2015.01.034>.
1855. Mann SS, Hammarback JA. Molecular characterization of light chain 3. A microtubule binding subunit of MAP1A and MAP1B. *J Biol Chem* 1994; 269:11492-7.
1856. Xie R, Nguyen S, McKeehan K, Wang F, McKeehan WL, Liu L. Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation. *J Biol Chem* 2011; 286:10367-77; <http://dx.doi.org/10.1074/jbc.M110.206532>.
1857. Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, Fumarola C, Farkas T, Lopez-Rivas A, Jaattela M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. *EMBO J* 2009; 28:677-85; <http://dx.doi.org/10.1038/emboj.2009.8>.
1858. Ogier-Denis E, Pattingre S, El Benna J, Codogno P. Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. *J Biol Chem* 2000; 275:39090-5; <http://dx.doi.org/10.1074/jbc.M006198200>.
1859. Fu MM, Nirschl JJ, Holzbaur EL. LC3 binding to the scaffolding protein JIP1 regulates processive dynein-driven transport of autophagosomes. *Dev Cell* 2014; 29:577-90; <http://dx.doi.org/10.1016/j.devcel.2014.04.015>.
1860. Raciti M, Lotti LV, Valia S, Pulcinelli FM, Di Renzo L. JNK2 is activated during ER stress and promotes cell survival. *Cell Death Dis* 2012; 3:e429; <http://dx.doi.org/10.1038/cddis.2012.167>.
1861. Keil E, Hocker R, Schuster M, Essmann F, Ueffing N, Hoffman B, Liebermann DA, Pfeffer K, Schulze-Osthoff K, Schmitz I. Phosphorylation of Atg5 by the Gadd45beta-MEKK4-p38 pathway inhibits autophagy. *Cell Death Differ* 2013; 20:321-32; <http://dx.doi.org/10.1038/cdd.2012.129>.
1862. Menon MB, Dhamija S, Kotlyarov A, Gaestel M. The problem of pyridinyl imidazole class inhibitors of MAPK14/p38alpha and MAPK11/p38beta in autophagy research. *Autophagy* 2015; 11:1425-7; <http://dx.doi.org/10.1080/15548627.2015.1059562>.
1863. Menon MB, Kotlyarov A, Gaestel M. SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition. *PLoS One* 2011; 6:e23054; <http://dx.doi.org/10.1371/journal.pone.0023054>.
1864. Colecchia D, Strambi A, Sanzone S, Iavarone C, Rossi M, Dall'Armi C, Piccioni F, Verrotti Di Pianella A, Chiariello M. MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins. *Autophagy* 2012; 8:1724-40; <http://dx.doi.org/10.4161/auto.21857>.
1865. Wang Z, Zhang J, Wang Y, Xing R, Yi C, Zhu H, Chen X, Guo J, Guo W, Li W, et al. Matriline, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases. *Carcinogenesis* 2013; 34:128-38; <http://dx.doi.org/10.1093/carcin/bgs295>.
1866. Liang Q, Seo GJ, Choi YJ, Kwak MJ, Ge J, Rodgers MA, Shi M, Leslie BJ, Hopfner KP, Ha T, et al. Crosstalk between the cGAS DNA Sensor and Beclin-1 Autophagy Protein Shapes Innate Antimicrobial Immune Responses. *Cell Host Microbe* 2014; 15:228-38; <http://dx.doi.org/10.1016/j.chom.2014.01.009>.
1867. Lorente M, Torres S, Salazar M, Carracedo A, Hernandez-Tiedra S, Rodriguez-Fornes F, Garcia-Taboada E, Melendez B, Mollejo M, Campos-Martin Y, et al. Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. *Autophagy* 2011; 7:1071-3; <http://dx.doi.org/10.4161/auto.7.9.15866>.
1868. Lorente M, Torres S, Salazar M, Carracedo A, Hernandez-Tiedra S, Rodriguez-Fornes F, Garcia-Taboada E, Melendez B, Mollejo M, Campos-Martin Y, et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. *Cell Death Differ* 2011; 18:959-73; <http://dx.doi.org/10.1038/cdd.2010.170>.
1869. Kimura T, Jain A, Choi SW, Mandell MA, Schroder K, Johansen T, Deretic V. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. *J Cell Biol* 2015; in press.
1870. Bagniewska-Zadworna A, Byczyk J, Eissenstat DM, Oleksyn J, Zadworny M. Avoiding transport bottlenecks in an expanding root system: xylem vessel development in fibrous and pioneer roots under field conditions. *Am J Bot* 2012; 99:1417-26; <http://dx.doi.org/10.3732/ajb.1100552>.
1871. van Doorn WG, Woltering EJ. Many ways to exit? Cell death categories in plants. *Trends Plant Sci* 2005; 10:117-22; <http://dx.doi.org/10.1016/j.tplants.2005.01.006>.
1872. Eastwood MD, Cheung SW, Lee KY, Moffat J, Meneghini MD. Developmentally programmed nuclear destruction during yeast gametogenesis. *Dev Cell* 2012; 23:35-44; <http://dx.doi.org/10.1016/j.devcel.2012.05.005>.

1873. Wang P, Lazarus BD, Forsythe ME, Love DC, Krause MW, Hanover JA. O-GlcNAc cycling mutants modulate proteotoxicity in *Caenorhabditis elegans* models of human neurodegenerative diseases. *Proc Natl Acad Sci USA* 2012; 109:17669-74; <http://dx.doi.org/10.1073/pnas.1205748109>.
1874. Oku M, Warnecke D, Noda T, Muller F, Heinz E, Mukaiyama H, Kato N, Sakai Y. Peroxisome degradation requires catalytically active sterol glucosyltransferase with a GRAM domain. *EMBO J* 2003; 22:3231-41; <http://dx.doi.org/10.1093/emboj/cdg331>.
1875. Ding WX, Guo F, Ni HM, Bockus A, Manley S, Stolz DB, Eskelinen EL, Jaeschke H, Yin XM. Parkin and mitofusins reciprocally regulate mitophagy and mitochondrial spheroid formation. *J Biol Chem* 2012; 287:42379-88; <http://dx.doi.org/10.1074/jbc.M112.413682>.
1876. Ding WX, Li M, Biazik JM, Morgan DG, Guo F, Ni HM, Goheen M, Eskelinen EL, Yin XM. Electron microscopic analysis of a spherical mitochondrial structure. *J Biol Chem* 2012; 287:42373-8; <http://dx.doi.org/10.1074/jbc.M112.413674>.
1877. Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. *Curr Drug Targets* 2013; 14:1135-43; <http://dx.doi.org/10.2174/13894501113149990185>.
1878. Pennati M, Lopercolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P, Folini M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in cisplatin-resistant prostate cancer cells. *Biochem Pharmacol* 2014; 87:579-97; <http://dx.doi.org/10.1016/j.bcp.2013.12.009>.
1879. Martina JA, Diab HI, Lishu L, Jeong AL, Patange S, Raben N, Puer-tollano R. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. *Sci Signal* 2014; 7:ra9.
1880. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. *Rejuvenation Res* 2005; 8:3-5; <http://dx.doi.org/10.1089/rej.2005.8.3>.
1881. Choi YJ, Hwang KC, Park JY, Park KK, Kim JH, Park SB, Hwang S, Park H, Park C, Kim JH. Identification and characterization of a novel mouse and human MOPT gene containing MORN-motif protein in testis. *Theriogenology* 2010; 73:273-81; <http://dx.doi.org/10.1016/j.theriogenology.2009.09.010>.
1882. Frost LS, Lopes VS, Bragin A, Reyes-Reveles J, Brancato J, Cohen A, Mitchell CH, Williams DS, Boesze-Battaglia K. The Contribution of Melanoregulin to Microtubule-Associated Protein 1 Light Chain 3 (LC3) Associated Phagocytosis in Retinal Pigment Epithelium. *Mol Neurobiol* 2014.
1883. Frost LS, Mitchell CH, Boesze-Battaglia K. Autophagy in the eye: implications for ocular cell health. *Exp Eye Res* 2014; 124:56-66; <http://dx.doi.org/10.1016/j.exer.2014.04.010>.
1884. Bhutia SK, Kegelman TP, Das SK, Azab B, Su ZZ, Lee SG, Sarkar D, Fisher PB. Astrocyte elevated gene-1 induces protective autophagy. *Proc Natl Acad Sci USA* 2010; 107:22243-8; <http://dx.doi.org/10.1073/pnas.1009479107>.
1885. Wu Y, Cheng S, Zhao H, Zou W, Yoshina S, Mitani S, Zhang H, Wang X. PI3P phosphatase activity is required for autophagosome maturation and autolysosome formation. *EMBO Rep* 2014; 15:973-81; <http://dx.doi.org/10.15252/embr.201438618>.
1886. Al-Qusairi L, Prokic I, Amoasii L, Kretz C, Messaddeq N, Mandel JL, Laporte J. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways. *FASEB J* 2013; 27:3384-94; <http://dx.doi.org/10.1096/fj.12-220947>.
1887. Taguchi-Atarashi N, Hamasaki M, Matsunaga K, Omori H, Ktistakis NT, Yoshimori T, Noda T. Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates constitutive autophagy. *Traffic* 2010; 11:468-78; <http://dx.doi.org/10.1111/j.1600-0854.2010.01034.x>.
1888. Vergne I, Roberts E, Elmaoued RA, Tosch V, Delgado MA, Proikas-Cezanne T, Laporte J, Deretic V. Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy. *EMBO J* 2009; 28:2244-58; <http://dx.doi.org/10.1038/emboj.2009.159>.
1889. Zou J, Zhang C, Marjanovic J, Kisseleva MV, Majerus PW, Wilson MP. Myotubularin-related protein (MTMR) 9 determines the enzymatic activity, substrate specificity, and role in autophagy of MTMR8. *Proc Natl Acad Sci USA* 2012; 109:9539-44; <http://dx.doi.org/10.1073/pnas.1207021109>.
1890. Hnia K, Kretz C, Amoasii L, Bohm J, Liu X, Messaddeq N, Qu CK, Laporte J. Primary T-tubule and autophagy defects in the phosphoinositide phosphatase Jumpy/MTMR14 knockout mice muscle. *Adv Biol Reg* 2012; 52:98-107; <http://dx.doi.org/10.1016/j.advenzreg.2011.09.007>.
1891. Rusten TE, Vaccari T, Lindmo K, Rodahl LM, Nezis IP, Sem-Jacobsen C, Wendler F, Vincent JP, Brech A, Bilder D, et al. ESCRTs and Fab1 regulate distinct steps of autophagy. *Curr Biol* 2007; 17:1817-25; <http://dx.doi.org/10.1016/j.cub.2007.09.032>.
1892. Brandstaetter H, Kishi-Itakura C, Tumbarello DA, Manstein DJ, Buss F. Loss of functional MYO1C/myosin 1c, a motor protein involved in lipid raft trafficking, disrupts autophagosome-lysosome fusion. *Autophagy* 2014; 10:2310-23; <http://dx.doi.org/10.4161/15548627.2014.984272>.
1893. Tumbarello DA, Waxse BJ, Arden SD, Bright NA, Kendrick-Jones J, Buss F. Autophagy receptors link myosin VI to autophagosomes to mediate Tom1-dependent autophagosome maturation and fusion with the lysosome. *Nat Cell Biol* 2012; 14:1024-35; <http://dx.doi.org/10.1038/ncb2589>.
1894. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. *Sci Signal* 2010; 3:ra9; <http://dx.doi.org/10.1126/scisignal.2000590>.
1895. Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, Patel R, Liu D, Qin ZH, Shih IM, et al. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. *Oncogene* 2012; 31:1055-64; <http://dx.doi.org/10.1038/onc.2011.290>.
1896. Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. *Autophagy* 2012; 8:77-87; <http://dx.doi.org/10.4161/auto.8.1.18274>.
1897. Naydenov NG, Harris G, Morales V, Ivanov AI. Loss of a membrane trafficking protein alphaSNAP induces non-canonical autophagy in human epithelia. *Cell Cycle* 2012; 11:4613-25; <http://dx.doi.org/10.4161/cc.22885>.
1898. Hitomi J, Christofferson DE, Ng A, Yao J, Degtrev A, Xavier RJ, Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. *Cell* 2008; 135:1311-23; <http://dx.doi.org/10.1016/j.cell.2008.10.044>.
1899. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, Bourquin JP. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *J Clin Invest* 2010; 120:1310-23; <http://dx.doi.org/10.1172/JCI39987>.
1900. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besancon F, Bauvy C, Codogno P. Regulation of autophagy by NF{κ}B transcription factor and reactive oxygen species. *Autophagy* 2007; 3:390-2; <http://dx.doi.org/10.4161/auto.4248>.
1901. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millan B, Heredia M, Roma-Mateo C, Mouron S, et al. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. *Hum Mol Genet* 2012; 21:1521-33; <http://dx.doi.org/10.1093/hmg/ddr590>.
1902. Cervia D, Perrotta C, Moscheni C, De Palma C, Clementi E. Nitric oxide and sphingolipids control apoptosis and autophagy with a significant impact on Alzheimer's disease. *J Biol Reg Homeos Ag* 2013; 27:11-22.
1903. Rabkin SW. Nitric oxide-induced cell death in the heart: the role of autophagy. *Autophagy* 2007; 3:347-9; <http://dx.doi.org/10.4161/auto.4054>.
1904. Zang L, He H, Ye Y, Liu W, Fan S, Tashiro S, Onodera S, Ikejima T. Nitric oxide augments oridonin-induced efferocytosis by human

- histocytic lymphoma U937 cells via autophagy and the NF-kappaB-COX-2-IL-1beta pathway. *Free Rad Res* 2012; 46:1207-19; <http://dx.doi.org/10.3109/10715762.2012.700515>.
1905. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, Yuan L, Soares F, Chea E, Le Bourhis L, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat Immunol* 2010; 11:55-62; <http://dx.doi.org/10.1038/ni.1823>.
  1906. Avelaira CA, Botelho M, Carmo-Silva S, Pascoal JF, Ferreira-Marques M, Nobrega C, Cortes L, Valero J, Sousa-Ferreira L, Alvaro AR, et al. Neuropeptide Y stimulates autophagy in hypothalamic neurons. *Proc Natl Acad Sci USA* 2015; 112:E1642-51; <http://dx.doi.org/10.1073/pnas.1416609112>.
  1907. Cao Y, Wang Y, Abi Saab WF, Yang F, Pessin JE, Backer JM. NRBF2 regulates macroautophagy as a component of Vps34 Complex I. *Biochem J* 2014; 461:315-22; <http://dx.doi.org/10.1042/BJ20140515>.
  1908. Lu J, He L, Behrends C, Araki M, Araki K, Jun Wang Q, Catanzaro JM, Friedman SL, Zong WX, Fiel MI, et al. NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. *Nat Commun* 2014; 5:3920.
  1909. Judith D, Mostowy S, Bourai M, Gangneux N, Lelek M, Lucas-Hourani M, Cayet N, Jacob Y, Prevost MC, Pierre P, et al. Species-specific impact of the autophagy machinery on Chikungunya virus infection. *EMBO Rep* 2013; 14:534-44; <http://dx.doi.org/10.1038/embor.2013.51>.
  1910. Kong DK, Georgescu SP, Cano C, Aronovitz MJ, Iovanna JL, Patten RD, Kyriakis JM, Goruppi S. Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function. *Mol Biol Cell* 2010; 21:1335-49; <http://dx.doi.org/10.1091/mbc.E09-09-0818>.
  1911. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. *Clin Cancer Res* 2011; 17:7116-26; <http://dx.doi.org/10.1158/1078-0432.CCR-11-0796>.
  1912. Liu XM, Sun LL, Hu W, Ding YH, Dong MQ, Du LL. ESCRTs cooperate with a selective autophagy receptor to mediate vacuolar targeting of soluble cargos. *Mol Cell* 2015; 59:1035-42; <http://dx.doi.org/10.1016/j.molcel.2015.07.034>.
  1913. Gundara JS, Zhao J, Robinson BG, Sidhu SB. Oncophagy: harnessing regulation of autophagy in cancer therapy. *Endocr Relat Cancer* 2012; 19:R281-95; <http://dx.doi.org/10.1530/ERC-12-0325>.
  1914. Mijaljica D. Autophagy in 2020 and beyond: eating our way into a healthy future. *Autophagy* 2010; 6:194-6; <http://dx.doi.org/10.4161/auto.6.1.10992>.
  1915. Zhang CF, Gruber F, Ni C, Mildner M, Koenig U, Karner S, Barresi C, Rossiter H, Narzt MS, Nagelreiter IM, et al. Suppression of autophagy dysregulates the antioxidant response and causes premature senescence of melanocytes. *J Invest Dermatol* 2015; 135:1348-57; <http://dx.doi.org/10.1038/jid.2014.439>.
  1916. Zhao Y, Zhang CF, Rossiter H, Eckhart L, Konig U, Karner S, Mildner M, Bochkov VN, Tschachler E, Gruber F. Autophagy is induced by UVA and promotes removal of oxidized phospholipids and protein aggregates in epidermal keratinocytes. *J Invest Dermatol* 2013; 133:1629-37; <http://dx.doi.org/10.1038/jid.2013.26>.
  1917. Bertolin G, Ferrando-Miguel R, Jacoupy M, Traver S, Grenier K, Greene AW, Dauphin A, Waharte F, Bayot A, Salamero J, et al. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. *Autophagy* 2013; 9:1801-17; <http://dx.doi.org/10.4161/auto.25884>.
  1918. Greene AW, Grenier K, Aguilera MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon EA. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. *EMBO Rep* 2012; 13:378-85; <http://dx.doi.org/10.1038/embor.2012.14>.
  1919. Jin SM, Youle RJ. The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria. *Autophagy* 2013; 9:1750-7; <http://dx.doi.org/10.4161/auto.26122>.
  1920. Meissner C, Lorenz H, Hehn B, Lemberg MK. Intramembrane protease PARL defines a negative regulator of PINK1- and PARK2/Parkin-dependent mitophagy. *Autophagy* 2015:0.
  1921. Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, Hattori N. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. *Sci Rep* 2012; 2:1002; <http://dx.doi.org/10.1038/srep01002>.
  1922. Durcan TM, Tang MY, Perusse JR, Dashti EA, Aguilera MA, McLelland GL, Gros P, Shaler TA, Faubert D, Coulombe B, et al. USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. *EMBO J* 2014.
  1923. Ren H, Fu K, Mu C, Li B, Wang D, Wang G. DJ-1, a cancer and Parkinson's disease associated protein, regulates autophagy through JNK pathway in cancer cells. *Cancer Lett* 2010; 297:101-8; <http://dx.doi.org/10.1016/j.canlet.2010.05.001>.
  1924. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol* 2010; 191:933-42; <http://dx.doi.org/10.1083/jcb.201008084>.
  1925. Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. *J Neurochem* 2011; 117:856-67; <http://dx.doi.org/10.1111/j.1471-4159.2011.07253.x>.
  1926. Shi G, Lee JR, Grimes DA, Racacho L, Ye D, Yang H, Ross OA, Farrer M, McQuibban GA, Bulman DE. Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease. *Hum Mol Genet* 2011; 20:1966-74; <http://dx.doi.org/10.1093/hmg/ddr077>.
  1927. Munoz-Gamez JA, Rodriguez-Vargas JM, Quiles-Perez R, Aguilar-Quesada R, Martin-Oliva D, de Murcia G, Menissier de Murcia J, Almendros A, Ruiz de Almodovar M, Oliver FJ. PARP-1 is involved in autophagy induced by DNA damage. *Autophagy* 2009; 5:61-74; <http://dx.doi.org/10.4161/auto.5.1.7272>.
  1928. Huang Q, Shen HM. To die or to live: the dual role of poly(ADP-ribose) polymerase-1 in autophagy and necrosis under oxidative stress and DNA damage. *Autophagy* 2009; 5:273-6; <http://dx.doi.org/10.4161/auto.5.2.7640>.
  1929. Thayyullathil F, Rahman A, Pallichankandy S, Patel M, Galadari S. ROS-dependent prostate apoptosis response-4 (Par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma. *FEBS Open Bio* 2014; 4:763-76; <http://dx.doi.org/10.1016/j.fob.2014.08.005>.
  1930. Wang LJ, Chen PR, Hsu LP, Hsu WL, Liu DW, Chang CH, Hsu YC, Lee JW. Concomitant induction of apoptosis and autophagy by prostate apoptosis response-4 in hypopharyngeal carcinoma cells. *Am J Pathol* 2014; 184:418-30; <http://dx.doi.org/10.1016/j.ajpath.2013.10.012>.
  1931. Silvente-Poirot S, Poirot M. Cholesterol metabolism and cancer: the good, the bad and the ugly. *Current Opin Pharmacol* 2012; 12:673-6; <http://dx.doi.org/10.1016/j.coph.2012.10.004>.
  1932. Bock BC, Tagscherer KE, Fassel A, Kramer A, Oehme I, Zentgraf HW, Keith M, Roth W. The PEA-15 protein regulates autophagy via activation of JNK. *J Biol Chem* 2010; 285:21644-54; <http://dx.doi.org/10.1074/jbc.M109.096628>.
  1933. Murrow L, Malhotra R, Debnath J. ATG12-ATG3 interacts with Alix to promote basal autophagic flux and late endosome function. *Nat Cell Biol* 2015; 17:300-10; <http://dx.doi.org/10.1038/ncb3112>.
  1934. Leu JI-J, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. *Mol Cell* 2009; 36:15-27; <http://dx.doi.org/10.1016/j.molcel.2009.09.023>.
  1935. Shibata M, Oikawa K, Yoshimoto K, Kondo M, Mano S, Yamada K, Hayashi M, Sakamoto W, Ohsumi Y, Nishimura M. Highly oxidized peroxisomes are selectively degraded via autophagy in Arabidopsis. *Plant Cell* 2013; 25:4967-83; <http://dx.doi.org/10.1105/tpc.113.116947>.
  1936. Ano Y, Hattori T, Oku M, Mukaiyama H, Baba M, Ohsumi Y, Kato N, Sakai Y. A sorting nexin PpAtg24 regulates vacuolar membrane dynamics during pexophagy via binding to phosphatidylinositol-3-

- phosphate. *Mol Biol Cell* 2005; 16:446-57; <http://dx.doi.org/10.1091/mbc.E04-09-0842>.
1937. Yano T, Mita S, Ohmori H, Oshima Y, Fujimoto Y, Ueda R, Takada H, Goldman WE, Fukase K, Silverman N, et al. Autophagic control of listeria through intracellular innate immune recognition in drosophila. *Nat Immunol* 2008; 9:908-16; <http://dx.doi.org/10.1038/ni.1634>.
1938. Seglen PO, Gordon PB, Holen I. Non-selective autophagy. *Semin Cell Biol* 1990; 1:441-8.
1939. He C, Klionsky DJ. Atg9 trafficking in autophagy-related pathways. *Autophagy* 2007; 3:271-4; <http://dx.doi.org/10.4161/auto.3912>.
1940. Huang H, Kawamata T, Horie T, Tsugawa H, Nakayama Y, Ohsumi Y, Fukusaki E. Bulk RNA degradation by nitrogen starvation-induced autophagy in yeast. *EMBO J* 2015; 34:154-68; <http://dx.doi.org/10.15252/embj.201489083>.
1941. Meijer AJ, Klionsky DJ. Vps34 is a phosphatidylinositol 3-kinase, not a phosphoinositide 3-kinase. *Autophagy* 2011; 7:563-4; <http://dx.doi.org/10.4161/auto.7.6.14873>.
1942. Devereaux K, Dall'Armi C, Alcazar-Roman A, Ogasawara Y, Zhou X, Wang F, Yamamoto A, De Camilli P, Di Paolo G. Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. *PLoS One* 2013; 8:e76405.
1943. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. *J Biol Chem* 2005; 280:33076-82; <http://dx.doi.org/10.1074/jbc.M507201200>.
1944. Roppenser B, Grinstein S, Brumell JH. Modulation of host phosphoinositide metabolism during Salmonella invasion by the type III secreted effector SopB. *Methods Cell Biol* 2012; 108:173-86; <http://dx.doi.org/10.1016/B978-0-12-386487-1.00009-2>.
1945. Cuesta-Geijo MA, Galindo I, Hernaez B, Quetglas JJ, Dalmau-Mena I, Alonso C. Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine fever virus entry. *PLoS One* 2012; 7:e48853; <http://dx.doi.org/10.1371/journal.pone.0048853>.
1946. Jin N, Mao K, Jin Y, Tevzadze G, Kauffman EJ, Park S, Bridges D, Loewith R, Saltiel AR, Klionsky DJ, et al. Roles for PI(3,5)P2 in nutrient sensing through TORC1. *Mol Biol Cell* 2014; 25:1171-85.
1947. Wang H, Sun HQ, Zhu X, Zhang L, Albanesi J, Levine B, Yin H. GABARAPs regulate PI4P-dependent autophagosome:lysosome fusion. *Proc Natl Acad Sci USA* 2015; 112:7015-20; <http://dx.doi.org/10.1073/pnas.1507263112>.
1948. Dou Z, Chattopadhyay M, Pan JA, Guerriero JL, Jiang YP, Ballou LM, Yue Z, Lin RZ, Zong WX. The class IA phosphatidylinositol 3-kinase p110- $\beta$  subunit is a positive regulator of autophagy. *J Cell Biol* 2010; 191:827-43; <http://dx.doi.org/10.1083/jcb.201006056>.
1949. Lindmo K, Brech A, Finley KD, Gaumer S, Contamine D, Rusten TE, Stenmark H. The PI 3-kinase regulator Vps15 is required for autophagic clearance of protein aggregates. *Autophagy* 2008; 4:500-6; <http://dx.doi.org/10.4161/auto.5829>.
1950. Murray JT, Panaretou C, Stenmark H, Miaczynska M, Backer JM. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. *Traffic* 2002; 3:416-27; <http://dx.doi.org/10.1034/j.1600-0854.2002.30605.x>.
1951. Chu CT. A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. *Hum Mol Genet* 2010; 19:R28-37; <http://dx.doi.org/10.1093/hmg/ddq143>.
1952. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proc Natl Acad Sci USA* 2010; 107:378-83; <http://dx.doi.org/10.1073/pnas.0911187107>.
1953. Budovskaya YV, Stephan JS, Reggiori F, Klionsky DJ, Herman PK. The Ras/cAMP-dependent protein kinase signaling pathway regulates an early step of the autophagy process in *Saccharomyces cerevisiae*. *J Biol Chem* 2004; 279:20663-71; <http://dx.doi.org/10.1074/jbc.M400272200>.
1954. Shahab S, Namolovan A, Mogridge J, Kim PK, Brumell JH. Bacterial toxins can inhibit host cell autophagy through cAMP generation. *Autophagy* 2011; 7:957-65.
1955. Yao Z, Delorme-Axford E, Backues SK, Klionsky DJ. Atg41/Icy2 regulates autophagosome formation. *Autophagy* 2015; 11:in press.
1956. McEwan DG, Popovic D, Gubas A, Terawaki S, Suzuki H, Stadel D, Coxon FP, Miranda de Stegmann D, Bhogaraju S, Maddi K, et al. PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and LC3/GABARAP proteins. *Mol Cell* 2015; 57:39-54; <http://dx.doi.org/10.1016/j.molcel.2014.11.006>.
1957. Broadley K, Larsen L, Herst PM, Smith RA, Berridge MV, McConnell MJ. The novel phloroglucinol PMT7 kills glycolytic cancer cells by blocking autophagy and sensitizing to nutrient stress. *J Cell Biochem* 2011; 112:1869-79; <http://dx.doi.org/10.1002/jcb.23107>.
1958. Dupont N, Chauhan S, Arko-Mensah J, Castillo EF, Masedunskas A, Weigert R, Robenek H, Proikas-Cezanne T, Deretic V. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. *Curr Biol* 2014; 24:609-20; <http://dx.doi.org/10.1016/j.cub.2014.02.008>.
1959. Bhullar KS, Rupasinghe HP. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. *Oxid Med Cell Longev* 2013; 2013:891748; <http://dx.doi.org/10.1155/2013/891748>.
1960. Macedo D, Tavares L, McDougall GF, Vicentes Miranda H, Stewart D, Ferreira RB, Tenreiro S, Outeiro TF, Santos CN. (Poly)phenols protect from alpha-synuclein toxicity by reducing oxidative stress and promoting autophagy. *Hum Mol Genet* 2015; 24:1717-32; <http://dx.doi.org/10.1093/hmg/ddu585>.
1961. Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. *Cell Death Dis* 2014; 5:e1509; <http://dx.doi.org/10.1038/cddis.2014.467>.
1962. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. *J Cell Sci* 2013; 126:1713-9; <http://dx.doi.org/10.1242/jcs.125773>.
1963. Palomer X, Capdevila-Busquets E, Botteri G, Salvado L, Barroso E, Davidson MM, Michalik L, Wahli W, Vazquez-Carrera M. PPAR-beta/delta attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. *Int J Cardiol* 2014; 174:110-8; <http://dx.doi.org/10.1016/j.ijcard.2014.03.176>.
1964. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. *Genes Dev* 2000; 14:1027-47.
1965. Phizicky EM, Fields S. Protein-protein interactions: methods for detection and analysis. *Microbiol Rev* 1995; 59:94-123.
1966. Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. *Gastroenterol Hepatol Bed Bench* 2014; 7:17-31.
1967. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W, Bulavin DV. Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. *Cell Metab* 2012; 16:68-80; <http://dx.doi.org/10.1016/j.cmet.2012.06.003>.
1968. Uddin MN, Ito S, Nishio N, Suganya T, Isobe KI. Gadd34 induces autophagy through the suppression of the mTOR pathway during starvation. *Biochem Biophys Res Comm* 2011; 407:692-8.
1969. Peti W, Nairn AC, Page R. Structural basis for protein phosphatase 1 regulation and specificity. *FEBS J* 2013; 280:596-611; <http://dx.doi.org/10.1111/j.1742-4658.2012.08509.x>.
1970. Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat Cell Biol* 2015; 17:288-99; <http://dx.doi.org/10.1038/ncb3114>.
1971. Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vps34 that mediates ROS-induced autophagy downstream of DAPk. *Cell Death Differ* 2012; 19:788-97; <http://dx.doi.org/10.1038/cdd.2011.149>.
1972. Moravcevic K, Oxley CL, Lemmon MA. Conditional peripheral membrane proteins: facing up to limited specificity. *Structure* 2012; 20:15-27; <http://dx.doi.org/10.1016/j.str.2011.11.012>.
1973. Baskaran S, Ragusa MJ, Boura E, Hurley JH. Two-site recognition of phosphatidylinositol 3-phosphate by PROPPINs in autophagy. *Mol Cell* 2012; 47:339-48; <http://dx.doi.org/10.1016/j.molcel.2012.05.027>.
1974. Krick R, Busse RA, Scacioc A, Stephan M, Janshoff A, Thumm M, Kuhnel K. Structural and functional characterization of the two phosphoinositide binding sites of PROPPINs, a beta-propeller protein family. *Proc Natl Acad Sci USA* 2012; 109:E2042-9; <http://dx.doi.org/10.1073/pnas.1205128109>.

1975. Watanabe Y, Kobayashi T, Yamamoto H, Hoshida H, Akada R, Inagaki F, Ohsumi Y, Noda NN. Structure-based analyses reveal distinct binding sites for Atg2 and phosphoinositides in Atg18. *J Biol Chem* 2012; 287:31681-90; <http://dx.doi.org/10.1074/jbc.M112.397570>.
1976. Marshall RS, Li F, Gemperline DC, Book AJ, Vierstra RD. Autophagic Degradation of the 26S Proteasome Is Mediated by the Dual ATG8/Ubiquitin Receptor RPN10 in Arabidopsis. *Mol Cell* 2015; 58:1053-66; <http://dx.doi.org/10.1016/j.molcel.2015.04.023>.
1977. Starokadomskyy P, Dmytruk KV. A bird's-eye view of autophagy. *Autophagy* 2013; 9:1121-6; <http://dx.doi.org/10.4161/auto.24544>.
1978. Neely KM, Green KN, Laferla FM. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a {gamma}-secretase-independent manner. *J Neurosci* 2011; 31:2781-91; <http://dx.doi.org/10.1523/JNEUROSCI.5156-10.2010>.
1979. Walsh CT, Garneau-Tsodikova S, Gatto GJ, Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem Int Ed Engl* 2005; 44:7342-72; <http://dx.doi.org/10.1002/anie.200501023>.
1980. Witze ES, Old WM, Resing KA, Ahn NG. Mapping protein post-translational modifications with mass spectrometry. *Nat Methods* 2007; 4:798-806; <http://dx.doi.org/10.1038/nmeth1100>.
1981. Popelka H, Klionsky DJ. Posttranslationally-modified structures in the autophagy machinery: an integrative perspective. *FEBS J* 2015; 282:3474-88.
1982. Huang YH, Al-Aidaroo AQ, Yuen HF, Zhang SD, Shen HM, Rozycka E, McCrudden CM, Tergaonkar V, Gupta A, Lin YB, et al. A role of autophagy in PTP4A3-driven cancer progression. *Autophagy* 2014; 10:1787-800; <http://dx.doi.org/10.4161/auto.29989>.
1983. Martin KR, Xu Y, Looyenga BD, Davis RJ, Wu CL, Tremblay ML, Xu HE, MacKeigan JP. Identification of PTPsigma as an autophagic phosphatase. *J Cell Sci* 2011; 124:812-9; <http://dx.doi.org/10.1242/jcs.080341>.
1984. Mandell MA, Jain A, Arko-Mensah J, Chauhan S, Kimura T, Dinkins C, Silvestri G, Munch J, Kirchhoff F, Simonsen A, et al. TRIM Proteins Regulate Autophagy and Can Target Autophagic Substrates by Direct Recognition. *Dev Cell* 2014; 30:394-409; <http://dx.doi.org/10.1016/j.devcel.2014.06.013>.
1985. Nagy G, Ward J, Mosser DD, Koncz A, Gergely P, Jr., Stancato C, Qian Y, Fernandez D, Niland B, Grossman CE, et al. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. *J Biol Chem* 2006; 281:34574-91; <http://dx.doi.org/10.1074/jbc.M606301200>.
1986. Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, et al. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. *J Immunol* 2009; 182:2063-73; <http://dx.doi.org/10.4049/jimmunol.0803600>.
1987. Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, Lai ZW, Miklossy G, Singh RR, Chudakov DM, et al. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. *Ann Rheum Dis* 2014; 73:1888-97; <http://dx.doi.org/10.1136/annrheumdis-2013-203794>.
1988. Talaber G, Miklossy G, Oaks Z, Liu Y, Tooze SA, Chudakov DM, Banki K, Perl A. HRES-1/Rab4 promotes the formation of LC3(+) autophagosomes and the accumulation of mitochondria during autophagy. *PLoS One* 2014; 9:e84392; <http://dx.doi.org/10.1371/journal.pone.0084392>.
1989. Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. *Annu Rev Biochem* 2011; 80:125-56; <http://dx.doi.org/10.1146/annurev-biochem-052709-094552>.
1990. Stenmark H. Rab GTPases as coordinators of vesicle traffic. *Nature Rev Mol Cell Biol* 2009; 10:513-25; <http://dx.doi.org/10.1038/nrm2728>.
1991. Jager S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, Eskelinen EL. Role for Rab7 in maturation of late autophagic vacuoles. *J Cell Sci* 2004; 117:4837-48; <http://dx.doi.org/10.1242/jcs.01370>.
1992. Pilli M, Arko-Mensah J, Ponpuak M, Roberts E, Master S, Mandell MA, Dupont N, Ornatowski W, Jiang S, Bradfute SB, et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. *Immunity* 2012; 37:223-34; <http://dx.doi.org/10.1016/j.immuni.2012.04.015>.
1993. Longatti A, Lamb CA, Razi M, Yoshimura S, Barr FA, Tooze SA. TBC1D14 regulates autophagosome formation via Rab11- and ULK1-positive recycling endosomes. *J Cell Biol* 2012; 197:659-75; <http://dx.doi.org/10.1083/jcb.201111079>.
1994. Matsui T, Fukuda M. Rab12 regulates mTORC1 activity and autophagy through controlling the degradation of amino-acid transporter PAT4. *EMBO Rep* 2013; 14:450-7; <http://dx.doi.org/10.1038/embr.2013.32>.
1995. Jean S, Cox S, Nassari S, Kiger AA. Starvation-induced MTMR13 and RAB21 activity regulates VAMP8 to promote autophagosome-lysosome fusion. *EMBO Rep* 2015; 16:297-311; <http://dx.doi.org/10.15252/embr.201439464>.
1996. Munafo DB, Colombo MI. Induction of autophagy causes dramatic changes in the subcellular distribution of GFP-Rab24. *Traffic* 2002; 3:472-82; <http://dx.doi.org/10.1034/j.1600-0854.2002.30704.x>.
1997. Ylä-Anttila P, Mikkonen E, Happonen KE, Holland P, Ueno T, Simonsen A, Eskelinen E-L. RAB24 facilitates clearance of autophagic compartments during basal conditions. *Autophagy* 2015; 10:1833-48 DOI: 10.1080/15548627.2015.108652210.1080/15548627.2015.1086522
1998. Hirota Y, Tanaka Y. A small GTPase, human Rab32, is required for the formation of autophagic vacuoles under basal conditions. *Cell Mol Life Sci* 2009; 66:2913-32; <http://dx.doi.org/10.1007/s00018-009-0080-9>.
1999. Itoh T, Fujita N, Kanno E, Yamamoto A, Yoshimori T, Fukuda M. Golgi-resident small GTPase Rab33B interacts with Atg16L and modulates autophagosome formation. *Mol Biol Cell* 2008; 19:2916-25; <http://dx.doi.org/10.1091/mbc.E07-12-1231>.
2000. Itoh T, Kanno E, Uemura T, Waguri S, Fukuda M. OATL1, a novel autophagosome-resident Rab33B-GAP, regulates autophagosomal maturation. *J Cell Biol* 2011; 192:839-53; <http://dx.doi.org/10.1083/jcb.201008107>.
2001. Chen XW, Leto D, Xiong T, Yu G, Cheng A, Decker S, Saltiel AR. A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action. *Mol Biol Cell* 2011; 22:141-52; <http://dx.doi.org/10.1091/mbc.E10-08-0665>.
2002. Gentry LR, Martin TD, Reiner DJ, Der CJ. Ral small GTPase signaling and oncogenesis: More than just 15 minutes of fame. *Biochim Biophys Acta* 2014; 1843:2976-88; <http://dx.doi.org/10.1016/j.bbamcr.2014.09.004>.
2003. Martin TD, Chen XW, Kaplan RE, Saltiel AR, Walker CL, Reiner DJ, Der CJ. Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. *Mol Cell* 2014; 53:209-20; <http://dx.doi.org/10.1016/j.molcel.2013.12.004>.
2004. Geng J, Nair U, Yasumura-Yorimitsu K, Klionsky DJ. Post-Golgi Sec proteins are required for autophagy in *Saccharomyces cerevisiae*. *Mol Biol Cell* 2010; 21:2257-69; <http://dx.doi.org/10.1091/mbc.E09-11-0969>.
2005. Shirakawa R, Fukui S, Kawato M, Higashi T, Kondo H, Ikeda T, Nakayama E, Okawa K, Nureki O, Kimura T, et al. Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases. *J Biol Chem* 2009; 284:21580-8; <http://dx.doi.org/10.1074/jbc.M109.012112>.
2006. Oeckinghaus A, Postler TS, Rao P, Schmitt H, Schmitt V, Grinberg-Bleyer Y, Kuhn LI, Gruber CW, Lienhard GE, Ghosh S. kappaB-Ras proteins regulate both NF-kappaB-dependent inflammation and Ral-dependent proliferation. *Cell Rep* 2014; 8:1793-807; <http://dx.doi.org/10.1016/j.celrep.2014.08.015>.
2007. Punnonen EL, Reunanen H, Hirsimäki P, Lounatmaa K. Filipin labelling and intramembrane particles on the membranes of early and later autophagic vacuoles in Ehrlich ascites cells. *Virchows Archiv B, Cell Pathol* 1988; 54:317-26; <http://dx.doi.org/10.1007/BF02899229>.

2008. Opirari AJ, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. *Cancer Res* 2004; 15:696-703; <http://dx.doi.org/10.1158/0008-5472.CAN-03-2404>.
2009. Ogier-Denis E, Petiot A, Bauvy C, Codogno P. Control of the expression and activity of the Alpha-interacting protein (GAIP) in human intestinal cells. *J Biol Chem* 1997; 272:24599-603; <http://dx.doi.org/10.1074/jbc.272.39.24599>.
2010. Yorimitsu T, Zaman S, Broach JR, Klionsky DJ. Protein kinase A and Sch9 cooperatively regulate induction of autophagy in *Saccharomyces cerevisiae*. *Mol Biol Cell* 2007; 18:4180-9; <http://dx.doi.org/10.1091/mbc.E07-05-0485>.
2011. Yonekawa T, Gamez G, Kim J, Tan AC, Thorburn J, Gump J, Thorburn A, Morgan MJ. RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis. *EMBO Rep* 2015; 16:700-8; <http://dx.doi.org/10.15252/embr.201439496>.
2012. Hillwig MS, Contento AL, Meyer A, Ebany D, Bassham DC, Macintosh GC. RNS2, a conserved member of the RNase T2 family, is necessary for ribosomal RNA decay in plants. *Proc Natl Acad Sci USA* 2011; 108:1093-8; <http://dx.doi.org/10.1073/pnas.1009809108>.
2013. Haud N, Kara F, Diekmann S, Henneke M, Willer JR, Hillwig MS, Gregg RG, Macintosh GC, Gartner J, Alia A, et al. rns2 mutant zebrafish model familial cystic leukoencephalopathy and reveal a role for RNase T2 in degrading ribosomal RNA. *Proc Natl Acad Sci USA* 2011; 108:1099-103; <http://dx.doi.org/10.1073/pnas.1009811107>.
2014. Xu C, Feng K, Zhao X, Huang S, Cheng Y, Qian L, Wang Y, Sun H, Jin M, Chuang TH, et al. Regulation of autophagy by E3 ubiquitin ligase RNF216 through BECN1 ubiquitination. *Autophagy* 2014; 10:2239-50.
2015. Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1. ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. *J Biol Chem* 2009; 284:12297-305; <http://dx.doi.org/10.1074/jbc.M900573200>.
2016. Dunlop EA, Hunt DK, Acosta-Jaquez HA, Fingar DC, Tee AR. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. *Autophagy* 2011; 7:737-47; <http://dx.doi.org/10.4161/auto.7.7.15491>.
2017. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan K-L. Regulation of TORC1 by Rag GTPases in nutrient response. *Nat Cell Biol* 2008; 10:935-45; <http://dx.doi.org/10.1038/ncb1753>.
2018. White E. Exploiting the bad eating habits of Ras-driven cancers. *Genes Dev* 2013; 27:2065-71; <http://dx.doi.org/10.1101/gad.228122.113>.
2019. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. *Proc Natl Acad Sci USA* 2004; 101:18030-5; <http://dx.doi.org/10.1073/pnas.0408345102>.
2020. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. *Leukemia* 2014; 28:577-88; <http://dx.doi.org/10.1038/leu.2013.264>.
2021. Dokudovskaya S, Waharte F, Schlessinger A, Pieper U, Devos DP, Cristea IM, Williams R, Salamero J, Chait BT, Sali A, et al. A conserved coatmer-related complex containing Sec13 and Seh1 dynamically associates with the vacuole in *Saccharomyces cerevisiae*. *Mol Cell Proteomics* 2011; 10:M110 006478.
2022. Nair U, Jotwani A, Geng J, Gammoh N, Richerson D, Yen W-L, Griffith J, Nag S, Wang K, Moss T, et al. SNARE proteins are required for macroautophagy. *Cell* 2011; 146:290-302; <http://dx.doi.org/10.1016/j.cell.2011.06.022>.
2023. Nair U, Jotwani A, Geng J, Gammoh N, Richerson D, Yen WL, Griffith J, Nag S, Wang K, Moss T, et al. SNARE proteins are required for macroautophagy. *Cell* 2011; 146:290-302; <http://dx.doi.org/10.1016/j.cell.2011.06.022>.
2024. Ishihara N, Hamasaki M, Yokota S, Suzuki K, Kamada Y, Kihara A, Yoshimori T, Noda T, Ohsumi Y. Autophagosome requires specific early Sec proteins for its formation and NSF/SNARE for vacuolar fusion. *Mol Biol Cell* 2001; 12:3690-702; <http://dx.doi.org/10.1091/mbc.12.11.3690>.
2025. Jiang S, Dupont N, Castillo EF, Deretic V. Secretory versus degradative autophagy: unconventional secretion of inflammatory mediators. *J Innate Immun* 2013; 5:471-9; <http://dx.doi.org/10.1159/000346707>.
2026. Mostowy S, Bonazzi M, Hamon MA, Tham TN, Mallet A, Lelek M, Gouin E, Demangel C, Brosch R, Zimmer C, et al. Entrapment of intracytosolic bacteria by septin cage-like structures. *Cell Host Microbe* 2010; 8:433-44; <http://dx.doi.org/10.1016/j.chom.2010.10.009>.
2027. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. *Science* 2010; 329:229-32; <http://dx.doi.org/10.1126/science.1190354>.
2028. Lee JH, Budanov AV, Karin M. Sestrins orchestrate cellular metabolism to attenuate aging. *Cell Metab* 2013; 18:792-801; <http://dx.doi.org/10.1016/j.cmet.2013.08.018>.
2029. Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG. Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. *Cell Metab* 2013; 17:73-84; <http://dx.doi.org/10.1016/j.cmet.2012.12.002>.
2030. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. *Cell* 2008; 134:451-60; <http://dx.doi.org/10.1016/j.cell.2008.06.028>.
2031. Park HW, Park H, Ro SH, Jang I, Semple IA, Kim DN, Kim M, Nam M, Zhang D, Yin L, et al. Hepatoprotective role of Sestrin2 against chronic ER stress. *Nat Commun* 2014; 5:4233.
2032. Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. *Cell Death Differ* 2013; 20:611-9; <http://dx.doi.org/10.1038/cdd.2012.157>.
2033. Takahashi Y, Coppola D, Matsushita N, Cuaing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mule JJ, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. *Nat Cell Biol* 2007; 9:1142-51; <http://dx.doi.org/10.1038/ncb1634>.
2034. Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, Cheung ZH, Ip NY. Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease. *Nat Cell Biol* 2011; 13:568-79; <http://dx.doi.org/10.1038/ncb2217>.
2035. Zhang C, Li A, Zhang X, Xiao H. A novel TIP30 protein complex regulates EGF receptor signaling and endocytic degradation. *J Biol Chem* 2011; 286:9373-81; <http://dx.doi.org/10.1074/jbc.M110.207720>.
2036. Khan MM, Strack S, Wild F, Hanashima A, Gasch A, Brohm K, Reischl M, Carnio S, Labeit D, Sandri M, et al. Role of autophagy, SQSTM1, SH3GLB1, and TRIM63 in the turnover of nicotinic acetylcholine receptors. *Autophagy* 2014; 10:123-36; <http://dx.doi.org/10.4161/auto.26841>.
2037. Belaid A, Ndiaye PD, Klionsky DJ, Hofman P, Mograbi B. Signalphagy: Scheduled signal termination by macroautophagy. *Autophagy* 2013; 9:1629-30.
2038. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc Natl Acad Sci USA* 2008; 105:3374-9; <http://dx.doi.org/10.1073/pnas.0712145105>.
2039. Webster BR, Scott I, Traba J, Han K, Sack MN. Regulation of autophagy and mitophagy by nutrient availability and acetylation. *Biochim Biophys Acta* 2014; 1841:525-34; <http://dx.doi.org/10.1016/j.bbali.2014.02.001>.
2040. Pi H, Xu S, Reiter RJ, Guo P, Zhang L, Li Y, Li M, Cao Z, Tian L, Xie J, et al. SIRT3-SOD2-mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin. *Autophagy* 2015; 11:1037-51; <http://dx.doi.org/10.1080/15548627.2015.1052208>.
2041. Polletta L, Vernucci E, Carnevale I, Arcangeli T, Rotili D, Palmerio S, Steegborn C, Nowak T, Schutkowski M, Pellegrini L, et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. *Autophagy* 2015; 11:253-70; <http://dx.doi.org/10.1080/15548627.2015.1009778>.
2042. Takasaka N, Araya J, Hara H, Ito S, Kobayashi K, Kurita Y, Wakui H, Yoshii Y, Yumino Y, Fujii S, et al. Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is

- involved in the regulation of human bronchial epithelial cell senescence. *J Immunol* 2014; 192:958-68; <http://dx.doi.org/10.4049/jimmunol.1302341>.
2043. Araki S, Izumiya Y, Rokutanda T, Ianni A, Hanatani S, Kimura Y, Onoue Y, Senokuchi T, Yoshizawa T, Yasuda O, et al. Sirt7 Contributes to Myocardial Tissue Repair by Maintaining TGF-beta Signaling Pathway. *Circulation* 2015.
2044. Birmingham CL, Canadien V, Kaniuk NA, Steinberg BE, Higgins DE, Brummell JH. Listeriolysin O allows *Listeria monocytogenes* replication in macrophage vacuoles. *Nature* 2008; 451:350-4; <http://dx.doi.org/10.1038/nature06479>.
2045. Bhardwaj V, Kanagawa O, Swanson PE, Unanue ER. Chronic *Listeria* infection in SCID mice: requirements for the carrier state and the dual role of T cells in transferring protection or suppression. *J Immunol* 1998; 160:376-84.
2046. Liu H, Ma Y, He HW, Wang JP, Jiang JD, Shao RG. SLC9A3R1 stimulates autophagy via BECN1 stabilization in breast cancer cells. *Autophagy* 2015:0.
2047. Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, Byers S, Giaccia AJ, Glasgow E, Albanese C, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. *Oncotarget* 2012; 3:1220-35; <http://dx.doi.org/10.18632/oncotarget.714>.
2048. Jung J, Genau HM, Behrends C. Amino Acid-Dependent mTORC1 Regulation by the Lysosomal Membrane Protein SLC38A9. *Mol Cell Biol* 2015; 35:2479-94; <http://dx.doi.org/10.1128/MCB.00125-15>.
2049. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK, Snijder B, Fauser A, Rudashevskaya EL, Bruckner M, et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. *Nature* 2015; 519:477-81; <http://dx.doi.org/10.1038/nature14107>.
2050. Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME, Yuan ED, Jones TD, Chantranupong L, Comb W, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. *Science* 2015; 347:188-94; <http://dx.doi.org/10.1126/science.1257132>.
2051. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. *Nat Rev Immunol* 2013; 13:722-37; <http://dx.doi.org/10.1038/nri3532>.
2052. Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M, Kimchi A. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. *Mol Cell* 2006; 22:463-75; <http://dx.doi.org/10.1016/j.molcel.2006.04.014>.
2053. Morelli E, Ginefra P, Mastrodonato V, Beznoussenko GV, Rusten TE, Bilder D, Stenmark H, Mironov AA, Vaccari T. Multiple functions of the SNARE protein Snap29 in autophagy, endocytic, and exocytic trafficking during epithelial formation in *Drosophila*. *Autophagy* 2014; 10:2251-68; <http://dx.doi.org/10.4161/15548627.2014.981913>.
2054. Batelli S, Peverelli E, Rodilossi S, Forloni G, Albani D. Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). *Neuroscience* 2011; 195:128-37; <http://dx.doi.org/10.1016/j.neuroscience.2011.08.030>.
2055. Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, Zhang HQ, Li M. HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. *Autophagy* 2014; 10:144-54; <http://dx.doi.org/10.4161/15548627.2014.981913>.
2056. Knaevelsrud H, Soreng K, Raiborg C, Haberg K, Rasmuson F, Brech A, Liestol K, Rusten TE, Stenmark H, Neufeld TP, et al. Membrane remodeling by the PX-BAR protein SNX18 promotes autophagosome formation. *J Cell Biol* 2013; 202:331-49; <http://dx.doi.org/10.1083/jcb.201205129>.
2057. Barnett TC, Liebl D, Seymour LM, Gillen CM, Lim JY, Larock CN, Davies MR, Schulz BL, Nizet V, Teasdale RD, et al. The globally disseminated M1T1 clone of group A *Streptococcus* evades autophagy for intracellular replication. *Cell Host Microbe* 2013; 14:675-82; <http://dx.doi.org/10.1016/j.chom.2013.11.003>.
2058. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. *Cell* 2011; 147:223-34; <http://dx.doi.org/10.1016/j.cell.2011.08.037>.
2059. Pietrocola F, Lachkar S, Enot DP, Niso-Santano M, Bravo-San Pedro JM, Sica V, Izzo V, Maiuri MC, Madeo F, Marino G, et al. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. *Cell Death Differ* 2015; 22:509-16.
2060. Ghidoni R, Houry JJ, Giuliani A, Ogier-Denis E, Parolari E, Botti S, Bauvy C, Codogno P. The metabolism of sphingo (glyco)lipids is correlated with the differentiation-dependent autophagic pathway in HT-29 cells. *Eur J Biochem* 1996; 237:454-9; <http://dx.doi.org/10.1111/j.1432-1033.1996.0454k.x>.
2061. Lavieu G, Scarlatti F, Sala G, Levade T, Ghidoni R, Botti J, Codogno P. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? *Autophagy* 2007; 3:45-7; <http://dx.doi.org/10.4161/15548627.2014.981913>.
2062. Rong Y, McPhee C, Deng S, Huang L, Chen L, Liu M, Tracy K, Baehrecke EH, Yu L, Lenardo MJ. Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. *Proc Natl Acad Sci USA* 2011; 108:7826-31; <http://dx.doi.org/10.1073/pnas.1013800108>.
2063. Chen Q, Yue F, Li W, Zou J, Xu T, Huang C, Zhang Y, Song K, Huang G, Xu G, et al. Potassium Bisperoxo (1,10-phenanthroline) Oxovanadate (bpV(phen)) Induces Apoptosis and Pyroptosis and Disrupts the P62-HDAC6 Interaction to Suppress the Acetylated Microtubule-dependent Degradation of Autophagosomes. *J Biol Chem* 2015; 290:26051-8.
2064. Tambe Y, Yamamoto A, Isono T, Chano T, Fukuda M, Inoue H. The drs tumor suppressor is involved in the maturation process of autophagy induced by low serum. *Cancer Lett* 2009; 283:74-83; <http://dx.doi.org/10.1016/j.canlet.2009.03.028>.
2065. Mesquita FS, Thomas M, Sachse M, Santos AJ, Figueira R, Holden DW. The *Salmonella* deubiquitinase SseL inhibits selective autophagy of cytosolic aggregates. *PLoS Pathog* 2012; 8:e1002743; <http://dx.doi.org/10.1371/journal.ppat.1002743>.
2066. Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, Souquere S, Marino G, Lachkar S, Senovilla L, et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. *Mol Cell* 2012; 48:667-80; <http://dx.doi.org/10.1016/j.molcel.2012.09.013>.
2067. Wang CW. Stationary phase lipophagy as a cellular mechanism to recycle sterols during quiescence. *Autophagy* 2014; 10:2075-6; <http://dx.doi.org/10.4161/15548627.2014.981913>.
2068. Wang CW, Miao YH, Chang YS. A sterol-enriched vacuolar microdomain mediates stationary phase lipophagy in budding yeast. *J Cell Biol* 2014; 206:357-66; <http://dx.doi.org/10.1083/jcb.201404115>.
2069. Wilkinson DS, Jariwala JS, Anderson E, Mitra K, Meisenhelder J, Chang JT, Ideker T, Hunter T, Nizet V, Dillin A, et al. Phosphorylation of LC3 by the Hippo kinases STK3/STK4 is essential for autophagy. *Mol Cell* 2015; 57:55-68; <http://dx.doi.org/10.1016/j.molcel.2014.11.019>.
2070. Maejima Y, Kyoi S, Zhai P, Liu T, Li H, Ivessa A, Sciarretta S, Del Re DP, Zablocki DK, Hsu CP, et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. *Nat Med* 2013; 19:1478-88; <http://dx.doi.org/10.1038/nm.3322>.
2071. Renna M, Schaffner C, Winslow AR, Menzies FM, Peden AA, Floto RA, Rubinsztein DC. Autophagic substrate clearance requires activity of the syntaxin-5 SNARE complex. *J Cell Sci* 2011; 124:469-82; <http://dx.doi.org/10.1242/jcs.076489>.
2072. Lu Y, Zhang Z, Sun D, Sweeney ST, Gao FB. Syntaxin 13, a genetic modifier of mutant CHMP2B in frontotemporal dementia, is required for autophagosome maturation. *Mol Cell* 2013; 52:264-71; <http://dx.doi.org/10.1016/j.molcel.2013.08.041>.
2073. Hamasaki M, Furuta N, Matsuda A, Nezu A, Yamamoto A, Fujita N, Oomori H, Noda T, Haraguchi T, Hiraoka Y, et al. Autophagosomes form at ER-mitochondria contact sites. *Nature* 2013; 495:389-93; <http://dx.doi.org/10.1038/nature11910>.
2074. Webber JL, Tooze SA. Coordinated regulation of autophagy by p38 {alpha} MAPK through mAtg9 and p38IP. *EMBO J* 2010; 29:27-40; <http://dx.doi.org/10.1038/emboj.2009.321>.

2075. Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, et al. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. *J Clin Endocrinol Metab* 2014; 99:498-509; <http://dx.doi.org/10.1210/jc.2013-2574>.
2076. Jackson DJ, Worheide G. Symbiophagy and biomineralization in the "living fossil" *Astrosclera willeyana*. *Autophagy* 2014; 10:408-15; <http://dx.doi.org/10.4161/auto.27319>.
2077. Criollo A, Niso-Santano M, Malik SA, Michaud M, Morselli E, Marino G, Lachkar S, Arkhipenko AV, Harper F, Pierron G, et al. Inhibition of autophagy by TAB2 and TAB3. *EMBO J* 2011; 30:4908-20; <http://dx.doi.org/10.1038/emboj.2011.413>.
2078. Takaesu G, Kobayashi T, Yoshimura A. TGFbeta-activated kinase 1 (TAK1)-binding proteins (TAB) 2 and 3 negatively regulate autophagy. *J Biochem* 2012; 151:157-66; <http://dx.doi.org/10.1093/jb/mvr123>.
2079. Nagahara Y, Takeyoshi M, Sakemoto S, Shiina I, Nakata K, Fujimori K, Wang Y, Umeda E, Watanabe C, Uetake S, et al. Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. *Biochem Biophys Res Comm* 2013; 435:657-63; <http://dx.doi.org/10.1016/j.bbrc.2013.05.040>.
2080. Bose JK, Huang CC, Shen CK. Regulation of autophagy by neuro-pathological protein TDP-43. *J Biol Chem* 2011; 286:44441-8; <http://dx.doi.org/10.1074/jbc.M111.237115>.
2081. Narita M, Young AR, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, Hong S, Berry LS, Reichelt S, Ferreira M, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. *Science* 2011; 332:966-70; <http://dx.doi.org/10.1126/science.1205407>.
2082. Newman AC, Scholefield CL, Kemp AJ, Newman M, McIver EG, Kamal A, Wilkinson S. TBK1 kinase addition in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-kappaB signalling. *PLoS One* 2012; 7:e50672; <http://dx.doi.org/10.1371/journal.pone.0050672>.
2083. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. *Mol Cell* 2012; 47:535-46; <http://dx.doi.org/10.1016/j.molcel.2012.06.009>.
2084. Alfaiz AA, Micale L, Mandriani B, Augello B, Pellico MT, Chrast J, Xenarios I, Zelante L, Merla G, Reymond A. TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. *Hum Mutat* 2014; 35:447-51; <http://dx.doi.org/10.1002/humu.22529>.
2085. Capo-Chichi JM, Tcherkezian J, Hamdan FF, Decarie JC, Dobrzniecka S, Patry L, Nadon MA, Mucha BE, Major P, Shevell M, et al. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. *J Med Genet* 2013; 50:740-4; <http://dx.doi.org/10.1136/jmedgenet-2013-101680>.
2086. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. *EMBO J* 1999; 18:6694-704; <http://dx.doi.org/10.1093/emboj/18.23.6694>.
2087. Neill T, Torres A, Buraschi S, Owens RT, Hoek JB, Baffa R, Iozzo RV. Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitostatin. *J Biol Chem* 2014; 289:4952-68; <http://dx.doi.org/10.1074/jbc.M113.512566>.
2088. Ogawa M, Yoshikawa Y, Kobayashi T, Mimuro H, Fukumatsu M, Kiga K, Piao Z, Ashida H, Yoshida M, Kakuta S, et al. A tecpr1-dependent selective autophagy pathway targets bacterial pathogens. *Cell Host Microbe* 2011; 9:376-89; <http://dx.doi.org/10.1016/j.chom.2011.04.010>.
2089. Li L, Khatibi NH, Hu Q, Yan J, Chen C, Han J, Ma D, Chen Y, Zhou C. Transmembrane protein 166 regulates autophagic and apoptotic activities following focal cerebral ischemic injury in rats. *Exp Neurol* 2012; 234:181-90; <http://dx.doi.org/10.1016/j.expneurol.2011.12.038>.
2090. Oz-Levi D, Ben-Zeev B, Ruzzo EK, Hitomi Y, Gelman A, Pelak K, Anikster Y, Reznik-Wolf H, Bar-Joseph I, Olender T, et al. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. *Am J Hum Genet* 2012; 91:1065-72; <http://dx.doi.org/10.1016/j.ajhg.2012.09.015>.
2091. Oz-Levi D, Gelman A, Elazar Z, Lancet D. TECPR2: a new autophagy link for neurodegeneration. *Autophagy* 2013; 9:801-2; <http://dx.doi.org/10.4161/auto.23961>.
2092. D'Eletto M, Farrace MG, Falasca L, Reali V, Oliverio S, Melino G, Griffin M, Fimia GM, Piacentini M. Transglutaminase 2 is involved in autophagosome maturation. *Autophagy* 2009; 5:1145-54; <http://dx.doi.org/10.4161/auto.5.8.10040>.
2093. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, Vazquez P, Blazquez C, Torres S, Garcia S, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J Clin Invest* 2009; 119:1359-72; <http://dx.doi.org/10.1172/JCI37948>.
2094. Salazar M, Lorente M, Garcia-Taboada E, Hernandez-Tiedra S, Davila D, Francis SE, Guzman M, Kiss-Toth E, Velasco G. The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. *Biochim Biophys Acta* 2013; 1831:1573-8; <http://dx.doi.org/10.1016/j.bbailip.2013.03.014>.
2095. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 2012; 12:436-44; <http://dx.doi.org/10.1038/nrc3247>.
2096. Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. *EMBO J* 2009; 28:3015-26; <http://dx.doi.org/10.1038/emboj.2009.242>.
2097. Lok CN, Sy LK, Liu F, Che CM. Activation of autophagy of aggregation-prone ubiquitinated proteins by timosaponin A-III. *J Biol Chem* 2011; 286:31684-96; <http://dx.doi.org/10.1074/jbc.M110.202531>.
2098. He P, Peng Z, Luo Y, Wang L, Yu P, Deng W, An Y, Shi T, Ma D. High-throughput functional screening for autophagy-related genes and identification of TM9SF1 as an autophagosome-inducing gene. *Autophagy* 2009; 5:52-60; <http://dx.doi.org/10.4161/auto.5.1.7247>.
2099. Boada-Romero E, Letek M, Fleischer A, Pallauf K, Ramon-Barros C, Pimentel-Muinos FX. TMEM59 defines a novel ATG16L1-binding motif that promotes local activation of LC3. *EMBO J* 2013; 32:566-82; <http://dx.doi.org/10.1038/emboj.2013.8>.
2100. Shi CS, Kehrl JH. Traf6 and A20 differentially regulate TLR4-induced autophagy by affecting the ubiquitination of Beclin 1. *Autophagy* 2010; 6:986-7; <http://dx.doi.org/10.4161/auto.6.7.13288>.
2101. Matsuzawa Y, Oshima S, Takahara M, Maeyashiki C, Nemoto Y, Kobayashi M, Nibe Y, Nozaki K, Nagaishi T, Okamoto R, et al. TNFAIP3 promotes survival of CD4 T cells by restricting mTOR and promoting autophagy. *Autophagy* 2015; 11:1052-62; <http://dx.doi.org/10.1080/15548627.2015.1055439>.
2102. Jacinto E. What controls TOR? *IUBMB Life* 2008; 60:483-96; <http://dx.doi.org/10.1002/iub.56>.
2103. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 2009; 137:873-86; <http://dx.doi.org/10.1016/j.cell.2009.03.046>.
2104. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschlegel S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. *Biochem J* 2007; 405:513-22; <http://dx.doi.org/10.1042/BJ20070540>.
2105. Vlahakis A, Graef M, Nunnari J, Powers T. TOR complex 2-Ypk1 signaling is an essential positive regulator of the general amino acid control response and autophagy. *Proc Natl Acad Sci USA* 2014; 111:10586-91; <http://dx.doi.org/10.1073/pnas.1406305111>.
2106. Renna M, Bento CF, Fleming A, Menzies FM, Siddiqi FH, Ravikumar B, Puri C, Garcia-Arencibia M, Sadiq O, Corrochano S, et al. IGF-1 receptor antagonism inhibits autophagy. *Hum Mol Genet* 2013; 22:4528-44; <http://dx.doi.org/10.1093/hmg/ddt300>.



2107. Arias E, Koga H, Diaz A, Mocholi E, Patel B, Cuervo AM. Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy. *Mol Cell* 2015; 59:270-84; <http://dx.doi.org/10.1016/j.molcel.2015.05.030>.
2108. N'Guessan P, Pouyet L, Gosset G, Hamlaoui S, Seillier M, Cano CE, Seux M, Stocker P, Culcasi M, Iovanna JL, et al. Absence of Tumor Suppressor Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) Sensitizes Mouse Thymocytes and Embryonic Fibroblasts to Redox-Driven Apoptosis. *Antioxid Redox Sign* 2011; 15:1639-53; <http://dx.doi.org/10.1089/ars.2010.3553>.
2109. Sancho A, Duran J, Garcia-Espana A, Mauvezin C, Alemu EA, Lamark T, Macias MJ, DeSalle R, Royo M, Sala D, et al. Absence of Tumor Suppressor Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) Sensitizes Mouse Thymocytes and Embryonic Fibroblasts to Redox-Driven Apoptosis. *PLoS One* 2012; 7:e34034; <http://dx.doi.org/10.1371/journal.pone.0034034>.
2110. Seillier M, Peugeot S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna JL, Dusetti NJ. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. *Cell Death Differ* 2012; 19:1525-35; <http://dx.doi.org/10.1038/cdd.2012.30>.
2111. Seillier M, Pouyet L, N'Guessan P, Nollet M, Capo F, Guillaumond F, Peyta L, Dumas JF, Varrault A, Bertrand G, et al. Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1. *EMBO Mol Med* 2015.
2112. Mauvezin C, Orpinell M, Francis VA, Mansilla F, Duran J, Ribas V, Palac[i]n M, Boya P, Teleman AA, Zorzano A. The nuclear cofactor DOR regulates autophagy in mammalian and *Drosophila* cells. *EMBO Rep* 2010; 11:37-44; <http://dx.doi.org/10.1038/embor.2009.242>.
2113. Nowak J, Archange C, Tardivel-Lacombe J, Pontarotti P, Pebusque MJ, Vaccaro MI, Velasco G, Dagorn JC, Iovanna JL. The TP53INP2 protein is required for autophagy in mammalian cells. *Mol Biol Cell* 2009; 20:870-81; <http://dx.doi.org/10.1091/mbc.E08-07-0671>.
2114. Sala D, Ivanova S, Plana N, Ribas V, Duran J, Bach D, Turkseven S, Laville M, Vidal H, Karczewska-Kupczewska M, et al. Autophagy-regulating TP53INP2 mediates muscle wasting and is repressed in diabetes. *J Clin Invest* 2014; 124:1914-27; <http://dx.doi.org/10.1172/JCI72327>.
2115. Cang C, Zhou Y, Navarro B, Seo YJ, Aranda K, Shi L, Battaglia-Hsu S, Nissim I, Clapham DE, Ren D. mTOR regulates lysosomal ATP-sensitive two-pore Na<sup>+</sup> channels to adapt to metabolic state. *Cell* 2013; 152:778-90; <http://dx.doi.org/10.1016/j.cell.2013.01.023>.
2116. Lin PH, Duann P, Komazaki S, Park KH, Li H, Sun M, Sermersheim M, Gumpfer K, Parrington J, Galione A, et al. Lysosomal two-pore channel subtype 2 (TPC2) regulates skeletal muscle autophagic signaling. *J Biol Chem* 2015; 290:3377-89; <http://dx.doi.org/10.1074/jbc.M114.608471>.
2117. Funasaka T, Tsuka E, Wong RW. Regulation of autophagy by nucleoporin Tpr. *Sci Rep* 2012; 2:878; <http://dx.doi.org/10.1038/srep00878>.
2118. Zou S, Chen Y, Liu Y, Segev N, Yu S, Liu Y, Min G, Ye M, Zeng Y, Zhu X, et al. Trs130 participates in autophagy through GTPases Ypt31/32 in *Saccharomyces cerevisiae*. *Traffic* 2013; 14:233-46; <http://dx.doi.org/10.1111/tra.12024>.
2119. Hua F, Li K, Yu JJ, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. *Nat Commun* 2015; 6:7951; <http://dx.doi.org/10.1038/ncomms8951>.
2120. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Egia A, Lorente M, Vazquez P, Torres S, Iovanna JL, Guzman M, et al. TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action. *Autophagy* 2009; 5:1048-9; <http://dx.doi.org/10.4161/auto.5.7.9508>.
2121. Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A, Ambrosio S. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. *Cancer Lett* 2012; 318:42-52; <http://dx.doi.org/10.1016/j.canlet.2011.11.036>.
2122. Micale L, Fusco C, Augello B, Napolitano LM, Dermitzakis ET, Meroni G, Merla G, Reymond A. Williams-Beuren syndrome TRIM50 encodes an E3 ubiquitin ligase. *Eur J Hum Genet* 2008; 16:1038-49; <http://dx.doi.org/10.1038/ejhg.2008.68>.
2123. Fusco C, Micale L, Augello B, Mandriani B, Pellico MT, De Nittis P, Calcagni A, Monti M, Cozzolino F, Pucci P, et al. HDAC6 mediates the acetylation of TRIM50. *Cell Signal* 2014; 26:363-9; <http://dx.doi.org/10.1016/j.cellsig.2013.11.036>.
2124. Fusco C, Micale L, Egorov M, Monti M, D'Addetta EV, Augello B, Cozzolino F, Calcagni A, Fontana A, Polishchuk RS, et al. The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome. *PLoS One* 2012; 7:e40440; <http://dx.doi.org/10.1371/journal.pone.0040440>.
2125. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* 2001; 294:1704-8; <http://dx.doi.org/10.1126/science.1065874>.
2126. Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, Bang ML, Trombitas K, Granzier H, Gregorio CC, et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. *J Mol Biol* 2001; 306:717-26; <http://dx.doi.org/10.1006/jmbi.2001.4448>.
2127. Gatliff J, East D, Crosby J, Abeti R, Harvey R, Craigen W, Parker P, Campanella M. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. *Autophagy* 2014; 10:2279-96; <http://dx.doi.org/10.4161/15548627.2014.991665>.
2128. Geisler S, Vollmer S, Golombek S, Kahle PJ. UBE2N, UBE2L3 and UBE2D2/3 ubiquitin-conjugating enzymes are essential for parkin-dependent mitophagy. *J Cell Sci* 2014; 127:3280-93; <http://dx.doi.org/10.1242/jcs.146035>.
2129. Fiesel FC, Moussaud-Lamodiere EL, Ando M, Springer W. A specific subset of E2 ubiquitin-conjugating enzymes regulate Parkin activation and mitophagy differently. *J Cell Sci* 2014; 127:3488-504; <http://dx.doi.org/10.1242/jcs.147520>.
2130. Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, Dugger D, Gordon N, Sidhu SS, Fellouse FA, et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. *Cell* 2008; 134:668-78; <http://dx.doi.org/10.1016/j.cell.2008.07.039>.
2131. Muller M, Kotter P, Behrendt C, Walter E, Scheckhuber CQ, Entian KD, Reichert AS. Synthetic quantitative array technology identifies the Ubp3-Bre5 deubiquitinase complex as a negative regulator of mitophagy. *Cell Rep* 2015; 10:1215-25; <http://dx.doi.org/10.1016/j.celrep.2015.01.044>.
2132. N'Diaye EN, Kajihara KK, Hsieh I, Morisaki H, Debnath J, Brown EJ. PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. *EMBO Rep* 2009; 10:173-9; <http://dx.doi.org/10.1038/embor.2008.238>.
2133. Chan EYW, Kir S, Tooze SA. siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. *J Biol Chem* 2007; 282:25464-74; <http://dx.doi.org/10.1074/jbc.M703663200>.
2134. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. *Curr Opin Cell Biol* 2010; 22:132-9; <http://dx.doi.org/10.1016/j.ccb.2009.12.004>.
2135. Dorsey FC, Rose KL, Coenen S, Prater SM, Cavett V, Cleveland JL, Caldwell-Busby J. Mapping the phosphorylation sites of Ulk1. *J Proteome Res* 2009; 8:5253-63; <http://dx.doi.org/10.1021/pr900583m>.
2136. Cornelissen T, Haddad D, Wauters F, Van Humbeeck C, Mandemakers W, Koentjoro B, Sue C, Gevaert K, De Strooper B, Verstreken P, et al. The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. *Hum Mol Genet* 2014; 23:5227-42.
2137. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, Foreman O, Kirkpatrick DS, Sheng M. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature* 2014; 510:370-5.
2138. Taillebourg E, Gregoire I, Viargues P, Jacomin AC, Thevenon D, Faure M, Fauvarque MO. The deubiquitinating enzyme USP36

- controls selective autophagy activation by ubiquitinated proteins. *Autophagy* 2012; 8:767-79; <http://dx.doi.org/10.4161/auto.19381>.
2139. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, Jung JU. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. *Nat Cell Biol* 2006; 8:688-99; <http://dx.doi.org/10.1038/ncb1426>.
2140. Kim YM, Jung CH, Seo M, Kim EK, Park JM, Bae SS, Kim DH. mTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation. *Mol Cell* 2015; 57:207-18; <http://dx.doi.org/10.1016/j.molcel.2014.11.013>.
2141. Munson MJ, Allen GF, Toth R, Campbell DG, Lucocq JM, Ganley IG. mTOR activates the VPS34-UVRAG complex to regulate autolysosomal tubulation and cell survival. *EMBO J* 2015.
2142. Pirooz SD, He S, Zhang T, Zhang X, Zhao Z, Oh S, O'Connell D, Khalilzadeh P, Amini-Bavil-Olyae S, Farzan M, et al. UVRAG is required for virus entry through combinatorial interaction with the class C-Vps complex and SNAREs. *Proc Natl Acad Sci USA* 2014; 111:2716-21; <http://dx.doi.org/10.1073/pnas.1320629111>.
2143. Kosta A, Roisin-Bouffay C, Luciani MF, Otto GP, Kessin RH, Golstein P. Autophagy gene disruption reveals a non-vacuolar cell death pathway in *Dictyostelium*. *J Biol Chem* 2004; 279:48404-9; <http://dx.doi.org/10.1074/jbc.M408924200>.
2144. Oku M, Nishimura T, Hattori T, Ano Y, Yamashita S, Sakai Y. Role of Vac8 in formation of the vacuolar sequestering membrane during micropexophagy. *Autophagy* 2006; 2:272-9; <http://dx.doi.org/10.4161/auto.3135>.
2145. Klionsky DJ, Herman PK, Emr SD. The fungal vacuole: composition, function, and biogenesis. *Microbiol Rev* 1990; 54:266-92.
2146. Hoffman M, Chiang H-L. Isolation of degradation-deficient mutants defective in the targeting of fructose-1,6-bisphosphatase into the vacuole for degradation in *Saccharomyces cerevisiae*. *Genetics* 1996; 143:1555-66.
2147. Zhang C, Lee S, Peng Y, Bunker E, Giaime E, Shen J, Zhou Z, Liu X. PINK1 triggers autocatalytic activation of Parkin to specify cell fate decisions. *Curr Biol* 2014; 24:1854-65; <http://dx.doi.org/10.1016/j.cub.2014.07.014>.
2148. Darsow T, Rieder SE, Emr SD. A multispecificity syntaxin homologue, Vam3p, essential for autophagic and biosynthetic protein transport to the vacuole. *J Cell Biol* 1997; 138:517-29; <http://dx.doi.org/10.1083/jcb.138.3.517>.
2149. Fader CM, Sanchez DG, Mestre MB, Colombo MI. TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. *Biochim Biophys Acta* 2009; 1793:1901-16; <http://dx.doi.org/10.1016/j.bbamcr.2009.09.011>.
2150. Moreau K, Ravikumar B, Renna M, Puri C, Rubinsztein DC. Autophagosome precursor maturation requires homotypic fusion. *Cell* 2011; 146:303-17; <http://dx.doi.org/10.1016/j.cell.2011.06.023>.
2151. Furuta N, Fujita N, Noda T, Yoshimori T, Amano A. Combinational soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins VAMP8 and Vti1b mediate fusion of antimicrobial and canonical autophagosomes with lysosomes. *Mol Biol Cell* 2010; 21:1001-10; <http://dx.doi.org/10.1091/mbc.E09-08-0693>.
2152. Ju JS, Fuentealba RA, Miller SE, Jackson E, Pivnicka-Worms D, Baloh RH, Wehl CC. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. *J Cell Biol* 2009; 187:875-88; <http://dx.doi.org/10.1083/jcb.200908115>.
2153. Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, Yao TP, Dantuma NP, Taylor JP. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. *Autophagy* 2010; 6:217-27; <http://dx.doi.org/10.4161/auto.6.2.11014>.
2154. Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN, Roberge M. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. *J Biol Chem* 2011; 286:7290-300; <http://dx.doi.org/10.1074/jbc.M110.139915>.
2155. Kaelin WG, Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nat Rev Cancer* 2008; 8:865-73; <http://dx.doi.org/10.1038/nrc2502>.
2156. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasaki C. Escape of intracellular *Shigella* from autophagy. *Science* 2005; 307:727-31; <http://dx.doi.org/10.1126/science.1106036>.
2157. Vaccaro MI, Ropolo A, Grasso D, Iovanna JL. A novel mammalian trans-membrane protein reveals an alternative initiation pathway for autophagy. *Autophagy* 2008; 4:388-90; <http://dx.doi.org/10.4161/auto.5656>.
2158. Calvo-Garrido J, King JS, Munoz-Braceras S, Escalante R. Vmp1 regulates PtdIns3P signaling during autophagosome formation in *Dictyostelium discoideum*. *Traffic* 2014; 15:1235-46; <http://dx.doi.org/10.1111/tra.12210>.
2159. Molejon MI, Ropolo A, Re AL, Boggio V, Vaccaro MI. The VMP1-Beclin 1 interaction regulates autophagy induction. *Sci Rep* 2013; 3:1055; <http://dx.doi.org/10.1038/srep01055>.
2160. Balderhaar HJ, Ungermann C. CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion. *J Cell Sci* 2013; 126:1307-16; <http://dx.doi.org/10.1242/jcs.107805>.
2161. Nickerson DP, Brett CL, Merz AJ. Vps-C complexes: gatekeepers of endolysosomal traffic. *Curr Opin Cell Biol* 2009; 21:543-51; <http://dx.doi.org/10.1016/j.ccb.2009.05.007>.
2162. Clancey LF, Beirl AJ, Linbo TH, Cooper CD. Maintenance of melanophore morphology and survival is cathepsin and vps11 dependent in zebrafish. *PLoS One* 2013; 8:e65096.
2163. Uttenweiler A, Schwarz H, Neumann H, Mayer A. The vacuolar transporter chaperone (VTC) complex is required for microautophagy. *Mol Biol Cell* 2007; 18:166-75; <http://dx.doi.org/10.1091/mbc.E06-08-0664>.
2164. Simonsen A, Birkeland HC, Gillooly DJ, Mizushima N, Kuma A, Yoshimori T, Slagsvold T, Brech A, Stenmark H. Alfyl, a novel FYVE-domain-containing protein associated with protein granules and autophagic membranes. *J Cell Sci* 2004; 117:4239-51; <http://dx.doi.org/10.1242/jcs.01287>.
2165. Filimonenko M, Isakson P, Finley KD, Anderson M, Jeong H, Melia TJ, Bartlett BJ, Myers KM, Birkeland HC, Lamark T, et al. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfyl. *Mol Cell* 2010; 38:265-79; <http://dx.doi.org/10.1016/j.molcel.2010.04.007>.
2166. Clausen TH, Lamark T, Isakson P, Finley K, Larsen KB, Brech A, Overvatn A, Stenmark H, Bjorkoy G, Simonsen A, et al. p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy. *Autophagy* 2010; 6:330-44; <http://dx.doi.org/10.4161/auto.6.3.11226>.
2167. Kast DJ, Zajac AL, Holzbaur EL, Ostap EM, Dominguez R. WHAMM Directs the Arp2/3 Complex to the ER for Autophagosome Biogenesis through an Actin Comet Tail Mechanism. *Curr Biol* 2015; 25:1791-7; <http://dx.doi.org/10.1016/j.cub.2015.05.042>.
2168. Haack TB, Hogarth P, Krueger MC, Gregory A, Wieland T, Schwarzmayr T, Graf E, Sanford L, Meyer E, Kara E, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. *Am J Hum Genet* 2012; 91:1144-9; <http://dx.doi.org/10.1016/j.ajhg.2012.10.019>.
2169. Abidi A, Mignion-Ravix C, Cacciagli P, Girard N, Milh M, Villard L. Early-onset epileptic encephalopathy as the initial clinical presentation of WDR45 deletion in a male patient. *Eur J Hum Genet* 2015.
2170. Saitsu H, Nishimura T, Muramatsu K, Kodera H, Kumada S, Sugai K, Kasai-Yoshida E, Sawaura N, Nishida H, Hoshino A, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat Genet* 2013; 45:445-9, 9e1; <http://dx.doi.org/10.1038/ng.2562>.
2171. Biagosch CA, Hensler S, Kühn R, Meitinger T, Prokisch HT. ALEN-mediated mutagenesis as a tool to generate disease models for diseases caused by dominant de novo mutations. *Eur J Hum Genet* 2014; 22:153.
2172. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. *Expert Opin Ther Tar* 2012; 16:1203-14; <http://dx.doi.org/10.1517/14728222.2012.719499>.
2173. Petherick KJ, Williams AC, Lane JD, Ordóñez-Moran P, Huelsken J, Collard TJ, Smartt HJ, Batson J, Malik K, Paraskeva C, et al. Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62

- crosstalk. *EMBO J* 2013; 32:1903-16; <http://dx.doi.org/10.1038/emboj.2013.123>.
2174. Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. *Semin Immunol* 2009; 21:156-63; <http://dx.doi.org/10.1016/j.smim.2009.01.001>.
2175. Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. *Cell* 2005; 120:159-62.
2176. Criollo A, Maiuri MC, Tasdemir E, Vitale I, Fiebig AA, Andrews D, Molgo J, Diaz J, Lavandro S, Harper F, et al. Regulation of autophagy by the inositol trisphosphate receptor. *Cell Death Differ* 2007; 14:1029-39.
2177. Kweon Y, Rothe A, Conibear E, Stevens TH. Ykt6p is a multifunctional yeast R-SNARE that is required for multiple membrane transport pathways to the vacuole. *Mol Biol Cell* 2003; 14:1868-81; <http://dx.doi.org/10.1091/mbc.E02-10-0687>.
2178. Cebollero E, van der Vaart A, Zhao M, Rieter E, Klionsky DJ, Helms JB, Reggiori F. Phosphatidylinositol-3-phosphate clearance plays a key role in autophagosome completion. *Curr Biol* 2012; 22:1545-53; <http://dx.doi.org/10.1016/j.cub.2012.06.029>.
2179. Cheng J, Fujita A, Yamamoto H, Tatematsu T, Kakuta S, Obara K, Ohsumi Y, Fujimoto T. Yeast and mammalian autophagosomes exhibit distinct phosphatidylinositol 3-phosphate asymmetries. *Nat Commun* 2014; 5:3207.
2180. Huang J, Birmingham CL, Shahnazari S, Shiu J, Zheng YT, Smith AC, Campellone KG, Heo WD, Gruenheid S, Meyer T, et al. Antibacterial autophagy occurs at PI(3)P-enriched domains of the endoplasmic reticulum and requires Rab1 GTPase. *Autophagy* 2011; 7:17-26; <http://dx.doi.org/10.4161/auto.7.1.13840>.
2181. Zoppino FC, Militello RD, Slavin I, Alvarez C, Colombo MI. Autophagosome formation depends on the small GTPase Rab1 and functional ER exit sites. *Traffic* 2010; 11:1246-61; <http://dx.doi.org/10.1111/j.1600-0854.2010.01086.x>.
2182. Pozuelo-Rubio M. Regulation of autophagic activity by 14-3-3zeta proteins associated with class III phosphatidylinositol-3-kinase. *Cell Death Differ* 2011; 18:479-92; <http://dx.doi.org/10.1038/cdd.2010.118>.
2183. Vantaggiato C, Crimella C, Airolidi G, Polishchuk R, Bonato S, Brighina E, Scarlato M, Musumeci O, Toscano A, Martinuzzi A, et al. Defective autophagy in spastizin mutated patients with hereditary spastic paraparesis type 15. *Brain* 2013; 136:3119-39; <http://dx.doi.org/10.1093/brain/awt227>.
2184. Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, Chen HE, Hwang TI. Zoledronic acid induces autophagic cell death in human prostate cancer cells. *J Urol* 2011; 185:1490-6; <http://dx.doi.org/10.1016/j.juro.2010.11.045>.
2185. Schneider EM, Lorezn M, Walther P. Autophagy as a hallmark of hemophagocytic diseases In: Gorbunov N, ed. *Autophagy: Principles, Regulation and Roles in Disease*: Nova Science Publishers, 2012.
2186. Ryhanen T, Hyttinen JM, Kopitz J, Rilla K, Kuusisto E, Mannermaa E, Viiri J, Holmberg CI, Immonen I, Meri S, et al. Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagy-mediated proteolysis in human retinal pigment epithelial cells. *J Cell Mol Med* 2009; 13:3616-31; <http://dx.doi.org/10.1111/j.1582-4934.2008.00577.x>.
2187. Amadoro G, Corsetti V, Florenzano F, Atlante A, Bobba A, Nicolin V, Nori SL, Calissano P. Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink-parkin pathway. *Front Aging Neurosci* 2014; 6:18; <http://dx.doi.org/10.3389/fnagi.2014.00018>.

## Glossary

**3-MA (3-methyladenine)**: An inhibitor of class I PI3K and class III PtdIns3K, which results in macroautophagy inhibition due to suppression of class III PtdIns3K,<sup>329</sup> but may under some conditions show the opposite effect.<sup>330</sup> At concentrations >10 mM 3-MA inhibits other kinases such as AKT (Ser473), MAPK/p38 (Thr180/Tyr182) and MAPK/JNK (Thr183/Tyr185).<sup>1534</sup>

**11'-deoxyverticillin A (C42)**: An epipolythiodioxopiperazine fungal secondary metabolite that is used as an anticancer drug; it triggers apoptotic and necrotic cell death, and enhances macroautophagy through the action of PARP1 and RIPK1.<sup>1535</sup>

**12-ylation**: The modification of substrates by covalent conjugation to ATG12, first used to describe the autocatalytic conjugation of ATG12 to ATG3.<sup>1536</sup>

**14-3-3ζ**: See YWHAZ.

**ABT737**: A BH3 mimetic that competitively disrupts the interaction between BECN1 and BCL2 or BCL2L1, thus inducing macroautophagy.<sup>1537</sup> It should be noted, however, that by its inhibitory action on the anti-apoptotic BCL2 family members, ABT737 also leads to apoptosis.<sup>1538</sup>

**ACBD5 (acyl-CoA binding domain containing 5)**: ACBD5 is the human ortholog of fungal Atg37; it is a peroxisomal protein that is required for peroxophagy.<sup>345,1539</sup> See also Atg37.

**Acetyl-coenzyme A**: A central energy metabolite that represses macroautophagy if present in the cytosol.<sup>1540,1541</sup>

**Acinus**: A protein that in *Drosophila* regulates both endocytosis and macroautophagy; the *acn* mutant is defective in autophagosome maturation, whereas stabilization of endogenous Acn by mutation of its caspase cleavage site,<sup>1542</sup> or overexpression of Acn leads to excessive macroautophagy.<sup>1543</sup> Note that

Acn can also induce DNA condensation or fragmentation after its activation by CASP3 in apoptotic cells.

**ActA**: A *L. monocytogenes* protein that recruits the Arp2/3 complex and other actin-associated components to the cell surface to evade recognition by xenophagy; this effect is independent of bacterial motility.<sup>1544</sup>

**Adaptophagy**: Selective degradation of signaling adaptors downstream of TLRs or similar types of receptor families.<sup>1545</sup>

**ADNP (activity-dependent neuroprotective homeobox)**: A protein that interacts with LC3B and shows an increased expression in lymphocytes from schizophrenia patients.<sup>1019</sup>

**AEG-1**: See MTDH.

**AEN/ISG20L1 (apoptosis-enhancing nuclease)**: A protein that localizes to nucleolar and perinucleolar regions of the nucleus, which regulates macroautophagy associated with genotoxic stress; transcription of *AEN* is regulated by TP53 family members.<sup>1546</sup>

**AGER/RAGE (advanced glycosylation end product-specific receptor)**: A member of the immunoglobulin gene superfamily that binds the HMGB1 (high mobility group box 1) chromatin binding protein.<sup>1547</sup> AGER overexpression enhances macroautophagy and reduces apoptosis. This can occur in response to ROS, resulting in the upregulation of macroautophagy and the concomitant downregulation of apoptosis, favoring tumor cell survival in response to anticancer treatments that increase ROS production.<sup>1548</sup> See also HMGB1.

**Aggrephagy**: The selective removal of aggregates by a macroautophagy-like process.<sup>731</sup>

**AGS3**: See GPSM1.

**Aggresome:** An aggregation of misfolded proteins formed by a highly regulated process mediated by HDAC6 or BAG3.<sup>1549,1550</sup> This process requires protein transport by a dynein motor and microtubule integrity. Aggresomes form at the microtubule-organizing center and are surrounded by a cage of the intermediate filament protein VIM/vimentin. Note that not all proteins that aggregate and form filaments like HTT or MAPT form aggresomes.

**AHA (L-azidohomoalanine):** An amino acid analog used for labeling newly synthesized protein and monitoring autophagic protein degradation.<sup>660</sup>

**AICAR (aminoimidazole-4-carboxamide riboside):** Cell permeable nucleotide analog that is an activator of AMPK; inhibits macroautophagy<sup>472</sup> through mechanisms that are not related to its effect on AMPK.<sup>483,1551</sup>

**AIM (Atg8-family interacting motif):** A short peptide motif that allows interaction with Atg8.<sup>1481</sup> See WXXL and LIR/LRS.

**AKT/PKB (v-akt murine thymoma viral oncogene homolog 1):** A serine/threonine kinase that negatively regulates macroautophagy in some cellular systems.

**Alfy:** See WDFY3.

**ALIS (aggresome-like induced structures):** These structures may function as protein storage compartments and are cleared by macroautophagy.<sup>315</sup> SQSTM1 may regulate their formation and macroautophagic degradation.<sup>317</sup> See also DALIS.

**Allophagy:** The selective degradation of sperm components by macroautophagy; this process occurs in *C. elegans*.<sup>739</sup>

**ALOX5 (arachidonate 5-lipoxygenase):** See lipoxygenases.

**ALOX15 (arachidonate 15-lipoxygenase):** See lipoxygenases.

**ALR:** See autophagic lysosome reformation.

**ALS2/alsin (amyotrophic lateral sclerosis 2 [juvenile]):** A guanine nucleotide exchange factor for the small GTPase RAB5 that regulates endosome and autophagosome fusion and trafficking; loss of ALS2 accounts for juvenile recessive amyotrophic lateral sclerosis, juvenile primary lateral sclerosis, and infantile-onset ascending hereditary spastic paralysis.<sup>1552,1553</sup>

**ALSFTD:** See C9orf72.

**AMBRA1 (autophagy/beclin-1 regulator 1):** A positive regulator of macroautophagy. AMBRA1 interacts with both BECN1 and ULK1, modulating their activity.<sup>488,501,1206</sup> Also, a role in both PARK2-dependent and -independent mitophagy has been described for AMBRA1.<sup>768</sup> AMBRA1 activity is regulated by dynamic interactions with DDB1 and TCEB2/Elongin B, the adaptor proteins of the E3 ubiquitin ligase complexes containing CUL4/Cullin 4 and CUL5, respectively.<sup>1554</sup> Finally, AMBRA1 is the macroautophagy adaptor linking this process to cell proliferation, by negatively regulating the oncogenic protein MYC through the latter's phosphorylation status.<sup>1555</sup>

**AMFR/gp78 (autocrine motility factor receptor, E3 ubiquitin protein ligase):** An ER-associated E3 ubiquitin ligase that degrades the MFN/mitofusin mitochondrial fusion proteins and induces mitophagy.<sup>1556</sup>

**Amiodarone:** An FDA-approved antiarrhythmic drug that induces macroautophagic flux via AMPK- and AKT-mediated MTOR inhibition.<sup>1557,1558</sup>

**Amphisome (AM):** Intermediate compartment formed by the fusion of an autophagosome with an endosome (this compartment can be considered a type of autophagic vacuole and may be equivalent to a late autophagosome, and as such has a single

limiting membrane); the amphisome has not yet fused with a lysosome.<sup>1559</sup> Amphisomes can also fuse with the plasma membrane to release the macroautophagic cargo (exosomal pathway). See also exophagy.

**AMPK (AMP-activated protein kinase):** A sensor of energy level that is activated by an increase in the AMP/ATP ratio via the STK11/LKB1 kinase. Phosphorylates the MTORC1 subunit RPTOR to cause induction of macroautophagy. AMPK also activates the TSC1/2 complex (thus inhibiting RHEB), and binds and directly phosphorylates (and activates) ULK1 as part of the ULK1 kinase complex, which includes ATG13, ATG101 and RB1CC1.<sup>477,478</sup> The yeast homolog of AMPK is Snf1.<sup>472,1560</sup> Conversely, ULK1 can phosphorylate AMPK through a negative feedback loop.<sup>496</sup> AMPK is a heterotrimeric enzyme composed of the PRKAA1/AMPK $\alpha$ 1 or PRKAA2/AMPK $\alpha$ 2 subunit, the PRKAB1/AMPK $\beta$ 1 or PRKAB2/AMPK $\beta$ 2 subunit and the PRKAG1/AMPK $\gamma$ 1, PRKAG2/AMPK $\gamma$ 2 or PRKAG3/AMPK $\gamma$  subunits.

**Ams1/ $\alpha$ -mannosidase:** A cargo of the Cvt pathway; Ams1 forms an oligomer in the cytosol similar to prApe1.

**AMSH1/3:** Two *Arabidopsis* deubiquitinating enzymes that have been linked to plant macroautophagy.<sup>1561,1562</sup>

**APC (activated protein C):** APC (PROC that has been activated by thrombin) modulates cardiac metabolism and augments macroautophagy in the ischemic heart by inducing the activation of AMPK in a mouse model of ischemia/reperfusion injury.<sup>1563</sup>

**Ape1 (aminopeptidase I):** A resident vacuolar hydrolase that can be delivered in its precursor form (prApe1) to the vacuole through either the cytoplasm-to-vacuole targeting (Cvt) pathway or macroautophagy, in vegetative or starvation conditions, respectively.<sup>128</sup> The propeptide of prApe1 is removed upon vacuolar delivery, providing a convenient way to monitor localization of the protein and the functioning of these pathways, although it must be noted that delivery involves a receptor and scaffold so that its transit involves a type of selective macroautophagy even in starvation conditions. See also Atg11, Atg19 and cytoplasm-to-vacuole targeting pathway.

**Ape1 complex/prApe1 complex:** A large protein complex comprised of multiple prApe1 dodecamers localized in the cytosol.<sup>131</sup>

**Ape4:** An aspartyl aminopeptidase that binds the Atg19 receptor and is transported to the vacuole through the Cvt pathway.<sup>1564</sup>

**APMA (autophagic macrophage activation):** A collection of macroautophagy-related processes in cells of the reticulo-endothelial system. APMA includes (1) convergence of phagocytosis and the macroautophagic machinery, (2) enhanced microbicidal properties of autolysosomes in comparison to standard phagolysosomes, (3) macroautophagic modulation of pathogen recognition receptor signaling, (4) cooperation between immunity-related GTPases and ATG proteins in attacking parasitophorous vacuoles, and (5) enhanced antigen presentation. APMA is thus recognized as a complex outcome of macroautophagy stimulation in macrophages, representing a unique composite process that brings about a heightened state of immunological activation.<sup>1565</sup>

**Appressorium:** A specialized infection structure produced by pathogenic fungi to rupture the outer layer of their host and gain entry to host cells. In plant pathogenic fungi, such as the rice blast fungus *M. oryzae*, formation of appressoria follows macroautophagy in conidia and recycling of the spore contents to the developing infection cell.<sup>275,1316</sup>

**ARD1:** See NAA10.

**Are1:** See Ayr1.

**Are2:** See Ayr1.

**ARRB1/ $\beta$ -arrestin-1 (arrestin, beta 1):** Members of the arrestin/beta-arrestin protein family are thought to participate in agonist-mediated desensitization of G-protein-coupled receptors and cause specific dampening of cellular responses to stimuli such as hormones, neurotransmitters, or sensory signals. ARRB1 is a cytosolic protein and acts as a cofactor in the ADRBK/BARK (adrenergic, beta, receptor kinase)-mediated desensitization of beta-adrenergic receptors. Besides the central nervous system, it is expressed at high levels in peripheral blood leukocytes, and thus the ADRBK/beta-arrestin system is thought to play a major role in regulating receptor-mediated immune functions. This protein plays a neuroprotective role in the context of cerebral ischemia through regulating BECN1-dependent autophagosome formation.<sup>1566</sup>

**ARHI:** See DIRAS3.

**ARN5187:** Lysosomotropic compound with dual inhibitory activity against the circadian regulator NR1D2/REV-ERB $\beta$  and autophagy. Although ARN5187 and chloroquine have similar lysosomotropic potency and are equivocal with regard to autophagy inhibition, ARN5187 has a significantly improved in vitro anticancer activity.<sup>1497</sup>

**ASB10 (ankyrin repeat and SOCS box containing 10):** The ASB family of proteins mediate ubiquitination of protein substrates via their SOCS box and as such have been implicated as negative regulators of cell signaling. ASB10 colocalizes with aggresome biomarkers and pre-autophagic structures and may form ALIS.<sup>1567</sup>

**ATF4 (activating transcription factor 4):** A transcription factor that is induced by hypoxia, amino acid starvation and ER stress, and is involved in the unfolded protein response, playing a critical role in stress adaptation; ATF4 binds to a cAMP response element binding site in the *LC3B* promoter, resulting in upregulation of *LC3B*,<sup>1568</sup> and also directs a macroautophagy gene transcriptional program in response to amino acid depletion and ER stress.<sup>408</sup>

**ATF5 (activating transcription factor 5):** A transcription factor that is upregulated by the BCR-ABL protein tyrosine kinase, a macroautophagy repressor, through the PI3K-AKT pathway that inhibits FOXO4, a repressor of *ATF5* transcription; one of the targets of ATF5 is MTOR.<sup>1569</sup>

**Atg (autophagy-related):** Abbreviation used for most of the components of the protein machinery that are involved in selective and nonselective macroautophagy and in selective microautophagy.<sup>1570</sup>

**ATG-11/EPG-7:** A scaffold protein mediating the macroautophagic degradation of the *C. elegans* SQSTM1 homolog SQST-1.<sup>1585</sup> ATG-11/EPG-7 interacts with SQST-1 and also with multiple ATG proteins. ATG-11/EPG-7 itself is degraded by macroautophagy.

**ATG-13/EPG-1:** The highly divergent homolog of Atg13 in *C. elegans*. ATG-13/EPG-1 directly interacts with the *C. elegans* Atg1 homolog UNC-51.<sup>1733</sup> See also Atg13.

**Atg1:** A serine/threonine protein kinase that functions in recruitment and release of other Atg proteins from the PAS.<sup>1571</sup> The functional homologs in higher eukaryotes are ULK1 and ULK2, and in *C. elegans* UNC-51.

**Atg2:** A protein that interacts with Atg18; in *atg2 $\Delta$*  mutant cells Atg9 accumulates primarily at the PAS.<sup>1572,1573</sup>

**Atg3:** A ubiquitin-conjugating enzyme (E2) analog that conjugates Atg8/LC3 to phosphatidylethanolamine (PE) after activation of the C-terminal residue by Atg7.<sup>1574,1575</sup> ATG3 can also be conjugated to ATG12 in higher eukaryotes.<sup>1536</sup> See also 12-ylation.


**Atg4:** A cysteine protease that processes Atg8/LC3 by removing the amino acid residue(s) that are located on the C-terminal side of what will become the ultimate glycine. Atg4 also removes PE from Atg8/LC3 in a step referred to as “deconjugation”.<sup>213</sup> Mammals have 4 ATG4 proteins (ATG4A to ATG4D), but ATG4B appears to be the most relevant for macroautophagy and has the broadest range of activity for all of the Atg8 homologs.<sup>172,1576</sup> See also deconjugation.

**Atg5:** A protein containing ubiquitin folds that is part of the Atg12–Atg5–Atg16 complex, which acts in part as an E3 ligase for Atg8/LC3–PE conjugation.<sup>1577</sup>

**Atg6:** See Vps30.

**Atg7:** A ubiquitin activating (E1) enzyme homolog that activates both Atg8/LC3 and Atg12 in an ATP-dependent process.<sup>1578,1579</sup>

**Atg8:** A ubiquitin-like protein that is conjugated to PE; involved in cargo recruitment into, and biogenesis of, autophagosomes. Autophagosomal size is regulated by the amount of Atg8.<sup>107</sup> Since Atg8 is selectively enclosed into autophagosomes, its breakdown allows measurement of the rate of macroautophagy. Mammals have several Atg8 homologs that are members of the LC3 and GABARAP subfamilies, which are also involved in autophagosome formation.<sup>142,148,600</sup> The *C. elegans* homologs are LGG-1 and LGG-2.




**Atg9:** A transmembrane protein that may act as a lipid carrier for expansion of the phagophore. In mammalian cells, ATG9A localizes to the *trans*-Golgi network and endosomes, whereas in fungi this protein localizes in part to peripheral sites (termed Atg9 reservoirs or tubulovesicular clusters) that are localized near the mitochondria, and to the PAS.<sup>536,1580</sup> Whereas mammalian ATG9A is ubiquitously expressed, ATG9B is almost exclusively expressed in the placenta and pituitary gland.<sup>1581</sup>

**Atg9 peripheral sites/structures:** In yeast, these are peri-mitochondrial sites where Atg9 localizes, which are distinct from the phagophore assembly site.<sup>536,537</sup> The Atg9 peripheral sites may be the precursors of the phagophore.

**Atg10:** A ubiquitin conjugating (E2) enzyme analog that conjugates Atg12 to Atg5.<sup>1582</sup>

**Atg11:** A scaffold protein that acts in selective types of macroautophagy including the Cvt pathway, mitophagy and pexophagy. Atg11 binds Atg19, *Pichia pastoris* Atg30 (PpAtg30) and Atg32 as part of its role in specific cargo recognition. It also binds Atg9 and is needed for its movement to the PAS.<sup>1583</sup> Atg11 in conjunction with receptor-bound targets may activate Atg1 kinase activity during selective macroautophagy.<sup>1584</sup> Homologs of Atg11 include RB1CC1 in mammals (although RB1CC1 does not appear to function as an Atg11 ortholog), ATG-11/EPG-7 in *C. elegans*,<sup>1585</sup> and ATG11 in *Arabidopsis*.<sup>1586</sup>



**Atg12:** A ubiquitin-like protein that modifies an internal lysine of Atg5 by covalently binding via its C-terminal glycine.<sup>1577</sup> In mouse and human cells, ATG12 also forms a covalent bond with ATG3, and this conjugation event plays a role in mitochondrial homeostasis.<sup>1536</sup> The *C. elegans* homolog is LGG-3.


**Atg13:** A component of the Atg1 complex that is needed for Atg1 kinase activity. Atg13 is highly phosphorylated in a PKA- and TOR-dependent manner in rich medium conditions. During starvation-induced macroautophagy in yeast, Atg13 is partially dephosphorylated. In mammalian cells, at least MTOR and ULK1 phosphorylate ATG13. The decreased phosphorylation of Atg13/ATG13 that results from TOR/MTOR inhibition is partly offset in terms of the change in molecular mass by the ULK1-dependent phosphorylation that occurs upon ULK1 activation.<sup>505,1587</sup> The *C. elegans* ortholog is ATG-13/EPG-1.

**Atg14:** A component of the class III PtdIns3K complex that is necessary for the complex to function in macroautophagy.<sup>1588</sup> Also known as ATG14/ATG14L/BARKOR in mammals,<sup>548</sup> or EPG-8 in *C. elegans*.<sup>1269</sup>

**Atg15:** A yeast vacuolar protein that contains a lipase/esterase active site motif and is needed for the breakdown of autophagic and Cvt bodies within the vacuole lumen (as well as MVB-derived and other subvacuolar vesicles) and the turnover of lipid droplets.<sup>1589-1591</sup>

**Atg16:** A component of the Atg12-Atg5-Atg16 complex. Atg16 dimerizes to form a large complex.<sup>1592</sup> There are 2 mammalian homologs, ATG16L1 and ATG16L2; mutations in either of the corresponding genes correspond to risk alleles associated with Crohn disease.<sup>1593,1594</sup>

**Atg17:** A yeast protein that is part of the Atg1 kinase complex. Atg17 is not essential for macroautophagy, but modulates the magnitude of the response; smaller autophagosomes are formed in the absence of Atg17.<sup>106,503</sup> In yeast, Atg17 exists as part of a stable ternary complex that includes Atg31 and Atg29; this complex functions as a dimer.<sup>1595-1597</sup> The functional counterpart of this complex in mammalian cells may be RB1CC1.



**Atg18:** A yeast protein that binds to PtdIns3P (and PtdIns[3,5]P<sub>2</sub>) via its WD40  $\beta$ -propeller domain. Atg18 interacts with Atg2, and in *atg18* $\Delta$  cells Atg9 accumulates primarily at the PAS. Atg18 has additional nonautophagic functions, such as in retrograde transport from the vacuole to the Golgi complex, and in the regulation of PtdIns(3,5)P<sub>2</sub> synthesis; the latter function affects the vacuole's role in osmoregulation.<sup>553</sup> See also WIPI.

**Atg19:** A receptor for the Cvt pathway that binds Atg11, Atg8 and the propeptide of precursor aminopeptidase I. Atg19 is also a receptor for Ams1/ $\alpha$ -mannosidase, another Cvt pathway cargo.<sup>1598,1599</sup>

**Atg20/Snx42:** A yeast PtdIns3P-binding sorting nexin that is part of the Atg1 kinase complex and associates with Snx4/Atg24.<sup>1600</sup> Atg20 is a PX-BAR domain-containing protein involved in pexophagy. *M. oryzae* Snx41 (MoSnx41) is homologous to both yeast Atg20 and Snx41, and carries out functions in both pexophagy and nonautophagy vesicular trafficking.<sup>1601</sup>

**Atg21:** A yeast PtdIns3P binding protein that is a homolog of, and partially redundant with, Atg18.<sup>335</sup> See also WIPI.

**Atg22:** A yeast vacuolar amino acid permease that is required for efflux after autophagic breakdown of proteins.<sup>1602,1603</sup>

**Atg23:** A yeast peripheral membrane protein that associates and transits with Atg9.<sup>538,1604,1605</sup>

**Atg24:** See Snx4.

**Atg25:** A coiled-coil protein required for macropexophagy in *H. polymorpha*.<sup>1606</sup>

**Atg26:** A sterol glucosyltransferase that is required for micro- and macropexophagy in *P. pastoris*, but not in *S. cerevisiae*.<sup>1607,1608</sup>

**Atg27:** A yeast integral membrane protein that is required for the movement of Atg9 to the PAS; the absence of Atg27 results in a reduced number of autophagosomes under autophagy-inducing conditions.<sup>1609</sup>

**Atg28:** A coiled-coil protein involved in micro- and macropexophagy in *P. pastoris*.<sup>1610</sup>

**Atg29:** A yeast protein required for efficient nonselective macroautophagy in fungi. Part of the yeast Atg17-Atg31-Atg29 complex that functions at the PAS for protein recruitment and initiation of phagophore formation.<sup>1595-1597,1611</sup>

**Atg30:** A protein required for the recognition of peroxisomes during micro- and macropexophagy in *P. pastoris*. It binds the peroxin PpPex14 and the selective autophagy receptor protein PpAtg11.<sup>708</sup>

**Atg31:** A yeast protein required for nonselective macroautophagy in fungi. Part of the yeast Atg17-Atg31-Atg29 complex that functions at the PAS for protein recruitment and initiation of phagophore formation.<sup>1595-1597,1612</sup>

**Atg32:** A mitochondrial outer membrane protein that is required for mitophagy in yeast. Atg32 binds Atg8 and Atg11

preferentially during mitophagy-inducing conditions.<sup>687,688</sup> See also BCL2L13.

**Atg33:** A mitochondrial outer membrane protein that is required for mitophagy in yeast.<sup>686</sup>

**Atg34:** A protein that functions as a receptor for import of Ams1/ $\alpha$ -mannosidase during macroautophagy (i.e., under starvation conditions) in yeast.<sup>1613</sup> This protein was initially referred to as Atg19-B based on predictions from in silico studies.<sup>1614</sup>

**Atg35:** The Atg35 protein relocates to the peri-nuclear structure and specifically regulates MIPA formation during micropexophagy; the *atg35* $\Delta$  mutant is able to form pexophagosomes during macropexophagy.<sup>1615</sup>

**Atg36:** Atg36 is a pexophagy receptor, which localizes to the membrane of peroxisomes in *S. cerevisiae*. Atg36 binds Atg8 and the scaffold protein Atg11 that links receptors for selective types of autophagy to the core autophagy machinery.<sup>1616</sup>

**Atg37:** Atg37 is a conserved acyl-CoA-binding protein that is required specifically for pexophagy in *P. pastoris* at the stage of phagophore formation.<sup>345</sup> See also ACBD5.

**Atg38:** Atg38 physically interacts with Atg14 and Vps34 via its N terminus. Atg38 is required for macroautophagy as an integral component of the PtdIns3K complex I in yeast, and Atg38 functions as a linker connecting the Vps15-Vps34 and Vps30/Atg6-Atg14 subcomplexes to facilitate complex I formation.<sup>1617</sup>

**Atg39:** A receptor for selective macroautophagic degradation of nuclear membrane in yeast.<sup>839</sup>

**Atg40:** A receptor that functions in yeast reticulophagy.<sup>839</sup> See also FAM134B.

**Atg41:** A protein that interacts with Atg9 and is needed for efficient Atg9 movement to the PAS in yeast.<sup>1955</sup>

**ATG101:** An ATG13-binding protein conserved in various eukaryotes but not in *S. cerevisiae*. Forms a stable complex with ULK1/2-ATG13-RB1CC1 (i.e., not nutrient-dependent) required for macroautophagy and localizes to the phagophore.<sup>1618,1619</sup> The *C. elegans* homolog is EPG-9.

**ATI1/2 (ATG8-interacting protein 1/2):** Two closely related ATG8-binding proteins in *Arabidopsis*, which are unique to plants and define a stress-induced and ER-associated compartment that may function in a direct, Golgi-independent, ER-to-vacuole trafficking pathway.<sup>1620</sup> ATI1 is also found in plastids following abiotic stress where it interacts with both ATG8 and plastid-localized proteins to act in their delivery to the central vacuole in an ATG5-dependent manner.<sup>801</sup>

**ATM (ATM serine/threonine kinase):** A protein kinase that activates TSC2 via the STK11/LKB1-AMPK cascade in response to elevated ROS, resulting in inhibition of mTOR and activation of macroautophagy.<sup>774</sup>

**ATP13A2 (ATPase type 13A2):** A transmembrane lysosomal type 5 P-type ATPase that is mutated in recessive familial atypical parkinsonism, with effects on lysosomal function.<sup>1621</sup> Loss of ATP13A2 function inhibits the clearance of dysfunctional mitochondria.<sup>1622</sup>

**ats-1 (Anaplasma translocated substrate-1):** A type IV secretion effector of the obligatory intracellular bacterium *Anaplasma phagocytophilum* that binds BECN1 and induces autophagosome formation; the autophagosomes traffic to, and fuse with, *A. phagocytophilum*-containing vacuoles, delivering macroautophagic cargoes into the vacuole, which can serve as nutrients for bacterial growth.<sup>1623,1624</sup>

**ATRA (all-trans retinoic acid):** A signaling molecule derived from vitamin A that activates macroautophagy and cell differentiation as demonstrated in leukemia cells.<sup>413,1625,1626</sup>

**AtTSPO (Arabidopsis thaliana TSPO-related):** An ER- and Golgi-localized polytopic membrane protein transiently induced by abiotic stresses. AtTSPO binds ATG8 and heme in vivo and may be involved in scavenging of cytosolic porphyrins through selective macroautophagy.<sup>1627</sup>

**AUTEN-67 (autophagy enhancer-67):** An inhibitor of MTMR14, which enhances macroautophagy.<sup>1628</sup>

**Autophagic lysosome reformation (ALR):** A self-regulating tubulation process in which the macroautophagic generation of nutrients reactivates mTOR, suppresses macroautophagy and allows for the regeneration of lysosomes that were consumed as autolysosomes.<sup>527</sup> See also autolysosome.

**Autolysosome (AL):** A degradative compartment formed by the fusion of an autophagosome (or initial autophagic vacuole/AVi) or amphisome with a lysosome (also called degradative autophagic vacuole/AVd). Upon completion of degradation the autolysosome can become a residual body,<sup>1559,1629</sup> or the autolysosomal membrane can be recycled to generate mature lysosomes during macroautophagic flux. This regenerative process, referred to as autophagic lysosome reformation, relies on the scission of extruded autolysosomal membrane tubules by the mechanoenzyme DNM2 (dynamin 2).<sup>527,1630</sup>

**Autophagic body (AB):** The inner membrane-bound structure of the autophagosome that is released into the vacuolar lumen following fusion of the autophagosome with the vacuole limiting membrane. In *S. cerevisiae*, autophagic bodies can be stabilized by the addition of the proteinase B inhibitor PMSF to the medium or by the deletion of the *PEP4* or *ATG15* genes. Visualization of the accumulating autophagic bodies by differential interference contrast using light microscopy is a convenient, but not easily quantified, method to follow macroautophagy.<sup>93</sup>

**Autophagic cell death:** A historically ambiguous term describing cell death with morphological features of increased autophagic vacuoles. This term is best reserved for cell death contexts in which specific molecular methods, rather than only pharmacological or correlative methods, are used to demonstrate increased cell survival following inhibition of macroautophagy.

**Autophagic stress:** A pathological situation in which induction of autophagy exceeds the cellular capacity to complete lysosomal degradation and recycling of constituents; may involve a combination of bioenergetics, acidification and microtubule-dependent trafficking deficits, to which neurons may be particularly vulnerable.<sup>15</sup>

**Autophagic vacuole:** A term typically used for mammalian cells that collectively refers to autophagic structures at all stages of maturation. We recommend using this term when the specific identity of autophagosomes, amphisomes and autolysosomes are not distinguished.

**AutophagamiR:** A term to describe miRNAs that function in the regulation of macroautophagy.<sup>1631</sup>

**Autophagist:** A researcher working in the field of autophagy.

**Autophagolysosome (APL):** A degradative compartment formed by the fusion of an LC3-containing phagosome (see

LAP) or an autophagosome that has sequestered a partial or complete phagosome with a lysosome. In contrast to a phagolysosome, formation of the autophagolysosome involves components of the macroautophagic machinery. Note that this term is not interchangeable with “autophagosome” or “autolysosome”.<sup>884</sup>

**Autophagoproteasome (APP):** A cytosolic membrane-bound compartment denoted by a limiting single, double or multiple membrane, which contains both LC3 and UPS antigens. The autophagoproteasome may be derived from the inclusion of ubiquitin-proteasome structures within either early or late autophagosomes containing cytoplasmic material at various stages of degradation.<sup>73</sup>

**Autophagosome (AP):** A cytosolic membrane-bound compartment denoted by a limiting double membrane (also referred to as initial autophagic vacuole, AVi, or early autophagosome). The early autophagosome contains cytoplasmic inclusions and organelles that are morphologically unchanged because the compartment has not fused with a lysosome and lacks proteolytic enzymes. Notably, the double-membrane structure may not be apparent with certain types of fixatives. Although in most cases the term autophagosome refers to a double-membrane compartment, the late autophagosome may also appear to have a single membrane (also referred to as an intermediate or intermediate/degradative autophagic vacuole, AVi/d).<sup>1559,1629</sup>

**Autophagy:** This term summarizes all processes in which intracellular material is degraded within the lysosome/vacuole and where the macromolecular constituents are recycled.

**Autophagy:** A journal devoted to research in the field of autophagy (<http://www.tandfonline.com/toc/kaup20/current#.VdzKoHjN5xu>).

**Autophagy adaptor:** A LIR-containing protein that is not itself a cargo for macroautophagy.

**Autophagy receptor:** A LIR/AIM-containing protein that targets specific cargo for degradation and itself becomes degraded by macroautophagy (e.g., SQSTM1, NBR1, OPTN, Atg19).<sup>1632</sup>

**Autophagy-like vesicles (ALVs):** Double-membraned vesicles (70–400 nm) that accumulate in cells infected by a number of different viruses. These vesicles also have been referred to as compound membrane vesicles (CMVs) or as double-membraned vesicles (DMVs).

**Autosis:** A form of macroautophagy-dependent cell death that requires Na<sup>+</sup>,K<sup>+</sup>-ATPase activity (in addition to the macroautophagy machinery).<sup>1080</sup> Morphologically, autosis has increased numbers of autophagosomes and autolysosomes, and nuclear convolution during its early stages, followed by focal swelling of the perinuclear space. Autosis occurs in response to various types of stress including starvation and hypoxia-ischemia.

**Ayr1:** A triacylglycerol lipase involved in macroautophagy in yeast.<sup>1633</sup> Enzymes that participate in the metabolism of lipid droplets including Dga1 and Lro1 (acyltransferases involved in triacylglycerol synthesis) and Are1/2 (Acyl-CoA:sterol acyltransferases) that generate the major components of lipid droplets, triacylglycerols and steryl esters, are required for efficient macroautophagy. Deletion of the genes encoding Yeh1 (a steryl ester hydrolase), Ayr1 or Ldh1 (an enzyme with esterase and

triacylglycerol lipase activities) also partially blocks macroautophagy. Finally, Ice2 and Ldb16, integral membrane proteins that participate in formation of ER-lipid droplet contact sites that may be involved in lipid transfer between these sites are also needed for efficient macroautophagy.

**AZD8055:** A novel ATP-competitive inhibitor of MTOR kinase activity. AZD8055 shows excellent selectivity against all class I PI3K isoforms and other members of the PI3K-like kinase family. Treatment with AZD8055 inhibits MTORC1 and MTORC2 and prevents feedback to AKT.<sup>1195</sup>

**Bafilomycin A<sub>1</sub> (BAFA1/BAF):** An inhibitor of the V-type ATPase as well as certain P-type ATPases that prevents acidification and alters the membrane potential of certain compartments; treatment with bafilomycin A<sub>1</sub> ultimately results in a block in fusion of autophagosomes with lysosomes, thus preventing the maturation of autophagosomes into autolysosomes.<sup>156,157,226</sup> Note that the abbreviation for bafilomycin A<sub>1</sub> is not “BFA,” as the latter is the standard abbreviation for brefeldin A; nor should BAF be confused with the abbreviation for the caspase inhibitor boc-asp(o-methyl)fluoremethyketone.

**BAG3 (BCL2-associated athanogene 3):** A stress-induced co-chaperone that utilizes the specificity of HSP70 molecular chaperones toward non-native proteins as the basis for targeted, ubiquitin-independent macroautophagic degradation in mammalian cells (“BAG3-mediated selective macroautophagy”); BAG3 is induced by stress and during cell aging, and interacts with HSP70 and dynein to target misfolded protein substrates to aggresomes, leading to their selective degradation.<sup>1559,1634</sup> BAG3 also interacts with HSPB6 and HSPB8 to target substrates for chaperone-assisted selective autophagy via a ubiquitin-dependent mechanism.<sup>1116</sup>

**BAG6/BAT3 (BCL2-associated athanogene 6):** BAG6 tightly controls macroautophagy by modulating EP300 intracellular localization, affecting the accessibility of EP300 to its substrates, TP53 and ATG7. In the absence of BAG6 or when this protein is located exclusively in the cytosol, macroautophagy is abrogated, ATG7 is hyperacetylated, TP53 acetylation is abolished, and EP300 accumulates in the cytosol, indicating that BAG6 regulates the nuclear localization of EP300.<sup>1635</sup>

**BARA (β-α repeated, autophagy-specific):** A domain at the C terminus of Vps30/Atg6 that is required for targeting PtdIns3K complex I to the PAS.<sup>1636</sup> The BARA domain is also found at the C terminus of BECN1 and in UVRAG.

**Barkor:** See ATG14.

**Basal autophagy:** Constitutive autophagic degradation that proceeds in the absence of any overt stress or stimulus. Basal autophagy is important for the clearance of damaged proteins and organelles in normal cells (especially fully differentiated, nondividing cells).

**BATS (Barkor/Atg14[L] autophagosome targeting sequence) domain:** A protein domain within ATG14 that is required for the recruitment of the class III PtdIns3K to LC3-containing puncta during macroautophagy induction; the predicted structure of the BATS domain suggests that it senses membrane curvature.<sup>550</sup>

**Bck1:** A MAPKKK downstream of Pkc1 and upstream of Mkk1/2 and SlT2 that controls cell integrity in response to cell wall stress; Bck1 is required for pexophagy<sup>683</sup> and mitophagy.<sup>508</sup> See also SlT2 and Hog1.



**BCL2 family of proteins:** There are 3 general classes of BCL2 proteins; anti-apoptotic proteins include BCL2, BCL2L1/Bcl-X<sub>L</sub>, BCL2L2/BCL-W and MCL1 that inhibit macroautophagy, the pro-apoptotic BH3-only proteins include BNIP3, BAD, BIK, PMAIP1/NOXA, BBC3/PUMA and BCL2L11/Bim/BimEL that induce macroautophagy, and the pro-apoptotic effector proteins BAX and BAK1. Interaction of BCL2 with BECN1 prevents the association of the latter with the class III PtdIns3K; however, anti-apoptotic BCL2 proteins require BAX and BAK1 to modulate macroautophagy.<sup>1637</sup>

**BCL2L13/BCL-RAMBO (BCL2-like 13 [apoptosis facilitator]):** BCL2L13 is a mammalian homolog of Atg32, which is located in the mitochondrial outer membrane and has an LC3-interacting region. BCL2L13 induces mitochondrial fission and mitophagy.<sup>1638</sup> See also Atg32.

**BCL10 (B-cell CLL/lymphoma 10):** The adaptor protein BCL10 is a critically important mediator of T cell receptor (TCR)-to-NFKB signaling. After association with the receptor SQSTM1, BCL10 is degraded upon TCR engagement. Selective macroautophagy of BCL10 is a pathway-intrinsic homeostatic mechanism that modulates TCR signaling to NFKB in effector T cells.<sup>1639</sup>

**BEC-1:** The *C. elegans* ortholog of BECN1.

**Beclin 1:** See BECN1.

**BECN1/Beclin 1 (beclin 1, autophagy related):** A mammalian homolog of yeast Vps30/Atg6 that forms part of the class III PtdIns3K complex involved in activating macroautophagy.<sup>1640</sup> BECN1 interacts with many proteins including BCL2, VMP1, ATG14, UVRAG, PIK3C3 and RUBCN/Rubicon through its BH3, coiled-coil and BARA domains, the latter including the evolutionarily conserved domain (ECD).<sup>1641</sup> The *C. elegans* ortholog is BEC-1.

**BECN1s (BECN1 short isoform):** A splice variant of BECN1 that lacks the sequence corresponding to exons 10 and 11; BECN1s associates with the mitochondrial outer membrane and is required for mitophagy.<sup>1642</sup> BECN1s can bind ATG14 and activate PIK3C3/VPS34, but does not bind UVRAG.

**BECN2/Beclin 2 (beclin 2):** A mammalian-specific homolog of yeast Vps30/Atg6 that forms part of the class III PtdIns 3K complex involved in activating macroautophagy and that also functions in the endolysosomal degradation of G protein-coupled receptors (independently of the class III PtdIns3K complex).<sup>1643</sup>

**Betulinic acid:** Betulinic acid and its derivatives activate macroautophagy as a rescue mechanism to deal with damaged mitochondria;<sup>235,1167,1168,1644</sup> however, betulinic acid impairs lysosomal integrity and converts macroautophagy into a detrimental process, leading to accumulation of nonfunctional autolysosomes that can be detected over a long time frame.<sup>235</sup>

**BH domain:** BCL2 homology domain. There are 4 domains of homology, consisting of BH1, BH2, BH3 and BH4.

**BH3 domain:** A BCL2 homology (BH) domain that is found in all BCL2 family proteins, whether they are pro-apoptotic or anti-apoptotic. A BH3 domain is also present in BECN1 and mediates the interaction with anti-apoptotic proteins possessing a BH3 receptor domain (i.e., BCL2, BCL2L1/bcl-x<sub>L</sub>, BCL2L2/BCL-W and MCL1).


**BH3-only proteins:** A series of proteins that contain a BH3 domain (but not any other BCL2 homology domains). Several

BH3-only proteins (BNIP3, BAD, BIK, PMAIP1/NOXA, BBC3/PUMA and BCL2L11/Bim/BimEL) can competitively disrupt the inhibitory interaction between BCL2 and BECN1 to allow the latter to act as an allosteric activator of PtdIns3K and to activate macroautophagy.

**Bif-1:** See SH3GLB1.

**BIPASS (BAG-instructed proteasomal to autophagosomal switch and sorting):** Upon proteasomal impairment, cells switch to autophagy to ensure proper clearance of substrates (the proteasome-to-autophagy switch). Following this proteasome impairment, increasing the BAG3:BAG1 ratio ensures the initiation of BIPASS.<sup>1645</sup>

**BNIP3 (BCL2/adenovirus E1B 19kDa interacting protein 3):** Identified in a yeast two-hybrid screen as interacting through its amino terminal 40 amino acids with BCL2 and adenovirus E1B.<sup>1646</sup> Originally classified as a pro-apoptotic protein, BNIP3 promotes mitophagy through direct interaction with LC3B-II mediated by a conserved LIR motif that overlaps with its BCL2 interacting region.<sup>1647,1648</sup> BNIP3 also modulates mitochondrial fusion through inhibitory interactions with OPA1 via its carboxy terminal 10 amino acids.<sup>1649</sup> BNIP3 is transcriptionally regulated by HIF1A,<sup>1650</sup> E2Fs,<sup>1651</sup> FOXO3,<sup>468</sup> TP53<sup>1652</sup> and NFKB<sup>1653</sup> and is most highly expressed in adult heart and liver.<sup>1654,1655</sup>



**BNIP3L/NIX (BCL2/adenovirus E1B 19kDa interacting protein 3-like):** Identified as a BNIP3 homolog, BNIP3L is required for mitophagy in red blood cells.<sup>1299,1300</sup> Like BNIP3, BNIP3L is hypoxia-inducible and also interacts with LC3B-II and GABARAP through a conserved LIR motif in its amino terminus.<sup>210</sup> BNIP3L also interacts with RHEB at the mitochondria and the LC3-BNIP3L-RHEB complex promotes mitochondrial turnover and efficient mitochondrial function.<sup>1656</sup>

**Bre5:** A cofactor for the deubiquitinase Ubp3. See also Ubp3.

**C/EBPβ:** See CEBPB.

**C9orf72/ALSFTD:** C9orf72 plays an important role in the regulation of endosomal trafficking, and interacts with RAB proteins involved in macroautophagy and endocytic transport. C9orf72 contains a DENN (differentially expressed in normal and neoplasia)-like domain, suggesting that it may function as a GDP-GTP exchange factor for a RAB GTPase, similar to other DENN proteins. The normal function of C9orf72 remains unknown but it is highly conserved and expressed in many tissues, including the cerebellum and cortex. Hexanucleotide (GGGGCC) repeat expansions in a noncoding region of the *C9orf72* gene are the major cause of familial ALS and frontotemporal dementia.<sup>1657</sup>

**C12orf5:** See TIGAR.

**C12orf44:** See ATG101

**Ca-P60A/dSERCA:** The *Drosophila* ER Ca<sup>2+</sup>-translocating ATPase. Inhibition of Ca-P60A with bafilomycin A<sub>1</sub> blocks autophagosome-lysosome fusion.<sup>226</sup>

**Cad96Ca/Stit/Stitcher (Cadherin 96Ca):** A *Drosophila* receptor tyrosine kinase that is orthologous to the human proto-oncogene RET. Cad96Ca suppresses macroautophagy in epithelial tissues through Akt1-TORC1 signaling in parallel to InR (Insulin-like receptor). This endows epithelial tissues with starvation resistance and anabolic development during nutritional stress.<sup>1658</sup>

**Caf4:** A component of the mitochondrial fission complex that is recruited to degrading mitochondria to facilitate mitophagy-specific fission.<sup>705</sup>

**CAL-101:** A small molecule inhibitor of the PIK3CD/p110 $\delta$  subunit of class 1A phosphoinositide 3-kinase; treatment of multiple myeloma cells results in macroautophagy induction.<sup>1659</sup>

**Calcineurin:** See PPP3R1.

**CALCOCO2/NDP52 (calcium binding and coiled-coil domain 2):** A receptor that binds to the bacterial ubiquitin coat and Atg8/LC3 to target invasive bacteria, including *S. typhimurium* and *Streptococcus pyogenes* for autophagosomal sequestration.<sup>878</sup>

**Calpains:** A class of calcium-dependent, non-lysosomal cysteine proteases that cleaves and inactivates ATG5 and the ATG12-ATG5 conjugate, hence establishing a link between reduced Ca<sup>2+</sup> concentrations and induction of macroautophagy.<sup>1660</sup>

**CALR (calreticulin):** A chaperone that is mainly associated with the ER lumen, where it performs important functions such as Ca<sup>2+</sup> buffering, and participates in protein folding and maturation of, as well as antigen loading on, MHC molecules.<sup>1661</sup> An extracellular role for CALR has emerged where it acts as an “eat me” signal on the surface of cancer cells.<sup>1662</sup> Importantly, in the context of Hyp-PDT, macroautophagy suppresses CALR surface exposure by reducing ER-associated proteotoxicity.<sup>1053,1058,1663</sup> Disruption of *LAMP2A* also affects CALR surface exposure.<sup>1058</sup>

**CaMKK $\beta$ :** See CAMKK2.

**CAMKK2 (calcium/calmodulin-dependent protein kinase kinase 2, beta):** Activates AMPK in response to an increase in the cytosolic calcium concentration,<sup>1664</sup> resulting in the induction of macroautophagy.<sup>1223</sup>

**CAPNS1 (calpain, small subunit 1):** The regulatory subunit of micro- and millicapain; CAPNS1-deficient cells are macroautophagy defective and display a substantial increase in apoptotic cell death.<sup>1665</sup>

**CASA (chaperone-assisted selective autophagy):** A degradative process that utilizes the *Drosophila* co-chaperone Starvin or its mammalian homolog BAG3 to direct the degradation of aggregated substrates through the action of HSPA8, HSPB8, the STUB1/CHIP ubiquitin ligase and SQSTM1.<sup>1116</sup> The requirement for ubiquitination of the substrates (and the absence of a requirement for the KFERQ motif) along with the involvement of the ATG proteins differentiate this process from CMA, which also uses chaperones for lysosome-dependent degradation.

**Caspases (cysteine-dependent aspartate-directed proteases):** A class of proteases that play essential roles in apoptosis (formerly called programmed cell death type I) and inflammation. Several pro-apoptotic caspases cleave essential macroautophagy proteins, resulting in the inhibition of macroautophagy.<sup>438</sup> For

example, CASP3 and CASP8 cleave BECN1 and inhibit macroautophagy.<sup>1666,1667</sup>

**CCCP (carbonyl cyanide m-chlorophenylhydrazone):** Protonophore and uncoupler of oxidative phosphorylation in mitochondria; stimulates mitochondrial degradation inducing mitophagic activity.<sup>250</sup>

**CCDC88A/GIV (coiled-coil domain containing 88A):** A guanine nucleotide exchange factor for GNAI3 that acts to downregulate macroautophagy.<sup>1668</sup> CCDC88A disrupts the GPM1-GNAI3 complex in response to growth factors, releasing the G protein from the phagophore or autophagosome membrane; GNAI3-GTP also activates the class I PI3K, thus inhibiting macroautophagy. See also GNAI3.

**CCI-779 (temsirolimus):** A water-soluble rapamycin ester that induces macroautophagy.

**Cdc48:** Yeast homolog of VCP that is a type II AAA<sup>+</sup>-ATPase that extracts ubiquitinated proteins from the membrane as part of the ER-associated protein degradation pathway and during ER homeotypic fusion,<sup>1669</sup> but is also required for nonselective macroautophagy.<sup>1670</sup> See also Shp1 and VCP.

**CD46:** A cell-surface glycoprotein that interacts with the scaffold protein GOPC to mediate an immune response to invasive pathogens including *Neisseria* and Group A *Streptococcus*. Interaction of pathogens via the Cyt1 cytosolic tail induces macroautophagy, which involves GOPC binding to BECN1. CD46 is also used as a cellular receptor by several pathogens.<sup>1671</sup>

**CDKN1A/p21 (cyclin-dependent kinase inhibitor 1A [p21, Cip1]):** A cyclin-dependent kinase inhibitor that is associated with the induction of macroautophagy in melanoma cells upon exposure to a telomeric G-quadruplex stabilizing agent.<sup>1672</sup>

**CDKN1B/p27 (cyclin-dependent kinase inhibitor 1B [p27, Kip1]):** A cyclin-dependent kinase inhibitor that is phosphorylated and stabilized by an AMPK-dependent process and stimulates macroautophagy.<sup>1673</sup>

**CDKN2A (cyclin-dependent kinase inhibitor 2A):** The *CDKN2A* locus encodes 2 overlapping tumor suppressors that do not share reading frame: p16<sup>INK4a</sup> and p14<sup>ARF</sup>. The p14<sup>ARF</sup> tumor suppressor protein (p19<sup>ARF</sup> in mouse) can localize to mitochondria and induce macroautophagy. Tumor-derived mutant forms of p14<sup>ARF</sup> that do not affect the p16<sup>INK4a</sup> coding region are impaired for macroautophagy induction, thus implicating this activity in tumor suppression by this commonly mutated locus.<sup>1674</sup> This gene also encodes a smaller molecular weight variant called smARF. See also smARF.

**CEBPB/C/EBP $\beta$  (CCAAT/enhancer binding protein [C/EBP], beta):** A transcription factor that regulates several autophagy genes; CEBPB is induced in response to starvation, and the protein levels display a diurnal rhythm.<sup>1000</sup>

**Cell differentiation:** This is a process through which a cell commits to becoming a more specialized cell type having a distinct form and a specific function(s). Autophagy is activated during the differentiation of various normal and cancerous cells, as revealed, for example, in adipocytes, erythrocytes, lymphocytes and leukemia cells.<sup>452</sup>

**CEP-1 (C. elegans P-53-like protein):** See TP53.

**Ceramide:** Ceramide is a bioactive sphingolipid, which plays a mitochondrial receptor role to recruit LC3-II-associated phagophores to mitochondria for degradation in response to

ceramide stress and DNMI1-mediated mitochondrial fission; the direct binding between ceramide and LC3-II involves F52 and I35 residues of LC3B.<sup>591</sup>

**Chaperone-mediated autophagy (CMA):** An autophagic process in mammalian cells by which proteins containing a particular pentapeptide motif related to KFERQ are transported across the lysosomal membrane and degraded.<sup>1675,1676</sup> The translocation process requires the action of the integral membrane protein LAMP2A and both cytosolic and luminal HSPA8.<sup>1677,1678</sup>

**CHKB (choline kinase beta):** A kinase involved in phosphatidylcholine synthesis; mutations in *CHKB* cause mitochondrial dysfunction leading to mitophagy and megaconial congenital muscular dystrophy.<sup>1679</sup>

**Chloroquine (CQ):** Chloroquine and its derivatives (such as 3-hydroxychloroquine) raise the lysosomal pH and ultimately inhibit the fusion between autophagosomes and lysosomes, thus preventing the maturation of autophagosomes into autolysosomes, and blocking a late step of macroautophagy.<sup>1680</sup>

**CHMP1A (charged multivesicular body protein 1A):** CHMP1A is a member of the CHMP family of proteins that are involved in multivesicular body sorting of proteins to the interiors of lysosomes. CHMP1A regulates the macroautophagic turnover of plastid constituents in *Arabidopsis thaliana*.<sup>802</sup>

**Chromatophagy:** A form of macroautophagy that involves nuclear chromatin/DNA leakage captured by autophagosomes or autolysosomes.<sup>803</sup>

**Ciliophagy:** Degradation by macroautophagy of proteins involved in the process of ciliogenesis (formation of primary cilia). Ciliophagy can modulate ciliogenesis positively or negatively depending on whether the subset of proteins degraded in autophagosomes are activators or inhibitors of the formation of primary cilia.

**CISD2/NAF-1 (CDGSH iron sulfur domain 2):** An integral membrane component that associates with the ITPR complex; CISD2 binds BCL2 at the ER, and is required for BCL2 to bind BECN1, resulting in the inhibition of macroautophagy.<sup>1681</sup> CISD2 was reported to be associated with the ER, but the majority of the protein is localized at mitochondria, and mutations in *CISD2* are associated with Wolfram syndrome 2; accelerated macroautophagy in *cisd2*<sup>-/-</sup> mice may cause mitochondrial degradation, leading to neuron and muscle degeneration.<sup>1682</sup>

**CLEAR (coordinated lysosomal expression and regulation) gene network:** A regulatory pathway involving TFEB, which regulates the biogenesis and function of the lysosome and associated pathways including macroautophagy.<sup>636</sup> See also PPP3R1 and TFEB.

**CLEC16A (C-type lectin domain family 16, member A):** See Ema.

**Clg1:** A yeast cyclin-like protein that interacts with Pho85 to induce macroautophagy by inhibiting Sic1.<sup>1683</sup>

**CLN3 (ceroid-lipofuscinosis, neuronal 3):** An endosomal/lysosomal protein whose deficiency causes inefficient autolysosome clearance and accumulation of autofluorescent lysosomal storage material and ATP5G/subunit c (ATP synthase, H<sup>+</sup> transporting, mitochondrial Fo complex, subunit C [subunit 9]).<sup>1684,1685</sup> In human, recessive *CLN3* mutations cause juvenile neuronal ceroid lipofuscinosis

(JNCL; Batten disease). Recessive *CLN3* mutations have also been reported in cases of autophagic vacuolar myopathy and non-syndromic retinal disease.<sup>1686,1687</sup>

**COG (conserved oligomeric Golgi) complex:** A cytosolic tethering complex that functions in the fusion of vesicles within the Golgi complex, but also participates in macroautophagy and facilitates the delivery of Atg8 and Atg9 to the PAS.<sup>1688</sup>

**Connexins:** See gap junction protein.

**CORM (CO-releasing molecule):** Carbon monoxide, partly through activation of macroautophagy, exerts cardioprotective effects in a mouse model of metabolic syndrome-induced myocardial dysfunction.<sup>1689</sup>

**Corynoxine/Cory:** An oxindole alkaloid isolated from *Uncaria rhynchophylla* (Miq.) Jacks (Gouteng in Chinese) that is a Chinese herb that acts as a MTOR-dependent macroautophagy inducer.<sup>1690</sup>

**Corynoxine B/Cory B:** An isomer of corynoxine, also isolated from the Chinese herb *Uncaria rhynchophylla* (Miq.) Jacks that acts as a BECN1-dependent macroautophagy inducer.<sup>1691</sup>

**Crinophagy:** Selective degradation of secretory granules by fusion with the lysosome, independent of macroautophagy.<sup>1692</sup> See also zymophagy.

**Cryptides:** Peptides with a cryptic biological function that are released from cytoplasmic proteins by partial degradation or processing through macroautophagy (e.g., neoantimicrobial peptide released from ribosomal protein FAU/RPS30).<sup>1693</sup>

**CSNK2 (casein kinase 2):** A serine/threonine protein kinase that disrupts the BECN1-BCL2 complex to induce macroautophagy.<sup>1694</sup> CSNK2 also phosphorylates ATG16L1, in particular on Ser139, to positively regulate macroautophagy. See also PPP1.

**Ctl1:** A multi-transmembrane protein in the fission yeast *Schizosaccharomyces pombe* that binds to Atg9 and is required for autophagosome formation.<sup>1695</sup>

**Cue5:** A yeast receptor similar to mammalian SQSTM1 that binds ubiquitin through its CUE domain and Atg8 via its C-terminal AIM.<sup>451</sup> Some Cue5-dependent substrates are ubiquitinated by Rsp5. See also CUET.

**CUET (Cue5/TOLLIP):** A family of macroautophagy receptor proteins containing a CUE domain that are involved in macroautophagic clearance of protein aggregates. See also Cue5.<sup>451</sup>

**CUP-5 (coelomocyte uptake defective mutant-5):** The ortholog of human MCOLN1 (mucolipin 1), in *C. elegans* CUP-5 localizes to lysosomes, and is required for endo-lysosomal transport, lysosomal degradation,<sup>1696-1698</sup> and proteolytic degradation in autolysosomes.<sup>1699</sup>

**CUPS (compartment for unconventional protein secretion):** A compartment located near ER exit sites that is involved in the secretion of Acb1; Grh1 is localized to the CUPS membrane, and Atg8 and Atg9 are subsequently recruited under starvation conditions.<sup>1700</sup> Atg8 and Atg9 function in Acb1 secretion, but rapamycin-induced macroautophagy does not result in CUPS formation.

**Cvt body:** The single-membrane vesicle present inside the vacuole lumen that results from the fusion of a Cvt vesicle with the vacuole.<sup>131</sup>

**Cvt complex:** A cytosolic protein complex consisting primarily of prApe1 dodecamers in the form of an Ape1 complex that are

bound to the Atg19 receptor. This complex may also contain Ams1 and Ape4, but prApe1 is the predominant component.<sup>131</sup>

**Cvt vesicle:** The double-membrane sequestering vesicle of the Cvt pathway.<sup>131</sup>

**Cysmethynil:** A small-molecule inhibitor of ICMT (isoprenylcysteine carboxyl methyltransferase); treatment of PC3 cells causes an increase in LC3-II and cell death with macroautophagic features.<sup>1701</sup>

**Cytoplasm-to-vacuole targeting (Cvt) pathway:** A constitutive, biosynthetic pathway in yeast that transports resident hydrolases to the vacuole through a selective macroautophagy-like process.<sup>1702</sup> See also Ams1, Ape1, Ape4 and Atg19.

**DAF-2 (abnormal dauer formation):** Encodes the *C. elegans* insulin/IGF1-like receptor homolog that acts through a conserved PI3K pathway to negatively regulate the activity of DAF-16/FOXO and limit life span. DAF-2 inhibits macroautophagy by a mechanism that remains to be elucidated.<sup>271,1703,1704</sup>

**DAF-16:** A *C. elegans* FOXO transcription factor ortholog.

**DALIS (dendritic cell aggresome-like induced structures):** Large poly-ubiquitinated protein aggregates formed in dendritic cells. These are similar to aggresomes, but they do not localize to the microtubule-organizing center. DALIS are transient in nature and small DALIS have the ability to move and form larger aggregates; they require proteasome activity to clear them.<sup>318</sup> See also ALIS.

**DAMP (danger/damage-associated molecular pattern):** DAMPs are recognized by receptors (DDX58/RIG-I-like receptors [RLRs] or TLRs) of the innate surveillance response system. DAMPs include “non-self” molecules such as viral RNA, or products of necroptosis such as HMGB1.<sup>295</sup> Response includes activation of macroautophagy to clear the DAMP molecule(s).<sup>1705</sup>

**DAP (death-associated protein):** A conserved phosphoprotein that is a substrate of MTOR and inhibits macroautophagy; inhibition of MTOR results in dephosphorylation of DAP and inhibition of macroautophagy, thus limiting the magnitude of the autophagic response.<sup>1706</sup>

**DAPK1 (death-associated protein kinase 1):** A kinase that phosphorylates Thr119 of BECN1 to activate it by causing dissociation from BCL2L1/Bcl-x<sub>L</sub> and BCL2, thus activating macroautophagy.<sup>1707</sup>

**DAPK3 (death-associated protein kinase 3):** See Sqa.

**DCN (decorin):** An archetypical member of the small leucine rich proteoglycans that functions as a soluble pro-autophagic and pro-mitophagic signal. DCN acts as a partial agonist for KDR/VEGFR2 and MET for endothelial cell macroautophagy and tumor cell mitophagy, respectively. DCN elicits these processes in a PEG3-dependent manner to induce endothelial cell macroautophagy, and in a TCHP/mitostatin-dependent manner for tumor cell mitophagy. It is postulated that induction of these fundamental cellular programs underlies the oncogenic and angiostatic properties of DCN.<sup>1708</sup>


**Dcp-1 (death caspase-1):** A *Drosophila* caspase that localizes to mitochondria and positively regulates macroautophagic flux.<sup>1709</sup>

**Dcp2/DCP2 (decapping mRNA 2):** A decapping enzyme involved in the downregulation of ATG transcripts.<sup>1710</sup> See also Dhh1.

**DCT-1:** The *C. elegans* homolog of BNIP3 and BNIP3L, which functions downstream of PINK-1 and PDR-1 to regulate mitophagy under conditions of oxidative stress.<sup>1275</sup>

**DDIT4/DIG2/RTP801/REDD1 (DNA-damage-inducible transcript 4):** The DDIT4 protein is notably synthesized in response to glucocorticoids or hypoxia and inhibits MTOR, resulting in the induction of macroautophagy and enhanced cell survival.<sup>1711</sup>

**Deconjugation:** The Atg4/ATG4-dependent cleavage of Atg8-PE/LC3-II that releases the protein from PE (illustrated for the nascent yeast protein that contains a C-terminal arginine). The liberated Atg8/LC3 can subsequently go through another round of conjugation. Atg8\*, activated Atg8.



**Decorin:** See DCN.

**Decoupled signaling:** When limited for an auxotrophic requirement, yeast cells fail to induce the expression of autophagy genes even when growing slowly, which contributes to decreased cell viability.<sup>1712</sup>

**Desat1:** A *Drosophila* lipid desaturase that localizes to autophagosomes under starvation conditions; the *Desat* mutant is defective in macroautophagy induction.<sup>1713</sup>

**DFCP1:** See ZFYVE1.

**Dga1:** See Ayr1.

**Dhh1:** An RCK member of the RNA-binding DExD/H-box proteins involved in mRNA decapping; Dhh1 in *S. cerevisiae* and Vad1 in *Cryptococcus neoformans* bind certain ATG transcripts, leading to the recruitment of the Dcp2 decapping enzyme and mRNA degradation.<sup>1710</sup> See also Dcp2.

**Diacylglycerol:** A lipid second messenger that contributes to macroautophagic targeting of *Salmonella*-containing vacuoles.<sup>1714</sup>

**DIG2:** See DDIT4.

**DIRAS3 (DIRAS family, GTP-binding RAS-like 3):** A protein that interacts with BECN1, displacing BCL2 and blocking BECN1 dimer formation, thus promoting the interaction of BECN1 with PIK3C3 and ATG14, resulting in macroautophagy induction.<sup>1715</sup>

**Dnm1:** A dynamin-related GTPase that is required for both mitochondrial and peroxisomal fission. Dnm1 is recruited to degrading mitochondria by Atg11, or to degrading peroxisomes by both Atg11 and Atg36 (or PpAtg30), to mediate mitophagy- or pexophagy-specific fission.<sup>705,1716</sup> See also DNM1L.

**DNM1L/Drp1 (dynamin 1-like):** The mammalian homolog of yeast Dnm1. PRKA-mediated phosphorylation of rat DNM1L on Ser656 (Ser637 in humans) prevents both mitochondrial fission and some forms of mitophagy in neurons.<sup>1717</sup> See also Dnm1.

**DNM2 (dynamin 2):** DNM2 is recruited to extruded autolysosomal membranes during the process of autophagic lysosome reformation and catalyzes their scission, promoting the

regeneration of nascent protolysosomes during macroautophagic flux.<sup>1630</sup> See also autophagic lysosome reformation.

**dom (domino):** A *Drosophila* SWI2/SNF2 chromatin remodeling protein. A loss-of-function mutation at the *dom* locus synergizes with genotypes depressed in macroautophagy pathway activity.<sup>1718</sup>

**Dopamine:** A neurotransmitter whose accumulation outside vesicles induces macroautophagy and cell degeneration.<sup>1719</sup>

**DOR:** See TP53INP2.

**DRAM1 (damage-regulated autophagy modulator 1):** *DRAM1* gene expression is induced by TP53 in response to DNA damage that results in cell death by macroautophagy.<sup>580</sup> DRAM1 is an endosomal-lysosomal membrane protein that is required for the induction of macroautophagy. The knockdown of DRAM1 causes downregulation of VRK1 by macroautophagy, similar to the effect of knocking down BECN1.

**Draper:** A *Drosophila* homolog of the *Caenorhabditis elegans* engulfment receptor CED-1 that is required for macroautophagy associated with cell death during salivary gland degradation, but not for starvation-induced macroautophagy in the fat body.<sup>1720</sup>

**Drs:** See SRPX.

**E2F1:** A mammalian transcription factor that upregulates the expression of *BNIP3*, *LC3*, *ULK1* and *DRAM1* directly, and *ATG5* indirectly.<sup>614</sup> E2F1 plays a role during DNA damage- and hypoxia-induced macroautophagy.

**EAT (early autophagy targeting/tethering) domain:** The C-terminal domain of Atg1, which is able to tether vesicles.<sup>1721</sup>

This part of the protein also contains the binding site for Atg13.

**EAT-2 (eating abnormal):** A ligand-gated ion channel subunit closely related to the non-alpha subunit of nicotinic acetylcholine receptors, which functions to regulate the rate of pharyngeal pumping. *eat-2* loss-of-function mutants are dietary restricted and require macroautophagy for the extension of life span.<sup>1703,1722,1723</sup>

**EDTP:** See MTMR14.

**EEA1 (early endosome antigen 1):** A RAB5 effector used as a common marker for early endosome vesicles.

**EEF1A1/EF1A/eF1 $\alpha$  (eukaryotic translation elongation factor 1 alpha 1):** Multifunctional member of the family of G-proteins with different cellular variants. The lysosomal variant of this protein acts coordinately with GFAP at the lysosomal membrane to modulate the stability of the CMA translocation complex. Release of membrane bound EEF1A1 in a GTP-dependent manner promotes disassembly of the translocation complex and consequently reduces CMA activity.<sup>1724</sup>

**eF1 $\alpha$ :** See EEF1A1.

**EGFR (epidermal growth factor receptor):** A tyrosine kinase receptor that negatively regulates macroautophagy through PI3K, AKT, and MTOR modulation.<sup>523</sup>

**EGO complex:** The Ego1, Ego3 and Gtr2 proteins form a complex that positively regulates yeast microautophagy.<sup>1725</sup>

**eIF2 $\alpha$  kinase:** See EIF2S1 kinase.

**EIF2AK2/PKR (eukaryotic translation initiation factor 2-alpha kinase 2):** A mammalian EIF2S1/EIF2 alpha kinase that induces macroautophagy in response to viral infection.<sup>558</sup>

**EIF2AK3/PERK (eukaryotic translation initiation factor 2-alpha kinase 3):** A mammalian EIF2S1/EIF2 alpha kinase that may induce macroautophagy in response to ER stress.<sup>602</sup>

**EIF2S1 (eukaryotic translation initiation factor 2, subunit 1, alpha, 35kDa):** An initiation factor that is involved in stress-induced translational regulation of macroautophagy.

**EIF2S1/eIF2 $\alpha$  kinase:** There are 4 mammalian EIF2S1/EIF2 alpha kinases that respond to different types of stress. EIF2AK2 and EIF2AK3 induce macroautophagy in response to virus infection and ER stress, respectively.<sup>602,1726</sup> See also Gcn2, EIF2AK2 and EIF2AK3.

**Elaiophyllin:** A natural compound late-stage macroautophagy inhibitor that results in lysosomal membrane permeabilization and decreased cell viability.<sup>1727</sup> See also LMP.

**Ema (endosomal maturation defective):** Ema is required for phagophore expansion and for efficient mitophagy in *Drosophila* fat body cells. It is a transmembrane protein that relocalizes from the Golgi to phagophores following starvation.<sup>1728</sup> The vertebrate ortholog CLEC16A regulates mitophagy and is a susceptibility locus for many autoimmune disorders.<sup>1729,1730</sup>

**Embryoid bodies/EBs:** Three-dimensional aggregates of pluripotent stem cells including embryonic stem cells and induced pluripotent stem cells.

**EMC6/TMEM93 (ER membrane protein complex subunit 6):** A novel ER-localized transmembrane protein, which interacts with both RAB5A and BECN1 and colocalizes with the omegasome marker ZFYVE1/DFCP1.<sup>1731</sup> EMC6 enhances autophagosome formation when overexpressed.

**Endorepellin:** The anti-angiogenic C-terminal cleavage product of HSPG2/perlecan. Endorepellin engages KDR/VEGFR2 and ITGA2/ $\alpha$ 2 $\beta$ 1 integrin in a novel mechanism termed dual receptor antagonism for achieving endothelial cell specificity and function. Endorepellin evokes endothelial cell macroautophagy downstream of KDR and in a PEG3-dependent manner.<sup>1732</sup>

**Endosomal microautophagy (e-MI):** A form of autophagy in which cytosolic proteins are sequestered into late endosomes/MVBs through a microautophagy-like process. Sequestration can be nonselective or can occur in a selective manner mediated by HSPA8. This process differs from chaperone-mediated autophagy as it does not require substrate unfolding and it is independent of the CMA receptor LAMP2A.<sup>1115</sup> This process occurs during MVB formation and requires the ESCRT-I and ESCRT-III protein machinery. See also endosome and multivesicular body.

**Endosome:** The endosomal compartments receive molecules engulfed from the extracellular space and are also in communication with the Golgi apparatus. The endosomal system can be viewed as a series of compartments starting with the early endosome. From there, cargos can be recycled back to the plasma membrane; however, more typically, internalized cargo is transported to the late endosome/MVB. These latter compartments can fuse with lysosomes. Endosomal maturation from early endosomes is a dynamic process that involves a progressive reduction in luminal pH. In mammalian cells, early and/or multivesicular endosomes fuse with autophagosomes to generate amphisomes.

**EP300/p300 (E1A binding protein p300):** An acetyltransferase that inhibits macroautophagy by acetylating ATG5, ATG7, ATG12 and/or LC3.<sup>656</sup> EP300 is also involved in the GLI3-

dependent transcriptional activation of *VMP1* in cancer cells.<sup>634</sup> See also GLI3.

**EPAS1/HIF2A/Hif-2 $\alpha$  (endothelial PAS domain protein 1):** Part of a dimeric transcription factor in which the  $\alpha$  subunit is regulated by oxygen; the hydroxylated protein is degraded by the proteasome. EPAS1 activation in mouse liver augments peroxisome turnover by pexophagy, and the ensuing deficiency in peroxisomal function encompass major changes in the lipid profile that are reminiscent of peroxisomal disorders.<sup>773</sup>

**epg (ectopic PGL granules) mutants:** *C. elegans* mutants that are defective in the macroautophagic degradation of PGL-1, SEPA-1 and/or SQST-1.<sup>633</sup> The EPG-3, ATG-11/EPG-7, EPG-8 and EPG-9 proteins are homologs of VMP1, Atg11/RB1CC1, ATG14 and ATG101, respectively, whereas ATG-13/EPG-1 may be a homolog of ATG13.<sup>1733</sup>

**EPG-1:** See ATG-13.

**EPG-2:** A nematode-specific coiled-coil protein that functions as a scaffold protein mediating the macroautophagic degradation of PGL granule in *C. elegans*. EPG-2 directly interacts with SEPA-1 and LGG-1. EPG-2 itself is also degraded by macroautophagy.<sup>633</sup>

**EPG-3:** A metazoan-specific macroautophagy protein that is the homolog of human VMP1. EPG-3/VMP1 are involved in an early step of autophagosome formation.<sup>633</sup>

**EPG-4:** An ER-localized transmembrane protein that is the homolog of human EI24/PIG8. EPG-4 is conserved in multicellular organisms, but not in yeast. EPG-4 functions in the progression of omegasomes to autophagosomes.<sup>633</sup>

**EPG-5:** A novel macroautophagy protein that is conserved in multicellular organisms. EPG-5 regulates lysosome degradative capacity and thus could be involved in other pathways that terminate at this organelle.<sup>633</sup> Mutations in the human *EPG5* gene lead to Vici syndrome.<sup>1734</sup>

**EPG-6:** A WD40 repeat PtdIns3P-binding protein that directly interacts with ATG-2.<sup>563</sup> EPG-6 is the *C. elegans* functional homolog of yeast Atg18 and probably of mammalian WDR45/WIPI4. EPG-6 is required for the progression of omegasomes to autophagosomes. See also Atg18.

**EPG-7:** See ATG-11.

**EPG-8:** An essential macroautophagy protein that functions as the homolog of yeast Atg14 in *C. elegans*.<sup>1269</sup> EPG-8 is a coiled-coil protein and directly interacts with the *C. elegans* BECN1 homolog BEC-1. See also Atg14.

**EPG-9:** A protein with significant homology to mammalian ATG101 in *C. elegans*.<sup>1268</sup> EPG-9 directly interacts with ATG-13/EPG-1. See also ATG101.

**EPG-11:** See PRMT-1.

**EPM2A/laforin (epilepsy, progressive myoclonus type 2A, Lafora disease [laforin]):** A member of the dual specificity protein phosphatase family that acts as a positive regulator of macroautophagy probably by inhibiting MTOR, as EPM2A deficiency causes increased MTOR activity.<sup>1736</sup> Mutations in the genes encoding EPM2A or the putative E3-ubiquitin ligase NHLRC1/malin, which form a complex, are associated with the majority of defects causing Lafora disease, a type of progressive neurodegeneration. See also NHLRC1.

**ER-phagy:** See reticulophagy.

**ERK1:** See MAPK3.

**ERK2:** See MAPK1.

**ERMES (ER-mitochondria encounter structure):** A complex connecting the endoplasmic reticulum and the mitochondrial outer membrane in yeast. The core components of ERMES are the mitochondrial outer membrane proteins Mdm10 and Mdm34, the ER membrane protein Mmm1, and the peripheral membrane protein Mdm12. ERMES plays an important role in yeast mitophagy presumably by supporting the membrane lipid supply for the growing phagophore membrane.<sup>1737</sup>

**Everolimus (RAD-001):** An MTOR inhibitor similar to rapamycin that induces macroautophagy.

**ESC8:** A macroautophagy inducer that bears a cationic estradiol moiety and causes downregulation of p-MTOR and its downstream effectors including p-RPS6KB.<sup>1738</sup>

**EVA1A/FAM176A/TMEM166 (eva-1 homolog A [*C. elegans*]):** An integral membrane protein that induces macroautophagy and cell death when overexpressed.<sup>1739,1740</sup> See also TMEM166.

**EXOC2/SEC5L1 (exocyst complex component 2):** A component of the exocyst complex; EXOC2 binds RALB, BECN1, MTORC1, ULK1 and PIK3C3 under nutrient-rich conditions and prevents these components from interacting with EXOC8/EXO84, thus inhibiting macroautophagy.<sup>1741</sup> See also RALB and EXOC8.

**EXOC8/EXO84 (exocyst complex component 8):** A component of the exocyst complex, and an effector of RALB that is involved in nucleation and/or expansion of the phagophore; EXOC8 binds RALB under nutrient-poor conditions, and stimulates the formation of a complex that includes ULK1 and the class III PtdIns3K.<sup>1741</sup> See also RALB and EXOC2.

**Exophagy:** A process in yeast and mammalian cells that is used for protein secretion that is independent of the secretory pathway (i.e., unconventional secretion), and dependent on Atg proteins and the Golgi protein Grh1; Acb1 (acyl-coenzyme A-binding protein) uses this route for delivery to the cell surface.<sup>1742-1744</sup> See also secretory autophagy.

**FAM48A:** See SUPT20H.

**FAM134B (family with sequence similarity 134, member B):** ER-resident receptors that function in reticulophagy through interaction with LC3 and GABARAP.<sup>845</sup>

**FAM176A:** See EVA1A.

**Fasudil:** A ROCK (Rho-associated, coiled-coil containing protein kinase) inhibitor that enhances macroautophagy.<sup>1745</sup>

**Far11:** A MAP kinase target that is involved in the dephosphorylation of Atg13 and the induction of macroautophagy.<sup>1746</sup> Far11 interacts with Pph21, Pph22 and Pph3 and may coordinate different cellular stress responses by regulating phosphatase activity.

**Ferritinophagy:** The selective degradation of ferritin through a macroautophagy-like process.<sup>804</sup> This process involves a specificity receptor, NCOA4.

**FEZ1 (fasciculation and elongation protein zeta 1 [zyglin I]):** FEZ1 interacts with ULK1 or with UVRAG, and forms a

trimeric complex with either component by also binding SCOC.<sup>1747</sup> FEZ1 appears to be a negative regulator of macroautophagy when it is bound only to ULK1, and this inhibition is relieved upon formation of the trimeric complex containing SCOC. Similarly, the SCOC-FEZ1-UVRAG complex is inhibitory; dissociation of UVRAG under starvation conditions allows the activation of the class III PtdIns3K complex. See also SCOC.

**FIP200:** See RB1CC1.

**FIG4 (FIG4 phosphoinositide 5-phosphatase):** A phospholipid phosphatase that controls the generation and turnover of the PtdIns(3,5)P<sub>2</sub> phosphoinositide. Loss of FIG4 causes a decrease of PtdIns(3,5)P<sub>2</sub> levels, enlargement of late endosomes and lysosomes and cytosolic vacuolization.<sup>1748</sup> In human, recessive mutations in *FIG4* are responsible for the neurodegenerative Yunis-Varón syndrome, familial epilepsy with polymicrogyria, and Charcot-Marie-Tooth type 4J neuropathy. Haploinsufficiency of *FIG4* may also be a risk factor for amyotrophic lateral sclerosis.

**Fis1:** A component of the mitochondrial fission complex. Fis1 also plays a role in peroxisomal fission by recruiting Dnm1 to peroxisomes; it interacts with Atg11 to facilitate mitophagy and pexophagy-specific fission.<sup>705,1716</sup> See also Dnm1.

**FKBP1A (FK506 binding protein 1A, 12kDa):** An immunophilin that forms a complex with rapamycin and inhibits MTOR.

**FKBP5/FKBP51 (FK506 binding protein 5):** An immunophilin that forms a complex with FK506 and rapamycin; FKBP5 promotes macroautophagy in irradiated melanoma cells, thus enhancing resistance to radiation therapy.<sup>1749</sup> FKBP5 also associates with BECN1 and shows synergistic effects with antidepressants on macroautophagy in cells, mice and humans, possibly explaining its requirement in antidepressant action.<sup>1750</sup>

**FKBP12:** See FKBP1A.

**FKBP51:** See FKBP5.

**FLCN (folliculin):** A tumor suppressor mutated in Birt-Hogg-Dubé syndrome.<sup>1751</sup> FLCN interacts with GABARAP and this association is modulated by the presence of either FNIP1 (folliculin interacting protein 1) or FNIP2. ULK1 can induce FLCN phosphorylation, which modulates the FLCN-FNIP-GABARAP interaction.<sup>1752</sup> FLCN is also linked to MTOR modulation through its interaction with the RAG GTPases on lysosomes.<sup>1753,1754</sup>

**FM 4-64:** A lipophilic dye that primarily stains endocytic compartments and the yeast vacuole limiting membrane.

**FNBP1L (formin binding protein 1-like):** An F-BAR-containing protein that interacts with ATG3 and is required for the macroautophagy-dependent clearance of *S. typhimurium*, but not other types of autophagy.<sup>1755</sup>

**FNIP1 (folliculin interacting protein 1):** An interactor with the tumor suppressor FLCN. FNIP1<sup>464</sup> and its homolog FNIP2<sup>1752</sup> can also interact with GABARAP.

**FOXO1 (forkhead box O1):** A mammalian transcription factor that regulates macroautophagy independent of transcriptional control; the cytosolic form of FOXO1 is acetylated after dissociation from SIRT2, and binds ATG7 to allow induction of macroautophagy in response to oxidative

stress or starvation.<sup>1756</sup> FOXO1 can also be deacetylated by SIRT1, which leads to upregulation of RAB7 and increased autophagic flux.<sup>1757</sup> The *C. elegans* ortholog is DAF-16. See also SIRT1.

**FOXO3 (forkhead box O3):** A transcription factor that stimulates macroautophagy through transcriptional control of autophagy-related genes.<sup>642,1758</sup> The *C. elegans* ortholog is DAF-16.

**Frataxin:** See FXN.

**Fsc1:** A type I transmembrane protein localizing to the vacuole membrane in the fission yeast *S. pombe*; required for the fusion of autophagosomes with vacuoles.<sup>1695</sup>

**FUNDC1 (FUN14 domain containing 1):** A mitochondrial outer membrane protein that functions as a receptor for hypoxia-induced mitophagy.<sup>1759</sup> FUNDC1 contains a LIR and binds LC3.

**FUS (FUS RNA binding protein):** A DNA/RNA binding protein involved in DNA repair, gene transcription, and RNA splicing. FUS has also been implicated in tumorigenesis and RNA metabolism, and multiple missense and nonsense mutations in FUS are associated with amyotrophic lateral sclerosis. Macroautophagy reduces FUS-positive stress granules.<sup>1760</sup>

**FXN (frataxin):** A nuclear-encoded protein involved in iron-sulfur cluster protein biogenesis. Reduced expression of the *C. elegans* homolog, FRH-1, activates autophagy in an evolutionarily conserved manner.<sup>1274</sup>

**FYCO1 (FYVE and coiled-coil domain containing 1):** A protein that interacts with LC3, PtdIns3P and RAB7 to move autophagosomes toward the lysosome through microtubule plus end-directed transport.<sup>1761</sup>

**Gai3:** See GNAI3.

**GABA ( $\gamma$ -aminobutyric acid):** GABA inhibits the selective autophagy pathways mitophagy and pexophagy through Sch9, leading to oxidative stress, which can be mitigated by the Tor1 inhibitor rapamycin.<sup>1762</sup>

**GNAI3 (guanine nucleotide binding protein [G protein], alpha inhibiting activity polypeptide 3):** A heterotrimeric G protein that activates macroautophagy in the GDP-bound (inactive) form, and inhibits it when bound to GTP (active state).<sup>1763,1764</sup> See also GPSM1, RGS19, MAPK1/3 and CCDC88A.

**GABARAP [GABA(A) receptor-associated protein]:** A homolog of LC3.<sup>534,1765</sup> The GABARAP family includes GABARAP, GABARAPL1/Atg8L/GEC1, and GABARAPL2/GATE-16/GEF2. The GABARAP proteins are involved in autophagosome formation and cargo recruitment.<sup>142</sup>

**GADD34:** See PPP1R15A.

**GAIP:** See RGS19.

**Gap junction proteins/connexins:** Multispan membrane proteins that mediate intercellular communication through the formation of hemi-channels or gap junctions at the plasma membrane. These proteins act as endogenous inhibitors of autophagosome formation by directly interacting and sequestering at the plasma membrane essential ATG proteins required for autophagosome biogenesis.

**GATA1:** A hematopoietic GATA transcription factor, expressed in erythroid precursors, megakaryocytes, eosinophils,

and mast cells, that provides the differentiating cells with the requisite macroautophagy machinery and lysosomal components to ensure high-fidelity generation of erythrocytes.<sup>641</sup> See also ZFPM1/FOG1.

**GATE-16:** See GABARAP.

**Gaucher disease (GD):** Caused by mutations in the gene encoding GBA/glucocerebrosidase (glucosidase, beta, acid), Gaucher disease is the most common of the lysosomal storage disorders and can increase susceptibility to Parkinson disease.<sup>1766-1768</sup>

**GBA/glucocerebrosidase (glucosidase, beta acid):** A lysosomal enzyme that breaks down glucosylceramide to glucose and ceramide. Mutations cause Gaucher disease and are associated with increased risk of Parkinson disease. Loss of GBA is also associated with impaired autophagy and failure to clear dysfunctional mitochondria, which accumulate in the cell.<sup>1769</sup>

**Gcn2:** A mammalian and yeast EIF2S1/eIF2 $\alpha$  serine/threonine kinase that causes the activation of Gcn4 in response to amino acid depletion, thus positively regulating macroautophagy.<sup>1726</sup>

**Gcn4:** A yeast transcriptional activator that controls the synthesis of amino acid biosynthetic genes and positively regulates macroautophagy in response to amino acid depletion.<sup>1726</sup>

**GCN5L1:** A component of the mitochondrial acetyltransferase activity that modulates mitophagy and mitochondrial biogenesis.<sup>1770</sup>

**GEEC (GPI-enriched endocytic compartments) pathway:** A form of clathrin-independent endocytosis that contributes membrane for phagophore expansion.<sup>1771</sup>

**GFAP (glial fibrillary acid protein):** intermediate filament protein ubiquitously distributed in all cell types that bears functions beyond filament formation. Monomeric and dimeric forms of this protein associate with the cytosolic side of the lysosomal membrane and contribute to modulating the stability of the CMA translocation complex in a GTP-dependent manner coordinated with EEF1A/eF1 $\alpha$  also at the lysosomal membrane.<sup>1724</sup>

**GFER/ERV1 (growth factor, augmenter of liver regeneration):** A flavin adenine dinucleotide-dependent sulfhydryl oxidase that is part of a disulfide redox system in the mitochondrial intermembrane space, and is also present in the cytosol and nucleus. Downregulation of GFER results in elevated levels of the mitochondrial fission GTPase DNM1L/DRP1, and decreased mitophagy.<sup>1772</sup>

**GILT:** See IFI30.

**GIV/Girdin:** See CCDC88A.

**GLI3 (GLI family zinc finger 3):** A C<sub>2</sub>H<sub>2</sub> type of zinc finger transcription factor that plays a role in the transcriptional activation of *VMP1* during the induction of autophagy by the oncogene KRAS.<sup>634</sup> See also EP300.

**Glycophagy (glycogen autophagy):** The selective sequestration of glycogen and its subsequent vacuolar hydrolysis to produce glucose; this can occur by a micro- or macroautophagic process and has been reported in mammalian newborns and adult cardiac tissues as well as filamentous fungi.<sup>46,1308,1309,1773-1775</sup>

**GOPC/PIST/FIG/CAL (Golgi-associated PDZ and coiled-coil motif-containing protein):** Interacts with BECN1, and the SNARE protein STX6 (syntaxin 6). GOPC can induce autophagy via a CD46-Cyt-1 domain-dependent pathway following pathogen invasion.<sup>1671</sup>

**Gp78:** See AMFR.

**GNPMB (glycoprotein [transmembrane] nmb):** A protein involved in kidney repair that controls the degradation of phagosomes through macroautophagy.<sup>1776</sup>

**GPSM1/AGS3 (G-protein signaling modulator 1):** A guanine nucleotide dissociation inhibitor for GNAI3 that promotes macroautophagy by keeping GNAI3 in an inactive state.<sup>1668</sup>

GPSM1 directly binds LC3 and recruits GNAI3 to phagophores or autophagosomes under starvation conditions to promote autophagosome biogenesis and/or maturation. See also GNAI3.

**Granulophagy:** The process of bulk autophagic degradation of mRNP granules. The process has been characterized in *S. cerevisiae* and mammalian cells and is dependent on Cdc48/VCP in addition to the core autophagic machinery. The process is partially impaired by disease-causing mutations in VCP.<sup>1777</sup>

**GSK3B/GSK-3 $\beta$  (glycogen synthase kinase 3 beta):** A regulator of macroautophagy. GSK3B may act positively by inhibiting MTOR through the activation of TSC1/2 and by activating ULK1 through KAT5.<sup>1778</sup> GSK3B modulates protein aggregation through the phosphorylation of the macroautophagy receptor NBR1.<sup>1529</sup> GSK3B, however, it is also reported to be a negative regulator of macroautophagy. See also KAT5.

**HDAC6 (histone deacetylase 6):** A microtubule-associated deacetylase that interacts with ubiquitinated proteins. HDAC6 stimulates autophagosome-lysosome fusion by promoting the remodeling of F actin, and the quality control function of macroautophagy.<sup>665,666,1779</sup> HDAC is also a biomarker of aggresomes.<sup>1780</sup>

**HIF1A/HIF-1 $\alpha$  (hypoxia-inducible factor 1, alpha subunit [basic helix-loop-helix transcription factor]):** A dimeric transcription factor in which the  $\alpha$  subunit is regulated by oxygen; the hydroxylated protein is degraded by the proteasome. HIF1A-mediated expression of BNIP3 results in the disruption of the BCL2-BECN1 interaction, thus inducing macroautophagy.<sup>1781,1782</sup> HIF1A also regulates xenophagic degradation of intracellular *E. coli*.<sup>1783</sup>

**HK2 (hexokinase 2):** The enzyme responsible for phosphorylation of glucose at the beginning of glycolysis; during glucose starvation, HK2 switches from a glycolytic role and directly binds to and inhibits MTORC1 to induce macroautophagy.<sup>1784</sup>

**HLH-30:** *C. elegans* ortholog of the helix-loop-helix transcription factor TFEB.

**HMGB1 (high mobility group box 1):** A chromatin-associated nuclear protein that translocates out of the nucleus in response to stress such as ROS; HMGB1 binds to BECN1, displacing BCL2, thus promoting macroautophagy and inhibiting apoptosis.<sup>295</sup> In addition, macroautophagy promotes the release of HMGB1 from the nucleus and the cell, and extracellular HMGB1 can further induce macroautophagy through binding AGER.<sup>1785,1786</sup> See also AGER.

**Hog1:** A yeast MAPK involved in hyperosmotic stress, which is a homolog of mammalian MAPK/p38; Hog1 is required for mitophagy, but not other types of selective autophagy or nonselective autophagy.<sup>1787</sup> See also Pbs2, Slt2 and MAPK.

**Hrr25:** A casein kinase  $\delta/\epsilon$  homologous protein kinase regulating diverse cellular processes such as DNA repair and vesicular trafficking. Hrr25 phosphorylates the C terminus of Atg19, which is essential for Atg19 binding to Atg11 and subsequent



Cvt vesicle formation.<sup>1788</sup> Hrr25 also phosphorylates Atg36, and this phosphorylation is required for the interaction of Atg36 with Atg11 and subsequent pexophagy.<sup>1789</sup>

**HSC70:** See HSPA8.

**HSP70 (heat shock protein 70):** The major cytosolic heat shock-inducible member of the HSP70 family. This form accumulates in the lysosomal lumen in cancer cells. HSP70 is also a biomarker of aggresomes.<sup>1794</sup> See also HSPA1A.

**HSP90:** See HSP90AA1.

**HSP90AA1/HSP90/HSPC1 (heat shock protein 90kDa alpha [cytosolic], class A member 1):** A cytosolic chaperone that is also located in the lysosome lumen. The cytosolic form helps to stabilize BECN1, and promotes macroautophagy.<sup>1795</sup> The lysosomal form of HSP90AA1 contributes to the stabilization of LAMP2A during its lateral mobility in the lysosomal membrane.<sup>1796</sup>

**HSPA1A (heat shock protein family A [Hsp70] member 1A):** The major cytosolic stress-inducible version of the HSP70 family. This protein localizes to the lysosomal lumen in cancer cells, and pharmacological inhibition leads to lysosome dysfunction and inhibition of autophagy.<sup>1790</sup>

**HSPA5/GRP78/BiP (heat shock protein 5 family A [Hsp70] member 5):** A master regulator of the UPR. This chaperone, maintaining ER structure and homeostasis, can also facilitate macroautophagy.<sup>1791</sup>

**HSPA8/HSC70 (heat shock protein family A [Hsp70] member 8):** This multifunctional cytosolic chaperone is the constitutive member of the HSP70 family of chaperones and participates in targeting of cytosolic proteins to lysosomes for their degradation via chaperone-mediated autophagy.<sup>1792</sup> The cytosolic form of the protein also regulates the dynamics of the CMA receptor, whereas the luminal form (lys-HSPA8) is required for substrate translocation across the membrane.<sup>1793</sup> This chaperone plays a role in the targeting of aggregated proteins (in a KFERQ-independent manner) for degradation through chaperone-assisted selective autophagy,<sup>1116</sup> and in KFERQ-dependent targeting of cytosolic proteins to late endosomes for microautophagy.<sup>1115</sup> See also chaperone-assisted selective autophagy, chaperone-mediated autophagy, and endosomal microautophagy.

**HSPC1:** See HSP90AA1.

**HTRA2/Omi (HtrA serine peptidase 2):** A nuclear-encoded mitochondrial serine protease that was reported to degrade HAX1, a BCL2 family-related protein, to allow macroautophagy induction.<sup>1797</sup> In this study, knockdown of HTRA2, or the presence of a protease-defective mutant form, results in decreased basal macroautophagy that may lead to neurodegeneration. Separate studies, however, indicate that mitochondrial HTRA2 plays a role in mitochondrial quality control; in this case loss of the protein leads to increased macroautophagy and in particular mitophagy.<sup>1798-1800</sup>

**Hypersensitive response:** A rapid and locally restricted form of programmed cell death as part of the plant immune response to pathogen attack. The hypersensitive response is activated by different immune receptors upon recognition of pathogen-derived effector proteins, and can be positively regulated by macroautophagy.<sup>1092,1096,1801</sup>

**IAPP (islet amyloid polypeptide):** A 37 amino acid polypeptide derived from processing of an 89 amino acid precursor,

which is coexpressed with INS/insulin by pancreatic  $\beta$ -cells. IAPP aggregation is implicated in the pathogenesis of type 2 diabetes. Macroautophagy regulates IAPP levels through SQSTM1-dependent lysosomal degradation.<sup>1802-1804</sup>

**iC-MA (immune cell-mediated autophagy):** IL2-activated natural killer cell- and T cell-induced macroautophagy.<sup>1805</sup>

**Ice2:** See Ayr1.

**ICP34.5:** A neurovirulence gene product encoded by the herpes simplex virus type 1 (nns) that blocks EIF2S1-EIF2AK2 induction of autophagy.<sup>1726</sup> ICP34.5-dependent inhibition of autophagy depends upon its ability to bind to BECN1.<sup>892</sup>

**IDP (Intrinsically disordered protein):** A protein that does not possess unique structure and exists as a highly dynamic ensemble of interconverting conformations.<sup>1806-1809</sup> IDPs are very common in nature<sup>1810</sup> and have numerous biological functions that complement the functional repertoire of ordered proteins.<sup>1811-1814</sup> Many proteins involved in autophagy are IDPs.<sup>1815,1816</sup>

**IDPR (intrinsically disordered protein region):** A protein region without unique structure that may be biologically important. IDPRs are considered as a source of functional novelty,<sup>1817</sup> and they are common sites of protein-protein interactions<sup>1818</sup> and posttranslational modifications.<sup>1819</sup>

**IFI30/GILT (interferon, gamma-inducible protein 30):** A thiol reductase that controls ROS levels; in the absence of IFI30 there is an increase in oxidative stress that results in the upregulation of macroautophagy.<sup>1820</sup>

**IKK (I $\kappa$ B kinase):** An activator of the classical NF $\kappa$ B pathway composed of 3 subunits (CHUK/IKK $\alpha$ /IKK1, IKBKB/IKK $\beta$ /IKK2, IKBKG/IKK $\gamma$ /NEMO) that are required for optimal induction of macroautophagy in human and mouse cells.<sup>1821</sup>

**iLIR:** A web resource for prediction of Atg8 family interacting proteins (<http://repeat.biol.ucy.ac.cy/iLIR>).<sup>1482</sup>

**Iml1 complex:** A protein complex containing Iml1, Npr2 and Npr3 that regulates non-nitrogen-starvation-induced autophagosome formation; the complex partially localizes to the PAS.<sup>1822</sup> See also non-nitrogen-starvation (NNS)-induced autophagy.

**Immunoamphisomes:** An organelle derived from the fusion of endosomes/phagosomes with autophagosomes that regulate dendritic cell-mediated innate and adaptive immune responses.<sup>1823</sup>

**Immunophagy:** A sum of diverse immunological functions of autophagy.<sup>1824</sup>

**InlK:** An internalin family protein on the surface of *L. monocytogenes* that recruits vault ribonucleoprotein particles to escape xenophagy.<sup>1825</sup>

**Innate immune surveillance:** Recognition and response system for the sensing of DAMPs, including pathogens and products of somatically mutated genes. Innate surveillance responses include activation of macroautophagy to degrade DAMPs.<sup>1705</sup> See also DAMP.

**IMPA/inositol monophosphatase:** An enzyme that regulates the level of inositol 1,4,5-triphosphate (IP<sub>3</sub>) levels. Inhibition of IMPA stimulates macroautophagy independent of MTOR.<sup>1220</sup>

**IP<sub>3</sub>R:** See ITPR.

**IRGM (immunity-related GTPase family, M):** Involved in the macroautophagic control of intracellular pathogens.<sup>1826</sup> In mouse, this protein is named IRGM1.

**Irs4:** Irs4 and Tax4 localize to the PAS under autophagy-inducing conditions in yeast and play a role in the recruitment of Atg17.<sup>1827</sup> These proteins have partially overlapping functions and are required for efficient nonselective macroautophagy and pexophagy.

**Isolation membrane:** See phagophore.

**ITM2A (integral membrane protein 2A):** A target of PRKA/PKA-CREB that interacts with the V-ATPase and interferes with macroautophagic flux.<sup>1828</sup>

**ITPR1/2/3 (inositol 1,4,5-trisphosphate receptor, type 1/2/3):** A large tetrameric intracellular  $Ca^{2+}$ -release channel present in the ER that is responsible for the initiation/propagation of intracellular  $Ca^{2+}$  signals that can target the cytosol and/or organelles. The ITPR is activated by inositol 1,4,5-trisphosphate produced in response to extracellular agonists. Many proteins regulate the ITPR including anti-apoptotic BCL2-family proteins and BECN1. The ITPR can inhibit autophagy by scaffolding BECN1 as well as by driving  $Ca^{2+}$ -dependent ATP production,<sup>1220,1244,1246</sup> whereas BECN1-dependent sensitization of ITPR-mediated  $Ca^{2+}$  release (e.g., in response to starvation) can promote macroautophagic flux.<sup>297</sup>

**JNK1:** See MAPK8.

**Jumpy:** See MTMR14.

**JUN/c-Jun/JunB (jun proto-oncogene):** A mammalian transcription factor that inhibits starvation-induced macroautophagy.<sup>1829</sup>

**KAT5/TIP60 (K[lysine] acetyltransferase 5):** In response to growth factor deprivation, KAT5 is phosphorylated and activated by GSK3 and then acetylates and activates ULK1.<sup>1778</sup>

**Kcs1:** A yeast inositol hexakisphosphate/heptakisphosphate kinase; the *kcs1Δ* strain has a decrease in macroautophagy that may be associated with an incorrect localization of the PAS.<sup>1830</sup>

**KDM4A (lysine [K]-specific demethylase 4A):** A mammalian demethylase that regulates the expression of a subset of *ATG* genes.<sup>597,598</sup> See also Rph1.

**KEAP1 (kelch-like ECH-associated protein 1):** An E3 ubiquitin ligase responsible for the degradation of transcription factor NFE2L2/NRF2 and the NFKB activator IKBKB/IKK $\beta$ . KEAP1 is a substrate for SQSTM1-dependent sequestration. SQSTM1 influences oxidative stress-related gene transcription and regulates the NFKB pathway via its interaction with KEAP1.<sup>428,1831,1832</sup>

**KIAA0226:** See RUBCN.

**KIAA1524/CIP2A/cancerous inhibitor of protein phosphatase 2A:** KIAA1524/CIP2A suppresses MTORC1-associated PPP2/PP2A activity in an allosteric manner thereby stabilizing the phosphorylation of MTORC1 substrates and inhibiting autophagy. KIAA1524/CIP2A can be degraded by autophagy in an SQSTM1-dependent manner.<sup>1833</sup>

**KillerRed:** A red fluorescent protein that produces a high amount of superoxide upon excitation. The construct with a mitochondria targeting sequence (mitoKillerRed) can be used to induce mitochondria damage and subsequent mitophagy.<sup>766,767</sup>

**Knockdown:** An experimental technique to reduce protein expression without altering the endogenous gene encoding that protein, through the means of short DNA or RNA oligonucleotides (miRNA, RNAi, shRNA, siRNA) that are complementary to the corresponding mRNA transcript.

**Knockout:** Targeted inactivation of an endogenous genetic locus (or multiple loci) via homologous recombination or gene targeting technology.

**Ku-0063794:** A catalytic MTOR inhibitor that increases macroautophagic flux to a greater level than allosteric inhibitors such as rapamycin; short-term treatment with Ku-0063794 can inhibit both MTORC1 and MTORC2, but the effects on flux are due to the former.<sup>341</sup> See also WYE-354.

**KU55933:** An inhibitor of the class III PtdIns3K, which inhibits autophagosome formation at concentrations not affecting the class I PI3K.<sup>244</sup> Also inhibits ATM.

**LACRT (lacritin):** A prosecretory mitogen primarily in tears and saliva that transiently accelerates autophagic flux in stressed cells.<sup>1834</sup> Lacritin targets heparanase-deglycanated SDC1 (syndecan 1) on the cell surface,<sup>1835</sup> and accelerates flux by stimulating the acetylation of FOXO3 as a novel ligand for ATG101 and by promoting the coupling of stress acetylated FOXO1 with ATG7.<sup>1836</sup>

**Laforin:** See EPM2A.

**LAMP2 (lysosomal-associated membrane protein 2):** A widely expressed and abundant single-span lysosomal membrane protein. Three spliced variants of the *LAMP2* gene have been described. Knockout of the entire gene results in altered intracellular vesicular trafficking, defective lysosomal biogenesis, inefficient autophagosome clearance and alterations in intracellular cholesterol metabolism.<sup>1837-1839</sup> In human, deficiency of LAMP2 causes a cardioskeletal autophagic vacuolar myopathy, called Danon disease.<sup>1840</sup>

**LAMP2A (lysosomal-associated membrane protein 2A):** One of the spliced variants of the *LAMP2* gene that functions as a lysosomal membrane receptor for chaperone-mediated autophagy.<sup>1108</sup> LAMP2A forms multimeric complexes that allow translocation of substrates across the lysosome membrane.<sup>1796</sup> Regulation of LAMP2A is partly achieved by dynamic movement into and out of lipid microdomains in the lysosomal membrane.<sup>1793</sup>

**Late nucleophagy:** A process in which bulk nucleoplasm is delivered to the vacuole after prolonged periods of nitrogen starvation and subsequently degraded within the vacuole lumen.<sup>720</sup>

**LC3:** See MAP1LC3.

**LC3-associated phagocytosis (LAP):** Phagocytosis in macrophages that involves the conjugation of LC3 to single-membrane phagosomes, a process that promotes phagosome acidification and fusion with lysosomes.<sup>182</sup> TLR signaling is required for LAP and leads to the recruitment of the BECN1 complex to phagosomes. See also NADPH oxidase.

**Ldb16:** See Ayr1.

**Ldh1:** See Ayr1.

**LGG-1:** A *C. elegans* homolog of Atg8.

**LGG-2:** A *C. elegans* homolog of Atg8.

**LGG-3:** A *C. elegans* homolog of Atg12.

**Lipophagy:** Selective degradation of lipid droplets by lysosomes contributing to lipolysis (breakdown of triglycerides into free fatty acids). In mammals, this selective degradation has been described to occur via macroautophagy (macrolipophagy),<sup>817</sup> whereas in yeast, microlipophagy of cellular lipid stores has also been described. This process is distinct from the PNPLA5-dependent mobilization of lipid droplets as contributors of lipid precursors to phagophore membranes.

**Lipoxygenases:** Mycobacterial infection-responsive expression of these proteins, such as ALOX5 and ALOX15, inhibits IFNG-induced macroautophagy in macrophages.<sup>528</sup>

**LIR/LRS (LC3-interacting region):** This term refers to the WXXL-like sequences (consensus sequence [W/F/Y]-X-X-[I/L/V]) found in proteins that bind to the Atg8/LC3/GABARAP family of proteins (see also AIM and WXXL-motif).<sup>364</sup> The core LIR residues interact with 2 hydrophobic pockets of the ubiquitin-like domain of the Atg8 homologs.

**LITAF (lipopolysaccharide-induced TNF factor):** An activator of inflammatory cytokine secretion in monocytes that has other functions in different cell types; LITAF is a positive regulator of macroautophagy in B cells.<sup>1841</sup> LITAF associates with autophagosomes, and controls the expression of *MAP1LC3B*.

**LKB1:** See STK11.

**LMP (lysosome membrane permeabilization):** The process by which lysosomal membranes become disrupted through the action of lysosomotropic agents, detergents or toxins.<sup>1842</sup> LMP blocks lysosomal activity and thus autophagy and induces the release of lysosomal content to the cytoplasm including cathepsins that can induce cell death.<sup>1843,1844</sup>

**LON2 (LON protease 2):** A protease localized to the peroxisome matrix that impedes pexophagy in *Arabidopsis*.<sup>1845</sup>

**Long-lived protein degradation (LLPD):** Macroautophagy is a primary mechanism used by cells to degrade long-lived proteins, and a corresponding assay can be used to monitor autophagic flux;<sup>3</sup> a useful abbreviation is LLPD.<sup>486</sup>

**Lro1:** See Ayr1.

**Lucanthone:** An anti-schistosome compound that inhibits a late stage of macroautophagy; treatment results in deacidification of lysosomes and the accumulation of autophagosomes.<sup>1846</sup>

**LRPPRC (leucine-rich pentatricopeptide repeat containing):** A mitochondrion-associated protein that binds BCL2 and PARK2 to control the initiation of general autophagy and mitophagy.<sup>1847,1848</sup>

**LRRK2 (leucine-rich repeat kinase 2):** A large multidomain, membrane-associated kinase and GTPase whose Parkinson disease-associated mutations affect the regulation of macroautophagy.<sup>196,1849</sup>

**LRS (LC3 recognition sequence):** See LIR/LRS.

**LRSAM1 (leucine rich repeat and sterile alpha motif containing 1):** A human leucine-rich repeat protein that potentially interacts with GABARAPL2; knockdown of *LRSAM1* results in a defect in anti-*Salmonella* autophagy.<sup>1850</sup>

**Ltn1:** See Rkr1.

**LY294002:** An inhibitor of phosphoinositide 3-kinases and PtdIns3K; it inhibits macroautophagy.<sup>1851</sup>

**LYNUS (lysosomal nutrient sensing):** A complex including MTORC1 and the V-ATPase located on the lysosomal surface that senses nutrient conditions.<sup>825</sup> The LYNUS complex regulates TFEB activity.

**Lys05:** A dimeric chloroquine derivative that accumulates in the lysosome and inhibits macroautophagy.<sup>1852,1853</sup>

**Lysophagy:** The macroautophagic removal of damaged lysosomes.<sup>829,830</sup>

**Lysosome:** A degradative organelle in higher eukaryotes that compartmentalizes a range of hydrolytic enzymes and maintains a highly acidic pH. A primary lysosome is a relatively small compartment that has not yet participated in a

degradation process, whereas secondary lysosomes are sites of present or past digestive activity. The secondary lysosomes include autolysosomes and telolysosomes. Autolysosomes/early secondary lysosomes are larger compartments actively engaged in digestion, whereas telolysosomes/late secondary lysosomes do not have significant digestive activity and contain residues of previous digestions. Both may contain material of either autophagic or heterophagic origin.

**Macroautophagy:** The largely nonselective autophagic sequestration of cytoplasm into a double- or multiple-membrane-delimited compartment (an autophagosome) of non-lysosomal/vacuolar origin and its subsequent degradation by the lysosomal/vacuolar system. Note that certain proteins and organelles may be selectively degraded via a macroautophagy-related process, and, conversely, some cytosolic components such as cytoskeletal elements are selectively excluded.

**MAGEA3 (melanoma antigen family A3):** MAGEA3 and MAGEA6 form a complex with the E3 ligase TRIM28, resulting in the degradation of AMPK and the subsequent increase in MTOR activity, which in turn causes a downregulation of macroautophagy.<sup>1854</sup> See also TRIM28.

**MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3):** A homolog of yeast Atg8, which is frequently used as a phagophore or autophagosome marker. Cytosolic LC3-I is conjugated to phosphatidylethanolamine to become phagophore- or autophagosome-associated LC3-II.<sup>269</sup> The LC3 family includes LC3A, LC3B, LC3B2 and LC3C. These proteins are involved in the biogenesis of autophagosomes, and in cargo recruitment.<sup>142</sup> Vertebrate LC3 is regulated by phosphorylation of the N-terminal helical region by PRKA/PKA.<sup>343</sup>

**MAP1S (microtubule-associated protein 1S):** A ubiquitously distributed homolog of the neuron-specific MAP1A and MAP1B with which LC3 was originally copurified. It is required for autophagosome trafficking along microtubular tracks.<sup>1855,1856</sup>

**MAP3K7/MEKK7/TAK1 (mitogen-activated protein kinase kinase 7):** Required for TNFSF10/TRAIL-induced activation of AMPK and for optimal macroautophagy induction by multiple stimuli.<sup>1857</sup>

**MAPK1 (mitogen-activated protein kinase 1):** A kinase that along with MAPK3 phosphorylates and stimulate RGS19/Gα-interacting protein/GAIP, which is a GTPase activating protein (GAP) for the trimeric GNAI3 protein that activates macroautophagy,<sup>1858</sup> and which may be involved in BECN1-independent autophagy.<sup>83</sup> Constitutively active MAPK1/3 also traffics to mitochondria to activate mitophagy.<sup>758</sup>

**MAPK3:** See MAPK1.

**MAPK8/JNK1:** A stress-activated kinase that phosphorylates BCL2 at Thr69, Ser70 and Ser87, causing its dissociation from BECN1, thus inducing macroautophagy.<sup>569</sup>

**MAPK8IP1/JIP1 (mitogen-activated protein kinase 8 interacting protein 1):** A LIR-containing LC3-binding protein that mediates the retrograde movement of RAB7-positive autophagosomes in axons.<sup>1859</sup> Movement toward the proximal axon involves activation of dynein, whereas binding of LC3 to MAPK8IP1 prevents activation of kinesin. The DUSP1/MKP1 phosphatase may dephosphorylate Ser421, promoting binding to dynein.

**MAPK9/JNK2:** A stress-activated kinase that prevents the accumulation of acidic compartments in cells undergoing macroautophagic flux, thus keeping stressed cells alive.<sup>1860</sup>

**MAPK14 (mitogen-activated protein kinase 14):** A signaling component that negatively regulates the interaction of ATG9 and SUPT20H/FAM48A, and thus inhibits macroautophagy. In addition, MAPK14-mediated phosphorylation of ATG5 at T75 negatively regulates autophagosome formation.<sup>1861</sup> The widely used pyridinyl imidazole class inhibitors of MAPK14 including SB202190 interfere with macroautophagy in a MAPK/p38-independent manner and should not be used to monitor the role of this signaling pathway in macroautophagy.<sup>1862,1863</sup> The yeast homolog is Hog1. See also Hog1.

**MAPK15/ERK7/ERK8 (mitogen activated protein kinase 15):** MAPK15 is a LIR-containing protein that interacts with LC3B, GABARAP and GABARAPL1.<sup>1864</sup> This kinase is localized in the cytoplasm and can be recruited to macroautophagic membranes through its binding to ATG8-like proteins. MAPK15 responds to starvation stimuli by self-activating through phosphorylation on its T-E-Y motif, and its activation contributes to the regulation of macroautophagy.

**MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2):** MAPKAPK2 is a Ser/Thr protein kinase downstream of MAPK/p38. Its activation contributes to starvation-induced macroautophagy by phosphorylating BECN1.<sup>1525</sup> See also BECN1.

**MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase 3):** MAPKAPK3 shares a similar function with MAPKAPK2 in macroautophagy.<sup>1525</sup> See also MAPKAPK2 and BECN1.

**Matrine:** A natural compound extract from traditional Chinese medicine that inhibits autophagy by elevating lysosomal pH and interfering with the maturation of lysosomal proteases.<sup>1865</sup>

**MB21D1/cGAS (Mab-21 domain containing 1):** A cytosolic sensor that produces cGAMP to initiate IFN production via TMEM173/STING upon binding microbial DNA.<sup>1866</sup> MB21D1 also binds to BECN1, releasing RUBCN, resulting in the induction of macroautophagy to eliminate cytosolic pathogens and cytosolic DNA; the latter serves to downregulate the immune response to prevent overactivation.

**MDC (monodansylcadaverine):** A lysosomotropic autofluorescent compound that accumulates in acidic compartments such as autolysosomes, and also labels (but is not specific for) autophagosomes.<sup>1,1134</sup>

**MDK-ALK axis:** MDK (midkine [neurite growth-promoting factor 2]) is a growth factor for which increased levels are associated with a poor prognosis in malignant tumors. MDK promotes resistance to cannabinoid-evoked autophagy-mediated cell death via stimulation of ALK (anaplastic lymphoma receptor tyrosine kinase). Targeting of the MDK-ALK axis could help to improve the efficacy of antitumoral therapies based on the stimulation of macroautophagy-mediated cancer cell death.<sup>1867,1868</sup>

**Mdm10:** A component of the ERMES complex in yeast that is required for mitophagy. See also ERMES.<sup>1737</sup>

**Mdm12:** A component of the ERMES complex in yeast. Mdm12 colocalizes with Atg32-Atg11 and is required for mitophagy. See also Atg11, Atg32, and ERMES.<sup>705,1737</sup>

**Mdm34:** A component of the ERMES complex in yeast. Mdm34 colocalizes with Atg32-Atg11 and is required for mitophagy. See also Atg11, Atg32, and ERMES.<sup>705,1737</sup>

**Mdv1:** A component of the mitochondrial fission complex. It plays a role in mediating mitophagy-specific fission.<sup>705</sup> See also Dnm1.

**MEFV/TRIM20/pyrin (Mediterranean fever):** The gene encoding MEFV is a site of polymorphisms associated with familial Mediterranean fever; MEFV/TRIM20 acts as a receptor for selective macroautophagy of several inflammasome components.<sup>1869</sup>

**Mega-autophagy:** The final lytic process during developmental programmed cell death in plants that involves tonoplast permeabilization and rupture, resulting in the release of hydrolases from the vacuole, followed by rapid disintegration of the protoplast at the time of cell death.<sup>1398,1870,1871</sup> This term has also been used to refer to the rupture of the yeast vacuole during sporulation, which results in the destruction of cellular material, including nuclei that are not used to form spores.<sup>1872</sup>

**Megaphagosomes:** Very large (5–10  $\mu\text{m}$ ) double-membraned, autophagy-related vesicles that accumulate in cells infected by coxsackievirus and, possibly, influenza virus.<sup>194</sup>

**MGEA5/NCOAT/O-GlcNAcase/oga-1 (meningioma expressed antigen 5 [hyaluronidase]):** MGEA5 removes the O-GlcNAc modification and regulates the macroautophagy machinery by countering the action of OGT.<sup>1873</sup> See also OGT.

**Microautophagy:** An autophagic process involving direct uptake of cytosol, inclusions (e.g., glycogen) and organelles (e.g., ribosomes, peroxisomes) at the lysosome/vacuole by protrusion, invagination or septation of the sequestering organelle membrane.

**MIPA (micropexophagic apparatus):** A curved double-membrane structure formed by the PAS that may serve as a scaffold for completion of the sequestration of peroxisomes during micropexophagy; fusion with the vacuolar sequestering membranes encloses the organelles within an intraluminal vesicle.<sup>1874</sup> See also vacuolar sequestering membranes.

**Mitochondrial spheroid:** A mitochondrial structure formed in PARK2-deficient cells treated with a mitochondrial uncoupler (such as CCCP).<sup>1875,1876</sup> Under this condition, mitophagy fails to occur and a damaged mitochondrion can transform into a spheroid containing cytosolic components in the newly formed lumen.

**MIR21 (microRNA 21):** A miRNA that is overexpressed in almost all types of solid tumors and is involved in cancer chemoresistance. MIR21 modulates macroautophagy and the sensitivity of tumor cells toward drugs that induce macroautophagy.<sup>1877</sup>

**Mir31 (microRNA 31):** A mouse miRNA that targets PPP2/PP2A to inhibit IFNG-induced macroautophagy in macrophages during mycobacterial infection.<sup>528</sup> See also Mir155.

**MIR95:** A human miRNA that inhibits macroautophagy and blocks lysosome function via repression of SUMF1.<sup>247</sup>

**MIR101:** A human miRNA that inhibits macroautophagy and the expression of STMN1, RAB5A and ATG4D.<sup>243</sup>

**Mir155:** A mouse miRNA that targets PPP2/PP2A to inhibit IFNG-induced macroautophagy in macrophages during mycobacterial infection.<sup>528</sup> See also Mir31.

**MIR205:** A microRNA precursor that impairs the autophagic flux in castration-resistant prostate cancer cells by downregulating the lysosome-associated proteins RAB27A and LAMP3.<sup>1878</sup>

**MITF (microphthalmia-associated transcription factor):** A transcription factor belonging to the microphthalmia/transcription factor E (MiT/TFE) family, along with TFEB and TFE3; MITF binds to symmetrical DNA sequences (E-boxes; 5'-CACGTG-3'), and regulates lysosomal biogenesis and macroautophagy (including the genes *BCL2*, *UVRAG*, *ATG16L1*, *ATG9B*, *GABARAPL1*, and *WIPI1*). MITF shares a common mechanism of regulation with TFEB and TFE3; MITF can partially compensate when TFEB is lost upon specific stimuli or in specific cell types.<sup>639,1879</sup> See also TFEB.

**Mitophagic body:** The single-membrane vesicle present inside the vacuole lumen following the fusion of a mitophagosome with a vacuole.

**Mitophagosome:** An autophagosome containing mitochondria and no more than a small amount of other cytoplasmic components, as observed during selective macromitophagy.<sup>42,748</sup>

**Mitophagy:** The selective autophagic sequestration and degradation of mitochondria; can occur by a micro- or macroautophagic process.<sup>1880</sup>

**Mitostatin:** See TCHP.

**Mkk1/2:** A MAPKK downstream of Bck1 that is required for mitophagy and pexophagy in yeast.<sup>1787</sup> See also Bck1 and Slt2.

**MLN4924:** An inhibitor of NAE1 (NEDD8-activating enzyme E1 subunit 1) that is required for CUL/CULLIN-RING E3 ligase activation; treatment with MLN4924 induces macroautophagy through the accumulation of the MTOR inhibitory protein DEPTOR.<sup>1505</sup>

**Mmm1:** A component of the ERMES complex in yeast that is required for mitophagy. See also ERMES.<sup>1737</sup>

**MORN2 (MORN repeat containing 2):** MORN2 is a membrane occupation and recognition nexus (MORN)-motif protein that was identified in mouse testis. The gene localizes on chromosome 17E3, spanning approximately 7 kb; *Morn2* contains 669 nucleotides of open reading frame, and encodes 79 amino acids.<sup>1881</sup> MORN domains have the sequence GKYYGQWQ. MORN2 promotes the recruitment of LC3 in LAP, and MORN2 co-immunoprecipitates with LC3.<sup>515</sup>

**MREG (melanoregulin):** A cargo sorting protein that associates with MAP1LC3 in LC3-associated phagocytosis.<sup>1882,1883</sup>

**MTDH/AEG-1 (metadherin):** An oncogenic protein that induces noncanonical (BECN1- and class III PtdIns3K-independent) macroautophagy as a cytoprotective mechanism.<sup>1884</sup>

**MTM-3:** A *C. elegans* myotubularin lipid phosphatase that is an ortholog of human MTMR3 and MTMR4; MTM-3 acts upstream of EPG-5 to catalyze the turnover of PtdIns3P and promote autophagosome maturation.<sup>1885</sup>

**MTM1 (myotubularin 1):** A PtdIns3P and PtdIns(3,5)P<sub>2</sub> 3-phosphatase.<sup>1886</sup> Mutations affecting MTM1 lead to myotubular myopathy and alteration of macroautophagy.

**MTMR3 (myotubularin related protein 3):** This protein localizes to the phagophore and negatively regulates macroautophagy. See also MTMR14.<sup>1887</sup>

**MTMR6 (myotubularin related protein 6):** A PtdIns3P-phosphatase; knockdown of MTMR6 increases the level of LC3-II.<sup>1888</sup>

**MTMR7 (myotubularin related protein 7):** A PtdIns3P-phosphatase; knockdown of MTMR7 increases the level of LC3-II.<sup>1888</sup>

**MTMR8 (myotubularin related protein 8):** A phosphoinositide phosphatase with activity toward PtdIns3P and PtdIns(3,5)

P<sub>2</sub>; MTMR8 in a complex with MTMR9 inhibits macroautophagy based on the formation of WIPI1 puncta.<sup>1889</sup>

**MTMR9 (myotubularin related protein 9):** A catalytically inactive myotubularin that increases the activity of other members of the MTMR family and controls their substrate specificity; MTMR8-MTMR9 preferentially dephosphorylates PtdIns3P and thus inhibits macroautophagy.<sup>1889</sup>

**MTMR13:** See SBF2.

**MTMR14/Jumpy (myotubularin related protein 14):** A member of the myotubularin family that is a PtdIns3P-phosphatase; knockdown increases macroautophagic activity.<sup>1888,1890</sup> MTMR14 regulates the interaction of WIPI1 with the phagophore. The *Drosophila* homolog is EDTP.

**MTOR (mechanistic target of rapamycin [serine/threonine kinase]):** The mammalian ortholog of TOR. Together with its binding partners it forms either MTOR complex 1 (MTORC1) or MTOR complex 2 (MTORC2). See also TORC1 and TORC2.

**MTORC1/2 (MTOR complex 1/2):** See TORC1 and TORC2.

**Multivesicular body (MVB)/multivesicular endosome:** An endosome containing multiple 50- to 80-nm vesicles that are derived from invagination of the limiting membrane. Under some conditions the MVB contains hydrolytic enzymes in which case it may be considered to be a lysosome or autolysosome with ongoing microautophagy.

**Multivesicular body sorting pathway:** A process in which proteins are sequestered into vesicles within the endosome through the invagination of the limiting membrane. This process is usually, but not always, dependent upon ubiquitin tags on the cargo and serves as one means of delivering integral membrane proteins destined for degradation into the vacuole/lysosome lumen. ESCRT (endosomal sorting complex required for transport) complexes are required for the formation of MVBs and for autophagosome maturation.<sup>1891</sup>

**MYO1C (myosin IC):** A class I myosin that functions as an actin motor protein essential for the trafficking of cholesterol-rich lipid rafts from intracellular storage compartments to the plasma membrane; MYO1C is important for efficient autophagosome-lysosome fusion.<sup>1892</sup>

**MYO6 (myosin VI):** A unique, minus-end directed actin motor protein required for autophagosome maturation and fusion with a lysosome via delivery of early endosomes to autophagosomes; mediated by the interaction of MYO6 with the alternative ESCRT-0 protein TOM1.<sup>879,1893</sup>

**NAA10/ARD1 (N[alpha]-acetyltransferase 10, NatA catalytic subunit):** A protein that interacts with and stabilizes TSC2 by acetylation, resulting in repression of MTOR and induction of macroautophagy.<sup>1894</sup>

**NACC1/NAC1 (nucleus accumbens associated 1, BEN and BTB [POZ] domain containing):** A transcription factor that increases the expression and cytosolic levels of HMGB1 in response to stress, thereby increasing macroautophagy activity.<sup>1895</sup>

**NADPH oxidases:** These enzymes contribute to macroautophagic targeting of *Salmonella* in leukocytes and epithelial cells through the generation of reactive oxygen species.<sup>881</sup> The CYBB/NOX2 NADPH oxidase in macrophages is required for LC3-associated phagocytosis.

**NAF-1:** See CISD2.

**NAMPT/visfatin (nicotinamide phosphoribosyltransferase):** NAMPT is a protein that catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein belongs to the nicotinic acid phosphoribosyltransferase (NAPRTase) family and is thought to be involved in many important biological processes, including metabolism, stress response and aging. NAMPT promotes neuronal survival through inducing macroautophagy via regulating the TSC2-MTOR-RPS6KB1 signaling pathway in a SIRT1-dependent manner during cerebral ischemia.<sup>1896</sup>

**NAPA/ $\alpha$ SNAP (N-ethylmaleimide-sensitive factor attachment protein, alpha):** A key regulator of SNARE-mediated vesicle fusion. Loss of NAPA promotes noncanonical macroautophagy in human epithelial cells by interrupting ER-Golgi vesicle trafficking and triggering Golgi fragmentation.<sup>1897</sup>

**NBR1 (neighbor of BRCA1 gene 1):** A selective substrate of macroautophagy with structural similarity to SQSTM1. Functions as a receptor that binds ubiquitinated proteins and LC3 to allow the degradation of the former by a macroautophagy-like process.<sup>364</sup> NBR1 shows specificity for substrates including peroxisomes<sup>783</sup> and ubiquitinated aggregates.<sup>364</sup> Phosphorylation of NBR1 by GSK3A/B prevents the aggregation of ubiquitinated proteins.<sup>1529</sup>

**NCOA4 (nuclear receptor coactivator 4):** A selective cargo receptor that is involved in iron homeostasis through the recycling of ferritin by macroautophagy.<sup>804</sup> See also ferritinophagy.

**NDP52:** See CALCOCO2.

**Necroptosis:** A form of programmed necrotic cell death;<sup>1898</sup> induction of macroautophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.<sup>1899</sup>

**NFKB/NF- $\kappa$ B (nuclear factor of kappa light polypeptide gene enhancer in B-cells):** NFKB activates MTOR to inhibit macroautophagy.<sup>1900</sup>

**NH<sub>4</sub>Cl (ammonium chloride):** A weak base that is protonated in acidic compartments and neutralizes them; inhibits the clearance of autophagosomes and amphisomes.

**NHLRC1/EPM2B/malin (NHL repeat containing E3 ubiquitin protein ligase 1):** A putative E3-ubiquitin ligase, which forms a complex with EPM2A/laforin. Recessive mutations in the genes *EPM2A*, or *NHLRC1/EMP2B* are found in the majority of cases of Lafora disease, a very rare type of progressive neurodegeneration associated with impaired macroautophagy.<sup>1901</sup>

**Nitric oxide:** A gas and a messenger that has complex regulatory roles in macroautophagy, depending on its concentration and the cell type.<sup>344,1902-1904</sup>

**NID-1 (novel inducer of cell death 1):** A small molecule that induces activation of an ATG5- and CTSL-dependent cell death process reminiscent of macroautophagy.<sup>1450</sup>

**NIX:** See BNIP3L.

**NOD (nucleotide-binding oligomerization domain):** An intracellular peptidoglycan (or pattern recognition) receptor that senses bacteria and induces macroautophagy, involving ATG16L1 recruitment to the plasma membrane during bacterial cell invasion.<sup>1905</sup>

**Non-nitrogen-starvation (NNS)-induced autophagy:** A type of macroautophagy that is induced when yeast cells are shifted from rich to minimal medium; this process is controlled in part by the Iml1, Npr2 and Npr3 proteins.<sup>1822</sup>

**Noncanonical autophagy:** A functional macroautophagy pathway that only uses a subset of the characterized ATG proteins to generate an autophagosome. BECN1-independent,<sup>83,1463</sup> and ATG5-ATG7-independent<sup>27</sup> forms of macroautophagy have been reported.

**NPY (neuropeptide Y):** An endogenous neuropeptide produced mainly by the hypothalamus that mediates caloric restriction-induced macroautophagy.<sup>1906</sup>

**NR1D1/Rev-erba (nuclear receptor subfamily 1, group D, member 1):** A nuclear receptor that represses macroautophagy in mouse skeletal muscle. *nr1d1*<sup>-/-</sup> mice display increased autophagy gene expression along with consistent changes in autophagy protein levels and macroautophagic flux.<sup>611</sup>

**NRBF2 (nuclear receptor binding factor 2):** NRBF2 is the mammalian homolog of yeast Atg38, and is a binding partner of the BECN1-PIK3C3 complex; NRBF2 is required for the assembly of the ATG14-BECN1-PIK3C3/VPS34-PIK3R4/VPS15 complex and regulates macroautophagy.<sup>1907,1908</sup> *Nrbf2* knockout mice display impaired ATG14-linked PIK3C3 lipid kinase activity and impaired macroautophagy.

**NSP2:** A nonstructural protein of Chikungunya virus that interacts with human CALCOCO2 (but not the mouse ortholog) to promote viral replication. In contrast, binding of SQSTM1 to ubiquitinated capsid leads to viral degradation through macroautophagy.<sup>1909</sup>

**Nucleophagy:** The selective autophagic degradation of the nucleus or parts of the nucleus.

**Nucleus-vacuole junction (NVJ):** Junction formed by the interaction between Nvj1, a membrane protein of the outer nuclear membrane, and Vac8 of the vacuole membrane, that are necessary for micronucleophagy.<sup>718</sup> See also piecemeal microautophagy of the nucleus.

**NUPR1/p8 (nuclear protein, transcriptional regulator, 1):** A transcriptional regulator that controls macroautophagy by repressing the transcriptional activity of FOXO3.<sup>1910</sup>

**NVP-BGT226 (8-[6-methoxy-pyridin-3-yl]-3-methyl-1-[4-piperazin-1-yl-3-trifluoromethyl-phenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one maleate):** A class I PI3K and MTOR dual inhibitor that induces macroautophagy.<sup>1911</sup>

**NVT (Nbr1-mediated vacuolar targeting):** A pathway used for the delivery of cytosolic hydrolases (Lap2 and Ape2) into the vacuole in *S. pombe* that involves interaction with Nbr1 and relies on the ESCRT machinery.<sup>1912</sup>

**OATL1:** See TBC1D25.

**OGT/ogt-1 (O-linked N-acetylglucosamine [GlcNAc] transferase):** OGT is a nutrient-dependent signaling transferase that regulates the autophagy machinery by adding the O-GlcNAc modification. Similar to phosphorylation, this modification is involved in signaling.<sup>1873</sup>

**Omeosome:** ZFYVE1-containing structure located at the ER that is involved in autophagosome formation during amino acid starvation.<sup>583</sup>

**Omi:** See HTRA2.

**Oncophagy:** A general term describing cancer-related autophagy.<sup>1913</sup>

**OPTN (optineurin):** An autophagy receptor that functions in the elimination of *Salmonella*; OPTN has a LIR and a ubiquitin-binding domain, allowing it to link tagged bacteria to the autophagy machinery.<sup>880</sup> Phosphorylation of OPTN by TBK1 increases its affinity for LC3. OPTN may function together with CALCOCO2/NDP52 and TAX1BP1/CALCOCO3. See also CALCOCO2, TAX1BP1 and TBK1.

**Organellophagy:** General terminology for autophagic processes selective for organelles such as peroxisomes, mitochondria, the nucleus, and ER.<sup>704,1914</sup>

**Oxiapoptophagy:** A type of cell death induced by oxysterols that involves OXidation + APOPTOsis + autoPHAGY.<sup>837,838</sup>

**Oxidized phospholipids:** Oxidized phospholipids induce macroautophagy, and in ATG7-deficient keratinocytes and melanocytes the levels of phospholipid oxidation are elevated.<sup>1915,1916</sup>

**Oxysterols:** Oxysterols are cholesterol oxide derivatives obtained either from auto-oxidation or by enzymatic oxidation of cholesterol (<http://lipidlibrary.aocs.org/Primer/content.cfm?ItemNumber=39304>). Some of them (7-ketocholesterol, 7 $\beta$ -hydroxycholesterol, 24[S]-hydroxycholesterol) can induce a complex type of cell death named oxiapoptophagy.<sup>836-838</sup> See also oxiapoptophagy.

**P0:** A plant virus-encoded F-box protein that targets AGO1/ARGONAUTE1 to macroautophagy in order to suppress RNA silencing.<sup>849</sup>

**p8:** See NUPR1.

**p14ARF:** See CDKN2A.

**p27/p27Kip1:** See CDKN1B.

**p38 $\alpha$ :** See MAPK14.

**p38IP:** See SUPT20H.

**p53:** See TP53.

**p62:** see SQSTM1.

**p97:** See VCP.

**PARK2/parkin (parkin RBR E3 ubiquitin protein ligase):**

An E3 ubiquitin ligase (mutated in autosomal recessive forms of Parkinson disease) that is recruited from the cytosol to mitochondria following mitochondrial depolarization, mitochondrial import blockade or accumulation of unfolded proteins in the mitochondrial matrix, or ablation of the rhomboid protease PARL, to promote their clearance by mitophagy.<sup>250,1917-1920</sup>

PINK1-dependent phosphorylation of Ser65 in the ubiquitin-like domain of PARK2 and in ubiquitin itself (see phosphorylated ubiquitin/p-S65-Ub) promotes activation and recruitment of PARK2 to mitochondria (reviewed in ref. 745),<sup>1921</sup> and USP8 deubiquitination of K6-linked ubiquitin on PARK2 to promote its efficient recruitment.<sup>1922</sup>

**PARK7/DJ-1 (parkinson protein 7):** An oncogene product whose loss of function is associated with Parkinson disease; overexpression suppresses macroautophagy through the MAPK8/JNK pathway.<sup>1923</sup>

**Parkin:** See PARK2.

**PARL (presenilin associated, rhomboid-like):** The mammalian ortholog of *Drosophila* rhomboid-7, a mitochondrial intra-membrane protease; regulates the stability and localization of PINK1.<sup>1920,1924,1925</sup> A missense mutation in the N terminus has been identified in some patients with Parkinson disease.<sup>1926</sup> See also PINK1.


**PARP1 (poly [ADP-ribose] polymerase 1):** A nuclear enzyme involved in DNA damage repair; doxorubicin-induced DNA

damage elicits a macroautophagic response that is dependent on PARP1.<sup>1927</sup> In conditions of oxidative stress, PARP1 promotes macroautophagy through the STK11/LKB1-AMPK-MTOR pathway.<sup>1928</sup>

**PAS:** See phagophore assembly site.

**PAWR/par-4 (PRKC, apoptosis, WT1, regulator):** A cancer selective apoptosis-inducing tumor suppressor protein that functions as a positive regulator of macroautophagy when overexpressed.<sup>1929,1930</sup>

**PBPE:** A selective and high affinity ligand of the microsomal antiestrogen-binding site (AEBS). PBPE induces protective macroautophagy in cancer cells through an AEBS-mediated accumulation of zymostenol (5 $\alpha$ -cholest-8-en-3 $\beta$ -ol).<sup>1239,1931</sup>



**Pbs2:** A yeast MAPKK upstream of Hog1 that is required for mitophagy.<sup>1787</sup>

**Pcd1:** A yeast cyclin that activates Pho85 to stimulate macroautophagy by inhibiting Sic1.<sup>1683</sup>

**Pcd5:** A yeast cyclin that activates Pho85 to inhibit macroautophagy through degradation of Gcn4.<sup>1683</sup>

**PDPK1/PDK1 (3-phosphoinositide dependent protein kinase 1):** An activator of AKT. Recruited to the plasma membrane and activated by PtdIns(3,4,5)P<sub>3</sub> which is generated by the class I phosphoinositide 3-kinase.

**PEA15/PED (phosphoprotein enriched in astrocytes 15):** A death effector domain-containing protein that modulates MAPK8 in glioma cells to promote macroautophagy.<sup>1932</sup>

**PDCD6IP (programmed cell death 6 interacting protein):** PDCD6IP is an ESCRT-associated protein that interacts with the ATG12-ATG3 conjugate to promote basal macroautophagy.<sup>1933</sup> See also 12-ylation.

**PEG3 (paternally expressed 3):** A DCN (decorin)- and endorepellin-induced, genomically imprinted tumor suppressor gene that is required for macroautophagy in endothelial cells.<sup>1708</sup>

PEG3 colocalizes with and physically binds to canonical macroautophagic markers such as BECN1 and LC3. Moreover, loss of PEG3 ablates the DCN- or endorepellin-mediated induction of BECN1 or MAP1LC3A; basal expression of BECN1 mRNA and BECN1 protein requires PEG3. See also DCN and endorepellin.

**Peripheral structures:** See Atg9 peripheral structures.

**PERK:** See EIF2AK3.

**PES/pifithrin- $\mu$  (2-phenylethanesulfonamide):** A small molecule inhibitor of HSPA1A/HSP70-1/HSP72; PES interferes

with lysosomal function, causing a defect in macroautophagy and chaperone-mediated autophagy.<sup>1934</sup>

**peup (peroxisome unusual positioning):** Mutants isolated in *Arabidopsis thaliana* that accumulate aggregated peroxisomes.<sup>1935</sup> The *peup1*, *peup2* and *peup4* mutants correspond to mutations in *ATG3*, *ATG18a* and *ATG7*.

**Pexophagic body:** The single-membrane vesicle present inside the vacuole lumen following the fusion of a pexophagosome with a vacuole.


**Pexophagosome:** An autophagosome containing peroxisomes, but largely excluding other cytoplasmic components; a pexophagosome forms during macropexophagy.<sup>1936</sup>

**Pexophagy:** A selective type of autophagy involving the sequestration and degradation of peroxisomes; it can occur by a micro- or macroautophagy-like process (micro- or macropexophagy).<sup>130</sup>

**PGRP (peptidoglycan-recognition protein):** A cytosolic *Drosophila* protein that induces autophagy in response to invasive *L. monocytogenes*.<sup>1937</sup>

**Phagolysosome:** The product of a single-membrane phagosome fusing directly with a lysosome in a process that does not involve macroautophagy (we include this definition here simply for clarification relative to autolysosome, autophagosome and autophagolysosome).<sup>884</sup>

**Phagophore (PG):** Membrane cisterna that has been implicated in an initial event during formation of the autophagosome. Thus, the phagophore may be the initial sequestering compartment of macroautophagy.<sup>1938</sup> The phagophore has previously been referred to as the “isolation membrane.”<sup>5</sup>



**Phagophore assembly site (PAS):** A perivacuolar compartment or location that is involved in the formation of Cvt vesicles, autophagosomes and other sequestering compartments used in macroautophagy and related processes in fungi. The PAS may supply membranes during the formation of the sequestering vesicles or may be an organizing center where most of the autophagic machinery resides, at least transiently. The PAS or its equivalent is yet to be defined in mammalian cells.<sup>177,1939</sup>

**Pho8:** A yeast vacuolar phosphatase that acts upon 3' nucleotides generated by Rny1 to generate nucleosides.<sup>1940</sup> A modified form of Pho8, Pho8 $\Delta$ 60, is used in an enzymatic assay for monitoring macroautophagy in yeast. See also Rny1 and Pho8 $\Delta$ 60 assay.

**Pho23:** A component of the yeast Rpd3L histone deacetylase complex that negatively regulates the expression of *ATG9* and other *ATG* genes.<sup>601</sup>


**Pho80:** A yeast cyclin that activates Pho85 to inhibit macroautophagy in response to high phosphate levels.<sup>1683</sup>

**Pho8 $\Delta$ 60 assay:** An enzymatic assay used to monitor macroautophagy in yeast. Deletion of the N-terminal cytosolic

tail and transmembrane domain of Pho8 prevents the protein from entering the secretory pathway; the cytosolic mutant form is delivered to the vacuole via macroautophagy, where proteolytic removal of the C-terminal propeptide by Prb1 generates the active enzyme.<sup>261,262,677</sup>

**Pho85:** A multifunctional cyclin-dependent kinase that interacts with at least 10 different cyclins or cyclin-like proteins to regulate the cell cycle and responses to nutrient levels. Pho85 acts to negatively and positively regulate macroautophagy, depending on its binding to specific cyclins.<sup>1683</sup> See also Clg1, Pcl1, Pcl5, Pho80 and Sic1.

**Phosphatidylinositol 3-kinase (PtdIns3K):** A family of enzymes that add a phosphate group to the 3' hydroxyl on the inositol ring of phosphatidylinositol. The 3' phosphorylating lipid kinase isoforms are subdivided into 3 classes (I-III) and the class I enzymes are further subdivided into class IA and IB. The class III phosphatidylinositol 3-kinases (see PIK3C3 and Vps34) are stimulatory for macroautophagy, whereas class I enzymes (referred to as phosphoinositide 3-kinases) are inhibitory.<sup>1941</sup> The class II PtdIns3K substantially contributes to PtdIns3P generation and autophagy in *Pik3c3* knockout MEFs, also functioning as a positive factor for macroautophagy induction.<sup>1942</sup> In yeast, Vps34 is the catalytic subunit of the PtdIns3K complex. There are 2 yeast PtdIns3K complexes, both of which contain Vps34, Vps15 (a regulatory kinase), and Vps30/Atg6. Complex I includes Atg14 and Atg38 and is involved in autophagy, whereas complex II contains Vps38 and is involved in the vacuolar protein sorting (Vps) pathway. See also phosphoinositide 3-kinase.



**Phosphatidylinositol 3-phosphate (PtdIns3P):** The product of the PtdIns3K. PtdIns3P is present at the PAS, and is involved in the recruitment of components of the macroautophagic machinery. It is important to note that PtdIns3P is also generated at the endosome (e.g., by the yeast PtdIns3K complex II). Additionally, FYVE-domain probes block PtdIns3P-dependent signaling, presumably by sequestering the molecule away from either interactions with downstream effectors or preventing its interconversion by additional kinases.<sup>1943</sup> Thus, general PtdIns3P probes such as GFP-tagged FYVE and PX domains are generally not good markers for the macroautophagy-specific pool of this phosphoinositide.



**Phosphatidylinositol 3,5-bisphosphate (PtdIns[3,5]P<sub>2</sub>):** This molecule is generated by PIKFYVE (phosphoinositide kinase, FYVE finger containing) and is abundant at the membrane of the late endosome. Its function is relevant for the replication of intracellular pathogens such as the bacteria *Salmonella*,<sup>1944</sup> and ASFV.<sup>1945</sup> PtdIns(3,5)P<sub>2</sub> also plays a role in regulating macroautophagy.<sup>1946</sup>

**Phosphoinositide 3-kinase/PI3K:** The class I family of enzymes that add a phosphate group to the 3' hydroxyl on the inositol ring of phosphoinositides. PI3K activity results in the activation of MTOR and the inhibition of macroautophagy.

**Phosphoinositides (PI) or inositol phosphates:** These are membrane phospholipids that control vesicular traffic and physiology. There are several different phosphoinositides generated by quick interconversions by phosphorylation/dephosphorylation at different positions of their inositol ring by a number of kinases and phosphatases. The presence of a particular PI participates in conferring membrane identity to an organelle.

**Phosphorylated ubiquitin/p-S65-Ub:** Phosphorylated ubiquitin is essential for PINK1-PARK2-mediated mitophagy and plays a dual role in the initial activation and recruitment of PARK2 to damaged mitochondria (reviewed in ref. 745). Specific antibodies can be used to faithfully detect PINK1-PARK2-dependent mitophagy at early steps;<sup>744</sup> however, the exact functions of p-S65-Ub during the different phases of mitophagy remain unclear.

**Piecemeal microautophagy of the nucleus (PMN)/micronucleophagy:** A process in which portions of the yeast nuclear membrane and nucleoplasm are invaginated into the vacuole, scissioned off from the remaining nuclear envelope and degraded within the vacuole lumen.<sup>715,716</sup>

**PI4K2A/PI4KII $\alpha$  (phosphatidylinositol 4-kinase type 2 alpha):** A lipid kinase that generates PtdIns4P, which plays a role in autophagosome-lysosome fusion.<sup>1947</sup> PI4K2A is recruited to autophagosomes through an interaction with GABARAP or GABARAPL2 (but the protein does not bind LC3).

**PIK3C3 (phosphatidylinositol 3-kinase, catalytic subunit type 3):** The mammalian homolog of yeast Vps34, a class III PtdIns3K that generates PtdIns3P, which is required for macroautophagy.<sup>1941</sup> In mammalian cells there are at least 3 PtdIns3K complexes that include PIK3C3/VPS34, PIK3R4/VPS15 and BECN1, and combinations of ATG14, UVRAG, AMBRA1, SH3GLB1 and/or RUBCN. See also phosphatidylinositol 3-kinase)

**PIK3CB/p110 $\beta$  (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta):** A catalytic subunit of the class IA phosphoinositide 3-kinase; this subunit plays a positive role in macroautophagy induction that is independent of MTOR or AKT, and instead acts through the generation of PtdIns3P, possibly by acting as a scaffold for the recruitment of phosphatases that act on PtdIns(3,4,5)P<sub>3</sub> or by recruiting and activating PIK3C3.<sup>1948</sup>

**PIK3R4/p150/VPS15 (phosphoinositide-3-kinase, regulatory subunit 4):** The mammalian homolog of yeast Vps15, PIK3R4 is a core component of all complexes containing PIK3C3 and is required for macroautophagy.<sup>1949</sup> PIK3R4 interacts with the kinase domain of PIK3C3, to regulate its activity and also functions as a scaffold for binding to NRBF2 and ATG14.<sup>1907,1908</sup> While PIK3R4 is classified as a protein serine/threonine kinase,

it possesses an atypical catalytic domain and lacks catalytic activity, at least in vitro (J. Murray, personal communication). PIK3R4 also interacts with RAB GTPases, including RAB5<sup>1950</sup> that may be responsible for recruitment of PIK3C3-PIK3R4-complexes to sites of autophagosome formation.

**PINK1/PARK6 (PTEN induced putative kinase 1):** A mitochondrial protein kinase (mutated in autosomal recessive forms of Parkinson disease) that is normally degraded in a membrane potential-dependent manner to maintain mitochondrial structure and function,<sup>1924,1951</sup> suppressing the need for mitophagy.<sup>757</sup> Upon mitochondrial depolarization, mitochondrial import blockade, accumulation of unfolded proteins in the mitochondrial matrix or ablation of the inner membrane protease PARL, PINK1 is stabilized and activated, phosphorylating ubiquitin (see phosphorylated ubiquitin/p-S65-Ub) and PARK2 for full activation and recruitment of PARK2 (reviewed in ref. 745) to facilitate mitophagy.<sup>1917-1921,1952</sup> See also PARL.

**PKA (protein kinase A):** A serine/threonine kinase that negatively regulates macroautophagy in yeast;<sup>1953</sup> composed of the Tpk1/2/3 catalytic and Bcy1 regulatory (inhibitory) subunits. The mammalian PKA homolog, PRKA, directly phosphorylates LC3.<sup>343</sup> Bacterial toxins that activate mammalian PRKA can also inhibit autophagy.<sup>1954</sup> In addition, cAMP inducers, such as  $\beta_2$ -adrenergic agonists (D.A.P. Gonçalves, personal communication), CALC/calcitonin gene-related peptide (J. Machado, personal communication) and forskolin plus isobutylmethylxanthine (W.A. Silveira, personal communication), block the conversion of LC3-I to LC3-II in C2C12 myotubes and adult skeletal muscles. Phosphorylation of the fission modulator DNM1L by mitochondrially-localized PRKA blocks mitochondrial fragmentation and autophagy induced by loss of endogenous PINK1 or by exposure to a neurotoxin in neuronal cell cultures.<sup>1717</sup> See also DNM1L.

**PKB:** See AKT.

**Pkc1:** A yeast serine/threonine kinase involved in the cell wall integrity pathway upstream of Bck1; required for pexophagy and mitophagy.<sup>1787</sup> See also Bck1 and Slr2.

**PKC $\delta$ :** See PRKCD.

**PKR:** See EIF2AK2.

**Plastolysome:** A plant plastid that transforms into a lytic compartment, with acid phosphatase activity, engulfing and digesting cytoplasmic regions in particular cell types and under particular developmental processes.<sup>811-814</sup>

**PLEKHM1:** An autophagic adaptor protein that contains a LIR motif, which directs binding to all of the LC3/GABARAP proteins. PLEKHM1 also interacts with GTP-bound RAB7 and the HOPS (homotypic fusion and protein sorting) complex. PLEKHM1 is present on the cytosolic face of late endosomes, autophagosomes, amphisomes and lysosomes, and serves to coordinate endocytic and macroautophagic pathway convergence at, and fusion with, the lysosome.<sup>1956</sup>

**PMT7:** A phloroglucinol derivative used as a chemotherapeutic drug to target glycolytic cancer cells.<sup>1957</sup>

**PND (programmed nuclear destruction):** A yeast cell death-related process that occurs during gametogenesis involving a noncanonical type of vacuole-dependent degradation.<sup>1872</sup>

**PNPLA5 (patatin-like phospholipase domain containing 5):** A lipase that mobilizes neutral lipid stores (e.g., triglycerides in lipid droplets) to enhance macroautophagic capacity of

the cell by contributing lipid precursors for membrane biogenesis (thus enhancing macroautophagic capacity) and signaling.<sup>1958</sup> This process should not be confused with the process of lipophagy, which is uptake of lipid droplets for triglyceride degradation in autolysosomes.

**PNS (peri-nuclear structure):** A punctate structure in *P. pastoris* marked by Atg35, which requires Atg17 for recruitment and is involved in micropexophagy; the PNS may be identical to the PAS.<sup>1615</sup>

**Polyphenol:** A class of plant phytochemicals that have been described as autophagy regulators in different disease models, such as neurodegenerative disease (reviewed in ref. 1959) including Parkinson disease,<sup>1960</sup> and cancer (reviewed in ref. 1961).

**PP242:** A pharmacological catalytic kinase inhibitor of TOR; inhibits TORC1 and TORC2.

**PPARs (peroxisome proliferator-activated receptors):** Ligand-activated transcription factors, members of the nuclear receptor superfamily, consisting of 3 isotypes: PPARA/PPAR $\alpha$ /NR1C1 (peroxisome proliferator-activated receptor alpha), PPARD/PPAR $\delta$ /NR1C2, and PPARG/PPAR $\gamma$ /NR1C3.<sup>772</sup> PPAR-mediated signaling pathways regulate, or are regulated by, molecules involved in macroautophagy.<sup>1962,1963</sup>

**PPI (protein-protein interaction):** Proper biological activity of many proteins depends on physical interactions with other proteins. Specific PPI has a functional objective. Therefore, complete understanding of protein function requires consideration of proteins in the context of their binding partners.<sup>1964,1965</sup> Often, interactions between proteins and protein complexes are presented in a form of large densely connected networks (PPI networks). Such network-based representation of PPIs provide the means for a more complete understanding of physiological and pathogenic mechanisms.<sup>1966</sup>

**PPM1D/Wip1 (protein phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent, 1D):** A protein phosphatase that negatively regulates ATM and macroautophagy.<sup>1967</sup>

**PPP1 (protein phosphatase 1):** A serine/threonine protein phosphatase that regulates ATG16L1 by dephosphorylation of CSNK2-modified Ser139 to inhibit macroautophagy. See also CSNK2.<sup>1694</sup>

**PPP1R15A/GADD34 (protein phosphatase 1, regulatory subunit 15A):** A protein that is upregulated by growth arrest and DNA damage; PPP1R15A binds to and dephosphorylates TSC2, leading to mTOR suppression and macroautophagy induction.<sup>1968</sup>

**PPP2 (protein phosphatase 2):** A serine/threonine protein phosphatase that positively regulates macroautophagy via BECN1.<sup>1969</sup>

**PPP2R5A (protein phosphatase 2, regulatory subunit B', alpha):** B56 subunit of PPP2/PP2A, a phosphatase that binds to and dephosphorylates GSK3B at Ser9 to make it active and thus activate macroautophagy.<sup>528</sup>

**PPP3R1 (protein phosphatase 3, regulatory subunit B, alpha):** A regulatory subunit of the calcium-dependent phosphatase PPP3/calcineurin. In response to a calcium pulse via the lysosomal calcium channel MCOLN1, PPP3 dephosphorylates Ser142 and Ser211 of TFEB, leading to nuclear localization and upregulation of the CLEAR network.<sup>1970</sup> See also CLEAR and TFEB.

**prApe1 (precursor Ape1):** See Ape1.

**Pre-autophagosomal structure (PAS):** See phagophore assembly site.

**PRKA (protein kinase, cAMP-dependent):** The mammalian homolog of yeast PKA. See also PKA.

**PRKCD/PKC $\delta$  (protein kinase C, delta):** PRKCD regulates MAPK8 activation. PRKCD also activates NADPH oxidases, which are required for antibacterial macroautophagy.<sup>1714</sup> See also NADPH oxidases.

**PRKD1 (protein kinase D1):** A serine/threonine kinase that activates PIK3C3/VPS34 by phosphorylation; recruited to phagophore membranes.<sup>1971</sup>

**PRMT-1/EPG-11:** An arginine methyltransferase in *C. elegans* that is the homolog of PRMT1.<sup>1735</sup> PRMT-1/EPG-11 regulates the association of PGL granules with EPG-2 and LGG-1 puncta. PRMT-1/EPG-11 directly methylates arginine residues in the RGG domain of PGL-1 and PGL-3.

**Programmed cell death (PCD):** Regulated self-destruction of a cell. Type I is associated with apoptosis and is marked by cytoskeletal breakdown and condensation of cytoplasm and chromatin followed by fragmentation. Type II is associated with macroautophagy and is characterized by the presence of autophagic vacuoles (autophagosomes) that sequester organelles. Type III is marked by the absence of nuclear condensation, and the presence of a necrotic morphology with swelling of cytoplasmic organelles (oncosis). These categories of cell death are based on morphological criteria, and the Nomenclature Committee on Cell Death now recommends the use of terms that are more precise and refer to different types of regulated cell death (RCD).<sup>1091</sup>

**PROPPINs ( $\beta$ -propellers that bind phosphoinositides):** A WD40-protein family conserved from yeast to human.<sup>1972</sup> These proteins fold as 7-bladed  $\beta$ -propellers, and each blade contains 4 antiparallel  $\beta$ -strands. With 2 lipid binding sites at the circumference of their propeller they bind PtdIns3P and PtdIns(3,5)P<sub>2</sub>.<sup>1973-1975</sup> The *S. cerevisiae* PROPPINs are Atg18, Atg21 and Hsv2, and the mammalian counterparts are termed WIPIs.

**Proteaphagy:** The selective macroautophagic degradation of the 26S proteasome.<sup>1976</sup> Proteaphagy is stimulated by either starvation or proteasome activation.

**Proto-lysosomes:** Vesicles derived from autolysosomes that mature into lysosomes during autophagic lysosome reformation.<sup>527</sup> See also autophagic lysosome reformation.

**Protophagy:** Autophagy-like processes in microbial populations. The term summarizes all self-destructing patterns in prokaryotic colonies including bacterial cannibalism, autolysis, programmed cell death, and other processes, in which a part of the colony is lysed and consumed by neighboring prokaryotic cells to recycle matter and energy.<sup>1977</sup>

**PSEN (presenilin):** A protease that is part of the  $\gamma$ -secretase complex. Mutations in PSEN1 result in the accumulation of autophagosomes resulting at least in part from a defect in lysosomal acidification; one of the V-ATPase subunits does not target properly to the lysosome.<sup>61,1978</sup>

**PTEN (phosphatase and tensin homolog):** A 3' phosphoinositide phosphatase that dephosphorylates PtdIns(3,4,5)P<sub>3</sub>, thereby inhibiting PDK1/PDK1 and AKT activity.

**PTM (posttranslational modification):** After biosynthesis, many proteins undergo covalent modifications that are often

catalyzed by special enzymes that recognize specific target sequences in particular proteins. PTMs provide dramatic extension of the structures, properties, and physico-chemical diversity of amino acids, thereby diversifying structures and functions of proteins.<sup>1979</sup> There are more than 300 physiological PTMs.<sup>1980</sup> Some PTMs (e.g., phosphorylation, acetylation, glycosylation, etc.) are reversible by the action of specific deconjugating enzymes. The interplay between modifying and demodifying enzymes allows for rapid and economical control of protein function.<sup>1979</sup> PTMs clearly play a role in regulating the macroautophagy machinery.<sup>651,1981</sup>

**PTP4A3 (protein tyrosine phosphatase type IVA, member 3):** A plasma membrane- and endosome-localized prenylated protein phosphatase that stimulates macroautophagy; PTP4A3 is also an autophagic substrate.<sup>1982</sup>

**PTPRS/PTP $\sigma$  (protein tyrosine phosphatase, receptor type, S):** A dual domain protein tyrosine phosphatase that antagonizes the action of the class III PtdIns3K; loss of PTPRS results in hyperactivation of basal and induced macroautophagy.<sup>1983</sup>

**PULKA (p-ULK1 assay):** This acronym describes the analysis of Ser317 phosphorylated (activated) ULK1 puncta by fluorescence microscopy.<sup>1984</sup>

**RAB1:** See Ypt1.

**RAB4A:** This small GTPase was previously called HRES-1/Rab4, as it is encoded by the antisense strand of the HRES-1 human endogenous retroviral locus in region q42 of human chromosome 1.<sup>1985</sup> It has been recently designated as RAB4A to distinguish it from RAB4B on human chromosome 19. RAB4A regulates the endocytic recycling of surface proteins, such as CD4, CD247/CD3 $\zeta$ , CD2AP, and TFRC/CD71, which control signal transduction through the immunological synapse in human T lymphocytes.<sup>1985,1986</sup> Among these proteins, CD4 and CD247 are targeted by RAB4A for lysosomal degradation via macroautophagy.<sup>1985-1987</sup> Beyond T lymphocytes, RAB4A generally promotes the formation of LC3<sup>+</sup> autophagosomes and the accumulation of mitochondria during macroautophagy.<sup>1988</sup> During accelerated macroautophagy, RAB4A also promotes the lysosomal degradation of intracellular proteins, such as DNM1L/Drp1 that initiates the fission and turnover of mitochondria.<sup>971,1989</sup> Thus, RAB4A-mediated depletion of DNM1L selectively inhibits mitophagy and causes the accumulation of mitochondria in patients and mice with lupus.<sup>1987</sup> The formation of interconnected mitochondrial tubular networks is enhanced by constitutively active RAB4A<sup>Q72L</sup> upon starvation, which may contribute to the retention of mitochondria during macroautophagy.<sup>1988</sup>

**RAB7:** A small GTPase of the RAS oncogene family functioning in transport from early to late endosomes and from late endosomes to lysosomes.<sup>1990</sup> RAB7 is also needed for the clearance of autophagic compartments, most likely for the fusion of amphisomes with lysosomes.<sup>1136,1991</sup> The yeast homolog is Ypt7.

**RAB8:** A small GTPase of the RAS oncogene family. RAB8A functions in secretory autophagy,<sup>1036</sup> whereas RAB8B plays a role in degradative autophagy.<sup>1992</sup>

**RAB11:** A small GTPase that is required for autophagosome formation; ULK1 and ATG9 localize in part to RAB11-positive recycling endosomes.<sup>1993</sup> See also TBC1D14.

**RAB12:** A small GTPase that controls degradation of the amino acid transporter SLC36A4/PAT4 (solute carrier family 36 [proton/amino acid symporter], member 4) and indirectly regulates MTORC1 activity and macroautophagy.<sup>1994</sup>

**RAB21:** A small GTPase that is required for autophagosome-lysosome fusion. Starvation induces RAB21 activity that promotes VAMP8 trafficking to the lysosome, where VAMP8 is needed to mediate fusion. See also SBF2.<sup>1995</sup>

**RAB24:** A small GTPase with unusual characteristics that associates with autophagic vacuoles and is needed for the clearance of autolysosomes under basal conditions.<sup>1996,1997</sup>

**RAB32:** A small GTPase that localizes to the ER, and enhances autophagosome formation under basal conditions.<sup>1998</sup>

**RAB33B:** A small GTPase of the medial Golgi complex that binds ATG16L1 and plays a role in autophagosome maturation by regulating fusion with lysosomes.<sup>1999</sup> RAB33B is a target of TBC1D25/OATL1, which functions as a GAP.<sup>2000</sup>

**RABG3b:** A RAB GTPase that functions in the differentiation of tracheary elements of the *Arabidopsis* xylem through its role in macroautophagy; this protein is a homolog of RAB7/Ypt7.<sup>1094</sup>

**RAD001 (Everolimus):** An orally administered derivative of rapamycin.

**RAG:** See RRAG.

**RAGE:** See AGER.

**RAL:** A RRAS-like subfamily in the RAS family, RAL small GTPases typically function downstream of the RRAS effector RALGDS/RalGEF and are inhibited by RALGAP, a heterodimeric GAP structurally analogous to TSC1/2 that functions as a GAP for RHEB.<sup>2001,2002</sup> The RAL subfamily includes mammalian RALA and RALB, *Drosophila* Rala, and *C. elegans* RAL-1. Mammalian RALB regulates exocytosis, the immune response and an anabolic/catabolic switch. In nutrient-rich conditions RALB-GTP binds EXOC2/Sec5 and EXOC8/Exo84, and through the latter associates with MTORC1 to promote anabolic metabolism.<sup>2003</sup> Under starvation conditions RALB-GTP nucleates phagophore formation through assembly of a ULK1-BECN1-PIK3C3 complex, also via interaction with the EXOC8/Exo84 protein.<sup>1741</sup> Although RALB direct activation and indirect inactivation (through MTORC1) of macroautophagy appears contradictory, RALB may function as a critical anabolic/catabolic switch in response to global and local nutrient contexts. RALB may be an analog of yeast Sec4.<sup>2004</sup> See also EXOC2, Sec4/RAB40B and EXOC8.

**RALGAP:** A heterodimeric complex consisting of catalytic alpha and regulatory beta subunits, RALGAP inactivates RAL small GTPases. RALGAP is structurally analogous to the TSC1/2 GAP, and like TSC1/2 is phosphorylated and inhibited by AKT.<sup>2001,2005</sup> An additional partner of the RALGAP complex, NKIRAS1/kappaB-Ras, also inhibits RAL function.<sup>2006</sup> See also RAL.

**RANS (required for autophagy induced under non-nitrogen-starvation conditions) domain:** Also referred to as domain of unknown function 3608 (DUF3608; PFAM: PF12257, <http://pfam.xfam.org/family/PF12257>), this sequence in Iml1 is required for non-nitrogen starvation-induced autophagy.<sup>1822</sup> This domain is spread throughout the eukaryotes (see for example, <http://pfam.xfam.org/family/PF12257#tabview=tab7>) and frequently reported in combination with a DEP

(Dishevelled, Egl-10, and Pleckstrin) domain (PFAM: PF00610), which is also the case with Iml1.<sup>1822</sup> See also non-nitrogen starvation (NNS)-induced autophagy.

**Rapamycin:** Allosteric TOR (in particular, TOR complex 1) inhibitor, which induces autophagy. TOR complex 2 is much less sensitive to inhibition by rapamycin.

**RAPTOR:** See RPTOR.

**Ras:** See RRAS.

**RB1-E2F1 (Retinoblastoma 1-E2 transcription factor 1):** RB1 is a tumor suppressor that promotes growth arrest, and protects against apoptosis. E2F1 regulates the transition from the G<sub>1</sub> to the S phase in the cell cycle, and is a pro-apoptotic member of the E2F transcription family. In addition to controlling the cell cycle and apoptosis, the interaction between RB1 and E2F1 regulates macroautophagy; RB1 and E2F1 downregulate and upregulate BCL2, respectively, resulting in the induction of macroautophagy or apoptosis.<sup>615</sup>


**RB1CC1/FIP200 (RB1-inducible coiled-coil 1):** A putative mammalian functional counterpart of yeast Atg17. RB1CC1 is a component of the ULK1 complex.<sup>1533</sup> In addition, RB1CC1 interacts with other proteins in several signaling pathways, suggesting the possibility of macroautophagy-independent functions, and a potential role in linking other cellular functions and signaling pathways to macroautophagy.

**Reactive oxygen species (ROS):** Chemically-reactive molecules that contain oxygen, including hydrogen peroxide, the hydroxyl radical ·OH, and the superoxide radical ·O<sub>2</sub><sup>-</sup>. Hydrogen peroxide transiently inhibits delipidation of LC3 by ATG4, which is permissive for starvation-induced autophagy.<sup>519</sup> Superoxide is essential for triggering injury-induced mitochondrial fission and mitophagy.<sup>757</sup>

**Ref(2)P:** The *Drosophila* homolog of SQSTM1.

**Residual body:** A lysosome that contains indigestible material such as lipofuscin.<sup>2007</sup>

**Resveratrol:** An allosteric activator of SIRT1 and inhibitor of several other cellular proteins<sup>1510</sup> that induces macroautophagy.<sup>2008</sup>



**Reticulophagy:** The selective degradation of ER by a macroautophagy-like process.<sup>843</sup> Macroautophagy counterbalances ER expansion during the unfolded protein response. Activation of the UPR in yeast induces reticulophagy.

**RGS19/GAIP (regulator of G-protein signaling 19):** A GTPase activating protein that inactivates GNAI3 (converting it to the GDP-bound form) and stimulates macroautophagy.<sup>2009</sup> See also GNAI3.

**RHEB (Ras homolog enriched in brain):** A small GTP-binding protein that activates MTOR when it is in the GTP-bound form.<sup>280</sup>

**Ribophagy:** The selective sequestration and degradation of ribosomes by a macroautophagy-like process.<sup>847</sup>

**Rim15:** A yeast kinase that regulates transcription factors in response to nutrients. Rim15 positively regulates macroautophagy and is negatively regulated by several upstream kinases including TOR, PKA, Sch9 and Pho85.<sup>1683,2010</sup>

**RIPK1 (receptor [TNFRSF]-interacting serine-threonine kinase 1):** RIPK1 inhibits basal macroautophagy independent of its kinase function, through activation of MAPK1/3 and inhibition of TFEB.<sup>2011</sup>

**Rkr1:** A yeast ubiquitin ligase that antagonizes ribophagy.<sup>848</sup>

**RNASET2/RNS2 (ribonuclease T2):** A conserved class II RNase of the T2 family that localizes to the lumen of the ER (or an ER-related structure) and vacuole in *Arabidopsis*, and to lysosomes in zebrafish; RNASET2 is involved in rRNA turnover, and *rns2* mutants display constitutive macroautophagy, likely due to a defect in cellular homeostasis.<sup>2012,2013</sup>

**RNF216 (ring finger protein 216):** An E3 ubiquitin ligase that mediates the ubiquitination and the subsequent degradation of BECN1, thus acting as a negative regulator of macroautophagy.<sup>2014</sup>

**Rny1:** A yeast vacuolar RNase that hydrolyzes RNA that has been delivered to the vacuole via macroautophagy into 3' nucleotides.<sup>1940</sup> See also Pho8.

**Rpd3:** A yeast histone deacetylase that negatively regulates the expression of ATG8.<sup>1233</sup> See also Sin3/SIN3 and Ume6.

**Rph1:** A histone demethylase that negatively regulates the expression of ATG7; demethylase activity is not required for transcriptional repression.<sup>597,598</sup>

**RPN10:** A component of the 26S proteasome lid. RPN10 acts as a receptor that binds ATG8 during proteophagy in *Arabidopsis*.<sup>1976</sup>

**RPS6KB1/p70S6 kinase/S6K1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1):** A substrate of MTORC1, in mammalian cells RPS6KB1/2 inhibits INSR (insulin receptor), which in turn causes a reduction in the activity of the class I PI3K and subsequently MTORC1; this may represent a feedback loop to help maintain basal levels of macroautophagy.<sup>1145,1218</sup> Conversely, under conditions of long-term starvation RPS6KB1/2 levels may fall sufficiently to allow reactivation of MTORC1 to prevent excessive macroautophagy. In *Drosophila*, the RPS6KB1/2 ortholog S6k may act in a more direct manner to positively regulate macroautophagy.<sup>280</sup>

**RPS6KB2:** See RPS6KB1.

**RPTOR/raptor (regulatory associated protein of MTOR, complex 1):** A component of MTORC1. RPTOR interacts with ULK1, allowing MTORC1 to phosphorylate both ULK1 and ATG13, and thus repress ULK1 kinase activity and autophagy.<sup>490,491,2015</sup> This interaction also permits a negative feedback loop to operate, whereby ULK1 phosphorylates RPTOR to inhibit MTORC1 activity.<sup>495,2016</sup>

**RRAG (Ras-related GTP binding):** A GTPase that activates MTORC1 in response to amino acids.<sup>2017</sup> There are RRAGA, B, C and D isoforms.

**RRAS/RAS (related RAS viral [r-ras] oncogene homolog):** The small GTPase RRAS is an oncogene involved in the regulation of several cellular signaling pathways. RRAS can

upregulate or downregulate autophagy through distinct signaling pathways that depend on the cellular contexts.<sup>2018</sup>

**Rsp5:** A yeast E3 ubiquitin ligase that is responsible for the autophagic clearance of certain cytosolic proteins via Cue5.<sup>451</sup> See also Cue5.

**RUBCN/Rubicon/KIAA0226 (RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein):** RUBCN is part of a PtdIns3K complex (RUBCN-UVRAG-BECN1-PIK3C3-PIK3R4) that localizes to the late endosome/lysosome and inhibits macroautophagy.<sup>546,547</sup>

**SAHA/vorinostat (suberoylanilide hydroxamic acid):** An HDAC inhibitor that induces macroautophagy;<sup>2019</sup> however, SAHA/vorinostat treatment has also been reported to suppress macroautophagy (e.g., see ref. 2020), suggesting context dependency.

**Saikosaponin d:** An ATP2A/SERCA inhibitor that induces macroautophagy and macroautophagy-dependent cell death in apoptosis-defective cells.<sup>1514</sup>

**SBF2/MTMR13 (SET binding factor 2):** A catalytically inactive myotubularin that is also a RAB21 guanine nucleotide exchange factor (GEF) required with RAB21 for autophagosome-lysosome fusion. Starvation induces SBF2 RAB21 GEF activity that promotes VAMP8 trafficking to the lysosome, where VAMP8 is needed to mediate fusion. See also RAB21.<sup>1995</sup> The *Drosophila* homolog is Sbf.

**Sch9:** A yeast kinase that functions in parallel with PKA to negatively regulate macroautophagy. Sch9 appears to function in parallel with TOR, but is also downstream of the TOR kinase.<sup>2010</sup>

**SCOC (short coiled-coil protein):** A protein in the Golgi that interacts with FEZ1 in a complex with either ULK1 or UVRAG; the ternary complex with ULK1 promotes macroautophagy, whereas the complex with UVRAG has a negative effect by sequestering the latter from the BECN1-containing PtdIns3K complex.<sup>1747</sup> See also FEZ1.

**SEA (Seh1-associated) protein complex:** A complex found in yeast that includes the Seh1 nucleoporin and the COPII component Sec13 (also a nucleoporin), in addition to Npr2 and Npr3, and 4 other relatively uncharacterized proteins; the SEA complex associates with the vacuole, potentially acting as a membrane coat and is involved in protein trafficking, amino acid biogenesis, and the starvation response including macroautophagy.<sup>2021</sup>

**Sec1:** Functions with the plasma membrane SNAREs Sso1/Sso2 and Sec9 to form the site for vesicle-mediated exocytosis; as with Sso1/Sso2 and Sec9, temperature sensitive *sec1* mutations also abrogate macroautophagic delivery of GFP-Atg9.<sup>2022</sup> See also Sso1/Sso2.

**Sec2:** A guanine nucleotide exchange factor for Sec4 that normally functions in exocytosis. Upon the induction of macroautophagy, Sec2 function is diverted to promote membrane delivery to the PAS.<sup>2004</sup>

**Sec4:** A Rab family GTPase that normally functions in exocytosis; under macroautophagy-inducing conditions yeast Sec4 is needed for the anterograde movement of Atg9 to the PAS.<sup>2004</sup> The mammalian homolog is RAB40B.

**SEC5L1:** See EXOC2.

**Sec9:** Plasma membrane SNARE light chain that forms a complex with Sso1/Sso2 to generate the target complex of vesicle

exocytosis; as with Sso1/Sso2, loss of Sec9 function blocks macroautophagy at an early stage by disrupting targeting of Atg9 to the Atg9 peripheral sites and PAS.<sup>2023</sup> See also Sso1/Sso2, and Atg9 peripheral sites/structures.

**Sec18:** Homolog of mammalian NSF, an ATPase globally responsible for SNARE disassembly. Loss of function inhibits SNARE-dependent early and late events of macroautophagy (that is, vesicular delivery of Atg9 to the Atg9 peripheral sites and PAS<sup>2023</sup> and fusion of autophagosomes with the vacuole<sup>2024</sup>). See also Atg9 peripheral sites/structures.

**Sec22:** A vesicle SNARE involved in ER and Golgi transport; mutations in Sec22 also block Atg9 trafficking to the Atg9 peripheral sites and PAS. Crosslinking experiments suggest Sec22 may be the v-SNARE responsible for the macroautophagy functions of the ordinarily plasma membrane Sso1/Sso2-Sec9 t-SNARE complex.<sup>2023</sup> See also Sso1/Sso2, and Atg9 peripheral sites/structures.

**Secretory autophagy:** A biosynthetic mode of autophagy that occurs in mammalian cells.<sup>1036,2025</sup> Secretory autophagy depends on the ATG proteins, RAB8A and the Golgi protein GORASP2/GRASP55, and is used for the extracellular delivery (via unconventional secretion) of proteins such as the cytokines IL1B and IL18, and HMGB1. See also exophagy.

**SEPA-1 (suppressor of ectopic P granule in autophagy mutants-1):** A *C. elegans* protein that is involved in the selective degradation of P granules through a macroautophagy-like process.<sup>1262</sup> SEPA-1 self-oligomerizes and functions as the receptor for the accumulation of PGL-1 and PGL-3 aggregates. SEPA-1 directly binds PGL-3 and LGG-1.

**Septin cages:** Septins are GTP-binding proteins that assemble into nonpolar filaments (characterized as unconventional cytoskeleton), often acting as scaffolds for the recruitment of other proteins. Septin cages form in response to infection by *Shigella*; the cages surround the bacteria, preventing intercellular spread, and serve to recruit autophagy components such as SQSTM1 and LC3.<sup>2026</sup>

**SERPINA1/A1AT (serpin peptidase inhibitor, clade A [alpha-1 antiproteinase, antitrypsin], member 1):** SERPINA1 is the most abundant circulating protease inhibitor and is synthesized in the liver. A point mutation in the *SERPINA1* gene alters protein folding of the gene product, making it aggregation prone; the proteasomal and macroautophagic pathways mediate degradation of mutant SERPINA1.<sup>2027</sup>

**sesB (stress-sensitive B):** A *Drosophila* mitochondrial adenine nucleotide translocase that negatively regulates autophagic flux, possibly by increasing cytosolic ATP levels.<sup>1709</sup> See also Dcp-1.

**SESN2 (sestrin 2):** A stress-inducible protein that reduces oxidative stress, inhibits MTORC1 and induces macroautophagy, also acting as an AMPK activator.<sup>2028</sup> SESN2 physically associates with ULK1 and SQSTM1, promotes ULK1-dependent phosphorylation of SQSTM1, and facilitates autophagic degradation of SQSTM1 targets such as KEAP1.<sup>1532,2029</sup> SESN2 suppresses MTORC1 in response to diverse stresses including DNA damage,<sup>2030</sup> ER stress,<sup>2031</sup> nutritional stress,<sup>822,2029</sup> or energetic stress.<sup>2032</sup>

**SH3GLB1/Bif-1 (SH3-domain GRB2-like endophilin B1):** A protein that interacts with BECN1 via UVRAG and is required for macroautophagy. SH3GLB1 has a BAR domain that may be involved in deforming the membrane as part of autophagosome

biogenesis.<sup>2033</sup> SH3GLB1 activity is regulated by phosphorylation at residue T145, which in starved neurons occurs via CDK5.<sup>2034</sup> SH3GLB1 regulates autophagic degradation of EGFR,<sup>2035</sup> NTRK1,<sup>2034</sup> and CHRNA1.<sup>2036</sup> Turnover of CHRNA1 is coregulated by TRIM63.<sup>2036</sup>

**SHH (sonic hedgehog):** A ligand of the sonic hedgehog pathway. Activation of this pathway suppresses IFNG-induced macroautophagy in macrophages during mycobacterial infection.<sup>528</sup>

**Shp1/Ubx1:** A yeast Ubx (ubiquitin regulatory x)-domain protein that is needed for the formation of autophagosomes during nonselective macroautophagy; Shp1 binds Cdc48 and Atg8-PE, and may be involved in extracting the latter during phagophore expansion.<sup>1670</sup>

**Sic1:** A yeast cyclin-dependent kinase inhibitor that blocks the activity of Cdc28-Clb kinase complexes to control entry into the S phase of the cell cycle. Sic1 is a negative regulator of macroautophagy that inhibits Rim15.<sup>1683</sup>

**Signalphagy:** A type of macroautophagy that degrades active signaling proteins.<sup>2037</sup>

**Sin3/SIN3 (SIN3 transcription regulator family member):** Part of the Rpd3L regulatory complex including Rpd3 and Ume6 in yeast, which downregulates transcription of *ATG8* in growing conditions.<sup>1233</sup> In mammalian cells knockdown of both SIN3A and SIN3B is needed to allow increased expression of LC3. See also Rpd3 and Ume6.

**Sirolimus:** An immunosuppressant also referred to as rapamycin.

**SIRT1 (sirtuin 1):** A NAD<sup>+</sup>-dependent protein deacetylase that is activated by caloric restriction or glucose deprivation; SIRT1 can induce macroautophagy through the deacetylation of autophagy-related proteins and/or FOXO transcription factors.<sup>2038</sup> Deacetylation of K49 and K51 of nuclear LC3 leads to localization in the cytosol and association with phagophores.<sup>657</sup> See also SIRT2.

**SIRT2 (sirtuin 2):** A NAD<sup>+</sup>-dependent protein deacetylase sharing homology with SIRT1 that is involved in neurodegeneration and might play a role in macroautophagy activation through regulation of the acetylation state of FOXO1.<sup>1756</sup> Under prolonged stress the SIRT2-dependent regulation of FOXO1 acetylation is impaired, and acetylated FOXO1 can bind to ATG7 in the cytoplasm and directly affect macroautophagy.

**SIRT3 (sirtuin 3):** A mitochondrial NAD<sup>+</sup>-dependent protein deacetylase sharing homology with SIRT1, which is responsible for deacetylation of mitochondrial proteins and modulation of mitophagy.<sup>2039,2040</sup>

**SIRT5:** A mitochondrial SIRT1 homolog with NAD<sup>+</sup>-dependent protein desuccinylase/demalonylase activity; SIRT5 modulates ammonia-induced macroautophagy.<sup>2041</sup>

**SIRT6:** A member of the sirtuin family with nuclear localization, that is associated with chromatin and promotes the repair of DNA. The involvement of SIRT6 in senescence has been proposed, possibly by the modulation of IGF-AKT signaling; a role for SIRT6 in macroautophagy linked to senescence has been determined.<sup>2042</sup>

**SIRT7:** A member of the sirtuin family that is highly expressed in the nucleus/nucleolus where it interacts with POLR1/RNA polymerase I as well as with histones. Many lines of evidence

point to a role for SIRT7 in oncogenic transformation and tumor growth. The involvement of SIRT7 in macroautophagy was recently suggested in a model of acute cardiovascular injury, where loss of SIRT7 activates autophagy in cardiac fibroblasts.<sup>2043</sup>

**SLAPs (spacious *Listeria*-containing phagosomes):** SLAPs can be formed by *L. monocytogenes* during infection of macrophages or fibroblasts if bacteria are not able to escape into the cytosol.<sup>2044</sup> SLAPs are thought to be immature autophagosomes in that they bear LC3 but are not acidic and do not contain lysosomal degradative enzymes. The pore-forming toxin listeriolysin O is essential for SLAPs formation and is thought to create small pores in the SLAP membrane that prevent acidification by the v-ATPase. SLAP-like structures have been observed in a model of chronic *L. monocytogenes* infection,<sup>2045</sup> suggesting that autophagy may contribute to the establishment/maintenance of chronic infection.

**SLC1A5 (solute carrier family 1 [neutral amino acid transporter], member 5):** A high affinity, Na<sup>+</sup>-dependent transporter for L-glutamine; a block of transport activity leads to inhibition of MTORC1 signaling and the subsequent activation of macroautophagy.<sup>340</sup> See also SLC7A5.

**SLC7A5 (solute carrier family 7 [amino acid transporter light chain, L system], member 5):** A bidirectional transporter that allows the simultaneous efflux of L-glutamine and influx of L-leucine; this transporter works in conjunction with SLC1A5 to regulate MTORC1.<sup>340</sup>

**SLC9A3R1 (solute carrier family 9, subfamily A [NHE3, cation proton antiporter 3], member 3 regulator 1):** A scaffold protein that competes with BCL2 for binding to BECN1, thus promoting macroautophagy.<sup>2046</sup>

**SLC25A1 (solute carrier family 25 [mitochondrial carrier; citrate transporter], member 1):** This protein maintains mitochondrial activity and promotes the movement of citrate from the mitochondria to the cytoplasm, providing cytosolic acetyl-coenzyme A. Inhibition of SLC25A1 results in the activation of macroautophagy and mitophagy.<sup>2047</sup>

**SLC38A9 (solute carrier family 38, member 9):** A multi-spanning membrane protein that localizes to the lysosome as part of the RRAG-Ragulator complex. SLC38A9 functions as a transceptor (transporter-receptor) to link amino acid status with MTORC1 activity.<sup>2048-2050</sup>

**Slg1/Wsc1:** A yeast cell surface sensor in the Slr2 MAPK pathway that is required for mitophagy.<sup>508</sup> See also Slr2.

**SLR (sequestosome 1/p62-like receptor):** A protein that acts as a macroautophagy receptor, and in proinflammatory or other types of signaling.<sup>2051</sup>

**Slr2:** A yeast MAPK that is required for pexophagy and mitophagy.<sup>508</sup> See also Pkc1, Bck1 and Mkk1/2.

**smARF (short mitochondrial ARF):** A small isoform of CDKN2A/p19ARF that results from the use of an alternate translation initiation site, which localizes to mitochondria and disrupts the membrane potential, leading to a massive increase in macroautophagy and cell death.<sup>2052</sup>

**SNAP29 (synaptosomal-associated protein, 29kDa):** A SNARE protein required for fusion of the completed autophagosome with a lysosome in metazoans.<sup>584,585,2053</sup>

**SNAPIN (SNAP-associated protein):** An adaptor protein involved in dynein-mediated late endocytic transport; SNAPIN is needed for the delivery of endosomes from distal processes

to lysosomes in the neuronal soma, allowing maturation of autolysosomes.<sup>149</sup>

**SNCA/ $\alpha$ -synuclein:** A presynaptic protein relevant for Parkinson disease pathogenesis because of its toxicity resulting from aggregation. SNCA degradation in neuronal cells involves the autophagy-lysosomal pathway via macroautophagy and chaperone-mediated autophagy.<sup>2054</sup> Conversely, SNCA accumulation over time might impair autophagy function, and an inhibitory interaction of SNCA with HMGB1 has been reported.<sup>2055</sup> This interaction can be reversed by the natural autophagy inducer corynoxine B. Similarly, in human T lymphocytes the aggregated form of SNCA, once generated, can be degraded by macroautophagy, whereas interfering with this pathway can result in the abnormal accumulation of SNCA. Hence, SNCA can be considered as an autophagy-related marker of peripheral blood lymphocytes.<sup>1340</sup>

**Snx4/Atg24:** A yeast PtdIns3P-binding sorting nexin that is part of the Atg1 kinase complex and binds Atg20.<sup>1600</sup> Snx4/Atg24 is also involved in recycling from early endosomes. In the filamentous fungus *M. oryzae*, Atg24 is required for mitophagy.<sup>709</sup>

**SNX18:** A PX-BAR domain-containing protein involved in phagophore elongation.<sup>2056</sup>

**SpeB:** A cysteine protease secreted by *Streptococcus pyogenes* that degrades macroautophagy components at the bacterial surface, leading to autophagy escape.<sup>2057</sup> The lack of SpeB allows capture and killing of cytoplasmic *S. pyogenes* by the macroautophagy system.<sup>126,2057</sup>

**Spautin-1 (specific and potent autophagy inhibitor-1):** An inhibitor of USP10 and USP13, identified in a screen for inhibitors of macroautophagy, which promotes the degradation of the PIK3C3/VSP34-BECN1 complex.<sup>2058</sup>

**Spermidine:** A natural polyamine that induces macroautophagy through the inhibition of histone acetylases such as EP300.<sup>631,2059</sup>

**Sphingolipids:** Sphingolipids are a major class of lipids. Some metabolites including ceramide, sphingosine and sphingosine 1-phosphate are bioactive signaling molecules. Ceramide and sphingosine 1-phosphate are positive regulators of macroautophagy.<sup>2060,2061</sup>

**SPNS/spinster:** A putative lysosomal efflux permease required for autophagic lysosome reformation.<sup>2062</sup>

**Sqa (spaghetti-squash activator):** A myosin light chain kinase-like protein that is a substrate of Atg1 in *Drosophila*; required for starvation-induced autophagosome formation, and the mammalian homolog DAPK3 is also involved in ATG9 trafficking.<sup>489</sup>

**SQST-1:** The *C. elegans* homolog of SQSTM1.

**SQSTM1/p62 (sequestosome 1):** An autophagy receptor that links ubiquitinated proteins to LC3. SQSTM1 accumulates in cells when macroautophagy is inhibited. SQSTM1 interaction with LC3 requires a WXXL or a LIR motif analogous to the interaction of Atg8 with Atg19.<sup>84</sup> SQSTM1 also interacts with HDAC6 to regulate microtubule acetylation and autophagosome turnover.<sup>2063</sup> See also HDAC6 and LIR/LRS.

**SRPX/Drs (sushi-repeat-containing protein, x-linked):** An apoptosis-inducing tumor suppressor that is involved in the maturation of autophagosomes.<sup>2064</sup>

**SseL:** A *Salmonella* deubiquitinase secreted by a type III secretion system; deubiquitination of aggregates and ALIS decreases

host macrophage macroautophagic flux and results in an environment more favorable to bacterial replication.<sup>2065</sup>

**Ssk1:** A yeast component of the Hog1 signaling cascade that is required for mitophagy.<sup>508</sup> See also Hog1.

**Sso1/Sso2:** Highly homologous plasma membrane syntaxins (SNAREs) of *S. cerevisiae* involved in exocytosis; the Sso1/Sso2 proteins also control the movement of Atg9 to the Atg9 peripheral sites and PAS during macroautophagy and the Cvt pathway.<sup>2023</sup>

**STAT3 (signal transducer and activator of transcription 3 [acute-phase response factor]):** A transcription factor that also functions in the cytosol as a suppressor of macroautophagy.<sup>2066</sup> STAT3 binds EIF2AK2/PKR and inhibits the phosphorylation of EIF2S1.

**Stationary phase lipophagy:** A type of lipophagy that occurs in yeast cells entering quiescence.<sup>2067,2068</sup>

**STK3 (serine/threonine kinase 3):** The mammalian homolog of the Hippo/Ste20 kinase, which can phosphorylate LC3 on Thr50; this modification is needed for the fusion of autophagosomes with lysosomes.<sup>2069</sup>

**STK4/MST1 (serine/threonine kinase 4):** As with STK3, STK4 can phosphorylate LC3.<sup>2069</sup> STK4 also phosphorylates Thr108 of BECN1, promoting the interaction of BECN1 with BCL2 or BCL2L1, inhibiting macroautophagy.<sup>2070</sup>

**STK11/LKB1 (serine/threonine kinase 11):** A kinase that is upstream of, and activates, AMPK.<sup>1673</sup>

**STX5 (syntaxin 5):** A Golgi-localized SNARE protein involved in vesicular transport of lysosomal hydrolases, a process that is critical for lysosome biogenesis; STX5 is needed for the later stages of autophagy.<sup>2071</sup>

**STX12/STX13/STX14 (syntaxin 12):** A genetic modifier of mutant CHMP2B in frontotemporal dementia that is required for autophagosome maturation; STX12 interacts with VTI1A.<sup>2072</sup>

**STX17 (syntaxin 17):** An autophagosomal SNARE protein required for fusion of the completed autophagosome with an endosome or lysosome in metazoans.<sup>584,585</sup> STX17 is also required for recruitment of ATG14 to the ER-mitochondria contact sites.<sup>2073</sup>

**Sui2:** The yeast homolog of EIF2S1/eIF2 $\alpha$ .

**SUPT20H/FAM48A (suppressor of Ty 20 homolog [S. cerevisiae]):** A protein that interacts with the C-terminal domain of ATG9; this interaction is negatively regulated by MAPK14.<sup>2074</sup>

**Sunitinib:** An autofluorescent multitarget tyrosine kinase inhibitor with lysosomotropic properties; sunitinib interferes with autophagic flux by blocking trafficking to lysosomes.<sup>2075</sup>

**Symbiophagy:** A process in which invertebrates such as the coralline demosponge *Astrosclera willeyana* degrade part of their symbiotic bacterial community, as part of a biomineralization pathway that generates the sponge skeleton.<sup>2076</sup>

**Syx13 (Syntaxin 13):** The *Drosophila* homolog of human STX12 that is required for autophagosome maturation.<sup>2072</sup>

**TAB2 (TGF-beta activated kinase 1/MAP3K7 binding protein 2):** MAP3K7-binding protein that constitutively interacts with TAB3 and inhibits macroautophagy; upon macroautophagy induction these proteins dissociate from BECN1 and bind MAP3K7.<sup>2077,2078</sup>


**TAB3 (TGF-beta activated kinase 1/MAP3K7 binding protein 3):** See TAB2.

**TAK1:** See MAP3K7.

**TAKA (transport of Atg9 after knocking out ATG1) assay:**

An epistasis analysis that examines the localization of Atg9-GFP in a double mutant, where one of the mutations is a deletion of *ATG1*.<sup>106</sup> In *atg1*Δ mutants, Atg9-GFP is restricted primarily to the PAS; if the second mutation results in a multiple puncta phenotype, the corresponding protein is presumably required for anterograde transport of Atg9 to the PAS.<sup>728</sup> This analysis can be combined with localization of RFP-Ape1 to determine if any of the Atg9-GFP puncta reach the PAS, in which case that punctum would colocalize with the RFP-Ape1 PAS marker.

**Tamoxifen:** A triphenylethylenic compound widely used for the management of estrogen receptor-positive breast cancers. This drug is a dual modulator of ESR (estrogen receptor) and a high affinity ligand of the microsomal antiestrogen binding site (AEBS). Tamoxifen induces protective macroautophagy in cancer cells through an AEBS-mediated accumulation of zymostenol (5α-cholest-8-en-3β-ol).<sup>1239,1931,2079</sup>



**TARDBP/TDP-43 (TAR DNA binding protein):** A DNA/RNA binding protein that stabilizes *Atg7* mRNA.<sup>2080</sup>

**TASCC (TOR-autophagy spatial coupling compartment):** A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RRAS-induced senescence to provide spatial coupling of protein secretion (anabolism) with degradation (catabolism); for example, amino acids generated from autophagy would quickly reactivate MTOR, whereas autophagy would be rapidly induced via MTOR inhibition when nutrients are again depleted.<sup>2081</sup>

**TAX1BP1/CALCOCO3 (Tax1 [human T-cell leukemia virus type I] binding protein 1):** An autophagy receptor that contains a LIR motif and a double zinc-finger ubiquitin binding domain. TAX1BP1 interacts with ubiquitinated substrates, such as *S. typhimurium*, and recruits LC3-positive autophagosomal membrane.<sup>879,1893,2082</sup>

**Tax4:** See *Irs4*.<sup>1827</sup>

**TBC1D7 (TBC1 domain family, member 7):** This protein is the third functional subunit of the TSC1-TSC2 complex upstream of MTORC1. Loss of function of TBC1D7 results in an increase of MTORC1 signaling, delayed induction of macroautophagy and enhancement of cell growth under poor growth conditions.<sup>2083</sup> Mutations in TBC1D7 have been associated with intellectual disability, macrocrania, and delayed autophagy.<sup>2084,2085</sup>

**TBC1D14 (TBC1 domain family, member 14):** TBC1D14 colocalizes and interacts with ULK1 and upon overexpression causes tubulation of ULK1-positive endosomes, inhibiting autophagosome formation.<sup>1993</sup> TBC1D14 binds activated RAB11, but

does not function as a GAP. TBC1D14 localizes to the Golgi complex during amino acid starvation. See also RAB11.

**TBC1D25/OATL1 (TBC1 domain family, member 25):** A Tre2-Bub2-Cdc16 (TBC) domain-containing GAP for RAB33B; TBC1D25 is recruited to phagophores and autophagosomes via direct interaction with the Atg8 family proteins (via a LIR/LRS-like sequence), and it regulates the interaction of autophagosomes with lysosomes by inactivating RAB33B.<sup>2000</sup> Overexpression of TBC1D25 inhibits autophagosome maturation at a step prior to fusion, suggesting that it might interfere with a tethering/docking function of RAB33B. See also RAB33B and LIR/LRS.

**TBK1 (TANK-binding kinase 1):** A serine/threonine protein kinase that is similar to IKK involved in the activation of NFKB.<sup>2086</sup> TBK1 binds and directly phosphorylates OPTN at Ser177 (in humans) within the LIR, increasing the affinity of the latter for LC3.<sup>880</sup>

**TCHP/mitostatin (trichoplein, keratin filament binding):** A DCN (decorin)-inducible tumor suppressor gene that functions in, and is required for, tumor cell mitophagy. TCHP/mitostatin responds to DCN as well as canonical cues (e.g., nutrient deprivation and rapamycin) for mitophagic induction. DCN regulates mitostatin in a PPARGC1A/PGC-1α-dependent manner. Moreover, DCN-induced mitophagy is entirely dependent on TCHP for angiogenic inhibition.<sup>2087</sup>

**TECPR1 (tectonin beta-propeller repeat containing 1):** A protein that interacts with ATG5 and WIPI2, and localizes to the phagophore (localization is dependent on WIPI2); TECPR1 is needed for phagophore formation during macroautophagic elimination of *Shigella*, but not for starvation-induced autophagy.<sup>2088</sup> TECPR1 also localizes to autophagosomes that target other pathogenic microbes such as group A *Streptococcus*, to depolarized mitochondria and to protein aggregates, suggesting a general role in selective macroautophagy. TECPR1 also plays a role in fusion of the autophagosome with the lysosome by competing with ATG16L1 to bind ATG5 and PtdIns3P, recruiting ATG5 to the lysosome membrane.<sup>2089</sup>

**TECPR2:** A WD repeat- and TECPR domain-containing protein that plays a role in macroautophagy; mutation of *TECPR2* results in a form of monogenic hereditary spastic paraparesis.<sup>2090,2091</sup>

**TFE3 (transcription factor binding to IGHM enhancer 3):** A transcription factor belonging to the microphthalmia/transcription factor E (MiT/TFE) family, along with TFEB and MITF.<sup>639,1879</sup> See also TFEB and MITF.

**TFEB (transcription factor EB):** A transcription factor that positively regulates the expression of genes involved in lysosomal biogenesis (those in the CLEAR network<sup>636</sup>), and also several of those involved in macroautophagy (including *UVRAG*, *WIPI*, *MAP1LC3B* and *ATG9B*); the use of a common transcription factor allows the coordinated expression of genes whose products are involved in the turnover of cytoplasm.<sup>625</sup> See also CLEAR and PPP3R1.

**TGFB1/TGF-β (transforming growth factor, beta 1):** A cytokine that activates macroautophagy through the SMAD and MAPK8 pathways. TGFB1 induces the expression of several *ATG* genes including *BECN1*.

**TGM2/TG2/TGase 2 (transglutaminase 2):** An enzyme that catalyzes the formation of an isopeptide bond between a free



amine group (e.g., protein- or peptide-bound lysine) and the acyl group at the end of the side chain of protein- or peptide-bound glutamine (protein crosslinking); TGM2 interacts with SQSTM1 and is involved in the macroautophagic clearance of ubiquitinated proteins.<sup>780,2092</sup>

**THC ( $\Delta^9$ -tetrahydrocannabinol):** The main active component of the hemp plant *Cannabis sativa*. The anticancer activity of THC in several animal models of cancer relies on its ability to stimulate autophagy-mediated cancer cell death. This effect occurs via THC binding to cannabinoid receptors, and the subsequent triggering of an ER stress-related response, which leads in turn to the inhibition of the AKT-MTORC1 axis.<sup>2093-2095</sup>

**TIGAR/C12orf5 (TP53 induced glycolysis regulatory phosphatase):** A protein that modulates glycolysis, causing an increase in NADPH, which results in a lower ROS level; this reduces the sensitivity to oxidative stress and apoptosis, but also has the effect of lowering the level of macroautophagy.<sup>2096</sup>

**Timosaponin A-III:** A medicinal saponin that induces a type of macroautophagy with some features that are distinct from rapamycin-induced macroautophagy.<sup>2097</sup>

**Tlg2:** A yeast endocytic SNARE light chain involved in early stages of the Cvt pathway<sup>729</sup> and in autophagosome membrane formation.<sup>2023</sup> Deletion of *TLG2* results in a modest impairment in Atg9 delivery to the PAS.

**TLR (toll-like receptor):** A family of receptors that induces macroautophagy following binding to a corresponding PAMP.

**TM9SF1 (transmembrane 9 superfamily member 1):** A protein with 9 transmembrane domains that induces macroautophagy when overexpressed.<sup>2098</sup>

**TMEM59 (transmembrane protein 59):** A type-I transmembrane protein able to induce an unconventional autophagic process involving LC3 labeling of single-membrane endosomes through direct interaction with ATG16L1.<sup>2099</sup>

**TMEM74 (transmembrane protein 74):** An integral membrane protein that induces macroautophagy when overexpressed.<sup>1739,1740</sup>

**TMEM166:** See EVA1A.

**TNFAIP3/A20 (tumor necrosis factor, alpha-induced protein 3):** An E3 ubiquitin ligase that also functions as a deubiquitinating enzyme that removes K63-linked ubiquitin from BECN1, thus limiting macroautophagy induction in response to TLR signaling.<sup>2100</sup> In contrast, TNFAIP3 restricts MTOR signaling, acting as a positive factor to promote macroautophagy in CD4 T cells.<sup>2101</sup>

**TNFSF10/TRAIL (tumor necrosis factor superfamily, member 10):** Induces macroautophagy by activating AMPK, thus inhibiting MTORC1 during lumen formation.

**TOLLIP (toll interacting protein):** A mammalian ubiquitin-binding receptor protein similar to yeast Cue5 that contains a CUE domain and plays a role in the macroautophagic removal of protein aggregates.<sup>451</sup> See also Cue5 and CUET.

**TOR (target of rapamycin):** A serine/threonine protein kinase that negatively regulates yeast macroautophagy. Present in 2 complexes, TORC1 and TORC2. TORC1 is particularly sensitive to inhibition by rapamycin. TORC1 regulates macroautophagy in part through Tap42-protein phosphatase 2A, and also by phosphorylating Atg13 and Atg1.

**TORC1 (TOR complex I):** A rapamycin-sensitive protein complex of TOR that includes at least Tor1 or Tor2 (MTOR),

Kog1 (RPTOR), Lst8 (MLST8), and Tco89.<sup>2102</sup> MTORC1 also includes DEPTOR and AKT1S1/PRAS40.<sup>2103</sup> In mammalian cells, sensitivity to rapamycin is conferred by RPTOR. TORC1 directly regulates macroautophagy.

**TORC2 (TOR complex II):** A relatively rapamycin-insensitive protein complex of TOR that includes at least Tor2 (MTOR), Avo1 (MAPKAP1/SIN1), Avo2, Avo3 (RICTOR), Bit61, Lst8 (MLST8) and Tsc11; MTORC2 also includes FKBP8/FKBP38, and PRR5/Protor-1.<sup>2102-2104</sup> A critical difference in terms of components relative to TORC1 is the replacement of RPTOR by RICTOR. TORC2 is primarily involved with regulation of the cytoskeleton, but this complex functions to positively regulate macroautophagy during amino acid starvation.<sup>2105</sup> Finally, studies also support the idea that TORC2 activity is required to sustain autophagosome biogenesis,<sup>2106</sup> whereas it exerts an inhibitory effect on CMA,<sup>2107</sup> suggesting that a switch in TORC2 substrates may contribute to coordinating the activity of these 2 types of autophagy.

**Torin1:** A selective catalytic ATP-competitive MTOR inhibitor that directly inhibits both TORC1 and TORC2.<sup>1193</sup>

**TP53/p53 (tumor protein 53):** A tumor suppressor. Nuclear TP53 activates macroautophagy, at least in part, by stimulating AMPK and DRAM1, whereas cytoplasmic TP53 inhibits macroautophagy.<sup>1273</sup> Note that the official name for this protein in rodents is TRP53. The TP53 *C. elegans* ortholog, *cep-1*, also regulates macroautophagy.<sup>1272,1274</sup>

**TP53INP1 (tumor protein p53 inducible nuclear protein 1):** A stress-response protein that promotes TP53 transcriptional activity; cells lacking TP53INP1 display reduced basal and stress-induced autophagy,<sup>2108</sup> whereas its overexpression enhances autophagic flux.<sup>2109</sup> TP53INP1 interacts directly with LC3 via a functional LIR and stimulates autophagosome formation.<sup>2110</sup> Cells lacking TP53INP1 display reduced mitophagy; TP53INP1 interacts with PARK2 and PINK1, and thus could be a recognition molecule involved in mitophagy.<sup>2111</sup>

**TP53INP2/DOR (tumor protein p53 inducible nuclear protein 2):** A mammalian and *Drosophila* regulatory protein that shuttles between the nucleus and the cytosol; the nuclear protein interacts with deacetylated LC3<sup>657</sup> and GABARAPL2 and stimulates autophagosome formation.<sup>2112</sup> TP53INP2 also interacts with GABARAP and VMP1 and is needed for the recruitment of BECN1 and LC3 to autophagosomes. TP53INP2 translocates from the nucleus to phagophores during macroautophagy induction and binds VMP1 and LC3 directly.<sup>2113</sup> In addition, TP53INP2 modulates muscle mass in mice through the regulation of macroautophagy.<sup>2114</sup>

**TPCN/two-pore channel (two pore segment channel):** TPCNs are endolysosomal cation channels that maintain the proton gradient and membrane potential of endosomal and lysosomal membranes. TPCN2 physically interacts with MTOR and regulates MTOR reactivation and macroautophagic flux.<sup>2115,2116</sup>

**TPR (translocated promoter region, nuclear basket protein):** TPR is a component of the nuclear pore complex that presumably localizes at intranuclear filaments or nuclear baskets. Nuclear pore complex components, including TPR, are jointly referred to as nucleoporins. TPR was originally identified as the oncogenic activator of the *MET* and *NTRK1/trk* proto-

oncogenes. Knockdown of TPR facilitates macroautophagy. TPR depletion is not only responsible for TP53 nuclear accumulation, which also activates the TP53-induced macroautophagy modulator DRAM, but also contributes to *HSF1* and *HSP70* mRNA trafficking, and transcriptional regulation of *ATG7* and *ATG12*.<sup>2117</sup>

**TRAF2 (TNF receptor-associated factor 2):** An E3 ubiquitin ligase that plays an essential role in mitophagy in unstressed cardiac myocytes, as well as those treated with TNF or CCCP.<sup>786</sup>

**TRAF6 (TNF receptor-associated factor 6, E3 ubiquitin protein ligase):** An E3 ubiquitin ligase that ubiquitinates BECN1 to induce TLR4-triggered macroautophagy in macrophages.<sup>2100</sup>

**TRAIL:** See TNFSF10.

**Transgenic:** Harboring genetic material of another species/organism or extra copies of an endogenous gene, usually gained through transfer by genetic engineering.

**Transmitophagy/transcellular mitophagy:** A process in which axonal mitochondria are degraded in a cell-nonautonomous mechanism within neighboring cells.<sup>796</sup>

**TRAPP II (transport protein particle II):** A guanine nucleotide exchange factor for Ypt1 and perhaps Ypt31/32 that functions in macroautophagy in yeast.<sup>2118</sup> TRAPP II is composed of Bet3, Bet5, Trs20, Trs23, Trs31, Trs33 and the unique subunits Trs65, Trs120 and Trs130.

**TRAPP III (transport protein particle III):** A guanine nucleotide exchange factor for Ypt1 that functions in macroautophagy in yeast.<sup>1321</sup> TRAPP III is composed of Bet3, Bet5, Trs20, Trs23, Trs31, Trs33 and a unique subunit, Trs85.

**TRIB3 (tribbles pseudokinase 3):** A pseudokinase that plays a crucial role in the mechanism by which various anticancer agents (and specifically cannabinoids, the active components of marijuana and their derived products) activate macroautophagy in cancer cells. Cannabinoids elicit an ER stress-related response that leads to the upregulation of TRIB3 whose interaction with AKT impedes the activation of this kinase, thus leading to a decreased phosphorylation of TSC2 and AKT1S1/PRAS40. These events trigger the inhibition of MTORC1 and the induction of macroautophagy.<sup>2094</sup> Conversely, TRIB3 binding to SQSTM1 via its UBA and LIR motifs interferes with autophagic flux, in particular of ubiquitinated proteins, and also reduces the efficiency of the UPS, promoting tumor progression due to the accumulation of tumor-promoting factors.<sup>2093,2119,2120</sup>

**Trichostatin A:** An inhibitor of class I and class II HDACs that induces autophagy.<sup>2121</sup>

**TRIM5/TRIM5 $\alpha$  (tripartite motif containing 5):** A selective macroautophagy receptor for xenophagy; TRIM5 binds the HIV-1 capsid.<sup>1984</sup>

**TRIM20:** See MEFV.

**TRIM21:** An antigen in autoimmune diseases such as systemic lupus erythematosus, and Sjögren syndrome, TRIM21 is a receptor for selective autophagy of IRF3 dimers, a key transcriptional activator of type I interferon responses.<sup>1869</sup>

**TRIM28 (tripartite motif containing 28):** TRIM28 is an E3 ligase that is part of a ubiquitin ligase complex that targets PRKAA1, leading to ubiquitination and proteasomal degradation in part through the upregulation of MTOR activity.<sup>1854</sup> See also MAGEA3.

**TRIM50 (tripartite motif containing 50):** TRIM50 is a cytoplasmic E3-ubiquitin ligase,<sup>2122</sup> which interacts and colocalizes with SQSTM1 and promotes the formation and clearance of aggresome-associated polyubiquitinated proteins through HDAC6-mediated interaction and acetylation.<sup>2123,2124</sup>

**TRIM63/MURF-1 (tripartite motif containing 63, E3 ubiquitin protein ligase):** Muscle-specific atrophy-related E3 ubiquitin ligase<sup>2125,2126</sup> that cooperates with SH3GLB1 to regulate autophagic degradation of CHRNA1 in skeletal muscle, particularly upon muscle-atrophy induction.<sup>2036</sup>

**TRPC4 (transient receptor potential cation channel, subfamily C, member 4):** A cation channel in human umbilical vascular endothelial cells; upregulation of TRPC4 increases the intracellular Ca<sup>2+</sup> concentration resulting in activation of CAMKK2, which leads to MTOR inhibition and the induction of macroautophagy.<sup>1517</sup>

**Trs85:** A component of the TRAPP III complex that is required specifically for macroautophagy.<sup>699</sup>

**Trs130:** A component of the TRAPP II complex that is required for the transport of Atg8 and Atg9 to the PAS.<sup>2118</sup>

**TSC1/2 (tuberous sclerosis 1/2):** A stable heterodimer (composed of TSC1/hamartin and TSC2/tuberin) inhibited by AKT and MAPK1/3 (phosphorylation causes dissociation of the dimer), and activated by AMPK. TSC1/2 acts as a GAP for RHEB, thus inhibiting MTOR.

**TSPO (translocator protein [18kDa]):** TSPO is a mitochondrial protein that interacts with VDAC1 to modulate the efficiency of mitophagy.<sup>2127</sup>

**Tubulovesicular autophagosome (TVA):** Cationic lipoplex and polyplex carriers used for nonviral gene delivery enter mammalian cells by endocytosis and fuse with autophagosomes, generating large tubulovesicular structures (tubulovesicular autophagosomes) that immunostain for LC3; these structures do not fuse efficiently with lysosomes and interfere with gene expression.<sup>220</sup>

**Tubulovesicular cluster (TVC):** A structure identified morphologically in yeast that corresponds to the Atg9 peripheral sites.<sup>537</sup> See also Atg9 peripheral sites/structures.


**UBE2N (ubiquitin-conjugating enzyme E2N):** A ubiquitin-conjugating enzyme involved in PARK2-mediated mitophagy.<sup>2128,2129</sup> UBE2N activity may be only partly redundant with that of UBE2L3, UBE2D2 and UBE2D3, as it is also involved during later steps of mitophagy.

**Ubiquitin:** A 76-amino acid protein that is conjugated to lysine residues. Ubiquitin is traditionally considered part of the ubiquitin-proteasome system and tags proteins for degradation; however, ubiquitin is also linked to various types of autophagy including aggrephagy (see SQSTM1 and NBR1). Lysine linkage-specific monoclonal antibodies, which are commercially available, can be used to investigate the degradation pathway usage.<sup>2130</sup> Proteins covalently tagged with polyubiquitin chains via K48 are destined for proteasomal degradation, whereas proteins tagged with K63-linked ubiquitin are degraded via the macroautophagy pathway. In addition, phosphorylated forms of ubiquitin have been identified including p-S65-Ub, which is specifically generated during PINK1-PARK2-mediated mitophagy. Potentially, several PTMs of the modifier ubiquitin may turn out to be highly relevant and specific for distinct forms of selective autophagy (reviewed in ref. 745). See also p-S65-Ub.

**Ubp3:** A yeast deubiquitinase that forms a complex with Bre5 and is required for ribophagy.<sup>847</sup> Conversely, the Ubp3-Bre5 complex inhibits mitophagy.<sup>2131</sup>

**UBQLN/Ubiquilins:** Receptor proteins that deliver ubiquitinated substrates to the proteasome. Ubiquilins may aid in the incorporation of protein aggregates into autophagosomes, and also promote the maturation of autophagosomes at the stage of fusion with lysosomes.<sup>2132</sup>

**ULK family (unc-51 like autophagy activating kinase):** The ULK proteins are homologs of yeast Atg1. In mammalian cells the family consists of 5 members, ULK1, ULK2, ULK3, ULK4, and STK36/ULK5. ULK1 and ULK2 are required for macroautophagy, and ULK3 for oncogene-induced senescence.<sup>535,2133,2134</sup> See also Atg1. Figure modified from Fig. 2 of ref. 2135.



**Ume6:** A component of the Rpd3L complex that binds to the URS1 sequence in the *ATG8* promoter and downregulates transcription in growing conditions.<sup>1233</sup> See also Rpd3 and Sin3/SIN3.

**UNC-51:** The *C. elegans* Atg1/ULK1/ULK2 homolog. See also Atg1.

**UPR (unfolded protein response):** A coordinated process to adapt to ER stress, providing a mechanism to buffer fluctuations in the unfolded protein load. The activation of this pathway is often related with macroautophagy.

**USP8 (ubiquitin specific peptidase 8):** A deubiquitinase that removes K6-linked ubiquitin chains from PARK2 to promote PARK2 recruitment to depolarized mitochondria and mitophagy.<sup>1922</sup>


**USP15 (ubiquitin specific peptidase 15):** A deubiquitinating enzyme that antagonizes PARK2-mediated mitophagy.<sup>2136</sup> See also USP30.

**USP30:** A deubiquitinating enzyme that antagonizes PARK2-mediated mitophagy.<sup>2137</sup> USP30 is also a substrate of PARK2 and is subject to proteasome-mediated degradation. See also USP15.

**USP36:** A deubiquitinating enzyme that negatively regulates selective macroautophagy in *Drosophila* and human cells.<sup>2138</sup>

**UVRAG (UV radiation resistance associated):** A Vps38 homolog that can be part of the class III PtdIns3K complex. UVRAG functions in several ways to regulate macroautophagy: 1) It disrupts BECN1 dimer formation and forms a heterodimer that activates macroautophagy. 2) It binds to SH3GLB1 to allow activation of class III PtdIns3K to stimulate macroautophagy. 3) It interacts with the class C Vps/HOPS proteins involved in fusion of autophagosomes or amphisomes with the lysosome. 4) It competes with ATG14 for binding to BECN1, thus directing the class III PtdIns3K to function in the maturation step of macroautophagy.<sup>2139</sup> MTORC1 phosphorylates UVRAG to inhibit macroautophagy.<sup>2140</sup> In contrast,

MTORC1 can also phosphorylate UVRAG to stimulate PIK3C3 activity and autophagic lysosome reformation.<sup>2141</sup> UVRAG also has an autophagy-independent function, interacting with membrane fusion machinery to facilitate the cellular entry of enveloped viruses.<sup>2142</sup>



**Vacuolar cell death:** One of the 2 major types of cell death in plants (another type is necrosis), wherein the content of the dying cell is gradually engulfed by growing lytic vacuoles without loss of protoplast turgor, and culminates in vacuolar collapse.<sup>1093</sup> Vacuolar cell death is commonly observed during plant development, for example in the embryo-suspensor and xylem elements, and critically depends on macroautophagy.<sup>1095</sup>

A similar type of macroautophagy-dependent vacuolar cell death is required for *Dictyostelium* development.<sup>2143</sup>

**Vacuolar-type H<sup>+</sup>-ATPase (V-ATPase):** A ubiquitously expressed proton pump that is responsible for acidifying lysosomes and the yeast or plant vacuole, and therefore is important for the normal progression of autophagy. Inhibitors of the V-ATPase (e.g., bafilomycin A<sub>1</sub>) are efficient macroautophagy inhibitors.<sup>156,157</sup>

**Vacuolar sequestering membranes (VSM):** Extensions/protrusions of the vacuole limiting membrane along the surface of peroxisomes that occurs during micropexophagy.<sup>2144</sup>

**Vacuole:** The fungal and plant equivalent of the lysosome; this organelle also carries out storage and osmoregulatory functions.<sup>2145</sup> The bona fide plant equivalent of the lysosome is the lytic vacuole.

**Vacuole import and degradation (Vid):** A degradative pathway in yeast in which a specific protein(s) is sequestered into small (30- to 50-nm) single-membrane cytosolic vesicles that fuse with the vacuole allowing the contents to be degraded in the lumen. This process has been characterized for the catabolite-induced degradation of the gluconeogenic enzyme Fbp1/fructose-1,6-bisphosphatase in the presence of glucose, and sequestration is thought to involve translocation into the completed vesicle. An alternate pathway for degradation of Fbp1 by the ubiquitin-proteasome system has also been described.<sup>2146</sup>

**Vacuolin-1:** A small chemical that potently and reversibly inhibits the fusion between autophagosomes or endosomes with lysosomes by activating RAB5A.<sup>1521</sup>

**Valinomycin:** A K<sup>+</sup> ionophore that destroys the electrochemical gradient across the mitochondrial membrane and is widely used as a stimulator of mitophagy, similar to CCCP.<sup>2147</sup>

**Vam3:** A yeast syntaxin homolog needed for the fusion of autophagosomes with the vacuole.<sup>2148</sup>

**VAMP3 (vesicle-associated membrane protein 3):** A SNARE protein that facilitates the fusion of MVBs with autophagosomes to generate amphisomes.<sup>2149</sup>

**VAMP7 (vesicle-associated membrane protein 7):** VAMP7 is a SNARE protein that colocalizes with ATG16L1 vesicles and phagophores, and is required, along with STX7 (syntaxin 7), STX8 and VTI1B, for autophagosome formation.<sup>2150</sup> VAMP7 is also involved in the maturation of autophagosomes by facilitating fusion with a lysosome.<sup>2149</sup>

**VAMP8 (vesicle-associated membrane protein 8):** A SNARE protein that, in conjunction with VTI1B, is needed for the fusion of autophagosomes with lysosomes.<sup>2151</sup>

**VCP/p97 (valosin-containing protein):** A type II AAA<sup>+</sup>-ATPase that is a protein segregase required for autophagosome maturation under basal conditions or when the proteasomal system is impaired; mutations of VCP result in the accumulation of immature, acidified autophagic vacuoles that contain ubiquitinated substrates.<sup>2152,2153</sup> See also Cdc48.

**Verteporfin:** An FDA-approved drug; used in photodynamic therapy, but it inhibits the formation of autophagosomes in vivo without light activation.<sup>2154</sup>

**VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase):** VHL serves as the substrate recognition subunit of a ubiquitin ligase that targets the  $\alpha$  subunit of the heterodimeric transcription factor HIF1 for degradation. This interaction requires the hydroxylation of HIF1A on one or both of 2 conserved prolyl residues by members of the EGLN family of prolyl hydroxylases.<sup>2155</sup>

**VirG:** A *Shigella* protein that is required for intracellular actin-based motility; VirG binds ATG5, which induces xenophagy; IcsB, a protein secreted by the type III secretion system, competitively blocks this interaction.<sup>2156</sup>

**VMP1 (vacuole membrane protein 1):** A multispanning membrane protein that is required for macroautophagy.<sup>632,2157</sup>

VMP1 regulates the levels of PtdIns3P,<sup>2158</sup> binding of the ATG12-ATG5-ATG16L1 complex, and lipidation of LC3.<sup>2159</sup>

**Vps1:** A dynamin-like GTPase required for peroxisomal fission. It interacts with Atg11 and Atg36 on peroxisomes that are being targeted for degradation by pexophagy.<sup>1716</sup> See also Dnm1.

**Vps11:** A member of the core subunit of the homotypic fusion and protein sorting (HOPS) and class C core vacuole/endosome tethering (CORVET) complexes, originally found in yeast but also conserved in higher eukaryotes.<sup>2160,2161</sup> These complexes are important for correct endolysosomal trafficking, as well as the trafficking of black pigment cell organelles, melanosomes; zebrafish Vps11 is involved in maintaining melanosome integrity, possibly through an autophagy-dependent mechanism.<sup>2162</sup>

**Vps30/Atg6:** A component of the class III PtdIns3K complex. Vps30/Atg6 forms part of 2 distinct yeast complexes (I and II) that are required for the Atg and Vps pathways, respectively. See also BECN1 and phosphatidylinositol 3-kinase.<sup>1588</sup>

**Vps34:** The yeast phosphatidylinositol 3-kinase; the lipid kinase catalytic component of the PtdIns3K complex I and II.<sup>1941</sup> See also PIK3C3 and phosphatidylinositol 3-kinase.

**Vps38:** A yeast component of the class III PtdIns3K complex II, which directs it to function in the vacuolar protein sorting pathway.

**VTC (vacuolar transporter chaperone):** A complex composed of Vtc1, Vtc2, Vtc3 and Vtc4 that is required for microautophagy in yeast.<sup>2163</sup>

**Vti1:** A yeast soluble SNARE that, together with Sec18/NSF, is needed for the fusion of autophagosomes with the vacuole.<sup>2024</sup>

In mammalian cells, the SNARE proteins VAMP8 and VTI1B mediate the fusion of antimicrobial and canonical autophagosomes with lysosomes.<sup>2151</sup>

**WAC (WW domain containing adaptor with coiled-coil):** A positive regulator of macroautophagy that interacts with BECN1, WAC also negatively regulates the UPS.<sup>1747</sup>

**WDFY3/ALFY (WD repeat and FYVE domain containing 3):** A scaffold protein that targets cytosolic protein aggregates for autophagic degradation.<sup>2164</sup> WDFY3 interacts directly with ATG5,<sup>2165</sup> GABARAP proteins,<sup>146</sup> and SQSTM1.<sup>2166</sup>

**WDR45/WIPI4 (WD repeat domain 45):** See WIPI.

**WHAMM:** A nucleation-promoting factor that directs the activity of the Arp2/3 complex to function in autophagosome formation.<sup>2167</sup> WHAMM colocalizes with LC3, ZFYVE1 and SQSTM1 and acts in autophagosome biogenesis through a mechanism dependent on actin comet tail formation.

**WIPI (WD repeat domain, phosphoinositide interacting):**

The WIPI proteins are putative mammalian homologs of yeast Atg18 and Atg21. There are 4 WIPI proteins in mammalian cells. WIPI1/WIPI49 and WIPI2 localize with LC3 and bind PtdIns3P.<sup>555</sup> WIPI2 is required for starvation-induced macroautophagy.<sup>559</sup> WDR45/WIPI4 is also involved in macroautophagy. In humans, *WDR45* is localized on the X-chromosome and so far only de novo loss-of-function mutations are described. Heterozygous and somatic mutations cause neurodegeneration with brain iron accumulation,<sup>2168</sup> while hemizygous mutations result in early-onset epileptic encephalopathy.<sup>2169</sup> Impaired autophagy has been shown in lymphoblastoid cell lines derived from affected patients, showing abnormal colocalization of LC3-II and ATG9A. Furthermore, lymphoblastoid cell lines from affected subjects, show increased levels of LC3-II, even under normal conditions.<sup>2170</sup> Surprisingly, complete *Wdr45* knockout mice develop normally, but show neurodegeneration, as of 9 months of age, thereby indicating overlapping activity of the 4 WIPI proteins in mammals.<sup>2171</sup> WDR45/WIPI4 appears to be the member of the mammalian WIPI protein family that binds ATG2.<sup>464,563</sup>

**WNT (wingless-type MMTV integration site family):** Cysteine-rich glycosylated secreted proteins that determine multiple cellular functions such as neuronal development, angiogenesis, tumor growth, and stem cell proliferation. Signaling pathways of WNT such as those that involve CTNNB1/beta-catenin can suppress macroautophagy.<sup>2172,2173</sup>

**WNT5A:** A ligand of the WNT signaling pathway. Activation of the WNT5A-CTNNB1 pathway suppresses IFNG-induced autophagy in macrophages during mycobacterial infection.<sup>528</sup>

**Wortmannin (WM):** An inhibitor of PI3K and PtdIns3K; it inhibits macroautophagy due to the downstream effect on PtdIns3K.<sup>1851</sup>

**WXXL motif:** An amino acid sequence present in proteins that allows an interaction with Atg8/LC3/GABARAP proteins; the consensus is [W/F/Y]-X-X-[I/L/V]. Also see AIM and LIR/LRS.<sup>1481</sup>

**WYE-354:** A catalytic MTOR inhibitor that increases macroautophagic flux to a greater level than allosteric inhibitors such as rapamycin (and may be used to induce macroautophagy in cell lines that are resistant to rapamycin and its derivatives);

short-term treatment with WYE-354 can inhibit both MTORC1 and MTORC2, but the effects on flux are due to the former.<sup>341</sup> See also Ku-0063794.

**XBP1 (X-box binding protein 1):** A component of the ER stress response that activates macroautophagy. The XBP1 yeast ortholog is Hac1.<sup>2174</sup>

**Xenophagy:** Cell-autonomous innate immunity defense, whereby cells eliminate intracellular microbes (e.g., bacteria, fungi, parasites and/or viruses) by sequestration into autophagosomes with subsequent delivery to the lysosome.<sup>2175</sup>

**Xestospongins B:** An antagonist of the ITPR that dissociates the inhibitory interaction between ITPR and BECN1 and induces macroautophagy.<sup>2176</sup>

**Yeh1:** See Ayr1.

**Ykt6:** A prenylated vesicle SNARE involved in Golgi transport and fusion with the vacuole (including Cvt vesicle delivery to the vacuole<sup>2177</sup>); temperature sensitive *ykt6* mutations also prevent closure of the phagophore.<sup>2023</sup>

**Ymr1:** A yeast PtdIns3P-specific phosphatase involved in autophagosome maturation.<sup>2178,2179</sup>

**Ypk1:** A downstream effector of TORC2 that stimulates macroautophagy under conditions of amino acid depletion.<sup>2105</sup> TORC2 activation of Ypk1 results in inhibition of the PPP3/calcineurin-Cmd1/calmodulin phosphatase, which otherwise dephosphorylates and inhibits Gcn2, a positive regulator of macroautophagy. See also Gcn2.

**Ypt1:** A yeast GTPase that functions in several forms of autophagy.<sup>1321</sup> Ypt1 is needed for correct localization of Atg8 to the PAS. The mammalian homolog, RAB1, is required for autophagosome formation and for autophagic targeting of *Salmonella*.<sup>2180,2181</sup> See also TRAPP3.

**Ypt7:** A yeast homolog of mammalian RAB7, needed for the fusion of autophagosomes with the vacuole.

**YWHAZ/14-3-3/(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta):** A member of the 14-3-3 family of proteins that inhibits macroautophagy; direct interaction with PIK3C3 negatively regulates kinase activity, and this interaction is disrupted by starvation or C<sub>2</sub>-ceramide.<sup>2182</sup>

**ZFPM1/FOG1 (zinc finger protein, FOG family member 1):** A cofactor of GATA1, a positive regulator of macroautophagy gene transcription.<sup>641</sup> See also GATA1.

**ZFYVE1/DFCP1 (zinc finger, FYVE domain containing 1):** A PtdIns3P-binding protein that localizes to the omega-some.<sup>583</sup> Knockdown of ZFYVE1 does not result in a macroautophagy-defective phenotype.

**ZFYVE26/spastizin/SPG15 (zinc finger, FYVE domain containing 26):** A protein involved in a complicated form of hereditary spastic paraparesis; it interacts with the macroautophagy complex BECN1-UVRAG-RUBCN and is required for autophagosome maturation.<sup>2183</sup>

**ZIPK:** See Sqa.

**ZKSCAN3/ZNF306 (zinc finger with KRAB and SCAN domains 3):** A zinc finger family transcription factor harboring Kruppel-associated box and SCAN domains that functions as a

master transcriptional repressor of autophagy and lysosome biogenesis. ZKSCAN3 represses the transcription of more than 60 genes integral to, or regulatory for, autophagy and lysosome biogenesis and/or function and a subset of these genes, including *MAP1LC3B* and *WIPI2*, are its direct targets. Starvation and torin1 treatment induce translocation of ZKSCAN3 from the nucleus to the cytoplasm.<sup>643</sup>

**Zoledronic acid:** A bisphosphonate that induces macroautophagy and may result in autophagic cell death in prostate and breast cancer cells.<sup>2184</sup>

**Zymophagy:** The selective degradation of activated zymogen granules by a macroautophagy-like process that is dependent on VMP1, SQSTM1 and the ubiquitin protease USP9X.<sup>909</sup> See also crinophagy.

## Quick guide

1. Whenever possible, use more than one assay to monitor autophagy.
2. Whenever possible, include flux measurements for autophagy (e.g., using tandem fluorochrome assays such as RFP-EGFP-LC3 or, preferably, cargo-specific variations thereof).
3. Whenever possible, use genetic inhibition of autophagy to complement studies with nonspecific pharmacological inhibitors such as 3-MA.
4. For analysis of genetic inhibition, a minimum of 2 *ATG* genes (including for example *BECN1*, *ATG7* or *ULK1*) should be targeted to help ensure the phenotype is due to inhibition of autophagy.
5. When monitoring GFP-LC3 puncta formation, provide quantification, ideally in the form of number of puncta per cell.
6. For the interpretation of decreased SQSTM1 levels, use a pan-caspase inhibitor to ensure that the reduced SQSTM1 amount is not due to a caspase-induced cleavage of the protein.
7. Whenever possible, monitor autophagic responses using both short-term and long-term assays.

## Index

### A


Acridine Orange 97, 113  
 Alzheimer disease 92, 109, 117  
 Ape1 187, 194, 195, 209, 215  
 Apicoplast 115, 117  
 Atg8-PE conjugation 182  
 Atg9 peripheral sites 182, 206, 208, 211  
 Atg12-Atg5 conjugation 67  
 ATG16L1 67, 68, 70, 71, 92, 118  
 Atg18 68, 69, 71, 106, 108, 115, 121, 183, 190, 200, 203, 213  
 Autophagic body 33, 34, 76, 82, 190  
 Autophagosome 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 59, 60, 61, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 79, 82, 83, 84, 85, 86, 87, 88, 91, 94, 97, 98, 99, 100, 101, 102, 104, 105, 107, 108, 110, 111, 113, 114, 115, 116, 117, 118, 120, 121, 186, 187, 188, 189, 190, 191, 192, 193, 194, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 207, 208, 209, 210, 212, 213, 214, 215, 216, 217, 218, 219, 220

### B

Bafilomycin A<sub>1</sub> 40, 42, 43, 47, 48, 50, 55, 63, 71, 78, 79, 84, 86, 87, 90, 91, 93, 95, 99, 100, 106, 111, 116, 191, 192  
 BHMT 73

### C

*C. elegans* 66, 69, 71, 72, 77, 83, 84, 104, 105, 180, 181, 182, 183, 185, 187, 188, 189, 190, 191, 192, 193, 195, 198, 204, 206, 208, 210, 212  
 Calcium 46, 48, 53, 55, 101, 102, 186, 203



Cell death 34, 37, 48, 51, 53, 55, 57, 62, 71, 75, 82, 83, 91, 93, 94, 99, 100, 101, 102, 107, 108, 112, 113, 117, 119, 120, 184, 186, 187, 188, 189, 191, 193, 195, 197, 198, 199, 200, 202, 203, 205, 207, 210, 212, 214  
 Chicken DT40 cells 103, 105  
 Chlamydomonas 106  
 Chloroquine 43, 44, 47, 48, 49, 50, 55, 59, 63, 67, 71, 84, 90, 91, 92, 93, 99, 100, 105, 109, 111, 181, 187, 196  
 Class III PtdIns3K 55, 99, 186, 189, 191, 192, 197, 198, 201, 204, 208, 210, 218, 219  
 Correlative light and electron microscopy (CLEM) 30, 37, 38, 54, 85  
 Cvt pathway 39, 40, 68, 74, 76, 87, 181, 182, 183, 188, 210

## D

*Dictyostelium* 32, 48, 51, 54, 72, 73, 94, 115, 212  
 DQ-BSA 30, 87, 88  
*Drosophila* 50, 51, 61, 62, 65, 69, 71, 80, 87, 94, 98, 106, 112, 116, 186, 192, 193, 195, 196, 204, 206, 207, 210, 211, 212, 214, 216, 218

## E

Electron microscopy 30, 34, 35, 61, 84, 117, 121  
 Endosomal microautophagy 96, 196, 200  
 EPG 69, 105, 189, 190, 197, 204, 212, 213, 214, 216, 217, 219, 220  
 Epithelial cell 34, 85, 92, 100, 111, 116, 204, 205  
 Erythroid cell 106, 107

## F

Flow cytometry 51, 53, 59, 60, 70, 73, 79, 80, 90, 96, 121  
 Fluorescence microscopy 35, 36, 37, 38, 44, 46, 47, 48, 49, 51, 52, 53, 54, 59, 68, 69, 75, 76, 77, 79, 80, 81, 82, 83, 84, 86, 87, 89, 92, 105, 106, 111, 113, 114, 117, 121, 203  
 Flux 32, 33, 34, 35, 37, 38, 39, 41, 43, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 66, 69, 71, 73, 74, 77, 79, 80, 81, 85, 86, 87, 89, 90, 91, 92, 94, 99, 103, 105, 109, 110, 111, 113, 114, 115, 116, 121, 187, 190, 195, 196, 198, 201, 202, 203, 205, 212, 214, 216, 217, 219, 220

## G

GFP-Atg8 35, 43, 46, 48, 49, 50, 51, 52, 54, 59, 71, 73, 74, 76, 86, 87, 89, 98, 106, 107, 108, 112, 114, 115, 121, 126, 148, 212  
 GFP-LC3 34, 36, 38, 44, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 67, 68, 69, 78, 79, 81, 82, 87, 88, 89, 92, 97, 98, 101, 103, 105, 106, 111, 117, 121, 220

## H

Honeybee 108  
 Hydra 110, 111

## I

ICP34.5 55, 85, 101, 194  
 Inhibitors 33, 35, 37, 42, 45, 47, 48, 49, 50, 51, 54, 55, 57, 59, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 74, 77, 80, 81, 84, 86, 87, 88, 90, 91, 93, 95, 96, 97, 98, 99, 100, 101, 102, 103, 106, 109, 110, 111, 115, 116, 121, 187, 192, 195, 196, 208, 212, 213, 214

## K

Keima 79, 80, 88

## L

Large animals 110, 111, 112  
 Late nucleophagy 30, 39, 74, 76, 195  
 LC3-II 34, 35, 41, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 59, 60, 63, 68, 70, 71, 86, 90, 91, 102, 103, 105, 106, 107, 109, 110, 111, 117, 121, 193, 194, 195, 202, 204, 208, 219, 220

LC3-associated phagocytosis (LAP) 30, 34, 37, 43, 66, 84, 117, 195, 197, 198  
 Lepidoptera 112  
 Lipofuscin 38, 61, 77, 87, 109, 121, 205  
 Lipophagy 71, 83, 107, 110, 201, 209, 214  
 LIR motif 44, 62, 119, 120, 192, 205, 214, 215, 217, 220  
 LysoTracker Red 82, 97, 98, 110, 111, 112, 113, 114, 117

## M

3-MA 30, 51, 54, 55, 62, 69, 71, 73, 84, 87, 88, 93, 99, 105, 106, 109, 114, 115, 116, 186  
 MDC 30, 91, 97, 196  
 Mitophagy 39, 40, 43, 45, 55, 57, 64, 70, 74, 75, 76, 77, 78, 79, 80, 81, 92, 105, 108, 110, 180, 182, 183, 185, 186, 187, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 204, 205, 207, 208, 209, 210, 211, 212  
 MitoTracker 74, 78, 79, 80, 81, 95, 115  
 MTOR 47, 55, 62, 63, 64, 65, 66, 67, 72, 81, 87, 93, 100, 101, 102, 105, 109, 110, 111, 113, 117, 121, 187, 188, 189, 190, 191, 194, 195, 196, 197, 198, 199, 200, 201, 202, 204, 205, 206, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219

## N

Neotropical teleosts 112  
 Nucleophagy 39, 57, 74, 75, 76, 201, 205

## O

Odontoblasts 113

## P

Parkinson disease 75, 92, 199, 202, 206, 208, 209, 214  
 Pexophagy 39, 40, 57, 74, 75, 77, 80, 81, 86, 103, 108, 180, 182, 183, 185, 189, 190, 191, 192, 193, 194, 195, 197, 200, 202, 207, 213  
 Pho8 $\Delta$ 60 assay 50, 74, 76, 121, 194, 207  
 Photodynamic therapy 30, 93, 213  
 Planarians 113  
 Plants 32, 34, 35, 39, 40, 46, 54, 81, 94, 100, 113, 114, 121, 183, 197, 212  
 PolyQ protein turnover 77  
 prApel 74, 76, 86, 87, 187, 194, 195, 209  
 Protists 32, 40, 114, 115, 117, 118  
 PtdIns3P 67, 68, 69, 99, 108, 117, 189, 197, 198, 204, 207, 208, 209, 214, 215, 219, 220

## R

Rainbow trout 115, 116  
 Reticulophagy 74, 83, 108, 183, 191, 205  
 Rosella 57, 76, 105, 121

## S

Saponin 54, 59, 210  
 Sea Urchin 116  
 Sequestration assays 86, 87, 121  
 SQSTM1 46, 81, 84, 86, 87, 89, 90, 92, 97, 102, 105, 106, 109, 110, 111, 117, 120, 121, 187, 191, 192, 193, 194, 197, 200, 201, 205, 206, 211, 212, 214, 216, 217, 219

## T

TAKA assay 67  
 Tandem mRFP/mCherry-GFP-LC3 61, 105  
 Ticks 116  
 Torin1 46, 55, 65, 72, 100, 102, 105, 216, 220  
 Trehalose 55, 89, 102

**V**

V-ATPase 40, 41, 55, 91, 99, 100, 201, 202, 209, 213, 218  
Viral BCL2 85, 101  
Viral FLIP 101

**W**

Western blot 34, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 54, 62, 63, 64, 65, 66, 69, 70, 73, 75, 76, 78, 81, 83, 84, 86, 90, 91, 92, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 116, 117, 121  
WIPI1 68, 69, 118, 197, 198, 213  
WIPI2 68, 69, 209, 213, 214  
Wortmannin 55, 62, 68, 87, 88, 99, 111, 115, 118, 213

**X**

Xenophagy 32, 40, 74, 84, 85, 180, 194, 211, 213, 214

**Y**

Yeast 34, 35, 38, 39, 40, 41, 42, 43, 45, 47, 49, 50, 54, 55, 57, 63, 65, 66, 67, 68, 69, 72, 73, 74, 75, 76, 77, 80, 81, 83, 84, 86, 87, 92, 102, 103, 104, 107, 108, 114, 115, 187, 188, 189, 190, 191, 192, 193, 196, 197, 198, 199, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 216, 217, 218, 219

**Z**

Zebrafish 116, 117, 205, 213  
Zymophagy 86, 188, 214